<SEC-DOCUMENT>0000950170-24-022056.txt : 20240228
<SEC-HEADER>0000950170-24-022056.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228160544
ACCESSION NUMBER:		0000950170-24-022056
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		24695215

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gern-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:gern="http://www.geron.com/20231231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_6ec6a41d-9455-4ff8-83c5-b2d8d51cbf16" name="ecd:TrdArrDuration" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" format="ixt-sec:durwordsen">365 days</ix:nonNumeric><ix:nonNumeric id="F_e009aa17-7b37-43f5-8f1e-7fd2d9e48a0b" name="dei:DocumentFiscalPeriodFocus" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a">FY</ix:nonNumeric><ix:nonNumeric id="F_47cf54a7-69b5-41ae-879b-70186fb43482" name="dei:AmendmentFlag" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a">false</ix:nonNumeric><ix:nonNumeric id="F_0fad2783-060e-47c0-a45e-43c7dd5b4410" name="dei:EntityCentralIndexKey" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a">0000886744</ix:nonNumeric><ix:nonFraction id="F_3c679760-c5e2-4438-adcc-f87bf3505474" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_30281e46-cdbe-4120-b004-3005ac2cc30f" name="us-gaap:CommitmentsAndContingencies" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_27f9fc38-8870-42a0-a389-b678747cd923" name="us-gaap:PreferredStockValue" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1802a09d-4883-4f3c-b335-1ded5d8337fd" name="us-gaap:PreferredStockValue" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_b8827fb4-805f-47b4-9575-17566fb60e0f" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" contextRef="C_96ebc7c1-7c8c-4ebe-ab6a-5ccbadc9e64d" format="ixt-sec:durwordsen">three month</ix:nonNumeric><ix:nonNumeric id="F_0194cff7-90da-4ed5-a176-f5577cc6d08c" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" contextRef="C_96ebc7c1-7c8c-4ebe-ab6a-5ccbadc9e64d" format="ixt-sec:durweek">6</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gern-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_ad45d3b5-1c71-49f5-8e18-c743e63e20bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_804bcb69-7593-4583-b546-4f5094a6b055"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e0d68e1-858b-451d-bee9-b7d9aeb45b2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e8f230f-35de-44f7-93b7-6df504f45fde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d275d231-4e07-4121-baa6-cdf238ed26ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3f33d08-a5ce-4365-a047-c2b41669086c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec95cdaa-3268-4317-a48c-594ad28bd481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03cae945-a223-49bc-8a34-e80048f4e61f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_794b0098-1158-41ef-a669-a1b32cd93046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9939d7d-974b-4606-83bd-5a5ddf499439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b6ebae4-b1af-4bd1-a220-87fe4159e558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9627054b-a059-4769-a822-511b43eb7d07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49393210-70a6-4185-bfbb-56a280b6cb40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6fcdb67-4d24-4d5f-be19-775334a4320f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_827f4149-4d34-435f-8a68-7494c346ac68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56aeac30-b895-473c-8b3a-f12592932ce7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a771635-513d-4f44-938f-c72a1da4876b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_510848a8-05e3-469a-b372-8265983b572a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d1ea305-4988-4375-9ee4-69c9f837ffb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bd9d30b-b6ce-417e-b7b2-8eb4d19cca93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56700b86-6b39-4ff6-939d-369ca954edba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6102220c-7833-4b4f-aa22-7bbaf7d6a11e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d124dfd-42e3-4007-856f-2bc59dc7e2da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42c6935a-1d5e-40dd-ab10-35f9472606c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c78574d-4d3a-47d2-9453-d6f12deab799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29eb0b35-f0bd-4b06-8287-c9e8fdd6d5b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:ClassActionStipulationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4453fc4-f1fc-4c46-81b8-a6f6809e0b65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95534f32-aee8-4d09-9da3-068375f3be3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bed0edb-6d63-45bc-b6ac-2fc53a07d1f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0d1eeee-15a6-49e0-b2a9-feba2070ca4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d9d0c34-60e7-4259-a55f-9fe02c166dc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f7e8c6c-6681-4a1d-9f84-ed77636d8cd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3194e6b-9d7d-47dd-b6df-8d8c89d54d48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70402503-27b5-4f37-815e-29f46b76e9fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75ecfc92-1a60-40ee-a4cb-7d76a1d3e92a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyStockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_320fa289-b36d-4239-a6c5-883f073fb751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a94a3320-6443-4a71-a8ed-f5a63144da7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38d32bf7-1b80-4b24-b2eb-46f7768d7421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a5892be-7d37-498c-be3e-05e931beae2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:SubsequentDirectorOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cefcefdd-0850-4f7b-b6b5-cd1f2132fb46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11088b90-d0a5-4112-af3e-c26b5cbb2191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:ClassActionStipulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-02</xbrli:startDate><xbrli:endDate>2022-09-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec2e5c75-1f30-4a48-82c7-38c0000d374c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31e1df9f-50c4-415c-947c-3b83ba778c1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9edf5ddf-277c-4136-a6a5-53a0c72bd66c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebd1ac89-5dde-4a45-937c-75b1eb1b2f48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95d2171c-44c4-4ef3-bcef-9a3bf9ca3146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e685bf88-6c83-46c0-b720-48d9693271f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16cb4e12-d0a4-4036-b565-a780727a5c13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fc0a461-b7df-4953-9697-a90dae088624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4111e6aa-d02c-4fab-8c2a-dc8d69eddc4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-21</xbrli:startDate><xbrli:endDate>2022-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_503221bc-7adf-491b-8898-576757f733b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8069d28b-213c-446c-bde1-39089012764b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7906f3d1-d5d9-439c-a646-5ec2a8601afe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f483b420-dc65-4430-8e6f-a781504fe525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1c57478-5d84-4116-a7da-630b0b684aa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df5a5ad0-ae6b-4ec7-b61c-d48e757c3148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_027d36e5-94d9-4e80-a37e-f864583a9ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff875ec1-8c1a-4ae6-b136-1138204345ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbd86ffc-7423-4bbf-b014-4111ef73acb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e13ec08-4d34-4c19-b5b5-3b79b45e37fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76c77a60-0095-4c7c-b9a6-6d9d39af8387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76b2a7dd-0da9-4a9f-bf20-e3fdac920246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cd1fdca-3697-4478-905e-43127481507e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_472cbb86-89e4-4a2f-aaed-c8771e492ab5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyStockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d042016-74bf-4e4b-9d87-54569fff49ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f69f345-ac6c-4afc-bd0d-534fc2cdd78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f801a8f-cd52-49ca-bf06-5622142e1b2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5aba5b57-05d2-4c06-90d4-6885ef672ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff3a58b5-efcc-4001-a2ea-2794d695b861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0880c107-5216-4914-bd93-f39768e97006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93ba27f0-5156-41ac-9f7e-063e7a0e3462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88e8fe22-6578-4995-bace-a30be752ddd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be269b1c-429d-477f-bb7d-ad125a3758a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91f09572-5c03-4d4f-9e6e-6b7a9683db52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c84962fe-b876-484c-8ac0-436ed90912a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsPlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:SubsequentDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6410ed5-b65f-42da-b01e-341e5ebcf276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3891a9a9-b40f-43be-a57b-26dd8899f2e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6310966f-16be-4280-aead-d0c892e948b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0942a03-12fc-439e-b31b-902f477607aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25ad2b3f-4a16-403c-a2dc-3b7d1fe99046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e976b4cb-7c40-4469-90e7-51a6622581cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1520a1d5-d2fd-4004-a5ce-578541558369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fb6bb85-bc11-42d4-90c8-60d500a4ce63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ff30090-bcbe-4192-9979-96ad9f967d1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdaff13f-48a1-4aed-808e-efa7e46b169b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a550d37d-7683-427c-9abd-810070f5905c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44d11214-5ff1-4fe2-9231-445ae761557a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_270b5c42-ba2a-4860-81af-6be293878e33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheSixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94686802-cc00-4b2a-8c6f-27ed9da5c87a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12a38d5d-ad5a-4d9a-a905-53cbdd8ad7e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5bfecec-6498-49b3-b2ca-dff2fad0c618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a74175ba-db98-47c3-a243-217ab36ff82c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44f56c70-bcea-4e2b-ac28-fae20f129a98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a0297cb-3318-4836-a868-af5440cc2bbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c52ecd16-7cd9-4157-8e8e-31af27e39a63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6536834-7d1a-4219-88e2-57d47d5dd378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9909923d-f176-4cf6-ba61-369530284669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89681771-d544-4757-ace7-4696d541ae50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_950b9119-6687-42b5-9831-7ca4ebac5451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e22f4a9-1f60-4ad4-9a3b-88792070760f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-10</xbrli:startDate><xbrli:endDate>2020-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d88ef09-b3cf-469e-a8fe-49f54977425e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a0593af-b72d-4eff-a7fa-e7458afe7976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74722c61-6ec4-4448-b0c8-a626d2b72e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01a342e9-84cb-4a8b-94b4-0c633e0e9043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e899757-4f56-49cf-873b-25770295bb58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7346f9b8-492d-46b8-8c82-4d22ec08ac7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e5d5abf-c356-4752-8616-9b666f658b7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c872764-390c-4717-890a-1fb8ba1afba9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoStockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_042608dc-1dba-4a63-acb9-58cb22cee7c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8226d454-2be9-44b7-b692-bf6354a4b418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b446414-84fd-4c21-bce4-7d4596128fd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa683e66-a550-45b2-b8b1-c738b0dfae20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyLeaseAndFosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46da631c-8b1d-4cf0-a98f-1721c6e53088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b86372fa-858a-445d-b041-163879e9a211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1a70717-d878-4158-aada-2b23be1cd942"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b59a05ad-a041-4c67-b50f-9f5d30c4be93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gern:EmployeesAboveTheVicePresidentLevelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf14b58a-81bb-4655-8483-d56e1f8dafe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_730d222b-ee44-44a3-8ae6-6f60f92122a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3acb4904-a13f-4209-a193-1dd7ea1e9043"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82f9062a-632d-417d-b946-eaa6dd00480f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7589db9-9bed-4ce5-b958-b8edb41a3509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c819bdf8-44a4-49a8-b407-9353eb20da0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6812ec1e-cd7d-4990-a1fa-445d65e04803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2693cf9-67f1-4ebd-9653-66d0ae99298c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9733c1c-7fd3-461a-9714-dca4f2863d20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a814b358-835d-4bd9-9991-025af00007a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09926111-0e38-4a7f-b821-d79344c2f8f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c46d828-b7f0-4eb1-b271-019ea82aead2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_40e9b0a7-aa9d-4ad8-8b64-211cce52e280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34991f42-499f-4b50-9059-0999669562cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-04</xbrli:startDate><xbrli:endDate>2020-09-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca648008-6ad8-4d06-8ece-4407c06a3407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e6e6755-b0cd-454c-bd57-da4270096040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb78444b-50bb-4a99-b63f-30026eed0bd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f95129c1-8a90-4b89-bb9a-b7b27d613844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eca18dbf-5f65-4638-9ffe-5784859f233f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4961fb6-61f4-47d9-9582-c48ee1cf31fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bf7166f-5b00-4240-90ed-a7f7c7a104bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1754f765-5745-4731-b5dc-3a11a9d12c42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c15f606e-8272-43fe-9517-3931c73040da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3599ea48-8821-4d91-8b3f-c643d3f1153a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fc0d7c6-e2ff-4bd5-b6f5-508937b233e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23c9ef8f-d893-45f7-9dae-127a81af3541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df1f41e8-3c99-453f-9b1f-eb930e82b8d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a2cda13-d3d5-412b-8639-f1337e897a80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d87baa2f-bd55-465b-8452-44ea0c0bd760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a1035cc-6adb-4cec-b9e1-c39d76644c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e59e3e0-f076-4d12-8cb2-4da3978cb2ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a432a676-25a6-4e7b-8197-e0e0d30df151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38ded4c9-172f-4a2a-a52d-e82dc8942a05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58825751-7a3a-48d2-a155-deb56a5efc70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9015a27f-f086-4d25-b575-d3055945fe84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f268f91-b8d0-43cd-a929-2ac72e87b0eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2eebd16c-0eef-470a-90b4-04639a5fa0b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e71ee43c-b505-4d11-b82b-9dd17fd5ffe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_933b24f2-1289-480e-b2b0-cd7ef795363d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcf8dab7-019f-4b57-8582-d13f9fbce0ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c590e1f-224c-4339-bfb7-fb2401f33f87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaf64096-d2f0-4874-95f7-f1e081c29515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e69d88b-4f35-4715-a7e6-4dd1f9e014e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd0bdfe4-5cbf-42ce-ab92-4660dc42c7cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18fdb42c-1e4c-4ab6-babf-f250735da19f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_423727df-44e5-4ea3-a181-865b8e657957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7044d4ee-a54a-4427-9cc2-9922f4676346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49ff1dd8-46db-4d4f-baa8-c884bec8fd8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d320b3d-6dfc-4827-907c-1c7a097695e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c110582-d865-4864-a523-b15ea80bf6ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f48fce0b-30ab-418f-a2f6-a6573c219376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b06c91e-d34a-427e-a1ea-6394120ede9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2007-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c14e1cc2-f8b1-4804-970a-08b5df83f4b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71f2bda0-5d65-46ba-85a1-918c8c1ac142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_228019f9-7d33-40bf-8f26-f89bae5c27ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0998544a-c764-4cf1-9f09-2276209f95bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_404e5fe1-4fb6-4444-9f07-c398ecd07fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsPlan2006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43c6bd94-f041-48f0-8b71-ece113bc20c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edfb6d0a-e261-47b0-b5f3-062c8bf0db56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea12e420-2fee-416f-88f6-87e5a5b23293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e3140e2-0589-47d4-86ac-5bdf695ba419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc68db16-fd2f-40cb-8dd2-0fdeb8ec048d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_688486b0-96f1-46aa-9bfc-41e54da2e10b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30549aaa-2d2b-429a-b2b7-bad54c937228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6afc8ee-1a57-40bd-8ddc-ffc4d5eb3fd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37a598a5-3c81-4923-b06f-67a5ec38fc90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eb3c3bc-3f1f-46d7-8b32-d6803d932f4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d5c94ef-47a2-4e1e-9aa3-b699facad362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f5be4ad-c744-4346-b707-675df68384fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5093ace2-fb77-487d-9798-18faea32c09f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4dcea29e-0f7f-420c-8854-7bbd432fdd3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0907aaf0-4f28-425e-a4e7-02bd5e2c9311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06b531c7-ec9f-4ac0-bc05-e1c34b4943b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d2d8379-582f-499f-a5c1-4b051c31e7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1780d47b-7074-43ea-83b7-6b37c8951dc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5c90d2a-1b3e-42ff-a354-2da100d5cdcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e1d1200-a6c0-43f1-9a9e-761058f49e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-30</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5ed2423-f046-4a7d-980c-b9f3fb922f38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_264544f1-3468-4c3f-888f-e76d69aa9c26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3775ee3a-1995-4ba0-9943-4a471b60aa73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73aa80a5-7000-451b-a950-0deff207777e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_557b50d4-874f-47b9-821c-244d8e7b719f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01a4fb2f-1285-4c86-abb6-10590d094c02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66810d71-5d1a-4728-8f3a-817e2201e76e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96ebc7c1-7c8c-4ebe-ab6a-5ccbadc9e64d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoPreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ad6c2d6-0303-48fa-82c0-130aee8c97e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f677506b-3ffc-40c8-bc4c-7bf4653d86d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsPlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a801fab-431b-4ace-91e0-07585e1a2682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bb2a462-3594-4a43-8344-076ee590e035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e81fdb75-1e1c-4290-ae83-e0a59c23e05d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_351a0c01-2dc4-4490-a644-a98d7ccf7278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a862b4ec-a5b7-430d-9f24-f6c95dc41dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95b50b47-d6b5-4c38-bcae-9f23b73905ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e79587f-734c-4e35-ae7f-098dee077ab7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cea26a02-14ec-4995-aac7-14c8a668c2f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21726de3-6057-4051-a03b-5bca72d4eae2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Item"><xbrli:measure>gern:Item</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Plan"><xbrli:measure>gern:Plan</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_d30983c0-aaf8-4127-9c9f-03919a470b03" fromRefs="F_77ad96f4-d53b-467e-a388-ebab05d54427"></ix:relationship></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5fc1cd0-88cc-4741-9fe0-9991e900970c" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_532737b9-f6d8-4b5d-a449-0a68859e6ca4" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746; </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the Fiscal Year Ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9cd4196-94ea-4013-b956-f2a4e81541d7" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94d5be6f-9740-4ebe-bba1-f504085a79fd" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82e25e09-e2cd-40e8-acf3-898271f45a06" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b49a62ec-c83b-47b4-a16c-dfe079f90c95" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">         </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> .</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2aff6fa-687c-49f3-9709-e64ab465d4ac" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">000-20859</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:15pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e05ce1b2-5253-4536-a1db-e068b0112309" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">GERON CORP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;min-width:fit-content;">ORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_8feacefd-a18b-4853-88b8-9b9dd3a7bf51" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_b733ccc4-e7a8-4cea-b559-075d31018a91" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">75-2287752</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_65b9cea3-cb65-4135-8b1c-faab34f1c870" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">919 East Hillsdale Blvd.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_e625c121-c629-4466-848a-e98f145f38ef" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_825fe9de-be78-447e-b95d-04c7aa4b010a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_42567756-fa97-45a8-9ae9-282511bfd81d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_c5f3813a-20ab-422e-a68e-2ee0380d6e06" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94404</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8778445-1f8e-4acf-a115-5d780bcc071a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c29291d-66e0-457a-acc6-c64412bde901" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">473-7700</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.26%;"/>
    <td style="width:23.12%;"/>
    <td style="width:43.62%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class:</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading symbol(s):</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered:</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fb68594f-5ed0-46b6-bab2-bdc31ac3f654" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_38d47595-c97b-43e2-9c9f-75fe0b38d8e8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GERN</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_b3357df8-958a-420a-b40c-27a4820f0560" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well&#8209;known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b245f16b-73f4-4c26-89e2-262a75e7c5ac" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744;    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c97f3e77-cc60-47fe-9196-aaf907c6b3cd" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f2bd12a-2956-4e60-bde2-294a173564f0" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S&#8209;T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_533440eb-b7c0-4023-9d67-371c6d83bb35" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non&#8209;accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b&#8209;2 of the Exchange Act.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.571%;"/>
    <td style="width:2.857%;"/>
    <td style="width:21.429%;"/>
    <td style="width:4.286%;"/>
    <td style="width:25.714%;"/>
    <td style="width:1.429%;"/>
    <td style="width:15.714%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_aaef2127-ae2e-4708-85ee-ab262a3608e1" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_d0f0756b-3aaa-48e1-8f46-4337b698866e" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_25f7c16a-8b95-4762-ba9d-fdd9a514a1d4" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b97f3786-bb2f-4930-9717-a68a5a5e1c01" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_855d7962-0932-41b2-9931-840039d87b90" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b&#8209;2 of the Act).  Yes    &#9744;  No  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b79e0e0-46b3-4c4b-9ca4-c5027648c5c7" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of voting and non&#8209;voting common equity held by non&#8209;affiliates of the registrant was approximately $</span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_174fb681-0350-4a87-90ff-0f651cb06796" contextRef="C_c52ecd16-7cd9-4157-8e8e-31af27e39a63" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,394,546,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> based upon the closing price of the registrant&#8217;s common stock on June 30, 2023 on the Nasdaq Global Select Market. The calculation of the aggregate market value of voting and non&#8209;voting common equity held by non&#8209;affiliates of the registrant excludes shares of common stock held by each officer, director and stockholder that the registrant concluded were affiliates on that date. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">As of February 23, 2024, there were </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0cb9095-bc97-4a08-ae8d-7db2ba6da53e" contextRef="C_dd0bdfe4-5cbf-42ce-ab92-4660dc42c7cf" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">546,059,309</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock outstanding.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07a2c449-a49e-4316-be25-638415335b53" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:90%;"/>
      <td style="width:1%;"/>
      <td style="width:9%;"/>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Document</span></p></td>
      <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form 10&#8209;K<br/>Parts</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
      <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Portions of the Registrant&#8217;s definitive proxy statement for the 2024 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2023.</span></p></td>
      <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">III</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc_page">&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.34%;"/>
    <td style="width:83.48%;"/>
    <td style="width:6.18%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;text-align:right;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases <br/>of Equity Securities</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder <br/>Matters</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="text-indent:10.1pt;vertical-align:top;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10&#8209;K Summary</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this report, unless otherwise indicated or the context otherwise requires, &#8220;Geron,&#8221; &#8220;the registrant,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Geron Corporation, a Delaware corporation, and its wholly owned subsidiaries, Geron UK Limited, a United Kingdom company, and Geron Netherlands, B.V., a Dutch company.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward&#8209;Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This annual report on Form 10&#8209;K, including &#8220;Business&#8221; in Part I, Item 1 of this annual report on Form 10-K and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of this annual report on Form 10-K, contains forward&#8209;looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Geron Corporation, or Geron or the Company, to differ materially from those expressed or implied by such forward&#8209;looking statements. All statements other than statements of historical fact are statements that could be deemed forward&#8209;looking statements. In some cases, forward&#8209;looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;predicts,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative thereof or other comparable terminology. The risks and uncertainties referred to above include, without limitation, risks and uncertainties related to: (a) whether the U.S. Food and Drug Administration, or FDA, and European Medicines Agency, or EMA, may have issues with the New Drug Application, or NDA, or marketing authorization application, or MAA, for imetelstat for Low or Intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, that delay or prevent approval and a potential commercial launch; (b) whether we will be able to continue to develop imetelstat or advance imetelstat to subsequent clinical trials, or that we will be able to receive regulatory approval for or successfully commercialize imetelstat, on a timely basis or at all; (c) whether imetelstat may cause, or have attributed to it, adverse events that could further delay or prevent the commencement and/or completion of clinical trials, delay or prevent its regulatory approval, or limit its commercial potential; (d) whether the IMpactMF Phase 3 trial for R/R MF has a positive outcome and demonstrates safety and effectiveness to the satisfaction of the FDA and international regulatory authorities, and whether our projected rates for enrollment and death events differ from actual rates, which may cause the interim and final analyses to occur later than anticipated; (e) whether we overcome all of the enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for, and to meet the expected timelines and planned milestones; (f) if imetelstat is approved for marketing and commercialization, whether we are able to establish and maintain effective sales, marketing and distribution capabilities, obtain adequate coverage and third-party payor reimbursement, and achieve adequate acceptance in the marketplace; (g) whether imetelstat actually demonstrates disease-modifying activity in patients; (h) whether there are failures in manufacturing or supplying sufficient quantities of imetelstat that would delay, or not permit, the anticipated commercial launch or not enable ongoing or planned clinical trials; (i) whether we are able to obtain and maintain the exclusivity terms and scopes provided by patent and patent term extensions, regulatory exclusivity, and have freedom to operate; (j) that we may be unable to successfully commercialize imetelstat due to competitive products, or otherwise; (k) that we may decide to partner and not to commercialize independently in the U.S. or in Europe and other international markets; (l) whether we have sufficient resources to satisfy our debt service obligations and to fund our planned operations; (m) that we may seek to raise substantial additional capital in order to complete the development and commercialization of imetelstat and to meet all of the expected timelines and planned milestones, and that we may have difficulty in or be unable to do so; and (n) the impact of general economic, industry or political climate in the U.S. or internationally and the effects of macroeconomic conditions on our business and business prospects, financial condition and results of operations; as well as other risks that are described herein and that are otherwise described from time to time in our Securities and Exchange Commission reports including, but not limited to, the factors described in &#8220;Risk Factors,&#8221; in Part I, Item 1A of this annual report on Form 10&#8209;K. Geron assumes no obligation for and except as required by law, disclaims any obligation to update these forward&#8209;looking statements to reflect future information, events or circumstances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Factor Summary</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this summary to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this annual report on Form 10-K. The summary below is qualified in its entirety by that more complete discussion of such risks and uncertainties. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this annual report on Form 10-K as part of your evaluation of an investment in our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to the Development of Imetelstat</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success depends solely on imetelstat, our only product candidate, and we cannot be certain that we will be able to continue to develop imetelstat or advance imetelstat to subsequent clinical trials, or that we will be able to receive regulatory approval for or to commercialize imetelstat, on a timely basis or at all.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could further delay or prevent the commencement and/or completion of clinical trials for imetelstat, delay or prevent its regulatory approval, or limit its commercial potential.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If IMpactMF fails to demonstrate safety and effectiveness to the satisfaction of the FDA or international regulatory authorities, we would incur additional costs, experience delays in completing or ultimately fail in completing the development and commercialization of imetelstat in patients with relapsed/refractory MF, which would have a material adverse effect on our business, business prospects and the future of imetelstat.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trials of imetelstat could be interrupted, delayed, terminated or abandoned for a variety of reasons which could severely and adversely affect our financial results, business and business prospects, and the future of imetelstat. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to conduct our current and potential future clinical trials of imetelstat. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to continue the development of, obtain regulatory approval for, or commercialize imetelstat.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Regulatory Approval and Commercialization of Imetelstat</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain regulatory approval for and successfully commercialize imetelstat, including obtaining and maintaining licenses where required for us to sell imetelstat, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If imetelstat is approved for marketing and commercialization and we are unable to establish and maintain effective sales, marketing and distribution capabilities, or obtain coverage and adequate third-party payor reimbursement, we will be unable to successfully commercialize imetelstat.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approval that we may potentially receive for imetelstat could be subject to restrictions, and we may be subject to penalties or product withdrawal if we fail to comply with regulatory requirements or if we experience unanticipated problems with imetelstat.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Related to Compliance with Healthcare Laws</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with federal, state and international healthcare laws, including fraud and abuse, transparency, and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Manufacturing Imetelstat</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third parties to manufacture and supply imetelstat, and we may be unable to ensure that we have adequate quantities of imetelstat that meet specifications that may be approved or required by regulatory authorities, and timelines necessary for current and potential future clinical trials and potential commercial uses, due to regulatory inspections of those third parties or otherwise.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Financing</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to obtain additional capital would force us to further delay, reduce or eliminate development and potential future commercialization of imetelstat, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no source of product revenue and may never become profitable.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Indebtedness</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our level of indebtedness and debt service obligations could adversely affect our financial condition, and may make it more difficult for us to fund our operations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Protecting Our Intellectual Propert</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for imetelstat, our competitors could develop and commercialize products similar or identical to imetelstat, and our ability to successfully commercialize imetelstat may be adversely affected.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Competitive Factors</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our competitors develop products, product candidates or technologies that are superior to or more cost-effective than imetelstat, this would significantly impact the development and commercial viability of imetelstat, which would severely and adversely affect our financial results, business and business prospects and the future of imetelstat, and might cause us to cease operations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Information Technology Systems, Data Security and Data Privacy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to legal and contractual obligations related to privacy, data protection and information security. Our actual or perceived failure, or that of third parties upon which we rely, to comply with such obligations or changes in such obligations may adversely affect our business, operations and financial performance. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Our Common Stock and Financial Reporting</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, our stock price has been extremely volatile, and your investment may suffer a decline in value.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Calculation of Aggregate Market Value of Non&#8209;Affiliate Shares</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For purposes of calculating the aggregate market value of shares of our common stock held by non&#8209;affiliates as set forth on the cover page of this annual report on Form 10&#8209;K, we have assumed that all outstanding shares are held by non&#8209;affiliates, except for shares held by each of our executive officers and directors. In the case of 5% or greater stockholders, we have not deemed any  such stockholders to be affiliates given the lack of facts and circumstances that would indicate that any such stockholders exercise, or have the ability to exercise, any control over Geron. These assumptions should not be deemed to constitute an admission that all executive officers and directors are, in fact, affiliates of Geron, or that there are no other persons who may be deemed to be affiliates of Geron. Further information concerning shareholdings of our executive officers, directors and principal stockholders is incorporated by reference in Part III, Item 12 of this annual report on Form 10&#8209;K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1.     BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead indication for imetelstat is in lower-risk MDS. In August 2023, our NDA for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk MDS who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents, or ESAs, was accepted by the United States, or U.S., FDA, for review and assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 16, 2024. In addition, the FDA has scheduled an advisory committee meeting as part of the NDA review on March 14, 2024. If imetelstat is approved for commercialization by the FDA, we anticipate commercial launch of imetelstat in lower-risk MDS in the U.S. could occur at the time of approval. In September 2023, we submitted an MAA in Europe that was validated for review by the EMA for imetelstat for the same proposed indication as in the U.S. We expect a review of the MAA could be completed in early 2025, and subject to approval by the European Commission, we believe EU commercial launch of imetelstat would occur in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our NDA and EMA submissions are based on positive data from the IMerge Phase 3 clinical trial. The trial met its primary endpoint of &#8805; 8-week transfusion independence rate and a key secondary endpoint of 24-week transfusion independence rate, demonstrating highly statistically significant (i.e., p&lt;0.001 for both) and clinically meaningful benefits with imetelstat treatment versus placebo. Furthermore, statistically significant and clinically meaningful efficacy results were observed in the trial across key subtypes, including patients who were ringed sideroblast positive, or RS positive, and ringed sideroblast negative, or RS negative; patients with high and very high baseline transfusion burden; and patients classified as Low or Intermediate-1 risk according to the International Prognostic Scoring System, or IPSS. Consistent with prior imetelstat clinical experience, the most common serious adverse events were primarily short-lived, manageable thrombocytopenia and neutropenia.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to lower-risk MDS, we are developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in patients with Intermediate-2 or High-Risk myelofibrosis who have relapsed after or are refractory to treatment with a janus associate kinase inhibitor, or JAK inhibitor, or relapsed/refractory MF, with overall survival, or OS, as the primary endpoint, that currently is enrolling patients. In November 2023, the trial reached 50% enrollment. Based on our current planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the first half of 2025, and the final analysis may occur in the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that currently is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes, or higher risk MDS, and acute myeloid leukemia, or AML, in which the first patient was dosed in June 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the positive data from IMerge Phase 3 and IMerge Phase 2, as well as our prior Phase 2 clinical trial of imetelstat in patients with relapsed/refractory MF, provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells enabling recovery of bone marrow and normal blood cell production, which suggest potential disease-modifying activity. We believe this potential for disease modification could differentiate imetelstat from currently approved treatments in myeloid hematologic malignancies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercial Plans for Imetelstat</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If imetelstat is approved in lower-risk MDS for marketing by regulatory authorities, we plan to commercialize imetelstat ourselves in the U.S. Our U.S. launch strategy is designed to prepare imetelstat, the market and the company to ensure broad reimbursement and deliver a seamless customer experience to all stakeholders at launch. Several long-lead time activities have already been completed, such as securing a global trademark for the imetelstat brand name; finalizing third party logistics, our distribution network, and our patient support providers; and onboarding highly experienced commercial and medical affairs leadership teams. We continue to conduct pre-commercial preparations for the U.S., such as enhancing and/or establishing company processes and systems to support a potential commercial launch, refining our market research in lower-risk MDS, engaging in marketing and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercial access/reimbursement preparatory efforts, and hiring our sales force, which we expect to occur in the first and second quarters of 2024.  We continue to evaluate our strategy for the potential launch and commercialization of imetelstat in Europe. Based on our internal estimates of pricing and addressable patient populations in 2031 and if regulatory authorities approve imetelstat for marketing in lower-risk MDS and relapsed/refractory MF, we believe the potential combined total addressable market opportunity in the U.S. and Europe for imetelstat is approximately $7.0 billion, of which lower-risk MDS represents approximately $3.5 billion and relapsed/refractory MF represents approximately $3.5 billion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Background of Telomerase Inhibition in Hematologic Malignancies and Imetelstat</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the human body, normal growth and maintenance of tissues occurs by cell division. However, most cells are only able to divide a limited number of times, and this number of divisions is regulated by telomere length. Telomeres are repetitions of a deoxyribonucleic acid, or DNA, sequence located at the ends of chromosomes. They act as protective caps to maintain stability and integrity of the chromosomes, which contain the cell&#8217;s genetic material. Normally, every time a cell divides, the telomeres shorten. Eventually, they shrink to a critically short length, and as a result, the cell either dies by apoptosis or stops dividing and senesces.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Telomerase is a naturally occurring enzyme that maintains telomeres and prevents them from shortening during cell division, such as stem cells that must remain immortalized to support normal health. Telomerase consists of at least two essential components: a ribonucleic acid, or RNA, template, which binds to the telomere, and a catalytic subunit with reverse transcriptase activity, which adds a specific DNA sequence to the chromosome ends. The 2009 Nobel Prize for Physiology or Medicine was awarded to Drs. Elizabeth H. Blackburn, Carol W. Greider and Jack Szostak, former Geron collaborators, for the discovery of how chromosomes are protected by both telomeres and telomerase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Telomerase is upregulated in many tumor cells and malignant stem and progenitor cells, enabling the continued and uncontrolled proliferation of the malignant cells that drive tumor growth and progression. We believe that inhibiting telomerase may be an attractive approach to treating cancer because it may limit the proliferative capacity of malignant stem and progenitor cells, which are believed to be important drivers of tumor growth and progression. We and others have observed in various in vitro, ex vivo and rodent tumor models that inhibiting telomerase: (a) results in telomere shortening and (b) arrests uncontrolled malignant cell proliferation and tumor growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hematologic malignancies, or blood cancers, are classified according to the precursor cell type. A myeloid hematologic malignancy is a cancer that occurs in the myeloid hematopoietic progenitor cells, such as the precursor cells of red blood cells, platelets and certain myeloid white blood cells, such as granulocytes. Myeloid neoplasms include myeloproliferative neoplasms, MDS and AML. Examples of myeloproliferative neoplasms include chronic myeloid leukemia, essential thrombocythemia, or ET, polycythemia vera and MF. These myeloid neoplasms are different from lymphocytic malignancies which typically occur in the lymphoid cell progenitor lineage, such as precursor cells of T lymphocytes and B lymphocytes. Examples of lymphoid malignancies include acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphomas and multiple myeloma.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many myeloid hematologic malignancies, such as ET, MF and MDS, have been shown to arise from malignant stem and progenitor cells that express higher telomerase activity and have shorter telomeres when compared to normal healthy cells. In vitro studies have suggested that tumor cells with short telomeres may be especially sensitive to the anti&#8209;proliferative effects of inhibiting telomerase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imetelstat: The First Telomerase Inhibitor to Advance to Clinical Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat, our proprietary telomerase inhibitor which was discovered and developed at Geron, was designed to inhibit telomerase in malignant cells with continuously upregulated telomerase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat is a lipid conjugated 13&#8209;mer oligonucleotide that we designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat does not act as an antisense inhibitor of protein translation. The compound has a proprietary thio&#8209;phosphoramidate backbone, which is designed to provide resistance to the effect of cellular nucleases, thus conferring improved stability in plasma and tissues, as well as improved binding affinity to its target. To improve the ability of imetelstat to penetrate cellular membranes, we conjugated the oligonucleotide to a lipid group. Imetelstat&#8217;s IC50, or half maximal inhibitory concentration, is 3 &#8211; 9 nM in cell free assays. Single&#8209;dose pharmacokinetics in patients has shown dose&#8209;dependent increases in exposure to imetelstat, with a plasma half&#8209;life, which is the time it takes for the concentration or amount of imetelstat to be reduced by half, ranging from 4 &#8211; 5 hours. Data from animal studies and clinical trials have suggested that the residence time of imetelstat in bone marrow is long, with 0.19 &#8211; 0.51 &#181;M</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">observed at 41 &#8211; 45 hours after a 7.5 mg/kg dose in patients. Imetelstat also has been shown in non-clinical studies to exhibit relatively preferential inhibition of the clonal proliferation of malignant progenitor cells compared to normal progenitor cells. For these reasons, imetelstat has been studied as a potential treatment for malignant diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe imetelstat is the first telomerase inhibitor to advance to clinical development. The Phase 1 trials that we completed evaluated the safety, tolerability, pharmacokinetics and pharmacodynamic effects of imetelstat. We established doses and dosing schedules that were tolerable and achieved target exposures in patients that were consistent with those required for efficacy in animal models. Following intravenous administration of imetelstat using tolerable dosing regimens, clinically relevant and significant inhibition of telomerase activity was observed in various types of tissue in which telomerase activity is measurable, including normal bone marrow hematopoietic cells, malignant plasma cells, hair follicle cells and peripheral blood mononuclear cells. Dose&#8209;limiting toxicities included thrombocytopenia, or reduced platelet count, and neutropenia, or reduced neutrophil count.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imetelstat&#8217;s Potential Disease&#8209;Modifying Activity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that imetelstat may have the potential to suppress the proliferation of malignant stem and progenitor cells while transiently affecting normal cells. Early clinical data from a Phase 2 trial of imetelstat in patients with ET, or the ET Trial, and a pilot study of imetelstat in patients with MF conducted at Mayo Clinic, or the Pilot Study, suggested that imetelstat inhibits the progenitor cells of the malignant clones believed to be responsible for the underlying diseases in a relatively select manner, indicating potential disease-modifying activity. These data were published in two separate articles in a September 2015 issue of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pipeline Chart</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43612817_0.jpg" alt="img43612817_0.jpg" style="width:624px;height:293px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lower-Risk Myelodysplastic Syndromes (MDS)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MDS is a group of blood disorders in which the proliferation of malignant progenitor cells produces multiple malignant cell clones in the bone marrow resulting in disordered and ineffective production of the myeloid lineage, which includes red blood cells, white blood cells and platelets. In MDS, bone marrow and peripheral blood cells may have abnormal, or dysplastic, cell morphology. MDS is frequently characterized clinically by severe anemia, or low red blood cell counts, and low hemoglobin. In addition, other peripheral cytopenias, or low numbers of white blood cells and platelets, may cause life&#8209;threatening infections and bleeding. Transformation to AML occurs in up to 30% of MDS cases and results in poorer overall survival.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MDS is the most common of the myeloid malignancies. There are approximately 60,000 people in the U.S. living with the disease and approximately 16,000 reported new cases of MDS in the U.S. every year, according to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decision Resources Group, MDS Syndicated Report 2020, 2021, 2022. MDS is primarily a disease of the elderly, with median age at diagnosis around 70 years. The majority of patients, approximately 70%, fall into what are considered to be the lower-risk groups at diagnosis, according to the International Prognostic Scoring System that assigns relative risk of progression to AML and overall survival by taking into account the presence of a number of disease factors, such as cytopenias and cytogenetics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Chronic anemia is the predominant clinical problem in patients who have lower-risk MDS. Typically, these patients are treated with ESAs, such as erythropoietin, or EPO. Although ESAs provide an improvement in anemia in approximately 50% of patients, the effect is transient with a median duration of response of approximately two years. Once ESAs fail for patients, HMAs and lenalidomide have been used to improve anemia, but with limited success, such as reported &#8805; 8-week red blood cell transfusion independence, or RBC-TI, rates of 17% for azacitidine, an HMA, and 27% for lenalidomide in non-del5q lower-risk MDS patients. In August 2023, Reblozyl, or luspatercept, was approved for the treatment of anemia in adult patients with very low-to-intermediate-risk MDS without previous erythropoiesis stimulating agent use, or ESA-naive, who may require regular RBC transfusions. In April 2020, luspatercept was approved for use in a subgroup of ESA-failed lower-risk MDS patients &#8211; those with ringed sideroblasts. Such patients comprise approximately 15% to 30% of all lower-risk MDS patients. The majority of patients who do not have ringed sideroblasts or who no longer respond to ESAs or other available drug therapies become dependent on red blood cell transfusions due to low hemoglobin. Serial red blood cell transfusions can lead to elevated levels of iron in the blood and other tissues, which the body has no normal way to eliminate. Iron overload is a potentially dangerous condition. Published studies in patients with MDS have shown that iron overload resulting from regular red blood cell transfusions is associated with a poorer overall survival and a higher risk of developing AML.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 IMerge Trial in Lower-Risk MDS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMerge is a two-part Phase 2/3 clinical trial evaluating imetelstat (7.5 mg/kg dose administered as a two-hour intravenous infusion every four weeks) in transfusion dependent lower-risk MDS patients who are relapsed after, refractory to, or ineligible for prior treatment with an ESA. To be eligible for IMerge, patients were required to be transfusion dependent, defined as requiring at least four units of packed red blood cells, or RBCs, over an eight-week period during the 16 weeks prior to entry into the trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMerge Phase 3 is a double-blind, 2:1 randomized, placebo-controlled clinical trial that, based on discussions with U.S. and European regulatory authorities, was designed to support, if successful, the registration of imetelstat in transfusion dependent lower-risk MDS. The trial enrolled patients with transfusion dependent lower-risk MDS who were relapsed, or refractory to, or ineligible for ESA, had not received prior treatment with either a hypomethylating agent, or HMA, or lenalidomide and were non-del(5q). IMerge Phase 3 was conducted at 118 medical centers globally in 17 countries in North America, Europe, Middle East and Asia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary efficacy endpoint of IMerge Phase 3 was the rate of red blood cell transfusion independence, or RBC-TI, lasting at least eight weeks, defined as the proportion of patients without any RBC transfusions during any consecutive eight weeks since entry to the trial, or &#8805; 8-week TI. Key secondary endpoints for IMerge Phase 3 included the rate of RBC-TI lasting at least 24 weeks, or 24-week TI, and the rate of hematologic improvement erythroid, or HI-E, which is a rise in hemoglobin of at least 1.5 g/dL above the pretreatment level for at least eight weeks or a reduction of at least four units of RBC transfusions over eight weeks compared with the prior RBC transfusion burden. Other secondary endpoints included the time to and duration of RBC-TI; the proportion of patients achieving Complete Response, or CR, or Partial Response, or PR, according to the 2006 International Working Group, or IWG, criteria for MDS; the proportion of patients requiring RBC transfusions and the transfusion burden; the proportion of patients requiring the use of myeloid growth factors and the dose; assessments of the change in the patients&#8217; quality of life using several validated instruments; as well as an assessment of OS, and time to progression to AML.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we reported positive top-line results from IMerge Phase 3. Additional data were subsequently published at the European Hematology Association Annual Meeting in June 2023, the American Society of Hematology Annual Meeting in December 2023, and in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Lancet</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in December 2023, as summarized below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A total of 178 patients were enrolled in IMerge Phase 3, with patients randomized on a 2:1 basis to imetelstat (n=118) or placebo (n=60), including patients with a broad range of lower-risk MDS subtypes and with high disease burden.  The trial met its primary endpoint of &#8805; 8-week TI rate and key secondary endpoint of 24-week TI rate, among others, demonstrating statistically significant and clinically meaningful results with imetelstat versus placebo with no new safety signals and safety results consistent with prior imetelstat clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Durability of TI and response rates were significantly higher with imetelstat versus placebo, as summarized below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43612817_1.jpg" alt="img43612817_1.jpg" style="width:624px;height:351px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, highly statistically significant (p&lt;0.001) increase in hemoglobin levels over time were observed for imetelstat patients as shown in the graph below. For patients achieving &#8805; 8-week TI, median increases in hemoglobin were 3.6 g/dL for imetelstat and 0.8 g/dL for placebo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43612817_2.jpg" alt="img43612817_2.jpg" style="width:547px;height:375px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A statistically significant decrease in the number of RBC units transfused was achieved for imetelstat treated patients versus placebo, as shown in the graph below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43612817_3.jpg" alt="img43612817_3.jpg" style="width:624px;height:381px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, as shown in the table below, statistically significant &#8805; 8-week RBC-TI rates were observed with imetelstat versus placebo across lower-risk MDS subtypes (p&lt;0.05) and similar &#8805; 8-week RBC-TI rates were observed for imetelstat within each subtype category in comparison to the overall population.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.469%;"/>
    <td style="width:21.429%;"/>
    <td style="width:18.367%;"/>
    <td style="width:23.469%;"/>
    <td style="width:13.265%;"/>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Imetelstat, n (%)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo, n (%)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Difference (95% CI)</span></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">P-value*</span></p></td>
   </tr>
   <tr style="height:14.25pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Overall</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47/118 (39.8)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9/60 (15.0)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.8 (9.9, 36.9)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&lt;0.001</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WHO category</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.25pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;RS+</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33/73 (45.2)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/37 (18.9)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3 (5.9, 42.2)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.016</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;RS-</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14/44 (31.8)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/23 (8.7)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1 (-1.3, 40.6)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.038</span></p></td>
   </tr>
   <tr style="height:14.25pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Transfusion burden</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;4-6 units</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28/62 (45.2)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7/33 (21.2)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.9 (1.9, 41.4)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.027</span></p></td>
   </tr>
   <tr style="height:14.25pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&gt;6 units</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19/56 (33.9)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2/27 (7.4)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.5 (4.7, 41.8)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.023</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IPSS risk category</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:14.25pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Low</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32/80 (40.0)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8/39 (20.5)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5 (-0.1, 35.2)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.034</span></p></td>
   </tr>
   <tr style="height:14.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Intermediate-1</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15/38 (39.5)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1/21 (4.8)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34.7 (8.8, 52.4)</span></p></td>
    <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.004</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">_________________</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">*      Cochran Mantel Haenszel test stratified for prior RBC transfusion burden (&#8804;6 units or &gt;6 units of RBCs/8 weeks) and baseline IPSS risk score (Low or Intermediate-1)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical and molecular evidence supporting the potential for disease modification with imetelstat includes a one-year median TI duration for imetelstat &#8805; 8-week TI responders, a median rise of 3.6 g/dL in hemoglobin levels in those same patients and </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&gt;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50% variant allele frequency decreases in SF3B1, TET2, DNMT3A and ASXL1 mutations, as shown in the graph below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img43612817_4.jpg" alt="img43612817_4.jpg" style="width:624px;height:351px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The safety results in IMerge Phase 3 were consistent with prior clinical trials of imetelstat in hematologic malignancies, and no new safety signals were identified. The most frequent non-hematologic toxicities occurring in &#8805;10% of patients on either imetelstat or placebo arms are listed in the table below. Grade 3 elevations in liver function tests, or LFTs, on imetelstat were short in duration (median &lt; 2 weeks) and more than 80% resolved to Grade 2 or lower within 4 weeks, with no cases of liver test elevations consistent with Hy&#8217;s Law or Drug Induced Liver Injury.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:41.412%;"/>
    <td style="width:15.157%;"/>
    <td style="width:14.137%;"/>
    <td style="width:15.157%;"/>
    <td style="width:14.137%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AE, n (%)</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Imetelstat</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(n=118)</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(n=59)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Grades</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grade 3/4</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Grades</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grade 3/4</span></p></td>
   </tr>
   <tr style="height:1.3pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asthenia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22 (18.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8 (13.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">COVID-19*</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21 (17.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2 (1.7)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (15.2)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (5.1)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Peripheral edema</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13 (11.0)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8 (13.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Headache</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15 (12.7)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (0.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (5.1)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Diarrhea</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.01in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;14 (11.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (0.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 (11.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (1.7)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Alanine aminotransferase increased</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14 (11.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (2.5)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4 (6.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2 (3.4)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hyperbilirubinemia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11 (9.3)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (0.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6 (10.2)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (1.7)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Constipation</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (7.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 (11.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
   <tr style="height:1.3pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pyrexia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (7.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2 (1.7)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 (11.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> _________________</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">*    Includes COVID-19, asymptomatic COVID-19, COVID-19 pneumonia</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The most frequent hematologic toxicities are listed in the table below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:41.412%;"/>
    <td style="width:15.157%;"/>
    <td style="width:13.997%;"/>
    <td style="width:15.297%;"/>
    <td style="width:14.137%;"/>
   </tr>
   <tr style="height:1.3pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AE, n (%)</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Imetelstat</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(n=118)</span></p></td>
    <td colspan="2" style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(n=59)</span></p></td>
   </tr>
   <tr style="height:1.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Grades</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grade 3/4</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Grades</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grade 3/4</span></p></td>
   </tr>
   <tr style="height:1.3pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thrombocytopenia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89 (75.4)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73 (61.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6 (10.2)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 (8.5)</span></p></td>
   </tr>
   <tr style="height:1.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Neutropenia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87 (73.7)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80 (67.8)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4 (6.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2 (3.4)</span></p></td>
   </tr>
   <tr style="height:1.3pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Anemia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24 (20.3)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23 (19.5)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6 (10.2)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4 (6.8)</span></p></td>
   </tr>
   <tr style="height:1.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leukopenia</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12 (10.2)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9 (7.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (1.7)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical consequences from cytopenias were low and similar between imetelstat and placebo groups as shown in the table below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48.81%;"/>
    <td style="width:27.714%;"/>
    <td style="width:23.476%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Event, n (%)</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Imetelstat</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(n=118)</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(n=59)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grade </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&gt;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 bleeding events*</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 (2.5)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (1.7)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grade </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&gt;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 infections+</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13 (11.0)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8 (13.6)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Grade febrile neutropenia**</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1 (0.8)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">_________________</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">*     No &#8805;Grade 3 bleeding events in the setting of Grade 3/4 thrombocytopenia; on imetelstat: two patients with Grade 4 gastrointestinal bleeding, unrelated and resolved and one Grade 3 hematuria, unrelated and resolved</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">+     On imetelstat: three patients with Grade 3/4 infections in setting of Grade 3/4 neutropenia; all three were sepsis and resolved with only one considered related</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">**   Occurred at day 33, lasted 8 days; assessed by investigator as possibly related to imetelstat; patient subsequently achieved TI &gt;40 weeks and remains on treatment at data cut-off</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, as shown in the table below, the median duration of cytopenias was shorter for imetelstat versus placebo and the percentage that resolved to &#8804;  Grade 2 within 4 weeks was higher for imetelstat versus placebo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48.81%;"/>
    <td style="width:27.714%;"/>
    <td style="width:23.476%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Imetelstat</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Thrombocytopenia events*</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Median duration, weeks, (range)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4 (0.1-12.6)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0 (0.3-11.6)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Resolved within &lt;4 weeks, %</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.3</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44.4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Neutropenia events*</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Median duration, weeks, (range)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9 (0-15.9)</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2 (1.0-4.6)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Resolved within &lt;4 weeks, %</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81.0</span></p></td>
    <td style="padding-top:0.05in;border-right:0.5pt solid #000000;padding-left:0.1in;vertical-align:top;padding-bottom:0.05in;border-bottom:0.5pt solid #000000;padding-right:0.1in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">_________________</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">+     18% of imetelstat treated patients received a median of 1 platelet transfusions; 35% of imetelstat treated patients received growth factor support</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">*     Analysis performed for patients who experienced Grade 3/4 cytopenias. Resolution determined by return to Grade 2 or lower</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat AEs were manageable with dose modifications. Most AEs leading to dose modifications were grade 3&#8211;4 neutropenia or thrombocytopenia, and 74% of patients treated with imetelstat had dose modifications due to AEs. Only less than 15%  of patients discontinued treatment due to treatment emergent AEs, or TEAEs. Imetelstat discontinuation due to TEAE generally occurred late in treatment (21.1 weeks median time to treatment discontinuation; range, 2.3 to 44.0 weeks).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Myelofibrosis (MF)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MF, a type of myeloproliferative neoplasm, is a chronic blood cancer in which abnormal or malignant precursor cells in the bone marrow proliferate rapidly, causing scar tissue, or fibrosis, to form. As a result, normal blood production in the bone marrow is impaired and may shift to other organs, such as the spleen and liver, which can cause them to enlarge substantially. People with MF may have abnormally low or high numbers of circulating RBCs, white blood cells or platelets, and abnormally high numbers of immature cells in the blood or bone marrow. MF patients can also suffer from debilitating constitutional symptoms, such as drenching night sweats, fatigue, severe itching, or pruritus, abdominal pain, fever and bone pain. There are approximately 13,000 patients living with MF in the U.S. and approximately 3,000 reported new cases each year, according to Decision Resources Group, Niche and Rare Disease Landscape &amp; Forecast 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approximately 70% of MF patients are classified as having Intermediate&#8209;2 or High-risk disease, as defined by the Dynamic International Prognostic Scoring System Plus described in a 2011 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Clinical Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> article. Drug therapies currently approved by the FDA and other regulatory authorities for treating these MF patients include JAK inhibitors, ruxolitinib and fedratinib, as well as pacritinib, a kinase inhibitor. Currently, no drug therapy is approved for those patients who fail or no longer respond to JAK inhibitor treatment, and median survival for MF patients after discontinuation from ruxolitinib is only approximately 14&#8211;16 months, representing a significant unmet medical need.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IMpactMF: Ongoing Phase 3 Clinical Trial in Relapsed/Refractory MF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trial Design</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMpactMF, our Phase 3 clinical trial in relapsed/refractory MF, is an open label, 2:1 randomized, controlled clinical trial designed to evaluate imetelstat (9.4 mg/kg administered by intravenous infusion over two hours every three weeks) in approximately 320 patients. Patients relapsed after or refractory to a JAK inhibitor are defined as having an inadequate spleen response or symptom response after treatment with a JAK inhibitor for at least six months, including an optimal dose of a JAK inhibitor for at least two months. The best available therapy, or BAT, control arm of IMpactMF excludes the use of JAK inhibitors. With respect to the trial design for IMpactMF, the FDA urged us to consider adding a third dosing arm to assess a lower dose and/or a more frequent dosing schedule that might improve the planned trial&#8217;s chance of success by identifying a less toxic regimen and/or more effective spleen response, one of the trial&#8217;s secondary endpoints. Based on data from IMbark, we believe that testing a lower dose regimen would likely result in a lower median OS, which is the trial&#8217;s primary endpoint, in the imetelstat treatment arm. We believe existing data also suggest that lowering the dose would not result in a clinically meaningful reduction in toxicity. For these reasons, we therefore determined not to add a third dosing arm to the trial design, and the FDA did not object to our proposed imetelstat dose and schedule of 9.4 mg/kg every three weeks. Our belief may ultimately be incorrect. Therefore, our failure to add a third dosing arm could result in a failure to maintain regulatory clearance from the FDA and similar international regulatory authorities, could result in the trial&#8217;s failure, or could otherwise delay, limit or prevent marketing approval of imetelstat for relapsed/refractory MF by the FDA or similar international regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary efficacy endpoint for IMpactMF is OS. Key secondary endpoints include symptom response; spleen response; progression free survival; complete remission, partial remission or clinical improvement, as defined by the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria; duration of response; safety; pharmacokinetics; and patient reported outcomes. There are IMpactMF sites across North America, South America, Europe, Australia and Asia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMpactMF is designed with &gt;85% power to detect a 40% reduction in the risk of death (hazard ratio=0.60; one-sided alpha=0.025). The final analysis for OS is planned to be conducted after more than 50% of the patients planned to be enrolled in the trial have died (referred to as an event). An interim analysis of OS, in which the alpha spend is expected to be approximately 0.01, is planned to be conducted after approximately 70% of the total projected number of events (deaths) for the final analysis have occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Status of IMpactMF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMpactMF opened for patient screening and enrollment in December 2020. As of December 31, 2023, we had all 180 selected sites open for patient enrollment, and we are continuing to evaluate potential additional sites. In November 2023, the trial reached 50% enrollment. Based on our planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the first half of 2025 and the final analysis may occur in the first half of 2026. Because these analyses are event-driven and it is uncertain whether actual rates for enrollment and events will reflect current planning assumptions, the results may be available</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at different times than currently expected. At the interim analysis, if the pre-specified statistical OS criterion is met, then we expect such data may potentially support the registration of imetelstat in relapsed/refractory MF. Subject to protocol-specified stopping rules for futility, if the pre-specified OS criterion is not met at the interim analysis, the trial will continue to the final analysis, which is expected to occur approximately one year later.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The timing and achievement of either or both of the planned analyses depend on numerous factors. In addition, our ability to enroll, conduct and complete IMpactMF depends on whether we can obtain and maintain the relevant clearances from regulatory authorities and other institutions to enroll, conduct and complete the trial, and our ability to raise additional capital in order to complete the trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Improvement in Overall Survival and Potential Disease-Modifying Activity Observed in IMbark Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IMbark Phase 2 clinical trial was designed to evaluate two dosing regimens of imetelstat (either 4.7 mg/kg or 9.4 mg/kg administered by intravenous infusion every three weeks) in patients with relapsed/refractory MF. The co-primary efficacy endpoints for IMbark were spleen response rate, defined as the proportion of patients who achieve a reduction of at least 35% in spleen volume as assessed by imaging, and symptom response rate, defined as the proportion of patients who achieve a reduction of at least 50% in Total Symptom Score, at 24 weeks. Key secondary endpoints were OS and safety.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We previously reported efficacy and safety results from the IMbark Phase 2 clinical trial, including median OS of 28.1 months for patients on the high dose arm of the study, which is almost twice the reported median OS of 14&#8211;16 months in medical literature. To evaluate this potential benefit, we conducted a post-hoc analysis of OS for patients treated with imetelstat 9.4 mg/kg in IMbark compared to OS calculated from real world data, or RWD, collected at the Moffitt Cancer Center for patients who had discontinued treatment with ruxolitinib, a JAK inhibitor, and who were subsequently treated with BAT. To make a comparison between the IMbark data and RWD, a cohort from the real-world dataset was identified that closely matched the IMbark patients, using guidelines for inclusion and exclusion criteria as defined in the IMbark clinical protocol, such as platelet count and spleen size. Calculations from two propensity score analysis approaches resulted in a median OS of 30.7 months for the imetelstat-treated patients from IMbark, which is more than double the median OS of 12.0 months using RWD for patients treated with BAT. These analyses also showed a 65% &#8211; 67% lower risk of death for the imetelstat-treated patients vs. BAT-treated patients. We believe these analyses suggest potentially longer OS for imetelstat-treated relapsed/refractory MF patients in IMbark, compared to BAT in closely-matched patients from RWD. However, comparative analyses between RWD and our clinical trial data have several limitations. For instance, the analyses create a balance between treatment groups with respect to commonly available covariates, but do not take into account the unmeasured and unknown covariates that may affect the outcomes of the analyses. Potential biases are introduced by factors which include, for example, the selection of the patients included in the analyses, misclassification in the matching process, the small sample size, and estimates that may not represent the outcomes for the true treated patient population. For these and other reasons, such comparative analyses and any conclusions from such analyses should be considered carefully and with caution, and should not be relied upon as demonstrative or otherwise predictive or indicative of any current or potential future clinical trial results of imetelstat in relapsed/refractory MF, including IMpactMF.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In IMbark, patients also experienced other positive clinical outcomes, including symptom improvement, spleen reduction and bone marrow fibrosis improvement. In June 2020, we reported correlation analyses from IMbark that showed a trend of longer OS in patients who achieved symptom response, spleen volume reductions and improved bone marrow fibrosis, in a dose-dependent manner. Furthermore, the reductions in the variant allele frequency of key driver mutations in MF and the improvement in bone marrow fibrosis observed in IMbark have also been correlated to the improvement in OS. We believe the improvement in bone marrow fibrosis, potential survival benefit, molecular data and correlations from IMbark provide strong evidence of the potential for disease modification with imetelstat, which we believe differentiates imetelstat from currently approved treatments for MF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The safety results observed in IMbark were consistent with prior clinical trials of imetelstat in hematologic malignancies, and no new safety signals were identified. In the 9.4 mg/kg arm, reversible and manageable Grade 3/4 thrombocytopenia and neutropenia were reported in 24/59 patients (41%) and 19/59 patients (32%), respectively, without significant clinical consequences. 1/59 patients (2%) had Grade 3 febrile neutropenia. 3/59 patients (5%) had Grade 3/4 bleeding. 6/59 patients (10%) had Grade 3/4 infections. Furthermore, more than 70% of the observed Grade 3/4 cytopenias resolved to Grade 2 or lower by laboratory assessment within four weeks.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Indications</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMproveMF: Phase 1 Combination Clinical Trial in Frontline Myelofibrosis (Frontline MF)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMproveMF is a two-part Phase 1 clinical trial evaluating imetelstat in combination with ruxolitinib in patients with frontline MF. The trial is designed to use a Bayesian Optimal Interval design to test various doses of imetelstat in an escalating dose sequence with a defined number of patients per dosing arm. Escalation to the next higher dosing arm will only occur if the prior dose is tolerable to the patients. The primary objective of the first part of IMproveMF is to identify a recommended dosing regimen for further evaluation. Up to 20 patients are expected to be enrolled into the first part of IMproveMF, or IMproveMF Part 1. The first patient was dosed in IMproveMF in August 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon identification of a tolerable dosing regimen for the combination treatment of imetelstat and ruxolitinib, the second part of IMproveMF, or IMproveMF Part 2, is planned to evaluate the efficacy and further evaluate the safety of that dosing regimen. Under IMproveMF Part 2, the primary endpoints are safety and symptom response rate, defined as the proportion of patients who achieve a </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&gt;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50% reduction in Total Symptom Score at 24 weeks. Secondary endpoints include change in fibrosis; spleen response rate, defined as the proportion of patients who achieve a </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&gt;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35% reduction in spleen volume from baseline as assessed by imaging; and the number of patients achieving complete remission, partial remission or clinical improvement, as defined by the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria. Up to 20 patients are expected to be enrolled into the IMproveMF Part 2.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, the Safety Evaluation Team, or SET, for IMproveMF evaluated patient data from the second cohort of patients enrolled in IMproveMF. No dose-limiting toxicities were identified, and the SET made a decision to escalate to the third dose cohort, effective immediately.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMpress: Investigator-Led Phase 2 Clinical Trial in Higher Risk Myelodysplastic Syndromes (Higher Risk MDS) and Acute Myeloid Leukemia (AML)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In collaboration with investigators in Germany, France and Australia, we are supporting IMpress, an investigator-led study of imetelstat in patients with higher risk MDS and relapsed/refractory AML, post-treatment with a hypomethylating agent, or HMA. The first patient in the IMpress study was dosed in June 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IMpress is an open-label, single arm, Phase 2 clinical trial being conducted at three clinical sites. The primary endpoint is overall response rate per criteria from the 2018 International Working Group for MDS and the European LeukemiaNet for AML. Secondary endpoints include safety, duration of response, progression-free survival and overall survival. In addition, pending the results of IMpress, we plan to support a Phase 1/2 investigator-led study, called TELOMERE, in relapsed/refractory AML, using a combination approach of imetelstat and venetoclax or azacitidine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Lymphoid Hematologic Malignancies</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Academic research data suggests that certain lymphoid hematologic malignancies have higher telomerase activity and shorter telomeres when compared to normal healthy cells. Thus, we believe a telomerase inhibition approach may have utility in this disease setting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on this scientific hypothesis, we initiated a preclinical research project with MD Anderson Cancer Center to determine the potential application of imetelstat in lymphoid hematologic malignancies. Preliminary results from this research were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Blood</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in November 2022. Based on early results, we plan to collaborate further with MD Anderson Cancer Center to conduct preclinical research to assess the potential therapeutic effect of imetelstat in lymphoid malignancies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Generation Telomerase Inhibitor Discovery</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have initiated a discovery program to identify lead compounds as a potential next generation oral telomerase inhibitor. If the leads we have identified are optimized, we may conduct preclinical experiments that may serve as a basis for potential future clinical testing. Discovery research is an uncertain and unpredictable process. As such, the timing and nature of any results from this discovery effort are difficult to forecast. If we optimize lead compounds from this discovery program, we expect to provide an update on our efforts at that time.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual property, including patent protection, is very important to our business. We file patent applications in the U.S. and other jurisdictions, and we also rely on trade secret protection and contractual arrangements to protect aspects of our business. An enforceable patent with appropriate claim coverage can provide an advantage over competitors who may seek to employ similar approaches to develop therapeutics, and so the future commercial success of imetelstat, and therefore our future success, will be in part dependent on our intellectual property strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our intellectual property strategy includes the early development of a technology, such as imetelstat, followed by rounds of increasingly focused innovation around a product opportunity, including identification and definition of a specific product candidate and uses thereof, manufacturing processes, product formulation and methods of treatment and administration. The result of this process is that products in development are often protected by several families of patent filings that are filed at different times during the development process and cover different aspects of the product. Consequently, earlier filed, broad technology patents will usually expire ahead of patents covering later developments, such as product formulations and methods of treatment and administration, so that patent expirations on a product may span several years. Patent coverage may also vary from country to country based on the scope of available patent protection. There are also opportunities to obtain an extension of patent coverage for a product in certain countries, which adds further complexity to the determination of patent life.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may endeavor to monitor worldwide patent filings by third parties that are relevant to our business. Based on this monitoring, we may determine that an action is appropriate to protect our business interests. Such actions may include negotiating patent licenses where appropriate, filing oppositions against a patent, filing a request for post grant review against a patent or filing a request for the declaration of an interference with a patent application or issued patent.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information provided in this section should be reviewed in the context of the section entitled &#8220;Risks Related to Protecting Our Intellectual Property&#8221; described in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imetelstat</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have global rights to imetelstat. We own issued patents related to imetelstat in the U.S., Europe and other countries. Composition of matter patents generally provide the most material coverage, and therefore may convey competitive advantages. Because imetelstat is still under development, subsequent innovation and associated patent filings may provide additional patent coverage with later expiration dates. Examination of overseas patent applications typically lags behind U.S. examination, particularly where cases are filed first in the U.S. It may be possible to obtain patent term extensions of some patents in some countries for claims covering imetelstat, which could further extend the patent term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have issued patents in the U.S., Europe and other countries that provide patent coverage into 2033 pertaining to the treatment of MF and MDS with imetelstat. We also hold issued patents in the U.S., Europe and other countries covering imetelstat composition of matter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., our composition of matter patent coverage extends until December 2025, and our method of treatment patent rights for MDS and MF expire in March 2033. Under the provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (as amended), or the Hatch-Waxman Act, upon receipt of drug product approval, potential patent term extensions, if any, may be available to extend the patent term of either our composition of matter patent or our method of treatment patent for MDS in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe and other countries, our composition of matter patent coverage expires in September 2024, and our method of treatment patent rights for MDS and MF expire in November 2033. One of our patents in each member country of the European Patent Convention may be eligible for patent term extension under a Supplementary Protection Certificate, or SPC, permitted under European Council (EC) Regulation No. 469/2009, or the European SPC Regulation, upon receipt of drug product approval, such as, for example, our method of treatment patent for MDS. Our patent rights relating to imetelstat also include reagents useful in manufacturing processes for the drug, and method of treatment and kit claims, certain of which are co&#8209;owned with other entities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If regulatory approval of imetelstat occurs after a patent has expired, we may be unable to obtain any patent term extension of that expired patent, and the scope of our patent rights will be limited. In addition, should we seek a patent term extension, we may not be granted any such patent term extension and/or the applicable time period of such patent term extension could be less than five years. Moreover, in some countries, including the U.S., the scope of protection for claims under such patent term extensions, if any, does not extend to the full scope of the claims but</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is limited to the product composition as approved. Thus, if we receive drug product approval in the U.S. for imetelstat in lower-risk MDS in the first half of 2024, we may potentially extend the term of our product composition claims in the U.S. for a maximum of five years until December 2030, subject to U.S. Patent and Trademark Office, or USPTO, approval. If we do not receive a patent term extension for our U.S. composition of matter patent for imetelstat, our U.S. composition of matter patent will expire in December 2025.If we receive drug product approval in Europe for imetelstat in lower-risk MDS in the first half of 2025, we may potentially extend the term of our patents in the EEA for the method of treatment of MDS for a maximum of five years, from November 2033 until November 2038, subject to European Patent Office approval. Since we do not expect to receive marketing approval and submit a request for an SPC before September 2024, our European composition of matter patents will expire in countries of the European Economic Area, or EEA, and we must rely on regulatory exclusivity and our method of treatment patents. If we do not have sufficient patent life to protect imetelstat, our financial results, business and business prospects, and the future of imetelstat would be materially and adversely affected, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the effective date of termination of the license and collaboration agreement, or the Prior Collaboration Agreement, with Janssen Biotech, Inc., or Janssen, on September 28, 2018, we regained global rights to imetelstat and are continuing development of imetelstat on our own. In accordance with the termination provisions of the Prior Collaboration Agreement, we have an exclusive worldwide license for intellectual property developed under the Prior Collaboration Agreement for the further development of imetelstat, without any economic obligations to Janssen with respect to such license. Janssen has assigned to us certain intellectual property developed by it under the Prior Collaboration Agreement. We now are responsible for the costs of maintaining, prosecuting and litigating all imetelstat intellectual property that we own.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Exclusivity and Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a drug to qualify for orphan drug designation by the FDA, both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act, or ODA, and FDA&#8217;s implementing regulations. Orphan drug designation is granted by the FDA&#8217;s Office of Orphan Drug Products in order to support development of medicines for underserved or rare diseases and patient populations that affect fewer than 200,000 people in the U.S. or, if the disease or condition affects more than 200,000 individuals annually in the U.S., if there is no reasonable expectation that the cost of developing and making the drug would be recovered from sales in the U.S. Orphan drug designation qualifies the sponsor of the drug for various development incentives of the ODA, including, if regulatory approval is received, the potential for seven years of market exclusivity with certain limited exceptions and certain tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan drug designation is not subject to a prescription drug user fee unless the application includes an indication for a disease or condition other than the rare disease or condition for which the drug was granted orphan drug designation. The granting of orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. The safety and effectiveness of a drug must be established through adequate and well&#8209;controlled studies. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2015 and December 2015, the FDA granted orphan drug designation to imetelstat for the treatment of MF and MDS, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., under the Hatch-Waxman Act, upon drug product approval a new chemical entity is entitled to four years of data exclusivity and one year of market exclusivity, conferring a total of five years exclusivity, or NCE exclusivity, for the first-approved indication. Thus, if we receive drug product approval for imetelstat in lower-risk MDS in the first half of 2024, we expect that we will receive exclusivity in lower-risk MDS under the Hatch-Waxman Act until the first half of 2029. In addition, under the Orphan Drug Act of 1983, orphan drug designation confers market exclusivity in the designated indication for seven years after drug product approval. Thus, if we receive drug product approval for imetelstat in the U.S. for imetelstat in lower-risk MDS in the first half of 2024, we anticipate that we may receive market exclusivity under the Orphan Drug Act of 1982 in the U.S. until the first half of 2031.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, a six-month pediatric extension may be available in the U.S. pursuant to the FDA Safety and Innovation Act of 2012, to the longest extension or exclusivity period available under any of the NCE exclusivity period, the orphan drug exclusivity period and a patent term extension.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe, orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life&#8209;threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union, or EU, and where no satisfactory treatment is available. In the EU, orphan drug designation also entitles a party to financial incentives such as reduction of fees or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fee waivers, as well as protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure. In addition, ten years of market exclusivity is granted following drug product approval, meaning that another application for marketing authorization of a later similar medicinal product for the same therapeutic indication will generally not be approved in the EU. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable to not justify maintenance of market exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2015 and July 2020, the EMA granted orphan drug designation to imetelstat for the treatment of MF and MDS, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe, under the European Union Data Exclusivity Directive 2004/27/EC, upon drug product approval a new medicinal product is entitled to eight years of data exclusivity and two years of market exclusivity, conferring a total of ten years of exclusivity for the first-approved indication. Thus, if we receive drug product approval in Europe for imetelstat in lower-risk MDS in the first half of 2025, we anticipate receiving a total of ten years of exclusivity for lower-risk MDS, until the first half of 2035. Separately, orphan drug designation under the European Union Orphan drug regulation (EC) No. 141/2000 confers market exclusivity for ten years following drug product approval for each of the orphan disease indications. Thus, if we receive drug product approval in Europe for imetelstat in lower-risk MDS in the first half of 2025 and we maintain orphan drug designation, we anticipate that we may receive market exclusivity in Europe for imetelstat in lower-risk MDS until the first half of 2035. In addition, if we fulfill the pediatric investigation plan agreed upon with the European Medicines Agency, such market exclusivity may be extended for an additional two years under the European Pediatric Regulation, which may enable us to receive market exclusivity in Europe for imetelstat in lower-risk MDS for an additional two years, until the first half of 2037. Further, if we receive drug product approval in Europe for imetelstat for relapsed/refractory MF, and we maintain orphan drug designation, we anticipate that we may receive ten years exclusivity in Europe for relapsed/refractory MF following drug product approval.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fast Track Designation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast Track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review. Fast Track designation is intended to facilitate and expedite development and review of an NDA to address unmet medical needs in the treatment of serious or life-threatening conditions. However, Fast Track designation does not accelerate conduct of clinical trials or mean that the regulatory requirements are less stringent, nor does it ensure that imetelstat will receive marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data emerging from the imetelstat clinical development program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2017, the FDA granted Fast Track designation to imetelstat for the treatment of adult patients with transfusion-dependent anemia due to lower-risk MDS who do not have a deletion 5q chromosomal abnormality, also known as non-del(5q), and who are refractory or resistant to treatment with an erythropoiesis stimulating agent, or ESA (i.e., the treatment population in IMerge Phase 3).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2019, the FDA granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-Risk MF whose disease has relapsed after or is refractory to JAK inhibitor treatment (i.e., the treatment population in IMpactMF).</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Licensing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no material license agreements.  We have global rights to imetelstat, which was discovered and developed at Geron.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A typical sequence of steps in the manufacture of imetelstat drug product includes the following key components:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">starting materials, which are well&#8209;defined raw materials that are used to make bulk drug substance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bulk drug substance, which is the active pharmaceutical ingredient in a drug product that provides pharmacological activity or other direct effect in the treatment of disease; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">final drug product, which is the finished dosage form that contains the drug substance that is shipped to the clinic for patient treatment.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since September 2018, we have engaged third&#8209;party contract manufacturers and have re-established our own manufacturing supply chain to manufacture and supply additional quantities of imetelstat that meet applicable regulatory standards for current and potential future clinical trials and potential commercial uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have direct control over third&#8209;party personnel or operations. These third&#8209;party contract manufacturers, and/or any other third parties that we may rely upon for the manufacture and/or supply of imetelstat, typically complete their services on a proposal by proposal basis under master supply agreements and may need to make substantial investments to enable sufficient capacity increases and cost reductions, and to implement those regulatory and compliance standards necessary for successful Phase 3 clinical trials and commercial production. These third&#8209;party contract manufacturers, and/or any other third parties that we may rely upon for the manufacture and/or supply of imetelstat, may not be able to achieve such capacity increases, cost reductions, or regulatory and compliance standards, and even if they do, such achievements may not be at a commercially reasonable cost. We are responsible for establishing any long&#8209;term commitments or commercial supply agreements with any of the third&#8209;party contract manufacturers for imetelstat. The information provided in this section should be reviewed in the context of the section entitled &#8220;Risks Related to Manufacturing Imetelstat&#8221; under Part I, Item 1A, &#8220;Risk Factors&#8221; of this annual report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by intense and dynamic competition with rapidly advancing technologies and a strong emphasis on proprietary products. While we believe our proprietary oligonucleotide chemistry; experience with the biological mechanisms related to imetelstat, telomeres and telomerase; clinical data to date indicating potential disease-modifying activity with imetelstat treatment; and knowledge and expertise around the development of potential treatments for myeloid hematologic malignancies provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Imetelstat will compete, if approved, with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware of.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competition in Lower-Risk MDS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current standard of care for the treatment of lower-risk MDS is the use of ESAs to address the patient&#8217;s chronic anemia. Once ESAs are no longer effective, serial blood transfusions are often administered that can cause damaging effects to other organs due to iron overload, resulting in shorter survival. In addition, other best available therapies are used without durable effect for the patient.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In lower-risk MDS, positive top-line results from IMerge Phase 3 describe potentially meaningful and durable transfusion independence, activity across MDS patient subtypes, and potential disease-modifying activity achievable with imetelstat treatment. We believe that these key features are differentiators compared to currently approved products as well as investigational drugs currently in clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved for commercial sale for the treatment of lower-risk MDS, imetelstat would compete against a number of currently existing therapies, including ESAs and other hematopoietic growth factors that are indicated for anemia; immunomodulators, such as Revlimid (lenalidomide) by Celgene Corporation, or Celgene, a Bristol Myers Squibb Company, or BMS, company; hypomethylating agents, such as Vidaza (azacitidine) by Celgene and manufacturers of generic azacitidine; Dacogen (decitabine) by Otsuka America Pharmaceutical, Inc. and other manufacturers in the U.S. and Janssen in the EU; Inqovi (oral combination of decitabine and cedazuridine) by Astex Pharmaceuticals, Inc., or Astex; and Reblozyl (luspatercept), a TGF-beta inhibitor, by Acceleron Pharma, Inc., or Acceleron (acquired by Merck &amp; Co., Inc., or Merck, in November 2021), in collaboration with Celgene. In August 2023, BMS announced that luspatercept was also approved for the treatment of anemia in ESA-naive adult patients with very low-to intermediate-risk MDS who may require regular RBC transfusions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other therapies currently in Phase 3 development in lower-risk MDS, some of which may obtain regulatory approval earlier than imetelstat include roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, by FibroGen, Inc; Onureg (oral azacytidine) by BMS; and Hengqu (hetrombopag), an oral nonpeptide thrombopoietin receptor agonist, by Jiangsu Hengrui Pharmaceuticals Co., Ltd.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there are multiple Phase 1 and Phase 2 clinical trials of other agents being developed for lower-risk MDS, including but not limited to: LB&#8208;100, a PP2A inhibitor, by Lixte Biotechnology Holdings, Inc.; bemcentinib, an AXL inhibitor, by BerGenBio ASA; H3B&#8208;8800, a spliceosome inhibitor, by H3 Biomedicine, Inc.; KER-050, a TGF-beta inhibitor, by Keros Therapeutics, Inc., or Keros Therapeutics; TP-0184, an inhibitor of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALK2 or ACVR1 kinase, by Sumitomo Dainippon Pharma Oncology, Inc; ilginatinib (NS-018), a JAK2 inhibitor, by NS Pharma, Inc., a U.S. subsidiary of Nippon Shinyaku Co., Ltd., or NS Pharma; a lower dose of ASTX727, an oral formulation of decitabine and cedazuridine, referred to as ASTX727 LD, by Astex; ASTX030, an oral formulation of azacitidine and cedazuridine, by Astex; R289, an oral inhibitor of interleukin receptor-associated kinases 1 and 4, or IRAK1/4, by Rigel Pharmaceuticals, Inc.; a combination treatment regimen of luspatercept and lenalidomide by BMS; roxadustat, a combination treatment of hypoxia-inducible factor prolyl hydroxylase inhibitor, by FibroGen, Inc. with luspatercept by BMS; and HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, by BMS and etavopivat, an oral, small molecule activator of erythrocyte pyruvate kinase (PKR) by Forma Therapeutics, Inc., a Novo Nordisk Company; canakinumab, an interleukin antagonist, by Novartis AG; and AG946, a next-generation pyruvate kinase-R (PKR) activator, by Agios Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competition in Relapsed/Refractory MF</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current standard of care for the treatment of Intermediate-2 or High-risk MF is the use of JAK inhibitors, to address the patient&#8217;s symptoms. Once JAK inhibitors fail or are no longer effective, a variety of best available therapies are used since there are no approved treatments for this patient population and median OS is 14 to 16 months after discontinuation from the predominant JAK inhibitor being used today.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Intermediate-2 or High-risk relapsed/refractory MF, data from IMbark suggest potential disease-modifying activity with imetelstat treatment and a potential meaningful improvement in OS, which is supported in a comparison to real-world data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved for commercial sale for the treatment of MF, imetelstat would compete against currently approved JAK inhibitors: Jakafi (ruxolitinib) by Incyte Corporation, or Incyte, and Inrebic (fedratinib) by Celgene, as well as a kinase inhibitor, Vonjo (pacritinib), by CTI Biopharma Corp., which was approved in February 2022 for the treatment of adults with Intermediate or High-Risk primary or secondary myelofibrosis with a platelet count below 50 &#215; 109/L and OJJAARA, or momelotinib, a kinase inhibitor which was approved in September 2023 for the treatment of intermediate or high-risk MF, including primary MF or secondary MF (postpolycythemia vera and post-essential thrombocytopenia), in adults with anemia, by GlaxoSmithKline plc, or GSK. Other treatment modalities for MF include hydroxyurea for the management of splenomegaly, leukocytosis, thrombocytosis and constitutional symptoms; splenectomy and splenic irradiation for the management of splenomegaly and co-existing cytopenias; chemotherapy; and pegylated interferon. Drugs for the treatment of MF-associated anemia include ESAs, androgens, danazol, corticosteroids, thalidomide and lenalidomide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other therapies currently in Phase 3 development in MF, some of which may obtain regulatory approval earlier than imetelstat, include momelotinib, a JAK inhibitor, by GSK; or momelotinib plus AZD5153, a BET inhibitor by GSK; pelabresib (CPI-0610), a BET inhibitor, by MorphoSys AG; navitoclax, a BCLXL, BCL-2 and BCLW inhibitor, by AbbVie, Inc.; and parsaclisib, a PI3K delta inhibitor, by Incyte. Other approaches for MF currently under investigation that could compete with imetelstat in the future include luspatercept; zinpentraxin alfa (RG6354, formerly PRM-151), an anti-fibrosis antibody, by F. Hoffmann-La Roche, Ltd.; LCL-161, an inhibitor of apoptosis protein (IAP), by Novartis; KRT-232, an inhibitor of MDM2, by Kartos Therapeutics, Inc.; GB2064, a LOXL2 inhibitor, by Galecto Biotech; elraglusib (9-ING-41), a glycogen synthase kinase-3 beta inhibitor, by Actuate Therapeutics, Inc.; XPOVIO (selinexor), a nuclear export inhibitor, by Karyopharm Therapeutics, Inc.; TL-895, an oral tyrosine kinase inhibitor, by Telios Pharma, Inc.; IMG-7289, a LSD1 inhibitor, by Imago Biosciences, Inc.; APG-1252, a dual BCL-2/BCL-XL inhibitor, by Ascentage Pharma; ilginatinib (NS-018), a JAK2 inhibitor by NS Pharma; DISC-0974, a monoclonal antibody against hemojuvelin (HJV) by DISC Management Inc.; KER-050 in combination with ruxolitinib, by Keros Therapeutics; CK0804, an allogeneic T-regulatory cell agent, by Cellenkos, Inc. in collaboration with Incyte; TP-3654, PIM kinase inhibitor by Sumitomo Pharma Co., Ltd.; and a mutated-CALR vaccine, a peptide-based vaccine, from the Icahn School of Medicine at Mount Sinai.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors, either alone or with their strategic partners, could have substantially greater financial, technical and human resources than we do and significantly greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. We believe that the commercial success of imetelstat is subject to a number of factors, including: product efficacy and safety; method of product administration; cost of manufacturing; the timing and scope of regulatory consents; status of coverage and reimbursement; price; the level of generic competition; and our patent position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We anticipate increased competition in the future as new companies explore treatments for myeloid hematologic malignancies, which may significantly impact the commercial viability of imetelstat. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research, clinical development and marketing of products similar to imetelstat. These companies and institutions compete with us in recruiting and retaining qualified development and management personnel as well as in acquiring technologies complementary to the imetelstat program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the foregoing, competitors may develop more commercially desirable or affordable products than imetelstat, or achieve earlier patent protection or product commercialization than we may be able to achieve with imetelstat. Competitors have developed, or are in the process of developing, technologies that are, or in the future may be, competitive to imetelstat. Some of these products may have an entirely different approach or means of accomplishing therapeutic effects similar or superior to those that may be demonstrated by imetelstat. Competitors may develop products that are safer, more effective, or less costly than imetelstat, or more convenient to administer to patients and, therefore, present a serious competitive threat to imetelstat. In addition, competitors may price their products below what we may determine to be an acceptable price for imetelstat, may receive better third-party payor coverage and/or reimbursement, or may be more cost-effective than imetelstat. Such competitive products or activities by competitors may render imetelstat obsolete, which may cause us to cease any further development or future commercialization of imetelstat, which would severely and adversely affect our financial results, business and business prospects, and the future of imetelstat, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation by governmental authorities in the U.S. and other countries is a significant factor in the development, manufacture and potential future marketing of imetelstat. Imetelstat will require regulatory approval by regulatory authorities prior to commercialization. In particular, potential human therapeutic products, such as imetelstat, are subject to rigorous preclinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in European and other countries. Various governmental statutes and regulations at both the federal and state level also govern or influence testing, manufacturing, safety, labeling, storage, import, export, distribution, sale and recordkeeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with appropriate statutes and regulations require the expenditure of substantial time and money, and there can be no guarantee that approvals will be granted. Moreover, compliance with government regulations governing personal information and information security requires the expenditure of substantial time and financial resources. The information provided in this section should be reviewed in the context of the sections entitled &#8220;Risks Related to the Development of Imetelstat&#8221; and &#8220;Risks Related to Regulatory Approval and Commercialization of Imetelstat&#8221; under Part I, Item 1A, &#8220;Risk Factors&#8221; of this annual report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">United States Food and Drug Administration Regulatory Approval Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to commencement of clinical trials involving humans, preclinical testing of new pharmaceutical products is generally conducted on animals in the laboratory to evaluate the potential efficacy and safety of a product candidate. The results of these trials are submitted to the FDA as part of an Investigational New Drug, or IND, application, which must become effective before clinical testing in humans can begin. The FDA can place an IND on clinical hold at any time, which prevents the conduct of clinical trials under the IND until safety concerns or questions are addressed by the IND sponsor to the FDA&#8217;s satisfaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Typically, clinical evaluation involves a time consuming and costly three phase trial process. In Phase 1, clinical trials are conducted with a small number of healthy volunteers or patients afflicted with a specific disease to assess safety and to evaluate the pattern of drug distribution and metabolism within the body. In Phase 2, clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety. The Phase 2 trials can be conducted comparing the investigational treatment to a comparator arm, or not. If used, a comparator usually includes standard of care therapy. Safety and efficacy data from Phase 2 clinical trials, even if favorable, may not provide sufficient rationale for proceeding to a Phase 3 clinical trial. In Phase 3, large scale, multi&#8209;center, comparative trials are conducted with patients afflicted with a target disease to provide sufficient data to demonstrate the efficacy and safety required by the FDA. The FDA closely monitors the progress of each of the three phases of clinical testing and may, at its discretion, re&#8209;evaluate, alter, suspend, or terminate the trials. Human clinical trials must be conducted in compliance with Good Clinical Practice, or GCP, regulations and applicable laws, with the oversight of Institutional Review Boards for the protection of human subjects. The manufacture of drug product candidates is subject to requirements that drugs be manufactured, packaged and labeled in conformity with current Good Manufacturing Practices, or cGMP, and applicable laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results of the preclinical and clinical testing of drugs and complete manufacturing information are submitted to the FDA in the form of an NDA for review and approval prior to commencement of commercial sales. Submission of an NDA requires the payment of a substantial user fee to the FDA, which may be waived in certain cases. In responding to an NDA submission, the FDA may approve the drug for commercialization, impose</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations on its indications for use and labeling, including in the form of Risk Evaluation and Mitigation Strategies or may issue a complete response letter. Even if an NDA is approved, its sponsor is subject to ongoing and pervasive regulatory compliance requirements.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union and Other Regulatory Approval Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to initiating clinical trials in a region outside of the U.S., a clinical trial application must be submitted and reviewed by the appropriate regulatory authority governing clinical trials in the country in which the trial will be conducted. Whether or not FDA clearance or approval has been obtained, approval of a product by comparable regulatory authorities in the EU and other countries is necessary prior to marketing the product in such countries. The competent regulatory authorities may impose their own requirements and may refuse to grant an approval, or may require additional data before granting it, even though the relevant product has been cleared or approved by the FDA or another authority. As with the FDA, the regulatory authorities in the EU and other developed countries have lengthy approval processes for pharmaceutical products. The process for gaining approval in particular countries varies, but generally follows a similar sequence to that described for FDA approval. In Europe, the European Medicine Agency, or EMA, and the European Committee for Proprietary Medicinal Products for Human Use, or CHMP, provide a mechanism for EU member states to exchange information on all aspects of product licensing. The EU has established the EMA for the evaluation of medical products, with a centralized procedure which is mandatory for orphan and oncology products and which grants a single marketing authorization valid in all EU member states.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fraud and Abuse, and Transparency Laws and Regulations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to additional regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. These additional regulations could affect our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third&#8209;party payors. Such laws include, without limitation, state and federal bribery/anti&#8209;kickback, the False Claims Act, privacy and data security laws, and healthcare professionals payment transparency laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti&#8209;Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare, Medicaid TRICARE, and the Veterans Health Administration. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals, the Anti&#8209;Kickback Statute has been violated. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act or ACA, among other things, amended the intent requirement of the federal Anti&#8209;Kickback Statute such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate, in order to commit a violation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims and false statement laws, including the federal civil False Claims Act and its whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> provisions that permit private individuals to bring an action on behalf of the government to enforce the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed. Entities can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product off&#8209;label, or for providing medically unnecessary services or items. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Criminal prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third&#8209;party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, transmission and breach reporting of individually identifiable health information, upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers and their respective business associates and their subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, and information related to ownership and investment interests held by physicians and their immediate family members.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti&#8209;kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non&#8209;governmental third-party payors, including private insurers. Additionally, we may be subject to state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and certain industry compliance guidance documents. Further, we may be subject to state and foreign laws that require drug manufacturers or other pharmaceutical companies to report information related to payments and other transfers of value to physicians, other healthcare providers and healthcare entities, or marketing expenditures, as well as state, foreign and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws that require the reporting of information related to drug pricing; and state, federal and foreign laws governing the privacy and security of personal information (including key-coded data and health information), including the European Union&#8217;s General Data Protection Regulation, or EU GDPR, many of which differ from each other in significant ways, thus complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of these or any other healthcare regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data Privacy and Security</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we may process personal or sensitive data. Accordingly, we are, or may become, subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy and security. Efforts to ensure that our current and future business arrangements will comply with applicable data privacy and data security laws and regulations will involve substantial costs. For example, foreign data privacy and security laws (including but not limited to the EU GDPR and UK GDPR) impose strict significant and complex compliance obligations on entities that are subject to those laws. As one example, the EU GDPR imposes heightened and codified standards for data subject consent, requiring the implementation and maintenance of technical and organizational safeguards for personal data, mandating data breach notifications to relevant supervisory authority(ies), and mandating the appointment of representatives in the UK and/or the EU in certain circumstances. Foreign privacy laws, such as the EU GDPR, also impose strict rules on the transfer of personal data out of the applicable jurisdiction. Further, the EU GDPR provides for significant penalties (such as restrictions or prohibitions on personal data processing) and large fines for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Moreover, we expect that there will continue to be new proposed data privacy and security laws, regulations and industry standards in the U.S. As one example, the California Consumer Privacy Act of 2018, or CCPA, imposes numerous obligations on covered business. Although the CCPA exempts certain data (such as some data processed in the context of clinical trials), the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we maintain about California residents.</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CCPA provides for civil penalties and a private right of action for data breaches which may include an award of statutory damages. Failure, or perceived failure, to comply with all applicable obligations could result in enforcement actions, fines, litigation, and other consequences. See the section titled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, industry standards,  policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration; fines and penalties; disruptions for our business operations; reputational harm; loss of revenue and profits; and other adverse business impacts,&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under &#8220;Risk Factors&#8221; in Part I, Item 1A of this annual report on Form 10-K for additional information about the laws and regulations to which we may become subject and about the risks to our business associated with such laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate that receives regulatory approval. In the U.S. and markets in other countries, sales of imetelstat, if approved for commercial sale, will depend, in part, on the extent to which third&#8209;party payors provide coverage and establish adequate reimbursement levels for imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., third&#8209;party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a product is safe, effective and medically necessary; appropriate for the specific patient; cost-effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. A third-party payor could also require that certain lines of therapy be completed or failed prior to reimbursing our therapy. The principal decisions about reimbursement for new medicines are typically made by CMS. CMS decides whether and to what extent products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Third-party payors determine which products and procedures they will cover and establish reimbursement levels. Third&#8209;party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost&#8209;effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA&#8209;approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost&#8209;effectiveness of imetelstat, in addition to the costs required to obtain the FDA approvals. Nonetheless, imetelstat may not be considered medically necessary or cost&#8209;effective. Moreover, the process for determining whether a third&#8209;party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product, as there is no uniform coverage and reimbursement policy among third-party payors in the U.S. Adequate third&#8209;party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in imetelstat. Even if a third-party payor covers a particular product or procedure, the resulting reimbursement payment rates may not be adequate. Coverage policies and third-party payor reimbursement rates may change. Thus, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce demand for the product and also have a material adverse effect on future sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries, Presidential executive orders, and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effect progressively starting in fiscal year 2023.  On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by CMS&#8217;s Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Additionally, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. and some foreign jurisdictions are considering or have enacted legislative and regulatory proposals to contain healthcare costs, as well as to improve quality and expand access. For example, in March 2010, the ACA was signed into law, which included a number of provisions of importance to the biopharmaceutical industry. There have been judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and additional downward pressure on the price that may be charged for imetelstat. It is unclear how any such healthcare reform measures will impact the pharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011 was enacted, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and, due to subsequent legislative amendments to the statute will stay in effect through 2032 unless additional Congressional action is taken. Additionally, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals and imaging centers. More recently, there has been heightened governmental scrutiny in the U.S. to control the rising cost of healthcare.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information About Our Executive Officers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth certain information with respect to our executive officers and other members of management as of January 31, 2024:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.2%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:5.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1.58%;"/>
    <td style="width:65.48%;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Age</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Position</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">John A. Scarlett, M.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michelle Robertson</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Finance, Chief Financial Officer<br/>&#160;&#160;&#160;and Treasurer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Faye Feller, M.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Chief Medical Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Andrew J. Grethlein, Ph.D.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Chief Operating Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Anil Kapur</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Corporate Strategy and Chief Commercial Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Scott A. Samuels, Esq.</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Chief Legal Officer and Corporate Secretary</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Other Members of Management</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Melissa A. Kelly Behrs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Business Operations and Chief Alliance Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Edward E. Koval</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Chief Business Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shannon T. Odam</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Senior Vice President, Chief People Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">John A. Scarlett, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has served as our Chief Executive Officer and a director since September 2011 and President since January 2012 and was appointed to Chairman of the Board in December 2018. Dr. Scarlett served as a director of CytomX Therapeutics, Inc., a biopharmaceutical company focused on developing antibody therapeutics for the treatment of cancer, from June 2016 to June 2022. He was also a director for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, from February 2015 until its acquisition by Amyrt Pharma plc, a biopharmaceutical company, in August 2021. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately held, oncology oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc., an oncology oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk A/S. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Michelle Robertson</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has served as our Executive Vice President, Chief Financial Officer and Treasurer since September 2023. Prior to joining Geron, she served as the Chief Financial Officer and Treasurer of Editas Medicine, Inc., a CRISPR genome editing company, from January 2020 to May 2023. Before that, she served as Chief Financial Officer of Momenta Pharmaceuticals, Inc. from 2018 until 2020, when Momenta was acquired by Johnson &amp; Johnson. Prior to joining Momenta, Ms. Robertson held multiple commercial finance roles of increasing responsibility, including Vice President, Oncology Finance for Baxalta Incorporated following its spin-off from Baxter International Inc., from 2015 to 2016; Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc. from 2012 to 2015; and various finance and commercial operations roles at Genzyme Corporation (acquired by Sanofi). She also currently serves as a member of the board of directors and as the chair of the audit committee for Verastem, Inc., a publicly-traded biopharmaceutical company. Ms. Robertson received her B.S. in Finance and A.S. in Accounting and Management from Bentley University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Faye Feller, M.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has served as our Executive Vice President, Chief Medical Officer since July 2022. Previously, she served as our Vice President of Clinical Development since she joined Geron in April 2019. In this role, Dr. Feller played a strategic role in designing and driving execution of Geron&#8217;s Phase 3 clinical trials, served as the primary medical point of contact between Geron and our clinical investigators and led the preparation of data for assessment by the data monitoring committees. Prior to joining Geron, Dr. Feller was Senior Director at Janssen Research and Development, LLC (Janssen), a global pharmaceutical company, and both a Compound Lead and Study Responsible Physician for multiple clinical trials of early and late-stage development assets at Janssen from February 2015 to March 2019. Prior to Janssen, Dr. Feller was an instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York from July 2013 to February 2015. She received a B.A. from New York</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Andrew J. Grethlein, Ph.D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has served as our Executive Vice President, Chief Operating Officer since January 2019. Previously, he served as our Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as our Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology&#8209;oriented biopharmaceutical company, where he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a non-profit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon&#8217;s Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anil Kapur </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has served as our Executive Vice President, Corporate Strategy and Chief Commercial Officer since December 2019. Prior to joining Geron, Mr. Kapur was Chief Commercial Officer at Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, from February 2018 to November 2019. From October 2016 until February 2018, Mr. Kapur was Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol Myers Squibb Company, a global biopharmaceutical company. Mr. Kapur served as Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Incorporated, a biopharmaceutical company, in a newly created Oncology Division, from November 2015 until after its acquisition by Shire plc in July 2016. Before joining Baxalta, Mr. Kapur held marketing and sales leadership roles of increasing responsibility during his 15-year tenure at the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (Janssen). As Vice President, Commercial Leader, Hematology Franchise in Janssen&#8217;s Global Commercial Strategy Organization, he led the development and execution of commercial strategy and launch plans for in-market development, late development, and early pipeline assets, including imetelstat. Among Mr. Kapur&#8217;s most recognized achievements while at Janssen were the successful global launches of two transformational blockbuster hematology-oncology drugs, Imbruvica and Darzalex. Mr. Kapur has served as a member of the board of directors of Verastem, Inc., a development-stage biopharmaceutical company, since October 2022. Mr. Kapur holds a Bachelor of Engineering from Birla Institute of Technology in India; an M.S. in Industrial Engineering from Louisiana Tech University; and an M.B.A. from the Fuqua School of Business at Duke University.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scott A. Samuels, Esq.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has served as our Executive Vice President, Chief Legal Officer and Secretary since August 2023. Prior to joining Geron, Mr. Samuels served as Chief Legal Officer and Chief Compliance Officer of Prilenia Therapeutics, Inc., a clinical-stage biotechnology company focused on novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, from March to May 2023. Before that, he served as the Senior Vice President, General Counsel of BeiGene, Ltd., from May 2017 to July 2022, where he built a large, global legal and compliance team, oversaw launches of three internally developed drug products in the U.S., Europe and China and development of a global healthcare compliance program, and led key strategic transactions with Amgen, Inc., Novartis AG and Celgene (now Bristol Myers Squibb). Prior to BeiGene, Mr. Samuels was assistant general counsel and then acting general counsel at ARIAD Pharmaceuticals, Inc., where he managed the company&#8217;s legal affairs, including SEC compliance and corporate governance and key licensing and distribution agreements prior to ARIAD&#8217;s acquisition by Takeda. Mr. Samuels also practiced law for 17 years in the corporate and life sciences practices at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., a highly regarded national law firm. Mr. Samuels received his B.A. in philosophy from Cornell University and his J.D. from George Mason University School of Law.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Melissa A. Kelly Behrs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> has served as our Executive Vice President, Business Operations and Chief Alliance Officer since December 2021. Previously, she was our Executive Vice President, Chief Business Officer from January 2019 to December 2021, Executive Vice President, Business Development and Portfolio &amp; Alliance Management, from February 2014 to January 2019, and our Senior Vice President, Portfolio and Alliance Management from September 2012 to February 2014. Ms. Behrs joined Geron in November 1998 as Director of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&amp;D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998, Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Edward E. Koval </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has served as our Executive Vice President, Chief Business Officer since December 2021. From 2020 to 2021, he was Chief Business Officer at ZebiAI Therapeutics, a company spun out of X-Chem, Inc. in order to discover and develop advanced drug discovery programs based on novel machine learning technologies, until its acquisition by Relay Therapeutics, Inc., a clinical-stage precision medicine company, in April 2021. Prior to the spin-out of ZebiAI, from 2013 to 2020, he was Senior Vice President, Corporate Development, at X-Chem, Inc., a drug discovery company, where he closed multiple transactions with multinational pharmaceutical companies for programs in oncology, hematology/oncology, inflammation, infectious disease and rare diseases. From 2012 to 2015, Mr. Koval served as an independent corporate and business development consultant, advising multiple private and public biotech companies on partnering and fundraising. Mr. Koval&#8217;s prior pharmaceutical experience from 1992 to 2012 includes serving roles in business and corporate development, strategic planning, alliance management and financial evaluation and analysis at Novartis Pharmaceuticals Corporation, a pharmaceutical company, Merck &amp; Co., Inc., a pharmaceutical company, and Chiron Corporation, a pharmaceutical company, where he finalized negotiations and executed and managed multiple strategic corporate partnerships and alliances. Mr. Koval holds an M.Sc. in Engineering from Rensselaer Polytechnic Institute and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shannon T. Odam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">has served as our Senior Vice President, Chief People Officer since January 2024. Previously, she served as our Vice President, Human Resources since joining Geron in June 2019. Prior to joining Geron, Ms. Odam served as Vice President, Human Resources at BioElectron Technology Corp., a clinical-stage biotechnology company, where she created and executed upon a unified vision by streamlining organizational design structure, designed leadership development programs to drive skills needed for future growth and led and executed human resources operations. from May 2017 to July 2018, before its acquisition by PTC Therapeutics Inc. in 2019. Before that, Ms. Odam served in various human capital roles at PricewaterhouseCoopers, or PWC, a multinational professional services firm, from 2007 to 2017. While at PWC, Ms. Odam served as the Silicon Valley Diversity and Inclusion Leader, the Audit Human Resources Leader, as well as an executive coach for PWC&#8217;s Coaching Center of Excellence. Ms. Odam received a B.S. in criminology from California State University, Fresno, an M.S. in Organizational Development from University of San Francisco and an Executive Coaching Credential from the Hudson Institute of Coaching.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Values</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fostering and maintaining a strong, healthy culture is a key strategic focus. Our corporate values are authenticity, accountability, excellence, integrity and respect, and we are committed to building a corporate culture that supports these values. These values reflect who we are and the way our employees interact with one another, our partners and our stockholders, and are the essential tenets that guide our decisions, govern our relationships, both internally and externally, and articulate what we stand for and who we are. These values dictate the ways in which we interact, work and communicate, how we resolve conflicts and ultimately, how we strive to make Geron successful. We are Authentic, having well-intentioned interactions that are genuine and real. We are Accountable, taking responsibility for our actions, including decisions, and the effect they have on Geron. We are Excellent, having relentlessly high standards. We have Integrity, requiring our employees to behave ethically in all situations and demanding the same from others. We encourage our employees to live out our core values and to discuss our core values with potential candidates looking to join our team. We believe that this is an important step in helping our culture stay strong and unique.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our team of talented professionals is the foundation of our company and fuels our historical and prospective achievements for patients. We consider the intellectual capital of our employees to be an essential driver of our business and key to our future opportunities. As of December 31, 2023, we had 141 full&#8209;time employees. Twenty of our employees hold Ph.D. degrees and 63 hold other advanced degrees. Of this current total workforce, 67 employees were engaged in, or directly supported, our research and development activities, and 74 employees were engaged in commercial, medical affairs, business development, legal, finance, human resources, information technology and administration. Every employee plays a vital role in furthering our goals and impacting our progress towards fully realizing our goal to develop and seek to commercialize imetelstat.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to our employee base, we have established, and expect to continue to establish, consulting agreements with drug development professionals, clinicians, attorneys and regulatory experts with experience in numerous fields, including clinical science, biostatistics, clinical operations, pharmacovigilance, quality, manufacturing and regulatory affairs. As of December 31, 2023, we had approximately 122 consultants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To succeed in our mission, we must attract, recruit, retain, develop and motivate qualified clinical, nonclinical, scientific, manufacturing, regulatory, management and other personnel needed to support our business and operations. As a biotechnology company with locations in the San Francisco Bay Area and northern New Jersey, we operate in a highly competitive industry and geographies for employee talent. In 2023, we engaged in extensive recruiting efforts to source and interview a talented and diverse pipeline of candidates, and enhanced our capabilities by significantly expanding our employee base. We grew our workforce by 46 employees, 23 of whom are part of our commercial team, and expected to play a critical role in implementing our plans to commercialize imetelstat, if approved. We maintain a comprehensive dashboard of measurements, including recruitment productivity, diversity, equity and inclusion metrics, employee engagement scores, total rewards benchmarking, participation rates and satisfaction scores for internal training, turnover rates and exit interview results, to guide our human capital management efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our ability to attract highly skilled and talented employees in a competitive labor market is enhanced by nurturing our workplace culture, providing competitive compensation and benefits programs and supporting employee career development and related management training. To that end, we continue to invest resources and energy into being an employer of choice &#8211; attracting and engaging individuals who are innovative, curious, driven, diligent, collaborative and of the highest integrity and ethics. Some of our key efforts in this area and management of our human capital assets generally are described here.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation and Benefits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our compensation philosophy is to provide pay and benefits that are competitive in the biotechnology and pharmaceutical industry where we compete for talent. We monitor our compensation programs closely and review them annually to provide what we consider a competitive mix of compensation and health, welfare and retirement benefits for all our employees. Our compensation package for all employees includes market-competitive base salaries, eligibility for annual performance bonuses and equity grants. Annual cash bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Any actual bonus payout is based on a combination of individual performance and corporate performance. All regular-status, full-time employees are eligible to participate in our comprehensive benefit program, pursuant to plan terms and conditions. Plan choices include medical, dental, vision, life insurance, flexible spending accounts, short and long-term disability insurance, a 401(k) retirement savings plan with a discretionary matching employer contribution, and an employee stock purchase plan. We also provide regular-status, full-time employees with a generous time off program that includes vacation, sick, holiday, and paid leave for certain life events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Every year, we undertake a detailed review of our compensation by position and level and make adjustments necessary to ensure that we continue to provide competitive compensation. In conjunction with the California&#8217;s Pay Transparency law (SB 1162), beginning January 1, 2023, we have published pay ranges in all job postings for jobs in California and also seek to comply with other states&#8217; pay disclosure requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diversity, Inclusion and Corporate Culture</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We value workplace diversity, including diversity of personal background, perspective, experience and other characteristics, such as gender, gender identity, ethnicity, sexual orientation, age, and underrepresented communities &#8211; not only because it is the right thing to do, but because we believe doing so enhances our corporate culture and is key to our long-term success. As of December 31, 2023, approximately 56% of our employees in managerial roles were women, and approximately 48% of our executive management, vice president and above, were women.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> During 2023, we furthered the development of our hybrid workforce program that provides a variety of virtual and in-person collaboration opportunities, such as leadership training and coaching resources.  Since 2021, we have utilized a peer-centric employee recognition program to empower employees to champion our workplace culture and values, and promote direct praise to peers. In addition, we have implemented a reward program that enables managers to recognize employees who have demonstrated exceptional performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we pride ourselves on an open culture that respects co-workers, values employees&#8217; health and well-being and fosters professional development. We support employee growth and development in a variety of ways, including with group training, individual mentoring and coaching, conference attendance and tuition reimbursement. Our management conducts annual employee engagement surveys and reports to our board of directors on human capital management topics, including corporate culture, diversity, equity and inclusion, employee development and retention, and compensation and benefits. Similarly, our board of directors regularly provides input on important decisions relating to these matters, including with respect to employee compensation and benefits, talent retention and development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Communication and Engagement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that part of what sets us apart from other companies is our culture and, in particular, our focus on providing timely and transparent communications and creating a strong sense of belonging and inclusiveness. In 2023, after nearly three years of the COVID-19 pandemic, we were able to re-engage in periodic in-office meetings and interactions, as well as in-office training and development opportunities, to encourage cross-functional team-building and collaboration, in conjunction with which many of our teams engage in group lunches and dinners. We held a summer contest that encouraged our employees to share summer travel experiences and special events, building rapport and strengthening employee relationships, and we conduct organizational and team-specific holiday events to promote connectivity among our employees. We share information and news with employees through quarterly all-hands meetings, semi-monthly newsletters to employees, social media posts on our intranet and outward facing social media sites, such as LinkedIn, and regular employee chats with our Chief Executive Officer and other members of senior management. We survey our employees each year to measure their level of engagement at the Company. Our employee engagement scores have remained relatively steady over the past three years, despite the challenges we faced through the COVID-19 pandemic. These surveys provide rich feedback each year that helps us to continue to grow our culture and make Geron a great place to work.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Health, Wellness and Safety</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to specific support relating to health and safety during the COVID-19 pandemic, we continue other activities that promote our employees&#8217; whole health and wellness, including reimbursement for certain wellness costs, external support from our employee assistance programs and mental wellness services, which covers therapy and/or coaching for our employees and their dependents, including high school and college-aged children.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relations with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate and Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Geron Corporation was incorporated in the State of Delaware on November 28, 1990.  Geron UK Limited was incorporated in the United Kingdom on September 29, 2021. Geron Netherlands B.V. was incorporated in the Netherlands on February 17, 2023. Our principal executive offices are located at 919 E. Hillsdale Blvd., Suite 250, Foster City, CA 94404, and our telephone number is 650-473-7700. Our website address is http://www.geron.com.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file or furnish electronically with the U.S. Securities and Exchange Commission, or the SEC, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We make copies of these reports available free of charge through the &#8220;SEC Filings&#8221; tab on the &#8220;Investors &amp; Media&#8221; page of our website as soon as reasonably practicable after we file or furnish them with the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information contained on or accessible through our website is not incorporated into, and does not form a part of, this Annual Report on Form 10-K or any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A.           R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ISK FACTORS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We operate in a dynamic and rapidly changing environment involving numerous risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described below, together with all of the other information included in this annual report on Form 10&#8209;K. Our business faces significant risks and uncertainties, and those described below may not be the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also significantly impair our business, financial condition or results of operations. If any of these risks or uncertainties occur, our business, financial condition or results of operations could suffer, the market price of our common stock could decline and you could lose all or part of your investment in our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO THE DEVELOPMENT OF IMETELSTAT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends solely on imetelstat, our only product candidate, and we cannot be certain that we will be able to continue to develop imetelstat or advance imetelstat to subsequent clinical trials, or that we will be able to receive regulatory approval for or to commercialize imetelstat, on a timely basis or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat is our sole product candidate, upon whose success we are wholly dependent. Our ability to develop imetelstat and launch it commercially is subject to significant risks and uncertainties, including, among other things, our ability to:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receive regulatory approval to commercialize imetelstat in lower-risk MDS from the FDA and European Commission, without the requirement for the conduct and completion of additional pre-approval clinical trials or further analyses, testing or development commitments, if at all, any of which could result in increased costs to us, and delay, limit or preclude our ability to generate revenue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">generate sufficient safety and efficacy data from the IMpactMF clinical trial to support any application for regulatory approval in relapsed/refractory MF, without clinically meaningful safety issues, side effects or dose-limiting toxicities related to imetelstat that may negatively impact its benefit-risk profile;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ascertain that the use of imetelstat does not result in significant systemic or organ toxicities, including hepatotoxicity, or other safety issues resulting in an unacceptable benefit-risk profile;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain additional capital when needed in order to enable us to further advance the imetelstat program;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain and maintain required regulatory clearances and approvals to enable continued clinical development, as well as potential commercialization, of imetelstat; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enter into and maintain commercially reasonable arrangements with third parties to provide services needed to further research and develop, and to potentially commercialize, imetelstat, including maintaining the agreements with our contract research organizations, or CROs, and third-party manufacturers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recruit and retain sufficient qualified and experienced personnel to support the development and potential commercialization of imetelstat in the U.S.;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enter into and maintain arrangements with third parties to provide services needed to support the potential commercialization of imetelstat for territories outside of the U.S. in compliance with applicable laws;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieve acceptance of imetelstat, if approved, by patients and the relevant medical communities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compete effectively with other approved treatments in lower-risk MDS and relapsed/refractory MF if imetelstat is approved in those indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain appropriate coverage and reimbursement levels for the cost of imetelstat from governmental authorities, private health insurers and other third-party payors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain, maintain and enforce adequate intellectual property and regulatory exclusivity for imetelstat both in the U.S. and globally.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to successfully achieve these goals and overcome other challenges that we may encounter in the research, development, manufacturing and potential commercialization of imetelstat, we may be forced to abandon our development and/or planned commercialization of imetelstat, which would severely harm our business, prospects and our ability to raise additional capital, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our clinical trials of imetelstat could be interrupted, delayed, terminated or abandoned for a variety of reasons which could severely and adversely affect our financial results, business and business prospects, and the future of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conduct and completion of our clinical trials could be interrupted, delayed or abandoned for a variety of reasons, including as a result of clinical trial failures, suspensions, terminations or delays related to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient recruitment, enrollment and retention challenges and operational delays, including in connection with opening new clinical sites, while also competing with clinical trials for other investigational drugs in the same patient population; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">use of trial endpoints such as overall survival, that inherently require prolonged periods of clinical observation or analysis of the resulting data to determine trial outcomes, including the need for a certain number of events, or deaths, to occur in IMpactMF prior to the final analysis in that trial of overall survival; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining and/or maintaining regulatory clearances in the U.S. or other countries to commence, conduct or modify current or potential future clinical trials of imetelstat, in a timely manner, or at all;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">investigational new drug applications, or INDs, and equivalent submissions in other countries for imetelstat being placed on full or partial clinical hold, suspended or subject to other requirements by the FDA or other similar international regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contracting with a sufficient number of clinical trial sites to conduct current and potential future clinical trials, and ensuring that such contracts contain all necessary terms and conditions required by applicable laws, including providing for valid mechanisms to engage in cross-border data transfers, as well as identifying, recruiting and training suitable clinical investigators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining or accessing necessary clinical data in accordance with appropriate clinical or quality practices and regulatory requirements, in a timely and accurate manner to ensure complete data sets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">responding to safety findings, recommendations or conclusions by the data safety review committees, independent data monitoring committees and/or expert committees of current and potential future clinical trials of imetelstat based on emerging data occurring during such clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing sufficient quantities that meet our specifications, cost and quality requirements, and timelines for imetelstat, or other clinical trial materials, in a manner that meets the quality standards of the FDA and other similar international regulatory authorities, and responding to any disruptions to drug supply, clinical trial materials or quality issues that may arise;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complying with current and future regulatory requirements, policies or guidelines, including domestic and international laws and regulations pertaining to fraud and abuse, transparency, and the privacy and security of health information;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reaching agreement on acceptable terms and on a timely basis, if at all, with collaborators, physician investigators, vendors and other third parties located in the U.S. or other countries, including our CROs, laboratory service providers and clinical trial sites, on all aspects of clinical development and collaborating with them successfully; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party clinical contractors, including investigators or our CROs not performing our clinical trials according to our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements, or not performing data collection or analyses in a timely or accurate manner.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failures or delays with respect to any of these events could adversely affect our ability to conduct or complete the clinical trials being conducted by us or our investigators, or to commence, conduct and complete potential future clinical trials of imetelstat, which could increase development costs, or interrupt, further delay or halt our development or potential commercialization of imetelstat, any of which could severely and adversely affect our financial results, business and business prospects, and the future of imetelstat.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Imetelstat may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could further delay or prevent the commencement and/or completion of clinical trials for imetelstat, delay or prevent its regulatory approval, or limit its commercial potential.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat may cause, or have attributed to it, undesirable or unintended side effects or other adverse events affecting its safety or efficacy that could interrupt, further delay or halt current or potential future clinical trials of imetelstat, as well as our expanded access program. In this regard, adverse events and dose-limiting toxicities observed in previous and ongoing clinical trials of imetelstat include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hematologic toxicities, such as profound and/or prolonged thrombocytopenia or neutropenia;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bleeding events, with or without thrombocytopenia, including Grade 3/4 bleeding events;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">febrile neutropenia;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hepatotoxicity and liver function test abnormalities, as well as hepatic failure;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gastrointestinal events;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infection events, with or without neutropenia, including Grade 3/4 infection events;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">muscular and joint pain;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fatigue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">headache; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infusion-related reactions.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If patients in any clinical trials of imetelstat or our expanded access program experience similar or more severe adverse events, or new or unusual adverse events, or if the FDA or other similar international regulatory authorities determine that efficacy and safety data in clinical trials of imetelstat do not support an adequate benefit-risk profile to justify continued treatment of patients, then the FDA or other similar international regulatory authorities may place one or more of the INDs for imetelstat on clinical hold, as occurred in March 2014. If this were to occur, there would be a significant delay in, or possible termination of, one or more of the imetelstat clinical trials and any potential commercialization efforts, which might cause us to cease operations. For example, we are aware of a case in our IMpactMF clinical trial of a patient with myelofibrosis associated with underlying progressive bone marrow failure, who died from febrile neutropenia, pulmonary hemorrhage and bilateral pneumonia, which, at the time of reporting, the investigator related to imetelstat. If such toxicities or other safety issues in any clinical trial of imetelstat are determined by us, the FDA or similar international regulatory authorities to result in an unacceptable benefit-risk profile, then:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional information supporting the benefit-risk profile of imetelstat may be requested by the FDA or similar international regulatory authorities and if any such information is not available or, if available, not deemed acceptable, current clinical trials of imetelstat could be suspended, terminated, or placed on clinical hold by the FDA or similar international regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to retain enrolled patients in our current clinical trials may be negatively affected, resulting in incomplete data sets and the inability to adequately assess the benefit-risk profile of imetelstat in a specific patient population; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional, unexpected clinical trials or non-clinical studies may be required to be conducted; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imetelstat may not receive or maintain any regulatory authorizations, including for commercial use.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, clinical trials by their nature examine the effect of a potential therapy in a sample of the potential future patient population. As such, clinical trials conducted with imetelstat, to date and in the future, may not uncover all possible adverse events that patients treated with imetelstat may experience. Because remaining patients in ongoing clinical trials and in our expanded access program continue to receive imetelstat treatment, additional or more severe toxicities or safety issues may be observed, and the benefit-risk profile of imetelstat will continue to be assessed, including the risk of hepatotoxicity, severe cytopenias, fatal bleeding with or without any associated thrombocytopenia, patient injury or death.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any of these events could interrupt, further delay, or halt, any development, and as a result, impact or preclude the potential regulatory approval and commercialization of imetelstat, as well as increase costs to develop imetelstat, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, business prospects and the future of imetelstat, any of which might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Results and data we disclosed from prior non-clinical studies and clinical trials may not predict success in later clinical trials, and we cannot assure you that any ongoing or future clinical trials of imetelstat will lead to similar results and data that could potentially enable us to obtain any regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The design of a clinical trial can determine whether its results will support regulatory approval of a product, and flaws in the trial design may not become apparent until the clinical trial is well advanced or during the approval process after the trial is completed. A clinical trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of imetelstat clinical trials with smaller sample sizes can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, making the trial results of clinical trials with smaller sample sizes less reliable than trials with a larger number of patients. As a result, there may be less certainty that imetelstat will achieve a statistically significant effect in any future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, success in non-clinical testing and early clinical trials, including Phase 2 clinical trials, such as IMbark, does not ensure that later clinical trials will be successful, nor does it predict final clinical trial results. In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful. Later stage clinical trials of imetelstat may fail to show an acceptable benefit-risk profile despite having progressed through non-clinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have frequently suffered significant setbacks in later clinical trials, even after achieving promising results in earlier non-clinical studies or clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, Phase 3 clinical trials with larger numbers of patients or longer durations of therapy may fail to replicate efficacy and safety results observed in earlier clinical trials, such as IMbark, and if this were to occur with IMpactMF, this would adversely affect future development prospects of imetelstat, and as a result, impact the potential commercialization of imetelstat in relapsed/refractory MF, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, business prospects and the future of imetelstat, any of which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, non-clinical and clinical data are often susceptible to varying interpretations and analyses. In some instances, there can be significant variability between different clinical trials of imetelstat due to numerous factors, including changes in trial procedures set forth in trial protocols, differences in the size and type of patient populations, and changes in and adherence to the dosing regimens. For example, although the statistical analyses comparing IMbark data to closely matched real world data, or RWD, published in the September 2021 issue of the Annals of Hematology, suggest potentially favorable overall survival in relapsed/refractory MF patients treated with imetelstat, compared to BAT using closely matched patients&#8217; RWD, such comparative analyses between RWD and our clinical trial data have several limitations. For instance, the analyses create a balance between treatment groups with respect to commonly available covariates, but do not take into account the unmeasured and unknown covariates that may affect the outcomes of the analyses. Potential biases are introduced by factors which include, for example, the selection of the patients included in the analyses, misclassification in the matching process, the small sample size, and estimates that may not represent the outcomes for the true treated patient population. Failure to achieve results supporting a positive benefit-risk profile in current or potential future imetelstat clinical trials would interrupt, further delay, or halt, any development, and as a result, prevent potential regulatory approval and commercialization of imetelstat, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, business prospects and the future of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, preliminary data are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Additional or updated safety and efficacy data from current or potential future clinical trials of imetelstat may result in a benefit-risk profile that does not justify the continued development and/or potential regulatory approval of imetelstat in a particular patient population, or at all. Any data reported from IMpactMF may materially differ from and be less positive than data previously reported from IMbark. Thus, reported data should be considered carefully and with caution, and not relied upon as indicative of future clinical results. Such additional data could result in a lower</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">benefit-risk profile than initially expected, which could hinder the potential success of IMpactMF, IMproveMF or IMpress, or cause us to abandon further development of imetelstat entirely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Top-line results and data may differ from future results of the same study, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Moreover, as remaining patients in IMerge Phase 3 continue to be treated and followed under the extension phase of the trial and longer-term outcomes are assessed, these additional and more mature data may alter the benefit-risk profile of imetelstat in an adverse manner, including with respect to overall survival. Material adverse differences in future results, compared to preliminary, interim or top-line data, could severely and adversely affect our financial results, business and business prospects, and the future of imetelstat, including the potential commercialization of imetelstat, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third parties to conduct our current and potential future clinical trials of imetelstat. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to continue the development of, obtain regulatory approval for, or commercialize imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have the ability to independently conduct clinical trials. Therefore, we rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, service providers, vendors, suppliers and consultants, to conduct clinical trials of imetelstat. The third parties we contract with for execution of our current and potential future clinical or investigator-sponsored trials of imetelstat play a critical role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control their performance, or the amount or timing of resources that they devote to imetelstat. For example, we have retained CROs to support our imetelstat clinical development activities, and any failure by our CROs to perform their contractual obligations, or disputes with our CROs about the quality of their performance or other matters, could further delay or halt our imetelstat clinical development activities. These third parties may also have relationships with other commercial entities, some of which may compete with us. Under certain circumstances, these third parties may terminate their agreements with us without cause and upon immediate written notice.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we rely on third parties to conduct our imetelstat clinical trials, we remain responsible for ensuring that each clinical trial is conducted in accordance with its investigational plan and protocol, and applicable laws. Moreover, the FDA and similar international regulatory authorities require us to comply with GCP regulations and standards for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the rights, integrity and confidentiality of patients participating in clinical trials are protected, including being adequately informed of the potential risks. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, or similar international regulatory authorities, may require us to perform additional clinical trials before approving any application for regulatory approval. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP or other applicable regulations. In addition, our clinical trials must be conducted with imetelstat produced under applicable GMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would further delay the process for any regulatory approval. Our ability to comply with these regulations and standards may be contingent upon activities conducted by third parties, and if they fail to perform in accordance with contractual obligations and legal requirements, our development of imetelstat may be interrupted, further delayed or halted. Any failures by us or third parties noted above would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, business prospects and the future of imetelstat, including the potential commercialization of imetelstat, any of which might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the execution of clinical trials and the subsequent compilation and analysis of the data produced, including the interim and final analyses for IMpactMF, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. If the quality or accuracy of the clinical data obtained, compiled or analyzed by third parties is compromised due to their failure to adhere to our clinical trial protocols, GCP or GMP requirements, or for any other reason, we may need to enter into new arrangements with alternative third parties, which would cause delay, and could be difficult, costly or impossible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Switching or adding CROs, investigators, vendors and other third parties involves additional costs and delays because of the time it takes to finalize a contract with a new CRO and for their commencement of work. Although we carefully manage our relationships with our CROs, investigators, vendors and other third parties, we and any of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">these third parties may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business, business prospects and the future of imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain principal investigators for our clinical trials serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected conduct of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of any applications for approval by the FDA and may ultimately lead to the denial of approval of imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not control the conduct of current or any potential future investigator-led clinical trials, and data from such trials could show marginal efficacy and/or clinically relevant safety concerns related to imetelstat resulting in an unfavorable benefit-risk assessment that could materially and adversely impact our ongoing clinical trials, our imetelstat development program as a whole, and/or the prospect for approval for imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not control the design or administration of the investigator-led clinical trial, IMpress, or any potential future investigator-led trials, nor the submission, approval or maintenance of any IND or international equivalent filings required to conduct these clinical trials. In addition, we do not have control over the timing and reporting of the data from any such investigator-led clinical trials. A delay in the timely completion of or reporting of data from any potential future investigator-led clinical trial could have a material adverse effect on our ability to further develop imetelstat or to advance imetelstat to subsequent clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investigator-led clinical trials may be conducted under less rigorous clinical standards than those used in company-sponsored clinical trials. Accordingly, regulatory authorities may closely scrutinize the data collected from these investigator-led clinical trials. In addition, any investigator-led clinical trials could show marginal efficacy and/or clinically relevant safety concerns that could delay, limit or preclude the further clinical development or marketing approval of imetelstat in any indication, including lower-risk MDS. To the extent that the results of any investigator-led clinical trials raise safety or other concerns regarding imetelstat, regulatory authorities may question the results of such investigator-led clinical trials, or question the results of any of our clinical trials. Safety concerns arising from future investigator-led clinical trials could result in partial or full clinical holds being placed on the imetelstat INDs by the FDA or other similar international regulatory authorities, as occurred in March 2014, which would further delay or prevent us from advancing imetelstat into further clinical development, would delay or preclude any marketing approvals for imetelstat and could cause us to discontinue our development of imetelstat, any of which would severely harm our business and prospects, including the potential commercialization of imetelstat, and could potentially cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory APPROVAL and Commercialization of Imetelstat</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our inability to obtain and maintain regulatory clearances and approvals to continue the clinical development of, and to potentially commercialize, imetelstat, would severely and adversely affect imetelstat&#8217;s future value, and our business and business prospects, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal, state and local governments in the U.S. and governments in other countries have significant regulations in place that govern drug research and development and may prevent us from successfully conducting development efforts or potentially commercializing imetelstat. Delays in obtaining or failure to maintain regulatory clearances and approvals, or limitations in the scope of such clearances or approvals, could:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impede, halt or increase the costs of our plans for clinical development and commercialization;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significantly harm the commercial potential of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminish any competitive advantages that may have been available to us; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or preclude any revenue we may receive from the future commercialization of imetelstat, if any.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any such event would significantly harm our business, business prospects, including any potential commercialization of imetelstat, and the future value of imetelstat and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain regulatory approval for and successfully commercialize imetelstat, or experience significant delays in doing so, our business will be severely harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining marketing approvals, both in the U.S. and in other countries, is lengthy, expensive and uncertain. It may take many years to obtain approval, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Of the large number of drugs in development, only a small percentage complete the regulatory approval process and are successfully commercialized. In addition, the lengthy review process as well as the unpredictability of future clinical trial results may result in a delay in obtaining, or our failure to obtain, regulatory approval for imetelstat in lower-risk MDS, relapsed/refractory MF, or any other indication, which would significantly harm our business, business prospects, including the potential commercialization of imetelstat, and the future value of imetelstat and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securing marketing approval requires the submission of extensive non-clinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish to the satisfaction of such regulatory authorities the product candidate&#8217;s safety and efficacy, as well as information about the product manufacturing process and any inspections of manufacturing facilities conducted by regulatory authorities through the filing of an NDA in the U.S. and an MAA in Europe. Although the FDA has accepted for standard review our NDA for imetelstat for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS who have failed to respond or have lost response to or are ineligible for ESAs, and the EMA has validated our MAA for imetelstat for the same proposed indication, there can be no assurance that we will receive regulatory approval by the FDA or the European Commission for the commercialization of imetelstat in a timely manner or at all. Further, because non-clinical and clinical data are often susceptible to varying interpretations and analyses, regulatory authorities, including the FDA and EMA, may disagree with our interpretation of the data and may require additional clinical testing and/or further analyses from completed clinical or non-clinical trials before we can obtain regulatory approval and begin commercialization of imetelstat, if at all, any of which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. For example, in connection with the anticipated FDA oncology drug advisory committee meeting concerning the NDA for imetelstat in lower-risk MDS, the FDA will release its review of our data, which may differ, perhaps materially, from our interpretation of our data. Additionally, many sponsors experience volatility in the stock price surrounding the advisory committee&#8217;s discussion and vote, even though FDA is not obligated to follow the advisory committee&#8217;s input.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, in IMerge Phase 3 we shortened the follow-up period after the last patient has been enrolled from 15 months to 12 months to enable an earlier clinical cut-off date for the primary analysis. Although we reported positive top-line results from IMerge Phase 3 in January 2023, our decision to shorten the follow-up period after the last patient has been enrolled may result in further clinical responses that may have occurred after the 12-month clinical cut-off date being excluded from the primary analysis. The exclusion of this future data from the primary analysis could reduce the overall efficacy results, including durability of transfusion independence, which could otherwise delay, limit or prevent marketing approval of imetelstat in lower-risk MDS by the FDA or similar international regulatory authorities or require additional clinical trials and further testing prior to granting any regulatory approval to market imetelstat in lower-risk MDS.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even though we reported positive top-line results from IMerge Phase 3 in January 2023, those results are not necessarily predictive of imetelstat activity in other indications and for other pivotal trials that may be needed to support any application to the FDA or similar international regulatory authorities for such other indications, such as from IMpactMF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events may result in a failure to further develop, obtain regulatory approval for or commercialize imetelstat, which would severely and adversely affect our business and business prospects, and might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, with respect to the trial design for IMpactMF, the FDA urged us to consider adding a third dosing arm to the trial to assess a lower dose and/or a more frequent dosing schedule that might improve the trial&#8217;s chance of success by identifying a less toxic regimen and/or more effective spleen response, one of the trial&#8217;s secondary endpoints. Based on data from IMbark, we believe that testing a lower dose regimen would likely result in a lower median OS, which is the trial&#8217;s primary endpoint, in the imetelstat treatment arm. Existing data also suggest that lowering the dose would not result in a clinically meaningful reduction in toxicity, and for these reasons we determined not to add a third dosing arm to the trial design and the FDA did not object to our proposed imetelstat dose and schedule of 9.4 mg/kg every three weeks. Our belief may ultimately be incorrect. Therefore, our failure to add a third dosing arm could result in a failure to maintain regulatory clearance from the FDA and similar international regulatory authorities, could result in the trial&#8217;s failure, or could otherwise delay, limit or prevent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing approval of imetelstat for relapsed/refractory MF by the FDA or similar international regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat must receive all relevant regulatory approvals before it may be marketed in the U.S. or other countries. Regulatory authorities have substantial discretion in the approval process and can delay, limit or deny approval of imetelstat or require us to conduct additional non-clinical or clinical testing or abandon a program for many reasons, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreement with the design or implementation of our clinical trials, including our statistical analysis of trial results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to demonstrate to the FDA or similar international regulatory authorities that imetelstat&#8217;s efficacy results provide sufficient evidence of overall clinical benefit;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable benefit-to-risk assessment, in the case of marginal efficacy and/or clinically relevant safety concerns, for any proposed indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreement with our interpretation of data from non-clinical studies or clinical trials, including disagreement from the oncology drug advisory committee that the FDA has scheduled for March 14, 2024 in connection with the review of the NDA for imetelstat in lower-risk MDS;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rejection by the FDA of foreign data included in the NDA and the non-applicability of this data to the U.S. population and U.S. medical practice; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identification of critical issues as a result of a pre-approval health authority inspection that could negatively impact the integrity of data in an NDA or MAA and lead to a rejection by the FDA, European Commission, or similar international health authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA, EMA, or similar international regulatory authorities that the appropriate indication for commercial use of imetelstat is narrower or more restrictive than anticipated;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to satisfy the requirement to develop a risk evaluation and mitigation strategy, or REMS, for the U.S. and a risk management plan for the EU including post-marketing studies, as a potential condition to approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreement regarding the formulation, labeling and/or the specifications for imetelstat; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the quality or stability of imetelstat to meet acceptable regulatory standards;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, EMA, the competent authorities of the individual EU Member States or similar international regulatory authorities may lack resources or be delayed in conducting pre-approval inspections due to lack of resources or other reasons;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or any third-party service providers may be unable to demonstrate compliance with GMP, GCP, or other applicable regulatory and other requirements to the satisfaction of the FDA, the competent authorities of the individual EU Member States or similar international regulatory authorities; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory policies or approval processes, or potential reduction of unmet medical need with the entry of competitive therapies to the market, could render our clinical efficacy or safety data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, in recent years, there has been increased public and political scrutiny on the FDA and similar international regulatory authorities with respect to the approval process for new drugs, and as a result regulatory authorities may apply more stringent regulatory standards, especially regarding drug safety, when reviewing regulatory submissions for new drugs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that increase our costs or render imetelstat not commercially viable, which would harm imetelstat&#8217;s future value and our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities may also not approve the labeling claims that are necessary or desirable for the successful commercialization of a drug, such as imetelstat. For example, regulatory authorities may not agree with our belief in the disease-modifying properties of imetelstat, and future regulatory clearances, if any, that we might obtain for imetelstat may be limited to fewer or narrower indications than we might request, or may be granted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to the performance of post-marketing studies, which may impose further requirements or restrictions on the distribution or use of imetelstat, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for imetelstat and affect reimbursement by third-party payors. Future regulatory clearances, if any, may be limited to a smaller patient population, or may require a different drug formulation or a different manufacturing process, than we might in the future decide to seek.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, failure by our former collaborator to comply with applicable regulatory guidelines prior to our assumption of sponsorship of the imetelstat program, or to provide information if requested by regulatory authorities, could result in administrative or judicially imposed sanctions on us, including warning letters, civil and criminal penalties, injunctions, product seizures or detention, product recalls, total or partial suspension of manufacturing activities, and the potential refusal to approve any NDAs, including the NDA for imetelstat in lower-risk MDS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay in obtaining or failure to obtain required approvals of imetelstat, or limitations on any regulatory approval that we might receive in the future, if any, could reduce the potential commercial use of imetelstat, and potential market demand for imetelstat and therefore result in decreased revenue for us from any commercialization of imetelstat, any of which would severely and adversely affect our financial results and ability to raise additional capital, the price of our common stock, our business and business prospects, including the potential commercialization of imetelstat, and the future of imetelstat, and might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any regulatory approval that we may potentially receive for imetelstat could be subject to restrictions, and we may be subject to penalties or product withdrawal if we fail to comply with regulatory requirements or if we experience unanticipated problems with imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;min-width:fit-content;">&#65279;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approval that we may potentially receive for imetelstat could be subject to restrictions or conditions of approval that may require potentially costly post-marketing clinical trials or surveillance to monitor safety and efficacy of the drug candidate. In addition, imetelstat and the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities related to imetelstat will be subject to continual requirements of, and review by, the FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration requirements, current Good Manufacturing Practice (cGMP) requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding promotional interactions with healthcare professionals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with these regulatory requirements or later discovery of previously unknown problems with imetelstat, or our manufacturers, or manufacturing processes for imetelstat, may result in actions such as restrictions on imetelstat manufacturing, distribution or use; restrictions on labeling or marketing; requirements to conduct post-marketing studies or clinical trials; warning letters, withdrawal of imetelstat from the market; refusal to approve our pending regulatory applications, or any supplements to approved applications that we might submit; recalls; suspension or termination of ongoing clinical trials; fines, restitutions or disgorgement of profits or revenues; refusal to permit the import or export of imetelstat; product seizure or detentions; injunctions or the imposition of civil or criminal penalties; and adverse publicity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. In addition, the FDA&#8217;s regulations, policies or guidance may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. We also cannot predict the likelihood, nature, or extent of adverse government regulation that may arise from pending or future legislation or administrative action, either in the United States or abroad.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;min-width:fit-content;">&#65279;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to fulfill any potential post approval commitments that may be applied to the approval and commercialization of imetelstat by any regulatory authority, or are unable to adapt, to changes in existing regulatory requirements or adoption of new regulatory requirements or policies,there may be a negative impact to our business and continued regulatory approval of imetelstat. Under such circumstances, we or our respective clinical investigators may be subject to the actions listed above, including losing marketing approval for imetelstat, which would severely and adversely affect our business and business prospects, including the potential commercialization of imetelstat, and the future of imetelstat, and might cause us to cease operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If imetelstat is approved for commercialization and we are unable to establish and maintain effective sales, marketing and distribution capabilities or enter into agreements with third parties to commercialize imetelstat, we will be unable to successfully commercialize imetelstat if and when it is approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We need to complete substantial preparations to be ready for any potential future commercialization of imetelstat, and we are in the process of establishing sales, marketing and distribution capabilities. As a company, we have no experience in selling and marketing products. To advance imetelstat to potential marketing approval and commercialization, we will be required to complete our commercialization preparatory activities, including obtaining and maintaining state licenses where required for us to sell imetelstat, and continue to incur related expenses, before we obtain any marketing approval. These activities include, among other things, the development of an in-house marketing and sales force, which will continue to require significant capital expenditures, management resources and time. We will have to compete with other companies to recruit, hire, train and retain qualified marketing and sales personnel. If we are unable to adequately prepare for the potential future commercialization of imetelstat, we may not be able to generate product revenue if marketing authorization is obtained.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are risks involved with both establishing our own sales, marketing and distribution capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of imetelstat for which we recruit a sales and marketing force and establish distribution capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses, which would be costly. Even if imetelstat is approved in lower-risk MDS and we are able to establish our own sales and marketing capabilities, imetelstat will be a newly-marketed drug. If we are unable to effectively train sales personnel and equip them with compliant and effective materials, our efforts to successfully commercialize imetelstat could be adversely affected, which would negatively impact our business, business prospects and the future value of imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we enter into arrangements with third parties to perform commercialization services like sales, marketing and distribution, we will be reliant on the efforts of such third parties, and our sales revenue from sales of imetelstat or the profitability from such sales to us are likely to be lower than if we were to market and sell imetelstat ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize imetelstat or may be unable to do so on terms that are favorable to us. In entering into third-party commercialization arrangements, any revenue we receive will depend upon the efforts of the third parties, and we cannot assure you that such third parties will establish adequate commercialization capabilities or devote the necessary resources and attention to commercialize imetelstat effectively. We also face competition in our search for third parties to assist us with the commercialization efforts of imetelstat.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to successfully establish and maintain effective commercialization capabilities for imetelstat, if we receive regulatory approval to do so, would severely and adversely affect our financial results, business and business prospects, including the potential commercialization of imetelstat, and the future of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain acceptable prices or adequate reimbursement for imetelstat, the use of imetelstat could be severely limited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability to successfully commercialize imetelstat, if approved, will depend significantly on obtaining acceptable prices and the availability of coverage and adequate reimbursement to the patient from third-party payors. Government payors, such as the Medicare and Medicaid programs, and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and the reimbursement levels. Assuming we obtain coverage for imetelstat by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. If imetelstat is approved for commercial sale, patients are unlikely to use it unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of its cost. Therefore, coverage and adequate reimbursement will be critical to new product acceptance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. The Inflation Reduction Act of 2022, or the Inflation Reduction Act, includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, which may ultimately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have a negative effect on the pricing for imetelstat, should it receive regulatory approval. However, the Medicare drug pricing negotiation program provisions of the law are currently subject to legal challenges. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of imetelstat to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be sure that coverage and reimbursement will be available for imetelstat, if approved for commercial sale, and, if reimbursement is available, what the level of reimbursement will be. There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar international regulatory authorities. Coverage and reimbursement may impact the demand for, or the price of imetelstat, if marketing approval is obtained. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize imetelstat, even if marketing approval is obtained, which would negatively impact our business and business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although orphan drug designation has been granted to imetelstat for the treatment of MF and MDS in the U.S. and in the EU, these designations may not be maintained, which would eliminate the benefits associated with orphan drug designation, including the potential for market exclusivity, which would likely result in decreased sales revenue from commercialization of imetelstat, if any, and would likely harm our business and business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA granted orphan drug designation to imetelstat in June 2015 for the treatment of MF and for the treatment of MDS in December 2015, and the European Commission granted orphan drug designation in December 2015 to imetelstat for the treatment of MF and in July 2020 for the treatment of MDS. The designation of imetelstat as an orphan drug does not guarantee that any regulatory authority will accelerate regulatory review of, or ultimately approve, imetelstat, nor does it limit the ability of any regulatory authority to grant orphan drug designation to product candidates of other companies that treat the same indications as imetelstat prior to imetelstat receiving any exclusive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may lose orphan drug exclusivity for certain reasons, including if the FDA or the European Commission determines that the request for orphan drug designation was materially defective or if we cannot ensure sufficient quantities of imetelstat to meet the needs of patients with MF or MDS. Failure to maintain orphan designation status, or failure to agree to and complete any agreed upon pediatric plan, would lead to the inability to obtain or the loss of such regulatory exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we maintain orphan drug exclusivity for imetelstat, the exclusivity may not effectively protect imetelstat from all competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug product is approved, the FDA or the European Commission can subsequently approve a different drug with the same active moiety for the same condition, if the FDA or the European Commission concludes that the later drug is safer, more effective, or makes a major contribution to patient care. The occurrence of any of these events could result in decreased sales of imetelstat, should it ever receive marketing approval, and may harm our business and business prospects. In addition, orphan drug designation will neither shorten the development time nor regulatory review time for imetelstat, and it does not give imetelstat any advantage in the regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although imetelstat has received Fast Track designation by the FDA for MDS and MF, this does not guarantee marketing approval and may not lead to a faster development, regulatory review or approval process.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2017, the FDA granted Fast Track designation to imetelstat for the treatment of adult patients with transfusion-dependent low red blood cell counts, or anemia, due to non-del(5q) lower-risk MDS and who are refractory or resistant to treatment with an ESA. In September 2019, the FDA granted Fast Track designation to imetelstat for the treatment of adult patients with relapsed/refractory MF.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast Track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of the sponsor&#8217;s NDA. Fast Track designation is intended to facilitate and expedite development and review of an NDA to address unmet medical needs in the treatment of serious or life-threatening conditions. However, Fast Track designation does not accelerate conduct of clinical trials or mean that the regulatory requirements are less stringent, nor does it ensure that any imetelstat NDA will be approved or that any approval will be granted within any particular timeframe. In addition, the FDA may withdraw Fast Track designation for any indication if it believes that the designation is no longer supported by data emerging from the imetelstat clinical development program.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to achieve continued compliance with government regulations could delay or halt potential commercialization of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approved products and their manufacturers are subject to continual review, and discovery of previously unknown problems with a product or its manufacturer may result in restrictions on the product or manufacturer, including import restrictions, seizure and withdrawal of the product from the market. If approved for commercial sale, future sales of imetelstat will be subject to government regulation related to numerous matters, including the processes of:</span></p>
  <div style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.745293988246756%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing;</span></div></div>
  <div style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.745293988246756%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advertising and promoting;</span></div></div>
  <div style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.745293988246756%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selling and marketing;</span></div></div>
  <div style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.745293988246756%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">medical information;</span></div></div>
  <div style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.745293988246756%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">labeling; and</span></div></div>
  <div style="margin-left:4.537%;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.745293988246756%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distribution.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If, and to the extent that, we are unable to comply with these regulations, our ability to earn potential revenue from the commercialization of imetelstat, if any, would be materially and adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if imetelstat causes serious or unexpected side effects or is associated with other safety risks after receiving marketing approval, a number of potential significant negative consequences could result, including, but not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw their approval of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to recall imetelstat, seek to change the way it is administered, conduct additional clinical trials or change the labeling of the product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require revisions to the labeling of imetelstat, including limitations on approved uses or the addition of further warnings, contraindications or other safety information, or may impose restrictions on distribution in the form of REMS in connection with approval, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience manufacturing delays and supply disruptions if regulatory inspectors identify regulatory noncompliance by third-party manufacturers requiring remediation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imetelstat may be rendered less competitive and sales may decrease;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer generally both among clinicians and patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be exposed to potential lawsuits and associated legal expenses, including costs of resolving claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or similar international regulatory authorities may refuse to approve pending applications or supplements to approved applications filed by us, or may suspend or revoke license approvals; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change or stop ongoing clinical trials of imetelstat, which would negatively impact the development of imetelstat for other potential indications.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance for imetelstat or could substantially increase the costs and expenses of commercializing imetelstat, which in turn could delay or prevent us from generating any revenues from the sale of the imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce regulations prohibiting the promotion of any drug product for off-label uses. If we were found to have improperly promoted off-label use of imetelstat, we would be subject to significant civil, criminal and administrative penalties, which would inhibit our ability to commercialize imetelstat and generate revenue, require us to expend significant time and resources in response, and generate negative publicity. Enforcement actions include, among others:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory inspection findings;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters, or untitled letters;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on, or prohibitions against, marketing imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on, or prohibitions against, importation or exportation of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of review or refusal to approve pending applications or supplements to approved applications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exclusion from participation in government-funded healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exclusion from eligibility for the award of government contracts for imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of product approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizures;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">civil and criminal penalties and fines.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The imposition of any of these penalties or other commercial limitations, including equivalent penalties or commercial limitations imposed by foreign regulatory authorities, would severely and adversely affect our financial results, business and business prospects, including the potential commercialization of imetelstat, and the future of imetelstat, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are seeking regulatory approval to market imetelstat in Europe, and as a result, we may experience additional risks related to marketing outside of the U.S. that would materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are seeking regulatory approval to market imetelstat in Europe, and may be subject to additional risks, including, if regulatory approval is obtained from the European Commission, risks related to operating outside of the U.S., such as:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">European Commission and other foreign regulatory approvals, if any, may take longer and be more costly to obtain than approvals in the U.S., due to differing regulatory requirements in foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EMA and other regulatory authorities outside of the U.S. may disagree with the design, implementation or results of our clinical trials or our interpretation of data from nonclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval policies or regulations of EMA or other regulatory authorities outside of the U.S. may significantly change in a manner rendering our clinical data insufficient for potential approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks of potential noncompliance with legal requirements applicable to privacy, data protection, information security and other matters;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks of potential noncompliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased taxes outside of the U.S., including withholding and payroll taxes;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing operations outside of the U.S.;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable regulations outside of the U.S.;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncertainty in the regulatory framework and future legislation could lead to disruption in the execution of international multi-center clinical trials, the monitoring of adverse events through pharmacovigilance programs, the evaluation of the benefit-risk profiles of new medicinal products, and determination of marketing authorization across different jurisdictions. Changes to existing regulations may add considerably to the time from clinical development to marketing authorization and commercialization of products in the EU and increase our costs. We cannot predict the impact of such changes and future regulation on our business or the results of our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with federal, state and international healthcare laws, including fraud and abuse, transparency, and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including federal and state fraud and abuse laws, including anti-kickback and false claims laws; data privacy and security laws, including the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH; and transparency laws related to payments and/or other transfers of value made to physicians, other healthcare professionals and teaching hospitals. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute imetelstat, if marketing approval is obtained. For details regarding the restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate, see Item 1 &#8220;Business&#8212;Government Regulation&#8212; Fraud and Abuse, and Transparency Laws and Regulations.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal and state enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. If our operations are found to be in violation of any of these or any other healthcare and privacy-related regulatory laws that may apply to us, our ability to operate our business and our results of operations could be adversely affected by:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement and imprisonment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reputational harm;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished profits and future earnings;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">curtailment of our operations. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Manufacturing Imetelstat</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure by us to establish and/or maintain a manufacturing supply chain to appropriately and adequately supply imetelstat for future clinical and commercial uses would result in a further delay in or cessation of clinical trials and a delay in our ability to obtain regulatory approvals of imetelstat, and affect our ability to commercialize imetelstat, and our business and business prospects could be severely harmed, and we could cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of imetelstat must comply with applicable regulatory standards for current and potential future clinical trials and potential commercial uses. The process of manufacturing imetelstat is complex and subject to several risks, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to scale-up and attain sufficient production yields with appropriate quality control and quality assurance to meet the needs of our clinical trials and potential future market demand, and to establish commercial supply agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reliance on third-party manufacturers and suppliers, whose efforts we do not control;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">supply chain issues, including the timely availability and shelf life requirements of raw materials and other supplies, any of which may be impacted by a number of factors, including the effects of macroeconomic or other global conditions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shortage of qualified personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory acceptance and compliance with regulatory requirements, which are less well-defined for oligonucleotide products than for small molecule drugs and vary in each country where imetelstat might be sold or used.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of these and other risks, we may be unable to establish and/or maintain a manufacturing infrastructure and supply chain capable of providing imetelstat for our clinical trials, our expanded access program, and potential future commercial uses, which would delay or result in a cessation of such current or potential future clinical trials, potential regulatory approvals and commercialization of imetelstat and cause financial and reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If third parties that manufacture imetelstat fail to perform as needed, the clinical and commercial supply of imetelstat will be limited, and we may be unable to conduct or complete current or potential future clinical trials of imetelstat or to commercialize imetelstat in the future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our imetelstat manufacturing supply chain relies, and will continue to rely, solely upon third-party manufacturers to perform certain process development or other technical and scientific work with respect to imetelstat, as well as to supply starting materials and manufacture drug substance and drug product. While we have established arrangements with third parties for the manufacture of imetelstat, our manufacturing supply chain is highly specialized, and as such we are reliant upon a small group of third-party manufacturers to supply starting materials, drug substance and drug product. Failure by such third-party manufacturers to perform in a timely manner and in compliance with all regulatory requirements, or at all, could further delay, perhaps substantially, or preclude our ability to pursue imetelstat development on our own, increase our costs and otherwise negatively affect our financial results, business and business prospects. In this regard, recent FDA inspections of one of our third-party manufacturers identified certain deficiencies in the manufacturer&#8217;s processes and facilities which, while not directly related to the production of imetelstat, could impact the manufacturer&#8217;s ability to produce and deliver products, including imetelstat, if not remediated by the manufacturer, and could lead to delays or shortages in drug supply, or the inability to manufacture or ship drug supply necessary for non-clinical and clinical activities and commercialization. We expect to rely on third-party manufacturers to produce and deliver sufficient quantities of imetelstat and other materials to support clinical trials and potential commercialization on a timely basis and to comply with applicable regulatory requirements. We do not have direct control over these third-party personnel or operations. Reliance on these third-party manufacturers is subject to numerous risks, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to execute timely contracts with third-party manufacturers and suppliers on acceptable terms, or at all;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays and disruptions experienced by third-party manufacturers that adversely impact the ability of such parties to fulfill their contractual obligations to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">capacity limitations and scheduling constraints experienced by third-party manufacturers due to scheduling and other commitments, and queued manufacturing activities in contracted facilities; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements by regulatory authorities to validate and qualify significant activities for any current or replacement manufacturer, which could involve new testing and compliance inspections;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of third-party manufacturers to timely formulate and manufacture imetelstat or to produce or ship imetelstat in the quantities or of the quality required to meet clinical and commercial needs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the possible mislabeling by third-party manufacturers of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or comparator not being properly identified;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decisions by third-party manufacturers to exit the contract manufacturing business during the time required to supply clinical trials or to successfully produce, store and distribute imetelstat to meet commercial needs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance by third-party manufacturers with GMP standards mandated by the FDA and state agencies and other government regulations, including foreign governing regulations, corresponding to similar international regulatory authorities, including any deficiencies identified during regulatory inspections, such as those identified in a recent FDA inspection of one of our third-party manufacturers;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">breach or termination of manufacturing or supply contracts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inadequate storage or maintenance at contracted facilities resulting in theft or spoilage; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">natural disasters that affect contracted facilities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each of these risks could lead to delays or shortages in drug supply, or the inability to manufacture or ship drug supply necessary for non-clinical and clinical activities, and commercialization, which could severely and adversely affect our financial results, business and business prospects, and the future of imetelstat and cause reputational harm.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, third-party manufacturers and/or any other manufacturers may need to make substantial investments to enable sufficient capacity increases and cost reductions, and to implement those regulatory and compliance standards necessary for successful Phase 3 clinical trials and commercial production of imetelstat. These third-party manufacturers may not be willing or able to achieve such capacity increases, cost reductions, or regulatory and compliance standards, and even if they do, such achievements may not be at commercially reasonable costs. Changing manufacturers may be prolonged and difficult due to inherent technical complexities and because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer on acceptable terms, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position and Need For Additional Financing</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to obtain additional capital would force us to further delay, reduce or eliminate development and potential future commercialization of imetelstat, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful drug development and commercialization requires significant amounts of capital. As of December 31, 2023, we had approximately $378.1 million in cash, cash equivalents, restricted cash and current and noncurrent marketable securities. Based on our current operating plan and our assumptions regarding the timing of the potential approval and commercial launch of imetelstat in lower-risk MDS in the U.S., we believe that our existing cash, cash equivalents, and current and noncurrent marketable securities, together with projected revenues from U.S. sales of imetelstat, if approved, potential proceeds from the exercise of outstanding warrants, and potential future drawdowns under the Loan Agreement, will be sufficient to fund our projected operating requirements into the third quarter of 2025. Our ability to generate revenues from sales of imetelstat in the U.S., if regulatory approval is granted, depends on us being able to establish sales and marketing capabilities and gain acceptance in the marketplace, which we may be unable to do in a timely manner or at all. In addition, we cannot predict with any certainty whether and to what extent the remaining outstanding warrants will be exercised for cash, or the timing or availability of additional funds under the Loan Agreement, if at all. Our ability to drawdown any remaining tranches under the Loan Agreement is subject to our achievement of certain regulatory milestones and satisfaction of certain capitalization requirements, as well as approval by an investment committee comprised of Hercules and SVB for the final $25.0 million tranche. In addition, even if imetelstat is approved in lower-risk MDS and commercialized by us in the U.S. in that indication and we are able to drawdown the remaining tranches under the Loan Agreement in full, we will still require substantial additional funding to further advance the imetelstat program, including through the completion of our ongoing clinical trials and any potential future clinical trials, as well as conducting the clinical, regulatory and potential commercialization activities necessary to potentially bring imetelstat to market in relapsed/refractory MF and any other indications we are pursuing or may pursue, and our need for additional funds</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may arise sooner than planned. If adequate funds are not available on a timely basis, if at all, we may be unable to pursue further development or potential commercialization of imetelstat, which would severely harm our business and we might cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the outcome of any clinical activities and/or regulatory approval process is highly uncertain, we cannot reasonably estimate whether any development activities we may undertake will succeed; whether we will obtain regulatory approval for imetelstat in any indication we pursue, including in lower-risk MDS; or, if approved, whether we will be able to effectively commercialize imetelstat, if at all. We may never recoup our investment in any imetelstat development which would adversely affect our financial condition and our business and business prospects, and might cause us to cease operations. In addition, our plans and timing expectations could be further delayed or interrupted by the effects of macroeconomic or other global conditions, including those resulting from inflation, rising interest rates, prospects of a recession, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues. Further, our future capital requirements are difficult to forecast and will depend on many factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accuracy of the assumptions underlying our estimates for our capital needs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, timing, magnitude and costs of non-clinical and clinical development, manufacturing and potential commercialization of imetelstat, including the number of indications being pursued, subject to clearances and approvals by the FDA and similar international regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or disruptions in opening sites, screening and enrolling patients or treating and following patients,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in our current or any potential future clinical trials of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcomes of regulatory reviews or other regulatory actions related to imetelstat, including with respect to our NDA and EMA submissions for imetelstat in lower-risk MDS;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of manufacturing, developing, commercializing and marketing imetelstat, including with respect to third-party vendors and service providers and our ability to achieve any meaningful reduction in manufacturing costs, if imetelstat receives future regulatory approval or clearance, in the U.S., EU or other countries; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sales price for imetelstat, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate third-party reimbursement for imetelstat, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other drugs and technologies, or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions, or to which we out-license imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we are able to enter into and conduct successful strategic partnerships, collaborations and alliances or licensing arrangements with third parties, including for the commercialization and marketing of imetelstat in certain global regions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the extent and scope of our general and administrative expenses, including expenses associated with potential future litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our level of indebtedness and associated debt service obligations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of maintaining and operating facilities in California and New Jersey, as well as higher expenses for travel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">macroeconomic or other global conditions that may reduce our ability to access debt capital or financing on preferable terms, which may adversely affect future capital requirements and forecasts; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of enabling our personnel to work remotely, including providing supplies, equipment and technology necessary for them to perform their responsibilities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until we can generate a sufficient amount of revenue from imetelstat to finance our cash requirements, which we may never achieve, we expect to finance future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, which may not be possible. Availability of such financing sources may be negatively impacted by any further delays in our clinical trials, regulatory developments, or the other risks described in this section.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional financing through public or private debt or equity financings, including pursuant to the 2023 Sales Agreement with B. Riley Securities, Inc., or B. Riley, the remaining tranches of up to $45.0 million available under the Loan Agreement, which are subject to the achievement of certain clinical and regulatory milestones and satisfaction of certain capitalization and other requirements, as well as approval by an investment committee comprised of Hercules and SVB for the final $25.0 million tranche; capital lease transactions or other financing sources, may not be available on acceptable terms, or at all. We may be unable to raise equity capital, or may be forced to do so at a stock price or on other terms that could result in substantial dilution of ownership for our stockholders. The receptivity of the public and private debt and equity markets to proposed financings has been substantially affected by uncertainty in the general economic, market and political climate due to the effects of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, and may in the future be affected by other factors which are unpredictable and over which we have no control. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, which could reduce or eliminate our ability to raise additional funds through financings, and could negatively impact the terms upon which we may raise those funds. Similarly, these macroeconomic conditions have created extreme volatility and disruption in the capital markets and is expected to have further global economic consequences. If the equity and credit markets deteriorate, including as a result of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. If we are unable to raise additional capital or establish alternative collaborative arrangements with third-party collaborative partners for imetelstat, the development and potential commercialization of imetelstat may be further delayed, altered or abandoned, which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may seek additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Due to uncertainty in the general economic, market and political climate, we may determine that it is necessary or appropriate to raise additional funds proactively to meet longer-term anticipated operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the 2023 Sales Agreement, your ownership interest as a stockholder may be diluted, and the terms may include liquidation or other preferences that materially and adversely affect your rights as a stockholder. In addition, we have borrowed, and in the future may borrow, additional capital from institutional and commercial banking sources to fund imetelstat development and our future growth, including pursuant to our Loan Agreement or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms under agreements, such as the Loan Agreement, that include restrictive covenants, including covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Moreover, if we raise additional funds through alliance, collaborative or licensing arrangements with third parties, we may have to relinquish valuable rights to imetelstat or our technologies or grant licenses on terms that are not favorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that our existing capital resources, future interest income, future revenues from sales of imetelstat, if approved, potential future sales of our common stock, including under the 2023 Sales Agreement, and potential future drawdowns, if available, of the remaining tranches under the Loan Agreement, will be sufficient to fund our operating plans. Moreover, while we did not hold cash deposits or securities at SVB, if other banks and financial institutions enter receivership, become insolvent or otherwise fail in the future in response to financial conditions affecting the banking system and financial markets or otherwise, our ability to access our cash, cash equivalents and marketable securities may be delayed or precluded, which could have a material adverse effect on our business, business prospects and financial position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently have no source of product revenue and may never become profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although in the past we have received license and other payments under former license and collaboration agreements, we do not currently have any material revenue-generating license or collaboration agreements, have no products approved for commercialization and have never generated any revenue from product sales. In addition, we are incurring and have incurred operating losses every year since our operations began in 1990, except for one. As of December 31, 2023, our accumulated deficit was approximately $1.6 billion. Losses have resulted principally from costs incurred in connection with our research and development activities and from general and administrative costs associated with our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of our revenues to date have been payments under collaboration agreements and milestones, royalties and other revenues from our licensing arrangements. Our license agreements related to our human telomerase reverse transcriptase, or hTERT, technology have expired or been terminated due to expiration of the underlying hTERT patents, and will not generate any further revenues. We have no ongoing collaborations related to imetelstat and have no current plans to enter into any corporate collaboration, partnership or license agreements that result in revenues, although we may seek a collaborative partner or partners, at an appropriate time, to assist us in the potential development and commercialization of imetelstat, especially outside the U.S., and to provide funding for such activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also expect to experience increased negative cash flow for the foreseeable future as we fund our operations and imetelstat clinical development activities and research programs continue, and we prepare for potential commercialization of imetelstat. This will result in decreases in our working capital, total assets and stockholders&#8217; equity. We will need to generate significant revenues to achieve consistent future profitability. We may never achieve consistent future profitability. Even if we do become profitable in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to achieve consistent future profitability could negatively impact the market price of our common stock and our ability to sustain operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to our Indebtedness</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the total outstanding principal amount under the Loan Agreement was $80.0 million. The tranches for the remaining $45.0 million available to us under the Loan Agreement are as follows: (a) the first remaining tranche of $20.0 million is available until December 15, 2024, subject to the achievement of a certain regulatory milestone, and satisfaction of certain capitalization requirements; and (b) the second remaining tranche of $25.0 million is available through December 31, 2024, subject to approval by an investment committee comprised of Hercules and SVB. Without the achievement of the required regulatory milestone and satisfaction of certain capitalization and other requirements, we will not be eligible to draw funds under the first remaining tranche. If we do not receive investment committee approval, we will not be eligible to draw funds under the second remaining tranche under the Loan Agreement. In addition, before we would consider drawing down any of the remaining tranches under the Loan Agreement, if available, we must first satisfy ourselves that we will have access to future alternate sources of capital, such as from commercial revenues or the equity capital markets or debt capital markets, in order to repay any additional principal borrowed, which we may be unable to do, in which case, our liquidity and ability to fund our operations may be substantially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All obligations under the Loan Agreement are secured by substantially all of our assets, excluding intellectual property, which is subject to a negative pledge. Further, the terms of the Loan Agreement place restrictions on our operating and financial flexibility, and limit or prohibit our ability to dispose of certain assets, change our line of business, and engage in other significant transactions. This indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing the outstanding debt obligations at maturity. If we are able to draw down any of the remaining tranches under the Loan Agreement, our indebtedness will increase, which would further increase our risk of being unable to pay off or refinance our outstanding debt obligations at maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our indebtedness could also have important negative consequences, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we will need to repay the indebtedness by making payments of interest and principal, which will reduce the amount of cash available to finance our operations, our research and development efforts and other general corporate activities; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to comply with the obligations of our affirmative and restrictive covenants in the Loan Agreement could result in an event of default that, if not cured or waived, would accelerate our obligation to repay this indebtedness, and Hercules and SVB could seek to enforce their security interest in the assets securing such indebtedness.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may borrow additional capital in the future to fund imetelstat development and our future growth, including pursuant to the Loan Agreement or potentially pursuant to new arrangements with different lenders. To the extent additional debt is added to our current debt levels, the risks described above could increase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The terms of the Loan Agreement place restrictions on our operating and financial flexibility.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement imposes operating and other restrictions on us. Such restrictions will affect, and in many respects limit or prohibit, our ability and the ability of any future subsidiaries to, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">dispose of certain assets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">change our line of business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">engage in mergers, acquisitions or consolidations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incur additional indebtedness;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">create liens on assets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pay dividends and make contributions or repurchase our capital stock; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">engage in certain transactions with affiliates.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement also contains financial covenants, including that we must maintain a minimum cash balance.  The breach of any of these restrictive covenants or any other terms of the Loan Agreement would accelerate our obligation to repay our indebtedness under the Loan Agreement, which could have a material adverse effect on our business, business prospects and financial position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> We may not have cash available in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to make scheduled payments on or to refinance our indebtedness depends on our future performance and ability to raise additional sources of cash, which is subject to economic, financial, competitive and other factors beyond our control. If we are unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets, restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. If we desire to refinance our indebtedness, our ability to do so will depend on the state of the capital and lending markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to satisfy our current and future debt obligations under the Loan Agreement or to comply with certain covenants in the Loan Agreement could result in an event of default, the occurrence and continuance of which provide Hercules and SVB with the right to demand immediate repayment of all outstanding obligations under the Loan Agreement, and to exercise remedies against us and the collateral securing the Loan Agreement. These events of default include, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">insolvency, liquidation, bankruptcy or similar events; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to observe any covenant or secured obligation under the Loan Agreement, which failure, in most cases, is not cured within 15 days; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of an event that could reasonably be expected to have a material adverse effect on our business, operations, properties, assets or financial condition; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">material misrepresentations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of any default under any other agreement involving indebtedness in excess of specified amounts, or the occurrence of a default under any agreement that could reasonably be expected to have a material adverse effect on us; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">certain money judgments being entered against us or any portion of our assets are attached or seized.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of default, Hercules and SVB could accelerate all of the amounts due under the Loan Agreement. Under such circumstances, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time of such acceleration. In that case, we may be required to delay, limit, reduce or terminate imetelstat development or potential commercialization efforts or grant to others rights to develop and market imetelstat. Hercules and SVB could also exercise their rights to take possession and dispose of the collateral securing the Loan Agreement, which collateral includes substantially all of our property other than intellectual property. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Protecting Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for imetelstat, both in the U.S. and in other countries, our competitors could develop and commercialize products similar or identical to imetelstat, and our ability to successfully commercialize imetelstat may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Protection of our proprietary technology is critically important to our business. Our success and the success of our planned future development and commercialization of imetelstat will depend on our ability to protect our technologies and imetelstat through patents and other intellectual property rights. Our success will depend in part on our ability to obtain, maintain, enforce, and extend our patents and maintain trade secrets, both in the U.S. and in other countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and in other countries. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing imetelstat or our technology and/or limit the duration of the patent protection for imetelstat and our technology. In the event that we are unsuccessful in obtaining, maintaining, enforcing and extending our patents and other intellectual property rights or having our licensors maintain the intellectual property rights we have licensed, the value of imetelstat and/or our technologies will be adversely affected, and we may not be able to further develop or potentially commercialize imetelstat.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have method-of-use patents that protect the use of imetelstat for the treatment of certain diseases, this type of patent does not prevent a generic competitor from making and marketing a product that is identical to imetelstat for an indication that is outside the scope of our approved use after our composition-of-matter patents or their patent term extensions have expired. Moreover, even if competitors do not actively promote their product for our approved indications, physicians may prescribe or use these generic products &#8220;off-label,&#8221; which would result in decreased sales for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss or impairment of our intellectual property rights related to imetelstat might further delay or halt ongoing or potential future clinical trials of imetelstat and any applications for regulatory approval, and might further delay or preclude any future development or commercialization of imetelstat by us. Furthermore, if imetelstat is approved for commercial sale, such loss of intellectual property rights could impair our ability to exclude others from commercializing products similar or identical to imetelstat and therefore result in decreased sales for us. Occurrence of any of these events would materially and adversely affect our financial results, business and business prospects and the future of imetelstat, and might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. Patent and Trademark Office, or the Patent Office, and various governmental patent agencies in other countries require compliance with a number of procedural, documentary, fee payment, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications.  Failure to respond to official actions within prescribed time limits, and nonpayment of fees, for example, maintenance fees, renewal fees, and annuity fees could result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the jurisdiction. In such an event, potential competitors might be able to enter the market with imetelstat or similar products, and this circumstance could harm our financial condition, business and business prospects and the future of imetelstat. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us or jointly owned with us, any of the foregoing could expose us to liability to the applicable patent owner or patent co-owner.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on imetelstat for an adequate amount of time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after its first effective nonprovisional filing date. Given the amount of time required for the development, testing and regulatory review of imetelstat, patents protecting imetelstat might expire before imetelstat is commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the Hatch-Waxman Act permits one patent per approved product to receive a patent term extension of up to five years beyond its normal expiration. The length of the patent term extension is typically</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">calculated as one half of the clinical trial period plus the entire period of time during the review of the NDA by the FDA, minus any time of delay by us during these periods. There is also a limit on the patent term extension to a term that is no greater than fourteen years from drug approval. Only one U.S. patent may be eligible for patent term extension under the Hatch-Waxman Act. We plan to apply to the Patent Office for patent term extension of one or more patent(s). Once the Patent Office and the FDA determine the extension period for each proposed eligible patent, we will select the one patent to be extended. Currently, communication of patent term extension approval and the length of the granted extension period by the Patent Office may occur up to five years from filing of an application for patent term extension. Accordingly, we will decide on the specific patent to be extended only after such communication from the Patent Office.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar extensions are also available in certain countries and territories outside the U.S., such as in Japan, and in Europe as Supplementary Protection Certificates, or SPCs. If we select and are granted a patent term extension on a recently filed and issued patent, we may not receive the full benefit of a possible patent term extension, if at all. We might also not be granted a patent term extension at all, because of, for example, failure to apply within the applicable period, failure to apply prior to the expiration of relevant patents or otherwise failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the Patent Office in the U.S., and any equivalent regulatory authorities in other countries, may not agree with our assessment of whether such extensions are available, may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. Should we seek a patent term extension, we may not be granted any such patent term extension and/or the applicable time period of such patent term extension could be less than five years. Moreover, in some countries, including the U.S., the scope of protection for claims under such patent term extensions, if any, does not extend to the full scope of the claims but is limited to the product composition as approved and, for a method of treatment patent, is limited to the approved indication. Thus, for example, if we do not receive a patent term extension for our U.S. composition-of-matter patent for imetelstat, as approved by the regulatory authorities, our U.S. composition-of-matter patent will expire in December 2025. If we do not have sufficient patent life to protect imetelstat, our financial results, business and business prospects, and the future of imetelstat would be materially and adversely affected, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe and other countries, our composition of matter patent coverage expires in September 2024, and our method of treatment patent rights for MDS and MF expire in November 2033. Our method of treatment patents may be eligible for patent term extension under a Supplementary Protection Certificate, or SPC, permitted under European Council (EC) Regulation No. 469/2009, or the European SPC Regulation, upon receipt of drug product approval, such as, for example, our method of treatment patent for MDS. Since we do not expect to receive marketing approval and submit a request for an SPC before September 2024, our European composition of matter patent will expire in countries of the European Economic Area, or EEA, and we must rely on regulatory exclusivity and our method of treatment patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If regulatory approval of imetelstat occurs after a patent has expired in a country that does not allow interim patent term extensions, as is the case in many countries and territories including Europe, we will be unable to obtain any patent term extension of that expired patent, and the duration of our patent rights may be limited.If we do not have sufficient patent life to protect imetelstat, our financial results, business and business prospects, and the future of imetelstat would be materially and adversely affected, which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, there are regulations for the listing of patents in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. If we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If imetelstat is approved for commercial sale and an appropriate patent covering imetelstat is not listed in the Orange Book or is subsequently removed from the Orange Book, a manufacturer of generic drugs would not be required to provide advance notice to us of any abbreviated NDA filed with the FDA to obtain permission to sell a generic version of imetelstat. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. or international patent law or interpretations of such patent laws could diminish the value of our patents in general, thereby impairing our ability to protect our technologies and imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent positions of pharmaceutical and biopharmaceutical companies, including ours, are highly uncertain and involve complex legal and technical questions. In particular, legal principles for biotechnology and pharmaceutical patents in the U.S. and in other countries are evolving, and the extent to which we will be able to obtain patent coverage to protect our technologies and imetelstat, or enforce or defend issued patents, is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. has enacted and implemented wide-ranging patent reform legislation, including the Leahy-Smith America Invents Act, or the AIA, signed into law on September 16, 2011. The U.S. Supreme Court has ruled on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on actions by Congress, the federal courts, and the Patent Office, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents or patents that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce our existing patents or patents that we may obtain in the future. Occurrence of these events and/or significant impairment of our imetelstat patent rights would severely and adversely affect our financial results, business and business prospects, and the future of imetelstat, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of the AIA, in March 2013, the U.S. transitioned to a first-inventor-to-file system under which, assuming the other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent. However, since the publication of discoveries in scientific or patent literature tends to lag behind actual discoveries by at least several months and sometimes several years, we are not able to be certain upon filing a patent application that the persons or entities that we name as inventors or applicants in our patent applications were the first to invent the inventions disclosed therein, or the first to file patent applications for these inventions. Thus, our ability to protect our patentable intellectual property depends, in part, on our ability to be the first to file patent applications with respect to our inventions, or inventions that were developed by our former collaboration partner and assigned to us, for the future development, commercialization and manufacture of imetelstat. As a result, if we are not the first inventor-to-file, we may not be able to obtain patents for discoveries that we otherwise would consider patentable and that we consider to be significant to the future success of imetelstat. Delay in the filing of a patent application for any purpose, including further development or refinement of an invention, may result in the risk of loss of patent rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2012, the European Patent Package, or EU Patent Package, was approved and included regulations with the goal of providing for a single pan-European Unitary Patent, and a new European Unified Patent Court, or UPC, for litigation of European patents. The EU Patent Package was ratified in February 2023 and currently covers certain EU states. As of June 1, 2023, all European patents, including those issued prior to ratification, by default automatically fall under the jurisdiction of the UPC and allow for the possibility of obtaining pan-European injunctions and be at risk of central revocation at the UPC in participating UPC states. Under the EU Patent Package, patent holders are permitted to &#8220;opt out&#8221; of the UPC on a patent-by-patent basis during an initial seven year transitional period after June 1, 2023. Owners of European patent applications who receive notice of grant after the EU Patent Package came into effect could, for the UPC contracting states, either obtain a Unitary Patent or validate the patent nationally and file an opt-out demand. The EU Patent Package may increase the uncertainties and costs surrounding the enforcement or defense of our issued European patents and pending applications. The full impact on future European patent filing strategy and the enforcement or defense of our issued European patents in member states and/or the UPC is not known.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, maintaining, defending and enforcing patents for imetelstat and our technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. are less extensive than those in the U.S. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover imetelstat and our technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights in the U.S or worldwide and challenges to our owned or licensed patent rights would result in costly and time-consuming legal proceedings that could prevent or limit development or potential commercialization of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our patents or those patent rights we have licensed, including patent rights that we may seek with respect to inventions made by past or future collaborators, may be challenged through administrative or judicial proceedings, which could result in the loss of important patent rights. For example, where more than one party seeks U.S. patent protection for the same technology in patent applications that are subject to the law before the implementation of the AIA, the Patent Office may declare an interference proceeding in order to ascertain the party to which the patent should be issued. Patent interferences are typically complex, highly contested legal proceedings, subject to appeal. They are usually expensive and prolonged and can cause significant delay in the issuance of patents. Our pending patent applications or our issued patents, or those we have licensed and may license from others, may be drawn into interference proceedings or be challenged through post-grant review procedures or litigation, any of which could delay or prevent the issuance of patents, or result in the loss of issued patent rights. We may not be able to obtain from our past or future collaborators the information needed to support our patent rights which could result in the loss of important patent rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the AIA, interference proceedings between patent applications filed on or after March 16, 2013, have been replaced with other types of proceedings, including derivation proceedings. The AIA also includes post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions, such as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review, or IPR, covered business method post-grant reviews and other post-grant reviews. This applies to all our U.S. patents and those we have licensed and may license from others, even those issued before March 16, 2013. A third party could attempt to use the Patent Office procedures to invalidate patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. U.S. patents owned or licensed by us may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. In addition, the IPR process under the AIA permits any person, whether they are accused of infringing the patent at issue or not, such as entities associated with hedge funds, to challenge the validity of certain patents. Significant impairment of our imetelstat patent rights would severely and adversely affect our financial results, business and business prospects, and the future of imetelstat, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain jurisdictions, such as Europe, New Zealand and Australia, permit oppositions to be filed against granted patents or patents proposed to be granted. Because we seek to enable potential global commercialization of imetelstat, securing both proprietary protection and freedom to operate outside of the U.S. is important to our business. Opposition proceedings require significant time and costs, and if we are unsuccessful or are unable to commit these types of resources to protect our imetelstat patent rights, we could lose our patent rights and we could be prevented or limited in the development and commercialization of imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in jurisdictions outside the U.S. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many countries outside the U.S. have compulsory licensing laws under which a patent owner must grant licenses to third parties. Proceedings to enforce our patent rights in jurisdictions outside the U.S. could result in substantial costs and divert our efforts and attention from other aspects of our business, and could put our patents at risk of being invalidated or interpreted narrowly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As more groups become engaged in scientific research and product development in the areas of telomerase biology and hematologic malignancies, the risk of our patents, or patents that we have in-licensed, being challenged through patent interferences, derivation proceedings, IPRs, post-grant proceedings, oppositions, re-examinations, litigation or other means will likely increase. Challenges to our patents through these procedures would be extremely expensive and time-consuming, even if the outcome was favorable to us. An adverse outcome in a patent dispute could severely harm our ability to further develop or commercialize imetelstat, or could otherwise have a material adverse effect on our business, and might cause us to cease operations, by:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">causing us to lose patent rights in the relevant jurisdiction(s);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjecting us to litigation, or otherwise preventing us from commercializing imetelstat in the relevant jurisdiction(s);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requiring us to obtain licenses to the disputed patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">forcing us to cease using the disputed technology; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requiring us to develop or obtain alternative technologies.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to infringement claims that are costly to defend, and such claims may limit our ability to use disputed technologies and prevent us from pursuing research, development, manufacturing or commercialization of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of imetelstat will depend upon our ability to research, develop, manufacture, market and sell imetelstat without infringing or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and many pharmaceutical companies, including potential competitors, have substantial patent portfolios. Since we cannot be aware of all intellectual property rights potentially relating to imetelstat and its uses, we do not know with certainty that imetelstat, or the intended commercialization thereof, does not and will not infringe or otherwise violate any third party&#8217;s intellectual property. For example, we are aware that certain third parties have or may be prosecuting patents and patent estates that may relate to imetelstat, and while we believe these patents will expire before imetelstat is able to be commercialized and/or that these patents are invalid and/or would not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infringed by the manufacture, use or sale of imetelstat, it is possible that the owner(s) of these patents will assert claims against us in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event our technologies infringe the rights of others or require the use of discoveries and technologies controlled by third parties, we may be prevented from pursuing research, development, manufacturing or commercialization of imetelstat, or may be required to obtain unblocking licenses from such third parties, develop alternative non-infringing technologies, which we may not be able to do at an acceptable cost or on acceptable terms, or at all, or cease the development of imetelstat. If we are unable to resolve an infringement claim successfully, we could be subject to an injunction that would prevent us from potentially commercializing imetelstat and could also require us to pay substantial damages. In addition, while our past collaboration agreements have terminated, we are still subject to indemnification obligations to certain collaborators, including with respect to claims of third-party patent infringement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to infringement claims, in the future we may also be subject to other claims relating to intellectual property, such as claims that we have misappropriated the trade secrets of third parties. Provided that we are successful in continuing the development of imetelstat, we expect to see more efforts by others to obtain patents that are positioned to cover imetelstat. Our success therefore depends significantly on our ability to operate without infringing patents and the proprietary rights of others.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become aware of discoveries and technologies controlled by third parties that are advantageous or necessary to further develop or manufacture imetelstat. Under such circumstances, we may initiate negotiations for licenses to other technologies as the need or opportunity arises. We may not be able to obtain a license to a technology required to pursue the research, development, manufacturing or commercialization of imetelstat on commercially favorable terms, or at all, or such licenses may be terminated on certain grounds, including as a result of our failure to comply with any material obligations under such licenses. If we do not obtain a necessary license or if such a license is terminated, we may need to redesign such technologies or obtain rights to alternative technologies, which may not be possible, and even if possible, could cause further delays in the development efforts for imetelstat and could increase the development and/or production costs of imetelstat. In cases where we are unable to license necessary technologies, we could be subject to litigation and prevented from pursuing research, development, manufacturing or commercialization of imetelstat, which would materially and adversely impact our business. Failure by us to obtain rights to alternative technologies or a license to any technology that may be required to pursue research, development, manufacturing or commercialization of imetelstat would further delay current and potential future clinical trials of imetelstat and any applications for regulatory approval, impair our ability to sell imetelstat, if approved, and therefore result in decreased sales of imetelstat for us. Occurrence of any of these events would materially and adversely affect our business and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are seeking registered trademarks for a commercial trade name for imetelstat in the U.S. and jurisdictions outside of the U.S. and failure to secure and maintain such registrations could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have secured a global trademark for a commercial trade name for imetelstat. During trademark registration proceedings, we may receive rejections or fail to maintain such registrations. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If our United States application which forms the basis for our international registration, or IR, for our commercial trade name is refused, withdrawn, or abandoned within the first 5 years of our IR we will lose our IR registrations which could adversely affect our business. Our product trademark is approved by the EMA and provisionally approved by the FDA.  If the FDA or EMA should reject the trademark, we may be required to expend additional time and resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA and the EMA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in disputes with past or future collaborator(s) over intellectual property inventorship, ownership or use, and publications by us, or by investigators, scientific consultants, research collaborators or others. Such disputes could impair our ability to obtain patent protection or protect our proprietary information, which, in either case, could have a significant impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inventions discovered under research, material transfer or other collaboration agreements may become jointly owned by us and the other party to such agreements in some cases and may be the exclusive property of either party in other cases. Under some circumstances, it may be difficult to determine who invents and owns a particular invention, or whether it is jointly owned, and disputes can arise regarding inventorship, ownership and use of those inventions. These disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business if we are not able to protect or license rights to these inventions. In addition, clinical trial investigators, scientific consultants and research collaborators generally have contractual</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rights to publish data and other proprietary information, subject to review by the trial sponsor. Publications by us, or by investigators, scientific consultants, previous employees, research collaborators or others, either with permission or in contravention of the terms of their agreements with us or with our past or future collaborators, may impair our ability to obtain patent protection or protect proprietary information which would have a material adverse effect on our business, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Much of the information and know-how that is critical to our business is not patentable, and we may not be able to prevent others from obtaining this information and establishing competitive enterprises.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on trade secrets to protect our proprietary technology, especially in circumstances in which we believe patent protection is not appropriate or available. We attempt to protect our proprietary technology in part by confidentiality agreements with our employees, consultants, collaborators and contractors. However, we cannot provide assurance that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors, any of which would harm our business significantly.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2016, the Defend Trade Secrets Act of 2016, or the DTSA, was enacted, providing a federal cause of action for misappropriation of trade secrets. Under the DTSA, an employer may not collect enhanced damages or attorney fees from an employee or contractor in a trade secret dispute brought under the DTSA, unless certain advanced provisions are observed. We cannot provide assurance that our existing agreements with employees and contractors contain notice provisions that would enable us to seek enhanced damages or attorneys&#8217; fees in the event of any dispute for misappropriation of trade secrets brought under the DTSA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Managing Our Growth and Other Business Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be unable to successfully retain or recruit key personnel to support the development and potential future commercialization of imetelstat or to otherwise successfully manage our growth.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to successfully develop imetelstat in the future and to potentially commercialize imetelstat depends to a significant extent on the skills, experience and efforts of our executive officers and key members of our staff. In addition, we need to recruit, maintain, motivate and integrate additional personnel with expertise and experience in clinical science, biostatistics, clinical operations, pharmacovigilance, quality, manufacturing, regulatory affairs, medical affairs, legal affairs, compliance, market access, pricing, commercial operations, sales, and marketing, to enable us to further develop and potentially commercialize imetelstat.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face intense competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions, and competition in our geographic regions is particularly intense. The substantial risks and uncertainties related to our development and the potential approval and commercialization of imetelstat, and the risks and uncertainties regarding our future business viability could have an adverse impact on our ability to retain and recruit qualified personnel. We may also face higher than expected personnel costs in order to attract new personnel due to shortages in qualified applicants, or to maintain our current management and personnel due to the increased number of opportunities in the biotechnology sector. If we are unable to successfully retain, motivate and incentivize our existing personnel, or to attract, assimilate and retain other highly qualified personnel in the future on acceptable terms, our ability to further develop and potentially commercialize imetelstat will be impaired, and our business and the price of our common stock would be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our personnel are currently performing their duties in multiple jurisdictions, and if we are unable or fail to comply with employment, tax, benefits and other laws in such jurisdictions, we may face penalties, fines or litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to develop, manufacture and commercialize imetelstat will depend, in part, on our ability to effectively manage any future growth. Our management may have to divert financial and other resources, as well as devote a substantial amount of time, to managing growth activities, such as enhancing operational, financial and management processes and systems. If we do not effectively manage the expansion of our operations, we could experience weaknesses in our infrastructure and ability to comply with applicable legal and regulatory requirements and regulations, operational mistakes or shortcomings, loss of business opportunities, loss of employees and reduced productivity among remaining employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we seek to establish potential future collaborative arrangements for imetelstat, we may be unable to establish such collaborative arrangements on acceptable terms, or at all, and may have to delay, alter or abandon our imetelstat development and commercialization plans.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to develop imetelstat broadly for hematologic malignancies, and to potentially commercialize, market and sell imetelstat in the U.S. and the EU. We may seek a collaborative partner or partners, at an appropriate time, to assist us in the potential development and commercialization of imetelstat, especially in the EU and other regions outside the U.S., and to provide funding for such activities. We face significant competition in seeking appropriate collaborative partners, and these potential collaborative arrangements are complex and time consuming to negotiate, document and implement. Our ability to seek and establish potential collaborative arrangements may be impacted by delays in marketing approvals of imetelstat in lower-risk MDS in the U.S. and/or EU and in reporting results from IMpactMF, as well as the period of the patent term for our intellectual property portfolio and market exclusivity for imetelstat. We may not be able to establish collaborative arrangements on acceptable terms, or at all. In this regard, collaborative arrangements with third parties may require us to relinquish material rights, including revenue from potential commercialization, or assume material ongoing development obligations that we would have to fund or otherwise support.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to negotiate collaborative arrangements, we may have to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or curtail the additional development of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">further delay or abandon the potential commercialization of imetelstat outside of the U.S.;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduce the scope of potential future sales or marketing activities; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase our expenditures and undertake development or commercialization activities at our own expense, which will require additional capital than our current resources.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have established subsidiaries in the United Kingdom and the Netherlands, which exposes us to additional costs and risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The wholly-owned subsidiaries we have established in the U.K. and the Netherlands subject us to certain additional costs and risks associated with doing business outside the U.S., including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the increased complexity and costs inherent in managing international operations in geographically disparate locations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges and costs of complying with diverse regulatory, financial and legal requirements, which are subject to change at any time;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially adverse tax consequences, including changes in applicable tax laws and regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially costly trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">natural disasters, political and economic instability, including terrorism and civil and political unrest, outbreak of health epidemics, including any resurgence of COVID-19, and the resulting global economic and social impacts; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our international operations in the U.K. and the Netherlands expose us to fluctuations in currency exchange rates between the British pound, the Euro and the U.S. dollar. Given the volatility of currency exchange rates, there is no assurance that we will be able to effectively manage currency transaction and/or conversion risks. To date, we have not entered into derivative instruments to offset the impact of foreign exchange fluctuations, which fluctuations could have an adverse effect on our financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to obtain or maintain sufficient insurance on commercially reasonable terms or with adequate coverage against potential liabilities in order to protect ourselves against product liability claims or claims related to clinical trial conduct, or claims related to data protection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business exposes us to potential product liability and other risks that are inherent in the testing, manufacturing and marketing of human therapeutic products. We may become subject to product liability claims or claims related to clinical trial conduct or the potential commercialization of imetelstat, if any, including if the use of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imetelstat is alleged to have injured patients, such as injuries alleged to arise from any hepatotoxicity or hemorrhagic event associated with the use of imetelstat. We currently have limited product liability and clinical trial liability insurance, and we may not be able to maintain this type of insurance for the potential commercialization of imetelstat, if any, or any of our current or potential future clinical trials of imetelstat. In addition, this type of insurance may become too expensive for us to afford because of the highly risky and uncertain nature of potential commercialization of imetelstat, clinical trials generally and the high cost of insurance for our business activities. We may be unable to obtain or maintain clinical trial insurance in all of the jurisdictions where we conduct current or potential future clinical trials. In addition, business liability, product liability and cybersecurity insurance are becoming increasingly expensive, particularly for biotechnology and pharmaceutical companies, and the pool of insurers offering insurance coverage to biotechnology and pharmaceutical companies generally is becoming smaller, making it more difficult to obtain insurance for our business activities at a reasonable price, or at all. Being unable to obtain or maintain product liability, clinical trial liability, cybersecurity or other insurance for our business activities in the future on acceptable terms or with adequate coverage against potential liabilities would have a material adverse effect on our business, and could cause us to cease our development of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the past, we and certain of our officers have been named as defendants in securities class action lawsuits and shareholder derivative lawsuits. Potential similar or related lawsuits that may be filed in the future, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. Any such lawsuits, or other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in their outcome.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities-related class action lawsuits and/or derivative lawsuits have often been brought against companies, including biotechnology and biopharmaceutical companies, that experience volatility in the market price of their securities. This risk is especially relevant for us because we often experience significant stock price volatility in connection with our activities.  In 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed. The other two lawsuits, filed in the U.S. District Court for the Northern District of California, were consolidated by the Court. In September 2022, the parties agreed to a settlement and entered into a Stipulation and Agreement of Settlement, which was subject to court approval. The Court granted final approval of the settlement on September 28, 2023 and final judgment was entered on October 3, 2023.  In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  On May 17, 2023, the Delaware Court of Chancery approved a settlement of the derivative case pending before it, and the case was dismissed with prejudice.  Subsequently, each of the remaining derivative cases were dismissed with prejudice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of any additional lawsuits, and we may not prevail. In addition, we have and may continue to incur substantial legal fees and costs in connection with such lawsuits. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A decision adverse to our interests in similar or related litigation, could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our business, our stock price, cash flow, results of operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to third-party litigation, and such litigation would be costly to defend or pursue and uncertain in its outcome.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business may bring us into conflict with our licensees, licensors, or others with whom we have contractual or other business relationships, or with our competitors or others whose interests differ from ours. We may experience employment-related disputes as we seek to expand our personnel resources. We may become involved in performance or other disputes with the CROs we have retained to support our imetelstat clinical development activities, or with other third parties such as service providers, vendors, manufacturers, suppliers or consultants, which could result in a further delay or cessation of current and potential future clinical trials and otherwise significantly further delay our ability to develop or potentially commercialize imetelstat. If we are unable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to resolve those conflicts on terms that are satisfactory to all parties, we may become involved in litigation brought by or against us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lawsuits are subject to inherent uncertainties, and defense and disposition costs depend upon many unknown factors. Despite the availability of insurance, we may incur substantial legal fees and costs in connection with litigation. Lawsuits could result in judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise negatively affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of such litigation could lead to increased volatility in our stock price and a decrease in the value of our stockholders&#8217; investment in our securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to export control and import laws and regulations, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Competitive Factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our competitors develop products, product candidates or technologies that are superior to or more cost-effective than imetelstat, this would significantly impact the development and commercial viability of imetelstat, which would severely and adversely affect our financial results, business and business prospects, and the future of imetelstat, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by intense and dynamic competition with rapidly advancing technologies and a strong emphasis on proprietary products. While we believe our proprietary oligonucleotide chemistry; experience with the biological mechanisms related to imetelstat, telomeres and telomerase; clinical data to date; and knowledge and expertise around the development of potential treatments for myeloid hematologic malignancies provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Imetelstat will compete, if approved, with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware of.  For a description of the competition that imetelstat may face in our lead indications of lower-risk MDS and relapsed/refractory MF, see Item 1, &#8220;Business &#8211; Competition.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors, either alone or with their strategic partners, could have substantially greater financial, technical and human resources than we do and significantly greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may develop more commercially desirable or affordable products than imetelstat, or achieve earlier or longer patent protection or product commercialization than we may be able to achieve with imetelstat. Some of these products may have an entirely different approach or means of accomplishing therapeutic effects similar or superior to those that may be demonstrated by imetelstat. Competitors may develop products that are safer, more effective, or less costly than imetelstat, or more convenient to administer to patients. In addition, competitors may price their products below what we may determine to be an acceptable price for imetelstat, may receive better third-party payor coverage and/or reimbursement, or may be more cost-effective than imetelstat. Such competitive products or activities by competitors may render imetelstat obsolete, which may cause us to cease any further development or future commercialization of imetelstat, which would severely and adversely affect our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">financial results, business and business prospects, and the future of imetelstat, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">To be commercially successful, imetelstat must be accepted by the healthcare community, which can be very slow to adopt or unreceptive to new technologies and products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if approved for marketing, imetelstat may not achieve market acceptance, or the potential U.S. or international revenue we believe may be possible, since hospitals, physicians, patients or the medical community in general may decide not to accept and utilize imetelstat. If approved for commercial sale, imetelstat will compete with a number of conventional and widely accepted drugs and therapies manufactured and marketed by major pharmaceutical companies. The degree of market acceptance of imetelstat will depend on a number of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which imetelstat is approved, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries and/or regions within which imetelstat is approved, if any;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the establishment and demonstration to the medical community of the clinical efficacy and safety of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to demonstrate that imetelstat is superior to alternatives on the market at the time, including with respect to efficacy, safety, cost or route of administration;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of medical professionals to prescribe, and patients to use, imetelstat, or to continue to use imetelstat; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the publication of unfavorable safety or efficacy data concerning imetelstat by third parties or us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on use of imetelstat in combination with other products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the label and promotional claims allowed by the FDA or similar international regulatory authorities for imetelstat, if any, including usage for only certain indications and any limitations or warnings about the prevalence or severity of any side effects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of imetelstat as well as competitive products, including sequencing of available products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales, marketing and distribution support for imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which imetelstat is approved for inclusion on National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and formularies in hospitals and managed care organizations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing of imetelstat, both in absolute terms and relative to alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate reimbursement by government and third-party payors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors, including governmental authorities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate any therapeutic or economic advantage for imetelstat compared to established or standard-of-care therapies, or newly developed therapies, for myeloid hematologic malignancies. Third-party payors may decide that any potential benefit that imetelstat may provide to clinical outcomes in myeloid hematologic malignancies is not adequate to justify the costs of treatment with imetelstat. If the healthcare community does not accept imetelstat for any of the foregoing reasons, or for any other reasons, our ability to further develop or potentially commercialize imetelstat may be negatively impacted or precluded altogether, which would seriously and adversely affect our business and business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for imetelstat are smaller than we believe, our potential revenue may be adversely affected, and our business may suffer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our initial focus for imetelstat development has been on the lead indications of lower-risk MDS and relapsed/refractory MF. The addressable patient populations, if imetelstat is approved in those indications, are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new information from us or others may change the estimated incidence or prevalence of those indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approval of imetelstat would be limited to the therapeutic indications examined in our clinical trials and as determined by the FDA and similar international regulatory authorities, which would not permit us to market imetelstat for any other indications not expressly approved by those regulatory authorities. Additionally, the potentially addressable patient population for imetelstat may not ultimately be amenable to treatment with imetelstat. Even if we receive regulatory approval for imetelstat, such approval could be conditioned upon label restrictions that materially limit the addressable patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our market opportunity may also be limited by the pricing we are able to achieve for imetelstat, if approved, the quality and expiration of our intellectual property rights and licenses, duration of imetelstat treatment in an indication and future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunities for imetelstat that we or any potential future collaborative partners develop could be significantly diminished which would have a material adverse impact on our business and business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The adoption of health policy changes and healthcare reform both in the U.S. and outside the U.S. may adversely affect our business and financial results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S. and some jurisdictions outside the U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could impact our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing, including specialty drug pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically, there have been U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, and reform government program reimbursement methodologies for drugs and biologics. For details regarding these legislative and regulatory changes and proposed changes regarding the healthcare system that may affect our ability to operate, see Item 1 &#8220;Business - Reimbursement and Healthcare Reform.&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial results. Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on future worldwide sales of imetelstat, if approved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO INFORMATION TECHNOLOGY SYSTEMS,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DATA SECURITY AND DATA PRIVACY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations, including our clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we (and third parties upon which we rely) collect, receive, store, use, transfer, make accessible, protect, secure, dispose of, transmit, disclose, or otherwise process (commonly known as processing) proprietary, confidential, and sensitive data, including personal data (such as health-related data and participant study related data), intellectual property, and trade secrets (collectively, sensitive information). In addition, we rely on third-party service providers to establish and maintain appropriate information technology and data security protections over the information technology systems they provide us to operate our critical business systems, including cloud-based infrastructure and systems, employee email, and data storage and management systems. However, except for contractual duties and obligations, we have limited ability to control or monitor third parties&#8217; safeguards and actions related to such matters, and these third parties may not have adequate information security measures in place. Furthermore, while we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. Most of our employees work remotely, resulting in increased risks to our information technology systems and data, as employees utilize network connections, computers, and devices outside our premises and networks, including working at home and while in transit and in public locations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the prevalent use of mobile devices that access our sensitive information increases the risk of security incidents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our information technology systems, including in our remote work environment, and those of the third parties upon which we rely, may be vulnerable to evolving threats. These threats are prevalent, continue to increase, and come from a variety of sources such as traditional &#8220;hackers,&#8221; threat actors, ""hacktivist," organized criminal threats actors, or internal bad actors, personnel (such as through theft, error or misuse), sophisticated nation states and nation-state-supported actors. These threats include, but are not limited to, social-engineering attacks, malicious code or malware, unauthorized intrusions, denial-of-service attacks, personnel misconduct or errors, ransomware attacks, supply-chain attacks, software bugs, computer viruses, server malfunctions, software, hardware or data center failures, loss of data or other information technology assets, natural disasters, terrorism, war, telecommunication and electrical failures and attacks enhanced or facilitated by artificial intelligence, or AI, and other similar threats. In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions in operations, loss of data and income, reputational harm, and diversion of funds. If we were to experience such an attack, extortion payments might alleviate the negative impact of a ransomware attack, but we might be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks and attacks on clinical trial sites as well as regulatory and health authorities have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains, or of clinical trial sites and regulatory and health authorities, have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems (including those related to imetelstat) or the third-party information technology systems that support us and the services provided to us. Any of these threats may result in unauthorized, unlawful or accidental loss, corruption, access, modification, destruction, alteration, acquisition or disclosure of sensitive information, such as clinical trial data or information, intellectual property, proprietary business data and personal data. The costs to us to attempt to protect against such security incidents could be significant, including potentially requiring us to modify our business, and while we have implemented security measures designed to protect our information technology systems and to identify and remediate vulnerabilities, such measures may not be successful. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are sophisticated in nature, and may not be detected until after a security incident has occurred. Unremediated high risk or critical vulnerabilities pose material risks to our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or third parties upon which we rely experience or are perceived to have experienced a breach, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections), interruptions in our operations, including disruption of our imetelstat development program, interruptions or restrictions on processing sensitive data (which could result in delays in obtaining, or our inability to obtain, regulatory approvals and significantly increase our costs to recover or reproduce the data), reputational harm, litigation (including class action claims), indemnification obligations, negative publicity, financial loss, and other harms. In addition, such a breach may require public notification of the breach. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position.  Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our contracts with relevant stakeholders include obligations relating to the safeguard of sensitive information, and a breach could lead to claims against us by such stakeholders. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities, damages, or claims relating to our data privacy and security obligations. In addition, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse business impacts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we process personal data and other sensitive data, including proprietary and confidential business data, trade secrets, intellectual property, clinical trial participant data, and other sensitive third-party data. We are therefore subject to or affected by numerous data privacy and security obligations, such as federal, state, local and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations governing the processing of personal data. These obligations may change, are subject to differing interpretations and may be inconsistent among jurisdictions or conflict. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business; affect us or our collaborators&#8217;, service providers&#8217; and contractors&#8217; ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal data; necessitate the acceptance of more onerous obligations in our contracts; result in liability; or impose additional costs on us. These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (GDPR) (EU) 2016/679, or the EU GDPR, imposes strict requirements on the processing of personal data. Under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines in the event of violations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be unable to transfer personal data from the EEA and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. The EEA and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the UK, have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some EEA regulators have prevented companies from transferring personal data out of the EEA for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to data privacy and security in the U.S. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health data. Additionally, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA, collectively CCPA, imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance. While the CCPA contains limited exceptions for clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In addition, the CPRA establishes a California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of an enforcement action, and applies to personal information of business representatives and employees. Other states have also enacted data privacy and security laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and became effective in 2023. If we become subject to new data privacy and security laws, at the state level or otherwise, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We may also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We may publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that, in the future, we may fail or be perceived to have failed to comply with applicable data privacy and security obligations. Moreover, despite our best compliance efforts, we may not be successful in achieving compliance if our personnel or third parties whom we rely on fail to comply with such obligations, which could negatively impact our business operations and compliance posture. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions; litigation; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations including, as relevant, clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize imetelstat; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. Moreover, clinical trial participants or research subjects about whom we or our vendors obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock AND Financial Reporting</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Historically, our stock price has been extremely volatile and your investment may suffer a decline in value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, our stock price has been extremely volatile. Between January 1, 2014 and December 31, 2023, our stock has traded as high as $6.38 per share and as low as $0.89 per share. Between January 1, 2023 and December 31, 2023, the price has ranged between a high of $3.84 per share and a low of $1.68 per share. The significant market price fluctuations of our common stock have been due to and may in the future be influenced by a variety of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements regarding the potential regulatory approval or non-approval of imetelstat and the timing thereof, specific label indications for or restrictions, warnings or limitations in its use, or delays in the regulatory review and commercialization process;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements regarding the research and development of imetelstat, or adverse efficacy or safety results of, further delays in the commencement, enrollment or conduct of, discontinuation of, or further modifications or refinements to any current clinical trials of imetelstat, as well as for our expanded access program or for potential future clinical trials of imetelstat, for any reason, or our inability, for any reason, to successfully continue the development of imetelstat;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain additional capital when needed to further advance the imetelstat program;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations applicable to imetelstat, including but not limited to clinical trial requirements for approval or other regulatory developments related to imetelstat; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of technological innovations, new commercial products, or clinical progress or lack thereof by us, potential future collaborative partners or our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse developments concerning our manufacturers, including our inability to obtain adequate product supply for imetelstat or inability to do so at acceptable prices;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth of the market for our lead imetelstat indications of lower-risk MDS and relapsed/refractory MF;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to imetelstat proprietary rights, including patents, litigation matters and our ability to obtain, enforce and defend patent protection for our technologies;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms and timing of any future collaboration agreements for the development and potential commercialization of imetelstat that we may establish;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, collaborations, joint ventures or capital commitments by us or our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand in the market for our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased or continuing operating losses;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general domestic and international market conditions or market conditions relating to the biopharmaceutical and pharmaceutical industries, especially given the volatility caused by macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceptions of the biotechnology and pharmaceutical industry by the public, legislature, regulators and the investment community;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publication of commentary, articles or research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage, by securities analysts, bloggers, news media or other third parties; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">large stockholders increasing or exiting their position in our common stock or an increase in the short interest in our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of or developments concerning any litigation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actions instituted by activist shareholders or others;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the issuance of common stock to partners, vendors or investors to raise additional capital or as a result of option or warrant exercises; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other events or factors that are beyond our control; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the occurrence of any other risks and uncertainties discussed under the heading &#8220;Risk Factors.&#8221;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our charter, bylaws and Delaware law may inhibit potential acquisition bids for us, which may adversely affect the market price of our common stock and/or prevent holders of our common stock from benefiting from what they believe may be the positive aspects of acquisitions and takeovers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions of our charter documents and bylaws may make it substantially more difficult for a third party to acquire control of us and may prevent changes in our management, including provisions that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent stockholders from taking actions by written consent;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divide the board of directors into separate classes with terms of office that are structured to prevent all of the directors from being elected in any one year; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">set forth procedures for nominating directors and submitting proposals for consideration at stockholders&#8217; meetings.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our certificate of incorporation provides our board of directors with the authority to issue up to 3,000,000 shares of undesignated preferred stock and to determine or alter the rights, preferences, privileges and restrictions granted to or imported upon these shares without further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction without further action by our stockholders. As a result, the market price of our common stock may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If in the future, we issue preferred stock that has preference over our common stock with respect to the payment of dividends or upon our liquidation, dissolution or winding up, or if we issue preferred stock with voting rights that dilute the voting power of our common stock, the rights of holders of our common stock or the market price of our common stock could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions of Delaware law may also inhibit potential acquisition bids for us or prevent us from engaging in business combinations. In addition, we have individual severance agreements with our executive officers and a company-wide severance plan, either of which could require a potential acquirer to pay a higher price. Either collectively or individually, these provisions may prevent holders of our common stock from benefiting from what they may believe are the positive aspects of acquisitions and takeovers, including the potential realization of a higher rate of return on their investment from these types of transactions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The exclusive forum provisions in our amended and restated bylaws could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or any of our directors, officers, or employees, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits with respect to such claims.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any derivative claim or cause of action or proceeding brought on our behalf;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees, or our stockholders, to us or to our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, arising pursuant to any provision of the General Corporation Law of the State of Delaware, our certificate of incorporation, or our bylaws;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, governed by the internal affairs doctrine or otherwise related to our internal affairs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act of 1933, as amended, or the Securities Act, or the rules and regulations thereunder. Our amended and restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, including for all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. The application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court, and our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions, and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such an instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions, which costs could be borne by stockholders, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the exclusive forum provisions in our amended and restated bylaws, including the Federal Forum Provision. These provisions could limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, or our stockholders or the underwriters of any offering giving rise to such claims, which may discourage lawsuits with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respect to such claims. Furthermore, if a court were to find the exclusive forum provisions contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material and adverse impact on our business and our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay cash dividends on our common stock in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend upon our financial condition, results of operations, capital requirements and other factors, and will be at the discretion of our board of directors. In addition, the terms of our Loan Agreement prevent us from paying dividends and any future debt agreements may continue to preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, principal investigators, clinical trial sites, contract research organizations, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, principal investigators, clinical trial sites, CROs, consultants or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the FDA&#8217;s or similar international regulatory authorities&#8217; regulations, including those laws requiring the reporting of true, complete and accurate information; manufacturing standards; healthcare fraud and abuse laws and regulations; or laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our non-clinical studies or clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could adversely affect our business, financial condition, results of operations or prospects through:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the imposition of civil, criminal and administrative penalties, damages and monetary fines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contractual damages;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reputational harm;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished potential profits and future earnings; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">curtailment of our operations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, requires that we establish and maintain an adequate internal control structure and procedures for financial reporting. Our Annual Reports on Form 10-K must contain an annual assessment by management of the effectiveness of our internal control over financial reporting and must include disclosure of any material weaknesses in internal control over financial reporting that we have identified. In addition, our independent registered public accounting firm must provide an opinion annually on the effectiveness of our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The requirements of Section 404 are ongoing and also apply to future years. We expect that our internal control over financial reporting will continue to evolve as our business develops, including as we prepare to potentially launch and commercialize imetelstat. Although we are committed to continue to improve our internal control processes and we will continue to diligently and vigorously review our internal control over financial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reporting in order to ensure compliance with Section 404 requirements, any control system, regardless of how well designed, operated and evaluated, can provide only reasonable, not absolute, assurance that its objectives will be met. Therefore, we cannot assure you that material weaknesses or significant deficiencies will not exist or otherwise be discovered in the future, particularly in light of our increased reliance on personnel working remotely. If material weaknesses or other significant deficiencies occur, such weaknesses or deficiencies could result in misstatements of our results of operations, restatements of our financial statements, a decline in our stock price, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign sales and earnings. Any new taxes could adversely affect our domestic and international business operations and our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to such legislation may adversely affect us, and certain aspects of such legislation could be repealed or modified in the future, which could have an adverse effect on us. For example, the Inflation Reduction Act includes provisions that will impact the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of earnings from other countries, and the deductibility of expenses or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, effective January 1, 2022, research and experimental expenses must be capitalized for tax purposes and amortized over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside the United States, instead of being deducted in the year incurred. Unless this provision is deferred, modified, or repealed by Congress, or the U.S. Department of the Treasury issues regulations narrowing its application, our future tax obligations could be increased, which could harm our operating results. The impact of this provision will depend on multiple factors, including the amount of research and experimental expenses we incur, whether we achieve sufficient income to fully utilize such deductions and whether we conduct our research and experimental activities inside or outside the United States.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our net operating loss carryforwards attributable to tax years beginning before January 1, 2018 could expire unused and be unavailable to offset future income tax liabilities. In addition, under current U.S. federal income tax law, federal net operating losses incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely, but the deductibility of such federal net operating losses is limited to 80% of taxable income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point cumulative change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change taxable income or taxes may be limited. Changes in our stock ownership, some of which are outside of our control, may have resulted in, or other future changes could result in, an ownership change. If a limitation were to apply, utilization of a portion of our domestic net operating loss and tax credit carryforwards could be limited in future periods, and a portion of the carryforwards may expire before being available to reduce future income tax liabilities, which could adversely impact our financial position. At the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. It is also uncertain if and to what extent various states will conform to current U.S. federal income tax law.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1B. UNRESOLVE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">D STAFF COMMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk management and strategy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in the biopharmaceutical sector, which is a highly regulated sector subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; disruption of our clinical trials, manufacturing or supply chain; violation of privacy laws and other litigation and legal risk; and reputational risk. We rely primarily on industry-leading third parties and a cloud-based infrastructure for our information technology systems, and accordingly are dependent on these third parties&#8217; own cybersecurity risk management practices and strategy. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including clinical trial data, intellectual property, confidential information that is proprietary, strategic, financial or competitive in nature, and personal data (&#8220;Information Systems and Data&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We take a risk-based approach to identify and assess the cybersecurity threats and risks that could affect our business and Information Systems and Data.  Our Information Technology personnel help identify, assess and manage our cybersecurity threats and risks, and support our efforts to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment. We use various methods and tools to identify, assess and manage cybersecurity threats and risks, including, for example, automated tools, industry reports, third party threat assessments and penetration testing. In addition, we encrypt data at rest and maintain network security controls, such as firewalls and virtual private networks.  We also conduct computerized system monitoring and access control, including asset management, tracking and disposal associated with onboarding and offboarding of personnel.  We maintain cybersecurity insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data.  For example, we have implemented and maintain an incident response plan, and we utilize automated tools designed to maintain email security. We have also implemented a computerized system security and password policy that defines security for access to computer systems managed and controlled by us, and a procedure for computerized system incident management to address any unplanned issues in regulated computerized systems that could impact subject safety, product quality, and data integrity.  We periodically conduct cybersecurity incident tabletop training exercises involving our personnel and plan to conduct similar training in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes.  For example, our head of Information Technology evaluates material risks from cybersecurity threats and reports periodically to our Audit Committee, which evaluates our overall enterprise risk.  We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, cybersecurity software providers such as Crowdstrike, cybersecurity service providers such as Mimecast, penetration testing firms, auditors, and professional services firms, including legal counsel.  These relationships enable us to leverage specialized knowledge and insights, enabling our cybersecurity strategies and processes to remain consistent with industry best practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party service providers to perform a variety of functions throughout our business, such as contract manufacturing organizations, contract research organizations, suppliers and consultants.  If we successfully obtain regulatory approval to commercialize imetelstat, we will rely on third party logistics organizations and distributors to distribute imetelstat. We conduct quality audits of regulated vendors, which typically include an assessment of such vendor&#8217;s information technology systems, and we impose appropriate contractual obligations on vendors pertaining to information security.  Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our efforts may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not encountered cybersecurity challenges that have materially impaired our business, operations or financial standing.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks Related to Information Technology Systems, Data Security and Data Privacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.  The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Management Personnel</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.  Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. We seek to hire information technology personnel with skills appropriate to help us prepare for cybersecurity incidents, approve cybersecurity processes, and review security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including executive management.   When appropriate given the nature of any potential cybersecurity incident, our executive management works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, and to make any legally required notifications to individuals or regulatory agencies, including making any required disclosures under the Securities Exchange Act of 1934, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2. P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ROPERTIES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is 11 years with an option to extend for an additional five years and a one-time option to terminate the New Jersey Lease without cause as of the 103</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">rd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> month anniversary of the commencement date of the lease. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is 87 months with an option to extend for an additional five years. The Foster City Lease commenced on March 10, 2020, upon our control of the office space on that date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3. LEGAL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> PROCEEDINGS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Note 6 on Commitments and Contingencies in Notes to Consolidated Financial Statements of this annual report on Form 10&#8209;K for information on legal proceedings.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4. MINE SAF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ETY DISCLOSURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> II</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is quoted on the Nasdaq Global Select Market under the symbol GERN. As of February 23, 2024, there were approximately 451 stockholders of record of our common stock. This number does not include &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never paid cash dividends on our capital stock and do not anticipate paying cash dividends in the foreseeable future, but intend to retain our capital resources for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of the board of directors and will be dependent upon our financial condition, results of operations, capital requirements and other factors our board of directors deems relevant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, there were no unregistered sales of equity securities by us.</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6. [RESERVED]</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following discussion should be read in conjunction with the section entitled &#8220;Business&#8221; in Part I, Item 1 and the audited financial statements and notes thereto included in Part II, Item 8 of this annual report on Form 10&#8209;K. The information provided should be reviewed in the context of the sections entitled &#8220;Risks Related to the Development of Imetelstat&#8221;, and &#8220;Risks Related to Regulatory Approval and Commercialization of Imetelstat&#8221; under &#8220;Risk Factors&#8221; in Part I, Item 1A and elsewhere in this annual report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS. In August 2023, our New Drug Application, or NDA, for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk MDS who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents, or ESAs, was accepted by the United States, or U.S., Food and Drug Administration, or FDA, for review and assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 16, 2024. In addition, the FDA has scheduled an advisory committee meeting as part of the NDA review on March 14, 2024. If imetelstat is approved for commercialization by the FDA, we anticipate commercial launch of imetelstat in lower-risk MDS in the U.S. could occur at the time of approval. In September 2023, we submitted a marketing authorization application, or MAA, in Europe that was validated for review by the European Medicines Agency, or EMA, for imetelstat for the same proposed indication as in the U.S. We expect a review of the MAA could be completed in early 2025, and subject to approval by the European Commission, we believe EU commercial launch of imetelstat would occur in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our NDA and EMA filings are based on positive data from the IMerge Phase 3 clinical trial. The trial met its primary endpoint of &#8805; 8-week transfusion independence rate and a key secondary endpoint of 24-week transfusion independence rate, demonstrating highly statistically significant (i.e., p&lt;0.001 for both) and clinically meaningful benefits with imetelstat treatment versus placebo. Furthermore, statistically significant and clinically meaningful</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efficacy results were observed in the trial across key subtypes, including patients who were ringed sideroblast positive, or RS positive, and ringed sideroblast negative, or RS negative; patients with high and very high baseline transfusion burden; and patients classified as Low or Intermediate-1 risk according to the International Prognostic Scoring System, or IPSS. Consistent with prior imetelstat clinical experience, the most common serious adverse events were primarily short-lived, manageable thrombocytopenia and neutropenia.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to lower-risk MDS, we are developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory MF with overall survival, or OS, as the primary endpoint, that currently is enrolling patients. In November 2023, the trial reached 50% enrollment. Based on our current planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the first half of 2025, and the final analysis may occur in the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that currently is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes, or higher risk MDS, and acute myeloid leukemia, or AML, in which the first patient was dosed in June 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the positive data from IMerge Phase 3 and IMerge Phase 2, as well as our prior Phase 2 clinical trial of imetelstat in patients with Intermediate-2 or High-Risk myelofibrosis who have relapsed after or are refractory to treatment with a janus associate kinase inhibitor, or JAK inhibitor, or relapsed/refractory MF, provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells enabling recovery of bone marrow and normal blood cell production, which suggest potential disease-modifying activity. We believe this potential for disease modification could differentiate imetelstat from currently approved treatments in myeloid hematologic malignancies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have primarily financed our operations through the sale of equity securities, interest income on our marketable securities and payments we received under our collaborative and licensing arrangements. As of December 31, 2023, we had approximately $378.1 million in cash, cash equivalents, restricted cash and current and noncurrent marketable securities, and a long-term debt principal balance of $80.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2023, we completed an underwritten public offering of 68,007,741 shares of our common stock and a pre-funded warrant to purchase 25,000,000 shares of our common stock, or the 2023 pre-funded warrant. The net cash proceeds from this offering were approximately $213.3 million, after deducting the underwriting discount and other offering expenses paid by us. In addition, in the year-ended December 31, 2023, we received $105.9 million in cash proceeds from the exercise of outstanding warrants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, we drew down the remaining $10.0 million available under Tranche A of the Loan Agreement with Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, a division of First-Citizens Bank &amp; Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), or SVB. In August 2021, we amended the Loan Agreement to adjust the timing threshold for certain clinical milestones associated with Tranche B under the Loan Agreement. In addition, under the first amendment to the Loan Agreement, the minimum cash covenant requirement beginning as of June 1, 2022, was increased from $25.0 million to $30.0 million, and the minimum cash covenant required upon the execution of certain licensing transactions being executed was increased from $30.0 million to $35.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, we drew down $15.0 million available under Tranche B of the Loan Agreement with Hercules and SVB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2022, we entered into a second amendment to the Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $75.0 million to $125.0 million, with such principal being available in a series of tranches, subject to certain terms and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 14, 2023, we entered into a third amendment to the Loan Agreement. After giving effect to the third amendment, the aggregate principal amount drawn down and remaining available to us under the term loan facility, or Term Loan, remains at $125 million, with such principal being available in a series of tranches, subject to certain terms and conditions. The third amendment also provides that (i) the fourth tranche of the Term Loan was increased from $10.0 million to $30.0 million, (ii) the commitment period for the fifth tranche of the Term Loan of $20 million, which is available subject to achievement of a regulatory milestone and satisfaction of certain capitalization requirements, was extended through December 15, 2024, (iii) the variable annual interest rate on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">outstanding loans has been decreased to the greater of: (x) 9.0%, or (y) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus 4.5%, plus (B) 9.0%; and (iv) the interest only period of the Term Loan has been extended through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. In connection with the third amendment, on the third amendment effective date, we borrowed and received the entire fourth tranche of the Term Loan in the amount of $30.0 million. After giving effect to such borrowing, the outstanding principal amount under the Loan Agreement is $80.0 million. As of February 23, 2024, remaining tranches of up to $45.0 million are available under the Loan Agreement, subject to certain conditions. See Note 8 on Debt in Notes to Consolidated Financial Statements of this annual report on Form 10&#8209;K for additional information on the Loan Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of our revenues to date have been payments under collaboration agreements, and milestones, royalties and other revenues from our licensing arrangements. We currently have no source of product revenue. We have incurred significant net losses since our inception in 1990, resulting principally from costs incurred in connection with our research and development activities and from general and administrative costs associated with our operations. As of December 31, 2023, we had an accumulated deficit of approximately $1.6 billion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significance of future losses, future revenues and any potential future profitability will depend primarily on the clinical and commercial success of imetelstat, our sole product candidate. In any event, imetelstat may require significant additional clinical testing prior to possible regulatory approval in the U.S. and other countries. We expect research and development expenses, general and administrative expenses, and losses to substantially increase in future periods as we continue to support the imetelstat development program, including the conduct and completion of IMpactMF, IMproveMF and IMpress, as well as the potential U.S. commercialization of imetelstat in lower-risk MDS, subject to receipt of regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan and our assumptions regarding the timing of the potential approval and commercial launch of imetelstat in lower-risk MDS in the U.S., we believe that our existing cash, cash equivalents, and current and noncurrent marketable securities, together with projected revenues from U.S. sales of imetelstat, if approved, potential proceeds from the exercise of outstanding warrants, and potential future drawdowns under the Loan Agreement, will be sufficient to fund our projected operating requirements into the third quarter of 2025. Our ability to generate revenues from sales of imetelstat in the U.S., if regulatory approval is granted, depends on us being able to establish sales and marketing capabilities and gain acceptance in the marketplace, which we may be unable to do in a timely manner, or at all. In addition, we cannot predict with any certainty whether and to what extent the remaining outstanding warrants will be exercised for cash, or the timing or availability of additional funds under the Loan Agreement, if at all. Our ability to drawdown any remaining tranches under the Loan Agreement is subject to our achievement of certain regulatory milestones and satisfaction of certain capitalization requirements, as well as approval by an investment committee comprised of Hercules and SVB for the final $25.0 million tranche. In addition, even if imetelstat is approved in lower-risk MDS and commercialized by us in the U.S. in that indication and we are able to draw down the remaining tranches under the Loan Agreement in full, we will still require substantial additional funding to further advance the imetelstat program, including through the completion of our ongoing clinical trials, as well as conducting the clinical, regulatory and potential commercialization activities necessary to potentially bring imetelstat to market in relapsed/refractory MF and any other future indications, and our need for additional funds may arise sooner than planned. If adequate funds are not available on a timely basis, if at all, we may be unable to pursue further development or potential commercialization of imetelstat, which would severely harm our business and we might cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved for marketing by regulatory authorities outside of the U.S., we may seek potential commercialization partners for such territories. Until the FDA or similar international regulatory authorities approve imetelstat for marketing in lower-risk MDS, if at all, we cannot begin commercialization.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 of Notes to Consolidated Financial Statements of this annual report on Form 10-K describes the significant accounting policies used in the preparation of our consolidated financial statements. Certain of these significant accounting policies are important to understanding and evaluating our reported financial results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Accruals</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current imetelstat clinical trials are being supported by CROs and other vendors. Invoicing from CROs for services rendered can be delayed. We accrue the cost of services rendered in connection with CRO activities, which include, management, monitoring costs, project management costs, and investigator fees. We accrue expenses for clinical trial activities performed by CROs based upon the amount of work completed on each trial. We maintain regular communications with our CROs to assess the reasonableness of our accrual. To date, differences between actual clinical trial expenses and accrued clinical trial expenses recorded have not been material and are adjusted for in the period in which they become known. However, if we incorrectly accrue activity levels associated with the CRO services at a given point in time, we could be required to record material adjustments in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations have fluctuated from period to period and may continue to fluctuate in the future. Results of operations for any period may be unrelated to results of operations for any other period. Thus, historical results should not be viewed as indicative of future operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue based on sales of imetelstat is dependent on obtaining regulatory approval to commercialize imetelstat in the U.S. and other countries. We are subject to risks common to companies in our industry and at our stage of development, including, but not limited to, risks inherent in research and development efforts, including the development, manufacture, regulatory approval for and commercialization of, imetelstat; uncertainty of non-clinical and clinical trial results or regulatory approvals or clearances; the future development of imetelstat by us, including any future efficacy or safety results that may cause the benefit-risk profile of imetelstat to become unacceptable; the uncertain and unpredictable drug research and discovery process; overcoming disruptions and/or delays due to macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises, and supply chain and resource issues; our need for substantial additional capital; enforcement of our patent and proprietary rights; reliance upon our CROs, contract manufacturing organizations, or CMOs, consultants, licensees, investigators and other third parties; and potential competition. In order for imetelstat to be commercialized, we must conduct non-clinical tests and clinical trials to demonstrate the safety and efficacy of imetelstat, obtain regulatory approvals or clearances, and enter into manufacturing, distribution and marketing arrangements, as well as obtain market acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenues</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We previously entered into license or collaboration agreements with companies involved with oncology, diagnostics, research tools and biologics production, whereby we granted certain rights to our non-imetelstat related technologies. As of December 31, 2020, our license agreements related to our hTERT technology have been terminated or expired due to patent expirations on such technology. The remaining active license agreement was a license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides. This license was terminated effective April 2021. In connection with these agreements, we were eligible to receive license fees, option fees, milestone payments and royalties on future sales of products, or any combination thereof. As of December 31, 2023, all of our patent license agreements have now expired or been terminated, and we expect no further revenue under such agreements in the future.  However, in connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.), or Lineage, in 2013, we are entitled to receive royalties on sales from certain research or commercial products utilizing our divested intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not recognize any license fee revenues during the year ended December 31, 2023 and 2022 and recognized license fee revenues of $28,000 in the year ended December 31, 2021, related to our various agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognized royalty revenues of $237,000, $596,000 and $1.4 million during the years ended December 31, 2023, 2022 and 2021, respectively. Royalty revenues reflect estimated royalties from sales of cell-based research products from our divested stem cell assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future license fee and royalty revenues are dependent on additional agreements being signed, if any, our current license agreement with Lineage being maintained, and the underlying patent rights for the license remaining active. We expect royalty revenues in 2024 to be lower than 2023 as a result of reduced royalties from sales of cell-based research products from our divested stem cell assets.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023, 2022 and 2021, we supported the imetelstat development programs and a research discovery program related to potential next generation telomerase inhibitors. For the imetelstat program, we incur direct external, personnel-related and other research and development costs. For the years ended December 31, 2023, 2022 and 2021, direct external expenses included costs for our CROs, consultants and other clinical-related vendors, as well as expenses for contract manufacturing and quality activities. Personnel-related expenses primarily consist of salaries and wages, stock-based compensation, payroll taxes and benefits for our employees involved with ongoing research and development efforts. Other research and development expenses primarily consist of research-related overhead associated with allocated expenses for rent and maintenance of facilities and other supplies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the years ended December 31, 2023, 2022 and 2021 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.96%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:13.940000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:13.940000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:13.940000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct external research and development expenses:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical program: Imetelstat</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,914</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,699</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61,516</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel related expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,595</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,042</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,716</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All other research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,537</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,777</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,495</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">125,046</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,518</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85,727</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in research and development expenses in 2023 as compared to 2022 primarily reflects the net result of increased manufacturing costs due to the timing of imetelstat manufacturing batches, and increased personnel-related expenses for additional headcount.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in research and development expenses in 2022 as compared to 2021 primarily reflects the net result of increased personnel-related expenses for additional headcount and higher consulting costs related to compilation and analysis of data for top-line results and preparations for regulatory submissions in lower-risk MDS, partially offset by decreased manufacturing costs due to the timing of imetelstat manufacturing batches and reduced clinical trial expenses due to declining number of patients in IMerge Phase 3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect research and development expenses to remain consistent in the future as we support IMpactMF, IMproveMF and IMpress, as well as the long-term treatment and follow-up of remaining patients in IMerge Phase 3.  The risks and uncertainties associated with the development of imetelstat are discussed in the sub-sections entitled &#8220;Risks Related to the Development of Imetelstat&#8221; and &#8220;Risks Related to Regulatory Approvals and Commercialization of Imetelstat&#8221; under &#8220;Risk Factors&#8221; in Part I, Item 1A and elsewhere in this annual report on Form 10&#8209;K. As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of imetelstat research and development projects, anticipated completion dates, or when and to what extent we will receive cash inflows from the commercialization and sale of imetelstat, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $69.1 million, $43.6 million and $29.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in general and administrative expenses in 2023 as compared to 2022 primarily reflects the net result of higher personnel-related expenses of approximately $19.0 million for additional headcount and expenses related to commercial launch readiness, as well as increased costs for commercial preparatory activities of approximately $9.7 million; partially offset by lower legal expenses in 2023 primarily related to $7.0 million that was recorded in the third quarter of 2022 for our portion of the settlement in connection with a class action lawsuit. We expect general and administrative expenses to increase in the future as the imetelstat program matures and stage-gated commercialization activities continue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in general and administrative expenses in 2022 as compared to 2021 primarily reflects the net result of increased costs for commercial preparatory activities of approximately $3.1 million; higher personnel-related expenses of approximately $5.4 million for additional headcount; and approximately $6.2 million related to our portion of settlement costs related to the class action and derivative lawsuits, net of lower legal fees in 2022 compared to 2021; partially offset by lower consulting expenses of $1.6 million.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income was $18.2 million, $2.5 million and $527,000 for the years ended December 31, 2023, 2022 and 2021, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in interest income in 2023 compared to 2022 primarily reflects a larger marketable securities portfolio, with the receipt of net cash proceeds from the underwritten public offering completed in January 2023 and cash proceeds from warrant exercises in 2023, as well as higher yields from marketable securities purchases. Interest earned in future periods will depend on the size of our marketable securities portfolio and prevailing interest rates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in interest income in 2022 compared to 2021 primarily reflects a larger marketable securities portfolio, with the receipt of net cash proceeds from the underwritten public offering completed in April 2022 and higher yields due to increasing interest rates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest expense was $8.3 million, $6.9 million and $3.7 million for the years ended December 31, 2023, 2022 and 2021, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The increase in interest expense primarily reflects rising interest rates and an increased principal debt balance under the Loan Agreement. Currently, we have $80.0 million in principal debt outstanding. Interest expense reflects interest owed under the Loan Agreement, as well as amortization of associated debt issuance costs and debt discounts using the effective interest method and accrual for an end of term charge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other (Loss) Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other (loss) income, net was a loss of $23,000 for the year ended December 31, 2023, and income of $1.0 million and $1.1 million for the years ended December 31, 2022 and 2021, respectively. Net other (loss) income and expense primarily reflects bank charges related to our cash operating accounts and marketable securities portfolio and foreign currency transaction adjustments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the second quarter of 2022, we recognized other income of approximately $1.3 million related to the reimbursement of certain legal expenses under our insurance policies. During the first quarter of 2021, we sold our entire equity investment in a diagnostics company, resulting in a net realized gain of $1.2 million, including foreign currency translation adjustments. See Note 2 on Fair Value Measurements &#8211; Equity Investment in Notes to Consolidated Financial Statements of this annual report on Form 10&#8209;K for additional information about the sales of our equity investment. Net other income also includes bank charges related to our cash operating accounts and marketable securities portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, restricted cash, cash equivalents and marketable securities of $378.1 million, compared to $173.1 million at December 31, 2022. The increase in cash, restricted cash, cash equivalents, and current and noncurrent marketable securities from December 31, 2022 was primarily the net result of the receipt of net cash proceeds of $213.3 million from the underwritten public offering of common stock and pre-funded warrants completed in January 2023, $105.9 million of cash proceeds from the exercise of outstanding warrants, and aggregate drawdowns of $29.7 million under the Loan Agreement with Hercules and SVB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, warrants to purchase 77,349,858 shares of our common stock were exercised for net cash proceeds of approximately $105.9 million. The warrants were issued in connection with underwritten public offerings of our securities in 2020 and 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had a long-term principal debt balance of $80.0 million under the Loan Agreement with Hercules and SVB. In June 2022, we entered into a second amendment to the Loan Agreement with Hercules and SVB. Under the second amendment, the aggregate principal amount available to us increased from $75.0 million to $125.0 million. On December 14, 2023, we entered into a third amendment to the Loan Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After giving effect to the third amendment, the aggregate principal amount draw down and remaining available to us under the Loan Agreement remains at $125 million, with such principal being available in a series of tranches, subject to certain terms and conditions. The third amendment also provides that (i) the fourth tranche of the Loan Agreement was increased from $10.0 million to $30.0 million, (ii) the commitment period for the fifth tranche of the Loan Agreement of $20 million, which is available subject to achievement of a regulatory milestone and satisfaction of certain capitalization requirements, was extended through December 15, 2024, (iii) the variable annual interest rate on the outstanding loans has been decreased to the greater of: (x) 9.0%, or (y) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus 4.5%, plus (B) 9.0%; and (iv) the interest only period of the Term Loan has been extended through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. In connection with the third amendment, on the third amendment effective date, we borrowed and received the entire fourth tranche of the Term Loan in the amount of $30.0 million. After giving effect to such borrowing, the outstanding principal amount under the Amended Loan Agreement is $80.0 million. See Note 8 on Debt in Notes to Consolidated Financial Statements of this annual report on Form 10-K for additional information on the third amendment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2023, we completed an underwritten public offering of 68,007,741 shares of our common stock and a pre-funded warrant to purchase 25,000,000 shares of our common stock, or the 2023 pre-funded warrant. The net cash proceeds from this offering were approximately $213.3 million, after deducting the underwriting discount and other offering expenses paid by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have an investment policy to invest our cash in liquid, investment-grade securities, such as interest-bearing money market funds, certificates of deposit, U.S. Treasury securities, municipal securities, government and agency securities, corporate notes and commercial paper. Our investment portfolio does not contain securities with exposure to sub-prime mortgages, collateralized debt obligations, asset-backed securities or auction rate securities and, to date, we have not recognized any other-than-temporary impairment charges on our marketable securities or any significant changes in aggregate fair value that would impact our cash resources or liquidity. To date, we have not experienced lack of access to our invested cash and cash equivalents; however, access to our invested cash and cash equivalents may be impacted by adverse conditions in the financial and credit markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 4, 2020, we entered into an At Market Issuance Sales Agreement, or the 2020 Sales Agreement, with B. Riley Securities, Inc., or B. Riley Securities, pursuant to which we were able to elect to issue and sell shares of our common stock having an aggregate offering price of up to $100.0 million in such quantities and on such minimum price terms as we set from time to time through B. Riley Securities as our sales agent. B. Riley Securities was eligible to receive an aggregate commission equal to up to 3.0% of the gross proceeds of the sales under the agreement. We did not sell any shares of our common stock pursuant to the 2020 Sales Agreement during 2023. Approximately $79.1 million of our common stock remained available for issuance under the 2020 Sales Agreement as of September 4, 2023, when the 2020 Sales Agreement expired. No further common stock will be sold pursuant to the 2020 Sales Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, we entered into a new At Market Issuance Sales Agreement, or the 2023 Sales Agreement, with B. Riley Securities, pursuant to which we may elect to issue and sell shares of our common stock having an aggregate offering price of up to $100.0 million in such quantities and on such minimum price terms as we set from time to time through B. Riley Securities as our sales agent. We have agreed to pay B. Riley Securities an aggregate commission equal to up to 3.0% of the gross proceeds of the sales under the agreement. To date, no sales of common stock have occurred under the 2023 Sales Agreement.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may, from time to time, consider additional funding through a combination of new collaborative arrangements, strategic alliances, and additional equity and debt financings or from other sources. We will continue to manage our capital structure and consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. Any such capital transactions may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan and our assumptions regarding the timing of the potential approval and commercial launch of imetelstat in lower-risk MDS in the U.S., we believe that our existing cash, cash equivalents, and current and noncurrent marketable securities, together with projected revenues from U.S. sales of imetelstat, if approved, potential proceeds from the exercise of outstanding warrants, and potential future drawdowns under the Loan Agreement, will be sufficient to fund our projected operating requirements into the third quarter of 2025. Our ability to generate revenues from sales of imetelstat in the U.S., if regulatory approval is granted, depends on us being able to establish sales and marketing capabilities and gain acceptance in the marketplace, which we may be unable to do in a timely manner or at all. In addition, we cannot predict with any certainty whether and to what extent the remaining outstanding warrants will be exercised for cash, or the timing or availability of additional funds under the Loan Agreement, if at all. Our ability to drawdown any remaining tranches under the Loan Agreement is subject to our achievement of certain regulatory milestones and satisfaction of certain capitalization requirements, as well as approval by an investment committee comprised of Hercules and SVB for the final $25.0 million tranche. In addition, even if imetelstat is approved in lower-risk MDS and commercialized by us in the U.S. in that indication and we are able to drawdown the remaining tranches under the Loan Agreement in full, we will still require substantial additional funding to further advance the imetelstat program, including through the completion of our ongoing clinical trials and any potential future clinical trials, as well as conducting the clinical, regulatory and potential commercialization activities necessary to potentially bring imetelstat to market in relapsed/refractory MF and any other indications we are pursuing or may pursue, and our need for additional funds may arise sooner than planned. If adequate funds are not available on a timely basis, if at all, we may be unable to pursue further development or potential commercialization of imetelstat, which would severely harm our business and we might cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because the outcome of any clinical activities and/or regulatory approval process is highly uncertain, we cannot reasonably estimate whether any development activities we may undertake will succeed; whether we will obtain regulatory approval for imetelstat in any indication we pursue, including lower-risk MDS; or, if approved, whether we will be able to effectively commercialize imetelstat, if at all. We may never recoup our investment in any imetelstat development, which would adversely affect our financial condition and our business and business prospects, and might cause us to cease operations. In addition, our plans and timing expectations could be further delayed or interrupted by the effects of macroeconomic or other global conditions, including those resulting from inflation, rising interest rates, prospects of a recession, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises, and supply chain and resource issues. Further, our future capital requirements are difficult to forecast and will depend on many factors, including:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accuracy of the assumptions underlying our estimates for our capital needs;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, timing, magnitude and costs of non-clinical and clinical development, manufacturing and potential commercialization of imetelstat, including the number of indications being pursued, subject to clearances and approvals by the FDA and similar international regulatory authorities;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays or disruptions in opening sites, screening and enrolling patients or treating and following patients,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in our current or any potential future clinical trials of imetelstat;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcomes of regulatory reviews or other regulatory actions related to imetelstat, including with respect to our NDA and MAA submissions for imetelstat in lower-risk MDS;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of manufacturing, developing, commercializing and marketing  imetelstat, including with respect to third-party vendors and service providers and our ability to achieve any meaningful reduction in manufacturing costs, if imetelstat receives future regulatory approval or clearance, in the U.S., EU or other countries;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sales price for imetelstat, if any;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of coverage and adequate third-party reimbursement for imetelstat, if any;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we acquire or in-license other drugs and technologies, or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions, or to which we out-license imetelstat;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we are able to enter into and conduct successful strategic partnerships, collaborations and alliances or licensing arrangements with third parties including for the commercialization and marketing of imetelstat in certain global regions; </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent and scope of our general and administrative expenses, including expenses associated with potential future litigation; </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our level of indebtedness and associated debt service obligations;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of maintaining and operating facilities in California and New Jersey, as well as higher expenses for travel;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">macroeconomic or other global conditions that may reduce our ability to access equity or debt capital or other financing on preferable terms, which may adversely affect future capital requirements and forecasts; and</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of enabling our personnel to work remotely, including providing supplies, equipment and technology necessary for them to perform their responsibilities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until we can generate a sufficient amount of revenue from imetelstat to finance our cash requirements, which we may never achieve, we expect to finance future cash needs through a combination of public or private equity offerings, debt or other financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, which may not be possible. Availability of such financing sources may be negatively impacted by any further delays in our clinical trials and regulatory developments, as well as macroeconomic or other global conditions, including those resulting from inflation, rising interest rates, prospects or a recession, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises, and supply chain and resource issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional financing through public or private debt or equity financings, including pursuant to the 2023 Sales Agreement with B. Riley Securities, the remaining tranches of up to $45.0 million available under the Loan Agreement, which are subject to the achievement of certain clinical and regulatory milestones and satisfaction of certain capitalization and other requirements, as well as approval by an investment committee comprised of Hercules and SVB for the final $25.0 million tranche; capital lease transactions or other financing sources, may not be available on acceptable terms, or at all. We may be unable to raise equity capital, or may be forced to do so at a stock price or on other terms that could result in substantial dilution of ownership for our stockholders. The receptivity of the public and private debt and equity markets to proposed financings has been substantially affected by uncertainty in the general economic, market and political climate due to the effects of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises, and supply chain and resource issues, and may in the future be affected by other factors which are unpredictable and over which we have no control. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, which could reduce or eliminate our ability to raise additional funds through financings, and could negatively impact the terms upon which we may raise those funds. Similarly, these macroeconomic conditions have created extreme volatility and disruption in the capital markets and is expected to have further global economic consequences. If the equity and credit markets deteriorate, including as a result of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises, and supply chain and resource issues, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly, or more dilutive. If we are unable to raise additional capital or establish alternative collaborative arrangements with third-party collaborative partners for imetelstat, the development and potential commercialization of imetelstat may be further delayed, altered or abandoned, which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may seek additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Due to uncertainty in the general economic, market and political climate, we may determine that it is necessary or appropriate to raise additional funds proactively to meet longer-term anticipated operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the 2023 Sales Agreement, your</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ownership interest as a stockholder may be diluted, and the terms may include liquidation or other preferences that materially and adversely affect your rights as a stockholder. In addition, we have borrowed, and in the future may borrow, additional capital from institutional and commercial banking sources to fund imetelstat development and our future growth, including pursuant to our Loan Agreement or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms under agreements, such as the Loan Agreement, that include restrictive covenants, including covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Moreover, if we raise additional funds through alliance, collaborative or licensing arrangements with third parties, we may have to relinquish valuable rights to imetelstat or our technologies or grant licenses on terms that are not favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot assure you that our existing capital resources, future interest income, future revenues from potential sales of imetelstat, if approved, potential future sales of our common stock, including under the 2023 Sales Agreement, and potential future drawdowns, if available, of the remaining tranches under the Loan Agreement, will be sufficient to fund our operating plans. Moreover, while we did not hold cash deposits or securities at SVB, if other banks and financial institutions enter receivership, become insolvent or otherwise fail in the future in response to financial conditions affecting the banking system and financial markets or otherwise, our ability to access our cash, cash equivalents and marketable securities may be delayed or precluded, which could have a material adverse effect on our business, business prospects and financial position.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows Used In Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities was $167.7 million, $127.4 million and $95.6 million in 2023, 2022 and 2021, respectively. The increase in net cash used in operating activities in 2023 and 2022 primarily reflects higher payments for research and development expenses in connection with supporting the clinical trials, IMerge Phase 3, IMpactMF, IMproveMF and IMpress, and increases in headcount.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows Used In/Provided By Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $180.3 million in 2023, which primarily reflects a higher rate of purchases than maturities of marketable securities. Net cash provided by investing activities was $62.1 million and $71.9 million in 2022 and 2021, respectively, which primarily reflects a higher rate of maturities than purchases of marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three years ended December 31, 2023, we purchased approximately $829,000 in property and equipment, none of which was financed through equipment financing arrangements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities in 2023, 2022 and 2021 was $362.0 million, $87.3 million and $48.6 million, respectively. Financing activities in 2023 primarily reflects the receipt of net cash proceeds of $213.3 million from the underwritten public offering of common stock and pre-funded warrants completed in January 2023, $105.9 million of cash proceeds from the exercise of outstanding warrants, and aggregate drawdowns of $29.7 million under the Loan Agreement with Hercules and SVB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing activities in 2022 and 2021 primarily reflect the receipt of net cash proceeds of $69.9 million from the underwritten public offering of common stock, pre-funded warrant and stock purchase warrants completed in April 2022; cash proceeds from the exercise of warrants, receipt of net cash proceeds from the sales of our common stock under the 2020 Sales Agreement in 2021 and aggregate drawdowns of $25.0 million in 2021 under the Loan Agreement with Hercules and SVB.</span></p>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our material cash requirements in the short- and long-term consist of the following operational and manufacturing expenditures, a portion of which contain contractual or other obligations. We plan to fund our material cash requirements with our current financial resources and may consider additional funding through a combination of additional equity and debt financings, new collaborative arrangements, strategic alliances, or from other sources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating expenditures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our primary uses of cash and operating expenses relate to paying employees and consultants, administering clinical trials, ensuring an adequate supply of imetelstat, and providing technology and facility infrastructure to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">support our operations. Our research and development expenses in 2023 were $125.0 million, and we expect our investment in research and development expenses to remain consistent in 2024. Our general and administrative expenses were $69.1 million in 2023, and we expect our general, and administrative expenses to increase in 2024 to support our planned growth, subject to FDA approval of imetelstat. On a long-term basis, we plan to manage future cash requirements relative to our long-term business plans.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>The leases for our office facilities in New Jersey and California contain rate escalations and options for us to extend the leases. Our operating expenditures primarily consist of our obligations under non-cancellable operating leases. The aggregate amount of future operating lease payments over the term of our leases is $4.0 million as of December 31, 2023. Refer to Note 7 on Operating Leases in Notes to Consolidated Financial Statements of this annual report on Form 10&#8209;K for additional detail of our lease obligations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had a long-term principal debt balance of $80.0 million under the Loan Agreement with Hercules and SVB. In June 2022, we entered into a second amendment to the Loan Agreement with Hercules and SVB. Under the second amendment, the aggregate principal amount available to us increased from $75.0 million to $125.0 million. On December 14, 2023, we entered into a third amendment to the Loan Agreement and borrowed and received $30.0 million. After giving effect to such borrowing, the outstanding principal amount under the Amended Loan Agreement is $80.0 million. See Note 8 on Debt in Notes to Consolidated Financial Statements of this annual report on Form 10-K for additional information on the third amendment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, we enter into agreements with CROs for clinical trials and CMOs for clinical  and commercial supply manufacturing and with other vendors for preclinical research studies, investigator-led trials and other services and products for operating purposes. We have not considered these commitments to be contractual obligations since the contracts are generally cancelable at any time by us upon less than 180 days&#8217; prior written notice. We also have certain in-license agreements that require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones, which may not be achieved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and Supply Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Imetelstat, our sole product candidate, requires long lead times to manufacture. Therefore, we make substantial and often long-term investments in our supply chain in order to ensure we have enough drug product to meet potential future commercialization requirements, as well as clinical trial needs.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7A. Q</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following discussion about our market risk disclosures contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. We are exposed to credit risk and interest rate risk. We do not use derivative financial instruments for speculative or trading purposes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Credit Risk. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple financial institutions in the United States. Deposits with banks may exceed the amount of insurance provided on such deposits. While we monitor the cash balances in our operating accounts and adjust the cash balances as appropriate, these cash balances could be impacted if the underlying financial institutions fail or could be subject to other adverse conditions in the financial markets. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, U.S. government-sponsored enterprise securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and marketable securities in our investment portfolio. The effect of a hypothetical decrease of 1% in the average yield earned on our cash equivalents and marketable securities would have resulted in an immaterial impact on our interest income for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk.   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The primary objective of our investment activities is to manage our marketable securities portfolio to preserve principal and liquidity while maximizing the return on the investment portfolio through the full investment of available funds without significantly increasing risk. To achieve this objective, we primarily invest in widely diversified investments with fixed interest rates, which carry a degree of interest rate risk. Fixed rate securities may have their fair value adversely impacted due to a rise in interest rates. Due in part to these factors, our future interest income may fall short of expectations due to changes in market conditions and in interest rates or we may suffer losses in principal if forced to sell securities which may have declined in fair value due to changes in interest rates.  The fair value of our cash equivalents and marketable securities at December 31, 2023 was $378.1 million. These investments include $16.8 million of cash equivalents which are due in less than 90 days, $263.7 million of short-term investments which are due in less than one year and $43.3 million of long-term investments which are due in one to two years. We primarily invest our marketable securities portfolio in securities with at least an investment grade rating to minimize interest rate and credit risk as well as to provide for an immediate source of funds. Although changes in interest rates may affect the fair value of the marketable securities portfolio and cause unrealized gains or losses, such gains or losses would not be realized unless the investments are sold. Due to the nature of our investments, which are primarily money market funds, U.S. government-sponsored enterprise securities, commercial paper and corporate notes, we have concluded that there is no material interest rate risk exposure and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 8. FINANCIAL STATEME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following financial statements and the related notes thereto, of Geron Corporation and its consolidated subsidiaries, and the Report of Independent Registered Public Accounting Firm, Ernst &amp; Young LLP, are filed as a part of this annual report on Form 10&#8209;K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.26%;"/>
    <td style="width:6.74%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#160;(PCAOB ID: </span><span><ix:nonNumeric id="F_cc0b9176-c4a3-4790-8fe2-5a95f944a680" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_stockholders_equity"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#note_1_"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Geron Corporation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Geron Corporation (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 28, 2024 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.28%;"/>
    <td style="width:83.72%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="text-indent:80.5pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:80.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Accounting for accrued CRO and clinical trial costs</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Company recorded accrued CRO and clinical trial costs of $23.5 million as of December 31, 2023. As described in Note 1, accrued expenses for clinical trial activities performed and managed by CROs are based upon the amount of work completed on each trial. Amounts recorded are determined based on contracted amounts agreed to with CROs and through monthly reporting provided by CROs. The Company monitors activities conducted and managed by the CROs through internal reviews, review of contractual terms and correspondence with CROs.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditing the accounting for accrued CRO and clinical trial costs is challenging because the evaluation of the activities being performed under the Company&#8217;s research and development agreements is dependent upon the accumulation of a high volume of information from third-party service providers. <br/><br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the accounting for accrued CRO and clinical trial costs, including controls over management&#8217;s review of the information provided by the CROs related to clinical trial progress and activities performed in comparison to contractual terms and invoices received from third-party service providers.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">To test the Company&#8217;s accounting for accrued CRO and clinical trial costs, our audit procedures included, among others, obtaining direct confirmation from third parties of contract terms and conditions and the research and development activities performed for significant clinical trials and comparing such data to the inputs used in management&#8217;s analyses to determine the costs incurred. We inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#8217;s analyses used in tracking the progress of service agreements. We met with internal clinical personnel to understand the status of significant clinical trial activities. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09fd0e72-40de-47d4-85d4-935343e8d38b" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 1992.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce34b79c-2cd0-4e99-b868-1b7373d5a57f" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Jose, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 28, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors of Geron Corporation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited Geron Corporation&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Geron Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes and our report dated February 28, 2024, expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Jose, California</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 28, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:16.76%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:13.86%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96e78744-7542-4d5c-b9b8-f5add86a8c7e" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,023</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a26895f-4bfa-43f6-a3e3-0e2587852794" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,845</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e37ab9f-a4d2-4fbe-b4a9-77808837a3c3" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e26ccb83-66af-429c-b215-87766702959b" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3">364</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de3fd88a-079b-4b28-813d-ec3713921528" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,676</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4e8ddaa-f08b-4928-b289-f7b7a1af4b14" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1ed8a62-dd8d-4908-bcd2-d613eb337c71" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:NontradeReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a6b8f6a-ef97-4bb8-bf95-9d7450d46c76" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:NontradeReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,144</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b91e583f-86c9-4461-92d9-b23ebfea40bf" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,879</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a4ce8a1-374c-492b-ae90-b1d733d703d7" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,992</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f734e9f-463c-4533-a4d8-0cbf6a9bdc3d" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341,348</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9091835-6399-4874-acb9-b613c90cce0c" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_324a8568-fc2d-40e4-86a1-d58c9630a40d" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c72ffa9-e600-4b50-afbf-b61906a885c3" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,177</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_572663b7-d6af-44d1-b138-48aa28ed0106" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3">793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f638481a-5bc9-4b02-8fa3-cd935af86415" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4a69e75-d1d2-4908-ae85-40c91f6e8919" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,147</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deposits and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7553ea67-ce99-498b-9729-50baa286d179" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a89dae08-b78e-4704-8253-af08fb64af55" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,389</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c76656fe-2524-4565-b4c5-e8d1e2cf5d9d" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,076</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27c681b5-d03a-41f8-92e6-24b0edda3f01" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ce165fa-414d-4b44-a3d4-8da789680fce" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b4ac2dd-f0df-408a-8f25-9d7ce7826066" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,190</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a5f1547-e7f3-4967-8697-caa1a12a94b2" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,759</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7e20a03-ed21-42cf-808f-c0a43e3cd15e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,534</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f945105e-dda5-41c6-baf4-93e0018813fd" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b4da910-c247-4909-9cd3-377f88af04eb" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">925</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7941ce1-34a2-4d83-ae74-6502090d5c4a" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,893</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdcdc5ec-26bb-4ec1-ad0f-64fcf01edea6" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,945</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a2142b7-1836-477b-a18a-ff6fb8c893d0" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,308</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21b30ef9-bc87-486a-9b7b-7220c1962c1f" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2f462b7-29aa-41ad-af20-04dc850b6cf6" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,070</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a72d03f4-e95b-47e2-8b38-936688809858" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69a60f85-0196-44a0-903c-dd8b0be532dd" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_842740a1-62c6-4481-8e16-cfd36930fcef" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,671</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_533629ce-23b6-416e-8cf1-1ca5fa51ebfa" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,051</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0645178-41e2-42fd-b461-468a2d784b5f" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,212</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1d1a6e9-efb6-4a78-9439-cd667dd4b566" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dea445f-a9fe-4038-900f-b6c8265ab41b" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,577</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_3c679760-c5e2-4438-adcc-f87bf3505474;"><span style="-sec-ix-hidden:F_30281e46-cdbe-4120-b004-3005ac2cc30f;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c31a1f5-ba52-492c-81cc-61f4a1f43924" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_73e5faf0-370a-4384-a343-b370f0b61b0d" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aae23ae3-0fb9-4da0-9ff0-d4ff36be72ae" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_51f892e0-81d5-48e2-aa4b-6685e2331c21" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d43c7c7-a9ce-406e-a1b8-176e3ecd85fe" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7e8c7036-9173-454d-b262-248f62abb592" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8f00ce9b-bd1a-4a74-b879-8c1abab81c6f" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e93498a0-2755-42eb-9327-e7f49857745e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/>&#160;&#160;&#160;shares issued and outstanding at December 31, 2023 and 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_27f9fc38-8870-42a0-a389-b678747cd923;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_1802a09d-4883-4f3c-b335-1ded5d8337fd;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3274547-0d74-4e6a-8931-405a514db895" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_97743461-5cda-475c-9d2f-2ebaab5d0923" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76d79208-ce66-4400-b87e-f2d22fe0559a" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_275d4538-8014-4380-9d4d-cb9f1a54aeea" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,350,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized; <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f913a196-798a-413d-923d-d7ca08354b5c" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_75d3f43a-c17c-4d75-96b8-5ffc3566ab1c" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">544,912,215</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f2539ca-ae83-4dde-a9e0-741e1483a463" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_355c2c25-1c1c-4146-949e-c56bcadd2497" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">390,262,524</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding<br/>&#160;&#160;&#160;at December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc07f928-c764-45fa-b5e1-6fd34dde0a0f" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6174f495-6b98-4798-a150-564e7b265e18" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">390</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca42bf12-fa04-4384-b99d-8e55b7417f50" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,844,988</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cc60e00-444a-47ba-adcb-2e6a959e65c7" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,493,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95a3516b-73fc-44ce-bb23-db0bfc31a554" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,597,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cc2de7f-b62b-4a9d-b514-20227c8cb636" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,413,642</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1a566f8-a391-4cb2-b83c-d77abc74ce04" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3">185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce6a5110-3589-48e0-86fd-bf0e4dcc730e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6514281c-4eca-41f2-9753-5fc2241db17b" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7cc4ede-04fa-4708-8c0a-a9bf3708662f" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c688ffc-c8d4-485e-bc13-85d0c123c803" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,076</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9877a77-e56f-4ede-b590-36f680c4bb38" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,575</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F OPERATIONS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.71%;"/>
    <td style="width:1.66%;"/>
    <td style="width:1.66%;"/>
    <td style="width:1%;"/>
    <td style="width:13.217%;"/>
    <td style="width:1%;"/>
    <td style="width:1.66%;"/>
    <td style="width:1%;"/>
    <td style="width:13.217%;"/>
    <td style="width:1%;"/>
    <td style="width:1.66%;"/>
    <td style="width:1%;"/>
    <td style="width:13.217%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenues:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License fees and royalties</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d7bfed2-deb6-48f1-be83-cda699b2a52d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3">237</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2508cc5-77a3-45f8-b669-ff3e559746d9" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3">596</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e008cca-9f23-4d85-97e3-e6d120ced327" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,393</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd6a70d3-243e-4f63-a6ba-63be03b08688" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,046</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50e6b317-aa38-4c45-8fc1-439ad6645db6" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,518</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61d6cf41-b97b-49c3-88a6-6c3605c36184" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85,727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a727a3e9-e4eb-4695-b009-80ba005fd114" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,135</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba14dfbd-6e92-4aa1-9370-021a00b22218" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,628</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8850eb62-563d-462c-b531-cc04ccf700b5" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,665</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_728d1984-53ea-4825-9796-375d08591736" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,181</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_703f4064-6463-4e83-8aed-3267571b8ea0" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58b03b09-8e55-4c18-8830-73b3d99df273" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,392</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0855f919-ecbb-46d3-97e6-91adedef7195" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">193,944</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53cc5d2c-3623-4269-8ab6-436c139a9ec8" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,550</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54df5fff-c268-419d-96c1-fe30ce19a727" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113,999</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a52e6509-ad2d-415b-96d2-36ec61ed6872" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,152</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82fcb17b-915e-4363-a3c5-ad3fe365f51a" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30b23999-c02e-4d84-bc78-621dcd8483e5" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3">527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bce75a29-a098-4497-a469-25fd96c246e8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73ce4e55-4935-4d1d-be84-6f66573559f1" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,882</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03b29610-5ba3-47b6-8154-752c0485258b" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,740</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2641c639-dc53-4cd8-9bf1-e86a5d1b9835" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e8b4e69-3b35-43af-bb45-9b79edaded73" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9e6972e-50a5-486c-bdad-1f5b9f11f770" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3362c50d-de2e-4fd2-80d4-aa048e4dc1d9" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfafc08c-f1e8-4f14-930a-a84ba62d3a03" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_421f2891-f73b-4644-9c86-2233fcc6e53f" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d55e74eb-8447-4f64-bdc5-d59823e42dac" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e785b969-4044-4cf3-b767-02691ab72ba5" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.32</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_880d150e-53c7-476b-979f-4cedee346e9a" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1784ef86-643a-4773-ac8d-89ff389a756c" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.37</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3ba698c-b84b-4f59-b703-60cad99bfec3" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9c62addb-5188-44ff-86e3-926471f3c8af" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.35</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares used in computing basic and <br/>&#160;&#160;&#160;diluted net loss per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0739a0a3-f077-4894-9e08-408aef773437" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a434ab23-68e1-47d8-8f85-7e6ca6933b57" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">570,645,405</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a74e87dc-c1b6-4664-bb1c-d3d6efe27043" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2baaa623-cc5c-4786-822a-865ea82a69ad" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">380,784,846</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f76e89e-8467-4125-be9e-be354189dbbe" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9df9957c-431b-44ed-b265-65b3450593f1" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">327,631,814</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF CO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MPREHENSIVE LOSS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.25%;"/>
    <td style="width:1.64%;"/>
    <td style="width:1%;"/>
    <td style="width:13.917%;"/>
    <td style="width:1%;"/>
    <td style="width:1.64%;"/>
    <td style="width:1%;"/>
    <td style="width:12.957%;"/>
    <td style="width:1%;"/>
    <td style="width:1.64%;"/>
    <td style="width:1%;"/>
    <td style="width:12.957%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74dee74a-9bb5-43e7-b1a1-ee9770e86915" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7b88a84-c50e-45d8-805d-28008dd1cd3e" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d3781ad-5b65-47e6-a381-3fda478edf9f" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net unrealized loss on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4d43b35-5294-4d40-b2c2-17e10ccccbaf" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3">431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ece6c32c-b173-4e88-8166-e9d13818b9be" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">68</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9fab7e0-70ef-47b3-abb5-63379237a174" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fae564c9-3531-4e6d-bd76-edf50eac961a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_028f6d5f-c94d-4d49-94dc-f3f829b43867" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8611a863-8d8a-40ed-8dd3-091654360d33" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">183,723</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_500327a5-2ec0-4021-a219-70f6bee3b14f" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bc230d1-eed8-47c4-baf0-440067615ff4" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.155%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.318%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.498%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.398%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.498%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.598%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.538%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-In</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders'</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands, except share data)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2020</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_873153e3-cb1e-48e6-8942-5c0d6ec9e742" contextRef="C_4f5be4ad-c744-4346-b707-675df68384fb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">310,566,853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_258a4d10-3ad7-4733-87ed-3bf78f9827a6" contextRef="C_4f5be4ad-c744-4346-b707-675df68384fb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">310</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07bb334c-c5f7-4f13-9cf4-b87750e2084c" contextRef="C_c15f606e-8272-43fe-9517-3931c73040da" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,366,188</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a41be74c-15b8-419b-acee-592f3708ae9f" contextRef="C_ff875ec1-8c1a-4ae6-b136-1138204345ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,155,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ad1fcda-d98f-4987-89b5-6dcd0fb78af8" contextRef="C_ec95cdaa-3268-4317-a48c-594ad28bd481" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b1a3ef9-681d-4590-8a69-f7026719c6b2" contextRef="C_66810d71-5d1a-4728-8f3a-817e2201e76e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_205c381a-4e05-4367-a806-7ef75fc536f1" contextRef="C_423727df-44e5-4ea3-a181-865b8e657957" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8283365-aa3b-42ee-a447-ce7d8e09b4e0" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8dc3b44-7794-4454-bb2a-0517b1a64fb7" contextRef="C_3acb4904-a13f-4209-a193-1dd7ea1e9043" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_071b0acd-1403-4c0d-8a80-cad57a5f1e2d" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with at market offering,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b2146d6-07c4-4a03-9e3b-e8453a35558c" contextRef="C_42c6935a-1d5e-40dd-ab10-35f9472606c2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c12e88d-7520-4cf6-b02b-876a9c101095" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,571,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12ec2a8a-ab42-4104-bbc0-c032d9d82e47" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf151a3-b4a3-477f-b803-bb416e14b13b" contextRef="C_6cd1fdca-3697-4478-905e-43127481507e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_774d46b7-6a56-4229-94ac-7f016b0f2b13" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa4d1767-f6a4-469f-977a-877b03b53417" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,906,341</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7114e0a3-1187-401a-a3ad-09cf37813896" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9526ca7d-bf3c-4945-89bb-a44cdb769487" contextRef="C_6cd1fdca-3697-4478-905e-43127481507e" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb964c39-87ec-4547-85b6-bdaf6ec9e2c6" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation related to<br/>&#160;&#160;&#160;issuance of common stock and <br/>&#160;&#160;&#160;options in exchange for services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35355664-2f33-4b0f-be7a-e6c1481a5469" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,783</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc8ac768-9b98-48df-9864-3e6572951a08" contextRef="C_6cd1fdca-3697-4478-905e-43127481507e" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aceb7648-3836-47af-96bb-24c09b132951" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuances of common stock <br/>&#160;&#160;&#160;under equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c051fa51-fb7d-4fde-a099-c64a7a9cf769" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">666,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1002965-87a5-4e4d-b2ca-1f4adb82668b" contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d51e2c61-8754-4717-ab5e-597528995fe1" contextRef="C_6cd1fdca-3697-4478-905e-43127481507e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3">796</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aa533bc-ef43-4f23-8b2c-c22ab49ce672" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3">797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation for equity-<br/>&#160;&#160;&#160;based awards to employees<br/>&#160;&#160;&#160;and directors</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc9b65a7-ae39-41d3-8c8c-dd413b95bfbc" contextRef="C_6cd1fdca-3697-4478-905e-43127481507e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9753806-358a-422e-b139-5c65e7ae0509" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34511551-e003-485e-8d00-a8ac1f01afa0" contextRef="C_dcf8dab7-019f-4b57-8582-d13f9fbce0ca" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">323,731,591</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_386493bf-072c-47c8-8415-fc56f1126d5f" contextRef="C_dcf8dab7-019f-4b57-8582-d13f9fbce0ca" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">324</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_852d4a74-9657-4911-b804-182bd928ce7e" contextRef="C_06b531c7-ec9f-4ac0-bc05-e1c34b4943b6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,398,006</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13119ccd-df4b-4bff-84d3-31f758e01e64" contextRef="C_a4961fb6-61f4-47d9-9582-c48ee1cf31fd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,271,741</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8a4dde7-05eb-4564-839b-0bdab72f8ac4" contextRef="C_cefcefdd-0850-4f7b-b6b5-cd1f2132fb46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">173</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0f7a5ec-33f7-414f-be32-3bedfc7ac8df" contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,416</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fed609eb-671f-421b-ac45-1a7e8f788791" contextRef="C_8226d454-2be9-44b7-b692-bf6354a4b418" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11cbe750-5148-4da0-ace1-331ab20fb521" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a34e2b0f-07e2-41f6-8c11-cb4b64d26438" contextRef="C_a550d37d-7683-427c-9abd-810070f5905c" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_481b25d6-cc6e-459d-b8b6-1f06e3e0538e" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">68</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd68bc0c-9ab6-445d-841e-c165d1c1ebb2" contextRef="C_a550d37d-7683-427c-9abd-810070f5905c" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0c3a519-c621-4ef7-a1af-d474e2db00a7" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">Issuance of common stock, pre-funded<br/>&#160;&#160;&#160;warrant and warrants to purchase  <br/>&#160;&#160;&#160;common stock in public offering,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ae3dd23-8882-47bc-a778-db1f070cf799" contextRef="C_4dcea29e-0f7f-420c-8854-7bbd432fdd3c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,066</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7209852-46c1-4058-848d-dfbdcfbe6e52" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,333,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61744273-46b3-45a2-854e-142dc2f335f4" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3">53</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13a13635-e6e9-426a-96ab-5d3420286430" contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,863</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c9ad256-1688-409d-acfc-569ebd49259b" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,916</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad98a163-ee38-4e67-96c1-37a4343ff336" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,663,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfa4e491-07dd-4f73-87b0-9f06693aaba7" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73ff568f-8bdd-41fa-abb0-0457f7e0bd89" contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,151</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2addaff9-411e-4cfc-a5a9-695f0d752ef7" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,163</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation related to<br/>&#160;&#160;&#160;issuance of common stock and <br/>&#160;&#160;&#160;options in exchange for services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b573458-09da-4180-a889-59b64b51dfd0" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,962</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4cb02bf-1dfe-4c39-b792-40ad3ac90b09" contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49a872c6-a68d-4be7-8dd5-8ca16131e99e" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuances of common stock <br/>&#160;&#160;&#160;under equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cd2aa6c-b531-4083-b7a5-b5b1a922f46a" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,518,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50aa4793-fecb-43eb-bd89-400c7fa2e055" contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_172de5bc-a9da-4187-a0b5-de2ad68bf566" contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98c2f102-731b-4eb9-b9ba-005e572ce6b8" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation for equity-<br/>&#160;&#160;&#160;based awards to employees<br/>&#160;&#160;&#160;and directors</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1fbe03c-508f-4627-b5fc-7ca44ab21a53" contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0f2bd9d-afba-42cd-bee5-eec577ad3050" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c9b2b72-5007-4baa-a71c-7934db53f7d6" contextRef="C_1d320b3d-6dfc-4827-907c-1c7a097695e8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">390,262,524</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ba171ed-e549-4383-a2e7-93c8f800874e" contextRef="C_1d320b3d-6dfc-4827-907c-1c7a097695e8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">390</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_504e7f1e-0f56-4195-b54e-13305197cff1" contextRef="C_6102220c-7833-4b4f-aa22-7bbaf7d6a11e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,493,469</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c804a4fa-266b-4177-a9da-0cf40d0771e8" contextRef="C_91f09572-5c03-4d4f-9e6e-6b7a9683db52" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,413,642</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf70377b-a4b1-421b-b11e-ee5fc413ac3b" contextRef="C_4111e6aa-d02c-4fab-8c2a-dc8d69eddc4f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">219</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb32f55c-6cc4-4a7f-8590-ab1fe9c0ddc5" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3791e9fe-b4f8-44a8-a950-610e096ef654" contextRef="C_e1a70717-d878-4158-aada-2b23be1cd942" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61737cbe-3b3e-45d1-9360-b40957a32e78" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9420b1b1-95f4-441e-bd8c-2e6791bd4ec4" contextRef="C_c5bfecec-6498-49b3-b2ca-dff2fad0c618" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3">431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84046cbc-48f8-443d-adfe-b57f0556aedb" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3">431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b829d0a8-ec61-499d-8afc-36a69545ff9a" contextRef="C_c5bfecec-6498-49b3-b2ca-dff2fad0c618" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca0e2ba-3022-410f-b2ab-780bb0c42124" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">Issuance of common stock, pre-funded<br/>&#160;&#160;&#160;warrant and warrants to purchase  <br/>&#160;&#160;&#160;common stock in public offering,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e51e1396-1796-4e9e-b0c2-d527d8c17291" contextRef="C_0880c107-5216-4914-bd93-f39768e97006" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,507</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f61e952-256f-4442-bb41-c95e723d0630" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,007,741</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_748b7476-358e-4fa1-8f83-bc6794fc011b" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3">68</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_969bb75c-46f7-49d7-8810-2483f201c09e" contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0fd9589-ffab-42c9-a7b3-9e8c668e895e" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4294f9a7-1d04-43c0-9c02-25a21d685ec5" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,349,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e767fd73-4995-454a-86ef-e88f46d6fbd5" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deb46f6f-8999-423b-b35f-4c5daec62fac" contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,834</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3e4443b-5b1b-443e-99fb-f706959c896c" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,912</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation related to<br/>&#160;&#160;&#160;issuance of common stock and <br/>&#160;&#160;&#160;options in exchange for services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ca483d6-d5eb-4b06-8b16-8905258496aa" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,864</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a5baa7a-65fb-4b8a-9d58-5e8927563148" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb13a7a8-11a1-473a-ba1c-21d8c10e9025" contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33c9b18e-bc4d-4f1b-9855-270c77ae50a3" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">829</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuances of common stock <br/>&#160;&#160;&#160;under equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8b40c7d-e6ab-4317-b493-4a80c0b874a6" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,255,228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_850e4448-6e84-4727-8d7b-ae8115c6e0a6" contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d88c061f-e597-41b6-a7c1-34430e88c2c8" contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec8ce1af-5df2-453e-b942-3742ace19a12" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,070</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation for equity-<br/>&#160;&#160;&#160;based awards to employees<br/>&#160;&#160;&#160;and directors</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a9de9b1-5bc5-400f-a53c-904f6a8f4471" contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,526</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15c2e8ab-3d71-416d-87fa-67b709b22e81" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,526</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f729517d-d770-4af6-9557-27c70dfe9715" contextRef="C_351a0c01-2dc4-4490-a644-a98d7ccf7278" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">544,912,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4419e880-c2a0-4589-8b19-374368af1d21" contextRef="C_351a0c01-2dc4-4490-a644-a98d7ccf7278" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">545</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40f67997-5eb2-440d-9a19-cb4dd066ec35" contextRef="C_3bd9d30b-b6ce-417e-b7b2-8eb4d19cca93" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,844,988</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d2af714-0681-452f-a415-d00f8a5f93a4" contextRef="C_01a4fb2f-1285-4c86-abb6-10590d094c02" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,597,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24fe18dd-47be-476f-9002-8553364ff6a9" contextRef="C_5aba5b57-05d2-4c06-90d4-6885ef672ae4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7847ddd8-a5f7-4879-9b8d-df4aff05bac2" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.07%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:14.343%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:13.363%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:13.363%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_597756fc-7f56-4956-b095-6659f73f5695" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb334b40-3fd2-4fab-a746-a531a15703d0" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8669bd2-2425-46cf-9336-6a1672be007c" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in<br/>&#160;operating activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3eb02f97-200a-4eb7-8643-87adbcf965ac" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb0d1c99-0542-44c4-8ea1-a75e3ea938eb" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bda21805-6d3f-4e6d-a678-537cdd077a36" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion and amortization on investments, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_972ea37d-46ff-4c76-b948-05ede80b6e18" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de3a7c9a-3ad6-4f0f-8c5b-82d3f9e31b17" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1e10370-362d-4f12-9eb1-29a48508a015" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,424</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of debt issuance costs/debt discount</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e6c271f-cb19-4b19-a07c-9785de79d726" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,088</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0469eec6-df42-4115-8626-dd51d006b50f" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72da0a58-aca3-47c0-993d-a17d95e20241" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">893</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net gain on exchange and sales of equity investment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_990a87ea-e679-4489-b033-c7afd1c110ea" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:GainLossOnSaleOfOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation for services by non-employees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22adb65e-9b09-40ce-aec5-5941ab57a9b6" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2b506be-3eb3-4890-b16d-396f50051974" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_037714fd-ba91-447a-b45c-a78ad4b1b141" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation for employees and directors</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74dd5f8d-e77e-40c0-86f5-50b33e16ec87" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,526</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b0fc41-970f-4db5-b909-4f6c0756b5a0" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6e924c0-6028-4629-8ff6-8901f0029b5c" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,080</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d47ab903-1ca7-4891-bdab-d8bd68c2ba58" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3569dfb8-cd3c-4b1f-81f7-330d3759997a" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34dbbcb0-db64-4a5b-8e77-2c8eee5592b1" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest and other receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02dcd237-67cb-413f-8b10-39307ba921ad" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faae59d4-4b3f-407a-9f20-669a1e694b3f" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b25019a8-bb92-4c0d-989f-d9b23cf27540" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,041</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_339630e2-c6c6-43ef-a822-ad379516777a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce045212-6690-4eae-a366-6e4c8ebfe0fb" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ffa8769-ac38-4838-b2b8-cc46579e374e" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,317</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deposit and other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_789ea9d8-7768-4d2e-a9cd-82ee05a4f1bb" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a7f0f2d-1657-4fbd-ae87-b0bfe04aebe8" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ec8db5f-b70d-495a-a00e-70c5edc0c5c0" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,807</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47938ac9-f462-47cb-aa8d-7d493b7a5683" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,029</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fef0634-fcca-4a4f-9c69-027133bc4fce" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,503</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46252dd5-f607-4a66-89d9-352d3bbe505c" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf8f1d55-5dc8-4cbd-b9d8-615b0fea1875" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_847a55ed-8f03-489f-976b-5d7cf92b7bc2" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9065cc4f-2d1f-4acc-8b25-b9a888cbea37" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7203a634-d6cf-4f32-98a8-c23a09c5eca4" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,208</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a88b438-5a95-4bcc-8585-29ef568ad4b4" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,266</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6da15e19-a495-431e-8cc4-1e22e975937f" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e63827b3-a2df-4a10-a9b4-3fddb3a41edb" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">640</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db6c43e6-7180-4ea6-a291-3a936da61b71" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d74b814-cd55-492a-a975-1f77ae9ba519" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffebb767-1efa-43de-98a6-c8a90e283b26" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf13bf97-6b21-4392-a32d-19067c421949" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">127,379</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fb10952-5c70-41ba-9ca1-9014c43ab79e" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77754d66-2d2d-4f66-b9f2-0ddc056f69d8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d4141db-7f1c-4062-8372-4050b8cbc6d9" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e6b2d20-4dd4-443a-ab15-1f89716f3d6c" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b1b48be-4510-4283-b367-6ad6c7dedc6f" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b81ee287-500b-46c4-a59f-9ca8886cd737" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,007</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88606d97-5763-46e9-b295-50d8d007cb4e" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">177,434</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41ebc8d5-180a-4cbc-88ce-3e34465c14d3" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42d32376-7bab-4f31-8c6f-6a2fc3df9e55" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,505</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89464e94-7400-4403-a31f-78b1400689fb" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,994</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sales of equity investment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dfcf174-3dbc-48f2-95d7-92405c5eb733" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,594</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4e7eb27-5f6c-4b20-aeaa-8af8ff0f6bd2" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">180,322</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a989827-f60e-4683-a7c2-b59ea9370e93" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,067</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bfe93f0-4bb2-4d82-a781-6dc7d427a6f5" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuances of common stock from equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bb83e91-c594-4607-b49e-ab0b1ea970f5" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,072</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b14a0d32-dbe5-463b-880b-9efa02026c90" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,185</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba9f5065-780e-408e-a9a3-5afc436b9c21" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock and warrants <br/>&#160;&#160;&#160;in public offering, net of paid issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e950d705-42bc-477c-bb7a-1101ed4954fc" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_474932e9-2e19-49a3-88a5-b21b3fd22110" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,916</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuances of common stock from <br/>&#160;&#160;&#160;at market offerings, net of paid issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d1492ec-f181-4dc3-9bbd-5a191fe4bc5b" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c1a23a2-d135-4242-a41f-fadc44cbad9e" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,912</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1718c85-c2fc-4c6f-b7d5-d1cd753e4438" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,163</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8901fc8-0548-4482-ab2f-629eb44d321c" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,479</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from debt financing, net of paid debt issuance costs and debt discounts</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adca3948-6052-4438-b131-314f8ef7950c" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,700</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16c8ceff-b92d-4c78-806b-2bbea2b98ce7" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0e88fe5-8a5e-49f9-b482-12a5f4e04ab3" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,021</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac1e458a-69ba-4805-b8e3-cdf37ebec46f" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,264</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d32b09c-2ae3-4860-889c-bbb9c6227735" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net effect of exchange rates on cash, cash<br/>&#160;&#160;&#160;equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_014bb4d4-0d67-4b9e-b686-cb2a15eac420" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_791d6cd1-0d04-432b-9dce-f9a5b7044abb" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents <br/>&#160;&#160;&#160;and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f553a7d7-cabc-408e-975a-657c972965b1" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eede17b2-ee4b-4426-8b50-7972379e64fa" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,974</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33ae5d07-d187-49a3-a99a-830b30fe4f64" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,947</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;at the beginning of the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd40d79-cc00-413c-890d-a30c7acfc082" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ed7de13-e031-4286-b9ab-2abc25d4b306" contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb10d437-3bf7-4ef2-bb54-5c210956d996" contextRef="C_66810d71-5d1a-4728-8f3a-817e2201e76e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;at the end of the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba5906cb-d9ce-45f1-a7be-a3b7e8e862b0" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,138</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a6fbbbf-3250-4f57-a324-20ac59ca22fb" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,209</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fa51378-98c2-4c8a-9192-8cbd7c33768b" contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,235</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See accompanying notes.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b3f3a6a-3248-4273-8a7d-b40707492541" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="note_1_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms &#8220;Geron&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; and &#8220;us&#8221; as used in this report refer to Geron Corporation, which was incorporated in the State of Delaware on November 28, 1990, and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. Geron UK was incorporated in September 2021, and its operations commenced in January 2022. Geron Netherlands was incorporated in February 2023, and its operations commenced in June 2023.  We are a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, an innovative therapeutic for hematologic malignancies. We have global rights to imetelstat, an investigational first-in-class telomerase inhibitor, which was discovered and developed at Geron. Principal activities to date have included obtaining financing, securing operating facilities and conducting research and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4ca573c-d58b-4ee1-a693-9955d60a3960" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. The resultant translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#8217; equity, on our consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cac5860-b3fb-49fc-bdf8-6f246e0bd897" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_2cac5860-b3fb-49fc-bdf8-6f246e0bd897_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebdc0cd8-5b12-4c4f-9b0a-497beeeff33e" contextRef="C_2d88ef09-b3cf-469e-a8fe-49f54977425e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,095,238</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c1063df-4fb8-4564-ac82-5db5fc4ae562" contextRef="C_16cb4e12-d0a4-4036-b565-a780727a5c13" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,335,239</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_744d80a1-bbae-4782-95c8-84395200bf97" contextRef="C_2d88ef09-b3cf-469e-a8fe-49f54977425e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_106d4e1d-fe05-4ea2-a0cd-a3ef3696ae27" contextRef="C_16cb4e12-d0a4-4036-b565-a780727a5c13" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. In January 2023, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb99fc41-2e9f-4c27-b5d4-7a972186c062" contextRef="C_c4453fc4-f1fc-4c46-81b8-a6f6809e0b65" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,007,741</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f26c2f3e-7710-41df-838d-8faed3da147d" contextRef="C_95d2171c-44c4-4ef3-bcef-9a3bf9ca3146" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2023 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 9 on Stockholders' Equity for further discussion of our public offerings.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2cac5860-b3fb-49fc-bdf8-6f246e0bd897_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2023, 2022, and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the diluted net loss per share calculation excludes potential dilutive securities of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02b14e9d-7941-4b23-9588-dc936facc0c4" contextRef="C_38d32bf7-1b80-4b24-b2eb-46f7768d7421" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,458,854</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7a37b0e-402f-4f22-9db2-0f0005c274fd" contextRef="C_ec2e5c75-1f30-4a48-82c7-38c0000d374c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,726,765</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4a13a6b-a9ad-4bea-9040-1f65b70f8d27" contextRef="C_7fc0d7c6-e2ff-4bd5-b6f5-508937b233e0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">105,725,875</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad19d589-afae-4847-96b0-ee4d8f46679d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c27b14ac-179a-49f9-9102-330edb20aec4" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations. We recognize a charge when the declines in the fair values below the amortized cost bases of our available for sale securities are judged to be other than temporary. We consider various factors in determining whether to recognize an other than temporary charge, including whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. Declines in market value judged as other than temporary result in a charge to interest income. We have not recorded any other&#8209;than&#8209;temporary impairment charges on our available&#8209;for&#8209;sale securities for the years ended December 31, 2023, 2022 and 2021. See Note 2 on Fair Value Measurements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure our investment in equity securities at fair value at each reporting date. Changes in fair value resulting from observable price changes are included in change in fair value of equity investment and changes in fair value resulting from foreign currency translation are included in other expense on our consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_364698c1-7758-485f-ab9f-418b462cebc2" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43cf0323-ae2f-4ffd-9bbd-33a9c854caed" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0059992-d67a-4150-9114-6ccab40ff503" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2589ce4-8877-403a-a5e2-d01b2534f5fe" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f584c6b5-f009-4a38-af35-292385a6f280" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current imetelstat clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35853b32-8948-4b6a-aa59-04cf1fd627fc" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and Amortization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record property and equipment at cost and calculate depreciation using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd40f709-d3b2-4e98-bca8-170a7a5049c5" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e61000b3-a972-416d-9661-92e312eeda16" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 9 on Stockholders&#8217; Equity.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5d7c0ea-8564-4a16-8355-d976fa9b532d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#8217; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b346028-465d-4e6a-9e23-ad6bf8b702d3" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4379adb0-f416-46a4-b6e2-a6824936d5f7" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive management team represents our chief decision maker. We view our operations as a single segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a646171-4322-48de-9393-67a5601b3eed" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued and Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2018-19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2018-19, for the purpose of clarifying certain aspects of ASU 2016-13. In May 2019, the FASB issued ASU 2019-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Targeted Transition Relief</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2019-05, to provide entities with more flexibility in applying the fair value option on adoption of the credit impairment standard. In November 2019, the FASB issued ASU 2019-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosure. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. ASU 2018-19, ASU 2019-05 and ASU 2019-11 have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 became effective for fiscal years beginning after December 15, 2022, using a modified retrospective approach, for smaller reporting companies. Early adoption is permitted. We adopted ASU 2016-13 and related updates as of January 1, 2023. The adoption of this standard did not have a material impact on our financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97725b5a-55e8-4ba9-9955-71832cc3bf7d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_804ae974-4309-400a-92ce-9f8ba9c253ff" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.869%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_168e1ed0-e6f5-4ba8-b3e3-add2682a3252" contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc67e1e7-e0f2-472b-8671-bf40605d2163" contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc45ec68-e843-4728-8010-6244824bd7e1" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08d40d39-39ef-417b-bd85-fd51fc3c5c50" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d02974c3-ce31-49e1-a6c8-1bc1502e9389" contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e03119b4-98a4-4bb7-98fe-8f4dfc803634" contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35a3f31e-936e-4fd1-bf5d-170d45e96c81" contextRef="C_3a0593af-b72d-4eff-a7fa-e7458afe7976" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_712dd065-d93f-4fdd-8cd5-d1ecdc85c263" contextRef="C_3a0593af-b72d-4eff-a7fa-e7458afe7976" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bed47220-3c55-4a62-b6ff-ea42c75d2fef" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4303875f-8fcd-408d-aa0d-52ddaf8d8b69" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5828eb6-4e61-42e2-aad5-4c0fb93fb91a" contextRef="C_264544f1-3468-4c3f-888f-e76d69aa9c26" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,752</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6351ab1c-8065-4673-8126-cd2a8e5a6859" contextRef="C_264544f1-3468-4c3f-888f-e76d69aa9c26" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46888630-93dc-47c2-a67e-75ac1974b05a" contextRef="C_264544f1-3468-4c3f-888f-e76d69aa9c26" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,847</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b4fe22-3a6d-4262-9b45-26b66dd3c5f1" contextRef="C_fb78444b-50bb-4a99-b63f-30026eed0bd9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,877</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d432630-22e7-4056-976c-6bd2661478d6" contextRef="C_fb78444b-50bb-4a99-b63f-30026eed0bd9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a8af07c-19e3-460a-a431-a19c2ca549a0" contextRef="C_fb78444b-50bb-4a99-b63f-30026eed0bd9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,894</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbb75585-a6ba-4975-9e4b-72a3a1538c2a" contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,250</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b6bbc50-0a37-416b-afcb-086cda22db58" contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6048dd0-bbac-410b-9e94-759b8b15f78c" contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a5ce75e-bd12-4c88-8876-b3349d6a7def" contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,201</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d79f045-9dea-48a0-9e36-8fa9908c7f39" contextRef="C_6310966f-16be-4280-aead-d0c892e948b2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,598</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1065203-6204-41e1-9c1f-e429b95fe9a0" contextRef="C_6310966f-16be-4280-aead-d0c892e948b2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33769c3d-7ebd-4a2e-9f0c-a47598329043" contextRef="C_6310966f-16be-4280-aead-d0c892e948b2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df574f8-1c03-46d2-bca1-dd5ad46aba61" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b680e92-4782-48b3-8ff0-6955380ed441" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec7286df-ef1e-4848-a4bb-5483feacf81e" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e0fb2b6-5400-4583-b3b2-522a9ddc31c0" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,268</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80fdebb2-afb5-42f1-8838-fcfc74487c1a" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,409</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fd80df9-6f2e-45ac-8f7f-eff7f5be1e1c" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e183486d-e0d3-4dba-8bea-f371ec9602e1" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6904fbd-6186-4483-b5c1-7ae5a6b6ee9c" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,360</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce0edead-617d-4629-999c-3b19abc179fd" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,628</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15ea9d0e-887c-4ad2-99af-b0bc01dbe1fd" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2eda6da9-d00c-414b-b2c1-fc960aee3acb" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd741336-bbdf-4bc3-8693-90ff4306e40f" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,734</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc37614a-dc8c-493b-8bbc-8a9341fe11d9" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,784</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a71c176-ae54-4d29-9521-a42a7df86290" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a48b35a-92f5-4b7c-a497-9b1951c7f887" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0db96cf8-ca5a-4d5e-960a-102f30297868" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,974</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at December 31, 2022 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.869%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.882%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16812dcb-0e0f-48e6-b75a-11eee7bfced7" contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54a428fb-c98a-4cec-98b0-93c8437bbe9e" contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_372c62b9-8f81-4b39-ba2b-c96171a84540" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d39c7b69-977e-4b90-b0ef-254bde2d2165" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d26cb5a6-539d-4769-9e6d-98668e6c91ef" contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3">93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0259a10-ebfe-4dd6-9194-b11a2ee39eaf" contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3">93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24632914-b537-4423-9c2e-847d87724634" contextRef="C_8d5c94ef-47a2-4e1e-9aa3-b699facad362" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3">271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c89ea9f9-7fff-4f58-9fd2-0adbabb0d033" contextRef="C_8d5c94ef-47a2-4e1e-9aa3-b699facad362" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3">271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2942cce-2012-4d16-907a-0c8b1fac17e2" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3">364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_290b2bba-1bd2-499f-929a-ed3c119a5c9b" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3">364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bddae142-88c5-46c3-aeb8-6ecbed7c9ee3" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,983</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bfa084e-b551-496c-a52a-057a2339a669" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2573afc7-3840-4a3a-9d18-16b28cb2daf5" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c36ea5f-2ebb-4c08-adc3-8420d18764e0" contextRef="C_b6536834-7d1a-4219-88e2-57d47d5dd378" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97a8af28-4cd2-42b8-9b5a-bc6345518a9a" contextRef="C_b6536834-7d1a-4219-88e2-57d47d5dd378" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3447fbc0-6b32-4ef3-afdd-ea9157e8a7d3" contextRef="C_b6536834-7d1a-4219-88e2-57d47d5dd378" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f0b8114-d60e-4d8f-ad3c-247508842698" contextRef="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,860</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4149ca6a-1187-47e0-b965-9cbcb722b2f8" contextRef="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f0374d-7838-426f-8db9-d8777acd959b" contextRef="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,846</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b11f9498-a12a-48a1-a1c9-f7755aba0dcf" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,285</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1be0fe6a-beef-4f4f-b2aa-e66e92d47804" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f0e3e1e-d404-46ba-86ea-400b041470c5" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5fa21ee-c4ab-4ece-a20c-9fde2924844f" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ac1b1c5-a2d3-4ed6-9d77-0f36a0bcf66d" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98c8e6a4-2668-46ea-a9c1-e1c5c60e0f32" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">55</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa84f6d1-fa9a-496a-9baf-95f595ceb411" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c1b3433-f89e-4bcd-ad37-af131366b4c1" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116,142</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04c62937-f1d2-48cc-a780-832861cd7e47" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6efd393e-320e-4ab2-8128-54fd2b8fd3aa" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61acfbd5-b736-4aec-afa4-804a49aacbd6" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,901</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_32c9e1fb-d747-438e-9c39-75f3745dc2a0" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.44%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.26%;"/>
        <td style="width:1%;"/>
        <td style="width:9.5%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored <br/>&#160;&#160;&#160;enterprise securities <br/>&#160;&#160;&#160;(due in less than <br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62fad5d1-395d-4308-abef-9e7b44c83313" contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b4ad9ac-4bb5-4f2b-910f-d3ff1e6b27e6" contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca1d3e8b-521c-4e69-a8b8-175339464562" contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c494367d-1d3a-4448-a8d4-5652ab7b2d00" contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3d1633c-5821-4d62-8eea-a137f68ac0bd" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f5847f7-a2bc-4501-aab5-a771b2d5996c" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5a1664e-27de-4c76-ba0b-cb79285893bc" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a26beb0-f9fc-4f77-b801-af9578d44714" contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">33</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dfb4388-f637-4497-9b2d-a36397247dc7" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_116f73a6-2ccb-4007-81f1-7e5e820fb179" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0adc5bf-8f34-46be-b64c-07f0a839198c" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da1deba4-bdd6-4dba-8628-fdee4a216c89" contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1641015a-c275-4123-b2d3-916225d8e109" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,952</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a51a618-5a62-4fd6-838a-449dccd20070" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12f4e3a7-36e9-4eb7-8464-955ec2c084f9" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,952</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c02de60-fa44-4544-9dd0-cc1d688d0a59" contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6578b20-8596-40e2-8115-16c572262217" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1995ce93-a075-437e-b613-814626518afa" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4477fe09-8132-4cce-9098-28efa8a2a5e3" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,518</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ee0b6ab-cab3-48b2-8bf3-91b596b80976" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury <br/>&#160;&#160;&#160;securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abfb3d33-abfb-469f-a9ac-c8a1a9715064" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f90508-a2d7-4565-8ad9-371a7ec0c456" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4337f37c-b948-4768-9db3-71f729852ad2" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,497</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5cdd829-4928-47d1-bdda-b0f42cdef1a1" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_474fd431-e0b6-4cce-98d5-19d2071ded0b" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eb5f622-0b14-4204-9a27-5f44a6c3af5a" contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities <br/>&#160;&#160;&#160;(due in less than a year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8395a4e3-40a6-45da-8cba-badb766d3d50" contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51da83ad-e779-408a-87f5-0d0021015cd0" contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e527e889-40cc-40d4-beff-e4a11923a1d5" contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5090a276-981a-4b8b-b585-87bc523c975f" contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored <br/>&#160;&#160;&#160;enterprise securities <br/>&#160;&#160;&#160;(due in less than <br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ff3fce6-48bc-4fd1-b24a-6301c106b085" contextRef="C_503221bc-7adf-491b-8898-576757f733b9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,845</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddf33baa-d079-4a5c-9d78-dafa3d83648b" contextRef="C_503221bc-7adf-491b-8898-576757f733b9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eeb63b5b-17d2-4874-adb4-90fc194eef14" contextRef="C_503221bc-7adf-491b-8898-576757f733b9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,845</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7071479c-1880-4dc9-b5df-4579021c22a0" contextRef="C_503221bc-7adf-491b-8898-576757f733b9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90f0d736-db46-43d4-849a-70b5031f9950" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22971dfe-85ab-4ada-9eaa-61cfc85b0768" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eafe069-9419-4a5a-a140-4e1b568c7c36" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,454</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb31f120-44b4-4b72-a026-415445a24916" contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">92</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb5f31bc-6ea0-41f8-a2f7-bc5ec15b72e0" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1bf8414-c332-46ad-a5db-de2e9240b470" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8498dac1-3b2f-44a9-83d6-e44195445d60" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,962</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27913af5-23b8-40a3-a122-1f612a5917a1" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c378df3-1c99-4b7c-936e-f22e0efe9628" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a374cbe6-825b-495c-a3d5-0877fe14e853" contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dba6317a-f4ce-4aa9-a56d-67d3863ed613" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,721</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_662b7589-1c9b-48e1-898c-4fa371140f8e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f33f4b6-47a4-4328-a86e-ce95d8bf10b1" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,435</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5299059d-fe7e-43b2-a710-978cef9647fb" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_427b6e3c-4e2f-4022-a0b7-a4414bb44c0d" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6fb3bb3-ff1d-46d6-89b5-8a072564a189" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gross unrealized losses related to U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of December 31, 2023 and 2022 were due to changes in interest rates and not credit risk. We determined that the gross unrealized losses on our cash equivalents and marketable securities as of December 31, 2023 and 2022 were temporary in nature. Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflict between Ukraine and Russia, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We review our investments quarterly to identify and evaluate whether any investments have indications of possible other-than-temporary impairment. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. We currently do not intend to sell these securities before recovery of their amortized cost bases.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value on a Recurring Basis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We categorize financial instruments recorded at fair value on our consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:1.84%;"/>
      <td style="width:7%;"/>
      <td style="width:1%;"/>
      <td style="width:90.16%;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b01ef453-3f39-4490-b16a-7fac3fccaf07" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_b01ef453-3f39-4490-b16a-7fac3fccaf07_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 and indicates the fair value category assigned.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:15.96%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.040000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:11.34%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:10.86%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Active Markets for</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70cfece5-5e04-411a-8e56-15e6828989fb" contextRef="C_2e8f230f-35de-44f7-93b7-6df504f45fde" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a598f6b0-9ece-44fd-9500-e3dc89498398" contextRef="C_c14e1cc2-f8b1-4804-970a-08b5df83f4b4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4639dbe4-6cba-4d7f-b33e-5fe949aafa0f" contextRef="C_3f7e8c6c-6681-4a1d-9f84-ed77636d8cd2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a700ccfb-3aff-40a0-8f8d-d0b996941be7" contextRef="C_7d2d8379-582f-499f-a5c1-4b051c31e7ed" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92a70d80-b47b-481c-9563-a5e48f8b228d" contextRef="C_49ff1dd8-46db-4d4f-baa8-c884bec8fd8e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,742</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95008b90-e9ea-42a6-8da3-e4691a35750a" contextRef="C_df1f41e8-3c99-453f-9b1f-eb930e82b8d9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,742</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_898e6471-0822-40ae-b04c-64c82c354ddd" contextRef="C_7044d4ee-a54a-4427-9cc2-9922f4676346" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91ac7770-bf2a-4b7f-ac8e-f885e851fb0c" contextRef="C_6812ec1e-cd7d-4990-a1fa-445d65e04803" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6933a5ec-f58d-43c3-877d-8a624440141b" contextRef="C_0907aaf0-4f28-425e-a4e7-02bd5e2c9311" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,268</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_300be5e3-c86e-49e9-a8bb-242d6af4d18c" contextRef="C_5e5d5abf-c356-4752-8616-9b666f658b7f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,268</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c3f8193-8e98-43db-b2f2-b01c3f20ba8c" contextRef="C_4d124dfd-42e3-4007-856f-2bc59dc7e2da" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,092</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46975070-7b06-4702-985f-caf7b5b0b401" contextRef="C_edfb6d0a-e261-47b0-b5f3-062c8bf0db56" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,092</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d356915-d9ae-4811-a660-cf7d49f0754a" contextRef="C_d3f33d08-a5ce-4365-a047-c2b41669086c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,930</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be693926-9e61-417a-8c8e-60bed1646881" contextRef="C_01a342e9-84cb-4a8b-94b4-0c633e0e9043" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,974</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_480f736b-f806-4907-9462-4a28b58c304e" contextRef="C_5c78574d-4d3a-47d2-9453-d6f12deab799" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324,904</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ccc70fe-27c0-4088-810c-e67f55615797" contextRef="C_cc68db16-fd2f-40cb-8dd2-0fdeb8ec048d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,864</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d50e916-17de-4533-ad83-1240780e59e6" contextRef="C_23c9ef8f-d893-45f7-9dae-127a81af3541" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,864</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77824295-0957-4da6-ab20-b0562344cf43" contextRef="C_5093ace2-fb77-487d-9798-18faea32c09f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aecfb94c-47d2-45cf-8164-30e8cfa2c54c" contextRef="C_8a0297cb-3318-4836-a868-af5440cc2bbf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_149391b9-e365-40a7-9137-bcf91168c2e7" contextRef="C_8fb6bb85-bc11-42d4-90c8-60d500a4ce63" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b8bf624-a20a-40ea-8c80-1e2c0576869f" contextRef="C_1520a1d5-d2fd-4004-a5ce-578541558369" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c106b46d-bba1-40e3-b191-e9f3d742f8ca" contextRef="C_7e59e3e0-f076-4d12-8cb2-4da3978cb2ff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b29f9f3-a974-497a-be2f-11d8de1115e6" contextRef="C_1780d47b-7074-43ea-83b7-6b37c8951dc8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55e26582-5768-40c3-9934-14d4511605d2" contextRef="C_56700b86-6b39-4ff6-939d-369ca954edba" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,846</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c64b589c-04bb-44e9-b5f5-a645495a8d37" contextRef="C_eca18dbf-5f65-4638-9ffe-5784859f233f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,846</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8205d90f-6b83-4619-b8ad-f6568f435957" contextRef="C_44f56c70-bcea-4e2b-ac28-fae20f129a98" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3de3ab2b-01a8-4a69-a5d0-08bec3a515e5" contextRef="C_0f69f345-ac6c-4afc-bd0d-534fc2cdd78f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,199</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a4d967d-373a-41f8-9415-51fcfa1546c6" contextRef="C_794b0098-1158-41ef-a669-a1b32cd93046" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_231cd8ee-27b5-4698-9844-988fb3dc3913" contextRef="C_46da631c-8b1d-4cf0-a98f-1721c6e53088" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_196107cc-9729-4b55-a579-2d1b83188964" contextRef="C_82f9062a-632d-417d-b946-eaa6dd00480f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,135</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_135e002c-c79c-4208-b4d0-480ee89cd83a" contextRef="C_94686802-cc00-4b2a-8c6f-27ed9da5c87a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,901</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56e2e29c-31f6-46b3-a42d-507cc98650c3" contextRef="C_09926111-0e38-4a7f-b821-d79344c2f8f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,036</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude></ix:nonNumeric></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.074%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b01ef453-3f39-4490-b16a-7fac3fccaf07_1"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in restricted cash on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in current portion of marketable securities on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in noncurrent portion of marketable securities on our consolidated balance sheets.</span></div></div></ix:continuation></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Investment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2007, we received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f9261de-d5cc-44a4-8394-58dc252c29be" contextRef="C_5b06c91e-d34a-427e-a1ea-6394120ede9b" name="us-gaap:InvestmentOwnedBalanceShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,842,625</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares in Sienna Cancer Diagnostics Limited, or Sienna, in connection with a license we granted to them for our hTERT technology for use in human diagnostics. The shares, which represented less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4c6f8fb-304a-419b-b513-1cff2afd10c0" contextRef="C_e3194e6b-9d7d-47dd-b6df-8d8c89d54d48" name="gern:CostMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="INF">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership, were recorded at a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10d27198-80cc-4273-a453-33dc283642a7" contextRef="C_8069d28b-213c-446c-bde1-39089012764b" name="gern:CostMethodInvestmentsCostBasis" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cost basis under the cost method of accounting, upon receipt. Since the adoption of ASU 2016-01 on January 1, 2018, we reassessed the fair value of our equity investment in Sienna at each reporting date and any resulting change in fair value was recognized on our consolidated statements of operations. In April 2020, Sienna announced its merger with BARD1 Life Sciences Limited, or BARD1, subject to approval by Sienna&#8217;s shareholders. Effective August 3, 2020, the merger was complete, and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a88c15c-5ea6-4e60-9150-3f050c18628a" contextRef="C_71f2bda0-5d65-46ba-85a1-918c8c1ac142" name="us-gaap:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we received 13 BARD1 shares for every five shares of Sienna ordinary shares, resulting in our ownership of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4ed767e-22af-41bd-90a0-635c79c4be21" contextRef="C_3bed0edb-6d63-45bc-b6ac-2fc53a07d1f3" name="us-gaap:InvestmentOwnedBalanceShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">35,990,825</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of BARD1.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the first quarter of 2021, we sold all of our holdings in BARD1 and recognized a net gain of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_809d96d3-a736-43ac-a2eb-9517cb94b99b" contextRef="C_18fdb42c-1e4c-4ab6-babf-f250735da19f" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,233,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the sales, including gains from foreign currency translation adjustments, which has been included in other income and expense on our consolidated statements of operations. As of March 31, 2021, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_713af094-0de8-409a-b8fb-1decc3837474" contextRef="C_a94a3320-6443-4a71-a8ed-f5a63144da7f" name="us-gaap:InvestmentOwnedBalanceShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> value remained for our equity investment in BARD1.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple institutions in the United States. Generally, these deposits may be redeemed upon demand and therefore, bear minimal risk. Deposits with banks may exceed the amount of insurance provided on such deposits. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, government-sponsored enterprise securities, U.S. Treasury securities, municipal securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. However, we are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents to the extent recorded in our consolidated balance sheets. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk of our financial position at the depository institutions in which those deposits are held.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_329f0a08-5830-4ccb-b072-7432675311a8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. PROPERTY AND EQUIPMENT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fc3b9bc-2b53-414a-b24f-3eea2d7d3f92" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, stated at cost, is comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.6%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:13.48%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:13.48%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd641f00-15e2-4c47-bbf9-e593edeceac0" contextRef="C_557b50d4-874f-47b9-821c-244d8e7b719f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,273</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c13f97c8-c89e-4aa1-8ccb-b62d6d8c6398" contextRef="C_a862b4ec-a5b7-430d-9f24-f6c95dc41dca" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,554</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc1b89de-0f3c-4959-ac8d-ac0c034aeba9" contextRef="C_730d222b-ee44-44a3-8ae6-6f60f92122a6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef3de22f-c674-40d5-9bf6-3df589ee13b6" contextRef="C_4d1ea305-4988-4375-9ee4-69c9f837ffb5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb8590cb-3c2d-4fa6-ae29-b7d99b4fcae8" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,408</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07e82a78-9b96-4fe6-b2a6-8b3b6a76c40a" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef70d7b2-a574-470e-951f-f19d3f57755b" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e91058e-6857-455f-90da-09d5ce3acded" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">896</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94923e1f-9df3-4b58-ab2f-e9cd9d4632fd" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,177</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c70c8a-ff0b-4e01-91a3-3dafd63630e0" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3">793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1528ea9-2476-48cf-8906-819b9c8c4bda" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. LICENSE AGREEMENT</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Janssen Pharmaceuticals, Inc. License Agreement</span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 15, 2016, we entered into the License Agreement with Janssen Pharmaceuticals whereby we granted to Janssen Pharmaceuticals an exclusive worldwide license, or the Exclusive License, under our proprietary patents for the research, development and commercialization of products based on specialized oligonucleotide backbone chemistry and novel amidates for ribonucleic acid interference. In addition to the Exclusive License, we granted to Janssen Pharmaceuticals a non&#8209;exclusive worldwide license, or the Non&#8209;Exclusive License, under our patents covering the synthesis of monomers. This agreement was terminated effective April 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce597597-0187-4bd5-b782-6ad06c1c0511" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. ACCRUED LIABILITIES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3206d9da-757a-4ab1-a460-1ff1eb9b554c" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.272%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:16.363%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:16.363%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CRO and clinical trial costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f3bc72e-a0f5-407e-993a-334ccb790720" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,541</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc4a0d34-6a4c-4a5a-8153-fda15eb582a3" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,040</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing activities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_755c6ab2-b1b8-481a-b5cb-dd15aeaf1eff" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:AccruedManufacturingActivitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,629</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9efac7de-05e1-494e-8ef2-fb0e2d07aaca" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:AccruedManufacturingActivitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,321</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional legal and accounting fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f32e26be-df4d-46fb-a694-102867031fee" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">556</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0860775a-1778-4514-8595-b6b7c0931093" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,668</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3217666e-6093-4731-8469-0d357f939cda" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5fc9169-fe66-420d-8ffe-d4a44fbf0e9e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db160ac6-0a06-4f6f-a832-1777086c485b" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">814</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82b8f9c3-d54f-49ff-a8a9-28ff188f455e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">510</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68d81d41-3e33-4d84-a0e4-1c6fd83e67da" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfa1e9f8-279f-4e7a-8b26-5ed08eb5d836" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b2d1ce9-ed13-4389-b0f2-49376cf43005" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purported Securities Lawsuits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed. The other two lawsuits, filed in the U.S. District Court for the Northern District of California, were consolidated by the court. In September 2022, the parties agreed to a settlement and entered into a Stipulation and Agreement of Settlement, which was subject to court approval. The court granted final approval of the settlement on September 28, 2023 and final judgment was entered on October 3, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the consolidated class action complaint, we agreed to pay and/or to cause our insurance carriers to pay a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f68dfcf-83e8-4a1b-9685-2b5817f168db" contextRef="C_11088b90-d0a5-4112-af3e-c26b5cbb2191" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">24,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a3781d6-aa08-4caa-b17f-08ab0f3f5f82" contextRef="C_11088b90-d0a5-4112-af3e-c26b5cbb2191" name="us-gaap:PaymentsForLegalSettlements" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">17,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash, which was paid into an escrow account under our available D&amp;O insurance coverage and, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5321a977-8658-425d-9eb0-c72bc7fcb752" contextRef="C_11088b90-d0a5-4112-af3e-c26b5cbb2191" name="gern:LitigationSettlementAmountPaidInCashOrKind" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash which was paid after final approval of the settlement by the court. The settlement does not constitute an admission of fault or wrongdoing by Geron or any of our officers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2022, our portion of the settlement amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49f64e11-c491-4672-bea6-cbbee1dfdb11" contextRef="C_29eb0b35-f0bd-4b06-8287-c9e8fdd6d5b7" name="gern:LitigationSettlementAmountAccruedLiabilitiesRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8dea7891-354d-4ffe-b29f-ef74dc45d7b2" contextRef="C_29eb0b35-f0bd-4b06-8287-c9e8fdd6d5b7" name="gern:LitigationSettlementAmountInterestAndOtherReceivableRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">7,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> had been included in accrued liabilities on our consolidated balance sheets and recognized as general and administrative expense on our consolidated statements of operations for the year ended December 31, 2022. Our portion of the settlement amount was paid in the fourth quarter of 2023. There is no liability outstanding as of December 31, 2023 as the matter was fully settled during the year ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  On December 21, 2022, the parties to the shareholder derivative action filed in the Delaware Court of Chancery entered into a stipulation of settlement, or the Derivative Stipulation, and on May 17, 2023, the Delaware Court of Chancery approved the Derivative Stipulation, and the case was dismissed with prejudice.  Subsequently, each of the remaining derivative cases were dismissed with prejudice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Derivative Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the consolidated shareholder derivative actions filed in the Northern District, we agreed to pay and/or to cause our insurance carriers to pay a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3e6ac04-b114-4379-bbef-ad9f26d28c3f" contextRef="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18ed6b5d-f455-4871-b41b-3297257ca8a3" contextRef="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5" name="us-gaap:PaymentsForLegalSettlements" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">525,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash, which was payable under our available D&amp;O insurance coverage and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3052b7ae-62a7-4819-9528-2198ed2aba36" contextRef="C_aaf64096-d2f0-4874-95f7-f1e081c29515" name="gern:LitigationSettlementAmountToBePaid" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">825,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash payable by us. The settlement does not constitute an admission of fault or wrongdoing by any of our officers or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">members of our board. As of December 31, 2022, we had recorded the total settlement amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6f8619e-c296-4c42-b2b9-2d20d76ec6c5" contextRef="C_9edf5ddf-277c-4136-a6a5-53a0c72bd66c" name="gern:LitigationSettlementAmountAccruedLiabilitiesRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as accrued liabilities and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_699c44d6-b02d-487e-9398-75f3c099641c" contextRef="C_9edf5ddf-277c-4136-a6a5-53a0c72bd66c" name="gern:LitigationSettlementAmountInterestAndOtherReceivableRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">525,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as interest and other receivables on our consolidated balance sheets. For the year ended December 31, 2022, we had recognized our portion of the settlement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c1dce66-076a-41cd-9125-b4b6089aa845" contextRef="C_9e13ec08-4d34-4c19-b5b5-3b79b45e37fd" name="gern:LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">825,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as general and administrative expense on our consolidated statements of operations. In the second quarter of 2023, our insurance carriers paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1be668aa-5c82-4858-8bea-4428d609e95b" contextRef="C_cdaff13f-48a1-4aed-808e-efa7e46b169b" name="us-gaap:PaymentsForLegalSettlements" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">525,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cash,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70351dbb-a3fb-405a-b0f4-53518aefb43f" contextRef="C_cdaff13f-48a1-4aed-808e-efa7e46b169b" name="gern:LitigationSettlementAmountPaidInCashOrKind" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">825,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash, for an aggregate total payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a51d12f-9d67-49e0-8d08-52d7b567148d" contextRef="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Accordingly, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_672b5cda-c9ae-4136-a223-2e7d6a073085" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:LitigationSettlementAmountOutstanding" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding amount to settle against this as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of any additional lawsuits, and we may not prevail. In addition, we have and may continue to incur substantial legal fees and costs in connection with such lawsuits. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive, and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Expenses associated with any potential future lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. We have not established any reserve for any potential liability relating to any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnifications to Officers and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Severance Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd438123-39e2-413a-81b3-79210b14f42e" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:NumberOfSeverancePlan" unitRef="U_Plan" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> severance plans that apply to all of our employees who are not subject to performance improvement plans, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_107363a6-8267-40f6-a807-6acf63f1ecb3" contextRef="C_b59a05ad-a041-4c67-b50f-9f5d30c4be93" name="gern:NumberOfSeverancePlan" unitRef="U_Plan" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> plan covering employees above the Vice President level, i.e., executives, and all other employees hired before January 1, 2022, and the other plan covering all non-executive employees hired on or after January 1, 2022.  The severance plans provide for, among other benefits: (i) a severance payment upon a Change of Control Triggering Event and Separation from Service and (ii) a severance payment for each non&#8209;executive employee upon a Non&#8209;Change of Control Triggering Event and Separation from Service. As defined in the severance plans, a Change of Control Triggering Event and Separation from Service requires a &#8220;double trigger&#8221; where: (i) an employee is terminated by us without cause in connection with a change of control or within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a41a71d-276c-4c8a-aa7b-2c99fd443efb" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months following a change of control provided, however, that if an employee is terminated by us in connection with a change of control but immediately accepts employment with our successor or acquirer, the employee will not be eligible for the benefits outlined in the plans, (ii) an employee resigns because in connection with a change of control, the offered terms of employment (new or continuing) by us or our successor or acquirer within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6bbd2c2-61e0-44b3-907a-a23b77554ca4" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days after the change of control results in a material change in the terms of employment, or (iii) after accepting (or continuing) employment with us after a change of control, an employee resigns within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a85eebe9-cbd7-4e90-9459-77c45a84e0a6" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months following a change of control due to a material change in the terms of employment. Under the severance plans, a Non&#8209;Change of Control Triggering Event and Separation from Service is defined as an event where an employee is terminated by us without cause. Severance payments range from</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b8827fb4-805f-47b4-9575-17566fb60e0f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bc14150-8106-4a55-aac6-19c720db0e59" contextRef="C_31e1df9f-50c4-415c-947c-3b83ba778c1f" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months of base salary in connection with a Change of Control Triggering Event or from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0194cff7-90da-4ed5-a176-f5577cc6d08c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six weeks</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_332247f8-d4f1-4611-a9cc-cbfe443e0452" contextRef="C_31e1df9f-50c4-415c-947c-3b83ba778c1f" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of base salary in connection with a Non-Change of Control Triggering Event, as well as a pro-rata portion of the employee&#8217;s annual target bonus, depending on the employee&#8217;s position with us, payable in a lump sum payment, and monthly COBRA payments for the severance period. The severance plans also provide that they shall not supersede the provisions of any individual employment agreements entered into between us and our employees, and that the employees with such agreements will be entitled to whichever benefits are greater under the severance plan or their employment agreement. A copy of the severance plan covering our executive officers is filed as an exhibit to our annual report on Form 10-K. As of December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all our executive officers have employment agreements with severance provisions and will receive the greater severance benefits of their agreements or those in the severance plan applicable to them.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41e9743a-0a9c-458e-8405-4f1284f66175" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. OPERATING LEASES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New Jersey Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_291871e8-42f6-4e42-b14e-69c49f78c102" contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><ix:nonNumeric id="F_c4e01abc-ef11-4c40-b674-2f0cdc89f702" contextRef="C_7906f3d1-d5d9-439c-a646-5ec2a8601afe" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5c24fea-b2bb-4986-8a2e-8ac39276179e" contextRef="C_7906f3d1-d5d9-439c-a646-5ec2a8601afe" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdb9d8bf-ea4e-4c02-98c5-cd92b42b8738" contextRef="C_1e1d1200-a6c0-43f1-9a9e-761058f49e47" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-time option to terminate the New Jersey Lease without cause as of the 103</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">rd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> month anniversary of the commencement date of the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date. Based on the initial term of the New Jersey Lease of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae44e612-9efc-4af0-a9c6-767205bcb40d" contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, the right-of-use asset and corresponding operating lease liability was approxima</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acf0bdb9-06a6-4fad-bbcf-40b9cd5988db" contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1f366c8d-c3a9-4287-bd30-dc4b67ed502e" contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,356,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hich represented the present value of lease pay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ments over the initial lease term, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1457d1e-7afc-4166-bcb7-db2733451703" contextRef="C_ebd1ac89-5dde-4a45-937c-75b1eb1b2f48" name="gern:OperatingLeaseRentAbatementPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rent abatement period, using an incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa682da2-c57a-4770-a01b-81da0df1f5b1" contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n information available as of October 1, 2019. Under the New Jersey Lease, we are also obligated to pay certain variable expenses separately from the base rent, including electricity and common area maintenance. Such costs are being expensed in the period they are incurred. As of December 31, 2023, the remaining lease term for the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb6bc4ef-b0ff-4595-8064-4ed275a5b822" contextRef="C_37a598a5-3c81-4923-b06f-67a5ec38fc90" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.8 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ye</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ars.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foster City Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1452dc22-027e-40e7-97c0-76a691746880" contextRef="C_70402503-27b5-4f37-815e-29f46b76e9fd" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2062ab6-43ca-46de-a534-97add136d436" contextRef="C_70402503-27b5-4f37-815e-29f46b76e9fd" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foster City Lease commenced on March 10, 2020, upon the substantial completion of all tenant improvements. As of the l</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ease commencement date, the right-of-use asset and corresponding operating lease liability was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a17cc91-e174-4f97-844b-f348cbba7d40" contextRef="C_03cae945-a223-49bc-8a34-e80048f4e61f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,868,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, wh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ich represented the present value of remaining lease payments using an incremental borro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">wing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfc46e3d-d6b4-4ced-95f2-ccb9bb2e5f2b" contextRef="C_03cae945-a223-49bc-8a34-e80048f4e61f" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="INF">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% over the initial lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ecb7549-78cd-45bd-8ca1-4bb39a307224" contextRef="C_03cae945-a223-49bc-8a34-e80048f4e61f" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0035037a-06b8-42dd-a4d1-02b9d0240f0e" contextRef="C_7e22f4a9-1f60-4ad4-9a3b-88792070760f" name="gern:OperatingLeaseRentAbatementPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rent abatement period. Under the Foster City Lease, we are also obligated to pay certain variable expenses separately from the base rent, including taxes and common area maintenance. Such costs are considered non-lease components and have been excluded from the calculation of the right-of-use asset and corresponding operating lease liability and are being expensed in the period they are incurred. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the remaining lease term for the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e643dea4-a236-428c-9b8f-264818689a66" contextRef="C_7a801fab-431b-4ace-91e0-07585e1a2682" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42c98f87-63a3-44dd-ae7d-c0bb298db9c3" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_42c98f87-63a3-44dd-ae7d-c0bb298db9c3_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, the Foster City Lease and a lease from a former location in Menlo Park, California, were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:19.516%;"/>
        <td style="width:22.555%;"/>
        <td style="width:1%;"/>
        <td style="width:16.296999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:2.639%;"/>
        <td style="width:1%;"/>
        <td style="width:15.077%;"/>
        <td style="width:1%;"/>
        <td style="width:3.259%;"/>
        <td style="width:1%;"/>
        <td style="width:14.657%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfcdba67-74e2-4f33-a98d-360eeac8c391" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">962</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f84a133c-4181-490e-bf8c-aadd44a411f3" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9d8c8f3-5fda-4e0f-bd7f-85e152c5bfef" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">946</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_632eddb0-d2c0-45d6-8d9c-93c2f75aa360" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fcc61cb-6bdd-43d5-b3e0-d606a74f1a08" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a0ce35-5297-4643-bb96-e81925b283fa" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bf9473e-7a50-4514-8d4d-babd090eb2ce" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,306</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b6587f5-732b-4e9d-b490-c80d9a6d0f9a" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,254</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e7f3623-aa6e-4da2-bb90-56947fb7ff24" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,198</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:10%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:60%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div><ix:continuation id="F_42c98f87-63a3-44dd-ae7d-c0bb298db9c3_1"><div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.588888888888889%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable lease costs represent non-lease components, such as common area maintenance charges.</span></div></div></ix:continuation></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f017d692-ade9-4c9f-adfa-38d39d666a2b" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.686%;"/>
        <td style="width:2.857%;"/>
        <td style="width:1%;"/>
        <td style="width:26.457%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_411d1890-0fed-4819-977e-43d6800cfed7" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">987</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68839025-e750-482d-a078-af0e19a3a0b7" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a565abf-4e30-452f-9519-455e493dd08d" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,040</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_986f6be8-8c95-4c55-b684-ef6c60fae9bd" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">716</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94e516d7-93ca-40f1-ae19-3fa04e2c7f88" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">376</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de196555-aca9-45f2-8e0c-44d22c818051" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a65a95ec-e3c8-4b2a-b461-eaf7880c4578" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,808</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_185085e0-02d6-46d2-bfc1-effe73753516" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">853</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52ad9738-6c61-4798-a7aa-15aa0088d9bd" contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,955</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f15aca69-0431-4fae-a30c-7e7c55de2e72" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. DEBT</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 30, 2020, or the Closing Date, we, Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, or SVB, entered into a term loan facility, or the Term Loan, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a7078d4-84f5-46bd-a82a-4c7c00073579" contextRef="C_ff3a58b5-efcc-4001-a2ea-2794d695b861" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was amended in August 2021, or the Original Loan Agreement. On June 30, 2022, we entered into a second amendment to the Original Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3417e435-8240-41c3-88b3-048c84535171" contextRef="C_ff3a58b5-efcc-4001-a2ea-2794d695b861" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_960a6646-48f9-44ee-a02c-343b122c7194" contextRef="C_9909923d-f176-4cf6-ba61-369530284669" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">125,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with such principal being available in a series of tranches, subject to certain terms and conditions. On December 14, 2023, we entered into a third amendment to the Original Loan Agreement, or as amended, the Loan Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02d28245-17ce-4a18-b9b4-590dd5553381" contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been drawn under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the effective date of the second amendment, we paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57f08a9d-fae9-4dc4-8944-d1bc672eb23a" contextRef="C_ca648008-6ad8-4d06-8ece-4407c06a3407" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">100,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a facility charge that we recognized as a debt discount and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method. Additional facility charges applied to future draw downs will be treated similarly. We also incurred legal fees in connection with the second amendment, which we recognized as debt issuance costs and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the third amendment, the aggregate principal amount drawn down and remaining available to us under the Term Loan remains at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0324f9a0-713b-438c-a0ea-602aa1bbe64b" contextRef="C_3891a9a9-b40f-43be-a57b-26dd8899f2e1" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with such principal being available in a series of tranches, subject to certain terms and conditions. The third amendment also provides that (i) the fourth tranche of the Term Loan was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4673669c-dfce-4d69-905a-8e109639bb97" contextRef="C_7ff30090-bcbe-4192-9979-96ad9f967d1a" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e31bb5e-ba50-4d12-9fa4-05e6f917b176" contextRef="C_cf14b58a-81bb-4655-8483-d56e1f8dafe5" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, (ii) the commitment period for the fifth tranche of the Term Loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92cf9df8-efbd-448d-93de-ca97297327c2" contextRef="C_89681771-d544-4757-ace7-4696d541ae50" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is available subject to achievement of a regulatory milestone and satisfaction of certain capitalization requirements, was extended through December 15, 2024, (iii) the variable annual interest rate on the outstanding loans has been decreased to the greater of: (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc801f29-c4d8-4e09-b786-c9780562efba" contextRef="C_8c590e1f-224c-4339-bfb7-fb2401f33f87" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, or (y) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2dd6b71-511d-45f2-82be-87e1a8512421" contextRef="C_1754f765-5745-4731-b5dc-3a11a9d12c42" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, plus (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43c92b0a-f709-4fd0-99b8-01bcb6acd403" contextRef="C_9015a27f-f086-4d25-b575-d3055945fe84" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%; and (iv) the interest only period of the Term Loan has been extended through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. In connection with the third amendment, on the third amendment effective date, we borrowed and received the entire fourth tranche of the Term Loan in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3d7014a-866a-4666-b8e2-a64f0c65d145" contextRef="C_e5c90d2a-1b3e-42ff-a354-2da100d5cdcc" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Afte</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r giving effect to such borrowing, the outstanding principal amount under the Loan Agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9212eb2e-116f-4b48-a803-32b850d73c24" contextRef="C_3891a9a9-b40f-43be-a57b-26dd8899f2e1" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On the effective date of the third amendment, we paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24b26fb1-c3bb-4395-bf7e-2fcc52989747" contextRef="C_43c6bd94-f041-48f0-8b71-ece113bc20c9" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a facility charge that we recognized as a debt discount and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method. Additional facility charges applied to future draw downs will be treated similarly. We also incurred legal fees in connection with the third amendment, which we recognize as debt issuance costs and amortize such cost to interest expense over the life of the loan using the effective interest rate method.  The third amendment of the Loan Agreement is not substantially different as compared to the Original Loan Agreement, and accordingly, we treated the amendment as a modification of the debt in accordance with ASC 470. On September 15, 2023, the third tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3bd8284-36a1-4b91-bed1-7118194ca917" contextRef="C_93ba27f0-5156-41ac-9f7e-063e7a0e3462" name="gern:DebtInstrumentFaceAmountExpired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Term Loan expired and is no longer available for us, but was added to the fourth tranche as part of the third amendment to the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Term Loan as amended, the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_847e7abe-6d3c-47d6-8595-b1fd3122ea59" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="us-gaap:LongTermDebtDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term Loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76c8ed04-711e-480f-8eda-4fa9b22b399e" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or the Loan Maturity Date, and may be extended up to an additional six months upon the achievement of certain regulatory and financial milestones.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c8707c5-eb7b-45cf-ac8c-9e9f9755f956" contextRef="C_44d11214-5ff1-4fe2-9231-445ae761557a" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loan bears interest at a floating rate per annum equal to the greater of either (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f637dec9-f3ee-4f69-b7ba-7325e870d319" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or (ii) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_930f01d2-2e49-450c-b738-b876c59b5706" contextRef="C_d9939d7d-974b-4606-83bd-5a5ddf499439" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, plus (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f03738ee-43ec-48f4-becc-1273fa11b9fa" contextRef="C_e81fdb75-1e1c-4290-ae83-e0a59c23e05d" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%  (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d51d0d7-021d-4320-a964-1c109de077b0" contextRef="C_9627054b-a059-4769-a822-511b43eb7d07" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">8.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of December 31, 2023).</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5372fa3-6165-4448-83b9-363e2853893d" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="gern:InterestOnlyPeriodPaymentTermDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The interest only period of the Term Loan is through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. Following the expiration of the interest-only period, we are required to repay the Term Loan in equal monthly amortization payments of principal and interest until the Loan Maturity Date.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Upon </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">full repayment of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan, we are also obligated to pay an end of term charge in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5224456-0390-484c-a709-0da41d65e11a" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="gern:DebtInstrumentEndOfTermChargePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">6.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the amount of the Term Loans actually borrowed. Such end of term charge is being accrued to interest expense over the term of the Term Loan using the effective interest rate method. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab9e32be-730b-4d60-9ee9-9412b2b7745f" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="us-gaap:DebtInstrumentPaymentTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At our option, upon at least five business days&#8217; prior written notice to Hercules, we may prepay all or any portion greater than or equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_322817b7-50b3-4756-ab04-e5f1cad1d638" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="gern:DebtInstrumentMinimumPrepaymentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the outstanding loan by paying the entire principal balance (or portion thereof) and all accrued and unpaid interest. There is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb2b8907-2d80-4a43-bfe2-f46e333a944c" contextRef="C_f2693cf9-67f1-4ebd-9653-66d0ae99298c" name="gern:PercentageOfPrepaymentCharge" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d5bf4e4b-7c1a-4b69-9dce-ae53e181d67c" contextRef="C_688486b0-96f1-46aa-9bfc-41e54da2e10b" name="gern:PercentageOfPrepaymentCharge" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prepayment charge for prepayments of drawdowns under Tranche 1 or Tranche 2.  Prepayments of drawdowns under Tranche 3, Tranche 4, Tranche 5 or Tranche 6 are subject to a prepayment charge of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21434346-ff79-4efe-8ca2-a005934e51e4" contextRef="C_5e69d88b-4f35-4715-a7e6-4dd1f9e014e6" name="gern:PercentageOfPrepaymentCharge" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_34702154-f502-435f-ae20-ab4591b28cb4" contextRef="C_e0d1eeee-15a6-49e0-b2a9-feba2070ca4a" name="gern:PercentageOfPrepaymentCharge" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6ab1adc6-7963-4a8c-bc38-a4e1054c59fa" contextRef="C_c819bdf8-44a4-49a8-b407-9353eb20da0d" name="gern:PercentageOfPrepaymentCharge" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_555865a2-ef01-4d08-8023-7ae403ebf9fc" contextRef="C_270b5c42-ba2a-4860-81af-6be293878e33" name="gern:PercentageOfPrepaymentCharge" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the prepayment amount, if the prepayment is made prior to June 30, 2025. Thereafter, any prepayment of Tranche 3, Tranche 4, Tranche 5 or Tranche 6 is not subject to a prepayment charge.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loan is secured by substantially all of Geron&#8217;s assets, except our intellectual property, which is the subject of a negative pledge. The Term Loan contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. We are in compliance with the covenants under the Term Loan as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of default (subject, in certain instances, to specified grace periods), the principal, interest and any other monetary obligations on all then outstanding amounts under the Term Loan may become due and payable immediately. Upon the occurrence of an event of default, a default interest rate of an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bad9cf2f-bebc-4002-854f-8042646c8849" contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff" name="gern:PercentageOfInterestOnPastDueOutstanding" unitRef="U_pure" scale="-2" decimals="INF">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% may be applied to the outstanding principal balance, and Hercules, as the administrative agent, may declare all outstanding obligations immediately due and payable (subject, in certain instances, to specified grace periods) and take such other actions as set forth in the Term Loan. Upon the occurrence of certain bankruptcy and insolvency events, the obligations under the Term Loan would automatically become due and payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Embedded Derivatives and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the net carrying value of the Term Loan was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee5ea7e7-3555-45f2-892e-420bbdd79597" contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">81.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hich includes the principal amount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_827af9f5-0692-49d9-b5a7-f457b6cf9f02" contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> less the net unamortized discounts and debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_710c6195-db38-4e7e-9f89-930010c19144" contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">605,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> plus an accrued end of term charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8f6cddc-9584-4e1d-adce-0b672e05312d" contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844" name="gern:AccruedEndOfTermCharges" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,691,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value of the debt approximates the fair value as of December 31, 2023. The debt discounts and debt issuance costs are being amortized to interest expense over the life of loan amounts under Term Loan using the effective interest rate method.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future Minimum Payments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_924d8028-10ed-4a45-b606-ece83f510d68" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.552%;"/>
        <td style="width:12.75%;"/>
        <td style="width:1%;"/>
        <td style="width:19.698%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4631a74-7275-48d3-8053-c339398606ca" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,066</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36a6d594-b729-4742-b6d7-d69e7899719c" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,262</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efcfbcc8-e28f-4a59-85f7-39f5d5c8fcdc" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:LongTermDebtGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,328</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  amount representing interest</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_883c19fd-2667-4dcf-9532-b2c7bd478efe" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:InterestPayableCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,088</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  unamortized debt discount and issuance costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83b9a1c4-4bed-4780-a287-750fc2c88679" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">605</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  unamortized end of term charge</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7092192-360b-4de6-b689-3e1aad3c6cdf" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:DebtInstrumentUnamortizedEndOfTermCharge" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,691</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  current portion of debt</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2fd5ed6-132d-47b4-8094-eeb4965ea7de" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,893</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent portion of debt</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dac70f06-251b-4f01-a165-846376b4223d" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,051</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_30a377e6-7c02-4168-9eab-e9347da9bc27" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Authorized Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023 our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16952ce7-9557-402b-9aa2-44ced1a5f44a" contextRef="C_027d36e5-94d9-4e80-a37e-f864583a9ab1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">675,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d910cfb7-2b79-4041-85b8-f8ba2e4dde8b" contextRef="C_a814b358-835d-4bd9-9991-025af00007a2" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,350,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 1, 2022, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_449c8b57-8104-4378-9321-75a711d4450b" contextRef="C_e685bf88-6c83-46c0-b720-48d9693271f9" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,333,334</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c8ac685-9002-4174-86a6-321be6006568" contextRef="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,095,238</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2022 pre-funded warrant, together with accompanying warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a3a11ed-f8c8-469b-a9d4-bc075f3d4fa4" contextRef="C_0c872764-390c-4717-890a-1fb8ba1afba9" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,714,286</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, also known as the 2022 stock purchase warrants. The shares of common stock and the 2022 pre-funded warrant were immediately separable from the 2022 stock purchase warrants. All of the securities were issued separately. The combined public offering price of the common stock and accompanying 2022 stock purchase warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10905000-f1c5-4ba0-9414-803f15306520" contextRef="C_5b6ebae4-b1af-4bd1-a220-87fe4159e558" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The 2022 stock purchase warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29b5de1d-719b-4bc3-910b-d4f3891d0a6c" contextRef="C_0c872764-390c-4717-890a-1fb8ba1afba9" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and are exercisable immediately. The term of the 2022 stock purchase warrants expired in the third quarter of 2023, pursuant to the terms of the warrant agreement.. The combined public offering price of the 2022 pre-funded warrant and accompanying 2022 stock purchase warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e524a19-d8b8-47dc-b84c-bda4af61157b" contextRef="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">1.049</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The 2022 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90063f64-8a7c-495d-abb7-7681dd058254" contextRef="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and may be exercised at any time until the 2022 pre-funded warrant is exercised in full. As of December 31, 2023, none of the 2022 pre-funded warrant and all of the 2022 stock purchase warrants have been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_211e0910-e5fe-4d7f-a096-2287a5285968" contextRef="C_e685bf88-6c83-46c0-b720-48d9693271f9" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">69,916,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2022 pre-funded warrant and 2022 stock purchase warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the issuance of the 2022 pre-funded warrant and 2022 stock purchase warrants, we evaluated the terms of each warrant to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and FASB Accounting Standards Codification Topic 815,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2022 pre-funded warrant and the 2022 stock purchase warrants include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2022 pre-funded warrant and the 2022 stock purchase warrants should be classified as equity with no subsequent remeasurement as long as such warrants continue to be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2023 we completed an underwritten public offering consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e402330-e092-4fc7-9515-8cd63eb2fb9b" contextRef="C_2eebd16c-0eef-470a-90b4-04639a5fa0b4" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,007,741</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and the 2023 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffd0acde-d6d6-4de9-90a2-33b29b8fee8c" contextRef="C_0a1035cc-6adb-4cec-b9e1-c39d76644c1a" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The public offering price of the 2023 pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e17544a3-67c4-4058-b063-4033a591475a" contextRef="C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.449</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The 2023 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f25d1ff4-dad9-4175-b89d-d6df93ac963b" contextRef="C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and may be exercised at any time until the 2023 pre-funded warrant is exercised in full. As of December 31, 2023, none of the 2023 pre-funded warrant has been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bba52c5-f0a8-4a24-acef-5036830082d8" contextRef="C_2eebd16c-0eef-470a-90b4-04639a5fa0b4" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">213,337,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2023 pre-funded warrant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the issuance of the 2023 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and FASB Accounting Standards Codification Topic 815, Derivatives and Hedging. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2023 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2023 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrant Exercises</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c8e023a-199a-4ddc-ad2d-49664431b05e" contextRef="C_f48fce0b-30ab-418f-a2f6-a6573c219376" name="gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,349,859</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c89cd9e-877b-4fb4-8e5f-498527eaff97" contextRef="C_be269b1c-429d-477f-bb7d-ad125a3758a2" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">105,912,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrants were issued in connection with underwritten public offerings of common stock and pre-funded warrants, together with accompanying stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">purchase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warrants in May 2020, April 2022, and January 2023. As of December 31, 2023, the following warrants remained outstanding:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pre-funded warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af32b43d-4614-4e8c-ad10-6d81309f33a6" contextRef="C_95534f32-aee8-4d09-9da3-068375f3be3c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7ae604a-c35e-40ec-b0a8-0dcdda0ebbb0" contextRef="C_95534f32-aee8-4d09-9da3-068375f3be3c" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,430,477</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, which have no expiration date; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock purchase warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc501508-9d01-4a3a-8045-92fbe0b1a911" contextRef="C_510848a8-05e3-469a-b372-8265983b572a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1de18eae-18c9-4324-a1b3-16bdd165dba8" contextRef="C_510848a8-05e3-469a-b372-8265983b572a" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,474,503</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock related to the public offering of our common stock in May 2020, which expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1eb7cdc1-b2c6-4803-ab5b-63305b4da528" contextRef="C_510848a8-05e3-469a-b372-8265983b572a" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0f70b2b-b58e-48a4-ad1f-99720b0d80d3" contextRef="C_75ecfc92-1a60-40ee-a4cb-7d76a1d3e92a" name="gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,663,387</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d59c1d85-d60f-440c-a600-108931e00324" contextRef="C_472cbb86-89e4-4a2f-aaed-c8771e492ab5" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,163,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The warrants were issued in connection with an underwritten public offering of common stock and a pre-funded warrant, together with accompanying stock purchase warrants in May 2020. As of December 31, 2022, the pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69a41c90-1a1d-42d5-a559-b932255fa5c2" contextRef="C_7f268f91-b8d0-43cd-a929-2ac72e87b0eb" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,335,239</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock was outstanding and stock purchase warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9fb57ec-a179-481c-8b5e-0d4b32214599" contextRef="C_75ecfc92-1a60-40ee-a4cb-7d76a1d3e92a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,110,079</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock associated with the May 2020 public offering remained outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 4, 2020, we entered into an At Market Issuance Sales Agreement, or the 2020 Sales Agreement, with B. Riley Securities, Inc., or B. Riley, pursuant to which we were able to elect to issue and sell shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50259692-9eec-4fe9-9781-a824aaadf46a" contextRef="C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba" name="gern:CommonStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in such quantities and on such minimum price terms as we set from time to time through B. Riley as our sales agent. We agreed to pay B. Riley an aggregate commission rate equal to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f0e6864-bba8-4de7-a504-41951c919378" contextRef="C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba" name="gern:MaximumCommissionRate" unitRef="U_pure" scale="-2" decimals="INF">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2020 Sales Agreement. In connection with the 2020 Sales Agreement, we terminated the 2018 Sales </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreement. The 2020 Sales Agreement expired on September 4, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement with B. Riley, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eba0409-59c1-4fba-90e2-8c290f500cdf" contextRef="C_38ded4c9-172f-4a2a-a52d-e82dc8942a05" name="gern:CommonStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from time to time through B. Riley as the sales agent. We have agreed to pay B. Riley an aggregate commission rate equal to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e335d8a-e1dd-4eb3-8411-743457a9b24c" contextRef="C_38ded4c9-172f-4a2a-a52d-e82dc8942a05" name="gern:MaximumCommissionRate" unitRef="U_pure" scale="-2" decimals="INF">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2023 Sales Agreement.  The 2023 Sales Agreement will automatically terminate upon the earlier of (i) the sale of all common stock subject to the 2023 Sales Agreement, or (ii) termination of the 2023 Sales Agreement in accordance with its terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2021, we sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3511f12-200c-484f-95aa-c47447574686" contextRef="C_9e0d68e1-858b-451d-bee9-b7d9aeb45b2f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,571,556</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock pursuant to the 2020 Sales Agreement, resulting in n</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">et cash proceeds to us of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92ce0a27-8a34-4093-a103-d64bda72acad" contextRef="C_9e0d68e1-858b-451d-bee9-b7d9aeb45b2f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting sales commissions and other offering expenses paid by us. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45639911-4ed5-4d3d-86c6-361a566f61d7" contextRef="C_95b50b47-d6b5-4c38-bcae-9f23b73905ee" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ca3ca787-39eb-4562-a4a4-99dfcb549f6e" contextRef="C_7e3140e2-0589-47d4-86ac-5bdf695ba419" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock were sold pursuant to the 2020 Sales Agreement or the 2023 Sales Agreement during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2011 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2011, our stockholders approved the adoption of the 2011 Incentive Award Plan, or 2011 Plan. The 2011 Plan provided for grants of either incentive stock options or nonstatutory stock options and stock purchase rights to employees (including officers and employee directors) and consultants (including non&#8209;employee directors). Upon the adoption of the 2018 Equity Incentive Plan in May 2018 (see below), no further grants of stock options or stock purchase rights were made under the 2011 Plan. Stock options granted under the 2011 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95c4a761-f42f-4831-abda-0ddd76fd1e0c" contextRef="C_933b24f2-1289-480e-b2b0-cd7ef795363d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Stock option exercise prices were equal to the fair market value of the underlying common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Service&#8209;based stock options under the 2011 Plan generally vested over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f95737e-ad71-44d1-9717-4dc495aea7de" contextRef="C_aa683e66-a550-45b2-b8b1-c738b0dfae20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Other stock awards (restricted stock awards and restricted stock units) had variable vesting schedules which were determined by our board of directors on the date of grant. All outstanding awards granted under the 2011 Plan remain subject to the terms of the 2011 Plan and the individual award agreements thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 15, 2018, our stockholders approved the adoption of the 2018 Equity Incentive Plan, or 2018 Plan, as the successor to the 2011 Plan. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">awards that may be settled in cash, stock, or other property. Eligible participants under the 2018 Plan include our employees, consultants and non-employee directors. The number of shares reserved for issuance under the 2018 Plan (subject to adjustment for certain changes in capitalization) is equal to the sum of (i) the unallocated shares of common stock remaining available for grant under the 2011 Plan as of May 15, 2018, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dd6fb19-2e97-4849-bc81-e8660f5dfd4d" contextRef="C_49393210-70a6-4185-bfbb-56a280b6cb40" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> newly reserved shares of common stock and (iii) the number of shares subject to awards granted under the 2002 Equity Incentive Plan, and the 2011 Plan as such shares become available from time to time, referred to as the Prior Plans&#8217; Returning Shares. Such Prior Plans&#8217; Returning Shares become available for issuance under the 2018 Plan if outstanding stock awards granted under the 2002 Equity Incentive Plan and the 2011 Plan, after May 15, 2018, expire or terminate for any reason prior to exercise or settlement or are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or, subject to certain exceptions, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award. In May 2023, May 2022 and May 2021, our stockholders approved amendments to our 2018 Eq</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uity Incentive Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f17c12c-d3f3-4faa-91e0-fd87377f6440" contextRef="C_df5a5ad0-ae6b-4ec7-b61c-d48e757c3148" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,360,000</ix:nonFraction></span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_784f0e99-0068-428a-8d13-24650425b0b3" contextRef="C_3599ea48-8821-4d91-8b3f-c643d3f1153a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d32a3e6-2b64-43bc-b836-8e9c6a613ec8" contextRef="C_3b446414-84fd-4c21-bce4-7d4596128fd2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options granted under the 2018 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab532651-a3f9-45ab-a19b-353a236ca254" contextRef="C_dbd86ffc-7423-4bbf-b014-4111ef73acb3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Stock option exercise prices shall be equal to the fair market value of the underlying common stock on the date of grant. If, at the time we grant a stock option, the optionee directly or by attribution owns stock possessing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e21d48f-93dd-48ef-b1cc-f57037c042fd" contextRef="C_5bf7166f-5b00-4240-90ed-a7f7c7a104bc" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" unitRef="U_pure" scale="-2" decimals="INF">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total combined voting power of all classes of our stock, the stock option exercise price shall be at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_17d9c8ac-900e-474b-ad72-edef8413d89a" contextRef="C_5bf7166f-5b00-4240-90ed-a7f7c7a104bc" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" unitRef="U_pure" scale="-2" decimals="INF">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the underlying common stock and shall not be exercisable more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2cf50216-55e1-4687-a7d2-e6c031073690" contextRef="C_7c46d828-b7f0-4eb1-b271-019ea82aead2" name="gern:ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We grant service-based and performance-based stock options to employees under the 2018 Plan. Service-based stock options generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b81d23bc-2151-4ed9-8a5b-63a749f5dcc1" contextRef="C_7c46d828-b7f0-4eb1-b271-019ea82aead2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of the stock option grant. Performance-based stock options vest upon the achievement of specified milestones. Other stock awards (restricted stock awards and restricted stock units) have variable vesting schedules as determined by our board of directors on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain circumstances, stock options may be exercised prior to vesting, subject to our right to repurchase the shares underlying such stock option at the exercise price paid per share. Our repurchase rights would generally terminate on a vesting schedule identical to the vesting schedule of the exercised stock option. During 2023 and 2022, we did not repurchase any shares under the 2018 Plan. As of December 31, 2023, we have no shares outstanding subject to repurchase under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our Non&#8209;Employee Director Compensation Policy adopted by our board of directors in March 2014, as amended and restated in February and March 2022, provides for the automatic grant to non&#8209;employee directors of the following types of equity awards under the 2018 Plan:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Each person who becomes a non&#8209;employee director, whether by election by our stockholders or by appointment by our board of directors to fill a vacancy, will automatically be granted a stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7d10bb2-93ad-4ded-b090-7337975bb518" contextRef="C_3775ee3a-1995-4ba0-9943-4a471b60aa73" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, or First Director Option, on the date such person first becomes a non&#8209;employee director. The First Director Option vests annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c14a7cc-2c7e-4fe2-9848-185dbab3596e" contextRef="C_40e9b0a7-aa9d-4ad8-8b64-211cce52e280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon each anniversary date of appointment to our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Each non&#8209;employee director (other than any director receiving a First Director Option on the date of the annual meeting) will automatically be granted a subsequent stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_def348a6-8d98-414f-98c8-ad2c121b3241" contextRef="C_4a5892be-7d37-498c-be3e-05e931beae2a" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, a Subsequent Director Option, on the date of the annual meeting of stockholders in each year during such director&#8217;s service on our board of directors. The Subsequent Director Option vests in full on the earlier of: (i) the date of the next annual meeting of our stockholders or (ii) the first anniversary of the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2006 Directors&#8217; Stock Option Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2006 Directors&#8217; Stock Option Plan, or 2006 Directors Plan, was terminated by our board of directors and replaced by the 2011 Plan in March 2014. No further grants of stock options were made from the 2006 Directors Plan upon the 2006 Directors Plan&#8217;s termination. All outstanding awards granted under the 2006 Directors Plan remain subject to the terms of the 2006 Directors Plan and the individual award agreements thereunder.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock options granted to non-employee directors under the 2006 Directors Plan were nonstatutory stock options, and they expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e294b98-3d0b-4529-957f-822f80678b76" contextRef="C_f677506b-3ffc-40c8-bc4c-7bf4653d86d8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. The option exercise price was equal to the fair market value of the underlying common stock on the date of grant. The first director option granted to non-employee directors under the 2006 Directors Plan vested annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f83965ed-8436-4950-a563-d3c601c986d3" contextRef="C_404e5fe1-4fb6-4444-9f07-c398ecd07fcd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon each anniversary date of appointment to the board of directors. The subsequent director option granted to non-employee directors on the date of the annual meeting of stockholders in each year during such director&#8217;s service on our board of directors under the 2006 Directors Plan vested </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f5a036f-777e-43b8-9578-1e2348f26815" contextRef="C_c84962fe-b876-484c-8ac0-436ed90912a4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, our board of directors approved the adoption of the 2018 Inducement Award Plan, or the Inducement Plan, pursuant to which we reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31c038a4-d1e4-479f-807a-6348cbfb5026" contextRef="C_9eb3c3bc-3f1f-46d7-8b32-d6803d932f4e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock to be used exclusively for grants of inducement awards to individuals who were not previously Geron employees or non-employee directors, other than following a bona fide period of non-employment.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the compensation committee of our board of directors approved amendments to our 2018 Inducement Award Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e373c7e-e340-4f35-93e9-69a0c36952b5" contextRef="C_1fc0a461-b7df-4953-9697-a90dae088624" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,900,000</ix:nonFraction></span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock. As of December 31, 2023, an aggregate total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1164f62e-9bb2-4624-b3aa-ff1864b4daff" contextRef="C_a432a676-25a6-4e7b-8197-e0e0d30df151" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">32,306,638</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock have been reserved under the Inducement Plan, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c54a6eab-f424-40da-bece-2975b183572a" contextRef="C_a432a676-25a6-4e7b-8197-e0e0d30df151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,616,841</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> available for grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards, and all awards under the Inducement Plan are intended to meet the standards under Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved 2018 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Directors&#8217; Market Value Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2018, our board of directors adopted a Directors&#8217; Market Value Stock Purchase Plan, or the Directors Market Plan. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb17b212-d5bc-4f39-86da-bbb58e77f1cb" contextRef="C_76b2a7dd-0da9-4a9f-bf20-e3fdac920246" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock have been reserved for the Directors Market Plan. Under the Directors Market Plan, non-employee directors may purchase shares of our common stock at the prevailing market price on the purchase date with cash compensation payable to them for their services as a board member. As stated in Geron&#8217;s Non-Employee Director Compensation Policy, each non-employee director receives annual cash compensation, payable quarterly in arrears, for their services on the board and various committees of the board. As provided in the Non-Employee Director Compensation Policy, a non-employee director may elect to receive fully vested shares of common stock in lieu of cash and such shares shall be issuable from the Directors Market Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023, 2022 and 2021, we issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ee1d149-2851-4cef-9126-05db733faabd" contextRef="C_042608dc-1dba-4a63-acb9-58cb22cee7c4" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,864</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee3d4f3e-bbc8-4935-9657-0667be438bff" contextRef="C_b6410ed5-b65f-42da-b01e-341e5ebcf276" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,962</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8a036b1-f93f-4c5a-bf13-a4eb1048cd0f" contextRef="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,783</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, respectively, under the Directors Market Plan. The weighted average grant date fair value of stock granted during the years ended December 31, 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec82237a-a3ac-46d9-9e34-d4765f175b89" contextRef="C_042608dc-1dba-4a63-acb9-58cb22cee7c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de4c7bc2-dfea-4822-b989-a79b54d41115" contextRef="C_b6410ed5-b65f-42da-b01e-341e5ebcf276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a67f90a-188d-4514-a687-a385b247c1a0" contextRef="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.38</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total fair value of vested stock grants during 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c69d6e2d-8ff4-41bf-ab2c-5f7b103d74e0" contextRef="C_042608dc-1dba-4a63-acb9-58cb22cee7c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">85,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bd5d1e3-04ed-41fa-a969-6cc0fea51e16" contextRef="C_b6410ed5-b65f-42da-b01e-341e5ebcf276" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">29,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8657594e-fb3f-4a4b-9f0f-ed19e9d17194" contextRef="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">29,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1450160-3765-4081-aa00-e8819f122cb7" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, 2006 Directors Plan, Inducement Plan and Directors Market Plan is as follows:</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.994%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.998%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:8.998%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:13.117%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:13.977%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.918%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Available</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual Life</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e39a1952-2f72-485d-bb08-d4fdcf52e196" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,370,729</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc19717-cb3b-4687-8fdd-ef4924f0f264" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">65,902,400</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1d2930e-4769-40c5-bad7-8ac5c02abfe0" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b6e606d-1a4d-4c97-bb1d-7446d48e3fc8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">56,368,058</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_574dfc62-2dc8-47e4-a41f-827cccbe9bbe" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,855,230</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68760ca3-2392-4b26-aa7d-c83776961c6a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,855,230</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3226ebb-c950-4bfd-b9a3-be20e983e33a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.72</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Awards granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa70ef11-ba24-4d0d-bb89-b58f05aa1694" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,864</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_168350dd-98b5-40a7-8fb4-48f996d8f9b3" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,869,302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c3b7031-64cf-4a0d-9860-67b4da0de951" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.39</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options cancelled/forfeited/expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4daaaae6-ffc8-4699-97a5-88066f5c399b" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,903,977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8ba4143-41e6-45f2-9850-c9997b8a8d5f" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,903,977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11c501f1-037b-4eab-8aea-9be657f773ec" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bc7cd4d-4d21-435f-be5b-e3b394f28ab5" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,750,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_283003cf-edbd-4792-9357-5c0ac76d189f" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">72,984,351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1c382a9-2507-4b75-9534-a47c73b36b9f" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_eaf3d11b-810b-4745-b919-09f0e2fadcfd" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.70</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0be7f18-f0f7-4d46-a980-f30c7f995bfa" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,391,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercisable at <br/>&#160;&#160;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1016c619-5f8a-4aed-a717-8b4c95110e73" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,995,642</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f914b65-62fc-4569-98e6-d2d02febd5c4" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_1fdddbb4-3fbc-4146-814a-37ee6626689e" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.28</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c9c8f46-1729-47da-8be9-e3ca2b69d1ed" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">15,557,976</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options fully vested and expected<br/>&#160;&#160;&#160;&#160;to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6decdf3-f873-43d7-a788-229d00293b31" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">71,983,176</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a0295f9-2fad-4923-b590-6d61ebff9d8c" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_fbfeb147-65e6-489d-82d3-f25b680a8765" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.67</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee5d018d-9fe7-4652-a36b-c382cfd4ce63" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,169,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_242647d4-6222-4da6-aef1-99712c736013" contextRef="C_d87baa2f-bd55-465b-8452-44ea0c0bd760" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,936,030</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> perfo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rmance-based stock options granted that have not achieved the specified performance milestones.</span></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on Geron&#8217;s closing stock price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d42a355-0b3c-4c2c-a33c-ffb6942bc654" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which would have been received by the option holders had all the option holders exercised their stock options as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not granted any stock options with an exercise price below or greater than the fair market value of our common stock on the date of grant in 2023, 2022, and 2021. As of December 31, 2023, 2022 and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cc5c97c-925e-401c-9ac1-bd2067c75bde" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,995,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6729774b-11db-4710-afd7-24d24f05c6fa" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,085,389</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29840fa2-0ac5-43c3-bc38-31828fdc30b1" contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,459,136</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> exercisable stock options outstanding at weighted average exercise prices per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea67676d-309d-49b7-8ac1-715b8b330276" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5501358-ebab-4ccb-b75d-b2db19e0e08e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.17</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_463c5734-8d78-4a78-a1d1-3f3dba8f82e4" contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total pretax intrinsic value of stock options exercised during 2023, 2022, and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3455db7a-7984-4f7d-9c57-7a82b0386dad" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">11,986,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fe9e446-596d-4f8b-8a2d-127f021de3ed" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">787,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95724eab-b727-47e4-9243-3f29d8025560" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">93,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Cash received from the exercise of stock options in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 totaled approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e26e225f-91c5-40b0-9ea2-465ad18a29ea" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">12,356,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce2838e7-fcec-45dc-86d3-a1c540d1e410" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,799,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3637cf62-207a-47af-820c-84f4976c3b9f" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">556,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2014, our board of directors adopted the 2014 Employee Stock Purchase Plan, or 2014 Purchase Plan. The 2014 Purchase Plan was approved by our stockholders in May 2014. The 2014 Purchase Plan replaced the 1996 Employee Stock Purchase Plan, or 1996 Purchase Plan, which was terminated effective as of the date the 2014 Purchase Plan was approved by our stockholders. In May 2022, our stockholders approved an amendment to our 2014 Purchase Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90e55705-4718-4db4-b7fe-d231e136090b" contextRef="C_228019f9-7d33-40bf-8f26-f89bae5c27ff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, for an aggregate total reserve of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4878368-c6a6-44eb-8b52-d5843abdb0fd" contextRef="C_9f801a8f-cd52-49ca-bf06-5622142e1b2a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03a883e3-5d8e-4d77-9612-fd1738c42dad" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,254,162</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock have been issued under the 2014 Purchase Plan since its adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2014 Purchase Plan is comprised of a series of offering periods, each with a maximum duration (not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_583a06de-61ae-4ee2-82df-1a48eed4eea2" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months) with new offering periods commencing on January 1st and July 1st of each year. The date an employee enters the offering period will be designated as the entry date for purposes of that offering period. An employee may participate only in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5beea9d-ea6a-48d7-b738-bc1daef19a41" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" unitRef="U_Item" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> offering period at a time. Each offering period consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_583945e1-ba6e-4ff9-8cf0-9a5cb753c88c" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" unitRef="U_Item" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive purchase periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b99bd1f8-441b-483e-b798-0d2c64772086" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; duration, with the last day of such period designated a purchase date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the 2014 Purchase Plan, employees can choose to have up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_535389d2-83dd-4ec6-a20c-ef327a18aa95" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" unitRef="U_pure" scale="-2" decimals="INF">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their annual salary withheld to purchase our common stock, up to a limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9595ff3-6a2b-4051-808a-b809d5bab54b" contextRef="C_f6fcdb67-4d24-4d5f-be19-775334a4320f" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per year. An employee may not make additional payments into such account or increase the withholding percentage during the offering period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price per share at which common stock is purchased by the employee on each purchase date within the offering period is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b2e4137-39b9-4ad1-a926-8abfe70ad069" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the lower of (i) the fair market value per share of our common stock on the employee&#8217;s entry date into that offering period or (ii) the fair market value per share of our common stock on the purchase date. If the fair market value per share of our common stock on the purchase date is less than the fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">value at the beginning of the offering period, a new </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89d712c6-7f8b-4c16-9195-351be7028ead" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> month offering period will automatically begin on the first business day following the purchase date with a new fair market value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation for Employees and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure and recognize compensation expense for all share&#8209;based payment awards made to employees and directors, including employee stock options, restricted stock awards and employee stock purchases, based on grant&#8209;date fair values for these instruments. We use the Black-Scholes option&#8209;pricing model to estimate the grant&#8209;date fair value of our service-based and performance-based stock options and employee stock purchases. The fair value for service&#8209;based restricted stock awards is determined using the fair value of our common stock on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As stock&#8209;based compensation expense recognized on the consolidated statements of operations for the years ended December 31, 2023, 2022 and 2021 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures, but at a minimum, reflects the grant&#8209;date fair value of those awards that actually vested in the period. Forfeitures have been estimated at the time of grant based on historical data and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, 2022 and 2021, our board of directors awarded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faaa8869-df64-4907-87cf-09359aa618c9" contextRef="C_5a771635-513d-4f44-938f-c72a1da4876b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">832,790</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_033962a5-485a-4558-9139-c6e6111478a6" contextRef="C_ea12e420-2fee-416f-88f6-87e5a5b23293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,741,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_053c3e8e-ff32-4073-889c-ed83329475c2" contextRef="C_25ad2b3f-4a16-403c-a2dc-3b7d1fe99046" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">550,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> perform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ance-based stock options, respectively, to certain employees. These performance-based stock options are included in the outstanding stock options table above. Performance-based stock options vest only upon achievement of discrete milestones. Stock-based compensation expense for performance-based stock options is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being achieved, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize stock&#8209;based compensation expense for service-based stock options on a straight&#8209;line basis over the requisite service period, which is generally the vesting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4223f4c6-dc0e-4151-b697-81d1b42f525b" contextRef="C_5a771635-513d-4f44-938f-c72a1da4876b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,167,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2023. We did not recognize any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended Dec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ember 31, 2022 and 2021, as the achievement of the specified milestones was not considered probable during that time. </span><span style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_901dbeb0-29d8-4a8c-b637-46407a169bef" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_901dbeb0-29d8-4a8c-b637-46407a169bef_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the stock&#8209;based compensation expense related to service-based stock options and employee stock purchases for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021, which was allocated as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_901dbeb0-29d8-4a8c-b637-46407a169bef_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.512%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1%;"/>
        <td style="width:14.728%;"/>
        <td style="width:1%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1%;"/>
        <td style="width:14.728%;"/>
        <td style="width:1%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1%;"/>
        <td style="width:13.278%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da42649c-286d-4829-843c-68ae2c8bb714" contextRef="C_88e8fe22-6578-4995-bace-a30be752ddd8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,426</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b13955a-b152-4560-a0d9-6c40be798362" contextRef="C_7346f9b8-492d-46b8-8c82-4d22ec08ac7d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,720</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a72d8b0c-685e-411c-a39f-f28d5ed7cb16" contextRef="C_76c77a60-0095-4c7c-b9a6-6d9d39af8387" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b6540c5-c431-4974-9dfb-e12e9eb42b2d" contextRef="C_e71ee43c-b505-4d11-b82b-9dd17fd5ffe9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,099</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a78a9138-b590-4b2d-99c4-62ece9486e5e" contextRef="C_f6afc8ee-1a57-40bd-8ddc-ffc4d5eb3fd9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc49b197-34cd-4321-bbe7-42868501ecde" contextRef="C_b86372fa-858a-445d-b041-163879e9a211" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,483</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense<br/>&#160;&#160;&#160;included in operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb316d28-c9ee-4a41-acb5-73b3cb773f06" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,525</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74a6f27f-e1dd-45f3-86bb-de7f48b4b35e" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce80c1b6-237c-4a4c-970f-b65be3998627" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,080</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_899cadcd-21a6-4048-b430-784eebb67d26" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 has been estimated at the date of grant using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.5%;"/>
        <td style="width:1.25%;"/>
        <td style="width:16.25%;"/>
        <td style="width:1.25%;"/>
        <td style="width:16.25%;"/>
        <td style="width:1.25%;"/>
        <td style="width:16.25%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29cbb3a8-1a6d-4733-8301-44623f728279" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7512326-b601-47a5-8552-1a993fc26f3b" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f15468c-7e71-4bfd-a2a2-b8d8a9ee97e8" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9000d78-e9d3-4ab4-9d22-bcf0f6138822" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.815</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa6c5a21-311a-4101-b9d6-de1c5194bbd5" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.827</ix:nonFraction></span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b103ff9-6ffc-440e-bf0e-44fd31ef595d" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.772</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_739c1da5-d5f3-49d7-a8d7-634a2b48ad32" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.817</ix:nonFraction></span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05f7cb8e-eb89-403e-81fe-c02f1389bb64" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.775</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f84f42da-b996-492a-a996-e1d5aaad23ad" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.783</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a60ba76-df76-4169-9b39-efc338774225" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f8b979f-8cf3-4b8b-8f33-3d8d421a1829" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_214b55b9-4875-4c06-a548-b113818510ee" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b9c7830-f405-4ca9-955a-d999b58bcf1d" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4c47cd7-6cbb-4630-af88-bc23b96a8fef" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.51</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb1ab1af-c8f0-45ad-a9a6-f79212fbe2f6" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3e0f681e-d232-4de6-a3ef-a161f08b5037" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fddab3cc-5090-4cc6-b010-da0a6144d173" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_06fd0b79-87e2-454a-be22-927098e019b8" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9121cf3-b742-492d-84b4-ff95adca227b" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of employee stock purchases in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 has been estimated using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40%;"/>
        <td style="width:1.25%;"/>
        <td style="width:22.5%;"/>
        <td style="width:1.25%;"/>
        <td style="width:16.8%;"/>
        <td style="width:1.25%;"/>
        <td style="width:16.95%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cf2115e-b48d-4ed6-a71e-cbd9d0629e8d" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29dfa152-0a70-47dc-9400-67e3aa62f9ad" contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31dce189-bdd7-4a0e-a5a6-11b933e679fc" contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b8884ff-47ef-4a93-88ed-e8fa6066b448" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.791</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6805872c-ce33-4eae-bff7-1af4c9761066" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.832</ix:nonFraction></span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4086a0fa-f3ac-4ac3-bd8a-42e362048d84" contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.614</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e3ce0b1-d452-4942-9358-2b383c890d3c" contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.865</ix:nonFraction></span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e466ad9-9ff1-45fd-bc20-543cdcd435df" contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.507</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3d1b35a-02c0-43dc-94a9-516ab245ff3e" contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">0.707</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_717ba260-ac2c-4a3f-824d-66e174e1510d" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d03a596-e6a6-426a-8a01-547b61672cde" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e68b15da-d203-428b-a665-72b4af71bd49" contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39ed6c2c-3d1a-4f92-aaf7-905525ff5dcc" contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13eb59f3-cb96-4990-80b1-722a1e10ff74" contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.09</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d74d8c4-c7e8-49b7-8f97-575f0e7dd6d3" contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4aca52f2-0ad6-4f87-b4d4-d48b59796394" contextRef="C_ad45d3b5-1c71-49f5-8e18-c743e63e20bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_296b7038-75e6-4e52-92b4-ed27c22c3163" contextRef="C_f6fcdb67-4d24-4d5f-be19-775334a4320f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_1fe5c3e5-76cd-4d6c-9702-6a5da736a79d" contextRef="C_e976b4cb-7c40-4469-90e7-51a6622581cb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_b1d7a707-c794-4dbd-8367-482ea618b024" contextRef="C_73aa80a5-7000-451b-a950-0deff207777e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5b6cbae1-c19d-43fb-837a-b4a253f69522" contextRef="C_3a2cda13-d3d5-412b-8639-f1337e897a80" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_35ac0297-dbc5-4059-8c94-b6cd20836cf3" contextRef="C_f483b420-dc65-4430-8e6f-a781504fe525" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend yield is based on historical cash dividend payments and we have paid no cash dividends to date. The expected volatility range is based on historical volatilities of our stock, since traded options on our common stock do not correspond to option terms and the trading volume of options is limited. The risk&#8209;free interest rate range is based on the U.S. Zero Coupon Treasury Strip Yields for the expected term in effect on the date of grant for an award. The expected term of stock options is derived from actual historical exercise and post&#8209;vesting cancellation data and represents the period of time that stock options granted are expected to be outstanding. The expected term of employees&#8217; purchase rights is equal to the purchase period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the Black-Scholes option&#8209;pricing model, the weighted-average estimated fair value of stock options granted during the years ended December 31, 2023, 2022 and 2021 w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf74c997-73f5-4c3d-854a-f560c0e65d2e" contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_362179eb-6207-4c9a-b52b-7315599ebb57" contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7219dfb4-68bd-4651-8515-3aa7d22dbd32" contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.17</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share, respectively. The weighted average estimated fair value of employees&#8217; purchase rights for the years ended December 31, 2023, 2022 and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2803f2ed-cd5d-48c1-9fdb-f17515eda2a4" contextRef="C_34991f42-499f-4b50-9059-0999669562cd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4692d2f8-1293-426a-9467-b852390b7e67" contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc693409-6021-4a75-9b89-a7572d427255" contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, total compensation cost related to unvested share&#8209;based payment awards not yet recognized, net of estimated forfeitures and as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suming no probability of achievement for outstanding performance-based stock options, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8e74e4d-c50a-48e7-ad16-bb1c6c5493ee" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">37,628,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, whi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ch is expected to be recognized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64ba28db-f1ae-4371-b189-3f6e2cd7859d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months on a weighted&#8209;average basis.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation to Service Providers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We grant stock options to consultants from time to time in exchange for services performed for us. In general, the stock options vest over the contractual period of the consulting arrangement. The fair value of stock options held by consultants is recorded as operating expenses over the vesting term of the respective equity awards. With the adoption of Accounting Standards Update 2018-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2018-07, in the first quarter of 2019, the measurement date of stock options granted to consultants was fixed at the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded stock&#8209;based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e3fbb64-e218-4f0e-a648-a0fc99b895d3" contextRef="C_3ad6c2d6-0303-48fa-82c0-130aee8c97e6" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">742,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65eafb12-e63e-4fb6-b105-9a3d1f1187f1" contextRef="C_2d9d0c34-60e7-4259-a55f-9fe02c166dc0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">235,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4d3cf96-0cce-44b9-9f9b-2e4321c40ae6" contextRef="C_12a38d5d-ad5a-4d9a-a905-53cbdd8ad7e8" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">62,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the vest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed portion of the fair value of stock options held by consultants in 2023, 2022, and 2021, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_292566fa-eca5-4b1c-a06e-519739c7eeab" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.133%;"/>
        <td style="width:1.667%;"/>
        <td style="width:1%;"/>
        <td style="width:23.201%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6ea0819-7652-4f0b-ac87-f5cb0f2e1fc1" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">72,984,351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and awards available for grant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bff0aed6-5486-4372-9b64-7869056873f9" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,750,670</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c17f173f-0e73-43e4-b3fa-e19a976b4e28" contextRef="C_f5ed2423-f046-4a7d-980c-b9f3fb922f38" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">745,838</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8efe1832-0f76-4699-95b3-7bd713e5a707" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,904,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bd872c5-ae50-46b7-948a-cf66dcb3ebf4" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">186,385,839</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:nonNumeric id="F_d9e4ddb8-50ab-40fe-b804-fa7de86205f0" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. INCOME TAXES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb9860c1-573e-4703-b160-39419a4cd6c4" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.8%;"/>
        <td style="width:1%;"/>
        <td style="width:10.1%;"/>
        <td style="width:1%;"/>
        <td style="width:3.28%;"/>
        <td style="width:5.16%;"/>
        <td style="width:1%;"/>
        <td style="width:10.1%;"/>
        <td style="width:1%;"/>
        <td style="width:3.1%;"/>
        <td style="width:4.26%;"/>
        <td style="width:1%;"/>
        <td style="width:7.92%;"/>
        <td style="width:1%;"/>
        <td style="width:3.28%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_969cf705-0930-48ff-bd1b-6893b932da00" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92aa6f5d-34a9-46f3-a7e2-f6cb03b56b1a" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_361550f3-4cd3-4938-9f39-e62f0dd42aff" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a85d897-e701-40b3-bf72-bd0d8e3852d8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_730ae8a2-5cb8-4c84-934a-d69028330cd1" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65b4da2c-5eba-4175-a055-78e9277775e4" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c743879-0c3e-4f69-8b84-78de8a04ca51" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbe2d79b-72eb-4134-ac67-575f5640416b" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26cafdc7-eadb-47c1-9b60-897630c0161d" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6036096c-7c8e-4314-bbf8-74c1100da70d" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e1cf9c8-e088-4654-b089-e70dc0af5b2c" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac00d061-919c-4ea2-bd20-784938788e83" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss not benefitted</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cff43695-c831-455c-b243-b8983a55cf8a" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ae758ff-d73d-4336-846b-d7b6cc4f4b33" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b67d981-fe6e-49a7-828d-00fc2cc5b6c2" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ccf0906-62d6-4758-b30f-749d5aeb3780" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8364aa4-c96d-466e-bd2b-aa23ee4f3d32" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b39108f-983a-4338-8d50-08eca6dadfa1" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2e22b2a-b103-49da-8d62-2817cd226eda" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31879fca-199f-448c-bddd-bd45c895fbb3" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3762dcc2-8aec-4e44-a32e-01fa7e7bafcb" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">28.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23ab15ba-79eb-441d-b40b-f0341682b005" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ce77d5b-e5b2-4f8c-8a10-5fdcd5a919e9" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13752874-08e0-4639-bbb0-59e3c1671037" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1e9feb3-7b30-4bcc-982c-938e4a932f11" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_f1e9feb3-7b30-4bcc-982c-938e4a932f11_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of our deferred tax assets are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f1e9feb3-7b30-4bcc-982c-938e4a932f11_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ee896ac-4160-4240-bec0-e73ff4ab05de" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,300</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79f268b9-18e7-4f29-85e3-65d4076b578f" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">254,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_527507d7-97cd-42b4-926a-cc063c29304c" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:DeferredTaxAssetsFederalAndStateCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf698b17-7c37-48bf-aa53-3f9801d3e3e3" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:DeferredTaxAssetsFederalAndStateCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5541fed8-495d-4a3a-ba35-930dbf92403c" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,300</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9808dfab-6fa0-4a1e-a18b-d4c5f997714c" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98599bcb-8df6-4b09-a1d0-10251782760f" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90bb985c-0152-4ae4-a583-3f98ff52cb17" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,800</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51f4567c-304b-476f-96d2-6ef4249a9c42" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ebad8ee-54e4-487e-b5dc-d1f26692c03e" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,300</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c48c2e4-efd6-41e9-af37-46eabb607232" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7b59155-c8ed-4c80-8218-33023736e946" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b1f1234-121b-439f-9fac-0cd753bd1db3" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1864984-f1c5-4ca1-89bd-5469201cc699" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">350,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82af20e5-f11f-4e71-bab8-ab14886e2357" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">395,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_270ee073-469e-4234-9f83-a5ecd4f6788f" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">349,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a96c5ff-90d4-4bad-8be9-a8e702efff83" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_989e2445-e82a-4c77-ad18-9ad014d2912c" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:15pt;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e184533-eb6a-4dfa-a84f-197480f829fc" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8acede7-adbf-4092-a9ba-929b6fc4f914" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cdf0cc4-5ef0-4033-86c9-4a1f3e5e76ee" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_194064de-ccf4-459c-aea0-349e1a31e6b8" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial performance. Forming a conclusion that a valuation allowance is not required is difficult when there is negative evidence such as cumulative losses in recent years. Because of our history of losses, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_816c0717-ed98-426e-9f5f-6c98cb9c6dcd" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9d60867-dbc7-489b-9f4e-517d0a07978d" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had domestic federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f11833d-b76e-4007-8854-f7632e00b769" contextRef="C_30549aaa-2d2b-429a-b2b7-bad54c937228" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion. Of this, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bcd2be68-abfb-4745-88dd-1c12f5ecaae4" contextRef="C_30549aaa-2d2b-429a-b2b7-bad54c937228" name="gern:OperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">635.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will expire at various dates beginning in 2024 through 2037 and the remaining will carryforward indefinitely under the new tax laws, but is subject to an 80% taxable income limitation for tax years beginning after 2020. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb27c04d-a7a6-453e-8133-94ddc07eefb6" contextRef="C_0998544a-c764-4cf1-9f09-2276209f95bc" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">841.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expiring at various dates beginning in 2028 through 2043, if not utilized. We also had federal tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84543349-62e2-47f3-b731-4a06036cdf8d" contextRef="C_30549aaa-2d2b-429a-b2b7-bad54c937228" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">72.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expiring at various dates beginning in 2024 through 2043, if not utilized. Our state tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bb7941c-1214-4c3f-af88-b7aeadff4f9c" contextRef="C_0998544a-c764-4cf1-9f09-2276209f95bc" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million carry forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized. The impact of any limitations that may be imposed due to such ownership changes has not yet been determined. Due to the Company's stock issuance in January 2023, the utilization of the Company's net operating loss and tax credit carryforwards are subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation may result in the expiration of the net operating loss and tax credit carryforwards before some or call of such amounts have been utilized. The final amount of the limitations imposed due to such ownership changes has not yet been determined.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div></ix:exclude><p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March and December 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic, including among other items, several U.S. income tax provisions related to, among other things, net operating loss carrybacks, alternative minimum tax credits, modifications to interest expense limitations, and an option to defer payroll tax payments for a limited period. In 2021, we assessed our eligibility to claim a refund of employer taxes available under the Employee Retention Credit provisions of the CARES Act. For the years ended December 31, 2022 and 2021, we calculated eligible credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_005b3019-93d0-4a0c-9580-c43eee54392f" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:EmployerTaxReceivable" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">483,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f7c1e8a-0bf4-4713-95da-84cc59a68883" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="gern:EmployerTaxReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, provided by the CARES Act, which have been recognized as offsets to salaries costs in operating expenses in 2022 and 2021, respectively. As of December 31, 2022, the aggregate eligible credit amount has been accrued as a receivable on our consolidated balance sheets. We received the Employee Retention Credit from the IRS, and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92f69fb3-4a42-41c8-89e7-330b560c992d" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="gern:EmployeeRetentionCreditAmountOutstandingReceivables" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding receivables as of December 31, 2023.</span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We adopted the provision of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, we recognized no material adjustment in the liability for unrecognized tax benefits. At December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34420faf-fede-4317-8c0d-5bdaaf28f609" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized tax benefits, none of which would currently affect our effective tax rate if recognized due to our net deferred tax assets being fully offset by a valuation allowance.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8d07f78-5ac6-4b1f-8a00-17e508a997bc" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97671845-553f-4083-b892-da18090e29a7" contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_637ef20c-0d73-4ef6-baf8-12f875343e74" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67834848-8632-4777-acb2-a14e809fe533" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,300</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If applicable, we would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2023, there has been no interest expense or penalties related to unrecognized tax benefits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently expect any significant changes to unrecognized tax benefits during the fiscal year ended December 31, 2023. In certain cases, our uncertain tax positions are related to tax years that remain subject to examination by the relevant tax authorities. Tax years for which we have carryforward net operating loss and credit attributes remain subject to examination by federal and most state tax authorities.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd84b3fc-9a2d-4ede-b214-033e3152b336" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d5c536-6737-41e5-b4d2-bec85fcc7f8f" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.291%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.437000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.437000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:14.437000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental operating and investing activities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net unrealized loss on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44bf290a-5c51-4056-91f7-9d5d2c53a547" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e00cbf67-d151-45bb-aa6c-60277a1305ad" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ec3ce2c-6173-4ee7-a292-783929c619e3" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Reclassification between prepaid and other<br/>&#160;&#160;&#160;current assets and deposits and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87242a63-5734-496c-b95f-39b0c0764988" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="gern:ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_161b5c87-8ba3-42e8-b91d-c6053a9e5fc8" contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,017</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b91c2fd4-9842-4366-a03b-bc124eed2db6" contextRef="C_1e899757-4f56-49cf-873b-25770295bb58" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb9eae10-5375-4b47-87f8-f7c2eb3820a0" contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,704</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9A. CONTROLS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> AND PROCEDURES</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(I)  Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have carried out an evaluation under the supervision and with the participation of management, including our Chief Executive Officer and our Chief Financial Officer, of our disclosure controls and procedures (as defined in Rule 13a&#8209;15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report on Form 10&#8209;K. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In designing and evaluating disclosure controls and procedures, our management recognizes that any system of controls, however well designed and operated, can provide only reasonable assurance, and not absolute assurance, that the desired control objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals in all future circumstances. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and our Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this annual report on Form 10&#8209;K, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(II)  Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(III)  Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management is responsible for establishing and maintaining an adequate internal control over financial reporting for us. Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on our evaluation under the framework set forth in &#8220;Internal Control&#8212;Integrated Framework,&#8221; our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(IV)  Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This annual report on Form 10-K includes an attestation report of our independent registered public accounting firm. It is set forth in Item 8 above.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9B. OTHE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_707b78ca-5291-4e64-9726-0583e688992f" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Arrangements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our last fiscal quarter, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:26%;"/>
      <td style="width:12%;"/>
      <td style="width:11%;"/>
      <td style="width:14%;"/>
      <td style="width:13%;"/>
      <td style="width:9.72%;"/>
      <td style="width:14.28%;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="border-top:0.5pt solid;padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Character of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Title</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Action</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rule 10b5-1*</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_13b342b6-71e2-42af-9baa-da680acd4e93" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b969e258-fa57-4fdc-b3a3-d58290cd463e" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-Rule 10b5-1</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">**</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Shares to be Sold</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Date</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_a7b9b832-6591-4f5a-b250-1b7f19801c34" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Faye Feller, M.D.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_265f1640-30ab-4771-8e4b-ba41b605aae9" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:TrdArrIndTitle" continuedAt="F_265f1640-30ab-4771-8e4b-ba41b605aae9_1"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_265f1640-30ab-4771-8e4b-ba41b605aae9_1"><p style="text-indent:10.8pt;margin-top:0;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President and</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:10.8pt;margin-top:0;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Medical Officer</span></p></ix:continuation></div></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2955f0c9-dba8-4ebb-8a84-1c93ac0a64e6" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Termination</span></ix:nonNumeric></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_77ad96f4-d53b-467e-a388-ebab05d54427" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 25, 2023</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c16ae972-0664-4fe1-a6c0-2d8316960998" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a46bd2e9-9f8d-4bed-b110-fc25f1f802b5" contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_18dd4e09-ffbf-40f0-a2f3-62dc6d7d2911" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="gern:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 12, 2024</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="7" style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="7" style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">** "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><ix:footnote id="FNT_d30983c0-aaf8-4127-9c9f-03919a470b03" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect when adopted on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63cbcee6-1fd4-4451-823f-7b86954faf0e" contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:footnote></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9C.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> III</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain information required by Part III is omitted from this annual report on Form 10&#8209;K because we will file with the U.S. Securities and Exchange Commission a definitive proxy statement pursuant to Regulation 14A in connection with the solicitation of proxies for Geron&#8217;s Annual Meeting of Stockholders expected to be held in May 2024, or the Proxy Statement, not later than 120 days after the end of the fiscal year covered by this annual report on Form 10&#8209;K, and certain information included therein is incorporated herein by reference, or an amendment to this annual report on Form 10-K under cover of Form 10-K/A containing the information required by this Part III.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identification of Directors and Nominees for Director</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item concerning our directors and nominees for director is incorporated by reference from the section captioned &#8220;Proposal 1: Election of Directors&#8221; contained in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identification of Executive Officers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item concerning our executive officers is set forth in Part I, Item 1 of this annual report on Form 10&#8209;K.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code of Ethics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted a Code of Conduct with which every person who works for Geron, including our board of directors, is expected to comply. The Code of Conduct is publicly available on our website under the Investors &amp; Media section at www.geron.com. This website address is intended to be an inactive, textual reference only; none of the material on this website is part of this annual report on Form 10&#8209;K. If any substantive amendments are made to the Code of Conduct or any waiver granted, including any implicit waiver, from a provision of the Code of Conduct to our Chief Executive Officer, Chief Financial Officer or Corporate Controller, we will disclose the nature of such amendment or waiver on that website or in a report on Form 8&#8209;K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Copies of the Code of Conduct will be furnished without charge to any person who submits a written request directed to the attention of our Corporate Secretary, at our offices located at 919 East Hillsdale Boulevard, Suite 250, Foster City, California, 94404.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain Corporate Governance Matters</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item concerning our audit committee, audit committee financial expert and procedures by which stockholders may recommend nominees to our board of directors, may be found under the sections captioned &#8220;Board Leadership and Governance&#8221; and &#8220;Other Matters&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 11. EXECUTI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VE COMPENSATION</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the sections captioned &#8220;Summary Compensation Table and Narrative Disclosure to Summary Compensation Table,&#8221; and &#8220;Compensation of Directors&#8221;  contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OW</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the sections captioned &#8220;Equity Compensation Plan Information&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">D TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the sections captioned &#8220;Proposal 1: Election of Directors&#8221; and &#8220;Certain Transactions&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NTANT FEES AND SERVICES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item is incorporated by reference from the section captioned &#8220;Principal Accountant Fees and Services&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 15. EXHIBITS AND FINAN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CIAL STATEMENT SCHEDULES</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) (1) Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in Part II, Item 8 of this Report:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.8%;"/>
    <td style="width:6.2%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets&#8212;December 31, 2023 and 2022</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Operations&#8212;Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a><a href="#statements_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Comprehensive Loss&#8212;Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a><a href="#statements_stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Stockholders&#8217; Equity&#8212;Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Cash Flows&#8212;Years Ended December 31, 2023, 2022 and 2021</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#note_1_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial statement schedules are omitted because they are not required or the information is disclosed in the financial statements listed in Item 15(a)(1) above.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.002%;"/>
    <td style="width:45.829%;"/>
    <td style="width:9.602%;"/>
    <td style="width:6.721%;"/>
    <td style="width:18.244%;"/>
    <td style="width:11.602%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporation by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing Date</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677412002137/exhibit3-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restated Certificate of Incorporation</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 18, 2012</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677412002137/exhibit3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 18, 2012</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677419001851/geron3600721-ex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0000886744/000120677421001453/geron3909221-ex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 13, 2021</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0000886744/000120677421001453/geron3909221-ex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 2, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.6</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677410000646/exhibit3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of Registrant</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 15, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="gern-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000104746913002849/a2213377zex-4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 15, 2013</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677420001694/geron3763911-ex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 26, 2020</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.4</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677420001694/geron3763911-ex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Common Stock</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 26, 2020</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459022012684/gern-ex41_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 30, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459022012684/gern-ex42_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Warrant to Purchase Common Stock</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 30, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023000349/gern-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 6, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677412000967/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2012</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000110465913082263/a13-19477_1ex10d5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated 2006 Directors&#8217; Stock Option Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2013</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677411001222/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2011 Incentive Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 16, 2011</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000104746913002849/a2213377zex-10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under 2011 Incentive Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 15, 2013</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000104746913002849/a2213377zex-10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Award Agreement under 2011 Incentive Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 15, 2013</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000110465915035645/a15-6935_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non&#8209;Employee Director Stock Option Agreement under 2011 Incentive Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 7, 2015</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677422001399/geron4061651-ex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2018 Equity Incentive Plan, as amended*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">June 2, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">UK Sub-Plan to 2018 Equity Incentive Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of 2018 Equity Incentive Plan Option Agreement (Time Based)*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of 2018 Equity Incentive Plan Option Agreement (Performance Based)*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677418001662/geron33139012-ex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Employee Director Stock Option Agreement under 2018 Equity Incentive Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 18, 2018</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1013_107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Non-Employee Director Stock Option Agreement under 2018 Equity Incentive Plan, as amended*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1014_106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Performance-Vesting Stock Option Agreement under 2018 Equity Incentive Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1015_105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Performance-Vesting Stock Option Agreement under 2018 Equity Incentive Plan, as amended*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022016839/gern-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2018 Inducement Award Plan, as amended</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">*</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 3, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">UK Sub-Plan to 2018 Inducement Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677418003435/geron33139022-ex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under 2018 Inducement Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 14, 2018</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1019_103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Stock Option Agreement under 2018 Inducement Award Plan, as amended*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1020_102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Performance-Vesting Stock Option Agreement under 2018 Inducement Award Plan*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677422001399/geron4061651-ex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2014 Employee Stock Purchase Plan, as amended*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 13, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.002%;"/>
    <td style="width:45.829%;"/>
    <td style="width:9.602%;"/>
    <td style="width:6.721%;"/>
    <td style="width:18.244%;"/>
    <td style="width:11.602%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of 2018 Inducement Award Plan Option Agreement (Time Based)*</span></a></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of 2018 Inducement Award Plan Option Agreement (Performance Based)*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.23</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Employee Director Compensation Policy, as amended February 16, 2022, March 7, 2022 and February 14, 2024*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.24</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459018026208/gern-ex101_99.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors&#8217; Market Value Stock Purchase Plan, effective October 1, 2018*</span></a><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 1, 2018</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.25</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459022009627/gern-ex1022_125.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Severance Plan, effective as of January 1, 2022*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.22</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 10, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.26</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1029_99.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Employment Agreement between the Registrant and John A. Scarlett, M.D., effective as of January 31, 2019*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.29</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.27</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1031_97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Employment Agreement between the Registrant and Andrew J. Grethlein, effective as of January 31, 2019*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.28</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1032_96.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Employment Agreement between the Registrant and Olivia K. Bloom, effective as of January 31, 2019*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.29</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459020010449/gern-ex1033_153.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement between the Registrant and Anil Kapur, effective as of December 2, 2019</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">*</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 12, 2020</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="gern-ex10_30.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement by and between the Registrant and Faye Feller, effective as of July 9, 2022*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.31</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023057760/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement by and between the Registrant and Scott A. Samuels, effective as of August 1, 2023*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.32</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023057760/gern-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement by and between the Registrant and Michelle Robertson, effective as of September 25, 2023*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2, 2023</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.33</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019015326/gern-ex1018_162.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Office Lease Agreement by and between Registrant and 3 Sylvan Realty LLC, effective as of April 30, 2019</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 2, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.34</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677419003542/geron3657421-ex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Office Lease Agreement by and between Registrant and Hudson Metro Center LLC, effective as of October 9, 2019</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 15, 2019</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.35</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677420002736/geron3801931-ex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">At Market Issuance Sales Agreement, dated November 1, 2023, by and between Registrant and B. Riley Securities, Inc.</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 2, 2023</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.36</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459020051288/gern-ex101_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Loan and Security Agreement, dated September 30, 2020, amongst Registrant, Hercules Capital, Inc., and Silicon Valley Bank</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#x5E;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 5, 2020</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.37</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0000886744/000156459021044618/gern-ex101_128.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to Loan and Security Agreement, dated August 12, 2021, amongst Registrant, Hercules Capital, Inc., and Silicon Valley Bank</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#x5E;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 16, 2021</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.38</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022016839/gern-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Loan and Security Agreement, dated June 30, 2022 amongst Registrant, Hercules Capital, Inc., and Silicon Valley Bank</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">&#x5E;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">August 11, 2022</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.39</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:7.9pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-7.9pt;padding-left:7.9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07013888888888889in;text-align:left;"><a href="gern-ex10_39.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to Loan and Security Agreement, dated December 14, 2023 amongst Registrant, Hercules Capital, Inc., and Silicon Valley Bank&#x5E;</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (see signature page)</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Form of Rule 13a&#8209;14(a), as Adopted Pursuant to</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.002%;"/>
    <td style="width:45.829%;"/>
    <td style="width:9.602%;"/>
    <td style="width:6.721%;"/>
    <td style="width:18.244%;"/>
    <td style="width:11.602%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-left:8.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="white-space:pre-wrap;min-width:fit-content;">Section 302(a) of the Sarbanes&#8209;Oxley Act of 2002, dated February 28, 2024</span></span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Form of Rule 13a&#8209;14(a), as Adopted Pursuant to Section 302(a) of the Sarbanes&#8209;Oxley Act of 2002, dated February 28, 2024</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002, dated February 28, 2024**</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002, dated February 28, 2024**</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Incentive Compensation Recoupment Policy, effective October 2, 2023*</span></a></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The following materials from the Registrant&#8217;s annual report on Form 10&#8209;K for the year ended December 31, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL) include: (i) Consolidated Balance Sheets as of December 31, 2023 and 2022, (ii) Consolidated Statements of Operations, Consolidated Comprehensive Loss, Stockholders&#8217; Equity and Cash Flows for each of the three years in the period ended December 31, 2023, and (iii) Notes to Consolidated Financial Statements</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x5E;    Certain portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted information is of the type that the Registrant customarily and actually treats as private or confidential.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*     Management contract or compensation plan or arrangement.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">**   The certifications attached as Exhibits 32.1 and 32.2 that accompany this annual report on Form 10&#8209;K, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this annual report on Form 10&#8209;K), irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 16. FORM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10&#8209;K SUMMARY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:1%;"/>
    <td style="width:4%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GERON CORPORATION</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: February 28, 2024</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michelle Robertson</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MICHELLE ROBERTSON</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Executive Vice President, Finance,</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer and Treasurer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">POWER OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, John A. Scarlett, M.D., and Michelle Robertson, and each one of them, attorneys&#8209;in&#8209;fact for the undersigned, each with the power of substitution, for the undersigned in any and all capacities, to sign any and all amendments to this annual report on Form 10&#8209;K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys&#8209;in&#8209;fact, or his or her substitutes, may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his/her name.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.82%;"/>
    <td style="width:8.88%;"/>
    <td style="width:15.02%;"/>
    <td style="width:17.98%;"/>
    <td style="width:5.32%;"/>
    <td style="width:18.36%;"/>
    <td style="width:6.34%;"/>
    <td style="width:4.9%;"/>
    <td style="width:5.38%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="text-indent:10pt;vertical-align:middle;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">John A. Scarlett</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board (Principal Executive Officer)</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">JOHN A. SCARLETT</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Michelle Robertson</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Finance, Chief</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial Officer and Treasurer (Principal</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial and Accounting Officer)</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MICHELLE ROBERTSON</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ GAURAV AGGARWAL</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GAURAV AGGARWAL</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Dawn C. Bir</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DAWN C. BIR</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">V. Bryan Lawlis</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">V. BRYAN LAWLIS</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="text-indent:10pt;vertical-align:middle;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">John McDonald</span></p></td>
    <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">JOHN F. McDONALD</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="text-indent:10pt;vertical-align:middle;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Susan Molineaux</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SUSAN M. MOLINEAUX</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Elizabeth G. O&#8217;Farrell</span></p></td>
    <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ELIZABETH G. O&#8217;FARRELL</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Robert J. Spiegel</span></p></td>
    <td colspan="3" style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 28, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ROBERT J. SPIEGEL</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>gern-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 4.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF CAPITAL STOCK</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">References herein to &#x201c;Geron,&#x201d; &#x201c;our,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and the &#x201c;Company&#x201d; refer only to Geron Corporation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 1,350,000,000 shares of common stock, par value $0.001 per share, and 3,000,000 shares of preferred stock, par value $0.001 per share.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following summary description of our capital stock is based on the provisions of our Restated Certificate, our amended and restated bylaws, as amended, or the Bylaws, and applicable provisions of the Delaware General Corporation Law, or DGCL. This information may not be complete in all respects and is qualified entirely by reference to the applicable provisions of our Restated Certificate, our Bylaws and the DGCL. The Restated Certificate and the Bylaws are filed as exhibits to this Annual Report on Form 10-K to which this Description of Capital Stock is an exhibit.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of our common stock are the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders. Subject to preferences that may be applicable to any outstanding shares of the preferred stock, the holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock legally available for distribution to stockholders. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preferred Stock</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to our Restated Certificate, our board of directors has the authority, without further action by our stockholders, to issue up to 3,000,000 shares of preferred stock in one or more series and to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the common stock. The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of our Company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-takeover Effects of Provisions of Charter Documents and Delaware Law</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Charter Documents. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Restated Certificate and Bylaws contain provisions that could discourage potential takeover attempts and make it more difficult for stockholders to change management, which could adversely affect the market price of our common stock. Our Restated Certificate limits the personal liability for monetary damages for breach of fiduciary duty of our directors to Geron and our stockholders to the fullest extent permitted by the DGCL. The inclusion of this provision in our Restated Certificate may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders or management from bringing a lawsuit against directors for breach of their fiduciary duty. Our Restated Certificate provides that all stockholder action must be effected at a meeting of stockholders and not by a consent in writing.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our Bylaws provide that special meetings of stockholders may only be called by the board of directors pursuant to a resolution adopted by the affirmative vote of a majority of the total number of authorized directors, the chairman of the board of directors, the chief executive officer or president (in the absence of a chief executive officer), or the Secretary following the Secretary&#x2019;s receipt of signed written requests to call a meeting from the holders of at least a majority of the voting power of our capital stock issued and outstanding and entitled to vote. We may postpone, reschedule or cancel any special meeting of stockholders previously scheduled by the board of directors at any time, before or after such notice has been sent to our stockholders. Further, our Bylaws establish procedures, including advance notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals. Finally, our Bylaws provide that our stockholders may alter, amend or repeal our Bylaws or adopt new bylaws only by the affirmative vote of 66&#x2154;% of the outstanding voting stock, but our board of directors may also unilaterally alter, amend, repeal our Bylaws or adopt new bylaws.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Bylaws also provide for the board of directors to be divided into three classes of directors, with each class as nearly equal in number as possible, serving staggered three-year terms. As a result, approximately one-third of the board of directors will be elected each year. The classified board provision could have the effect of discouraging a third party from making a tender offer or attempting to obtain control of us. In addition, the classified board provision could delay stockholders who do not agree with the policies of the board of directors from removing a majority of the board of directors for two years.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions may have the effect of delaying, deferring or preventing a change in control and may also delay or prevent changes in management of Geron, which could have an adverse effect on the market price of our common stock.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delaware Law. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to Section 203 of the DGCL. Section 203 generally prohibits a public Delaware corporation such as us from engaging in a &#34;business combination&#34; with an &#34;interested stockholder&#34; for a period of three years following the time that the stockholder became an interested stockholder, unless:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prior to the time the stockholder became an interested stockholder, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (but not the outstanding voting stock owned by the interested stockholder) (a) those shares owned by persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66&#x2154;% of the outstanding voting stock which is not owned by the interested stockholder.</font>
   </div>
  </div>
  <p style="margin-left:2.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 203 defines a business combination to include:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any merger or consolidation involving the corporation and the interested stockholder;</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% of the aggregate market value, determined on a consolidated basis, of either all of the assets of the corporation or its outstanding stock;</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;">
   <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">&#x2022;</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation.</font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, Section 203 defines an &#x201c;interested stockholder&#x201d; as an entity or person who, together with the person&#x2019;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although Section 203 permits us to elect not to be governed by its provisions, we have not made this election. As a result of the application of Section 203, potential acquirers of Geron may be discouraged from attempting to effect an acquisition transaction with us, thereby possibly depriving holders of our securities of certain opportunities to sell or otherwise dispose of such securities at above-market prices pursuant to such transactions.</font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Choice of Forum</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall be the sole and exclusive forum for the following claims or causes of action under Delaware statutory or common law: (i) any derivative claim or cause of action brought on our behalf; (ii) any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees, or our stockholders, to us or our stockholders; (iii) any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, arising out of or pursuant to any provision of the DGCL, the Restated Certificate or our Bylaws (as each may be amended from time to time); (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Restated Certificate or our Bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (vi) any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, governed by the internal affairs doctrine or otherwise related to our internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.  However, our Bylaws provide that unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision of our Bylaws is intended to benefit and may be enforced by us, our officers and directors, the underwriters for any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Bylaws further provide that any person or entity holding, owning or otherwise acquiring any interest in any security issued by us shall be deemed to have notice of and consented to these choice of forum provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>gern-ex10_23.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html>
 <head>
  <title>EX-10.23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.23</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORIGINALLY ADOPTED BY THE BOARD OF DIRECTORS: MARCH 10, 2014</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AMENDED BY THE BOARD OF DIRECTORS: FEBRUARY 12, 2015, MAY 6, 2015,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FEBRUARY 11, 2016, JANUARY 31, 2018, MAY 15, 2018, OCTOBER 1, 2018,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">JANUARY 30, 2019, FEBRUARY 12, 2020, FEBRUARY 16, 2022, MARCH 7, 2022 AND FEBRUARY 14, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each member of the board of directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Geron Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) who is not an Employee (as defined in the Geron Corporation 2018 Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)) (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will be eligible to receive cash and equity compensation as set forth in this Geron Corporation Non-Employee Director Compensation Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The cash and equity compensation described in this Policy will be paid or granted, as applicable, automatically and without further action of the Board to each Non-Employee Director who is eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Policy, as amended, is effective as of January 1, 2024, and will remain in effect until it is revised or rescinded by further action of the Board. Capitalized terms not explicitly defined in this Policy but defined in the 2018 Plan will have the same definitions as in the 2018 Plan, except when specific reference is made to the Directors&#x2019; Market Value Stock Purchase Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Value Stock Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), in which case such terms will have the definitions set forth in the Market Value Stock Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. CASH COMPENSATION.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Annual Retainers. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Non-Employee Director will be eligible to receive the following annual retainers for service as (i) an individual, member and/or chairperson of the Board and (ii) an individual, member or chairperson of a committee of the Board (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) set forth below, as applicable.</font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.4%;"></td>
    <td style="width:38.88%;"></td>
    <td style="width:14.72%;"></td>
   </tr>
   <tr style="height:10.8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Board or Committee</font></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Retainer*</font></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount (Per Year)</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="border-right:0.75pt solid;text-indent:4.75pt;border-left:0.75pt solid;vertical-align:top;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Board</font></p><p style="margin-left:36.25pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chair</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$40,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lead Independent Director</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$30,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$50,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Audit Committee</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chair</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member (Non-Chair)</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$12,500</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Compensation Committee</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chair</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$15,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member (Non-Chair)</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$7,500</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nominating and Corporate Governance Committee</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chair</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member (Non-Chair)</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$5,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="2" style="border-right:0.75pt solid #000000;text-indent:4.75pt;border-left:0.75pt solid #000000;vertical-align:top;"><p style="margin-left:4.75pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Strategic Committee</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chair</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$15,000</font></p></td>
   </tr>
   <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Member (Non-Chair)</font></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:bottom;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$7,500</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.833%;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.08%;"></td>
    <td style="width:92.92%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">*</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Lead Independent Director and the chairperson of the Board are eligible to receive a retainer for service as the Lead Independent Director or chairperson, as applicable, and an additional retainer for service as a member of the Board. The chairperson of each Committee is eligible to receive a retainer for service as the chairperson, but not an additional retainer for service as a member of the Committee.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The annual retainers will be paid in arrears in four equal quarterly installments, earned upon the completion of service in each calendar quarter. Notwithstanding the foregoing, each person who is elected or appointed to be a Non-Employee Director or who is appointed to serve on one of the Committees set forth above or as the Lead Independent Director or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">chairperson of the Board or one of the Committees set forth above, in each case other than on the first day of a calendar quarter, will be eligible to receive a pro rata amount of the annual retainers described above with respect to the calendar quarter in which such person becomes a Non-Employee Director, a member of one of the Committees, or the Lead Independent Director or chairperson of the Board or one of the Committees, as applicable, which pro rata amount reflects a reduction for each day during the calendar quarter prior to the date of such election or appointment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The annual retainers will be paid on a pro-rata basis in arrears after the end of each quarter in the form of cash, or alternatively, subject to each Non-Employee Director&#x2019;s written election pursuant to the requirements set forth in this paragraph, in the form of fully vested shares of Common Stock on the same date the cash retainer would otherwise have been paid.  Such shares of Common Stock shall be issued under the Market Value Stock Plan based on the Market Value (as defined in the Market Value Stock Plan) for retainers paid for service in and after 2019. Subject to the following sentence, all written elections must be submitted (A) with respect to continuing Non-Employee Directors, in January of each calendar year or (B) with respect to any person who first becomes a Non-Employee Director in any calendar year, in the first month of the next quarter following the quarter in which he or she first became a Non-Employee Director (such elections, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Elections</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and all Annual Elections must also be submitted during an &#x201c;open window period&#x201d; in accordance with the Company&#x2019;s then-effective Insider Trading Compliance Program or any other policy on trading in Company securities and when the Non-Employee Director submitting the Annual Election is not otherwise aware of any material, nonpublic information with respect to the Company or any of its securities (collectively, each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Open Window</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). If a Non-Employee Director is unable to submit an Annual Election within the applicable timeframe set forth in the preceding sentence due to the fact that there were no Open Windows within such applicable timeframe during which an Annual Election could be submitted, then the Annual Election for that calendar year will be due no later than the tenth business day following the commencement of the next Open Window (provided that an Annual Election is actually submitted during such next Open Window). If, as a result of the preceding sentence, an Annual Election for any calendar year is submitted after the date that is thirty days prior to the end of the next quarter, then such Annual Election will be applicable only to the quarters ending after the end of such next quarter. Subject to the preceding sentence, an Annual Election to be paid in Common Stock will be applied to each quarter&#x2019;s payment during the calendar year of such Annual Election.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Expenses. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Non-Employee Director will be eligible for reimbursement from the Company for all reasonable out-of-pocket expenses incurred by the Non-Employee Director in connection with his or her attendance at Board and Committee meetings.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any taxable reimbursements are provided to a Non-Employee Director, they will be provided in accordance with Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and other guidance thereunder and any state law of similar effect, including, but not limited to, the following provisions: (i) the amount of any such expenses eligible for reimbursement during the Non-Employee Director&#x2019;s taxable year may not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense must be made no later than the last day of the Non-Employee Director&#x2019;s taxable year that immediately follows the taxable year in which the expense was incurred; and (iii) the right to any reimbursement may not be subject to liquidation or exchange for another benefit.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. EQUITY COMPENSATION. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The options described in this Policy will be granted under the 2018 Plan and will be subject to the terms and conditions of (i) this Policy, (ii) the 2018 Plan and (ii) the forms of Option Agreements approved by the Board for the grant of options to Non-Employee Directors under the 2018 Plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) Initial Grants. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each person who first becomes a Non-Employee Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy, automatically will be granted a Nonstatutory Stock Option to purchase 270,000 shares of Common Stock (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Director Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on the date of his or her initial election or appointment to be a Non-Employee Director. For the avoidance of doubt, an executive chairman of the Board will not be eligible to receive a First Director Option pursuant to this Section 2(a).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) Annual Grants. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the date of each annual meeting of the Company&#x2019;s stockholders each person who is then a Non-Employee Director and will be continuing as a Non-Employee Director following the date of such annual meeting (other than any Non-Employee Director receiving a First Director Option on the date of such annual meeting) automatically will be granted a Nonstatutory Stock Option to purchase 180,000 shares of Common Stock (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Director Option</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). For</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the avoidance of doubt, an executive chairman of the Board will not be eligible to receive a Subsequent Director Option pursuant to this Section 2(b).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(c) Terms of Options.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:7.987%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The exercise price of each First Director Option and Subsequent Director Option will be equal to 100% of the Fair Market Value of the Common Stock subject to such option (as determined in accordance with the 2018 Plan) on the date such option is granted.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:7.987%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(ii) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Each First Director Option and Subsequent Director Option will vest and become exercisable as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:12.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(A) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each First Director Option will vest and become exercisable in installments cumulatively as to 33 1/3% of the shares of Common Stock subject to such option on each of the first, second and third anniversaries of the date of grant of such option, subject to the Non-Employee Director&#x2019;s Continuous Service through such dates.</font></p>
  <p style="text-indent:12.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:12.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(B) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each Subsequent Director Option will vest and become exercisable as to 100% of the shares of Common Stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company&#x2019;s stockholders (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Next Annual Meeting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or (ii) the first anniversary of the date of grant of such option, subject to the Non-Employee Director&#x2019;s Continuous Service through such dates. For the sake of clarity, if a Non-Employee Director either (x) does not stand for reelection at the Next Annual Meeting and is a member of the class of directors whose term expires at the Next Annual Meeting or (y) otherwise resigns from the Board effective at or on the date of the Next Annual Meeting and, in either case, the Non-Employee Director&#x2019;s Continuous Service terminates at or on the date of the Next Annual Meeting, then such Non-Employee Director&#x2019;s Continuous Service shall be deemed to have continued through the date of the Next Annual Meeting for purposes of this Policy.</font></p>
  <p style="text-indent:12.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:12.107%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(C) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding Sections 2(c)(ii)(A) and 2(c)(ii)(B) above, the vesting of a First Director Option and Subsequent Director Option will be subject to (i) full acceleration in the event of a Change in Control and (ii) partial acceleration in the event of the Non-Employee Director&#x2019;s termination of Continuous Service by reason of the Non-Employee Director&#x2019;s Disability or death pursuant to, and in accordance with, the 2018 Plan and each Option Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>4
<FILENAME>gern-ex10_30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<html>
 <head>
  <title>EX-10.30</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">EXHIBIT 10.30</font></p></div>
  <p style="margin-left:80.08%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Geron Corporation</font></p>
  <p style="margin-left:80.08%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;min-width:fit-content;">919 E. Hillsdale Blvd., Suite 250 Foster City, CA 94404</font></p>
  <p style="margin-left:80.08%;font-size:10pt;margin-top:1.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+1 650 473 7700 </font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;min-width:fit-content;">main</font></p>
  <p style="margin-left:80.08%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;min-width:fit-content;">+1 650 473 7750 </font><font style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:'Calibri',sans-serif;min-width:fit-content;">fax</font></p>
  <p style="margin-left:80.08%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font><font style="white-space:pre-wrap;font-size:7pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.geron.com</font></font></p>
  <p style="font-size:10pt;margin-top:3.75pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.278%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:10.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:7.465%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.407%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Employment Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) is made effective as of July 9, 2022 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;), by and between Faye Feller (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) and Geron Corporation, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) with corporate offices in Parsippany, New Jersey and Foster City, California.</font></p>
  <p style="margin-left:1.293%;text-indent:7.466%;font-size:10pt;margin-top:13.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.417%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive&#x2019;s services;</font></p>
  <p style="margin-left:1.293%;text-indent:7.469%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.454%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; and</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, Executive will be assigned to the Company&#x2019;s Parsippany, New Jersey office.</font></p>
  <p style="margin-left:1.293%;text-indent:7.473%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.5%;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Now, Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.278%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE I</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.296%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">DEFINITIONS</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For purposes of the Agreement, the following terms are defined as follows:</font></p>
  <div style="margin-left:8%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="margin-left:8%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means any of the following:</font></div></div>
  <div style="margin-left:1.333%;text-indent:14.947%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:3.5138394802720265%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">any willful act or omission by Executive constituting dishonesty, fraud or other malfeasance against the Company;</font></div></div>
  <div style="margin-left:1.333%;text-indent:14.947%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:3.5138394802720265%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive&#x2019;s conviction of a felony under the laws of the United States or any state thereof or any other jurisdiction in which the Company conducts business;</font></div></div>
  <div style="margin-left:1.333%;text-indent:14.947%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:3.5138394802720265%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive&#x2019;s debarment by the U.S. Food and Drug Administration (FDA) from working in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992, or other ineligibility under any law or regulation to perform Executive&#x2019;s duties to the Company; or</font></div></div>
  <div style="margin-left:14.667%;display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:3.905874632322783%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive&#x2019;s breach of any of the material policies of the Company.</font></div></div>
  <div style="margin-left:8%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Equity Incentive Plan.</font></div></div>
  <div style="margin-left:8%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended.</font></div></div>
  <div style="margin-left:8%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means Geron Corporation or its successors in interest.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">1.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Comparable Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means employment on terms which provide (a) the same or greater rate of base pay or salary as in effect immediately prior to Executive&#x2019;s termination, (b) the same, equivalent or higher job title and level of responsibility as Executive had prior to Executive&#x2019;s termination,</font></div></div>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.417%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">(c) equivalent or higher bonus opportunity as the bonus opportunity for the year preceding the year in which the termination occurs, and (d) a principal work location that is both (i) no more than forty-five (45) miles from Executive&#x2019;s principal work location immediately prior to Executive&#x2019;s termination and (ii) no more than thirty (30) miles farther from Executive&#x2019;s principal weekday residence than was Executive&#x2019;s principal work location immediately prior to the termination.</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">1.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means an Involuntary Termination Without Cause that occurs at any time, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">that such termination constitutes a &#x201c;separation from service&#x201d; within the meaning of Section 409A of the Code and the regulations promulgated thereunder, including Treasury Regulation Section 1.409A-1(h) (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">1.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Involuntary Termination Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means Executive&#x2019;s dismissal or discharge other than (i) for Cause, or (ii) after an involuntary or voluntary filing of a petition under chapter 7 or 11 of 11 USC Section 101 et. seq., an assignment for the benefit of creditors, a liquidation of the company&#x2019;s assets in formal proceeding or otherwise or any other event of insolvency by the Company, in any case, without an offer of Comparable Employment by the Company or a successor, acquirer, or affiliate of the Company. For purposes of this Agreement, the termination of Executive&#x2019;s employment due to Executive&#x2019;s death or disability will not constitute a termination for Cause.</font></div></div>
  <div style="margin-left:8%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Inducement Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means the Company&#x2019;s 2018 Inducement Award Plan.</font></div></div>
  <div style="margin-left:8%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Calibri;min-width:7.246739130434782%;display:inline-flex;justify-content:flex-start;">1.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Equity Incentive Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d; means the Company&#x2019;s 2018 Equity Incentive Award Plan.</font></div></div>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.259%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE II</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.306%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">EMPLOYMENT BY THE COMPANY</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Position and Duties. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Subject to the terms set forth herein, the Company agrees to employ Executive in the position of Executive Vice President and Chief Medical Officer. During the Executive&#x2019;s employment in this position, Executive will report to the Chief Executive Officer. Executive shall serve in an employee capacity and shall perform such duties as are assigned to Executive by the Chief Executive Officer and, except as otherwise instructed by the Chief Executive Officer, such other duties as are customarily associated with the position of Executive Vice President and Chief Medical Officer. During Executive&#x2019;s employment with the Company, Executive will devote Executive&#x2019;s best efforts and substantially all of Executive&#x2019;s business time and attention (except for vacation periods as set forth herein and reasonable periods of illness or other incapacities permitted by the Company&#x2019;s general employment policies or as otherwise set forth in this Agreement) to the business of the Company.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Employment at Will. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Both the Company and Executive acknowledge and agree that Executive&#x2019;s employment with the Company is &#x201c;at-will&#x201d; and not for any specified period of time, and may be terminated at any time by Executive or the Company, with or without Cause, and with or without prior notice; provided, however, that if Executive&#x2019;s employment with the Company is terminated under circumstances that constitute a Covered Termination, Executive will be eligible to receive certain severance payments and benefits as set forth in Article IV below.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Employment Policies. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including but not limited to</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.444%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">those policies relating to protection of confidential information and assignment of inventions. In the event of a conflict between the terms of this Agreement and the Company&#x2019;s general employment policies or practices, this Agreement shall control.</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Indemnification. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company shall provide for indemnification of the Executive as set forth in the Indemnification Agreement attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.287%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE III</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.287%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">COMPENSATION</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Executive shall receive for services to be rendered hereunder such annual base salary as is approved by the Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) or the Compensation Committee of the Board, payable on the regular payroll dates of the Company, subject to increase in the sole discretion of the Board or Compensation Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;). As of the Effective Date of this agreement, Executive&#x2019;s Base Salary is $445,000.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. As of the Effective Date of this agreement, Executive shall be eligible to earn, for each fiscal year of the Company ending during Executive&#x2019;s employment with the Company, an annual discretionary cash bonus (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) targeted at forty-five percent (45%) of Executive&#x2019;s Base Salary. For the avoidance of doubt, for the 2022 performance year, your target bonus will reflect a blended amount using a target bonus percentage of 45% of base wages earned for the portion of the year you serve as Chief Medical Officer and a target bonus percentage of 40% of base wages earned for the portion of the year you served as Vice President, Clinical Development. Your discretionary Annual Bonus will be paid during the standard timing for year-end performance bonuses. If the Company determines, in its reasonable discretion, that Executive has engaged in any misconduct intended to affect the payment of his/her Annual Bonus or has otherwise engaged in any act or omission that would constitute Cause for termination of employment, as defined by Section 1.2 of the Agreement, Executive will automatically and immediately forfeit his/her entire Annual Bonus. If the Annual Bonus has already been paid to Executive, such Annual Bonus will be deemed unearned, and the Company shall have the right to recover the entire amount of the Annual Bonus paid to Executive for the calendar year(s) in which such misconduct or other act or omission constituting Cause occurred. Without limiting the foregoing, any such misconduct or other act or omission constituting Cause will subject Executive to disciplinary action up to and including termination of employment. In addition, any Annual Bonus paid to Executive for the calendar year(s) in which such misconduct or other Cause occurred is subject to recoupment in accordance with The Dodd&#x2013; Frank Wall Street Reform and Consumer Protection Act and any implementing regulations, any other clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable laws, regulations, or statutes. Recovery by the Company of an Annual Bonus in accordance with this Section shall not constitute an event giving rise to a right by Executive to voluntarily terminate his/her employment for Cause based on such recovery by the Company, nor shall it constitute &#x201c;constructive termination&#x201d;, or any similar term or circumstance under the Agreement or any other plan or agreement with the Company.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. In accordance with the terms approved by the Company&#x2019;s Board of Directors, on the Effective Date, the Executive shall receive the following options to purchase: (a) one hundred and twenty (120,000) shares of Company common stock (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Promotion Options&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">), (b) one hundred and eighty thousand (180,000) shares of Company common stock (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Performance Options 180K&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">), and (c) two hundred thousand (200,000) shares of the Company common stock (the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Performance Options 200K&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">). All these stock option grants will have an exercise price for the shares</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.417%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">equal to the fair market value of Company common stock, as reported by the Nasdaq Global Select Market, as of close on July 8, 2022. The shares of the Promotion Options shall vest in equal installments on each monthly anniversary of the Effective Date over a period of 48 months. The shares of Performance Options 180K shall vest in full upon written certification by the Compensation Committee of the Board of the achievement of acceptance for review by the United States Food and Drug Administration (FDA) of a New Drug Application (NDA) for the first imetelstat indication. The shares of the Performance Options 200K shall vest in full upon written certification by the Compensation Committee of the Board of the achievement of regulatory approval by the FDA of an NDA for the first imetelstat indication. All stock options will be granted under the Company&#x2019;s Equity Incentive Plan and shall be subject to and governed by the terms of the Equity Incentive Plan and respective stock option agreements to be entered into between the Company and Executive.</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Standard Company Benefits; Vacation. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive shall be entitled to all rights and benefits for which Executive is eligible under the terms and conditions of the Company&#x2019;s benefit and compensation plans, practices, policies, and programs, as in effect from time to time, that are provided by the Company to its executive employees generally. Except as specifically provided herein, nothing in this Agreement is construed or interpreted to provide greater rights, participation, coverage, or benefits under such benefit plans or programs provided to executive employees pursuant to the terms and conditions of such benefit plans and programs. Executive will be eligible for vacation accruals in accordance with the Company&#x2019;s current time off policy.</font></div></div>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.278%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE IV</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.296%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SEVERANCE BENEFITS AND RELEASE</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Severance Benefits. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If Executive&#x2019;s employment terminates due to a Covered Termination after the date of execution of this Agreement, Executive shall receive:</font></div></div>
  <div style="margin-left:1.333%;text-indent:14.947%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:3.5138394802720265%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Payment of Accrued Obligations Upon Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Upon a termination of Executive&#x2019;s employment for any reason at any time following the Effective Date, the Company shall pay to Executive in a single lump-sum cash payment as soon as administratively practicable following the date of termination, the aggregate amount of Executive&#x2019;s (A) earned but unpaid Base Salary, and (B) accrued but unpaid vacation pay. In addition, Executive shall be promptly paid for incurred but unreimbursed business expenses upon his/her submission of such expenses in accordance with the Company&#x2019;s expense reimbursement policies. The amounts set forth in this Section 4.1(i) are collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;.</font></div></div>
  <div style="margin-left:1.333%;text-indent:14.947%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:3.5138394802720265%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Severance Upon a Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. If Executive&#x2019;s employment terminates due to a Covered Termination at any time after the Effective Date, then, in addition to the Accrued Obligations:</font></div></div>
  <div style="margin-left:1.333%;text-indent:22.421%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.3510089492940902%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive shall be paid target Annual Bonus for the fiscal year in which the termination occurs, prorated for the length of service provided during the calendar year through the termination date, payable in a single lump-sum payment within thirty (30) days following the date of termination;</font></div></div>
  <div style="margin-left:1.333%;text-indent:22.421%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.3510089492940902%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive shall be paid an aggregate amount equal to twelve (12) months of Executive&#x2019;s Base Salary in effect on the date of termination, payable to Executive in a single lump-sum amount on the sixtieth (60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) day following the date of termination;</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.333%;text-indent:22.421%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.3510089492940902%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive and Executive&#x2019;s covered dependents will be eligible to continue their health care benefit coverage as permitted by COBRA (Internal Revenue Code Section 4980B) at the Company&#x2019;s expense for the lesser of (i) twelve (12) months following the Covered Termination, or (ii) until the Executive and/or Executive&#x2019;s covered dependents are no longer eligible for COBRA (for clarification and as an example, in the event Executive is covered by another health plan, etc.). Thereafter, Executive and Executive&#x2019;s covered dependents shall be entitled to maintain coverage for Executive and Executive&#x2019;s eligible dependents at Executive&#x2019;s own expense for the balance of the period that Executive is entitled to coverage under COBRA; and</font></div></div>
  <div style="margin-left:1.333%;text-indent:22.421%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.3510089492940902%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">the Promotion Options and Performance Options, along with any subsequent options or other exercisable equity interest in the Company held by Executive as of the date of termination shall remain outstanding and exercisable through the earlier of (i) the second (2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">) anniversary of the date of termination or (ii) the original expiration date of the option or other equity interest.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.454%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For the avoidance of doubt, all amounts payable under this Agreement shall be subject to applicable federal, state, local or foreign tax withholding requirements.</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Parachute Payments. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If any payment or benefit Executive would receive in connection with a Change in Control from the Company or otherwise (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;), then such Payment shall be reduced to the Reduced Amount. The &#x201c;Reduced Amount&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#x2019;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#x201c;parachute payments&#x201d; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless Executive elects in writing a different order (provided, however, that such election shall be subject to Company approval): reduction of cash payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits. In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of Executive&#x2019;s stock awards unless Executive elects in writing a different order for cancellation.</font></div></div>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.426%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company for general audit purposes shall engage a nationally recognized public accounting firm (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) to perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Accounting Firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive&#x2019;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the Accounting Firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding, and conclusive upon the Company and Executive.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Release. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Notwithstanding the foregoing, Executive&#x2019;s right to receive the amounts provided for in Sections 4.1(ii) and 4.2, and the Change of Control acceleration in any stock option agreement shall be subject to and conditioned upon Executive&#x2019;s execution and non-revocation of a release of claims in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;) (as such form may be modified to take into account changes in the law) within fifty (50) days following the termination date. Such Release shall specifically relate to all of Executive&#x2019;s rights and claims in existence at the time of such execution and shall confirm Executive&#x2019;s obligations under the Proprietary Information Agreement (as defined below). It is understood that Executive has a certain period to consider whether to execute such Release, as set forth in the Release, and Executive may revoke such Release within seven (7) business days after execution. In the event Executive does not execute such Release within the applicable period, or if Executive revokes such Release within the subsequent seven (7) business day period, none of the aforesaid benefits set forth in Sections 4.1(ii), 4.2, and the Change of Control acceleration in any stock option agreement shall be payable to Executive under this Agreement and this Agreement shall be null and void.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Section 409A. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of the Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (a) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service or (b) the date of Executive&#x2019;s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 4.4 shall be paid in a lump sum to Executive (or Executive&#x2019;s estate or beneficiaries), and any remaining payments due under the Agreement shall be paid as otherwise provided herein. For purposes of Section 409A of the Code, Executive&#x2019;s right to receive the payments of compensation pursuant to the Agreement shall be treated as a right to receive a series of separate payments and accordingly, each payment shall at all times be considered a separate and distinct payment.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Mitigation. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination, or otherwise.</font></div></div>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE V</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.287%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">PROPRIETARY INFORMATION OBLIGATIONS</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive agrees to continue to abide by the Proprietary Information and Inventions Agreement (the &#x201c;Proprietary Information and Inventions Agreement&#x201d;) which was completed at Executive&#x2019;s original date of hire.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Remedies. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Executive&#x2019;s duties under the Proprietary Information and Inventions Agreement shall survive termination of Executive&#x2019;s employment with the Company and the termination of this Agreement. Executive acknowledges that a remedy at law for any breach or threatened breach by Executive of the provisions of the Proprietary Information and Inventions Agreement would be inadequate, and Executive therefore agrees that the Company shall be entitled to injunctive relief in case of any such breach or threatened breach.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.278%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE VI</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.287%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">OUTSIDE ACTIVITIES</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No Other Employment. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Except with the prior written consent of the Board, Executive shall not during the term of Executive&#x2019;s employment with the Company, undertake or engage in any other employment, occupation, or business enterprise. Notwithstanding the foregoing, during the term of Executive&#x2019;s employment with the Company, Executive may (a) undertake or engage in any other employment, occupation or business enterprise in which Executive is a passive investor, and/or (b) engage in civic and not-for-profit activities, in each case, so long as such activities do not materially interfere with the performance of Executive&#x2019;s duties hereunder.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No Conflicting Business Interests. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">During the term of Executive&#x2019;s employment by the Company, except on behalf of the Company, Executive shall not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by, or have any business connection with any other person, corporation, firm, partnership, or other entity whatsoever which were known by Executive to compete directly with the Company, throughout the world, in any line of business engaged in (or planned to be engaged in) by the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities of any competitor corporation, so long as Executive&#x2019;s direct holdings in any one such corporation shall not in the aggregate constitute more than 1% of the voting stock of such corporation.</font></div></div>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE VII</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.287%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">NONINTERFERENCE</font></p>
  <p style="margin-left:1.293%;text-indent:7.467%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;margin-right:9.426%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee&#x2019;s employment in order to become an employee, consultant, or independent contractor to or for any pharmaceutical or biotechnology competitor of the Company. Executive&#x2019;s duties under this Article VII shall survive termination of Executive&#x2019;s employment with the Company and the termination of this Agreement.</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:15.278%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE VIII</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.296%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">DEBARMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:7.471%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.472%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">You certify that you have never been: (a) debarred by any relevant authorities, pursuant to any applicable law, including, but not limited to, Section 306(a) and (b) of the US Federal Food, Drug, and Cosmetic Act; (b) convicted of any of the felonies identified among the Exclusion Authorities listed on the</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.417%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">U.S. Department of Health and Human Services (HHS) Office of Inspector General website; or (c) listed as being suspended, debarred, or excluded, or otherwise ineligible to participate in Federal procurement or non-procurement programs, including, but not limited to, being listed on the List of Excluded Individuals/Entities (LEIE) database on the HHS Office of Inspector General website. If you become suspended, debarred, or excluded pursuant to any of the foregoing, you must notify the Company immediately in writing.</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.417%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:9.417%;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.278%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ARTICLE IX</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.16%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:15.269%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">GENERAL PROVISIONS</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Notices. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by telex) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#x2019;s address as listed on the Company payroll.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Section 409A. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">To the extend applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulations or other such guidance that may be issued after the Commencement Date (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201d;). Notwithstanding any provision of this Agreement to the contrary, in the event that following the Commencement Date, the Company determines in good faith that any compensation or benefits payable under this Agreement may not be either exempt from or compliant with Section 409A, the Company may adopt such amendments to this Agreement or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take any other commercially reasonable actions necessary or appropriate to preserve the intended tax treatment of the compensation and benefits payable hereunder, including without limitation actions intended to (i) exempt the compensation and benefits payable under this Agreement from Section 409A, and/or (ii) comply with the requirements of Section 409A, provided, that this Section 8.2 does not, and shall not be construed so as to, create any obligation on the part of the Company to adopt any such amendments, policies or procedures or to take any other such actions or to create any liability on the part of the Company for any failure to do so.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Severability. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed, and enforced in such jurisdiction as if such invalid, illegal, or unenforceable provisions had never been contained herein.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Waiver. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">If either party should waive any breach of any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Complete Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Agreement and Exhibits A, B, and C hereto constitute the entire agreement between Executive and the Company and are the complete, final, and exclusive embodiment of their agreement with regard to this subject matter (except for the Equity Incentive Plan and the Inducement Plan, and any successors thereto). As of the Effective Date, this Agreement supersedes any prior agreement between Executive and the Company or any predecessor employer in its entirety Executive and the Company acknowledge and agree that this Agreement is entered into without reliance on any promise or representation other than those expressly contained herein or therein and cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Counterparts and Electronic Signatures. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. The parties agree that execution of this Agreement by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this Agreement, each party hereby waives any right to raise any defense or waiver based</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:11.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.028%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">upon execution of this Agreement by means of such electronic signatures or maintenance of the executed agreement electronically.</font></p>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:13.4pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Headings. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Successors and Assigns. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors, and administrators, except that Executive may not assign any of Executive&#x2019;s duties hereunder and Executive may not assign any of Executive&#x2019;s rights hereunder, without the written consent of the Company, which shall not be withheld unreasonably.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Arbitration. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In the event of any contractual, statutory or tort dispute or claim relating to or arising out of Executive&#x2019;s employment relationship with the Company (including but not limited to any claims of wrongful termination or age, sex, race, or other discrimination, but not including workers&#x2019; compensation claims), Executive and the Company agree that all such disputes will be finally resolved by binding arbitration conducted by a single neutral arbitrator associated with the American Arbitration Association in Menlo Park, California. Executive and the Company hereby waive their respective rights to have any such disputes or claims tried to a judge or jury. However, the Company agrees that this arbitration provision will not apply to any claim, by either Executive or the Company, for injunctive relief. The administrative costs of any arbitration proceeding between Executive and the Company and the fees and costs of the arbitrator shall be borne by the Company.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Attorneys&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. If either party hereto brings any action to enforce rights hereunder, each party in any such action shall be responsible for its own attorneys&#x2019; fees and costs incurred in connection with such action.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Executive acknowledges that Executive (a) has had the opportunity to discuss this matter with and obtain advice from independent counsel of Executive&#x2019;s own choice and has been advised to do so by the Company, (b) has carefully read and fully understands all the provisions of this Agreement, and (c) is knowingly and voluntarily entering into this Agreement. Executive represents that Executive (i) is familiar with the restrictive covenants set forth in the Proprietary Information and Inventions Agreement and (ii) is fully aware of his/her obligations thereunder.</font></div></div>
  <div style="margin-left:1.333%;text-indent:7.474%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:9.463%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:1.081415265488968%;">9.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Choice of Law. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of New Jersey.</font></div></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:11.95pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, the parties have executed this Agreement on the respective dates set forth</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">below:</font></p>
  <p style="font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.827%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.315%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:13.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:41.293%;text-indent:-11.617%;padding-left:5%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:10.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">	/s/ John Scarlett	 John A. Scarlett, MD</font></p>
  <p style="margin-left:46.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Chairman of the Board, President &amp; CEO</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:3.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:17.467%;text-indent:32.347%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:10.315%;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:7.16%;text-indent:44.687%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:17.472%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Date:		21 &#x2013; Jun - 2022</font></p>
  <p style="font-size:10pt;margin-top:4.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Accepted and agreed this [21] day of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> June	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, 2022,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.28in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:5.5pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">/s/ Faye Feller				</font></p>
  <p style="margin-left:1.293%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Faye Feller</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.54in;min-height:0.19in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>5
<FILENAME>gern-ex10_39.htm
<DESCRIPTION>EX-10.39
<TEXT>
<html>
 <head>
  <title>EX-10.39</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.39</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="text-transform:uppercase;color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTAIN </font><font style="text-transform:uppercase;color:#252525;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONFIDENTIAL</font><font style="text-transform:uppercase;color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="text-transform:uppercase;color:#252525;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PORTIONS</font><font style="text-transform:uppercase;color:#212121;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#x201c;[***]&#x201d;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) is the type that the registrant customarily and actually treats as private or confidential.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THIS </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), dated as of December 14, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendment Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is entered into by and among Geron Corporation, a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), each of its Subsidiaries (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), other than any Excluded Subsidiaries, and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SILICON VALLEY BANK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a division of FIRST-CITIZENS BANK &amp; TRUST COMPANY (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SVB</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), HERCULES CAPITAL, INC., a Maryland corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hercules</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), each as a Lender, the several banks and other financial institutions or entities from time to time party thereto (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and Hercules, in its capacity as administrative agent and collateral agent for itself and the Lender (in such capacity, together with its successors and assigns in such capacity, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Borrower, the Lenders and Agent are parties to a Loan and Security Agreement dated as of September 30, 2020 (as amended by the First Amendment to Loan and Security Agreement, dated as of August 12, 2021 and by the Second Amendment to Loan and Security Agreement, dated June 30, 2022, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Existing Loan and Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Borrower, Lenders and Agent desire to modify the terms of the Existing Loan and Security Agreement as set forth in this Amendment and as further amended, restated, supplemented or otherwise modified from time to time (as set forth in Exhibit B hereto, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan and Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, the parties hereto agree as follows:</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions; Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Terms Defined in Loan and Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan and Security Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The rules of interpretation set forth in Sections 1.3 and 1.4 of the Loan and Security Agreement shall be applicable to this Amendment and are incorporated herein by this reference.</font>
   </div>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amendments to the Existing Loan and Security Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon satisfaction of the conditions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> hereof, the Existing Loan and Security Agreement is hereby amended as follows:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> attached hereto sets forth a clean copy of the Loan and Security Agreement as amended hereby;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> hereto, deletions of the text in the Existing Loan and Security Agreement (including, to the extent included in such </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, each Schedule or Exhibit to the Existing Loan and Security Agreement) are indicated by </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">struck-through text</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and insertions of text are indicated by </font><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bold, double-underlined text</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">References Within Existing Loan and Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Each reference in the Existing Loan and Security Agreement to &#x201c;this Agreement&#x201d; and the words &#x201c;hereof,&#x201d; &#x201c;herein,&#x201d; &#x201c;hereunder,&#x201d; or words of like import, shall mean and be a reference to the Existing Loan and Security Agreement as amended by this Amendment.  This Amendment shall be a Loan Document.</font>
   </div>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conditions of Effectiveness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The effectiveness of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this Amendment shall be subject to the satisfaction of each of the following conditions precedent:</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Agent shall have received this Amendment, executed by Agent, the Lenders and Borrower.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tranche 4 Facility Charge.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On or prior to the Amendment Effective Date, Borrower shall have paid the applicable Tranche 4 Facility Charge, being three hundred thousand dollars ($300,000).  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Representations and Warranties; No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On the Amendment Effective Date, after giving effect to the amendment of the Loan and Security Agreement contemplated hereby: </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The representations and warranties contained in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shall be true and correct in all material respects on and as of the Amendment Effective Date as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Agreement as to such representations and warranties (which updates may be disclosed to Agent); and</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There exist no Events of Default or events that with the passage of time would result in an Event of Default.</font>
   </div>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  To induce Agent and Lender to enter into this Amendment, Borrower hereby confirms, as of the Amendment Effective Date, (a) that the representations and warranties made by it in Section 5 of the Loan and Security Agreement and in the other Loan Documents are true and correct in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; (b) that there has not been and there does not exist a Material Adverse Effect; and (c) that the information included in the Perfection Certificate delivered to Agent on the Second Amendment Closing Date is true and correct in all material respects except for those updates disclosed on Exhibit C attached hereto; provided that, Borrower shall deliver an updated Perfection Certificate to Agent by the end of the day on December 22, 2023 and failure to do so shall constitute an immediate Event of Default. For the purposes of this Section 4, (i) each reference in Section 5 of the Loan and Security Agreement to &#x201c;this Agreement,&#x201d; and the words &#x201c;hereof,&#x201d; &#x201c;herein,&#x201d; &#x201c;hereunder,&#x201d; or words of like import in such Section, shall mean and be a reference to the Loan and Security Agreement as amended by this Amendment, and (ii) any representations and warranties which relate solely to an earlier date shall not be deemed confirmed and restated as of the date hereof (provided that such representations and warranties shall be true, correct and complete as of such earlier date). </font>
   </div>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">Section 5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents Otherwise Not Affected; Reaffirmation; No Novation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly amended pursuant hereto or referenced herein, the Loan and Security Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects.  The Lenders&#x2019; and Agent&#x2019;s execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby reaffirms the grant of security under Section 3.1 of the Loan and Security Agreement, subject to the provisions set forth in Section 3.2 of the Loan and Security Agreement, and hereby reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Loan and Security Agreement and the other Loan Documents.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents.  Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrower&#x2019;s Secured Obligations under or in connection with the Loan and Security Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of Agent&#x2019;s security interest in, (on behalf of itself and the Lenders) security titles to or other liens on any Collateral for the Secured Obligations.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of determining compliance with the conditions specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless Agent shall have received notice from such Lender prior to the Amendment Effective Date specifying its objection thereto.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower hereby fully, finally and forever acquits, quitclaims, releases and discharges Agent and Lenders and their respective officers, directors, employees, agents, successors and assigns of and from any and all obligations, claims, liabilities, damages, demands, debts, liens, deficiencies or cause or causes of action to, of or for the benefit (whether directly or indirectly) of Borrower, at law or in equity, known or unknown, contingent or otherwise, whether asserted or unasserted, whether now known or hereafter discovered, whether statutory, in contract or in tort, as well as any other kind or character of action now held, owned or possessed (whether directly or indirectly) by Borrower on account of, arising out of, related to or concerning, whether directly or indirectly, proximately or remotely (i) the negotiation, review, preparation or documentation of the Loan Documents or any other documents or agreements executed in connection therewith, (ii) the administration of the Loan Documents, (iii) the enforcement, protection or preservation of Agent&#x2019;s and Lenders&#x2019; rights under the Loan Documents, or any other documents or agreements executed in connection therewith, (iv) the negotiation, review, preparation and documentation of this Amendment or any other documents or agreements executed in connection herewith, and/or (v) any action or inaction by Agent or Lender in connection with any such documents, instruments and agreements. </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower acknowledges having read and understood and hereby waives the benefits of Section 1542 of the California Civil Code, which provides as follows (and hereby waives the benefits of any similar law of the state that may be applicable):</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:12.5%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#x201d;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Borrower acknowledges that the foregoing provisions of this Section 5(c) are intended to be a general release with respect to the matters described therein. Borrower does hereby expressly acknowledge and agree that the waivers and releases contained in this Amendment shall not be construed as an admission of and/or the existence of any claims of Borrower against Agent or Lender. Borrower does hereby acknowledge and agree that the value to Borrower of this Amendment and of the covenants and agreements on the part of Lender contained in this Amendment substantially and materially exceeds any and all value of any kind or nature whatsoever of any claims or liabilities waived or released by Borrower hereunder.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Reliance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Each Borrower hereby acknowledges and confirms to Agent and the Lender that such Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person. .</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  Each Borrower agrees to pay to Agent on the Amendment Effective Date the reasonable out-of-pocket costs and expenses of Agent and the Lenders party hereto, and the fees and disbursements of counsel to Agent and the Lenders party hereto (including allocated costs of internal counsel), in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the Amendment Effective Date or after such date. .</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment binds and is for the benefit of the successors and permitted assigns of each party.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governing Law.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  This Amendment and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complete Agreement; Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents..  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Severability of Provisions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment.  Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This Amendment shall constitute a Loan Document. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Electronic Execution of Certain Other Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The words &#x201c;execution,&#x201d; &#x201c;execute&#x201d;, &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Balance Of Page Intentionally Left Blank; Signature Pages Follow</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BORROWER:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Michelle Robertson</font></p>
  <p style="margin-left:46.667%;text-indent:-33.333%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:	Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Third Amendment to Loan and Security Agreement]</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Zhuo Huang</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:		Associate General Counsel</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LENDER:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Zhuo Huang</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:		Associate General Counsel		</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LENDER:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">First-Citizens Bank &amp; Trust Company</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	Peter Sletteland</font></p>
  <p style="margin-left:46.667%;text-indent:-33.333%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title:	Managing Director</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[Signature Page to Third Amendment to Loan and Security Agreement]</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LOAN AND SECURITY AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2020 and is entered into by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) other than any Excluded Subsidiaries, SILICON VALLEY BANK, a California corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SVB</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), HERCULES CAPITAL, INC., a Maryland corporation (&#x201c;Hercules&#x201d;), and the other several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Hercules, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A.	Borrower has requested the Lenders make available to Borrower a loan in an aggregate principal amount of up to One Hundred Fourty-Five Million Dollars ($145,000,000) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B.	The Lenders are willing to make the Term Loan on the terms and conditions set forth in this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, Borrower, Agent and the Lenders agree as follows:</font></p>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS AND RULES OF CONSTRUCTION</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the following capitalized terms shall have the following meanings:</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Account Control Agreement(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any agreement entered into by and among the Agent, Borrower and a third party bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent&#x2019;s first priority security interest in the subject account or accounts.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACH Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the ACH Debit Authorization Agreement in substantially the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit H</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, which account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of a Person, or of any business, line of business or division or other unit of operation of a Person, (b) the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving a merger, consolidation or similar transaction with such other Person, or otherwise causing any Person to become a Subsidiary of Borrower, or (c) the acquisition or exclusive in-licensing of any product, product line or Intellectual Property of or from any other Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Term Loan Advance.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the funding date of any Advance.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance Request</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a request for an Advance submitted by Borrower to Agent in substantially the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, which account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, (b) any Person directly or indirectly owning, controlling or holding with power to vote [***] or more of the outstanding voting securities of another Person or (c) any Person [***] or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities.  As used in the definition of &#x201c;Affiliate,&#x201d; the term &#x201c;control&#x201d; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Loan and Security Agreement, as amended from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amortization Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means July 1, 2024; provided however,  if the Performance Milestone III Interest Only Extension Conditions are satisfied, then January 1, 2025.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti&#x2011;Terrorism Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Blocked Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person:  (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#x201c;terrorism&#x201d; as defined in Executive Order No. 13224, or (e) a Person that is named a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d; on the most current list published by OFAC or other similar list.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower Products</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all products, software, service offerings, technical data or technology currently being designed, manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed or distributed by Borrower since its incorporation.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s Books</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Borrower&#x2019;s or any of its Subsidiaries&#x2019; books and records including ledgers, federal, state, local and foreign tax returns, records regarding Borrower&#x2019;s or its Subsidiaries&#x2019; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any day other than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all cash, cash equivalents and liquid funds.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any (x) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower in which the holders of Borrower&#x2019;s outstanding shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower is the surviving entity or (y) &#x201c;change of control&#x201d;, &#x201c;fundamental change&#x201d; or any comparable term under and as defined in any indenture governing any Permitted Convertible Debt has occurred.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Common Stock, $0.001 par value per share, of the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contingent Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any Hedging Agreement; provided, however, that the term &#x201c;Contingent Obligation&#x201d; shall not include endorsements for collection or deposit in the ordinary course of business.  The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.  For the avoidance of doubt, no Permitted Bond Hedge Transaction or Permitted Warrant Transaction will be considered a Contingent Obligation of Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Copyright License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States of America, any State thereof, or of any other country.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Collaborations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any corporate collaborations, including without limitation: cost-sharing arrangements with collaborative partners, collaborative work on manufacturing process improvements and academic or development collaborations for discovery research projects, arrangements with contract research organizations, preclinical work, animal studies or investigator-sponsored clinical trials or proof of concept studies.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Deposit Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any &#x201c;deposit accounts,&#x201d; as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Disclosure Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain letter, dated the date hereof, delivered by Borrower to Agent.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Disqualified Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Equity Interests that are not Qualified Equity Interests.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or use of the sign &#x201c;$&#x201d; means only lawful money of the United States and not any other currency, regardless of whether that currency uses the &#x201c;$&#x201d; sign to denote its currency or may be readily converted into lawful money of the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dollar Equivalent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is, at any time, (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Agent at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Domestic Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Subsidiary organized under the laws of the United States of America, any State thereof, the District of Columbia, or any other jurisdiction within the United States of America.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Due Diligence Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means $50,000, which fee is due to the Lenders on or/has been paid to the Lenders prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excluded Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) any Deposit Account that is used solely as a payroll account for the employees of Borrower or any of its Subsidiaries or the funds in which consist solely of funds held in trust for any director, officer or employee of such Borrower or Subsidiary or any employee benefit plan maintained by such Borrower or Subsidiary or funds representing deferred compensation for the directors and employees of such Borrower or Subsidiary, collectively not to exceed [***] of the amount to be paid in the ordinary course of business in the then-next payroll cycle, (ii) escrow accounts, Deposit Accounts and trust accounts, in each case holding assets that are pledged or otherwise encumbered pursuant to clauses (vi), (xv), (xviii) or (xxi) of the definition of Permitted Liens (but only to the extent required to be excluded pursuant to the underlying documents entered into in connection with such Permitted Liens in the ordinary course of business), (iii) accounts containing no (zero) balance or (iv) any Deposit Account with a balance less than [***]; provided, that the aggregate balance of all such Deposit Accounts excluded pursuant to this clause (iv) shall at no time exceed [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excluded Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each direct and indirect Subsidiary of the Borrower that is a Foreign Subsidiary (and any Domestic Subsidiary whose only material assets are Equity Interests in one or more Foreign Subsidiaries).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration or any successor thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the monthly net product revenue projections for Borrower, as delivered to Agent 6 months prior to the Tranche 5 Advance, for a period covering at least 6 months preceding the Tranche 5 Advance, in the event Borrower elects to comply with Performance Covenant C, and every 6 month period thereafter in the event Borrower elects to comply with Performance Covenant C, in each case, in form and substance reasonably acceptable to Lenders; provided however, that Borrower may from time</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to time update the Forecast with a forecast approved by the board of directors of the Borrower and deliver such updated Forecast to Agent.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means lawful money of a country other than the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foreign Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Subsidiary other than a Domestic Subsidiary.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means generally accepted accounting principles in the United States of America, as in effect from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governmental Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the government of any nation or any political subdivision thereof, whether state, local, territory, province or otherwise, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supranational bodies such as the European Union or the European Central Bank).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Hedging Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement incurred by the Borrower or any of its Subsidiaries not for speculative purposes and entered into in the ordinary course of business.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, (d) Disqualified Equity Interests, (e) &#x201c;earnouts&#x201d;, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature arising out of purchase and sale contracts, and (f) all Contingent Obligations. For the avoidance of doubt no Permitted Warrant Transaction shall be considered Indebtedness of the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Initial Facility Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Three Hundred Ninety Five Thousand Dollars ($395,000), which is payable to the Lenders in accordance with Section 4.1(f).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Insolvency Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other similar relief.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all of Borrower&#x2019;s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; service marks, designs, business names, data base rights, design rights, domain names, moral rights, inventions, confidential information, know-how and other intellectual property rights and interests whether registered or unregistered; Borrower&#x2019;s applications therefor and reissues, extensions, or renewals thereof; and Borrower&#x2019;s goodwill associated with any of the foregoing, together with Borrower&#x2019;s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain Intercreditor Agreement dated as of the Closing Date by and between Hercules (on behalf of itself and its Affiliates party hereto from time to time) and SVB, as may be amended from time to time in accordance with the provisions thereof.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">11</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investment&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means, of any Person, (a) any beneficial ownership (including stock, partnership, limited liability company interests, or other securities) of or in any other Person, (b) any loan, advance or capital contribution to any other Person or (c) any Acquisition.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Internal Revenue Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Janssen License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain License Agreement, dated as of September 15, 2016, by and between Geron Corporation, as licensor, and Janssen Pharmaceuticals Inc., as licensee.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Joinder Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit F</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Copyright License, Patent License, Trademark License or other license of rights or interests.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Advances made under this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements, the Intercreditor Agreement and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Market Capitalization</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date of determination, the product of (a) the number of outstanding shares of Common Stock publicly disclosed in the most recent filing of Borrower with the United States Securities Exchange Commission as outstanding as of such date of determination and (b) the closing price of Borrower&#x2019;s Common Stock (as quoted on Bloomberg L.P.&#x2019;s page or any successor page thereto of Bloomberg L.P. or if such page is not available, any other commercially available source).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a material adverse effect upon: (i) the business, operations, properties, assets or financial condition of Borrower and its Subsidiaries taken as a whole; or (ii) the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Agent or the Lenders to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Agent&#x2019;s Liens on the Collateral or the priority of such Liens.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Term Loan Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means One Hundred Fourty Five Million Dollars ($145,000,000).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a new drug application submitted to the FDA under 21 U.S.C. &#167; 355(b)(1) seeking authorization to commercialize a new drug product in the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NDA Milestone</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) Performance Milestone II; and (ii) the Borrower has [***].</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Non-Disclosure Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain Non-Disclosure Agreement/Confidentiality Agreement by and between the Borrower and Agent, dated as of February 21, 2020.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is the U.S. Department of Treasury Office of Foreign Assets Control.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OFAC Lists</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Patent License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all letters patent of, or rights corresponding thereto, in the United States of America or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America or any other country.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Perfection Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a completed certificate delivered by Borrower to Agent and the Lenders, signed by Borrower entitled &#x201c;Hercules Capital, Inc. Perfection Certificate and Diligence Request&#x201d;.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Borrower, solely during the period such Performance Covenant A is elected, maintains Qualified Cash in an amount not less than forty percent (40%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means satisfaction of each of the following solely during the period such Performance Covenant B is elected: (i) Borrower&#x2019;s Market Capitalization is or exceeds Seven Hundred Fifty Million Dollars ($750,000,000), and (ii) Borrower maintains Qualified Cash in an amount not less than twenty five percent (25%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means from and after [***], Borrower shall, solely during the period such Performance Covenant C is elected, maintain T6M Net Product Revenue of at least 70% of the T6M Net Product Revenue included in the Forecast, with such compliance to be tested at the end of the applicable month during the period such covenant is elected by Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone I</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) the Borrower has publicly announced no later than [***] that the Phase 3 portion of the IMerge clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (&#x201c;MDS&#x201d;) has completed full enrollment of One Hundred Seventy (170) patients, and (ii) Borrower has publicly announced that the planned Phase 3 Refractory MF clinical trial of imetelstat in patients with intermediate-2 or high-risk myelofibrosis (&#x201c;MF&#x201d;) has been initiated with the first patient dosed, in each case, subject to reasonable verification by the Agent (including supporting documentation reasonably requested by the Agent).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone I Interest Only Extension Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean satisfaction of each of the following events: (a) no Event of Default shall have occurred and be continuing; and (b) the Borrower shall have achieved Performance Milestone I on or prior to [***].</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">13</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone II</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) prior to [***], the Borrower has [***], and that [***], such that the [***], and (ii) either [***], in each case, subject to reasonable verification by the Agent (including supporting documentation reasonably requested by Agent), or [***] in, cumulatively, [***] in each case, subject to verification by Agent (including supporting documentation reasonably requested by Agent).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone II Interest Only Extension Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean satisfaction of each of the following events:  (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have achieved the Performance Milestone I Interest Only Extension Conditions on or prior [***]; and (c) the Borrower shall have achieved Performance Milestone II on or prior to [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone III</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) the Borrower has publicly announced that the FDA has approved imetelstat [***] (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FDA Approval Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); and (ii) [***] in each case, subject to reasonable verification by the Agent (including supporting documentation reasonably requested by Agent).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone III Interest Only Extension Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean satisfaction of each of the following events:  (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have achieved the Performance Milestone I Interest Only Extension Conditions on or prior [***]; (c) the Borrower shall have achieved Performance Milestone II on or prior to [***]; and (d) the Borrower shall have achieved Performance Milestone III on or prior to [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Acquisition (including Corporate Collaborations constituting Acquisitions) which is conducted in accordance with the following requirements:</font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of a business or Person or product engaged in a line of business similar, related or complementary to that of the Borrower or its Subsidiaries;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if such Acquisition is structured as a stock acquisition, then the Person so acquired shall either (i) become a wholly-owned Subsidiary of Borrower or of a Subsidiary and the Borrower shall comply, or cause such Subsidiary to comply, with 7.13 hereof or (ii) such Person shall be merged with and into Borrower (with the Borrower being the surviving entity);</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if such Acquisition is structured as the acquisition or exclusive in-licensing of any product, product line or Intellectual Property, such product, product line or Intellectual Property shall be acquired by Borrower, and shall be free and clear of Liens other than Permitted Liens;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Borrower shall have delivered to the Lenders not less than ten (10) nor more than forty five (45) days prior to the date of such Acquisition, notice of such Acquisition together with pro forma projected financial information (to the extent available or applicable), copies of then-current drafts of all material documents relating to such acquisition, and historical financial statements (to the extent available or applicable) for such acquired entity, division or line of business, in each case in form and substance reasonably satisfactory to the Lenders (such approval not to be unreasonably withheld), demonstrating compliance with the covenants set forth in Section 7.20 hereof on a pro forma basis immediately prior to and immediately after the consummation of such transaction and subject to the confidentiality provisions of Section 11.13;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">14</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">both immediately before and immediately after such Acquisition no Event of Default shall have occurred and be continuing; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the cash consideration for the purchase price of such proposed new Acquisition (including, for the avoidance of doubt, any Acquisitions permitted pursuant to clause (iii) of the definition of Permitted Licenses), when taken together with all consideration paid in respect of earnouts, milestones and other similar deferred purchase price consideration as and when paid, in each case by the Borrower with respect thereto, and including the amount of Permitted Indebtedness assumed or to which such assets, businesses or business or ownership interest or shares, or any Person so acquired, remain subject (excluding Indebtedness comprised of performance-based milestones, earnouts, or royalties that qualify as Permitted Indebtedness pursuant to subsection (vi) of the definition thereof and have not been paid) may not exceed [***] with respect to consideration other than Equity Interests of the Borrower, provided, that, for the avoidance of doubt, the remainder of such purchase price may be paid in Equity Interests of the Borrower or the net cash proceeds of any substantially concurrent offering of Equity Interests of the Borrower, in each case, to the extent permitted hereunder.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Bond Hedge Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any call or capped call option (or substantively equivalent derivative transaction) relating to the Common Stock (or other securities or property following a merger event or other change of the Common Stock) purchased by Borrower in connection with the issuance of any Permitted Convertible Debt and as may be amended in accordance with its terms; provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">that the terms, conditions and covenants of each such call option transaction are customary for agreements of such type, as determined in good faith by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Convertible Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Indebtedness of the Borrower that is convertible, at the option of the holders thereof, into shares of Common Stock (or other securities or property following a merger event or other change of the Common Stock), cash or any combination thereof, at the election of the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that such Indebtedness shall (a) not require any scheduled amortization or otherwise require payment of principal prior to, or have a scheduled maturity date, earlier than, [***] after the Term Loan Maturity Date, (b) be unsecured, (c) not be guaranteed by any Subsidiary of Borrower that has not executed a Joinder Agreement and (d) be on terms and conditions customary for Indebtedness of such type, as determined in good faith by the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that any cross-default or cross-acceleration event of default (each howsoever defined) provision contained therein that relates to indebtedness or other payment obligations of Borrower (or any of its Subsidiaries) (such indebtedness or other payment obligations, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cross-Default Reference Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) contains a cure period of at least thirty (30) calendar days (after written notice to the issuer of such Indebtedness by the trustee or to such issuer and such trustee by holders of at least [***] in aggregate principal amount of such Indebtedness then outstanding) before a default, event of default, acceleration or other event or condition under such Cross-Default Reference Obligation results in an event of default under such cross-default or cross-acceleration provision.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of Borrower in favor of the Lenders or Agent arising under this Agreement or any other Loan Document; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(viii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness existing on the Closing Date which is disclosed in Schedule 1A to the Disclosure Letter; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of up to [***] at any time prior to the achievement of Positive Topline Results and, at all times following the achievement of Positive Topline Results, </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">15</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Three Million Dollars ($3,000,000) at any time outstanding, secured by a Lien described in clause (vii) of the defined term &#x201c;Permitted Liens,&#x201d; provided such Indebtedness does not exceed the cost of the assets financed with such Indebtedness;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness to trade creditors incurred in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness incurred in the ordinary course of business (i) with corporate credit cards, merchant cards, purchase cards and debit cards in an amount not to exceed [***] at any time outstanding, and (ii) in connection with cash management services in an amount not to exceed [***] at any time outstanding; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness that also constitutes a Permitted Investment and Indebtedness consisting of obligations under deferred or contingent consideration arrangements (including, without duplication, earn-outs, milestone payments, royalties and other contingent or deferred obligations as long as such obligations are not evidenced by any &#x201c;seller notes&#x201d; or similar Indebtedness in connection with Permitted Acquisitions); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subordinated Indebtedness; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">reimbursement obligations in connection with letters of credit provided by financial institutions other than SVB that are secured by Cash and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed [***] at any time outstanding;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">other unsecured Indebtedness not otherwise permitted hereunder in an amount not to exceed [***] at any time outstanding; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">intercompany Indebtedness as long as each of the obligor and the obligee under such Indebtedness is the Borrower or a Subsidiary that has executed a Joinder Agreement or otherwise in connection solely with Permitted Investments in Subsidiaries of Borrower; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Permitted Convertible Debt not to exceed [***] in principal amount at any one time outstanding;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness to non-Affiliate third parties limited to synthetic royalty participations (and not royalty purchases or buyouts) and specific asset-level financings, in each case to the extent such Indebtedness is subordinated to the Secured Obligations in amounts and on terms and conditions reasonably satisfactory to the Agent and the Lenders (collectively, the &#x201c;Permitted Third Party Financings&#x201d;); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">obligations under any Hedging Agreement entered into in the ordinary course of business for non-speculative purposes in an aggregate amount not to exceed [***] at any time outstanding;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Licenses, solely to the extent involving the incurrence of Permitted Indebtedness;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">16</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">financing of insurance premiums in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contingent Obligations of Permitted Indebtedness incurred in the ordinary course of business, in each case without duplication for the amount(s) of Permitted Indebtedness otherwise permitted hereunder;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">advances or deposits received in the ordinary course of business from customers or vendors; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness with respect to performance bonds, appeal bonds and other similar obligations, in an aggregate amount not to exceed [***] at any time outstanding; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">guarantees of the obligations of suppliers, customers and licensees of the Borrower incurred to third parties for the purpose of enabling such suppliers, customers and licensees to purchase products that will be supplied, or incorporated into products that will be supplied, to the Borrower by such suppliers, customers or licensees, in an amount not to exceed [***] in the aggregate in any fiscal year.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Investment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments existing on the Closing Date which are disclosed in Schedule 1B to the Disclosure Letter;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least A-2 or P-2 from either Standard &amp; Poor&#x2019;s Corporation or Moody&#x2019;s Investors Services, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard &amp; Poor&#x2019;s Corporation or Moody&#x2019;s Investors Service, (c) certificates of deposit issued by any bank with assets of at least [***] maturing no more than one year from the date of investment therein, (d) money market accounts and (e) other Investments described in Borrower&#x2019;s investment policy as approved by Agent in writing and the Borrower&#x2019;s Board of Directors from time to time;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(A) repurchases of shares or stock from former or current employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed [***] in any fiscal year or (B) equity derivatives and stock repurchases (including without limitation by means of accelerated stock repurchases and forward purchases) as permitted by Section 7.7, in each case provided that no Event of Default has occurred, is continuing or would exist immediately after giving effect to such derivatives or repurchases; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments accepted in connection with Permitted Transfers; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments (including debt obligations) (a) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent or doubtful obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower&#x2019;s business and (b) consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">17</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee share or stock purchase plans or other similar agreements approved by Borrower&#x2019;s Board of Directors; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of travel advances, relocation loans, and other loan advances (or guarantees thereof) to employees, officers and directors in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments (A) in Borrower and (B) in Subsidiaries that have entered into a Joinder Agreement and executed such other documents as shall be reasonably requested by Agent; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments in Subsidiaries that have not executed a Joinder Agreement in an aggregate amount not to exceed [***] in any fiscal year;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">joint ventures or strategic alliances in the ordinary course of Borrower&#x2019;s business, provided that any cash Investments by Borrower do not exceed [***] in the aggregate in any fiscal year; provided further, that such joint ventures and strategic alliances shall not include any licenses other than Permitted Licenses;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s entry into (including payments of premiums in connection therewith), and the performance of obligations under, and the receipt of Common Stock upon termination, settlement or unwind of, any Permitted Bond Hedge Transactions and Permitted Warrant Transactions; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Acquisitions; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xl)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Hedging Agreements permitted under clause (xiv) of the definition of Permitted Indebtedness; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xli)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Licenses, to the extent constituting Investments; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Patents assigned by Janssen Biotech, Inc. and its Affiliates; and </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xliii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">additional Investments not otherwise permitted hereunder that do not exceed [***] in the aggregate.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xliv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Janssen License; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">licenses and similar arrangements for the use of Intellectual Property (including Corporate Collaborations not constituting Acquisitions) satisfying each of the following conditions:  (a) such license is entered into in the ordinary course of business, (b) such license could not result in a legal transfer of title of the licensed property, (c) such </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">18</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">license is entered into with non-Affiliate third parties and constitutes an arms-length transaction on commercially reasonably terms, and (d) such license is (x) non-exclusive, (y) exclusive as to territory but only as to discrete geographical areas outside of the United States of America in the ordinary course of business, or (z) exclusive as to any territory including the United States solely with respect to co-promotion, co-development and co-commercialization agreements entered into with counterparties typically party to such agreements in the ordinary course of their business; provided that, solely with respect to this clause (ii)(d)(z), both immediately prior to and upon consummation of any such transaction the Borrower is in compliance with Section 7.20(b) and no Event of Default has occurred and is continuing; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any in-license permitted hereunder that relates [***]; provided that, the consideration paid in connection with such in-license does not exceed [***] and, both immediately prior to and upon consummation of any such in-license, no Event of Default has occurred and is continuing.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means: </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of Agent or the Lenders; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens existing on the Closing Date which are disclosed in Schedule 1C to the Disclosure Letter; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings diligently conducted; provided, that Borrower maintains adequate reserves therefor on Borrower&#x2019;s Books in accordance with GAAP (to the extent required thereby); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(li)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of Borrower&#x2019;s business and imposed without action of such parties; provided, that the payment thereof is not yet sixty (60) days past due;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(liii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the following deposits, to the extent made in the ordinary course of business:  deposits to secure the performance of obligations (including by way of deposits to secure letters of credit issued to secure the same) under commercial supply and/or manufacturing agreements, deposits under worker&#x2019;s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(liv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens on Equipment or software or other intellectual property constituting purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii) of &#x201c;Permitted Indebtedness&#x201d;;  </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">19</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with Subordinated Indebtedness;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">leasehold interests in leases or subleases (whether as lessor or lessee thereunder) and licenses or sublicenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor (including any non-exclusive licenses of personal property (other than Intellectual Property) granted to third parties in the ordinary course of Borrower&#x2019;s business), if such leases, subleases, licenses or sublicenses do not prohibit granting Agent a security interest therein; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent constituting Liens, Permitted Licenses;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(A) Liens on Cash securing obligations permitted under clause (viii) of the definition of Permitted Indebtedness and (B) security deposits in connection with real property leases, the combination of (A) and (B) in an aggregate amount not to exceed [***] at any time; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with Permitted Third Party Financings; provided that such Liens are limited to the specific assets financed and not all assets or substantially all assets of the Borrower;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">additional Liens not otherwise permitted hereunder in an aggregate amount not to exceed [***] at any time; provided that such liens be limited to specific assets and not all assets or substantially all assets of any Borrower;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens on Cash securing obligations permitted under clause (v) of the definition of Permitted Indebtedness;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of financial institutions arising in connection with Borrower&#x2019;s deposit and/or securities accounts held at such institutions, provided that (i) such accounts are permitted by this Agreement and (ii) Agent has a first priority perfected security interest in the amounts held in such deposit and/or securities accounts other than Excluded Accounts; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with sales, transfers, licenses, sublicenses, leases, subleases or other dispositions of assets in the ordinary course of business and </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">20</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">permitted by Section 7.8 and, in connection therewith, customary rights and restrictions contained in agreements relating to such transactions pending the completion thereof or during the term thereof, and any option or other agreement to sell, transfer, license, sublicense, lease, sublease or dispose of an asset permitted by Section 7.8;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in the nature of deposits, or liens on deposit accounts, to secure (i) the performance of tenders, bids, trade and commercial contracts, licenses and leases, statutory obligations, surety bonds, performance bonds, bank guaranties and other obligations of a like nature incurred in the ordinary course of business (including earnest money deposits in respect of any asset acquisition) or (ii) indemnification obligations relating to any disposition; provided that, in each case, such Liens do not secure Indebtedness for borrowed money and are incurred in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">good faith deposits required in connection with any Permitted Acquisition in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent constituting Liens, escrow arrangements securing indemnification obligations associated with any acquisition;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type described in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">sales, transfers or other dispositions of Inventory in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transfers consisting of Permitted Licenses; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transfers expressly permitted under Sections 7.5, 7.6 or 7.7; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the surrender, waiver or settlement of contractual rights in the ordinary course of business, or the surrender, waiver or settlement of claims and litigation claims (whether or not in the ordinary course of business) as long as no Event of Default has occurred and is continuing;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the use of cash and cash equivalents subject to the restrictions and limitations set forth in the Loan Documents; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">dispositions of Borrower&#x2019;s Investment in Bard1 Life Sciences Limited identified on Schedule 1B to the Disclosure Letter; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Janssen License; </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">21</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">retirements of abandoned or expired Intellectual Property not material to Borrower&#x2019;s business; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">other transfers not otherwise permitted hereunder of assets (other than Intellectual Property) having a fair market value of not more than [***] in the aggregate in any fiscal year. </font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Warrant Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating to Common Stock (or other securities or property following a merger event or other change of the Common Stock) and/or cash (in an amount determined by reference to the price of such Common Stock) sold by Borrower substantially concurrently with any purchase by Borrower of a related Permitted Bond Hedge Transaction and as may be amended in accordance with its terms; provided that (x) that the terms, conditions and covenants of each such call option transaction are customary for agreements of such type, as determined in good faith by the Borrower and (y) such call option transaction would be classified as an equity instrument in accordance with GAAP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Qualified Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means unrestricted Cash of the Borrower maintained in domestic Deposit Accounts or other domestic accounts in the Borrower&#x2019;s name subject to an Account Control Agreement in favor of Agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Qualified Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Equity Interests of Borrower that do not include a cash dividend (other than dividends that are solely payable as and when declared by Borrower&#x2019;s board of directors) and are not mandatorily redeemable by Borrower or any of its Subsidiaries or redeemable at the option of the holder of such Equity Interests, in each case prior to the [***] following the Term Loan Maturity Date (other than redemptions solely for Qualified Equity Interests in such Person and cash in lieu of fractional shares of such Equity Interests and redemptions upon the occurrence of an &#x201c;asset sale&#x201d; or a &#x201c;change in control&#x201d; (or similar event, however denominated) so long as any such redemption requirement becomes operative only after repayment in full (or waiver thereof) of all the Secured Obligations (other than inchoate indemnity obligations); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that an Equity Interest in any Person that is issued to any employee or to any plan for the benefit of employees or by any such plan to such employees shall constitute a Qualified Equity Interest notwithstanding any obligation of Borrower or any Subsidiary to repurchase such Equity Interest in order to satisfy applicable statutory or regulatory obligations or as a result of such employee&#x2019;s termination, death or disability).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Receivables</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) all of Borrower&#x2019;s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Redemption Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any payment of cash in respect of the principal amount of any Permitted Convertible Debt, satisfaction of each of the following events: (a) no Event of Default shall exist or result therefrom, and (b) both immediately before and at all times after such redemption, Borrower&#x2019;s Qualified Cash shall be no less than the sum of [***] of the outstanding Secured Obligations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning specified in Section 11.7.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">22</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, subject to the terms of the Intercreditor Agreement, at any time, the holders of more than 50% of the sum of the aggregate unpaid principal amount of the Term Loan Advances then outstanding.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Requirement of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as to any Person, the certificate of incorporation and by-laws or other organizational or governing documents of such Person, and any law, treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctioned Country</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, at any time, a country or territory which is the subject or target of any Sanctions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctioned Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty&#x2019;s Treasury of the United Kingdom.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain Second Amendment to Loan and Security Agreement, effective as of the Second Amendment Closing Date, by and among the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date on which the Second Amendment is executed by the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Secured Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Borrower&#x2019;s obligations under this Agreement and any Loan Document including any obligation to pay any amount now owing or later arising.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subordinated Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Indebtedness subordinated to the Secured Obligations on terms and conditions satisfactory to the Agent in its sole discretion and subject to a subordination agreement in form and substance satisfactory to Agent in its sole discretion.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">T6M Net Product Revenue</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Borrower&#x2019;s net product revenue (as determined in accordance with GAAP), measured on a trailing six-month basis as of the date of the most recently delivered monthly financial statements in accordance with Section 7.1(a).  For the avoidance of doubt, net product revenue shall not include any of the following to the extent not recognizable as revenue in accordance with GAAP (i) trade, quantity and cash discounts allowed by the Borrower, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustment and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for shipping or other distribution expenses, (v) set-offs and counterclaims, and (vi) any other similar and customary deductions that are typically deducted from gross revenue and not included in net revenue in accordance with GAAP.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">23</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any governmental authority, including any interest, additions to tax or penalties applicable thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#x201c;Term Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> each Tranche 1 Advance, Tranche 2 Advance, Tranche 3 Advance, Tranche 4 Advance, Tranche 5 Advance, Tranche 6 Advance, and any other term loan funds advanced under this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means for any day a per annum rate of interest equal to the greater of either (i) 9.00% plus the prime rate as reported in The Wall Street Journal minus 4.50%, and (ii) 9.00%.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means October 1, 2024; provided, however, that if Borrower achieves Performance Milestone II prior to September 15, 2024, then April 1, 2025, and if Borrower achieves Performance Milestone III prior to March 15, 2025, then October 1, 2025, provided further, that if the applicable day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding Business Day.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain Third Amendment to Loan and Security Agreement, effective as of the Third Amendment Closing Date, by and among the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date on which the Third Amendment is executed by the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trademark License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof or any other country or any political subdivision thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to the Tranche 1A Commitment, all Tranche 1A Advances; with respect to the Tranche 1B Commitment, all Tranche 1B Advances; with respect to the Tranche 2 Commitment, all Tranche 2 Advances; with respect to the Tranche 3 Commitment, all Tranche 3 Advances; with respect to the Tranche 4 Commitment, all Tranche 4 Advances; with respect to the Tranche 5 Commitment, all Tranche 5 Advances; with respect to the Tranche 6 Commitment, all Tranche 6 Advances.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1A Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 1A Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1B Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 1B Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">24</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 2 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 2 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 2 Facility Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means One Hundred and Five Thousand Dollars ($105,000), which is payable to the Lenders in accordance with Section 4.2(d).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 3 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 3 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 3 Facility Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) zero point five percent (0.50%) of the Tranche 3 Commitment amount, due and payable on or prior to the Second Amendment Closing Date, and (ii) [***] of any Tranche 3 Advance, due and payable prior to such Tranche 3 Advance; which is payable to the Lenders in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 4 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 4 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 4 Facility Charge&#x201d; means [***] of the principal amount of any Tranche 4 Advance, due and payable on the Third Amendment Closing Date in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 5 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 5 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 5 Facility Charge&#x201d; means [***] of the principal amount of any Tranche 5 Advance, which is payable to the Lenders in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 6 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 6 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 6 Facility Charge&#x201d; means [***] of the principal amount of any Tranche 6 Advance, which is payable to the Lenders in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent&#x2019;s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term &#x201c;UCC&#x201d; shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">U.S. Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person that is a &#x201c;United States person&#x201d; as defined in Section 7701(a)(30) of the Code.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following terms are defined in the Sections or subsections referenced opposite such terms:</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">25</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:55.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.58%;"></td>
    <td style="width:47.42%;"></td>
   </tr>
   <tr style="height:14.4pt;background-color:#000000;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Defined Term</font></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Section</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Agent</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assignee</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.14</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Borrower</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Claims</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.11</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Collateral</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Confidential Information</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.13</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cross Default Reference Obligation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Permitted Convertible Debt&#x201d;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">End of Term Charge</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Event of Default</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">FDA Approval Date</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Performance Milestone III&#x201d;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Indemnified Person</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lenders</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Market Cap Threshold</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1(a)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maximum Rate</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Open Source License</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.10</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participant Register</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Permitted Third Party Financings</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Permitted Indebtedness&#x201d;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Prepayment Charge</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Publicity Materials</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.19</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Register</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.7</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rights to Payment</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 1 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(ii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 2 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(iii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 3 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(iv)</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 4 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(v)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 5 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(vi)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 6 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(vii)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a &#x201c;Section,&#x201d; &#x201c;subsection,&#x201d; &#x201c;Exhibit,&#x201d; &#x201c;Annex,&#x201d; or &#x201c;Schedule&#x201d; shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement or the Disclosure Letter, as applicable.  Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied; provided that, no effect shall be given to Accounting Standards Codification 842, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (or any other Accounting Standards Codification having similar result or effect) (and related interpretations) to the extent any lease (or similar arrangement) would be required to be treated as a capital lease thereunder where such lease (or arrangement) would have been treated as an operating lease under GAAP as in effect </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">26</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">immediately prior to the effectiveness of such Accounting Standards Codification. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.  For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#x2019;s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement or any other Loan Document, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made without giving effect to any treatment of Indebtedness in respect of convertible debt instruments under Accounting Standards Codification 470-20 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any such Indebtedness in a reduced or bifurcated manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal amount thereof. For the avoidance of doubt, and without limitation of the foregoing, Permitted Convertible Debt shall at all times be valued at the full stated principal amount thereof and shall not include any reduction or appreciation in value of the shares deliverable upon conversion thereof.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">THE LOAN</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advances. </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, the Lenders will severally (and not jointly) make in an amount not to exceed its respective Tranche 1A Commitment, and Borrower agrees to draw, a Term Loan Advance of Twenty Five Million Dollars ($25,000,000) on the Closing Date (the &#x201c;Tranche 1A Advance&#x201d;). </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, beginning on the Closing Date and continuing through June 15, 2021, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 1B Commitment an additional Term Loan Advance in a principal amount of Ten Million Dollars ($10,000,000) (the &#x201c;Tranche 1B Advance&#x201d; and together with the Tranche 1A Advance, each a &#x201c;Tranche 1 Advance&#x201d;).</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of Performance Milestone I, beginning on January 1, 2021 and continuing through December 15, 2021, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 2 Commitment an additional Term Loan Advance in a principal amount of Fifteen Million Dollars ($15,000,000) (the &#x201c;Tranche 2 Advance&#x201d;).</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of Performance Milestone II, beginning on the date of satisfaction of Performance Milestone II and continuing through the earlier date of 30 days following the satisfaction of </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">27</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone II and September 15, 2023, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 3 Commitment an additional Term Loan Advance in a principal amount of Twenty Million Dollars ($20,000,000) (the &#x201c;Tranche 3 Advance&#x201d;).</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of the NDA Milestone, Borrower agrees to draw and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 4 Commitment an additional Term Loan Advance in a principal amount of Thirty Million Dollars ($30,000,000) (the &#x201c;Tranche 4 Advance&#x201d;) on the Third Amendment Closing Date.</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of Performance Milestone III, beginning on September 15, 2023 and continuing through December 15, 2024, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 5 Commitment an additional Term Loan Advance in a principal amount of Twenty Million Dollars ($20,000,000) (the &#x201c;Tranche 5 Advance&#x201d;). </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and conditioned on future approval by each Lender&#x2019;s investment committee, which shall be granted or denied in its sole and unfettered discretion, on or prior to December 31, 2024, Borrower may request, and Lenders may severally (and not jointly) make, an additional Term Loan Advance of $25,000,000 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 6 Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The aggregate outstanding Term Loan Advances may be up to the Maximum Term Loan Amount.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance Request</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least one (1) Business Day before the Closing Date and at least five (5) Business Days before each Advance Date other than the Closing Date) to Agent. The Lenders shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The principal balance shall bear interest thereon from such Advance Date at the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.  The Term Loan Interest Rate will float and change on the day the prime rate changes from time to time.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower will pay interest on each Term Loan Advance on the first Business Day of each month, beginning the month after the applicable Advance Date.  Borrower shall repay the aggregate principal balance of the Term Loan Advances that are outstanding on the day immediately preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style) beginning on the Amortization Date and continuing on the first Business Day of each month thereafter until the Term Loan Advances (other than inchoate indemnity obligations) together with all other Secured Obligations owing in connection therewith are repaid. The entire principal balance of the Term Loan Advances and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date.  Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense.  If a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.  The Lenders will initiate debit entries to the Borrower&#x2019;s account as authorized on the ACH Authorization </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">28</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) on each payment date of all periodic obligations payable to the Lenders under each Term Loan Advance and (ii) reasonable and documented out-of-pocket legal fees and costs incurred by Agent or the Lenders in connection with Section 11.12 of this Agreement; provided that, with respect to clause (i) above, in the event that the Lenders or Agent inform Borrower in writing that the Lenders will not initiate a debit entry to Borrower&#x2019;s account for a certain amount of the periodic obligations due on a specific payment date, Borrower shall pay to the Lenders such amount of periodic obligations in full in immediately available funds on such payment date; provided, further, that, with respect to clause (i) above, if the Lenders or Agent inform Borrower in writing that the Lenders will not initiate a debit entry as described above later than the date that is three (3) Business Days prior to such payment date, Borrower shall pay to the Lenders such amount of periodic obligations in full in immediately available funds on the date that is three (3) Business Days after the date on which the Lenders or Agent notify Borrower of such; provided further that with respect to clause (ii) above (other than fees paid on the Closing Date), Borrower shall pay to the Lenders such amount in full in immediately available funds within ten (10) Business Days of Agent or the Lenders furnishing Borrower an invoice of such out-of-pocket legal fees and costs incurred by Agent or the Lenders.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties&#x2019; intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  If a court of competent jurisdiction shall finally determine that Borrower has actually paid to the Lenders an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower shall be applied as follows:  first, to the payment of the Secured Obligations consisting of the outstanding principal; second, after all principal is repaid, to the payment of the Lenders&#x2019; accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Default Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event any payment is not paid on the scheduled payment date (other than a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#x2019;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower&#x2019;s knowledge of such failure to pay), an amount equal to five percent (5.00%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.2(c) plus five percent (5%) per annum.  In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.2(c) or Section 2.4, as applicable.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prepayment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  At its option upon at least seven (7) Business Days prior written notice to Agent, Borrower may prepay all, or a portion of the outstanding Advances by paying the entire principal balance (or such portion thereof), all accrued and unpaid interest thereon, together with a prepayment charge equal to the following percentage of the Advance amount being prepaid: (i) with respect to each Advance made pursuant to Tranche 1 and Tranche 2, if such Advance amounts are prepaid in any of the first thirty-six (36) months following the Closing Date, 1.50%, and thereafter, 0.00%, and (ii) with respect to each Advance made pursuant to Tranche 3, Tranche 4, Tranche 5, or Tranche 6 after the Second Amendment Closing Date, if such Advance amounts are prepaid in any of the first thirty-six (36) months following the Second Amendment Closing Date, 1.50%, and thereafter, 0.00% (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prepayment Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); provided that any partial prepayment shall be in minimum increments of principal in the amount of $5,000,000 (or such lesser amount as is then outstanding).  If at any time Borrower elects to make a prepayment, and at such time, there are outstanding Advances under multiple Tranches, the Prepayment Charge shall be </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">29</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">determined by applying the amount of such prepayment in the following order: first, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the latest initial funding date; second, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the next latest initial funding date and so on until the entire principal balance of all Advances made hereunder (and all accrued but unpaid interest thereon) is paid in full.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees that the Prepayment Charge is a reasonable calculation of the Lenders&#x2019; lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances.  Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control or any other prepayment hereunder. Notwithstanding the foregoing, Agent and the Lenders agree to waive the Prepayment Charge if Agent and the Lenders (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan Maturity Date. Any amounts paid under this Section shall be applied by Agent to the then unpaid amount of any Secured Obligations (including principal and interest) in such order and priority as Agent may choose in its sole discretion.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">End of Term Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On any date that Borrower partially prepays the outstanding Secured Obligations pursuant to Section 2.5, Borrower shall pay to the Lenders a charge of 6.55% of such Term Loan Advances being repaid. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) in full, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay the Lenders a charge of (x) 6.55% of the aggregate amount of all Term Loan Advances funded minus (y) the aggregate amount of payments made pursuant to Section 2.5 (collectively with any charge made pursuant to Section 2.5, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">End of Term Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the required payment date of such End of Term Charge, the applicable pro rata portion of the End of Term Charge shall be deemed earned by the Lenders as of each date a Term Loan Advance is made.  For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Treatment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each payment (including prepayment) on account of any fee and any reduction of the Term Loan Advances shall be made pro rata according to the Term Commitments of the relevant Lender.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Taxes; Increased Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower, the Agent and the Lenders each hereby agree to the terms and conditions set forth on Addendum 1 attached hereto.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Prepayment Charge and End of Term Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise required by applicable Tax law, Borrower agrees that any Prepayment Charge and any End of Term Charge payable prior to the Term Loan Maturity Date shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower agrees that it is reasonable under the circumstances currently existing and existing as of the Closing Date.  The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure, or by any other means.  Borrower expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of the </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">30</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration.  Borrower agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is the product of an arm&#x2019;s length transaction between sophisticated business people, ably represented by counsel; (b) each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates at the time payment is made; (c) there has been a course of conduct between the Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge in the event of prepayment or acceleration; (d) Borrower shall be estopped from claiming differently than as agreed to in this paragraph.  Borrower expressly acknowledges that its agreement to pay each of the Prepayment Charge and the End of Term Charge to the Lenders as herein described was on the Closing Date and continues to be a material inducement to the Lenders to provide the Term Loan Advances. For U.S. federal and applicable state and local income tax purposes, the parties acknowledge and agree that the Term Loan is being issued with original issue discount within the meaning of Section 1273 of the Code and shall take all tax reporting positions consistent with the foregoing unless otherwise required by a Governmental Authority.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SECURITY INTEREST</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower&#x2019;s right, title, and interest in, to and under all of Borrower&#x2019;s personal property and other assets including without limitation the following (except as set forth herein) whether now owned or hereafter acquired (collectively, the &#x201c;Collateral&#x201d;):  (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property; (g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower&#x2019;s property in the possession or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing; provided, however, that the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the &#x201c;Rights to Payment&#x201d;).  Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Agent&#x2019;s security interest in the Rights to Payment.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the broad grant of the security interest set forth in Section 3.1, above, the Collateral shall not include (a) any property, right or asset held by Borrower to the extent that a grant of a security interest therein is prohibited by any Requirement of Law of a Governmental Authority or constitutes a breach or default under or results in the termination of or requires any consent not obtained under, any contract, license, agreement, instrument or other document evidencing or giving rise to such property, right or asset, except (A) to the extent that the terms in such contract, license, instrument or other document providing for such prohibition, breach, default or termination, or requiring such consent are not permitted under this Agreement or (B) to the extent that such Requirement of Law or the term in such contract, license, agreement, instrument or other document providing for such prohibition, breach, default or termination or requiring such consent is ineffective under Section 9406, 9407, 9408 or 9409 of the UCC (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code of the United States); provided, however, that such security interest shall attach immediately at such time as such Requirement of Law is not effective or applicable, or such prohibition, breach, default or termination is no longer applicable or is waived, and to the extent severable, shall attach </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">31</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">immediately to any portion of the Collateral that does not result in such consequences, (b) any Excluded Accounts, (c) the assets of any non-wholly owned Subsidiaries pursuant to customary restrictions and conditions contained in agreements governing joint ventures or strategic alliances in the ordinary course of business, provided that Borrower has exercised its good faith best efforts to not agree to such contractual limitations, (d) interests in joint ventures that constitute Permitted Investments pursuant to customary restrictions and conditions contained in agreements governing such joint ventures in the ordinary course of business, provided that Borrower has exercised its good faith best efforts to not agree to such contractual limitations, or (e) with respect to shares or stock in Excluded Subsidiaries, more than 65% to the extent that the pledge of more than 65% of such shares or stock of any Excluded Subsidiary would result in an adverse tax consequence to Borrower.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Reserved].</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If this Agreement is terminated, Agent&#x2019;s Lien in the Collateral shall continue until the Secured Obligations (other than inchoate indemnity obligations) are repaid in full in cash.  Upon payment in full in cash of the Secured Obligations (other than inchoate indemnity obligations) and at such time as the Lenders&#x2019; obligation to make credit extensions has terminated, Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower. </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CONDITIONS PRECEDENT TO LOAN</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The obligations of the Lenders to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Initial Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  On or prior to the Closing Date, Borrower shall have delivered to Agent the following:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">other than as permitted pursuant to Schedule 4.4 of the Disclosure Letter, executed copies of the Loan Documents, Account Control Agreements, and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance reasonably acceptable to Agent;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a legal opinion of Borrower&#x2019;s counsel in form and substance reasonably acceptable to Agent; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a certificate executed by Borrower&#x2019;s corporate secretary, which shall attach and contain customary certifications as to: (i) the resolutions of Borrower&#x2019;s board of directors and the financing committee of Borrower&#x2019;s board of directors evidencing approval of the Loan and other transactions evidenced by the Loan Documents; (ii) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower; and (iii) a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified could have a Material Adverse Effect;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">payment of the Due Diligence Fee, Initial Facility Charge and reimbursement of Agent&#x2019;s and the Lenders&#x2019; current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">all certificates of insurance and copies of each insurance policy required hereunder; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">an executed copy of the Perfection Certificate and Addendum 1 thereto; and </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">32</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">such other documents as Agent may reasonably request.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All Advances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  On each Advance Date:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent shall have received (i) an Advance Request for the relevant Advance as required by Section 2.2(b), each duly executed by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Agent may reasonably request.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 2, Borrower shall have paid the applicable Tranche 2 Facility Charge. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 3, Borrower shall have paid the applicable Tranche 3 Facility Charge.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 4, Borrower shall have paid the applicable Tranche 4 Facility Charge. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 5, Borrower shall have paid the applicable Tranche 5 Facility Charge. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 6, (x) each Lender&#x2019;s investment committee shall, in its sole and absolute discretion, have approved the requested Advances, as contemplated by Section  and (y) Borrower shall have paid the Tranche 6 Facility Charge.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  As of the Closing Date and each Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or would reasonably be expected to have a Material Adverse Effect has occurred and is continuing.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Post-Close Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Borrower agrees to deliver all items as required under Schedule 4.4 to the Disclosure Letter within the corresponding timeframes as set forth in Schedule 4.4 to the Disclosure Letter or such later date as Agent may agree in writing in its sole discretion.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES OF BORROWER</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower represents and warrants that:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower is a corporation duly organized, legally existing and in good standing under the laws its state of incorporation, and is duly qualified as a foreign corporation in all </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">33</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect.  Borrower&#x2019;s present name, former names (if any), locations, place of formation, taxpayer identification number, organizational identification number and other information are correctly set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower owns the Collateral and the Intellectual Property, free of all Liens, except for Permitted Liens.  Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower&#x2019;s execution, delivery and performance of this Agreement and all other Loan Documents, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower&#x2019;s Certificate or Articles of Incorporation (as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, do not violate any material contract or material agreement or require the consent or approval of any other Person which has not already been obtained.  The individual or individuals executing the Loan Documents are duly authorized to do so.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Since December 31, 2019, no event that has had or would reasonably be expected to have a Material Adverse Effect has occurred and is continuing. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Actions Before Governmental Authorities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as disclosed on the Perfection Certificate, there are no actions, suits or proceedings at law or in equity or by or before any Governmental Authority now pending or, to the knowledge of Borrower, threatened in writing against or affecting Borrower or its property, that is reasonably expected to result in a Material Adverse Effect. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any Governmental Authority, where such violation or default is reasonably expected to result in a Material Adverse Effect.  Borrower is not in default in any manner under any material provision of any agreement or instrument evidencing material Indebtedness, or any other material agreement to which it is a party or by which it is bound.  </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Neither Borrower nor any of its Subsidiaries is an &#x201c;investment company&#x201d; or a company &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; under the Investment Company Act of 1940, as amended.  Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).  Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act.  Neither Borrower nor any of its Subsidiaries is a &#x201c;holding company&#x201d; or an &#x201c;affiliate&#x201d; of a &#x201c;holding company&#x201d; or a &#x201c;subsidiary company&#x201d; of a &#x201c;holding company&#x201d; as each term is defined and used in the Public Utility Holding Company Act of 2005.  Neither Borrower&#x2019;s nor any of its Subsidiaries&#x2019; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#x2019;s Knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.  Borrower and each of its Subsidiaries has obtained all material consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">34</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">None of Borrower, any of its Subsidiaries, or, to Borrower&#x2019;s knowledge, any of Borrower&#x2019;s or its Subsidiaries&#x2019; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.  None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.  None of the funds to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any payment to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Information Correct and Current</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  No written information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained, or, when taken as a whole, contains or will contain any material misstatement of fact or, when taken together with all other such written information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not materially misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to or after the Closing Date, shall be (i) provided in good faith and based on the most current data and information available to Borrower at the time delivered, and (ii) the most current of such projections provided to Borrower&#x2019;s Board of Directors (it being understood that such projections are subject to significant uncertainties and contingencies, many of which are beyond the control of Borrower, that no assurance is given that any particular projections will be realized, and that actual results may differ). </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tax Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, (a) Borrower and its Subsidiaries have filed all federal and state income Tax returns and other material Tax returns that they are required to file, (b) Borrower and its Subsidiaries have duly paid all federal and state income Taxes and other material Taxes or installments thereof that they are required to pay as and when due, except (i) Taxes being contested in good faith by appropriate proceedings and for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP or (ii) to the extent the failure to do so could not reasonably be expected to have a Material Adverse Effect, and (c) to the best of Borrower&#x2019;s knowledge, no proposed or pending Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property material to Borrower&#x2019;s business.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter (as may be supplemented by disclosures provided in the Compliance Certificate or as disclosed to Agent), (i) each of the material registered Copyrights, registered Trademarks and issued Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) no claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the contracts, licenses or agreements </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">35</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">identified in Sections 5(c) and 5(d) of the Perfection Certificate and, to Borrower&#x2019;s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter (as may be supplemented by disclosures provided in the Compliance Certificate or as disclosed to Agent), Borrower has all material rights with respect to Intellectual Property necessary or material in the operation or conduct of Borrower&#x2019;s business as currently conducted and proposed to be conducted by Borrower.  Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower&#x2019;s business, to freely transfer, license or assign Intellectual Property necessary or material in the operation or conduct of Borrower&#x2019;s business as currently conducted and proposed to be conducted by Borrower, without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are material to Borrower&#x2019;s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products except customary covenants in inbound license agreements and equipment leases where Borrower is the licensee or lessee. </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No material software or other materials used by Borrower or any of its Subsidiaries (or used in any Borrower Products or any Subsidiaries&#x2019; products) are subject to an open-source or similar license (including but not limited to the General Public License, Lesser General Public License, Mozilla Public License, or Affero License) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Open Source Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in a manner that would cause such software or other materials to have to be (i) distributed to third parties at no charge or a minimal charge (royalty-free basis); (ii) licensed to third parties to modify, make derivative works based on, decompile, disassemble, or reverse engineer; or (iii) used in a manner that could require disclosure or distribution in source code form.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower Products</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter (as may be supplemented by disclosures provided in the Compliance Certificate or as disclosed to Agent), no material Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation in writing, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any material manner Borrower&#x2019;s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any material future Intellectual Property related to the operation or conduct of the business of Borrower or Borrower Products.  Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower&#x2019;s ownership in any material Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower&#x2019;s knowledge, is there a reasonable basis for any such claim, in each case to where such notice or claim would reasonably be expected to have a Material Adverse Effect.  To Borrower&#x2019;s knowledge, neither Borrower&#x2019;s use of its Intellectual Property nor the production and sale of Borrower Products infringes the valid Intellectual Property or other rights of others in any material respect. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, as may be updated by the Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">36</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as permitted hereunder, Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalization and Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments.  Attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">INSURANCE; INDEMNIFICATION</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Coverage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower&#x2019;s line of business.  Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section 6.3.  Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance for each occurrence.  Borrower has and agrees to maintain a minimum of $2,000,000 of directors&#x2019; and officers&#x2019; insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations (other than inchoate indemnity obligations) outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused as is standard for companies in Borrower&#x2019;s industry and location, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. If Borrower fails to obtain the insurance called for by this Section 6.1 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately due and payable, bearing interest at the then highest rate applicable to the Secured Obligations, and secured by the Collateral.  Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter.  No payments by Agent are deemed an agreement to make similar payments in the future or Agent&#x2019;s waiver of any Event of Default.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall deliver to Agent certificates of insurance that evidence Borrower&#x2019;s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2.  Borrower&#x2019;s insurance certificate shall state Agent (shown as &#x201c;Hercules Capital, Inc., as Agent&#x201d;) is an additional insured for commercial general liability, a lenders loss payable for all risk property damage insurance, subject to the insurer&#x2019;s approval, and a lenders loss payable for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer.  Attached to the certificates of insurance will be additional insured endorsements for liability and lender&#x2019;s loss payable endorsements for all risk property damage insurance.  All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10) days&#x2019; advance written notice shall be sufficient).  Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any of Agent&#x2019;s rights, all of which are reserved.  Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and shall promptly deliver to Agent updated insurance certificates with respect to such policies.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">37</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower agrees to indemnify and hold Agent, the Lenders and their officers, directors, employees, agents, in-house attorneys, representatives and shareholders (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable and documented out-of-pocket attorneys&#x2019; fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting solely from any Indemnified Person&#x2019;s gross negligence or willful misconduct.  This Section 6.3 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.  In no event shall any Indemnified Person be liable on any theory of liability for any special, indirect, consequential or punitive damages (including any loss of profits, business or anticipated savings). This Section 6.3 shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, this Agreement.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COVENANTS OF BORROWER</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall furnish to the Agent the financial statements and reports listed hereinafter (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if Borrower&#x2019;s Market Capitalization is less than [***] for a period of thirty (30) consecutive trading days (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Market Cap Threshold</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), Borrower shall furnish to the Agent and Lenders, as soon as practicable beginning with the month following the trigger of the Market Cap Threshold (and in any event within thirty (30) days) after the end of each month, unaudited monthly non-GAAP financial statements as of the end of such month, including balance sheet and related statements of income accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, all certified by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer; provided that, if Borrower&#x2019;s Market Capitalization is greater than [***] for a period of thirty (30) consecutive trading days following the trigger of the Market Cap Threshold, Borrower shall no longer be required to deliver monthly financials pursuant to this Section 7.1(a); </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if Borrower&#x2019;s Market Capitalization is greater than or equal to the Market Cap Threshold, as soon as practicable (and in any event within forty-five (45) days) after the end of each of the first three calendar quarters, unaudited interim and year-to-date financial statements as of the end of such calendar quarter, including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, certified by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable (and in any event within ninety (90) days) after the end of each fiscal year, unqualified (other than a going concern qualification based on Borrower having negative profits or based on a determination that Borrower has less than twelve (12) months liquidity) audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">38</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied by any management report from such accountants (it being understood that Ernst &amp; Young LLP and any other firm of national standing are reasonably acceptable to Agent);</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(x) if monthly Financial Statements are required to be delivered pursuant to Section 7.1(a), as soon as practicable (and in any event within 30 days) after the end of each such month, a Compliance Certificate in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, or (y) if quarterly Financial Statements are required to be delivered pursuant to Section 7.1(b), as soon as practicable (and in any event within 45 days) after the end of each of the first three calendar quarters and concurrently with the Financial Statements delivered pursuant to Section 7.1(c), a Compliance Certificate in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent not provided pursuant to Section 7.1(a), as soon as practicable (and in any event within 30 days) after the end of each month, a cash balance report;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">promptly after the sending or filing thereof, as the case may be, copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable after the end of each calendar quarter, a report detailing [***] during the calendar quarter just ended; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">annually, within ten (10) days following approval thereof by Borrower&#x2019;s board of directors, a summary of Borrower&#x2019;s annual budget; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">prompt notice if Borrower or any Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">nolo contendere</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. </font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall not, without prior notice to Agent, make any change in its (a) accounting policies or reporting practices, except as required by GAAP or (b) fiscal years or fiscal quarters.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The executed Compliance Certificate, and all Financial Statements required to be delivered pursuant to clauses (c) and (e)  shall be sent via e-mail to [***] and with a copy to [***] provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be faxed to Agent at: [***], attention Account Manager: Geron Corporation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, documents required to be delivered under Sections 7.1(a), (b), (c) or (f) (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower files such documents with the SEC and such documents are publicly available on the SEC&#x2019;s EDGAR filing system or any successor thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the avoidance of doubt, any reports, communications, information or other documents provided pursuant to this Section 7.1 shall be subject to the confidentiality provisions of Section 11.13.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Management Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall permit any representative that Agent or the Lenders authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">39</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, however, that such examinations shall be limited to no more often than twice per fiscal year.  In addition, upon two (2) Business Days&#x2019; prior written notice, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records.  In addition, upon two (2) Business Days&#x2019; prior written notice, Agent or the Lenders shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower.  Such consultations shall not unreasonably interfere with Borrower&#x2019;s business operations.  The parties intend that the rights granted Agent and the Lenders shall constitute &#x201c;management rights&#x201d; within the meaning of 29 C.F.R. Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Agent or the Lenders with respect to any business issues shall not be deemed to give Agent or the Lenders, nor be deemed an exercise by Agent or the Lenders of, control over Borrower&#x2019;s management or policies.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements or other documents to perfect, give the highest priority to Agent&#x2019;s Lien on the Collateral, subject to Permitted Liens which may have priority over Agent&#x2019;s Lien in accordance with applicable law, or otherwise evidence Agent&#x2019;s rights herein.  Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further action that may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby and thereby.  In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and deliver on behalf of Borrower and to file such financing statements (including an indication that the financing statement covers &#x201c;all assets or all personal property other than intellectual property&#x201d; of Borrower in accordance with Section 9-504 of the UCC), collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Agent&#x2019;s name or in the name of Agent as agent and attorney-in-fact for Borrower.  Borrower shall protect and defend Borrower&#x2019;s title to the Collateral and Agent&#x2019;s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for (a) the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b) in connection with refinancing or replacement Indebtedness, (c) (i) purchase money Indebtedness pursuant to its then applicable payment schedule or (ii) Indebtedness owed pursuant to clause (v) of the definition of Permitted Indebtedness and prepaid in the ordinary course of business, (d) prepayment by any Subsidiary of (i) inter-company Indebtedness owed by such Subsidiary to any Borrower, or (ii) if such Subsidiary is not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Borrower, (e) trade debt incurred in the ordinary course of business or (f) as otherwise permitted hereunder or approved in writing by Agent.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in the foregoing, the issuance of, performance of obligations under (including any payments of interest), and conversion, exercise, repurchase, redemption, settlement or early termination or cancellation of (whether in whole or in part and including by netting or set-off) (in each case, whether in cash, Common Stock, or following a merger event or other change of the Common Stock, other securities or property), or the satisfaction of any condition that would permit or require any of the foregoing, any Permitted Convertible Debt shall not constitute a prepayment of Indebtedness by Borrower for the purposes of this Section 7.4; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">40</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Permitted Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of shares of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower&#x2019;s business or in which Borrower now or hereafter holds any interest free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process adverse to the Collateral, the Intellectual Property, or such other property and assets, or any Liens thereon, provided however, that the Collateral and such other property and assets may be subject to Permitted Liens.  Borrower shall not agree with any Person other than Agent or the Lenders not to encumber its property other than pursuant to (a) any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby) and (b) customary restrictions on assets subject to Liens permitted under clause (xv) of the definition of &#x201c;Permitted Liens&#x201d; (in which case, any prohibition or limitation shall only be effective against the cash collateral provided thereto). Borrower shall not enter into or suffer to exist or permit to become effective any agreement that prohibits or limits the ability of any Borrower to create, incur, assume or suffer to exist any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations under the Loan Documents to which it is a party other than (a) this Agreement and the other Loan Documents, (b) any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby), (c) customary restrictions on the assignment of leases, licenses and other agreements, (d) customary restrictions on the assignment, sublicense or sublease of leases, licenses and other agreements, (e) customary restrictions in agreements relating to Corporate Collaborations permitted herein and (f) customary restrictions and conditions contained in agreements governing joint ventures or strategic alliances in the ordinary course of business. Borrower shall cause its Subsidiaries to use commercially reasonable efforts to protect and defend such Subsidiary&#x2019;s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary&#x2019;s property and assets free and clear from any Liens whatsoever (except for Permitted Liens or as otherwise permitted by this Section 7.5), and shall give Agent prompt written notice of any legal process adverse to such Subsidiary&#x2019;s assets in an amount greater than [***]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments. </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, and for the avoidance of doubt, this Section 7.6 shall not prohibit the conversion by holders of (including any payment upon conversion, whether in cash, Common Stock or a combination thereof), or required payment of any principal or premium on (including, for the avoidance of doubt, in respect of a required repurchase in connection with the redemption of Permitted Convertible</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">41</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Debt upon satisfaction of a condition related to the stock price of the Common Stock) or required payment of any interest with respect to, any Permitted Convertible Debt in each case, in accordance with the terms of the indenture governing such Permitted Convertible Debt; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Permitted Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of shares, stock or other Equity Interest other than (i) pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in each case the repurchase or redemption consideration does not exceed the original consideration paid for such shares, stock or Equity Interest, (ii) repurchases of such shares, stock or Equity Interest deemed to occur upon exercise of stock options or warrants if such repurchased shares, stock or Equity Interest represents a portion of the exercise price of such options or warrants, (iii) repurchases of such shares, stock or Equity Interest deemed to occur upon the withholding of a portion of such shares, stock or Equity Interest granted or awarded to a current or former officer, director, employee or consultant to pay for the Taxes payable by such Person upon such grant or award (or upon vesting thereof), (iv) purchases of capital stock pledged as collateral for loans to employees, provided that such purchases do not exceed [***] in the aggregate, (v) [reserved], (vi) purchases of fractional shares of capital stock arising out of stock dividends, splits or combinations or business combinations or in connection with exercises or conversions of options, warrants and other convertible securities, (vii) the payment of the net purchase price in respect of any Permitted Bond Hedge Transaction with the proceeds of the issuance of Permitted Convertible Debt, provided that such purchase price (net of any payments to Borrower in respect of any Permitted Warrant Transaction) is less than [***] of the net proceeds of such Permitted Convertible Debt and (viii) the settlement, unwind or other termination of all or any portion of any Permitted Warrant Transaction by (x) set-off against the concurrent settlement, unwind or other termination of all or any portion of any Permitted Bond Hedge Transaction or (y) delivery of shares of Common Stock, or (b) declare or pay any cash dividend or make any other cash distribution on any class of stock or other Equity Interest, except that a Subsidiary may pay dividends or make other distributions to Borrower or any Subsidiary of Borrower, or (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of [***] in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees, officers or directors in excess of [***] in the aggregate.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, and for the avoidance of doubt, this Section 7.7 shall not prohibit the conversion by holders of (including any payment upon conversion, whether in cash, Common Stock or a combination thereof), or required payment of any principal or premium on (including, for the avoidance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">42</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of doubt, in respect of a required repurchase in connection with the redemption of Permitted Convertible Debt upon satisfaction of a condition related to the stock price of the Common Stock) or required payment of any interest with respect to, any Permitted Convertible Debt in each case, in accordance with the terms of the indenture governing such Permitted Convertible Debt; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Permitted Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except for Permitted Transfers, Borrower shall not, and shall not allow any Subsidiary to, voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Mergers and Consolidations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than (a) Permitted Acquisitions, (a) mergers or consolidations of a Subsidiary which is not a Borrower into another Subsidiary or into Borrower or (b) mergers or consolidations of a Borrower into another Borrower).</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall, and shall cause each of its Subsidiaries to, pay when due all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower or the Collateral or upon Borrower&#x2019;s ownership, possession, use, operation or disposition thereof or upon Borrower&#x2019;s rents, receipts or earnings arising therefrom.  Borrower shall, and shall cause each of its Subsidiaries to, accurately file on or before the due date therefor (taking into account proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed.  Notwithstanding the foregoing, Borrower and its Subsidiaries may contest, in good faith and by appropriate proceedings diligently conducted, Taxes for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days&#x2019; prior written notice to Agent.  Neither Borrower nor any Subsidiary shall suffer a Change in Control.  Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has provided prior written notice to Agent; and (ii) such relocation shall be within the continental United States of America.  Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (w) drug supplies or clinical trial materials utilized in the ordinary course of business, (x) sales of assets made in accordance with Section 7.8, (y) relocations of Equipment having an aggregate value of up to [***], and (z) relocations of Collateral from a location described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter to another location described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">43</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter) unless (i) it has provided prompt written notice to Agent, (ii) such relocation is within the continental United States of America and, (iii) if such relocation is to a third party bailee, if not prohibited by applicable law, it has delivered a bailee agreement in form and substance reasonably acceptable to Agent.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Deposit Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Other than Excluded Accounts, neither Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except with respect to which Agent has an Account Control Agreement. Notwithstanding the foregoing, the accounts described in Section 4.4 to the Disclosure Letter may be maintained without an Account Control Agreement for the period of time required by Section 4.4, so long as Borrower maintains Cash in an amount of not less than the aggregate amount of all Term Loan Advances at all times until all accounts described in Section 4.4 to the Disclosure Letter are subject to Account Control Agreements. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Formation or Acquisition of Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall notify Agent of each Subsidiary formed or acquired (in accordance with the terms hereof) subsequent to the Closing Date and, within thirty (30) days of formation, shall cause any such Subsidiary (unless such Subsidiary is an Excluded Subsidiary) to execute and deliver to Agent a Joinder Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.15</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notification of Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall notify Agent promptly (and in any event within two (2) Business Days) after becoming aware of the occurrence of any Event of Default.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.16</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.17</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower agrees that the proceeds of the Loans shall be used solely to pay related fees and expenses in connection with this Agreement and for working capital and general corporate purposes.  The proceeds of the Loans will not be used in (i) violation of Anti-Corruption Laws or applicable Sanctions, or (ii) for personal, family, household or agricultural purposes. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.18</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.19</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respects with all applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required material governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower&#x2019;s business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti&#x2011;Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti&#x2011;Terrorism Law.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">44</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers and employees and, to the knowledge of Borrower, its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">None of Borrower, any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge of Borrower, any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person.  No Loan, use of proceeds or other transaction contemplated by this Agreement will violate Anti-Corruption Laws or applicable Sanctions.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.20</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pre-FDA Approval Minimum Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If the FDA Approval Date has not occurred, inclusive of any Qualified Cash amounts maintained in accordance with Sections 7.20(c) and 7.20(d) from and after June 1, 2022, Borrower shall at all times maintain Qualified Cash in an amount equal to the greater of (i) not less than fifty percent (50%) of the sum of the outstanding principal amount of the Term Loan Advances, or (ii) not less than $30,000,000.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Post-FDA Approval Performance Covenant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If the FDA Approval Date has occurred, Borrower shall thereafter elect (at its option and at any time) and satisfy any one of the following performance covenants: (i) Performance Covenant A, tested at all times during the period such covenant is elected by Borrower, (ii) Performance Covenant B, tested at all times during the period such covenant is elected by Borrower, or (iii) Performance Covenant C, tested at the end of the applicable month during the period such covenant is elected by Borrower.  Borrower shall indicate its election(s) of the applicable performance covenant(s) during the period covered by the Compliance Certificate delivered pursuant to Section 7.1(d).</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Inclusive of any Qualified Cash amounts maintained in accordance with Sections 7.20(a) (or Section 7.20(b) if applicable) and 7.20(d), from and after the date that Borrower first enters into a transaction described in clause (ii)(d)(z) of the definition of Permitted Licenses, Borrower shall at all times maintain Qualified Cash in an amount of not less than $35,000,000.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Inclusive of any Qualified Cash amounts maintained in accordance with Sections 7.20(a) (or Section 7.20(b) if applicable) and 7.20(c), if Borrower makes cash payment in respect of Permitted Convertible Debt subject to satisfaction of the Redemption Conditions, Borrower shall, at all times thereafter, maintain Qualified Cash in the amount required by the defined term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Redemption Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.21</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall (i) protect, defend and maintain the validity and enforceability of its material Intellectual Property; (ii) promptly advise Agent in writing of material infringements of its Intellectual Property known to Borrower; and (iii) not allow any Intellectual Property material to Borrowers&#x2019; business to be abandoned, forfeited or dedicated to the public without Agent&#x2019;s written consent, in each case subject to Borrower&#x2019;s reasonable discretion and standard commercial practices.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.22</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transactions with Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not and shall not permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such Subsidiary, as the case may be, than </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">45</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">those that might be obtained in an arm&#x2019;s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Reserved]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EVENTS OF DEFAULT</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any one or more of the following events shall be an Event of Default:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower fails to pay any amount due under this Agreement or any of the other Loan Documents on the due date; provided, however, that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#x2019;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower&#x2019;s knowledge of such failure to pay; or</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other Loan Documents, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.19, 7.21, and 7.22) or any other Loan Document, such default continues for more than thirty (30) days after the earlier of the date on which (i) Agent or the Lenders have given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.19, 7.20, 7.21, and 7.22, the occurrence of such default; or </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  A circumstance has occurred that could reasonably be expected to have a Material Adverse Effect; provided that, solely for purposes of this Section 9.3, the following events shall not, in each case in and of itself, constitute a Material Adverse Effect: (a) adverse results or delays in any nonclinical or clinical trial, (b) the failure to achieve any clinical or non-clinical trial goals or objectives, including without limitation, the failure to demonstrate the desired safety or efficacy of any drug or companion diagnostic, (c) the denial, delay or limitation of approval of, or taking of any other regulatory action (e.g., a clinical hold) by the applicable regulatory authority with respect to any drug, delivery system or companion diagnostic, (d) a change in or discontinuation of a strategic partnership or other collaboration or license arrangement so long as the same does not affect the ability of Borrower to perform the Secured Obligations or (e) failure to achieve Performance Milestone I, Performance Milestone II or Performance Milestone III so long as the same does not affect the ability of Borrower to perform the Secured Obligations; or </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any representation or warranty made by Borrower in any Loan Document shall have been false or misleading in any material respect when made or when deemed made; or </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Insolvency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">46</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(vi); or (B) either (i) thirty (30) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) thirty (30) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attachments; Judgments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any material portion of Borrower&#x2019;s assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money (not covered by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in the aggregate, of at least [***], and such judgment remains unsatisfied, unvacated or unstayed for a period of twenty (20) days after the entry thereof, or Borrower is enjoined or in any way prevented by court order from conducting any material part of its business; or</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The occurrence of any default (after giving effect to any grace period or cure period) under any agreement or obligation of Borrower involving any Indebtedness in excess of [***], which has resulted in a right by the holder of such Indebtedness, whether exercised or not, to accelerate the maturity of such Indebtedness, or any early payment is required or unwinding or termination occurs with respect to any Permitted Bond Hedge Transaction or Permitted Warrant Transaction, or any condition giving rise to the foregoing is met, in each case, with respect to which Borrower or its Affiliate is the &#x201c;affected party&#x201d; or &#x201c;defaulting party&#x201d; under the terms of such Permitted Bond Hedge Transaction or Permitted Warrant Transaction, as a result thereof Borrower would be required to make cash payments or otherwise settle any such unwind or termination in cash and if a Material Adverse Effect could reasonably be expected to result from such default, early payment, unwinding or termination.  </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REMEDIES</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the occurrence and during the continuation of any one or more Events of Default, Agent may, and at the direction of the Required Lenders shall, without notice or demand, do any or all of the following: (i) accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.5, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge) shall automatically be accelerated and made due and payable, in each case without any further notice or act); (ii) place a &#x201c;hold&#x201d; on any account maintained with SVB and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral.  In addition, upon the occurrence of any one or more Events of Default, any Lender may stop advancing money or extending credit for Borrower&#x2019;s benefit under this Agreement or under any other agreement between Borrower and such Lender. </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact to:  (a) exercisable following the occurrence and continuation of an Event of Default, (i) sign Borrower&#x2019;s name on any invoice or bill of lading for any account or drafts against account debtors; (ii) demand, collect, sue, and give releases to any account debtor for monies due, settle and adjust disputes and claims about the accounts directly with account debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Agent&#x2019;s or Borrower&#x2019;s name,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">47</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as Agent may elect); (iii) make, settle, and adjust all claims under Borrower&#x2019;s insurance policies; (iv) pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; (v) transfer the Collateral into the name of Agent or a third party as the UCC permits; and (vi) receive, open and dispose of mail addressed to Borrower; (vii) endorse Borrower&#x2019;s name on any checks, payment instruments, or other forms of payment or security; and (viii) notify all account debtors to pay Agent directly.  Borrower hereby appoints Agent as its lawful attorney-in-fact to sign Borrower&#x2019;s name on any documents necessary to perfect or continue the perfection of Agent&#x2019;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Secured Obligations have been satisfied in full and the Loan Documents have been terminated.  Agent&#x2019;s foregoing appointment as Borrower&#x2019;s attorney in fact, and all of Agent&#x2019;s rights and powers, coupled with an interest, are irrevocable until all Secured Obligations have been fully repaid and performed and the Loan Documents have been terminated.  Agent may, and at the direction of the Required Lenders shall, exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral.  All Agent&#x2019;s rights and remedies shall be cumulative and not exclusive.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Collection; Foreclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the occurrence and during the continuance of any Event of Default, Agent may, and at the direction of the Required Lenders shall, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Agent may elect.  Any such sale may be made either at public or private sale at its place of business or elsewhere.  Borrower agrees that any such public or private sale may occur upon ten (10) calendar days&#x2019; prior written notice to Borrower.  Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower.  The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order of priorities:</font>
   </div>
  </div>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	First, to Agent and the Lenders in an amount sufficient to pay in full Agent&#x2019;s and the Lenders&#x2019; reasonable costs and professionals&#x2019; and advisors&#x2019; fees and expenses as described in Section 11.12;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Second, to the Lenders in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Agent may choose in its sole discretion; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Finally, after the full and final payment in Cash of all of the Secured Obligations (other than inchoate obligations), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cumulative Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative.  The exercise </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">48</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">MISCELLANEOUS</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by electronic mail or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to Agent:</font>
   </div>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br>Legal Department<br>Attention:  [***]<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA  94301<br>email: [***]<br>Telephone:  [***]</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Lenders:</font>
   </div>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br>Legal Department<br>Attention:  [***]<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA  94301<br>email: [***]<br>Telephone:  [***]</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SILICON VALLEY BANK<br>505 Howard Street, Floor 3<br>San Francisco, CA 94105<br>Attn: 	[***]<br>Email:  	[***] <br>Telephone:  [***]</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to Borrower:</font>
   </div>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Geron Corporation<br>919 E. Hillsdale Blvd., Suite 250 <br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">49</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foster City, CA 94404<br>Attention:  Executive Vice President and Chief Financial Officer and Chief Legal Officer <br>email:  [***]<br>Telephone: 650-473-7700</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With a copy to:</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COOLEY LLP</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">101 California Street, 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Floor</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, CA 94111</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attn:  [***]e</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Email:  [***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as each party may designate for itself by like notice.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement; Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent&#x2019;s revised proposal letter dated September 1, 2020 and the Non-Disclosure Agreement).  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Neither this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this Section 11.3(b).  The Required Lenders and Borrower party to the relevant Loan Document may, or, with the written consent of the Required Lenders, the Agent and the Borrower party to the relevant Loan Document may, from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the Required Lenders or the Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or modification shall (A) forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan, reduce the stated rate of any interest (or fee payable hereunder) or extend the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby; (B) eliminate or reduce the voting rights of any Lender under this Section 11.3(b) without the written consent of such Lender; (C) reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Borrower from its obligations under the Loan Documents, in each case without the written consent of all Lenders; or (D) amend, modify or waive any provision of Section 11.18 or Addendum 3 without the written consent of the Agent.  Any such waiver and any such amendment, supplement or modification shall apply equally to each Lender and shall be binding upon Borrower, the Lender, the Agent and all future holders of the Loans.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Strict Construction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">50</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The powers conferred upon Agent and the Lenders by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or the Lenders to exercise any such powers.  No omission or delay by Agent or the Lenders at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or the Lenders is entitled, nor shall it in any way affect the right of Agent or the Lenders to enforce such provisions thereafter.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent and the Lenders and shall survive the execution and delivery of this Agreement. Sections 6.3, 11.13, 11.14, 11.15 and 11.17 shall survive the termination of this Agreement, subject in each case to the applicable statute of limitations.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any).  Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents without Agent&#x2019;s express prior written consent, and any such attempted assignment shall be void and of no effect.  Agent and the Lenders may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the benefit of Agent&#x2019;s and the Lenders&#x2019; successors and assigns; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or under the Loan Documents to any party that is a direct competitor of Borrower (as reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender or Agent shall be allowed.  Notwithstanding the foregoing, (x) in connection with any assignment by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party and (y) in connection with a Lender&#x2019;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such assignee as Agent reasonably shall require.  The Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its offices in the United States a register for the recordation of the names and addresses of the Lender(s), and the Term Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Agent and the Lender(s) shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">51</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">each participant and the principal amounts (and stated interest) of each participant&#x2019;s interest in the Loans or other obligations under the Loan Documents (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant's interest in any commitments, loans, its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register.  Borrower agrees that each participant shall be entitled to the benefits of the provisions in Addendum 1 attached hereto (subject to the requirements and limitations therein, including the requirements under Section 7 of Addendum 1 attached hereto (it being understood that the documentation required under Section 7 of Addendum 1 attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 11.7; provided that such participant shall not be entitled to receive any greater payment under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and the other Loan Documents have been negotiated and delivered to Agent and the Lenders in the State of California, and shall have been accepted by Agent and the Lenders in the State of California.  Payment to Agent and the Lenders by Borrower of the Secured Obligations is due in the State of California.  This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consent to Jurisdiction and Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  All judicial proceedings (to the extent that the reference requirement of Section 11.11 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of California.  By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents.  Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2.  Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Mutual Waiver of Jury Trial / Judicial Reference</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.  EACH OF BORROWER, AGENT AND THE LENDERS SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CLAIMS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) ASSERTED BY BORROWER AGAINST AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, THE LENDERS OR THEIR </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">52</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RESPECTIVE ASSIGNEE AGAINST BORROWER.  This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and the Lenders; Claims that arise out of or are in any way connected to the relationship among Borrower, Agent and the Lenders; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the waiver of jury trial set forth in Section 11.11(a) is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County, California.  Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding.    </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.10, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Professional Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower promises to pay Agent&#x2019;s and the Lenders&#x2019; reasonable fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable and documented out-of-pocket attorneys&#x2019; fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable and documented out-of-pocket attorneys&#x2019; and other professionals&#x2019; fees and expenses incurred by Agent and the Lenders after the Closing Date in connection with or related to:  (a) the Loan; (b) the collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or the Lenders in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower&#x2019;s estate, and any appeal or review thereof.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent and the Lenders acknowledge that the Collateral and information provided to Agent and the Lenders by Borrower are confidential and proprietary information of Borrower, if and to the extent such information should reasonably be understood to be confidential (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Accordingly, Agent and the Lenders agree that any Confidential Information shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and the Lenders may disclose any such information:  (a) to its Affiliates and its partners, investors, lenders, directors, officers, employees, agents, advisors, counsel, accountants, counsel, representative and other professional advisors if Agent or the Lenders in their sole discretion determines that any such party should have access to such information in connection with such party&#x2019;s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public or to the extent such information becomes publicly available other than as a result of a breach of this Section or becomes available to Agent or any Lender, or any of their respective Affiliates on a non-confidential basis from a source other than the Borrower; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or the Lenders </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">53</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and any rating agency; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent&#x2019;s or the Lenders&#x2019; counsel; (e) to comply with any legal requirement or law applicable to Agent or the Lenders or demanded by any governmental authority; (f) to the extent reasonably necessary in connection with the exercise of, or preparing to exercise, or the enforcement of, or preparing to enforce, any right or remedy under any Loan Document (including Agent&#x2019;s sale, lease, or other disposition of Collateral after default), or any action or proceeding relating to any Loan Document; (g) to any participant or assignee of Agent or the Lenders or any prospective participant or assignee, provided, that such participant or assignee or prospective participant or assignee is subject to the confidentiality provisions of this Section 11.13; (h) otherwise to the extent consisting of general portfolio information, aggregate datasets, for analyses or reporting, that does not identify Borrower; or (i) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan Documents. Agent&#x2019;s and the Lenders&#x2019; obligations under this Section 11.13 shall supersede all of their respective obligations under the Non-Disclosure Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Assignment of Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower acknowledges and understands that Agent or the Lenders may, subject to Section 11.7, sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Assignee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  After such assignment the term &#x201c;Agent&#x201d; or &#x201c;Lender&#x201d; as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and the Lenders hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Agent and the Lenders shall retain all rights, powers and remedies hereby given.  No such assignment by Agent or the Lenders shall relieve Borrower of any of its obligations hereunder.  Each Lender agrees that in the event of any transfer by it of the promissory note(s) (if any), it will endorse thereon a notation as to the portion of the principal of the promissory note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.15</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Revival of Secured Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower&#x2019;s assets, or if any payment or transfer of Collateral is recovered from Agent or the Lenders.  The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, the Lenders or by any obligee of the Secured Obligations, whether as a &#x201c;voidable preference,&#x201d; &#x201c;fraudulent conveyance,&#x201d; or otherwise, all as though such payment, performance, or transfer of Collateral had not been made.  In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or the Lenders in Cash.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.16</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.17</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">54</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person other than Agent, the Lenders and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely among Agent, the Lenders and the Borrower.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.18</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent and each Lender hereby agree to the terms and conditions set forth on Addendum 3 attached hereto.  Borrower acknowledges and agrees to the terms and conditions set forth on Addendum 3 attached hereto.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.19</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Publicity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties&#x2019; prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party's name (including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties&#x2019; web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the &#34;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Publicity Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#34;); (b) the names of officers of such other parties in the Publicity Materials; and (c) such other parties&#x2019; name, trademarks, servicemarks in any news or press release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i) to the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.13.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.20</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED].</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.21</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Electronic Execution of Certain Other Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The words &#x201c;execution,&#x201d; &#x201c;execute&#x201d;, &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.22</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination Prior to Term Loan Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  So long as Borrower has satisfied the Secured Obligations (other than inchoate indemnity obligations), this Agreement may be terminated prior to the Term Loan Maturity Date by Borrower, effective seven (7) Business Days after written notice of termination is given to Agent.  Those obligations that are expressly specified in this Agreement as surviving this Agreement&#x2019;s termination shall continue to survive notwithstanding this Agreement&#x2019;s termination.  No termination of this Agreement shall in any way affect or impair any right or remedy of Agent or any Lender, nor shall any such termination relieve Borrower of any Secured Obligation to any Lender, until all of the Secured Obligations (other than inchoate indemnity obligations) have been paid and performed in full. Those Secured Obligations that are expressly specified in this Agreement as surviving this Agreement&#x2019;s termination shall continue to survive notwithstanding this Agreement&#x2019;s termination and payment in full of the Secured Obligations then outstanding. </font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(SIGNATURES TO FOLLOW)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">55</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, Borrower, Agent and the Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">BORROWER:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accepted in Palo Alto, California:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LENDERS:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SILICON VALLEY BANK</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">56</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.38</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Table of Addenda, Exhibits and Schedules</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Addendum 1:  	Taxes; Increased Costs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Addendum 2:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Addendum 3:	Agent and Lender Terms</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E:	Compliance Certificate</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit F:	Joinder Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit G:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit H:	[RESERVED]</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit I:	[RESERVED]</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-1:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-2:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-3:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-4:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1	Commitments</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 1 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TAXES; INCREASED COSTS</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Addendum 1:</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Connection Income Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excluded Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Term Commitment pursuant to a law in effect on the date on which (A) such Lender acquires such interest in the Loan or Term Commitment or (B) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2 or Section 4 of this Addendum 1, amounts with respect to such Taxes were payable either to such Lender&#x2019;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#x2019;s failure to comply with Section 7 of this Addendum 1 and (iv) any withholding Taxes imposed under FATCA.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FATCA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among governmental authorities and implementing such Sections of the Code.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">d.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foreign Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Lender that is not a U.S. Person.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">e.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (ii) to the extent not otherwise described in clause (i), Other Taxes.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">f.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Connection Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">g.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">h.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Agent or any Lender, as applicable.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">i.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Borrower and the Agent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payments Free of Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law.  If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2 or Section 4 of this Addendum 1) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment of Other Taxes by Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower shall timely pay to the relevant governmental authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under Section 2 of this Addendum 1 or this Section 4) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant governmental authority.  A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by the Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Lender shall severally indemnify the Agent, within 10 days after demand therefor, for (a) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (b) any Taxes attributable to such Lender&#x2019;s failure to comply with the provisions of Section 11.8 of the Agreement relating to the maintenance of a Participant Register and (c) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant governmental authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error.  Each Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Agent to the Lender from any other source against any amount due to the Agent under this Section 5.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">6.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Evidence of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  As soon as practicable after any payment of Taxes by the Borrower to a governmental authority pursuant to the provisions of this Addendum 1, the Borrower shall deliver to the Agent the original or a certified copy of a receipt issued by such governmental authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Agent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">7.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Status of Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections 7(b)(i), 7(b)(ii) and 7(b)(iv) of this Addendum 1) shall not be required if in the Lender&#x2019;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person,</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">i.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Lender that is a U.S. Person shall deliver to the Borrower and the Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">ii.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), whichever of the following is applicable:</font>
   </div>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">A.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;interest&#x201d; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;business profits&#x201d; or &#x201c;other income&#x201d; article of such tax treaty;</font>
   </div>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">B.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">executed copies of IRS Form W-8ECI;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">C.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit J-1 to the effect that such Foreign Lender is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, a &#x201c;10 percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">U.S. Tax Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or</font>
   </div>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">D.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-2 or Exhibit J-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-4 on behalf of each such direct and indirect partner;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">iii.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Agent to determine the withholding or deduction required to be made; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">iv.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#x2019;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment.  Solely for purposes of this clause (iv), &#x201c;FATCA&#x201d; shall include any amendments made to FATCA after the date of this Agreement.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">8.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Certain Refunds</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to the provisions of this Addendum 1 (including by the payment of additional amounts pursuant to the provisions of this Addendum 1), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under the provisions of this Addendum 1 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant governmental authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 8 (plus any penalties, interest or other charges imposed by the relevant governmental authority) in the event that such indemnified party is required to repay such refund to such governmental authority.  Notwithstanding anything to the contrary in this Section 8, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">9.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Increased Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any change in applicable law shall subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing or maintaining any Term Loan or of maintaining its obligation to make any such Loan, or to reduce the amount of any sum received or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient, the Borrower will pay to such Recipient such additional amount or amounts as will compensate such Recipient for such additional costs incurred or reduction suffered. Failure or delay on the part of any Recipient to demand compensation pursuant to this Section 9 shall not constitute a waiver of such Recipient&#x2019;s right to demand such compensation; provided that the Borrower shall not be required to compensate a Recipient pursuant to this Section 9 for any increased costs incurred or reductions suffered more than nine months prior to the date that such Recipient notifies the Borrower of the change in law giving rise to such increased costs or reductions, and of such Recipient&#x2019;s intention to claim compensation therefor (except that, if the change in law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">10.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each party&#x2019;s obligations under the provisions of this Addendum 1 shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font>
   </div>
  </div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 3 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent and Lender Terms</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the Agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Lender agrees to indemnify the Agent in its capacity as such (to the extent not reimbursed by Borrower and without limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding Term Commitments) in effect on the date on which indemnification is sought under this Addendum 3, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against the Agent in any way relating to or arising out of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Agent under or in connection with any of the foregoing.  The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent in Its Individual Capacity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Person serving as the Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent and the term &#x201c;Lender&#x201d; shall, unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent hereunder in its individual capacity.  Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with Borrower or any Subsidiary or other Affiliate thereof as if such Person were not Agent hereunder and without any duty to account therefor to Lenders. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exculpatory Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Agent shall have no duties or obligations except those expressly set forth herein and in the other Loan Documents.  Without limiting the generality of the foregoing, the Agent shall not:</font>
   </div>
  </div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">be subject to any fiduciary or other implied duties, regardless of whether any default or any Event of Default has occurred and is continuing;</font>
   </div>
  </div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Lenders, provided that the Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or applicable law; and</font>
   </div>
  </div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and the Agent shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by any Person serving as the Agent or any of its Affiliates in any capacity.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Lenders or as the Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross negligence or willful misconduct.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reliance by Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties.  In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of this Agreement or any of the other Loan Documents.  Agent may consult with legal counsel, independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.  Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction.  Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement and the other Loan Documents in accordance with a request of the Lenders, and such request and any action taken or failure to act pursuant thereto shall be binding upon Lenders and all future holders of the Loans.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT E</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Hercules Capital, Inc. (as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA 94301</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to that certain Loan and Security Agreement dated September 30, 2020 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among Hercules Capital, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time party thereto (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and GERON CORPORATION (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending ___________ of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties.  Attached are the required documents supporting the above certification. [The undersigned further certified that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statements and subject to normal year end adjustments) and are consistent from one period to the next except as explained below.]</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.48%;"></td>
    <td style="width:29.42%;"></td>
    <td style="width:23.1%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">REPORTING REQUIREMENT</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">REQUIRED</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CHECK IF ATTACHED</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[Interim Financial Statements</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Monthly within 30 days]</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[Interim Financial Statements</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quarterly within 45 days]</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audited Financial Statements</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FYE within 90 days</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">See SEC filings</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACCOUNTS OF BORROWER AND ITS SUBSIDIARIES AND AFFILIATES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby also confirms the below disclosed accounts represent all depository accounts and securities accounts presently open in the name of the Borrower or Borrower&#x2019;s Subsidiary/Affiliate, as applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each new account that has been opened since delivery of the previous Compliance Certificate is designated below with a &#x201c;*&#x201d;.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.4%;"></td>
    <td style="width:3.16%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.3%;"></td>
    <td style="width:14.3%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Depository AC #</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Institution</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Account Type (Depository / Securities)</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Last Month Ending Account Balance</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Purpose of Account</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BORROWER Name/Address:</font></p></td>
    <td colspan="6" style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="4" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.4%;"></td>
    <td style="width:3.16%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.3%;"></td>
    <td style="width:14.3%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="3" style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SUBSIDIARY / AFFILIATE Name/Address</font></p></td>
    <td colspan="6" style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="7" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 7.20 - Financial Covenants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent applicable, the undersigned hereby confirms that the Borrower is in compliance with Section 7.20 of the Loan Agreement (as applicable, below are the required calculations supporting this certification, as of the date first set forth above).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.58%;"></td>
    <td style="width:52.7%;"></td>
    <td style="width:8.92%;"></td>
    <td style="width:15.8%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Covenant</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Required</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Actual</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">In Compliance?</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-FDA Approval Minimum Cash </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(a) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Greater than or equal to the greater of (i) fifty percent (50%) of the sum of the outstanding principal amount of the Term Loan Advances, or (ii) $30,000,000.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Post-FDA Approval Performance Covenant A<br></font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Performance Covenant A&#x201d; means Borrower at all times maintains Qualified Cash in an amount not less than forty percent (40%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elected: Y/N</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compliance:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Post-FDA Approval Performance Covenant B<br></font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(i) Borrower&#x2019;s Market Capitalization is or exceeds Seven Hundred Fifty Million Dollars ($750,000,000), and (ii) Borrower maintains Qualified Cash in an amount not less than twenty five percent (25%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elected: Y/N</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compliance:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Post-FDA Approval Performance Covenant C<br></font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrower achieves T6M Net Product Revenue of at least 70% of the T6M Net Product Revenue included in the Forecast, determined at the end of the applicable month.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elected: Y/N</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compliance:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective from and after June 1, 2022, or the date that Borrower first enters into a transaction described in clause (ii)(d)(z)] of the definition of Permitted Licenses. See Section 7.20. 	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a)  The amount of Qualified Cash as of the date hereof:  $_________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Is the amount reported in clause (a) equal to or greater than $35,000,000*?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	__ Yes; __ No</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">		If No: not in compliance</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">* Upon the date that Borrower first enters into a transaction described in clause (ii)(d)(z) of the definition of Permitted Licenses, the Qualified Cash Amount shall be permanently increased to $35,000,000.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Very Truly Yours,</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:   _____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Its:	____________________________</font></p>
  <p style="text-indent:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT F</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF JOINDER AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Joinder Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Joinder Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is made and dated as of [          ], 20[  ], and is entered into by and between__________________., a ___________ corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation (as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A.  Subsidiary&#x2019;s Affiliate, [                              ] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) [has entered/desires to enter] into that certain Loan and Security Agreement dated September 30, 2020, with the several banks and other financial institutions or entities from time to time party thereto as lender (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Agent, as such agreement may be amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), together with the other agreements executed and delivered in connection therewith;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B.  Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company&#x2019;s execution of the Loan Agreement and the other agreements executed and delivered in connection therewith;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW THEREFORE, Subsidiary and Agent agree as follows:</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">11.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The recitals set forth above are incorporated into and made part of this Joinder Agreement.  Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">12.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement, Subsidiary represents that it is an entity duly organized, legally existing and in good standing under the laws of [        ], (b) neither Agent nor the Lenders shall have any duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other Loan Documents, (c) that if Subsidiary is covered by Company&#x2019;s insurance, Subsidiary shall not be required to maintain separate insurance or comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d) that as long as Company satisfies the requirements of Section 7.1 of the Loan Agreement, Subsidiary shall not have to provide Agent separate Financial Statements.  To the extent that Agent or the Lenders has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other Loan Documents, those duties, responsibilities or obligations shall flow only to Company and not to Subsidiary or any other Person or entity.  By way of example (and not an exclusive list): (i) Agent&#x2019;s providing notice to Company in accordance with the Loan Agreement or as otherwise agreed among Company, Agent and the Lenders shall be deemed provided to Subsidiary; (ii) a Lender&#x2019;s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (iii) Subsidiary shall have no right to request an Advance or make any other demand on the Lenders.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">13.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary agrees not to certificate its equity securities without Agent&#x2019;s prior written consent, which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect Agent&#x2019;s security interest in such equity securities.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">14.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary acknowledges that it benefits, both directly and indirectly, from the Loan Agreement, and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the fullest extent provided by law, any and all </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">claims, rights or defenses to the enforcement of this Joinder Agreement on the basis that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b) its obligations under this Joinder Agreement are avoidable as a fraudulent conveyance.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">15.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Subsidiary grants to Agent a security interest in all of Subsidiary&#x2019;s right, title, and interest in and to the C</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ollateral</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[SIGNATURE PAGE TO JOINDER AGREEMENT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SUBSIDIARY:</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_________________________________.</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	By:			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Name:			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Title: 			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Address:</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Telephone: ___________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	email: ____________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:0.933%;text-indent:-21.405%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br><br>By:____________________________________<br>Name:__________________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.933%;text-indent:-21.405%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Title: ___________________________________<br><br>Address:<br>400 Hamilton Ave., Suite 310<br>Palo Alto, CA 94301<br>email: legal@htgc.com<br>Telephone:  650-289-3060</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-1</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 (as amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished the Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF LENDER]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-2</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 (as amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF PARTICIPANT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-3</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 as amended, supplemented or otherwise modified from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such participation, (iii) with respect to such participation, neither the undersigned nor any of its direct or indirect partners/members is a &#x201c;bank&#x201d; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#x2019;s/member&#x2019;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF PARTICIPANT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-4</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 (as amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any promissory note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Loan Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is a &#x201c;bank&#x201d; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished the Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#x2019;s/member&#x2019;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF LENDER]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1.1</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COMMITMENTS</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.48%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
    <td style="width:10.94%;"></td>
   </tr>
   <tr style="height:58.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LENDERS</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 1A TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 1B TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 2 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 3 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 4 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 5 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 6 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERM COMMITMENT</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hercules Capital, Inc.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hercules Private Credit Fund 1 L.P.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hercules Private Global Venture Growth Fund I L.P.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Silicon Valley Bank</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TOTAL COMMITMENTS</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000,000</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000,000</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$15,000,000</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$20,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$30,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$20,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$145,000,000*</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*Funding of Tranche 6 is subject to approval by the Lenders&#x2019; investment committee in its sole discretion.</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LOAN AND SECURITY AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2020 and is entered into by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) other than any Excluded Subsidiaries, SILICON VALLEY BANK, a California corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SVB</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), HERCULES CAPITAL, INC., a Maryland corporation (&#x201c;Hercules&#x201d;), and the other several banks and other financial institutions or entities from time to time parties to this Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Hercules, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A.	Borrower has requested the Lenders make available to Borrower a loan in an aggregate principal amount of up to One Hundred </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Twenty</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fourty</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">-Five Million Dollars ($</font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">125</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">145</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,000,000) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B.	The Lenders are willing to make the Term Loan on the terms and conditions set forth in this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, Borrower, Agent and the Lenders agree as follows:</font></p>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">DEFINITIONS AND RULES OF CONSTRUCTION</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the following capitalized terms shall have the following meanings:</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Account Control Agreement(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any agreement entered into by and among the Agent, Borrower and a third party bank or other institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment Property and which perfects Agent&#x2019;s first priority security interest in the subject account or accounts.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACH Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the ACH Debit Authorization Agreement in substantially the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit H</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, which account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in (a) the acquisition of all or substantially all of the assets of a Person, or of any business, line of business or division or other unit of operation of a Person, (b) the acquisition of fifty percent (50%) or more of the Equity Interests of any Person, whether or not involving a merger, consolidation or similar transaction with such other Person, or otherwise causing any Person to become a Subsidiary of Borrower, or (c) the acquisition or exclusive in-licensing of any product, product line or Intellectual Property of or from any other Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Term Loan Advance.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the funding date of any Advance.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">25</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance Request</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a request for an Advance submitted by Borrower to Agent in substantially the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, which account numbers shall be redacted for security purposes if and when filed publicly by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (a) any Person that directly or indirectly controls, is controlled by, or is under common control with the Person in question, (b) any Person directly or indirectly owning, controlling or holding with power to vote [***] or more of the outstanding voting securities of another Person or (c) any Person [***] or more of whose outstanding voting securities are directly or indirectly owned, controlled or held by another Person with power to vote such securities.  As used in the definition of &#x201c;Affiliate,&#x201d; the term &#x201c;control&#x201d; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Loan and Security Agreement, as amended from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amortization Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">November 1, 2022; provided however, if the Performance Milestone I Interest Only Extension Conditions are satisfied, then May 1, 2023, and provided further, if the Performance Milestone II Interest Only Extension Conditions are satisfied, then April 1, 2024, and provided further,</font><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">July 1, 2024; provided however,</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> if the Performance Milestone III Interest Only Extension Conditions are satisfied, then January 1, 2025.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all laws, rules, and regulations of any jurisdiction applicable to Borrower or any of its Affiliates from time to time concerning or relating to bribery or corruption, including without limitation the United States Foreign Corrupt Practices Act of 1977, as amended, the UK Bribery Act 2010 and other similar legislation in any other jurisdictions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Anti&#x2011;Terrorism Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any laws, rules, regulations or orders relating to terrorism or money laundering, including without limitation Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Blocked Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person:  (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#x201c;terrorism&#x201d; as defined in Executive Order No. 13224, or (e) a Person that is named a &#x201c;specially designated national&#x201d; or &#x201c;blocked person&#x201d; on the most current list published by OFAC or other similar list.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower Products</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all products, software, service offerings, technical data or technology currently being designed, manufactured or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service offerings under development, collectively, together with all products, software, service offerings, technical data or technology that have been sold, licensed or distributed by Borrower since its incorporation.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s Books</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Borrower&#x2019;s or any of its Subsidiaries&#x2019; books and records including ledgers, federal, state, local and foreign tax returns, records regarding Borrower&#x2019;s or its Subsidiaries&#x2019; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">26</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any day other than Saturday, Sunday and any other day on which banking institutions in the State of California are closed for business.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all cash, cash equivalents and liquid funds.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any (x) reorganization, recapitalization, consolidation or merger (or similar transaction or series of related transactions) of Borrower, sale or exchange of outstanding shares (or similar transaction or series of related transactions) of Borrower in which the holders of Borrower&#x2019;s outstanding shares immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each case without regard to whether Borrower is the surviving entity or (y) &#x201c;change of control&#x201d;, &#x201c;fundamental change&#x201d; or any comparable term under and as defined in any indenture governing any Permitted Convertible Debt has occurred.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Common Stock, $0.001 par value per share, of the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contingent Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any Indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any Hedging Agreement; provided, however, that the term &#x201c;Contingent Obligation&#x201d; shall not include endorsements for collection or deposit in the ordinary course of business.  The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations under the guarantee or other support arrangement.  For the avoidance of doubt, no Permitted Bond Hedge Transaction or Permitted Warrant Transaction will be considered a Contingent Obligation of Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Copyright License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States of America, any State thereof, or of any other country.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Collaborations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any corporate collaborations, including without limitation: cost-sharing arrangements with collaborative partners, collaborative work on manufacturing process improvements and academic or development collaborations for discovery research projects, arrangements with contract research organizations, preclinical work, animal studies or investigator-sponsored clinical trials or proof of concept studies.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">27</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Deposit Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any &#x201c;deposit accounts,&#x201d; as such term is defined in the UCC, and includes any checking account, savings account, or certificate of deposit.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disclosure Letter&#x201d; means that certain letter, dated the date hereof, delivered by Borrower to Agent.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Disqualified Equity Interests&#x201d; means any Equity Interests that are not Qualified Equity Interests.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or use of the sign &#x201c;$&#x201d; means only lawful money of the United States and not any other currency, regardless of whether that currency uses the &#x201c;$&#x201d; sign to denote its currency or may be readily converted into lawful money of the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dollar Equivalent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is, at any time, (a) with respect to any amount denominated in Dollars, such amount, and (b) with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Agent at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Domestic Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Subsidiary organized under the laws of the United States of America, any State thereof, the District of Columbia, or any other jurisdiction within the United States of America.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Due Diligence Fee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means $50,000, which fee is due to the Lenders on or/has been paid to the Lenders prior to the Closing Date, and shall be deemed fully earned on such date regardless of the early termination of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Person, the capital stock, partnership or limited liability company interest, or other equity securities or equity ownership interests of such Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Excluded Accounts&#x201d; means (i) any Deposit Account that is used solely as a payroll account for the employees of Borrower or any of its Subsidiaries or the funds in which consist solely of funds held in trust for any director, officer or employee of such Borrower or Subsidiary or any employee benefit plan maintained by such Borrower or Subsidiary or funds representing deferred compensation for the directors and employees of such Borrower or Subsidiary, collectively not to exceed [***] of the amount to be paid in the ordinary course of business in the then-next payroll cycle, (ii) escrow accounts, Deposit Accounts and trust accounts, in each case holding assets that are pledged or otherwise encumbered pursuant to clauses (vi), (xv), (xviii) or (xxi) of the definition of Permitted Liens (but only to the extent required to be excluded pursuant to the underlying documents entered into in connection with such Permitted Liens in the ordinary course of business), (iii) accounts containing no (zero) balance or (iv) any Deposit Account with a balance less than [***]; provided, that the aggregate balance of all such Deposit Accounts excluded pursuant to this clause (iv) shall at no time exceed [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excluded Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each direct and indirect Subsidiary of the Borrower that is a Foreign Subsidiary (and any Domestic Subsidiary whose only material assets are Equity Interests in one or more Foreign Subsidiaries).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;FDA&#x201d; means the U.S. Food and Drug Administration or any successor thereto.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">28</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the monthly net product revenue projections for Borrower, as delivered to Agent 6 months prior to the Tranche 5 Advance, for a period covering at least 6 months preceding the Tranche 5 Advance, in the event Borrower elects to comply with Performance Covenant C, and every 6 month period thereafter in the event Borrower elects to comply with Performance Covenant C, in each case, in form and substance reasonably acceptable to Lenders; provided however, that Borrower may from time to time update the Forecast with a forecast approved by the board of directors of the Borrower and deliver such updated Forecast to Agent.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means lawful money of a country other than the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foreign Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Subsidiary other than a Domestic Subsidiary.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means generally accepted accounting principles in the United States of America, as in effect from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Governmental Authority&#x201d; means the government of any nation or any political subdivision thereof, whether state, local, territory, province or otherwise, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supranational bodies such as the European Union or the European Central Bank).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Hedging Agreement&#x201d; means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement incurred by the Borrower or any of its Subsidiaries not for speculative purposes and entered into in the ordinary course of business.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or services (excluding trade credit entered into in the ordinary course of business), including reimbursement and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, (d) Disqualified Equity Interests, (e) &#x201c;earnouts&#x201d;, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature arising out of purchase and sale contracts, and (f) all Contingent Obligations. For the avoidance of doubt no Permitted Warrant Transaction shall be considered Indebtedness of the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Initial Facility Charge&#x201d; means Three Hundred Ninety Five Thousand Dollars ($395,000), which is payable to the Lenders in accordance with Section 4.1(f).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Insolvency Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other similar relief.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all of Borrower&#x2019;s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; mask works; service marks, designs, business names, data base rights, design rights, domain names, moral rights, inventions, confidential information, know-how and other intellectual property rights and interests whether registered or unregistered; Borrower&#x2019;s applications therefor and reissues, extensions, or renewals thereof; and Borrower&#x2019;s goodwill associated with any of the foregoing, together with Borrower&#x2019;s rights to sue for past, present and future infringement of Intellectual Property and the goodwill associated therewith.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">29</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain Intercreditor Agreement dated as of the Closing Date by and between Hercules (on behalf of itself and its Affiliates party hereto from time to time) and SVB, as may be amended from time to time in accordance with the provisions thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investment&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> means, of any Person, (a) any beneficial ownership (including stock, partnership, limited liability company interests, or other securities) of or in any other Person, (b) any loan, advance or capital contribution to any other Person or (c) any Acquisition.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the United States Internal Revenue Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Janssen License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain License Agreement, dated as of September 15, 2016, by and between Geron Corporation, as licensor, and Janssen Pharmaceuticals Inc., as licensee.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Joinder Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit F</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Copyright License, Patent License, Trademark License or other license of rights or interests.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional sale or other title retention agreement, and any lease in the nature of a security interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Advances made under this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Agreement, the promissory notes (if any), the ACH Authorization, the Account Control Agreements, the Joinder Agreements, all UCC Financing Statements, the Intercreditor Agreement and any other documents executed in connection with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified, supplemented or restated.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Market Capitalization</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date of determination, the product of (a) the number of outstanding shares of Common Stock publicly disclosed in the most recent filing of Borrower with the United States Securities Exchange Commission as outstanding as of such date of determination and (b) the closing price of Borrower&#x2019;s Common Stock (as quoted on Bloomberg L.P.&#x2019;s page or any successor page thereto of Bloomberg L.P. or if such page is not available, any other commercially available source).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a material adverse effect upon: (i) the business, operations, properties, assets or financial condition of Borrower and its Subsidiaries taken as a whole; or (ii) the ability of Borrower to perform or pay the Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Agent or the Lenders to enforce any of its rights or remedies with respect to the Secured Obligations; or (iii) the Collateral or Agent&#x2019;s Liens on the Collateral or the priority of such Liens.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Term Loan Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means One Hundred </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Twenty</font><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Fourty</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Five Million Dollars ($</font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">125</font><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">145</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,000,000).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;NDA&#x201d; means a new drug application submitted to the FDA under 21 U.S.C. &#167; 355(b)(1) seeking authorization to commercialize a new drug product in the United States.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">30</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;NDA Milestone&#x201d; means the achievement of both of the following: (i) Performance Milestone II; and (ii) the Borrower has [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Non-Disclosure Agreement&#x201d; means that certain Non-Disclosure Agreement/Confidentiality Agreement by and between the Borrower and Agent, dated as of February 21, 2020.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is the U.S. Department of Treasury Office of Foreign Assets Control.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OFAC Lists</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Patent License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any written agreement granting any right with respect to any invention on which a Patent is in existence or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all letters patent of, or rights corresponding thereto, in the United States of America or in any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States of America or any other country.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Perfection Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a completed certificate delivered by Borrower to Agent and the Lenders, signed by Borrower entitled &#x201c;Hercules Capital, Inc. Perfection Certificate and Diligence Request&#x201d;.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Borrower, solely during the period such Performance Covenant A is elected, maintains Qualified Cash in an amount not less than forty percent (40%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means satisfaction of each of the following solely during the period such Performance Covenant B is elected: (i) Borrower&#x2019;s Market Capitalization is or exceeds Seven Hundred Fifty Million Dollars ($750,000,000), and (ii) Borrower maintains Qualified Cash in an amount not less than twenty five percent (25%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Covenant C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means from and after [***], Borrower shall, solely during the period such Performance Covenant C is elected, maintain T6M Net Product Revenue of at least 70% of the T6M Net Product Revenue included in the Forecast, with such compliance to be tested at the end of the applicable month during the period such covenant is elected by Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone I</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) the Borrower has publicly announced no later than [***] that the Phase 3 portion of the IMerge clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes (&#x201c;MDS&#x201d;) has completed full enrollment of One Hundred Seventy (170) patients, and (ii) Borrower has publicly announced that the planned Phase 3 Refractory MF clinical trial of imetelstat in patients with intermediate-2 or high-risk myelofibrosis (&#x201c;MF&#x201d;) has been initiated with the first patient dosed, in each case, subject to reasonable verification by the Agent (including supporting documentation reasonably requested by the Agent).</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">31</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone I Interest Only Extension Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean satisfaction of each of the following events: (a) no Event of Default shall have occurred and be continuing; and (b) the Borrower shall have achieved Performance Milestone I on or prior to [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone II</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) prior to [***], the Borrower has [***], and that [***], such that the [***], and (ii) either [***] in each case, subject to reasonable verification by the Agent (including supporting documentation reasonably requested by Agent), or [***] in cumulatively, [***]; in each case, subject to verification by Agent (including supporting documentation reasonably requested by Agent).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone II Interest Only Extension Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean satisfaction of each of the following events:  (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have achieved the Performance Milestone I Interest Only Extension Conditions on or prior to [***]; and (c) the Borrower shall have achieved Performance Milestone II on or prior to [***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone III</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the achievement of both of the following: (i) the Borrower has publicly announced that the FDA has approved imetelstat [***] (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FDA Approval Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); and (ii) [***] in each case, subject to reasonable verification by the Agent (including supporting documentation reasonably requested by Agent).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Performance Milestone III Interest Only Extension Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean satisfaction of each of the following events:  (a) no Event of Default shall have occurred and be continuing; (b) the Borrower shall have achieved the Performance Milestone I Interest Only Extension Conditions on or prior to [***]; (c) the Borrower shall have achieved Performance Milestone II on or prior to [***]; and (d) the Borrower shall have achieved Performance Milestone III on or prior to </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">March </font><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">31</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[***].</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Acquisition (including Corporate Collaborations constituting Acquisitions) which is conducted in accordance with the following requirements:</font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">of a business or Person or product engaged in a line of business similar, related or complementary to that of the Borrower or its Subsidiaries;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if such Acquisition is structured as a stock acquisition, then the Person so acquired shall either (i) become a wholly-owned Subsidiary of Borrower or of a Subsidiary and the Borrower shall comply, or cause such Subsidiary to comply, with 7.13 hereof or (ii) such Person shall be merged with and into Borrower (with the Borrower being the surviving entity);</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if such Acquisition is structured as the acquisition or exclusive in-licensing of any product, product line or Intellectual Property, such product, product line or Intellectual Property shall be acquired by Borrower, and shall be free and clear of Liens other than Permitted Liens;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Borrower shall have delivered to the Lenders not less than ten (10) nor more than forty five (45) days prior to the date of such Acquisition, notice of such Acquisition together with pro forma projected financial information (to the extent available or applicable), copies of then-current drafts of all material documents relating to such acquisition, and historical financial statements (to the extent available or applicable) for such acquired entity, division or line of business, in each case in form and substance reasonably satisfactory to the Lenders (such approval not to be unreasonably withheld), demonstrating compliance with the covenants set forth in Section 7.20 hereof on a pro </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">32</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">forma basis immediately prior to and immediately after the consummation of such transaction and subject to the confidentiality provisions of Section 11.13;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">both immediately before and immediately after such Acquisition no Event of Default shall have occurred and be continuing; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the cash consideration for the purchase price of such proposed new Acquisition (including, for the avoidance of doubt, any Acquisitions permitted pursuant to clause (iii) of the definition of Permitted Licenses), when taken together with all consideration paid in respect of earnouts, milestones and other similar deferred purchase price consideration as and when paid, in each case by the Borrower with respect thereto, and including the amount of Permitted Indebtedness assumed or to which such assets, businesses or business or ownership interest or shares, or any Person so acquired, remain subject (excluding Indebtedness comprised of performance-based milestones, earnouts, or royalties that qualify as Permitted Indebtedness pursuant to subsection (vi) of the definition thereof and have not been paid) may not exceed [***] with respect to consideration other than Equity Interests of the Borrower, provided, that, for the avoidance of doubt, the remainder of such purchase price may be paid in Equity Interests of the Borrower or the net cash proceeds of any substantially concurrent offering of Equity Interests of the Borrower, in each case, to the extent permitted hereunder.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Bond Hedge Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any call or capped call option (or substantively equivalent derivative transaction) relating to the Common Stock (or other securities or property following a merger event or other change of the Common Stock) purchased by Borrower in connection with the issuance of any Permitted Convertible Debt and as may be amended in accordance with its terms; provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">that the terms, conditions and covenants of each such call option transaction are customary for agreements of such type, as determined in good faith by the Borrower.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Convertible Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Indebtedness of the Borrower that is convertible, at the option of the holders thereof, into shares of Common Stock (or other securities or property following a merger event or other change of the Common Stock), cash or any combination thereof, at the election of the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that such Indebtedness shall (a) not require any scheduled amortization or otherwise require payment of principal prior to, or have a scheduled maturity date, earlier than, [***] after the Term Loan Maturity Date, (b) be unsecured, (c) not be guaranteed by any Subsidiary of Borrower that has not executed a Joinder Agreement and (d) be on terms and conditions customary for Indebtedness of such type, as determined in good faith by the Borrower; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that any cross-default or cross-acceleration event of default (each howsoever defined) provision contained therein that relates to indebtedness or other payment obligations of Borrower (or any of its Subsidiaries) (such indebtedness or other payment obligations, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cross-Default Reference Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) contains a cure period of at least thirty (30) calendar days (after written notice to the issuer of such Indebtedness by the trustee or to such issuer and such trustee by holders of at least [***] in aggregate principal amount of such Indebtedness then outstanding) before a default, event of default, acceleration or other event or condition under such Cross-Default Reference Obligation results in an event of default under such cross-default or cross-acceleration provision.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of Borrower in favor of the Lenders or Agent arising under this Agreement or any other Loan Document; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(viii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness existing on the Closing Date which is disclosed in Schedule 1A to the Disclosure Letter; </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">33</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness of up to [***] outstanding at any time prior to the achievement of Positive Topline Results and, at all times following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time outstanding, secured by a Lien described in clause (vii) of the defined term &#x201c;Permitted Liens,&#x201d; provided such Indebtedness does not exceed the cost of the assets financed with such Indebtedness; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(x)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness to trade creditors incurred in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness incurred in the ordinary course of business (i) with corporate credit cards, merchant cards, purchase cards and debit cards in an amount not to exceed [***] at any time outstanding prior to the achievement of Positive Topline Results and, at all times following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time outstanding, and (ii) in connection with cash management services in an amount not to exceed [***] at any time outstanding prior to the achievement of Positive Topline Results and, at all times following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time outstanding; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness that also constitutes a Permitted Investment and Indebtedness consisting of obligations under deferred or contingent consideration arrangements (including, without duplication, earn-outs, milestone payments, royalties and other contingent or deferred obligations as long as such obligations are not evidenced by any &#x201c;seller notes&#x201d; or similar Indebtedness in connection with Permitted Acquisitions); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subordinated Indebtedness; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">reimbursement obligations in connection with letters of credit provided by financial institutions other than SVB that are secured by Cash and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed [***] at any time outstanding prior to the achievement of Positive Topline Results and, at all times following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time outstanding;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">other unsecured Indebtedness not otherwise permitted hereunder in an amount not to exceed [***] at any time outstanding prior to the achievement of Positive Topline Results and, at all times following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time outstanding; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">intercompany Indebtedness as long as each of the obligor and the obligee under such Indebtedness is the Borrower or a Subsidiary that has executed a Joinder Agreement or otherwise in connection solely with Permitted Investments in Subsidiaries of Borrower; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Permitted Convertible Debt not to exceed [***] in principal amount at any one time outstanding;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">34</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness to non-Affiliate third parties limited to synthetic royalty participations (and not royalty purchases or buyouts) and specific asset-level financings, in each case to the extent such Indebtedness is subordinated to the Secured Obligations in amounts and on terms and conditions reasonably satisfactory to the Agent and the Lenders (collectively, the &#x201c;Permitted Third Party Financings&#x201d;); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">obligations under any Hedging Agreement entered into in the ordinary course of business for non-speculative purposes in an aggregate amount not to exceed [***] at any time outstanding prior to the achievement of Positive Topline Results and, at all times following achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time outstanding;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Licenses, solely to the extent involving the incurrence of Permitted Indebtedness;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">financing of insurance premiums in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Contingent Obligations of Permitted Indebtedness incurred in the ordinary course of business, in each case without duplication for the amount(s) of Permitted Indebtedness otherwise permitted hereunder;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">advances or deposits received in the ordinary course of business from customers or vendors; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness with respect to performance bonds, appeal bonds and other similar obligations, in an aggregate amount not to exceed [***] at any time outstanding; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">guarantees of the obligations of suppliers, customers and licensees of the Borrower incurred to third parties for the purpose of enabling such suppliers, customers and licensees to purchase products that will be supplied, or incorporated into products that will be supplied, to the Borrower by such suppliers, customers or licensees, in an amount not to exceed [***] in the aggregate in any fiscal year prior to the achievement of Positive Topline Results and, following the achievement of Positive Topline Results, Five Million Dollars ($5,000,000) in the aggregate in any fiscal year.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Investment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments existing on the Closing Date which are disclosed in Schedule 1B to the Disclosure Letter;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a) marketable direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing within one year from the date of acquisition thereof currently having a rating of at least A-2 or P-2 from either Standard &amp; Poor&#x2019;s Corporation or Moody&#x2019;s Investors Services, (b) commercial paper maturing no more than one year from the date of creation thereof and currently having a rating of at least A-2 or P-2 from either Standard &amp; Poor&#x2019;s Corporation or Moody&#x2019;s Investors Service, (c) certificates of deposit issued by any bank with assets of at least [***] maturing no more than one year from the date of investment therein, (d) money market accounts and (e) other Investments described in Borrower&#x2019;s investment policy as approved by Agent in writing and the Borrower&#x2019;s Board of Directors from time to time;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">35</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(A) repurchases of shares or stock from former or current employees, directors, or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities in an aggregate amount not to exceed [***] in any fiscal year or (B) equity derivatives and stock repurchases (including without limitation by means of accelerated stock repurchases and forward purchases) as permitted by Section 7.7, in each case provided that no Event of Default has occurred, is continuing or would exist immediately after giving effect to such derivatives or repurchases; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments accepted in connection with Permitted Transfers; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments (including debt obligations) (a) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent or doubtful obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower&#x2019;s business and (b) consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to Investments of Borrower in any Subsidiary; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of loans not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating to the purchase of capital stock of Borrower pursuant to employee share or stock purchase plans or other similar agreements approved by Borrower&#x2019;s Board of Directors; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments consisting of travel advances, relocation loans, and other loan advances (or guarantees thereof) to employees, officers and directors in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments (A) in Borrower and (B) in Subsidiaries that have entered into a Joinder Agreement and executed such other documents as shall be reasonably requested by Agent; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments in Subsidiaries that have not executed a Joinder Agreement in an aggregate amount not to exceed [***] in any fiscal year;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">joint ventures or strategic alliances in the ordinary course of Borrower&#x2019;s business, provided that any cash Investments by Borrower do not exceed [***] in the aggregate in any fiscal year prior to the achievement of Positive Topline Results and, following the achievement of Positive Topline Results, Five Million Dollars ($5,000,000) in the aggregate in any fiscal year; provided further, that such joint ventures and strategic alliances shall not include any licenses other than Permitted Licenses;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s entry into (including payments of premiums in connection therewith), and the performance of obligations under, and the receipt of Common Stock upon termination, settlement or unwind of, any Permitted Bond Hedge Transactions and Permitted Warrant Transactions; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xxxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Acquisitions; </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">36</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xl)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Hedging Agreements permitted under clause (xiv) of the definition of Permitted Indebtedness; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xli)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Licenses, to the extent constituting Investments; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Patents assigned by Janssen Biotech, Inc. and its Affiliates; and </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xliii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">additional Investments not otherwise permitted hereunder that do not exceed [***] in the aggregate prior to the achievement of Positive Topline Results and, following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) in the aggregate.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xliv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Janssen License; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">licenses and similar arrangements for the use of Intellectual Property (including Corporate Collaborations not constituting Acquisitions) satisfying each of the following conditions:  (a) such license is entered into in the ordinary course of business, (b) such license could not result in a legal transfer of title of the licensed property, (c) such license is entered into with non-Affiliate third parties and constitutes an arms-length transaction on commercially reasonably terms, and (d) such license is (x) non-exclusive, (y) exclusive as to territory but only as to discrete geographical areas outside of the United States of America in the ordinary course of business, or (z) exclusive as to any territory including the United States solely with respect to co-promotion, co-development and co-commercialization agreements entered into with counterparties typically party to such agreements in the ordinary course of their business; provided that, solely with respect to this clause (ii)(d)(z), both immediately prior to and upon consummation of any such transaction the Borrower is in compliance with Section 7.20(b) and no Event of Default has occurred and is continuing; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any in-license permitted hereunder that relates to [***]; provided that, the consideration paid in connection with such in-license does not exceed [***] and, both immediately prior to and upon consummation of any such in-license, no Event of Default has occurred and is continuing.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of Agent or the Lenders; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens existing on the Closing Date which are disclosed in Schedule 1C to the Disclosure Letter; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(xlix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings diligently conducted; provided, that Borrower maintains adequate reserves therefor on Borrower&#x2019;s Books in accordance with GAAP (to the extent required thereby); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and other like Persons arising in the ordinary course of </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">37</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower&#x2019;s business and imposed without action of such parties; provided, that the payment thereof is not yet sixty (60) days past due;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(li)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens arising from judgments, decrees or attachments in circumstances which do not constitute an Event of Default hereunder; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the following deposits, to the extent made in the ordinary course of business:  deposits to secure the performance of obligations (including by way of deposits to secure letters of credit issued to secure the same) under commercial supply and/or manufacturing agreements, deposits under worker&#x2019;s compensation, unemployment insurance, social security and other similar laws, or to secure the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure statutory obligations (other than Liens arising under ERISA or environmental Liens) or surety or appeal bonds, or to secure indemnity, performance or other similar bonds; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(liii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens on Equipment or software or other intellectual property constituting purchase money Liens and Liens in connection with capital leases securing Indebtedness permitted in clause (iii) of &#x201c;Permitted Indebtedness&#x201d;;  </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(liv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with Subordinated Indebtedness;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">leasehold interests in leases or subleases (whether as lessor or lessee thereunder) and licenses or sublicenses granted in the ordinary course of business and not interfering in any material respect with the business of the licensor (including any non-exclusive licenses of personal property (other than Intellectual Property) granted to third parties in the ordinary course of Borrower&#x2019;s business), if such leases, subleases, licenses or sublicenses do not prohibit granting Agent a security interest therein; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent constituting Liens, Permitted Licenses;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or before the date they become due; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens on insurance proceeds securing the payment of financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only to such insurance proceeds and not to any other property or assets); </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">statutory and common law rights of set-off and other similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business so long as they do not materially impair the value or marketability of the related property; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(A) Liens on Cash securing obligations permitted under clause (viii) of the definition of Permitted Indebtedness and (B) security deposits in connection with real property leases, the combination of (A) and (B) in an aggregate amount not to exceed [***] </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">38</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">at any time prior to the achievement of Positive Topline Results and, following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with Permitted Third Party Financings; provided that such Liens are limited to the specific assets financed and not all assets or substantially all assets of the Borrower;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">additional Liens not otherwise permitted hereunder in an aggregate amount not to exceed [***] at any time prior to the achievement of Positive Topline Results and, following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) at any time; provided that such liens be limited to specific assets and not all assets or substantially all assets of any Borrower;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens on Cash securing obligations permitted under clause (v) of the definition of Permitted Indebtedness;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in favor of financial institutions arising in connection with Borrower&#x2019;s deposit and/or securities accounts held at such institutions, provided that (i) such accounts are permitted by this Agreement and (ii) Agent has a first priority perfected security interest in the amounts held in such deposit and/or securities accounts other than Excluded Accounts; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with sales, transfers, licenses, sublicenses, leases, subleases or other dispositions of assets in the ordinary course of business and permitted by Section 7.8 and, in connection therewith, customary rights and restrictions contained in agreements relating to such transactions pending the completion thereof or during the term thereof, and any option or other agreement to sell, transfer, license, sublicense, lease, sublease or dispose of an asset permitted by Section 7.8; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens in the nature of deposits, or liens on deposit accounts, to secure (i) the performance of tenders, bids, trade and commercial contracts, licenses and leases, statutory obligations, surety bonds, performance bonds, bank guaranties and other obligations of a like nature incurred in the ordinary course of business (including earnest money deposits in respect of any asset acquisition) or (ii) indemnification obligations relating to any disposition; provided that, in each case, such Liens do not secure Indebtedness for borrowed money and are incurred in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">good faith deposits required in connection with any Permitted Acquisition in the ordinary course of business;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent constituting Liens, escrow arrangements securing indemnification obligations associated with any acquisition;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liens incurred in connection with the extension, renewal or refinancing of the Indebtedness secured by Liens of the type described in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness being extended, renewed or refinanced (as may have been reduced by any payment thereon) does not increase.</font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">39</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">sales, transfers or other dispositions of Inventory in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transfers consisting of Permitted Licenses; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxiii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">dispositions of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxiv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">transfers expressly permitted under Sections 7.5, 7.6 or 7.7; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the surrender, waiver or settlement of contractual rights in the ordinary course of business, or the surrender, waiver or settlement of claims and litigation claims (whether or not in the ordinary course of business) as long as no Event of Default has occurred and is continuing;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxvi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the use of cash and cash equivalents subject to the restrictions and limitations set forth in the Loan Documents; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxvii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">dispositions of Borrower&#x2019;s Investment in Bard1 Life Sciences Limited identified on Schedule 1B to the Disclosure Letter; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxviii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Janssen License; </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxix)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">retirements of abandoned or expired Intellectual Property not material to Borrower&#x2019;s business; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(lxxx)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">other transfers not otherwise permitted hereunder of assets (other than Intellectual Property) having a fair market value of not more than [***] in the aggregate in any fiscal year prior to the achievement of Positive Topline Results and, following the achievement of Positive Topline Results, Three Million Dollars ($3,000,000) in the aggregate in any fiscal year. </font>
   </div>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Permitted Warrant Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating to Common Stock (or other securities or property following a merger event or other change of the Common Stock) and/or cash (in an amount determined by reference to the price of such Common Stock) sold by Borrower substantially concurrently with any purchase by Borrower of a related Permitted Bond Hedge Transaction and as may be amended in accordance with its terms; provided that (x) that the terms, conditions and covenants of each such call option transaction are customary for agreements of such type, as determined in good faith by the Borrower and (y) such call option transaction would be classified as an equity instrument in accordance with GAAP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation, limited liability company, institution, other entity or government.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Qualified Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means unrestricted Cash of the Borrower maintained in domestic Deposit Accounts or other domestic accounts in the Borrower&#x2019;s name subject to an Account Control Agreement in favor of Agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Qualified Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Equity Interests of Borrower that do not include a cash dividend (other than dividends that are solely payable as and when declared by Borrower&#x2019;s board of</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">40</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">directors) and are not mandatorily redeemable by Borrower or any of its Subsidiaries or redeemable at the option of the holder of such Equity Interests, in each case prior to the [***] following the Term Loan Maturity Date (other than redemptions solely for Qualified Equity Interests in such Person and cash in lieu of fractional shares of such Equity Interests and redemptions upon the occurrence of an &#x201c;asset sale&#x201d; or a &#x201c;change in control&#x201d; (or similar event, however denominated) so long as any such redemption requirement becomes operative only after repayment in full (or waiver thereof) of all the Secured Obligations (other than inchoate indemnity obligations); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that an Equity Interest in any Person that is issued to any employee or to any plan for the benefit of employees or by any such plan to such employees shall constitute a Qualified Equity Interest notwithstanding any obligation of Borrower or any Subsidiary to repurchase such Equity Interest in order to satisfy applicable statutory or regulatory obligations or as a result of such employee&#x2019;s termination, death or disability).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Receivables</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) all of Borrower&#x2019;s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit, proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Redemption Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any payment of cash in respect of the principal amount of any Permitted Convertible Debt, satisfaction of each of the following events: (a) no Event of Default shall exist or result therefrom, and (b) both immediately before and at all times after such redemption, Borrower&#x2019;s Qualified Cash shall be no less than the sum of [***] of the outstanding Secured Obligations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning specified in Section 11.7.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, subject to the terms of the Intercreditor Agreement, at any time, the holders of more than 50% of the sum of the aggregate unpaid principal amount of the Term Loan Advances then outstanding.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Requirement of Law&#x201d; means, as to any Person, the certificate of incorporation and by-laws or other organizational or governing documents of such Person, and any law, treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctioned Country</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, at any time, a country or territory which is the subject or target of any Sanctions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctioned Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country or (c) any Person controlled by any such Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty&#x2019;s Treasury of the United Kingdom.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that certain Second Amendment to Loan and Security Agreement, effective as of the Second Amendment Closing Date, by and among the Borrower, Agent and the Lenders.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">41</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Second Amendment Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the date on which the Second Amendment is executed by the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Secured Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Borrower&#x2019;s obligations under this Agreement and any Loan Document including any obligation to pay any amount now owing or later arising.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subordinated Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Indebtedness subordinated to the Secured Obligations on terms and conditions satisfactory to the Agent in its sole discretion and subject to a subordination agreement in form and substance satisfactory to Agent in its sole discretion.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an entity, whether a corporation, partnership, limited liability company, joint venture or otherwise, in which Borrower owns or controls 50% or more of the outstanding voting securities, including each entity listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">T6M Net Product Revenue</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Borrower&#x2019;s net product revenue (as determined in accordance with GAAP), measured on a trailing six-month basis as of the date of the most recently delivered monthly financial statements in accordance with Section 7.1(a).  For the avoidance of doubt, net product revenue shall not include any of the following to the extent not recognizable as revenue in accordance with GAAP (i) trade, quantity and cash discounts allowed by the Borrower, (ii) discounts, refunds, rebates, charge backs, retroactive price adjustment and any other allowances which effectively reduce net selling price, (iii) product returns and allowances, (iv) allowances for shipping or other distribution expenses, (v) set-offs and counterclaims, and (vi) any other similar and customary deductions that are typically deducted from gross revenue and not included in net revenue in accordance with GAAP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any governmental authority, including any interest, additions to tax or penalties applicable thereto.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to the Borrower in a principal amount not to exceed the amount set forth under the heading &#x201c;Term Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> each Tranche 1 Advance, Tranche 2 Advance, Tranche 3 Advance, Tranche 4 Advance, Tranche 5 Advance, Tranche 6 Advance, and any other term loan funds advanced under this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means for any day a per annum rate of interest equal to the greater of either (i) 9.00% plus the prime rate as reported in The Wall Street Journal minus </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3.25</font><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4.50</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">%, and (ii) 9.00%.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means October 1, 2024; provided, however, that if Borrower achieves Performance Milestone II prior to September 15, 2024, then April 1, 2025, and if Borrower achieves Performance Milestone III prior to March 15, 2025, then October 1, 2025, provided further, that if the applicable day is not a Business Day, the Term Loan Maturity Date shall be the immediately preceding Business Day.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Third Amendment&#x201d; means that certain Third Amendment to Loan and Security Agreement, effective as of the Third Amendment Closing Date, by and among the Borrower, Agent and the Lenders.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">42</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Third Amendment Closing Date&#x201d; means the date on which the Third Amendment is executed by the Borrower, Agent and the Lenders.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trademark License</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States of America, any State thereof or any other country or any political subdivision thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to the Tranche 1A Commitment, all Tranche 1A Advances; with respect to the Tranche 1B Commitment, all Tranche 1B Advances; with respect to the Tranche 2 Commitment, all Tranche 2 Advances; with respect to the Tranche 3 Commitment, all Tranche 3 Advances; with respect to the Tranche 4 Commitment, all Tranche 4 Advances; with respect to the Tranche 5 Commitment, all Tranche 5 Advances; with respect to the Tranche 6 Commitment, all Tranche 6 Advances.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1A Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 1A Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 1B Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 1B Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 2 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 2 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 2 Facility Charge&#x201d; means One Hundred and Five Thousand Dollars ($105,000), which is payable to the Lenders in accordance with Section 4.2(d).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 3 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 3 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 3 Facility Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) zero point five percent (0.50%) of the Tranche 3 Commitment amount, due and payable on or prior to the Second Amendment Closing Date, and (ii) [***] of any Tranche 3 Advance, due and payable prior to such Tranche 3 Advance; which is payable to the Lenders in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 4 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 4 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 4 Facility Charge&#x201d; means [***] of the principal amount of any Tranche 4 Advance, </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">which is</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">due and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> payable </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">on</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> the </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> in accordance with Section .</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">43</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 5 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 5 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 5 Facility Charge&#x201d; means [***] of the principal amount of any Tranche 5 Advance, which is payable to the Lenders in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tranche 6 Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as to any Lender, the obligation of such Lender, if any, to make a Term Loan Advance to Borrowers in a principal amount not to exceed the amount set forth under the heading &#x201c;Tranche 6 Commitment&#x201d; opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Tranche 6 Facility Charge&#x201d; means [***] of the principal amount of any Tranche 6 Advance, which is payable to the Lenders in accordance with Section .</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with respect to, Agent&#x2019;s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time, in effect in a jurisdiction other than the State of California, then the term &#x201c;UCC&#x201d; shall mean the Uniform Commercial Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">U.S. Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Person that is a &#x201c;United States person&#x201d; as defined in Section 7701(a)(30) of the Code.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The following terms are defined in the Sections or subsections referenced opposite such terms:</font>
   </div>
  </div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:55.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.58%;"></td>
    <td style="width:47.42%;"></td>
   </tr>
   <tr style="height:14.4pt;background-color:#000000;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Defined Term</font></p></td>
    <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Section</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Agent</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assignee</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.14</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Borrower</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Claims</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.11</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Collateral</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Confidential Information</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.13</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cross Default Reference Obligation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Permitted Convertible Debt&#x201d;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">End of Term Charge</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Event of Default</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">FDA Approval Date</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Performance Milestone III&#x201d;</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Indemnified Person</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Lenders</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preamble</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Market Cap Threshold</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1(a)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maximum Rate</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Open Source License</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.10</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">44</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:55.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.58%;"></td>
    <td style="width:47.42%;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid #666666;border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participant Register</font></p></td>
    <td style="border-top:0.5pt solid #666666;border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.8</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Permitted Third Party Financings</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Permitted Indebtedness&#x201d;</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Prepayment Charge</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.5</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Publicity Materials</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.19</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Register</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.7</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rights to Payment</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 1 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(ii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#cccccc;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 2 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(iii)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 3 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(iv)</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 4 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(v)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 5 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(vi)</font></p></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid #666666;border-left:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Tranche 6 Advance</font></p></td>
    <td style="border-right:0.5pt solid #666666;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #666666;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2(a)(vii)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise specified, all references in this Agreement or any Annex or Schedule hereto to a &#x201c;Section,&#x201d; &#x201c;subsection,&#x201d; &#x201c;Exhibit,&#x201d; &#x201c;Annex,&#x201d; or &#x201c;Schedule&#x201d; shall refer to the corresponding Section, subsection, Exhibit, Annex, or Schedule in or to this Agreement or the Disclosure Letter, as applicable.  Unless otherwise specifically provided herein, any accounting term used in this Agreement or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations hereunder shall be computed in accordance with GAAP, consistently applied; provided that, no effect shall be given to Accounting Standards Codification 842, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> (or any other Accounting Standards Codification having similar result or effect) (and related interpretations) to the extent any lease (or similar arrangement) would be required to be treated as a capital lease thereunder where such lease (or arrangement) would have been treated as an operating lease under GAAP as in effect immediately prior to the effectiveness of such Accounting Standards Codification. Unless otherwise defined herein or in the other Loan Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them in the UCC.  For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#x2019;s laws): (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its Equity Interests at such time.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement or any other Loan Document, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made without giving effect to any treatment of Indebtedness in respect of convertible debt instruments under Accounting Standards Codification 470-20 (or any other Accounting Standards Codification or Financial Accounting Standard having a similar result or effect) to value any such Indebtedness in a reduced or bifurcated manner as described therein, and such Indebtedness shall at all times be valued at the full stated principal amount thereof. For the avoidance of doubt, and without limitation of the foregoing, Permitted Convertible Debt shall at all times be valued at the full stated principal amount thereof and shall not include any reduction or appreciation in value of the shares deliverable upon conversion thereof.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">THE LOAN</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">45</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, the Lenders will severally (and not jointly) make in an amount not to exceed its respective Tranche 1A Commitment, and Borrower agrees to draw, a Term Loan Advance of Twenty Five Million Dollars ($25,000,000) on the Closing Date (the &#x201c;Tranche 1A Advance&#x201d;). </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement, beginning on the Closing Date and continuing through June 15, 2021, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 1B Commitment an additional Term Loan Advance in a principal amount of Ten Million Dollars ($10,000,000) (the &#x201c;Tranche 1B Advance&#x201d; and together with the Tranche 1A Advance, each a &#x201c;Tranche 1 Advance&#x201d;).</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of Performance Milestone I, beginning on January 1, 2021 and continuing through December 15, 2021, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 2 Commitment an additional Term Loan Advance in a principal amount of Fifteen Million Dollars ($15,000,000) (the &#x201c;Tranche 2 Advance&#x201d;).</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of Performance Milestone II, beginning on the date of satisfaction of Performance Milestone II and continuing through the earlier date of 30 days following the satisfaction of Performance Milestone II and September 15, 2023, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 3 Commitment an additional Term Loan Advance in a principal amount of Twenty Million Dollars ($20,000,000) (the &#x201c;Tranche 3 Advance&#x201d;).</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of the NDA Milestone, </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">beginning on January 1, 2023 and continuing through December 15, 2023, Borrower may request</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees to draw</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 4 Commitment an additional Term Loan Advance in a principal amount of </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Ten</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Thirty</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Million Dollars ($</font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">,000,000) (the &#x201c;Tranche 4 Advance</font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) on the Third Amendment Closing Date.</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and satisfaction of Performance Milestone III, beginning on September 15, 2023 and continuing through </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">September</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">December</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> 15, 2024, Borrower may request and the Lenders shall severally (and not jointly) make in an amount not to exceed its respective Tranche 5 Commitment an additional Term Loan Advance in a principal amount of Twenty Million Dollars ($20,000,000) (the &#x201c;Tranche 5 Advance&#x201d;). </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms and conditions of this Agreement and conditioned on future approval by each Lender&#x2019;s investment committee, which shall be granted or denied in its sole and unfettered discretion, on or prior to December 31, 2024, Borrower may request, and Lenders may severally (and not jointly) make, an additional Term Loan </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">46</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance of $25,000,000 (the &#x201c;Tranche 6 Advance&#x201d;).  The aggregate outstanding Term Loan Advances may be up to the Maximum Term Loan Amount.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Advance Request</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least one (1) Business Day before the Closing Date and at least five (5) Business Days before each Advance Date other than the Closing Date) to Agent. The Lenders shall fund the Term Loan Advance in the manner requested by the Advance Request provided that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term Loan Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The principal balance shall bear interest thereon from such Advance Date at the Term Loan Interest Rate based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed.  The Term Loan Interest Rate will float and change on the day the prime rate changes from time to time.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower will pay interest on each Term Loan Advance on the first Business Day of each month, beginning the month after the applicable Advance Date.  Borrower shall repay the aggregate principal balance of the Term Loan Advances that are outstanding on the day immediately preceding the Amortization Date, in equal monthly installments of principal and interest (mortgage style) beginning on the Amortization Date and continuing on the first Business Day of each month thereafter until the Term Loan Advances (other than inchoate indemnity obligations) together with all other Secured Obligations owing in connection therewith are repaid. The entire principal balance of the Term Loan Advances and all accrued but unpaid interest hereunder, shall be due and payable on the Term Loan Maturity Date.  Borrower shall make all payments under this Agreement without setoff, recoupment or deduction and regardless of any counterclaim or defense.  If a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.  The Lenders will initiate debit entries to the Borrower&#x2019;s account as authorized on the ACH Authorization (i) on each payment date of all periodic obligations payable to the Lenders under each Term Loan Advance and (ii) reasonable and documented out-of-pocket legal fees and costs incurred by Agent or the Lenders in connection with Section 11.12 of this Agreement; provided that, with respect to clause (i) above, in the event that the Lenders or Agent inform Borrower in writing that the Lenders will not initiate a debit entry to Borrower&#x2019;s account for a certain amount of the periodic obligations due on a specific payment date, Borrower shall pay to the Lenders such amount of periodic obligations in full in immediately available funds on such payment date; provided, further, that, with respect to clause (i) above, if the Lenders or Agent inform Borrower in writing that the Lenders will not initiate a debit entry as described above later than the date that is three (3) Business Days prior to such payment date, Borrower shall pay to the Lenders such amount of periodic obligations in full in immediately available funds on the date that is three (3) Business Days after the date on which the Lenders or Agent notify Borrower of such; provided further that with respect to clause (ii) above (other than fees paid on the Closing Date), Borrower shall pay to the Lenders such amount in full in immediately available funds within ten (10) Business Days of Agent or the Lenders furnishing Borrower an invoice of such out-of-pocket legal fees and costs incurred by Agent or the Lenders.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties&#x2019; intent not to contract for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible rates of interest on commercial loans) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Maximum Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  If a court of competent jurisdiction shall finally determine that Borrower has actually paid to the Lenders an amount of interest in excess of the amount that would have been payable if all of the Secured Obligations had at all times borne interest at the Maximum </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">47</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Rate, then such excess interest actually paid by Borrower shall be applied as follows:  first, to the payment of the Secured Obligations consisting of the outstanding principal; second, after all principal is repaid, to the payment of the Lenders&#x2019; accrued interest, costs, expenses, professional fees and any other Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Default Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  In the event any payment is not paid on the scheduled payment date (other than a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#x2019;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower&#x2019;s knowledge of such failure to pay), an amount equal to five percent (5.00%) of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder, all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate per annum equal to the rate set forth in Section 2.2(c) plus five percent (5%) per annum.  In the event any interest is not paid when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate set forth in Section 2.2(c) or Section 2.4, as applicable.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prepayment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  At its option upon at least seven (7) Business Days prior written notice to Agent, Borrower may prepay all, or a portion of the outstanding Advances by paying the entire principal balance (or such portion thereof), all accrued and unpaid interest thereon, together with a prepayment charge equal to the following percentage of the Advance amount being prepaid: (i) with respect to each Advance made pursuant to Tranche 1 and Tranche 2, if such Advance amounts are prepaid in any of the first thirty-six (36) months following the Closing Date, 1.50%, and thereafter, 0.00%, and (ii) with respect to each Advance made pursuant to Tranche 3, Tranche 4, Tranche 5, or Tranche 6 after the Second Amendment Closing Date, if such Advance amounts are prepaid in any of the first thirty-six (36) months following the Second Amendment Closing Date, 1.50%, and thereafter, 0.00% (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Prepayment Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); provided that any partial prepayment shall be in minimum increments of principal in the amount of $5,000,000 (or such lesser amount as is then outstanding).  If at any time Borrower elects to make a prepayment, and at such time, there are outstanding Advances under multiple Tranches, the Prepayment Charge shall be determined by applying the amount of such prepayment in the following order: first, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the latest initial funding date; second, to the outstanding principal amount (and accrued but unpaid interest thereon) of Advances outstanding under the Tranche with the next latest initial funding date and so on until the entire principal balance of all Advances made hereunder (and all accrued but unpaid interest thereon) is paid in full.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees that the Prepayment Charge is a reasonable calculation of the Lenders&#x2019; lost profits in view of the difficulties and impracticality of determining actual damages resulting from an early repayment of the Advances.  Borrower shall prepay the outstanding amount of all principal and accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control or any other prepayment hereunder. Notwithstanding the foregoing, Agent and the Lenders agree to waive the Prepayment Charge if Agent and the Lenders (in their sole and absolute discretion) agree in writing to refinance the Advances prior to the Term Loan Maturity Date. Any amounts paid under this Section shall be applied by Agent to the then unpaid amount of any Secured Obligations (including principal and interest) in such order and priority as Agent may choose in its sole discretion.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">End of Term Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On any date that Borrower partially prepays the outstanding Secured Obligations pursuant to Section 2.5, Borrower shall pay to the Lenders a charge of 6.55% of such Term Loan Advances being repaid. </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">48</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding Secured Obligations (other than any inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) in full, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay the Lenders a charge of (x) 6.55% of the aggregate amount of all Term Loan Advances funded minus (y) the aggregate amount of payments made pursuant to Section 2.5 (collectively with any charge made pursuant to Section 2.5, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">End of Term Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the required payment date of such End of Term Charge, the applicable pro rata portion of the End of Term Charge shall be deemed earned by the Lenders as of each date a Term Loan Advance is made.  For the avoidance of doubt, if a payment hereunder becomes due and payable on a day that is not a Business Day, the due date thereof shall be the immediately preceding Business Day.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pro Rata Treatment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each payment (including prepayment) on account of any fee and any reduction of the Term Loan Advances shall be made pro rata according to the Term Commitments of the relevant Lender.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Taxes; Increased Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower, the Agent and the Lenders each hereby agree to the terms and conditions set forth on Addendum 1 attached hereto.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Prepayment Charge and End of Term Charge</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise required by applicable Tax law, Borrower agrees that any Prepayment Charge and any End of Term Charge payable prior to the Term Loan Maturity Date shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination, and Borrower agrees that it is reasonable under the circumstances currently existing and existing as of the Closing Date.  The Prepayment Charge and the End of Term Charge shall also be payable in the event the Secured Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure, or by any other means.  Borrower expressly waives (to the fullest extent it may lawfully do so) the provisions of any present or future statute or law that prohibits or may prohibit the collection of the foregoing Prepayment Charge and End of Term Charge in connection with any such acceleration.  Borrower agrees (to the fullest extent that each may lawfully do so): (a) each of the Prepayment Charge and the End of Term Charge is reasonable and is the product of an arm&#x2019;s length transaction between sophisticated business people, ably represented by counsel; (b) each of the Prepayment Charge and the End of Term Charge shall be payable notwithstanding the then prevailing market rates at the time payment is made; (c) there has been a course of conduct between the Lenders and Borrower giving specific consideration in this transaction for such agreement to pay the Prepayment Charge and the End of Term Charge in the event of prepayment or acceleration; (d) Borrower shall be estopped from claiming differently than as agreed to in this paragraph.  Borrower expressly acknowledges that its agreement to pay each of the Prepayment Charge and the End of Term Charge to the Lenders as herein described was on the Closing Date and continues to be a material inducement to the Lenders to provide the Term Loan Advances. For U.S. federal and applicable state and local income tax purposes, the parties acknowledge and agree that the Term Loan is being issued with original issue discount within the meaning of Section 1273 of the Code and shall take all tax reporting positions consistent with the foregoing unless otherwise required by a Governmental Authority. </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SECURITY INTEREST</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As security for the prompt and complete payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Borrower grants to Agent a security interest in all of Borrower&#x2019;s right, title, and interest in, to and under all of Borrower&#x2019;s personal property and other assets </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">49</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">including without limitation the following (except as set forth herein) whether now owned or hereafter acquired (collectively, the &#x201c;Collateral&#x201d;):  (a) Receivables; (b) Equipment; (c) Fixtures; (d) General Intangibles (other than Intellectual Property); (e) Inventory; (f) Investment Property; (g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any of Borrower&#x2019;s property in the possession or under the control of Agent; and, to the extent not otherwise included, all Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of each of the foregoing; provided, however, that the Collateral shall include all Accounts and General Intangibles that consist of rights to payment and proceeds from the sale, licensing or disposition of all or any part, or rights in, the Intellectual Property (the &#x201c;Rights to Payment&#x201d;).  Notwithstanding the foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically, and effective as of the date of this Agreement, include the Intellectual Property to the extent necessary to permit perfection of Agent&#x2019;s security interest in the Rights to Payment.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the broad grant of the security interest set forth in Section 3.1, above, the Collateral shall not include (a) any property, right or asset held by Borrower to the extent that a grant of a security interest therein is prohibited by any Requirement of Law of a Governmental Authority or constitutes a breach or default under or results in the termination of or requires any consent not obtained under, any contract, license, agreement, instrument or other document evidencing or giving rise to such property, right or asset, except (A) to the extent that the terms in such contract, license, instrument or other document providing for such prohibition, breach, default or termination, or requiring such consent are not permitted under this Agreement or (B) to the extent that such Requirement of Law or the term in such contract, license, agreement, instrument or other document providing for such prohibition, breach, default or termination or requiring such consent is ineffective under Section 9406, 9407, 9408 or 9409 of the UCC (or any successor provision or provisions) of any relevant jurisdiction or any other applicable law (including the Bankruptcy Code of the United States); provided, however, that such security interest shall attach immediately at such time as such Requirement of Law is not effective or applicable, or such prohibition, breach, default or termination is no longer applicable or is waived, and to the extent severable, shall attach immediately to any portion of the Collateral that does not result in such consequences, (b) any Excluded Accounts, (c) the assets of any non-wholly owned Subsidiaries pursuant to customary restrictions and conditions contained in agreements governing joint ventures or strategic alliances in the ordinary course of business, provided that Borrower has exercised its good faith best efforts to not agree to such contractual limitations, (d) interests in joint ventures that constitute Permitted Investments pursuant to customary restrictions and conditions contained in agreements governing such joint ventures in the ordinary course of business, provided that Borrower has exercised its good faith best efforts to not agree to such contractual limitations, or (e) with respect to shares or stock in Excluded Subsidiaries, more than 65% to the extent that the pledge of more than 65% of such shares or stock of any Excluded Subsidiary would result in an adverse tax consequence to Borrower.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Reserved].</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If this Agreement is terminated, Agent&#x2019;s Lien in the Collateral shall continue until the Secured Obligations (other than inchoate indemnity obligations) are repaid in full in cash.  Upon payment in full in cash of the Secured Obligations (other than inchoate indemnity obligations) and at such time as the Lenders&#x2019; obligation to make credit extensions has terminated, Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower. </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 15</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CONDITIONS PRECEDENT TO LOAN</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">50</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The obligations of the Lenders to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Initial Advance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  On or prior to the Closing Date, Borrower shall have delivered to Agent the following:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">other than as permitted pursuant to Schedule 4.4 of the Disclosure Letter, executed copies of the Loan Documents, Account Control Agreements, and all other documents and instruments reasonably required by Agent to effectuate the transactions contemplated hereby or to create and perfect the Liens of Agent with respect to all Collateral, in all cases in form and substance reasonably acceptable to Agent;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a legal opinion of Borrower&#x2019;s counsel in form and substance reasonably acceptable to Agent; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a certificate executed by Borrower&#x2019;s corporate secretary, which shall attach and contain customary certifications as to: (i) the resolutions of Borrower&#x2019;s board of directors and the financing committee of Borrower&#x2019;s board of directors evidencing approval of the Loan and other transactions evidenced by the Loan Documents; (ii) certified copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower; and (iii) a certificate of good standing for Borrower from its state of incorporation and similar certificates from all other jurisdictions in which it does business and where the failure to be qualified could have a Material Adverse Effect;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">payment of the Due Diligence Fee, Initial Facility Charge and reimbursement of Agent&#x2019;s and the Lenders&#x2019; current expenses reimbursable pursuant to this Agreement, which amounts may be deducted from the initial Advance; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">all certificates of insurance and copies of each insurance policy required hereunder; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">an executed copy of the Perfection Certificate and Addendum 1 thereto; and </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">such other documents as Agent may reasonably request.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">All Advances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  On each Advance Date:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent shall have received (i) an Advance Request for the relevant Advance as required by Section 2.2(b), each duly executed by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Agent may reasonably request.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The representations and warranties set forth in this Agreement shall be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 2, Borrower shall have paid the applicable Tranche 2 Facility Charge. </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">51</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 3, Borrower shall have paid the applicable Tranche 3 Facility Charge.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 4, Borrower shall have paid the applicable Tranche 4 Facility Charge. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 5, Borrower shall have paid the applicable Tranche 5 Facility Charge. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With respect to any Advance pursuant to Tranche 6, (x) each Lender&#x2019;s investment committee shall, in its sole and absolute discretion, have approved the requested Advances, as contemplated by Section  and (y) Borrower shall have paid the Tranche 6 Facility Charge.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Default</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  As of the Closing Date and each Advance Date, (i) no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or would reasonably be expected to have a Material Adverse Effect has occurred and is continuing.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Post-Close Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. The Borrower agrees to deliver all items as required under Schedule 4.4 to the Disclosure Letter within the corresponding timeframes as set forth in Schedule 4.4 to the Disclosure Letter or such later date as Agent may agree in writing in its sole discretion.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 16</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES OF BORROWER</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower represents and warrants that:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Status</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower is a corporation duly organized, legally existing and in good standing under the laws its state of incorporation, and is duly qualified as a foreign corporation in all jurisdictions in which the nature of its business or location of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material Adverse Effect.  Borrower&#x2019;s present name, former names (if any), locations, place of formation, taxpayer identification number, organizational identification number and other information are correctly set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, as may be updated by Borrower in a written notice (including any Compliance Certificate) provided to Agent after the Closing Date. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower owns the Collateral and the Intellectual Property, free of all Liens, except for Permitted Liens.  Borrower has the power and authority to grant to Agent a Lien in the Collateral as security for the Secured Obligations.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower&#x2019;s execution, delivery and performance of this Agreement and all other Loan Documents, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement and the other Loan Documents, (iii) do not violate any provisions of Borrower&#x2019;s Certificate or Articles of Incorporation (as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and (iv) except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, do not violate any material contract or material agreement or require the consent or </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">52</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">approval of any other Person which has not already been obtained.  The individual or individuals executing the Loan Documents are duly authorized to do so.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Since December 31, 2019, no event that has had or would reasonably be expected to have a Material Adverse Effect has occurred and is continuing. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Actions Before Governmental Authorities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as disclosed on the Perfection Certificate, there are no actions, suits or proceedings at law or in equity or by or before any Governmental Authority now pending or, to the knowledge of Borrower, threatened in writing against or affecting Borrower or its property, that is reasonably expected to result in a Material Adverse Effect. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Borrower nor any of its Subsidiaries is in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree of any Governmental Authority, where such violation or default is reasonably expected to result in a Material Adverse Effect.  Borrower is not in default in any manner under any material provision of any agreement or instrument evidencing material Indebtedness, or any other material agreement to which it is a party or by which it is bound.  </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Neither Borrower nor any of its Subsidiaries is an &#x201c;investment company&#x201d; or a company &#x201c;controlled&#x201d; by an &#x201c;investment company&#x201d; under the Investment Company Act of 1940, as amended.  Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).  Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act.  Neither Borrower nor any of its Subsidiaries is a &#x201c;holding company&#x201d; or an &#x201c;affiliate&#x201d; of a &#x201c;holding company&#x201d; or a &#x201c;subsidiary company&#x201d; of a &#x201c;holding company&#x201d; as each term is defined and used in the Public Utility Holding Company Act of 2005.  Neither Borrower&#x2019;s nor any of its Subsidiaries&#x2019; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#x2019;s Knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.  Borrower and each of its Subsidiaries has obtained all material consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">None of Borrower, any of its Subsidiaries, or, to Borrower&#x2019;s knowledge, any of Borrower&#x2019;s or its Subsidiaries&#x2019; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.  None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.  None of the funds to be provided under this Agreement will be used, directly or indirectly, (a) for any activities in violation of any applicable anti-money laundering, economic sanctions and anti-bribery laws and regulations laws and regulations or (b) for any payment to any governmental official or employee, political party, official of a political party, candidate for political office, or anyone else acting in an official capacity, in order to obtain, retain or direct business or obtain any improper advantage, in violation of the United States Foreign Corrupt Practices Act of 1977, as amended.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">53</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Information Correct and Current</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  No written information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf of Borrower to Agent in connection with any Loan Document or included therein or delivered pursuant thereto contained, or, when taken as a whole, contains or will contain any material misstatement of fact or, when taken together with all other such written information or documents, omitted, omits or will omit to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were, are or will be made, not materially misleading at the time such statement was made or deemed made. Additionally, any and all financial or business projections provided by Borrower to Agent, whether prior to or after the Closing Date, shall be (i) provided in good faith and based on the most current data and information available to Borrower at the time delivered, and (ii) the most current of such projections provided to Borrower&#x2019;s Board of Directors (it being understood that such projections are subject to significant uncertainties and contingencies, many of which are beyond the control of Borrower, that no assurance is given that any particular projections will be realized, and that actual results may differ). </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tax Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.8</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, (a) Borrower and its Subsidiaries have filed all federal and state income Tax returns and other material Tax returns that they are required to file, (b) Borrower and its Subsidiaries have duly paid all federal and state income Taxes and other material Taxes or installments thereof that they are required to pay as and when due, except (i) Taxes being contested in good faith by appropriate proceedings and for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP or (ii) to the extent the failure to do so could not reasonably be expected to have a Material Adverse Effect, and (c) to the best of Borrower&#x2019;s knowledge, no proposed or pending Tax assessments, deficiencies, audits or other proceedings with respect to Borrower or any Subsidiary have had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower is the sole owner of, or otherwise has the right to use, the Intellectual Property material to Borrower&#x2019;s business.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter (as may be supplemented by disclosures provided in the Compliance Certificate or as disclosed to Agent), (i) each of the material registered Copyrights, registered Trademarks and issued Patents is valid and enforceable, (ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) no claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of the contracts, licenses or agreements identified in Sections 5(c) and 5(d) of the Perfection Certificate and, to Borrower&#x2019;s knowledge, no third party to any such contract, license or agreement is in material breach thereof or has failed to perform any material obligations thereunder.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter (as may be supplemented by disclosures provided in the Compliance Certificate or as disclosed to Agent), Borrower has all material rights with respect to Intellectual Property necessary or material in the operation or conduct of Borrower&#x2019;s business as currently conducted and proposed to be conducted by Borrower.  Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower&#x2019;s business, to freely transfer, license or assign Intellectual Property necessary or material in the operation or conduct of Borrower&#x2019;s business as currently conducted and proposed to be conducted by Borrower, without condition, restriction or payment of any kind (other than license payments in the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all software development tools, library functions, compilers and all other third-party software and other items that are material to Borrower&#x2019;s business and used in the design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products except customary covenants in inbound license agreements and equipment leases where Borrower is the licensee or lessee. </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">54</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No material software or other materials used by Borrower or any of its Subsidiaries (or used in any Borrower Products or any Subsidiaries&#x2019; products) are subject to an open-source or similar license (including but not limited to the General Public License, Lesser General Public License, Mozilla Public License, or Affero License) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Open Source Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in a manner that would cause such software or other materials to have to be (i) distributed to third parties at no charge or a minimal charge (royalty-free basis); (ii) licensed to third parties to modify, make derivative works based on, decompile, disassemble, or reverse engineer; or (iii) used in a manner that could require disclosure or distribution in source code form.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower Products</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter (as may be supplemented by disclosures provided in the Compliance Certificate or as disclosed to Agent), no material Intellectual Property owned by Borrower or Borrower Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation in writing, proceeding (including any proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree, order, judgment, settlement agreement or stipulation that restricts in any material manner Borrower&#x2019;s use, transfer or licensing thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation, arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant licenses or ownership interest in any material future Intellectual Property related to the operation or conduct of the business of Borrower or Borrower Products.  Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or claim, challenging or questioning Borrower&#x2019;s ownership in any material Intellectual Property (or written notice of any claim challenging or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has any claim of legal or beneficial ownership with respect thereto nor, to Borrower&#x2019;s knowledge, is there a reasonable basis for any such claim, in each case to where such notice or claim would reasonably be expected to have a Material Adverse Effect.  To Borrower&#x2019;s knowledge, neither Borrower&#x2019;s use of its Intellectual Property nor the production and sale of Borrower Products infringes the valid Intellectual Property or other rights of others in any material respect. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, as may be updated by the Borrower in a written notice provided to Agent after the Closing Date, is a true, correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property, and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which the account is held, a description of the purpose of the account, and the complete account number therefor.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Employee Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as permitted hereunder, Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the payment of any loan made to an employee, officer or director of the Borrower by a third party.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Capitalization and Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments.  Attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete list of each Subsidiary.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 17</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">INSURANCE; INDEMNIFICATION</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Coverage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks customarily insured against in Borrower&#x2019;s line of business.  Such risks shall include the risks of bodily injury, including death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement found in Section </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">55</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6.3.  Borrower must maintain a minimum of $2,000,000 of commercial general liability insurance for each occurrence.  Borrower has and agrees to maintain a minimum of $2,000,000 of directors&#x2019; and officers&#x2019; insurance for each occurrence and $5,000,000 in the aggregate. So long as there are any Secured Obligations (other than inchoate indemnity obligations) outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral, insuring against all risks of physical loss or damage howsoever caused as is standard for companies in Borrower&#x2019;s industry and location, in an amount not less than the full replacement cost of the Collateral, provided that such insurance may be subject to standard exceptions and deductibles. If Borrower fails to obtain the insurance called for by this Section 6.1 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document or which may be required to preserve the Collateral, Agent may obtain such insurance or make such payment, and all amounts so paid by Agent are immediately due and payable, bearing interest at the then highest rate applicable to the Secured Obligations, and secured by the Collateral.  Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter.  No payments by Agent are deemed an agreement to make similar payments in the future or Agent&#x2019;s waiver of any Event of Default.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certificates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall deliver to Agent certificates of insurance that evidence Borrower&#x2019;s compliance with its insurance obligations in Section 6.1 and the obligations contained in this Section 6.2.  Borrower&#x2019;s insurance certificate shall state Agent (shown as &#x201c;Hercules Capital, Inc., as Agent&#x201d;) is an additional insured for commercial general liability, a lenders loss payable for all risk property damage insurance, subject to the insurer&#x2019;s approval, and a lenders loss payable for property insurance and additional insured for liability insurance for any future insurance that Borrower may acquire from such insurer.  Attached to the certificates of insurance will be additional insured endorsements for liability and lender&#x2019;s loss payable endorsements for all risk property damage insurance.  All certificates of insurance will provide for a minimum of thirty (30) days advance written notice to Agent of cancellation (other than cancellation for non-payment of premiums, for which ten (10) days&#x2019; advance written notice shall be sufficient).  Any failure of Agent to scrutinize such insurance certificates for compliance is not a waiver of any of Agent&#x2019;s rights, all of which are reserved.  Borrower shall provide Agent with copies of each insurance policy, and upon entering or amending any insurance policy required hereunder, Borrower shall provide Agent with copies of such policies and shall promptly deliver to Agent updated insurance certificates with respect to such policies.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower agrees to indemnify and hold Agent, the Lenders and their officers, directors, employees, agents, in-house attorneys, representatives and shareholders (each, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Person</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims, costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable and documented out-of-pocket attorneys&#x2019; fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal) (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Liabilities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), that may be instituted or asserted against or incurred by such Indemnified Person as the result of credit having been extended, suspended or terminated under this Agreement and the other Loan Documents or the administration of such credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases Liabilities to the extent resulting solely from any Indemnified Person&#x2019;s gross negligence or willful misconduct.  This Section 6.3 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.  In no event shall any Indemnified Person be liable on any theory of liability for any special, indirect, consequential or punitive damages (including any loss of profits, business or anticipated savings). This Section 6.3 shall survive the repayment of indebtedness under, and otherwise shall survive the expiration or other termination of, this Agreement.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 18</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COVENANTS OF BORROWER</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">56</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower agrees as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall furnish to the Agent the financial statements and reports listed hereinafter (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if Borrower&#x2019;s Market Capitalization is less than [***] for a period of thirty (30) consecutive trading days (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Market Cap Threshold</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), Borrower shall furnish to the Agent and Lenders, as soon as practicable beginning with the month following the trigger of the Market Cap Threshold (and in any event within thirty (30) days) after the end of each month, unaudited monthly non-GAAP financial statements as of the end of such month, including balance sheet and related statements of income accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, all certified by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer; provided that, if Borrower&#x2019;s Market Capitalization is greater than [***] for a period of thirty (30) consecutive trading days following the trigger of the Market Cap Threshold, Borrower shall no longer be required to deliver monthly financials pursuant to this Section 7.1(a); </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if Borrower&#x2019;s Market Capitalization is greater than or equal to the Market Cap Threshold, as soon as practicable (and in any event within forty-five (45) days) after the end of each of the first three calendar quarters, unaudited interim and year-to-date financial statements as of the end of such calendar quarter, including balance sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or any other occurrence that could reasonably be expected to have a Material Adverse Effect, certified by Borrower&#x2019;s Chief Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, and (ii) that they are subject to normal year-end adjustments;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable (and in any event within ninety (90) days) after the end of each fiscal year, unqualified (other than a going concern qualification based on Borrower having negative profits or based on a determination that Borrower has less than twelve (12) months liquidity) audited financial statements as of the end of such year (prepared on a consolidated basis, if applicable), including balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably acceptable to Agent, accompanied by any management report from such accountants (it being understood that Ernst &amp; Young LLP and any other firm of national standing are reasonably acceptable to Agent); </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(x) if monthly Financial Statements are required to be delivered pursuant to Section 7.1(a), as soon as practicable (and in any event within 30 days) after the end of each such month, a Compliance Certificate in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, or (y) if quarterly Financial Statements are required to be delivered pursuant to Section 7.1(b), as soon as practicable (and in any event within 45 days) after the end of each of the first three calendar quarters and concurrently with the Financial Statements delivered pursuant to Section 7.1(c), a Compliance Certificate in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent not provided pursuant to Section 7.1(a), as soon as practicable (and in any event within 30 days) after the end of each month, a cash balance report;</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">promptly after the sending or filing thereof, as the case may be, copies of any regular, periodic and special reports or registration statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted therefor, or any national securities exchange;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">57</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as soon as practicable after the end of each calendar quarter, a report detailing [***] during the calendar quarter just ended; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">annually, within ten (10) days following approval thereof by Borrower&#x2019;s board of directors, a summary of Borrower&#x2019;s annual budget; </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">prompt notice if Borrower or any Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">nolo contendere</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. </font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall not, without prior notice to Agent, make any change in its (a) accounting policies or reporting practices, except as required by GAAP or (b) fiscal years or fiscal quarters.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The executed Compliance Certificate, and all Financial Statements required to be delivered pursuant to clauses (c) and (e)  shall be sent via e-mail to [***] and with a copy to [***] provided, that if e-mail is not available or sending such Financial Statements via e-mail is not possible, they shall be faxed to Agent at: [***], attention Account Manager: Geron Corporation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, documents required to be delivered under Sections 7.1(a), (b), (c) or (f) (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which Borrower files such documents with the SEC and such documents are publicly available on the SEC&#x2019;s EDGAR filing system or any successor thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the avoidance of doubt, any reports, communications, information or other documents provided pursuant to this Section 7.1 shall be subject to the confidentiality provisions of Section 11.13.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Management Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall permit any representative that Agent or the Lenders authorizes, including its attorneys and accountants, to inspect the Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon reasonable notice during normal business hours; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, however, that such examinations shall be limited to no more often than twice per fiscal year.  In addition, upon two (2) Business Days&#x2019; prior written notice, any such representative shall have the right to meet with management and officers of Borrower to discuss such books of account and records.  In addition, upon two (2) Business Days&#x2019; prior written notice, Agent or the Lenders shall be entitled at reasonable times and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting Borrower.  Such consultations shall not unreasonably interfere with Borrower&#x2019;s business operations.  The parties intend that the rights granted Agent and the Lenders shall constitute &#x201c;management rights&#x201d; within the meaning of 29 C.F.R. Section 2510.3-101(d)(3)(ii), but that any advice, recommendations or participation by Agent or the Lenders with respect to any business issues shall not be deemed to give Agent or the Lenders, nor be deemed an exercise by Agent or the Lenders of, control over Borrower&#x2019;s management or policies.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall from time to time execute, deliver and file, alone or with Agent, any financing statements, security agreements, collateral assignments, notices, control agreements or other documents to perfect, give the highest priority to Agent&#x2019;s Lien on the Collateral, subject to Permitted Liens which may have priority over Agent&#x2019;s Lien in accordance with applicable law, or otherwise evidence Agent&#x2019;s rights herein.  Borrower shall from time to time procure any instruments or documents as may be reasonably requested by Agent, and take all further action that may be necessary, or that Agent may reasonably request, to perfect and protect the Liens granted hereby and thereby.  In addition, and for such purposes only, Borrower hereby authorizes Agent to execute and deliver on behalf of Borrower </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">58</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">and to file such financing statements (including an indication that the financing statement covers &#x201c;all assets or all personal property other than intellectual property&#x201d; of Borrower in accordance with Section 9-504 of the UCC), collateral assignments, notices, control agreements, security agreements and other documents without the signature of Borrower either in Agent&#x2019;s name or in the name of Agent as agent and attorney-in-fact for Borrower.  Borrower shall protect and defend Borrower&#x2019;s title to the Collateral and Agent&#x2019;s Lien thereon against all Persons claiming any interest adverse to Borrower or Agent other than Permitted Liens.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except for (a) the conversion of Indebtedness into equity securities and the payment of cash in lieu of fractional shares in connection with such conversion, (b) in connection with refinancing or replacement Indebtedness, (c) (i) purchase money Indebtedness pursuant to its then applicable payment schedule or (ii) Indebtedness owed pursuant to clause (v) of the definition of Permitted Indebtedness and prepaid in the ordinary course of business, (d) prepayment by any Subsidiary of (i) inter-company Indebtedness owed by such Subsidiary to any Borrower, or (ii) if such Subsidiary is not a Borrower, intercompany Indebtedness owed by such Subsidiary to another Subsidiary that is not a Borrower, (e) trade debt incurred in the ordinary course of business or (f) as otherwise permitted hereunder or approved in writing by Agent.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in the foregoing, the issuance of, performance of obligations under (including any payments of interest), and conversion, exercise, repurchase, redemption, settlement or early termination or cancellation of (whether in whole or in part and including by netting or set-off) (in each case, whether in cash, Common Stock, or following a merger event or other change of the Common Stock, other securities or property), or the satisfaction of any condition that would permit or require any of the foregoing, any Permitted Convertible Debt shall not constitute a prepayment of Indebtedness by Borrower for the purposes of this Section 7.4; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Permitted Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of shares of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall at all times keep the Collateral, the Intellectual Property and all other property and assets used in Borrower&#x2019;s business or in which Borrower now or hereafter holds any interest free and clear from any Liens whatsoever (except for Permitted Liens), and shall give Agent prompt written notice of any legal process adverse to the Collateral, the Intellectual Property, or such other property and assets, or any Liens thereon, provided however, that the Collateral and such other property and assets </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">59</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">may be subject to Permitted Liens.  Borrower shall not agree with any Person other than Agent or the Lenders not to encumber its property other than pursuant to (a) any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby) and (b) customary restrictions on assets subject to Liens permitted under clause (xv) of the definition of &#x201c;Permitted Liens&#x201d; (in which case, any prohibition or limitation shall only be effective against the cash collateral provided thereto). Borrower shall not enter into or suffer to exist or permit to become effective any agreement that prohibits or limits the ability of any Borrower to create, incur, assume or suffer to exist any Lien upon any of its property (including Intellectual Property), whether now owned or hereafter acquired, to secure its obligations under the Loan Documents to which it is a party other than (a) this Agreement and the other Loan Documents, (b) any agreements governing any purchase money Liens or capital lease obligations otherwise permitted hereby (in which case, any prohibition or limitation shall only be effective against the assets financed thereby), (c) customary restrictions on the assignment of leases, licenses and other agreements, (d) customary restrictions on the assignment, sublicense or sublease of leases, licenses and other agreements, (e) customary restrictions in agreements relating to Corporate Collaborations permitted herein and (f) customary restrictions and conditions contained in agreements governing joint ventures or strategic alliances in the ordinary course of business. Borrower shall cause its Subsidiaries to use commercially reasonable efforts to protect and defend such Subsidiary&#x2019;s title to its assets from and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times to keep such Subsidiary&#x2019;s property and assets free and clear from any Liens whatsoever (except for Permitted Liens or as otherwise permitted by this Section 7.5), and shall give Agent prompt written notice of any legal process adverse to such Subsidiary&#x2019;s assets in an amount greater than [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries to do so, other than Permitted Investments. </font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, and for the avoidance of doubt, this Section 7.6 shall not prohibit the conversion by holders of (including any payment upon conversion, whether in cash, Common Stock or a combination thereof), or required payment of any principal or premium on (including, for the avoidance of doubt, in respect of a required repurchase in connection with the redemption of Permitted Convertible Debt upon satisfaction of a condition related to the stock price of the Common Stock) or required payment of any interest with respect to, any Permitted Convertible Debt in each case, in accordance with the terms of the indenture governing such Permitted Convertible Debt; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Permitted Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso).</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">60</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of shares, stock or other Equity Interest other than (i) pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in each case the repurchase or redemption consideration does not exceed the original consideration paid for such shares, stock or Equity Interest, (ii) repurchases of such shares, stock or Equity Interest deemed to occur upon exercise of stock options or warrants if such repurchased shares, stock or Equity Interest represents a portion of the exercise price of such options or warrants, (iii) repurchases of such shares, stock or Equity Interest deemed to occur upon the withholding of a portion of such shares, stock or Equity Interest granted or awarded to a current or former officer, director, employee or consultant to pay for the Taxes payable by such Person upon such grant or award (or upon vesting thereof), (iv) purchases of capital stock pledged as collateral for loans to employees, provided that such purchases do not exceed [***] in the aggregate, (v) [reserved], (vi) purchases of fractional shares of capital stock arising out of stock dividends, splits or combinations or business combinations or in connection with exercises or conversions of options, warrants and other convertible securities, (vii) the payment of the net purchase price in respect of any Permitted Bond Hedge Transaction with the proceeds of the issuance of Permitted Convertible Debt, provided that such purchase price (net of any payments to Borrower in respect of any Permitted Warrant Transaction) is less than [***] of the net proceeds of such Permitted Convertible Debt and (viii) the settlement, unwind or other termination of all or any portion of any Permitted Warrant Transaction by (x) set-off against the concurrent settlement, unwind or other termination of all or any portion of any Permitted Bond Hedge Transaction or (y) delivery of shares of Common Stock, or (b) declare or pay any cash dividend or make any other cash distribution on any class of stock or other Equity Interest, except that a Subsidiary may pay dividends or make other distributions to Borrower or any Subsidiary of Borrower, or (c) lend money to any employees, officers or directors or guarantee the payment of any such loans granted by a third party in excess of [***] in the aggregate or (d) waive, release or forgive any Indebtedness owed by any employees, officers or directors in excess of [***] in the aggregate.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, and for the avoidance of doubt, this Section 7.7 shall not prohibit the conversion by holders of (including any payment upon conversion, whether in cash, Common Stock or a combination thereof), or required payment of any principal or premium on (including, for the avoidance of doubt, in respect of a required repurchase in connection with the redemption of Permitted Convertible Debt upon satisfaction of a condition related to the stock price of the Common Stock) or required payment of any interest with respect to, any Permitted Convertible Debt in each case, in accordance with the terms of the indenture governing such Permitted Convertible Debt; provided that principal payments in cash (other than cash in lieu of fractional shares) shall only be allowed if the Redemption Conditions are satisfied in respect of such payment and at all times after such payment; provided further that, to the extent both (a) the aggregate amount of cash payable upon conversion or payment of any Permitted Convertible Debt (excluding any required payment of interest with respect to such Permitted Convertible Debt and excluding any payment of cash in lieu of a fractional share due upon conversion thereof) exceeds the aggregate principal amount thereof and (b) such conversion or payment does not trigger or correspond to an exercise or early unwind or settlement of a corresponding portion of the Permitted Bond Hedge Transactions relating to such Permitted Convertible Debt (including, for the avoidance of doubt, the case where there is no Permitted Bond Hedge Transaction relating to such Permitted Convertible Debt), the payment of such excess cash shall not be permitted by the preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, Borrower may repurchase, exchange or induce the conversion of Permitted Convertible Debt by delivery of Common Stock and/or a different series of Permitted Convertible Debt and/or by payment of cash (in an amount that does not exceed the proceeds received by Borrower from the substantially concurrent issuance of Common Stock and/or Permitted Convertible Debt plus the net cash proceeds, if any, received by Borrower pursuant to the related exercise or early unwind or termination of the related Permitted Bond Hedge Transactions and Permitted Warrant Transactions, if any, pursuant to the immediately following proviso).</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">61</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except for Permitted Transfers, Borrower shall not, and shall not allow any Subsidiary to, voluntarily or involuntarily transfer, sell, lease, license, lend or in any other manner convey any equitable, beneficial or legal interest in any material portion of its assets.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Mergers and Consolidations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than (a) Permitted Acquisitions, (a) mergers or consolidations of a Subsidiary which is not a Borrower into another Subsidiary or into Borrower or (b) mergers or consolidations of a Borrower into another Borrower).</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall, and shall cause each of its Subsidiaries to, pay when due all material Taxes of any nature whatsoever now or hereafter imposed or assessed against Borrower or the Collateral or upon Borrower&#x2019;s ownership, possession, use, operation or disposition thereof or upon Borrower&#x2019;s rents, receipts or earnings arising therefrom.  Borrower shall, and shall cause each of its Subsidiaries to, accurately file on or before the due date therefor (taking into account proper extensions) all federal and state income Tax returns and other material Tax returns required to be filed.  Notwithstanding the foregoing, Borrower and its Subsidiaries may contest, in good faith and by appropriate proceedings diligently conducted, Taxes for which Borrower and its Subsidiaries maintain adequate reserves in accordance with GAAP.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without twenty (20) days&#x2019; prior written notice to Agent.  Neither Borrower nor any Subsidiary shall suffer a Change in Control.  Neither Borrower nor any Subsidiary shall relocate its chief executive office or its principal place of business unless: (i) it has provided prior written notice to Agent; and (ii) such relocation shall be within the continental United States of America.  Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other than (w) drug supplies or clinical trial materials utilized in the ordinary course of business, (x) sales of assets made in accordance with Section 7.8, (y) relocations of Equipment having an aggregate value of up to [***], and (z) relocations of Collateral from a location described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter to another location described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> to the Disclosure Letter) unless (i) it has provided prompt written notice to Agent, (ii) such relocation is within the continental United States of America and, (iii) if such relocation is to a third party bailee, if not prohibited by applicable law, it has delivered a bailee agreement in form and substance reasonably acceptable to Agent.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Deposit Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Other than Excluded Accounts, neither Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except with respect to which Agent has an Account Control Agreement. Notwithstanding the foregoing, the accounts described in Section 4.4 to the Disclosure Letter may be maintained without an Account Control Agreement for the period of time required by Section 4.4, so long as Borrower maintains Cash in an amount of not less than the aggregate amount of all Term Loan Advances at all times until all accounts described in Section 4.4 to the Disclosure Letter are subject to Account Control Agreements. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Formation or Acquisition of Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall notify Agent of each Subsidiary formed or acquired (in accordance with the terms hereof) subsequent to the Closing Date and, within thirty (30) days of formation, shall cause any such Subsidiary (unless such Subsidiary is an Excluded Subsidiary) to execute and deliver to Agent a Joinder Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.15</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notification of Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall notify Agent promptly (and in any event within two (2) Business Days) after becoming aware of the occurrence of any Event of Default.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">62</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.16</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.17</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower agrees that the proceeds of the Loans shall be used solely to pay related fees and expenses in connection with this Agreement and for working capital and general corporate purposes.  The proceeds of the Loans will not be used in (i) violation of Anti-Corruption Laws or applicable Sanctions, or (ii) for personal, family, household or agricultural purposes. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.18</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED]. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.19</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower shall maintain, and shall cause its Subsidiaries to maintain, compliance in all material respects with all applicable laws, rules or regulations (including any law, rule or regulation with respect to the making or brokering of loans or financial accommodations), and shall, or cause its Subsidiaries to, obtain and maintain all required material governmental authorizations, approvals, licenses, franchises, permits or registrations reasonably necessary in connection with the conduct of Borrower&#x2019;s business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti&#x2011;Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti&#x2011;Terrorism Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and Borrower, its Subsidiaries and their respective officers and employees and, to the knowledge of Borrower, its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">None of Borrower, any of its Subsidiaries or any of their respective directors, officers or employees, or to the knowledge of Borrower, any agent for Borrower or its Subsidiaries that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person.  No Loan, use of proceeds or other transaction contemplated by this Agreement will violate Anti-Corruption Laws or applicable Sanctions.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.20</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Financial Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pre-FDA Approval Minimum Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If the FDA Approval Date has not occurred, inclusive of any Qualified Cash amounts maintained in accordance with Sections 7.20(c) and 7.20(d) from and after June 1, 2022, Borrower shall at all times maintain Qualified Cash in an amount equal to the greater of (i) not less than fifty percent (50%) of the sum of the outstanding principal amount of the Term Loan Advances, or (ii) not less than $30,000,000.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Post-FDA Approval Performance Covenant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If the FDA Approval Date has occurred, Borrower shall thereafter elect (at its option and at any time) and satisfy any one of the following </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">63</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">performance covenants: (i) Performance Covenant A, tested at all times during the period such covenant is elected by Borrower, (ii) Performance Covenant B, tested at all times during the period such covenant is elected by Borrower, or (iii) Performance Covenant C, tested at the end of the applicable month during the period such covenant is elected by Borrower.  Borrower shall indicate its election(s) of the applicable performance covenant(s) during the period covered by the Compliance Certificate delivered pursuant to Section 7.1(d).</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Inclusive of any Qualified Cash amounts maintained in accordance with Sections 7.20(a) (or Section 7.20(b) if applicable) and 7.20(d), from and after the date that Borrower first enters into a transaction described in clause (ii)(d)(z) of the definition of Permitted Licenses, Borrower shall at all times maintain Qualified Cash in an amount of not less than $35,000,000.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Inclusive of any Qualified Cash amounts maintained in accordance with Sections 7.20(a) (or Section 7.20(b) if applicable) and 7.20(c), if Borrower makes cash payment in respect of Permitted Convertible Debt subject to satisfaction of the Redemption Conditions, Borrower shall, at all times thereafter, maintain Qualified Cash in the amount required by the defined term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Redemption Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.21</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall (i) protect, defend and maintain the validity and enforceability of its material Intellectual Property; (ii) promptly advise Agent in writing of material infringements of its Intellectual Property known to Borrower; and (iii) not allow any Intellectual Property material to Borrowers&#x2019; business to be abandoned, forfeited or dedicated to the public without Agent&#x2019;s written consent, in each case subject to Borrower&#x2019;s reasonable discretion and standard commercial practices.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.22</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transactions with Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower shall not and shall not permit any Subsidiary to, directly or indirectly, enter into or permit to exist any transaction of any kind with any Affiliate of Borrower or such Subsidiary on terms that are less favorable to Borrower or such Subsidiary, as the case may be, than those that might be obtained in an arm&#x2019;s length transaction from a Person who is not an Affiliate of Borrower or such Subsidiary.  </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 19</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[Reserved]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 20</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EVENTS OF DEFAULT</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any one or more of the following events shall be an Event of Default:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower fails to pay any amount due under this Agreement or any of the other Loan Documents on the due date; provided, however, that an Event of Default shall not occur on account of a failure to pay due solely to an administrative or operational error of Agent or the Lenders or Borrower&#x2019;s bank if Borrower had the funds to make the payment when due and makes the payment within three (3) Business Days following Borrower&#x2019;s knowledge of such failure to pay; or</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other Loan Documents, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.19, 7.21, and 7.22) or any other Loan Document, such default continues for more than thirty (30) days after the earlier of the date on which (i) Agent or the Lenders have given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect to a default under any of Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 7.15, 7.17, 7.19, 7.20, 7.21, and 7.22, the occurrence of such default; or </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">64</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  A circumstance has occurred that could reasonably be expected to have a Material Adverse Effect; provided that, solely for purposes of this Section 9.3, the following events shall not, in each case in and of itself, constitute a Material Adverse Effect: (a) adverse results or delays in any nonclinical or clinical trial, (b) the failure to achieve any clinical or non-clinical trial goals or objectives, including without limitation, the failure to demonstrate the desired safety or efficacy of any drug or companion diagnostic, (c) the denial, delay or limitation of approval of, or taking of any other regulatory action (e.g., a clinical hold) by the applicable regulatory authority with respect to any drug, delivery system or companion diagnostic, (d) a change in or discontinuation of a strategic partnership or other collaboration or license arrangement so long as the same does not affect the ability of Borrower to perform the Secured Obligations or (e) failure to achieve Performance Milestone I, Performance Milestone II or Performance Milestone III so long as the same does not affect the ability of Borrower to perform the Secured Obligations; or </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any representation or warranty made by Borrower in any Loan Document shall have been false or misleading in any material respect when made or when deemed made; or </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Insolvency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee, receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower; or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all of its employees; or (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the foregoing actions described in clauses (i) through (vi); or (B) either (i) thirty (30) days shall have expired after the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings; or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such proceedings; or (v) thirty (30) days shall have expired after the appointment, without the consent or acquiescence of Borrower, of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such appointment being vacated; or</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attachments; Judgments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any material portion of Borrower&#x2019;s assets is attached or seized, or a levy is filed against any such assets, or a judgment or judgments is/are entered for the payment of money (not covered by independent third party insurance as to which liability has not been rejected by such insurance carrier), individually or in the aggregate, of at least [***], and such judgment remains unsatisfied, unvacated or unstayed for a period of twenty (20) days after the entry thereof, or Borrower is enjoined or in any way prevented by court order from conducting any material part of its business; or</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The occurrence of any default (after giving effect to any grace period or cure period) under any agreement or obligation of Borrower involving any Indebtedness in excess of [***], which has resulted in a right by the holder of such Indebtedness, whether exercised or not, to accelerate the maturity of such Indebtedness, or any early payment is required or unwinding or termination occurs with respect to any Permitted Bond Hedge Transaction or Permitted Warrant Transaction, or any </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">65</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">condition giving rise to the foregoing is met, in each case, with respect to which Borrower or its Affiliate is the &#x201c;affected party&#x201d; or &#x201c;defaulting party&#x201d; under the terms of such Permitted Bond Hedge Transaction or Permitted Warrant Transaction, as a result thereof Borrower would be required to make cash payments or otherwise settle any such unwind or termination in cash and if a Material Adverse Effect could reasonably be expected to result from such default, early payment, unwinding or termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 21</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">REMEDIES</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the occurrence and during the continuation of any one or more Events of Default, Agent may, and at the direction of the Required Lenders shall, without notice or demand, do any or all of the following: (i) accelerate and demand payment of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable (provided, that upon the occurrence of an Event of Default of the type described in Section 9.5, all of the Secured Obligations (including, without limitation, the Prepayment Charge and the End of Term Charge) shall automatically be accelerated and made due and payable, in each case without any further notice or act); (ii) place a &#x201c;hold&#x201d; on any account maintained with SVB and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral.  In addition, upon the occurrence of any one or more Events of Default, any Lender may stop advancing money or extending credit for Borrower&#x2019;s benefit under this Agreement or under any other agreement between Borrower and such Lender. </font>
   </div>
  </div>
  <p style="text-indent:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact to:  (a) exercisable following the occurrence and continuation of an Event of Default, (i) sign Borrower&#x2019;s name on any invoice or bill of lading for any account or drafts against account debtors; (ii) demand, collect, sue, and give releases to any account debtor for monies due, settle and adjust disputes and claims about the accounts directly with account debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Agent&#x2019;s or Borrower&#x2019;s name, as Agent may elect); (iii) make, settle, and adjust all claims under Borrower&#x2019;s insurance policies; (iv) pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; (v) transfer the Collateral into the name of Agent or a third party as the UCC permits; and (vi) receive, open and dispose of mail addressed to Borrower; (vii) endorse Borrower&#x2019;s name on any checks, payment instruments, or other forms of payment or security; and (viii) notify all account debtors to pay Agent directly.  Borrower hereby appoints Agent as its lawful attorney-in-fact to sign Borrower&#x2019;s name on any documents necessary to perfect or continue the perfection of Agent&#x2019;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Secured Obligations have been satisfied in full and the Loan Documents have been terminated.  Agent&#x2019;s foregoing appointment as Borrower&#x2019;s attorney in fact, and all of Agent&#x2019;s rights and powers, coupled with an interest, are irrevocable until all Secured Obligations have been fully repaid and performed and the Loan Documents have been terminated.  Agent may, and at the direction of the Required Lenders shall, exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon, or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral.  All Agent&#x2019;s rights and remedies shall be cumulative and not exclusive.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Collection; Foreclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon the occurrence and during the continuance of any Event of Default, Agent may, and at the direction of the Required Lenders shall, at any time or from time to time, apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then condition or following any commercially reasonable preparation or processing, in such order as Agent may elect.  Any such sale may be made either at public or private sale at its place of business or elsewhere.  Borrower agrees that any such public or private sale may occur upon ten (10) calendar days&#x2019; </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">66</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">prior written notice to Borrower.  Agent may require Borrower to assemble the Collateral and make it available to Agent at a place designated by Agent that is reasonably convenient to Agent and Borrower.  The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Agent in the following order of priorities:</font>
   </div>
  </div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">First, to Agent and the Lenders in an amount sufficient to pay in full Agent&#x2019;s and the Lenders&#x2019; reasonable costs and professionals&#x2019; and advisors&#x2019; fees and expenses as described in Section 11.12;</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Second, to the Lenders in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default Rate interest), in such order and priority as Agent may choose in its sole discretion; and</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Finally, after the full and final payment in Cash of all of the Secured Obligations (other than inchoate obligations), to any creditor holding a junior Lien on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent shall be deemed to have acted reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured party under the UCC.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person, and Borrower expressly waives all rights, if any, to require Agent to marshal any Collateral.  </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Cumulative Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The rights, powers and remedies of Agent hereunder shall be in addition to all rights, powers and remedies given by statute or rule of law and are cumulative.  The exercise of any one or more of the rights, powers and remedies provided herein shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Agent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:center;">
   <font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">Section 22</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">MISCELLANEOUS**</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.1</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.2</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by electronic mail or hand delivery or delivery by an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States of America mails, with proper first class postage prepaid, in each case addressed to the party to be notified as follows:</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to Agent:</font>
   </div>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br>Legal Department<br>Attention:  [***]<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">67</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">400 Hamilton Avenue, Suite 310<br>Palo Alto, CA  94301<br>email: [***]<br>Telephone:  [***]</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to the Lenders:</font>
   </div>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br>Legal Department<br>Attention:  [***]<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA  94301<br>email: [***]<br>Telephone:  [***]</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SILICON VALLEY BANK</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">505 Howard Street, Floor 3</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, CA 94105<br>Attn: 	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br>Email:  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Telephone:  [***]</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If to Borrower:</font>
   </div>
  </div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Geron Corporation</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">919 E. Hillsdale Blvd., Suite 250</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foster City, CA 94404</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attention:  Executive Vice President and Chief Financial Officer and Chief Legal Officer <br>email:  </font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OBloom@Geron.com and srosenfield@Geron.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[***]<br>Telephone: [***]</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">With a copy to:</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COOLEY LLP</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">101 California Street, 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Floor</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, CA 94111</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attn:  [***]</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Email:  [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">or to such other address as each party may designate for itself by like notice.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.3</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement; Amendments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof or thereof (including Agent&#x2019;s revised proposal letter dated September 1, 2020 and the Non-Disclosure Agreement).  </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">68</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Neither this Agreement, any other Loan Document, nor any terms hereof or thereof may be amended, supplemented or modified except in accordance with the provisions of this Section 11.3(b).  The Required Lenders and Borrower party to the relevant Loan Document may, or, with the written consent of the Required Lenders, the Agent and the Borrower party to the relevant Loan Document may, from time to time, (i) enter into written amendments, supplements or modifications hereto and to the other Loan Documents for the purpose of adding any provisions to this Agreement or the other Loan Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (ii) waive, on such terms and conditions as the Required Lenders or the Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or the other Loan Documents or any default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or modification shall (A) forgive the principal amount or extend the final scheduled date of maturity of any Loan, extend the scheduled date of any amortization payment in respect of any Term Loan, reduce the stated rate of any interest (or fee payable hereunder) or extend the scheduled date of any payment thereof, in each case without the written consent of each Lender directly affected thereby; (B) eliminate or reduce the voting rights of any Lender under this Section 11.3(b) without the written consent of such Lender; (C) reduce any percentage specified in the definition of Required Lenders, consent to the assignment or transfer by the Borrower of any of its rights and obligations under this Agreement and the other Loan Documents, release all or substantially all of the Collateral or release a Borrower from its obligations under the Loan Documents, in each case without the written consent of all Lenders; or (D) amend, modify or waive any provision of Section 11.18 or Addendum 3 without the written consent of the Agent.  Any such waiver and any such amendment, supplement or modification shall apply equally to each Lender and shall be binding upon Borrower, the Lender, the Agent and all future holders of the Loans.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.4</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Strict Construction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.5</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The powers conferred upon Agent and the Lenders by this Agreement are solely to protect its rights hereunder and under the other Loan Documents and its interest in the Collateral and shall not impose any duty upon Agent or the Lenders to exercise any such powers.  No omission or delay by Agent or the Lenders at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Agent or the Lenders is entitled, nor shall it in any way affect the right of Agent or the Lenders to enforce such provisions thereafter.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.6</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered pursuant hereto or thereto shall be for the benefit of Agent and the Lenders and shall survive the execution and delivery of this Agreement. Sections 6.3, 11.13, 11.14, 11.15 and 11.17 shall survive the termination of this Agreement, subject in each case to the applicable statute of limitations.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.7</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower and its permitted assigns (if any).  Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents without Agent&#x2019;s express prior written consent, and any such attempted assignment shall be void and of no effect.  Agent and the Lenders may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and all of such rights shall inure to the benefit of Agent&#x2019;s and the Lenders&#x2019; successors and assigns; provided that as long as no Event of Default has occurred and is continuing, neither Agent nor any Lender may assign, transfer or endorse its rights hereunder or under the Loan Documents to </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">69</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any party that is a direct competitor of Borrower (as reasonably determined by Agent), it being acknowledged that in all cases, any transfer to an Affiliate of any Lender or Agent shall be allowed.  Notwithstanding the foregoing, (x) in connection with any assignment by a Lender as a result of a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party and (y) in connection with a Lender&#x2019;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Agent and the Lenders may assign, transfer or indorse its rights hereunder and under the other Loan Documents to any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such assignee as Agent reasonably shall require.  The Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its offices in the United States a register for the recordation of the names and addresses of the Lender(s), and the Term Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Agent and the Lender(s) shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.8</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each participant and the principal amounts (and stated interest) of each participant&#x2019;s interest in the Loans or other obligations under the Loan Documents (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Participant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant's interest in any commitments, loans, its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Agent (in its capacity as Agent) shall have no responsibility for maintaining a Participant Register.  Borrower agrees that each participant shall be entitled to the benefits of the provisions in Addendum 1 attached hereto (subject to the requirements and limitations therein, including the requirements under Section 7 of Addendum 1 attached hereto (it being understood that the documentation required under Section 7 of Addendum 1 attached hereto shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 11.7; provided that such participant shall not be entitled to receive any greater payment under Addendum 1 attached hereto, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.9</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and the other Loan Documents have been negotiated and delivered to Agent and the Lenders in the State of California, and shall have been accepted by Agent and the Lenders in the State of California.  Payment to Agent and the Lenders by Borrower of the Secured Obligations is due in the State of California.  This Agreement and the other Loan Documents shall be </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">70</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.10</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Consent to Jurisdiction and Venue</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  All judicial proceedings (to the extent that the reference requirement of Section 11.11 is not applicable) arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court located in the State of California.  By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement or the other Loan Documents.  Service of process on any party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2, and shall be deemed effective and received as set forth in Section 11.2.  Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.11</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Mutual Waiver of Jury Trial / Judicial Reference</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Because disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced and expert Person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.  EACH OF BORROWER, AGENT AND THE LENDERS SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">CLAIMS</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) ASSERTED BY BORROWER AGAINST AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE OR BY AGENT, THE LENDERS OR THEIR RESPECTIVE ASSIGNEE AGAINST BORROWER.  This waiver extends to all such Claims, including Claims that involve Persons other than Agent, Borrower and the Lenders; Claims that arise out of or are in any way connected to the relationship among Borrower, Agent and the Lenders; and any Claims for damages, breach of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other Loan Document.  </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the waiver of jury trial set forth in Section 11.11(a) is ineffective or unenforceable, the parties agree that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County, California.  Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding.    </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">In the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.10, any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.12</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Professional Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower promises to pay Agent&#x2019;s and the Lenders&#x2019; reasonable fees and expenses necessary to finalize the loan documentation, including but not limited to reasonable and documented out-of-pocket attorneys&#x2019; fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises to pay any and all reasonable and documented out-of-pocket attorneys&#x2019; and other professionals&#x2019; fees and expenses incurred by Agent and the Lenders after the Closing Date in connection with or related to:  (a) the Loan; (b) the collection, or enforcement of the Loan; (c) the </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">71</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">amendment or modification of the Loan Documents; (d) any waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, audit, field exam, sale, lease, liquidation, or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative, arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure, or other action related to Borrower, the Collateral, the Loan Documents, including representing Agent or the Lenders in any adversary proceeding or contested matter commenced or continued by or on behalf of Borrower&#x2019;s estate, and any appeal or review thereof.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.13</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent and the Lenders acknowledge that the Collateral and information provided to Agent and the Lenders by Borrower are confidential and proprietary information of Borrower, if and to the extent such information should reasonably be understood to be confidential (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Accordingly, Agent and the Lenders agree that any Confidential Information shall not be disclosed to any other Person or entity in any manner whatsoever, in whole or in part, without the prior written consent of Borrower, except that Agent and the Lenders may disclose any such information:  (a) to its Affiliates and its partners, investors, lenders, directors, officers, employees, agents, advisors, counsel, accountants, counsel, representative and other professional advisors if Agent or the Lenders in their sole discretion determines that any such party should have access to such information in connection with such party&#x2019;s responsibilities in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the public or to the extent such information becomes publicly available other than as a result of a breach of this Section or becomes available to Agent or any Lender, or any of their respective Affiliates on a non-confidential basis from a source other than the Borrower; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having or claiming to have jurisdiction over Agent or the Lenders and any rating agency; (d) if required or appropriate in response to any summons or subpoena or in connection with any litigation, to the extent permitted or deemed advisable by Agent&#x2019;s or the Lenders&#x2019; counsel; (e) to comply with any legal requirement or law applicable to Agent or the Lenders or demanded by any governmental authority; (f) to the extent reasonably necessary in connection with the exercise of, or preparing to exercise, or the enforcement of, or preparing to enforce, any right or remedy under any Loan Document (including Agent&#x2019;s sale, lease, or other disposition of Collateral after default), or any action or proceeding relating to any Loan Document; (g) to any participant or assignee of Agent or the Lenders or any prospective participant or assignee, provided, that such participant or assignee or prospective participant or assignee is subject to the confidentiality provisions of this Section 11.13; (h) otherwise to the extent consisting of general portfolio information, aggregate datasets, for analyses or reporting, that does not identify Borrower; or (i) otherwise with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations of Borrower or any of its Affiliates or any guarantor under this Agreement or the other Loan Documents. Agent&#x2019;s and the Lenders&#x2019; obligations under this Section 11.13 shall supersede all of their respective obligations under the Non-Disclosure Agreement.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.14</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Assignment of Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Borrower acknowledges and understands that Agent or the Lenders may, subject to Section 11.7, sell and assign all or part of its interest hereunder and under the Loan Documents to any Person or entity (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Assignee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  After such assignment the term &#x201c;Agent&#x201d; or &#x201c;Lender&#x201d; as used in the Loan Documents shall mean and include such Assignee, and such Assignee shall be vested with all rights, powers and remedies of Agent and the Lenders hereunder with respect to the interest so assigned; but with respect to any such interest not so transferred, Agent and the Lenders shall retain all rights, powers and remedies hereby given.  No such assignment by Agent or the Lenders shall relieve Borrower of any of its obligations hereunder.  Each Lender agrees that in the event of any transfer by it of </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">72</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the promissory note(s) (if any), it will endorse thereon a notation as to the portion of the principal of the promissory note(s), which shall have been paid at the time of such transfer and as to the date to which interest shall have been last paid thereon.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.15</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Revival of Secured Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower&#x2019;s assets, or if any payment or transfer of Collateral is recovered from Agent or the Lenders.  The Loan Documents and the Secured Obligations and Collateral security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance of the Secured Obligations or any transfer of Collateral to Agent, or any part thereof is rescinded, avoided or avoidable, reduced in amount, or must otherwise be restored or returned by, or is recovered from, Agent, the Lenders or by any obligee of the Secured Obligations, whether as a &#x201c;voidable preference,&#x201d; &#x201c;fraudulent conveyance,&#x201d; or otherwise, all as though such payment, performance, or transfer of Collateral had not been made.  In the event that any payment, or any part thereof, is rescinded, reduced, avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible payment to Agent or the Lenders in Cash.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.16</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.17</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any third-party beneficiary rights or any other rights of any kind in any Person other than Agent, the Lenders and Borrower unless specifically provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely among Agent, the Lenders and the Borrower. </font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.18</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent and each Lender hereby agree to the terms and conditions set forth on Addendum 3 attached hereto.  Borrower acknowledges and agrees to the terms and conditions set forth on Addendum 3 attached hereto.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.19</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Publicity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  None of the parties hereto nor any of its respective member businesses and Affiliates shall, without the other parties&#x2019; prior written consent (which shall not be unreasonably withheld or delayed), publicize or use (a) the other party's name (including a brief description of the relationship among the parties hereto), logo or hyperlink to such other parties&#x2019; web site, separately or together, in written and oral presentations, advertising, promotional and marketing materials, client lists, public relations materials or on its web site (together, the &#34;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Publicity Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#34;); (b) the names of officers of such other parties in the Publicity Materials; and (c) such other parties&#x2019; name, trademarks, servicemarks in any news or press release concerning such party; provided however, notwithstanding anything to the contrary herein, no such consent shall be required (i) to the extent necessary to comply with the requests of any regulators, legal requirements or laws applicable to such party, pursuant to any listing agreement with any national securities exchange (so long as such party provides prior notice to the other party hereto to the extent reasonably practicable) and (ii) to comply with Section 11.13.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.20</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[RESERVED].</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">73</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.21</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Electronic Execution of Certain Other Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The words &#x201c;execution,&#x201d; &#x201c;execute&#x201d;, &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transaction Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font>
   </div>
  </div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.22</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Termination Prior to Term Loan Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  So long as Borrower has satisfied the Secured Obligations (other than inchoate indemnity obligations), this Agreement may be terminated prior to the Term Loan Maturity Date by Borrower, effective seven (7) Business Days after written notice of termination is given to Agent.  Those obligations that are expressly specified in this Agreement as surviving this Agreement&#x2019;s termination shall continue to survive notwithstanding this Agreement&#x2019;s termination.  No termination of this Agreement shall in any way affect or impair any right or remedy of Agent or any Lender, nor shall any such termination relieve Borrower of any Secured Obligation to any Lender, until all of the Secured Obligations (other than inchoate indemnity obligations) have been paid and performed in full. Those Secured Obligations that are expressly specified in this Agreement as surviving this Agreement&#x2019;s termination shall continue to survive notwithstanding this Agreement&#x2019;s termination and payment in full of the Secured Obligations then outstanding. </font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(SIGNATURES TO FOLLOW)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">74</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, Borrower, Agent and the Lenders have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">BORROWER:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accepted in Palo Alto, California:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">LENDERS:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SILICON VALLEY BANK</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Signature:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Print Name:	_______________________</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:		_______________________</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">75</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Table of Addenda, Exhibits and Schedules</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Addendum 1:  	Taxes; Increased Costs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Addendum 2:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Addendum 3:	Agent and Lender Terms</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E:	Compliance Certificate</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit F:	Joinder Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit G:	[RESERVED]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit H:	[RESERVED]</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit I:	[RESERVED]</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-1:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-2:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-3:	Form of U.S. Tax Compliance Certificate (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit J-4:	Form of U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Schedule 1.1	Commitments</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 1 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">TAXES; INCREASED COSTS</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">16.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  For purposes of this Addendum 1:</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Connection Income Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Excluded Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (i) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (A) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (B) that are Other Connection Taxes, (ii) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Term Commitment pursuant to a law in effect on the date on which (A) such Lender acquires such interest in the Loan or Term Commitment or (B) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2 or Section 4 of this Addendum 1, amounts with respect to such Taxes were payable either to such Lender&#x2019;s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (iii) Taxes attributable to such Recipient&#x2019;s failure to comply with Section 7 of this Addendum 1 and (iv) any withholding Taxes imposed under FATCA.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FATCA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code, and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among governmental authorities and implementing such Sections of the Code.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">d.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Foreign Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Lender that is not a U.S. Person.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">e.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnified Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means (i) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (ii) to the extent not otherwise described in clause (i), Other Taxes.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">f.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Connection Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">g.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">h.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recipient</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Agent or any Lender, as applicable.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">i.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Borrower and the Agent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">17.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payments Free of Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law.  If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant governmental authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section 2 or Section 4 of this Addendum 1) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">18.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Payment of Other Taxes by Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower shall timely pay to the relevant governmental authority in accordance with applicable law, or at the option of the Agent timely reimburse it for the payment of, any Other Taxes.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">19.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under Section 2 of this Addendum 1 or this Section 4) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant governmental authority.  A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Agent), or by the Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error. </font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">20.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification by the Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each Lender shall severally indemnify the Agent, within 10 days after demand therefor, for (a) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (b) any Taxes attributable to such Lender&#x2019;s failure to comply with the provisions of Section 11.8 of the Agreement relating to the maintenance of a Participant Register and (c) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant governmental authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the Agent shall be conclusive absent manifest error.  Each Lender hereby authorizes the Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Agent to the Lender from any other source against any amount due to the Agent under this Section 5.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">21.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Evidence of Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  As soon as practicable after any payment of Taxes by the Borrower to a governmental authority pursuant to the provisions of this Addendum 1, the Borrower shall deliver to the Agent the original or a certified copy of a receipt issued by such governmental authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Agent.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">22.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Status of Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Agent, at the time or times reasonably requested by the Borrower or the Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by the Borrower or the Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Agent as will enable the Borrower or the Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Sections 7(b)(i), 7(b)(ii) and 7(b)(iv) of this Addendum 1) shall not be required if in the Lender&#x2019;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Without limiting the generality of the foregoing, in the event that the Borrower is a U.S. Person,</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">i.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Lender that is a U.S. Person shall deliver to the Borrower and the Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">ii.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), whichever of the following is applicable:</font>
   </div>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">A.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;interest&#x201d; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;business profits&#x201d; or &#x201c;other income&#x201d; article of such tax treaty;</font>
   </div>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">B.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">executed copies of IRS Form W-8ECI;</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">C.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit J-1 to the effect that such Foreign Lender is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, a &#x201c;10 percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, or a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">U.S. Tax Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and (y) executed copies of IRS Form W-8BEN or IRS Form W-8BEN-E; or</font>
   </div>
  </div>
  <div style="margin-left:20%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:8.33375%;display:inline-flex;justify-content:flex-start;">D.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-2 or Exhibit J-3, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit J-4 on behalf of each such direct and indirect partner;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">iii.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Agent), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Agent to determine the withholding or deduction required to be made; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.692662720527998%;display:inline-flex;justify-content:flex-start;">iv.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Agent as may be necessary for the Borrower and the Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#x2019;s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment.  Solely for purposes of this clause (iv), &#x201c;FATCA&#x201d; shall include any amendments made to FATCA after the date of this Agreement.</font>
   </div>
  </div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Agent in writing of its legal inability to do so.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">23.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Certain Refunds</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to the provisions of this Addendum 1 (including by the payment of additional amounts pursuant to the provisions of this Addendum 1), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under the provisions of this Addendum 1 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant governmental authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this Section 8 (plus any penalties, interest or other charges imposed by the relevant governmental authority) in the event that such indemnified party is required to repay such refund to such governmental authority.  Notwithstanding anything to the contrary in this Section 8, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 8 the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This Section 8 shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">24.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Increased Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any change in applicable law shall subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (ii) through (iv) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto, and the result shall be to increase the cost to such Recipient of making, converting to, continuing or maintaining any Term Loan or of maintaining its obligation to make any such Loan, or to reduce the amount of any sum received or receivable by such Recipient (whether of principal, interest or any other amount), then, upon the request of such Recipient, the Borrower will pay to such Recipient such additional amount or amounts as will compensate such Recipient for such additional costs incurred or reduction suffered. Failure or delay on the part of any Recipient to demand compensation pursuant to this Section 9 shall not constitute a waiver of such Recipient&#x2019;s right to demand such compensation; provided that the Borrower shall not be required to compensate a Recipient pursuant to this Section 9 for any increased costs incurred or reductions suffered more than nine months prior to the date that such Recipient notifies the Borrower of the change in law giving rise to such increased costs or reductions, and of such Recipient&#x2019;s intention to claim compensation therefor (except that, if the change in law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">25.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Each party&#x2019;s obligations under the provisions of this Addendum 1 shall survive the resignation or replacement of the Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Term Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font>
   </div>
  </div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ADDENDUM 3 to LOAN AND SECURITY AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent and Lender Terms</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Lender hereby irrevocably appoints Hercules Capital, Inc. to act on its behalf as the Agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each Lender agrees to indemnify the Agent in its capacity as such (to the extent not reimbursed by Borrower and without limiting the obligation of Borrower to do so), according to its respective Term Commitment percentages (based upon the total outstanding Term Commitments) in effect on the date on which indemnification is sought under this Addendum 3, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever that may at any time be imposed on, incurred by or asserted against the Agent in any way relating to or arising out of, this Agreement, any of the other Loan Documents or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Agent under or in connection with any of the foregoing.  The agreements in this Section shall survive the payment of the Loans and all other amounts payable hereunder.</font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent in Its Individual Capacity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Person serving as the Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent and the term &#x201c;Lender&#x201d; shall, unless otherwise expressly indicated or unless the context otherwise requires, include each such Person serving as Agent hereunder in its individual capacity.  Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with Borrower or any Subsidiary or other Affiliate thereof as if such Person were not Agent hereunder and without any duty to account therefor to Lenders. </font>
   </div>
  </div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exculpatory Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  The Agent shall have no duties or obligations except those expressly set forth herein and in the other Loan Documents.  Without limiting the generality of the foregoing, the Agent shall not</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">be subject to any fiduciary or other implied duties, regardless of whether any default or any Event of Default has occurred and is continuing;</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent is required to exercise as directed in writing by the Lenders, provided that the Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent to liability or that is contrary to any Loan Document or applicable law; and</font>
   </div>
  </div>
  <div style="margin-left:13.333%;text-indent:7.692%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.0772958565543975%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and the Agent shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by any Person serving as the Agent or any of its Affiliates in any capacity.</font>
   </div>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Lenders or as the Agent shall believe in good faith shall be necessary, under the circumstances or (ii) in the absence of its own gross negligence or willful misconduct.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reliance by Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Agent may rely, and shall be fully protected in acting, or refraining to act, upon, any resolution, statement, certificate, instrument, opinion, report, notice, request, consent, order, bond or other paper or document that it has no reason to believe to be other than genuine and to have been signed or presented by the proper party or parties or, in the case of cables, telecopies and telexes, to have been sent by the proper party or parties.  In the absence of its gross negligence or willful misconduct, Agent may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to Agent and conforming to the requirements of this Agreement or any of the other Loan Documents.  Agent may consult with legal counsel, independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.  Agent shall have the right at any time to seek instructions concerning the administration of the Collateral from any court of competent jurisdiction.  Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement and the other Loan Documents in accordance with a request of the Lenders, and such request and any action taken or failure to act pursuant thereto shall be binding upon Lenders and all future holders of the Loans.</font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT E</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Hercules Capital, Inc. (as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)<br>400 Hamilton Avenue, Suite 310<br>Palo Alto, CA 94301</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to that certain Loan and Security Agreement dated September 30, 2020 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among Hercules Capital, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time party thereto (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and GERON CORPORATION (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as Borrower. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned is an Officer of the Company, knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company; hereby certifies, in such capacity, that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period ending ___________ of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties.  Attached are the required documents supporting the above certification. [The undersigned further certified that these are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statements and subject to normal year end adjustments) and are consistent from one period to the next except as explained below.]</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47.48%;"></td>
    <td style="width:29.42%;"></td>
    <td style="width:23.1%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">REPORTING REQUIREMENT</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">REQUIRED</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CHECK IF ATTACHED</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[Interim Financial Statements</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Monthly within 30 days]</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[Interim Financial Statements</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Quarterly within 45 days]</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Audited Financial Statements</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">FYE within 90 days</font></p></td>
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">See SEC filings</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ACCOUNTS OF BORROWER AND ITS SUBSIDIARIES AND AFFILIATES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned hereby also confirms the below disclosed accounts represent all depository accounts and securities accounts presently open in the name of the Borrower or Borrower&#x2019;s Subsidiary/Affiliate, as applicable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each new account that has been opened since delivery of the previous Compliance Certificate is designated below with a &#x201c;*&#x201d;.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.4%;"></td>
    <td style="width:3.16%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.3%;"></td>
    <td style="width:14.3%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Depository AC #</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Institution</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Account Type (Depository / Securities)</font></p></td>
    <td style="border-top:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Last Month Ending Account Balance</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Purpose of Account</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BORROWER Name/Address:</font></p></td>
    <td colspan="6" style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="4" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.4%;"></td>
    <td style="width:3.16%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.28%;"></td>
    <td style="width:14.3%;"></td>
    <td style="width:14.3%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="3" style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SUBSIDIARY / AFFILIATE Name/Address</font></p></td>
    <td colspan="6" style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td rowspan="7" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 7.20 - Financial Covenants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent applicable, the undersigned hereby confirms that the Borrower is in compliance with Section 7.20 of the Loan Agreement (as applicable, below are the required calculations supporting this certification, as of the date first set forth above).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:22.58%;"></td>
    <td style="width:52.7%;"></td>
    <td style="width:8.92%;"></td>
    <td style="width:15.8%;"></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Covenant</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Required</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Actual</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">In Compliance?</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-FDA Approval Minimum Cash </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(a) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Greater than or equal to the greater of (i) fifty percent (50%) of the sum of the outstanding principal amount of the Term Loan Advances, or (ii) $30,000,000.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Post-FDA Approval Performance Covenant A<br></font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;Performance Covenant A&#x201d; means Borrower at all times maintains Qualified Cash in an amount not less than forty percent (40%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elected: Y/N</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compliance:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Post-FDA Approval Performance Covenant B<br></font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(i) Borrower&#x2019;s Market Capitalization is or exceeds Seven Hundred Fifty Million Dollars ($750,000,000), and (ii) Borrower maintains Qualified Cash in an amount not less than twenty five percent (25%) of the sum of the outstanding principal amount of the Term Loan Advances.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elected: Y/N</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compliance:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.002in;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Post-FDA Approval Performance Covenant C<br></font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Section 7.20(b) of the Loan Agreement</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrower achieves T6M Net Product Revenue of at least 70% of the T6M Net Product Revenue included in the Forecast, determined at the end of the applicable month.</font></p></td>
    <td style="padding-top:0.002in;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.002in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0.002in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elected: Y/N</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compliance:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Yes</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">N/A</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective from and after June 1, 2022, or the date that Borrower first enters into a transaction described in clause (ii)(d)(z)] of the definition of Permitted Licenses. See Section 7.20. 		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a)  The amount of Qualified Cash as of the date hereof:  $_________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Is the amount reported in clause (a) equal to or greater than $35,000,000*?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	__ Yes; __ No</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">		If No: not in compliance</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">* Upon the date that Borrower first enters into a transaction described in clause (ii)(d)(z) of the definition of Permitted Licenses, the Qualified Cash Amount shall be permanently increased to $35,000,000.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="text-indent:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Very Truly Yours,</font></p>
  <p style="text-indent:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:   _____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Its:	____________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT F</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF JOINDER AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Joinder Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Joinder Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is made and dated as of [          ], 20[  ], and is entered into by and between__________________., a ___________ corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation (as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RECITALS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">A.  Subsidiary&#x2019;s Affiliate, [                              ] (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) [has entered/desires to enter] into that certain Loan and Security Agreement dated September 30, 2020, with the several banks and other financial institutions or entities from time to time party thereto as lender (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Agent, as such agreement may be amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), together with the other agreements executed and delivered in connection therewith;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">B.  Subsidiary acknowledges and agrees that it will benefit both directly and indirectly from Company&#x2019;s execution of the Loan Agreement and the other agreements executed and delivered in connection therewith;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOW THEREFORE, Subsidiary and Agent agree as follows:</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">26.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The recitals set forth above are incorporated into and made part of this Joinder Agreement.  Capitalized terms not defined herein shall have the meaning provided in the Loan Agreement.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">27.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis, provided however, that (a) with respect to (i) Section 5.1 of the Loan Agreement, Subsidiary represents that it is an entity duly organized, legally existing and in good standing under the laws of [        ], (b) neither Agent nor the Lenders shall have any duties, responsibilities or obligations to Subsidiary arising under or related to the Loan Agreement or the other Loan Documents, (c) that if Subsidiary is covered by Company&#x2019;s insurance, Subsidiary shall not be required to maintain separate insurance or comply with the provisions of Sections 6.1 and 6.2 of the Loan Agreement, and (d) that as long as Company satisfies the requirements of Section 7.1 of the Loan Agreement, Subsidiary shall not have to provide Agent separate Financial Statements.  To the extent that Agent or the Lenders has any duties, responsibilities or obligations arising under or related to the Loan Agreement or the other Loan Documents, those duties, responsibilities or obligations shall flow only to Company and not to Subsidiary or any other Person or entity.  By way of example (and not an exclusive list): (i) Agent&#x2019;s providing notice to Company in accordance with the Loan Agreement or as otherwise agreed among Company, Agent and the Lenders shall be deemed provided to Subsidiary; (ii) a Lender&#x2019;s providing an Advance to Company shall be deemed an Advance to Subsidiary; and (iii) Subsidiary shall have no right to request an Advance or make any other demand on the Lenders.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">28.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary agrees not to certificate its equity securities without Agent&#x2019;s prior written consent, which consent may be conditioned on the delivery of such equity securities to Agent in order to perfect Agent&#x2019;s security interest in such equity securities.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">29.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary acknowledges that it benefits, both directly and indirectly, from the Loan Agreement, and hereby waives, for itself and on behalf on any and all successors in interest (including without limitation any assignee for the benefit of creditors, receiver, bankruptcy trustee or itself as debtor-in-possession under any bankruptcy proceeding) to the fullest extent provided by law, any and all </font>
   </div>
  </div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">claims, rights or defenses to the enforcement of this Joinder Agreement on the basis that (a) it failed to receive adequate consideration for the execution and delivery of this Joinder Agreement or (b) its obligations under this Joinder Agreement are avoidable as a fraudulent conveyance.</font>
   </div>
  </div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;">
   <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">30.</font>
   <div style="width:100%;display:inline;">
    <font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of all the Secured Obligations, Subsidiary grants to Agent a security interest in all of Subsidiary&#x2019;s right, title, and interest in and to the Collateral.</font>
   </div>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">[SIGNATURE PAGE TO JOINDER AGREEMENT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SUBSIDIARY:</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_________________________________.</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	By:			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Name:			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Title: 			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Address:</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">			</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Telephone: ___________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	email: ____________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AGENT:</font></p>
  <p style="margin-left:0.933%;text-indent:-21.405%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">HERCULES CAPITAL, INC.<br><br>By:____________________________________<br>Name:__________________________________</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:0.933%;text-indent:-21.405%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Title: ___________________________________<br><br>Address:<br>400 Hamilton Ave., Suite 310<br>Palo Alto, CA 94301<br>email: legal@htgc.com<br>Telephone:  650-289-3060</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-1</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 (as amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished the Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF LENDER]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-2</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 (as amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a &#x201c;bank&#x201d; within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or IRS Form W-8BEN-E. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF PARTICIPANT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-3</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 as amended, supplemented or otherwise modified from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such participation, (iii) with respect to such participation, neither the undersigned nor any of its direct or indirect partners/members is a &#x201c;bank&#x201d; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#x2019;s/member&#x2019;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF PARTICIPANT]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT J-4</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">FORM OF U.S. TAX COMPLIANCE CERTIFICATE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Reference is hereby made to the Loan and Security Agreement dated as of September 30, 2020 (as amended, supplemented or otherwise modified from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Loan Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation, and each of its Subsidiaries (as defined in the Loan Agreement) (hereinafter collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (in such capacity, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of Addendum 1 of the Loan Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any promissory note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any promissory note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Loan Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is a &#x201c;bank&#x201d; extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a &#x201c;ten percent shareholder&#x201d; of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a &#x201c;controlled foreign corporation&#x201d; related to the Borrower as described in Section 881(c)(3)(C) of the Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The undersigned has furnished the Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or IRS Form W-8BEN-E from each of such partner&#x2019;s/member&#x2019;s beneficial owners that is claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided in this certificate changes, the undersigned shall promptly so inform the Borrower and the Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, terms defined in the Loan Agreement and used herein shall have the meanings given to them in the Loan Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: _____________ ___, 20___		[NAME OF LENDER]</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name:	____________________________</font></p>
  <p style="margin-left:40%;text-indent:-66.667%;padding-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Title:	____________________________</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132047445.10</font></p>
  </div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  </div>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SCHEDULE 1.1</font></p>
  <p style="margin-left:0.867%;text-indent:-21.388%;padding-left:17.467%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">COMMITMENTS</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.302%;"></td>
    <td style="width:10.562%;"></td>
    <td style="width:10.562%;"></td>
    <td style="width:10.642%;"></td>
    <td style="width:10.562%;"></td>
    <td style="width:11.962%;"></td>
    <td style="width:10.562%;"></td>
    <td style="width:10.562%;"></td>
    <td style="width:13.283%;"></td>
   </tr>
   <tr style="height:58.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LENDERS</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 1A TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 1B TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 2 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 3 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 4 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 5 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TRANCHE 6 TERM COMMITMENT</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERM COMMITMENT</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hercules Capital, Inc.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hercules Private Credit Fund 1 L.P.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Hercules Private Global Venture Growth Fund I L.P.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Silicon Valley Bank</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[***]</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TOTAL COMMITMENTS</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000,000</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$10,000,000</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$15,000,000</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$20,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;min-width:fit-content;">10</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$20,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$25,000,000</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</font><font style="color:#ff0000;white-space:pre-wrap;text-decoration:line-through;min-width:fit-content;">125</font><font style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">145</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">,000,000*</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*Funding of Tranche 6 is subject to approval by the Lenders&#x2019; investment committee in its sole discretion.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;">
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">US-DOCS\132048673.4</font></p>
  </div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>gern-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:1in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">List of Subsidiaries</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Geron UK Limited, incorporated September 29, 2021</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Geron Netherlands B.V., incorporated February 17, 2023</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>gern-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-225184, 333-238595, 333-248637 and 333-269111) and in the related prospectuses and prospectus supplements,</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-239324, 333-258864, and 333-273669) pertaining to the 2018 Inducement Award Plan and the 2018 Equity Incentive Plan,</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-230171) pertaining to the 2018 Inducement Award Plan,</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-228147) pertaining to the Directors&#x2019; Market Value Stock Purchase Plan,</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-225190) pertaining to the 2018 Equity Incentive Plan,</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-196677) pertaining to the 2014 Employee Stock Purchase Plan,</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-174350) pertaining to the 2011 Incentive Award Plan, the 2002 Equity Incentive Plan, the 1996 Directors&#x2019; Stock Option Plan and the 1992 Stock Option Plan, </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-136330) pertaining to the 2002 Equity Incentive Plan and the 2006 Directors&#x2019; Stock Option Plan, and</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.333%;display:inline-flex;justify-content:flex-start;">9)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registration Statement (Form S-8 No. 333-266795) pertaining to the 2018 Equity Incentive Plan, the 2018 Inducement Award Plan and the 2014 Employee Stock Purchase Plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our reports dated February 28, 2024, with respect to the consolidated financial statements and the effectiveness of internal control over financial reporting of Geron Corporation included in this Annual Report (Form 10-K) for the year ended December 31, 2023.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Jose, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 28, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>gern-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 31.1</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM OF RULE 13A&#x2011;14(A)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302(A) OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, John A. Scarlett, M.D., certify that:</font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this annual report on Form 10&#x2011;K of Geron Corporation;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 28, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">John A. Scarlett</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">JOHN A. SCARLETT, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>gern-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 31.2</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM OF RULE 13A&#x2011;14(A)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 302(A) OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Michelle Robertson, certify that:</font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this annual report on Form 10&#x2011;K of Geron Corporation;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: February 28, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;border-bottom:0.5pt solid;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Michelle Robertson</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">MICHELLE ROBERTSON</font></p><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Executive Vice President, Finance,</font></p><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer and Treasurer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>gern-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, the undersigned officer of Geron Corporation (the &#x201c;Company&#x201d;) hereby certifies, to such officer&#x2019;s knowledge, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accompanying annual report on Form 10&#x2011;K of the Company for the year ended December 31, 2023 (the &#x201c;Report&#x201d;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: February 28, 2024</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">John A. Scarlett</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">JOHN A. SCARLETT, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10&#x2011;K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10&#x2011;K), irrespective of any general incorporation language contained in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>11
<FILENAME>gern-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 32.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, the undersigned officer of Geron Corporation (the &#x201c;Company&#x201d;) hereby certifies, to such officer&#x2019;s knowledge, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accompanying annual report on Form 10&#x2011;K of the Company for the year ended December 31, 2023 (the &#x201c;Report&#x201d;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55%;"></td>
    <td style="width:45%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:bottom;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: February 28, 2024</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">Michelle Robertson</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">MICHELLE ROBERTSON</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Executive Vice President, Finance,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Chief Financial Officer and Treasurer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10&#x2011;K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10&#x2011;K), irrespective of any general incorporation language contained in such filing.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>12
<FILENAME>gern-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Geron Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Incentive Compensation Recoupment Policy</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Introduction</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Geron Corporation, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Nasdaq Listing Rule 5608 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Incentive Compensation is deemed &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Company&#x2019;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></div></div>
  <p style="text-indent:7.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee or, in the absence of such committee, the Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each current and former Executive Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lookback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#x2019;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverable Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Applicability of Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period. </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment Generally.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#x2019;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Impracticability of Recovery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Recoupment may be determined to be impracticable if, and only if:</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:5.14287551026968%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sources of Recoupment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Indemnification of Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#x2019;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Indemnification of Administrator.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> Any members of the Administrator, and any other </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:11pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No &#x201c;Good Reason&#x201d; for Covered Officers.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Administration</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#x2019;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Impairment of Other Remedies</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#x2019;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">SOX 304</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Amendment; Termination</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:11pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Successors</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10.	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Required Filings</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">*	*	*	*	*</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img43612817_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43612817_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .(!X # 2(  A$! Q$!_\0
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M*G+EEN%%%%:$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%7M(TF[UO4H["Q17N),E0S!1P,GFDVHJ[&DY.R*-%=C+\+O
M%<<;.+&)\#.U)U)/ZURMW97-A=M:WD+V\Z'#)(N"*B%:G4^"29<Z52'Q)H@J
M9/\ CTE_WU_]FKK/%_@VP\.:397=KJRW<DYPR<<C&=RX[?7UKDT_X])?]]?_
M &:E"K&K'FCL$Z<J<N66Y#1116IF%%%% !1110 4444 %%%% !1110 4444
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MO^1\L?I)_P"@&N1KKOAE_P CY8_23_T UABOX$_1FV&_C1]4='XW\8ZWX?\
M'TJ6=Z_V6-(F-NW*'Y<GCMGVJ]\7+&VN?#^G:VB!;@N(\@?>1E+ 'Z$?J:M>
M*/AS>^(_&3ZBUS!%8.L8;DE\ 8/&,?K61\6M?M)+:UT"S=9/(;S)BIR$PI"K
M]<$_I7E4'"52C[+=+7[NIZ=53C"K[39O3_@%;QSX/TG1]$TF?3X6BFNI51V:
M0L.5SW]ZW=2\,^#O"6EVZ:IIUW<I,0LETNXA6QU." .^!3?BA%)<>&-"AB&9
M))E51ZDI@5K^'8O&&GS1:5K%M;:AI^T+]J#C*KCH<_>QP.GXU+JS=&,G/J[J
M]F_GY%*G!5I14>W2Z1YEIGAJP\3^-I-/T>26/2U)<R2<L$'7'U/ S73:S%\.
M="N9])FL+B:YA0AI4=CA\9 SGK^&!5_2KG2-!^+E_96QBA@NH50 $!5EX)4>
MF?3UK%\5?#G7[WQ7>W-C!'+;7+M,LAD VYY*D'G.:W]JIU$JDG&/*FM;7]3'
MV;A3;A%2E=IZ7L5_ _@O3]4TZ[U[6BR:; 6*1!L9"C+$GT'3WYK8A\,>$O&F
MBW<OAR"6RO+;A5<GYCU&02>#ZU:\!O%K/P]U+PX)!%?*LT31MP1N!P<>F>#]
M*G\ Z+=^"](U74-=5+53@A2X/"YYX/<G@5G6K34IOF:DFK+R].II2I0<8+E3
MBT[O_@]#FO#'A+2]?\$:E(MN_P#;-IYBC#GE@,K\OOT_"H? 'A73-6T?5-5U
MB)WMK;A,.5^ZNYNGMBI/A?KAA\:7,#';#J0<[3_?!++^A8?C70>,XT\(?#Q]
M(MRJR7URXRO]PL6/_CNU:TJU*L:CHIZR:MY+J9TX4W35:WPIW\WT.;\&>$=,
MU'3K[Q#K/F#3;=F\N%,_-CDY(Y..!CO6E>>&O#7B;PS?ZCX<M)[*ZL06,4N1
MO &>A)ZC.#ZBMGX7ZHUQX+N-.L7@&I6S.R)-G:=QR"0.<9)%0ZOKOQ!MM%OY
M[[1=,BM8XRLC*2S;3P2H#GIG-9SJU77DE*S3TUMIZ=;EPITE13M=-:Z7_'I8
MR_"O@G0]8\"+J=\S03!W,EQO("HK\\=/N@BHH(O >K>)]+TRPLG^SRK)')(7
M=29.-G4]\'\ZUO#W_)#[W_KE/_Z$:\BAFDM[B.>)BDD;!T8=00<@UT4H3K3J
M7F]&TM3&K.%*-.T5JDV=Q=^"$B^)\.AK$_V"9A,O)SY.,GGZ@BLKQYI^EZ3X
MFDT_2HBD4"*),N6RYY/7V(KV2TN[&]L+7QD^W='I[@^W(+#\"I'XU\^ZA>RZ
MCJ-S>SG,L\K2-]2<T8.I4JSO)_"K/U%BZ=.E"T?M.Z]"M1117IGG!1110 44
M44 %%%% !1110 4444 %>N_!7_CVUG_?A_DU>15Z[\%?^/;6?]^'^35PYE_N
MTOE^9VY?_O$?G^1+X'O/&$_BV9-0-\VE@R;S=(0HZ[=I(]<=.U4WT?2=>^,6
MI6<L8DM_(+.(V*_O J!N1]3GWKGM4^)7BB62YM5O4A0.R;HH@K8!]:L?"5F?
MQPSNQ9FM9223DDY6N:5"I",ZSM'W;:?F=$:T)RC15WK?4O:_I?@GPU::CIS*
M]UK#(YAY8B(G[@R#C@$=<U8MO"OAOPKX=M-0\2V\][=W8R((@WRY&<  CH.I
M)ZUR/CIMGCO5&ZXGS^@KV.?6M6O_  M9ZEX5CLKN1E!DAG)STY PPPP/8U-9
MU*=.'O/WM];=-K]"J2A.<_=7N[:7_#J>9^-_"FFVFF:?KN@B1;*](4PODE21
MD8SSZC'M6X_A3PIX,T*VNO$L4MY=SX'EJ3PV,D* 1P/4FJ/C;6_%B6.G+X@T
MVRMX&N!,GD9+;D.=I.X@=:Z+Q]H=UXST33=1T/9<A,ML#@%E8#H3QD$=*/:3
MY:<:D[1;>J?W:A[.'-.4(WDDM&OOT.;\,2Z)-\4K-M @DAL_+;B0DY;8<X!Z
M#M1XIL8-3^,L=E=*6@G>%'4'&1L'>J_A'0[WPS\1]-M-418I98V9<-N!RIXS
MZYXK9\06%S;_ !HTN\ECQ;W4L7E/D'=M4!OI@U<I*->\7?W'9DQ3E1M)?;U1
MGZSX1T>S^)&E:/# XLKA%,B&0DG.[OU["M:_\-^!?#OB*"ROHIYYKYE6*#<2
ML(/R@D@YY.:F\1_\EDT+_KFO_L]8_P 0?^2JZ1]+;_T::SA*=1PBY/X;[ESC
M""E)17Q6,WQUX3L-!\4:?#9JRVEX5)B+$[3N (!ZXYJW\0O!MAI%[HMIHMNZ
MS7TCQE2Y;<<H%Z]/O&M7XJ_\C/X?^O\ [.M:'Q+OX]+\1^$[Z4$Q07$COC^Z
M#'G]*=*M5?L7>]U+YVV)J4::]JK6LU\C/O\ P[X*\$V5I%KD$U]=SCDJ3VZD
M $8'ZUQ<9\*7'C)@Z7,&A9.TAB6) ZGC(!/;K7?_ !'\*ZCXGET_4]%5+M!%
ML(611P3D,"3@CFL'P+X6CL?'L^G:[#$UQ;0>;%&?F1SD<CUP#_G%50JQ]BZD
MIMRL[J_Z=!5J4O:JG&"4;JSM^O4V]%T#P1XJBN+;3](O;?8ORW3AU#>X))!/
ML:SOA;8OI?CC6["0Y>WA>(GUQ(!FN^TB3Q%)XBO_ .T8X+?2D^2TC3:2_P#M
M<<]/IUZ5R/A"5$^+GB6-F =Q)M![X=<US*K*4*D;W5D][_B=#IQC.G*UG>VU
MCSCQ?_R.&K?]?3_SK%KH?'-E<67C+4EN(]AEE,J<@Y1CP:YZO<HM.G%KLCQJ
MR:J2OW"BBBM#(***6@ HHI:0A,4M%%, HHHH *]LT22]B^#43Z>9A=")_+,(
M)?/F'IBO$Z]MT+4;C2?@[#?6A43PQ.R%ER,^8>U>=F-^6%OYD=^7_%._\K)_
M UQKT_AW47\3>=Y !\MKI=KE-IW9SSCIU]ZS_A>D,OA368VD\N!IG4O_ '5*
M#G\J\^UCQQX@URV-M>7N+=OO1Q($#?7')KNOAE_R(^M_[TG_ *+KEKX>5.E*
M4K+F:T6R.JA7C4JQC&[LGJ^H[1?#?@CQ5IE[;Z3;SI-; )]H<L&)(.UNN"#@
M]JX;PS#X;@O;Q?$GGGR.(DB)P[ X(XYS^-=C\%_N:W](/_9ZF^&NGV<MSKE]
MY$4VH0W#+$),?*.2,>F3QGVJY5'2=6+DVE;KKKYD1IJJJ4DDF[]--/(?_P (
MAX;\3^&;F[T;3;G3[B,-Y1F#*68#(X)((/J*Q/AYX1TS6=,O=5U.*2Y2!RB6
M\9.3A0QX')/. *]*\-2Z]-I]S)XA6&*Y=R8X(\?NTQQG!/?/<UYCX'L_%EM:
MW.K:"(9(/-V/;3, )L=2.G3UR*RIU:CIU(\]K-6=_P +FE2E!5*<N2]T[Z?C
M8H>*9/!\NGHVBV=W:Z@)-KP/D!0.NX$GGZ&NCC\+>&O">@VEUXBM;B]O;D9\
MJ/)VG&2  1TSU)K3^($$$_@J'4]5L8;36 Z%45@S;L\KN'48Y]JZ*_UG5[[P
M_:ZGX6AM+PR#<\4Q.<8Z#YAR#U!HE7DZ<5%NUVGK^O8(T(JI)R2O96T_3N>7
M^//"MAI5K8:QI =;"] ^1R3L)&X=>>1GCVKDM.OYM+U&WOK?;YT#ATW#(R/4
M5VWC_5O%,VFV=GK]A96T<C^<GD9+94$8)W$?Q5Q>E:7=ZUJ,=A9(KW$F=JLP
M4<#)Y/TKT<,VZ'[UWWUO?3U/.Q*7M[4U;;I;7T/9#J]UKOPAO-1O-GGRV\N[
M8N!PQ X^@KP^O=].\.:E;_"Z70Y(D%^T4JA X(RSDCGIT->*ZKI5WHNHR6-Z
MBI/'@LJL&'(SU%<^7RAS5(Q?5V]#?,(SY:<I+HK^I2HI:*],\T****0!12T4
M %%%+0(3%+110 4444 %%%+0(*D@_P"/B+_?'\ZCJ2#_ (^(O]\?SI/8:W'V
M_P#Q_P 7_74?SKV3XBW.OVZ:7_8;7H9B_F"U1FS]W&<#ZUXY;_\ '_%_UU'\
MZ]E^(?BC4_#<.FG3GC7S]^_?&&Z;<?SKSL6FZ]-))[[['I8-I4*KDVEIMON5
MO%KW+_"N)M; &HMY?# !M^[T]=N<_C5R\32F^&FEOK3R"RBB@=DC^](=O"_F
M?TKR36?$.JZ_*KZE=M-M^ZF JK] .*]'\6?\DATS_<M__0:PGAW35.+>KE?3
MIZ&\,1&HZDTM%'KUMW*/B3PSX?N_! \0:%;O;!0'P6/*[MI!!)Y!K&\.-X,B
MTF-]3M+R\U)F*M @)[\$8QQCW]:Z>+_DAS_]<F_]&U?T*TGTWX>6UUX9LH)]
M2G12SN1DDGYCDXSCTSVI>V<:;C)OXK+6WWL/8J512BE\-WI?[D<[XX\'Z5:>
M'H-=TB&6V0E/,@?/W6Z'#<@@XXJY8>%O#FC>#[76-5L+G4&F17D,63L#<] 1
M@#UK<\:BZ'PTE%]*DMV!&)G3&"^X9QCWK+\+P^-=$L+"-+:"_P!.G4-Y32!7
M@!]SCMSCFIC5J2H:SV;ZVNO4N5*G&OI#=+I>S]#C;W2]&UOQ39Z?X:\Y(;C&
M]I,D(>IP#SP*["71/ ^F:I!H$]E=3W<A5&N?F(5FZ9(( _ <9J?7I-(T#XDZ
M-=HL4#2(ZW.W  W#:K'TZUNZ]>^,+?4%&B6&GW=G(!M9R0RGOGYP,>XHJ5YR
MY$FTFNKMKZBIT(1YVTFT^BOIZ=#Q_P 7:!_PC?B":Q5B\! DA8]2I]?<'(_"
MFZ-XLU;0;&YM+"=8XYSDDJ"4/J#]*L^-M0U6^\0LFLP00W=N@B*P [2.H/).
M>M6?!/@R7Q-=F>?='IT+8D<'!<]=J_U/:O1YHK#J5>S/-Y9/$.-"ZU.V\/WU
M]J7PSU.XUZ0S1%)1%)+U9 O7W^;.#7CM>S>--%U_5+2'1]%L(X=+A S^^5?,
MQT&,]![]Z\;9"CLK=5.#66 <6I25M7>RZ&N8*47&#OHK7?4;2T45Z!YP4444
M@"BBEH$)2T44 %%+10 4444""BBB@"2X_P"/F7_>/\Z94EQ_Q\2?[QJ.DMAO
M<ZGX=?\ (\V'TD_] :NP\2W?BN/QVL6D?;C:XC^54)BZ?-GC%<?\.O\ D>;#
MZ2?^@-74>./&NMZ+XCFL+&:)(5C1AF(,02.>37F8B,I8JT4G[O7U/6PTXQP=
MY-KWNGH:/CHV_P#PEWA0#;]J%VI;'79O3&?QS^M6O&7_  C,>L6+Z]'-/+(G
ME11)G:HW<L<$=S7F&D7]WJ?C/2[J]G>>9KR'+N>?OBNO^*7_ ",FC_\ 7/\
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M+ Y.:K44N5/H/F?<LC4;Y;TWHO+@79_Y;B5M_3'WLYZ4RYO+F]F\Z[N9IY<
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M /?)H\F7_GD__?)HN@LQE%/\F7_GD_\ WR:/)E_YY/\ ]\FBZ"S&44_R9?\
MGD__ 'R:/)E_YY/_ -\FBZ"S&44_R9?^>3_]\FCR9?\ GD__ 'R:+H+,913_
M "9?^>3_ /?)H\F7_GD__?)HN@LQE%/\F7_GD_\ WR:/)E_YY/\ ]\FBZ"S&
M44_R9?\ GD__ 'R:/)E_YY/_ -\FBZ"S&44_R9?^>3_]\FCR9?\ GD__ 'R:
M+H+,913_ "9?^>3_ /?)H\F7_GD__?)HN@LQE%/\F7_GD_\ WR:/)E_YY/\
M]\FBZ"S&44_R9?\ GD__ 'R:/)E_YY/_ -\FBZ"S&5,G_'I+_OK_ .S4SR9?
M^>3_ /?)J9(9?LDO[M_OK_"?>DV@296HI_DR_P#/)_\ ODT>3+_SR?\ [Y-.
MZ"S&44_R9?\ GD__ 'R:/)E_YY/_ -\FBZ"S&44_R9?^>3_]\FCR9?\ GD__
M 'R:+H+,913_ "9?^>3_ /?)H\F7_GD__?)HN@LQE%/\F7_GD_\ WR:/)E_Y
MY/\ ]\FBZ"S&44_R9?\ GD__ 'R:/)E_YY/_ -\FBZ"S&44_R9?^>3_]\FCR
M9?\ GD__ 'R:+H+,913_ "9?^>3_ /?)H\F7_GD__?)HN@LQE%/\F7_GD_\
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M?_ODT7"S&44_R9?^>;_]\FE\J3_GF_\ WR:+H+,CQ2T_RI?^>;_]\FCR9?\
MGF__ 'R:+H5F,HI_DR_\\W_[Y-'DR_\ /-_^^31=!9C**?Y,O_/-_P#ODTOD
MR_\ /)_^^31<+,913_)E_P">;_\ ?)H\F3_GF_\ WR:+BLQE+3_*D_YYO_WR
M:/*E_P">;_\ ?)I7"S&44_RI/^>;_P#?)H\J3_GF_P#WR:+A9C*D@_X^(O\
M?'\Z3R9?^>;_ /?)J2"*3[1%^[?[X_A/K0WH-)W(G^^WU-)4CQ2;V_=OU/\
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M%PLQE%/\F7_GF_\ WR:/)D_YYO\ ]\FBZ%9C**?Y,G_/-_\ ODT>5)_SS?\
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MZ6W_ 'V?\*/K%+^8/J];^4Y;>W]X_G1O;^\?SKJ?^$ U;_GI:_\ ?9_PI?\
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M'U6O_*SD-[?WC^=&]O[Q_.NP_P"%:ZU_SUM/^_A_PI?^%::W_P ];3_OX?\
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M4\1_*SBM[?WC^=&]O[Q_.NV_X5;KO_/6S_[^'_XFE_X59KO_ #UL_P#OX?\
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MK7_^>EG_ -_#_P#$T?7*'\R#ZEB?Y&</O;^\?SHWM_>/YUW'_"JM?_YZ6?\
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M>K_]]5'13NQ_5:'\B^Y$GVB;_GJ__?57-.ED>=@[LPV]"?>L^KVE_P#'P_\
MN?UJHO4\O.L/1CE]5Q@D[=D:M%+16Q^6!112T )BEHHH$%%%% !112T <U11
M170>J%%%% !7LOQ._P"2=Z3_ -=H?_1;5XU7I'CCQ?H^M^#]/TZQG=[F&2-G
M5HRH "$'D^YKBQ,)2JTFELSLP\XJE43>Z*_P@_Y&V;_KU;^:UF>(/-_X6E=>
M1N\W^T5V[>N<BE^'>O6'A[Q#)=ZC(T<+0,@*H6Y)'I]*[4^+OA]9ZK-K4-O+
M/J+L7W^4Q;<1CC<<"L:KG3Q$I*#=U8VI*$Z$8N25G<K?&HILT4<>9F;ZX^2N
M5^%__(_V'^Y+_P"BVK,\6>)[CQ5K!O9D\J)!LABSG8N?7U]:E\#:M::'XMM-
M0OG9+>-9 S*I8\H0.![FM(4)T\&Z;WL_Q,YUHSQ:J+:Z+_Q0_P"1\O/]R/\
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MGDG'%7.,U6O1C).^O9^9,90=*U62:MIW7D>5T445[!Y(4444 %%%% !1110
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M\(2>$M0DU:X=-67?Y"AF!^[\NT#@\]<U)X6M/!5]HTD&MWDUIJ)<D3$X4+V
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MK-M\]2Q)Z?-N'0<],50\)+X=DU-X_$;3) T9$;H?E5O5L<_3]:ZH2Y8-ZO\
M,ZZ<N6#>K]=SNO!/_)(/$/TN/_10K,M?#^DO\&YM9:RC.HKNQ/D[O]=M]<=.
M*OZAK?AKPSX$O=$T+4C?S7F\9Z[=P )/  ^45!X6US0;WX=7/AK5M273WW,
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MPWJM[HEQK%O;;K*WSYDFX#&,9XZGK2E*,=9.PXQ<M$C*HHHIB"BBB@ HHHH
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MVVNVBQVFIQ")<2*V1E\]#QC<#5T_#:71/AOK.B:;+]NOKU@P=@(]V&7 Y/&
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MGPCXBN9-$LX;^.],3&"]DD&)&49Y3L/;TJ;P7>W&HZYXGO+M56XET^=I%5<
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MV#VD>YL4X5C?V]'_ ,\'_P"^A3O[?C_Y]W_[Z%+V<^P_:1[FR*=6+_PD$?\
MS[O_ -]"E'B&+_GW?_OH4O93[#]I#N;8IPK$'B*+_GW?_OH4O_"1Q?\ /N__
M 'T*7LI]@]K#N;HI16%_PDD7_/M)_P!]"E_X26'_ )]I/^^A2]E/L/VL.YO"
MGBN?_P"$FA_Y]I/^^A3O^$HA_P"?:3_OH4>QGV'[6'<WQ3A7/CQ3#_SZR?\
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MBO-_^%O67_0)N/\ OXM'_"WK/_H$W'_?Q:/J.(_E_(/[1PW\_P"9Z117F_\
MPMZS_P"@3<?]_%H_X6]9_P#0)N/^_BT?4<1_+^0?VCAOY_S/2**\W_X6]9_]
M FX_[^+1_P +=L_^@3<?]_5H^HXC^7\@_M'"_P _YGI%%>;_ /"W;/\ Z!-Q
M_P!_%H_X6[9_] FX_P"_BT?4<1_+^0?VCA?Y_P STBBO-_\ A;MG_P! FX_[
M^+1_PMVS_P"@3<?]_%H^HXC^7\@_M'"_S_F>D45YQ_PMVS_Z!-Q_W\6C_A;M
MG_T";C_OXM'U'$?R_D']HX7^?\ST>BO.G^+5FDC)_95QP<?ZQ:;_ ,+<L_\
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MK2K2E.2E%]&C2M1G.2E%]&OO/3$_Y+Q)_P!>O_M,55T-W;XYZON8G]U(.3V
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M\67,?BK0;F?2)]+?3P&\N5LEHVP/Y BNWU"WB\.7GB+Q< I,UG&(#G[SX/\
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M0 4444 %%+10 4444 27'_'Q)_O'^=1U)<?\?,G^\:CI+8'N%+110(***6@
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M*E\M/[B_E1[,/]<8?\^7]_\ P#GJ*Z'RT_N+^5'EI_<7\J/9A_KC#_GR_O\
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MK#1_D?X#_P!0<5_S^7W,K?:9_P#GJWYT?:9O^>K?G5GRU]*/+7TH_P!8:/\
M(_P#_4'%?\_E]S*WVF;_ )ZM^='VF;_GJWYU9\M?2C8OI1_K#1_D?X!_J#BO
M^?R^YE;[3-_SU;\Z/M,W_/5_SJSL7THV+Z4?ZPT?Y'^ ?Z@XK_G\ON94>5Y,
M;W+8]:;5W8OI1L7TH_UBI?R,7_$/\5_S^C]S*5+5S8OI1L7TI_ZQ4OY&+_B'
M^)_Y_1^YE.BKFQ?2C8OI1_K%2_D8?\0_Q/\ S^C]S*E%6]B^E&Q?2C_6*E_(
MP_XA_B?^?T?N94HJWL7THV+Z4O\ 6*E_(P_XA_B?^?T?N94HJWL7THV+Z4?Z
MQ4OY&'_$/\3_ ,_H_<RK15K8OI1L7TH_UBI?R,7_ !#[$_\ /Z/W,JTM6=B^
ME&Q?2C_6*E_(P_XA]B?^?T?N96HJSL7THV#TH_UBI?R,/^(?8G_G]'[F5J*L
M[!Z4;!Z4?ZQ4OY&'_$/L3_S^C]S*^**L;!Z4;!Z4?ZQ4OY&'_$/L3_S^C]S*
M]%6-@]*-@]*/]8J7\C#_ (A]B?\ G]'[F0458VCTHVBC_6*E_(P_XA]BO^?T
M?N97HJQM%&T4?ZQ4OY&+_B'V*_Y_1^YE>EJ?:*-HH_UBI?R,/^(>XK_G]'[F
M045/M%&T4?ZQ4OY&'_$/<5_S^C]S(:*FVBC:*/\ 6*E_(P_XA[BO^?T?N9#1
M4VT5#7H8#,8XSFY8VM;\3Y[/N'JN3^S]I-2Y[[>5O\PHI:*]$^>"BBB@0444
MM "4M%% !12T4""BBBD 4444 %%+10(Y>BBBND]@**** .V^&>AZ;KVN7-OJ
M=J+B)(-ZJ69<'<!G@BNL&G?#6YUN30ULGBO1*8?O2@;QQ@'=BL/X.?\ (R7G
M_7L?_0A79Z5X8\+7?BZ^U6TN[BZU&VN6>:%FPL4A)[;1GG/<BO%Q=3EK3O*2
M22M;N>QA:?-1C:*;;ZGE/C?PVGA?Q$UE"[/;R1B:(MU"DD8/T(-;6KPIH_PF
MTBWV*+G4K@SNQ49V#)'/_?%9?C;69?$WB]V%O)#Y96UCB<?.,,>H]<DUJ_%*
M5(-2TS2(\;;&S52!V)_^L!76G.7LH3WW?R7_  3E:A'VLH;;+YG2VWAWP7IO
M@C3=9UC3-WFP1&1U>0DNP'. U5KWP=X4\1^&;K5/#&^&6W5CMW,0649VL&Z<
M=Q6[-;:-=?"W2(M=NY;6R-O 3)'UW;1@=#_*J^OM8?#_ ,"O;:/;RRK>EE6<
MMN&YE^\Q^@XP.U>=&K-R]V4N;FT[6.Z5."C[T5R\OS/$*]E7X?Z)??#]+JVL
M0FI/9"59A(V2^W/3..>G3O7C5>_V6JII.@>$Y)3B&X$=LY]-\?!_[Z KOS"=
M2*A[-ZW./ 1A+FYUI8\R^''AFW\1:_*+^'S+*VB+2*20"QX49'XG\*F\?:#I
MFC^,[&QL+40VTD<3/&&8Y)<@\DD]!7H$>F0>#H;F-&42:OJJ)"!U\LL#C\!N
M_2N0^*'_ "4+3?\ KC#_ .C&K&GB)5<3S)^[9V-*E"-+#\K7O71T?B#1/A[X
M8, U+2F4S9V;&E;IC/\ %[UYSXPG\+SS6A\,V[PH%;SPP;D\;?O$^]>J_$ >
M%2]E_P )(URIP_D^2&]LYP/I7C?B,:(-5QX?:8V6P<RYW;N_6GE]YVE)R;\]
M@QR4;QBHV_$R****]8\L**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J9/\ CTE_WU_]FJ&ID_X])?\
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M^^S_ (4O_"(:C_STMO\ OL_X5V@IPI?6J@?5:9Q/_"'ZC_STMO\ OL_X4O\
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M1_:=?R^X/[)PWG]YXS_PJG7_ /GOI_\ W]?_ .(H_P"%4Z__ ,]]/_[^O_\
M$5[-11_:=?R#^R<-Y_>>-?\ "J=?_P">^G_]_7_^(H_X53K_ /SWT_\ [^O_
M /$5[+11_:=?R^X/[(PWG]YXU_PJG7_^>^G_ /?U_P#XBC_A5.O_ //?3_\
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MX[-)GF,0,3.0!O&>N.U>'^,)FU^[UOQ*V3;M?K:6K=B%4D_H%_[ZKTCXE_\
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M2-'OM=U!+'3X?,F;GDX"CN2>PKI)_AQ?B&0V.IZ9?W,7W[:WFS)QUP".:A\
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MVQCO!G@R3]0?IQ^=3B*LH)*&^_R0\/3C-MSV_5GE-%;<WAZ2/QD= 9MC&[$
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MP9-V^0CV.,"O&CEV(<K-6/6ECZ"5T[ECXK>((K_4(-)MI Z6I+S%3QYAXQ^
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MN2GW?.E9]OTR:M4Y1JN:>C2_"Y+J)T^1[I_F5:***V,0HHHH **** "BBB@
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M?]]"G?\ "11_\^[_ /?0KGZ*/8P'[:9T/_"1Q_\ /N__ 'T*4>)8_P#GV?\
M[Z%<[12]C#L'MI]SH_\ A)HO^?9_^^A3O^$GB_Y]G_[Z%<W11["'8/;S[G2_
M\)1%_P ^S_\ ?0I1XIB_Y]G_ .^A7,TM'L(=@]O/N=./%47_ #ZO_P!]"E_X
M2N+_ )]7_P"^A7+T4OJ]/L'UBIW.I_X2R+_GU?\ [Z%+_P );#_SZ/\ ]]"N
M5HH^KT^P?6*G<ZO_ (2Z'_GTD_[Z%*/%\/\ SZ2?]]BN3I:7U>GV#ZS4[G6C
MQA"/^723_OL4O_"8P_\ /G)_WV*Y&EQ1]6I]@^LU.YUP\90_\^<G_?8IW_"9
MP_\ /G)_WV*X^BE]6I]@^LU>YV/_  FD/_/G)_WV*4>-8!_RYR?]]BN-HH^K
M4NP_K57N=G_PF\'_ #Y2?]]BE_X3B#_GRD_[[%<72T?5:78/K=7N=J/'$'_/
ME)_WV*DB\<0%\?8I.A_C'I7#5)!_K/\ @+?R-)X6EV!8NK?<[,>.H/\ GQD_
M[[%+_P )Y!_SXR?]]BN'HH^J4NP?6ZO<[G_A/8/^?&7_ +[%*/'UO_SXR_\
M?8KA:6CZI2[!]<K=SNAX_M_^?"7_ +[%._X6!;_\^$O_ 'V*X.C%+ZI2[!]<
MK=SO1\0;?_GPE_[[%+_PL*W_ .@?+_W\%<%11]3H]@^NUNYWW_"P[?\ Z!\O
M_?P4H^(EO_T#Y?\ OX*X"BE]3H]@^O5NYZ#_ ,+%MO\ H'R_]_!_A2_\+&MO
M^@?+_P!_!_A7GM+1]3H]A_7J_<]"_P"%CVW_ $#Y?^_@_P *4?$BV_Z!TO\
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M12T4""BC%+0 8HHHH **** "BBEH$%%%+0 E+110!RE%%%=)[(4444 %%%%
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MM!E&*D\^;_GJ_P#WT://F_YZO_WT:-0T(Z,&I//F_P">K_\ ?1I?/F_YZO\
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M?]UOY&MD>%+P_P#+>W_-O\*EA\*7@<_O[?[I[MZ'VH=:G;<:HSOL<[170?\
M"(WO_/Q;_FW^%.'@^^/_ "\6WYM_A2]O3[A["IV.=HKHQX-OO^?BV_-O\*</
M!E]_S\VWYM_A1[>GW#V%3L<W172_\(5?G_EYMOS;_"G#P1?_ //S:_FW^%'U
MBGW#V%3L<QBEKIQX'U _\O-K^;?X4H\"ZA_S]6OYM_A2^L4NX?5ZO8Y>BNJ_
MX0/4?^?JT_-O_B:4> =1/_+U:?FW_P 31]9I?S!]6J_RG*45UH^'^I?\_=I^
M;?\ Q-*/A]J7_/W9_FW_ ,32^LTOYA_5JO\ *<E177_\*\U,_P#+W9_FW_Q-
M*/AUJ?\ S]V?YO\ _$T?6:/\P?5:W\IQ^*6NQ_X5SJG_ #^67YO_ /$TO_"M
M]4/_ "^67YO_ /$TOK5'^8/JE;^4XVBNS'PUU7_G\LOS?_XFG?\ "L]5_P"?
MRR_[Z?\ ^)H^MT?Y@^J5OY3BJ*[8?#'5C_R^V/\ WT__ ,33O^%8:M_S^V/_
M 'T__P 32^MT?YA_4Z_\IP]+7<?\*NU8_P#+[8_]]/\ _$TH^%FKG_E^L?\
MOI__ (FCZY0_F%]3K_RG#45W?_"J]7/_ "_6'_?3_P#Q-+_PJG6/^?ZP_P"^
MG_\ B:7URA_,/ZEB/Y3@Z*]%'PFO?L9)U&W^U9X4*?+Q[GK^E0CX3:S_ ,_^
MG_\ ?3__ !-)8[#O[0W@,0OLG U)!_K/^ M_(UW8^$FM'_E_T_\ [Z?_ .)J
M2+X2ZRCY^W:?T(^\_I_NT/&X>WQ L#B+_ >>4M>@?\*BUO\ Y_M/_P"^G_\
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MO]G@DD+I"&SL![9J\%0E"7-)--*VMK?@1C*T91Y8M-7OUO\ B>H_"_</!/B
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I:**!!4R?\>DO^^O]:AJ9/\
MCTE_WU_D:3&B&BBEIB$I:*!0 Y14\,,D\JQ0QM)(YPJ(,DGV%1*I9@J@DG@
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M; _.O**]/^%UQ;QZ)KEO)?0VDLP"QO)(%P2K#(Y[5QY@KT'\OS.S NU9?/\
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M"VNO:KJ#:?JGEZ':8S>SKRWR@GCCISR<5U&M:?;Z9\&YK:TOXKZW$ZM'<1C
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M44 %+110(***6@ HHHH **** "BEHI %%%+0 F*6BB@ HHHH$%%%+0 4444
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MGXG>:X:5]*@+P20.-DA^;GH<C@5DL52:YD[_ -6-'AJB=FCE:***Z# ****
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M=  =REL<'MQFN0JJ=6%17@[DU*<Z;M-6"BBBK("BBB@ HHHH **** "BBB@
MHHHH **** "M>R_X]$_'^=9%:]C_ ,>B?C_.IGL88CX2Q112UF<8F*6BBD 4
M444 %%&*6@04444 %+110 4444 %%%+0 E+112 *,4M% !1110(**** "BEH
MH ****!!112T )2T44 %%+10(****0!1110 44M% @HHQ2T &**** "BBB@
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M!4__ ']'^%'U#$?R_D']HX7^?\SL/$WARS\3Z2]C=?*WWHI0.8V]1_45\_\
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M)2[Z&.*JPJN+CV"BBBNLY0HHHH **** "BBB@ HHHH **** "BBB@ K7L?\
MCT3\?YUD5MVR>7;HIZ@<U$]CGQ#]U(EHHHK,Y HHHH *6BB@0444M !1110
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M%;/V$?\ /L?^^*7["/\ GV/_ 'Q1SH/;+L8M%;7V$?\ /L?^^#1]A'_/L?\
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M%% !1110 4444 %+110(*,4N** "BBB@ HHHH$%+110 4444@"BBB@04M%%
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M]-?_ !VKPIPI<\A\D2A_90/_ "U_\=IW]DC_ )[?^.U?%/%+GD/DB9PT@?\
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M9_\ "I1_T%C_ -^/_LJ/^%2C_H+'_OQ_]E7IE%'U_$?S?D']EX7^7\6>:?\
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MYH_C!IHK SQW$(W20S1X('3.1D?K7&_$#P;KDOBJV\7>'D2[D14+6[@$@J,
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M4MXFEOY[*=!A@A.#^5<_J$D<EXYBGEGB& KRGG%5:*6*Q\\3&TTK]]=?QM^
MZ.&C2?NO3M_6H4445PG0%%%% &1K_P#QZ1_[_P#0USU=%K__ !Z1_P"__0US
MM?KO"'_(KCZO\S\HXM_Y&<O1?D%+BBBOICYH**** "BBB@ I:**!!12T4 %%
M%% !1110(*6BB@ HHHI %%%% @I:** "BBEH ***,4 %+110 4444""BBEH
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M\CG\:T)]&\<BX9[?Q)+)IY)*7G]ID1[>Q/S<5RWBSQ!#KMY:K:0O%964"V\
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M#VDNYJ_V]<?\\HOUJ6'7KC>?W47W3Z^AK&J2'_6'_=;^1J73A;8:JSON:?\
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MLGMZ+1!2T45Z)YP48I:* "BBBD 4444Q!2T44 %%%% !1112$%+110 444M
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MH2?9I_\ GC)_WR:7[-/_ ,\9/^^346?>EY]31J&A)]FG_P">,G_?)H^S3_\
M/&3_ +Y-1T4:AH2?9Y_^>,G_ 'R:7[-/_P \9/\ ODU%^-&?>C45T2_9I_\
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MN3ZFDHI::20F[A112T"$Q2T44 %%%% !112T"$I:** "BBBD 444M @HHHH
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M'_\ LJ7UZA_-^#'_ &?B?Y?Q1YU17HX^%B?]!=O_  '_ /LJ</A6A_YB[?\
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ME,;$YR .<_2M,)&O22IRCIKK?]",5*C5]^,M=-+'+T44M=YYXE+113 ****
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MSY! '&,]ZY9XGEJ\G1*[W..>*Y:WL^B5WN<1171ZAX9M],LYC/J*->@_NK9
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M3?XT?\+6U?\ Y\[/\F_QH_LVOV_$/[6PW=_<>O45Y#_PM;5_^?.S_)O\:/\
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M-<U-M!6*6UB<*T#OP_L#[<\UR"7MW'%Y274ZQ_W%D8+^6:9%/-;OOAEDC?\
MO(Q4_F*2PLO>U6O2VGYDK"27-JM>EM/S_([#QC96J:9:WC6J6E_(^'B0@Y&#
MG..#CCFN+J26>6=]\TKR-_>=BQ_6HZZ*--TX<K=SIH4G2ARMW"BBBM38****
M "BBB@ HHHH **** "BBB@"*X_U#_2LJM&\DVP[>[5GU2/S/C&M&>-C".\8Z
M_-M_D%%%%!\D%%%% !12T4""BBEH ,4444 %%%% !112T""BBEH 2EHHH **
M** "BBEH$%%%% !1112 ***6@0444M "4M%% !11BEH **** "BBB@04M%%
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M_E6ET19D5%2_9I_^>3_E1]FF_P">3_E1="LR*EJ7[--_SR?\J/LT_P#SR?\
M*E=!9D5&*E^S3?\ /)_RH^SS?\\G_*BZ"S(ZE7_CUD_WU_K1]GF_YY/^52K;
MS?99/W3_ 'E[?6DV@295HJ7[--_SR?\ *C[--_SR?\J=T%F14M2_9IO^>3_E
M1]FF_P">3_E1="LR*BI?LTW_ #R?\J/LTW_/)_RHN@LR*BI?LTW_ #R?\J/L
MTW_/)_RHN@LR*EJ7[--_SR?\J/LT_P#SR?\ *BZ%9D5%2_9IO^>3_E1]GF_Y
MY/\ E1=!9D=%2_9YO^>3_E1]FF_YY/\ E1=!9D5%2_9IO^>3_E1]FF_YY/\
ME2NA69%14OV:;_GD_P"5+]FF_P">3_E1=!9D5%2_9IO^>3_E1]GF_P">3_E1
M=!9D5+4GV>;_ )Y/^5+]FF_YY/\ E1="LR*BI?LTW_/)_P J/LTW_/)_RHN@
MLR*BI?LTW_/)_P J/L\W_/)_RHN@LR.I(?OG_=;^1I?L\W_/)_RJ2&WFWG,3
M_=;M[&DVK#2=RM14OV:;_GD_Y4?9IO\ GD_Y4[HFS(J*E^S3?\\G_*E^SS?\
M\G_*BZ"S(J*E^S3?\\G_ "H^SS?\\G_*E=!9D5+4GV>;_GD_Y4?9YO\ GD_Y
M4[H+,CHJ7[/-_P \G_*C[/-_SR?\J+H5F145+]FF_P">3_E2_9YO^>3_ )4K
MH+,BHJ7[/-_SR?\ *C[--_SR?\J+H+,BHJ7[/-_SR?\ *C[/-_SR?\J+H+,C
MHJ7[/-_SR?\ *C[/-_SR?\J+H+,BHJ7[/-_SR?\ *C[/-_SR?\J+H5F14M2?
M9YO^>3_E2_9YO^>3_E1=!9D5%2_9YO\ GD_Y4?9YO^>3_E1=!9D=%2?9YO\
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M ,^/_)O^ :^Y?4?G1N7^\/SK,G@E\^3]VWWCVIGD2_\ /-_RHT!\9S_Y\?\
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MHIB"EHHH ****0!1110(*6BB@ HHI: "BBC% !2T44 %%%% @HHI: "BBB@
MHHHH *6BB@ HHHH$%+110 4444@"BBEH$)2T44P"C%+12 ****!!1110 4M%
M% !1110 444M @Q1110!Q5%%%=9[X4444 %%2PV\UPQ6"&25@,D(I8C\J8Z-
M&Y1U*LIP588(-*X>8E%%+0(2EHHI@%&*** "C%%7M+TB_P!9NC;:=;-<3!2V
MQ2!P._)%2VHJ[&DY.R*.*6I[VRN-.O);.[B,5Q$=KH2"5/7M4%---70FFG9A
M1BBK>FZ=<ZKJ,%C:('GF;:@)P/Q-#:2NP2;=D5,4M:FO>'M0\-WXL]11%D9
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MBB@ HHHH **** "EHHH$%&*6B@ HHHH ****!!12T4 %%%%( HHHH$%+110
M444M !111B@ I:** "BBB@0444M !1110 4444 %+110 4444""EHHH ****
M0!112T"$I:**8!1BEHI %%%% !1110(*6BB@ HHHH ***6@08HHHH **6B@
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M>I-%+#3J1<*FD;JVU_P"KB84Y*5/65G?>WXGI'PS\0:5HVE:E%J%[';O*ZE
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M\Z+,.678FHJ'[7;_ //9?SH^UV__ #V7\Z+,7++L345#]KM_^>R_G1]KM_\
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M44M @HHI: $I:** "BBEH **** "BBB@04M%% !1110 444M !1110 444M
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MM_XX:/+B_P">W_CAJ+%+18+^1)LB_P">W_CAHV1?\]O_ !PU'118+HEV1?\
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M+LB_Y[?^.&CRXO\ GM_XX:CHHL%_(EV1?\]O_'#3X4BWG]]_"W\!]#4 !)P
M2?:I88WWGY&^ZW;V-)^HXZO839%_SV_\<-&R+_GM_P".&F>6_P#<;\J7RW_N
M-^5%UW"S[#O+B_Y[?^.&C9%_SV_\<--\M_[C?E1Y;_W&_*BZ[BL^P_9%_P ]
MO_'#1Y<7_/;_ ,<--\M_[C?E1Y;_ -QORHNNX6?8=LB_Y[?^.&C9%_SV_P#'
M#3?+?^XWY4>6_P#<;\J5UW"S[#]D7_/;_P <-&R+_GM_XX:9Y;_W&_*CRW_N
M-^5%UW"S[#]D7_/;_P <-'EQ?\]O_'#3?+?^XWY4>6_]QORHNNXK/L.V1?\
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M_/7_ ,=-1T4!?R)-D7_/7_QTT;(O^>O_ (Z:CHHL%_(DV1_\]?\ QTTNR/\
MYZ_^.FHZ*+!==B39'_SU_P#'31LC_P">O_CIIE% K^1)LC_YZ_\ CIHV1_\
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M.WS8RN['7&?K56O6?C*I9=$51DEI@ ._W*SH/AYH^F6%M)XEUG[)=7(^6),
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M*_#UQIW@G3;V36KVZB8Q!+:5ODCW(3QSVQBETOP!80:%%JWB34S8QS8,<:@
M@'IDGN?3%*GBHJGS3E?6VB_0=3"2=3EA&VE]7^IY_178>+_ YT"UAU&QN3=Z
M;-C$A RA/3..H/K6I!\-[.7P_8:O-JYMH)8DFN6D0812N?E]\X%:/%TN53OH
MS-8.LY.%M4>=TM=]XE\!V5AX;77-&OWNK88+[\'*DXW CW[5P-:4JT*L>:)E
M6HSHRY9A1116ID%%%+0 4448H$%+110 4444@"BBEH$)2T44 %3+_P >LG^^
MO]:BJ5?^/63_ 'U_K28T14444R0HHHH *6G)&TAPOYU?ALXN-^6-2Y)%*+>Q
MG45T$5G;<9A0_45;CL;0];:(_P# :S=9+H:*@WU.4HKMH]-L3UM(?^^:MQZ3
MIYZV4'_?%9O%170T6$D^IY]2UZ5'HVF'K86__? JW'H6DGKIUM_W[%0\;%=#
M18";ZGE5&*]@C\/Z.>NF6O\ W[%6X_#>B'KI5I_WZ%9O,(+HS199-_:1XK17
MND?A?03UTBS/_;(5;C\*>'SUT:R_[]"H>:4U]EFBRBH_M(\ Q17O5]HGA'3D
M#76F6"$]%\D$G\*PY;GP>K8C\.PN/4PH*G^UJ?\ *RO[%J_S(\AI:]:;3_ ^
MJ#9)IYLG/\:90#\CC\Q6!XB^'%Q80&^T>8WMKC<4XWJ/48^\*VHYC1J.VS\S
MGKY77I+FW7D<)11BEKO/-"BBB@ K7TK2!<J)Y\^5_"O][_ZU9EO'YUQ''_>8
M"NV10B!5&% P *\S,<5*E%0ANSU<KPD:TG.>J0V*&.%=L:*@]ABI***^?;;=
MV?3))*R"BBBD,**** "BBB@ HHHH **FM(/M5Y#!NV^8X7=C.,FK>M:7_9%\
M+;SO-R@?=MV]<^_M0!G444I4J<,"#[C% "44JJS?=4GZ#-)0 45I:'81ZAJT
M-O.'$3AN5XS@$]?PIFM6<5AJ\]K#N\M"-NXY/(!_K0!0HI2K*<,I!]QBKNDQ
MV$E\%U&4QV^T\@XY["@"C14]ZMNE[*MH[/;AL(S=2*V- T:VU&VO'N?,#P@%
M0#CL3_2@# HH ). ,GTH((.""#Z&@ HH'S'"\GT%*JEI G1B0N#ZT )16AJ^
ME2:/<I!+*DC.F_*C'?']*EU:'2(X+<Z;.\LA'[P'_/!H RJ*Z?4=%TK2;%!=
M33&\D0E=O0G_  K,UB+2HO(_LR9I,J?,R<X/;^M%@,NBEVG;NP=OKCBDH **
MZ#1-%MK_ $R]GN/,$D.=H!Q_#GD5S^: "BBB@ HHHH **** "BBB@ HHHH *
MANO^/2;_ '#_ "J:H;K_ (])O]P_RJZ?QHBK_#EZ,Y2BBBOKC\_"BC%+0(**
M** "EHHH **** "GP_Z^/_>'\Z94D'^OC_WA_.DP6XUOOM]324K??;ZFDH *
M*6B@ HHHH$%%%% !2T44 %%%% @HHI: $I:** "BEHH$%%%%( HHHH **6B@
M0448I: "BBB@!\W^OD_WC3*?-_KY/]XTRA;#>X444M!(444N* $Q2T44 %%%
M% !112T""BBB@ HHHI %%%+0(***6@!*6BB@ HHQ2T %%%% !1110(*6BB@
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M5^+Q%IEC:W-I8V$RPRJ<,6&22,<Y/3I2Z!Y+>'[]+FS C5&;[0PX8] /K]*
M.6HHHI %%%% !1110 4444 %%%% !4-U_P >DW^X?Y5-4-U_QZ3?[A_E5T_C
M1G5^"7HSE*6BBOKC\_"BBEH **** "BBB@ HI:* "GP_Z^/_ 'A_.F5)#_KX
M_P#>'\Z3!;C6'SM]:2E;[Y^M)0#"BBB@0444M !1110 4444""BEHH ***6@
M!*6BB@04444@"BBEH 2EHHH$%+BBB@ HHHH ***6@!\W^OD_WC3*?-_KY/\
M>-,H6P/<**6B@04444 %%%% @I:** "BBBD 4444""EHHH **6B@ HHHH *6
MBB@ HHHH$%%%+0 4444 %%%% !2T44 %%%% @I:** "BBBD 444M @HHHI@%
M%+12 ****!!1110 4M%% !1110 444M @HHHH **6B@ HHHI %%%% @HI:*
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M+0 4444 %%%+0(****0!1110 4M%%,0444M(!,4M%% !1110(***6@ HHHH
M****!!2XHHH ***6@!*6BB@ HHHI""BBEH 2EHHQ0 4N*** "BBB@0444M "
M4M%% !112T""BBEQ2 3%+113 ****0!112T".)HHHKL/H HHI:0"5[#\2O\
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MI:>-_$%N@ 2+>B@=@),"K6G>)_!7A_6KR>UN[F>2])DEN"C,J<Y"#C/<GO\
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M!!12T4 %%%% #YO]?)_O&F4^;_7R?[QIE); ]PI:**8@HHHI %%%% @I:**
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ME']I6?\ SW2N6V-_=/Y4NQO[I_*G_95+^9A_;=?^5?B=1_:5G_SW2C^TK/\
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M]NZQ_P!!6^_\"'_QH_MW6/\ H*WW_@0_^-4**.2/8/:3[FA_;NL?]!6^_P#
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M_P# AO\ &J%%')'L'M)]V7_[<U?_ *"E[_X$-_C2_P!N:O\ ]!2]_P# AO\
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MNR__ &WJW_04O?\ O^W^-']MZM_T%+W_ +_M_C5"BCDCV#VD^[+_ /;>K?\
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M]V7?[9U3_H)7G_?]O\:/[9U3_H)7G_?]O\:I44<D>P>UGW9=_MG5/^@E>?\
M?]O\:/[9U3_H)7G_ '_;_&J5%')'L+VL^[+W]LZI_P!!*\_[_M_C1_;.J?\
M02O/^_[?XU2HHY(]@]K/NR[_ &SJG_02N_\ O^W^-']LZI_T$KO_ +_M_C5*
MEHY(]@]K/NR[_;&J?]!*[_[_ +?XT?VQJG_02N_^_P"W^-4J*7)'L+VL^[+O
M]L:I_P!!*[_[_M_C1_;&J?\ 02N_^_[?XU2HHY(]@]K/NR[_ &SJG_02N_\
MO^W^-']LZI_T$KO_ +_M_C5*EHY(]@]K/^9EW^V-4_Z"5W_W^;_&C^V=4_Z"
M5W_W^;_&J5&*.2/8/:S_ )F7?[8U3_H)7?\ W^;_ !I?[8U3_H(W?_?]O\:I
M44<D>PO:S_F9=_MC4_\ H(W?_?YO\:/[8U3_ *"-W_W_ &_QJE11R1[![6?\
MS+O]L:I_T$;O_O\ -_C1_;&J?]!&[_[_ #?XU2HHY(]@]K/^9EW^V-4_Z"-W
M_P!_F_QI?[8U/_H(W?\ W^;_ !JE11R1[![6?\S^\N_VQJ?_ $$;O_O\W^-'
M]L:G_P!!&[_[_-_C5.BCDCV#VL_YF7?[8U/_ *"-W_W^;_&C^V-3_P"@C=_]
M_F_QJE11R1["]K/^9_>7?[8U/_H(W?\ W^;_ !H_MC4_^@C=_P#?YO\ &J5%
M')'L'M9_S/[R[_;&I_\ 01N_^_S?XTO]L:G_ -!&[_[_ #?XU2HHY(]@]K/^
M9_>7?[8U/_H(W?\ W^;_ !H_MC4_^@C=_P#?YO\ &J5%+DCV%[6?\S^\N_VQ
MJ?\ T$;O_O\ -_C1_;&I_P#01N_^_P W^-4J*.2/8/:U/YG]Y=_MC4_^@C=_
M]_F_QI?[7U/_ *"-W_W^;_&J5%')'L'M9_S/[R[_ &QJ?_01N_\ O\W^-']K
MZG_T$;O_ +_-_C5*EHY(]@]K4_F?WES^U]3_ .@C=_\ ?YO\:/[7U/\ Z"-W
M_P!_F_QJG2T<D>P>UG_,_O+G]KZG_P!!&[_[_-_C1_:^I?\ 01N_^_S?XU3H
MHY(]A>UJ?S/[RY_:^I_]!"[_ ._S?XT?VOJ?_01N_P#O\W^-4Z*.2/8/:U/Y
MG]Y=_M?4_P#H(W?_ '^;_&C^U]3_ .@C=_\ ?YO\:I4M')'L'M:G\S^\N?VO
MJ?\ T$;O_O\ -_C1_:^I_P#01N_^_P W^-4Z*.2/8/:S_F?WES^U]3_Z"-W_
M -_F_P :/[7U/_H(W?\ W^;_ !JG12Y(]@]K4_F?WEW^U]3_ .@C=_\ ?YO\
M:/[7U+_H(7?_ '^;_&J=%')'L+VM3^9_>7/[7U+_ *"%W_W^;_&C^U]2_P"@
MA=_]_F_QJG13Y(]@]K4_F?WES^UM2_Z"%W_W^;_&E_M?4O\ H(7?_?YO\:IT
M4N2/8/:U/YG]Y<_M?4O^@A=_]_F_QH_M?4O^@A=_]_F_QJG11R1["]K4_F?W
MES^U]2_Z"%W_ -_F_P :/[7U+_H(7?\ W^;_ !JG2T<D>P>UJ?S/[RY_:VI?
M]!"[_P"_S?XT?VMJ7_00N_\ O\W^-4Z*.2/8/:U/YG]Y<_M?4O\ H(7?_?YO
M\:7^UM2_Z"%W_P!_F_QJG11R1[![6I_,_O+G]K:E_P!!"Z_[_-_C1_:VI?\
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M=1TQ4RQ%X-PWLRX8-JHE4>ETNNMSC+B$V]S+ 3N,;LA([X.*CJUJ7_(5O/\
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M $,/0@\$5,\.N2T>UBJ>):GS2[W^XZ.:VA\2Z?>W,>KZE/)80^;B]C&TKGD
MAC@U!=ZEHVN_9;K5);R"\AB6*80Q!Q.%X!!)&TD=<\5FWWB/5-0M3:S7 6W)
MW-%%&L:L?4A0,_C651"B_M.W:W3\!U*\;^ZKWWOU_']3K(/%T/\ PEYU>>"1
M;98&MX88\$HFPJHY/XFLZTUB"#PKJ.ELDAFN9XY$8 ;0%ZYYS6+15*A!;>7X
M;&;Q%1[^?X[FZFHQW?AJQT..)S<K>F3+8"$,  ,Y]:Z36M1M+O6Y=(;4]8@4
MLELUO#&IB4@!2%&X';GVKS\$J002".016[_PF6ND _;%\T+M$WE)YF/][&:S
MJ4&VG'S_ !^3-:6(2BU/R^Y?-%RXT"RTZPUZ&Z65[JRD5;>Z4XC8Y'R8[L0<
M]\8_/"TK49M(U2WOX,&2%]P!Z$=P?J*KO/-*I62:1U+%R&8D%CU/U]ZCK6--
MV:F[W,9U5S)P5K?YG533^#KB[;4#'J,>YM[6"*NPMZ!\\+^M5++5=/ETNZTF
M_CFAM9)_M%O)$-YA;&,$$C((XK HI>Q5K78WB'>Z2^[<WM4U:S&@PZ)IGFM;
MK*9YIY5"M(^,# R< "GZEKUM>>*;/5$CE$, @W*P&X[,9QSCM7/4M"HQ7X_B
M)XB;_#\-CH].\06MIXWGUMXIC;R332!% WX?..^._K5W1Q9M\/M26]>9(3?Q
M_/$H8J=O!P>HKCZL)?726$EBLS"UD<2-'Q@L.AJ9T$_A\OP*IXEJ_-KO][-B
M^U>Q@T>VTG3!+- D_P!IGEG4+YKXP !DX4"MB7Q)HLGBB'7WDU"4JRLMIL4"
M+ QP<X(] *XBBAX>#_'\06*FGTZ?*VQT$6NVT>GZ_;F.7=J+*8C@87#[OFY]
M/3-0)J\"^#Y-'V2>>UV)P^!MVA<8ZYS6-2J2K!AU!R*KV4?QO]Q'MY_@U]YV
M=IJ<EI\/9))49;C>]G:2'@F-\,^/I@C\:XU"JR*77<@()7.,CTS5K4-5O]6E
M62^NI)V087<>%'L!P*IT4J?)=O=A6J\[26R5CJ5D\'FYCOE.IVY5@YLT56&0
M<X#D]/KS6GHVI1ZQ<^*]0NT>.*>UW,L6-RKD 8SU. *X2K%M?W5G%<16\S1I
M<)Y<H&/F7TK.>'NM'KY^MS2&*M+5*WEWLT;,FHZ7IVA7>GZ8UQ//>LOG3RQA
M J*<A0,GOU-27.IZ1KEO9/J<EU;7=M"L#F&,.)D7H1R,']*YJEJ_8K>^O<S^
ML2VLK=NAUD'BV >,;75GMI$LK6,0Q0I@LJ!2!U.,\UF:)J\&FWFH33)(RW-K
M+"@0#(+=">>E8U%'L()6\K?<#Q-1M-]V_O-O2WT>%+>XDO\ 4+2\C;+F&,,&
M&>-I!!''K5^3Q-9WNIZP+NWE33]3VDB/!>-E^Z^.A/K7*T4.C&3N_P"NHHXB
M44HQ7_!TL=#-JMA8:#<:7I;33M=NK3SRQA/E7D*HR>_<U4U?5(=0LM)AB216
ML[40N6 P3DG(]JRJ*<:44[]12KRDK=-OU.ENM3TK6[>TDU":ZM+VWB6%VBC$
MBRJO0]1@U!I&K6-A<ZC:3"XDTR^C\IFP/-4 Y5L=,CTK!I:7L8VY>@_K$N92
MMK^?J=)'J>D:=H>J:=:/=W$EZB 2O&J*-K9QC)/KS^E<W1150@HW\S.I4<[7
MZ!1115F8444M !1110(**** "O1OAGI4$;S:Q=21J1F*!68 _P"TW]/SKSFE
MK&O2=6#@G:YT8:LJ-55&KV/H_P"V6O\ S\Q?]]BO-?B9I4$CPZQ:RQL3B*=5
M8$_[+?T_*O.\FBN2A@'1FIJ7X'?BLU6(I.G*'X_\ 2N@TW5M/ET;^Q]8CF\A
M)#+!<0 %XF/48/4&L"BNZ<%-69Y=.HZ;NCHKK5=+L-%N-,T87$C71'VBZG4*
M64<A5 Z"JFJZK#?:1I%I&DBO9PM'(6 P26SQS6114JE%._7?]"Y8B<DUTM;Y
M7O\ F=CH][%J?BO2[B.%C'962"4..1Y:'+*!G)[BFJ(/%$CVB:QJLDB(\J"[
MC4QC:,\D,<?7%<Q97MSI]TEU:3-%,GW66M"Z\3:M=V\D#W"I'+_K!#&L>_ZE
M0,UC*A+FO#_AOP.B&)@X6J=[OSV\UV\RR^H:7JVGV,6I2W%O<V<?DB2*,2"2
M,'CC(P1^53CQ/;_\)-IEZ()$L-/0111#!?: >3SC))KF*,5K["/7S_$P^M35
MFM]/G;8W+#6K>UM]<C>.0G4(]L6 /E^8GGGW[56M]1BB\.WNG%',MQ/%(K#&
MT!<YS^=9M%5[./Y?@1[>>GDFOOW_ #.ZU;4(-/6STV:^U.R>.TC22&S53'DC
M.1D@DG//O5)/#NGV5_J=M?--+%'9^?%<+\GE$C(#CU/ Q69%XKUB*&*,72MY
M2[8WDB1G0>S$9K+GO+FYDE>:XED:9MTA9B=Y[$^M<\*,TK7M_7H=53$TI.]K
M^OIMN_R0ME,MM?6\[@E8Y%<@=< YKH/^$DM/^$FU74_*F\F[@DC1<#<"R@#/
M/M7,48K>=.,W=^AR4Z\Z:M'O<U]*U6&QTC5K21)&>\B5$*@8!#9YYJ]H/B.W
MTO3)(+B&22>*0S6;+C".4*G.>W(/X5S=%*5&,DT^I4,34@TUTT_4V-&U6WM8
MKVROUE>TO5 D:/[Z,IRK#/7FH+Q-+C$8M;J[N#OR^^,( OMR>?TK.I:KV:YN
M9$^U;@HM7L=18ZIH^C"ZELKF^F6:%HQ:31@+EACYB#@X]A52*_T^Z\-0:;>2
MS02VLSR1LD>\.&'0\C!S6%14>QCO?4OZS*UK*W;U_P"&-R6[76++0=)MHF-Q
M S1'>0%8NXQ@YZ5O:G>VNI:W-I?]IZM$LDWDB!(U,2GI@#<#M_"N&5F1PZ,5
M93D$'!!K;;Q;K3 G[6!(5VF41()"/][&:SG1=UR^?XN_9FM+$QL_:=;?<E:V
MZ+QN+*PTV]\.WEU/"\-X6,ULFY90!C!&15?4==LI5T1;*&<+IQY\[&7^8-V^
ME<\26))))/))[T5:HQO=F4L5*W*E9?HG='1W6L6-MXD37--EFDD:<S/#+'MV
M@]1G)SU(J2UU/0]+U-]6LA=23_,T%M)& L;-GJV>0,\8KF*6CV$;6OY?(/K4
MT[I+>_H^YL0ZQ&OAW4K"59&N+N=)0X VC!R<\UCT45I&*C>W4QG4E.U^FAU%
M_J?A[51:/=C5$E@MD@(B6/:=O?DY[U!::IIHL+O2)_M2V$DPFMY@ 9(V Q\P
MZ'(]*YZBLU0BE:[-7BIN7-97_,U#<VFFZA9W6G3W$[P2"1FE0("000 ,D^N<
MUKPZIH%MX@36HC?%C+YIM?+4;&/7YL\CGBN4I:<J*EN_(4,3*+T2WOZ,FNY5
MN+V>900LDC. >N"2:AHHK5*RL<[=W=A1110(**6B@ HHI: $I>U%% CV?3O%
MF@Q:9:QOJ<"ND**PYX( ]JL_\)AX?_Z"D'Z_X5X?17FO+*;=[L]N.>UDDN5?
MC_F='XWO[74O$CW%G,LT)B0!UZ9&<USG:BEKOIP4(J*Z'D5JKJU'4>[U-7Q#
MJ<.KZI]J@1T3RD3#@9RHP>E/\.:E;:9?SM=;Q%/;20%D7<5+8YQWZ5CT8I>S
MCR<G0?MY^U]KUO<Z&#4]/E\.1Z7<3W5N89FDW0QAA,#ZC(Y'O4MSX@L7U70[
MB"&X6#3T1&5\%CM;/'/I]*YJBI]A&]_7\33ZW4LDK=/PV-O2]9M['Q/+J<D<
MAA=I6"J!N^;.._O4,6IPQ^%[C3"C^=+<K,&&-H &,?6LJBG[*-[^GX&:Q$TK
M>OX[FM_:RQZ/I]M"'6XM+EY]Q V\XQC\JN:A>:+JEV^H237EO-+\TMO'&&&[
MOM8GH?>N=I:/9*]UI_P1K$RM9JZT_#1&W8ZC82Z)+I.HF:-!-Y\$T:ABK8P0
M1GD$4[4-3L)/#UMI-FMPQAN&D,DH WY'8 \?2L*@9!R.*7LHWO\ ,/K,N7EL
MMK7ZV-GQ)9V-E>6RV*2Q;[='EAE;+1N<\'\,''O38]5A7PK+I123SGN5F#8&
MW &/7.:RG=I'+NS,[')9CDDTE-4_=2D[V%*M[\I05KZ&KK.J0ZC#IJ1(ZFUM
M1"^[')!/(]JEU/7%N/$4.J6BNGE"+:'P#E0 >GTK%HH5**_'\0EB)N_G;\-C
M<\0ZU;:C+!'I\4D%K$7D"/C/F.V6/'X8J:^O](UF9+VZFN[6Z**LZ11AU<@8
MRIR,$X[USM%)48I)+H-XJ<FW))WMIZ;&E9C2F$OVBXO()0^8I40,-ON,@Y]P
M:UY/$MN/$.F7BI-+#91")I),>9*,$%C^?%<O11*E&3U%#$S@K126S^[5'0:=
MJ.FZ-KZ7L,MQ<0;'#?N@K G('4\U/HLPTWPU/=2S7-L)[E4CFM<%SM4Y!R1Q
MSZUS%7[#6;[38I(K:8"*0Y>-T#J3ZX(QFHG1NM-]/P-*.*49:Z+6UNC?S\NY
MMXAMC9>)A=7-Y&MT(Y$NE <D#.0<D$4Z#6])LM5O+X37]W)<1R*-Z!=FX=^>
M?TKG[_5;W4V0W<Y<(,(H 55'L!P*ITE0NO?_ *0Y8SEE^Z6F^O?OO_F;FGW]
MB^@3:5?230@W"SI)''OY P01D4L>H:?>:/#IM^TT1M9&:">--V5;JK+FL.BM
M'25[_,Q6)DDE9;6]4;UWK=LTFEV]K'(+'3V!!8#?(=V68CH/I5#6KV/4M:N[
MV)66.:0LH?J![U1HIQIQB[HFIB)U$T]M/P5E^!LZ#J5E8Q:A!?+.8KN'RLP!
M<CG/<TR6XTFS>&YTMK_[5%*KC[0$VX'/\//I631BDZ:YF^XUB)*"A9:;=^YO
MW]SHFHW4M^TU[!)*2[VZ1AL,?1L],^U1VE_8SZ'_ &7J#31".8S031J&P2,%
M2,]/I6+12]DK6N-XF3DY66N_G?\ KI8VM4U.RGT6RTZS6?%M([%Y0!NW8YP#
MQ]*Q:**N$%%61E5JNI+F?]6"BBEJC,**** "BBB@ I:** "BBB@04M%% !11
M12 ***6@0E+113 *,4M%( HHHH$%%%% !2T44 %%%% !112T"#%%%% !12T4
M %%%%( HHHH$%%+10 448I: #%%%% @HHHH **6B@ HHI:!"4M%%( HQ2XHI
M@%%%% !1112 *6BB@04444 %%%+0 E+110 444M !1110(**** "EHHI <32
MUM?\(AXC_P"@)??]^31_PB'B/_H"7W_?DUT>VI_S+[SZ/V-3^5_<8M%;7_"(
M>(_^@)??]^31_P (AXC_ .@)??\ ?DT>VI_S+[P]C4_E?W&+16U_PB'B/_H"
MWW_?DTO_  B'B+_H"WW_ 'Y-'MJ?\R^\/8U/Y7]QB4M;7_"(>(_^@+??]^31
M_P (AXB_Z M]_P!^31[:G_,OO%[&I_*_N,6BMK_A$/$7_0%OO^_)H_X1#Q%_
MT!;[_OR:/;4_YE]X>QJ?RO[C%HK:_P"$0\1?] 6^_P"_)I?^$0\1?] 6^_[\
MFCVU/^9?>'L:G\K^XQ:*VO\ A$?$7_0%OO\ OR:/^$0\1?\ 0%OO^_)I>VI_
MS+[Q>QJ?RO[C%I:VO^$1\1?] 6^_[\FC_A$?$7_0%OO^_)I^VI_S+[P]C4_E
M?W&+16U_PB/B+_H"WW_?DT?\(CXB_P"@+??]^32]M3_F7WA[&I_*_N,6BMK_
M (1'Q%_T!;[_ +\FC_A$?$7_ $!;[_OR:/;4_P"9?>'L:G\K^XQ:6MK_ (1'
MQ%_T!;[_ +\FC_A$?$7_ $!;[_OR:/:T_P"9?>'L:G\K^XQ:6MG_ (1'Q#_T
M!;[_ +\FC_A$?$7_ $!;[_OR:/;4_P"9?>+V-7^5_<8U%;/_  B/B+_H"WW_
M 'Y-'_"(^(O^@+??]^31[6G_ #+[P]C4_E?W&-16S_PB/B+_ * M]_WY-+_P
MB/B'_H"WO_?DT>VI_P R^\/8U/Y7]QBTM;/_  B/B'_H"WO_ 'Y-'_")>(?^
M@+>_]^31[6G_ #+[P]C4_E?W&-16S_PB/B'_ * M[_WY-'_")>(?^@+>_P#?
MDT>VI_S+[Q>QJ_RO[C&HK9_X1'Q#_P! 6]_[\FE_X1+Q#_T!;W_OR:/;4_YE
M]X>QJ_RO[C%I:V?^$2\0_P#0&O?^_)H_X1+Q#_T!KW_OR:7MJ?\ ,OO#V-3^
M5_<8U&*VO^$2\0_] :]_[\FC_A$O$/\ T!KW_OR:/:T_YE]XO8U?Y7]QC45L
M_P#")>(?^@->_P#?DT?\(EXA_P"@->_]^31[:G_,OO#V-7^5_<8U%;/_  B7
MB'_H#7O_ 'Y-'_")>(?^@->_]^31[:G_ #+[P]C5_E?W&-2UL_\ ")>(?^@-
M>_\ ?DT?\(EXA_Z U[_WY-'M:?\ ,OO#V-7^5_<8U%;/_")>(?\ H#7O_?DT
M?\(GX@_Z U[_ -^31[6G_,OO#V-7^5_<8]%;/_")^(?^@->_]^31_P (EXA_
MZ U[_P!^31[6G_,OO%[&K_*_N,:BMG_A$_$/_0&O?^_)H_X1/Q#_ - :]_[\
MFCVM/^9?>'L:O\K^XQJ*V?\ A$_$'_0&O?\ OR:/^$3\0?\ 0&O?^_)H]M3_
M )E]X>QJ_P K^XQZ*V?^$3\0?] :]_[\FC_A$_$'_0&O?^_)I>UI_P R^\/8
M5?Y7]QC4M;'_  B?B#_H#7O_ 'Y-'_")^(/^@->_]^31[6G_ #+[Q>PJ_P K
M^XQZ*V/^$3\0?] :]_[\FC_A$_$'_0&O?^_)H]K3_F7WA["K_*_N,>BMG_A$
M_$'_ $!KW_OR:/\ A$_$'_0&O?\ OR:/:T_YE]X>QJ_RO[C&I:V/^$4\0?\
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M&/16Q_PBFO\ _0'O?^_)H_X137_^@/>_]^31[6G_ #+[P]A5_E?W&/2UK_\
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M<_Z!-W_WZ-+_ ,(QKG_0)N_^_1H]K3_F7WA]7J_RO[F9-%:W_",:[_T";O\
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M_P"_1H_X1K6_^@5=_P#?HT>UA_,@^KUOY']S,NBM3_A&M;_Z!5W_ -^C2_\
M"-:W_P! J[_[]&E[6'\R#ZO6_D?W,RJ*U?\ A&M;_P"@5=_]^C1_PC6M_P#0
M*N_^_1H]K#N@^KUOY']S,NBM3_A&M;_Z!5W_ -^C1_PC6M_] J[_ ._1H]K#
MNA?5ZW\C^YF716K_ ,(UK?\ T"[O_OT:/^$;UK_H%W?_ 'Z-'M8=T'U>M_(_
MN9ET5J?\(WK?_0+N_P#OT:/^$;UO_H%W?_?HT>UAW0?5ZW\C^YF716I_PC>M
M_P#0+N_^_1H_X1O6_P#H%W?_ 'Z-'M8?S(/J];^1_<S+I:U/^$;UK_H%W?\
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M**T_^$<UK_H%W7_?HT?\(YK7_0+NO^_9H]K#N@^KUOY']S,RBM3_ (1S6O\
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M$?UC_H&W7_?LT>TAW0?5J_\ (_N9[!1117S1^GA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$KE.L"/SC8_9T^SDXSY6/TS_ /KJ%2ZWT*YO(]%HKSO4_&USJ7P;N/$VG/\
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MZY+JTBPJPM_+$<22$X"ICL2RC/H,UG6>A>.-4T:/6G\626NISQB>*R2!/LZ
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M7TACMH'N6D8*6(&$'09)ZU6\8>,M/\<Z#/X9\,6]SJ5]=M&"WD,B0*'#;F+
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M_4/&FJV4EBDL M=/M9AB18L@EF'8G'_CQ[8SZ#16DZJ;;BK-DJ+TOT*NI_\
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M@/M&<?6GU$W%_"K%)/J>:>)-;^'>N2W5MXDC:SOK5FC#3V[Q3@ G#(P&2#U
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M)WU//?"__)8?&O\ USM?_18J'2C_ ,(%\0Y=%?Y-#UUC/8G^&&X_BC]L\?\
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M>'=1-AJ,\Z7 0/A+=W&#TY Q51BY.T4)M+<Z:BN&7XN^#W&4O;E@#CBTE/\
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MN2.^CTO4(KN58'#@JH(8<=QN!^F:OZ_X]\.#P9=WT&J6UP;BV98($D!D=V7
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MY6__ *"E+W=7;IV\QZE2T\5>-+7Q'=>$[JUT^^U9HEGM;Q<QPK&>K2#J0.F
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M;C(6!64%BP!RYR0 !CWKOHY$EC62-E=' 964Y!!Z$5Y_H?\ R6WQ3_UY6_\
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M/2KG@R9?$'Q+\1^)K,%M,$*64,V,"9AMW$>H&W\B*TJ17O*UDA1>VI-\)O\
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M](PPW8]]P_$&JJJ[G=;/3[Q1Z69-H?B+Q%XF^&!U>W>PBU(F7<9(V\O8I(.
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M:+2IKZ2\MVDB6!OG9P<!<'@#N6)X%4K;QIKUCXHT_2?$NA06,6IEEM9X+CS
M''\+>_(';K0J4FKAS([RBBBLR@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1W$[7$HWLVZ1L9/S$XZ#@<4FGZ%INE7%_/96PCDOY3-<DNS>8YSDX)('4\#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "JQT^R:X^T-9VYFSGS#$N[/UQFK-% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img43612817_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43612817_1.jpg
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M,2QT.C(T,#$R.3$X_^$%'6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M#@\,$!<4&!@7%!86&ATE'QH;(QP6%B L(",F)RDJ*1D?+3 M*# E*"DH_]L
M0P$'!P<*" H3"@H3*!H6&B@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@$. >  P$B  (1 0,1 ?_$ !\
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MK\?\@^MU/^?,O_)?_DCI-X]:-X]:YO\ L?Q-_P!!^#_P$6C^Q_$W_0?@_P#
M1:/9+^=?C_D'UNI_SYE_Y+_\D=)O'K1O'K7-_P!C^)O^@_!_X"+1_8_B;_H/
MP?\ @(M'LE_.OQ_R#ZW4_P"?,O\ R7_Y(Z3>/6C>/6N;_L?Q-_T'X/\ P$6C
M^Q_$W_0?@_\  1:/9+^=?C_D'UNI_P ^9?\ DO\ \D=)O'K1O'K7-_V/XF_Z
M#\'_ ("+1_8_B;_H/P?^ BT>R7\Z_'_(/K=3_GS+_P E_P#DCI-X]:-X]:YO
M^Q_$W_0?@_\  1:/['\3?]!^#_P$6CV2_G7X_P"0?6ZG_/F7_DO_ ,D=)O'K
M1O'K7-_V/XF_Z#\'_@(M']C^)O\ H/P?^ BT>R7\Z_'_ "#ZW4_Y\R_\E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]:WXNBUM4_AP^9Q4/]YJ_P#;OY$Z&I*C2I*Q.T6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ****  TAI333TH C?O7+?$$_P#%+7/^]'_Z&*ZE^]<K\0?^17N?]Z/_
M -#%;8?^+'U1QYC_ +I5_P +_(ZZ'_5)_NBG4V'_ %2?[HIU8LZUL%%%% PH
MHHH **** "BBB@ KQ?Q%J^K:AXMN[?3+R[4--Y4444S*#CC@9QV)KV2Z9DMI
M7C4NZH2JCJ3CI7@]A'K%G>-J=M:3B6)F)D:$L$)R#GC'<UZ>703YI.U^ESYG
MB.K)*E35[-W=M[+_ (<V1H_C8D#S-2&>_P!K/'_CU>C^)!JL'AXC1F#7<:@$
ML-S, .<?[7UKE?!'C>[U#4H]/U41NTN1'*B[3G&<$=*]&J,74J1G%5(K3MLS
M;*</AZE"<L/4D^;35ZKT^\\2U31_$MG:?VM?2W"\@LQG.]<^HSQ7;?#/Q#=:
MO;W%K?N99K?#+*>K*?7W&/UJE\4O$,*VIT>V8/,Y#3$'A .0OU-7?A;HDFGZ
M9+>W(*RW>-JD<A!T_//\JWK3]IA>>JDGT.#!T?89I['#3<HI>]=WU_X>QV]8
ML?BC1Y+\627JFY,GE!-K?>SC'3UK:KQ*!?+^)2KZ:F?_ $97'A:$:W-S=%<]
MG-,?4P;I\B3YG9W/7-6UO3](,8U&Y6$R9V@@G./H*E@U.SGTTW\4ZFS"E_,P
M0,#J?TKR'QW>R:SK]])$<VU@@0'VW!2?Q9OTK4N=3%K\++2W5OWER[0@?[(8
MEOZ#\:W^HKD@[ZMJ_P"9PK/7[:M%I<D$VO.SM]S9Z#I7B'2]5N##I]T)I NX
M@*PP/Q%.UC7=-T<+_:%TD3L,JG5C^ YKAO!JKX<\&WVN3*#-.,1*?3.%_-CG
MZ5RNC+9:QJL]SXDU,PH?F8DG=(3V'!P!3C@H.<FF^6/WMDSSJM"E3BXKVD]=
M=$ET;N^IZ[HWB;2M8E,5C<AI@,^6RE6(]L]:V&8*I9B%4#)). *\)8VNF^+K
M=M"N6FMTGC,<G<Y(R.WJ174?%;79?M2:3;R%8U4//M.-Q/13[8Y_&E/ WJ1C
M3>C5]>A5#/G'#U*E=+F@[:;.^UOZV.KN/&V@P3^4;T.0<%HT++^8%;UE=07M
MM'<6DJRPN,JZG(->,2:9X=C\./+_ &KYFKB/>(TSMW?W,8_7-=/\(KEUL-2C
M<GR8V60>Q(.?Y"BO@X1IN<+Z=PP.<5ZN)C1KJ-I*ZY7>WKJSE_B+<F\\7W2I
M\WE[85 ]0/\ $FO53?:?X<TFRAO[A(%6-8USDY('/ KQ:._C;Q'_ &A=AGC-
MR9V4=6^;=BMBSM]0\=>(GDF?9$O+GJ(DSP![UV5\.I0A&;M&*U/&P.8N%:K4
MHQYJE25DO+5ZGK>E:O8ZK%)+83^;'&<,VT@ _B*R[KQIH5M.8FO5=@<$QJ6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH #36Z4XTUNE $;]ZY7X@_P#(KW/^]'_Z&*ZI^]<K\0?^17N?]Z/_
M -#%:X?^-#U1QYC_ +I5_P +_(ZZ'_5)_NBG4V'_ %2?[HIU9,ZUL%%%% PH
MHHH **** "BBB@#G?&7B6/P[:1MY+37$Q(C7HO'4D_TK/D\?Z,VE/*&?SRA_
MT<H<[L=,],>]=/J>G6FJ6K6]]"LL1YP>Q]0>U<I_PK;1O.W^;>;/^>>\8_/&
M:[*+PW+:I>_YGCXR.9*JWAG%Q:V?3S_K[CB/ASI\M[XHMI44^5;'S7;L/0?G
M74>-O'7V=I=/T8_OE)26X(^Z>X7W]Z[G2M+L]*M?L]A"L4?4XZD^I/>N<E^'
MNBRRO(YNR[L6)\WN?PK=XJC5K>TJK1;?\$X(Y7C,)A/8862YI.\GM\D>=>%Y
MM%M[O[;KLDTTBMN2%8]P)_O,3U^E>RZ'JMOK.GK=V8D$)8J-Z[3Q[5SG_"N=
M#_Z>_P#O[_\ 6KIM(TZ#2=/BL[0,(8\XW')Y.>M1C*]*M[T;W_ WR; XK!MP
MJJ*CY;M^9<KP[6KD:?XZOKK;DPW+R*/]KDC]<5[C7+:EX&TC4;^>[N/M/G3-
MN;;)@9_*L\'7A1E+GV:-\YP-;%PA["UXN^IP%KISQ?#[4]1F!WW4T:J3W4.,
MG\\_E63;K+K,ND:7!G*Y0>Q9R6/Y8_*O:+KP_8W.A)I#K(MF@4 *V#P<CFJ6
MB>#M*T>_6[M%F,R@@>8^X#/X5UQS""4F][MK[K(\FIP_6<Z<8M<BBE+OO=_B
M4OB!II3P0UO9J?+M?+;:/[J\'_'\*\[\)IX?E,T?B!I8VX,;JQ"X[@XKW-U5
MT*N RD8(/0BN.O\ X=Z-=3F2)KFVR<E8F&W\ 0<5CA<5&--TYMJ^MT=F9Y55
MJUXXBA&,K*W++8I^&M%\)WVI%]*::6:T99/G<X//!P>HR*Y+XE6\D'BZYDE!
M*3!'0^HV@8_,&O3_  _X7TW0F:2RC=IF&TRR-EL>GI5G7=#L-<@6+4(MVW[K
MJ<,OT-%/&1IUN:[<;6UW"OD\\1@O9<L83O?3;K^C/.HH? K6:S/+=*Y7)BW,
M6!].E=5-9:;X>\':E<:5N\J:$N'9MQ)(PO/XU7@^&VCQS;Y)KR5,_<9P!^@S
M717^A65YHPTME>.S&T!8VP< Y S16KTVTE)M7UN/!X#$0C-SI0C*S46M[GC7
MA'07\0:I]G#^7#&N^5^X'M[UH>"KU_#_ (O^S71VH[FVE] <X!_/'YUZAX=\
M-V&@&<V ES-C<9&W=,XQ^=4M4\%:3J6HRWLXN%GD(9O+DVC/KTK:>/A4E*,O
MA:.*ED%?#TZ=6E;VL7=ZZ6[?UW9-XH\1Z9HYBM=14R_:.&C5=V$/!)'I7EWB
MZRT* QSZ#>^8)"=T&"=@]<G^1KUO6?#^GZQ:QP7\1D,8PD@.'7\:P;3X<Z-!
M-OE>ZG .0CN /T K+"UZ-%7NT^O9G7FN QF,DX*,7'HW>\>Y9^&,ES+X3A-T
M6(61EB+=2@Z?KD?A75TR"&.WA2*%%2)!M55& !3ZX:L_:3<DK7/<PM%T*,*3
M=VDE<****S.@**** "BBB@ HHHH Y3X@_P"IT7_L(Q?UK>B_AK!^(/\ J=%_
M[",7]:WHOX:VJ?PX?,XJ'^\U?^W?R+"5)4:5)6)VBT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%-D<1QL['"J,DUX5:?M!RZB)I=&\ >)M3LTE:(7-I$9(V*GU52/3C
MWH ]WHKGK'Q3;GP3'XEUN";1K;[-]IGAO 5D@ ZAAC.?;%>32?'_ %%[236;
M+X>ZU/X3C8AM4\S;E0<%PFS&/?=CWH ]ZHK)\*>(=.\5>'[/6=%G$]E=)N1N
MA!Z%2.Q!R"/:KFJZA:Z5IMS?ZA,D%I;1M++*YP%4#)- %JBO!7^/^H36TVL:
M5\/]9O/"D+$/JGF;<J#@L$V$$#_>^N*]A\'>)=.\7>';/6M&E,EG<KN7<,,I
MZ%6'8@\4 ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  ::W2
MG&FMTH C?O7*_$'_ )%>Y_WH_P#T,5U3]ZY7X@_\BO<_[T?_ *&*UP_\:'JC
MCS'_ '2K_A?Y'70_ZI/]T4ZFP_ZI/]T4ZLF=:V"BBB@84444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ?10 SS5]&_*CS5]&_*GT4 ,\U?1ORH\U?1ORI]% #/-7T;\J/-7T;\J?10
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M6_\  @T?\(1%_P!!?5O_  (-'LZ7\_X!]8Q7_/G_ ,F7^1TN_P!J-_M7-?\
M"$1?]!?5O_ @T?\ "$1?]!?5O_ @T>SI?S_@'UC%?\^?_)E_D=+O]J-_M7-?
M\(1%_P!!?5O_  (-'_"$1?\ 07U;_P "#1[.E_/^ ?6,5_SY_P#)E_D=+O\
M:C?[5S7_  A$7_07U;_P(-'_  A$7_07U;_P(-'LZ7\_X!]8Q7_/G_R9?Y'2
M[_:C?[5S7_"$1?\ 07U;_P "#1_PA$7_ $%]6_\  @T>SI?S_@'UC%?\^?\
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M_P (1%_T%]6_\"#1[.E_/^ ?6,5_SY_\F7^1TN_VHW^U<U_PA$7_ $%]6_\
M @T?\(1%_P!!?5O_  (-'LZ7\_X!]8Q7_/G_ ,F7^1TN_P!J-_M7-?\ "$1?
M]!?5O_ @T?\ "$1?]!?5O_ @T>SI?S_@'UC%?\^?_)E_D=+O]J-_M7-?\(1%
M_P!!?5O_  (-'_"$1?\ 07U;_P "#1[.E_/^ ?6,5_SY_P#)E_D=+O\ :C?[
M5S7_  A$/_07U;_P(-'_  A$/_07U;_P(-'LZ7\_X!]8Q7_/G_R9?Y'3!L]J
M<#7'ZCX/CM=/N9TU;52T<;. ;@XR!FM/P5*\OA?3WE=W=H\EF))/)[TITHJ'
M/&5];;%4<54E5]E4ARNU][]4OU.A4TM1J:D7I6)VBT444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &D/2EI#0!$_>N6^
M(/\ R*]S_O1_^ABNI?J:Y?X@C_BEKG_?C_\ 0Q6V'_BQ]4<>8_[I5_PO\CK(
M?]4G^Z*=38?]4G^Z*=6+.M;!1110,**** ,/4/"VF7^JC4;J.5[D%2#YA ^7
MIQ1K?A?3-:NDN+^.5Y$78-LA48^@K<HK55JBLU)Z'-+!X>2DG!>\[O3=^9CZ
MYX<T_6E@6^CD98 0@1RN,X]/I6@ME;BP6R,2M;+&(_+89&T#&*L45+J2:4;Z
M(T5"FI.:BKO=]SF1X&T 3^;]B/\ N>8VW\LUK:CH]CJ&F?8+F &V  55XV8Z
M8]*T**;K5)--R>AG#!X>"<8023WT6IS4?@C0TLGMA:L0^-TA<[SCW[?A5V7P
MYITNAQZ2R2?8D.0HD(/7/)^IK8HINO4>\GW%' X>*:C32NK;=.QFZ9HECINF
M/86T7^BONW(YW9SUSFLVR\%:'9R.\=J69L@&1RVW/I7244E6J*]I/4;P="7*
MG!>[MIMZ&3HGA^PT6&>*P1T6;[Y9RQZ>IJ+0_"^F:)<O/812+*Z["7D+<9SW
MK;HH=6;O=[[CCA*$>6T%[NVFWH8=CX6TNRU<ZE!%)]K)9MS2$C+=>/Q-;E%%
M3*<IN\G<NE1IT4XTXI)ZZ'.W/@S1;K4WOIK8M(YW,F\A"?7%3V/A?2['5CJ5
MM"R7)S_&=HSQP.@K;HJW7J-6<F9+!8=2YE35[WV6_<P-5\(Z1JFI?;;R!VF(
M 8*Y56QTR!2MX2T<ZA;WBVQ26#;Y81B%&WIQ6]11[>HE;F8/ X=MR=-7;OLM
MS#U3PMIFIZDM]>1R/.NW&)"!QTXK;90RE6 ((P0:6BHE.4DDWL:PH4Z;E*$4
MG+?S]3G+7P7H=M>FY2TW/NW*KL653["K>A^'-.T2>:6PC=7E&&+.6[Y[UL45
M<JU22LY,RA@L/3:E""37DNIBZWX8TK6IUFOK<M,!C>C%21Z''6H[KPEI-SIU
MO8O#(+:!BR(LK#D]3FMZBA5JB22D]!RP6'DY2E!7EOHM?4J6VG6UOIJ6"1 V
MJIY>QN<K[^M8L7@?0([GSA99.<[&=BH_#-=+12C5G&_*VKCGA*%2W/!.VUTM
M"GJ.FVU_IKV$Z$6S@*50[> <XX^E5-.\.Z?I^F7%A:I(MO<9\P%R2<C!Y^E:
M]%)5))<J>A4L/2E/VCBKVM?R[&1H/AW3M":9M/C=#* &+.6Z9QU^M:]%%*4Y
M3?-)W95*E"C%0IJR71!1114F@444V:1(8GDE=4C0%F9C@ >M -VU9ROCY@TF
MA6XYD>_1@/90<_SKH8ATKDM.D/B7Q,=5 8:;8@Q6I(_UCGJWT_\ K5UZ#I6]
M9<JC![K?YG!@G[652NMI/3S25K_-WMY$J=*>*8M2"L#O"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%,_>?[%'[S_8H ?13/WG^Q1^\_V* 'T4S]Y_L4?O/]B@!]%,_>?[%'[S_8H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM\Q0<9ZUL\Q7.FE[MK6.)<./V$E*2]HW=/\ KY_@8NH>)O(\(1ZS;P-.TB#
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MIFU#PW?/IY<G.4&0HSZ JP'L!0![)1110 4444 %%%% !1110 4444 %%%%
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M %%%% "  =!BEHHH 3 SG'-+110 8&<]Z*** $VC.<#-+110 A /4 XI:**
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M )T>4OO^=/HH 9Y2^_YT>4OO^=/HH 9Y2^_YT>4OO^=/HH 9Y2^_YT>4OO\
MG3Z* &>4OO\ G1Y2^_YT^B@!GE+[_G1Y2^_YT^B@!GE+[_G1Y2^_YT^B@!GE
M+[_G1Y2^_P"=/HH 9Y2^_P"='E+[_G3Z* &>4OO^='E+[_G3Z* &>4OO^='E
M+[_G3Z* &>4OO^='E+[_ )T^B@!GE+[_ )T>4OO^=/HH 9Y2^_YT>4OO^=/H
MH 9Y2^_YT>4OO^=/HH 9Y2^_YT>4OO\ G3Z* &>4OO\ G1Y2^_YT^B@!GE+[
M_G1Y2^_YT^B@!GE+[_G1Y2^_YT^B@!GE+[_G1Y2^_P"=/HH 9Y2^_P"='E+[
M_G3Z* &>4OO^='E+[_G3Z* &>4OO^='E+[_G3Z* &>4OO^='E+[_ )T^B@!G
ME+[_ )T>4OO^=/HH 9Y2^_YT>4OO^=/HH 9Y2^_YT>4OO^=/HH 9Y2^_YT>4
MOO\ G3Z* &>4OO\ G1Y2^_YT^B@!GE+[_G1Y2^_YT^B@!GE+[_G1Y2^_YT^B
M@!GE+[_G1Y2^_P"=/HH 9Y2^_P"='E+[_G3Z* &>4OO^='E+[_G3Z* &>4OO
M^='E+[_G3Z* &>4OO^='E+[_ )T^B@!GE+[_ )T>4OO^=/HH 9Y2^_YT>4OO
M^=/HH 88EQW_ #I/*7W_ #J2D- $+Q)CO^=59H4PWWOSJZW2H)1\K?2@#GOA
ME_R+)_Z^9?YUUE<G\,O^1:/_ %\R_P#H5=96^)_C2]3ARS_=*7H@HHHK [@H
MHHH @O+.VO45+N"*95.0)%# '\::^GV;VBVK6T)MEZ1%!M'X59HI\S74ATX-
MMM;E9=/M%M#:K;0BV;K$$&T_A3K.SMK)&2T@BA5CDB-0H)_"IZ*.9OJ"IP33
M2V*MSIUE<R"2XM()7'\3Q@FK$<:1H$C550= HP!3J*&V]!J$4[I:E2'3+&"X
M>>&T@29CDNJ $GZTMIIUG:,[6MK#"7&&*(%S]<5:HI\TGU$J4%LD5+33;*SD
M:2UM8(788+(@4D?A2SZ;93W*W$UI!).HP'9 2/QJU11S2O>X>RA;ELK%4:=9
MB\^U"UA^T]?-V#=TQU^E)+IME-="YEM('N 01(R L".G-6Z*.:7</90VLN_S
M*MWIUE>2+)=6L$SJ,!I$#$#\:M    < 444FV]!J,4VTM65[VQM;Y%2\MXIU
M4Y D4'!J.;2[&=(UFL[=UC^X&C!"_2KE%-2:V8G2A*[:6I!>6EO>P>3=PQS1
M==KKD5$^F6+VZV[V=N8%.0AC&T'UQ5RBA2:V8.G"3NTBM-I]I-;1V\UM"\$>
M-D;("JX&!@5+;P16T*Q6\:1QKT5!@#\*DHI<S:L-0BG=+4JW6G6=W*DMU:PS
M2)]UG0$BA].LWN4N'M8#.F-LA0;EQTP:M44^9]Q.E!N[2&311SQM',BR1MU5
MAD&JT6EV$44D<5G;I'(-KJL8 8>AJY124FM$QN$9.[17L[&UL@XL[>* /][R
MT"Y^N*2ZT^SNW#W-K#*PZ%T#$?G5FBCF=[W%[.'+RV5AL:+&@2-0JC@ # %5
MK?3+&WN#/!:01S'.75 #SUYJW10FT-PB[76Q4&FV0N_M0M(/M.=WF[!NSZYJ
MW110VWN$8QC\*L%%%%(H***1F5%+,0J@9))X H S/%%PMMX=U&5R JPL.?4C
M _4UF^$[/R/#FGI*&#^2I(STSS_6LO5;L^+M3CT[3R6TFVD#W4X^[(1T0>M=
M@B@# & *Z*B]G34'N]?\CSZ$EB,1*M'X4N5/OK=V\ME]XL<*9'7\ZE$2^_YT
M**>*YST!OE+[_G1Y2^_YT^B@!GE+[_G1Y2^_YT^B@!GE+[_G1Y2^_P"=/HH
M9Y2^_P"='E+[_G3Z* &>4OO^='E+[_G3Z* &>4OO^='E+[_G3Z* &>4OO^='
ME+[_ )T^B@!GE+[_ )T>4OO^=/HH 9Y2^_YT>4OO^=/HH 9Y2^_YT>4OO^=/
MHH \J^,'Q U#P5J.GV^G6MK.MQ$SL9MV00<<8(KS[_A>NO?] W3?_(G_ ,55
M_P#:>_Y#FB_]>[_^A"O%*^GP.#H5*$92C=L^=QN+K4Z\HQE9'KG_  O77O\
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M (JC_A>NO?\ 0-TW_P B?_%5Y'11_9^&_D0?7L1_,>N?\+UU[_H&Z;_Y$_\
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M SRE]_SH\I??\Z?10 SRE]_SH\I??\Z?10 SRE]_SH\I??\ .GT4 ,\I??\
M.CRE]_SI]% #/*7W_.CRE]_SI]% #/*7W_.CRE]_SI]% #/*7W_.CRE]_P Z
M?10 SRE]_P Z/*7W_.GT4 ,\I??\Z/*7W_.GT4 ,\I??\Z/*7W_.GT4 ,\I?
M?\Z/*7W_ #I]% "*H7IG\Z6BB@ HHHH **** "BBB@ HHHH *Y;XA>!M'\=Z
M2MCK2RCRB7AFA?:T3$8R.Q^A!KJ:*:;3NA-)JS/G63X-^//#S%/!_C)OLP^Y
M'+*\6/P&Y:C7P3\;+HF*Y\4QQ1="WVS_ .)3-?14T\4)C$TJ1F1MB;F W-UP
M/4\'CVJIJVLZ9HZ1/JVH6EDLK;4-Q,L88^@R>:V]M)]$_D8^PBNMOF>*Z#\
M?M5_'?\ CO7KG5Y5.3 CL%;V+L=V/IBO=H(D@ACBB7;'&H51Z # I8W61%>-
ME9&&0RG((]:=6<YRGN:0A&'PA1114%A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 444E "TE&<4W- #LT9J,
MGFC=0!)FC/O4>ZC- $F?>C/O4>:,T 29]Z,^]1YHS0!)GWHS[U'FC- $F?>C
M/O4>:,T 29]Z,^]1YHS0!)GWHS[U'FC- $F?>C/O4>:,T 29]Z,^]1YHS0!)
MGWHS[U'FC- $F?>C/O4>:,T 29]Z,^]1YHS0!)GWHS[U'FC- $F?>C/O4>:,
MT 29]Z,^]1YHS0!)GWHS[U'FC- $F?>C/O4>:,T 29]Z,U'FC=0!)F@&H]U*
M&H D%%-!IWO0 44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BB@T ,8<5$ZY!J<TPB@#B;#P[KNFPF"PUR.& N7"?9P>2>>35@Z;XH_P"A
MBC_\!EKK-M)MKH>)FW=I?<O\CSXY91@N6+DE_BE_F<G_ &?XG_Z&%/\ P&6C
M^S_$_P#T,*?^ RUUFWV%&WV%+ZQ+LON7^17]GT_YI?\ @<O\SD_[/\3_ /0P
MI_X#+1_9_B?_ *&%/_ 9:ZS;["C;["CZQ+LON7^0?V?3_FE_X'+_ #.3_L_Q
M/_T,*?\ @,M']G^)_P#H84_\!EKK-OL*-OL*/K$NR^Y?Y!_9]/\ FE_X'+_,
MY/\ L_Q/_P!#"G_@,M']G^)_^AA3_P !EKK-OL*-OL*/K$NR^Y?Y!_9]/^:7
M_@<O\SD_[/\ $_\ T,*?^ RT?V?XG_Z&%/\ P&6NLV^PHV^PH^L2[+[E_D']
MGT_YI?\ @<O\SD_[/\3_ /0PI_X#+1_9_B?_ *&%/_ 9:ZS;["C;["CZQ+LO
MN7^0?V?3_FE_X'+_ #.3_L_Q/_T,*?\ @,M']G^)_P#H84_\!EKK-OL*-OL*
M/K$NR^Y?Y!_9]/\ FE_X'+_,Y/\ L_Q/_P!#"G_@,M']G^)_^AA3_P !EKK-
MOL*-OL*/K$NR^Y?Y!_9]/^:7_@<O\SD_[/\ $_\ T,*?^ RT?V?XG_Z&%/\
MP&6NLV^PHV^PH^L2[+[E_D']GT_YI?\ @<O\SD_[/\3_ /0PI_X#+1_9_B?_
M *&%/_ 9:ZS;["C;["CZQ+LON7^0?V?3_FE_X'+_ #.3_L_Q/_T,*?\ @,M'
M]G^)_P#H84_\!EKK-OL*-OL*/K$NR^Y?Y!_9]/\ FE_X'+_,Y/\ L_Q/_P!#
M"G_@,M']G^)_^AA3_P !EKK-OL*-OL*/K$NR^Y?Y!_9]/^:7_@<O\SD_[/\
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M=HHVBG8HQ0 W I0!2XHH 3%**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^>/VGO^0YHO\ U[O_ .A"O%*]K_:>_P"0
MYHO_ %[O_P"A"O%*^PRW_=H?UU/E,P_WB7]= HHHKN.,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "@=:*!UH ^U/ /_ ")6A_\
M7G%_Z *WJP? /_(E:'_UYQ?^@"MZOA:OQR]3[2G\"] HHHK,L**** "BBB@
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MZ]!4$?7\*G7H*Q.T?2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\\?M/?\AS1?\ KW?_ -"%>*5[7^T]_P AS1?^O=__ $(5XI7V&6_[
MM#^NI\IF'^\2_KH%%%%=QQA1110 4444 %%%% !1110 4444 %%%% !1110
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MLJVG_#A\SBH?[Q5_[=_(****Q.T**** "BBB@ HHHH \O\2^$-?U/6[RZA:
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MZ"L3M'TM)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_L(1?UKLJXKQAO^TZ)OVX^WQ=*[6MI_PX?,XJ'^\5?^W?R"BBBL3M"BBB@
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M.MZ(^A;?(CU9]PN8X.FS&.N..A/HWI]"44 ><V?PW?0/A'<^$?"FHO97\D+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\?M/?\AS1?^O=_P#T
M(5XI7M?[3W_(<T7_ *]W_P#0A7BE?89;_NT/ZZGRF8?[Q+^N@4445W'&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.M% ZT ?:
MG@'_ )$K0_\ KSB_] %;U8/@'_D2M#_Z\XO_ $ 5O5\+5^.7J?:4_@7H%%%%
M9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_G[?_OTW^%'U:K_*_N#^TL)_S]C]Z.GHKF/^$[T#_G[?_OTW^%'_  G>@?\
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M_G[?_OTW^%'U:K_*_N#^TL)_S]C]Z.GHKF/^$[T#_G[?_OTW^%'_  G>@?\
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MY7G& >W?O5K]F36]1N?"^K>'-<D,NH>&[Y]/9RV24&=O/L58#V H ]DHHHH
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M*+L+(J?9D_N)_P!\BC[,G]Q/^^15O:?2C:?2B["R*GV9/[B?]\BC[,G]Q/\
MOD5;VGTHVGTHNPLBI]F3^XG_ 'R*/LR?W$_[Y%6]I]*-I]*+L+(J?9D_N)_W
MR*/LR?W$_P"^15O:?2C:?2B["R*GV9/[B?\ ?(H^S)_<3_OD5;VGTHVGTHNP
MLBI]F3^XG_?(H^S)_<3_ +Y%6]I]*-I]*+L+(J?9D_N)_P!\BC[,G]Q/^^15
MO:?2C:?2B["R*GV9/[B?]\BC[,G]Q/\ OD5;VGTHVGTHNPLBI]F3^XG_ 'R*
M/LR?W$_[Y%6]I]*-I]*+L+(J?9D_N)_WR*/LR?W$_P"^15O:?2C:?2B["R*H
MMT_N)_WR*<D*J<JJ@^H&*L;3Z4;?:@+(C"FGJ*<%]J4#VH&*!2XH%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 >+_M._\B_H_P#U]-_Z!7SK
M7T5^T[_R+^C_ /7TW_H%?.M?695_NR^?YGS&9_[P_D%%%%>D>>%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]:_ W_DFNE_
M]M/_ $8U=[7!? W_ ))KI?\ VT_]&-7>U\3B_P"//U?YGV&&_@P]$%%%%<YN
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\?M/?\AS1?\
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M==."Y$[7O^!QU)OG:YK6_$]S\%^)M/\ %WAVUUC27)MY@05;[T;#@JP]0?\
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M]%<YN,\I?5OSH\I?5OSI]% #/*7U;\Z/*7U;\Z?10 SRE]6_.CRE]6_.GT4
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M.GT4 ,\I?5OSH\I?5OSI]% #/*7U;\Z/*7U;\Z?10 SRE]6_.CRE]6_.GT4
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XO^T[_ ,B_H_\
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M+9))X_+*;7(R1M/(^AI8J/O<P\*_=Y39HHHKE.H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#YX_:>_Y#FB_P#7N_\ Z$*\4KVO]I[_ )#FB_\
M7N__ *$*\4K[#+?]VA_74^4S#_>)?UT"BBBNXXPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *!UHH'6@#[4\ _\ (E:'_P!><7_H
M K>K!\ _\B5H?_7G%_Z *WJ^%J_'+U/M*?P+T"BBBLRPHHHH **** "BBB@
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MK$LOZ$5S_@E_!/Q7TI;S_A&(8X=*E^SPQSQ*-HP&P IQMYZ5ZLBJBA4 50,
M 8 %16G?2UF:4:;6M[H6BBBN<Z HHHH Q/%?A31?%EM:V_B&R%Y!;3K<Q(9'
M0"1>A.TC/T.1[5R'Q\\1Z1H7P[U*QU$+-=:G"UI9V2KN>:1A@8'H"0<^P[XK
MHOB-XUT[P)X;FU74]\C#Y8+>,9>9^R@?S/85\N^!_B9HESXQN?&7Q&M]4O\
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M_*GT4 ,\U/4_E1YJ>I_*GT4 ,\U/4_E1YJ>I_*GT4 ,\U/4_E1YJ>I_*GT4
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M[0V23U8DG)[UZ?6%7XV;TO@04445F:!1110 UT5\;U#8]13?(B_YYI^5244
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M%?.M?17[3O\ R+^C_P#7TW_H%?.M?695_NR^?YGS&9_[P_D%%%%>D>>%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]:_ W_
M ))KI?\ VT_]&-7>UP7P-_Y)KI?_ &T_]&-7>U\3B_X\_5_F?88;^##T0444
M5SFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SQ^T]_P A
MS1?^O=__ $(5XI7M?[3W_(<T7_KW?_T(5XI7V&6_[M#^NI\IF'^\2_KH%%%%
M=QQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#K
M10.M 'VIX!_Y$K0_^O.+_P! %;U8/@'_ )$K0_\ KSB_] %;U?"U?CEZGVE/
MX%Z!1116984444 %%%% !1110 4444 %%%% '!^*M1UR-YAL>WLE?:LB#&X=
MN>M:_@*>:XTJ5IY7D82D9=B3T%.\?_\ (OG_ *ZI4'P[_P"01-_UV/\ (5\U
M3A.EFW(YN2<6]3V9RC/ <RBEK;0B^(5U/;1V0MYI(BS-G8Q&<8]*Q[?2O$=Q
M!'-%/*4D4,I-SC@_C6]XWTF\U,V9LXPX0L&&[&,XY_2L*]N?$&@&#[1/^Z(V
MH!AEX[=*X\QA;%U*F(4_9Z6<=MD=&$E?#PA2<>;71G=Z3'-#IEK'=$F=8P')
M.><<\]ZMU2T6_&I:;!=!=I<?,OH1P:NGH<5]90<72BX.ZLK'A55)3:EH[G :
MWJ5[K&O?V;I\QCB5S&,' )'4DCM4$-WJ/AG64M[N8S0-@L-Q*E3W&>A%,\&<
M^*B6ZXD/XU:^)&/M]F1][RC_ #KXMRJ3PT\QYGSJ6FNEM-+?,^B48QK1PG*N
M5Q_'N7?%MQ+>:Q8Z7%*T<,N&<J>N3_@*BT;?HOBTZ8DSO;2KP&.<?+D4_7+"
M\#:5JMI"TSPQ)YB+R>.?\:AM6GDU>X\0:A;O;6T"$HK\%CC  _.NNJY+%>TD
MFI<R=];<EM?*W<P@HNAR*W+RM6Z\U]#1\32/J>J6NC6Y.TD2W!7LH['_ #Z5
MT\2+'&J1@*B@* .PK@4O)])TM]3=0=1U*0["W.Q.N?\ /M5H:IK&C:A9C5Y5
MFM[GK@#Y>F>W49KLP^8TZ=256JG>5KOI&+^%/UW^9SU<'.<%"#5E?YOK;\OD
M=M1117T1Y 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %9_B'3$UK0=1TN61HH[RW>W9U&2H92,@?C6A10M >I\B>-/@'J^CZQIMK
MH!N-5L[IL37 @"BW^8#+#=SP2?PK?C_9DNMXW^([4+GG;:MG_P!"KI/VF_$W
MB'3I]!T/P_<3VBZD6W20-L>1MRJJ!NH'S<X]17GP^#GQ38;C>D$\\ZL^:[HS
MFXIN21PRA!2:46SZ2^'/@RP\"^&X])TUGE^8R33R?>E<]2?3H !Z"NGKS/X$
M^%?$7A30=0MO%4WFW,UR)(S]I,^%V =3TY!XKTRN.?Q/6YV0^%:6"BBBI*"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,OVB?^2<R?]?4
M7]:^6J^I?VB?^2<R?]?47]:^6J^IR?\ W?YL^;S7^/\ (****]4\P**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z6_9J_Y$
MR]_Z_&_] 6O7*\C_ &:O^1,O?^OQO_0%KUROC<?_ +Q/U/K<#_ AZ!1117&=
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B_[3O_(OZ/\
M]?3?^@5\ZU]%?M._\B_H_P#U]-_Z!7SK7UF5?[LOG^9\QF?^\/Y!1117I'GA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?6
MOP-_Y)KI?_;3_P!&-7>UP7P-_P"2:Z7_ -M/_1C5WM?$XO\ CS]7^9]AAOX,
M/1!1117.;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/'[
M3W_(<T7_ *]W_P#0A7BE>U_M/?\ (<T7_KW?_P!"%>*5]AEO^[0_KJ?*9A_O
M$OZZ!1117<<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 % ZT4#K0!]J> ?^1*T/_KSB_P#0!6]6#X!_Y$K0_P#KSB_] %;U?"U?
MCEZGVE/X%Z!1116984444 %%%% !1110 4444 %%%% 'G'B7Q#-J,$MBUJ$5
M9?O@DG@T>$M<EL&BLEM@ZS3#+DD8S@5Z+L3^Z/RH"*.BC\J\#^R,1]86)=?W
MO\*V[;GJ_7Z/LO8JEIZ]3F/$FNZAI6I1^7:[K(+RQ'#D^XZ8KF]=UJ?Q$UO;
MP6I 1LA5.XENE>F, PPP!'H:;'#%&28XT0G^ZH%:XO+,1B7*/MGR2W5E]R9%
M#&TJ*4O9^\NMS$MH+C0_"C+&H>ZBC+[1R-QY/UQ_2LWP1J]_J%S<QWCF6-5W
M!RH&TYZ<?YXKL*;'&D8(C15!Y.T8KI^HSC5I2IS:A!6Y>YA]9BX34XWE)WOV
M/.]4AG\.^)3>QQ%K=G+KZ$'JN?QJ*9[GQ9KL31PE(5 4]PBCDDGUKTIT5U*N
MH93V(S21QI$N(T5!Z*,5P2R/FDX*I:DWS.-NOKV.J.9V2DX>^E:__ %10B*J
M] ,"N6\0.=8UJVT>(_N8SYMPP]/3_/K754Q8HU=G5%#MU8#DUZV*P[Q$%3O:
M-U?S7;YG#0J^RDYVUZ>O<Y;Q[82/86T]M'N6V;#*HZ*>_P"@K)U6]'BB_P!-
MM[.*0;/]86'W<XS^ Q7H1Y'-,CBCC)\N-$SUV@#-<.*RGV]234[1G;F5M^7:
MSZ'31QWLX).-Y1O9^H\<"BBBO8//"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \#_:A.MW@T;3M(T.:^C&;D7<%M))+;R*P
M VLO"Y'KZ>U<%'\0_C*B*HM=5(4 9;1LD_4^77N/QI^(Y\!Z99Q6%J+O6;]R
MEO$P)50,98@<GD@ =R:XGX7_ !'\9ZEKWB:R\26\#W.FV$ERED(A"PD7!"EA
MDC(/?-=<&_9WY58Y*B7M+<S3.R^!6N>*M=T'4)O&D=Q'=QW(2(3VGV<[-H/
MVC/.>:],KA/@WXX?Q[X3;4KF".WO(IWAECCSM&.5(S_LD?B#7=USU/B>ECHI
M_"K.X4445!84444 4=>AOKG1;Z#2;B.VU"2%TMYY%++&Y! 8@=<'G\*\:^"&
MJ^*D^)?C'PSXKUY]8.E0P[)"@5=S8)(&,]#BO<Z\/^&7_)Q_Q0_ZYVO_ * M
M 'N!Z5\R:+J/CSXD>+?%,WASQS%HVEV>H-:VL#JK;P/[HQG'0_C7TK>Q23V<
M\4,IAD=&59 ,E"1@''MUKP7Q+^SCX8M/#ES<Z!>:E9:W:Q--'>-<D[G49^8=
MLD=L8H ]:^'FDZ]HOAX6GBG61K.H^:S?:0FWY3C"X]J9\3?%]OX%\%:CKUU&
M93;J%BB'_+21CM5?ID\^P-8'[/GBN_\ &'PQT^_U=O,OXG>UEEQCS2AP&/N1
MC/OFN:_:Y1S\,+>09\B/4H&E]-O(Y_$B@# L?!_Q:U_P\OBI_&\MEJ\\?VJW
MTF./$04C*H3G .,<$'W->E? [QW+X^\%)>W\:PZM:2FTOHU&W$J@<X[9!!QZ
MY':NXTF2.72[.2 @Q-"C(1TP0,5XM^S:R7'B7XH7EGSI\^NOY#+]UOFD)(_
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MLU?\B9>_]?C?^@+7KE?&X_\ WB?J?6X'^!#T"BBBN,Z@HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UK\#?\
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MKY/BGX*7S_0][(_BG\B"BBBOC3Z$**** "BBB@ HHHH **** "BBB@ HHHH
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M[,VN:E=^%]6\.Z[*TVI>&[Y]/>1FR2@R%Y[X*L/H!0![%1110 4444 %%%%
M!1110!YE^T3_ ,DYD_Z^HOZU\M5]2_M$_P#).9/^OJ+^M?+5?4Y/_N_S9\WF
MO\?Y!1117JGF!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** "BBB@ HHHH **** /K7X&_P#)-=+_ .VG_HQJ[VN"^!O_ "372_\
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MC_KHW\Z]G/2O&+[_ (_;C_KHW\Z^3XI^"E\_T/>R/XI_(@HHHKXT^A"BBB@
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MI6C^,-;\2VGVC^T=7"+<[Y,IA  -HQQT]: //_VK["YNOA9]LM$+G3;V&\<
M?PC()/M\PKT?3/%&EWO@V'Q(EU&-+>U^TM,6&%4#)S[CD?45L7EK!>VDUK=Q
M)-;3(8Y(Y!E74C!!'<$5XW+^SEX3:Z=8M0UV'29)?.?2TNP+=F^FW/IWS[T
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MUF5?[LOG^9\QF?\ O#^04445Z1YX4444 %%%% !1110 4444 %%%% !1110
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M?89;_NT/ZZGRF8?[Q+^N@4445W'&%%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBB@ HHHH \R_:)_P"2<R?]?47]:^6J^I?VB?\
MDG,G_7U%_6OEJOJ<G_W?YL^;S7^/\@HHHKU3S HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /I;]FK_D3+W_ *_&_P#0%KUR
MO(_V:O\ D3+W_K\;_P! 6O7*^-Q_^\3]3ZW _P "'H%%%%<9U!1110 4444
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M^NC?SKY/BGX*7S_0][(_BG\B"BBBOC3Z$**** "BBB@ HHHH **** "BBB@
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M7]:^6J^IR?\ W?YL^;S7^/\ (****]4\P**** "BBB@ HHHH **** "BBB@
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MA"O%*^PRW_=H?UU/E,P_WB7]= HHHKN.,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "@=:*!UH ^U/ /_(E:'_UYQ?\ H K>K!\
M_P#(E:'_ -><7_H K>KX6K\<O4^TI_ O0****S+"BBB@ /2O&+[_ (_;C_KH
MW\Z]G/2O&+[_ (_;C_KHW\Z^3XI^"E\_T/>R/XI_(@HHHKXT^A"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH VO!O_(Q6GU/
M\C7JE>5^#?\ D8K3ZG^1KU2ONN&/]UE_B_1'S&=?QUZ?JPHHHKZ0\<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AO
MIFM[*>:.)YGCC9UC099R!D >YZ5\N:%HWQ=^%FG:KXAAL-(OK2[N#J&I6@;S
M)\'[W(QT&?NDXY.#7OOQ-\47_A#PM-JVF:)<:U)$XWP0M@HG=SP20/8=Z\RU
M[]HCPMJ/AF:V\.V^HZAK][$8(=.^RL&61AC#'I@9[9S0!ZO\/_%ECXV\)6&N
MZ8&6&Y4[HW^]&X.&4_0@UYS^UG>S0?"O[)"[(M]?06\A!Q\F[=C\U%/^'MAJ
M?PE^ <MQ>V#WFJV\<E])91G[K.<A"1GH,9QZ&H_$%O??&KX!?:5L&TW5IA]J
MMH')P9(F.,$]G (!_P!H4 >IZ#H]E8>%['28;>/[#%:K (MHVE=N""/?G/UK
MR']F.,Z5>_$'PW"[-8:3K3I; G.U26&/_'!5'1_VAM(T[P@MGK=CJ$/C&SC%
MLVF?9VS-,!M!!Q@ G!YY'. >,]7^SKX4U/0/"E]J?B*-H]<UV\?4+E'&&3=T
M!'8\DX[;J /5Z***  \#-,\U/7]*?10 SS4]?TH\U/7]*?10 SS4]?TH\U/7
M]*?10!Y?^T.ZM\.9,'_EZB_K7R[7U)^T3_R3F3_KZB_K7RW7U.3_ .[_ #9\
MWFO\?Y!1117JGF!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?2G[-KJO@V]W'_E\;_T!:];\U/7]*\F_9J_Y$R]_P"OQO\
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M%%%=QQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUQ7<445>$P:PW,^9RE+=LFOB'6LK62V04445V'.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!XO^T[_ ,B_H_\ U]-_Z!7SK7T5^T[_ ,B_H_\
MU]-_Z!7SK7UF5?[LOG^9\QF?^\/Y!1117I'GA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?6OP-_P"2:Z7_ -M/_1C5WM<%
M\#?^2:Z7_P!M/_1C5WM?$XO^//U?YGV&&_@P]$%%%%<YN%%%% !117EGB.^N
MH]=OD2YF51*0 '( KS<RS&.7P4Y1O=V.S!X1XJ3BG:QZG17C?]HWO_/W<?\
M?P_XT?VC>_\ /W<?]_#_ (UXW^M-/_GV_O/1_L.?\_X'LE%>-_VC>_\ /W<?
M]_#_ (T?VC>_\_=Q_P!_#_C1_K33_P"?;^\/[#G_ #_@>R45XW_:-[_S]W'_
M '\/^-']HWO_ #]W'_?P_P"-'^M-/_GV_O#^PY_S_@>R45XW_:-[_P _=Q_W
M\/\ C1_:-[_S]W'_ '\/^-'^M-/_ )]O[P_L.?\ /^![)17C?]HWO_/W<?\
M?P_XT?VC>_\ /W<?]_#_ (T?ZTT_^?;^\/[#G_/^![)17C?]HWO_ #]W'_?P
M_P"-']HWO_/W<?\ ?P_XT?ZTT_\ GV_O#^PY_P _X'LE%>-_VC>_\_=Q_P!_
M#_C1_:-[_P _=Q_W\/\ C1_K33_Y]O[P_L.?\_X'LE%>-_VC>_\ /W<?]_#_
M (T?VC>_\_=Q_P!_#_C1_K33_P"?;^\/[#G_ #_@>R45XW_:-[_S]W'_ '\/
M^-']HWO_ #]W'_?P_P"-'^M-/_GV_O#^PY_S_@>R45XW_:-[_P _=Q_W\/\
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M+[O^"']C8CR^_P#X!Z917F?_  F.K?WX?^_='_"8ZM_?A_[]T?ZRX/M+[O\
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M@ HHHH **** "@=:*!UH ^U/ /\ R)6A_P#7G%_Z *WJP? /_(E:'_UYQ?\
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MGC!^M>;_ /"@;;_H,W/_ 'PG^%>[EV.HT*/)4>MSQ<?@JM>KS06ECP"BO?\
M_A0-M_T&;G_OA/\ "C_A0-M_T&;G_OA/\*[_ .U<-_-^#.+^S,1V_$\ HKW_
M /X4#;?]!FY_[X3_  H_X4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\
MX4#;?]!FY_[X3_"C_A0-M_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4
M#;?]!FY_[X3_  H_X4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;
M?]!FY_[X3_"C_A0-M_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]
M!FY_[X3_  H_X4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!F
MY_[X3_"C_A0-M_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_
M[X3_  H_X4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!FY_[X
M3_"C_A0-M_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_[X3_
M  H_X4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!FY_[X3_"C
M_A0-M_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_[X3_  H_
MX4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$U_V:O^1,O?\ K\;_ - 6O7*X[X?>
M$'\%Z3-86L_VI))3*7E^4@X QQ]*ZC==_P!R'_OHU\WBZD:M:4X[,^@PM.5.
ME&$MT6:*K;KO^Y#_ -]&C==_W(?^^C7.;EFBJVZ[_N0_]]&C==_W(?\ OHT
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MM?\ A!V_Y^C^0_PH_P"$';_GZ/Y#_"C_ %?QW\J^]?YA_:V%_F_!G%45VO\
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M^C7T1Y!9HJMNN_[D/_?1HW7?]R'_ +Z- %FBJVZ[_N0_]]&C==_W(?\ OHT
M6:*K;KO^Y#_WT:-UW_<A_P"^C0!9HJMNN_[D/_?1HW7?]R'_ +Z- 'D'[3O_
M "+^C_\ 7TW_ *!7SK7UW\1/!3>-[&TMKNY-JMO(9 T6&)R,8YK@_P#A0-M_
MT&;G_OA/\*^@P&/H4:"A-Z^AX>.P-:M6<X+0\ HKW_\ X4#;?]!FY_[X3_"C
M_A0-M_T&;G_OA/\ "NS^U<-_-^#.3^S,1V_$\ HKW_\ X4#;?]!FY_[X3_"C
M_A0-M_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_[X3_  H_
MX4#;?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!FY_[X3_"C_A0-
MM_T&;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_[X3_  H_X4#;
M?]!FY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!FY_[X3_"C_A0-M_T&
M;G_OA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_[X3_  H_X4#;?]!F
MY_[X3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!FY_[X3_"C_A0-M_T&;G_O
MA/\ "C^U<-_-^##^S,1V_$\ HKW_ /X4#;?]!FY_[X3_  H_X4#;?]!FY_[X
M3_"C^U<-_-^##^S,1V_$\ HKW_\ X4#;?]!FY_[X3_"C_A0-M_T&;G_OA/\
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M(?X4?ZOX[^5?>O\ ,/[6PO\ -^#.*HKM?^$';_GZ/Y#_  H_X0=O^?H_D/\
M"C_5_'?RK[U_F']K87^;\&<517:_\(.W_/T?R'^%'_"#M_S]'\A_A1_J_COY
M5]Z_S#^UL+_-^#.*HKM?^$';_GZ/Y#_"C_A!V_Y^C^0_PH_U?QW\J^]?YA_:
MV%_F_!G%45VO_"#M_P _1_(?X4?\(.W_ #]'\A_A1_J_COY5]Z_S#^UL+_-^
M#.*HKM?^$';_ )^C^0_PH_X0=O\ GZ/Y#_"C_5_'?RK[U_F']K87^;\&8G@W
M_D8K3ZG^1KU2N1TGPK)IU_%=),'9,X5N >,5TNZ[_N0_]]&OJ<CP=7!T'"LK
M-N_X(\/,\13Q%52INZL6:*K;KO\ N0_]]&C==_W(?^^C7M'G%FBJVZ[_ +D/
M_?1HW7?]R'_OHT 6:*BA,QSYRH/3:<U+0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;+(L43R.
M<(@+$^PK'\.>*M#\21&31-3MKS'58W^=?JIY'XBMF1%D1D<!E8$$'N*\<\3?
M ?0IYC?^&+Z[\/ZC&=\<D,A:-3],@C\#5P47\3L1-R7PJY[)17RT_P 6?%OP
M]UD:7K&J:3XJMT.&:";=( #W<#AO9@:^FM'O1J6E6=\(VB%S"DNQNJ[@#@_G
M3G3<-6*%53T0_4;R#3M/N;V\D$=M;1--*Y&=JJ,D_D*X_P *_%7PCXIUF+2M
M$U&2>^E5F5&MI$!"C)Y90.E=?J=A;:II]Q8W\*S6EPACEC;.'4C!!Q7S#\.-
M.M-)_:?O+#3H$M[.W:Y2*).BKY9X%.G",HN^Z)J3E&44MF?4]%(S*OWB!]35
M/5;R6UTR[N+* 7EQ#$TB6XD"F0@9VYP<9^E9&Q=HK@?A3\2;3X@VU^8K)]/N
M[.0+);R2!SM/1LX'<$=.U5O!_P 4H/%?C?5=#TS3'-EIP<R:D9QL(4[00NWN
M<XYZ#-6Z<E=6V(52+MKN>CT5XM=_&;4M3U&_3P+X4N-<T_3S_I%WYNP$#^Z,
M'/0X[GTKM/ _Q(T7Q7X4NM<C<V<5DI-Y%,1F# R<XZC&<'O3=.45=H2JQD[)
MG:T5X18?'][_ %6ZFM?"M_-X;M3B>_BW.T(/1W 7 'MG-==\,OBG#X[M-:GA
MTJ2S7355L-.'\S(8_P!T8^[^M#I3BKM!&M"3LF>DT5X3H'[0*:_<65II_ANY
M%[<7<,)C\TR!(F(#2$JO&,__ *J]VI2A*'Q#C.,_A/'KW]H7P?9WD]M+:ZSY
MD,C1L5MTQE20<?/[5J>#?C3X9\7>(K71=+M]42[N Q1IX%5/E4L<D.>P/:N!
M_:2\$>&]!\&+J>D:1;VM_-?J))DSN8,')ZGN:[?X)^"?#EMX2\.>((-)MTUE
MK4.;H9WDL"">N.036SC3Y.9)F,95.?E;1M>$?B?H7BKQ5?>']-AOTOK,2&1I
MHE5#L<(<$,3U/I7=5\N?L_?\EW\3_P"Y=_\ I0M?4=9UH*$K(THS<XW84445
MD:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %8>C^+=!UB^N++3M4MI;VWD:*2WW;9%93@C:>>HK<KRKQG\$/#7B"[G
MU"S>YTG4Y',IN+9\@N3DL5/OZ$545%_$1-R7PGJM%?+>K>.O&?PJU./3[SQ'
MI7B>V4[?)>7?,J_[7\2'ZDU]#>!/$0\5^$].UL6K6@NXR_DLVXK@D=<#/2JG
M2<%?H*%53=NILW=Q#:6TMQ=2I%!$I=Y'.%51U)->67/Q^\#0:G]D%S?2QAMI
MNH[8F(>_7<1]%KI/B[X8U7QAX,GT71;R"TEN)4,KS%@K1@Y*_*">2!7E/C3X
M?>'/ OP-N(M;M;";Q ?E2]C3]X\[,2H5B VT+VZ8!JJ<8/XMR*LIKX=D>_Z3
MJ5GJ^G07^FW$=S:3KNCEC.0PK ^('CS1/ FGPW6N2RDS/LB@@4/(_J0"1P.Y
MS7G'P'U1/!_P0FUCQ%/Y-B+F6> ,>2AVJ%4=RSAL#WKS/X@Z=J_BSP;JGQ$\
M2"2 2RQ0:59]!' 7^\1WR.A[Y)]*J-%<]GL*59\ETM;'U+X0\16?BKP_:ZQI
MJS):W()03*%?@D<@$^GK6Q7G/[/S!?A+H1) &Q^O_71J]#,BX.QE9L<#=UK&
M:M)I&T'S138^BO-_ /Q1A\4>+=4\-WVE2Z3JECN_=R3"02%6PP! '3@^X-/M
M/BMI5S\4I?!BP,)$RBWAD&QY0NXQ@8^HSGJ,4_9RO:PO:1M>YZ+17G'BCXH1
M:1\0M/\ "&GZ5)J-_<[-[K.$6'=SR-ISA?F/M53QI\59=/\ %!\,^$=$FU_7
M4&9D5]D<7&2"<'G'7H!GK0J<GT!U(KJ>I45YS\-OB=#XKU2\T/5=.ET;Q%9Y
M,MG*V[<!C)4X'3(X].>16/KOQ=O9_$UYH?@/PY+X@N+'/VF82[(U(." <'//
M&<\GIFG[*5[6%[6-KGK<T@BA>0@D(I; ]JXCX7?$>S^(2:FUC87-F+%T1O/9
M3NW;NF"?[M0_#_XBV/CO2-21+:6PU2S5ENK*8Y9#R,@]QD$= 0:\:_9\\4V'
M@[PIXUUC5&_=130!(P<-*Y$F$7W/_P!>J5+W976JL0ZJYHV>CN?4M8WC#Q%9
M^%/#]UK.II.]I;!2X@4,YR0!@$CN?6L3X7^,[OQSHSZI)HDNEV1;; TLXD,V
M.I VC !XSWYKIM<TBPUW3)M/U>V2ZLIL>9$^<-@Y'3W K.W+*TC6_-&\3R;_
M (:-\&?\^NM_^ R?_%UTFC_%SP]JWA+6/$5M!J0L-+95G5X5$AW8QM&[!Z^H
MKP;XA>%=$TWX_:)H5CIT,.DSR68DMESM8.^&SSGD5[)\4O"VB>%O@YXJA\/Z
M=#8Q3Q(\BQ9PQ#J >371*%-<MNISQG4]Z[V.W\"^+=/\::$NK:0EREJTC1@7
M"!6RO7@$_P ZZ&O(OV7?^260_P#7W-_,5Z[6%2*C)I&].3E%-A1114%A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4V618HG
MDD.$12Q/L*=22(LB,C@,K#!![B@#$\->+-"\30^9H>J6UX,9*H_SCZJ>1^5;
ME>-^)O@-H%Q+]N\,7MWX?U",[HY()"T:GZ9!'X$5Y])\5_%OP[U@:9K&JZ3X
MJMT.&:&;=(H'JX'#>S ULJ2G\#,'5</XB/J6J^HWMMIMC/>7TR06L"%Y)7.%
M51U)IFCWHU+2;*^$;1"Y@281MU7<H.#],UQWQQT.Y\0?#+6+.SGCAE55GS(^
MQ&6-@Y4D\#@=^^*SBKR29K)VBVC"B^/_ ('?4_LAN+Y(]VW[4UL1%]>N['_
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M+<+Y@MGDWLJGIN.!@D<X[4JE-Q;?0*=12274H?$'QMIG@32(=1UF.ZDMY9A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW^FZ/I]I?3;A)<06Z)(^XY.6 R<GFM:BK/G=T%*'(K,****S- HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM*\Z&:,L3$=P08R,<$$>U>I1_##P5%J?]H)X:TX7(;<#Y?R@^NS[OZ5V(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\:_:;_Y%K2?^OL_
M^@&O9:\;_:95F\-Z3M4G_2CT'^P:[<N_WF!R8_\ W>1\XT4_R9/^>;_E1Y,G
M_/-_RK["Y\I9C*]4_9P_Y*!)_P!>4G_H25Y=Y,G_ #S?\J]3_9RC=?'\A96
M^Q2=1_M)7+CG_L\_0Z<$OW\/4^G*\H/_ "<NG_8O-_Z.6O5ZP_\ A%]._P"$
MR'B;$W]IBT-E]_Y/++!ON^N1UKXZ+M<^KDKV.#^$L:'XD_$R0HOF"_B4/CG&
MUN,^E-^#D,2>._B4R1HK#5MH(49Q@G'YUWV@^&-/T/5]9U&Q$WVG5IEFN=[[
MAN (&T=NM&@>%]/T+4]9OK 3>?JL_P!IN=[[AOQCY1V%6YIW\[$1@U;RN>7>
M&?M:W_QICTH$78F9K=5_YZF%\$>Y.*J_"RW\<7?PYTI/#UWX3.DM"4"31S&0
M')WB3'&[.<UZYH7AC3]$U;6M1LA+]HU>99[G>^X;@"!M'8<U@77PM\.2W\]U
M:C4-.-PQ>>*QO9((Y2>I95./RQ5>T3NO0GV;6OJ>>>/_  U?^$_V;;W1M3N(
M+B>"0$-!NV!6FW #(!XS74?'LW9^#4YLC^[)MOM!&<>3O7.<=NF?;-=[<>&=
M)N/#!\/SV@DTDP^1Y+,Q^7M\Q.<^^<U1\-^"M*T#3[JQMVO;JTN$$3Q7MRTZ
MA "-H#< 8)I*HM&^]QNF]EVL<#J/AWX@>)O!K:7]M\'G2;RU5$,4<W$9 VE>
M,=,8I;FUN+'XR_#RTO)5FNK?1)HI9%SAW50"PSZD&NE@^%'ANW?; =3CLMVX
M6*:A*+<'.?N ]/;I6_KOA+3-:UC2=5NA/'?Z8Y:WF@E,9P<95L?>4XZ&CVB_
M,.1[G,>(O"NMV/B?4O$_@:_M!J%VD:7MA>INBG** N''*-C'M7,>//%0\9?L
M[ZOJHM3:RD"*:'=N"2)*H;![C/>N[UKX<:'JNI7%]NU&RN+H[KG[%>20K.<8
M^< X/'>M>W\*Z+;^%V\.Q6$2Z.T1A:WYP5/7)ZY[YZYH4TK/J@<&[KHS/FUV
MW\-_#.+6;M&E@L].CE9%ZO\ (, ?4D"O,?BC_P )7JGPBU+5==O]+LK*:!)4
MTVVM_,.UBI4&5C][D?=%>FZ%X!T71],O-.C-[=6%U%Y#P7ET\R+'S\J@GY1S
MVK(?X0>%I=+FT^X34+BV9/+B6>]DD%N/^F8)POUQFB,HQ=PE&4E8Y3XEN7\.
M_"F21LDZII[,Q_W5Y->W5SVN>#M&USPU;Z'J5N\ME;K&(B'*NA085@PY!]ZN
M>&M"M_#^G&SM)[R="Y<O=W#3.3@#[S=N.E3*2:2*C%IG&>&_D^.GB]9?OR:=
M9O'_ +@W _K5#P_%&_[17BEW1&=-*MMK$9*YQG![5M^*+&72_B+X?\26D$TL
M5PC:5?")"Q56.Z)R!V#9!/8&NAM/#&GVOBR_\1Q";^T;V!+>7+Y38G3"]C3<
MDM>Z$H].S.!4;/VF'V<;]!RV/XL2#K6G)>_$GS&V>&?#)7)P3J,F2/\ OW74
M_P#"+:=_PF7_  D^)O[3^R_8\[_D\O.?N^N1UK=I.:T'&%KG/^$)O$4T%P?$
M^FZ;82AAY2V5PTP88Y))48-<+IO_ "<KJ_\ V!(O_0Z]0U6R34M.N+.26>%)
MT*&2"0I(N>ZL.A]ZX%?@_H:ZD^H+JGB(7SH(VG&I/O*CHI;KCVHC):W"2>EC
MM/%7_(L:O_UYS?\ H!KC?V?3CX0: ?\ IF__ *,:M[Q/X+L_$45M'=ZAJ\$<
M,1AVVMXT0D4]=^/O'ZU6\&?#W2_"$T;:5>:L88T:-+>>\:2%03DX3IFBZY+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4V2-)0!(BN!_>&:=10!#]EM_\ GA%_WP*/LMO_
M ,\(O^^!4U%.[%9$/V6W_P">$7_? IT<$4;;HXD4^JJ!4E%%V%D%%%%(8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !2,BM]Y0?J*6BC<!OE1_W%_*CRH_[B_E3
MJ*7*NP[L;Y4?]Q?RI515^ZH'T%+119!=A1113$%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 444 @]* "BBB@ HHHH **** "BBB@ HHHH ***3<,9R,>M "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44$XZT4 %% (/2B@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHR,XSS0 4444 %%%% !111D9QGGT
MH **** "BBB@ HHHR.>1QUH ** 01D<BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HH!!Z'-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO/,,9Y/,9&TCC!X'6B.'<I.-U=!*M9*5CZTHKQ?X@?$G5[?X(Z1XET9%@O\
M4S'#)*J[A;DJV]@#G^),#/KZUA?"BV\9:O=Z/JUA\18-3M9"LFI6,LAED@4C
M)38V<'/RY&WKD9%2J#Y7)NPW55^5(^A:\W^(/QB\-^"[]M/N#<7^I( 9(+4
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M[/'CK5;_ $;QEJ7BG4[F^M]+AAG'FD$HH69GQ]0H_*I=)*,[:VL4JEW&^A]
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M\-7L-]9O&^J:K,-RERI78&!/#,V0/E^Z.#UK[C(!&#R*9##' FR&-(TZ[44
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MJNC(X#*PP0>A%+12K5/:S<[6'3AR1Y3X@ATNZ@\877P_"M]GN->A4\_PHTB
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M_<:)H<EQ;1VZS)M-P5F&Z3J<_> SD_=Z]AVWQ9_Y.8\*_P#7?3__ $=7TV
M    . !13>*U3MTMN+V&EKA7S_\ M>_\@'P[_P!?,O\ Z"*^@*;O3S-FY=Y&
M=N><?2L*4_9S4NQK4ASQ<3FM(T]=6^&5EISML6\T=+<MZ!X0N?UKY2T"T\.>
M"=7U'2/BGX4O;N97S!-;RNA '' #HK*>"&S_ /6^U*CG@AN% GBCE .0'4-@
M_C6E*OR771_(B=+FL^QXOX&B\+S_  J\9:IX2\/W>BQ7-G<1.+F21S,J1.49
M2S$8^<_=/7KVKRKX,?$^#X>^'M6CN])N[L74P:"6,A8_,"_<8GIV/&3STKZM
M\4V,NI>%]7L+4+Y]U9S01AC@;F0J,^@R:\\^ _@'4_!FA:K9>(X[1VN;A98U
MC?S%P%QSD=:UC5@X2YM;M:7(E3DI1Y3COV8O#>HB;7?%FI0-!'?1&&WW+M\W
M<V]V _NY"@'OSZ50_8^_X_\ Q1_URM_YR5]+C@<4$X&3P*SEB')236]OP+C1
MY>778^=/VGO"5[)KFE>*[>P?4-.@B6"]A7=PJN6&[;R%8,02.F.V16+X4O?A
M-K^OZ3IVF^!=7^UW,JK(QN)G6#_:^64EE!QDD# Y]J^I$=9%#(P93T(.0:9#
M;PP%C##'&6.6V*!GZXIQQ+4.5]/.PG1O+F7Y'B'QI\7>$T\1?V'XX\+:A<V4
M<(:#4HEVN'/)$9)7*CC)#8R""#BN1_9YT>]U6_\ &%MIWVZ'P??6<]M&UR.K
MN=J'C@N$+9Q_A7T]-#%.FR>-)$/\+J"/UIR*J(%10J@8  P!25=1AR)?B-TK
MRYFSXLT"T\.>"=7U'2/BGX4O;N97S!-;RNA '' #HK*>"&S_ /6]?\,Q>%Y_
M@WXYU3PEX?N]%BN;&XB<7,DCF94B<HREF(Q\Y^Z>O7M7N,\$-PH$\4<H!R Z
MAL'\:D P,#I3GB>?I^.GW"C0Y?\ ACP']EW_ ))GXD_Z^Y/_ $2E9O['?7Q;
M_P!NG_M:OI"BIEB.925OBL.-*W+KL?(WA3Q(/A+\6_$C^(M/NWCG\Z)1"HW$
M-*'1QN(!4@>O?\*]!^+OC;P?<:M#I?C+POJ%UIK6R36NIQ)M?<XW8C)*Y7!7
M)#8R""#BO<YK>"=D::&.1DY4NH./I3IH8ITV3QI(A_A=01^M4Z\924FM?42I
M-)Q3T]#YO_9<M[X>*O$%QI:WR>$F1EB^T_QOO'EYQP7";LX]?I7LWQ/\3:AX
M2\+2:II.D2ZK.DB*T:9Q&F<L[8YQ@8R <$@GBNL151 J*%4#  & *6LZE53G
MSM%PI\L>5,^3_BM\5-*^(GAVWTC2_#EU_:\DR,LCJKO&1U6/;EFSTZ"OH#X0
MZ3J&A_#?0M.UG<+Z&$^8C')0,[,J'_=4@?A75QVT$<K2QP1+*W5U0 GZFI:=
M2LI14(JR%"FU+FD[L^8OVE)+B'XDZ')XBAO)_":)&PBA;:'^8^: >!OQCN#C
M'(KD?/TV]^,?@Z]\/Z!/HFBS7MF+6.9-IF"S &3OG)XZGIUK[(FABG39-&DB
M9SM=01^M/ P,#I6D<5RQ4;=+;D2H7E>Y\P?&:WO_  /\:['QL+-[G39GBEW#
MA=RH(WC+=F*C(SZ^QKF/BMXR_P"$Z\6>'-8M=*O++35*V\,MP/\ 7,L@9\8X
MXW*.">M?8DD:2QE)45T;@JPR#^%*BJB!44*H&  , "B&*4;-QU6@2H-WL]&?
M-O[2FDZCHWCK0O&EG;-/:6XA#D E4EBD+*&/8," /H:XWXX?$!?B'I^C7=AH
M][9V%B\D;W$^"K2R!3L!'' C)ZY]A7V(RJZE6 92,$$9!I(HTAC"1(J(.BJ,
M ?A1#$J*C>-V@E0<KV>C/G+]J#_D1?!GU/\ Z*6MOXTZ1>:M\ M :QA>8V2V
MEU*J#)""!D)Q[;P3[9->Z45"KV44ELRG2NWKN>'_  4^(>G:]X-'A>.VN8=1
MTW27,COM\MU3"Y4YSGY@<$"N-_9DTH:YX8^(6E%]GVVVAM]_]TNDZY_#-?3L
M-O# 6,$,<98Y;8H&?KBI:;KJTE%6O8%2>C;V/DWX;>.[CX._VYH'B?1+PW#R
M^=$J$+EP-O4]4.%PPS^-=;^S3X7U1+O7?%VK6[VRW\310*ZE3(&;>[@'G;D*
M >_/I7T#-!#,5\Z*.3:<KO4'!]JDISQ/,G96;W%&C9J[T1\T?L??\?\ XH_Z
MY6_\Y*C_ &?_ /DO/B__ *XWG_I5'7TW12EB.9R=OB"-&RBK['QAH&HV&G>/
M==?XEZ!J.NZX\A2"V'S9FW'@J2,J1@+@$8Z \5VW[*,,MOXO\4P7$+031PJC
MQ,,&-A(05/T/%?2@2WDG,@6)IT^4N "R^V>HJ6JGBN:+C;?S%&ARM.^Q\L?L
M\W__  C/Q8U?P_JEO-%>WI>W3(P$>,L_.>Q ."/;UKV_XX?\DH\2_P#7M_[,
MM=H8(3.)C%'YP& ^T;L>F:DK.I6YZBJ6+A3Y8N-SYY^$G_)M'BW_ *XZA_Z(
M%+^S-_R2[Q9_UVE_]$"OH6BG+$74E;=W$J5FG?8^8?V9M*&N>$/'^E%]GVV"
M*WW_ -TNDRY_#-9?PV\=W'P=_MS0/$^B7AN'E\Z)4(7+@;>IZH<+AAG\:^LJ
MCF@AF*^=%')M.5WJ#@^U6\2I.7-'1B5%I*SU1\_?LT^%]42[UWQ=JUN]LM_$
MT4"NI4R!FWNX!YVY"@'OSZ5F_L??\?\ XH_ZY6_\Y*^EZ*F6(<E)-;V_ <:/
M+RZ['S)^S_\ \EY\7_\ 7&\_]*HZR]6U9_AG^T+J>LZU8W,EC<232(8@,O'(
M,ADR0#@\'GL:^KZCGMX;A0)XHY0#D!U#8/XT_K*<FVM&K"]C:*2>SN?+_P"U
M#JUOKVD>!-6LPXM[VVGG17^\H80G!QW'0UTW[5/_ "3[PY_U]K_Z*:O?@ !@
M<"BE'$<O+9?#?\1NC?FUW/$?$/BK2_#_ ,(_!%MX@\.7&M:3>:;;"Y*IE(%$
M*X.X\;\G@9'0\BO,?AW':WGQKTRX^&5OJUOHR,C78N>=D?/F*Q!/RD<#<2<_
MA7UVRAE*L 5(P0>],@@B@39!$D29SM10H_2B.(48M);^?Z"=%MIWV,KQIHQ\
M0^$]7TA7$;WEK)"CGHK$?*3[9Q7S/\-OB)<?"+3]:\.>(M$O/MOGFXA7A1YA
M4*=V?X3L4AESWKZQJ.6"&9D:6*-V0Y4LH.T^U13JJ,7"2NF5.FY-23LSP?\
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MQI/&YN4$9(+B,8!!([D\#TK4U#1=/UW]I*:#5K9+JW@T-+A89.49UE !9>C
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M^S7$%V&,%W#G(5BO((/?V'3%:7A8^-Y]3,WB==#M+!8RJVUEYDDCOD88NV
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M2<QC"LPR<9./<BMKX=_#^70O"/B#0-?GAOX-3OKB4O&3EX9$5?FX&'^4DXR
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MNWHHJ7)M)/H4HI-L\A_:#CGFE\"Q6=P+:Y?7H%BG*!_+<\!MIZX.#CO4FO\
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M&;S?M+0^66(V[<9+'.?2F^,OAMJ.M_$>SUBTNK./1)9+6?4K>1F$DSV[/MP
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M&$5;R\_^&'&4F[^9G2_$#7M=U[4;'P%H%OJ5GILI@N;^[N?*B>4=4C]<>O\
M3!.-\*;VZU#XR^/+G4-/DTV\>"T$MK(X<QL(PIPPX8'&0>X(JU^S1/%%X(O-
M*E8)JEA?S)>1,?G#$_>(Z]L9_P!DTGP[N[>]^.OQ$GLYHYX3%:H'C8,I*QA6
M&1Z$$?A5-*//%+9?JB4V^63>YU/P_P#$4.MZYXNMH=+MK%M-U%K9Y8L9N2,_
M.W YX]ZS=1\4>/I6NI]&\%PK96[,%6^O0L]P%)Y5%X&<<9)S67\(YUMO$7Q0
MG<,RQ:Q(Y"]2!O/%1^#I-6\?^&O^$IU[Q7=:/I4K2-'9:7(ENMNB,5_>3$%B
M>,]1V]<4G!*3=M-._8:DVDNNIT%MXXNO$/PS'B/PQI:W-TZLLEI-<"/R2N0_
MS8YQC(XY!'2N5_9SU#Q&?!>@V9T2W'AX"XQJ/VL>83YLA_U6,_?^7K[TOP"4
M/\(-:2%C(INKP(<Y+#8,<]ZWOV<I$?X.Z$J,&9#<*P!^Z?/D.#^!!_&G-*$9
M12Z_YBBW*46WT_R);OQOKNL:YJ.G^!-$MM0@TV0P75_>7'E0F4=8T !+$=ST
M_0G<\!^+#XF@OX+VQ?3=9TV;[/>V;.'\ML9#*P^\K#D'V/U/DWP;T+5;JTUO
M2H?&&H:1J5AJ,RW5C%#"QR2,2_,I)#>OM7H?A_P+/IL_B6Z@\4WMQJ^JK#%-
M>M%%OA:-?E.T#&=K#J.F*FI"$;Q_S'"4G9G?UX9\?_"FE6LFC>(HHYSJMQK5
MM"\CSNRA"&)"H3M7[B]!7I/ACPYK>DZDUQJGBV^U> QE!;SV\4:AB1ALJ,Y&
M#^=<I^T5_P BSX=_[#UK_*2IH^[423*J:P=T>J.JNC*ZAE88((R"*\[^"4CV
MVBZUH$C$C0M6N+&')R?)W;D_1B/PKT6O-_A%^_UOQ_>IS#)KLL2GL3&J@D?B
M:B/P2^14OB1Z11116984444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5CEO .GW5[\/G\.>*[.4M:+)I4Q?<BW4*C:KHPP=K(1R#G(-9_\ PI#X>?\
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MUUIVJ)^ZNH+B%HOWB\%E!'*GJ"..<=JBO9WY>^I5*ZMS=CHZ\H_9G_Y)L_\
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MP<U#XL\7PV6H7NE>)?!^K7>E''D7,-H+R&X&!G<H^Z<Y !],\5RO@'0=2M?
M7C\PZ7?:?I>I+</I.E3J3-&IB8?<Y(+$J O7CZ$F\5?2UO1CVD[:[DD7C*^\
M-?LZZ9K22/<ZM+;K##),2Y,CN0&)/7 R>?05;?X47BZ$;U/$^NGQ>(O-^V_;
M&V&;&=FSILSQCT_*H(?!-]XB_9ZTW0'BDL]7BMUEBCN%,;)*CDA6!Y&1D<],
MYJP_Q,UM]#.GIX-\0#Q<8O)\K[+BW$N,>9YN<;,\_IGO3UU]GO=W_KL+33G[
M&9J_C2]\2?LVWVO"9[75%C6*62!C&1(LZ*64CID<\>N*=X@\"W=_X N/$NH>
M)]:D\0Q:>;^*2&X,4,16/>$2,=!QC.<GK3]8\#WWA_\ 9RO?#MO!+?:JT:R2
M1VR&1GD:968* ,G X^BYKO=2M;A_A5=6B02M=G16B$(0ER_D$;=O7.>,4G-1
M^#N_NT#E<OB[$OPSU>XU[P!H6IWS;[JXM4,K8QN8<%OQ(S^->;?'SP_#>>*_
M!-P]]J*&^U:"S9([@JD2[A\\8_A?G[WTKOO@_9W-A\,_#]K?6\UM<Q6^V2&9
M"CH=QX*GD5B_&#3;Z_USP!)8V5S<I;:[!-.T,3.(D##+,0/E4>IXJ(/EK.WF
M5)7IJ_D9WCE[_1?^$2^'_AK5;Z&?5II?-U&>4RW$<"DN^'/.X[C@]@N*H>.?
M"US\-M"_X2KPEK&K/-8.C7EK>W3317<98*VX'HW.<CWQS71_%G0M5?5?#GBS
MP[:F^U#0IG,EFIPUQ X <+_M 9P/<]>E<]XU\0ZI\2M$_P"$6\-^'=:LOMKH
M+Z\U*U,$=K&K!B,D_,V1T';]-(-OE:VZ_P!>A,DE>^_0M_&37-2;3_ EYX:N
MFMKC4=2A$.YB$;S$^4.!]Y<L"17:^#/!L'AF:ZNO[3U/4KZ[51<3WLY?<P).
M57HO)Z>@%<I\5-"NL_#NUTFRNKFWT[6;7>88FD\J),#<Y X  Y)XKU2LIRM!
M)>?YEQ5Y-LYKQ[IJ:EHZ+<^(;K0;&*0/=3V\RPEX\$;#(?N#)'(^G>O&;?6-
M#\-?$3PL/ GB/4-1M-0O!8ZA;33230MO(57#,-NX$D\$]/3.>T^-UE=OK'A'
M4I]*NM8\.6%S))J%E;1^:22H$;E/X@/F]NQZUC>+[S4_%NN>!;C1O"VK6NB:
M?K5N[33VQC;&X$D1#)6-0.7.!R*UI*T5?9W(J/73<K_%/PM!=_&7P=')J6KH
MNJ/<E]EVR^1MC7_4_P!S..<=:]F\.:1%H.CP:=!<WEU'$6(EO)C+*V6+<L>O
M7 ]L5YY\8+>^L/%W@KQ5:Z=>:A9:3-,EW':1^9(BR*H#!1U'#?IZUZ%X;UF/
M7])CU""TOK2.1F BO8##)P<9VGL>HK.HVZ<>W_!9<$E.7<\]UK_DY'P]_P!@
M27_T.2L7Q?XCT[Q#\2=3T#Q#XD.A^'='CC#0QW7V=[Z=QN.6Z[5'&!WQZUM^
M+8KJP^.WA;5VL;R?3IK%K SP0F18Y6=L;R/NCYAR??T-4O$&F7/@WXD:IXC;
M0)M=\/ZU'']I6V@$\UI,@P&"'DJ1DG'K[#.D;:>FGWD2OKZD7@#6]/TKXEQ^
M'O#?B%M:\/ZA9//'&]U]H-G.AY 8\[2N3@]ZM>.M&\+1:M=3^-O&VIK-.Y:V
MLDO3%]G0] D48R?]X@YXKJ/!6NV&N:E,=,\*W^FV\4>1?7=DML'8G&Q1]X\=
M\8XKSWP#J$W@[5]?M]=\)ZW?^*+J_EE2^MK/S1<QM]S$I.%7KWP,_@$KN3:T
M:]+AT2Z&K\&_$6KZEX$\46EK=RZI?:1<7%OIUQ<@AYE"DQ;]W.<^O(! /2N>
M^'&GZ!XFM+?[?XLUZS\=!R;I9+YX9UD#<HL;?*5QQ@ \>G2NE^%-MX@T:+X@
M7]]H-PFI7&I2WD%D6VK,S MM21@%89.-PXK#^)&JVGCG0WL+?P-KZ>+6*+;R
M2V!B-LX8?,9^FP<]\'CIVO[;4=GUT_JQ/V4V6?VB-!BN+WPI>-?:DK76K6UF
MT27!$:#YOG5>@D_VJ]5\)>'(/#.GRVEM>ZC>))*92]_<&9P2 , GH..GN:X/
MXP:+K,O@?PQ<P6\VJZCHE]:WETD(+/,$4AV4=2=V#],UW7A'Q+!XGL9;JVL-
M3LDC?9MO[8P,W .5!ZCG&?45C-MTTELC2*2FS@_C!XG\KQ/H7A1];_L&PO8W
MNM0OUE$<@A&0L:,?NEB",_3W!YQ=7\/>$?%/AN7P1XJ?4;:_OX["_P!.>_-R
M&23@3 $Y4J<9(]0/7/6?%/0=0A\5:'XQTG2QK/\ 9\;VM[IX4,\L#9(9 >K*
M23CKT]ZM^'?%.DZUK-G:Z9X*U:$ELRW5SIBVZ6V 2"6;J<@# ^O:KBTH*RTZ
MDM-R=RM:7UV?VB[VR-U.;(: )!;F0^6'\U!NV],X[UE6=@?B!\2O%UEXBO[^
M*QT5XH+33K:Y:!<,I)E;:06)QD'W^E;%KIM\O[0UYJ365R-.;01"+HQ-Y1D\
MU#LWXQNP"<9S7$>*9M/?XK^)I-?TWQ!=O#';PVMSX=W9AC*$LDQC(.YCV;)P
M.,#%.*N].R"6F_<W/@[H_D^./%D4FK:Q?IHMX+>VDGO7DC='4Y1E)P63&,^I
MK$^%'A%_%,'BQ+_6-1MM(CUVZ L[*7R3)+\N7=QRPQM 7ID$UW'PP\3^#TF'
MACP_8WNCW85K@6E_;O%+-_>?+$ECQW.<#T'#?@7IM]ING>*5U&RN;1IM>N9H
MA/$T9>,A,.N1RIP>1QQ1*<ES/;8(Q3LO4R_A/%=B_P#'W@F\U34+BRTV5(K6
MY:8^?'',C\!^H(P"#V.2*YWX1^";6^\4>,&DU;7$.EZVT4?EWS+YP1C@R_WR
M<<D]:[;X=Z;?6GQ3^(UW=65S!:W4MH;>:2)E28!'SL8C#8R,XK"\+:C=>!/'
MWB^RU70]9N(=8U+[99W-E:--&ZN3D$CIC(_7VR.3]Y1W:7Z7%9>[?S/8KZYC
MLK*XNILB*"-I7QZ*,G^5>,^!?#EU\3])?Q7XMU;5$CO99/L-C9W30Q6T2L5!
MP.K9!Y]N<YKV:]MH[RRN+6<$Q3QM$X'HPP?YUXUX&UW5/AEI;^%?$GA_6;V"
MSED^P7^FVIGCGC9BP!P>&R3Q[XXQSE2OROEW_0TG:ZYMC9^(FHZGX'\!Z3HN
MCZE=7FLZC=IIMM?7C!Y%WD_.3CD@84'W![5G^)/AQ<>'/#-WKGA[Q)KO_"1:
M?"UTUQ<7;2)=%!N970\8(!P/IG-:'CS2]9\=^ ].U2QTJ?2]?TZ]74+2RNV7
M>VQCA6QT+#!P<8(Q[U0\1^/=7\2^&[K0=#\(:_!K]_"UK(+NV,<%KN&UV,AX
M( )P>,\?2M(<UER]]?Z[$2M=W^1!\2O%]WJ?P"M/$NGRR65W<&WD8PN5VOY@
M#J"#G&01]*9\1? UY8>#=0\3R>*-;E\2V47VO[0EP8X0002B1#A5QG _/-2_
M$[P?>:;\ [?PWI-M<:C=VHMU*6T32,[!P78* 3C))^E=U\4+2XO?AKX@M;."
M6XN9;%TCAB0N[MCH%')-"FHVY=KO[M <6[\W8XWXC:[K=Y\(/#NK6,EY!'?"
MTFU:>Q'[Z*W>/=(R8Z<D<C^6:U/AMHWA=[Z/5O!GB;4+RV6,K/9M?M,CDCAI
M$?YE8<^E6-+U?4O"?PV\(G_A'-3U'R[*WBO8;91Y]L!$,GRC\S'/&WMSFN1L
M;>+Q'\5= UGP=X=U+1H;7S6U6]N+0VB3H1Q'M_C;.<\=P>W E>+2T6O]/] >
MZ>[T*U_XAT7QAXW\00>+O%!TG1-)N#96NGQWGV8W#KD/*Y!!89&!_P#KSK_#
M;Q-9Z;XJ\0Z#8:\^N>'[6P&IVL[S^>\"@XDB+]P,@@'H/K4!LI?A[XT\07&H
M^&[C6O#FLW!O8KFTM1<26LK<NKKU"DG@_3WQVWA2^L/$UMJ:V_AF^TBR>+R!
M/=6JV[7"N"&"K][ XY/!S[4YM<NBT_K\0BG?7<X;P+X<NOB?I+^*_%NK:HD=
M[+)]AL;.Z:&*VB5BH.!U;(//MSG-7_C+!>^%O@E/;VNL:E/<VTD*+>RS$3L#
M*."RX)X./H*H^!M=U3X9:6_A7Q)X?UF]@LY9/L%_IMJ9XYXV8L <'ALD\>^.
M,<[?Q'L]7\>_!O4%BT:ZT_4Y"LT5A.0965) 1P.C%1G;USQ[T-M5$W\-]!*W
M([;V-_XGW$]M\+->N+>:2*=+!F62-BK*<=01R#7 _$#3VU;]G72]3NK_ % 7
M%KI%O*0EP0L[.L8/FC^/UY[FG^(O%VL^,_AYJ.CZ-X1UN+4'L66[:\MS%''M
M7++'_%(Y(PJ@9R1FNAU#0-0U3]GV#1(;:1-3.BV\8MY%V/YB1H=A!Z'*XP>]
M**]G:_<<GSWMV)/A_P"%H-!\&)J5MJ6KSS76DHQCNKLR1QDQAOD7^'G]*XK1
MQK.L?LRVNH6>I7W]LV1FODG$[&1_*GDRK'.6&S/!]!79_#_Q,VL^$ET5]$UJ
MQU"QTL13?:K-HXRZH$VJQZDGD#KBI_@/IMUI_P )M(L=6LI[6X7SQ);W,11P
M#-(>589Y!'X&DY.-W+>Z_4:2E9+:S_0@\<^-O^+-?V[I;,+S5;:.&T6,_,)I
ML+A?]I<L?JM8/C[5[GPKH_@SP:VO/ILM^FW4-8EF^>..-09"KMT9V) /;I61
MX1\+ZT/&6E>%+_3;Q?#?AO4KG4H+N2)A#.AP;=5<C!96=B0,]_0UVGQ=\.:A
M<ZCX>\3Z)8)J=YHLK^;8-C-S X 8+GC<!G ]^^ *I*$)*/J_\A/FDF_Z\SAM
M3U7PUX-O=(U3P1XOEOI3>107VGR:B;D74+G#-M)X<=<BOH&5!+$\;9VL"IP<
M'!]Z\VT7Q9I.KZE9VEAX%UA)Y)%69[C2U@2U'=G=N./0<GM7I=8UGM=:ETUO
M8\:^'WB>[T'X:>+X=7NIKC4?#-S=0>9.Y=Y,9,9)/7+$@5-\'-4OM TKQ+I/
MBB\N+FZTF.+46EN)"S>5+ '8 GLK*P_&L?QUX8U9_B?>:=8:;>3:%XGDL)K^
MXBB9H8A"YWAF P"0H//7=5GXY:1KB:\;KPWIMY>G7-+?1[HV\3.L7[U&#O@<
M#:SC)]*WM&6G\VO]?B9W<=>W]?Y%:Q\4ZOX6^ R:_/=.^M:W=LT$ES(76 RN
M0I^;HH1-P'3-9VLCPMI/AVXU70_B-<7'BVUB-PMPVI[Q=2*,F,QDX*M@@+[C
MK7I'Q'\#2:U\-8-"T4HMWIHADL0^ K-$,!3VY7(],FL.S\;61M4M[SX=:RNN
M@!7M(]+4QE^Y$AXV?[1[41DFN:*Z_P!?('%K1]BIX^\?27>B>";.'5%T%?$D
M*W-Y?APAM80BLRJQZ,2< ^WO6'J>J^&O!M[I&J>"/%\M]*;R*"^T^343<BZA
M<X9MI/#CKD5VOQ4\-WT]SX:\3:#I:7MSHCMYFF,%S- Z@,BCD;E&< >O&< 4
M_1?%FDZOJ5G:6'@76$GDD59GN-+6!+4=V=VXX]!R>U*+7*G%:=?^"#3YG=F3
MXSU2ST7X]Z5J6ISK!9VV@3222-T #O\ F>P'<UJ?#&6_\::E-XXU&[ECT^3?
M!I>FQS'RXHU)4R2@'!D)SUZ?EC/\;>$!XD^.?AZ;4M-N;G1K?32[R>4Q@,JR
M.51VQCN#M)YX[5>T73K_ ,#_ !*N+.PL;J?PIK[&X4P1,Z6%U_%NVCY4;CDX
M'3LII/E<$EO8:OS7>USCD;2]7\?>([+XE:YJ>EZDMXRZ7%]K>U@%M_RS>-AA
M2Q]^OUSCW#P_8-IFC6EDU]<Z@84V_:KEP\DONQ'6O.?$_BZPU"WO-)\8^ =<
MGD5W6&)++[4DPR0K1R+P&(QTZ>M;GP4TC5M#^'>GV6O"2.Z5G9()&W-!&6)1
M"?4#MVSCM4U;N-WIY?Y%4[*5D<M\9+SRO&N@6WB6^U'3_!,L#^=-9NZ*]SDX
M65DY"XVD?C[D=M\/-%TS2[*XGT#7;S5=*NBK0K+>?:8X< Y$;=1G/()[5#XQ
M\6-H>HFSU/PQJFH:+-",WEI +E-^3E'C'(&,<GJ3T[UROPBTJ5/&_B36=(T>
M\T+PM=Q1I!9W,9A,LPQND6+^%>O_ 'UQZ =W3[6_'_@AM/N,^#^HWMW\&=9N
MKJ\N9[E'O=LLDK,ZX4XP2<\5F_#KP9<^.OAWI6H^)O$NM2-)"R6T=M<&)80K
M,H9NID<D9W-]*U?A'I.HV'P=UBROM/N[:\D>\*030LDC;E.W"D9.>WK72_!&
MRN].^%N@VFH6T]I=1QR!X9XS&Z9E<\J>1P155)<O,X]R81YN5/L<M\-_&=]I
M_P %]6U;6)GO[O1)+BV$DC$M,4QL#'KU8#/7%-\)_#VX\5^'+3Q!XK\0ZXVM
M:C$MU&UK=F%+17&Y!&@X& 1^-)\./"-YJ/PK\5Z#JMM<Z?+J%_=^7]HB:,@,
M%V/@C)7(S[XIWA+QUJOA;P]:>'O$OA/Q!+J^GQ"UB:QM#-%=*HVH5<''0#/Y
M^P<KWE[/>_X"6RY]K%SXM^(KCPYIWAGPY%KCV$NJ2>1<:Q.P$D4,87S'SP [
M;AS]?J..US5/#'@M+'6O!/C*:]O(;F-;RREU(W(O868!\J3]X9SD=.:[3XDZ
M)K&O:=X6\4V&CAM9TB3[1+I$[*QDC<#S(L]"PVC'X\9XJ72?%VDZI?6EG9^
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MWWS1KNVM&S=QPV/]WWKMO'VDIK'A6_MY+J]M0D;2A[28Q.2JDX)'8]QWKC/
M^GZKXE^(]YXYU?3;G2K*.S%AIMK=+MF9-VXR.O\ #R6P/]KVR?2]1MS=Z?=6
MP(4S1-&">V016-1VFGUZ^II!7BUT/'OV<_"EN/!>@^(O[1U7[0PN!]E-T?LW
M^MD3_5].G/UYK-\#>%Y?$_C'XA07.KW]GI,>LR&2VLG\IIW);&^0<[0!]T=2
M>>E;7P-UFYT/1-.\%:QH.M6NIVDDZ-.;0FWVEWD#&3I@YP#W./6M;X2Z;?6/
MB?X@RWME<VT5UK#RP/-$R"5,M\R$CYA[BM9RDI3?W?>9QBFHK^MC/^%7VKP[
M\0_%_A!]1N[[2[*.&[M&NY"[Q!U!9<^GS#\L]S7)Z)KOASQY)?ZUXW\7M8QO
M</'8:7%J!MEMX5.%=@""7/7)_P  .\\.:9>Q_'3QA?3V5RFGW%C;)%</$PBD
M(5,A6Q@D8.0*Y?PQ'_PK(WN@^(O"UYJ>E"X>73]3LK$7.Z-CD))W5A_CVP2T
MTVVM[+_@A9JRZ:G3?!37WU!O$6B_VL=:M='ND6TU!G\QI8)%)4,W\17:PS69
M^TYI27'P[N=2-W>QO:&-!!',5ADW2H,NG1B.WI7?>";^+5-.FO(/#]UHD;2[
M4CNH%ADE4 8<J.0.2,'FL?XW:'>^(OAEK&GZ7"T]Z1'+'$O5]DBL0/? .!W-
M91E:LGMJBW&]-K<9I/A>'PMX.UFXLM3U>YDN-/+YO+MI?**QL1LS]WK^@]*Y
M+X0^&;WQ7X7\/^(_$^MZG.]N5:RM8KAEC58W(W2=W9BIR2>F!74Z%XI_X2KP
M=JEI#HNM65Y!IS(Z7=FT8:0QD;$/\1R.GN*L_!&RN].^%N@VFH6T]I=1QR!X
M9XS&Z9E<\J>1P13<I1B[[W!)-JVUC*^%E[=7/C[XCPW-S/-#;W\2PI)(66,8
M?A0>@^E8WC/1?"=MJ-V?&/CO5GU*:1F@ACO2K6RDY4)#&#T&.2.<5M?#/3=0
ML_''Q&GN;2YMHKN^C>VFFA94E #_ #*2,,!D=*Y/X6ZG<>$+&[TO4O!VMW?C
M%[F5IKF.U#+=EF)5C<$X">YX[\YJ_M-Q\OR)Z)/S-KX5^(+W7_@UK9U.ZDO+
MBQ%W9?:9 =\JK'N5FSSG# <\\<\U:^%-E?:C\ --L])O387\UK,D-R!GRV,K
MX/\ ]<<BJWPAT/5[7X?^,+#5-/FL]0NM2O2D4BE0^Z- &0D#<I.<,.#BI_A)
MJ5_I/P8\M-#U%]6T=)HVL9HFB>:0,7 3(Y!##D#J",4JGVN7N@ATOV.^\'Z?
MJ.E>&=/L=:U ZCJ,,>V:Z.<R')]>3@8&3R<9K8KFOAUXG/C#PE::Q)9O932L
M\<ENQSL='*D9P/3TIWC'Q5_PC(M#_86O:O\ :-_&DV?VCRMN/O\ (QG/'K@U
MSN,G)KJ;)I1OT.-_9P_Y$K4_^PQ<_P#LM86GZQJ(^-WCA]*T9]5U:.*VM+8/
M((H;>'9ER\AS@%@I  )//I2_ W6[[0[)]#U/PGXJ@FO=2EG6Y?366")7Q@NQ
M(QC'/!K>UN._\#?$G4/$T&EWNI:%K5O''>K8Q>9+;S1C"OL')4KU([D^V>F6
ME27GL8+6$?(V?"7C:^O?%-QX8\4:0-)UN.#[5#Y4_G0W$6<%E; P0>WL?2M2
MU\?>$[N^BL[;Q#IDMW+((HXDN%+,Y. H'KGBN0\,QW_C#XIIXN?3+W3-%T^P
M:SM?ML7E2W+LQ+-L/(4 GK[>^/1(]"TF*99HM+L$E5@RNMN@8$<Y!QUK&:@F
M:P<FC@? =_<:5\3/'6@ZE=S26X9-4M#-(6"1./G"YZ*I*C XXK ^#NNZI+XU
MN)=6N[B2T\3VDNJ644SDK#LN'41H#T_=E6X[8J;XXZ5K=OXAL=9\,Z;>7MQ?
M:;<Z/<_98F<QJX^1FP. "Q.3TQ5[XE:)J'AW1/!^I>%["YOKWP\?LBPVL32.
MT+PF-CM R>54UM[LE_B_3_@F6J?I^I6\,^)[BVTSXD^-[B6:YM(KN2"Q@>0F
M/;"NU2HS@!F89(]*YS1QX6UK0HM5\3?$6:/Q3=1B<RPZGY2V;L,A$C!P O (
M]0>E=_X8\#[O@C;^%KL-;W-W8-YI<'='-)ESN'7*L>?I7.>&/$2>&]%M=$\7
M>!M3?5[*,6XELM,%S'=A1A65QU) &<]_R#33OR[W_ &GIS?TRO<?$[4H_@=I
MNJ_:8$UR\NO[*%XV-BN&8&8]ON+GTR?3BLC7W\+:%H$VL>&?B%<7/BFT3SQ)
M+J?FB\8<LC1DX(;G ^G6N^^('AF[\8_#BR.E:8NF:M:SQZE;6$ZHN)%S\C8^
M7D$_CC..:H6GC:PEACMY?AUK0UKA7M%TM=@;N?-.%V?[1HBU:\5UUV_JP-/:
M3Z%3XJZDFJ6OPKU0@11W6LV5S@GA0P5NOMFKFC:O)\3_ !M--IVHR0^$] F"
M[+>8H]_.>A;!SY0YP#][\\+\=O#<WB*W\':=;V%W+9'5HDNA:Q$^1 1M9B5!
M"@ ]>@I?$OA^?P-XJTCQ+X/TN:73G1-.U73K&%G9H1PDJHN263'/?IZDU,7%
MP26^MAN_,[[:'J]>4?M'_P#(I:'_ -ARV_D]>K*=R@C.",\C%>:?'W3;[5/#
M&C1:997-Y+'K%O*Z6\32,J /EB #@#(YK&AI41I5^!GIE>4? C_C_P#B!_V,
M5S_.O5Z\R^"^FWVG7OCAM0LKFU6XUVXFA,\3()4)X9<CE3ZCBB#]R7R'+XD=
M9XUTZ+4K"".;Q!?:$%EW":SN4@9^#\I+ @COCVKCO^$4LO\ HJ'B/_P:P_\
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M:\EYDE@D&5#GN0"O/O[5A>"M=U/X8Z0_A;Q%X?UJ^ALY9/L%[IMJ9X[B-F+
M'!^5LD\'U]N>@^%.AZJVN^(_&'B*T:POM;D00V;G+P0(,*'_ -H@+Q_L^^*5
M3:5]NG]>@0W5M^IR'PO\.WOCO0M3?Q#XBU<Z;;:E<00VEM<&,D@@EG?DMC<
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M*+R8K:"U6%G4#""1P=Q4<?+GG&,XH<XSUO;6X*,H]+Z6*FD_\FNO_P!@.?\
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MWXC"35]:TW[/-;8_LR\-OYFY&^_@<XQQZ9/K7I%GX*_L[XBW?B?3-0^S07\
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M;J^GR>;97\ R\+<9!'\2G XR.E*%2*23??\ $)0;;:\CK#&AD5RBEU!"L1R
M>N#^ _*O!?AI?^*6\0>-]0TG0].U&\EUB:&XFNKWR9(U3A(P-I^4#IS_ "KT
M7PYX;\60ZS;7OB3QB]_!;!@EI:V:6Z2DC&9",[NN<<8(S576O -_%XEN]?\
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M^[C&[I@]*TYXJT;[)_B3RMZVZHZJO)?A-;0-\3OB7<M#&;A+^-%E*C<JD.2
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M@<);^;(? 6B>([?Q]K^NZWI]EIMMJ=M$K06MSYH:5#@.?E'.TFLK]F:TMXO
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M[1_;=REQY7E;/)VAN,[CN^]UP.E*4XVDD^B2&HO1LY/X)_\ (R_$G_L/S?\
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M-;8R/@.,Y,G')'%=CXT\4^(]&?PGX>MGTQ?$6M,\<M[*K?9HB@!8JN<DG<,
M_3O3=':SW$JF]UL>ET5RWA*#QA:WUS#XHN]*O[(1AH+FUB:*4OGE63E<8[@U
M5^+GB'5/"O@R;6M&CAD>TFB:=)4+;HBVUL8(P<D<_6H4+RY4R^:RNSLZ*\\^
M+'C2_P##_A?3[KPPD%SJ.H/NMUE4LIB6)I7; (_A4?G2^-O'4^G_  QL/$&A
MI#)J&I_9DLXY 64R2D'!&0>!N_$4U2D[/N)U$K^1O:SXMM]+\6Z/H$MC?S3Z
MFK,D\46Z*/;G[QS[>G'%;,VIV4&I6VGS74*7URK/# S@/(%^\0.^*X[7_%&I
MZ9\2O!WAY?LSVNJ0W#73E#NW1QEAM.>!D>]<%XS7Q@_QWT2&SN]&2Z^RW+Z>
MTD4A1(3NR)!G)? ZCBKC2YK=-+DNI;[SU#Q_XO7PA!H\K61N_P"T=1BL !)L
M\LN&^;H<XV]*ZFO%?CF^J6O@_P %R:LL%YJL6NVS2): HDKA9"%3=TSP.:F\
M8^)?B)X/L(O$VKC0Y-(69%NM-MU8R0HQ &)#]YAD#/3)Z$4U1YHJV[N'M+-W
M/9*BN[>*[M9K:X7?#,C1NN2,J1@C(]C7(?$?QH_AK2].72;5;_6=7F6VT^W8
MX5V./F8_W1D9^HZ=1S&MZ]X_\#6<6N>)I-(UC15=5O8K*%HY;96(&Y"?O $C
MK^G41&E*6I4II'I?A_1K#P_H]MI>D0?9[&W!$46]GV@DD\L23R3U-:%<#X[\
M8W>D:EX)31VMY;36]0CMY'=2V8FVX*\C!P:F^,/BB_\ "/A./4=*$!N&O(H"
M)D++M8G/ (YXI>SE)KS#G23\CK=3U.RTJ!)]2NH;6%Y%B5Y7"@NQP%Y[FK=>
M*_M)'75L=$^R3:>NDR:C;(J.C&;[3ER"3G'EX XZYKTWPE%XDBM)QXLN=,N+
MDOF)K"-T4)CH=W?.:'3M!2ON"G>3C8W:RK#P]I=AKVI:U:6OEZEJ(1;J;S&/
MF!!A?E)P,#T JKXPD\2K;6T7A*#3FN99-LL]\[!($Q][:O+'MC/I^'%6OB/Q
M=X7\<Z)HWC&XTW4M/ULO';W5I"8FAE4 [2,X(.0/Q]L41@VM&$I)/5'JE%>:
M^,_&7B'3?B38>&O#]A:7K7NG&>,3L4$<F]AO=@?N!5)( R3TJE:>)/&/AKX@
M:'HWC&;2[_3];\Q()[.)HS#*H!VD'J.0.?7.>"*:HMJ_S%[17L>KT5P^F^*-
M1B^*NI^%]7$ M9;1+W3)$0JSJ#B16.2"0<^G"^]/O/$U_+\5K#PSIH@-E#8O
M>ZB[(2R@G;&JG. <X/?@U/LW^%RN='6ZE>P:=IUU?7;%+:VB>:5@"<*H))P.
MO KS]/C5X):,2&_O%A//FFPGV@>N0M=5X_\ ^1$\2?\ 8-N?_135P/PG\<^%
M=*^%VA6VIZ_I<$\-MB6![A=Z_,>"F<Y]L5<()QYFF]292:E:]CTO1-;TW7=+
M34='O(;RR?.)8CD<=01U!]CS7#Q?&OP3+'YJWUX8>\@L)BH_$+65\#(O./C7
M5["VDMO#^I7[2Z<C)L#* VYU7L#E?RQVKF/@?\2O"_ACX:VMAK%[/%=Q2S.T
M:6DKC!<D?,%*]/>M/8KWK)NUB/:/36USW'PWXATGQ+IPOM"OH;VU)VEXS]T^
MA!Y!]B*S/&/COP]X0,,>M7VRZFYBMHD,DKCU"KR![G KBO@4L.I:QXQ\3:<(
MK?2M6NH_LUHCJ638&R[JI.PL6S@\]?:H_@-;1:_-K_CC4%6;5-0OY(89'&3!
M N J+Z=<?0"I=*,6V]E^HU-M*V[.S\(?$/P[XKO)++3+N2/4(QN:TNHFAEV^
MH#=1],UUM5VL;1[^.^:VA-['&8DG*#>J$@E0W7!('%4?%1U<:)<-X=ELHM17
M#(UXK-& /O9"\YQG%8NS?NZ&BNEJ6]*U.RU:S6[TRZAN[9B5$L+AE)!P1D>A
M&*MUX;^S?%XI;PEI$J7>E?\ "-^;/OA:-_M).YNC?=^_@_2M2#QCXQ\0>+/$
MWAOP[!IT,FG7>W^T+E&\N"'' *@G=(QSCH, UK*C:3BGL0JMXIM;GKU96D>'
MM+TC4=4O].MO)NM3D$MV_F,WF,,X."2!U/3%86M+XZ^RZ59:,^C"<VX^WZE<
MAB%E &1'$/4Y(R<8ZX[XWA3Q-XDT_P"(+>$/&3V-W+<6AO+*]M(S&' )#*RG
MOP?R[YXE0=G9E.2NKH]+HKR_6/&/BF3XF:GX3\.V5A,4M(IXKBY)5+<'&]WP
M<OU "@#D]<4GACQ+XJTOXCQ^$_&<FGWHO;1KJSN[.,Q\J3E6!]@WZ<G/![%V
MO\Q>T5['J-0:A=PZ?87-Y=-LM[>)II&]%4$D_D*\TN?$?BGQ+X\UW0?"U[IF
MDV^BB,2R7<)FEN'<9X7( 0=,_3UP+?C9?%[_  DU@7SZ+'JJ6UP+MHQ(T4EL
M(WR4'4.1@C/ H]E9I-[ASZ.R+?P]\9ZYXO>.^;PQ]@\/7".]O>R7JM(^#@9B
M R,\]\<=^*[RO%_AK>^)]$^#,^K7$^ER6%IHTEQIT<<3^8K(K,/-R<$<=J]%
M\!ZS=:[X$TG6+T1B[NK432"-<+N([#/2G5A9MK:]@IRNDGN='17EOA3XBW]Q
M\%KGQEJUO#->0+,WE0*41BKE5'4X'3)^M3>%YOB+?VVDZR^I>'+NQO?+EFLT
MA=/*B?!.R0$Y8 ]^.*3I-7OTT&JB=K'4:EXMMK#QKI?AM[&_DN+^%IDN8XLP
MH!NX9L]?E/;C(]:Z2N'UKQ1?V7Q8\.^'(1!_9]_:33S%D)?<@8C!SP.!VJAX
MG\6:]J/C9_"/@A+-+RUA6?4-0O 6CM@V"JJHZL00?Q^I![-NUNUQ<]KW/1Z*
M\TT/Q7XAT/QK9>%_'(L9SJ2,^G:E9H8UD91EHW4]&^GJ.N>(_$/C+Q,GQ.N/
M"GAZQL;EGTY+F*6Y)5("7PTDA!RR@8 4#.2.:/92O;YC]HK7/3Z*\LT#Q+XL
MT;XD6/A;QE+IU]%JEO)-9W5G&8RK("S*0?93^G/:O2M3%XVG70TQH$OC&P@:
M<$QA\?*6 YQG&<5,H.+28XRYD<)9>/\ 5M:\7W^F>&O#?V[2]-NQ9WNH27JP
MA'SARJ$$MMY/!YQVR*]$KP?X"0^*?[9\2-]JTG^S5UNX&H)Y;^8\N.3$>@7.
M.O/6NALO$_B_QWJ.I2>"9=,TS0;&=K9+R\B:5[N1>I51P$Z<]>?J!K4I+FM&
MUD9PJ:7?4]7HKA/AWXPU#5M4U?P[XGM8+7Q'I)4R_9R3%<1M]V1,\@<C(]Q]
M!R^B^,/&_B[4O$.D^'X],M'TO4YX'U&YC8HL*MMC15!.Z0X8D] ,>M1[&5WY
M%^T6A['145HLRVL*W3K)<!%$CJ,!FQR0.PS7":K#\2M0OKQM,N= TBSBD9;9
M)$>XDG4'AG;HH/' &141C?J-NW0] JII>IV6JV[7&FW4-U KM&7B<, RG!&1
MW%<+X)\5Z]XR\!WLUC'I]CXGLKIK&=;A6:W$B,NXX!W8*GCGK7'?LZ+XLF\/
M6UQ#=Z2- :]G:>)XG^T%B>=K9V]<5I[&RDV]43[2[274]LU6[_L_2[R\*>8+
M>%YMF<;MJDXSVZ5E> _$8\6^$M.UQ;8VHO%9A"7W[<.R]<#/W?2K?BO_ )%;
M6?\ KRF_] ->?_"K6[7PW\ =,UC4"?LUG;2R,%ZM^]?"CW)( ^M2H7A=;W&Y
M6E;I8]4HKRB/4/B;=Z#_ ,)+"=#@B:+[5'HKPNSM%C<%,N>'*_AGTZ5U,7B/
M4_$'@*QUOP=9VLU[?(C)%>RE4BR</N(&6VG/ QG''I0Z;74%-,ZZBO(M:\1>
M./ U_I%[XIN](U/1+Z[2SN!:0-$]LSYPRDGD#!Z^F.^:W/B-XJU?3_$?A[PS
MX=-E;ZAK!D/VR]!:.)4&<*H(W,>P^GKP_9.ZMU#VB._FC6:)XY 2CJ5;!(X/
MN*Y+P'X:\(>'KC4HO"5O:I=1N(;QDF:61&ZA&9B2/7%&AP>.+>#5+?5[S1+N
M009L+N.)X\RD'B5,_=!Q]TYYKR_X3)XVG\5>,&L[W0U":R5U'S(9#O8$AO*P
M>!@'&:J,'RR]XF4M5H>_UQ%[\5O!%C>3VEUX@MX[B"1HI$,<AVLIP1POJ*[>
MOGSX;>*M'T'0]:EUG0-6NVDU:ZN)[J'2VFBA!8#YG(P,;>G:E2IJ2;8YS<6D
M>VZ3XCTC5M#_ +9L+^&32\,3<L=B *2&)+8P!@]:Y[3OBMX)U'54TZT\06[7
M4C;$#(Z([=,!V4*?SK4MHO#?C;PC&MO';7^@W8#!$4JIPV<$#!!##D?G7)_'
M^#2K;X4WEI+:PB1FBAT^&- ")BXVB,#IP#T[9HA&+ERN^X2E)+F1Z?15'0(K
MF#0M.BOV+7D=M&LS$YRX4!C^>:O5BS0**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \^^/T,D_PA\1)$I9A'$Y ]%F1B?P )K3\/ZWIFK>!
M(AINH6MRZZ8K,D4JLR?N\?,H.1SQSWKK)8TEB>.5%>-P596&0P/4$>E8^C>%
M- T22X?2-&T^R>X79*8(%7>O]TX'3VZ5HIKDY7W(<7S71Q_[.7_)'="^MQ_Z
M/DKF-,OM.\8>*/%?_">Z^]G:Z5?/:V^D&^-I$(5Z2O@J7)]<\?0BO:--L+/2
M[..TTVTM[.TCSLAMXUC1<G)PH  R23^-9FI^$?#NJ:FNH:EHFG75\N,3S6ZL
MQQTR2.<=LU?M5S2EW)Y'RI=CR_\ 9^&F#QA\0_[ 0)I7GVIM@ P!3$N"-W.#
MUR>N<UK_ +.?_(H:S_V&KK_V2O3+;3[*UN[FZMK2WAN;G;Y\T<2J\NT87<P&
M6P.!GI2:;IMCID+Q:;96UG$[F5DMXEC5G/5B !DG'6E.JI7\[?@$:?+;RN>8
M?"R:.W\>_%.>=PD4=_&[L>BJ%D)-8GBBT\%_V-J'C+P/XJCT/4Q&USFSN@J7
M$@!(22 ]V/&,#DYP:]JM--L;*YNKBSLK:WGNF#W$D42HTS#H7(&6/)Y-8\W@
M?PM-J/V^7P[I+WF[?YIM4R6]3QR?>J55<W-KT$Z;Y;'EWQ4U.]UKX(^&-2U2
M$0WMU=V<LJ 8&3NYQVSUQ[UO?M)*Z_#^VN@C-%9ZE;SRE1G:@)&?S8?G7I6I
M:;8ZI;K!J5E;7D"L'6.XB610PZ$ @C(]:FN[:"\MI;>[ACGMY5*O%*H97!Z@
M@\$4E52:=MF-TVT]=SR#XY^-/#^H_"_4K+2M3M]0NKZ-&BBM'$K*BNK,[@?<
M4 =3CGBNGUBX\)R>"_#^D>-9;-;74;:)84NF**S+&IR'_@(SUR.N.]=!IW@[
MPWIUK<VUCH6F0V]T-L\:VR;95]&&.1['BM"_TC3M0T\6%_86MS9 !1;RQ*T8
M X&%(P,4N>*22OHQ\LKML\@T"<^$OBAH?AWPMXAFUO0M1BF:XL99Q<?8 BY5
ME<?=4GC!]#U)!K4^&B[OBY\45R1F6S&1_N25Z#H/AG0_#_F'1-)LK!I.':"%
M49AZ$CDBKMKIMC:7EU=VME;075T5-Q-'$JO,1TWL!EL9.,TY54[^:_6XHTVK
M'D7P+UG3O"VAZAX2\0WEMINK:5>2[DNI!$)8V.1(I8@$'V[8/>K/P^G3Q/\
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MRMK5KB0S3&")4,LAZNV!RQ]3S4<^CZ9<:I!J4^G6<NHP+LBNG@5I8QSPKD9
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M=KF^BD$+S,@P(A(?N9P,X_O"N2U>R\)V'Q?\!0>$9$N)X[J7[=.EP]QEBJ[
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M&*Y@D@N(TEAE4I)'(H974C!!!X(([5'8V=M86D5K8V\-M;1#;'#"@1$'H%'
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MXX(X/(-6*@L+*UTZSCM-/MH+6UB&$A@C"(@SGA1P.34]<[\C8**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNDA<EU9L\@N=%\9>(OB%X/\ $FJZ5!86%A+,#9)<)));(R8WR/D;BQP-J@X
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M_P"(O!&NW_P3\.Z-;VT1U?3#;3RV,LB[9C&"&B+ [3USUQQUJK\1+?QU\0/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCTKN- L;2#3+*2&U@CD,"?,D8!^Z.XKH3BJ2YEU?Z&+OSNW;_,\0GT*_\/\
M[+&IVNK0M;W,N+CR&X,2O<(0I'8XYQVS7K:0:O<_#_38?#U[;V.HO:6X2>>+
MS50;5W';GDXSC/&:ROCQ#)/\)/$:0HSN(4?"C)PLB,3^ !-<C\0M<EN/@QX:
MO=%NKDZ-++;0ZE<6>X2); %9<=Q\R[3^70U2O52?=O\ 06D&UY%/QGJVL?#J
MYT_4_P#A/3KC"Z2*^TNZ\H,\;9W,B+RN,=NF?P-G]HG3]3EO/"TL.MS0V<^K
MVT$5JL*$0S?-B8-U)&?NGBN2^*MYX%E^'<MIX TV&;RIH7N+VUM"!"NX "29
M@"68D #)/K7HO[0Z20^'_#^JB*22VTO6;>[N?+7)2(;LM],X'XUJM)0=M=>A
M#U4EZ'3V_AKQ!'X9NM.D\87<NHRS"2/43:1AXD^7Y GW2.#R?[U>>*OC _$V
MQ\-Z9XWO=22V47.K2-:0HEO'D$1Y .78=NV0?7'3^+_BYH.G^!+[7= O(]1D
M606D"JK >>R[E#9 X RQ^F.M<Q\+/'G@'PUHRPW'B07>O:C+]HO[DVDY,T['
MIGR^@S@?B>]9PC-1<G'\"I.-TK_B2^,;?6+O]H:TM_#][!874F@!7NI8O-,4
M?G/N*+T+= ,\<FK>H7?B7X<^+/#_ /:7B*?7?#^L70L9ENXU62WE;[K*P[>W
MH#[&J_BW6[7P[^T);ZEJ*7/V&+P^%GFAA:00*9F&]PN2%S@9QW%1^*-<L_BE
MXP\+Z/X4:2]TW3+Y-2U"^$;+%&$^Z@) R3DC\1Z'%)-VNO=L)M*]GK<Z'QAK
M^JZQX\7P?H&JIHT-M;"[U'4-JM( Q&V*,-P"00<^A]N8M#U/5?"WQ TKP]J.
MOMK^E:S#,;6><)YUO-$NYE9E^\I7IGO].><^(FC:/HGQ6D\0^,M(%_X8U6U2
M%[HQ&1;.= %!8#D*5 Y]_:NC\"CX8WGB>(>#;"TEU*WC:87-M;2;(OX<%R,
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M*'^]\S>_3@\BM3P7\3]"\4:@-+D2YTK74^]I]_'Y<F0.=IZ'C/'!QVJ7Q?\
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M\"?\EW^(W_7*R_\ 10HN?^3F;3_L7#_Z.:AVUC;HOR0+OYG):;X=\17/QO\
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M<8M=]?-F;DIIR7](E_:.B"_#.?48\+=Z;=V]U;R=T?S%7(_!C7HUM%;S/%J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ (!!!&0:9'%''$(HXT2,<;%4 ?E110 0PQP1A(8TC0?PHH _(4]
M@&!# $'@@]Z** &0PQP($AC2-!_"B@"GT44 %,AAB@39#&D:9SM10!G\***
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MI54*H50%4#  & *** %HHHH 1E#*58!E(P01D&FPQ1P1A(8TC0=%10!^5%%
M"3V\,X43Q1RA3D!U#8/XU)110!&L$2S-*L2"5AAG"C<?J:DHHH **** (XH8
MHBYBB1"YRQ50-Q]34E%% !4<\$4Z;)XDD7KAU!'ZT44 /50JA5 "@8 ':EHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img43612817_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43612817_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 5-![D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBL'Q1XKM/"EM9RW5I>W;WER+:&&RB$DC.02!@D?W30!O45A:!XE.O23H=#
MUK3?* .[4;7R@^>R\G)&*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5JB@"KYMW_S[+_WW1YMW_P ^R_\ ?=6J* *OFW?_ #[+_P!]T>;=_P#/LO\
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M;=_\^R_]]T>;=_\ /LO_ 'W5JB@"KYMW_P ^R_\ ?='FW?\ S[+_ -]U:HH
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M_?='FW?_ #[+_P!]U:HH J^;=_\ /LO_ 'W1YMW_ ,^R_P#?=6J* *OFW?\
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M=_\ /LO_ 'W5JB@"KYMW_P ^R_\ ?='FW?\ S[+_ -]U:HH J^;=_P#/LO\
MWW1YMW_S[+_WW5JB@"KYMW_S[+_WW1YMW_S[+_WW5JB@"KYMW_S[+_WW1YMW
M_P ^R_\ ?=6J* *OFW?_ #[+_P!]T>;=_P#/LO\ WW5JB@"KYMW_ ,^R_P#?
M='FW?_/LO_?=6J* *OFW?_/LO_?='FW?_/LO_?=6J* *OFW?_/LO_?='FW?_
M #[+_P!]U:HH J^;=_\ /LO_ 'W1YMW_ ,^R_P#?=6J* *OFW?\ S[+_ -]T
M>;=_\^R_]]U:HH J^;=_\^R_]]T>;=_\^R_]]U:HH J^;=_\^R_]]T>;=_\
M/LO_ 'W5JB@"KYMW_P ^R_\ ?=.22Y+@-;J%SR=_2K%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %</\6=9N-%\#2O:7
M,MM<SSQPQRPN4=>=QP1R.%(_&NXKQGX\ZAB/1M.4\DR3N/R5?YM6E)7FD95Y
M<M-LXG19?B'XBBEETG4M;NHXF"NRW[C!/;EA4T'CGQQX1U46^H7=V[QD&2VU
M#,FX'GJW./<&O3_@G9?9O KW!'S75V[Y]@ O\U-<'\;=2L[[Q9:V]LZ22VMO
MLG=#G#%B=I]QU_X%74I*4W"VAR.#C34[ZGN6A:O#KVA6>JVX*QW,8<*>JGH1
M^!R/PK1KS70/$FF?#_X9Z"NLM,LUQ#)+##'&6=\L7]@.'7J1UKE-2^+OB7Q#
M<&R\,:6T!;H8XS/,1Z],#\C]:Y_8RDW;8Z?;QBES;GM>H:G8Z5;&YU"[@M81
M_',X4?KU-3^;'Y/G%U$6W?N)P ,9S7@UE\*/%_B:Y%[XAO\ [-OY+7,AFEQ[
M*#@?3(QZ5VWQ=UE]$\"II\$A$M\PMBPX/E@9?\\ ?\"H=-744[L%5ERN4E9'
M,^)_C'J-SJ9T_P *0*4#[%N&C\QYCT^1>F#VR"3[55\/_%WQ!IFMI8>*H_,A
M+A)C) (9H,]R  ,#/((S6A\#?#L31WOB&>,-('^S6Y(^[P"[#ZY S]?6L#XX
M+&OCFW* ;FL(R^/7>XY_ "MDH.7L['.Y5%#VK?R/H0$, 000>012UD^%I))?
M".BR2DF1["!GSUR8US6M7(U9V.Y.ZN8?BOQ38>$=&;4+TEB3MAA4_-*WH/ZG
MM7BUQ\5O'.J/<7FFQ>19P?-(+>T$J1K_ +;,#CZ\55^+NM2ZSXYDL8R6@L +
M>)!W<X+'ZYX_X"*]R\->';3PYX4M])V)M6+-RW3S'(^<G_/0#TKH2C3BFU=L
MY6Y59M1=DCFOAK\17\7B:PU&*.+4H$\P-'PLJ9P3CL02,_6MCQQXYLO!>G))
M(GVB]GR(+<-C./XF/91_GV\1^$<DB?$G350G:ZS*^/3RF/\ ,"H?%%Y<>-_B
M7)#&Y*S72V=MW"QAMH/TZL?J:IT8^T\B57E[+SV-67XI^/9T?5(L1Z>C[6,=
MD#"">BER"<_\"S7K'P]\<)XTTF5Y8D@O[8A9XT/RD'HRYYP<'CMBK/B+2['2
MOAGJNG01*EK;Z;*L:^X0D'ZEN?<UY3\"I)!XOOXP3Y;6#,WID2)C^9J7RS@V
ME:Q2<Z=11;O<]8\;>,[?P7I<-Y-:O=/-+Y:1(X7L3DGGC@?G7C>K_&?Q1?7(
M;3WATV$=(XXUE)^K.#^@%?0-WI]EJ 07MG;W(3)431*^WZ9%?+%W%%KWC^6"
MVB2.&\U+RXHXP %1I, #'MBG04'>Z%B7--6>Y]/Z ]Y+X=TZ34)O.O)+:-YG
MV@9<J">  .IK1I%4*H50  , #M2URLZUH@HHHH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7SE\9K_ .V>/Y( V5L[>.''
M8$C>?_0Z^C:^5=:9O$OQ'ND5L_;=2,*$?W2^U?TQ71AE[S9RXM^ZEW-FP\"?
M$5["!+2&[BLI$#(@U!$0*W/W=_'7.,5U/A3X*31WL=YXDGA:)&W"TA);>?\
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M2".,CI1&HIRDEU"5-TXQ;Z;GK/Q:U>/2_ 5W"6 FO2MO&OKDY;_QT'\Q7(?
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MUV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\
M/9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@
M":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^
MUV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\
M/9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C
M[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\
M\]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z
M )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'
M[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\
M\]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z
M/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__
M #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/S
MH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH
M?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__
M #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/S
MH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_
M //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_
M.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*
MA^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_
M //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_
M.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O
M_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3
M\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FH
MJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O
M_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3
M\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV
M_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9
M/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":
MBH?M=O\ \]D_.C[7;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV
M_P#SV3\Z/M=O_P ]D_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9
M/SH^UV__ #V3\Z )J*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7
M;_\ /9/SH FHJ'[7;_\ /9/SH^UV_P#SV3\Z )J*A^UV_P#SV3\Z/M=O_P ]
MD_.@":BH?M=O_P ]D_.C[7;_ //9/SH FHJ'[7;_ //9/SH^UV__ #V3\Z )
MJ*A^UV__ #V3\Z/M=O\ \]D_.@":BH?M=O\ \]D_.C[7;_\ /9/SH C.IV .
M#?6V?^NJ_P"-.BO[.:01Q7<$CGHJR D_A7GOCCPSX;L?">H7MC9PQW:E"KK(
MQ(S(H/!/H374:?X9\,:5?1WME9P0W$>=CB1B1D$'J?0FNB4*2AS)OKT[6\_,
MQ4JCERM+^OD=%14/VNW_ .>R?G2K<P,P594)/0 USFQ+1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7)>+?"&H^(]6TF^M-=%@NFN98H7LQ.AE
M/ D(+ 9 Z9SCK76T4 >6^"M-UV#XJ^+#=^($NEA^Q_:U%BL?VG,#;,8;Y-O'
M3.<=J]2HHH *888B23&A)[[13Z* (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R
M(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B
M_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_
M )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\
MGDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">
M2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)
M_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_
M 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\
M?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\
MBCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*
M/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\
MB+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(
MO^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_
MYY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_G
MDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2
M?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_
MWR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?
M(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\B
MI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*D
MHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B
M@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI**
M(_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C
M\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R
M(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B
M_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_
M )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\
MGDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">
M2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)
M_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_
M 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\
M?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\
MBCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*
M/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\
MB+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(
MO^>2?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_
MYY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2?]\BI** (_(B_P">2?\ ?(H\B+_G
MDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_WR*DHH C\B+_ )Y)_P!\BCR(O^>2
M?]\BI** (_(B_P">2?\ ?(H\B+_GDG_?(J2B@"/R(O\ GDG_ 'R*/(B_YY)_
MWR*DHH Y+XCQ1KX"U,K&H/[KD#_IJE=3Y$7_ #R3_OD5S/Q)_P"1 U/_ +9?
M^C4KJJVE_"CZO\D9K^(_1?J1^1%_SR3_ +Y%*(8@01&@([A13Z*Q- HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJNI:C;:3I\U]>.4MX0"[!2<9..@^M-)MV0F[*[+5%<?\ \+.\*_\ /[+_
M . [_P"%:^A^*M)\1O,FFSO*T(!?=&RXSG'4>U:2H5(J\HM(A582=DT;-%%%
M9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !115/5=4M=&TV:_O)-D$2Y/J3V ]2::3;LA
M-I*[.8^*%_:VW@RYM)90L]TR+#'W;:ZL?P '7Z>M=+I&K6>N:;%?V,A>"3.,
MC!!!P01ZU\]>(]>N_$FKRW]SD+TCC!R(TSP/\]S7OWAW0X?#NB0:= Q?RP2[
MG^-CR3[5W8F@J-&,9/WKO]/^ <E"JZM636QJT445P'8%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9-SXGT.SN'M[G5K2*:,X='E *GW%,3Q;X>DD5
M$UFR9V("@3#)--UC0M'FLKZYETJQDN#$[&5K="Q.T\YQG-97@S0M'F\)Z5<R
MZ58R7!B#&5K="Q.>N<9S70HTN3FU,7*IS<NAV%%%%<YL%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN7^(NHS:5X
MU>[MW9)1$L:LIP5WNJ9'_?5.*N["D^5-FS%K>DS7ILHM4LI+M3@P+<(7!_W<
MYK+U/QYX8T?4CI]_J\,5T#ADVLVT_P"T0"%_$BO%=.^&=Q<?#]O%D6J>5/'%
M)<I (^B1DY^?/#?*2./2K6@> +;Q)X U7Q->7MP=3S-*AW#:2@W'=QDECGG/
MI71[*"W9S>VJ/11\SZ BECGB26)UDC<!E=#D,#T(/<4^O//@O?S7O@+RY6+"
MTNI($)/\.%8#_P ?->AUA./+)HZ(2YHJ04445)04444 %%%% !1110 4444
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M10!0NM<TBQG,%WJMC;S+@F.6X1&&>G!.:A_X2?P__P!!W3/_  +C_P :;?\
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MU/A1AB:SC^[A\3-+P#X/?Q+J1O+U6_LZ!LR$_P#+9^NW/ZG_ .O7NJJJ*%4
M*!@ #@"JNFZ;:Z3IT-C9QB."%=JCN?<^I/6K=98G$.M._3H:4**I1MU.5^)/
M_(@:G_VR_P#1J5U5>?>(XO&FOZ/=:6^AVD<4Q7]XMTN0%8,."?:MW2]0\5SZ
ME%'J6BVEM9G/F2QW 9EX.,#/K@?C1*G^Z2NM&WNO+_((S_>-V>MNGJ=)1117
M,;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW_+UKNJK%XA/]U3^%"PU%K]Y/=A1117 =84444 %%%% !1110 4444 %%%%
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M0?8;;_GD/S-'V&V_YY#\S0!/N7^\/SHW+_>'YU!]AMO^>0_,T?8;;_GD/S-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M7D_Q6\2>(K;7=+\/Z#)- ]V@</"=KR.S%0H;MC&>W6N<_P"$/^+/_03U'_P;
MG_XNMHTKJ[=C"5:TFE%NQ[W17(_#O3?$.E^'YX/$L\TUZUTSHTUSYQ$>Q !N
MR<#(;BNNK*2L[&T7=7"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4\/SS^)8)H;U;ID19K;R28]B$';@9&2W-==7(_#OQ9=^,?#\^HWEO#!)'=-
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MBBL30**** ,'6]'UK4+U)=.\1/IL(C"F%;59-S9)W9)'8@8]JYC0[+Q5K/\
M:7_%7RP_8KZ6S_X\D;?LQ\W48SGIS]:]%KE? _\ S,?_ &'+G_V6NFG4:IO;
M2W1?Y&$X)S6^OFSIK>.2*VBCEE\Z1$"O(1C>0.3CMFI***YC<*1F5%+,P55&
M22< "EKRGXF^--WF>'].EXZ7<JG_ ,A@_P _R]:VH495I\L3.K55./,SGO'O
MB^3Q-J0L[)F.G0/B-1_RV?INQ_(?XUS=M)J&AW5IJ,(>"3)>&3L=I*D?F""/
M\:]%^&7@O=Y?B#48N.MI$P_\B$?R_/TK1T/PW:^)_APEG/A)5GG:";',;[V_
M0]"/_K5ZWUBE17LXKW59/YW/-]C4J/G;U>J^5CJ/"GB6V\3Z.EW%A)TPMQ#G
M[C?X'L?\*W:^=]+U'5/ GB=_,C*R1-Y=Q 3Q(G^>0?I7ONF:E:ZOIT%_9R;X
M)EW*>X]0?0@\&O.Q>&]E+FC\+V.W#U_:*TMT6Z***Y#I.4^(O_(H3?\ 7>'_
M -&+75URGQ%_Y%";_KO#_P"C%KJZVE_"CZO]#-?Q'Z+]0KA/BCKXTSP^-.A?
M%S?Y4XZK&/O'\>!^)KNF944LQ 51DD]A7SSXAU*X\8^,&:V!?SI!!:H>R9PO
MTSR3]36^!H\]3F>RU,<74Y(<JW9UOPD\/^9<3Z[.GRQYAM\C^(_>;\!Q^)KU
MJJ&BZ5#HFC6NG0?<@0+G^\>I/XDD_C5^L<36]K4<C6A3]G!1,3QA_P B=K'_
M %Z2?RJWH/\ R+VF?]>D7_H KF]7T;QEJ<-[9_VGI8LKC>@4QMN"'H,XZXJ?
M2-,\8V+V4%QJ6F/8P;$=$B;>4'& <=<53@O9VYEO<GF?/?E9UM%%%<QN%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3D?D!7+>#/A[I>H->76H22W"6UY);I"/E5MAZL1SSZ#%>LURG@/_ )!^K?\
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M-23OIR2J9P ^]]W3./YUO4=)P2BW=>7GZF4/:*3;6_G_ , W****YS8****
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M\K[H9 3F)NNTGU]#W_ UO^&_%<OB7Q3X6CNU/VRS^U++(!Q(&B^5OK\IS_\
M7KU+4-/M=4L)K*\B66WE7:RG^?L?>O!/$/AW4O!OB",6\DN"3):7,?#,!UZ=
MQW_P->O0JQQ,.2?Q).S^5CS:M-T)<\?A=OS/H2BO!['XH>)K/ EN(;M1VGB'
M\UP:Z:Q^,<9PNH:2R^KV\N?_ !TX_G7+/+ZT=E<Z(XRD]W8]2HKDK#XD^&+[
M -ZULY_AN(ROZC(_6NDM-1LM03=9WEO<+C.89 _\JYITIP^)6-XU(2^%EFN4
MN/\ DJ=G_P!@I_\ T975UREQ_P E3L_^P4__ *,JJ.[]&*KLO5'5T4$@ DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \Z^)G@V[U^XL=5T6Y2+6;,82,R!&D4'*[3V8
M'..W)KS$^'_B)J&LWTKZ;>K=ZC%]GNIFC6-73Y<@MP #L&<=?QKI_B>FKO\
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M=YMC)OSCC&3CK71445,Y<SO:PXQY5:X4445)04444 %%%% !1110 5RNO?\
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MJS10!6^U2_\ /K)^8H^U2_\ /K)^8JS10!6^U2_\^LGYBC[5+_SZR?F*LT4
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MNF<'!VD8QDI*Z"O,_B'X^-EYFBZ1+_I!&VXN$/\ J_\ 94_WO4]OKTD^('Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2^)A1115$A1110 4444 %%%% !67?_\ (>TG_MM_Z"*U*R[_ /Y#VD_]MO\
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M&+75UM+^%'U?Z&:_B/T7ZA1116)H%%%% !1110 4444 %%%% !1110 4444
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M7ZH:W_R!;O\ W*PQ7\"?H_R-:/\ %CZHM6O_ !Z0_P#7-?Y5+45K_P >D/\
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M>/\ ^O75T5ZCR?!O['XO_,X5F&(_F_!'(GP?<<XNH_;Y33#X1O,<3P$^Y/\
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M ,_4W_?5'V1_^?J;_OJK5% %7[(__/U-_P!]4?9'_P"?J;_OJK5% %7[(_\
MS]3?]]4?9'_Y^IO^^JM44 5?LC_\_4W_ 'U1]D?_ )^IO^^JM44 5?LC_P#/
MU-_WU1]D?_GZF_[ZJU10!5^R/_S]3?\ ?5'V1_\ GZF_[ZJU10!5^R/_ ,_4
MW_?5'V1_^?J;_OJK5% %7[(__/U-_P!]4?9'_P"?J;_OJK5% %7[(_\ S]3?
M]]4?9'_Y^IO^^JM44 5?LC_\_4W_ 'U1]D?_ )^IO^^JM44 5?LC_P#/U-_W
MU1]D?_GZF_[ZJU10!5^R/_S]3?\ ?5.2V97#&XE;!Z$\&K%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'GWCKPAJNK>+?#VMZ,L)GLY )C,^U556WJ3W(^\./45
MRWC;PKXMTGQ-JM_X9CGEL=90K<) H8C(PP8'IDY(8=,GFMWXF^*M:M-8TSPO
MX?D\F^OPK-*" V&8JH!/3D')Z\5S'A.Y\2Z+XJ\46%]K$MS>6.D33 RSO-%Y
M@\ME.&Z\'&<=S75#F44]#CJ<KDUKZGH7PQ\.7WAGP>MIJ/RW,TS3M%NSY0(
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MS>[_ ,C#$XR5;W5I'L96O_\ 'A'_ -=T_G6K65K_ /QX1_\ 7=/YUJUTT_\
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M]$_YB/\ U_2_TKFJ_P :G\_R-H?PY_(U****Z3$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVV[AB\7[;]U12]FNZO?\5IV[[GG_ (?\8QW=W'I>FW-I+/.[NJO%*,G!8\D
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MMH_XE^9M1WEZ,U****Z3$**** "N9O\ 1+.;6X8$4PK+&SML/<'T-=-65/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M5S'B/6]H:PMFY/$KCM_LC^M<V*Q4,-3=2?\ PYM0H2K3Y(E/Q#K?VMS:6S?N
M%/S,/XS_ (5R5GI\_C#5CIMJ[)IL!!O+A>_^PON<?Y[HT=WKFJ+H>EG;*PS<
MW':"/O\ C_GZ>I:-I%IH6F16%E'MBC')/5F[L?<UQY=A9RG]?Q/Q/X5V7?\
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MKB24C5G2*0G]WY>0 >W6FVNCWMJT(&K.T,9'[ORL @=NM;-%<GU*CS<^M_\
M%+_,W^LU.7ETMZ+_ ""BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N3\2Z-Y9:_MU^4G]ZH['^]764C*&4J
MP!4C!![URXS"0Q5)TY?)]F;X>O*C/FB<-H>B-J;^;*=MLAP<=6/H*[>**.")
M8HD"(HP%':LW05"VUTJ@ "ZD  [=*U:Y\KPM.C14HK5[LUQM>=2HT]D%%%%>
MD<84444 %%%% !1110 4444 %%%% !1110 50UO_ ) MW_N5?JAK?_(%N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "L+Q1XFC\-VMJ5M);Z^O9UMK.SB8*TTAYZGA0 ,DGI6[7 >,
M,Q_%'P!++S;>9>Q^PE:$;?ZXH V_#?BI]:OK_2]0TR32]7L=C36KRK*"CC*N
MCKPPX(]C725P,?[SX^3M!]R+PXJ7!'3<;C*@^^,_A7?4 %%%5VGG#D"U9@#P
M=PYH L455^T7'_/HW_?8J&[O;J&TFD2T;<J$C+9J9248N3Z#BN9I(I^(-:%A
M$;>!O])<<D?P#U^M>>7EQ=3W<6F::GG:C<G"CM&.[MZ 59U"YO&5I(;>:\NY
MGVHJ(6W,?7'05U'A+P_+H%M)<7-L9]4N>;B;<./]A?0#]?RQXN#HO,*OUO$+
M]VOACW_X'?OL>CB*BPL/J]%^^]WV_P"#V[;FKX:\.VWAO3!;0GS)W.^XG/WI
M7]?IZ#_Z];-5?M%Q_P ^C?\ ?8H^T7'_ #Z-_P!]BO=E)R=V>8DDK(M455^T
M7'_/HW_?8H^T7'_/HW_?8I#+5%5?M%Q_SZ-_WV*/M%Q_SZ-_WV* +5%5?M%Q
M_P ^C?\ ?8H^T7'_ #Z-_P!]B@"U157[1<?\^C?]]BC[1<?\^C?]]B@"U157
M[1<?\^C?]]BC[1<?\^C?]]B@"U157[1<?\^C?]]BC[1<?\^C?]]B@"U157[1
M<?\ /HW_ 'V*/M%Q_P ^C?\ ?8H M455^T7'_/HW_?8H^T7'_/HW_?8H M45
M5^T7'_/HW_?8H^T7'_/HW_?8H M455^T7'_/HW_?8H^T7'_/HW_?8H M455^
MT7'_ #Z-_P!]BC[1<?\ /HW_ 'V* +5%5?M%Q_SZ-_WV*/M%Q_SZ-_WV* +5
M%5?M%Q_SZ-_WV*/M%Q_SZ-_WV* +5%5?M%Q_SZ-_WV*/M%Q_SZ-_WV* +5%5
M?M%Q_P ^C?\ ?8H^T7'_ #Z-_P!]B@"U157[1<?\^C?]]BC[1<?\^C?]]B@"
MU157[1<?\^C?]]BC[1<?\^C?]]B@"U157[1<?\^C?]]BC[1<?\^C?]]B@"U6
M7H_^OU+_ *^F_D*M?:+C_GT;_OL5FZ5-,LVH;;=FS<L3\PX.!Q7-5_C4_G^1
MM3_AS^7YFY157[1<?\^C?]]BC[1<?\^C?]]BNDQ+5%5?M%Q_SZ-_WV*/M%Q_
MSZ-_WV* +5%5?M%Q_P ^C?\ ?8H^T7'_ #Z-_P!]B@"U157[1<?\^C?]]BC[
M1<?\^C?]]B@"U157[1<?\^C?]]BC[1<?\^C?]]B@"U157[1<?\^C?]]BC[1<
M?\^C?]]B@"U157[1<?\ /HW_ 'V*/M%Q_P ^C?\ ?8H M455^T7'_/HW_?8H
M^T7'_/HW_?8H M455^T7'_/HW_?8H^T7'_/HW_?8H M455^T7'_/HW_?8H^T
M7'_/HW_?8H M455^T7'_ #Z-_P!]BC[1<?\ /HW_ 'V* +5%5?M%Q_SZ-_WV
M*/M%Q_SZ-_WV* +5%5?M%Q_SZ-_WV*/M%Q_SZ-_WV* +5%5?M%Q_SZ-_WV*/
MM%Q_SZ-_WV* +5%5?M%Q_P ^C?\ ?8H^T7'_ #Z-_P!]B@"U157[1<?\^C?]
M]BC[1<?\^C?]]B@"U157[1<?\^C?]]BC[1<?\^C?]]B@"U157[1<?\^C?]]B
MC[1<?\^C?]]B@"U157[1<?\ /HW_ 'V*/M%Q_P ^C?\ ?8H M455^T7'_/HW
M_?8H^T7'_/HW_?8H M455^T7'_/HW_?8H^T7'_/HW_?8H M455^T7'_/HW_?
M8H^T7'_/HW_?8H M455^T7'_ #Z-_P!]BLZ^TX7\_G2V]PK;0N$E '\JSJ2G
M&-X*[];%P46_>=D3Z%_J+O\ Z^I/YUJ5S8T"$=(+L?\ ;8?X5L12S11)&MHY
M"*%&7&>*PPBJP@H5(VMYW_0TKN$I<T'>_D7**J_:+C_GT;_OL4?:+C_GT;_O
ML5UF!:HJK]HN/^?1O^^Q1]HN/^?1O^^Q0!:HJK]HN/\ GT;_ +[%'VBX_P"?
M1O\ OL4 6J*J_:+C_GT;_OL4?:+C_GT;_OL4 6J*J_:+C_GT;_OL4?:+C_GT
M;_OL4 6J*J_:+C_GT;_OL4?:+C_GT;_OL4 6J*J_:+C_ )]&_P"^Q1]HN/\
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M !J?S_(VA_#G\C<HJK]HN/\ GT;_ +[%'VBX_P"?1O\ OL5TF):HJK]HN/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_F(_P#7]+_2M2LO1/\ F(_]?TO]*YJO\:G\_P C:'\.?R-2BBBNDQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *RI_P#D9;3_ *X/6K65/_R,MI_UP>N;
M%?#'_%'\T;4-WZ/\C5HHHKI,0HHHH *R]$_YB/\ U_2_TK4K+T3_ )B/_7]+
M_2N:K_&I_/\ (VA_#G\C4HHHKI,0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LJ?\ Y&6T_P"N#UJUE3_\C+:?]<'KFQ7PQ_Q1_-&U#=^C_(U:***Z3$**
M** "LO1/^8C_ -?TO]*U*R]$_P"8C_U_2_TKFJ_QJ?S_ "-H?PY_(U****Z3
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*G_ .1EM/\ K@]:M94__(RV
MG_7!ZYL5\,?\4?S1M0W?H_R-6BBBNDQ"BBB@ K+T3_F(_P#7]+_2M2LO1/\
MF(_]?TO]*YJO\:G\_P C:'\.?R-2BBBNDQ"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\
MGJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+
M?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#G
MBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]
M]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J
M?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E
M1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [
MSXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]
M"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]
MDM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_
M^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_
M )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_Y
MZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">
M*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBG
MY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_
MWT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0I
MOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4
M?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #
MO/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+
M_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM
M_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_
M )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJ
MG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_
M 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GB
MGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4
M .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CS
MXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"
MF_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM
M_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^
M>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSX
MO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^
M>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?
ME0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI
M_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_W
MT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1
M]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?_GBGY4 .
M\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_YZI_WT*/
M/B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG_?0IOV2W
M_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#GBGY4?9+?
M_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI^5 #O/B_
MYZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0H\^+_GJG
M_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*;]DM_P#G
MBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?9+?_ )XI
M^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^+_GJG_?0
MH\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\ GJG_ 'T*
M;]DM_P#GBGY4?9+?_GBGY4 .\^+_ )ZI_P!]"CSXO^>J?]]"F_9+?_GBGY4?
M9+?_ )XI^5 #O/B_YZI_WT*//B_YZI_WT*;]DM_^>*?E1]DM_P#GBGY4 .\^
M+_GJG_?0H\^+_GJG_?0IOV2W_P">*?E1]DM_^>*?E0 [SXO^>J?]]"CSXO\
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MSXO^>J?]]"E$T1( D0D]@PIGV2W_ .>*?E2K;0*P98D!'0@4 2T444 %%%%
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M%W$$EF/0*H!+$^@!- %ZBL;0O%FA^)'GCTJ_6::#_6PO&T4B>Y1P& ]\5LT
M%%%% !116?K.MZ?X?TU[_4[@06ZD*#@LS,> JJ.68]@.: -"BL?P[XHTGQ3:
M2W&ESL_DR&*:.2-HY(F]&5@"*V* "BBB@ HHK&\2>)+3PSIPN+A))[B5O+M;
M.!=TMS(>B(O<^_84 ;-%9V@:O#K_ (?T_5X%V1WENDP0G)3<,E2?4'C\*T:
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M.WM8$+RRR' 4"@"S16!X=\9Z)XHFN8--N)/M%N 9()X7BD"GHVU@"0?6M^@
MHHHH ***S]:UJP\/Z5-J.HS>5;Q\<#+.QZ*HZEB> !0!H45B^%?$*^)]"34A
M:2V<GFRPRVLW^LA='*%6]#QG'O6U0 4444 %%%4=3UG3=&6W;4KV&U6YF6"$
MRM@/(>BC\J +U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME;=EWP#CT' XH X^\\"Z;J<$/B;P?>BTUJ21KV#4=Q=;D2?,8Y<]8R, #^'
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M5+:TA'RHO))[DGJ2?4UHT44 %%%% !69J_A[2]>DL7U.T2Y^Q3BX@5\[0X!
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M&I%544*H"J!@ #  I:* "BBB@ HHHH AGM;>Z"BXMXIMAW+YB!MI]1FIJ**
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M*LR)(N0'4Y4X]JMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]>F0PQ6\2Q0QI'&HPJ(H  ]@*< 0H!)) ZGO2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 445'<3Q6MM+<3R+'#$A>1V. J@9))] * )**H:9K>EZTLC:9?V]VL1 <PN
M&VYZ9Q]*OT-6!.^P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M82K1CS36A<HHHKM.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \_^+_\
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M/A__ )+-XO\ ^O>V_P#1:4^1:^ER?:/3UL>@45S.K^.=+TK4Y-,2WU#4+^(
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M7%=7L7:***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A7RF?4YRK1<5?3]3WLKG%4W=]2K15K^S+__ )\;G_OTW^%']F7_ /SXW/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*7M'IY#]DM?,\M_X1#7?^%#?\(U]A_XF_P#S[^:G_/UYGWMVW[O/7]:Y/3_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^5'E1_\ /-?RH\J/_GFOY4 ']IVWJWY4?VG;>K?E1Y4?_/-?RH\J/_GFOY4
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ME#'T!8 $_C4\K[%<R[FW<W]G9R01W5W! \[B.%99 ID8_P *@]3ST%6*\_\
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M_P"0F?\ =_I5RJ8_Y"9_W?Z5!9<HHK!\::G<Z-X.U/4+.7RKF&(&-]H;:Q8
M<'([TTKNPF[*YO45P>F:/XVU#2K.];QSY37$"2F/^R86V%E!QG(SC/7 KHM;
M/B"'1X8M%6UN=08K')-<G8JC',FT=>>WOWZ4W&SM<2DVKV-JBO-];U/Q?X(B
MM=5U/6+;5M/:98[F$6JPM'G^Z1UZ=_RKTBAQMJ"E?0CG_P"/>3_=/\JCLO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJGVN7_GU?]?\*/M<O_/J_P"O^% %NBJGVN7_ )]7_7_"C[7+_P ^K_K_ (4
M6Z*J?:Y?^?5_U_PH^UR_\^K_ *_X4 6Z*J?:Y?\ GU?]?\*/M<O_ #ZO^O\
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M?^?5_P!?\* +=%5/M<O_ #ZO^O\ A1]KE_Y]7_7_  H MTU_]6WT-5OM<O\
MSZO^O^%(UU*5(^S.,CKS_A0 ZP_X]S_O&K59UM.\<6U8&<9ZC_\ 54WVN7_G
MU?\ 7_"@"W153[7+_P ^K_K_ (4?:Y?^?5_U_P * +=%5/M<O_/J_P"O^%'V
MN7_GU?\ 7_"@!!_R$S_N_P!*N5FB=_MAD\EMV/N=ZG^UR_\ /J_Z_P"% %NB
MJGVN7_GU?]?\*/M<O_/J_P"O^% %NBJGVN7_ )]7_7_"C[7+_P ^K_K_ (4
M)9?ZZX_WO\:N5FV\[QO*5A9RQY [=:G^UR_\^K_K_A0!;HJI]KE_Y]7_ %_P
MH^UR_P#/J_Z_X4 6Z*J?:Y?^?5_U_P */M<O_/J_Z_X4 .OO^/8_45-%_J4_
MW15&YN))(=K0,@SU/_ZJD2ZE$:@6SD #GGG]*0%VBJGVN7_GU?\ 7_"C[7+_
M ,^K_K_A3 MT54^UR_\ /J_Z_P"%'VN7_GU?]?\ "@"W5,?\A,_[O]*7[7+_
M ,^K_K_A4 G?[89/);=C[G>@#2HJI]KE_P"?5_U_PH^UR_\ /J_Z_P"% %NB
MJGVN7_GU?]?\*/M<O_/J_P"O^% %NBJGVN7_ )]7_7_"C[7+_P ^K_K_ (4
M)<_\?D'U_K5RLV6=WN(W,+*5Z*>]3_:Y?^?5_P!?\* +=%5/M<O_ #ZO^O\
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M_P#/J_Z_X4?:Y?\ GU?]?\* $O\ [L?^]5RLVYG>0)NA9,'OWJ?[7+_SZO\
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M_M_J/YTGVN7_ )]7_7_"HO-:2]@+1%,,!@_6@9LT444@"BBB@ HHHH ****
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M_E5?3/\ CS'^\:L3_P#'O)_NG^55],_X\Q_O&D,N453U/5M/T:T-WJ5Y#:P
MXWRMC)]!ZGV%9>D>./#6O7?V73=6AFN#G$9#(S8] P&?PI\K:O83DD[-G045
MA:]XQT#PQ-##K%_]FDF4M&/)D?(!Q_"IK(_X6QX(_P"@W_Y*S?\ Q%-0D]4B
M74@G9L[2J _Y#+?[O]*O*P=%9>C#(XQ5$?\ (9;_ '?Z5)9?HHJ"\O+;3[62
MZO+B.WMXQEY)6"JH]R: )Z*YO3O'WA;5K];*RUF"2X9MJHRLFX^@+  _A6[>
MWMKIUG)=WMQ';V\0R\DC!54?6FXM:-"4DU=,GHKG](\<>&M=O/LFG:O!-<'.
M(R&0MCTW 9_"N@H::W!-/5$5S_QZS?[A_E4.F_\ 'DGU/\ZFN?\ CUF_W#_*
MH=-_X\D^I_G2&6Z**Q=4\6Z!HUW%:7^J017,KA%A4EWR>F54$CKU/%-)O83:
M6YM45#>7<%A8W%Y<OY=O;QM+*^"=JJ,DX')X':N1_P"%L>"/^@W_ .2LW_Q%
M-1D]D)SC'=G:4V3_ %3_ .Z:R=!\4:-XGBGDT>\^TI 0LA\ITP3T^\!GIVK6
MD_U3_P"Z:336C&FFKHJ:7_QZ'_>-7:I:7_QZ'_>-6I98X8FEE=8XT&6=S@*/
M4FD,?161I?BC1-;O[FRTS4(KJ>V :41 E0#QPV-I_ FM5W2.-I)&5$4$LS'
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M%<W,%G;27-S-'#!&NYY)&"JH]236!IOC_P +:OJ*Z?8ZQ#)=,=JH4=-Q]%+
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M_P"0O/\ [O\ A5^J$'_(7G_W?\*OTAA15/5=5LM$TR;4=1G$%I#CS)"I;&2
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M^=6* "BBB@ JA>?\A"V^O]:OU0O/^0A;?7^M %^BBB@ HHHH **** "BBB@
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M6_T^_P!-T+0X89=8U(ML:;.R&,#EVQU[_D?H<?XJW4&I6&G^%[:19=1U"\C
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M4+WT.JU/_CS/^\*L0?\ 'O'_ +H_E5?4_P#CS/\ O"K$'_'O'_NC^59&I)7
M?$RV='T'5Y[9KK2=-O/-OH%&?E. 'QW"X/'O7?UY]XJG@F^).@Z=K3JNBM;O
M-$DIQ%-<@D /G@X&T@'N1ZU=/XC.K\-BGX@U32?%FN^%%\-W$5SJ$=ZMR\\(
M^:"V7[X?NN<C@]>G>O3:\P^)FF:1H=A%KNE;-/\ $*S)]E-IA&N"6 8%1]X8
MR>G;'?%>E6[2O:Q/,@25D!=1_"V.13G;E30H7YFGN2U0'_(9;_=_I5^J _Y#
M+?[O]*S-2_7GWQ<T?39/!&IZJ]E U_&L*I<E!O4>:HP#]"?SKT&N+^+'_),M
M7_[8_P#HY*NF_?1G55X/T.HTG_D#6/\ U[Q_^@BN(^%T$.JZ?JWB.YC26[U.
M]ER[C)$0P G/;KQZ8]*[?2?^0-8_]>\?_H(KB/A?/%I5EJ_ANY=8KK3+V0E'
M8 F(X(?Z=>?IZTU\,K"?Q1N.\#*-(\;^+?#L("V<,L=U!&O2/S%RP [#E?RK
MT&O/_ Q&K^-/%GB.$[K.>:.UMY!TD$:X8CU'"_G7H%*I\0Z7P_>4+S_D(6WU
M_K4U_IUGJEHUI?VT5S;L06CE7<IP<CBH;S_D(6WU_K5^H-#SGX>6EO8>./&]
MK:0I#!%/;JD<8PJC$G %2^.5&K^-_"7AV8!K.:66ZGC;[LGEKE01W'#?G2^!
M_P#DH7CS_KXM_P"4E)XZ9='\:>$_$<QVV<,TEK<2'I'YBX4GVY;\JW_Y>?+]
M#G_Y=_/]1OQ1@ATJPTGQ';1I%=Z9>Q8=!@F(Y!3CMTX],^M>AUYY\4)HM6LM
M(\-VKI+=:G>QG8C9Q$,EGX[=.?3/I7H=1+X4:1^.5O(H:3_J'_WOZ5QOQ<T?
M39/!&IZJ]E U_&L*I<E!O4>:HP#]"?SKLM)_U#_[W]*YKXL?\DRU?_MC_P"C
MDI4W[Z"JKP?H=1I/_(&L?^O>/_T$5YY\8=#TN+PG<ZK'86ZW[W$0:Y"#>><=
M?H*]#TG_ ) UC_U[Q_\ H(KB_C+_ ,D]F_Z^(OYU5-_O$*JDZ;]#T"J&K?ZA
M/][^E7ZH:M_J$_WOZ5D:E^BBB@#E?'NLW6FZ-#8Z8V-5U29;.U(_@+?>?\!W
M[$BMC0=$M/#VBVVF6:@10K@MC!=N['W)YKD]2(U#XU:/:OS'IVG27(!_ON2O
M\MIKOJN6D4C..LF_D%4(_P#D,R_[O]!5^J$?_(9E_P!W^@J#0OUEZCI^B)=I
MKFIPV:36L>Q;NX( C4GU/ YZ'W/J:U*R+S5-"NK^70+Z>SEN&C5WM+@ AU)X
MX;ANF<?2FKBE:VIQ,]Q9>)_BEH=]X< F2P24ZA?PK^[*D?*A;HQZ^OWO8X]-
MKRSQ5::;X6\2:$_A;9:ZK<7R13V-JV$FA/WMZ X&..<#J3VX]3JZFRL9T]VG
MN1S_ /'O)_NG^55],_X\Q_O&K$__ ![R?[I_E5?3/^/,?[QK,U)[HRBTF-O@
MS"-O+S_>QQ^M<!\)QIC^"7DD\EK]YI3J1EP7W;S]_/.-N.OO7HE<9=^&? .M
M2S:W<6VG3>6[>=<+/M3<#SOVL%)X[U<6K-,SFGS)HR?AS?6<7BKQ1HNE3K+I
M,4R7%KL.43=]]5]LX QQQ[UZ37G?PXA34-;\1>);>#R;"\F2WL@$V Q1#;D#
ML.%_(UZ)3J_$*C\!0U3[D/\ O5?JAJGW(?\ >J_69J<7\4=-O-2\'D6D+3K;
MW$=Q<6ZG!FB7.Y1^A_"N=\7:]X>\7>$;+3_#SQ3:K/<1)801KMEMF# L2.J
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MK,:?;O"H$;OG<VWUZMSWR#GFM[IW?D<]FN5>9Z95#5/N0_[U7ZH:I]R'_>K
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M&[KL+$I_XYMKG2\WQ1U950/%X1L9<L6!!U"0=AZ(/\\_=])5510J@*H&  ,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_#6@W0NM-TB"&X7.V5BSLN?0L3C\*FOO"6@ZEJ,]_?:;%<7,\(@D:4E@4!!
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M ]0"Q)%;M%%)MO<:26B(KG_CUF_W#_*H=-_X\D^I_G4US_QZS?[A_E4.F_\
M'DGU/\Z0RW7'S?"SP9<3R3RZ-NDD8NQ^U3#))R?XZ["BFI-;,EQC+=&3H/AG
M1_#,$T&CV?V:.9@[CS7?) Q_$34SZ)ITFNQZV]OG48X?LZ3;VXCR3C;G'4GG
M&:T**+O<?*K6L%-D_P!4_P#NFG4V3_5/_NFD,J:7_P >A_WC3-9T33O$&G-8
M:I;_ &BU9@Q3>R<CIRI!I^E_\>A_WC5VA.VPFD]&<7_PJ?P1_P! 3_R:F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'GH:EH **** "BFK(C.R*ZEE^\ >1]:=0 4444 %%%% !1110 4444 %%%%
M!1110 45S=[X^\+Z=K(TBYU>);\N(_*5'?#'H"5! /L3724VFMQ)I[!1112&
M%%%% !1110 4444 %%%% !1169I?B#2]9NK^UT^Z\Z;3YC!<KY;+Y;@D8R0
M>5/(R*+!<TZ*** "BBB@ HHHH **** "BBN>USQSX:\.7BV>JZK%;W# 'RPC
MN0#TSM!Q^--)O83:6K.AHID4J3PI+&=R.H93C&0>12^8GF>7O7?C.W/./7%(
M8ZBBB@ HHHH **** "BBB@ HKGM<\<^&O#EXMGJNJQ6]PP!\L([D ],[0<?C
M6]%*D\*2QG<CJ&4XQD'D4VFM1)IZ(?1112&%%%5S?V8OQ8&[@%X4WBW\P>85
M]=N<X]Z +%%%% !1110 4444 %%%5[N_L[!8VO+N"V$CA$,T@3<QZ 9/)]J
M+%%%% !112,RHI9F"J.22< 4 +12*P90RD%2,@CH:S;?Q!I=UK]WH<-UNU*T
M19)X?+8;%(!!W$;3PPZ'O185S3HHHH&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG$[Z?;>:D1[Y;(_3-94/]J>%_@(?/\R._AL6'(PT>]SM^A56'TQ67X)\7?\
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MT)6*"T#R0[0XQ(-WRGG@<]#7ML;^9&KX*[@#AA@CZUYM\.?^2@?$'_K]B_\
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M32+'%&I=W<X"@<DD]A6#X-\1Z3XAT.(Z7=_:/LL<<4W[MTVOM''S 9_"N?\
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MZU\JVU&ZCDM7\Q6\Q09,G )(^\.N.M=Q10YMW\Q*"5O(*\Z\0:%XETGX@_\
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MK&V%U:W\(W/:7L7ER@>N,D'MW[U+XB\;:-X9N8;2\>>6]F7=':VT)DD9>1G
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MI6=KCYE>QN45S5KXWTR\MO$-S#!=F'0C(MP^Q<2% Q;R_FY^[WQU%9ES\5-
MBMX9+6#4=0D>!+B2*RM_-:!64,!(<[0<'D9.*?)+L+GCW.XHK(\-^)=,\5Z4
M-1TN8O#N*,KC:R,.S#L>0?QK7I-6T8TT]4%%%%(84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M03]T],]*?,O:7_K8GE?L[6_JYD^-XDU?XK^#]&O1NT_;)<E'^Y(X#$ CH?N
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MXR7QIK3:S)"=!.?L 79G[PVXQ\WW<YW=^E1*.KU-(RT6AUM>:?##_D:O'O\
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MP/\ EG(/7V(_H>U4Y14E]XE&3B_N.;G\<_:-*DTQ_A[XF%G)"8#$-/(4(1C
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MSI&J:,\!U'2+@SQ07'$<V=I(/O\ */UY%=!H%UJ]YIOG:WIT>GW9<_N(YA*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKX)VHHR3@<G@'I46E:I9:UID&HZ?-YUI."8Y-I7< 2.A (Y!HMU"_0N4444
M%%%% !1110 45!>WD&GV-Q>W4GEV]O$TLKX)VHHR3@<G@'I46E:I9:UID&HZ
M?-YUI."8Y-I7< 2.A (Y!HMU"_0N5R'@[PK?>'M:\37MW+;O'JM\US (F8E5
M+.<-D#!^8=,UU]%--I6$TFTPHHJ"]O(-/L;B]NI/+M[>)I97P3M11DG Y/ /
M2D,GHJGI6J66M:9!J.GS>=:3@F.3:5W $CH0".0:N4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !13?,3S/+WKOQG;GG'KBL[6_$&E^'+6&ZU:Z^SPS
M3"!&\MGRY!(&%!/0'GI0E<3:6YIT444#"BBB@ HHHH **S-+\0:7K-U?VNGW
M7G3:?,8+E?+9?+<$C&2 #RIY&16G0U8$[[!1110 4444 %%%% !1110 445F
M:7X@TO6;J_M=/NO.FT^8P7*^6R^6X)&,D 'E3R,BBP7-.BBB@ HHHH **:\B
M(5WNJ[CA<G&3Z4Z@ HHHH **** "BBB@ HJN;^S%^+ W< O"F\6_F#S"OKMS
MG'O5B@ HHK,U+Q!I>DZAI]A?77E7.HN8[5/+9O,88R,@$#[PZXZT)7V!NVYI
MT45!>WD&GV-Q>W4GEV]O$TLKX)VHHR3@<G@'I0!/15/2M4LM:TR#4=/F\ZTG
M!,<FTKN )'0@$<@U<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]XVN[:0203ZF98G7HRLTA!_(BNBUSXC:+HNJ-I:Q7VI7Z#,EOIT'FM&/]KD
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M##(5_+B&[Z@$X^M/DC=W[$\\N56ZO_,[C1_%=CJWA^76Y(;G3K.)F#_;T$;
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MZB\N^A$;G$).0,GCYNOL:Y?P5\0=(T/P'I-CY&H:A=P0DSQ6%N93""[$;CD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&H:](SW,5ORD2G=A1GJ?G;].O6L+PUI_Q$\):8WAVTTC3[RVCD?[-J$MT%1
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MS61DCN%(\D)AUY^;.["L.G0BJ=.S:9*J<R31T>N>(](\-6BW6L7T=K$[;5+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:Z?;-<WMS#;0+C=+-($49Z9)XJ9'61%=&#*PR&!R"* %HHHH **** "BBB@
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M') &T$\G' &37#?#33;67Q]XXU*2(/=0ZG+%$[#.P-)(6QZ$X'Y5#\4-0/\
MPGGA>PN-/NM1LH@]VUE;1>8T[C.!M[XV\^Q-5R1YN5$\\N7F9T%I\6?#\]Q"
MEQ;:I86\[!8;N\M=D,A/3# G\S74:[K^F^&]+?4=4N!#;J< XR6)Z!0.IKSS
MQ3XNN/$?AC4-);P)XF#7$)6)GL#M1^J-^# &L_Q)'?P>$_ &LZS;3FUTN:/^
MTHI(SO490*SJ>>-IZ]2WO1[-.W07M&D^IT5U\8-*LI8([CP_XCB:X_U >R5?
M.]-@+@GMTKH+CQG96G@MO%-U8ZA!:+C=;RPA9US)Y?*EL=3GKT_*N.^(VN:5
MXKTS2]%\/WL.H:K<WD<MN;5@Y@ SEV(^[@=C@UO?%[_DEVL_]L/_ $='1RK3
M3<?-+WG>]BU_PL31I/$ZZ#9Q7M[<><(9)K:(-#"_HS$CISTST-3^(_'>C>&K
MN*RN/M-WJ$HW)9V47FRD>N,@#\34_@K3;72_!FDP6D0C1K6.5R!R[LH+,?4D
MFO+/!'BN6SU;Q!K$GAG6M6OKR]=6N;.U,BQH.D>>QY''H%I**=[= <VK7>YZ
MAX;\;:1XHFGMK3[1;WL W2V=W%Y<J#UQ^(Z'^=4M;^(VCZ+JTFEI;:CJ5]$
M9H=.M_-,6?[W('I^=<FVJ:CKOQ.\.:M:>%=<TX0B2WO)KNS9%:-A\N3TP"6Z
M^U79-.\2^!/%&M:QI>E+K>E:I-]HFCB?;<0MDD@#^(?,> #VZ4^2-PYY6.VT
M#Q-IGB339+^QDD$4+F.83QF-HF R0V?0$5S3_%OP_P";(8+/5[FSB8J]_!9E
MH%QU^;.?T[UJZ3KFD^/_  QJ$=@\L FCDMKF-UVRPLRD'(]<'@@]O8XY#2=8
MU_X8Z1'I6OZ$UWHUL6":EIYW84L3ET/3D]3C\:2BM=->PW)Z:Z=SI_&]SX<U
M'X?2ZGJ\5Q=Z.1%.OV8;9#N8!64,5_O=^V:F7Q7H^C'PUI26MW%!JD*)8MM7
M8@"KM1B6R#@J.,]:R/B9?6FI_!S4+VPE66TGCMWB=1@%?.C[=OIVJCXUTN6\
M^$>DZC:C%YI,%M>Q,.H"H-WY [O^ T1BFDGW%*33;78]#U;4[?1M(N]2NRPM
M[6)I7VC)( S@>YZ"JUAXALKWPU#K\F^SL9(?/S=84HG8G!(Y'/7N*X;Q_K!\
M2>#_  ]IE@Q63Q)/", _=CX9OR)7/XU!\7Y!9:-X<T2&WF>PGO$CDM[=<O(B
M8 C4=R<\#U HC"]D^HY5+7:V1KK\7O#I;S#:ZLM@6VC4&LS]G/..N<_I7=03
MQ75O'<02+)#*H='0Y#*1D$&O.I_'/VC2I-,?X>^)A9R0F Q#3R%"$8P!Z8K4
M^%,6I6W@"RM=4MKBWG@>1%CN(V1PFXD<-SCGCVHE%)7"$VW;<Z'Q'KUKX8T&
MYUB]29[>WV;UA4%SN8*, D#JP[US>I_%;P[IMS+&([^\@A?RYKNTM]\$3>A?
M(S^&:7XO?\DNUG_MA_Z.CJPEE;1_"(VR01K"=%)**N!DPY)^I)SGUI14;)L)
M.7,TNP:E\2M L4A-K]KU626)9_*TZ#S61#R"W("_0G/M6OX:\3Z9XKTO^T-+
ME9HPQ1T==KQL.S#\JYOX.6MO!\-=-FBA1);AI6F=5P7(E=02>^  /PK.^&B+
M!XW\?6\2A(4OXRJ#HI+2YQ3<8ZI= C*6C?4Z;Q%X]T7PW>I83FXN]0<;EL[*
M+S9<>XX _$T>'?'FB^)+Q["W-Q:ZA&-S6=[%Y4N/IR#^!KF/A%"E])XDU^Y4
M-J5QJ4D+L_+(@ 8*/09;'_ 1Z4?%V)+"7PWK]LH74K?4XX4*CYG0@L5/J,KC
M'^T?6GR1OR=1<\N7GZ'9:?XJL=0\4:EX>2&YBOK!%>3S54*ZG&"A#$D<CJ!U
MI?$GBBR\,0V3W<5Q.]Y<K;0Q6ZJSL[=."0,?CW%<CXN7_A'OBAX:\1J-MM?9
MTV[/09;[A/YY_P" 5)J2GQ'\:-.LC\UIH%J;J0'IYSXVCZXV'\#245H^EAN;
MU76Y>\7+X:B\9^%I=7LKJ;4YIS'8R0D;$964C?\ ,. 6!& >];>M^*]+\/:E
MIUGJ4C0_;EF9)S@1QB)0S;B3D9!XP#DUR'Q&_P"2@?#[_K]E_P#0H:B^)]M!
M>>-_ 5M<Q)+!)>2J\;C*L-T/!'<4U%/EOYB<FN:WE^AI_P#"W/#J7<*36^J6
M]I.VV*^FM"D#^X).<?A79ZCJ5GI6G3:A?7"0VL*[GD;H!_6N/^+\$3?"_5"4
M4F)H6CX^Z?-1>/P)'XUD>/[*]U+X.Z9+ CS"WCMKFYC7J\0C^;\B0?PI*,96
MMH-RE&Z>I=N_C'HMG;QW4FB^(/L<IQ#=&S58I?\ =9G&:ZSPYX@C\2:=)>1:
M?J%DJ2F+R[Z$1N< '(&3Q\W7V-<1XW\8>&=;^'LMAIES!>W5^B16EC" TJOD
M8R@Y7'OCIQ7?Z%;7%EX?TVUNVWW,-K%'*WJX0 G\P:4DE':P1;<K7N2ZIJEE
MHVG3:AJ-PMO:0@&21@2!DX' Y/)%<6?B]X?1HY);+6(K*0@"^DLR(>??.?R%
M=7XBU;2]$T2XOM8*?8H\;E9-^\YX 7N<UP?B77O$GB#P9JS1>$UM-)>RD<S:
MA<A9"@0MN$2C((QD9/7%$(I[H<Y-;,[#Q!XPTWPY86%_=+/-9WTJ11SVX5D7
M<,JS$L/E(R<C/2MZ21(8GED8*B*69CT '4UY?I^C/XF^ %O98\RX%HSP>N^-
MR5 ^NW;^-,U3Q?)>? N"\B8M?7\2Z< #\S2D['_$A6/XBGR=%WL+VG5]KG;:
M'XPTS7/#3^(%$UGIR%P9+P*G"\%N">,Y'X5@+\7O#I;S#:ZLM@6VC4&LS]G/
M..N<_I7,_$6T_P"$>\&>$?#"1336KW$:7,5NN7G*X+*H[EF8D#UQ6W/XY^T:
M5)IC_#WQ,+.2$P&(:>0H0C& /3%-06]B7-WM<[N\U:UL]"N-9W&:SAMFNMT.
M&+HJEOEYP<@<<URUQ\4]!BFLH+>#4+VXNH8IO)M80[0K( 5\PE@ <,,\G&:Q
MO#D6I6WP'U2UU2VN+>>"PO$6.XC9'";'(X;G'/'M6M\(M-M;'X>:?/!$%FN]
MTL\F/F<[B!D^@  %+EBDV^Y7-*3278T-=^(.BZ%J3:8RWE[J*+N>UL;<RNH(
M!&>@Z'UJ;PQXWTCQ7+<6]E]H@O+?F:TNXO+E0=,XR1U]#Q^-4=3\9Q6WB"YT
MCP_H<NL:P@4W7DE8HX_022GO[<UR5E+JY^.^G2ZM8VMC=7&FONBMI?,#(-^"
MQQU^4#CLHH4$T)S:>YWWB/QGI7AJ>"UN1<W-]<<PV=G%YLSCU"_AZUS8^,.E
M&^DL1X>\2&[B&9(/L2^8@]UWY'4?G5.ZNK;PS\;KC4M=D6&SU&P$=C=2\1QL
MNP,N[H.AY_VAZU+%>VOB7XS6%_H4BW%KIME)'?7</,;E@P5-W1L$@\9_2FHQ
MMJN@G.3>CZG;>(?$NE>%].^VZK<B&,G:B@;GD;T51U-8>D_$S1-3U.#3IK?4
M=,N+DXMQJ%MY0F/^R<D?GBN.\3ZRT?QJB:XT>_U:+2[(-;VMG!YK*[8)D*^@
MW=?4+2>._$=_XL\-M8VW@GQ-#>QRI-;3R6+ 1NK#)R.1\NX4*FM+]0=1W=NA
M[)7">-#_ &SXP\,^&#S;22M?WB]F2(913Z@MG]*[2RDEEL;>2=2LSQ*SJ1@A
MB.1CMS7$H?,^/#B0?ZKP_P#N^W_+8?XFHANV:3V2.TU"]ATW3;J^N#B&VB:5
MS_LJ,G^5>(^$6N]#\3^'?%%Z[!?%$EQ%<Y/"LTF8_P SM_#-=E\9=6DL_!R:
M7;!WNM4G6!4C7+%!\S8'?HHQ_M5R7C/Q)9ZIX$M]*L/#GB.UFTWRI+6>>Q")
M'Y8QDD,<#;G\<5I3B[>IE5DN;T/5_&?_ "(WB#_L&W/_ **:O.O OPP\+:[X
M)TS4KZSF:[GC9G=;AUY#,.@..PKL;_5TU_X1:AJJ8_TG1IW8#^%O*;</P.1^
M%<#X<NOB%I?PRMM1TEM&ETR"!Y(XBDC7&T,<\8VDCD]>@H@FHV3MJ.;BY)M7
MT-SPZMWX.^*/_")1:A<WFD7MF;J".X?>UNPW< ^GR-^8^M<UKM[)H?QPU'7P
MV+>TN;.&Y&?^64L 5F_# _$BNM^&6D+JF?'&H:J=3U2^B\O.S8ML!PR >O'7
MCCZY.7=:*/$7Q!^(>E$ O<6%N(\]G$:%#_WT!5)KF=^VI+3<5;OH>A^+M;7P
MYX4U+521O@A/E@]W/RJ/^^B*\Y^"-E+IVI^*+6<L9T%H9=QR0Y60L#]"2*C3
M5G\;Z7X(\/29+R2F74U(P0MO\I#?[Q'YXK9^'/\ R4#X@_\ 7[%_Z%-4VY8-
M?UN._--/^MC9^*.K2:9X&NX;?/VO4&6Q@4=2TG!_\=W5B?#: ^%O%&O^#)'+
M)%Y=[:DG[RLJA\?CM'X&L_X@:]&?B;H-F]E?7UKHX^VW$-E#YK^8?N<9'3"'
M/^U6=K7C.W?XB^'?$<.D:QIT:$V5Y)?VOE(T;GC!!.2-S'\!3C%\MNX2DN>_
M8]"^)&K3Z3X(O6M"1=W16T@P<'=(=O'OC<?PK8TS18M*\,V^C6LC0K#;>0LL
M?# XP7'OG)^M<M\33OE\(PL,Q2>(+;?^9[_B:[VLGI%&JUDSQM-!DT#XY>'(
MY=6O]2>>WGE,M[)O9?W<HP/0<5[)7FFO_P#)>_"?_7E-_P"@35Z73J.]GY"I
MJUTNY%<1-/:RPK*\32(5$B?>0D8R/<5Y F@R:!\<O#D<NK7^I//;SRF6]DWL
MO[N48'H.*]DKS37_ /DO?A/_ *\IO_0)J*;W7DQ5%L_-'H\\,=S;R03('BE4
MHZGHRD8(KB_AG/);Z9J?AV=V>31+Z2V1F/)B)RA_+/X 5W%<#X6_=_%?QS%&
M/W1%F[?[WE?_ %S2CK%HJ6DDSOJX_6OB3H>C:J^EI%?:E?Q_ZR#3H/-:/Z\@
M9]NU=)JUS)9Z-?74*[I8;>21!CJP4D?RKB?@S8V\/@*'45P]W?S2R7,IY9B'
M90"?H,_\"/K1%*SDPDW=11U7ASQ-IWBBQDNM/,P$4ABECFB*/&XZJ0>_TS6!
M??%/0+6_FL[.#4M5> XF?3K;S4C^K9 _+-:'Q NI=.\ :Y<V@*S?9R-R<$;L
M*3^ /Z4WX<Z;::;X T9+5$'GVJ7$K*.6=U#,3ZD9Q^%-*-N83<K\IH:%XITK
MQ+I<E_I$YN4CR'B"[9%;&=I4XP3V['UI/"_B>Q\6Z.-3T])DB\QHF2=0'5AU
M! )'<'KWKBXXDT?X_>38J%BU/3#-=(@PH<%OF(]?D!S_ +1]>9?!R_\ ".?$
MSQ+X<8;;>\QJ5H.@P3A@/Q./^ 4W!6=O42F[J_H=<_BBR7QA'X96*XDO6MOM
M+.BKY<:<CYCG.>G0'J*H:[\0=%T+4FTQEO+W447<]K8VYE=00",]!T/K6)\.
M%.M>(/$WBY^5O+K[+:L?^>,?&1['Y?Q6M/4_&<5MX@N=(\/Z'+K&L(%-UY)6
M*./T$DI[^W-+E7-:P<S<;W+WACQOI'BN6XM[+[1!>6_,UI=Q>7*@Z9QDCKZ'
MC\:=J_C71]"U:?3]1DD@:&P^WM*5&S9YGEA1SDMN[8[UP5E+JY^.^G2ZM8VM
MC=7&FONBMI?,#(-^"QQU^4#CLHJUXETVUU3X^:!!>1"6%=,\WRV&58JTQ&1W
M&0#^%5R1O\KBYY<OG>Q=UOQ5X9\6>!=4O=4TK5_[*LI(2VZ-8Y)"S *T?S\C
MYAUQP:Z^+5=(T?PE:ZB[_8])BM8BGF DQQD *#C))Y [U@_%[_DEVL_]L/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)!/W3TSTKN**:FU;R$X)W\SEOB-I%]KW@+4],TR#S[R;RO+CWJN<2HQY8@=
M>]8GCN(VGPABTJXN&M;V6WM[6.)1N:64;?W0V]<[2../PKT2N;\8^%?^$HL+
M407C65_8W"W-I<!0VR1>F1W'3\OPHA*S28IQNFT<M9W_ (UL]EPGPTTY+@(
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M;GYL?>^M=1X"TJ\T7P/I>FZC#Y-U!&RR1[@V"78]02#P172454IMBC!1//\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5Q'Q>_Y)=K/_ &P_]'1UV]<1
M\7O^27:S_P!L/_1T=73^-$5/@?H9VD?%?P;8>'-/@EU5VN(+6*-XDM92=P4
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M3L3JWL,]ZR::W-DT]CR>"Q\6?#*_U!M+TH:WX>NKAKCRH6(FA)QVY/0 =#G
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M9Y_WP?J*U/B-_P E ^'W_7[+_P"A0T?$;_DH'P^_Z_9?_0H:/B-_R4#X??\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J"\LK74+5[6]MH;FW?&^*:,.C8.1D'@\@'\*GHH
M;%%'#$D42+'&BA41!@*!P !V%.HHH JKIFGKJ+:BMC;"^9=AN1"OF%?3=C.*
MBGT32;F]6]N-+LI;M?NSR6Z-(/HQ&:OT4[L5D5DT^RBOY;^.SMTO)5"27"Q*
M)'48P"V,D<#\J9?Z3IVJQK'J.GVMXBG*K<0K( ?8,#5RBBX61E7'ACP_=F,W
M.A:9-Y2>7'YEI&VQ<D[1D<#))Q[FHXO"/AJ&5)8O#VDQR(P9'2RC!4CD$';P
M:V:*.9ARKL02V=K-=074MM#)<6^[R970%X]PPVT]1D<''6H+;1-*L[Q[RUTR
MR@NG^]-%;JKM]6 R:O447"R"LR3PWH4MY]KDT73GN<Y\YK5"^?7=C-:=%*]A
MVN     P!VK-F\/Z+<WGVR?1]/ENLY\][9&?/^\1FM*BBX6N07=E::A:/:7M
MK#<VSXW0S1AT;!R,@\'D _A4L44<,211(L<:*%1$& H'  '84ZB@"K8Z98:7
M&\>GV-M:1NV]UMXEC#-ZD #)]ZK2>&]"EO/M<FBZ<]SG/G-:H7SZ[L9K3HIW
M8K(CF@AN+>2WFB22"1"CQNH*LI&""#P01VIMK:6UC;);6EO%;V\8PD4*!%7O
MP!P*FHI#.,AT.[U3XC#7[O3HK*VTQ)(+5_E,MVS#:9&(Y"A<@ \\YXS79T44
MV[B2L4+_ $32=58-J.EV5X5Z&XMTDQ_WT#4]G8VFGP""RM8+:$<B.&,(OY"K
M%%%V%D5+_2M.U5%34;"UO$0Y5;B%9 I]MP-(^DZ;(;4OI]HQM#FV+0J?)/'*
M<?+T'3TJY11=A9%:YTZQO+BWN+JRMYYK9BT$DL2LT1.,E21E3P.GH*=>65KJ
M%J]K>VT-S;OC?%-&'1L'(R#P>0#^%3T4KCL,CBCAA2&*-4B10JHHPJ@<  =A
M5*UT+2+&[:[M-*L;>Y;.Z:*W1'/U8#-:%%%PL5K73K&QEN);2RM[>2X?S)WB
MB5#*W)W,0/F/)Y/K1'IUC%?RW\=E;I>S*%EN%B42.!C 9L9(X'7T%6:*+A8K
M7.G6-Y<6]Q=65O/-;,6@DEB5FB)QDJ2,J>!T]!1<Z=8WEQ;W%U96\\ULQ:"2
M6)6:(G&2I(RIX'3T%6:*+A8*BN+:"\@:"Y@CGA;[T<J!E/U!J6B@"A8:)I.E
M,S:=I=E9LWWC;VZ1Y_[Y JU<6T%W \%S#'-"XPT<J!E8>X/!J6BBXK(J6&EZ
M?I431:=86MG&QR5MX5C!_!0*LNB2QM'(JNC##*PR"/<4ZB@9GVVA:/90S0VN
ME6,$4ZE9DBMT59 >H8 <CZU:M;2VL;5+6TMXK>W082*) B*/8#@5-13NQ611
MAT32K:UGM8-,LHK>X),T26ZJDI/7< ,'\:M06\-K D%O#'##&NU(XU"JH] !
MP!4E%*X[!59-.L8]0?4$LK=;V1/+>Y$2B1EX^4MC)' X]A5FB@ JM8Z=8Z7;
M_9]/LK>TAW%O+MXEC7)[X  S5FB@"M'IUC%?RW\=E;I>S*%EN%B42.!C 9L9
M(X'7T%+>Z?9:E!Y%]:074/7RYXPZ_D15BBBX6*EAI6G:7&8].L+6S0]5MX5C
M!_  5;HHH QYO"?ANYGDGG\/Z5+-(Q>21[*-F=B<DDD<DGO4UCX>T32[C[1I
M^CZ?:3;2OF6]LD;8/;( .*TJ*=V*R*-[HVEZE+'+?Z;9W4D?W'G@5ROT)'%2
M'3;!KZ*]-E;&[B3RXYS$OF(G/RAL9 Y/'O5JBB["R*T>G6,5_+?QV5NE[,H6
M6X6)1(X&,!FQDC@=?047.G6-Y<6]Q=65O/-;,6@DEB5FB)QDJ2,J>!T]!5FB
ME<=A&574JRAE(P01D$5GVF@:-87)N;/2;"VG;K+#;(C'\0,UHT47"PV2-)HV
MCE171AAE89!'N*S[/P_HNG7!N++1]/MICUD@MD1C^(&:TJ*+BL17%M!=P/!<
MPQS0N,-'*@96'N#P:AL-+T_2HFBTZPM;.-CDK;PK&#^"@5;HHN.Q2U#1],U9
M8UU+3K2]6,DH+F!9 N>N-P.*H_\ "&>%O^A:T?\ \ 8O_B:VZ*=V*R9!9V5K
MI]JEK96T-M;IG9%#&$1<G)P!P.23^-5SH>D'4/[0.E6)O<Y^T&W3S,_[V,U?
MHHN%D5K[3K'5+?[/J%E;W<.X-Y=Q$LBY'?!!&:S?^$,\+?\ 0M:/_P" ,7_Q
M-;=%%V@:3*MAIEAI4#0:=8VUG"S;S';Q+&I; &<*!S@#GVJK+X:T&:Z^U2Z)
MILEQG/FM:H7S]<9K4HHNPL@    & .U%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img43612817_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43612817_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" V %AL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **0G )]*\C\4_&2UTZYGLK>TN1+&2I8*<9_*@#UVBOEF/XM^);W7H
MXXKQXX6D4;&!Z9KZ=T^1IM.MI7.6>)6)]\4 6:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  C((KB
MM2^'6D7<L]S)DNYW'Y:[6H[C_4/]* /D3Q+IL.E?$MK2#_5I*F/^^J^M-*_Y
M!%G_ -<4_E7ROXX_Y*S+_P!=4_\ 0C7U1I7_ ""+/_KBG\J +=%%% !1110
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M7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\*
M'44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS
M%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q
M?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH
M=13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,
M7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%
M_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!
MU%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q
M?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7
M^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '
M44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%
M_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?
M[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =
M13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7
M^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_
MO"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U
M%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?
M[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^
M\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '4
M4WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_
MO"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[
MPH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =1
M3?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^
M\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O
M"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%
M-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[
MPH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\
M*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44
MWS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O
M"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[P
MH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13
M?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\
M* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"
MCS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-
M\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[P
MH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*
M/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44W
MS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"
M@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH
M\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?
M,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\*
M '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"C
MS%_O"@!U%-\Q?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\
MQ?[PH\Q?[PH =13?,7^\*/,7^\* '44WS%_O"CS%_O"@!U%-\Q?[PH\Q?[PH
M =13?,7^\*/,7^\* '44W>O]X4X$'I0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1W'^H?Z5)4
M=Q_J'^E 'RAXX_Y*S+_UU3_T(U]4:5_R"+/_ *XI_*OE?QQ_R5F7_KJG_H1K
MZHTK_D$6?_7%/Y4 6Z*** "BBB@ HHHH **** *-X)#C953;<>M;! /44;%]
M!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&
MQ?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6
MC;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T%
M &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%
M]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-
MMQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04
M8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T
M%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW
M'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C
M[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04
M;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>
MM;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/M
MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L
M7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZU
ML;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX
M]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?
M04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6Q
ML7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CU
MHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!
M0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C;<>M;&Q
M?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T% &/MN/6C
M;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T%
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MMQZUL;%]!1L7T% &/MN/6C;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04
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M;<>M;&Q?04;%]!0!C[;CUHVW'K6QL7T%&Q?04 8^VX]:-MQZUL;%]!1L7T%
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M/6C;<>M;&Q?04;%]!0!C@7&>M:EON\H;NM2;%]!2XQ0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\^\7_? H^R6W_/O%_WP* ,[PQ<W%WX>M)[H,)G3+;AS6O2*H484  =@*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.RY2\+"[YBY61XGB23PY?%U!(B.*UZR/$SA?#E^">L1KCCN=TMF?)4O^N?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MD9@HRQP* %HK/?6]-C<HUW&&'49I/[>TO_G\C_.JY)=B>:/<T:*SO[>TO_G\
MC_.C^WM+_P"?R/\ .CDEV#FCW-&BL[^WM+_Y_(_SJY#<0W"[HG#CU%)Q:W0U
M)/8EHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5_PKW5O^?:7\J/\ A7NK?\^TOY4<\>X>SGV.5^UW/_/Q+_WV:/M=S_S\2_\
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M/^@7/^59T+*)KB%)SV,.GI-+&,)*ZC_98BMG_A#_ !!_T"Y_RH_X0_Q!_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M85Y]?%^UCRVL=E'#>S=[CJ***XSJ"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4R7_4O_NFGTR7_4O_ +IH0'B6M_\ (VP_
M[QKV'1O^05#]*\>UO_D;8?\ >->PZ-_R"H?I7H8S^' XL-\<B_1117GG:%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <+XT\"W
M'BF0F.[$2D8P:XG_ (47=?\ 016O<**UC6G%61E*A"3NT>*VOP1N(+J*5M04
MA'#8^AKV.TMQ:VD4(_@0+^0J>BIG4E/<<*<8?"%%%%0:!1110 4444 %%%%
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M!/H)!5I75QE6!'J* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %,E_U+_[II],E_P!2_P#NFA >):W_ ,C;
M#_O&O8=&_P"05#]*\>UO_D;8?]XU[#HW_(*A^E>AC/X<#BPWQR+]%%%>>=H4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 (2 ,FHS<1@]:9>AS:MLSN]JXN>/5//?:
MLN,\5YV-QTL,TE%NYUX;#*M>\K';_:8_6C[3'ZUP>S5?[LM0M<7JOM9W#>E>
M>\\E'>FSK66I[31Z%]IC]:/M,?K7!*NJ,,@2D4X1ZKG[LM/^VI_\^V+^SH_S
MH[Y7#C(-.K,T83"#]\&SCO6G7MT:GM(*35KGFU(<DG$****U("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]31]A?U- %_[7'ZT?:X_6J'V%_4T?87]30!?^UQ^M'VN/UJA]A?U-'V%_4T
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MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
MM<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:
MX_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?U- %_P"UQ^M'VN/UJA]A
M?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\ M<?K1]KC]:H?87]31]A?
MU- %_P"UQ^M'VN/UJA]A?U-'V%_4T 7_ +7'ZT?:X_6J'V%_4T?87]30!?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<C)25T%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&LG8Y)8^M=JY!:P^1"$ST%3T45ZD8J*LCA;N[L****H04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?</TKBK[_D*I]:[
M5ON'Z5Q5]_R%4^M>/G'P1]3T,O\ B?H==9?\>J?2K%5[+_CU3Z58KU:7P+T.
M&?Q,****LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *XKQ_X337[ R(F98E^4 =37:TA 8$$9!IQDXNZ)E%2
M5F?(&IZ1=Z3<-#=1[&7J*HAB.A(^E?5NN>$--UB,[K>,2$\N17"ZC\&4NF)A
MNUB'L/\ ZU=L<1%[G!/"R3]T\-+N>K-^=.AA>>0)&,L:]EMO@@T,@:34%<>F
M/_K5V&B_#K3M,E5Y8HY2/:G+$06PHX:;W.*^&W@29)DO[V(J5.Y/0U[4 %&
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M]#L[;_CWC^E2U%;?\>\?TJ6O8A\*//ENPHHHJA!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?</TKBK[_D*I]:[
M5ON'Z5Q5]_R%4^M>/G'P1]3T,O\ B?H==9?\>J?2K%5[+_CU3Z58KU:7P+T.
M&?Q,****LD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"*>XCMHC)(P 'J:RHO$^GS3^2L@W=/O"O/\ XOZ[/IS16L+L
MGFIU!Q7C%OJU[#<I+]IER&!^]713H<T;G+4Q')+E/L!6#J&4@@^E1FY@!P9H
MP?0N*Y+X=ZQ)K/ADW$ARRG;FO!_$VLZE'XDOT2]G51*0 '/%3"BY2:[%SKJ,
M5*VY]2_:K?\ Y[Q?]]BC[5;_ //>+_OL5\B?VYJG_/\ W'_?9H_MS5/^?^X_
M[[-:_57W,?KB['UW]JM_^>\7_?8H^U6__/>+_OL5\B?VYJG_ #_W'_?9H_MS
M5/\ G_N/^^S1]5?</KB['UW]JM_^>\7_ 'V*D5E<95@1Z@U\@?VYJG_/_<?]
M]FOI?X>323^"[*25V=R.68Y)Z5E4H\BO<UI5_:.UCJ:***Q.@**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;+_J
MF^E<3-_R&!7;2_ZIOI7$S?\ (8%>+F^T/4]'+_M>AV=M_P >\?TJ6HK;_CWC
M^E2U[$/A1Y\MV%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $;[A^E<5??\ (53ZUVK?</TKBK[_ )"J?6O'
MSCX(^IZ&7_$_0ZZR_P"/5/I5BJ]E_P >J?2K%>K2^!>APS^)A1115DA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 V7_5-]*XF;_D,"NVE_U3?2N)
MF_Y# KQ<WVAZGHY?]KT.SMO^/>/Z5+45M_Q[Q_2I:]B'PH\^6["BBBJ$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "-]P_2N*OO^0JGUKM6^X?I7%7W_ "%4^M>/G'P1]3T,O^)^AUUE_P >J?2K
M%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[A^E<5??
M\A5/K7:M]P_2N*OO^0JGUKQ\X^"/J>AE_P 3]#KK+_CU3Z58JO9?\>J?2K%>
MK2^!>APS^)A1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJPEU'7K>(*2&?!-?4VB67]GZ5%;?W!5XEZ)$81:N1H4445QG<%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ##%&>J+^5-:&/8W[M>GI4M(_W&
M^E2XKL--G$WJJ-54 #&:ZVSBC-JGR+T]*Y.]_P"0JGU-=?9_\>J?2O$RQ+VU
M3U/2QK?LX$GDQ?\ /-?RIP4+T 'TI:*]Q)+8\V["O.OB1X<6ZMGU&-</&N,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJO<7<=N<.P'UJ#^UK?^^OYU
ME*O3B[-EJG-JZ1?HJA_:UO\ WU_.C^UK?^^OYU/UFE_,BO8U.Q?HJA_:UO\
MWU_.I(=0AGD"(P)/H::Q%)NRD)TII7:+=%%%;&84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "-]P_2N*OO^0JGUKM6^X?I7%7W_ "%4^M>/G'P1]3T,O^)^AUUE_P >
MJ?2K%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CFA2>)HW *L,&I.@K
MG\::!;3O#+J$:R(<,#V--)O83:6YG:C\-M!U.8RSQ-N/I5C2/ 6C:+*LEK$=
MP.1FI?\ A._#G_02BH_X3OPY_P!!**KO4M8SM3O?0Z)5"J !@"L?7O#EGKUJ
MT5RF<U5_X3OPY_T$HJ/^$[\.?]!**DHR6J13E!JS9B>%OA];Z+>RSO'@A\I7
M?5SG_"=^'/\ H)15N6=[;ZA;+<VT@DB?HP[T3YGK((**TB3T445!84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %(_P!QOI2TC_<;Z4GL".*O
M?^0JGU-=?9_\>J?2N0O?^0JGU-=?9_\ 'JGTKQ,K_C5/4]+&_P .!/1117N'
MFA1110!Q_CKP^NJZ<9@F3"I->$2Q-%(488(-?4DL:S1-&PR&&#7B7Q!\/&PU
M"2ZC3$)X&.E>KE]?_EVSSL;1^VCA:]/^''B3RY3:7#_(!A17F%6].NWL[R*5
M6(PP)KTJ])58.+.*E4=.2DCZ>4AE!'0C-+6%X7UM-8TQ)01D87%;M?-3BXR<
M6>Y&2DKH****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ;+_JF^E<3-_P A@5VTO^J;Z5Q,W_(8%>+F^T/4]'+_ +7H=G;?\>\?TJ6H
MK;_CWC^E2U[$/A1Y\MV%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/6],N+Z0&'IC%8G_"
M-ZA[?G7;T5YE?*J%>;J2O=G92QU6E'EC8\_O-'O+&'S9?N_6F6.F76H*S0GA
M>N374^)_^06?K53PE_J)OK7CRRZDL<J&O*U<]&.+J/#.KUN9O_"-ZA[?G5[2
M-$O+34$FE^X.O-=317JT\GP].:FKW7F<$\PJSBXNVH4445ZQPA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 (WW#]*XJ^_Y"J?6NU;[A^E<5??\ (53ZUX^<?!'U/0R_
MXGZ'767_ !ZI]*L57LO^/5/I5BO5I? O0X9_$PHHHJR0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2^GD6?.%"]_UKWW1M*@T73(K&W),4?3-<V(FFN4Z\+3:?,7Z***Y#M"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% "-]P_2N*OO^0JGUKM6^X?I7%7W_ "%4^M>/
MG'P1]3T,O^)^AUUE_P >J?2K%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!B^)_^06?K53PE_J)OK5OQ/_R"S]:J>$O]
M1-]:\.I_R-8^AZ<?]Q?J=+1117N'F!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "-]P_2N*OO^0JGUKM6^X?I7%7W_ "%4^M>/G'P1]3T,O^)^AUUE_P >J?2K
M%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKN3OL<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !63KO\ QY2?2M:LG7?^/*3Z
M5RXW^!+T-\-_%B9GA?\ UA^E=37+>%_]8?I74USY3_NL37'_ ,=A1117I'&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8OB?_ )!9^M5/"7^HF^M6_$__
M ""S]:J>$O\ 43?6O#J?\C6/H>G'_<7ZG2T445[AY@4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 C?</TKBK[_ )"J?6NU;[A^E<5??\A5/K7CYQ\$?4]#+_B?
MH==9?\>J?2K%5[+_ (]4^E6*]6E\"]#AG\3"BBBK)"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \/\ C=<21ZE:1K]U
MDYKSKPU>1VNKP-*[!=X[U['\6]':\MOM@3(B3K7@8)1@1P17H4;.G8\RO>-2
MY]?:=J-M>:<DD4BX" <GVKYI\2:[>Q^([]$E;:)3C#5CQZ]JL*;([^95] U4
M))'ED:21BSL<DGO13H\C;"K7YTDCVGX2ZI-=7Y$\O&SNWL:]A\V/_GHOYU\>
MVNHWEDVZVN)(CZJ<5:_X236?^@E<?]]5$\/S.Z9=/$J$;-'UQYL?_/1?SH\V
M/_GHOYU\C_\ "2:S_P!!*X_[ZH_X236?^@E<?]]5'U5]S3ZXNQ]<>;'_ ,]%
M_.G @C(((]J^1?\ A)-9_P"@E<?]]5])_#ZXENO!ME+/(TDC#EFZGI6=2BX*
M]S6E751VL=11116)N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7Q/\
M\@L_6JGA+_43?6K?B?\ Y!9^M5/"7^HF^M>'4_Y&L?0]./\ N+]3I:***]P\
MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[A^E<5??\ (53ZUVK?
M</TKBK[_ )"J?6O'SCX(^IZ&7_$_0ZZR_P"/5/I5BJ]E_P >J?2K%>K2^!>A
MPS^)A1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%1RS)"I9S@"LB\\0V\0(B<%O>L*V)I45>;L:TZ,ZC]U&RSJOWF ^IK/O-9
M@M0<G=]#7*7FN7%T3G@>QK,:1W.68GZFO"Q.>K:BOF>G1RSK49N7OB.:7(@8
MJ#ZUCS7,L[9D;)J&BO!K8JK6=YR/4IT*=->Z@HI\<+RMA!DUK6?A^XF(,B$*
M>]*CAZM9V@KCJ5H4U>3,<*S=%)^@J_::1<71& 5^HKJ[/0;>VPW)/N*U5C1!
MA54?05[N&R)O6L_D>96S-;4T8-EX;CC \]0QK9@M(K=<1KBIZ*]VAA*-%6@C
MRZE>I4?O,;+_ *IOI7$S_P#(8%=M+_JF^E<3-_R&!7G9OM#U.O+_ +7H=0--
MMKFV3S$R<5F7?AI'!\@!:WK;_CWC^E2UVSP5"M!<\3FCB:M.7NLX"ZT6XMB<
M_-]!6>T3H?F1A]17II16ZJ#]15.ZTNWNAA@%^@KR:^0K>DSOI9H]IH\[HKJK
MOPPBY,.XUB3Z/=P$[H\"O%KY?B*/Q1/1IXNE4V90J>"\FM_]6V*A92C8/6DK
MDC*4'=:,Z&E):FY:>(IXR/.<L*W+7Q#;3X&"#[UP]*&(Z$CZ5Z5#-L12TO='
M'5P%*?2QZ9'<12C*NOYU*"#TKS>WOIK<Y5B?J:V+3Q-,IVRA0OK7M8?/*4]*
MBLSSJN6U(ZPU.PHK*MM=M)@ TGS>E:4<J2KE#D5Z].O3JJ\'<X)TIP^)#Z**
M*U,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LG7?^/*3Z5K5DZ[_QY2?2N7&_P)>AOAOXL3,\+_ZP_2NIKEO"_P#K#]*Z
MFN?*?]UB:X_^.PHHHKTCC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7Q
M/_R"S]:J>$O]1-]:M^)_^06?K53PE_J)OK7AU/\ D:Q]#TX_[B_4Z6BBBO</
M,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *J7.FVUV<S1[JMT5,X1FK25T5&3B
M[Q9F?V!IW_/&L?7=,M;2)3#'M)KJZP/$W^H2O,Q^&HQP\G&*3]#LPM:I*LDY
M,I:%IEK=VX::/<:V?[ T[_GC5+PU_P >H^M=!1E^&HRP\7**;] Q=:I&JTI,
MI6^E6EJ^Z*/::NT45Z4*<*:M!61QRG*3O)W"BBBK)"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 1ON'Z5Q5]_R%4^M=JWW#]*XJ^_Y"J?6O'SCX(^IZ&7_$
M_0ZZR_X]4^E6*KV7_'JGTJQ7JTO@7H<,_B844459(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y%\4_%LUA)
M!#:2%6.02I^M>N-PI^E?+GCV_-WK]Q'G/ER$5O0CS2U.?$S<8:'H'PW\>7-[
M*NG3H\KJN2YKU/5=5BTO3'O)<849P:\@^#VCI]N^VL/O)_C6S\7-<%K:-IH?
M_6)G ^E.<%*I9$TYN-+F9Y_XM\>7^I:A(MM</'$&X /%<U'X@U2)]Z7D@/UJ
MA#"]Q,D2<LQP*Z.\\"ZM8Z3_ &C*H\GZ<UUVC'0XKSF[G??#WX@S27"65Z[2
M-(<!F/2O:$=74,I!![BOD'29VL]6AES@HU?4WA2Z-[X>MIR<[AUKEQ$%%W1V
MX:HY*S-JBBBN8Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^9;,]7"5N>/*]T:5%%%>>=@4444 %%%% !1110 4444 %%%% !1110 4444
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MJIX2_P!1-]:M^)_^06?K53PE_J)OK7AU/^1K'T/3C_N+]3I:***]P\P****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *P/$W^H2M^L#Q-_J$KAS'_=IG3@_X
MT1/#7_'J/K705S_AK_CU'UKH*,M_W:(\9_&D%%%%=QRA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !132Z#JP'XT>8G]]?SI70[,=13?,3
M^^OYT>8G]]?SHN@LQU%-\Q/[Z_G2A@>A!^E%T*PM%%%, HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** $;[A^E<5??\A5/K7:M]P_2N*OO^0JGUKQ\X^"/J>AE_Q/
MT.NLO^/5/I5BJ]E_QZI]*L5ZM+X%Z'#/XF%%%%62%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(M6S2HHHKC.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** ,7Q/_R"S]:J>$O]1-]:M^)_^06?K53PE_J)OK7AU/\
MD:Q]#TX_[B_4Z6BBBO</,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#
MQ-_J$K?K \3?ZA*X<Q_W:9TX/^-$3PU_QZCZUT%<_P"&O^/4?6N@HRW_ ':(
M\9_&D%%%%=QRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !113)9!%&7/04FTE=@E<?168VM0*<?UI/[<M_P#)KG^N
M4/YC;ZO4[&I167_;EO\ Y-']N6_^31]<H?S!]7J]C4HK+_MRW_R:OP3K.@9>
MAJZ=>G4=HNY,J4X*\D2T445L9A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH Q?$_\ R"S]:J>$O]1-]:M^)_\
MD%GZU4\)?ZB;ZUX=3_D:Q]#TX_[B_4Z6BBBO</,"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "L#Q-_J$K?K \3?ZA*X<Q_P!VF=.#_C1$\-?\>H^M=!7/
M^&O^/4?6N@HRW_=HCQG\:04445W'*%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %5[Z)YK1T3[QZ58HJ9Q4HN+ZCB^
M5W1P\OA_46D)"<?6F_\ "/:E_<_6NZH/0UX[R/#O6[/0695>R/-6MITG$)SO
M)QC-7ET#477(7CZT^Y_Y#2_[]=I;_P"I%>;@<MI5YSC)O1G9B<9.E&+BMSBO
M^$>U+^Y^M=9I=O);VRI*,,!5ZBO<PN6TL-+F@V>;7QDZT>604445Z!R!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 <KXFZI_O5JZ!_R#Q]:RO$W5/\ >K5T#_D'CZUX>'_Y
M&,_0].K_ +I$U:***]P\P**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ON
M'Z5Q5]_R%4^M=JWW#]*XJ^_Y"J?6O'SCX(^IZ&7_ !/T.NLO^/5/I5BJ]E_Q
MZI]*L5ZM+X%Z'#/XF%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2O\ D$6?_7%/Y5\K^./^2LR_]=4_]"-?5&E?\@BS_P"N*?RH MT444 %%%%
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M(]J/[1'M0!H45G_VB/:C^T1[4 :%%9_]HCVH_M$>U &A16?_ &B/:C^T1[4
M:%%9_P#:(]J/[1'M0!H45G_VB/:C^T1[4 :%%9_]HCVH_M$>U &A16<=40=2
M*0ZM&.XJ7.*W8^5OH:5%9?\ ;$7]X4TZW .KBI=:FMY(KV<WT-:BL@Z[;C^,
M4W_A(;7_ )Z"H>*HK>:^\I4*CVBS9HK"?Q' #\K@TP^)(@.&%9O'8=?;1:PM
M5_9.@HKFO^$F_P!VHW\4./NA363S/#+[1:P59]#J:*Y,^*I<<*M1'Q9=9_U:
MUG+.,(NOX%K+Z[Z'8Y [TFX>HKBW\3W3_P "BHSXBN2/NBLGGF&Z7+66UNIW
M&]?[P_.DWH/XU_.N".M7!.?ZU&^JW#C[Q'XUD\^I=$6LKGU9Z#YB?WU_.D\V
M/_GHG_?0KSLZA.1]]OSJ$W,Q.?-?_OJLY<016T/Q+65/K([#Q+*C:80KJ3GL
M:I^%9TCBD5F )/<US+2R.,,[$>YH21XSE6(^AKSI9IS8I8CEV5K'7'!6H.C<
M].#*>C _0TM<%:ZY<6V /F^IK:MO$JOCS2JU[V'S?#U=&[,\NK@*L-5JCHZ*
MS$U>.3[K T_^T1[5ZD9*2NF<333LS0HK/_M$>U']HCVIB-"BL_\ M$>U']HC
MVH T**S_ .T1[4?VB/:@#0HK/_M$>U']HCVH T**S_[1'M1_:(]J -"BL_\
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M]J -"BL_^T1[4?VB/:@#0HK/_M$>U']HCVH T**S_P"T1[4?VB/:@#0HK/\
M[1'M1_:(]J -"BL_^T1[4?VB/:@#0HK/_M$>U']HCVH T**S_P"T1[4?VB/:
M@#0HK/\ [1'M1_:(]J -"BL_^T1[4?VB/:@#0HK/_M$>U']HCVH T**S_P"T
M1[4?VB/:@#0HK/\ [1'M1_:(]J -"BL_^T1[4?VB/:@#0HK/_M$>U']HCVH
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M[4 :%%9_]HCVH_M$>U &A16?_:(]J/[1'M0!H45G_P!HCVH_M$>U &A16?\
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M6[E"07FT,<86I--\1^,)-3MDE@O!&9 &RO;-?0?D1?\ /)/^^12^3$.D2?\
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M:C^SU]JNT4 4O[/7VH_L]?:KM% %+^SU]J/[/7VJ[10!2_L]?:C^SU]JNT4
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M?:KM% %+^SU]J/[/7VJ[10!2_L]?:D.GK@]*O4'H: ."GB U54_VZZR"P4Q
M\5R]S_R&E_WZ[2W_ -2*\/*?XE3U/3QWP0]"O_9Z^U']GK[5=HKW#S"E_9Z^
MU']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH
MI?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^
MU7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[
M4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"
ME_9Z^U']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[
M5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM
M1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^U7:* *
M7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM
M5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U
M']GK[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I
M?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@#C_$%N(2F/[U:.BV:RV6XXZU4\3=4
M_P!ZM70/^0>/K7AX?_D8S]#TZO\ ND2Q_9Z^U']GK[5=HKW#S"E_9Z^U']GK
M[5=HH I?V>OM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>O
MM1_9Z^U7:* *7]GK[4?V>OM5VB@"E_9Z^U']GK[5=HH I?V>OM1_9Z^U7:*
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M5VB@"E_9Z^U']GK[5=HH I"P4'M5J-!&FT4^B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKRRW&&[5]%44 ?(U[X"\5WNHF]DL9S*2#D]:Z2*T\=11)&+6ZPH 'S5]*T4
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M2U[$/A1Y\MV%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:(GAK_CU'UKH*Y_PU_QZCZUT%&6_[M$>,_C2"BBBNXY0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &M(J]32><G]ZN;UZXNXI$\C=CV%8WVW4O^FG_?)KQZ^;*C
M4<.5NQZ%+ .I!2YCO?.3^]1YR?WJX!M1U!/O,P^HH74-0?[K.?H*P_MV%[<C
M-?[,E_,CO_.3^]2B16Z&N!^VZE_TT_[Y-:^B7%Y)+B;=C/<5M0S=5:BARO4R
MJX!PBY<R.IHHHKV3SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *#T-%!Z&@#AKG_D-+_OUVEO\
MZD5Q=S_R&E_WZ[2W_P!2*\/*?XE3U/2QWP0]"6BBBO</-"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM GZW,^F?^%K>%/^?[]!_C75Z9J5MJ]A'>6C[X9/NFOCNOJ/X;?\B/8?[O\
MA6-:E&"NC>A7E4E9G64445SG4%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH *P/$W^H2M^L#Q-_J$KAS'_=IG3@_P"-$3PU_P >H^M=!7/^&O\
MCU'UKH*,M_W:(\9_&D%%%%=QRA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -*(W
MWE4_44GE1_\ /-/^^13Z*5D.[.;\2(JQG:H''85-X>C1H>44\=Q47B7_ %9^
ME3^'?]3^%>'%+^T6>DV_JAL^5'_SS3_OD4H1%Z*H^@IU%>Y9'FW84444Q!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 444TNJG!(%%P'44WS$_O"CS$_O"E=#LQU%-\Q
M/[PH\Q/[PHN@LQU%(&4]#FEIB"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#T-
M%!Z&@#AKG_D-+_OUVEO_ *D5Q=S_ ,AI?]^NTM_]2*\/*?XE3U/2QWP0]"6B
MBBO</-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGA?_ %A^E=37+>%_]8?I74USY3_NL37'_P =A1117I'&%%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 'D5X-\7=!DM+J"X0;A(2Q
MP.G6O>:Q/$&A6FO6_E3X/&*TI3Y)7,JT.>-CYW\!W=YIVMK/;PR/OPI*CM7N
M'C313K7A5BJ_OVC&/4<5;\.>"M-T&-3"F7 QR,UTS(K)M(&/2KJ54Y71%*BX
MPY6?'E[9RZ?>/"X(9#C-0O/)(,,V:^@?%?PSMM5E>XMD)F<Y-< WPAU_[3Q"
MOE5TQK1:U..="<7HCAM*LGO]0B@12=QQQ7U+X0L6T[PW;6S#!0=*Y7PA\-+7
M29$N;I")T.1]:]'  & ,"N>O54M$=>'I.&K"BBBN<Z0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV1I#'']Q<5)1170DEHC)MO<****8CAKS_D,K_P!=*[.V_P!2*XR\_P"0RO\
MUTKL[;_4BO#RK^+5]3T\=\$/0FHHHKW#S HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *M^':V(3K7'RV]]YK8WXSZ5W76DV+_='Y5Y^,P"Q+3YK'5A\5[%6M<X/
M[/?G^_\ E41T^Z+;MK9^E>@[%_NC\J-B_P!T?E7$\CB]YLZ5F4EM$X,6U^!@
M;_RI4M[_ 'KDOU]*[O8O]T?E1L7^Z/RIK)4OML7]HO\ E17L@PMU#=<59HHK
MVH1Y8I'G2=W<****H04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^/4?6N@HRW_ ':(\9_&D%%%%=QRA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '.>)?]6?I4_AW_4_A4'B7_5GZ5/X=_U/X5X<?^1BSTW_ +FC<HHHKW#S
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?$_\ J5_WJZ:N9\3_ .I7
M_>KSLT_W61UX'^.B[X<_X\C]:V:QO#G_ !Y'ZULUM@/]VAZ&>*_C2"BBBNLP
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *#T-%!Z&@#AKG_D-+_OUVEO\ ZD5Q
M=S_R&E_WZ[2W_P!2*\/*?XE3U/2QWP0]"6BBBO</-"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH :_\ JVQUP:X2XN=0%S(%+XW''%=[U%5S9Q$Y*C\J\_'X.>)4
M>65K'7A<1&C>ZO<X7[3J/J_Y4QK^]0X:1@?>N]^Q0_W1^5<=XCC6/4PJC Q7
MA8W U<+2]I[1L]/#8J%:?)RE476H$9!<CZ4X7.HY'+_E78V-I$UC"2HR5]*L
M?8X?[H_*NJ&45914O:/4PECZ:;7(4]#>5[0F7.[/>M2FI&L8PHP*=7O4*;IT
MU!N]CRZDU.;D@HHHK4@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?$W5/]ZM7
M0/\ D'CZUE>)NJ?[U:N@?\@\?6O#P_\ R,9^AZ=7_=(FK1117N'F!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "-]P_2N*OO\ D*I]:[5ON'Z5Q5]_R%4^
MM>/G'P1]3T,O^)^AUUE_QZI]*L57LO\ CU3Z58KU:7P+T.&?Q,****LD****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH HZJ7%@YC)#>U> W/Q!U'2]:NHRSN%DP 37T3)&)$*L."*^=OB'X,N=-U
M*2[1-R3,6^49Q710Y6[,YL3S))Q/1OA_XZN/$MV;:6WV +G=7HU?._PJUR+2
MM;*7.54I@9X]:^A(9XYXU>-U8,,\'-36CRRT*H3YH:DE%%%8FX4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[,RZGBNYHB"LC"HVC=#AE8?44RN!.4'IH=32DM3>L_$<L.%==WN:Z"TUJWG
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M@ HHHH **** .<\2_P"K/TJ?P[_J?PJ#Q+_JS]*G\._ZG\*\./\ R,6>F_\
M<T;E%%%>X>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SXG_P!2O^]7
M35S/B?\ U*_[U>=FG^ZR.O _QT7?#G_'D?K6S6-X<_X\C]:V:VP'^[0]#/%?
MQI!111768!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z&B@]#0!PUS_R&E_WZ
M[2W_ -2*XNY_Y#2_[]=I;_ZD5X>4_P 2IZGI8[X(>A+1117N'FA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7$^)_^0J/I7;5Q/B?_D*CZ5X^>?[K\T>A
MEO\ &^1UNG_\>$/^[5FJVG_\>$/^[5FO4H_PX^B.*I\;"BBBM" HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#E?$W5/]ZM70/^0>/K65XFZI_O5JZ!_P @
M\?6O#P__ ",9^AZ=7_=(FK1117N'F!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "-]P_2N*OO^0JGUKM6^X?I7%7W_ "%4^M>/G'P1]3T,O^)^AUUE_P >
MJ?2K%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1CA2?05X-XN^)U^;Z[T
M[[+;O&C%,LH)'Z5[P_W&^AKY.\46TQ\3:@1&Q'FFNC#Q3;N<N*E**5C,EO9)
M+K[0OR-G/R\5V.D_%+6=)A$<:(X']\Y_I7%?99_^>3?E1]EG_P">3?E78XQ>
MYPQE*.J/2?\ A=VO?\^\'Y#_  H_X7=KW_/O!^0_PKS;[+/_ ,\F_*C[+/\
M\\F_*I]E3[%^VJ=STG_A=VO?\^\'Y#_"O9O"6KS:[X<MM0N%59)1DA>E?*'V
M6?\ YY-^5?3_ ,.%*>";$,,''3\JPKPC&.B.C#5)RDU)G5T445R':%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XGQ/_P A4?2NVKB?$_\
MR%1]*\?//]U^:/0RW^-\CK=/_P"/"'_=JS5;3_\ CPA_W:LUZE'^''T1Q5/C
M84445H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <KXFZI_O5JZ!_R#Q]
M:RO$W5/]ZM70/^0>/K7AX?\ Y&,_0].K_ND35HHHKW#S HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!&^X?I7%7W_(53ZUVK?</TKBK[_D*I]:\?./@CZG
MH9?\3]#KK+_CU3Z58JO9?\>J?2K%>K2^!>APS^)A1115DA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU(U08 %.Q1170DD8W"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <->?\AE?^NE=G;?ZD5QEY_R&5_ZZ
M5V=M_J17AY5_%J^IZ>.^"'H34445[AY@4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63KO_
M !Y2?2M:LG7?^/*3Z5RXW^!+T-\-_%B9GA?_ %A^E=37+>%_]8?I74USY3_N
ML37'_P =A1117I'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8OB?_D%G
MZU4\)?ZB;ZU;\3_\@L_6JGA+_43?6O#J?\C6/H>G'_<7ZG2T445[AY@4444
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MV:VP'^[0]#/%?QI!111768!1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (WW#]*XJ^_Y"J?6NU;[A^E<5?G&JI]:\;./@CZG
MH9?\3]#KK+_CU3Z58JO9'-HGTJQ7JTO@7H<,_B84445H2%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_D'CZUX>'_Y&,_0].K_ +I$U:***]P\P**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4A (P1D4M% 'E/Q)\.XWZA"O)., 5Y8002#U%?3FJ6$6H63PS+
MN&"0*^>O$6E2:9J4BLN%9B5X[5[> K\T>1[H\K&4>67,NIEPRF&9)%ZJ<U[C
MX!\0+J6F+'*_[[. IZUX570>$];.CZO',Q/ECL*WQ=#VM/S,<-5]G/R/HJBJ
MUA=)>644ZL"'7/6K-?/-6=CVT[A1112 **** "BBB@"*Y_X]Y/I7&Q?\A@UV
M5S_Q[R?2N-B_Y#!KQ,V_B4_4]+ _#,[2+_5)]!3Z9%_JD^@I]>U'9'G/<***
M*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *",T44 -\M/[HH\M/[HIU%*R'=C?+3^Z
M*/+3^Z*=119!=C?+3^Z*<  ,"BBBR0KA1113 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LG7?^
M/*3Z5K5DZ[_QY2?2N7&_P)>AOAOXL3,\+_ZP_2NIKEO"_P#K#]*ZFN?*?]UB
M:X_^.PHHHKTCC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **IWFHQ6;8D!JI_P
MD5IZ&N>>*HP?+*23-8T*DE>*&>)_^06?K53PE_J)OK46N:O!>6!BC!SFJ_A_
M4X;&*19 <DUXD\32>91J<VEMSTHT9_4W&VMSLJ*R/^$BM/0U-:ZS;W<XB0'<
M:]J.,H2=E)7/.>'JI7<31HHHKI,0HHHH **** "BBB@ HHHH **** "BBB@
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M_P#J5_WJZ:N9\3_ZE?\ >KSLT_W61UX'^.B[X<_X\C]:V:QO#G_'D?K6S6V
M_P!VAZ&>*_C2"BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#T-%!Z&@#
MAKG_ )#2_P"_7:6_^I%<7<_\AI?]^NTM_P#4BO#RG^)4]3TL=\$/0EHHHKW#
MS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?$__ "%1]*[:N)\3_P#(
M5'TKQ\\_W7YH]#+?XWR.MT__ (\(?]VK-5M/_P"/"'_=JS7J4?X<?1'%4^-A
M1116A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROB;JG^]6KH'_(/'UK
M*\3=4_WJU= _Y!X^M>'A_P#D8S]#TZO^Z1-6BBBO</,"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"ZCJP'XU#+=PQ=74_0U,I
MQCJV-1;V)Z*R)_$%K#D$$_2LRX\3AL^46%<57,L-3WD=,,'6GLCJ20!DFH7O
M+>/[TJBN*F\07LG EXJC+>33??;->=5SZFOX<;G73RN3^-G;SZU;1 [9%:LR
MX\5!,JL6?>N3HKS:N=XB?PZ'9#+:4=]38N->GFSMROTK/>^N7)S,Q_&J]%>=
M4Q-:H[RDSKA1IPV0YI'?[S$TVE"D] 33T@D<X"-^596E)FETB.BM*'1;F;&.
M,^HK2M_"\W!D*D5U4L!B*GPQ9A/%4H;R.;J5+>63[J$UV4'ART4?O(P35^+3
M+6'[B8KTJ615I:S=CCGF=-?"CAXM*NI#S$P'K4;696X6)CC->C%0L9 Z8KB[
M[_D*I]:,9E=/#0BT[W88?&SK2:M8W=(TF.WB60X8D5LU7LO^/5/I5BOI<-2A
M3II05CQZTY3FW)A1116YD%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIGPJM;8AKORYCWS72V_@;0(0,Z?$3ZU5Z2Z7,[5I=;'F_P#PMW6]N?LD6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 5@>)O]0E;]8'B;_4)7#F/^[3.G!_QHB>&O\
MCU'UKH*Y_P -?\>H^M=!1EO^[1'C/XT@HHHKN.4**** "BBB@ HHHH ****
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MF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7,^)_\ 4K_O5TU<SXG_ -2O^]7G
M9I_NLCKP/\=%WPY_QY'ZULUC>'/^/(_6MFML!_NT/0SQ7\:04445UF 4444
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MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ.R-=\J<'I_C5PISG\*N3*<8_$SI;G_CWD^E<;%_R&#5F3XA>'IHVC2[RS#
MZ?XUD)JUHEV;MI/W1[UXN;TJD:E.ZZGHY?.,H3LST*+_ %2?04^N27XB>'44
M*UWR!@]/\:<OQ%\.,P N^3]/\:]N.'JV7NL\QUJ=]SJZ*J:?J-MJ=L)[5]T9
M[U;J&FG9EIWU04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8'B;_4)6_6!XF_U"5PYC_NTSIP?\:(GAK_ (]1]:Z"N?\ #7_'J/K7049;
M_NT1XS^-(****[CE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<\2_P"K
M/THT.TAG@_>+GBCQ+_JS]*G\._ZG\*\'E4LQ::/4NUA$T69M"LG'$0!K-F\,
M[L^7M%=+17HU,OP]3>)QPQ=:&S.)F\-7$9)W _2J$VF3P]5)^@KT3 /44AC0
M]47\JX*F149? ['7#,ZB^)7/,C#*O6-ORII4CJ"*]'ET^"7JH'T%4)O#EI+D
MDL/I7GU,AJKX'<ZH9I3?Q*QPU%=1-X8 SY88UGS>'KU2=L>17!4RW$T]X_<=
M4,91ELS'HJW+IUS#]],55*E3@UQRIRAI)6.B,HRV8Y)7C^Z<5:CU6\B^Y*15
M*BG&K.'PNP2A&6Z-J'Q#<KCS')K1A\4Q+]]6-<I1793S/$T]I?><\\%1GNCO
M(=>MYNV/J:OQWD,@XD7\Z\U#,.C$?C3TGD0Y#M^=>A2SZHOCC<Y)Y7!_"['I
M@D0]'!_&G5Y[#K%S">#GZFM"#Q/<CAPN*[Z6>4)?%H<L\LJKX=3LJ*YZ#Q+"
M?]:X%:$6N64OW9,UZ%/'X>IM)'+/"U8[Q-&BH8KJ*7[C9J:NJ,E)71@TUN%%
M%%,04444 %%%% !1110 4444 %%%% !1110 4444 %<SXG_U*_[U=-7,^)_]
M2O\ O5YV:?[K(Z\#_'1=\.?\>1^M;-8WAS_CR/UK9K; ?[M#T,\5_&D%%%%=
M9@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4'H:*#T- '#7/\ R&E_WZ[2W_U(
MKB[G_D-+_OUVEO\ ZD5X>4_Q*GJ>ECO@AZ$M%%%>X>:%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<3XG_P"0J/I7;5Q/B?\ Y"H^E>/GG^Z_-'H9;_&^
M1UNG_P#'A#_NU9JMI_\ QX0_[M6:]2C_  X^B.*I\;"BBBM" HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#E?$W5/]ZM70/^0>/K63XE=2R#/1JDTS6;6T
ML=COA\]*^?IUJ=/'SE-V5CU94Y3PL5%'3TA91U(%<O<>)V7/D[36;-XANYNH
M ^E=-7.<-#1:F,,NK2WT.V>YA09,B_G5&;6[>'.><>AKAY;N64Y+M^=0EV/5
MC^=>=5SZ;^"-CLAE<5\3.KN/%$1R(U8&LR?Q!=.?W<A K&HKS:N9XFIO*WH=
MD,%1ALBW)J5U-]^3-568L<GK245Q2J3G\3N=$81CL@HJ2."24X09J[%HE[+]
MV/-5"C4G\$6Q2J0C\3,ZE )Z#-=%;^&I&QYRD5IP>&K2/DELUZ%+*,34Z6.6
M>/HPZW.,$,C=(V/X5;@TN>?HI'U%=S#IT$'W5!^HJR(T'1%_*O1I9 MZDCCG
MFG\J..@\,7#G)=<5J6_AR),>:H:M_ %%>E2RG#4^ESCGCJT^I1BTFSB'RQ 5
M:CA2/[HQ4E%=T*4(?"K'-*I*6["BBBM" HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!&^X?I7%7W_(53ZUVK?</TKBK[_D*I]:\?./@CZG
MH9?\3]#KK+_CU3Z58JO9?\>J?2K%>K2^!>APS^)A1115DA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!##.,\U=K&<Y2^(VIPC%>Z%%%%0:!1110 4444 %%%% !1110 4444 %%%%
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M*8#19K1A\1Q2@;E"UQ-%=]/.,3#=W.6>7T9;*QZ-%J=K(N?.0'TJ=;B%_NR
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M1Q5/C84445H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K \3?ZA*WZP/$W^H2N',?]VF=.#_C1$\-?\>H^M=!7/\ AK_CU'UKH*,M
M_P!VB/&?QI!1117<<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.R,Z,'%7>["BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***R+OQ/H]BY2YOHXV'8T :]%8D'BW0KIPD.HQ.Q[ ULHZR*&4Y!Z&@
M!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",H88(R*\5^(?A
MTV%W]K1.)6S7M=8_B+2X]3TR560,RH=N:Z<+6=*I?H88BE[2%CYMJQ8W3V5V
MDZ'#*<BI=5L)-.O7@E4JP/0U2KZ)6DCQ-8L^AO!^N1ZKI,(+9FQEJZ2O!O G
MB%M*U+;(V4?"@&O=8)5FA1U.00#7SV+H>RJ>3/:PU7VD/,9>_P#'G+_NUYM?
M?\?*?[X_G7I-[_QYR_[M>;7W_'RG^^/YUX&8?Q:7J>Q@O@GZ'I5I_P ></\
MN"IJAM/^/.'_ '!4U>J>>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *P/$W^H2M^L#Q-_J$KAS'_=IG3@_XT1/#7_'J/K705S_A
MK_CU'UKH*,M_W:(\9_&D%%%%=QRA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '.>)?]6?I4_AW_4_A4'B7_5GZ5/X=_P!3^%>''_D8L]-_[FC<HHHKW#S
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M@CZGH9?\3]#KK+_CU3Z58JO9?\>J?2K%>K2^!>APS^)A1115DA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&0?:G9H2:>@^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6!XF_U"5OU@>)O]0E<.8_[M,Z<'_&B)X:_
MX]1]:Z"N?\-?\>H^M=!1EO\ NT1XS^-(****[CE"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .<\2_ZL_2I_#O^I_"H/$O^K/TJ?P[_J?PKPX_\C%GIO\
MW-&Y1117N'F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ->-9!AAD55DTNTE^_'
MFKE%1.G"?Q*Y49RCLS&F\/6C [(P#7.ZMI1L?F&,$XKNZYGQ/_J5_P!ZO'S/
M!4(T)3C&S1Z&"Q-1U5%O0HZ7HAO(O,., UIIX:B!^90:L>'/^/(_6MFJP67X
M>5&,G'5DXG%U54<4S&3P[: _-&"*F&@Z>#GR>:TZ*[XX+#K["^XYGB:K^TRB
M-'LATBJ0:?;CHE6J*U5"DMHHAU9O=D0MXUQA:D  &!2T5HHI;$-M[A1113$%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4'H:*#T- '#7/_ "&E_P!^NTM_]2*XNY_Y#2_[]=I;_P"I
M%>'E/\2IZGI8[X(>A+1117N'FA1110 4444 ,DC61<,,BLZYT.TF4D1C=6I1
M652A3JJTU<N%2</A9R-UX8F&6C*@>E8MQ836[892?H*](ZU&\$<@(9%_*O(Q
M&1T9ZTW9G?2S*I'2>IYD59>H(^HI*[J[T"WN >H/M6'=^')H\^2A85XV(RC$
M4M4KH]&ECZ4]W8P:4$J<CK4\]E/;G$B8JO7F2C*#LU8[4U)71>M]6N[<@))@
M5M6GB8*0)MQKEZ*ZZ&/KT?AD85,+2J;H]#MM6M[G&"!GU-70Z-T8'Z&O,5D=
M>CL/QK0M-9N+7&#N^IKV</GRVJKYGG5<KZP9Z!17-6GB8.1]H*J/:MF#4[6X
M_P!7)DU[-''4*R]V1YU3#5:?Q(N44@((R*6NLP"BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^6/B'_P CK?\
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M6, UM4:Y$84TU.1;HHHK$W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]*/[.3TH /[27^[1_:2_W:/[.3TH_LY/2@ _M)?[M']I+_=H_LY/2C^SD]*
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MZ4?V<GI0 ?VDO]VC^TE_NT?V<GI1_9R>E !_:2_W:/[27^[1_9R>E']G)Z4
M']I+_=H_M)?[M']G)Z4?V<GI0 ?VDO\ =H_M)?[M']G)Z4?V<GI0 ?VDO]VC
M^TE_NT?V<GI1_9R>E !_:2_W:/[27^[1_9R>E']G)Z4 ']I+_=H_M)?[M']G
M)Z4?V<GI0 ?VDO\ =H_M)?[M']G)Z4?V<GI0 ?VDO]VC^TE_NT?V<GI1_9R>
ME !_:2_W:/[27^[1_9R>E']G)Z4 ']I+_=H_M)?[M']G)Z4?V<GI0 ?VDO\
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M]I+_ ':/[.3TH_LY/2NXY0_M)?[M']I+_=H_LY/2C^SD]* #^TE_NT?VDO\
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M0C%?QI!_:2_W:/[27^[1_9R>E']G)Z5UG.']I+_=H_M)?[M']G)Z4?V<GI0
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M:/[27^[7$?\ "P?#WI)6_HNIZ?KBAK4-@C/->Y*A4@KR1YD:L).R9L?VDO\
M=H_M)?[M']G)Z4?V<GI61H']I+_=H_M)?[M']G)Z4?V<GI0 ?VDO]VC^TE_N
MT?V<GI1_9R>E !_:2_W:/[27^[1_9R>E']G)Z4 ']I+_ ':/[27^[1_9R>E'
M]G)Z4 ']I+_=H_M)?[M']G)Z4?V<GI0 ?VDO]VC^TE_NT?V<GI1_9R>E !_:
M2_W:/[27^[1_9R>E']G)Z4 ']I+_ ':/[27^[1_9R>E']G)Z4 ']I+_=H_M)
M?[M']G)Z4?V<GI0 ?VDO]VC^TE_NT?V<GI1_9R>E !_:2_W:/[27^[1_9R>E
M']G)Z4 ']I+_ ':/[27^[1_9R>E']G)Z4 ']I+_=H_M)?[M']G)Z4?V<GI0
M?VDO]VC^TE_NT?V<GI1_9R>E !_:2_W:/[27^[1_9R>E']G)Z4 ']I+_ ':/
M[27^[1_9R>E']G)Z4 ']I+_=H_M)?[M']G)Z4?V<GI0 C:DNT_+VKE+R4-J2
MMCO75MIR;3QVKE;R(+J2K[UX^<?!'U/0R_XI>ATMKJ"K;J-M3?VDO]VH;6P1
MK=3BIO[.3TKU:7P(X9_$P_M)?[M']I+_ ':/[.3TH_LY/2K)#^TE_NT?VDO]
MVC^SD]*/[.3TH /[27^[1_:2_P!VC^SD]*/[.3TH /[27^[1_:2_W:/[.3TH
M_LY/2@ _M)?[M']I+_=H_LY/2C^SD]* #^TE_NT?VDO]VC^SD]*/[.3TH /[
M27^[1_:2_P!VC^SD]*/[.3TH /[27^[1_:2_W:/[.3TH_LY/2@!1J*D_=JW%
M()$#"J@TY >E6XHQ&@44 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH6#1L,@CO4M9VAV#Z7H]O9R,&>)<$BM&@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \3?ZA*WZP/$W^H2N',?\
M=IG3@_XT1/#7_'J/K705S_AK_CU'UKH*,M_W:(\9_&D%%%%=QRA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '.>)?]6?I4_AW_ %/X5!XE_P!6?I4_AW_4
M_A7AQ_Y&+/3?^YHW****]P\P**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*YGQ/_J5_P!ZNFKF?$_^I7_>KSLT_P!UD=>!_CHN^'/^/(_6MFL;PY_QY'ZU
MLUM@/]VAZ&>*_C2"BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5@>)O]0E;]8'B;_4)7#F/^[3.G!_QHB>&O^/4?6N@KG_#7_'J/
MK7049;_NT1XS^-(****[CE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<
M\2_ZL_2I_#O^I_"H/$O^K/TJ?P[_ *G\*\./_(Q9Z;_W-&Y1117N'F!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A_$7_'PWUK:\)_\
M(*_X%6+XB_X^&^M;7A/_ )!7_ J\FC_O\_1'HU/]TB;U%%%>L><%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (WW#]*XJ^_P"0JGUKM6^X?I7%7W_(53ZU
MX^<?!'U/0R_XGZ'767_'JGTJQ5>R_P"/5/I5BO5I? O0X9_$PHHHJR0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^[0]#/%?QI!111768!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4445L9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 </XB_X^&^M;7A/_ )!7_ JQ?$7_ !\-]:VO"?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7RQ\0_^1UO_P#>KZGKY<^(4,K>
M-+\B-R-W4*:Z<-\3.3%_"C'T?6[G1[A9K>1E8>E=%_PLG5_^?F2N-\B;_GD_
M_?)H\B;_ )Y/_P!\FNMQB]SB4Y+1'82?$;5I(V0W,F&!!KCI9#+*\C<EB2:7
MR)O^>3_]\FCR)O\ GD__ 'R::BEL*4I2W-K1?%%[HN[[/*R9&.*V/^%DZO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3"S*2#C(:M/3=?L=30&*:/)_AW#-4XM:DJ<6[7-6B@'(R**DH**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%!( R: "BJLNI64!(EN$4CU-0?V_I7_/]%^=.S%=&C16;_;^E?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,^)_
M]2O^]735S/B?_4K_ +U>=FG^ZR.O _QT7?#G_'D?K6S6-X<_X\C]:V:VP'^[
M0]#/%?QI!111768!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z&B@]#0!PUS_
M ,AI?]^NTM_]2*XNY_Y#2_[]=I;_ .I%>'E/\2IZGI8[X(>A+1117N'FA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7$^)_\ D*CZ5VU<3XG_ .0J/I7C
MYY_NOS1Z&6_QOD=;I_\ QX0_[M6:K:?_ ,>$/^[5FO4H_P ./HCBJ?&PHHHK
M0@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH X?Q%_Q\-]:VO"?_(*_X%6+
MXB_X^&^M;7A/_D%?\"KR:/\ O\_1'HU/]TB;U%%%>L><%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 (WW#]*XJ^_Y"J?6NU;[A^E<5??\ (53ZUX^<?!'U
M/0R_XGZ'767_ !ZI]*L57LO^/5/I5BO5I? O0X9_$PHHHJR0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?$_P#J5_WJZ:N9
M\3_ZE?\ >KSLT_W61UX'^.B[X<_X\C]:V:QO#G_'D?K6S6V _P!VAZ&>*_C2
M"BBBNLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *#T-%!Z&@#AKG_ )#2_P"_
M7:6_^I%<7<_\AI?]^NTM_P#4BO#RG^)4]3TL=\$/0EHHHKW#S0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KB?$__ "%1]*[:N)\3_P#(5'TKQ\\_W7YH
M]#+?XWR.MT__ (\(?]VK-5M/_P"/"'_=JS7J4?X<?1'%4^-A1116A 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!P_B+_CX;ZUM>$_^05_P*L7Q%_Q\-]:
MVO"?_(*_X%7DT?\ ?Y^B/1J?[I$WJ***]8\X**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH 1ON'Z5Q5]_R%4^M=JWW#]*XJ^_Y"J?6O'SCX(^IZ&7_$_0ZZ
MR_X]4^E6*KV7_'JGTJQ7JTO@7H<,_B844459(4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C<J1[5\R_$32&T_
M6Y)MA F<G.*^FZ\N^)NGV.J69E!'FP*>GK6U"7+(Y\1#F@<I\(+*TN-8)F56
M;9G!_&O>D144*HP!7RCX5U^7PYJPN4; . WTKW"#XN>&_(C\R=M^T;OK6E>G
M)RNC/#U(J-F>@45P7_"W?#'_ #W:C_A;OAC_ )[M6'LY]CH]K#N=[17!?\+=
M\,?\]VKL-*U2WUC3X[VU8M#)]TFDX26Z*C.,MF7:***DH**** "BBB@ HHHH
M XKQ_P"%O[=TV62( 3@84]^E>/22^+=.!TY&N##]SA>,5ZCXV\8:CHGB"&RM
MMGE.FXY_"NRTK9?Z9;W,T49D=<GY171&;A%75T<TH*I)V=F>=?#CP9/;S+JE
MZ,N1@AAS7IFI7)L=.DF1"VP<**MJJJ,*H ]A22(LB%6&0:RE-R=V;0@H1LCP
MW1["Z\0^.;FYFC>.-6##>*]QB79$B^B@5Y#J7B:XTCQBUK&$6-I0O ]Z]=@;
M?!&Y_B4']*NK?0SHV5T24445B;A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%5;ZY-M 7'7%<FWB>^#D K@&N:KBZ-)\LW8WIX
M>I45XHZ^]_X\Y?\ =KS:^_X^4_WQ_.M:7Q)>RQLAVX(Q6+,6E(;^('->3C<;
M1G4IN,MF>AA<-4A&2:W/3K3_ (\X?]P5-7"Q^);V.)4!7"C%._X2F]')*X%>
MDLPP[T4CB>#K+6QW%%9NB:@=2L?/)YSBM*NTY0HHHH **** "BBB@ HHHH *
M",CFBB@#F]=\(V6K1.1$HE(^\?6O'_$'@^\T>9@%:11W45]"57N[*&\B,<J
M@^U=>'QDZ6FZ.:MAHU->I\O,I4D,"".U)7J_BCX=#+3Z>A.>3FO,;VPGL)VA
MF0AEZ\5[=&O"JKQ9Y52C*F[,?8:G=:=*)+:4H1Z5ZEX7^(<<P2WN\[^A9C7D
M-*K,IRI(/M2K8>%5:CI5I4WH?4=O=0W*!HI%<'T-35X%X<\:WND,D1?]T/4U
MZ]H7BFQUF%3%)E^ASZUXM?"3I.^Z/5HXF-3U-^BC.>E%<AT!1110 4444 %%
M%% !1110 4444 %%%% !67K6LIHUF]PZ%PHS@5J5F:SI4>JVCP2 X88JX<O,
MN;8F=[>[N<1_PMZR_P"?-Z/^%O67_/F]._X5?8_W6J&[^&EE! SA6R*]!+!O
MHSB_VHD_X6]9?\^;T?\ "WK+_GS>O/;+1X[C7FLB#M$FVO1!\+[''W6K2I2P
MM.W,B*=3$3V9+9?%2TO+I(%M'!;O7>6EP+JV28# 89Q7#6?PWLK6Y295;*UW
M5I +:V2)>BBN'$>QT]D=='VO_+PFHHHKF-PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAZ^AX%V6\:GLH'Z50TO0-/T9<64/EC&*TZRJ3YGH:TJ?(M=PHHHK,U"BBB@
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M^T5@Z%XHLM9@!1PK <AFZUN@@C(.17DR@XNTCT8R4E="T445)04444 %%%%
M!1110 4444 %%%% !534O^/)ZMU4U+_CR>G'="EL>*:1_P CI)_UW_I7NPZ"
MO"=(_P"1TD_Z[_TKW8=!7=C_ (H^AR8/9^H4445P'8%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<SXG_ -2O^]735S/B?_4K_O5YV:?[K(Z\#_'1
M=\.?\>1^M;-8WAS_ (\C]:V:VP'^[0]#/%?QI!111768!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %!Z&B@]#0!PUS_P AI?\ ?KM+?_4BN+N?^0TO^_7:6_\
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M\17T46HS*BRD* >E1"BY-KL7.NHQ4NY].T5\G?\ "9^(?^@G-^='_"9^(?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!&^X?I7%7W_(53ZUVK?</TKBK[_D*I]:\?./@CZGH9?\3]#KK+
M_CU3Z58JO9?\>J?2K%>K2^!>APS^)A1115DA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 >7?%?PQ-JZ)>1+DQ)7BMGH
M=Y<WZVPA?.X Y4U]<211S*5D0,I[$5572-/1]ZV<(;U"UT0KN,;'-4PZG*Y@
M^!-!?0/#OV6089OFKP7Q+H-[+XCOW6)BK2DCY37U(  , 8%5FTRR=BS6L18]
M25J85G%M]RJE!2BH]CY/_P"$>O\ _GDW_?)H_P"$>O\ _GDW_?)KZN_LJP_Y
M](?^^:/[*L/^?2'_ +YK7ZSY&/U3S/E'_A'K_P#YY-_WR:/^$>O_ /GDW_?)
MKZN_LJP_Y](?^^:/[*L/^?2'_OFCZSY!]4\SY1_X1Z__ .>3?]\FOI+X?0/;
M>#;**088#D?E6Y_95A_SZ0_]\U9CB2% D:A5'0"LJE;G5C6E0]F[W'T445B=
M 4444 %%%% !2;1G.!2T4 !P.M1F:$=94'U85QWCWQ<?#UE(D8!EVY KQ]]4
M\3Z[(9K5)L'G"M6T*+DKF%2LHNVY](?:(/\ GM'_ -]"C[1!_P ]H_\ OH5\
MW_8?&G_/.Y_[ZH^P^-/^>=S_ -]57L%_,1]8?\I](B>$G ECS_O"I*^>=(T_
MQ<=3MS.MR(Q(,Y;M7T% "+>(-][8,_E6=2')U-:=3GZ6)****S-0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !534O^/)ZMU4U+_CR>G'="EL>*:1_R.DG_7?^E>[#H*\)TC_D=)/^N_\
M2O=AT%=V/^*/H<F#V?J%%%%<!V!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z&B@]
M#0!PUS_R&E_WZ[2W_P!2*XNY_P"0TO\ OUVEO_J17AY3_$J>IZ6.^"'H2T44
M5[AYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'BC_D)_\  :[>N(\4
M?\A/_@->/G?^[?-'H9;_ !OD7_!_W)ZZBN7\'_<GKJ*]A?"O1?D>=U?JPHHH
MH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 </XB_X^&^M;7A/_D%?\"K%
M\1?\?#?6MKPG_P @K_@5>31_W^?HCT:G^Z1-ZBBBO6/."BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $;[A^E<5??\ (53ZUVK?</TKBK[_ )"J?6O'SCX(
M^IZ&7_$_0ZZR_P"/5/I5BJ]E_P >J?2K%>K2^!>APS^)A1115DA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1XH_Y"?\
MP&NWKB/%'_(3_P" UX^=_P"[?-'H9;_&^1?\'_<GKJ*Y?P?]R>NHKV%\*]%^
M1YW5^K"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^T5@Z'XILM:A5HF"D]F:MT$$9!R*\F4)1=I'HQDI*Z%JIJ7_ !Y/5NJFI?\
M'D]*.Z'+8\4TC_D=)/\ KO\ TKW8=!7A.D?\CI)_UW_I7NPZ"N['_%'T.3![
M/U"BBBN [ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 1ON'Z5Q5]_R%4^M=JWW#]*XJ^_Y"J?6O'SCX(^IZ&7_ !/T.NLO^/5/
MI5BJ]E_QZI]*L5ZM+X%Z'#/XF%%%%62%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'BC_D)_P# :[>N(\4?
M\A/_ (#7CYW_ +M\T>AEO\;Y%_P?]R>NHKE_!_W)ZZBO87PKT7Y'G=7ZL***
M*!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4A&012T4 9=SH<%S*9&8Y-0_\(Y;?WC6
MU17++!8>3NXHW6)JI64CRKQJQT8Q>3SN;'-;OA/3X]5TD7$IPV>U8/Q-ZP?[
M]=5\/_\ D7A_O5VU,NPOU9/D5SEAC:[KN/,[&E_PCEM_>-7[.PCLQA#FK=%<
ME/"4:;YH1LSIG7J35I,****Z#$**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^X
M?I7%7W_(53ZUVK?</TKBK[_D*I]:\?./@CZGH9?\3]#KK+_CU3Z58JO9?\>J
M?2K%>K2^!>APS^)A1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?()2/NBMX$$9%>+*$HNTCU(R4E="T445)04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1XH_P"0G_P&
MNWKB/%'_ "$_^ UX^=_[M\T>AEO\;Y%_P?\ <GKJ*Y?P?]R>NHKV%\*]%^1Y
MW5^K"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y3\3>L'^_75?#_
M /Y%X?[U<K\3>L'^_75?#_\ Y%X?[U>C5_W6)Q4_]X9UE%%%><=H4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 C?</TKBK[_D*I]:[5ON'Z5Q5]_R%4^M>
M/G'P1]3T,O\ B?H==9?\>J?2K%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH :_W&^AKY)\4_\ (SZC_P!=C7UL_P!QOH:^2?%/_(SZC_UV-=6%W9QXS9'=
M> ?&=EX=LT^T(6PN./I7:6OQDTBYG$0MY%).,FOGO<0, G\Z Q!R"0?:MI48
MR=V<\<1.*LCZZTO7K+58P\,J9(SC=S6FQPI/H,U\K^$?$5UI&JQ8E8H[@-N8
M\"OIBPU!-0THW$;9&P\_A7+5I<C.VC6]HCR/XG>,[F.Y6ULY2B]&%>1RW,L\
MOFR-E\YS6QXMNS<Z]=#.=LA%'AOPO?>([AXK2+>5&:[()0B<-24IS)M#\9:E
MI%RC+.WEKV%?17A/Q'#KVG1NIS(JY?FOG#Q#X4U#P_-LNH2@QFNQ^$NLR6E[
M+ 6R)& Y/TK.M",H\R-:$Y0ERR/?Z*!THKA/0"BBB@#E_%?B1M >%_)DD0C+
M; 35?1?B!IVJX4CR6/\ ST.*Z:^T^#4(&BF0$$8R1FO.M>^%L$A,]A)-YI/1
M6('\ZUCR-69C/G3O$](CO;:4 I<1MGT85,'5NC UX1)I'C+06S# S1KW9R?Z
M4Y?'GBZPPLEK%@=<_P#ZJKV-]F3[>WQ(]VII=5ZL!]37B7_"UO$&,>1#G_/M
M4#>.O%^H K':Q8/H?_K4O82']8AT/;I+ZUB4E[B(8]6%<KK/Q#T[2R553,P_
MYYG-><QZ'XPUULSP,D;=U<_X5UF@_"ZVAVSWTDQE'9B2/U-/DA'XF+VDY?"C
MI_"GB!M>6:0Q21J.5W@BNEJM9V4-C L4*@ #' Q5FL9--Z&\4TM0HHHI#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KR7UI"<2W,2?[S@5SOC
MC7[WP_HLMW9HK.O3=7B)L_'/C6=Y4MV$6<DHY''X"@#Z-75+!SA;V!C[2"K2
MNKC*L"/4&OF&]\%^,_#L7VN-)F53GYI&[5W7PM^(]QJ\@TS4BJW(?8%'MQ0!
M[+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<1XH_Y"?_ :[>N(\4?\A/\ X#7C
MYW_NWS1Z&6_QOD7_  ?]R>NHKE_!_P!R>NHKV%\*]%^1YW5^K"BBB@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Y3\3>L'^_75?#_P#Y%X?[U<K\3>L'
M^_75?#__ )%X?[U>C5_W6)Q4_P#>&=91117G':%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 (WW#]*XJ^_Y"J?6NU;[A^E<5??\A5/K7CYQ\$?4]#+_B?H
M==9?\>J?2K%5[+_CU3Z58KU:7P+T.&?Q,****LD**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?;YO?\J ->BLC[?-[_E1]OF]_P J ->BLC[?-[_E1]OF]_RH UZ*R/M\WO\
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M UZ*R/M\WO\ E1]OF]_RH UZ*R/M\WO^5'V^;W_*@#7HK(^WS>_Y4?;YO?\
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MBLC[?-[_ )4?;YO?\J ->BLC[?-[_E1]OF]_RH UZ*R/M\WO^5'V^;W_ "H
MUZ*R/M\WO^5'V^;W_*@#7HK(^WS>_P"5'V^;W_*@#7HK(^WS>_Y4?;YO?\J
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M?;YO?\J ->BLC[?-[_E1]OF]_P J ->BLC[?-[_E1]OF]_RH UZ*R/M\WO\
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M UZ*R/M\WO\ E1]OF]_RH UZ*R/M\WO^5'V^;W_*@#7HK(^WS>_Y4?;YO?\
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MBLC[?-[_ )4?;YO?\J ->BLC[?-[_E1]OF]_RH UZ*R/M\WO^5'V^;W_ "H
MUZ*R/M\WO^5'V^;W_*@#7HK(^WS>_P"5'V^;W_*@#7HK(^WS>_Y4?;YO?\J
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M?;YO?\J ->BLC[?-[_E1]OF]_P J ->BLC[?-[_E1]OF]_RH UZ*R/M\WO\
ME1]OF]_RH UZ*R/M\WO^5'V^;W_*@#7HK(%_+GO^5:5NYDB#'K0!+1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U%
M$/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U% $/V:/T%'V:
M/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U% $/V:/T%'V:/T%344 0_9
MH_04?9H_05-10!#]FC]!1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05
M-10!#]FC]!1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!
M1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U%
M$/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U% $/V:/T%'V:
M/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U% $/V:/T%'V:/T%344 0_9
MH_04?9H_05-10!#]FC]!1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05
M-10!#]FC]!1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!
M1]FC]!4U% $/V:/T%'V:/T%344 0_9H_04?9H_05-10!#]FC]!1]FC]!4U%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %5-2_X\GJW534O^/)Z<=T*6QXII'_(Z2?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJDK"7+?W59&RO;WG=A1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5-2_X\GJW534O^/)Z<=T
M*6QXII'_ ".DG_7?^E>[#H*\)TC_ )'23_KO_2O=AT%=V/\ BCZ')@]GZA11
M17 =@4444 %%%% !1110 4444 %9VI:+9ZG R30JS$<$]JT:*:;3NA-)JS/%
M?%'P_GLG:XMLNI_@4=*X2>VFMG*2QLA]Z^HV174JP!!XKCO$?@6TU.-Y(8_W
M_8UZF'S"WNU#SZV#ZP/"*DAFD@</&Q5AW%:VM>&[S2)F65#MSQ@5BD$=:]6,
MHS5T>>TXNS.\\,>/;BPD6&Z+2J3U)Z5ZUI>NVFJ0J\<J;C_"#7S36II.O7FD
M3![>3'KFN+$8&-36.C.JCBY0TEJCZ6HKS_PO\0;>^"V]VY\\]#VKO(IDFC#H
MP((SP:\:I2G3=I(]2G4C-7B24445F6%%%% !1110 4444 %%%% !1110 444
M4 %%%% %+4]-AU2U\B= R9S@UA_\(/IG_/O'^5=315QJSBK)D2IQD[M''7W@
MO38["=UMX\JA(X]J\L\(Z=#?^+EM)5#1EV&#]:]ZU+_D&77_ %R;^5>(^ _^
M1]3_ *Z-_P"A5Z.%J2E2FVSBQ$(JI!)'I_\ P@^F?\^\?Y5+!X-TZ"0.D$8(
M]JZ2BN#VU3N=GLH=AJ((XU0= ,4ZBBLC0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<FO#Q.$E2=UL>M0Q,:FCW.BHH!STHKC.H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^J?_=->):]
M_P C9#_O&O;9/]4_^Z:\2U[_ )&R'_>-=^!^)^AQXSX4>OZ)_P @F'Z5H5GZ
M)_R"8?I6A7%/XF=4?A04445)04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 A&017 WWPNL+Z^FN7F(:1MQ&*[^
MBJC)QV)E!2W/./\ A4>G?\]S^5'_  J/3O\ GN?RKT&6[MX?]9,B?5L5 =8T
MT=;Z#_OL57M)]R/94^QPO_"H]._Y[G\J/^%1Z=_SW/Y5W/\ ;.F_\_UO_P!]
MBC^V=-_Y_K?_ +[%/VDP]E3['#?\*CT[_GN?RKN-&TN/1],BLHCE(QP:7^V=
M-_Y_K?\ [[%6XI8YXQ)$ZNAZ,IR*F4I/<J,(1?NCZ***@L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ JGJ.HQ:? TLK!549R:N5@^*-+DU33988S@LN*NFDY)2V)FVHMHSO^$^
MTS_GX2J][XZTV6V9%G0DUPG_  K34/\ GJ/RH_X5IJ'_ #U'Y5Z2H85?:.!U
M<1_*9FG:G##XF>Z9@$,N[->JCQ]IF/\ CX2O/?\ A6FH?\]1^5'_  K34/\
MGJ/RK6K'#U6FY;&=-UZ=[1/2+?QQIUQ,L:3H2:Z:"59X5D4Y!KQW3/AY?VU_
M'*THPI]*]<TZ V]C'$W517GXFG2A;V;N=M"=27QJQ:HHHKE.@**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\*/7]$_Y!,/TK0K/T3_ )!,/TK0KBG\3.J/PH****DH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YC\4?^/1/^N@_F*].KS'XH_\>B?]=!_,5U8/^,CGQ7\)FU\-_P#D!O\
M[U=I7%_#?_D!O_O5VE1B?XLBZ'\-!1116!J%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% 'E/Q-ZP?[]=5\/_P#D7A_O5ROQ-ZP?[]=5\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<EXW\*KXDM57@.B_*3VKK:*<6T[H4HJ2LSS3PC\,;?2PDUZ$F8>H
M[UZ)+:Q36OV=E!CQC%2EE7JP'XTGFQ_\]%_.G*;D[LF,(Q5D>(^,_AG.;N6[
MM3D.<[5%>>-X4U9;GROL4Q'][;7U@7A;JR'ZD4W%MZ1?I6T<1)*S,)X:,G='
MC'@?X9S"[BOKML!#G8PZU[5#"D$8CC4*HZ 4@>%>C(/H13P01D$$>U93FYN[
M-J=-05D+1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9O?#_P#Y!I_W1795QOP__P"0:?\ =%=E48C^*RZ'\-!1116!J%%%% !1110
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M'C/A1Z_HG_()A^E:%9^B?\@F'Z5H5Q3^)G5'X4%%%%24%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?[]=5\/_ /D7A_O5Z-7_ '6)Q4_]X9UE%%%><=H4444 %%%% !1110 4444
M%%%% !44]O%<1E)4# ^M2T4 >7^+O (D+W5F.3SL4=*\MO+.:RF,4Z%&]#7U
M"0&!!Z&N/\4^";;6('>"-5N".&->GA<<X^[4V.#$81/WH'@U3VMW-:2B2*1E
M(]#5W5M#NM)N&BE1C@XSCBLNO834E='FM.+U/5_"7C\,4MKPA1TW,:]-M[F&
MZC$D+AT/0BOEQ6*,&!Y%=OX4\<3Z9*L%U(S1=% [5YF*P-_>IG=A\7;W9GN5
M%9^F:M;:G;K)$ZY/;/-:%>0TT[,])--704444AA1110 4444 %%%% !1110
M4444 %%%% !1110 V3_5/_NFO$M>_P"1LA_WC7MLG^J?_=->):]_R-D/^\:[
M\#\3]#CQGPH]?T3_ )!,/TK0K/T3_D$P_2M"N*?Q,ZH_"@HHHJ2@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=0A5X9D8D<@'I7B5L/.D]3U:5>-1:$FI?\@RZ_ZY-_*O$? ?_(^I_P!=&_\
M0J]NU+_D&77_ %R;^5>(^ _^1]3_ *Z-_P"A5U8/^#4]##$_Q('O%%%%><=H
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7/^+?^0/-_N&N@KG_ !;_ ,@>;_<-:4?C1%3X&>>_#/\
MY#/YU[%7COPS_P"0S^=>Q5TX_P#BF&#_ (84445Q'4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ><?$W_ (]V_P!VKGPY_P"/'_@-4_B;_P >[?[M7/AS
M_P >/_ :]%_[JCB7^\'=T445YQVA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7F/Q1_X]$_ZZ#^8KTZO,?BC_ ,>B?]=!_,5U8/\ C(Y\5_"9M?#?_D!O
M_O5VE<7\-_\ D!O_ +U=I48G^+(NA_#04445@:A1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<_XM_Y \W^X:Z"N?\6_\@>;
M_<-:4?C1%3X&>>_#/_D,_G7L5>._#/\ Y#/YU[%73C_XIA@_X84445Q'4%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ><?$W_CW;_=JY\.?^/'_@-4_B;_
M ,>[?[M7/AS_ ,>/_ :]%_[JCB7^\'=T445YQVA1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7/^+?^0/-_N&N@KG_ !;_ ,@>;_<-:4?C1%3X&>>_#/\
MY#/YU[%7COPS_P"0S^=>Q5TX_P#BF&#_ (84445Q'4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ><?$W_ (]V_P!VKGPY_P"/'_@-4_B;_P >[?[M7/AS
M_P >/_ :]%_[JCB7^\'=T445YQVA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7F/Q1_X]$_ZZ#^8KTZO,?BC_ ,>B?]=!_,5U8/\ C(Y\5_"9M?#?_D!O
M_O5VE<7\-_\ D!O_ +U=I48G^+(NA_#04445@:A1110 4444 %%%% !1110
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M'C/A1Z_HG_()A^E:%9^B?\@F'Z5H5Q3^)G5'X4%%%%24%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKCKU.9Z'=AZ?)&["BBBL#H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\)_"04445R'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5S_BW_D#S?[AKH*Y_Q;_R!YO]
MPUI1^-$5/@9Y[\,_^0S^=>Q5X[\,_P#D,_G7L5=./_BF&#_AA1117$=04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!YQ\3?^/=O]VKGPY_X\?^ U3^)O\
MQ[M_NU<^'/\ QX_\!KT7_NJ.)?[P=W1117G':%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !112$A1DG H 6BHC=0*,F5143:C9H,M<1@?6G9BNBU7F/Q1_X]$_ZZ#^8K
MOVUK34^]>Q#\:\U^)&I6EW;HMO.DA\P'Y3[BNO!QE[9.QSXF2]F]3I?AO_R
MW_WJ[2N#^'5]:QZ.Z/.@;=T)KNDD6095@1[5EB4_:R+H/]VAU%%%8&P4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME7'HU:K+9O=F;QT>B/HJ74[6$X:5?^^A5&;Q/I\#[6<9]C7STVJ7[=;N4_\
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MA6?HG_()A^E:%<4_B9U1^%!1114E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449'K2;AZB@!:*3</4
M4;AZB@!:*3</44M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17.:WXW
MT7P_(4OY]C X-6_#_B73?$UJ]SILOF1J<$^] &Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:NK!?QD<^*_ALWOA_P#\@T_[HKLJXWX?_P#(-/\ NBNRJ,1_%9=#^&@HHHK
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9'B/6(-&T>XN9)%#(FY5/>M5W6-2S, !W)KY\^)GBN7Q#KEM
MHNG,Q!<QR=QWH \[\6:K?^(]6DU-VD2UD/RCM7N/P'X\+W/_ %U_J:Y'QCX0
M@\/?#"Q22,"Y$N&(_P" UUWP(_Y%BZ_ZZ_U- 'K%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-17!.I*;O)G9&$8Z)!7/^+?^0/-_N&N@KG_%O_('F_W#3H_&A5/@9Y[\,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 (W*'Z5\L^.M-:R\07,C9Q+(2,U]3UY'\
M5O#L5W$EU RJ8@68#O6^'E:1SXF'- Y/X6>'[?5=7+7 RH3.",^M>\Q:-I\4
M806<!P,9,8KYP^'WB7_A'];\R4DQL N/2OHB#Q)I$D$;F_@!90<;NE5B%+F(
MPSCREK^RM/\ ^?*#_OV*/[*T_P#Y\H/^_8J#_A(=(_Z",'_?5'_"0Z1_T$8/
M^^JP]XZ;Q)_[*T__ )\H/^_8JU'&D*!(T5%'0*,"L[_A(=(_Z",'_?57X)XK
MF(2PR*Z'HRG@TG?J-6Z$E%%%(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !45Q<Q6L1DF;:H[U+6;K
M>G2:G8-;QR;&/>@#.?QUX?C<HUZ 0<&EB\<:!-*L:7H+,< 5YK<?!?5)KF24
M:J &8G%,3X.:M9.+D:H&,1WX'?% '3?%+QG%HNB2002@7+ %5]B*Y7X5>"WO
MKJ;6=25MSMYD>[G/2N+\<Z7KVJ:XK/:W$L:)M^[UQ5RPUKQ9IUK'!!:WB(@P
M %H ])^.0"^#X !@>=_A4/P(_P"19NO^NO\ 4UY#XUUOQ)?:2D>H1W*Q!\@N
M.,\4SP3K7B.PTV1-.CN6C+9/EC(H ^N:*R/#$UQ<>';26Z#"9DRP;KFM>@ H
MHHH **** "BBB@"&:X6'J:A^WQ_WJ?<6OGXYJO\ V9_M"@"7[?'_ 'J/M\?]
MZHO[,_VA1_9G^T* )?M\?]ZC[?'_ 'JB_LS_ &A1_9G^T* )?M\?]ZC[?'_>
MJ+^S/]H4?V9_M"@"7[?'_>H^WQ_WJB_LS_:%']F?[0H E^WQ_P!ZC[?'_>J+
M^S/]H4?V9_M"@"7[?'_>H^WQ_P!ZHO[,_P!H4?V9_M"@"7[?'_>H^WQ_WJB_
MLS_:%']F?[0H E^WQ_WJ/M\?]ZHO[,_VA1_9G^T* )?M\?\ >H^WQ_WJB_LS
M_:%']F?[0H E^WQ_WJ/M\?\ >J+^S/\ :%']F?[0H E^WQ_WJ/M\?]ZHO[,_
MVA1_9G^T* )?M\?]ZC[?'_>J+^S/]H4?V9_M"@"7[?'_ 'J/M\?]ZHO[,_VA
M1_9G^T* )?M\?]ZC[?'_ 'JB_LS_ &A1_9G^T* )?M\?]ZC[?'_>J+^S/]H4
M?V9_M"@"7[?'_>H^WQ_WJB_LS_:%']F?[0H E^WQ_P!ZC[?'_>J+^S/]H4?V
M9_M"@"7[?'_>H^WQ_P!ZHO[,_P!H4?V9_M"@"7[?'_>H^WQ_WJB_LS_:%']F
M?[0H E^WQ_WJ/M\?]ZHO[,_VA1_9G^T* )?M\?\ >H^WQ_WJB_LS_:%']F?[
M0H E^WQ_WJ/M\?\ >J+^S/\ :%']F?[0H E^WQ_WJ/M\?]ZHO[,_VA1_9G^T
M* )?M\?]ZC[?'_>J+^S/]H4?V9_M"@"7[?'_ 'J/M\?]ZHO[,_VA1_9G^T*
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M]ZHO[,_VA1_9G^T* )?M\?\ >H^WQ_WJB_LS_:%']F?[0H E^WQ_WJ/M\?\
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MA1_9G^T* )?M\?\ >H^WQ_WJB_LS_:%']F?[0H E^WQ_WJ/M\?\ >J+^S/\
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MSCL)?M\?]ZC[?'_>J+^S/]H4?V9_M"@"7[?'_>H^WQ_WJB_LS_:%']F?[0H
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M<$_Q5V/V^/\ O5Q?P^LO.T9VS_%77_V9_M"HQ/\ %D71_AHE^WQ_WJ/M\?\
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M]ZHO[,_VA1_9G^T* )?M\?\ >H^WQ_WJB_LS_:%']F?[0H E^WQ_WJ/M\?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!&.$)]J^:_%?C357U:_L2Z^2'*X]J^E&&5(]J^>->^'^J7>NWD
MZ6\A5Y"0171A^6[YCFQ/-9<IYR6).<\T_P ^7_GJ_P#WT:[+_A6VK_\ /M)1
M_P *VU?_ )]I*Z_:1[G#[.?8XWSYO^>K_P#?1H\^;_GJ_P#WT:[+_A6VK_\
M/M)1_P *VU?_ )]I*.>/</9S['&^?-_SU?\ [Z-?4'PX8MX(L2Q)..I_"O$?
M^%;:O_S[25[QX)L)=,\+6EK,I5T'(-88B2<=#IPL)*3N=#1117&=P4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 1F"(G)B0_\!%'V>'_GC'_WR*DHH \K^.,4:>$(2L:
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M[:>#A'?4Q-,\+Z?I8'DQ_F*V515Z*!]!3J*XI2E)W;.N,5'1!1114C"BBB@
MHHHH **** "BBB@ KG_%O_('F_W#705S_BW_ ) \W^X:TH_&B*GP,\]^&?\
MR&?SKV*O'?AG_P AG\Z]BKIQ_P#%,,'_  PHHHKB.H**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH \X^)O_ ![M_NU<^'/_ !X_\!JG\3?^/=O]VKGPY_X\
M?^ UZ+_W5'$O]X.[HHHKSCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO,?BC_QZ)_UT'\Q7IU>8_%'_ (]$_P"N@_F*ZL'_ !D<^*_A,VOAO_R W_WJ
M[2N+^&__ " W_P!ZNTJ,3_%D70_AH****P-0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 0J#U -03V4%PI5XUQ]*L44TV@L<Q?>!=(OMQDC.3Z5R6I_#
M 9/V)/IFO5**WABJL-F8SP].6Z/G^^\!ZM9EBT8VCTKGKBQGMG*O&V1[5].R
M012C#QJWU%4+K0=/NHRIM8@3WVUV4\R:^-'+/ K[+/FDJ1U!%)7MNH_#6TN]
MS)+L]@*Y#4OAO<VH/V??+BNVGC:4^IRSPM2/0X&E#L.C$?C6M=>&M4M"?,M'
M4#N:RY(7A.'4@UU*49;,P<6MRU::K=63AHI&S[FNET[XBZO:,$+KY?>N-HJ)
MT83^)%1J2CLSV'3?B=:G O)#GVKJ;'QAI=^!Y4G7UKYUJ:.[N(?]7,Z_0UR5
M,OIR^'0Z88V:W/J!)XY%#*ZD'WJ0$'H:^<=/\4ZC9-DW$CCT+5UNG?%*XA"Q
MR6X(]2:XJF75(_#J=4,;![Z'L-%<;IOC_3[HK]HE2+/6NBM];T^ZQY-RK9Z8
MKCG1G#='3&I"6S-"BD5@PR#D4M9EA0>E%!Z4 >._$;_D*VG^]_C7H?@W_D6K
M?_/I7G?Q&_Y"MI_O?XUT>F>*K/1_"D*^:IF&04/T%>G5A*=""B<%.2C6DV=K
M?:C;Z?;M-.X"KUYKR[Q5\0VE#06$G!X;-<KX@\6W>L3MAFC3I@'@USA)8Y)R
M:WPV!4?>GN8U\6Y:0V);BYDN9"\C$D^]0T5JZ5H-YJDZK%"Q0GEAVKT6U%79
MQI.3T,Z&"2>14C4DDXZ5Z'X7^'DUPZ37T?[KOBNL\+^!K;38EFG =R/NL.E=
MK'&D2A44 #L*\G$X^_NTST:&#^U,J:?IEOIT"Q0H  ,=*NT45Y;;;NSO22T0
M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 44A. 3Z5S]_XLL;";RY9D4^]5&$I.T43*2CN=#7E_Q-Z-
M72?\)WIG_/Q'7">.=?M=4!\B16^E=N$HSC53:.7$U(.FTF=K\/\ _D&G_=%=
ME7EW@_Q59:=8[)ID4X[UTO\ PG>F?\_$=9UZ-1U&TBZ-6"@DV=9165I.NVVK
M(6@D5AG'%:M<LHN+LSH335T%%%%(84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
ME/Q-ZP?[]=5\/_\ D7A_O5ROQ-ZP?[]=5\/_ /D7A_O5Z-7_ '6)Q4_]X9UE
M%%%><=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R7_5/_NFO$M> _P"$
MKA&!]XU[=)_JG_W37B6O?\C9#_O&N_ _$SCQGPH]>T-5&E0X4#CL*T:S]$_Y
M!,/TK0KBG\3.J/PH****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ***J7^H6^G6[37#[449)H#8MT5Y3KG
MQ<M[9V73Y4D(Z9Q7*2?&O70YV0P$?Y]JV5";,)8BFCZ!HKY[_P"%U^(/^>,'
M^?PH_P"%U^(/^>,'^?PI_5YB^M4SZ$HKY[_X77X@_P">,'^?PKVCPCJ\^N>&
M[;4+@ 2RC) Z5$Z4H*[+IUHS=D;E%%%9FH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "N?\6_\@>;_ '#705S_ (M_Y \W^X:TH_&B*GP,\]^&?_(9_.O8J\=^&?\
MR&?SKV*NG'_Q3#!_PPHHHKB.H**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \X^)O\ Q[M_NU<^'/\ QX_\!JG\3?\ CW;_ ':N?#G_ (\?^ UZ+_W5'$O]
MX.[HHHKSCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,?BC_P >B?\
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MJ_U>]\Z*>-1GO7IM%:TJTZ3O$SJ4HU%:1XS_ ,*DU7_GYB_S^-'_  J35?\
MGYB_S^->S45T?VA7[F/U.D>,_P#"I-5_Y^8O\_C1_P *DU7_ )^8O\_C7LU%
M']H5^X?4Z1QO@WPG=>'8"EQ(K$MGBNRHHKEJ5)5)<TMS>$%!<J"BBBH+"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HYB5A<CJ!4E(P#*0>] 'C?BKQ5K]EK<D-K,ZQCH IK$
M_P"$U\3_ //Q)_WR:]EN_#%C>3F:0?,?:H/^$-TW^[_X[7IPQ5!12<3@EAZK
MDVI'AVHZMJ^J[?M9DDVG(^4U9L?$NOZ=!Y-M+(B>FTU[1_PANF_W?_':/^$-
MTW^[_P".UH\=1:MRZ$?5*M[W/(?^$U\3_P#/Q)_WR:](\":OJ.I1*;Z1F)7N
M*UO^$-TW^[_X[6GI^DV^G "$?I7/7Q%*<+1C9FU&A4C*\F7Z***X#L"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ;)_JG_P!TUXEKW_(V0_[QKVV3
M_5/_ +IKQ+7O^1LA_P!XUWX'XGZ''C/A1Z_HG_()A^E:%9^B?\@F'Z5H5Q3^
M)G5'X4%%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ><?$W_CW;_=JY\.?^/'_@-4_B;_ ,>[?[M7/AS_ ,>/_ :]%_[JCB7^
M\'=T445YQVA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F/Q1_P"/1/\
MKH/YBO3J\Q^*/_'HG_70?S%=6#_C(Y\5_"9M?#?_ ) ;_P"]7:5Q?PW_ .0&
M_P#O5VE1B?XLBZ'\-!1116!J%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C ,I
M!&12T'I0!XY\10!JMI@8^;_&O1/!G_(M6_\ GTKSSXC?\A6T_P![_&O0_!G_
M "+5O_GTKT:_^[0.*C_'D;]%%%><=H4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]4_\ NFO$M>_Y
M&R'_ 'C7MLG^J?\ W37B6O?\C9#_ +QKOP/Q/T./&?"CU_1/^03#]*T*S]$_
MY!,/TK0KBG\3.J/PH****DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KG_%O_('F_P!PUT%<_P"+?^0/-_N&M*/QHBI\#//?AG_R&?SK
MV*O'?AG_ ,AG\Z]BKIQ_\4PP?\,****XCJ"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /./B;_ ,>[?[M7/AS_ ,>/_ :I_$W_ (]V_P!VKGPY_P"/'_@-
M>B_]U1Q+_>#NZ***\X[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS'X
MH_\ 'HG_ %T'\Q7IU>8_%'_CT3_KH/YBNK!_QD<^*_A,VOAO_P @-_\ >KM*
MXOX;_P#(#?\ WJ[2HQ/\61=#^&@HHHK U"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *#THH/2@#QWXC?\ (5M/][_&O0_!G_(M6_\ GTKSSXC?\A6T_P![_&O0
M_!G_ "+5O_GTKT:_^[0.*C_'D;]%%%><=H4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 0\ FO!/BGXFFN+M;6&7Y4)5A7
MO3_<;Z5\F>+)6D\37X8D@2G'-=&&C>5SEQ4FHV,ZRL9[^810HS,?09K:U'P;
MJ&FV)NIB-@&<8KM/@[:03:LQD16/E]&&?6NR^*42)X>N J*/E[#VK>55J?*C
MGA13I\[/"?#O_(Q6'_785[O\4=,2Y\("1 !+@<_A7A'AW_D8K#_KL*^@_B1<
M1P>#@9&P,#^5*M\<2J'\.1\\Z5.;#6(I2<&-NM?4OA6\^W>'K>XSG<*^3I6W
MW#%3U/%?4'PXS_PA%CGKC_"IQ*T3'A'[S1U=%%%<9WA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M</*BGT+ 5)7D?Q$N[^'Q"%MV8)L[,16U"C[6?+>QE6J>SCS'J_VJW_Y[Q?\
M?8KS/XG2QO:ILD1OW@Z'/<5PW]HZO_>?_OLU5NFU"\&)=QYSRQ->E0P7LYJ7
M,<-7%<\'&QZY\.9X4T1P\J*=W=@*[/[5;_\ />+_ +[%?.=M/J5K'LB+ >S$
M5/\ VCJ_]Y_^^S4U<#SS<N;<=/%\L5&Q]#I-$YPDB,?9@:?7EWP^NKV;45%P
M6*X[L37J->=6I>RERW.ZE4]I'F"BBBLC0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@
M]**#TH \=^(W_(5M/][_ !KT/P9_R+5O_GTKSSXC?\A6T_WO\:]#\&?\BU;_
M .?2O1K_ .[0.*C_ !Y&_1117G':%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_5/_NFO$M>_Y&R'
M_>->VR?ZI_\ =->):]_R-D/^\:[\#\3]#CQGPH]?T3_D$P_2M"L_1/\ D$P_
M2M"N*?Q,ZH_"@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]4_\
MNFO$M>_Y&R'_ 'C7MLG^J?\ W37B6O?\C9#_ +QKOP/Q/T./&?"CU_1/^03#
M]*T*S]$_Y!,/TK0KBG\3.J/PH****DH**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJI)JEC"Y22[A1QU#. : N6Z"
M,U2_MC3?^?ZW_P"^Q1_;&F_\_P!;_P#?8IV8KHAU+0K'4XRLL$98_P 17FN&
MU'X/:??REQ<F/V45W_\ ;&F_\_UO_P!]BC^V--_Y_K?_ +[%5&4X[$2A"6YY
MDOP.L P/V]ZZ?0OAWINC%20LQ']X5TW]L:;_ ,_UO_WV*/[8TW_G^M_^^Q5.
MI-[B5*G'5(M10QPH%C0*!V%/JE_;&F_\_P!;_P#?8JU%+'-&)(G5T/1E.16=
MF:)H?1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5R7CS_D"3_[E=;7)>//^0)/_N5M0_B(RK? SE_A7_Q\/_N5
MZK7E7PK_ ./A_P#<KU6M<;_&9GA/X2"BBBN0Z0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#"\6?\ (&>O-_ G_(:E_P"NM>D>+/\ D#/7F_@3_D-2_P#7
M6O1P_P# D<5;^-$]EHHHKSCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **QM4\1VNENJS
M8R?>L_\ X3G3_4?G6BHS:ND0ZD$[-F#\3?\ CW;_ ':N?#G_ (\?^ US?CKQ
M#;:G"PBQ]W'6K/@KQ+:Z=:;9<9VXZUZ#IR^K<MM3B4X^WO<]6HKEO^$YT_U'
MYU?T[Q):ZD^V+&<XZUY[HS2NT=JJ0;LF;5%%%9EA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'I
M10>E 'COQ&_Y"MI_O?XUZ'X,_P"1:M_\^E>>?$;_ )"MI_O?XUZ'X,_Y%JW_
M ,^E>C7_ -V@<5'^/(WZ***\X[0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R?ZI_]TUXEKW_(V0_[
MQKVV3_5/_NFO$M>_Y&R'_>-=^!^)^AQXSX4>OZ)_R"8?I6A6?HG_ ""8?I6A
M7%/XF=4?A04445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]&NL\&>%-8TJY#WD9"[L]37IM%14QU2<>5I%PPD(.Z"BBBN(Z@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *#THH/2@#QWXC?\A6T_WO\:]#\&?\BU;_ .?2O//B-_R%;3_>_P :
M]#\&?\BU;_Y]*]&O_NT#BH_QY&_1117G':%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_ %3_ .Z:
M\2U[_D;(?]XU[;)_JG_W37B6O?\ (V0_[QKOP/Q/T./&?"CU_1/^03#]*T*S
M]$_Y!,/TK0KBG\3.J/PH****DH**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K"U3PCI.KEFNX-[-6[133:V$TGN>3ZU
M\(;:;<=-B2,]LXKS[5_AIK&E[F?:R]MHS7TS4;P12_ZR-&^HS6T:\D83PT)'
MQ_)9W=I+AH9 1WV&M.Q\7:SI;#[/.4(Z9!KZ%\06'A]E9+L10GN0@KR/Q1I'
MA) \EIJ):4=% _\ KUT1JJ>Z.6=%PV9H:/\ %VZA"#4)7?'7&:]!TCXF:/JB
M+MW*3_>.*^:IE196"'*CH:5)Y8ON2,OT.*<J$6*.)G'<^P[6\@NXP\,B,#Z,
M#5BO%/@]>W$JS++,[C=_$V:]KKBJ0Y)6.^G/GC<****@T"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ;)_JG_W37B6O?\C9#_O&O;9/]4_^Z:\2U[_D;(?]XUWX
M'XGZ''C/A1Z_HG_()A^E:%9^B?\ ()A^E:%<4_B9U1^%!1114E!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% #9/]4_^Z:\2U[_ )&R'_>->VR?ZI_]TUXEKW_(
MV0_[QKOP/Q/T./&?"CU_1/\ D$P_2M"L_1/^03#]*T*XI_$SJC\*"BBBI*"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\6?\ (&>O-_ G_(:E_P"N
MM>D>+/\ D#/7F_@3_D-2_P#76O1P_P# D<5;^-$]EHHHKSCM"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!LG^J?_ '37B6O?\C9#_O&O;9/]4_\ NFO$M>_Y&R'_ 'C7?@?B?H<>,^%'
MK^B?\@F'Z5H5GZ)_R"8?I6A7%/XF=4?A04445)04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!C:WK]OHR%IW"@#-<[_P +*TO_ )^%_2M?Q/X7/B&,J)_+R,5QG_"GF_Z"
M/Z?_ %J[:,<,X_O'J<E65=2]Q:%G7/'VG7VGM#',"Q^E<AX9UZWTS47FE<*I
M?.:Z;_A3S?\ 01_3_P"M1_PIYO\ H(_I_P#6KLA4PL(N*EN<\H8B4E)HW/\
MA96E_P#/POZ58LOB!IUY<K"DX+'Z5S?_  IYO^@C^G_UJMZ;\*VL+U+C[?NV
M]L?_ %JPE#"6T9JI8F^J/2(91-"DB]&&:DJ*VA^SVT<6<[1C-2UYSW.Y!111
M2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKE#) RKU-2T
M4 >1:UX$U6\U6:>-)"C'C#&J'_"N]9_YYR?]]&O;**[5CJJ5CE>$IMW/$3\-
M]6;K"Y^I-.'PZU@# CD ]F->V44_[0JB^I4SQ/\ X5WK/_/.3_OHUZ/X3T>Y
MTJVV7 (.,<FNEHK*KBIU8\LC2GAX4W=!1117,;A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V3_5/_NFO$M>
M_P"1LA_WC7MLG^J?_=->):]_R-D/^\:[\#\3]#CQGPH]?T3_ )!,/TK0K/T3
M_D$P_2M"N*?Q,ZH_"@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^J?_=->):]_P C9#_O&O;9
M/]4_^Z:\2U[_ )&R'_>-=^!^)^AQXSX4>OZ)_P @F'Z5H5GZ)_R"8?I6A7%/
MXF=4?A04445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !111D>M #9/\ 5/\ [IKQ+7O^1LA_WC7MDA'E/S_"
M:\2U[_D;(?\ >-=^!^)^AQXSX4>P:)_R"8?I6A6=HA']DP\]JT<CUKBG\3.J
M/PH****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH
M?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/
M^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/
M^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?1
M3/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\
M*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH
M ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_
M[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_
M[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%
M,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[P
MH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[P
MH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8
M_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_
M +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4
MSS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"
MCS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"
M@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS
M8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS
M8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T
M4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*
M/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\*
M 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-
MC_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-
MC_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* '
MT4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\
MO"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\
M* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V
M/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V
M/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?
M13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^
M\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^
M\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\
MV/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8
M_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]
M%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[
MPH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[
MPH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,
M\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH
M\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!
M]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O
M"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O
M"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4S
MS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"C
MS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@
M!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_
M +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\
MO"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/
M-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/
M-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\*
M'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C
M_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C
M_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13
M/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\
MV/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH
M?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/
M^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/
M^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?1
M3/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\
M*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH
M ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_
M[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_
M[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%
M,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[P
MH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[P
MH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8
M_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_
M +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4
MSS8_[PH\V/\ O"@!]%,\V/\ O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"
MCS8_[PH ?13/-C_O"CS8_P"\* 'T4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"
M@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS
M8_[PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/\ O"@!]%,\V/\ O"CS
M8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_[PH ?13/-C_O"CS8_P"\* 'T
M4SS8_P"\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*/-C_O"@!]%,\V/^\*
M/-C_ +PH ?13/-C_ +PH\V/^\* 'T4SS8_[PH\V/^\* 'T4SS8_[PH\V/^\*
M 'T4SS8_[PH\V/\ O"@!]%,\U/[PIP((R#0 M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH
MQOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH Q
MOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QO
MLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOL
MT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT
M]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]
M'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'
MV:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V
M:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:
M>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>
MMG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>M
MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG
M:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:
M/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/
M2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2
MC:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C
M:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:
M/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/
M2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2
M@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@
M#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#
M&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&
M^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^
MS3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S
M3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3
MT?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T
M?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?
M9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9
MIZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9I
MZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZ
MV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV
M=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=
MH]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H
M]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]
M*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*
M-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-
MH]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H
M]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]
M* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]*
M ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]*
M,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,
M;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;
M[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[
M-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-
M/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/
M1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1
M]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]
MFGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]F
MGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FG
MK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK
M9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9
MVCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9V
MCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VC
MTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCT
MHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTH
MVCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHV
MCTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVC
MTH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCT
MH QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH
M QOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH
MQOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH Q
MOLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QO
MLT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOL
MT]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT
M]'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]
M'V:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'
MV:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V
M:>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:
M>MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>
MMG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>M
MG:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG
M:/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:
M/2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/
M2C:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2
MC:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C
M:/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:
M/2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/
M2@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2
M@#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@
M#&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#
M&^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&
M^S3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^
MS3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S
M3T?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3
MT?9IZV=H]*-H]* ,;[-/1]FGK9VCTHVCTH QOLT]'V:>MG:/2C:/2@#&^S3T
M?9IZV=H]*-H]* ,<6T^:U+=66(!NM28'I2T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",H88/2
ML*^\&Z'J3%KJS5R>N:WJ* .5@^'/ABW8-%IR*1R*Z.UM(;.(1P)M4=JGHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ5]JEII\9:>>-2/X2X!H
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M_P!?\*[K0]=MM>LDNK96".,C=0!JT444 %%%% !1110 4444 %%%% !1110
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MBEWDXY__ %5WR,'16'1AF@!U%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O&_'_@35]>\03W-O-<+"W0(Y KV2D;[I^E 'QAXI\.77AS6(8+EI"SC/SDF
MOJGX>_\ (DZ=_N5X9\</^1ML_P#<KW/X>_\ (DZ=_N4 =/1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !69K^JIHVE27KD )ZUIUPGQ>:1?A]>F/.[V^AH
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M-=,%4L=SDUF_!=2GCZW0]58C]:^D/%7_ " +O_KDW\J^<O@__P E'3_KJ_\
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M1@.V:^EX7\R"-_[R@_I7S+-;OXC^*$\MJI*1S*VX<C&:^F+==MK$IZA /TH
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M>AKZ%^'GA8^'/#\$,H83*,$'Z5YK\)_#C:SJMWK%XN6\SS$+#Z5[Y0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4C?=/TI:1ONGZ4 ?,WQP_Y&VS_P!RO<_A[_R).G?[E>&?
M'#_D;;/_ '*]S^'O_(DZ=_N4 =/1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !6+XIT@ZWH4UB!G?VK:HH ^5-,U&_^'/BBY$BLMO++S@'IC_ZU>M)\:_#W
MV .SR^8?]GO7::QX4TS6%/G6L6X_Q%>:YN+X4Z7'*&(0J#]W;0!Y/XX\5:SX
MLTVXGL_^0>HP^X8-:_[/<>S4+WUV5T/Q373=!\+7&GV\,43R)QM&,\5%\#M*
M>UM&NV4@2IP: /9J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \,^/_ /R"
M;7_KL/YBNC^!G_(F/_UT_P :YSX__P#()M?^NP_F*Z/X&?\ (F/_ -=/\: /
M4**** .3^(>JC2_"-Y,&PZKD5Y%\&],;6/$=[J%RNX,-RFNC^..IM;V#6@;
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M3TKV*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML?'+4]UN;#=_&.*Z[X16(L]!)"XWJ#0!Z-1110 4444 %%%% !1110 4444
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MXW7BE[]1E%N'P?\ @5?2E !1110 4444 %%%% !1110 4444 %%%% !1110
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M4W_/U'/UH ]]\":1'IGAJS*KAWB&ZNHJIID?DZ9;Q@8VH!5N@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M \,_&.?346WUJ"Y>0#!)4CFO>GBCE&)$5QZ,,UQ^M?#71=;E,DP,9)S\BXH
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MHZ+\+-#T2X$T1:1A_?7- '(_"/P+/8#^T[Q1YQ?>"1@\G->T4R*)(8PD:JH
MQP,4^@#YJ^-DI;Q7Y(Y^9>/QKVWP);K!X<M<#&Z)35#Q'\,-(\2ZQ_:5W+*)
M>.%Z?SKK-.T^+3+..VA)*(H49H MT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1SP1W,
M+12KE&ZBI** /FKQYX<U'PIXH.LV*MY$DH)5%R<9]J[;0OC5IS6:175O,)5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7 _%#PDWB71BZ %K="0#7?4A 8$, 0>QH ^:O OCN?P
M(5TW4;>X:!.P0@5Z@WQ?T=8!+Y+\C.W/-;FO> =(U]V>=!&3_<4"N;'P1T 3
M"3[5<\=LG'\Z /+O%WB.\^(&L0VEI!.(%E&,H< 9KW;P'H#>'/#R6KXR<-Q4
M^@^#-+T YMXU<XQEU!-=#@8P.!0!R.N_$'3M"G$4Z,Q)QP:\:^+?C>R\2Z1%
M!:QN&67=S]17KNO_  RTKQ#<":YGF5@<_*3_ (UBM\#?#S?>N+@_4G_&@#B?
MA-\0+#P[X?FMKJ)RY?/\Z]A\,>,[+Q1)*EJC*8^N:Y5?@;X>486XN!]"?\:Z
M;PGX#T[PA+,]E+*YE&#O/_UZ .JHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%&B_V_
MH4VG\?O/6OG/2KR_^&GB>ZW0S&W>3G8AP17U+6)K?A?3]=BV7,2#W"#- '(V
M?QCT>YM1+Y$B>S<'^5<'X_\ B2WB2!M,TRWG"RC:<*2#7<3?!+0)FS]IN%]E
M)']:V]%^&VC:),DL69&7IYBYH YSX/\ A&;1+$7TXVO,G((P:Z'Q[XN?PYIC
MO%!,T@[HI-=DB(B[44*!V Q574=,MM3MF@N(U93ZKF@#S'3_ (X:4]JHFM9U
ME4?-N!&3^5<-XY\>W7C25-.TR"=8S(/X21@FO2KSX+Z!>7/G--,ASG"\#^=;
MN@_#_2- D#P+YC8QEU!H R_ACX0'AW1<SJ/.D(?(]^:] I%4* %  'I2T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9FN:J-)TZ2?RW<A3@*,UITR6))HV1U# C'(S0!X[I
M'QLM8'EM]1M;CS/,(#,I'&?I5'Q=\7X=1L&L],MYP\JE20I-=MK7PHT/6I3)
M*SQD_P#/,8_K2:3\)M#TF99(V>0J<C>,_P!: .)^$?@RY:[77-03YG&,,,&O
M<U4*H4=!4<%O%;QA(D55'91BI: ,[7GV:#?'.,0M_*OF3X;[[SXHJ6!/S-_Z
M%7U%J%C'J%I);RL0CJ5.*Y#P_P#"[1O#NM#5+621I@2<-TY/UH [:%=L*KZ"
MGT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445S
MVI>+M/TV]>UFFC5UZ@FFDWL)M+<Z&BN6C\=:7(X5;B(D^]=);3K<P),A!5AD
M$4.+6X*2>Q+1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI^GW&IW0@@7<YKO8_A-J[VBR>1R1D5V<M.&C.'FJU-46-!^*UU;R1I>N\N2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_NC%> ?"2RW>(8+G;T.,_C7T+7%B7[UCOPJM"YROC[1CK6@-  3LRW%?,-Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;W*44M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1/VV'_>%?0WA/_D#)7)BL(J"33N=.'Q+JNS1NT445PG6%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "O-_B[_ ,@JU_WZ](KS?XN_\@JU_P!^NK!_QXF&*_A,
M\=HHHKZ(\,**** "BBB@ HHHH **** "BBB@">R_X_8?]X5]#>$_^0,E?/-E
M_P ?L/\ O"OH;PG_ ,@9*\S,OA1WX'XF;M%%%>,>H%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R'BC[T?UKG*Z/Q1]Z/ZUSE?"YI_O
M4CZ?!?P$%%%%>>=04444 %%%% !1110 4444 %3V7_'[%_O5!4]E_P ?L7^]
M6E+XUZDS^%GHMM_J14U0VW^I%35^AP^%'R4MV%%%%62%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_Q=_Y!5K_ +]>
MD5YO\7?^05:_[]=6#_CQ,,5_"9X[1117T1X84444 %%%% !1110 4444 %%%
M% $]E_Q^P_[PKZ&\)_\ (&2OGFR_X_8?]X5]#>$_^0,E>9F7PH[\#\3-VBBB
MO&/4"BBB@ HK(OO$^CZ==&VN[V.*8?PFK]I>V]]'YEO*)%]13LQ76Q8HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK/O-;TZPE$=S<I&Y&<&A
M*X-V-"BF0S1SQ++$P9&&01WI] !1110 4444 %%%% "%@O4@?6D61&.%=2?8
MUQ_Q"N9[;22T,K1MM/*FO,OA3J^H7GC+RKB\EECVGY6.16L:5XN1C*KRS4;'
MO]%%%9&P4444 %%%% !13)94AC+R-M4#)-4K77-.O9_(M[E'D_NBG85T:%%%
M%(84444 %%%% !1110 454O-2M-/Q]JF6//3-%IJ=I??\>TRR?2G9BNMBW11
M12&%%%% !1110 4444 %%%% !1110 4444 <AXH^]']:YRNC\4?>C^M<Y7PN
M:?[U(^GP7\!!1117GG4%%%% !1110 4444 %%%% !4]E_P ?L7^]4%3V7_'[
M%_O5I2^->I,_A9Z+;?ZD5-4-M_J14U?H</A1\E+=A1115DA115+4M6LM)A$M
M].L*$X!:BUP;L7:*Y[_A./#O_03B_.C_ (3CP[_T$XOSJN678GGCW.AHK$C\
M7:', 4U"-LUI6U_;78S!*''M2::W&I)[%FBBFO\ ZMOH:0Q/-CSCS$SZ9IX(
M/0YKYEO-<U1?'$\(OIA&+@@+NXQ7T+X<D>7187=BS'N:UJ4^1)F-.KSMJQJT
M445D;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 -:1%.&=0?<TH
M8-T(/TKP3XM:OJ%GXN6*VNY8DV?=4X':O1_AU=3W6E!IY6D;:.6-:RI6BI&,
M:O--QL=K11161L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>;_%W_D%6
MO^_7I%>;_%W_ )!5K_OUU8/^/$PQ7\)GCM%%%?1'AA1110 4444 %%%% !11
M10 4444 3V7_ !^P_P"\*^AO"?\ R!DKYYLO^/V'_>%?0WA/_D#)7F9E\*._
M _$S=HHHKQCU HHHH ^;?BK_ ,C]+]1_.O8/AW_R!1_NBO'_ (J_\C]+]1_.
MO8/AW_R!1_NBNNK_  D<='^+([*BBN=UGQOH>@WHM-0NO+F(SMX_QKE2;V.M
MM+5G1453LM3M=0MA<6\FZ,C(/M6=J7B_1]*8K=W.PCK0HMZ Y)*YNT5REM\1
M?#=VV(;W)Z=!_C72VUU%=PK+"VY&&0:'%K<2DGLR:BJUY?V]C$9+A]JCO7.2
M_$?PU!-Y3WN'SC&!_C0HM[ Y);LZRBLS3M?T_51FTFWUIT-6W&FGL%%%%(84
M5FZAKMAI?_'U+LK%_P"%C^&O,*?;?F'L/\:I1;V1+G%;LZRBLO3?$.G:L0+2
M;?FM2DU;<::>PV0XB8CT-?._Q2U&Y3Q&@$F!L_PKVO6/%ND:0)([NXV. 1BO
MGKQ[K%KK.MB>TDWQ@$9KHP\7S7.7%27+9,^B?"#M)X5T]F.28N:VZ\V\-?$C
MPU8>';*UN+W;+''AA@<'\ZZ?1O&^A:_>?9-/NO,FQG''^-92A*[=C>$XM)7.
MBHHIDLJPH7<X &369H/HKG+SQSH-@Q%Q=;2/8?XU';>/_#UTX2*\R3TX'^-5
MR2[$\\>YT]%16]Q'=0B6)LH>AJ6I*.(^)/\ R!C_ +IKRKX0?\CO_P !->J_
M$G_D#'_=->5?"#_D=_\ @)KJI_PF<=7^-$^C***"<#-<IV!16+J?BK2=)8K>
M7&PBL@?$_P +-((Q??,3C&!_C5*$GLB7.*W9V-%9>G>(=.U0@6LV_-7KFZBM
M+=IYFVQKU-*S'=/4Q/&$\D&B3F,X/EFO&_A9?3S^.@DCY7G^==UXS\=:'+IT
MMM'=9E*D8P*\L^'NM6.B^+A>WTOEP<_-^-=5.+]F]#CJS7M(ZGT]17&?\+3\
M*?\ /_\ H/\ &NGTS4[75[&.]LWWP/\ =:N9QDMT=:G&6S+E%(2%&36+>>+-
M(L'*W%QM(ZTDF]AMI;FW17(GXE>&!+Y9OOF],#_&MC3_ !)INJ$"UGWYIN,E
MNA*<7LS6HHJAJ.L6>E1&6[DV*.IJ4KE-V/*_C9?7%I)8+"^T,.?UJ_\ ":>2
M:U1I&R=O]*X[XL^)M-\0W%H+";S/*X;VZU?^''C#1M"MD2_N?+(7!Z5V<K]E
M:QPJ:]LW?0]VHKDK7XD^&;RX6"&]W2-T&!_C74PS)<0K+&<HW(-<CBUN=BDI
M;,DHHHI%!1110 4444 %%%% !1110 4444 <AXH^]']:YRNC\4?>C^M<Y7PN
M:?[U(^GP7\!!1117GG4%%%% !1110 4444 %%%% !4]E_P ?L7^]4%3V7_'[
M%_O5I2^->I,_A9Z+;?ZD5-4-M_J14U?H</A1\E+=A1115DA7EWQO_P"1:MO^
MNO\ 45ZC7EWQO_Y%JV_ZZ_U%:4?C1E7_ (;/)O#/@V\\3L!;2HF3CYJZW_A2
M&M?\_4/Z?XU;^#_^M3_?_K7N5;U:THRLCGHT(3C=GSM=_#;7M'!"SJP7GY1G
M^M9MKXI\0>';U4FED6-3R"I&:^F6C1_O(I^HKS/XH^&8;C2Y=0CB"^4O\*XI
M0K<SM)#J4.17@SIO!WBF+Q!8)@YE"Y;)KIG_ -6WT-?/WPCU5[/5Y4+?*PP
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M^-5R2[$\\>YU-%5[2\AO8A+ VY3T-6*DH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS?XN_\ (*M?
M]^O2*\W^+O\ R"K7_?KJP?\ 'B88K^$SQVBBBOHCPPHHHH **** "BBB@ HH
MHH **** )[+_ (_8?]X5]#>$_P#D#)7SS9?\?L/^\*^AO"?_ "!DKS,R^%'?
M@?B9NT445XQZ@4444 ?-OQ5_Y'Z7ZC^=>P?#O_D"C_=%>/\ Q5_Y'Z7ZC^=>
MP?#O_D"C_=%==7^$CCH_Q9'95\[?&0X\9*?]C_"OHFOG;XR\^,E_W/\ "L\/
M\9>*_ADEIXQO[K38--TZ"0-LV%T[5IV?PRUC7;?SKW4Y%8C)#C_ZU;_PO\.6
M*VANC'^\P&S7J> .@JIU>5VB*G2YU>9\T^(O VH>&$:6.=W1>2P%:/@CQ]<Z
M7%<)=R-* OR*QKV7QE91WOARYB=<Y%?-4%E'_P )5%9D?NS,%(K2$O:1?,8U
M(NE-<IW4]SKOC:^+6YGM[9O3I4NH?""]AM/M0OVEDQG;CG^5>Q:'H]KI&GQP
M6R;5P#6IBL76:?N['0L.FKRW/EFSU35?#>M+;O-*H5P"#7T=X;U8:OI23CL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%8NH>)K#3;HV\\R*X[%L4TF]A-I;FU17-?\)KI?_/Q%_WU
M6]9W<=[:I/$04;H10TUN":>Q/1112&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%(S*BY8@#U-<MKGCK3=&;:TB2
M'N%;I32;V$VEN=517DTWQRTV*<Q_8G..XK<T+XH6&N726\4!5VZ FK=*2U:(
M56#T3.]HIL;^9&KCN*=69H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%-D=8T+L0%'))H =17 >(_BGIN@7+0F/SBIZH:=X=^*&G:_<
M+"L?DECCYC5^SE:]B/:1O:YWM%(K*ZAE((/<4M06%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*WP^S.?$[H^IX?\ 41_[H_E3Z9#_ *B/_='\J?7*=AX-\7?^/D_[]=?\%?\
MD49/^NO^-<A\7?\ CY/^_77_  5_Y%&3_KK_ (UU3_@G'#^.SM/$TAB\-7\@
MZK$37RY:ZW):ZH;WRU=L]#7U+XDB,WAV^C'5HB*^9M-M;:R\0>1?1ATR!@_6
MGA[68L5?F1V</QMU*&%(Q91X4 "G_P#"\=3_ .?&.O2+'P+X8N;*&4:?&=R
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M:T_A!_QYQ_[G]*T?\%&:_P!X9ZQ1117*=@4444 %%%% !1110 4444 %%%%
M!1110!R'BC[T?UKG*Z/Q1]Z/ZUSE?"YI_O4CZ?!?P$%%%%>>=04444 %%%%
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M+(>?QKKI?PW<XZW\56/H^BBBN0[ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]8?#C_D1]/\ ]VM<1\*,L-\3.KHHHKC.T**** "BBB@ HHHH **** "BBB@
MHHI"0!DT +15=KZV5L&90:F1UD4,AR#WH =1110 4444 %%%% !1110 4444
M <'\1_%)T/1Y! P$W2OFN^U">]NI)I)&)=L_>->E?&6^;_A()+7<=N,XKRJN
M^C%*-SSZ\FY6'!6;D FN_P#A3IDMQXMM97#",=?S%>B?##P=I\N@P:A=01S>
M:OW6'2O1+;0M/LKA9K6UCB(_NBLZE9:Q1I3H/23-!$"(%'04ZBBN0[ HHHH
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M***X3O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS?X
MN_\ (*M?]^O2*\W^+O\ R"K7_?KJP?\ 'B88K^$SQVBBBOHCPPHHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7?0^ \_$?&>Z_#NRCUCPKJ%LV'8I@>W2O)/%&D/HVM36I4A4[UZY\!G+V>H
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M_,UJ7O\ QXW'_7)OY5Y\F^8]&*7*?&^K((]7NT'02L!^=.T:)9]9M(G&5>4
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MSKYG[U]#? Q&3PU<[O\ GI_4UOB%[AAAW[YP?Q7UE[S57M2Y(B?&*\WC ,J
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MAQ+]ZQVWPVT--:UHJZ!A&0U?3EI906MLD44850HX%>$_ C']N7F<?ZOO7O\
M6.(;YK&V'2Y+GFGQ/\,6]WI;W<<(#1(6) KYOKZ]\9X_X1'4LX_U1_G7R%6V
M';<3'$I*1WOPKU1[;Q5:6N\K&[9/IUKZ=5@PR#D&ODGP)G_A+;3'K_A7U=89
M^Q1Y]*RQ"]ZYKAG[MCYP^,O_ "/$O^[7GE>A_&7_ )'B7_=KSRNFG\".6I\;
M/JSX9?\ (B6'^[_A77UR'PR_Y$2P_P!W_"NOK@G\3/1A\*"BBBI*"ODOX@_\
MCMJ/^_7UI7R7\0?^1VU'_?KHPWQ,YL3\*.;B&9D'^T*^N?"-A:VOAVR>&)49
MX@6([U\C0_ZZ/_>'\Z^PO#/_ "+.G_\ 7$5>)V1&%W9=OK>.XLY4D4,"AZ_2
MOE?QYIJ:9KK1QJ%#$M@5]72\0O\ [IKYD^*[J_B5-O\ =/\ 2HP[]XO$KW;G
M#VTAAN(Y!U4YKZD^&-XU[X/@F8Y)-?*X&3@5].?")2G@6#=V/]*UQ'PF6&^(
M[+4]/@U*RDMYT#(XP<UAVVD^&M$B 9;>)UZDFL;QWX_AT"%H(7Q<,/EKP?6/
M&&IZQ*S32DAO0UC3I2DO(VJ58Q?F?1-UX[T?3P4BFB8#T:O/?&7CC2-8L)HO
MLJ&3;A6STKR>RTV^U%\1"0Y[\UL2^!=9BL9+MU_=QKN;/I6RI1B]S%U9R6B.
M6KO/A5?-%XOL[89PS?UK@Z['X7_\CY8?7^HK6?PLRI_$CZJKYG^,O_(\2_[M
M?3%?,_QE_P"1XE_W:Y,/\9UXGX#SROJWX9_\B)I_^[_A7RE7U;\,_P#D1-/_
M -W_  K7$_"C'#?$SKJQ?%O_ "*>I?\ 7$UM5B^+?^13U+_KB:Y([H[9;,^/
MV^\?K76?#7_D>M/_ -ZN3;[Q^M=9\-?^1ZT__>KT9_"SS(?$CZDU*4P:;<2@
MX*(37RCXTU1]4UV29G+8R*^IM?.- OB/^>+5\>WC%KR8MUWM_.N?#+=G3B7L
MBWH$,-QKEK%.RK$SX8MT%?3V@WOAW1]/C@BO[8%>X:OE 9S\N<^U2YN/67]:
MVJ4^?J8TZG)T/IOQI>^']5T*=3>6SRD<'=S7S1J*)'J$R1D% W!%1'[0>OF_
MK3?+D/\  _Y&BG3Y.HJE3GUL>Q?!B^!ODM=W1<XKTWXB?\B1J'^Y7C7P6BD7
MQCN96"^7W'UKV7XB?\B1J'^Y7/57[Q'32=Z3/DVNP^&FFP:KXPM[:X0/&1R#
M7'UWOP@_Y'RV^G]:ZI_"SEI_$CZ3L=/M[" 101J@ QQ7EOQNTZ&+P_'=J@$C
M2X)_$5Z[7E_QR_Y%"'_KK_45PTG[Z.ZJO<9\Z5[/\!Y':]OU9L@+Q^E>,5[+
M\!?^/_4/]W_"NRM\#..A\:/=JYKQ]_R)>H_]<ZZ6N:\??\B7J/\ USKAC\2.
M^?PL^2:[GX2?\C_9?Y[BN&KN?A)_R/\ 9?Y[BO0J?"SSJ?QH^HJY#XB6$FH>
M'6CC!)!)XKKZCGA6>%XW&0P(KSHNSN>E)75CXNNXS%=RHPY5B*Z+P5XI'AC4
M&F:(N']*[WQQ\+)Q<27>FQC8<LV?6O*+W2;NPE,<L3Y'HIKT%*,T><XRA(^C
M]&^)^FZDB^9LASQ\QKI(O[$U:2.=3#-(.00>E?(.Z1#U9?TKH_#_ (SU'1+E
M#'+^[SSDUC+#_P IM'$=)'UFB*B[5&!3JYCP;XIB\1:7%)NS,1EJZ>N5IIV9
MUIIJZ"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF-&P?SKZ; "C &!7#?#OP<OA_2@TZ@ROAP1VKNJXZT^:6AV48<L=3YG^,O\
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MMI;:0I*C*0<<C%:FF^*-7TE EG=&-1T KIJ0<MF<M.:B]4?11^&^E@9PF/\
M=JE)X,\/13+$\T8=C@#%>*GXD^*",'4GQ5:'QAK$NHPSSW+.5?-9*E/JS9UH
M=$?2NB>$;+1;G[1 %W8QP*A^(G_(D:A_N5)X)UJ36] BN90P<\?-4?Q$_P"1
M(U#_ '*PUY]3HTY-#Y-KO?A!_P CY;?3^M<%7>_"#_D?+;Z?UKNJ?"S@I_&C
MZ>KR_P".7_(H0_\ 77^HKU"O+_CE_P BA#_UU_J*X:7QH[ZOP,^=*]E^ O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \X^+'A;5/$VGVL6FP^8T;985Y+_P
MJ/Q9_P ^0_,_X5]0T5K"M**LC&=&,W=GFGPE\*:KX8M[Q-3A\LR'Y?TKTNBB
MHE)R=V:1BHJR(;FVCNX&AD&5/6O ?%/PIURYUB>?3[7=&[Y'7I7T)13A4<-B
M9TU/<^7O^%1^+/\ GR'YG_"O6_A/X7U/PSIMU%J4/EN[945Z-153K2DK,F%&
M,'=!7(>,/!%GXD@=G4^:1@;177T5FFT[HU<4U9GSCJGP>UI)3]AMBRY[YJQI
M'P=U1RG]H6Y3UQFOH:BM?;RL8_5X7N<7H?P^T[1++9"I9SR=P[UY/XB^%GB6
M\UVZGM;,&%VRIY_PKZ,HI1JRB[E2HQDK'B/PT^'^O^'_ !0MYJ%L(X0N,\U[
M=114SFYN[*A!05D> ^./AMXCUCQ7=WMG:AX)#\IYKG1\(_%F?^/(?F?\*^H*
M*T5>25C-X>+=S+\.6<UAX>L;6==LL4>UAZ&K]RADM)D7[S(P'Y5+16-];FR5
ME8^:=3^%/BJXU.YFCLP4>1F4Y/3/TI^D?"KQ3:ZO:3RV8$<<@9CD]/RKZ3HK
M;ZQ*UC#ZO&]R.!2EO&IZA0#^59?BFQGU+PW>VELNZ61,*/6MBBL4[.YNU=6/
ME[_A4?BS_GR'YG_"NG\ _#GQ%HGBZTOKVU"01_>//J*]ZHK9UY-6,5AXIW"O
M#?B/\/?$&O\ BN:]L+8/ PP#S7N5%9PFX.Z-)P4U9GSQX5^%OB&R\16L]]9@
M6ZM\YKN_%?PLL=24S6JMYIYP!BO3**IUI-W)5&*5CYGO/A#XD6<BVM,Q^I)K
M<T#X/7AG1M3A9%!YQFO?**IUY-$K#P3N8^A^'+'0;=8;5>%XR1S6Q116+=]S
M9*VPC*&4@@$'UKD/$W@#3/$",9%*N?[@Q7844*36J!Q35F?/FJ_!S44+_8(&
M<?PYS6&OPB\5[ANLAC//)_PKZ?HK98B2,7AX,\*T?X,O(R_VC&Z#OC->K>'/
M"EEX=@V6N>1@YK?HK.524MRXTHQV(KE#):3(OWF1@/RKYNU/X4^*KC4[F:.S
M!1Y&93D],_2OI:BG"HX;!4IJ>Y\V:1\*O%-KJ]I/+9@1QR!F.3T_*OH^!2EO
M&IZA0#^52443J.>X4Z:AL%%%%9F@4444 %4]0TRWU*!H9T4AAC.,U<HH \<\
M0?""&XN9)K-')8]*XJ\^$/B19\6]IE/4DU],45LJ\D8RH09\_:9\'+Y]OVZ!
ME]<9KT[PK\/M-\/!943=+C!#C-=G14RJREN.-*,=A  H  P!2T45F:GB'Q*^
M'^O^(/%+WMA;"2$K@'FN-_X5'XL_Y\A^9_PKZAHK:->25C"6'BW<YWP/I=SH
M_A2TLKQ-D\8^85T5%%9-W=S9*RL%%%%(85\E_$'_ )';4?\ ?KZTKY+^(/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF'QSX>OKG
MQ??RQQ.59^"%-?3U5WL;21BSV\3,>I*BM*=3D=S.I3YU8^28O"^HB5#Y+_>'
M\!KZK\.QM%X>L8V&&6( U:_LZR_Y]8?^^!5A5"J%4  = *=2KSDTJ7(+1116
M1L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>:Z$38-1
M?V@OM5:_C9IB15/R6]#0!J_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM1_:"^U97
MDMZ&CR6]#0!J_P!H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0
MT :O]H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O\ :"^U
M']H+[5E>2WH:/);T- &K_:"^U']H+[5E>2WH:/);T- &K_:"^U']H+[5E>2W
MH:/);T- &K_:"^U']H+[5E>2WH:/);T- &K_ &@OM1_:"^U97DMZ&CR6]#0!
MJ_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM1_:"
M^U97DMZ&CR6]#0!J_P!H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH
M\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O\
M:"^U']H+[5E>2WH:/);T- &K_:"^U']H+[5E>2WH:/);T- &K_:"^U']H+[5
ME>2WH:/);T- &K_:"^U']H+[5E>2WH:/);T- &K_ &@OM1_:"^U97DMZ&CR6
M]#0!J_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM
M1_:"^U97DMZ&CR6]#0!J_P!H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y
M+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T
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M\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O\
M:"^U']H+[5E>2WH:/);T- &K_:"^U']H+[5E>2WH:/);T- &K_:"^U']H+[5
ME>2WH:/);T- &K_:"^U']H+[5E>2WH:/);T- &K_ &@OM1_:"^U97DMZ&CR6
M]#0!J_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM1_:"^U97DMZ&CR6]#0!J_V@OM
M1_:"^U97DMZ&CR6]#0!J_P!H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y
M+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T :O]H+[4?V@OM65Y+>AH\EO0T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,@!;I4>T>@J23[U,IB
M$VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>
M@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VC
MT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:
M* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&
MT>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $
MVCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@
MI:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT
M%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:*
M $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* *]X +=N!6;'_ *Q?K6G>
M?\>[5F1?ZQ?K2&:\8&P<"G;1Z"DC^X*=3$)M'H*-H]!2T4 )M'H*-H]!2T4
M)M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]
M!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'
MH*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T
M4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*-H]!2T4 )M'H*H
MWP (P*OU1ONHH KVWWZU0HQT%95K]^M8=*0Q-H]!1M'H*6BF(3:/04;1Z"EH
MH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;
M1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3
M:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"
MEHH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04;1Z"EHH AN /+Z"LH??K5N?\
M5UE#[](#6A \I>!4FT>@ID'^J6I*8";1Z"C:/04M% ";1Z"C:/04M% ";1Z"
MC:/04M% ";1Z"C:/04M% ";1Z"C:/04M% ";1Z"C:/04M% ";1Z"C:/04M%
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M&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:* $VCT%&T>@I:*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 0R?>IE/D^]3*8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O/\ CW:L
MR+_6+]:T[S_CW:LR+_6+]:0S8C^X*=38_N"G4Q!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %4;[J*O51ONHH KVOWZUATK)M?OUK#I2&%%
M%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_ZNLH??K5N?]764/OT
M@->#_5+4E1P?ZI:DI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W/\
MJS]*FJ&Y_P!6?I0!DC[P^M;2?<7Z5BC[P^M;2?<7Z4ACJ***8@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"O>?\>[5FQ?ZQ?K6E>?\>[5FQ?ZQ?K2&;$?
MW!3J;']P4ZF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^^^_\
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MBBB@ HHHH **** $;[IK(G_UE:[?=-9$_P#K*0R]9?<-6JJV7W#5JF(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ,FZ_UIJQ9=JKW7^M-6++M2&7
MJ***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG>]*N53O>E %.W_U@
M^M; Z5CV_P#K!]:V!TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *]Y_JA]:SHO]8*T;S_5#ZUG1?ZP4AFO']P4ZFQ_<%.IB"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LJ[^_6K65=_?I 6M,^_P#A6I67IGW_ ,*U*!A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,GWJ93Y/O4RF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH KWG_'NU9L7^L7ZUI7G_ ![M6;%_K%^M(9L1_<%.
MIL?W!3J8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S[[[_X5':?
M?J2^^_\ A4=I]^D,U****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MGJ'^K'UJY5/4/]6/K0!4MO\ 7"M9?NBLFV_UPK67[HI +1113 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH BN/]0WTK(7[X^M:]Q_J&^E9"_?'UI#-F+[
M@I],B^X*?3$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07?^IJ>H+O\
MU- &8G^L'UK7B_U8K(3_ %@^M:\7^K%(!]%%%, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!&^Z:R)_\ 65KM]TUD3_ZRD,O67W#5JJME]PU:IB"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#)NO]::L67:J]U_K35BR[4AEZ
MBBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IWO2KE4[WI0!3M_P#6
M#ZUL#I6/;_ZP?6M@=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"O>?ZH?6LZ+_ %@K1O/]4/K6=%_K!2&:\?W!3J;']P4ZF(**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *RKO[]:M95W]^D!:TS[_X5J5EZ9]_\*U*!A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $,GWJ93Y/O4RF(**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KSWQ7\2'\.730K9B7!QFO0J\ ^*?_(3?_?K6C%2E9F5:3C!M'KG
M@SQ,WBK1S?-#Y1#8VUT=>=_!W_D46_ZZ?XUZ)4U$E)I%4VW!-A14+W5O&^Q[
MB)6_NEP#4I=0NXL OKGBH+%HJ WMJO6YA'UD%.2Y@D.$GC8_[+@T 2T49&,Y
MXJ)KJW0X>>)3[N!0!+14*WEJQPMS"?HXJ8$$9!R* "BBB@ HIKR)&,NZJ/\
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M906%N(+==L8Z"LIN#^%&U-37QLL4445F:A1110 4444 %%%% !1110 4444
M%4;[J*O51ONHH KVOWZUATK)M?OUK#I2&%%%%,04444 %%%% !1110 4444
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M*** "BBJFI7:65A-.S!=BDC)H PO%OC"'PU:-(%624'[E<EH7Q<DU?6H+ V
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M'?$Q_%&M"P:R$0(SN_R:]&KYY^$8QXR _P!FOH:E6BHRLA4)N4+LK7U_;Z?
M9;B144#C->?:K\5[>QD98(DFQZ&F_$73-=O$58)@8&; 4#./UK&\-_"SS4$N
MHHC@G)%.$8)7DQSE.]HH!\;I/,V_V<,9ZY_^O73:%\3;+5)%2XV09]34MQ\+
MO#[6VV*S EQUR.OY5Y'XO\*3>&KTR* (U88P/>K2I3T1DY5::O+4^D8+B*YC
M#Q.&4C.14M>8?"WQ.UY8FVN6+2;L*?:O3ZPG'E=CHC)25T%%%%24%%%% !11
M10 4444 %%%% !1110 5!=_ZFIZ@N_\ 4T 9B?ZP?6M>+_5BLA/]8/K6O%_J
MQ2 ?1113 **** "BBB@ HHHH **** "BBB@ ILDB1(6=@ .YIU<_XM@U"?1Y
M%L) DIZ$TTKL&9>O?$*QTAML3QRL.HSTKD)OC:\<I5=.##US_P#7K(TCX=:E
MK-_-)=E2%;+;AC->@V?PN\/)9A;BS#38Y((_PK>U*.^ISOVLMM#$TSXOQWDJ
MK/;+"#W)_P#KUZ)I>L6FJP+);S*YQDA>U>1>,_AJFG6$M]9(J1(.G>L/X?\
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MHHH **** $;[IK(G_P!96NWW361/_K*0R]9?<-6JJV7W#5JF(**** "BBB@
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M#M>K NG@JS ;L_\ UZ]0TC43J=DMP4VY XKY<:T^Q:I# XQ(L@S^=?2GA/\
MY T?T'\JUK0C%*QE0G*3?,;U%%%<YT!1110 4444 %%%% !1110 4444 %%%
M% %>\_U0^M9T7^L%:-Y_JA]:SHO]8*0S7C^X*=38_N"G4Q!1110 4444 %%%
M% !1110 4444 %%%% !52\U2RL/^/JX2+_>JW7"^._"6I>(Y$-E*B*%P=W_Z
MZJ*3>HI-I:#-=^)ECI@/V9H[@CT-4_"?Q0?Q)KJ:<;(1AOXL_P#UZ\XUWX:Z
MMHEO]HN9HF!_N_\ ZZ?\*AM\;P#T&/UKI]G#D;6IR>UJ<Z35CZ-HHHKD.P0D
M 9/2N0\1>/;+1251TED'5<]*/'GB<:'I4J1,5N2,J:\6T/1KWQCK#RN=PW9<
MD=:VITTUS2V,:E1I\L=SM9/C:ZR;1IP(]<__ %ZW]#^*-MJ<Z1SHD.X]S5BV
M^%N@K9!9K0&;'7(KSCQEX'G\/SBYM%"Q#G@=*M*E+1$-U8:O4^@(9X[B(2Q.
M'0]"*DKRKX7>*Y;Y?L%Q)D1KP#7JH.1FL)Q<79F\)*2N@HHHJ2@HHHH ****
M "BBB@ HHHH **** "LJ[^_6K65=_?I 6M,^_P#A6I67IGW_ ,*U*!A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $,GWJ93Y/O4RF(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KP#XI_P#(3?\ WZ]_KP#XI_\ (3?_ 'ZVH?&8XC^&SN_@[_R*+?\
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M"NC$[HY\+\):HHHKF.D*\.^+?_'[)]:]QKP[XM_\?LGUK:A\9E7^!F_\%/\
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MG_!.3_E^>LU%<3QV\1DD.%'>I:Q?%,ODZ%,_I7,E=G6?/.MW!U#QI,F=R&?
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M'154^.'^HT_Z_P"-6_A+_P @Z*FW>D3'2NSU2BBBN4Z@HHHH **** "BBB@
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M>)]!45Q7A'Q[:Z^!$X$3XS\QKM000".AK&47%V9JFFKH****0PHHHH ****
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MI?.&KWK0=&AT73H[6,#Y>XK6HU&'(94XN4W,U:***YCI"BBB@ HHHH ****
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MBBF(**** "BBB@ HHHH **** "BBB@ HHHH @GLX+@@R1(Q!R,J#4RHJ+A5
M'H!2T4 %>6?&6WA70HY1CS#+SQ[BO47=8U+,0%'4FO!OBEKGV[4WT^.3>BN,
M8Z=:UHIN:,J[M!DWPF=Q=HH)VE^?SKW0@,,$9![&O,?A/H;6VEM<3+A]^1FO
M3Z*SO-A134$F5TLX(YO,2)%;V4"K%%%9&I7OP&L)P1QL/\J^8O$B^3KS>3UW
M'I]:^B/%.M0Z3I,K2$9="HKY[TFVFU[Q-MVE@SGG\:Z:"M=G-B-;1/HOPR2?
M#5@6Z^4*UJI:3 ;;2K:$C!1,5=KG>YT+8****0PHHHH **** "BBB@ HHHH
M**** "J=[TJY5.]Z4 4[?_6#ZUL#I6/;_P"L'UK8'2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *X;XK_\B3/]:[FN&^*__(DS_6KI_&C.K\#/+OAI
M_P A9/\ ?KZ*KYU^&G_(63_?KZ*K3$?$1A_X:"BBJ&KW\6GZ=-,\@4JA(R>M
M8&YR?Q#\4+I.FO#$X\_IBO/? /AZYUG6O[2E0LB2;CGD5EWL]WXP\3%4+LA/
M3\:]W\-:/%I&F11QH%9E&['K72_W<+=6<Z_>3OT1X#XQ18O'\R*, 2C@?6O>
MO"?_ "!H_H/Y5X/XU_Y*'/\ ]=1_.O>/"?\ R!H_H/Y45O@1.'^*1O4445S'
M4%%%% !1110 4444 %%%% !1110 4444 5[S_5#ZUG1?ZP5HWG^J'UK.B_U@
MI#->/[@IU-C^X*=3$%%%% !1110 4444 %%%% !1110 4444 %%%% '$?$K_
M ) P^AKRKX6?\CU%^/\ .O5?B5_R!A]#7E7PL_Y'J+\?YUU4_P"$SDK?Q(GT
M92$A02>@YI:CG.+>4^B'^5<IUGA7Q@U)9]<BCA?*>7@_I77_  KL$ALC-L&7
M7KBO+O'TWG:X3Z9%>\^"((H_"MBZ( S1\GUKJJ>[32.6GK6D=%6%XNM4NO#E
MVC("2O7'-;M4=74-IDP(R,5S+<Z6KH^>O"LQTKQ,8E8@%@.M?1\!W6\9]5!_
M2OF6^?R/&ZA.!YRC]:^F+3FR@/\ TS7^5;U^C,,.]X]B:BBBN<Z HHHH ***
M* "BBB@ HHHH **** "LJ[^_6K65=_?I 6M,^_\ A6I67IGW_P *U*!A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $,GWJ93Y/O4RF(**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KP#XI_\ (3?_ 'Z]_KP#XI_\A-_]^MJ'QF.(_AL[OX._\BBW_73_
M !KT2O._@[_R*+?]=/\ &O1*FK\;*H_PT?-WQ+_Y*!<_[P_F:]?^'7_(#/X5
MY!\2_P#DH%S_ +P_F:]?^'7_ " S^%;5?X:,:'\21V5>+?%S_CXDKVFO%OBY
M_P ?$E94?C-:WP,T/@C_ ,@^^_WJ]9KR;X(_\@^^_P!ZO6:*WQL5#^&CC/BE
M_P B-=_Y[&O(_AQ_R&%_WQ7KGQ2_Y$:[_P ]C7D?PX_Y#"_[XK6G_"9E4_C(
M^C'.V%CZ*3^E?.GQ+O?M>MKSG;D5]%R#,#CU4_RKYN^(MJUMK7S C<2:G#_$
M7B?@.T\(_$#P[H>C00R[Q<!</BNA_P"%O>'/[TE<;X:^%^G:[I,-U]O9977+
M(.U;/_"D;+_G_>G)4KZLB+KV5D.\2_$SP_JNAW5K"7,LB87-<5\++N6T\0NT
M1Y9<']:[/_A2-E_S_O6SX<^&%KX?OC<I=-(2,8-/GIQBT@4*LIJ4NAWL9+1J
M3U(!KY@\0_\ (]77_7>OJ!1M4+Z#%?+_ (A_Y'JZ_P"N]+#[L>*V7J>_^"_^
M1>BKHJYWP7_R+T5=%7/+=G2MCYQ^(=VK>*IXV/RI)S77>$/B)H&AZ0+64N&S
MGBN+^(-H5\7W+L2%=\9KHO#'PNL=?TP7?VYASC KL:AR+F.-.ISOE.S_ .%O
M>'/[TE9'B+XFZ!J>FM!$7+$'&:;_ ,*1LO\ G_>C_A2-E_S_ +UDO8KJ7>OV
M.&^'ETQ\<VZH?D=R?UKZ&U/_ )!EQ_N&N'\/_"NUT'5X;^.[9VC/ -=QJ?\
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MWXS1PI?69BQDCG'XU%&;;Y677BE'F6YZMX1U1M7\/6]X[ L_6MRO.OA7YO\
M8D&XG9MX'X5Z+6,U:31O!WBF%%%%24%%%% !1110 4444 %%%% !1110!7O/
M^/=JS8O]8OUK2O/^/=JS8O\ 6+]:0S8C^X*=38_N"G4Q!1110 4444 %%%%
M!1110 4444 %%%% !7A'Q:S]ICSG[U>[UY)\9;#=:VLD:\YR<5K1=IHQKJ]-
MG%^#]&U'742S4_Z*3G%>JV7PQT6. ":)BY'-<]\)+N+[*EOM7S/7O7K=55G)
M2LA48+D3/$_''P]ATR#[3IR$<Y/TJ/X6^))TU:/29'^5F.0?K7KFOQPR:1<^
M;CB-L9^E?._A'>/&@\HD'S&QCZU<'SP:9G->SJ)QZGKGQ/B:32U9>@0UY_\
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MU)'U)&VZ)&]5!IU1V_\ Q[1?[@_E4E<AU!1110 4444 %%%% !1110 4444
M%%%% $5Q_J&^E9"_?'UK7N/]0WTK(7[X^M(9LQ?<%/ID7W!3Z8@HHHH ****
M "BBB@ HHHH **** "BBB@#+UW5$TK3)IRV&5<BOGZXNKCQCXF9BX*E@3D^]
M>N_$33[_ %"Q$=E&[Y7!"UXQ#X-\46[[XK*9&]5KJHI)7OJ<M>3NE;0^@_#N
MGV>CZ:D4;Q@E03\PZUE>/9HFT:0+*A^0]&%>.C0O&X& EW_WU5/4-)\500%K
MU;GR\<[FH5)7OS"==VMRFQ\)W5/&F68*-IY)Q7T(LL;?=D0_1A7R;I%MJ5U?
M>7I@D-Q_L'!KU/P)IGB6VOU;41<!-W\9IUX)OFN3AIM+EL>Q5A:YX4TW7\_;
M4)R,<5N!@6P#S2URIM:H[6D]&>5ZE\)+(@_8XS[9KA=5TS5_!=SN4!8U(Q@5
M]'5Q7Q(LX)] W.B[LGG%;0JN]F8SI1M>.C*O@+QL-:MA!=/F8':M=_7S=\/K
MB2+QG;P*3L,A_G7TC4UH*,M!T9\\=0HHHK(U"BBB@ HHHH **** "BBB@ HH
MHH *@N_]34]07?\ J: ,Q/\ 6#ZUKQ?ZL5D)_K!]:UXO]6*0#Z***8!1110
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M^T_%/F 9PX/ZU])VXVVT0]$ _2MZ_1'/AUNR2BBBN<Z HHHH **** "BBB@
MHHHH **** "LJ[^_6K65=_?I 6M,^_\ A6I67IGW_P *U*!A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $,GWJ93Y/O4RF(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKP#XI_\ (3?_ 'Z]_KR+Q[X*UK6KYY+*WWJ6S6M%I2U,JZ;@TC9^#O\ R*+?
M]=/\:]$KC?AOH=]H'ATVM_'Y<N_.*[*IJ.\W8=)-029\W?$O_DH%S_O#^9KU
M_P"'7_(#/X5PWC?P%KVL>+Y[ZTMM\#,"&_&O1_!FE76DZ5Y-VFU^.*VJ23II
M(RHQ:G)LZ2O%OBY_Q\25[37F7Q#\)ZKKLSM8P[P:SHM*6IK53<&D4_@C_P @
M^^_WJ]9KSWX7>&=2\.6=U'J,7ELYRM>A4JK3FVA44U!)G&?%+_D1KO\ SV->
M1_#C_D,+_OBO:?'FDW6M>%;BRLTWS/T'X&O//!7@/7=)U$2W=L$0-G-:TY)4
MVC.<6ZR9[0.5Q[5Y3\5/#3WF+V!,^6O( S7JXZ"H;FVCNH6CD4%3ZBL(2Y7<
MWG%25F>">!/&+:!<M;W@;;]T \8KVK3_ !'IU];"87,29[,XK@O$WPNBNIGN
M;!7,K') XKBY?AKXL1\0QR[/]]JW:IU-;V.=.I35K7/:-7\7:;I2!C-'+D9^
M5@:N:+K=OK5FEQ!P&[9KQK3_ (8:Y-(HOQ*$SS\Y->L^&?#4.@6:1QLY(&,,
M:SG&"6C-H2F]U8Z"OFCQI:-8^*IKEE(#2Y'%?2]<)XV\#1Z_&KQ*3*O/'K11
MFHRU%6@YQT(_A_XFLI=$C@EF2-Q_>;%=C#JUI<2;(IXW/^RV:\$D^&7BF*4B
MWA<)[,179^"O!FLZ3>QRWHD !R<L353A#=,FG.;=FB+XG^%99T^VP+EBV3@9
MKFO GC5_#\JV5UO\K=RIXKWN>".YA:*10588Y&:\O\3?"Z.YN&GL%8L?3BG"
MHG'ED$Z<E+G@=YIWB;3K^$2"YB3C.&<5#J7BW3=/!)FCDQ_=85XM+\-/%B.1
M#')M[8=JNZ?\,=?E<?;EE"]_G-'LX;\PE5J-VY3V/0?$-MK]N\T P%;&":O:
MD,Z;< ?W#6'X4\*Q>'K3RT9\DY.XUTDB"2-D/0C%8NR>ANKVU/EOQ*"GB+YA
MCYAU^M?1GAF^M[C0[-(YD9EB (#5YWXX^'-YJ6HO=:="6)JSX!\*:]HDQ^W(
MRIN[L3Q714<9P6IS4XRA4>FYM^+O'2:%,L7E29#@$@=:NZ'X]TW5]B[EB)ZE
MVQ5GQ%X.L?$$+>?N#=1CUKRS4/A;K$+M]@63&>/F(K.*IR5GHS23G%W6J/9Y
MM;TZ&%Y/MD!VC. XKPWXB>(8-9OVM[<$Y8<CGO4"_#;Q>7 9)=G?]XU=5X<^
M%9%RLNJ*X(YZD\UI%0IN][F;E4J+EM8V_A+ITNGZ),)%(WMD9%0_%ZQ:\TJW
M*J3L.>E>A6=I%90+#$ %4 =*KZOI<6J64D,HSE2!6//[_,;<BY.4\*^&VN0Z
M9JR1S'"CN3BO<UUW3V1&%U"2PZ;Q7C&L?"O5HKAVTV%B"<@Y(J+3/ASXICND
M>X24*I_OM6TXPG[US&$JD/=:.W^*\+ZEX8A:W.X!\Y'/I7G7P\UJ'2=9CCGX
M 8Y)X[U[=9Z)YGAY+&[!+!2.>>U>6:_\*]06Y>32XF;))SDBE3E'E<&54A)2
MYXGKO]OZ=]C-Q]JA^[G;O&:\Q\<>/(M1LWL;.-V<'.5YKG;7X:^*6<+.DH3V
M=J[WP_\ #:WLK=I;D.;@H1AN>U+EA!WO<%*I-;6/)_ [%O&]DS=3)S7T_7B.
MA?#[7+#QI'?26P6U64MN]J]NI5Y)M6##1<4[GEGQ9TZ22PENU&0!CI7)_"W7
MXM&NIH9FVB9L<G'I7MNN:3#K.G/:3#Y6]*\8U;X6:NET[:?"Q4G@Y(JJ<HN'
M)(52$E-3B>SOKNGJBL+J$ECC <5H(ZR(&4@@C/%>!Z;\-_$XNHVNEE"*P/WV
M]:]PTJ&:WLHXIA\RJ!64XQCL[FM.4I;JQ>HHHK,T"BBB@""\_P"/=JS(O]8O
MUK3O/^/=JS(O]8OUI#-B/[@IU-C^X*=3$%%%% !1110 4444 %%%% !1110
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MU>B^$?AW;:0PGN%/G YYYYJER4]4[LE\]71JR-_P7I8TSP[;PLN'4<UT5(
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MS4?A;K4,K'3XWVYXPQ%5+7X9>)I9,7<<FSW<FM.2FW>YE[2HO=L94\UQXO\
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MHUHEO;*-JC&<<U>EB2:,HX!4]B*RG4YI7-J<.2-CQW1_B?+:ZI/%J(D9&?"
MC&*])TWQ5INHQAQ/''GLSBN2\3_#*UOY#<6@?S6.2!QS7#7/PR\2Q\6J2X_W
MS6G+3GUL9N52'2Y[!K/C'3=(B+F5)<#.$;->"^(]8E\4:XPA5S&S_*,=*UX/
MAEXGE8"YCD*^[DUZ#X5^&UII96>X5O.ZD'GFJ7)3U3NR7[2KHU9&C\.]"&E:
M$@E3$N<YKLZ:B*BA5  'I3JYI.[N=*5E9!1112&%%%% !1110 4444 %%%%
M!1110 53U#_5CZU<JGJ'^K'UH J6W^N%:R_=%9-M_KA6LOW12 6BBBF 4444
M %%%% !1110 4444 %%%% !1110 4444 8OB?_D#R?0UX!X9_P"2A0?]=S7T
M-KMI+>:<\4*Y<@\5Y#H?P_U^S\8Q7\UL! LI8MSTKHHR2B[G-7BVXV/<&;:I
M;T%>5>-/'%[I&N*D2RK %YX.*]6KG?$7A*Q\01L)UPQ&,J*R@XI^\;S4FO=,
M?0/B-8:E'%%)\DF,%F.*ZJ76].BC+_;(#@9P'%>-ZE\*]3AF?^STD*YX.XBL
MD_#?QANQLE(_ZZ-6OLZ;U3,74J1WB='X_P#'T=U!)I]J3AQ@X.161\-O#,^H
MZB;F52%0A@6'6M/0_A3<O<HVJ(X7N<DUZYI6DVVD6J6]NH"J,9QS3E.,8\L0
MC"4I<TRZB[45?08IU%%<QT!1110 4444 %%%% !1110 4444 %%%% $5Q_J&
M^E9"_?'UK7N/]0WTK(7[X^M(9LQ?<%/ID7W!3Z8@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *Y'Q]_R!9/]PUUU<[XNTRYU33'AMDW.5(Q51W%+9GCG
MPE_Y'7_@)KZ#D?RT+8SBO'_A[X'UO0_$_P!LOK?9#@\U[%UK2NTY:&.'BU"S
M/&O$?CC4-*\22*/-6 ..QP1FNST3XA:=JHC4D1M@ EVQS5SQ%X+T_7XF,P(?
MJ-H[UY=J'PLU>%V^P))C/'S$52]G)6>@2]I%W6J/9I=<TZ*W:7[7"<#. XKR
M;XA>.X=1M#86@.X-G<.0:Y\?#;Q>6PT<NWO^\:NAT7X43O*KZDCC')Y)IJ-.
M#NW<ASJ35DK%#X7:'+<:FFH.A&Q^I%>\5F:-HEMHUJ(;=>.^16G6-2?/*YO3
MAR1L%%%%06%%%% !1110 4444 %%%% !1110 5!=_P"IJ>H+O_4T 9B?ZP?6
MM>+_ %8K(3_6#ZUKQ?ZL4@'T444P"BBB@ HHHH **** "BBB@ HHHH *\\^(
MGB&^TJ%TM!(#UW*#BO0ZH:KI-MJ]HUO<*-K=\<U46D[L4DVK(\^\+?$VWN(E
M@NPWF 8)8XYKOH-=TZ: 2_:X1[%Q7EVN?"AUE:33!(2QSU(KF9/AMXN5R(TE
MV_\ 71JV<*<M4['/SU(K57/3?%GCVST^QDC@<-+CAE;->-:7;7'B#Q.MP$8A
MY06.*Z6P^%NMS./M\<FWO\Q->I>%_!=CH$(9%)E8?-N'2JYH4U[NXN6=5IRT
M1K6MNND:1L1.B]!]*\F?XA7^F^(&6Y\T6XD.5((R*]L*AEP1D5QGB;X?Z?K4
M;38(G ^4*,9K&$HW]XVFI6]TN:/XYTW5@"'6+(_C;%:=[XATZSM6F-U"^.P<
M5XO>_"_7H6/V)),?[Q%4X_AKXN9\2QR[/]]JT]G3>MS-U:BTY2U\0O&:Z]+'
M;V@8!#@^]=%\)=#DMRNHNA7>N.12:!\*MDJRZ@KA@<^M>IZ=I\&FVJV\"@*O
M3BB<XJ/+$(4Y.7/(MT445SG0%%%% !1110 4444 %%%% !1110 4444 (WW3
M61/_ *RM=ONFLB?_ %E(9>LON&K55;+[AJU3$%%%% !1110 4444 %%%% !1
M110 4444 %<KXM\66^@V3DL#(.P/-=/*&,3A?O8XKQCQKX)\2ZUJYFMX"T6/
M4UI3BF]3.I)QC>*.+GO[GQ5K:B><",OQN["O;?"6G:-H&GQ@7-M]H PS!QS7
MD<7PS\5P@A+3&>X)_P *=_PK?QE_SSE_[^-73-1DK*6ARPE..O+=GO\ _:VG
M?\_L'_?8IR:E8R,%2[A8GL'%?/W_  KCQE_SSE_[^-6QX<\">*;+5(9KE)!&
MK@G+L>*Q=**7Q&T:TV[.)[DPW(1ZBO#/B5X<FL-02\@4XY8E17N2 A%!Z@"J
M6JZ3;:O:/;W"_*PQG'-9TY\KN:SASQL>:> O'<"6D5C=-@J,98XKO]0\4:=8
MVIF-Q$_&<*XS7EFN_"N]CNG;2D<IG@Y(K&A^&GBMY@L\<GE_[[5LX4Y:W,>>
MI'W;7*?B?6'\5ZXD,2LRK)@<9KVSP+I/]E>'((77$@Z_E6%X2^'-OI3BXN5;
MS1SSSS7H84*,  #VJ*LTURQV+I0:;E+=BT445B;!1110 4444 %%%% !1110
M 4444 %%%% &3=?ZTU8LNU5[K_6FK%EVI#+U%%%,04444 %%%% !1110 444
M4 %%%% !1110!SOBGQ1:Z!8LS,&D8$  \@UX%J.K7?BO6-LD^%)ZMZ5W?CCP
M9XCUK5)7M82\);*_,:Y6/X9>*XCE;3!]<G_"NNDH15[ZG)6<Y2M;0]6\(:7H
MVBZ?&WVBW$K*"QWCK76?VMIW_/[!_P!]BO #\./&6?\ 5RC_ +:-1_PKCQE_
MSSE_[^-4NG%N[D-59I643Z 34[&1@J7<+,>P<5-+/'#"TK,-H&<YKPWP]X"\
M5V6LPSW*2")>N7:O4]:L-0GT#[-;*3*4(//>LI02=DS:$W)7:L>?^/\ Q^=S
MV-E(0W]X'(KG_ ^@V^J7_P!MU"XB"JV2'8 FJTWPQ\5RRL[6NXD]22:>?AOX
MOP MNR ?W6(KI2@HV3.5RFY<SB>\6M[I-G;K!!=VZQKT&\5-_:VG?\_L'_?8
MKP#_ (5QXR_YYR_]_&H_X5QXR_YYR_\ ?QJR]E#^8T]O/^4^AH;F"X!,,J28
MZ[3FI:X7X=:#JNB0W"ZF&!8?+N8GT]:[JL)))V1TQ=U=A1112&%%%% !1110
M 4444 %%%% !1110 53O>E7*IWO2@"G;_P"L'UK8'2L>W_U@^M; Z4 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $,GWJ93Y/O4RF(**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"O>?ZH?6LZ+_6"M&\_U0^M9T7^L%(9KQ_<%.IL?W!3J8@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K*N_OUJUE7?WZ0%K3/O\ X5J5EZ9]
M_P#"M2@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#)]ZF4^3
M[U,IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""\_X]VK,B_P!8OUK3O/\
MCW:LR+_6+]:0S8C^X*=38_N"G4Q!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %4;[J*O51ONHH KVOWZUATK)M?OUK#I2&%%%%,04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!#<_ZNLH??K5N?\ 5UE#[](#7@_U2U)4
M<'^J6I*8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-S_JS]*FJ&Y_U9
M^E &2/O#ZUM)]Q?I6*/O#ZUM)]Q?I2&.HHHIB"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** *]Y_P >[5FQ?ZQ?K6E>?\>[5FQ?ZQ?K2&;$?W!3J;']P4ZF
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^^^_^%1VGWZDOOO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!&^Z:R)_P#65KM]TUD3_P"LI#+UE]PU:JK9?<-6J8@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH R;K_ %IJQ9=JKW7^M-6++M2&7J***8@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JG>]*N53O>E %.W_U@^M; Z5C
MV_\ K!]:V!TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]Y_JA
M]:SHO]8*T;S_ %0^M9T7^L%(9KQ_<%.IL?W!3J8@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K*N_OUJUE7?WZ0%K3/O_ (5J5EZ9]_\ "M2@84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!#)]ZF5!=W9BD*[<U6_M _W:
M8C0HK/\ [0/]VC^T#_=H T**S_[0/]VC^T#_ ': -"BL_P#M _W:/[0/]V@#
M0HK/_M _W:/[0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M _P!V@#0H
MK/\ [0/]VC^T#_=H T**S_[0/]VC^T#_ ': -"BL_P#M _W:/[0/]V@#0HK/
M_M _W:/[0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M _P!V@#0HK/\
M[0/]VC^T#_=H T**S_[0/]VC^T#_ ': -"BL_P#M _W:/[0/]V@#0HK/_M _
MW:/[0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M _P!V@#0HK/\ [0/]
MVC^T#_=H T**S_[0/]VC^T#_ ': -"BL_P#M _W:/[0/]V@#0HK/_M _W:/[
M0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M _P!V@#0HK/\ [0/]VC^T
M#_=H T**S_[0/]VC^T#_ ': -"BL_P#M _W:/[0/]V@#0HK/_M _W:/[0/\
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M#_=H_M _W: -"BL_^T#_ ':/[0/]V@#0HK/_ +0/]VC^T#_=H T**S_[0/\
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M: -"BL_^T#_=H_M _P!V@#0HK/\ [0/]VC^T#_=H T**S_[0/]VC^T#_ ':
M-"BL_P#M _W:/[0/]V@#0HK/_M _W:/[0/\ =H +[[_X5':??ID\YF.<8IL4
MOE'.,TAFS16?_:!_NT?V@?[M,1H45G_V@?[M']H'^[0!H45G_P!H'^[1_:!_
MNT :%%9_]H'^[1_:!_NT :%%9_\ :!_NT?V@?[M &A16?_:!_NT?V@?[M &A
M16?_ &@?[M']H'^[0!H45G_V@?[M']H'^[0!H45G_P!H'^[1_:!_NT :%%9_
M]H'^[1_:!_NT :%%9_\ :!_NT?V@?[M &A16?_:!_NT?V@?[M &A16?_ &@?
M[M']H'^[0!H45G_V@?[M']H'^[0!H45G_P!H'^[1_:!_NT :%%9_]H'^[1_:
M!_NT :%%9_\ :!_NT?V@?[M &A16?_:!_NT?V@?[M &A16?_ &@?[M']H'^[
M0!H53U#_ %8^M1_V@?[M13W1G4 C%(!MM_KA6LOW16-&_EN&Q5H:@0/NT#-"
MBL_^T#_=H_M _P!VF(T**S_[0/\ =H_M _W: -"BL_\ M _W:/[0/]V@#0HK
M/_M _P!VC^T#_=H T**S_P"T#_=H_M _W: -"BL_^T#_ ':/[0/]V@#0HK/_
M +0/]VC^T#_=H T**S_[0/\ =H_M _W: -"BL_\ M _W:/[0/]V@#0HK/_M
M_P!VC^T#_=H T**S_P"T#_=H_M _W: -"BL_^T#_ ':/[0/]V@#0HK/_ +0/
M]VC^T#_=H T**S_[0/\ =H_M _W: -"BL_\ M _W:/[0/]V@#0HK/_M _P!V
MC^T#_=H T**S_P"T#_=H_M _W: -"BL_^T#_ ':/[0/]V@#0HK/_ +0/]VC^
MT#_=H MW'^H;Z5D+]\?6K4EZ9$*[>M50<$&D,V8ON"GUG+?%1C;2_P!H'^[3
M$:%%9_\ :!_NT?V@?[M &A16?_:!_NT?V@?[M &A16?_ &@?[M']H'^[0!H4
M5G_V@?[M']H'^[0!H45G_P!H'^[1_:!_NT :%%9_]H'^[1_:!_NT :%%9_\
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M/[0/]V@#0HK/_M _W:/[0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M
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M/[0/]V@#0HK/_M _W:/[0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M
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M/[0/]V@#0HK/_M _W:/[0/\ =H T**S_ .T#_=H_M _W: -"BL_^T#_=H_M
M_P!V@#0HK/\ [0/]VC^T#_=H T**S_[0/]VC^T#_ ': -"BL_P#M _W:/[0/
M]V@#0HK/_M _W:/[0/\ =H T**S_ .T#_=H_M _W: -"LJ[^_4O]H'^[5:67
MS3G&*0R]IGW_ ,*U*R=,/[TCVK6H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH SKRU>60D56_L^3UK:HP/2@#%_L^3UH_L^3UK:P/2C ]* ,7
M^SY/6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#%_L^3UH_L^3UK:P/
M2C ]* ,7^SY/6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#%_L^3UH_
ML^3UK:P/2C ]* ,7^SY/6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#
M%_L^3UH_L^3UK:P/2C ]* ,7^SY/6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL
M#THP/2@#%_L^3UH_L^3UK:P/2C ]* ,7^SY/6C^SY/6MK ]*,#TH Q?[/D]:
M/[/D]:VL#THP/2@#%_L^3UH_L^3UK:P/2C ]* ,7^SY/6C^SY/6MK ]*,#TH
M Q?[/D]:/[/D]:VL#THP/2@#%_L^3UH_L^3UK:P/2C ]* ,7^SY/6C^SY/6M
MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#%_L^3UH_L^3UK:P/2C ]* ,7^SY/
M6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#%_L^3UH_L^3UK:P/2C ]
M* ,7^SY/6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#%_L^3UH_L^3U
MK:P/2C ]* ,7^SY/6C^SY/6MK ]*,#TH Q?[/D]:/[/D]:VL#THP/2@#$.GR
M =:;]BDK=P/2DP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?
MV*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?
MV*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?
MV*2C[%)6Y@>@HP/04 8,EJ\:%CTJ$#) K;U #[(W%8T/^N7ZT 3"SD(S1]BD
MK:C V#@4[ ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/
ML4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/
ML4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/
ML4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/
ML4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/
ML4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/
ML4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*C
MEA:+K708'H*S=3'S#Z4 9R(7.!4_V*2ELO\ 6UM@#'04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8+VKH,FH<<XK=NP/)Z5B#_6_C0!*MH[*"*7[%)6O;@>0O%2X'H* ,/[
M%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[
M%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[
M%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[
M%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[
M%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[
M%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[
M%)37M709-;V!Z"J]X!Y)X[4 874XJR+.0@&JZ_?'UKHHP/+7@=* ,7[%)1]B
MDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]B
MDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]B
MDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]B
MDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]B
MDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]B
MDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]B
MDK<P/048'H* ,&2V>-"QZ5"!N(%;>H ?9&XK&A_UR_6@"86<A&:/L4E;48&P
M<"G8'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P
M/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P
M/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P
M/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P
M/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P
M/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P/048'H* ,/[%)1]BDK<P
M/048'H* ,/[%)1]BDK<P/048'H* .>DA:(X-)'&9#@5>U(?O/PJ*P_UE #/L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E1RV[1#+5T&!Z"J&J >2OUH RT0NVT5/]CD--L_
M^/A:W5 VC@4 8GV*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%
M)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%
M)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%
M)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%
M)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%
M)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%
M)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 83VCHI8]!5<#)Q6_=@?9GX[5A)]]
M?K0!,MH[#(I?L4E;$ 'EC@5)@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS
M ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS
M ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS
M ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS
M ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS
M ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS
M ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E->U>-<FM[ ]!5:^ ^SGB@#$ R<
M5.MF[#(J./\ UP^M;L 'E#@4 8_V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@H
MP/04 8?V*2C[%)6Y@>@HP/04 8?V*2C[%)6Y@>@HP/04 89LY ,U RE3@UT3
M@;#P.E8-S_KJ ".W:09%/^Q25?TX#RSQ5W ]!0!A_8I*/L4E;F!Z"C ]!0!A
M_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A
M_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A
M_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A
M_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A
M_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A
M_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!S
MCH4.#3XX&DZ5)>?ZYOK5K3ATH J_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"
MC ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"
MC ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"
MC ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"
MC ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"
MC ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"
MC ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*/L4E;F!Z"C ]!0!A_8I*CDMVC'-=!
M@>@JAJ(&TT 9:J7.!4_V*2FVO^M'UK> &.@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L
M4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P)+
M9XUR:B52S8%;.H >0.*RH?\ 7"@!XLY",TOV*2MF(#RQP*?@>@H P_L4E'V*
M2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*
M2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*
M2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*
M2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*
M2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*
M2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E'V*2MS ]!1@>@H P_L4E0R1
MF,X-=%@8Z"L6^_UE $NEC]\3[5K5EZ9]_P#"M2@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *NH?\ 'HU8T/\ KE^M;.H?\>C5C0_ZY?K0!T$7W!3Z9%]P4^@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "LS4_O#Z5IUF:G]X?2@"M9
M?ZVMP=*P[+_6UN#I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0
M7?\ J36&/];^-;EW_J36&/\ 6_C0!O6W^H6I:BMO]0M2T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %5[S_4GZ58JO>?ZD_2@#"7[X^M=''_ *I?I7.+
M]\?6NCC_ -4OTH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5U#
M_CT:L:'_ %R_6MG4/^/1JQH?]<OUH Z"+[@I],B^X*?0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 96I?ZS\*BL/]9^-2ZE_K/PJ*P_UGXT ;5%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?JO^I7ZUH5GZK_J5^M
M%"S_ ./A:WE^Z*P;/_CX6MY?NB@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% %34/\ 4#ZUDP_ZX5K:A_J!]:R8?]<* -Z+_5BGTR+_ %8I] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !VK$OO]96WVK$OO]90!/IGW_PK4K+T
MS[_X5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %5[S_ %)^E6*KWG^I/TH
MPE^^/K71Q_ZI?I7.+]\?6NCC_P!4OTH =1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!5U#_CT:L:'_7+]:V=0_P"/1JQH?]<OUH Z"+[@I],B^X*?
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 96I?ZS\*BL/\ 6?C4
MNI?ZS\*BL/\ 6?C0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M9^J_ZE?K6A6?JO\ J5^M %"S_P"/A:WE^Z*P;/\ X^%K>7[HH 6BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@""[_X]G^E82??7ZUNW?\ Q[/]*PD^
M^OUH Z"#_5BI*C@_U8J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM
M??\ 'N:LU6OO^/<T 8T?^N'UK>@_U0K!C_UP^M;T'^J% $E%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% #7^X?I6#<_P"NK>?[A^E8-S_KJ -+3?\
M5FKU4=-_U9J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 85[_K
MF^M6M-[55O?]<WUJUIO:@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *S]1^Z?I6A6?J/W3]* *%K_KA]:WQTK M?\ 7#ZUOCI0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5-0_U ^M9,/^N%:VH?Z@?6LF'_ %PH
M WHO]6*?3(O]6*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =JQ+[_6
M5M]JQ+[_ %E $^F??_"M2LO3/O\ X5J4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^/K71Q_ZI?I7.+]\?6NCC_U2_2@!U%%% !1110 4444 %%%% !1110 4444
M%%%!Y% &/KGB*RT.V:6ZDV@5Y9J_Q?N4=QIY5L'C(K?\<^#+W6[PRQW4GED_
MZL=*O>'OAK8:=%&]RJ3L1DAA6\?9Q5WJ<T_:2E:.B/.(OC%XBWCS$0+WX_\
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M%%% $%W_ ,>S_2L)/OK]:W;O_CV?Z5A)]]?K0!T$'^K%25'!_JQ4E !1110
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M10 4444 %%%% !1110 4444 %%%% !1110 U_N'Z5@W/^NK>?[A^E8-S_KJ
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MZ@?6LF'_ %PK6U#_ % ^M9,/^N% &]%_JQ3Z9%_JQ3Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *:[!$9CT S3JXOXA>)DT/1SY3!I7)0J#R
M,\4XQ<G9$RDHJ[.6\;_$^\TC41!IC(RXYSZUI_#+QMJ?BNXNTO\ 9B(?+MKR
M)]/GOM$N]3N"Q8.2,^AS7<? O_C\U#Z?X5USIQ5-VW..%2<JBN]&>WT445QG
M<%%%% !1110 4444 %%%% !1110 4444 %%%% !VK$OO]96WVK$OO]90!/IG
MW_PK4K+TS[_X5J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ58JO>?ZD_2@#"7[X^M=''_JE^E<XOWQ]:Z./_5+]* '4444 %%%% !1110
M4444 %%%% !1110 4444 %%%<)X\\<S>%+B"*)4/F#/S548N3LB9245=G<LZ
MH,LP ]SBO$OB[K,$ET;.-@[,O53D5D:K\7=6U!# (HU0\97@_P JC\)^'HO$
M^HI+?32%F/<DUT0I<GO2.6I653W('9_!G3)+*WNY74J)0",CZ5ZO5+2].ATV
MRC@A4 (N,XZU=K"<N:5SIIQY8I"!0O2EHHJ"R"\V?99/,QMVGK7RXPSX\D"?
M\_!Q7N_Q"\01:3HDBK)B;TKQWP/I$NN>)Q?!2R)+N8UU4%RQ<F<>(?-)11]
M^'PRZ/"&ZUJ4R*)88PB]!3ZYGJSK2L@HHHI#"BBB@ HHHH **** "BBB@ HH
MHH JZA_QZ-6-#_KE^M;.H?\ 'HU8T/\ KE^M '01?<%/ID7W!3Z "BBB@ HH
MHH **** "BBB@ HHHH **** "D*ANM+10 445'-,EO$TLAPB]30!Y3\;3%_8
MMMMQO\SGGWK.^#JOM5AG;O\ ZUS_ ,1]=_MG7&L8GW1B0!?SKT_X8Z"VDZ#^
M^3#LP89KKE[M*S.*/OUKH[RBBBN0[0Z5XQ\4O$;W,\6FVDF'W[6%>J>(+_\
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M% !1110 4444 %9^J_ZE?K6A6?JO^I7ZT 4+/_CX6MY?NBL&S_X^%K>7[HH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K+\1_\BY?_ /7$UJ5E^(_^
M1<O_ /KB:<=Q2V9\V>#?^1F_X%_6OI^P_P"/"#_<%?,'@W_D9O\ @7]:^G[#
M_CP@_P!P5T8G='+A-F6*YWQM/]G\-3R#M715S7CN)YO"UPB#+&L(?$CIG\+/
M&_ 4<5QXFFFEQD2Y!)^E?0?VJW'!GB!_WQ7S!HZZM#JEPNGP;WW\\UTD^D^.
M9V,YM9 /9S_A755I\SW..C4Y8['ORS1.<+*C?1@:?7SI#XR\0>&KQ%NXL$=F
M;->O^#_&4'B6W'SKYX&74=JPG2<5<Z(5HR=NIUE%%%9&P4444 %%%% !1110
M 4444 %%%% !1110!!=_\>S_ $K"3[Z_6MV[_P"/9_I6$GWU^M '00?ZL5)4
M<'^K%24 %%%% !1110 4444 %%%% !1110 4444 %%%% '(?$W_D1;[Z?T->
M-_#'_D+G_>%>R?$W_D1;[Z?T->-_#'_D+G_>%=5+^$SCK?Q4?22?<7Z4M(GW
M%^E+7*=@5P/Q&\5+I.ERV\$F+@C((-==K&HPZ;I\LTK[?D.WZU\^RFZ\<>+5
MCRQ0DK@'WK:C"[N]D85YV7*MV;/P[\+3:SJLFJ72Y*OO!(Q6'\2U"_$24#^^
MO_H5?0.@Z5'I6EP0*@5E3#<5X!\3?^2BR_[Z_P#H5;4Y\U1F%6GR4TCW/PC_
M ,@6'_<7^5=!7/\ A'_D"P_[B_RKH*Y9;G9#X4%%%%24%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK6SJ'_'HU8T/^N7ZT =!%]P4^F1?<%/H **** "BBB@ HHHH **** "BBB@
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M,2G]!55XI--=2,/-M.+Z$]%%%8'2%%%% !1110 4444 %%%% !1110 4444
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M^M_&MR[_ -2:PQ_K?QH WK;_ %"U+45M_J%J6@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH RM2_UGX5%8?ZS\:EU+_6?A45A_K/QH VJ***
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MS!X-_P"1F_X%_6OI^P_X\(/]P5T8G='+A-F6*CF@CN(S'*H9#U!J2D+J#@L
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MDZ5ZW7AGP3M)8]7N)F'R-'Q7N=%=)3T##MNFKA1116)N%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \T^)^BZAJMLZV=NTI*]JI_!W0-2T5K_[
M?;-#OQMW=^E>KT5I[1\G*9>R7/SA11169J%%%% %/5;07VF3VQZ2+BO M=\
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MPFH?:0IZ[CFO5?"7@&UT1!*^'D//S#D&NYHI3K2EH.%",7<.E%%%9&P4444
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MG_Q\+6\OW10 M%%% !1110 4444 %%%% !1110 4444 %!.!DT4C#<A'J,4
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MH **** "BBB@ HHHH **** "JU]_Q[FK-5K[_CW- &-'_KA]:WH/]4*P8_\
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M78T@  P*6N:3<G=G5&*BK(****104444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH .U8E]_K*V^U8E]_K* )],^_P#A6I67IGW_ ,*U* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH JZA_P >C5C0_P"N7ZULZA_QZ-6-#_KE^M '01?<%/ID
M7W!3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 -?[A^E8-S_KJWG^X?I6#<_ZZ@#2TW_5FKU4=-_U
M9J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 85[_KF^M6M-[55
MO?\ 7-]:M:;VH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_4
M?NGZ5H5GZC]T_2@"A:_ZX?6M\=*P+7_7#ZUOCI0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 5-0_P!0/K63#_KA6MJ'^H'UK)A_UPH WHO]6*?3
M(O\ 5BGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ':L2^_UE;?:L2^_
MUE $^F??_"M2LO3/O_A6I0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %74/^/1JQH?]<OU
MK9U#_CT:L:'_ %R_6@#H(ON"GTR+[@I] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9FI_>'TK3K,U/[P^E %:R_UM;@Z5AV7^MK<'2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @N_]2:PQ_K?QK<N_P#4
MFL,?ZW\: -ZV_P!0M2U%;?ZA:EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *KWG^I/TJQ5>\_U)^E &$OWQ]:Z./_5+]*YQ?OCZUT<?^J7Z4 .HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH JZA_QZ-6-#_KE^M;.H?\>C5C
M0_ZY?K0!T$7W!3Z9%]P4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH RM2_UGX5%8?ZS\:EU+_6?A45A_K/QH VJ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "L_5?\ 4K]:T*S]5_U*_6@"A9_\?"UO+]T5@V?_ !\+
M6\OW10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%W_ ,>S_2L)
M/OK]:W;O_CV?Z5A)]]?K0!T$'^K%25'!_JQ4E !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5:^_X]S5FJU]_Q[F@#&C_ -</K6]!_JA6#'_KA]:WH/\
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M -FIZ4?V:GI0!0^US_WS1]KG_OFK_P#9J>E']FIZ4 4/M<_]\T?:Y_[YJ_\
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M]KG_ +YH^US_ -\U?_LU/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH
MH?:Y_P"^:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U?_LU/2C^S4]*
M *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH H?:Y_P"^:/M<_P#?-7_[-3TH_LU/
M2@"A]KG_ +YH^US_ -\U?_LU/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-
M3TH H?:Y_P"^:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U?_LU/2C^
MS4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH H?:Y_P"^:/M<_P#?-7_[-3TH
M_LU/2@"A]KG_ +YH^US_ -\U?_LU/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]
M*/[-3TH H?:Y_P"^:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U?_LU
M/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH H?:Y_P"^:/M<_P#?-7_[
M-3TH_LU/2@#,>5Y#EFS2([(<J<5J?V:GI1_9J>E &?\ :Y_[YI?M<_\ ?-7_
M .S4]*/[-3TH H?:Y_[YH^US_P!\U?\ [-3TH_LU/2@"A]KG_OFC[7/_ 'S5
M_P#LU/2C^S4]* *'VN?^^:/M<_\ ?-7_ .S4]*/[-3TH H?:Y_[YH^US_P!\
MU?\ [-3TH_LU/2@"A]KG_OFC[7/_ 'S5_P#LU/2C^S4]* *'VN?^^:/M<_\
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M -\T?:Y_[YJ__9J>E']FIZ4 4/M<_P#?-'VN?^^:O_V:GI1_9J>E %#[7/\
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M]FIZ4?V:GI0!GBZF P'-+]KG_OFK_P#9J>E']FIZ4 4/M<_]\T?:Y_[YJ_\
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M -\T?:Y_[YJ__9J>E']FIZ4 4/M<_P#?-'VN?^^:O_V:GI1_9J>E %#[7/\
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M +-3TH_LU/2@"A]KG_OFC[7/_?-7_P"S4]*/[-3TH H?:Y_[YH^US_WS5_\
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M %#[7/\ WS1]KG_OFK_]FIZ4?V:GI0!0^US_ -\T?:Y_[YJ__9J>E']FIZ4
M4/M<_P#?-'VN?^^:O_V:GI1_9J>E %#[7/\ WS1]KG_OFK_]FIZ4?V:GI0!0
M^US_ -\T?:Y_[YJ__9J>E']FIZ4 4/M<_P#?-'VN?^^:O_V:GI1_9J>E %#[
M7/\ WS1]KG_OFK_]FIZ4?V:GI0!0^US_ -\T?:Y_[YJ__9J>E']FIZ4 4/M<
M_P#?-'VN?^^:O_V:GI1_9J>E %#[7/\ WS1]KG_OFK_]FIZ4?V:GI0!0^US_
M -\T?:Y_[YJ__9J>E']FIZ4 4/M<_P#?-'VN?^^:O_V:GI1_9J>E %#[7/\
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M -FIZ4?V:GI0!0^US_WS1]KG_OFK_P#9J>E']FIZ4 4/M<_]\T?:Y_[YJ_\
MV:GI1_9J>E &<]Q*XPS$BHP2#D=:U?[-3TH_LU/2@#/%U,!@.:7[7/\ WS5_
M^S4]*/[-3TH H?:Y_P"^:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U
M?_LU/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH H?:Y_P"^:/M<_P#?
M-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U?_LU/2C^S4]* *'VN?\ OFC[7/\
MWS5_^S4]*/[-3TH H?:Y_P"^:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_
M -\U?_LU/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH H?:Y_P"^:/M<
M_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U?_LU/2C^S4]* *'VN?\ OFC[
M7/\ WS5_^S4]*/[-3TH H?:Y_P"^:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH
M^US_ -\U?_LU/2C^S4]* *'VN?\ OFC[7/\ WS5_^S4]*/[-3TH H?:Y_P"^
M:/M<_P#?-7_[-3TH_LU/2@"A]KG_ +YH^US_ -\U?_LU/2C^S4]* *'VN?\
MOFC[7/\ WS5_^S4]*/[-3TH S_M<_P#?-1L[.<L<UJ?V:GI1_9J>E $>F??_
M  K4JO;VJP'(JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAO@&]NI->@#W,S#S!P9":UA2YH\QC.KRR4;'U-12+]Q?I2UD;!1110 4444
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M0 452OM4M=/@,LTJ8';<*Y:]^*&A6.?,9CCT-4HM[$N26[.VHKSJ#XR^')Y
MB^:"?6NPTGQ!8ZQ")+>1<'L6&:'"2W0*<7LS5HHHJ2@HHHH **0G )]*XJ/X
MGZ))KATD>9]H\SR_;--1;V$Y);G;454OM1M]/A,D\B@#MFN-OOBUX?L)3'(7
M)'I346]A.26[.]HKC-)^)>B:Q($@9E)_O'%=A%,DT8=&!4]P:3BUN-23V'T5
MCZOXDL-&7=<2 \9P&%<E+\9?#D4QB;S<YQ34)/9"<XK=GHM%<UHOC?2M=D5+
M9\%NFXUTH((R#D4FFMQII[#77?&R_P!X$5XKXX^&<]]J0GMY"0<DX%>V5R?B
MCQ]I/A2[CM]0#EW&1M%73E)/W2*D8M>\9GPZ\%MX:B:9Y-S2+@C%=_7.^&_&
M&G>)MWV$-\HR<UN75REK"97!*CTJ9W<M1PY5'0FHKS^;XO>'X+YK1UE$BMM.
M1_\ 6KL]*U2WU>PCO+8YC?I0XM;H:G%[,NT45DZYXALM M_.NVPN,\&DE?8;
M=MS6HKB-&^*&BZY>_9;592_N*[5&#H&'0C-#BUN"DI;#J*:[K&I9F  ]37,Z
MQX\TC17*W#[B/[IS0DWL#:6YU%%><K\9O#;S",>;DG%=/I/B_3-8($$@!(S\
MS"FX26Z)4XO9F_12!@PR""*6I+"BBLK5/$%CI*;KB1>G0,*:5Q-V-6BO/+CX
MP^';:4QOYA(]*TM*^)&B:N0(&*Y_O'%5[.78E5(O2YPGQ]^[I?X_UJG\%?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQ!_P B_?\
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M1T)PVS+5%%%<QU!1110!\[?'/CQ=!_UQ_H*@F\<7^H:%8:18*=ZIL.T\U/\
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M@D]:O7OPAN+*$R6<DK/CH#7LWA_4+.XTBU$,T9(C&0&K8ZBI=:5RE0A8\(\
MZ%XBL/$D45X)UMQURQQUKW6-=L:J>PIH@C$F\+\WK4E9SGS.YI"'(K'SA\7_
M /D8KG_>_K7<_ K_ )%BY_ZZ_P!37#?%_P#Y&*Y_WOZUW/P*_P"18N?^NO\
M4UT3_@G-#^,SU:F3?ZB3_=/\J?3)O]1)_NG^5<AV'R?XY_Y#T_\ UT-?0OPS
M_P"1$T__ '?\*^>O'/\ R'I_^NAKZ%^&?_(B:?\ [O\ A776^!')0_B,ZZO$
MOC[Q_9?X_P!:]MKQ+X^]-+_'^M8T?C1K7^!F'8>.?[*^'=M8V[@W.[!7//(
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MIH='9Z-K_C2X-U-YT<$G(PQQ6A??!V1+8RQR2O)CH:]OTW3+;2[5(+>,(JC
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M_:Q:>Y$E[*2:V/JY3N4$=",TM4M)NUO-.AD7^XN?RJ[7(=B"BBB@#Y/\;_\
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MP'P'_P AZ#_KH*]^^*/_ "(5_P#3^AKYZ\&W4=IK,,DC *'!Y-=='X&<=?\
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M5TGQ\_U^F_3_ !K"^$_ANUU;5RUW&LB!=P!['FMHV]FFS&=_:M(=H_@'6?$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,WQ!_R+]_\ ]<6KY :*2;4)4C^\9#_.OK_Q!_R+]_\ ]<6KY.TL
M Z\P/_/0_P ZZL/LSDQ.Z-B#P1XFF@22/S-C#(^<U(/ 7BDD#][S_MM7TCH=
MK =$LR8ESY8K0^R6X_Y9+2>(?8I8==SYSL/A/XDN)5-W&QB/7YC7IWA3X8Z?
MHS+/(C>=U.?6O0P HP!@4M9RK2D:1HQB(JA% 4  >E<SXI\76OALJ+A]N1FN
MGKCO&?@5?%I0M=>3M&*B%K^\7.]O=.<_X7'I7_/>C_A<>E?\]ZRO^%!Q?]!4
M_E_]:C_A0<7_ $%3^7_UJWM1[G/>MV/0/!_C"U\5+.;9]WE=:O>*=+75='EB
M9<[59OTK'\!^ U\%+<A;KS_._3I_A782KOB=/[RD5C)I2]TWBFX^\?)VC7#:
M'XR$S':(Y6_G7U)HEW]NTBWN<YWKFOG;XJ:.=)U]#$N X+$BO8/AMK N_#MO
M"Q_U4?)K>M[T5)&%%\LG%F=\7=9%KX<D@C;][NZ5Y_\ ";1CJ6IF_9<F*3)-
M/^+VK"X\1-9QMN0XZ5Z%\*=%_LS2'D9>90&%'P4O47QU?0]%HHK-UW4ETG2Y
M+ML87UKE2N=;=B#6_$NGZ%"7NY=O&17EVN?&1E=AI3AQVR*\_P!8U74/$_B1
MK99I#&\NT '@"O6_"/POM+&TCEO LK]U<5T\D8*\CEYYU':)P;>-O%NM@[(U
MP?3/^%<YXLCUT6L,FJKB-C\O)KZ<@T'2[=0L=E$N/05Y9\=+>*#2+$11A?G[
M4Z=1.220JE-J+;9@?!O_ )#D7TKZ$KY[^#?_ "'(OI7T)6=?XS3#_ >5?'7_
M )%6V_ZZ_P!17"?"+_D8K?\ WOZUW?QU_P"15MO^NO\ 45PGPB_Y&*W_ -[^
MM:P_A&4_XQ](5\\_&/\ Y#LU?0U?//QC_P"0[-65#XS7$? =/\!_^0->_P"_
M7K]>0? ?_D#7O^_7K]36^-E4?@0C?=/TKY4^(/\ R,%Q_P!=#7U6WW3]*^5/
MB#_R,%Q_UT-:8?XC/$_"CW7X3?\ )/['_/85M^+I_L_ARYDSC K$^$W_ "3^
MQ_SV%;'C*$S^&;J->I%9R^,UC_#^1\N37:+XH%U(?D$H8FO9K+XL:-96R0I-
M@ #L*\6FLA/XB%F[; \@4MZ5ZK:? RWN[=94U;(89X'_ -:NJIR:<QR4^>[Y
M3<_X7'I7_/>@_&+22,>?^E97_"@XO^@J?R_^M1_PH.+_ *"I_+_ZU96H]S6]
M;L>>?$+Q!;>(]=2[M6W($QG\J]L^%KLVC*"> @KEO^%!Q?\ 05/Y?_6KTGPO
MX9'ANT\@3>;\N,T5)P<;1"E":GS2.@HHHKF.H*\_^,7_ "(LW^]7H%>?_&+_
M )$6;_>JZ?QHBI\#/&_AK_R,-O\ ]=*^I*^6_AK_ ,C#;_\ 72OJ2M<1\1EA
MOA.3\:^$HO$>FR *3.1A:^?]2\,ZUX6OC*$9%5LK@GFOJRJ5WI5C>J1<6T<F
M?[PJ*=5QT*J45/7J> :#\6=5LBL5T5$0ZDUZKX<^)&DZTR0B?,S<8]ZSO$GP
MKL=41VMBD!Z@**\2US1=1\(ZB%5Y(SD[6K7EA4VW,G*I3WU1]:*P89!R*6O.
MOA?XJ;6=.2SE;?+$F68GDUZ+7/*+B[,Z8R4E=!1114E''?%#_D0[_P"G]#7S
M_P"!/^0]!_UT%?0'Q0_Y$._^G]#7S_X$_P"0]!_UT%=='^&SDK?Q$?5T7^I3
M_=%/ID7^I3_=%/KD.LSM<A671KO<.D3']*^3]/<P^))&7J)6_G7U1XGOUL=%
MN"P'SQL/TKY=T*#[;XJ,8_BD8_K750V9R8CXD?5'AYB^@63'J8ZTZH:+'Y.C
M6L?]U,53\4ZPNBZ0]P<<@@?E7-:[LCIO979'KWBW3- C)NY=IQGBO+M:^,=Q
MYA72V5U)XR*X&2?4?%_B(VIFD*.Y Y]Z]I\+?#.QTZUC>Z1)GQR&%=')"FO>
M.?GG4?NZ(\X;Q=XNUM<K&N#Z9_PKEO%T>LH\#:LN"PRG-?4L6AZ9 H$=E$N/
M05XO\=H8X;O3A&@48[?C54ZB<K)$U:;4;MECX)_\?S?]<_Z&O9[ZRBU"T:WF
M'R-UKQCX)_\ '\W_ %S_ *&O<*QK?&;4/@/G;QI\-M0LKZ6\L8CY9;=GVK"T
MCQMK?AEQ;C)"_P![)KZBF@BN%VRH'7T-<UK/@72M4B8+;11,?X@*N-9-6DB)
M4&G>#./\/?%^SN-D>HS!7/I7IVGZE;ZG:I<6S[D89%?/?C+X:7&@;[NVD:2,
M?,2!TH^&GC"ZTS5/LUS,SQOA55CP*<J49+F@*-649<LSVOQS<?9O#4TF<8KY
MAM[R.#Q4MW,?W:R[F-?3'CF(WGA*0+U8 _I7S)#IXO?$BV,C^6))=I;TJL/\
M+)Q%^9'MEM\6]'M81%'-\H]A4O\ PN/2O^>]8L'P)@N(A(FK94]P/_K5+_PH
M.+_H*G\O_K5-J7<J];L:A^,6DD8,_P"E>1^-]<M]?\3?;;9LH<#/XUZ1_P *
M#B_Z"I_+_P"M2K\!(E8'^U3P<]/_ *U5&5*+NF3.-62LT=E\-G9]$7)Z**\I
M^+MVTFKRP$\*_P#6O<?#?A\>'[(6XE\SC&:\+^+=L4UJ:4]&;^M32:=2Y=5-
M4['<?!&SB;PT]R1\ZR8'ZUZO7DOP2OT3P^]H<;FDS_.O6JRJ_&S2C\""N2^)
M7_(BZA_NUUM<E\2O^1%U#_=J8?$BY_"SYX\#_P#(=@_ZZ"OK"#_CWC_W1_*O
MD_P/_P AV#_KH*^L(/\ CWC_ -T?RK;$;HPPVS)****YSI.=\;SO;>%[F5/O
M#_Z]?,VFG[5XUMO,_CG&:^G?&-J;SPW<0@X+?_7KYBLQ]B\;09Y\N<5U4/A9
MR8CXD?6=E;):VJ1QCY<"K%4]+O%OK&.9>A JY7,SJ05YU\8+.)O!MQ<D?.#C
M]*]%KS3XPZBJ^%;BSP-QY_2JI_$B*OP,\J^&5W);ZY%&G1Y!FOJ"OF3X6V!N
MM924''EN#7TW6F(^(SPWPGSW\=?^1FM?^N7]!72?!;[L_P#NUS?QU_Y&:U_Z
MY?T%=)\%ONS_ .[6DOX*(C_&9[!1117(=9\K?$?_ )*#>?[X_G7MWPI_Y%@_
M[P_K7B/Q'_Y*#>?[X_G7MWPI_P"18/\ O#^M==7^&CCH_P 1G=T445R'8%(2
M ,FEKF/&VO#1-(=\X9U(!II7=A-V5Q?$'C;2M 5A<S;7'I7E^K_&.^:4KIA5
ME)XR*XBP@U#QIKWD232%6)Y//>O<O#GPXT[3;:,W$4<SXYW"NAQA3^+5G,I3
MJ?#HCRYO$WB_6@&6-<-Z9KC_ !9'JD>H)_:JXF*Y'/:OJZ+1M-A $=G$H'H*
M\"^.$21>*[=44*/)Z#Z"JI5$Y62)JTW&-VSK_@M_J+C_ '?\*]<KR/X+?ZBX
M_P!W_"O7*PJ_&S>C\""BBBLS4:_^K;Z&OD;7?^1VO?\ KN:^N7_U;?0U\C:[
M_P CM>_]=S73A]V<N)V1])_#_P#Y%"U_SV%=17+_  __ .10M?\ /85U%82^
M)G1#X4>8?&/_ )!4'XUYS\&O^1Y7_=->C?&/_D%0?C7G/P:_Y'E?]TUTP_A,
MY9_QD?2M%%%<AV'A/QK_ .0E_P!L_P"@J?X!?>U3\/Z5!\:_^0E_VS_H*G^
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MSJJRO$O_ "+M[_USK5K*\2_\B[>_]<ZYEN=3V/E"X_Y&*'_KJG_H5?7.E?\
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M@U+5/4[Q;&R>9N@%<J.IGRAK'[KQM=[?X9SBOI'P9*S^"8Y&Z[&/Z5\WWO\
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MYCQ__P BA=_Y[&N2/Q([)_"SYKT3_D=;/_KN*^N8_P#5)_NBOD;1/^1UL_\
MKN*^N8_]4G^Z*WQ&Z.?#;,=7SC\6[LRZK)#G[K]*^CJ^;?BQ:M%K4TQSAGXJ
M:'Q%XCX2Q\/O&NF>'-*\NXDVS!L]*[;_ (7'I7_/>O//!'PW@\6Z;]I;4/)D
MW8V?Y%==_P *#B_Z"I_+_P"M6D_9\VIE!U>7W35_X7'I7_/>N>\9?$G3=<\.
MW-G%+ND<<#%7/^%!Q?\ 05/Y?_6H_P"%!Q?]!4_E_P#6I+V2=[E/VS5K''_"
MIV36& /5A6_\8KMC=M;YXP#77^%_A.GAR\,XOS+SG&/_ *U<=\9+4KJ#R]@,
M4U)2J71+BXTK,TO@79Q36=Y,P^9&XKVJO$?@=?I;VUU V,N_%>W5C6^-FU#X
M$%8OB[_D4]2_ZXG^=;58OB[_ )%/4O\ KB?YUG'=&LMF?+/AK_D-1_[X_G7U
MMIO_ "#+;_KFO\J^2?#7_(:C_P!\?SKZVTW_ )!EM_US7^5=&(Z'-AMF6J**
M*YCJ"BBB@#YV^.?_ "-L'_7'^@KK?@M_J+C_ '?\*Y+XY_\ (VP?]<?Z"NM^
M"W^HN/\ =_PKKE_!1QQ_C,]<K!\9?\BM>?[M;U8/C+_D5KS_ ':Y8[HZI;,^
M7;;_ )&NV_Z[K_.OKJT_X\H/^N:_RKY%MO\ D:[;_KNO\Z^NK3_CR@_ZYK_*
MNC$=#GPW4FK@OBQ_R+"?[Y_I7>UP7Q8_Y%A/]\_TK&G\2-ZGPL\5^&G_ "4*
MS_WS_,5]-ZL_EZ5<OZ1DU\R?#3_DH5G_ +Y_F*^FM70OI%THZF,UKB/B1CA_
M@9\H^*;K[1XA:4G(#<_G7JFA?$_1]*TR& 388( W ZUY/XEM3#KK0MQEL?K7
MHNC_  7M]6T^*Y35<%U#$ =/TK:?)RKF,:?/S/E.F_X7'I7_ #WH_P"%QZ5_
MSWK*_P"%!Q?]!4_E_P#6H_X4'%_T%3^7_P!:LK4>YK>MV..^)?BZS\4&T-J^
MXQ_>_6N[^#<C&RB3/&W^E5?^%!Q?]!4_E_\ 6KNO!W@A?"D2HMSYV!BB<X<G
M+$(0GS\TCKZR=9\0V.B0&2[DVBK&KWRZ;ILMTW1!7S/XDUR_\1^(GMHYI/*>
M3  / K.G3YS6K4Y#T#7?C&$9AI3A_3(KFF\=^+-;R(XUV^W_ .JNV\'?"^VM
M;5)[W;(QYVN*]"M_#^EVR!8[*%<>@JW.$=$C-0J2U;/FCQ4GB Z;'+JBXA+?
M+R>M;?PA_P"1BMO][^M=K\<+:&#PO;>5&J?O>WU%<5\(?^1BMO\ >_K6JES4
MVS)QY:J1]%SPK<0/$_W7&#7B'Q ^&ER]Y)>Z;$2M>YTV2-)5VNH8>AKEA-P=
MT=<X*:LSY4T[Q%K?A*?RESD'HQ)KTCP_\8HWVIJD@4GTKT35?!^E:G$RFTB5
MS_%BO(_&/PIDTY'O+.1I!U*J.E;J<*FYSN%2GLSVK1]<LM;M1/:2;E-:=?+7
M@CQ1>:#KT:S3.85."A/'6OIS3[D7FGP7(Z2+NK&I3Y&;4JG.CYY^+_\ R,5S
M_O?UKN?@5_R+%S_UU_J:X;XO_P#(Q7/^]_6NY^!7_(L7/_77^IK>?\$PA_&9
MZM3)O]1)_NG^5/IDW^HD_P!T_P JY#L/D_QS_P AZ?\ ZZ&OH7X9_P#(B:?_
M +O^%?/7CG_D/3_]=#7T+\,_^1$T_P#W?\*ZZWP(Y*'\1G75XE\?>FE_C_6O
M;:\2^/O32_Q_K6-'XT:U_@94^"JC^U,X&=G]*]XKPCX*_P#(3_X!_2O=Z=?X
MPH? %>&_&:[(N)+?/;.*]RKPCXS6K?;GGYVXI4?C"O\  <W\.O%.G^'5G:\?
M:['*\5Z/_P +CTK_ )[UY=X%\#0>+EF\R]^SLAP!Z_I7>?\ "@XO^@J?R_\
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MMIMNT]P^U%ZUYGX@^+UE;,T>G2[I%X((KB/B3XNN]0U8VUK*ZQX*E5/&:WO
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M..'\9V/2+O\ X\I_^N;?RKY%NO\ D;+G_KNW\Z^NKO\ X\I_^N;?RKY%NO\
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M_P 9EB?@/3/@[_R!Y_PKTRO,_@[_ ,@>?\*],K.I\;-*7P(1ONGZ5\C>(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/TFWB"X;RQFIM<_Y =]_UQ;^57P !@=*H:Y_R [[_KBW\JY;W9UVLCY+T_\
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MZ5[O7A'P5_Y"?_ /Z5[O3K_&%#X KSWXI>'WU30)7@7,N?2O0J9+&DL91U#
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MH=[KE@NHZ9-$1GY&Q]<5\L:G9WGAGQ"\C95][,IQVS7UM'(LJ;E.5-<+XZ\
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MZE_UR-?+WA3_ )#,7^^O\ZZ:'PLY<1\:/K>Q_P"/"W_ZYK_*K%5['_CPM_\
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M]*^1O$/_ "/%[_U\'^5?7+?=/TKY&\0_\CQ>_P#7P?Y5MA]V98G9'TA\//\
MD4;;_/857^(>AMJWAZY\I<R[<+5CX>?\BC;?Y["NI95==K $>AK%NT[FJ5X6
M/DK0K^Y\+Z^J.2N' ?BOIKP_XCLM9L(Y8YD4X PSC->?^.?A@M_-+?6*L9F.
M[:O KR]+7Q'X6N2TB2*%_A+G%=$E&JKK<YXN5)V:T/JD2QGI(OYTU[F! 2TT
M8QZL*^:(_BKK, V;%)'')H?Q1XD\0 B",_/_ '6(J/J[ZFGUB/0^E;>\@N@3
M%*C8./E8&IZ\I^&&D:]IZYU%) C/N)9B>]>K5C./*[(VA+F5V%%%%248GBG3
M$U+1KA67)6,D5\LDW&@:XS'*N'...V:^OW0.A4]",&O'/B/\.9=0NGO["(L^
M/NC@5T4)I:,YZ\&]4=YX,\3V>L:/"JR*LD: -N8<FNF\V/&?,3'UKY.@?6_"
M\YR'7!Y&XUM0_$W7+A?(CC4GIUIRH-NZ)CB$E:1[]KWBBPT*S>>:56VCHK#-
M?+FMW\>I^*I[R($)+)D9KJ[;PUXE\6W:2W,<H@/7#G%9/B7PW'X?NK9%+%R^
M&!K2E&,':^IG5E*:O;0]Y^&O_(IQ?6NKNH!<V[Q,,AA7*?#7_D4XOK78UR3^
M)G7#X4?+WQ"T*YTCQ+->!2(BX*X'O7H_PN\;0SV*V-W+B4G@L<#%=KXN\*6O
MB6P\J5=K+D@J.2:\&USP#KFA7;26<4HA'.X,170I1J1Y7N<\HRIRYEL?3*7$
M,B@K*A!]&%.,L8&3(@^K"OF"W\>:YHJ"&1<E>/F;-6#\2]<U(>3'&,^QJ?J\
MB_K$3Z0;4+59EB\^(L>@WBK0((R#D5\Y:#IWBO4]=M[UHY?+4\_.<5]!::DJ
M6$2S#$@'-9SAR]32G/FZ'$?&3_D1I?\ >KQ/P#J,-AK]NTW W]<U[9\9/^1&
ME_WJ^?="TF;5;@16^[S2<+M-=%&SINYS5VU45CZYM-2M;R!98IHR#VWBIVGA
M09:5 /=A7S8)/%'A.5D:)RJ?WG)JG>?$/6M54VH&UCQ\K8K/V#>S-?K"6Z.O
M^+7B];@QV5G)]TE7P<YJC\'_  X\VK"_G0F$KQQWK!\/^!]9\0:@DMQ%(T1;
M+,23Q7T1X<T&WT#2X[2$9"_Q$<U4Y*$>5$0BYSYV:ZJ$4*.@&!7DOQ>\-2WM
MC'<6R_,#N;C->MU7O;2.]M9()5!#J5Y&<5SPERNYT3CS1L?-?PZ\4MH&L)#<
M,1 #R.G>OHZQU2UOK9)HYH\,,XWC->)>,?A7<V\LESI2/(<D]2*Y"UU/Q#X7
M9ED#\=F<\5TRA&IK%G-"<J6DD?5'FQ_WU_.H9KVV@0L\\8 ]7%?-J_%C6=NP
M1KSQUJ.6]\4^)%*01O\ /_=<BH]@^K-/K"Z(^FH9HYT#QNK ^AS27/\ QZS?
M[C?RKDO %CJ=CI:1ZBK!@F/F)-=;<_\ 'K-_N-_*L6K.QLG=7/D6_P#^1ONO
M^N[5]/>"/^15M/I7S#?_ /(WW7_7=J^GO!'_ "*MI]*Z*_PHYL/\3.AK$\7_
M /(I:G_UQ/\ ,5MUB>+_ /D4M3_ZXG^8KFCNCJELSY:\,?\ (9B_WU_G7UOI
MW_(-MO\ KFO\J^2/#'_(9B_WU_G7UOIW_(-MO^N:_P JZ,3NCFPVS/(OC+H!
M>VAN8$Y+98@9KC?AEXH71=:CBN&/D#C'O7T+KFE1:MITL$B@DJ0.*^<_$OP\
MU71KQY;6%S""3NR:=*2E'E8JL7&7.CZ6M;ZWN[=)HY4(<9 W"I'N(8U+-*@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "LSQ%!)<^'KZ&)=TCQ$*!W-:=%"T$U<^7]$\#^
M(8-76233I%3?G/XU]+::C1:;;HXPRQ@$5:HK2I4<]R*=-0V"BBBLS0**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#*UO0K;6[4PSJO(P"1TKQS6_A-<6=X\FGRR-Z%:]XHJXU)1V
M,YTXRW/F.Y\,>-K5]EO]L*^S5+:>%O&ERVVX:\5?=J^EZ*T]N^QG]77<\+TK
MX27%]<*^H7,H]=U>KZ!X7LM!@$<*(6QC=CFMVBLY5)2W-(TXQV"BBBH- HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/BGIEW
MJWA"2VLH3+*6X45YAX \(:YI^MP2W5C)&@?))KZ&HK2-5QCRF4J2E+F"BBBL
MS4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L:7PW83W
MK7,L$;N3GE:V:*:=A-)C(H8X$"1H%4=A3Z**0PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
M#XD:W>Z!X4EO;"39,IP#7FW@GXB^(=7UB&"[N@\;/@CFNX^,7_(BS?[U>-_#
M7_D8;?\ ZZ5TTXITVV<M2351),^I****YCJ"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"G>ZE;V*[IG51[G%+8ZA!J$9>!@P'7!S7D'QBO[B%&CBE= &
MZJ<5I_ Z>:?0;LRR,Y$G5CFM73]SF,54]_E/5Z***R-@HHHH **** "BBB@
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M?#FJ6.K)=W".L.,8)XK?V<>2]]3G]I/GY;:'N-%%%8'0%%%% !1110 4444
M%%%% !1110 4444 %-=UC4LQP*=6-XHF:#1970X(II78F[(E77[%[D0"5=Y.
M,;A6I7RQHVH7<GQ$MU:XEVFX^[N..E?4]74AR6,Z53GN%%%%9FH4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XA\06N@6
M+3W#=0<8/>MFO OC#K$DEPUFLA 1^@-73AS2L9U)\D;E;5_B[K,L[KIDS@ D
M 8)J/1OB?XJFU"*&ZED*NV/N&KOPI\'P:Q:C4)UW*KX.1D5ZRO@S3$FCD6)
M4.1A:WE*G'W;&$(U)>]<T]$N9KO38Y9R2YZYK1ID4:Q($0  >E/KE9U(****
M!A1110 4444 %%%% !1110 V218HV=C@#K7$ZG\4=$TK4#9S!S("!E3Q76:M
M"]QI=Q%'G>RX&*^9O$OA765\02#R789')/O6U*$9;F-6<H_"?2NDZO;ZQ:_:
M+8Y3ZUH5POPOTB\TC07BO X=FR-QSQ7=5G)).R-(MM784445)04444 %%%%
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M#@]*^>O"M_=R?$6W5KB0J9S\I8XK6%/F39C4J<K2/J.BBBLC8**** "BBB@
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ME%%%9&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;. 1S7OHZ5\J_#S_ )&"W_ZZ"OJH=!6M=)/0RP\FXZA1116!T!1110 4444
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M#<]\;7=*0X:_@!]VI\6KZ?/_ *J\A?/HU?,<7A;Q)K*BX3?AN?O&ED3Q%X3
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M<\27;1J2=Q.,9K6%%R5S*=91=D?3']OZ3G']H6^?]^K4-]:W'^IN(W_W37S
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MDUO3(3B2^A4^A:O$/$OQ3O\ 4;IK?2FW1$X7BN>F\,>*=:_T@[N>>&-6J/\
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MM?&#F>9O+ 8\M]:T?&OQ(O+Z^:STY\H"5;%:.@^:R,E77+=GN3:]I2MM;4(
M?3?5RWNH+J/?!*LB^JG-?*D.@ZYJ$T=TQDVNP[FOH7P#ISZ;H/E2%MQ(/)I5
M*:BMRJ=5S>QU=02WEM <2S(A]S7'^/\ QB_AB"+R3B20<<5XU=>+_$7B.\8)
MGYO3-*%)R5PG6478^BVU[2D.&OX ?=ZDBU?3YSB*\A<^S5\TS>#/$]Y^^;=Z
M\,:SUO=;\+7(W,P93W)K3V">S(]NUNCZR!!&0<BEKS3X<^/GU]$M;QQ]I/8>
ME>EUA*+B[,WC)25T(S!5+,< #)-4X=7T^XF\F&\A>3.-JMS3]2XTN[_ZXO\
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MK$78%",[B>E?1'@3Q4GB72!,7RZD+4U*3BKE4ZRF['74445B;!1110 4444
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MX=>$=;TO6GEO-VPKW8U[D@Q&H/8"N2<5%V3.RG)R5VAU%%%06%(2 ,G@"@G
MR:\=\;_$R]TR_GL;(_,IVGBJA!R=D1.:@KL]8DU.QB_UEU$OU:H/[?TG./[0
MM\_[]?.$=SXF\1DE,_,?<57N/!7B2W5KAR^!R?F-;>P75F/MWT1]0P7UK<_Z
MB=)/]TYJQ7RQHWC76?#EZD6\@ @-NSTKZ'\)^(8O$.EBXC;)  ;ZU%2DX:FE
M.JIZ'05#<W4%I'YEQ*D2?WF.!4U>=_&5V3P4Q1BIW]0<5$5S.Q<Y<L6SO;:]
MMKQ2UM.DH'4J<T37MM;_ .NG1/\ >->(_"[Q,NE^&M2N+F4[D.1DYKEM?\;Z
MMXBU"2*V8F%C\N,UJJ+<FC)UTHIGT:->TEFVC4("?3?5]'61 Z,&4\@CO7R_
MH?A36'U6,SF38W)^8U]*:/";?2+6(YRJ8YJ:D%'9E4ZCGNA9M6T^WG\F:\B2
M7^ZS<U;\Q-@?<-I&<U\U_$ZZEM_B3*1*X4.I(#'^]77^(OB:+;2+:TTV0M*8
M5!^N*?L796ZD^V5W?H>M2ZQIT!Q+>0H?=J2+6M-F;;'>PN?0-7S;)I?BCQ&G
MVGYL-SP2*QWEUCPO>@2,X=?4G%6J"?4EXAKIH?6ZLKC*D$'TILLT<*[I'"CU
M->4>!?B7'/ILQU24 Q#"XK!\3_$#4M;OGLM(.Z('BLU2E>QHZT;7/:'UW2HV
MP]_ I]"U2PZI8W!Q#=1.3_=:OF:\\(>)[H?:9-V.O#&J.G>(M5\.:@J.[#8W
MS9)K3V">S,_K#3U1]945R_@KQ.GB+2(YV8&4]:ZBN=IIV9T)IJZ"BBBD,*"<
M#)I"<#->2^._B1=Z+J,UA9'YUXY%5&#D[(F<U%79ZC)J5E%GS+F-<>K57.OZ
M2#@ZA;Y_WZ^<$U#Q+XC=C'GYC[BH)_!/B6,-</OXY^\:V]@NK,/;OHCZ?@U"
MTN3^XN(Y/]TYJS7RKI?B_6O#-XL>XC!P=Q-?0G@WQ-'XCTT2JX+J!N^M14I.
M.I=.JIZ'3445RWC/Q7%X<TR20/B8#(K-)MV1JVDKLZ";4+.WSYUQ&F/[QJM_
MPD&D?]!&W_[[KYKOO$VM^*;UXHF)5FP,$T+X!\38WC?QS]XUO[!+=G/[=OX4
M?3T-_:W!'DW$;Y_NFK%?,5MXA\2>%[M$;.5]<FO?O">IW>JZ-!=W6-TBYJ)T
M^74TIU5+0WZ***R-2O<7UK:#-Q.D8]6.*\>^+NJV5U;2);W,<I*?PMGM6Y\3
MM%U75;14L,YW]B17A>MZ#J>CR;;XMDC/))KIHP6]SEK5'\-CT?X&ZA:6,VHF
MZN(X=PXWG&>E>T#Q!I!.!J%OG_?KY0T'P_J6N-(-/SE/O8)%;\/P_P#$RSQD
M[\!@3\Q]:NI3C*5VR*=648V2/I^.:.90T;AE/<52UW_D!7W_ %Q;^54_"]I-
M9Z3%%/\ ?" &KFN_\@*^_P"N+?RKEV9UWNCY,T[_ )#[_P#71OYU]8:&ZIH%
MF68 "(<FODJUF2WUJ21^@D;^=>FWOQ*NKC3K73M(;<P38V1756@Y6L<=&:C>
MY[9)K6FPG$E["I]VI8M9TV<XBO87/LU?.%UX8\5:NAN'W8//#&L(7FK^&;D(
MSN''/)-0J">S-7B&MT?7*L'4,I!![BEKSCX;>-O[?MC;3.#)$O->CUA*+B[,
MWC)25T%-9U098@#U-1W5S':6[32G"*,FO%_'/Q2FCF>STJ0$@X/TIP@Y/04Y
MJ"NSU^36M-B.)+V%3[M1'K>F2G$=] Q]FKYBAT_Q#XGS+'O^8^I%3-X?\2^'
ME-PV_ Y^\36WL%W,?;OL?4<<L<J[HW##U%/KP+P5\4+N"Z2TU%\1< >N:]WM
M;A+JVCF0Y#*#6,X.#U-H5%-:$U%%%06%4M2>P2$?VA)&D>>"YP*NUY7\<W>/
MPQ;%'93YO8X[BJA'FDD3.7+%L] TZYT@'RK&>%B3T1LUJ5\Y_".:5_$5N&D=
MAN[L3WKZ,JJD.5V)I3YXW D $G@"J4>KZ=+/Y,=Y"TN<;0W-3W?_ !YS_P#7
M-OY5\P:)JQT_XC&:XF?R5N&S\WO13I\Z8JE3D:/J-G5!EF 'J:I2:UID1Q)?
M0J?=J\=\6_%"[N;EK/1VW G;T[5R,OAKQ3K*F<[L-SPQJXT=+R=B95];15SZ
M0CUO3)CB.^A8^S5=1UD4,C!@>XKY'D.L>&+D>8SAL]R:]D^&/CQ]8VZ?=2 R
MHN3_ )_"B='E5T$*_,[,]6HH!R 14-W<QVEK)/(<*BY-8&Y(\B1KN=@H]35*
M36M,B.)+V%3[M7BWC;XJ7#W$EKID@,5</!::_P")W,D9?.?4BMXT&U=Z'/*N
MD[15SZBCUK39CB.]A8^S5R/Q9=9/A_>%&##/4?0UX[#X;\4Z'^_&[CGEB:?J
M?CG4;WP]+I&I<!CSQ5*C:2:=R95KQ:DK%#X>?\C!;_\ 705]5#H*^5OA]C_A
M(X-O3S1BOJD=!2Q'Q#PWPA37=8UR[ #U-17=W%96[3S-A%ZUXGXW^*5QY[V>
MER X.TUE"#D]#:=106I[))K>F1'$E]"I]VHCUO3)3B.^A8^S5\QPZ7XB\2CS
MH]_S>Y%2/H?B3PXAG;?@<]2:V]@NYC[=]CZE21)5W(P8>HIU>#^!_BA<I<I:
M:D^$. OKDU[G;S+<0)*AR&4'\ZQG!P>IM"HIJZ):ISZMI]M-Y,UW%')_=9L&
MKE?-7Q4NY;?XAR,LCJJD$@,?6G3ASNPJD^17/I,2(4#AAM(R#52;5M/@.);R
M)/JU>*ZM\5I5TNVM-+?<PB"MGUQ7,OI_BGQ/&)N<-SP2*M47]K0AUU]E7/HU
M-=TN0X2_@8^S5=CFCF7,;AAZBOE&[T?7_#G[^8O\ON:[/P)\3;J.[2SOY %9
MMHIRH:7B[BC7UM)6/?J*AMKF.[@6:(Y0]#4U<YT!TJK-J5E;'$US&A_VFKB?
M''Q!M]!@:*"3]^<C'O7BT^NZ_P"++LJ"=S>F:VA1<E=F,ZRB[(^F!K^DLVT:
MA 3Z;ZMPWEO<?ZF9'_W37R^/!/B:#_2?GXY^\:M:3XYUKP[J @G;"@@-G/2J
M=#^5D*N_M(^G**P?"WB.#Q#IJW$3Y/ /UK>K!JSLSH3NKHAN;RWLX_,N9DB3
MIEC@4EM>VUZA>VG251U*'->=?&UWC\(1E&93YO4''I7'?#KQK;Z!X5O/M,S>
M?ORN3GUK14KPYD9NK:?*SW>:[M[<9FF1!_M&JAU_25.#J%N#_OU\_P"H>*O$
M7BV[>*UYAS\I&16/?>#?$D*&XFWXZ\,:M4%U9FZ[^RCZ@AU&SN"/)N8WS_=-
M6:^4M#\8ZEH.HHDDAV(V&R37TEX7UV/7M&ANU;)<5%2DX&E.JIFW117-^+O%
M5KX:L2\KXE=?D^M9I-NR-&TE=F[->6]O_KID3_>-53K^D@X.H09_WZ^;M;\?
MZQKETR(V48X&W-00>#O$FH 3QE\'G[QK=4++WF<[Q%W[J/J"'4+.X_U-Q&_^
MZ:^=_C5_R.B_]<_\*@AOO%'A-DW@[ ><Y-8/B[Q ?$>HK>3G]\%"U=*GRRN1
M5J\T;=3V/X,_\@^Y^@_I7J=>6?!G_D'W/T']*]3K"K\;.BE\""H)KRWMQF:9
M$'^T:P_%7BJT\.V3O+)B0#(KP36_'>L^(KYH(6S$6PFW-.%)RU%4JJ&A]&G7
M])!P=0MP?]^IX=2LIR!%<QOGT:OF)?!/B6['GC?CK]XTY-;\0>$[F-9"1CUS
M5^P71F?MVMT?4O6BN#\!>.8_$<"Q2R W"KEA7>5A*+B[,WC)25T-DD2*-I)&
M"HO))[56MM4L;R39;744K>BMFJ'BXD>$]2()!\D\CZBOG_X7>(8]'\0S3WLS
M^7Y1QEL\\UI"GS1;(G4Y9)=SZ7DFCA4M(X4#N:I/KNE1G#W\"GW:O#O$/Q%U
M76[TV>EG=$Q(KGKCPAXHO8S</NP>>&-4J/\ ,[$.O_*KGTK%J^G3G$5Y"_T:
MK@(8 @Y!KY'AU75_#5V(R[!E/\1->_?#OQBOB/3RLCYDB !^M*I1<5=#IUE)
MV9W+R)&NYV"@=S7,>*M<TS^Q)T%["7_N[N:U/$$$T^F2)!]\J0/RKYMUSPAX
M@M_/N[C=Y0<G[Q]:*4%+=CJS<=D9]A/&/'D$Q<"/[0"6[5]1IX@TCRU_XF-O
MT'\=?($%M-/>I;)GS6;:/K76CX?>)B ?G_[Z-=%6FI6NSFI5)1O97/IRVU&S
MO/\ CWN8Y?\ =.:M5Y1\+_#FJ:/'(+[=RV1DDUZO7'.*B[([82<E=A1114E%
M2XU.RM#BXNHHS_M-BEMM1L[P?Z/<QR_[IS7E/QFTJ5--%[$S@M)S@GU%<[\(
MM9,6IQV,DK%G?N<]ZV5*\.9&+JM3Y6CZ"HHHK$V&2RQPQF21PB#J3VJFFMZ7
M(^Q+Z!F] U<Q\2=7^P^';F%6VLZ<<UXM\.;&XUK7SNDD/ED-]XUK"E>+DS&=
M7EDHH^GP00".AI&8*"2< =ZCC_=6R _PJ!^E>+>,/BAJ%K>SV-B>C%3Q4P@Y
M.R+G-05V>QR:I81??NXE^K5!_;^DDX_M"WS_ +]?.$9\3>(EW)NPWN156Y\&
M^([)3<2%\#G[QK;V"ZLQ]N^B/J2"\MKD?N9DD_W3FIZ^7O#_ (\U?0;Y('?"
M;@&W>E?1/AO6XM=TM+N)L@\&LJE)P-*=53-BH+J]MK) ]S.D2G@%SBIZ\K^.
M4CQ^&K5D9E/F]CCN*F$>:5BYRY8MGIUM=V]W'OMYDE7U4YILU_:6W^NN(T_W
MC7C?P]\61Z-X N[FXE/F)+QDY]:XC6/%VL^);Z2*%B8F;"XS6JHMMHR==**9
M])+KVE.VU;^ GT#U9N7MC:,\[J(",EB>,5\V^&?"FK?VPGVDR; 0?O&O:?&R
MM!\.KE02&6$#.?:IE32:28X5')-M&O9W.@QR_P"BW-OO;CY6K:!!&1TKY-\%
MSS-KD(,LA^<=6-?5UO\ \>T7^X/Y45:?(QTJG.MB2@G R:0G S7DOCOXD7>B
MZC-8V1^=>.141@Y.R+G-15V>HR:E919\RYC7'JU5SK^D@X.H6^?]^OG!+_Q+
MXC9C'GYC[BH)_!/B6,-</OXY/S&MO8+JS#V[Z(^GX-0M+D_N+B.3_=.:LU\J
MZ5XOUKPU>+'N(P<'=FOH3P;XFC\1Z:)5<%U W?6HJ4G'4NG54]#IJ^<?C=_R
M.4?_ %R_PKZ.KYQ^-W_(XQ_]<O\ "JP_QBQ'P';_  8.+*Z_W1_2O39M2LK<
MXFN8T_WFKYR\+>.O^$?TV>*V;]](N ,=Z20^*_%J>=@X;G@D54J3<FV1"JE%
M):L^B%UW2G.%OX"?0/5R*>*89BD5Q[&OE2\T#Q!H.;B8O\O/WC73^"OB9>6E
MXEK?28C8A12=#2\7<J-?6TE8^B**K6-[%?VRS1'*D"K-<YT'E/QU_P"18MO^
MNO\ 45PWP@_Y&.V_WOZUW/QU_P"18MO^NO\ 45PWP@_Y&.V_WOZUUP_@G)/^
M,?1]%%4M3U.#2[1IYVPH!KD.LM22QQ*6D<*!W-4GUS2XSA[^!3[M7A?C#XH7
MU[=/:Z<^8LE3ZUS,/AWQ'KJB=-^&Y^\:Z%0TO)V.>5?6T5<^G(M8TZ;_ %=[
M"WT:KJLK@%2"#W%?+$EGXC\*IYDF["^Y->A^ ?B;)>3)9:C( Y.U!2E1:5UJ
M.-=-VEH>RT4BL'7(.145U=1V=NTTIPB]:P-Q\LT<(S(ZJ/4FJ3Z[I4;;7OX%
M/H7KP_QO\2;VXU![*Q<%5;;7*Q>&?$>NC[6A?#?[1KHC0TO)V.>5?6T5<^G(
MM9TV8XBO87^C5=5U=0RD$'N*^7!I'B;PTAE.[ YZDUZ1\-/&.LZS<M97(&R-
M<]*F5&RNF.%:[LT>N44@Z#-+6)N(SJBEF( '<U0_MW2R^S[?!N!QC=4]_$)K
M*9#G[C8Q]*^4]?2[T;Q!*QED&9&(^8^M:TZ?.95:CAT/K..1)4#HP93T(IU<
MUX&OUO?"]F2V7V<UTM9M6=C1.ZN5[B]M;09N)TB_WCBH8=9TVX?;#>PNWHK5
MY!\:-6<7-K;V\A&X8.#7FWA75I]+UR+S)7^9U7ECZUM&CS1N82K\LN4^M@<C
M(HJ&S?S+*!\YW1J?TJ21Q&A=N@&36!T%:XU2QM'V7%U%&WHS8J2VO+:\4M;3
M)*HZE3FOG#XI:M+<^,I8896$1(QAO>O6/A;8M9Z(Q8L=^#\QS6LJ?+'F,8U>
M:?*=Y(4$3&0@)CG/I6)#<^'H[C?%<VPESV;FKNN$C0KXCKY+?RKY0TVXF.O.
M/.DQYA_B/K3IT^=/4*M3D:T/KU71HPZL"A&0:S[W6-.MXI4EO(4?8>"WM4>E
MAG\-6P7EC$*\0\:^$?$-_KMS/#N\G&1AC[U,(*3LV.<W%72.5\?W,5UKA>)U
M=>>0:]^\%ZYI</A'3XY;Z!'6/E2W(KY=O+::UG,<Y.\'!R:Z6Q\#^(;VSCN+
M??Y3C*_,:ZIP3BDV<E.HU)M(^H(-9TVYDV0WL,C>BM5X$$9'2O O G@W7=-\
M0+/=;O+QW8U[S""L* ]0*Y)Q47HSLIS<E=JQY3\=_P#D7[3_ *Z?UKC_ (/?
M\C!!]?ZUV'QW_P"1?M/^NG]:\R\">(K?P]?1W4S8VFNB"O2LCGJ.U:[/J&:Z
M@MQF:54'^T:J'7])4X.H0 ^F^O"-2\5>(?%ER\=CS"#A>HXKG=1\(>([8&YG
MW@=>&-0J*ZLT==_91]0PW]I<X\FXC?/]TU9KY7\.>-]1T/44660^4APV2:^D
MO#VKIK.DP72MDNN:BI2<"Z=53-:BBBLC4**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLMFCMMCDVJ >M?0?BZZ^Q^';B;^[7S!!B_\ &L7I+..M3AUNRL1+:)ZO\+_
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M_*OD;5_^1SO/^NYKIP^[.7$[(]F^&W@*RBTZ'5+C;,T@^XPZ5Z<EC:QJ%2!
M!V K"\!_\BE:?3^@KI:QG)N3N;TXI15CF?%7AFQU329\P1APAP<<U\T3PS>'
M/$ B1V#!QS^-?74J"6)D/1ABOF#XHVXM/',L:C &#^M;8>5WRF&(C9*2/HCP
MOJ*ZAHMNP.2L8S6U7GWPIN3<:(^?X<"O0:PFK2:.B#O%,^;OC9_R.B_]<_\
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M?YBOJ"OE_P"$_P#R4.U^I_F*^H*K$?$3AOA"O%/C7_Q\1_[G]*]KKQ3XU_\
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MA7QC\-1Z=);W-L@_>DEL#IUKWVO+/C-_R#[;Z'^M946U(UK13@SE?@OJ3MK
MLMQVA,XKWVOF[X*_\CJW_7/_ !KZ1IUU[XL.[P"BBBL3<*Y35? UCJNIM>RA
M"S$$@BNKIDDT<*[I'51ZL<4TVMA-)[E"ST+3K*-5BM(@0.H%6VLK9EVM"A'I
MBN:UKQ]I6BY\QA)C^XV:XR^^-%G+E;2WN P[@'_"K4)R(=2$=#/^+_AJ"UMW
MU*")8USCY167\']4:&Z-NTI&]^F:RO&'CN\\0:0;61)A&3G+*0*@^&'_ ",5
MO_OUT\K]G9G+S+VEXGT_7S_\;+N==?6W&[RC'SZ=J^@*\R^*7A&76+22^A +
MJN!ZUST6E+4Z:R;AH87P9TVQN([IY$21UP1D=.E>R?9+?&/*7'TKY4T/7M7\
M'W[K&9(X]W[SY3S7KWA_XOZ==A(9U?S.['BM*M.3=T94:D4K,[Z\\.Z9><R6
MD1;U*U>M+6.SMTAB4*BC  JO8:Q9ZC&'AGC)/;>,U?KG=]F=*MN@HHHI#&/$
MDGWU!^M>&?&F)(]0 10/W?;Z"O=J\,^-G_(1'_7/^@K:A\9C7^ 3X#1))/J6
M]0V!W_"O;OLL'_/)?RKQ/X!_Z_4OH/Z5[E17^-A0^!"!0HP!@50UW_D!7W_7
M%OY5H5GZ[_R K[_KBW\JR6YJ]CX_:%I]3E1,Y,C=/K7T'\/_ (?6FGV$=Y<!
M96E4, PZ5X3IW_(??_KHW\Z^LM!_Y -G_P!<Q777DTDD<>'BFVV6ELK95VK"
M@'IBO+?BUX<@_LJ;4(H%3RUZ@>U>LUQOQ1_Y$*_^G]#7-3;4D=-1)Q9XC\,;
MUK36@JL1O8"OIY#F-3["OE'P'_R'H/\ KH*^JP<6N?1/Z5KB/B,L,_=/,?BQ
MXG.G6GV.&3#2KU!KSKX=^$7\2ZJ9;MFV+AMS?Q5#\4+YKS6@&;.PD5Z-\-=0
MT_3-!@EDEC61EP<L :O6%/0C2=34](LM%L+&!(XK:-< #(%27.F6=U$T<D",
M",<BLW_A+=,_Y[Q_]]BC_A+=,_Y[Q_\ ?8KFM(ZKQ/"_B9X;&B:X]];KLBW#
M 48'6O3OA1K[:OH;B5OFC(4 US?Q>U2PU#P^IMW1I#)SA@?2L[X,W+QL8@?E
M9^?SKH:YJ6IS1]VK9'O-%%%<IUA7E/QU_P"17MO^NO\ 45ZM7E/QU_Y%>V_Z
MZ_U%:4OC1G6^!G#?"'_D8K;_ 'OZU]'U\X?"'_D8K;_>_K7T?5U_B(P_P$-W
M_P >4_\ US;^5?'VJAV\1W@C)#><V,?6OL&[_P"/*?\ ZYM_*OD6Z_Y&RY_Z
M[M_.KP_4C$]#V3X<> (%M(]4NR)6E7.UQTKU2.PM8D"I @ [ 5D^#/\ D5K/
M_=K>K"<FY:F].*4=#SCXF>&K>ZT>6ZC@53$F20*\6\ 7C6>OJRL5W8%?27C3
M_D3]2_ZY&OE[PI_R&8O]]?YUT47>#3.:LK331]<VK;K2%O5 ?TKS7XM^)3I>
MG100/DR@JP!Z5Z18_P#(/M_^N:_RKYV^+-]]HU0Q?W'K*C&\S:M*T#(\#>&9
M/$FM*)=WEGG=7TEI?A^PTVTCBCMHPRJ 2!UK@?@WI:CP_%?8&2<5ZI16FW*P
MJ$$HW*[V-K(NUX$8>A%>7?%GPI8P^'KC4X(DB9.-JCVKUFN%^+G_ "(-Y]?Z
M&IIMJ2+J).+/#_AY_P C!;_]=!7U2.%KY6^'G_(P6_\ UT%?4TIVV[MZ(3^E
M:8CXD98;X6>4_%OQ0;& V$,F&D3J#7#_  W\'MXAU%KB[)VIALM_%69\2[YK
MW7<LV=A(KU/X>:CIVEZ%!(\L8=DY^<5>L*>A&DZFIZ'9Z/8V4*QQ6T:X'84Z
MZTJSNX6CEMXV!&.16=_PENF?\]X_^^Q1_P );IG_ #WC_P"^Q7-:1U7B>#?$
M7P]_8&OO>P#9%Y@V@<#K7K7PLUYM9\.EI6^=&"@'VS7&?&+4K&_T:%K=T:3S
M.<,#W%)\%[EUC$(/RF3I^-=$O>I79S1]VK9'N-?,7Q>&?'MP/8?SKZ=KYC^+
MG_(_S_A_.HP_Q%XGX#H_A=X&MM4']H7+AA$WW&'6O;H-,L[9 D5O&H'H*X'X
M0?\ ($F^HKTFIJR;D71BE%&7J>AV.HVKQ2V\9R.I%?,?C'1F\/:\\D9(#2$K
MCM7UAVKP/XXV:VUW8N!]_)_G5T)/FL1B(KEN>@?"[6#?^%[:*1MTH&23UZ"M
M_P 6:NNCZ%/=;@&0<"O,_@O=%Y!!_=C_ *5H?&*_:*QDM0WRNF<?A2</WEAJ
M?[JYY+BZ\5^*.69XY)1^%?1/A?P;8:'I\<9ACDDQG>1S7BGPH:UCU&>6Y9%V
M<C<P%>[#Q9I@4#SX^/\ ;%56;ORHB@E;F9L&RMBNTPICTQ7F'Q2\'6UQIHN+
M6%8Y 2Q*CFNX_P"$MTS_ )[Q_P#?8K,UWQ%I=YI%RAEC)\ML?./2LH<T7<VG
MRRC8\J^$NOR6NO1Z4['RRQR2?>OH4$, 0<@U\G^$)S!XS$B''[QL?G7U/IKF
M33H'/4K6F(5I7,\/*\;'G?QO_P"1.C_ZZ_X5XEX4T:77=5BL1(R1R'!(KVWX
MW_\ (G1_]=?\*\V^%'_(Q6W^]6E)VI7,JJO5L>Y>'/"%AHEC'%Y*.ZC!8CDU
MN2V%K+$4>!"".A%6:*Y&VW<[%%)6/F;XJZ&FCZK&R($$I)P!7>?!N^:6W6V+
M$A4Z?A6-\>_^/[3_ /=_QJ?X*?\ 'X__ %S_ *&NJ3O2NSDBK5K(]LDE2%"\
MC!5'<U\Q?$+Q!/K.ORV:LQ6*3:O/6OH3Q;<_9?#T\OI_]>OF&W OO&\0[23B
MIPZWD5B);1/5?A?X$A-K'J5Y&'+#[CBO7(["UB0*D"*!V J'1[$:=IT< Q@#
MM5^L9S<G<WA!15C/O-%L+V%XY;6-MPQDCI7S5\3=%AT/Q1]F@QM*[N*^I:^;
MOC5_R.H_ZY_X5KAV^:QEB$N6YWWP9_Y!]S]!_2O3+R=;>UED8XVH3^E>9_!G
M_D'W/T']*ZCQ]>M9: SJV-V1435ZEBJ;M3N>#>-]=N?$>O&*)V*J2NT'KBO6
M?AYX#L[#38KVYC65Y5SM8?=KQ3PKY4OC)#.0$:1B23@=:^D++Q+IEK:1PB:/
MY!C[XK:M=)1B8T;2;E(WULK9%VK"@'IBN7\9^%K+4]$N"MN@EV\,!S6C_P )
M;IG_ #WC_P"^Q4<WBG2Y8BC31X/^V*YUS)W.E\K5CYX\/W\_A7Q2+8%N75#^
M=?45G,L]I%(ISE 3^5?*_BN:)_'LDL!!3S000<]Z^C?!EPUQH<;,<D #]*VK
MJZ4C##NS<2QXO_Y%+4O^N)_F*^2=/AEGO%BB)!9@"1[FOK;Q?_R*6I?]<3_,
M5\L^&/\ D-1_[X_G58?X63B/B1[_ .!O -GI%@DTZK-)( ^6'(S7="RM@NT0
MIM],4S3O^0;;?]<U_E5JN:4FW=G5&*2LCQ;XP>'88+*348H50=.!7+_":^:W
MU00AB []*]/^,G_(C2_[U>/_  S_ .1AM_\ KI73!WI.YRS5JJL?4) 88(S7
M*>/K>%?"5TPC4'U_ UUE<Q\0/^10NO\ /8US0^)'5/X6?-6AJ#XTLP1QYXKZ
MTCM8/+7]TO0=J^3-#_Y':S_Z^!7US'_JU^@K?$;HY\-LQ$BCC^X@'TI]%%<Q
MU!1110!SGC/21JVAR1$9V*S?I7S=X<NWT;QBLI)41R,/UKZPN$\RVE3^\A'Z
M5\N_$/2FT/Q#\B[2^6S730=[Q.7$*UI'TSI%U]LTN"X_OKFKA. 3Z5Q?PXUA
M=0\/V\&[+11\UU]W*L-K([$ !3U^E825G8Z(NZN>&?&?6_,O8+>)LKMPV*V?
M@YHGV>+[>R\2IUKS/Q!<MK_BU[<9.)2HKZ*\$Z<-.\,VL)7#*.:Z*GNTU$YJ
M?OU'(Z$@$8KD9? &GSZDUY(J,6;<0177U%-<PVZ%I9$0#^\V*YDVMCJ:3W*U
MOH]A:J%BM8EQZ"II+"TE7:\",I[$5R>M?$G2=&9E?]Z1_<;-<???&:WGR+.W
MN ?]T_X5:IS9FZD(Z'-?%KP]'I-TMU%&$65^ !71?!O4V:WCM&E)YSBN!\;^
M,+KQ);PI.DH5#D;U(_G71?!K_D-Q_2NF2?L]3FC)>UT/H.O*?CK_ ,BQ;?\
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MU+Q65(S@9S7TY;IY5O&G]U0*TQ#VB9X=;R*>N_\ (!OO^N+?RKY,TW_D/O\
M]=3_ #KZSUW_ ) -]_UQ;^5?)FF_\A]_^NI_G58?9DXC='UEH/\ R ;/_KF*
MFO;>%K.X8QJ3Y;<X]JAT'_D!67_7,5;O/^/*X_ZYM_*N9[G4MCY(\6 #690!
MCYV_G7TOX'MH6\':<3&I/E^E?-'BW_D-3?[[?SKZ<\#?\B;IW_7*NFO\".6A
M\;-U;>)#E8U!]JDHHKE.L\E^._\ R+]I_P!=/ZUY%X.\.-XCUB*T+%$?^(5Z
M[\=_^1?M/^NG]:X_X/?\C!!]?ZUV4W:E='%42=6S/:]!\*V&CV4<0@C9U7!;
M')K4N=/M9X'1X$8%2.15NBN1MMW.Q))6/ESXFZ*NC:ZJ(@429; KU+X17S3V
M'DER0B=*X[X[?\C%:?\ 7/\ H*Z#X*_\MO\ <KJGK239R0TK-(]BHHHKD.P*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR,%O_P!=!7U4/NCZ5KB/B,<-\+.?\;?\BK>?[M?,-C_R-UK_ -=UKZ>\;?\
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M?QK_ .1T7_KG_A7>?!G_ (\+GZ#^E=,_X2.:'\9GJE%%%<AV'C7QZ_X\-/\
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MC[U6YZ17R?XX_P"1^O?^NM?6%?)_CC_D?KW_ *ZU&'W9>)^%'O?PP_Y%5/\
M>KM:XKX8?\BJG^]7:UE/XF;4_A15U/\ Y!5W_P!<7_D:^18/^1CG_P"NS_\
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M_.OHCXB:E:Q>$[Z!ID$CIPI/)KYW\'?\AR'_ 'U_G6M%MP=S*LDIJQ]:6O\
MQZ0_]<U_E65XN_Y%/4O^N)_F*U;7_CTA_P"N:_RK*\7?\BGJ7_7$_P Q7*MS
MJ?PGRSX9_P"0U'_OC^=?6VF_\@RV_P"N:_RKY)\,_P#(:C_WQ_.OK;3?^09;
M?]<U_E71B.ASX;9EJO/OC'_R(TW^]7H->??&/_D1IO\ >K&G\:-ZGP,\=^&G
M_(PV_P#UTKZ<O>;"X'_3-OY5\Q_#3_D8;?\ ZZ5]03)YD$B?WE(K7$?$8X?X
M6?(WBZ-H]:E##G<W\Z^FO \Z2>$M/53DK$,UX'\5-)?3O$0&TE64MG\J]%^$
M?B.*ZM'M)I AC4!03UJZJYJ::(I/EJ-,]9HHI"P49)P*Y#L/(_CQ_P @2R_W
MZY7X.?\ (>AK?^.&HVMSIMK!%,CR(_S*#R*P/@Y_R'H:ZX_PCCE_&/H>BBBN
M0[ HHHH XOXG?\BJ_P!:\"\$_P#(^V7_ %UKW_XEHTGA9PJDG/:O /!A$?CV
MS+G:!+SFNNC\#..M_$1]8T4U'610R$$'N*=7(=AB^+O^13U+_KB?YBOEGPS_
M ,AJ/_?'\Z^IO%W_ "*>I?\ 7$_S%?+/AG_D-1_[X_G750^%G)B/C1];:;_R
M#+;_ *YK_*K55=-_Y!EM_P!<U_E5JN5G4MCP/XS1O_:CO_#BO/\ P_X9US7D
MD.DQNP3[VUB/Y5[-\8-'>?2)+N-"S=,"O//AEXB.B:J+60[%E?#9[5VTY/V>
MAQ5(KVFI!_PK7QO_ ,^\W_?QJ/\ A6OC?_GWF_[^-7TW;W,5U$)(G#*>A%2U
ME]8EV-OJ\>Y\OGX9^-F!!MI2#V,C?X5M>$/ASXETW65GNK+9&,<Y/^%?0Q.!
MDT@8,,@Y%)UY-6!8>*=R*U1H[6)&&&50#7 ?$7QR=!M/*M64RME6![5Z+7R]
M\2+Z2X\87-LY.Q).]*C%2EJ56DXQT&:5I>M^-M2$N93"QYVN:]/T;X.:;$JR
MW4DWF=2#D\_G6E\)K6U3PT)$52^[J*]#IU*KO9$TZ4;79R#>!M*L;"Y9$#$1
M-U4>AKYJC4)XCF4=!*P'YU]9:UJ%M9Z9<F>94S$P&3WQ7R;&P?Q',P.09F(_
M.M*#;O<SQ"2:L?5?A3_D6K+_ '*UIO\ 42?[I_E63X4_Y%JR_P!RM:;_ %$G
M^Z?Y5RO<ZX['R?XY_P"0[/\ ]=#7T+\-/^1$T_\ W?\ "OGSQW&Z:[-N4C+G
M%?0'PREC;P18('!8+R*Z:WP(Y:/\1G8T445RG6?,'Q8_Y*'<_4?S->M?"+_D
M 2_[U>2_%C_DH=S]1_,UZU\(O^0!+_O5UU/X2..E_%9Z+7'?$O\ Y%.7ZUV-
M<=\2_P#D4Y?K7-#XD=4_A9\^^$/^1\LO^NU?6=?)GA#_ )'RR_Z[5]9UMB-T
M88;9A7EGQF_Y!]M]#_6O4Z\L^,W_ "#[;Z'^M9TOC1K5^!G _!7_ )'4_P#7
M/_&OI&OF[X*_\CJ?^N?^-?2-7B/C(P_P'S/\58W77YV/W2_%86A>$/$>MV?V
MC2XI&ASCY7(_E7HGQET6142ZCC+;GYP*S_A)XG2QNH]-F<(A.22>*V4G[.Z.
M>45[2TC _P"%:^-_^?>;_OXU'_"M?&__ #[S?]_&KZ=BE2:,.C J>013ZR^L
M2[&_U:/<^7F^&7C5UVO:RL#V+L?Z5U?@#P%X@T?4C+>V?EIN!SD_X5[J2%&2
M<"E!!&12=>35AK#Q3N0S#%G(/^F9_E7R/J'_ "-]U_UW:OKFY_X]9?\ </\
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M*=HCZ_@*UH_&8U_@$^ ?^OU+Z#^E>Y5X5\!I8X[C40[ $XQG\*]UHK_&PH?
M@K/UW_D!7W_7%OY5H5GZ[_R K[_KBW\JS6YJ]CY,T[_D/O\ ]=&_G7UEH/\
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M!2M3:.C^#.E@3)?8Y9<9KV^N#^%6FBS\)0%E_>9ZUWE<U5WDSJI*T$9^N_\
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M[&E)MP5PHHHK,T&3?ZB3_=/\J^0/$*L_BJ_5>IF.*^OYO]1)_NG^5?(NL?\
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MTU*UC.A3E"]R:CM116!T'S?\3?"5QI^JO>I&2)G+9 S4?@_XCW7AZU2SG=A
MG08KZ'U'2[;4X#'/$C9& 2,XKSW4O@SIFH3F3[2T>>RBNF-6+C:9RRI24N:!
MD7'QDB>$BV,ADQZ&N:NI/$?C2*ZG=O\ 1XE+@,".*]$TGX1:9I<JN9C+@]&%
M=J-$LTTZ2SBB2,.A0LHQ2YX1^%%>SG+XF?)FB*4UE5/4-@_G7UKH?_($L_\
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M3TRXLG8JLR;21VKSC3_@MI^GW:W"WLA((.**4XQBTPK4Y2DFCTC3?^09;?\
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MN_@AIEU,9/MCIDYP*Z8U8N-IG+*E.,KP&Z9\5$U._6&$OM) Y%>JPOYD*/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7(^,/&MKX;M9 Z[Y,%=H/-==7#
M>(_ %KXBU8W-R9-IYP#Q5PY;^\1/FM[IY;X=TR^\7^*$U"97\A9"<,.U?0=E
M:K9VB0(,*O2J6BZ#::):B&V08QU(K5IU)\ST%3ARK7<****S- HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KYC^+G_(_S_A_.OIROF7XN*Q\?SD*3T[>];X?XCGQ/PGJ/P@_Y DWU%>DU
MYO\ " $:)-D$<BO2*SJ?$S2E\""BBBH- HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ",C!K*?PWHSS&5M.@,A.2Q'.:U:*=V
MA-)D<$$5M$(H4"(.BBI***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K.NM!TJ]G,]S8PRRGJS#FM&BB]@M<KVM
MC:V*%+6!(E/915BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **:\B(,LP'UI$D23[C!OI0 ^BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9)+'"I:
M1PJCN: 'T50CUO3)9/+CO86?T#5>!# $'(/>BP7%HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@^M+4E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4453N=5L+1MMQ=Q1GT8T 7**@M[R
MVNUW6\R2#U4U/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13'FCC^\X'UIRL
MKKN4@CU% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4C,J#+$ 4 +13$FCD.$<,?:GT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >8_$_Q/>:+:N+1P'!IWPA\17VOV-X]ZX8HV!BN>^,K
M#;(.]6O@+_R#;_\ WJZ>5>RN<RD_:V/8Z***YCI"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_B-=7EMHQ^R=U.[%=I4%W
M:0WD#13(K!ACD4XNSN*2NK'R9I&H:G'K0DA,GF;N^?6OJO1'DDT6T>7[YC!;
MZUB67@73;.]^TB*,GTVUU"(L:!% "@8 %:U:BGL94J;AN.HHHK$V"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N+^(UU>6VC'[)GE3NQ7:5!=VD-Y T4R
M*P88Y%.+L[DR5U8^3-(U#4X]:$D)D\S=WSZU]5Z(\DFBVCR_?,8+?6L2R\"Z
M;9WOVD11D^FVNH1%C0(H 4#  K6K44]C.E3<-QU%%%8FP4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1137.(V/H#0!Y[\4O$O]DZ6UFKX:=,<5RWPB\.-+
M<?VI<*2LB<&N9\;:DWB'Q;%8AR=DA3%>Y>#-,72O#EO;[0&4=:Z)>Y3MW.:/
MOU+]CH -J@#H.*6BBN<Z2"[N%MK:25CC:I(_*OG[6OB[X@M]3GAM95\M'*CB
MO5/B3J_]E>&VD5L,3BO"]!T/^WH+RYYSO)S711BK<TCFK3E?EB>I_#3X@7WB
M2]E@U"0$JN1CUKU4<BOEKPQ>-X=\5^0&QN<*:^G[602VT3@YR@/Z5-:*3NBJ
M$W)69-1116)N>1_%+Q[K'A?6X+;3W58W3<<_A7"+\8?%;?=<'Z UI?'7_D9K
M;_KE_05?^%/A^SU5)OM$2-A>XKLBHJFI-'')S=1Q3.?_ .%O>+?7_P =-30?
M%_Q.''G-\O?Y37M'_"#:5_S[Q?\ ?-5KKX>Z7<IM$<:>X6H]I3[%>SJ=SB=&
M^,4;3*FH2')(' KU?2-8M=8M!/;."I]Z\'\=_#1]&!O+(M(">0.U5/AGXHNK
M'7X;*:1C%GG)XZT2IQE'FB$:LHRY9GTG7$_$WQ'?>&?#J7E@P64OC)_"NR@E
M$\"2CHPS7FWQN_Y$Z/\ ZZ_X5C35YI,WJ.T&T>>Z?\8O$3WJ+<3)Y7?%>^:!
MJ!U31K>[)R9%S7R%#9R26KW"@X3O7T)\)=>_M#3%LMV3"E;UX)*Z.>A4;=I'
MIE%%%<IUE>]N!:V<TQ.-B%A^ KY]UCXPZ]%J$L=G*OEHQ7GV->I_$K65TK0<
M^9M+Y6OFUK+[1:7%]D\.?YFNFA!-79RUYM.T3WGX4^--5\52WBZBZL(A\N/P
MKU"O#?@'_P ?&I?3_"O<JSK)*;2-:+;@FPHHH)P,UD:G*^//$4GAWP_+=6[
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MUX1L-9E622- 1[5I2FHN[,JL'-61Y]\&KW4)Y)(KG/DJGRYS7L59NDZ+:Z1
ML<$:*0,$@=:TJ4Y<TKHJG%QC9A1114%A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,<*3[4M
M-?[C?2@#P[XC>-]3TO44BM) !D@UZ9X U&?5?"%I=W)S*XY/X"O"OBD0=8&/
M[QKVKX6_\B%8?3^@KHJ12IHYJ<FZC1V5%%%<YTA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<9\0-;GT?2W>!L/LR*[.O-?BRP&ED'^Y5TU>2(
MJ.T687PD\7:GKVOSP7CAD6/(_(U[/7SS\"O^1HN?^N7]#7T-5UTE/0B@VX:A
M1116)L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% $<\RV\#RO]U1DUYEXD^+-C8J]O;HYE'\2FO1]2MOMFGSP
M#.70@8KR6V^$$=QJ1DO/-$9).<GUK6FH;R,JCGM$Y6^^)GB"Z!-DTZ@],*:S
M8OB'XOMY UQ<3[,]U(KW;3O 6DZ?$$1-V!_$M,UCP'I6HV<BLFTA21M7'-:*
MK#:QDZ53>YR'@WXK0WT\=E>;C*Y^^W %>L0RK/"LB'*L,@BODOQ)I4OAC6_+
MCW*<DKSVKZ'^'NKR:EH4"2$$I'2JTTES1*HU&WRR.NF)6"1AU"DC\J^<_%?C
M_P 1V.KRQ6]^R('( KZ+N/\ CVE_W#_*OD[QM_R'9_\ KH:,.DWJ+$-I*Q])
M^![^XU+PG975T^^9URS>M=%7*?#C_D1]/_W:ZNL9?$S>'PHSM=GDM=$NYHFV
MR(F0:^=9_B)XF76XH1J#>69%!'MFOH;Q+_R+M[_USKY0N?\ D8H?^NR?^A5O
M02:=SGQ$FFK'UWITC2Z;;2.<LT2DGWQ7F?Q,\2:UI(C&FM*I)P=JDUZ5I7_(
M(L_^N*?RJ.]TFUO\><BMCU7-8Q:4KLWE%RC9'R;K6O:UJK'^TY'8GKN!%2Z!
MX@U[1HI%TB2158_-L4FNP^+.GP6.KR)"H48[#%;?P4TFUU'3[UIT5BK<97-=
MCFN3FL<2@W4Y;G*6?CGQJ][ CSW&TN ?D/3-?1&@SSW&FQO<$ERHSGZ5$OAG
M3E8,(4R#G[@K51$MX\#A17+4FI;(ZZ<''=D5]?P:?;/--(JA1G!.,UY'XE^+
MT45P]O9!PPZ,.:P?B?XVFO;TV%O)@1,5;:<56^'_ ,.G\0%+Z^5_LS<ALGK6
MD*<8QYIF4ZLI2Y8&?=?$+Q=/)NMIIPG^X:O:;\4=;L74ZB\S#OE2*]KL_!FE
MV<"QK&I &.5%8OB/X:Z9JMHY52)0"5"C'-'M*;TL'LJBU3)?"7Q$L/$02,?N
MW/\ ?.*[<$, 000>XKY,U*RU#P9KOEG<C*<@9/3->_\ P[\4?\)%I>"P+0J
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M\6+R>XEATMI$*D@$9-4/#'B_Q=J6JI#+=R[-PSE3TS74^"_A5;M;)>:D'#L
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MEOJ'C#7O)4L[N3@;CTS3I4N;WGL*K5Y?=CN=7J7Q3UF^9O[.>91VPI-9UO\
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M(7ZU\[6=OJ7C?Q!Y?S.S'H"<8S4TJ:EJ]BJM5Q]U;F_J/Q/UZ^E8Z=+,JYX
M4FJUG\0_%EM+ONYIS'[H:]>\-_#33-*M$9U)E8 L&&>:V+_P5I=];M$T8&0>
MBBK]I36EB/95'K<X[P?\5+?49DM+K<)&/WF.!7J4,J3Q+(A!5AD8KYD\=>$Y
M/"6L;K/>(<;BQ)%>P_#'Q*-;TKR-^YK= #_G\:FI!6YHE4JCORR.^HHHK Z
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MZBBBN4ZSYZ^.O_(S6W_7+^@KI?@M]R?_ ':YKXZ_\C-;?]<OZ"NE^"WW)_\
M=KKE_!1R1_C,]@HHHKD.LRO$-M'<:+="0 [8F(_*OE/39'@\1NT9P1*V/SKZ
M)^(7BBVT;2'C:0!Y 4Q]:\ \*6C:KXK6)!DR.3^M==!6BVSCKN\DD?4OA]B^
M@V3-U,?-<)\;O^1.C_ZZ_P"%>@Z5 ;;2[>$C!1,5Y]\;O^1.C_ZZ_P"%84_X
MB-ZG\-GEGAC35O\ PA? 8\W=Q^M7OAGJ,FA>(9;9WVER%JS\*K9;L- ^=K/R
M*Q/$%I-HGCQI -L0G&#74]6XG*M$I'U%&=T:MZ@&G=*R/#>I_P!J:3'/D'
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MIK@I_N&N\\*?%@3W,=G>1RO*YVY(->B3^$-,GA,;1*!CL@KEHOA5IMIK45[
M9.'W'TI.=.2U12IU(O1GH=M.+B%95! /K4M1PQ+!$(UZ"LOQ+K*Z%HTUZQ V
M>M<]KNR.ANRNRIXE\6V/AZV+RNK-CH&Y%>0:K\6KZ]D8::94]  37':QJMYX
MIU\QJ[,)),* QKUWP9\*[2TM8[F_5A<GJI&173R0IJ\MSEYYU':.QYLGC[QD
MLN]IKCR\_P!PUU&A?%^6VF6+4A*Y)QR"*]9?PEICP^68EQC'W!7F?COX611P
M/>Z8K,XRSCH *%.G+1H'"I#5,]4T/7[37+19X'49_ASS5Z^\TV4ODG$F/E-?
M,7@SQ7=>&]86.1R(E;!W'WKZ;TVZ%]IL%SP1*FZLJE/D9M2J<Z/GSQ/XW\3Z
M1XH>S^WL(U89&/>O:?!FKOK&D":23>P !/O7D?QBT0V^HR:F%P'?&?Q_^O6Y
M\%];_P")>]G(WS,_ _&M9Q3IW1E"3C4<6>R4$X!-%0W,JPV\CL< *?Y5RG4>
M1?%3QOJ&CWL$.FW)BR/FQ6O\+]5UO5E^T:E<F6)D^7(KR#Q7>OK_ (H>W!W;
M9"HKZ"\ Z8NG>%K1"N' YKIFE&"74Y:;<JC?0W-4U*'2K)[J8_(O7FO*O$7Q
M@@$GDV,<@<'!(YS7HGB[16US0IK-"VY_[IK@-%^#UH+AI;[S 0<KU-13Y+7D
M:5.=NT3A[[XB^*;CFT>X4?[AJ&T^)/B>TF#7UQ,4[@J17O%KX,TNTB$:1@@>
MJBL#Q=\/-.O=,EEB4B8#Y0HQ5JI!Z6,W2J+6XG@OXD6FO@6[Y691R6/6O0@<
M@'UKY&LWGT#Q0D"$J4E (S7U+X?U!M1TN.9L9P!Q]*BM34=471J.6C-6O!O%
MOCG6],^(4EA#>,ML)54)[$U[S7RS\3)##\0[N1>J.&'X$TZ"3D[AB&U%6/<_
M$GC>UT#1XY)&W3&)6X//(S7CFJ_$_P 07LQ;3IY43/0 UGVL6I^/-7MHV!*J
M@3"D]L"O9M"^%VE:?9+Y@8RLOS@C.#5VA36NYG>=5Z;&+\,-;U_5KM7U*X=X
MBOW6&*K?%_Q7K&@:I:Q:==&%'3) KT[2M M-(Q]G&,>U>+_'C_D-67^Y4P:E
M4V*J)PI[G5_"OQ)JFN22"_N#* N1FO4J\8^"G^ME_P!RO9ZSJJTM#2BVX:D%
MW=)9VLD\GW4&37EWB3XNV=L#;VL;^:#]Y>:](UNQ.HZ3<6PSF1,#%>6:9\'H
M7O=]]YH3KG)-.GR;R"IS[1.1OOB3XDN@39M<*#TPAJC!\1?%EM*&NKB;9GD%
M2*]XL? VE6,01$# ?WE%4O$'@'2]0T^4[-KJIV[5QS6BJPVL9.E4WN8'@OXI
M6^JRI97.[SC_ !L<"O48W$D:NIR&&17R-JEG-X:\0>2A965AW]Z^EO!>JOJ6
MB0ER,H@%36II>\BJ-1OW9&WJ<KPZ7=2H<.D3$'WQ7A_@7QWK-_XX6RO[[-MY
MC AC@8W5[;K'_(&O/^N+?RKY"%U-9ZU/- 2)!*V,''>G1BI)H5>3BTSZ!\6_
M%"STDM;0*TDI^4%#G!KS&^^(?BN=RUK)<*G;Y#6[X)^'5QK,G]H:LKA&.^,Y
M)S7K4'@_3((/*6)2,8R5%.\(:;BM4J:WL>$:;\4=>LI1_:%Q(PST((KV[P?X
MMM_$=DA0_O N6R:\Q^)_@:VL$:]M5.U5R>*P/A3JLMCK#H'.'(&":J48SAS(
MF,I0GRR/I:BFH=T:GU -4]8OQIFE3WA( B7-<AV7*7B#Q)9Z#:-+,ZEL'Y0W
M->,:S\6[V[F=-.:5#D@8!KE/%?B.Z\3:XRI(3&[@* ?>O2? _P *[<VJWFI*
MZS<%1V(-=2A&FKR.1SG4E:)P0\?>,_,W^?<;,_W#75>'_BW<6TZ1:FLLC$@$
M$&O65\(Z8L'E>4N,8SL%<MJOPHTNZNQ=1[P^X' '%+VE.6C0_9U(ZIG<:5J:
M:I9I<(I4, >:OD@#)X%4M,T^/3K.."/.%4#FLGQCKZ:%I+R%@&=2%^M<]KNR
M.B]E=E/Q9XZL?#<#ER)' Z*>:\>U/XHZY?3,=-DF5<\ *37/1+J7C;Q#Y0W.
MS$X4$XQFO</#'PRTW2[1'E5C,PRX89P:Z>6%-:[G-S3JO38\DM/B%XNMY=]U
M-.8_]PUZ'X1^*T%].EI=[O,8XW,< 5VU[X,TR\MVB:-1D'HHKP?Q[X/?PIJ@
MDL=XB(W$DD8H3A4TM8&IT];W/I>"=+B%98R"K#((-25YU\+/$PUC31:%]SP)
MS7HM<\H\KL=,9<RN%%%%249NLZS;Z+8/=3L,+VSS7BFO_%F\N)Y8M,:5"#@8
M!-6OC1K<L.H?V:KD*Z9X-4?A9X.M-:>:XN]Q,>".^>E=,(1C'FD<LYRE/DB<
M\OCSQMN!,]QC/]PUU.B?%NZM)HUU-9G]<@BO71X4TT)M\E,?[@KF=8^%.D:A
M)YHWJX[*,4>TIO1H/9U(ZIG5Z5KD>LZ8+N%&567(S7C_ (^\7^);'6GM[!YE
MCQ_"I(KV71-)BTC2HK./.U%QS4=[H-E=%Y9(U+;3R5%91E&,MC6492CN?)&I
MZC?:C.9+YV:3/\0K=TKQ=XJT_3X[:PFF6W7[H52147C6W2WUN=(P !(1P*]O
M^&^@65WX)LII8E+L.25!["NN<THIM')3@Y2:3//_  AXP\6WOB.W@O)IS"W4
M%#CM7T!:LSVL;/\ >(YJA;^'K&VF$L<2!AZ**U% 4 #H*Y*DE)Z([*<'%:L\
M,\?^-M:T?QTUE;7;);94;!]:]!U?QI;Z+X=@N)W#3/"&X/).*\7^+K%/'\SC
MJN#^M4(&U/QM>VEK@E(U" *371[-.*9S^T:DT:^K?%'7;Z4G3)I47/0 FNQ^
M&>O^(M7U&-M1N7>'NK BM[P[\+-,T^S1IPWGL,,",XKK-*\.66D$&W&,>U9S
MG"UDBX4YWO)G'_%/Q!J.B00-83F(LO./QKFOA+XPUK7O$LUMJ%V98A'D ^O-
M:7QI_P"/>V_W?\:Y#X&?\C=/_P!<?Z&JC%>R;%*3]LD?15%%%<IU'C'Q/\6Z
MSHNJO%8W9B0#@"MKX/\ B+4_$%A>2:C<&9D;"D]JXGXR_P#(;D^E=#\!O^07
M?_[U=4HKV5SEC)^VL>Q4V21(D+R,%4=R<4ZO*OBOXP?2H)-,A<"1UR.>>E<\
M(N3LCHG)15V2^,/BE:Z5(;>WRTF<94YKS6[^)'B>[<M933!3TPI-9_A/PS=^
M+M4+R!WC#YD.2<"O>M'^'FDZ3"J(N[ _B7-=+Y*>G4Y5[2IKLCQFP^)'B>SD
M#W\L[(.N5(KU;P9\18/$/^C^5)YJCDFM75? 6E:G;M$Z;<C^%<52\+?#^S\.
M7TLL._#=,UG*4)+;4TC"I%[Z$7Q%UO4M*TEY=/+B3MM!->"ZUXH\0ZFNW499
M2G8,I'%?5EYI\%['LF4,/<9KQSXN:3:V*0>2BKE>RXJJ,EM85>#M>YY1H.KZ
MKH]TTVDNZRD8.P9XKHO^$[\;_P#/>X_[X-:?P8T^#4/$=Q'.H91%GD9[&O=O
M^$7T[_GBG_? K2I4C&5FC.E3E*-TREX*OKV^T:&6^9C(4R=PQS7GGQ.\7ZUH
MNL2Q6-V8D'0"O9+>VCM8PD8  ]!7S_\ &/\ Y#TU8TK2F;5;Q@=Y\(/$.I:_
MI5U+J-P9G1\ FO2J\A^ _P#R!;W_ 'Z]>J*JM-V+I.\%<1N%)]J^=_&7CSQ#
MIVLS0VU\R(KD 5]$/]QOI7RG\0/^1@N/^NAJZ"3>IGB&U'0^@_AUJ=UJ_@RT
MO+R0R3O]YCWX%=57$_"C_DG]C_GL*[:LI_$S:'PH\P^+_B34O#UM8OI]P8B[
M?-COUJ]X,\7M+X)74]2G#R9())QVKF_CW_QXZ?\ [W^->5V6KZA=Z.FAP?ZL
MMG@X-=$*:E31S3J.-1G=>(OBQ>W%Q)#I;R(5) (!-5?"OB[Q;J>K)%-=R; P
MR"IZ5U/@SX4VWV9+O45<2$!E[YKOK+P=IMC/YT2X;Z4I3A'1(<85):MF] 2;
M>,L?F*C/UQ6)XC\4V6@6K23.K'&<!N:NZUJ2:/I3W3D!4&,U\RZ_K%]XK\1F
MV5B5,NU &ZUG2I\[N]C2K4Y%9;G3:S\6=2U"=O[+:6,'H ":QHO'_C&.8/+-
M<&/N-AKTOP;\++2RM([F_5A<D?,I&17:R^$-,E@,1B4#&,A!6KJ4XZ)&:IU)
M:MGF?AGXM_Z2MOJ D9F.,GC%>PV%_#J%LLT+!E/H<UX-\1_ ":&RWVGA\LV6
M]JW?A#XH:79I,LF7SG!.34SA%QYHCA.49<DCV:BBBN<Z0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *1F"C+' J"]O([&UDGE("HN>M>)>+_ (K74MP]OH\CKVQ@FKA!SV(G
M44-SV*Y\0:5:9$]]$A'8FN?U#XBZ1:Y$<\,H]C7CEIX6\3>+6$TL@PW/S C^
MM=58?!F147[6J,>^#6OLX1W9E[2<MD<-\3-=MM>UZ*XMD55"8.W\*]+^#$KO
M;SJS$@+P/RKS+XD>&K?PQK4-I;IM5H]Q^N!7I?P6_P!1<?[O^%:5+>RT,J=_
M:ZGK%Q_Q[2_[A_E7R=XV_P"0[/\ ]=#7UC<?\>TO^X?Y5\G>-O\ D.S_ /70
MU&'W9>)V1]%?#C_D1]/_ -VNKKE/AQ_R(^G_ .[75UA/XF=$/A1E>)?^1=O?
M^N=?*%S_ ,C%#_UV3_T*OJ_Q+_R+M[_USKY0N?\ D8H?^NR?^A5T8?9G-B=T
M?7.E?\@BS_ZXI_*K=5-*_P"019_]<4_E5NN5G4MCY]^,O_(:D^E;_P !?^0;
M?_[U8'QE_P"0U)]*W_@+_P @V_\ ]ZNN7\$Y(_QCV.LCQ+=_8M%EFW;<=ZUZ
MY;XA GPC<X&?_P!1KECJT=4G9,^;7']I>--A.X2SX^O%?4/A?35TO18K<)MV
M]J^7] X\<66>/]('\J^N$(*#!!XKHQ#V1SX9;L=1117,=1XW\9-&7[')J(09
M'&ZN<^#^I-;7CP>9@2/C'K7HWQB(_P"$&F&1G=7COPT!/B&W(!_UE=<-:3N<
M<_=JJQ]1UQ?Q5_Y$"^_SV-=I7%_%7_D0+[_/8US0^)'34^%GSOX1TY;_ %ZU
M5C\HD&1ZU]9:?9Q6-FD,2A5 ' KY;\ ?\A^W_P"N@KZL3_5K]!6^(>J,<,M&
MQU>%?&75Y) MJK$;'KW6OFGXK2.VO3J?NA^*B@KR*Q#M Z3X.Z=;[$U"3:&5
ML9->U_;+;_GJM?)FC>)-<TNT\C3_ #/*SGY4)_E6C_PF_BO_ *;?]^VK6I1<
MI7N94ZRC&UCZB^V6_P#SV6O/_BI!:W/ABZN0ZLZK@?E7CO\ PF_BO_IM_P!^
MVJMJ'BCQ)J5F]K<K,T3]1Y;4HT&G>XY5U)6L=+\'K]K759U!.'P*^B)23:.1
MUV'^5?-OPPMKB/6"7@D4;AU0BOI0#=#M]5Q^E17^(O#_  GR1K8E'BRY^T [
M?..-U?2O@/9_PB-GLQMQQBO'/BIX8N+'4%NHT^5LL2!6_P###Q]!%:1:7<N0
M(UP,G K2HN>":,Z3Y)M,]IKSOXK>5_9(WXSL.,UV=QK=C;VAN6N(BH&<!QFO
M"/B5XT'B"ZBL[ L=AVMWSUK&E%N1M6FE$3X)B;_A+')!\OR^/3O7T37E'PD\
M.2V-G'?RK@L,<CFO5Z*SO,*"M \?^//_ "";'_?KB/A1H\5]XDBDEPRX^Z:[
M?X\_\@FQ_P!^N;^#?_(<BK:+M2,9J]8^@8HUAB6-1A5& *?117(=AYC\7-6>
MVT6>T1B"RYX^E>;?"S3HM0U=YI\$Q,#DUU/QKD<780?=,?\ 05Y5H>M:II#2
M'3=^7^]M4G^5=M.-Z>APU)6J:GUVEW;*@ E7@4OVRW_Y[+7R[_PF_BO_ *;?
M]^VH_P"$W\5_]-O^_;5E]7?<U^LKL?0GBV.TO]$N TB$I&Q%?/7@.Z-EXV5U
M/ =A^M-E\9>*9H7B?SBKC!'EM4'@^VNO^$CC=[>49.22A]:UA#EBTS*=3GDF
MCZ;U*)M2\+S1@9,L6*^7M7L+GPYKQW1,JQL#GUP:^KM+&-,MP1_!7.^*? NF
M^(4>26$-,W.:PI5.1V9O5IN:NMSGO"'Q1LM0M(H;H);E %RQ]*]!M=5L;U0;
M>Y23/]TU\_:[\)=6T]VFMM@B'8=:P+3Q%X@\,7'EH[HJG!RIJW2C+6+(5:4-
M)H^K:*\T\!?$F'72EE=N3='DL>!7I0(8 CH:PE%Q=F=$9*2NCYY^*_AZXAUB
M744B8AWZ@>]2?#CXBIHD TRYB!5FR9&/2O<M8T:TUJU,%W'O7'%>0>)/@Y*S
MO)I:HBGGFMXU(RCRR.>=.49<T3U?3O$^E:A&ICO(BQ'W0:V%=77*G(KY2GT_
M7O"5QE=VX'JJG%=GX/\ BS=07*0:Q*SH<# !ZTI4-+Q*C7UM+0][K-\0?\B_
M?_\ 7%JM65Y%?6L<\3 JZ@]:J^(/^1?O_P#KBU8+<W>Q\G:5_P AYO\ KH?Y
MU]9Z'_R [/\ ZYBODS2O^0\W_70_SKZST/\ Y =G_P!<Q73B.ARX;J3W\*SV
M,\;+G,; ?E7RKXELI/#WB-B 0Q9F'YU]9$9!![UX3\9]!/\ : OXUQ&D?/Y"
MHH2M*Q>(C>-SU/P3J27_ (;L\,"XCYKH)V"02,3C"D_I7D'P6UDW*7-O(_$:
MX /X5Z%XRU0Z5H4DP;;D$?I43C:=C2$[PN?/?CF^?7?$?DJQ8HY45[O\/=+6
MP\,6A*@2%>?6O!/"MBVK>.$D(W(TQ)KZALK9;2U2%!A5K6N[)1,:"NW(\Q^,
M&K/#I,UFC$$C/%<+\)].BO=2>YFP3$^<FMGXT2.-19/X=E>::'KFK:.)!IN_
MY_O;5)_E6E.-Z=D9U)6J79]=B[M@.)5H^V6__/9:^7?^$W\5_P#3;_OVU'_"
M;^*_^FW_ '[:LOJ[[FOUE=CW[QI%:7V@7),B$I&2*\%^'-XUEXOWJ>Y'ZU7G
M\8>*+B!X9!,4<8(\MJ3P1:W(\1(SV\HSSDH1WK6,.6+3,I5.>::/JFU?S+6-
MS_$N:EJM8#%A!G^X*LUQ'<@HHHH \S^-W_(G)_UU_P *\Q^%:*WB.V)&3NKT
M[XW?\B<G_77_  KS/X4_\C%;?[]==/\ A,XZG\9'TP!BFR?ZI_\ =-.ILG^J
M?_=-<AV'R?X[14U^X*J!F0YKWWX5Q(/ EBX4!B.3^ KP3Q[_ ,A^X_ZZ&O??
MA9_R(-A]/Z"NNM_#1QT?XC.SK-U\!M!O01D&(UI5G:]_R KS_KF:Y5N=;V/D
MR^ AUY!&-H\P=/K7UIH1SH-B?^F*_P J^3-2_P"0^O\ UU'\Z^LM!_Y -C_U
MQ7^5=.(V1RX;=GB?QCU$S3"W$F=C]*O_  9T99(DU$H"5;&:Y3XJ CQ#<'!Q
MOKT[X)D?\(:PR,^9_C3EI2%#WJNIZ71117(=AE>(K!=2T>:V*[MPZ5\MWD7]
MF>,S&OR>5,/PKZY) ')XKY,\8<^/+W'/[[M73AWNCEQ*V9]+^%+TW^B1RE]W
M &:\\^,FA_:HX[M%P(DR<5UWPU!'A2+((YK1\9:<NH^'+N,+ERF!6:?+,U:Y
MJ9Y!\&=:\K59;>5L*$P,U[\IW*".XS7R=H\TOAWQ0D!.UO,53^=?55C,LUC"
MZG.8U/Z55>.MR,/+W;'GGQ<UC^S],C@#X\Y2,?G7 ?![1C<Z^;B1<QE.,].]
M,^+.JMJNJQ6H;)B<J!^=>D?"?1A:>&K>Y=<2G@G\*OX*7J1\=7T/1$4(@4=
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M_P (_8[NODC-:55[*'[/90P_W% JQ7,]SI6P4444AA2$A1DG J.XG2WA:1R
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MC^M=]651WDS2DK005X%\>/\ D-67^Y7OM>!?'C_D-67^Y5T/C)Q'P&M\%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG-=O_P )QI7_ #\1?]]4#QOI1./M$7_?59NI4:L6J=-.YT-K:Q6D(BB4*H[
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MQMN2S@5O4(*X[4OB?IMBC[0LA _A-7/!WC>'Q/%E(BAW8YI.,K7&IQ;LCL
MH  P!VI:Y;QMKD^CZ5(;>%W=DX91]VO./#'Q;>VVVVI1N\@'+-3C3E)70I5(
MQ=F>W/&D@PZAAZ$5Q_C/P?I^J:3/+Y:1O&A8%5QFGVGQ TNYBWF6-/8M6!XM
M^)=A;Z9-!"!(TJE05/2B,9IZ"E*#6IX=8W,NA:\IC8@A\=?>OK#1)3/HMG*W
M5H@37S#X5TB?Q%XA4M$S(3NW$<=:^FD8Z7H$>U"QAC VBM<1T1EA]+OH:=!
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M)'^4%.>:YU3DV=#J12///C 0WCN0CT'\Z]+^#O\ R")_PKPOQ'=7MYK!EO\
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M12""TC);</F4USJG)G2ZD5U/7J^??C%IK6]S]I*X$C]:]C\*ZX=<TX3&-D(
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M$$U]25Y=\5/"1U.RDOH8]TRC P.:QHRY9:F]>'-'0O\ PMUN+4-(%NLFXPH
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MN:5>6)CN;L-NN/F^85I0ARZLSKS4M$?1OPH_Y)_8_P">PKMJXGX4?\D_L?\
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MZT5QOPWUZ7Q!X?:XF+%D8+D_C795G)6=C2+YE<****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *]Y:17
MML\,J@JPP:\@\3_"(SRO+I<9W'GFO9Z*N,W'8B<%+<^<(/A#XF$P$BD1Y[,:
M[[PW\*+.T9)KY7,HYY.>:]1HJI5I,B-""/'_ (D?#G4=>U2&;2X5\N.()Z=
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MB""Y$GS8Z]17._![3YI=0CNE!\M'P?SK634Z?,S**<*G*CZ$(# @]#7*>(_
MFE^($8S1X<_W17645R)M:H[&D]&>!:K\'=21V_LY#M[<UCK\(O%NX;EXSS\Q
MKZ5HK55Y&+P\#Q+2/@XSLO\ ::MCO@UZOH6@6NA6HAMLXQCFM:BHE4E+<TC3
MC'8****@L*@NX$N+9XW&00:GH(R,4 ?+TT4NA?$%9W&U#<$BOI/2+X:EIL=R
M#D/7D7Q>\.LLL-];*1L&YBM=)\*/$27^AP:>6!EC7)]>E=%3WH*1S4_<FXD?
MQ*\+ZYXAD\O3D5H2F#D]ZSOAI\/M2\/W5Q+JD:KGE,5ZY16?M'R\IK[)<W,
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:_M$O+5XG&00:LT4
M ?,GBSPIJ?A[6WOK96)+EU*+G%;WA[XLW.FVZ1ZFD[[>ORFO<[S3[>^@:*:)
M&##&2H)KD;[X7:+?YWLRY_NC_P"O70JL9*TT<SI2B[P9A#XZ:'@ VL^?H?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVSS2#(49-7*YKQF2-$NL''[LTTKL3=D4M+^(5AJEUY$:8;<5KL0<@'UKYE\
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M$CZC!!&0<BEKG?">LC5-*@;.6(KHJP:L['0G=7"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX-@M=.>[B&&R>@Q4Q<&[6+DII7N>E>&_$46M6D;!EWD9(%=!7@GPJU*2+53
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MF9A;V3N ?X0*RU^)6LPRAI=/E5?4@?XUZAI?P]L+",8(8X[C-.USP797-A(
MJAL<86MN>&UC'DJ6O<S/"7Q!CU?9%,51V[&O0E=7&5.17R[/;MX9\8Q1([!1
MGO[BOHGPM>F^T=)B<DU-6"6J*I3;T9S'Q \53:!8^;&A;YL<4MIX]@30H+AI
M$\QUR5KG?C'QH[?[QKAO!>A3^(I$@E+B-.1@FKC"+A=D2G)2LCJM4^).JR2L
M+>PD=0>J@53L/BEJ$%RB75H\8)_BQ7J.E^"+*SM54@,2N#D9K@_B1X-@AC\^
M 8VC/ Q1&4&[6"2FE>YZ3X:\1PZY:>:KKGT%=!7@/PHU.2%OLY8D%R.3[U[[
MD!03652/+*QK3ES(ANKN&TB,DL@11W->9>)?B9]CE>&U42E?[M4_B?XKE@BF
MLH6Y&>AKF_ _@MM=NENKPN%?'))-7""2YI&<YMOEB.;XCZY(^Y-.F*^H _QK
MHM ^)=W).L5Q:LA8X^8"N[MO!MC;P",*IP,9VUEW'PYL7NTG5R"K;L"CG@]+
M!R5%K<["RN?M4"R8QD TV^OX;&!I))%7;ZTL$"6-H #PBXKR#XE>*)3>?8+=
ML^8,<&LX1YG8UG+E5V7O$?Q.>"=H+./SO3;BN87XC:YOW?V;-M]<#_&M#P)X
M!748$OKLMOXX8DUZ?_PA]CY'E;4QZ[:V;A'2QBE.6MSC?#?Q+-U.L%V@A/\
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M2Z.^^R0_[(K1K"]M#HLGJ(%4#  %<WXQLX;C2V#JO /45TM<7\0-7BL-)^^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'P[A@O#<RRL[!RP#$GO6E-I:LRJ*3T1-\.=";3=+.]2"3GFN]J.&%8(PB
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M3Z* *XL;4'(@3/TJ945!A5 'M3J* "D(##!&:6B@"NUC:L<F!"?I2?V?:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img43612817_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img43612817_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0X!X # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **BN21:S$'!"'^5<%\%[JXO/AW#+<SRSR&YF&^5RQQO/<
MT >A4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% $5U_QZ3?[C?RKSWX'_ /)-
MH/\ KZG_ /0S7H5U_P >DW^XW\J\]^!__)-H/^OJ?_T,T >CT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_(/[2I=F?1U%?./_"Q?%G_09E_[]I_A1_PL7Q9_T&9?^_:?X4?V75[K\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&_E7GOP/_P"2;0?]?4__ *&: /1Z*** "BBB@ HHHH **** "N*U7_D*7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !37^XWTIU-?[C?2@#Y0NO\ C[G_ .NC?S-15+=?\?<__71OYFHJ
M^O6Q\J]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W/!
MO_(Z:+_U^1_^A5AUN>#?^1TT7_K\C_\ 0JSJ_P .7HS2E\:]4?35%%%?)GTX
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !112,RH,L0!ZDT >#_ !X$"^-/"$NL
M+(="#$3[<]-Z^9T_V<5ZP9O"7_"-X\S2?[&\KIF/RMF/3ITIWBSPSH_C'0VT
MS5@#$QWQR(P#1L/XE->1?\,Z67VG'_"4O]ESG9Y*[L?7=C]* )?@"JGQ'XOD
MTT,-%,RB -_OOL_';_,5[O6!X1\+:1X0T1-+TA?W:G=)(S!GD8_Q,:WZ "BB
MB@ HHHH **** (KK_CTF_P!QOY5Y[\#_ /DFT'_7U/\ ^AFO0KK_ (])O]QO
MY5Y[\#_^2;0?]?4__H9H ]'HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW?B9X%T;QS?6<":Q!8>(8$(A!8%G3[V&7.>,$@CU->;W=]\3?A!<6\VI7O\
M:&CM*(QOE\Z-^^T%OF0X!]/QH ^E$<.BN,X89&:=5>PNTU#3K:]C!$=Q$DJ@
M]<, 1_.K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %-?[C?2G4U_N-]* /E"Z_X^Y_\
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M -#- 'H]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ IK_<;Z4ZFO\ <;Z4 ?*%U_Q]S_\ 71OYFHJE
MNO\ C[G_ .NC?S-15]>MCY5[A1113$%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5N>#?\ D=-%_P"OR/\ ]"K#K<\&_P#(Z:+_ -?D?_H59U?X
M<O1FE+XUZH^FJ***^3/IPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[X
MO>-]5\/G2]"\.Q;]9U1B(W"!F1<@#:#W)/7M@UT.N0^*;CX8M%IY:/Q(UK$,
MK(%(D!7?ANF<!OSKD?C-HFLPZCH?C30X#<7&CO\ O80I8[<A@<#J.H/UKGW_
M &D7-L8X_#1%YC&&N/EW?3&: .P^#_CS4O%5IJ6EZZ -6TR0)(VW:74DCD#N
M"I!_"O3J\>^!OAW58#K7BG68'@N-7EW1HZ[21N9F;'8$GCZ5[#0 4444 %%%
M% !1110!%=?\>DW^XW\J\]^!_P#R3:#_ *^I_P#T,UZ%=?\ 'I-_N-_*O/?@
M?_R3:#_KZG_]#- 'H]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ IK_<;Z4ZFO]QOI0!\H77_ !]S_P#71OYFHJENO^/N
M?_KHW\S45?7K8^5>X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %;G@W_D=-%_Z_(__0JPZW/!O_(Z:+_U^1_^A5G5_AR]&:4OC7JCZ:HH
MHKY,^G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXL\3ZEX+T6\U71%<1Q6L;,,@O\AY!/ #=><'FO1/^%E^./\ HF.I_P#?T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_<;Z4ZFO]QOI0!\H
M77_'W/\ ]=&_F:BJ6Z_X^Y_^NC?S-15]>MCY5[A1113$%%%% !1110 4444
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MGOP/_P"2;0?]?4__ *&: /1Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %-?[C?2G4U_N-]* /E"Z_X^Y_^NC?S-15+=?\
M'W/_ -=&_F:BKZ];'RKW"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K<\&_\ (Z:+_P!?D?\ Z%6'6YX-_P"1TT7_ *_(_P#T*LZO\.7H
MS2E\:]4?35%%%?)GTX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YE\7?A
MY?>+[>RU70YO+UG3LF)=^SS%R#@-V8$9'U-<%_:_QU:#^S_LER&V[//^S1;L
M>N_IGWKT3XK>/K[PI;V&E:%!Y^N:HY2W&S=L&0,X[DD@ ?6N*\(:G\0H/'6J
M:-KVH33:@-(EN(+;S5*B0XV=/E!S0!V7PD^'EYX-LKV_UF99=8U$AIL-N\L
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M<)V!..N*;\#<_P#"M+?=C=]IFSCUWF@#TBBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^5-4_Y"][_U\2?^A&OJNOE35/\ D+WO_7Q)_P"A&O7RK>7R/+S/
M:/S*E%%%>R>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M:GAO_D:-*_Z_(O\ T,5]1=J^7?#?_(T:5_U^1?\ H8KZB[5XF:_'$]C+/AD%
M%%%>4>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U_N-]*=37^XWT
MH ^4+K_C[G_ZZ-_,U%4MU_Q]S_\ 71OYFHJ^O6Q\J]PHHHIB"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *W/!O_(Z:+_U^1_\ H58=;G@W_D=-
M%_Z_(_\ T*LZO\.7HS2E\:]4?35%%%?)GTX4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS_0_^ Z?X5Q=%'U:C_(ON#ZQ6_F?WG:?\+4\6?\ /]#_ . Z?X4?\+4\6?\
M/]#_ . Z?X5Q=%'U:C_(ON#ZQ6_F?WGT)\-_$&H^(]!GN]2E629+@Q@J@7C:
M#T'UKLJ\Z^#?_(JW7_7VW_H*UZ+7SV*BHUI);'O8:3E2BV%%%%<YN%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\J:I_R%[W_KXD_]"-?5=?*FJ?\ (7O?^OB3_P!"->OE6\OD>7F>
MT?F5****]D\@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MU/#?_(T:5_U^1?\ H8KZB[5\N^&_^1HTK_K\B_\ 0Q7U%VKQ,U^.)[&6?#(*
M***\H],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_<;Z4ZFO]QOI
M0!\H77_'W/\ ]=&_F:BJ6Z_X^Y_^NC?S-15]>MCY5[A1113$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5N>#?^1TT7_K\C_\ 0JPZW/!O_(Z:
M+_U^1_\ H59U?X<O1FE+XUZH^FJ***^3/IPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H1KZKKY4U3_ )"][_U\2?\ H1KU\JWE\CR\SVC\RI1117LGD!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &IX;_Y&C2O^OR+_ -#%?47:
MOEWPW_R-&E?]?D7_ *&*^HNU>)FOQQ/8RSX9!1117E'IA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %-?[C?2G4U_N-]* /E"Z_X^Y_^NC?S-15+=?\
M?<__ %T;^9J*OKUL?*O<****8@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "MSP;_R.FB_]?D?_ *%6'6YX-_Y'31?^OR/_ -"K.K_#EZ,TI?&O
M5'TU1117R9].%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=?*FJ?\ (7O?^OB3_P!"->OE6\OD>7F>T?F5****]D\@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH U/#?_(T:5_U^1?\ H8KZB[5\N^&_
M^1HTK_K\B_\ 0Q7U%VKQ,U^.)[&6?#(****\H],**** "BBB@ HHHH ****
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M**^3/IPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1117,= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOR/_ -"K#K<\&_\ (Z:+_P!?D?\ Z%6=7^'+T9I2^->J/IJBBBODSZ<****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_0C7U77RIJG_ "%[W_KXD_\ 0C7KY5O+Y'EYGM'YE2BBBO9/("BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** -3PW_R-&E?]?D7_ *&*^HNU
M?+OAO_D:-*_Z_(O_ $,5]1=J\3-?CB>QEGPR"BBBO*/3"BBB@ HHHH ****
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MJ/IJBBBODSZ<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF_&UMXEN-!5O"E
MU%!J<,RR@2XVRJ,Y0Y!'.1U_,4 =)7G_ (K^,/AGPGJSZ7<?:KJ[BQYJ6T88
M1D\X)) S6+I7QF;3KY-*\=Z-/HE[G;YX0F%CZ]R![C(K%FL_%?A_Q5J^O^$-
M*TOQ+I>LR"<2Y$C1'^[D,".ON.G2@#TGP9\0M"\<QS_V5+(L\&#);SKM=0>A
MQDY'TKJZ\L^'?AGQ))XPU'QCXEL+72Y[BV%M%96P &,@EF )Y^4=3GGM7J=
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK_<;Z4ZFO\ <;Z4 ?*%U_Q]
MS_\ 71OYFHJENO\ C[G_ .NC?S-15]>MCY5[A1113$%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5N>#?\ D=-%_P"OR/\ ]"K#K<\&_P#(Z:+_
M -?D?_H59U?X<O1FE+XUZH^FJ***^3/IPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N5^(OBF3P=X)OM7@0/<IMC@##(WL< GV')_"NJK \:>&(?&'A2]T69_+
M,Z@QR8SL=3E3^8_+- '@FG?#;XA?$.QAU[4=>1(;M?,B%S<.25/0A%&%'MQ5
MI_@/XXTT?:--\0VIF3D".XEB;/L<4R/3_C-X$MUTW3TGNK"'(B,$:7"A?8$;
MA],4J:Y\<M8_T>.SOX=WREC9I!C_ ($P&* .[^#'C;6->35=!\02-+J6E,%\
MU@-S+DJ0Q'4@CKWS7J]><?"7X>77@JPO;O5IDFU;4&#3%6W! ,G&>Y)))->C
MT <?\2Y?$(\&7%OX8M)KC4;EA#F(@-$A!W,"3Z#'XUXOX3L?BMX+LI+;2/"<
M*F5]\LTL*M(Y]"V[H.PKZ8HH \K\5>#]>^(GPKL$U2*.U\2P,9_*(VKNRP*'
MDXRN/QQ7(3>%_B3X^;1M"\26$=AI6GNIFN<C=( -N>"<MC(&,#G-?0=% #(8
MD@ACAC&$10JCT X%/HHH BNO^/2;_<;^5>>_ _\ Y)M!_P!?4_\ Z&:]"NO^
M/2;_ '&_E7GOP/\ ^2;0?]?4_P#Z&: /1Z*** "BBB@#S/XT?\B_IW_7U_[(
M:\5KVKXT?\B_IW_7U_[(:\5KZ++OX"^9X./_ (["BBBNXX@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#W'X-_\BK=?]?;?^@K7HM>=?!O
M_D5;K_K[;_T%:]%KYC&?QY>I]'A/X,0HHHKF.@**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY4U3_D
M+WO_ %\2?^A&OJNOE35/^0O>_P#7Q)_Z$:]?*MY?(\O,]H_,J4445[)Y 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!J>&_P#D:-*_Z_(O
M_0Q7U%VKY=\-_P#(T:5_U^1?^ABOJ+M7B9K\<3V,L^&04445Y1Z84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/OQ=_P!=;?\ G-7N] !1110 4444 %%%% $5U_QZ3?[C?RKSWX'_ /)-H/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_?PT?ZP4_P"1_>']E2_F/2J*\U_M"]_Y^Y_^_AH_M"]_Y^Y_^_AH_P!8*?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN1_F*P*W_"7_ "%)/^N1_F*[LM_WNGZG-C/X$O0[2BBBONSY<**** "BBB@
MHHHH **** "BBB@ HHHH *9+-%!&9)I$C0=6=L"GUS?CKPI_PFGA:?1?MQLO
M-='\X1>9C:P/3(_G0!YE\9K"PU/Q9X4O]1NDD\/I-]GO3'*#Y09P<G'(!'&?
M;Z5V4/@'X920H\>EZ0Z$9#"7.1]=U>8:E\"M(TJ^L['4/'R07-ZVRVBDL.96
MR!@?O/4C\ZTA^S3@8'B]P/\ L'__ &V@#U[PWX?\-:$+G_A'K2TM_.V^?]G;
M.[&=N>3ZFMZO+/@_X;T;PS<Z]:Z9XGCUJ8M$MPBP&(P%3(,'YCG))^F*]3H
M**** "BBB@ HHHH BNO^/2;_ '&_E7GOP/\ ^2;0?]?4_P#Z&:]"NO\ CTF_
MW&_E7GOP/_Y)M!_U]3_^AF@#T>BBB@ HHHH \S^-'_(OZ=_U]?\ LAKQ6O:O
MC1_R+^G?]?7_ +(:\5KZ++OX"^9X./\ X["BBBNXX@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#W'X-_\BK=?]?;?^@K7HM>=?!O_ )%6
MZ_Z^V_\ 05KT6OF,9_'EZGT>$_@Q"BBBN8Z HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE35/^0O>
M_P#7Q)_Z$:^JZ^5-4_Y"][_U\2?^A&O7RK>7R/+S/:/S*E%%%>R>0%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 :GAO_D:-*_Z_(O_ $,5
M]1=J^7?#?_(T:5_U^1?^ABOJ+M7B9K\<3V,L^&04445Y1Z84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6?#(****\H],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /71OYFHJ^O6Q\J]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *T= _Y#]C_UU%9U:.@?\A^Q_P"NHKEQW^ZU?\+_ "9TX/\ WBG_ (E^
M9ZE1117X@?J84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0<-DKM'/N"1GG%?0M06EE:V$ @M+:*WB'1(D"J/P%3T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?[C?2G4U_N
M-]* /E"Z_P"/N?\ ZZ-_,U%4MU_Q]S_]=&_F:BKZ];'RKW"BBBF(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K1T#_ )#]C_UU%9U:.@?\A^Q_
MZZBN7'?[K5_PO\F=.#_WBG_B7YGJ5%%%?B!^IA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6_X2_Y"DG_ %R/\Q6!6_X2_P"0I)_UR/\
M,5W9;_O=/U.;&?P)>AVE%%%?=GRX4444 %%%% !1110 4444 %%%% !1110
M4444 <-\1/B1IG@.*UAOK">]DO5<QQ)@*0N,[B?]X=C7AFHV>O\ Q.NF?0O
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M_P Q6!6_X2_Y"DG_ %R/\Q7=EO\ O=/U.;&?P)>AVE%%%?=GRX4444 %%%%
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M6:** .9U'P+X4NOM5W/X<TN6XD#.\KVJ%F8\Y)QUKG?@< /AK;@# %S/@?\
M S7H=U_QZ3?[C?RKSWX'_P#)-H/^OJ?_ -#- 'H]%%% !1110!YG\:/^1?T[
M_KZ_]D->*U[5\:/^1?T[_KZ_]D->*U]%EW\!?,\''_QV%%%%=QQ!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'N/P;_P"15NO^OMO_ $%:
M]%KSKX-_\BK=?]?;?^@K7HM?,8S^/+U/H\)_!B%%%%<QT!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?*FJ?\ (7O?^OB3_P!"-?5=?*FJ?\A>]_Z^)/\ T(UZ^5;R^1Y>9[1^94HH
MHKV3R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#4\-_\
M(T:5_P!?D7_H8KZB[5\N^&_^1HTK_K\B_P#0Q7U%VKQ,U^.)[&6?#(****\H
M],**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KRSXU_\@[2?^NTG_H(KU.O+/C7_ ,@[2?\ KM)_Z"*Z
M\#_O$?ZZ'+C?X$OZZGCE%%%?2GSP4444 %%%% !1110 4444 %%%% !1110
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M /)-H/\ KZG_ /0S0!Z/1110 4444 >9_&C_ )%_3O\ KZ_]D->*U[5\:/\
MD7]._P"OK_V0UXK7T67?P%\SP<?_ !V%%%%=QQ!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'N/P;_ .15NO\ K[;_ -!6O1:\Z^#?_(JW
M7_7VW_H*UZ+7S&,_CR]3Z/"?P8A1117,= 4444 %%%% !1110 4444 %%%%
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M_P"8?V72[L[_ /X2'2_^?D?]\G_"C_A(=+_Y^1_WR?\ "N HH_M[$?RK\?\
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M1"BBBN\Y0HHHH **** "BBB@ KRSXU_\@[2?^NTG_H(KU.O+/C7_ ,@[2?\
MKM)_Z"*Z\#_O$?ZZ'+C?X$OZZGCE%%%?2GSP4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5[O\(/\ D37_ .OI_P"2UX17N_P@_P"1-?\
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MH **** (KK_CTF_W&_E7GOP/_P"2;0?]?4__ *&:]"NO^/2;_<;^5>>_ _\
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MI)_UR/\ ,5@5O^$O^0I)_P!<C_,5W9;_ +W3]3FQG\"7H=I1117W9\N%%%%
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M 4444 %%%% !1110 4444 %%%% !1110!N>%/^0Q_P!LF_I7;UQ'A3_D,?\
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MBBOQ _4PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K?\
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M/^V3?TKMZXCPI_R&/^V3?TKMZ^QR/_=?FSY[,_X_R"BBBO8//"BBB@ HHHH
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M/_UT;^9J*OKUL?*O<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?,8S^/+U/H\)_!B%%&1ZT9'K7,= 449'K1D>M !11D>M&1ZT %%&1ZT9'K0
M449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9
M'K0 4444 %%%% !1110 4444 %%%% !7RIJG_(7O?^OB3_T(U]5U\J:I_P A
M>]_Z^)/_ $(UZ^5;R^1Y>9[1^94HHHKV3R HHHH **** "E568X523Z 4E=U
MX2\32:=ID6E>'M)637[F4[KB4!@R@$X'3& !^M9U9N$;I7-*4%.5F['"D8.#
M2JK,<*"3Z 5Z!\5H[%-4T]DCACU1X,WR0_=#8&/Q^]^&*Z#X7:#;Z5Y&H7X
MO]11OLD9'*Q*,EO;/'X8]:PEBU&BJMM^AO'"MUG33VZGCW2E"ECA023V%6M4
M_P"0O>_]?$G_ *$:Z;PAXD31;*6UTW2Q/K]W*J03R ,H!( 4#C'>MYS<8\T5
M<PA!.7*W8X\@@X((([&DKTKXH)!_9VC2WL4$/B"1,W20X^[CO^/3\:\UI4:O
MM8*5K#K4_9SY;A1116ID%%%% !1110!?T3_D.6/_ %V7^=>J5Y7HG_(<L?\
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M7^XWTH ^4+K_ (^Y_P#KHW\S452W7_'W/_UT;^9J*OKUL?*O<****8@HHHH
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M)*"JKT7*@D?@2:Y^NJFU*":['+47+-IA1115D!1110 4444 >A^"7==#8*[
M><W0X["NC\Z7_GH__?1KFO!?_(#;_KLW\A715^.Y[)_VC6UZGZ7E27U*GZ#_
M #I?^>C_ /?1H\Z7_GH__?1IE%>3S/N>A9#_ #I?^>C_ /?1H\Z7_GH__?1I
ME%',^X60_P Z7_GH_P#WT:/.E_YZ/_WT:911S/N%D/\ .E_YZ/\ ]]&N7\5:
M[K]M>6.EZ'$QN+LX:ZD5C'"/?MG@G\*Z6L;Q+XBMO#>F&ZG4R2N=D$*_>D?T
M^GK71A92]JDH\SZ(RKI<CN[>9A:-XE\1:;XNB\->(+F.[>XB,D%S"-O8G!
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M>=+_ ,]'_P"^C1YTO_/1_P#OHTRBO'YGW/0LA_G2_P#/1_\ OHT>=+_ST?\
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M=.GNC>2HZF)PNW (YS]:^D?^$&\)_P#0LZ/_ . 4?^%'_"#>$_\ H6='_P#
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MM"L_0_\ D"6G_7.M"OT+"_P(>B_(^3K_ ,67JPHHHK<R"BBB@ HHHH ****
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M%%?2GSP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[O\
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M_)BN0$0$] ,=*S;'X,)IEJ+:Q\9>([: $L(XKA57)ZG %>HT4 ><?\*IN?\
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M]/HK&5.$G=J[-%.25DSS#_A32?\ 0X^(O^_Z_P#Q-'_"FD_Z''Q%_P!_U_\
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M)K7_ 'U'_P#$T?\ "A=,_P"ADUK_ +ZC_P#B:];HH]I/NPY(]CR3_A0NF?\
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M)/\ A0NF?]#)K7_?4?\ \31_PH73/^ADUK_OJ/\ ^)KUNBCVD^[#DCV/)/\
MA0NF?]#)K7_?4?\ \31_PH73/^ADUK_OJ/\ ^)KUNBCVD^[#DCV/)/\ A0NF
M?]#)K7_?4?\ \31_PH73/^ADUK_OJ/\ ^)KUNBCVD^[#DCV/)/\ A0NF?]#)
MK7_?4?\ \31_PH73/^ADUK_OJ/\ ^)KUNBCVD^[#DCV/)/\ A0NF?]#)K7_?
M4?\ \31_PH73/^ADUK_OJ/\ ^)KUNBCVD^[#DCV/)/\ A0NF?]#)K7_?4?\
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MBC_P*'^%'_"J;G_H>_%'_@4/\*]'HH \X_X53<_]#WXH_P# H?X4?\*IN?\
MH>_%'_@4/\*]'HH \X_X53<_]#WXH_\  H?X4?\ "J;G_H>_%'_@4/\ "O1Z
M* /./^%4W/\ T/?BC_P*'^%'_"J;G_H>_%'_ (%#_"O1Z* /./\ A5-S_P!#
MWXH_\"A_A1_PJFY_Z'OQ1_X%#_"O1Z* /./^%4W/_0]^*/\ P*'^%'_"J;G_
M *'OQ1_X%#_"O1Z* /./^%4W/_0]^*/_  *'^%'_  JFY_Z'OQ1_X%#_  KT
M>B@#SC_A5-S_ -#WXH_\"A_A1_PJFY_Z'OQ1_P"!0_PKT>B@#SC_ (53<_\
M0]^*/_ H?X4G_"J+G_H>_%'_ (%#_"O2** /)3\!]-8DGQ+K1)Y)WQ__ !-)
M_P *%TS_ *&36O\ OJ/_ .)KUNBK]I/N3R1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
MXFC_ (4+IG_0R:U_WU'_ /$UZW11[2?=AR1['DG_  H73/\ H9-:_P"^H_\
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MD)(P/)=#@J>.HQ^-9_P?\6:O;>'_ !3!JMXUY;:*I:&=VW#@-E0QZCY01]:
M,^S37/B'\6?$ME;>*]8TS3;%V""SN7"C:P0 *& &2&-=_H/PZU+0]8@U*;QK
MK^J);[F^QW%RWERG:0 <L1U.?PKRWX4?#./QEH5[KM]K.J64LMTT8^QRA/,
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MJ"PLSNALYF4/M!8LQ##)/3\*\W^&7A?Q)XZT"XU2[\=^(K14N#%&L=Y(VX
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MZBC8((VY.WY3P>/P KK?V>+M_LGB/394:*2WNU<Q/PR;@P(/N"N* /;:***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]E?7;;2_:_<?U:HX<]M#;HHHKK.<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""ZL[6^A\J[MH;
MB+.=DJ!QGZ&O-/&^L#7Y(_!?ARV69PRB=HP!'"JGA1C@ =_3&*ZSQU-K*>''
M@T*UFGN[AA&6BQF-.YZ_A^->:Z!#X]\,VKP:;X=1=YR\CP!G;ZG=7H82FN7V
MEU=;)O\ $XL3-W]G9V>[2_ ]>TK1X--T.RTUE25;:)4RRYR0.3S7E_C9=23Q
M-8W_ (KMM^@17+I EJP)"YR-P]2%&?I72Z[I/BC7_"6FW4%Q)9ZS$-T]NCF-
M7YZ=<9&!UKGM0TSQWXX^RZ=JMA#I]I X:2;@;CTW8W'/&>!QS589*,N>4EUO
MW7IZD8AN4>2,7TMV?J:_Q&G75Y?#>D6[;TOKI9>.Z<#/Y,:[K4[^#1='N;Z;
M_56T1<@=\#@#Z]*Y"'0;N;XE6EP]I(FEZ38B&VE?&'?&/_9C^57_ (C6>HZA
MX1EM-,MI+B:65 R1]=H.3_(5C)1DZ=.^G7YO_(UBY)3J6U_R7^9E_#/3YKQ+
MWQ5J'S7FHR,(\_PQ@]OQX^@%8_B>2<_%.#_A%U+:VL6+CS,>5C;W_P" XS^%
M>B>&K%M-\-:=9NA1XK=%=3V;'/ZYKBM<\.Z[HOCIO%.AV:W\<PQ-;[PK<@ C
MGUP#Q6E.JI5YMOHTNWDB*E-QHQ2[IOOZE+P=+)%\2[Y?$:LNO2H1$4QY6W:"
M0/\ @(X_&O5Z\W\.^']=U7QRWBK7+-;%44K#;[PS?=VC./0$]>]>D5CC&G-6
M[*]MOD:X5-0=^[]0HHHKE.D**** "JU]91:A;>1,6V%@3M.,XJS14SA&<7&2
MNF.,G%W6YRBV\5KXPAAA0)&J# '^Z:O>)W+6EO:K]Z>4#'^?PIDEE<GQ:ET(
M6, 4 OV^[4]W:SW7B.T=HF^S6Z%M_8M_G%>*J4E1JTHQMS3MMT=OPL>DYIU(
M3;VC?YZFJL2+$B[%.P +QZ5RKF>#7[:YUE.N!$8SE5(/&?H36KK5GJ$DL5S8
M2MNCZQ;L!OZ5GFQU76KV"2_A6W@B/0=_7OWJL<YSDJ<(.Z:M_*_7T)PRC&+E
M*2LT[]UZ#M:;_B?VOV$$WX Z_=QSU_"F632)XGSJ@Q=,N(BGW>G_ .NK6IZ=
M>0ZO'JEC&)6 &Z/.#TQ_*F6UC?:AK<>H7D MXXL;4+9/'2L)4ZGUA^Z[\Z=K
M>[;OZFL9P]DM5;EMYW[>AT=%%%?0GDA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/CKPII=
MAX=US6$B,E]<,K&20YV9D7(4=OYUZ-7.>.[&ZU+P;?VEG T]Q)LVQIU.'4G]
M!6^&FX58V=E=7^\PQ,%.E+2[L[?<1?#]5?P#IB.H96B8$$9!&YJ@\4>(-,\'
MZ>]K86D O[K_ %5M!&%W,>-S ?Y.,59\*P7NC^ K6*:SD^V00N?L_&XMEB!^
M/%>:6MCXZMM>FUHZ$T]](<[YXP^S_=&[CTKIITXU*LY2:LGM?<YJE25.E",4
M[M+6VQVO@W29_"'A"_U'41LN95:X>/\ N@ X!]_\:E^&%CL\(M<SH&DOIWF<
ML,[NP_D?SK)NKGQIK'@W5;;4=)87<K1QPI%&%RI.6)^8^GZUU4OAZ<^!X=&M
M+J2TN8K=%26-BI#C!YQV)SGZT57H^=J\GT[+_API1U7(G:*Z]W_PQSGQ*MM=
MDT]X[:&(:!$J/.L1 D;!R>/0<4S5K?\ M_X7V-KX8M998-RJ8F(WJ%SG//)S
M69)!\0YM&;PU+IR21,/+:\=P24]"V['XXS6]<^"-2M? EOI>EW[QZA"QE9HY
M"BRD_>7/IZ9]*TO&G&$7)73TMMZLRM*I*<E%V:U[^B.?NY?'7@G3;.^N;RWF
ML4"1&U4 B,8X!^4>G4'K7J>F7\>J:7:W\((CN(ED4'J,C.*\OO;'QYXJL[?1
M-0L([6VB9?-N6(&_'0GYCG\.]>HZ=8Q:9IMM8PY\JWB6-<]2 ,5CB^7E5[<W
MEV-\)S<SM?ETW[EJBBBN$[@HHHH **** "D8;E(]1BEHH X_7]+MM-TZ!8$^
M9I/F=N2>*Z2YG^S:0\W]V'/XXK.\3VEQ>6D"V\+2,KY(7L,5+K<-S-HZ6UO$
MSNY57QV Y_I7C*#P]2NZ<;+E5K+K9GHN7M84E-]7<BT;3UF\."&7(%QEF(ZX
MS_\ 6K/OK."Q\0Z;#;H$0!3[D[CR:ZF"(0P1Q*,*BA1^ K$U6SN9O$-C/'"S
M1(%W..@^8T\5A%##P48WDN5?B*A7<JLFWH[LVY8(9U FB211V=0?YUS>JW!U
MNZ33K%=T:-F27L.WY5H^(#>O9+!90NYD.'9>R^GXUBV9UZP@\FWT]57J28^2
M?<YJ<?6O4]CROE^TTKW\AX6G:/M+J_1-[>9UT48BA2->B*%'X4^H[<R-;Q-*
M,2% 6'H<<U)7L1M96//>^H44450@HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>YX]<>F^,/ .E^-FM&U*YO8OLH<(+9U4'=C.=RG^Z*Y?_A0_A?\ Y_\ 6/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1I, 'CJ"/>B%"\K-Z"E4TT/HRBO.;C5-?^'?P^OKS7]0CU74VN-MJVXE1N4
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M?6X:)\;7#JQ,;'' R,$CFJ/BU/%_A/21XG?Q.UV\$J&YL?LZI 59@-JCKC)
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M_P"1C\;_ /87;^;4?!S_ )$9O^OV;^8KT"BG*=[^=OP!1L>?_#O_ )&/QO\
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MN/"ME$C1*(I+F*!D1@3G:&(P>5&<>U=<\:2H4D174]589!I418U"HH51T &
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M1V7E2R@D?2GU3JZW0N32QYSJ7Q*T'6_"EY;6#7%QJ=U:21BQC@8R(Q0@[N,
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M,'&15.$8J5Q<S;1Z55/5YI+?1;^>)MLL=O(Z-Z$*2#5RL_7O^1>U/_KTE_\
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M([:5J-O=[/OB)\E?J.HKBGMH?$?QHNK74XUGM-'L4>VMY!E-[[27(/!/S8_
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MGN=IJWB?0]"94U35;6UD89"22#<1Z[>N*GM=:TR]TMM3MK^WEL45F:X60;%
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M5M>VUG/=11W-UN\B)F :3:,G [X%>3^(I'D\3:EXS7)BT+5+6S5O2)01./\
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MDC?Y@/7'7'O4]SK6EV<T\5SJ%M#);Q":99) I2,G 8YZ#/%>>ZG_ &AJ6O\
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M0U*6[B\IB=J,> V0.?IGZUD^&_#OBGPKJES8V1TRXT*XO6N?,E9UFC1B-R@
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MN(+XN-CJ,;AMZCDG\3QT-6O#OA'5],\:WFOZEJ4-XUW9"*0J"I63<#A5Q@(
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M(98/L<FFBT"!CYF_>&SC&,8'K^%:FMZY;Z'%:M-')-+=7*6T,,0!=V8]LD<
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M0RVKQHC>>JJ%*C>#T(/ ]#7467@Z:'Q18:MJ'B2[U"ZLTD\J*:.-?E<;6^Z
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M_2L_^UM4\)_#GPIIUN(X=2U!X;19;@96WW\Y8>H! Q_A63\2M&?2]%T^2_\
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MY1N".NP8X'N?TZ55^%UP]UK/C&XEMY+:234=SPR8W1D[LJ<<<&M'X3WMI/\
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M[4O-;Y\J:.1HW4'ME2.*U;"Q@TVP@LK566"! D:LY8@#IR22:H7_ (AMM/\
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ML207BM;L27$:GOM_B/L/TI6G-7;"\4=9>Z'IVH:G8:E=6_F7=@6-M)O8>66
M#< X.<#J#1J6AZ=J\UE-?6_FR6,XN+<[V79(.AX(S]#D5?4[D#;2N1G!ZBLE
M_$-LGBV+PZ8I3<R69O!(,; H;;CKG.14KFZ%.Q/J^B:=KUM%;ZE;^?%%,LZ+
MO9<.N<'Y2/4U'KWAW2O$VG_8M6M5N(0V]?F*E6]01R*U**2DUL%D<Q:?#[PQ
M96J6\6F A9TN/,>5RYD3[I+9R0,].GM6MK>A:;XBTUM/U6V6XMF(;:2058="
M".0:T:*?-)N]PLC M?!>A6N@W&B"T::PN6WRQSRO(6; &<DY!^4=,=*I6WPU
M\*6]K-;G3#,DJ>63/,[LJ=<*2<KT_AQ7644<\NX<J[%&^T;3]2TAM*O+99K%
MD$9B8GH.G/7(P.>M9FF>"="TG2[[3;:WE-K?1^5.DEP[;DP1M!)^7ACTQ70U
MY[<W_B+Q)X^U;1=*UL:19Z3%$6=+9)6E=QGG=V'/Y>]./,[J^@G9=#M[32[*
MQTJ/2X+=191Q>2L+$N-F,8.[.1CUKFH_A?X0CO!<#2LJK[U@:9VB#>NPG'X=
M*Z]00H!)) ZGO2TE*2V8VDRAJVC:?KFE2:9J-N)K.3;NB#,F=I!'*D$<@5-=
M:?:WFF2Z=<1;[26(PO'N(RA&",@YZ>]6:SM>?58]$NGT.*"74@H\A)SA"<C.
M>G;./?%)7V!EC3["VTO3X+"SB\JVMT$<2;BVU1T&223^-9OB#PEHWB<0'5+4
MR2P',4L;LCIZX92#CVK1TUKU],M6U%(DO3$IG6(Y0/CD#VS5JB[3NF%DT<_8
M^"/#NG3V5Q:Z:D<]F[O#-O8ON888L<_.2/[V<=JE\0>$M&\3B ZI:F22W),4
ML<C(Z9ZX*D<5MT4^:5[W"RV*NG:?;:5I\%C:*RV\*[4#.7('U))-96J>"O#V
MM7=Q=ZAIJ37,ZJKREV# +]W;@_*1ZC%;]<AJ>N:A;?$_0]%BG"V%U:S231[%
M.YE#8.<9'0=*<>9O1B=K:FEX?\'Z'X8:632[/RYIN))I':21AZ;F)./85%K?
M@;P_X@U%-0OK-_M:KL,L,SQ,R^C;2,UT5%+GE>]]1\JM8Q]-\*:'H]\M[IVG
M16UPMM]E#1D@>7NW8(S@G/.<9]ZR;KX9>%+JYDF.G-")3F6*">2.-_JJD#\L
M5UU%'/):W#E78J)I=A'I8TQ+.$6(C\K[/L&S;Z8KFH?AAX2@N%E7379%;>L#
MW$C1 ^NPMC\^*["L7Q=J%SI7A'5;^SD$=S;VSR1N5!PP'!P>#3C*5[)[@TMV
M/U_PSI7B:""+4X&D^SR>9$Z2,C(WL0<U/<Z'IUYK%EJT]OOOK(.MO+O8; PP
MW .#D'N#4/A>^N-2\*:3?73[[BXM(I96  RS*"3@<#FM:DVUI<-'J9[:'IS:
M\NN&W_XF2P?9Q-O;_5YSC;G'4]<9HO=#T[4-3L-2NK?S+NP+&VDWL/++ !N
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MMI7(S@]12U/,^X[(K)I]JFF+IJQ8M%A\@1[C]S;MQG.>G?.:I1^&M'B\._V
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MG;4?#NO7=W9M'L>V-X9HPQ.0Q5N5;@^E2R:S>>'?#NB!M!O[Z VJ)=&V0-)
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M')%.8XHR$W!%0=!QC/7O4^K>%+K1O@A/H%M#)=WJPJ62!"[.YE5FV@<D#)_
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M4R&)P^W@GZ']/2JJV>I^(_B=XIT9]7O+;28Q;22I!*5<_NQA$/\ "I));'7
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M\YK:16PR!NNTCG_/)?64_A'QMJ>K2Z'+JVBZMLDD:W@$TMM*HP?EZ[3DG/\
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MM-;%8L ;>']2#Q^-8^@3GP/9-H'B#PU=7BV\C?9=0M+(3K/&22-V.0W/0_\
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M-G%(P"JQ*C>Q/103^/YXZ/P-I[MXWU;6-+TFZTG0)[98Q;SQ>5YTVX'>L?8
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MN%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#E_ /AN\\+>&SIU])!),;B27,#$KACQU YKJ***<FY.[$E96"BB
MBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'U_05UK[!
M*EP;:[L;E+B"=5W$8X92,C(9<@__ %JV**:;3N@:N%%%%( HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JO?6[W>GW-M',8'FB:-90,E"1C<![=:L44 4=
M&TN'1=%L],MSF*UA6)21@M@8R?<]?QJ]110W?4 HHHH **** "BBB@ HHHH
M**** "L>^T%=1\1:;JEQ<%H=/5S%;;>/-; \PG/.%R ,=\UL44TVM@M<****
M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>*/!SZUJ=GK6EZD^EZS9J4CN5C#JZ'/RLIZCD_F>M-22TO\ F%GN8_Q&1/\
MA)O \FU=_P#:R+NQSC*\9IWB7_DL/@O_ *Y77_HMJED\ ZGJ6IZ5JFM>)9+N
M\T^[2=$6V"0A5.2JJ",$G&6.>G2MS4_#']H^,=%\0?;/+_LQ)5\CRL^9O4K]
M[/&,^AHYHJROT86;*6K>)9E\3OHN@Z1'?ZQ' K7$\L@BCMXR<J&;!)ZYVCUK
MF]#&JP_&ZX_M7[$MU/H^Z060;80'4#.[DGCK6_JW@[4SXIF\0>'];73KJZB6
M*ZCEMQ,D@7 !&2,$ "GZ1X'DTWQ</$5QK5Q?73VAMYO.C WL6!W+@X10  %
M_&A.*CIV!IMF;H'_ "6GQ;_UZVW_ * E9_B&?5)/C-:)9V%O>R6FEF6VAN9O
M*52SD,X.#ENWX>U;^K^#M3?Q5)XAT#6UTZZN(1!<I+;B9' Q@@$\'@?E5OQ!
MX0.N?V?>Q:E)9:W8+B'4(8QSD?,&3."IYXSW^N12C=/RL%G:QBW.F^+-8\4Z
M#J5WI%A8C3IV9YHKSS&:-AAEQM%;$^J>,TU"6.#PY8R6@E*I*;_#,F>&V[>#
MCG%2:/HWB:'48[K6?$JW<,:D"UM[18D<D8RQY)]<#%=+42DMM']XTC.\0?\
M(MZI_P!><O\ Z :P?A=_R3;1?^N3_P#H;5:\3:!KVM2%--\3_P!F64D!BEM_
ML$<^\G.3N8@C((&!Z53\(^$-;\+BVM9/%/VW2K=&5+/^STCZY.=^XMP3FC3D
MM<->;8B\0_\ )5/!NS[PBO=_^[Y8Q^M=M7%Z:O\ ;GQ-U'5%^:TTBV&GQ-V:
M9CNDQ[J,*?K6FOA_4%\<OKIUJ<V+6WDC3N=@;UZX]^F<FB26B?1#7<Z&BBBL
MR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRR6>0)DP-ORGHQ)QCI3<&A<R.FHKSRVO?B-J>E+KML-(@CD3SH=+DC9F>/J
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M4%CR2<=SZUBZ%XF76]:US3A:&$Z5.L)D,F[S<YYQ@8Z>];]>?^ O^1V\=?\
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M35=>U2*_.NZ0NG-%<&.  G]XGKR>?KT-0X-7\BD[V-/6-7L]"TJ?4]0D,=K
M 9&"EB,D <#GJ14.I^(=-TC03K=Y,R6 5'\P(2<.0%X'/<5A?%7_ ))GK/\
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M-XD8@DT^^BV(>,;1G@CT!P?:MWQ5?:QH6@P-X:T>.^G65(A;@85(\'D $=,
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MV_\ 8]]#"MO)97L6R-L#& 3Q@^AQU[UJ^+M:N?!]EI%U8PVZ:/'<I;WB"/\
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MI+I&G)JKZJEE M^Z>6]R$ =EXX)[]!^59QE9-=RVM4<7\,?^/SQA_P!AV?\
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MOA?_ *%O1_\ P!B_^)JAXP\.RZ]I-IH-I96:6+L!+.X'^BQKC B3'WB,J",
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M6\D0(]P(P)&4=BW4C@<4/86<M[%>R6D#W<2E8YVC!D0'J W4 U7/K?RL3RG
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MA5F^F<9HYU=6Z!RLXKP[JFJ:_P##7Q-#=W'V\VZW=I:WH3'VI!&0K8[]>O\
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M!EB>4!XVQRNWKG/H.>U8GBW66O/&.BZ')K#Z9HEY:M<O=02B(W#9.$$G\(P
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M)]:R;4M7H7L= 2%4DD #DD]JB>[MHVB5[B)3*<1AG WGV]:S_%/_ "*.M?\
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ML^'?AK2/ >HS6-B8;JUM'9+E96$C''.XYY!YR.G-==X(_P"1$T#_ +!\'_H
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MN=#FUN]T_3;"R64+97'DF25B.2W?&>GM]:]%M+2"PLX;2UB$5O"@2-%Z*HX
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M;B>')DN)?FD.3W)Y-8OA\Z./A!J<.CF?9#:7*7"W(Q*LVPEPX]>1^&*I^!?
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M(CLRJZEE^\ <D?6O-=.L(?!WQ<@TG20T.EZO9-*]KN)1)4W'<,].%_4^U6_
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M,9+]3H%UH\5GY8RMY'(7WY.?N\8QBKWAK1%\.>'K325NI;H6ZD>;+]YLL3^
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MUJ&EZ%_;&GZP8Y/DN%B:*101@[NV2?TYXQ7H]%5[1]M!<IP7AO0O$4/Q#O\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>gern-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-28T14:04:59.9007+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.geron.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:gern="http://www.geron.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION" id="Role_DocumentDOCUMENTANDENTITYINFORMATION">
        <link:definition>100000 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" id="Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100040 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>995455 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" id="Role_DisclosureFAIRVALUEMEASUREMENTS">
        <link:definition>995465 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT" id="Role_DisclosurePROPERTYANDEQUIPMENT">
        <link:definition>995475 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureLicenseAgreement" id="DisclosureLicenseAgreement">
        <link:definition>995485 - Disclosure - LICENSE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES" id="Role_DisclosureACCRUEDLIABILITIES">
        <link:definition>995495 - Disclosure - ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" id="Role_DisclosureCOMMITMENTSANDCONTINGENCIES">
        <link:definition>995505 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES" id="Role_DisclosureOPERATINGLEASES">
        <link:definition>995515 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT" id="Role_DisclosureDEBT">
        <link:definition>995525 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY" id="Role_DisclosureSTOCKHOLDERSEQUITY">
        <link:definition>995535 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES" id="Role_DisclosureINCOMETAXES">
        <link:definition>995545 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1" id="DisclosureConsolidatedStatementsOfCashFlowsData1">
        <link:definition>995555 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995565 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>995575 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" id="Role_DisclosureFAIRVALUEMEASUREMENTSTables">
        <link:definition>995585 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables" id="Role_DisclosurePROPERTYANDEQUIPMENTTables">
        <link:definition>995595 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables" id="Role_DisclosureACCRUEDLIABILITIESTables">
        <link:definition>995605 - Disclosure - ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables" id="Role_DisclosureOPERATINGLEASESTables">
        <link:definition>995615 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTTables" id="Role_DisclosureDEBTTables">
        <link:definition>995625 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables" id="Role_DisclosureSTOCKHOLDERSEQUITYTables">
        <link:definition>995635 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables" id="Role_DisclosureINCOMETAXESTables">
        <link:definition>995645 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables" id="DisclosureConsolidatedStatementsOfCashFlowsDataTables">
        <link:definition>995655 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail">
        <link:definition>995665 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1">
        <link:definition>995675 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails">
        <link:definition>995685 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails">
        <link:definition>995695 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails">
        <link:definition>995705 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails">
        <link:definition>995715 - Disclosure - FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails">
        <link:definition>995725 - Disclosure - FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails">
        <link:definition>995735 - Disclosure - FAIR VALUE MEASUREMENTS - CREDIT RISK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails" id="Role_DisclosurePROPERTYANDEQUIPMENTDetails">
        <link:definition>995745 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails" id="Role_DisclosureLICENSEAGREEMENTSDetails">
        <link:definition>995755 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails" id="Role_DisclosureACCRUEDLIABILITIESDetails">
        <link:definition>995765 - Disclosure - ACCRUED LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails" id="DisclosureCommitmentsAndContingenciesLitigationSettlementDetails">
        <link:definition>995775 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation Settlement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" id="Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails">
        <link:definition>995785 - Disclosure - COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails" id="Role_DisclosureOPERATINGLEASESDetails">
        <link:definition>995795 - Disclosure - OPERATING LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" id="Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails">
        <link:definition>995805 - Disclosure - OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2" id="Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2">
        <link:definition>995815 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" id="Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails">
        <link:definition>995825 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails" id="Role_DisclosureDEBTAdditionalInformationDetails">
        <link:definition>995835 - Disclosure - DEBT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" id="Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails">
        <link:definition>995845 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails">
        <link:definition>995855 - Disclosure - STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails">
        <link:definition>995865 - Disclosure - STOCKHOLDERS' EQUITY - PUBLIC OFFERING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails" id="DisclosureStockholdersEquityWarrantExercisesDetails">
        <link:definition>995875 - Disclosure - STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails">
        <link:definition>995885 - Disclosure - STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails">
        <link:definition>995895 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails">
        <link:definition>995905 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails">
        <link:definition>995915 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails">
        <link:definition>995925 - Disclosure - STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails">
        <link:definition>995935 - Disclosure - STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails">
        <link:definition>995945 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails">
        <link:definition>995955 - Disclosure - STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails">
        <link:definition>995965 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails">
        <link:definition>995975 - Disclosure - STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" id="Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails">
        <link:definition>995985 - Disclosure - INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" id="Role_DisclosureINCOMETAXESDEFERREDTAXESDetails">
        <link:definition>995995 - Disclosure - INCOME TAXES - DEFERRED TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" id="Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails">
        <link:definition>996005 - Disclosure - INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" id="Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails">
        <link:definition>996015 - Disclosure - INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" id="Role_DisclosureINCOMETAXESCARESACTIMPACTDetails">
        <link:definition>996025 - Disclosure - INCOME TAXES - CARES ACT IMPACT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" id="Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails">
        <link:definition>996035 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" id="DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails">
        <link:definition>996045 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996055 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="gern-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="gern-20231231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" xlink:href="gern-20231231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" xlink:href="gern-20231231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails" xlink:href="gern-20231231.xsd#Role_DisclosurePROPERTYANDEQUIPMENTDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureLICENSEAGREEMENTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails" xlink:href="gern-20231231.xsd#DisclosureCommitmentsAndContingenciesLitigationSettlementDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" xlink:href="gern-20231231.xsd#Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails" xlink:href="gern-20231231.xsd#Role_DisclosureOPERATINGLEASESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails" xlink:href="gern-20231231.xsd#Role_DisclosureDEBTAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails" xlink:href="gern-20231231.xsd#DisclosureStockholdersEquityWarrantExercisesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="gern-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="gern-20231231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="gern-20231231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="gern-20231231.xsd#Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="gern-20231231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails" xlink:href="gern-20231231.xsd#Role_DisclosureACCRUEDLIABILITIESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2" xlink:href="gern-20231231.xsd#Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" xlink:href="gern-20231231.xsd#Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION" xlink:href="gern-20231231.xsd#Role_DocumentDOCUMENTANDENTITYINFORMATION" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="gern-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:href="gern-20231231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT" xlink:href="gern-20231231.xsd#Role_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureLicenseAgreement" xlink:href="gern-20231231.xsd#DisclosureLicenseAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES" xlink:href="gern-20231231.xsd#Role_DisclosureACCRUEDLIABILITIES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:href="gern-20231231.xsd#Role_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES" xlink:href="gern-20231231.xsd#Role_DisclosureOPERATINGLEASES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT" xlink:href="gern-20231231.xsd#Role_DisclosureDEBT" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1" xlink:href="gern-20231231.xsd#DisclosureConsolidatedStatementsOfCashFlowsData1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="gern-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:href="gern-20231231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables" xlink:href="gern-20231231.xsd#Role_DisclosurePROPERTYANDEQUIPMENTTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables" xlink:href="gern-20231231.xsd#Role_DisclosureACCRUEDLIABILITIESTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables" xlink:href="gern-20231231.xsd#Role_DisclosureOPERATINGLEASESTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTTables" xlink:href="gern-20231231.xsd#Role_DisclosureDEBTTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables" xlink:href="gern-20231231.xsd#DisclosureConsolidatedStatementsOfCashFlowsDataTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" xlink:href="gern-20231231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" xlink:href="gern-20231231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" xlink:href="gern-20231231.xsd#Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" xlink:href="gern-20231231.xsd#DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingTable" xlink:label="gern_PublicOfferingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MenloParkOfficeSpaceLeaseMember" xlink:label="gern_MenloParkOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SiliconValleyBankMember" xlink:label="gern_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionTwoMinCashDebtCovenantMember" xlink:label="gern_OptionTwoMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinCashUponLicensingTransaction" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheBMember" xlink:label="gern_TrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DirectorsMarketValueStockPurchasePlanMember" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtTheMarketOfferingMember" xlink:label="gern_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingLineItems" xlink:label="gern_PublicOfferingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CostMethodInvestmentOwnershipPercentage" xlink:label="gern_CostMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLeaseRentAbatementPeriod" xlink:label="gern_OperatingLeaseRentAbatementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DueToCounterParty" xlink:label="gern_DueToCounterParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LicenseAgreementDisclosureAbstract" xlink:label="gern_LicenseAgreementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsFederalAndStateCredits" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheOneMember" xlink:label="gern_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ThirdAmendmentMember" xlink:label="gern_ThirdAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheAMember" xlink:label="gern_TrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedEndOfTermCharge" xlink:label="gern_AccruedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_JanssenBiotechIncMember" xlink:label="gern_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_HerculesAndSiliconValleyBankMember" xlink:label="gern_HerculesAndSiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_BorrowingAvailableStartDate" xlink:label="gern_BorrowingAvailableStartDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommonStockAggregateOfferingPrice" xlink:label="gern_CommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfSeverancePlan" xlink:label="gern_NumberOfSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LongTermDebtGross" xlink:label="gern_LongTermDebtGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceSalesAgreementsTable" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfInterestOnPastDueOutstanding" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NewJerseyOfficeSpaceLeaseMember" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MarketCapMinimumToUseOptionTwo" xlink:label="gern_MarketCapMinimumToUseOptionTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MaximumCommissionRate" xlink:label="gern_MaximumCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfFinancialInstitutions" xlink:label="gern_NumberOfFinancialInstitutions"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentMinimumPrepaymentAmount" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ConsultantsMember" xlink:label="gern_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ExpiryDateOfTranche" xlink:label="gern_ExpiryDateOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SeverancePlanLineItems" xlink:label="gern_SeverancePlanLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountToBePaid" xlink:label="gern_LitigationSettlementAmountToBePaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DirectorsPlan2006Member" xlink:label="gern_DirectorsPlan2006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfPrepaymentCharge" xlink:label="gern_PercentageOfPrepaymentCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CostMethodInvestmentsCostBasis" xlink:label="gern_CostMethodInvestmentsCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CARESActImpactAbstract" xlink:label="gern_CARESActImpactAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAbstract" xlink:label="us-gaap_DepreciationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheFourMember" xlink:label="gern_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementNumberOfStudies" xlink:label="gern_CollaborativeArrangementNumberOfStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountPaidInCashOrKind" xlink:label="gern_LitigationSettlementAmountPaidInCashOrKind"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DepositsAndOtherAssetsNoncurrent" xlink:label="gern_DepositsAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClinicalSupplyAgreementMember" xlink:label="gern_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseDueToCounterparty" xlink:label="gern_IncreaseDecreaseDueToCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PurchaseWarrantsMember" xlink:label="gern_PurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinimumCashBalance" xlink:label="gern_DebtCovenantMinimumCashBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedEndOfTermCharges" xlink:label="gern_AccruedEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SeverancePlanTable" xlink:label="gern_SeverancePlanTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SecondAmendmentMember" xlink:label="gern_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FosterCityOfficeSpaceLeaseMember" xlink:label="gern_FosterCityOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_InterestOnlyPeriodPaymentTermDescription" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" xlink:label="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedManufacturingActivitiesCurrent" xlink:label="gern_AccruedManufacturingActivitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployerTaxReceivable" xlink:label="gern_EmployerTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheSixMember" xlink:label="gern_TrancheSixMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionOneMinCashDebtCovenantMember" xlink:label="gern_OptionOneMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityCosts" xlink:label="us-gaap_FacilityCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployeesAboveTheVicePresidentLevelMember" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncentiveAwardPlan2011Member" xlink:label="gern_IncentiveAwardPlan2011Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheFiveMember" xlink:label="gern_TrancheFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_HerculesMember" xlink:label="gern_HerculesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" xlink:label="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencySettlementAgreementDate" xlink:label="us-gaap_LossContingencySettlementAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheTwoMember" xlink:label="gern_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DerivativeStipulationMember" xlink:label="gern_DerivativeStipulationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheCMember" xlink:label="gern_TrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentFaceAmountExpired" xlink:label="gern_DebtInstrumentFaceAmountExpired"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountOutstanding" xlink:label="gern_LitigationSettlementAmountOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheThreeMember" xlink:label="gern_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionThreeMinCashDebtCovenantMember" xlink:label="gern_OptionThreeMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" xlink:label="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployeeRetentionCreditAmountOutstandingReceivables" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FormerCollaborativeArrangementMember" xlink:label="gern_FormerCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrdArrExpirationDate" xlink:label="gern_TrdArrExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentEndOfTermChargePercentage" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SubsequentDirectorOptionMember" xlink:label="gern_SubsequentDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EquityInvestmentReverseStockSplit" xlink:label="gern_EquityInvestmentReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfSharesSoldFromEquityInvestment" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FirstDirectorOptionMember" xlink:label="gern_FirstDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassActionStipulationMember" xlink:label="gern_ClassActionStipulationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of new offering period in a case where the fair market value of common stock on the purchase date is less than the fair market value at the beginning of the offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration Of New Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of the new offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to the treatment of research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting period of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of six-month product revenue forecast to satisfy minimum cash balance debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt covenant percentage of product revenue against forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum cash balance requirement to be met as a percentage of six-month product revenue against forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of common stock reserved for future issuance, which may include but is not limited to outstanding options and outstanding warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fees and royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government sponsored enterprise securities due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Sponsored Enterprise Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At Market Issuance Sales Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Sales Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At Market Issuance Sales Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost not yet recognized, net of estimated forfeitures (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MenloParkOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Menlo park office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MenloParkOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Menlo Park Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MenloParkOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Menlo Park Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less Than 12 Months - Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of loan amount outstanding to be held as minimum cash balance under debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt covenant minimum cash balance percentage of loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum cash balance as a percentage of loan amount outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease term additional period extension.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term Additional Period Extension</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term, additional period extension</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to unsecured promissory note (generally negotiable) that provides institutions with short-term funds ), due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Municipal securities due in one to two years member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of financial instruments measured at fair value on recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Public Offering of Common Stock and Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Public Offering Of Common Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Public Offering of Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionTwoMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option two min cash debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionTwoMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Two Min Cash Debt Covenant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt discount amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum cash covenant required upon certain licensing transactions being executed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Covenant Min Cash Upon Licensing Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt covenant minimum cash balance upon licensing transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_LitigationCaseTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US Treasury securities due in one to two years member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with at market offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplier [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplier</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that Geron must pay during certain phases of the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Cost Sharing Percentage Of Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of costs to be paid by Geron</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average estimated fair value of employee stock options granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors&#8217; market value stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors Market Value Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors Market Value Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of options to be granted to purchase shares in each year during the optionee's service on the Board of Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options to be granted to purchase shares (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of restricted stock that vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Municipal securities due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities (due in less than a year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Municipal securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Amount Awarded to Other Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new shares issued during the period in connection with exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Warrant Exercise Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection exercise of warrants (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost method investment ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Method Investment Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost method investments ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock outstanding warrants to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term, option to extend additional period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Investment Holdings [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DEBT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property and equipment, stated at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseRentAbatementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease rent abatement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseRentAbatementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Rent Abatement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseRentAbatementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent abatement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Research Organizations And Clinical Trial Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRO and clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 Months or Greater - Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DueToCounterParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of obligations due to counterparty. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DueToCounterParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due To Counter Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DueToCounterParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due to Janssen Biotech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain on Sale of Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on sales of available for sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseAgreementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseAgreementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Notes Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets federal and state credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Federal And State Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of term loan, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of consecutive purchase periods in an offering period in the purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Consecutive Purchase Periods In Each Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive purchase periods in an offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with public offering (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new shares of common stock issued during the period in connection with public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Of Common Stock Issued During Period Shares New Issues Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares under options that were cancelled or that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Forfeitures And Expirations In Period Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options cancelled/forfeited/expired (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING LEASES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in cash and cash equivalents:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, initial term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating leases, right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant components of deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from public offering after deducting underwriting discount and other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less Than 12 Months - Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental operating and investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued end of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment charge assessed upon debt prepayment occurring 36 months after June 30, 2022 under second amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dollar prepayment charge 36 months after effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Charge for prepayment occurring 36 months after effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae, due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the Janssen Biotech Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Biotech Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Biotech</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from exercise of stock options (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Remaining Contractual Life (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weight Average Remaining Contractual Life (in years) - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility range, minimum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization related to 401(k) contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen inducement award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Inducement Award Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs/debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions used to estimate fair value of awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum expiration term of options granted to employees having more than 10 % outstanding common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Award Options Maximum Expiration Term For Options Granted To Optionees With Ownership Of More Than10 Percentage Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum expiration term of stock options granted to employees having more than 10 % outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in the amount due for interest payments related to marketable securities and in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Interest Receivable Net And Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2022 pre-funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Variable interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage added to prime rate for debt instrument interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (loss) related to foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Issuance Costs and Debt Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of aggregate stock option and award activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock from at market offerings, net of paid issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesAndSiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules and Silicon Valley Bank. member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesAndSiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules And Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesAndSiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules and Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and awards available for grant (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BorrowingAvailableStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First date to available to drawdown any amount under a tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BorrowingAvailableStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowing Available Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BorrowingAvailableStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Start date to borrow under a tranche for a debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 1,350,000,000 shares authorized; 544,912,215 and 390,262,524 shares issued and outstanding at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Roll Forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the aggregate offering price for which the entity may elect to issue and sell shares of its common stock under the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Aggregate Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation for employees and directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the gross unrealized losses for cash and cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">severance plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Severance Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ACCRUED LIABILITIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense included in operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility range, maximum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LongTermDebtGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate value of term loan, including accrued interest payable and end of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LongTermDebtGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LongTermDebtGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At Market Issuance Sales Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Sales Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At Market Issuance Sales Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Added percentage to current interest rate under debt instrument to past due amounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Interest On Past Due Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional percentage of interest on past due amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principle amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income , net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined public offering price per share of pre-funded warrants and accompanying stock purchase warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Liabilities, Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of offering periods in which an employee can participate at a time in the purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Offering Periods In Which Employee May Participate At One Time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of offering periods in which an employee can participate at a time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Stock and Warrants for Services or Claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation for services by non-employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation for services by non-employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New jersey office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Jersey Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Jersey Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risks, Types, No Concentration Percentage [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MarketCapMinimumToUseOptionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum market capitalization required for this option to be available to meet the minimum cash balance debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MarketCapMinimumToUseOptionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market cap minimum to use option two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MarketCapMinimumToUseOptionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum market capitalization requirement for option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MaximumCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum commission rate, based on gross proceeds of sale price per share of common stock sold through sales agent under the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MaximumCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Commission Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MaximumCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum commission rate (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Investment Owned, Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Investment Owned, Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum borrowing capacity under term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of financial institutions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institutions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental schedule of non-cash operating and investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted future non-cancellable lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_LitigationCaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity impact of the value of stock issued in connection with exercise of warrants during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Warrant Exercise Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum amount allowed to be prepaid under debt instrument.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Minimum Prepayment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum amount of prepayment allowed under debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, increase in option reserves (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, increase in shares reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ExpiryDateOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date to borrow under a tranche for a debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ExpiryDateOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiry Date Of Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ExpiryDateOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Last date to drawdown any amounts under a tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Investment Holdings [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of months following a change in control when an employee is terminated without cause to be classified as a triggering event for severance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within which employee is terminated by entity without cause following a change of control</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PROPERTY AND EQUIPMENT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deposit Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposit and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deposit Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Plan [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of net product revenues maintenance period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum percentage of net product revenues maintenance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum percentage of net product revenues maintenance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost related to unvested stock awards not yet recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation settlement amount to be paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Amount to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement amount to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsPlan2006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the 2006 Directors Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsPlan2006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors Plan2006 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsPlan2006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Directors Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of maturity date terms for term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of the purchase period under the employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration Of Purchase Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of the purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Payments Under Term Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfPrepaymentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment amount to be paid upon prepayment under debt instrument.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfPrepaymentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayment Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfPrepaymentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment charge (as a percentage)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock options exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentsCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost method investments cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentsCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Method Investments Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentsCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost method investments cost basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CARESActImpactAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES act impact.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CARESActImpactAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Impact [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae) due in 1 to 2 years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Sponsored Enterprise Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the minimum percentage of ownership required for granting of options at a price not less than 110 percent of the fair market value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Ownership Required For Granting Options At Minimum110 Percent Of Fair Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of ownership required for granting stock options at least 110% of fair market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, if recognized would impact effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Employee Related Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of cash equivalents and marketable securities with unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Awards granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of term loan payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that the company must pay after the termination of the Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement After Termination Cost Sharing Percentage Of Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of costs to be paid by Geron after termination of Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering of Common Stock and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Of Common Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering of Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax Rate reconciliation net operating loss not benefitted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss not benefitted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementNumberOfStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of agreed upon studies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementNumberOfStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Number Of Studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementNumberOfStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of agreed upon studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum duration of the offering period under the employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Duration Of Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum duration of offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountPaidInCashOrKind_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of the settlement to be paid by the company in either cash or shares, at the company's election.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountPaidInCashOrKind_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Amount Paid in Cash or Kind</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountPaidInCashOrKind_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement to be paid in cash or shares as elected by company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stated interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum interest rate (as a percentage)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for recognition of compensation cost on weighted average basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE AGREEMENT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits And Other Assets Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation for equity-based awards to employees and directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Two Thousand And Twenty Three Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At market issuance two thousand and twenty three sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseDueToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period for amount due to counterparty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseDueToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Due To Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseDueToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due to Janssen Biotech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of remaining term commitments held under loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Remaining Term Commitments Held Under Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of remaining term commitments held under loan agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Stock Issued During Period Value New Issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering stock issued during period value new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of cash equivalents, restricted cash and marketable securities by security type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Covenant Minimum Cash Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Covenant Minimum Cash Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt covenant minimum cash balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from debt financing, net of paid debt issuance costs and debt discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of base salary in connection with a non-change of control to be considered for severance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan Non Change of Control Triggering Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency period of current base salary to be paid under severance plan non change of control triggering event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee stock purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued end of term charges.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued End Of Term Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assumptions used to estimate the fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate notes (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional legal and accounting fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of significant components of the entity's deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At market issuance two thousand and twenty sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Two Thousand And Twenty Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Second Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of allocation of stock-based compensation expense related to share-based payment awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains (Losses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized investment gains (losses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Realized Investment Gains (Losses), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion and amortization on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of securities available for sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of options to be granted to purchase shares upon appointment to Board of Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares Upon Appointment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options to be granted to purchase shares upon appointment (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available remaining loan principal under second amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information by type of sale of the entity's stock. = 2022 Underwritten Public Offering [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FosterCityOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foster City office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FosterCityOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foster City Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FosterCityOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foster City Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest only period payment term description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Only Period Payment Term Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest only period payment term description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Legal Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement to be paid by insurers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the period following change of control within which an employee is not offered comparable employment (new or continuing) by the entity or its successor or acquired and to be considered as triggering event for severance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within which no comparable employment is offered by the entity following a change of control</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation Settlement Amount, Interest and other receivable Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Amount, Interest and other receivable Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement amount, Interest and other receivable recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net gain on exchange and sales of equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average estimated fair value of other than employee stock options granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock from equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration term of stock options from date of grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of annual salary that can be withheld to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Of Annual Salary That Can Be Withheld Per Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award maximum amount of annual salary that can be withheld per year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum cash covenant required upon achievement of certain regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Covenant Min Cash Upon Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt covenant minimum cash balance upon regulatory milestone achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedManufacturingActivitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedManufacturingActivitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Activities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedManufacturingActivitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Goods and Nonemployee Services Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation to Service Providers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployerTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of employer taxes paid to tax authorities representing refunds based on calculated eligible credits. Also called employer tax refund receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployerTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employer Tax Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployerTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee retention credit, CARES Act</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating leases right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Leases Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating leases, right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options cancelled/forfeited/expired (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionOneMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option one min cash debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionOneMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option one min cash debt covenant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FacilityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FacilityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facility Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total pretax intrinsic value of stock options exercised (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees Above The Vice President Level</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees Above The Vice President Level [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees above the vice president level.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncentiveAwardPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the 2011 Incentive Award Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncentiveAwardPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Award Plan2011 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncentiveAwardPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2011 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and cash equivalents gross unrealized losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplier [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplier</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total - Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expire beginning 2024 through 2037</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncurrent portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At market issuance, 2018 sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Two Thousand And Eighteen Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Basis for Effective Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan interest rate description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation settlement amount, General and administrative expense recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation settlement amount, General and administrative expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement amount, General and administrative expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments, at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencySettlementAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Settlement Agreement, Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencySettlementAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement agreement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nontrade Receivables, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nontrade Receivables, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock, exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the gross unrealized gains for cash and cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock options cancelled/forfeited/expired (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument unamortized end of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and cash equivalents unrealized gains.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the aggregate number of share instruments issued under a share-based compensation plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Aggregate Shares Issued Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate shares issued under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate range, minimum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Purchase Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate range, maximum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the period within which employee resigns following a change of control due to material change in terms of employment and to be considered as triggering event for severance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within which employee resigns following a change of control due to material change in terms of employment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DerivativeStipulationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative stipulation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DerivativeStipulationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Stipulation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DerivativeStipulationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Stipulation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing stock price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount outstanding under term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock under equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFaceAmountExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument face amount expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFaceAmountExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFaceAmountExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument face amount expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Settlement Amount Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement Amount Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation settlement amount outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Equity Securities, FV-NI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in fair value of equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of equity investment, including foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum percentage of annual salary that an employee can choose to have withheld to purchase common stock under the purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Annual Salary That Can Be Withheld</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of annual salary that can be withheld</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionThreeMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option three min cash debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionThreeMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option three min cash debt covenant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation settlement amount, Accrued liabilities recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation settlement amount, Accrued liabilities recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement amount, Accrued liabilities recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Claims [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance Claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US Treasury Securities Due In less than one Year Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Pre-funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Pre Funded Warrant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three pre funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2023 Underwritten Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total - Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae), due in one to two years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Retention Credit, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Retention Credit Amount Outstanding Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee retention credit amount outstanding receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FormerCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Former collaborative arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FormerCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FormerCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Former Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification between prepaid and other current assets and deposits and other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Between Prepaid And Other Current Assets And Deposits And Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification between prepaid and other current assets and deposits and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Percentage of Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrdArrExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading arrangement expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrdArrExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrdArrExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trd Arr Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and warrants excluded from diluted net loss per share calculation due to net loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term, option to terminate lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from public offering issuance of common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Public Offering Issuance Of Common Stock And Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that Janssen must pay during certain phases of the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Cost Sharing Percentage Of Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of costs to be paid by Janssen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award minimum exercise price of options granted to employees with more than 10 percentage of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Exercise Price Of Options Granted To Employees With More Than10 Percentage Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum exercise price as a percentage of fair market value for employees having more than 10 % outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding loan amount payable upon maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument End Of Term Charge Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">End of term charge for loan, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) from effect of unrealized losses and exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Borrowing Capacity, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date to borrow under a tranche for a debt instrument, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency period of current base salary to be paid under severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of base salary to be considered for severance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SubsequentDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the stock options to be granted by the entity subsequent to the grant upon first appointment to the Board of Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SubsequentDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Director Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SubsequentDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Director Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2022 Stock Purchase Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Stock Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in one to two years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate notes (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Jersey lease and Foster city lease member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Jersey Lease And Foster City Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Jersey Lease And Foster City Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion, and Amortization [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock under equity plans (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule reconciles the federal statutory tax rate to the effective income tax rate from continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offering price of common stock per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined public offering price per share of common stock and accompanying stock purchase warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Other Assets, Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EquityInvestmentReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split ratio for equity investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EquityInvestmentReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investment Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EquityInvestmentReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Goods and Nonemployee Services Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Goods And Nonemployee Services Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease,remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage applied to common stock market value in calculating purchase price under purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAXES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation related to issuance of common stock and options in exchange for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total number of shares from equity investment that have been sold during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Sold From Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number Of Shares Sold From Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">12 Months or Greater - Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants Purchase [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FirstDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the stock options to be granted by the entity to a person who first becomes a non-employee director.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FirstDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Director Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FirstDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Director Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassActionStipulationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class action stipulation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassActionStipulationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Action Stipulation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassActionStipulationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Action Stipulation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expire beginning 2028 through 2041</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating loss carryforwards</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:to="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingTable" xlink:to="gern_PublicOfferingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MenloParkOfficeSpaceLeaseMember" xlink:to="gern_MenloParkOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:to="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:to="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CommercialPaperDueInLessThanOneYearMember" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SiliconValleyBankMember" xlink:to="gern_SiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:to="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OptionTwoMinCashDebtCovenantMember" xlink:to="gern_OptionTwoMinCashDebtCovenantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinCashUponLicensingTransaction" xlink:to="gern_DebtCovenantMinCashUponLicensingTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheBMember" xlink:to="gern_TrancheBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DirectorsMarketValueStockPurchasePlanMember" xlink:to="gern_DirectorsMarketValueStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtTheMarketOfferingMember" xlink:to="gern_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_PublicOfferingLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CostMethodInvestmentOwnershipPercentage" xlink:to="gern_CostMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OperatingLeaseRentAbatementPeriod" xlink:to="gern_OperatingLeaseRentAbatementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:to="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DueToCounterParty" xlink:to="gern_DueToCounterParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LicenseAgreementDisclosureAbstract" xlink:to="gern_LicenseAgreementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsFederalAndStateCredits" xlink:to="gern_DeferredTaxAssetsFederalAndStateCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheOneMember" xlink:to="gern_TrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ThirdAmendmentMember" xlink:to="gern_ThirdAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheAMember" xlink:to="gern_TrancheAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" xlink:to="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedEndOfTermCharge" xlink:to="gern_AccruedEndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:to="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_JanssenBiotechIncMember" xlink:to="gern_JanssenBiotechIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:to="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:to="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:to="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_HerculesAndSiliconValleyBankMember" xlink:to="gern_HerculesAndSiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_BorrowingAvailableStartDate" xlink:to="gern_BorrowingAvailableStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CommonStockAggregateOfferingPrice" xlink:to="gern_CommonStockAggregateOfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CashAndCashEquivalentsUnrealizedLosses" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NumberOfSeverancePlan" xlink:to="gern_NumberOfSeverancePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LongTermDebtGross" xlink:to="gern_LongTermDebtGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="gern_AtMarketIssuanceSalesAgreementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfInterestOnPastDueOutstanding" xlink:to="gern_PercentageOfInterestOnPastDueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NewJerseyOfficeSpaceLeaseMember" xlink:to="gern_NewJerseyOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MarketCapMinimumToUseOptionTwo" xlink:to="gern_MarketCapMinimumToUseOptionTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MaximumCommissionRate" xlink:to="gern_MaximumCommissionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NumberOfFinancialInstitutions" xlink:to="gern_NumberOfFinancialInstitutions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_StockPurchaseWarrantsMember" xlink:to="gern_StockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentMinimumPrepaymentAmount" xlink:to="gern_DebtInstrumentMinimumPrepaymentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ConsultantsMember" xlink:to="gern_ConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ExpiryDateOfTranche" xlink:to="gern_ExpiryDateOfTranche_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:to="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_SeverancePlanLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:to="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LitigationSettlementAmountToBePaid" xlink:to="gern_LitigationSettlementAmountToBePaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DirectorsPlan2006Member" xlink:to="gern_DirectorsPlan2006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:to="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfPrepaymentCharge" xlink:to="gern_PercentageOfPrepaymentCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_UnderwrittenPublicOfferingMember" xlink:to="gern_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CostMethodInvestmentsCostBasis" xlink:to="gern_CostMethodInvestmentsCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CARESActImpactAbstract" xlink:to="gern_CARESActImpactAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalBondsMember" xlink:to="us-gaap_MunicipalBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:to="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_DepreciationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:to="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheFourMember" xlink:to="gern_TrancheFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementNumberOfStudies" xlink:to="gern_CollaborativeArrangementNumberOfStudies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LitigationSettlementAmountPaidInCashOrKind" xlink:to="gern_LitigationSettlementAmountPaidInCashOrKind_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DepositsAndOtherAssetsNoncurrent" xlink:to="gern_DepositsAndOtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ClinicalSupplyAgreementMember" xlink:to="gern_ClinicalSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncreaseDecreaseDueToCounterparty" xlink:to="gern_IncreaseDecreaseDueToCounterparty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PurchaseWarrantsMember" xlink:to="gern_PurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:to="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinimumCashBalance" xlink:to="gern_DebtCovenantMinimumCashBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedEndOfTermCharges" xlink:to="gern_AccruedEndOfTermCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SeverancePlanTable" xlink:to="gern_SeverancePlanTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SecondAmendmentMember" xlink:to="gern_SecondAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:to="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FosterCityOfficeSpaceLeaseMember" xlink:to="gern_FosterCityOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_InterestOnlyPeriodPaymentTermDescription" xlink:to="gern_InterestOnlyPeriodPaymentTermDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" xlink:to="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:to="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedManufacturingActivitiesCurrent" xlink:to="gern_AccruedManufacturingActivitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EmployerTaxReceivable" xlink:to="gern_EmployerTaxReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:to="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheSixMember" xlink:to="gern_TrancheSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OptionOneMinCashDebtCovenantMember" xlink:to="gern_OptionOneMinCashDebtCovenantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FacilityCosts" xlink:to="us-gaap_FacilityCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EmployeesAboveTheVicePresidentLevelMember" xlink:to="gern_EmployeesAboveTheVicePresidentLevelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncentiveAwardPlan2011Member" xlink:to="gern_IncentiveAwardPlan2011Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheFiveMember" xlink:to="gern_TrancheFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PerformanceBasedStockOptionsMember" xlink:to="gern_PerformanceBasedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_HerculesMember" xlink:to="gern_HerculesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" xlink:to="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencySettlementAgreementDate" xlink:to="us-gaap_LossContingencySettlementAgreementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivablesCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CashAndCashEquivalentsUnrealizedGains" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:to="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheTwoMember" xlink:to="gern_TrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DerivativeStipulationMember" xlink:to="gern_DerivativeStipulationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheCMember" xlink:to="gern_TrancheCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentFaceAmountExpired" xlink:to="gern_DebtInstrumentFaceAmountExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LitigationSettlementAmountOutstanding" xlink:to="gern_LitigationSettlementAmountOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheThreeMember" xlink:to="gern_TrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OptionThreeMinCashDebtCovenantMember" xlink:to="gern_OptionThreeMinCashDebtCovenantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" xlink:to="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceClaimsMember" xlink:to="us-gaap_InsuranceClaimsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EmployeeRetentionCreditAmountOutstandingReceivables" xlink:to="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FormerCollaborativeArrangementMember" xlink:to="gern_FormerCollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" xlink:to="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrdArrExpirationDate" xlink:to="gern_TrdArrExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:to="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentEndOfTermChargePercentage" xlink:to="gern_DebtInstrumentEndOfTermChargePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SubsequentDirectorOptionMember" xlink:to="gern_SubsequentDirectorOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:to="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:to="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EquityInvestmentReverseStockSplit" xlink:to="gern_EquityInvestmentReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NumberOfSharesSoldFromEquityInvestment" xlink:to="gern_NumberOfSharesSoldFromEquityInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PreFundedWarrantsMember" xlink:to="gern_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FirstDirectorOptionMember" xlink:to="gern_FirstDirectorOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ClassActionStipulationMember" xlink:to="gern_ClassActionStipulationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:to="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DepositsAndOtherAssetsNoncurrent" xlink:label="gern_DepositsAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DebtCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NontradeReceivablesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="gern_DepositsAndOtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_3"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_4"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtTheMarketOfferingMember" xlink:label="gern_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseDueToCounterparty" xlink:label="gern_IncreaseDecreaseDueToCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainOnSaleOfInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gern_IncreaseDecreaseDueToCounterparty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetsFairValueAdjustment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gern_IncreaseDecreaseInOperatingLeaseLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrdArrExpirationDate" xlink:label="gern_TrdArrExpirationDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="gern_TrdArrExpirationDate" order="13.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureLicenseAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LicenseAgreementDisclosureAbstract" xlink:label="gern_LicenseAgreementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAbstract" xlink:label="us-gaap_DepreciationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DepreciationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CostMethodInvestmentsCostBasis" xlink:label="gern_CostMethodInvestmentsCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfSharesSoldFromEquityInvestment" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EquityInvestmentReverseStockSplit" xlink:label="gern_EquityInvestmentReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CostMethodInvestmentOwnershipPercentage" xlink:label="gern_CostMethodInvestmentOwnershipPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentsCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquitySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_NumberOfSharesSoldFromEquityInvestment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_EquityInvestmentReverseStockSplit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentOwnershipPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfFinancialInstitutions" xlink:label="gern_NumberOfFinancialInstitutions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="gern_NumberOfFinancialInstitutions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FormerCollaborativeArrangementMember" xlink:label="gern_FormerCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LicenseAgreementDisclosureAbstract" xlink:label="gern_LicenseAgreementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementNumberOfStudies" xlink:label="gern_CollaborativeArrangementNumberOfStudies"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_JanssenBiotechIncMember" xlink:label="gern_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClinicalSupplyAgreementMember" xlink:label="gern_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DueToCounterParty" xlink:label="gern_DueToCounterParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_FormerCollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementNumberOfStudies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gern_JanssenBiotechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_ClinicalSupplyAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfEntity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_DueToCounterParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedManufacturingActivitiesCurrent" xlink:label="gern_AccruedManufacturingActivitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="gern_AccruedManufacturingActivitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassActionStipulationMember" xlink:label="gern_ClassActionStipulationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencySettlementAgreementDate" xlink:label="us-gaap_LossContingencySettlementAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DerivativeStipulationMember" xlink:label="gern_DerivativeStipulationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountOutstanding" xlink:label="gern_LitigationSettlementAmountOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountPaidInCashOrKind" xlink:label="gern_LitigationSettlementAmountPaidInCashOrKind"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" xlink:label="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" xlink:label="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" xlink:label="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountToBePaid" xlink:label="gern_LitigationSettlementAmountToBePaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="gern_ClassActionStipulationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencySettlementAgreementDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_InsuranceClaimsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="gern_DerivativeStipulationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountPaidInCashOrKind" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountToBePaid" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployeesAboveTheVicePresidentLevelMember" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SeverancePlanTable" xlink:label="gern_SeverancePlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SeverancePlanLineItems" xlink:label="gern_SeverancePlanLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfSeverancePlan" xlink:label="gern_NumberOfSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gern_EmployeesAboveTheVicePresidentLevelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="gern_SeverancePlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_NumberOfSeverancePlan" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_InsuranceClaimsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="gern_SeverancePlanLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MenloParkOfficeSpaceLeaseMember" xlink:label="gern_MenloParkOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NewJerseyOfficeSpaceLeaseMember" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FosterCityOfficeSpaceLeaseMember" xlink:label="gern_FosterCityOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLeaseRentAbatementPeriod" xlink:label="gern_OperatingLeaseRentAbatementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseTermAdditionalPeriodExtension" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_MenloParkOfficeSpaceLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyOfficeSpaceLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_FosterCityOfficeSpaceLeaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseRentAbatementPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyLeaseAndFosterCityLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SecondAmendmentMember" xlink:label="gern_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_HerculesAndSiliconValleyBankMember" xlink:label="gern_HerculesAndSiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheOneMember" xlink:label="gern_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ThirdAmendmentMember" xlink:label="gern_ThirdAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_HerculesMember" xlink:label="gern_HerculesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheTwoMember" xlink:label="gern_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SiliconValleyBankMember" xlink:label="gern_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheThreeMember" xlink:label="gern_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheFourMember" xlink:label="gern_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_BorrowingAvailableStartDate" xlink:label="gern_BorrowingAvailableStartDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheFiveMember" xlink:label="gern_TrancheFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ExpiryDateOfTranche" xlink:label="gern_ExpiryDateOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheSixMember" xlink:label="gern_TrancheSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionOneMinCashDebtCovenantMember" xlink:label="gern_OptionOneMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionTwoMinCashDebtCovenantMember" xlink:label="gern_OptionTwoMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionThreeMinCashDebtCovenantMember" xlink:label="gern_OptionThreeMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheAMember" xlink:label="gern_TrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheBMember" xlink:label="gern_TrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_InterestOnlyPeriodPaymentTermDescription" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheCMember" xlink:label="gern_TrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentEndOfTermChargePercentage" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentMinimumPrepaymentAmount" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfPrepaymentCharge" xlink:label="gern_PercentageOfPrepaymentCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinimumCashBalance" xlink:label="gern_DebtCovenantMinimumCashBalance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MarketCapMinimumToUseOptionTwo" xlink:label="gern_MarketCapMinimumToUseOptionTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityCosts" xlink:label="us-gaap_FacilityCosts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentFaceAmountExpired" xlink:label="gern_DebtInstrumentFaceAmountExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinCashUponLicensingTransaction" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfInterestOnPastDueOutstanding" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedEndOfTermCharge" xlink:label="gern_AccruedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedEndOfTermCharges" xlink:label="gern_AccruedEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="gern_SecondAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesAndSiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="gern_ThirdAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_SiliconValleyBankMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_BorrowingAvailableStartDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_ExpiryDateOfTranche" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionOneMinCashDebtCovenantMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionTwoMinCashDebtCovenantMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionThreeMinCashDebtCovenantMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheAMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheBMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_InterestOnlyPeriodPaymentTermDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheCMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentEndOfTermChargePercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentMinimumPrepaymentAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfPrepaymentCharge" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MarketCapMinimumToUseOptionTwo" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FacilityCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentFaceAmountExpired" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponLicensingTransaction" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponRegulatoryMilestone" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfInterestOnPastDueOutstanding" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharge" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharges" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LongTermDebtGross" xlink:label="gern_LongTermDebtGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="gern_LongTermDebtGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="gern_DebtInstrumentUnamortizedEndOfTermCharge" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingTable" xlink:label="gern_PublicOfferingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingLineItems" xlink:label="gern_PublicOfferingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoPreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_PublicOfferingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingTable" xlink:to="gern_PublicOfferingLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PurchaseWarrantsMember" xlink:label="gern_PurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyStockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommonStockAggregateOfferingPrice" xlink:label="gern_CommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceSalesAgreementsTable" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MaximumCommissionRate" xlink:label="gern_MaximumCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_CommonStockAggregateOfferingPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_AtMarketIssuanceSalesAgreementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_MaximumCommissionRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="gern_AtMarketIssuanceSalesAgreementsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncentiveAwardPlan2011Member" xlink:label="gern_IncentiveAwardPlan2011Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DirectorsPlan2006Member" xlink:label="gern_DirectorsPlan2006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DirectorsMarketValueStockPurchasePlanMember" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FirstDirectorOptionMember" xlink:label="gern_FirstDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SubsequentDirectorOptionMember" xlink:label="gern_SubsequentDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_IncentiveAwardPlan2011Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsPlan2006Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsMarketValueStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_FirstDirectorOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_SubsequentDirectorOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ConsultantsMember" xlink:label="gern_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="gern_ConsultantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsFederalAndStateCredits" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsFederalAndStateCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="gern_OperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CARESActImpactAbstract" xlink:label="gern_CARESActImpactAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployerTaxReceivable" xlink:label="gern_EmployerTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployeeRetentionCreditAmountOutstandingReceivables" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_CARESActImpactAbstract" xlink:to="gern_EmployerTaxReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_CARESActImpactAbstract" xlink:to="gern_EmployeeRetentionCreditAmountOutstandingReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtTheMarketOfferingMember" xlink:label="gern_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CostMethodInvestmentsCostBasis" xlink:label="gern_CostMethodInvestmentsCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfSharesSoldFromEquityInvestment" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EquityInvestmentReverseStockSplit" xlink:label="gern_EquityInvestmentReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CostMethodInvestmentOwnershipPercentage" xlink:label="gern_CostMethodInvestmentOwnershipPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentsCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquitySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_NumberOfSharesSoldFromEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_EquityInvestmentReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FormerCollaborativeArrangementMember" xlink:label="gern_FormerCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementNumberOfStudies" xlink:label="gern_CollaborativeArrangementNumberOfStudies"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_JanssenBiotechIncMember" xlink:label="gern_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClinicalSupplyAgreementMember" xlink:label="gern_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DueToCounterParty" xlink:label="gern_DueToCounterParty"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_FormerCollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementNumberOfStudies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gern_JanssenBiotechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_ClinicalSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_DueToCounterParty" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassActionStipulationMember" xlink:label="gern_ClassActionStipulationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencySettlementAgreementDate" xlink:label="us-gaap_LossContingencySettlementAgreementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DerivativeStipulationMember" xlink:label="gern_DerivativeStipulationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountOutstanding" xlink:label="gern_LitigationSettlementAmountOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountPaidInCashOrKind" xlink:label="gern_LitigationSettlementAmountPaidInCashOrKind"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" xlink:label="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" xlink:label="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" xlink:label="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LitigationSettlementAmountToBePaid" xlink:label="gern_LitigationSettlementAmountToBePaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="gern_ClassActionStipulationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencySettlementAgreementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_InsuranceClaimsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="gern_DerivativeStipulationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountPaidInCashOrKind" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="gern_LitigationSettlementAmountToBePaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SeverancePlanLineItems" xlink:label="gern_SeverancePlanLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SeverancePlanTable" xlink:label="gern_SeverancePlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EmployeesAboveTheVicePresidentLevelMember" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NumberOfSeverancePlan" xlink:label="gern_NumberOfSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_SeverancePlanTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gern_EmployeesAboveTheVicePresidentLevelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_NumberOfSeverancePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_InsuranceClaimsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_SeverancePlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_SeverancePlanTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_SeverancePlanTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MenloParkOfficeSpaceLeaseMember" xlink:label="gern_MenloParkOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NewJerseyOfficeSpaceLeaseMember" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FosterCityOfficeSpaceLeaseMember" xlink:label="gern_FosterCityOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLeaseRentAbatementPeriod" xlink:label="gern_OperatingLeaseRentAbatementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseTermAdditionalPeriodExtension" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_MenloParkOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_FosterCityOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseRentAbatementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyLeaseAndFosterCityLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SecondAmendmentMember" xlink:label="gern_SecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_HerculesAndSiliconValleyBankMember" xlink:label="gern_HerculesAndSiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheOneMember" xlink:label="gern_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ThirdAmendmentMember" xlink:label="gern_ThirdAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_HerculesMember" xlink:label="gern_HerculesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheTwoMember" xlink:label="gern_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SiliconValleyBankMember" xlink:label="gern_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheThreeMember" xlink:label="gern_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheFourMember" xlink:label="gern_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_BorrowingAvailableStartDate" xlink:label="gern_BorrowingAvailableStartDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheFiveMember" xlink:label="gern_TrancheFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ExpiryDateOfTranche" xlink:label="gern_ExpiryDateOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheSixMember" xlink:label="gern_TrancheSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionOneMinCashDebtCovenantMember" xlink:label="gern_OptionOneMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionTwoMinCashDebtCovenantMember" xlink:label="gern_OptionTwoMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OptionThreeMinCashDebtCovenantMember" xlink:label="gern_OptionThreeMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheAMember" xlink:label="gern_TrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheBMember" xlink:label="gern_TrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_InterestOnlyPeriodPaymentTermDescription" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TrancheCMember" xlink:label="gern_TrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentEndOfTermChargePercentage" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentMinimumPrepaymentAmount" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfPrepaymentCharge" xlink:label="gern_PercentageOfPrepaymentCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinimumCashBalance" xlink:label="gern_DebtCovenantMinimumCashBalance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MarketCapMinimumToUseOptionTwo" xlink:label="gern_MarketCapMinimumToUseOptionTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityCosts" xlink:label="us-gaap_FacilityCosts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentFaceAmountExpired" xlink:label="gern_DebtInstrumentFaceAmountExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinCashUponLicensingTransaction" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfInterestOnPastDueOutstanding" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedEndOfTermCharge" xlink:label="gern_AccruedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedEndOfTermCharges" xlink:label="gern_AccruedEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="gern_SecondAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesAndSiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="gern_ThirdAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_BorrowingAvailableStartDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_ExpiryDateOfTranche" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionOneMinCashDebtCovenantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionTwoMinCashDebtCovenantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionThreeMinCashDebtCovenantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_InterestOnlyPeriodPaymentTermDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentEndOfTermChargePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentMinimumPrepaymentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfPrepaymentCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MarketCapMinimumToUseOptionTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FacilityCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentFaceAmountExpired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponLicensingTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfInterestOnPastDueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingLineItems" xlink:label="gern_PublicOfferingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PublicOfferingTable" xlink:label="gern_PublicOfferingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_PublicOfferingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoPreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PurchaseWarrantsMember" xlink:label="gern_PurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyPreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyStockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails">
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceSalesAgreementsTable" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CommonStockAggregateOfferingPrice" xlink:label="gern_CommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_MaximumCommissionRate" xlink:label="gern_MaximumCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_AtMarketIssuanceSalesAgreementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_CommonStockAggregateOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_MaximumCommissionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncentiveAwardPlan2011Member" xlink:label="gern_IncentiveAwardPlan2011Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_FirstDirectorOptionMember" xlink:label="gern_FirstDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_SubsequentDirectorOptionMember" xlink:label="gern_SubsequentDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DirectorsPlan2006Member" xlink:label="gern_DirectorsPlan2006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DirectorsMarketValueStockPurchasePlanMember" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_IncentiveAwardPlan2011Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_FirstDirectorOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_SubsequentDirectorOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsPlan2006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsMarketValueStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ConsultantsMember" xlink:label="gern_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="gern_ConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="gern_OperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DebtCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="gern_DepositsAndOtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DepositsAndOtherAssetsNoncurrent" xlink:label="gern_DepositsAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainOnSaleOfInvestments" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets" order="5" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetsFairValueAdjustment" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="9" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" order="12" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="13" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="14" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="15" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="16" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_IncreaseDecreaseDueToCounterparty" order="17" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="18" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_IncreaseDecreaseInOperatingLeaseLiabilities" order="19" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="us-gaap_GainOnSaleOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities" xlink:label="us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseDueToCounterparty" xlink:label="gern_IncreaseDecreaseDueToCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gern_AccruedManufacturingActivitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_AccruedManufacturingActivitiesCurrent" xlink:label="gern_AccruedManufacturingActivitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="gern_LongTermDebtGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="gern_DebtInstrumentUnamortizedEndOfTermCharge" order="4" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_LongTermDebtGross" xlink:label="gern_LongTermDebtGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsFederalAndStateCredits" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsOperatingLeaseLiabilities" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsFederalAndStateCredits" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20231231.xsd#gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gern_CashAndCashEquivalentsUnrealizedGains" name="CashAndCashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_EquityInvestmentReverseStockSplit" name="EquityInvestmentReverseStockSplit" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_SeverancePlanTable" name="SeverancePlanTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_USTreasurySecuritiesDueInLessThanOneYearMember" name="USTreasurySecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_NumberOfSharesSoldFromEquityInvestment" name="NumberOfSharesSoldFromEquityInvestment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ConsultantsMember" name="ConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_FirstDirectorOptionMember" name="FirstDirectorOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CommercialPaperDueInLessThanOneYearMember" name="CommercialPaperDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PublicOfferingLineItems" name="PublicOfferingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_FormerCollaborativeArrangementMember" name="FormerCollaborativeArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_PublicOfferingOfCommonStockAndWarrantsMember" name="PublicOfferingOfCommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_AtMarketIssuanceSalesAgreementsLineItems" name="AtMarketIssuanceSalesAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ThirdAmendmentMember" name="ThirdAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CollaborativeArrangementNumberOfStudies" name="CollaborativeArrangementNumberOfStudies" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtCovenantMinCashUponLicensingTransaction" name="DebtCovenantMinCashUponLicensingTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" name="LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_OperatingLeaseRentAbatementPeriod" name="OperatingLeaseRentAbatementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_JanssenBiotechIncMember" name="JanssenBiotechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DerivativeStipulationMember" name="DerivativeStipulationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandTwentyStockPurchaseWarrantsMember" name="TwoThousandTwentyStockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LitigationSettlementAmountPaidInCashOrKind" name="LitigationSettlementAmountPaidInCashOrKind" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_PublicOfferingTable" name="PublicOfferingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandAndEighteenInducementAwardPlanMember" name="TwoThousandAndEighteenInducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" name="LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EmployeesAboveTheVicePresidentLevelMember" name="EmployeesAboveTheVicePresidentLevelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LitigationSettlementAmountOutstanding" name="LitigationSettlementAmountOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" name="EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_IncreaseDecreaseDueToCounterparty" name="IncreaseDecreaseDueToCounterparty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" name="GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CashAndCashEquivalentsUnrealizedLosses" name="CashAndCashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" name="TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" name="TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PurchaseWarrantsMember" name="PurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheFourMember" name="TrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_MaximumCommissionRate" name="MaximumCommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TrdArrExpirationDate" name="TrdArrExpirationDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandTwentyPreFundedWarrantsMember" name="TwoThousandTwentyPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LitigationSettlementAmountToBePaid" name="LitigationSettlementAmountToBePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_NewJerseyLeaseAndFosterCityLeaseMember" name="NewJerseyLeaseAndFosterCityLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_DebtInstrumentMinimumPrepaymentAmount" name="DebtInstrumentMinimumPrepaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" name="LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" name="RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ClinicalSupplyAgreementMember" name="ClinicalSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" name="DebtCovenantPercentageOfProductRevenueAgainstForecast" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_OptionTwoMinCashDebtCovenantMember" name="OptionTwoMinCashDebtCovenantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_NumberOfSeverancePlan" name="NumberOfSeverancePlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EmployeeRetentionCreditAmountOutstandingReceivables" name="EmployeeRetentionCreditAmountOutstandingReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_TrancheThreeMember" name="TrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_IncentiveAwardPlan2011Member" name="IncentiveAwardPlan2011Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LongTermDebtGross" name="LongTermDebtGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" name="USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" name="ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_CostMethodInvestmentOwnershipPercentage" name="CostMethodInvestmentOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtCovenantMinimumCashBalance" name="DebtCovenantMinimumCashBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_NewJerseyOfficeSpaceLeaseMember" name="NewJerseyOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LitigationSettlementAmountAccruedLiabilitiesRecognized" name="LitigationSettlementAmountAccruedLiabilitiesRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" name="TwoThousandTwentyTwoStockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CostMethodInvestmentsCostBasis" name="CostMethodInvestmentsCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TrancheFiveMember" name="TrancheFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" name="ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PerformanceBasedStockOptionsMember" name="PerformanceBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DirectorsPlan2006Member" name="DirectorsPlan2006Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" name="RestrictedCashAndCashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" name="AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" name="ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtInstrumentUnamortizedEndOfTermCharge" name="DebtInstrumentUnamortizedEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" name="AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_SeverancePlanLineItems" name="SeverancePlanLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyPurchaseWarrantsMember" name="TwoThousandTwentyPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" name="IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" name="DollarPrepaymentCharge36MonthsAfterEffectiveDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_MarketCapMinimumToUseOptionTwo" name="MarketCapMinimumToUseOptionTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" name="TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" name="CollaborativeArrangementCostSharingPercentageOfCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_CollaborativeArrangementCostSharingPercentageOfEntity" name="CollaborativeArrangementCostSharingPercentageOfEntity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" name="LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_FosterCityOfficeSpaceLeaseMember" name="FosterCityOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PercentageOfPrepaymentCharge" name="PercentageOfPrepaymentCharge" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" name="PublicOfferingStockIssuedDuringPeriodValueNewIssue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" name="CorporateNoteSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtCovenantMinCashUponRegulatoryMilestone" name="DebtCovenantMinCashUponRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_OptionOneMinCashDebtCovenantMember" name="OptionOneMinCashDebtCovenantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" name="DebtCovenantMinimumCashBalancePercentageOfLoanAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" name="LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" name="TwoThousandTwentyTwoPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_NumberOfFinancialInstitutions" name="NumberOfFinancialInstitutions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandAndEighteenEquityIncentivePlanMember" name="TwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" name="USTreasurySecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AccruedManufacturingActivitiesCurrent" name="AccruedManufacturingActivitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_SubsequentDirectorOptionMember" name="SubsequentDirectorOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheCMember" name="TrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheSixMember" name="TrancheSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DirectorsMarketValueStockPurchasePlanMember" name="DirectorsMarketValueStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AccruedEndOfTermCharge" name="AccruedEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TrancheAMember" name="TrancheAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AccruedEndOfTermCharges" name="AccruedEndOfTermCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TrancheBMember" name="TrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CommonStockAggregateOfferingPrice" name="CommonStockAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" name="ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_InterestOnlyPeriodPaymentTermDescription" name="InterestOnlyPeriodPaymentTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_StockPurchaseWarrantsMember" name="StockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_MunicipalSecuritiesDueInLessThanOneYearMember" name="MunicipalSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" name="LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" name="GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PercentageOfInterestOnPastDueOutstanding" name="PercentageOfInterestOnPastDueOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ClassActionStipulationMember" name="ClassActionStipulationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtInstrumentEndOfTermChargePercentage" name="DebtInstrumentEndOfTermChargePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_AtMarketIssuanceSalesAgreementsTable" name="AtMarketIssuanceSalesAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" name="AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" name="CorporateNoteSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized" name="LitigationSettlementAmountInterestAndOtherReceivableRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_HerculesMember" name="HerculesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" name="CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" name="MunicipalSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_MenloParkOfficeSpaceLeaseMember" name="MenloParkOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyThreePreFundedWarrantMember" name="TwoThousandTwentyThreePreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EmployerTaxReceivable" name="EmployerTaxReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TwoThousandTwentyTwoPreFundedWarrantMember" name="TwoThousandTwentyTwoPreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheTwoMember" name="TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_BorrowingAvailableStartDate" name="BorrowingAvailableStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" name="USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ExpiryDateOfTranche" name="ExpiryDateOfTranche" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" name="IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" name="PublicOfferingStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" name="IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_LicenseAgreementDisclosureAbstract" name="LicenseAgreementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DeferredTaxAssetsFederalAndStateCredits" name="DeferredTaxAssetsFederalAndStateCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" name="ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_HerculesAndSiliconValleyBankMember" name="HerculesAndSiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DueToCounterParty" name="DueToCounterParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" name="MinimumPercentageOfNetProductRevenuesMaintenancePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" name="PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" name="AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_OptionThreeMinCashDebtCovenantMember" name="OptionThreeMinCashDebtCovenantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_OperatingLeaseTermAdditionalPeriodExtension" name="OperatingLeaseTermAdditionalPeriodExtension" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TrancheOneMember" name="TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CARESActImpactAbstract" name="CARESActImpactAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtInstrumentFaceAmountExpired" name="DebtInstrumentFaceAmountExpired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219614421040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 23, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,394,546,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">546,059,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-20859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 East Hillsdale Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:90%;"></td>
      <td style="width:1%;"></td>
      <td style="width:9%;"></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Document</span></p></td>
      <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form 10&#8209;K<br/>Parts</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
      <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Portions of the Registrant&#8217;s definitive proxy statement for the 2024 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2023.</span></p></td>
      <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">III</span></p></td>
     </tr>
    </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613657872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 70,023<span></span>
</td>
<td class="nump">$ 56,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">263,676<span></span>
</td>
<td class="nump">115,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Interest and other receivables</a></td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">341,348<span></span>
</td>
<td class="nump">180,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent marketable securities</a></td>
<td class="nump">43,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases, right-of-use assets</a></td>
<td class="nump">3,556<span></span>
</td>
<td class="nump">4,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">4,697<span></span>
</td>
<td class="nump">5,389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">394,076<span></span>
</td>
<td class="nump">190,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,161<span></span>
</td>
<td class="nump">10,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">13,759<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt</a></td>
<td class="nump">46,893<span></span>
</td>
<td class="nump">20,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">40,308<span></span>
</td>
<td class="nump">33,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">108,070<span></span>
</td>
<td class="nump">76,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">3,006<span></span>
</td>
<td class="nump">3,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent debt</a></td>
<td class="nump">35,051<span></span>
</td>
<td class="nump">30,212<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">146,127<span></span>
</td>
<td class="nump">110,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,350,000,000 shares authorized; 544,912,215 and 390,262,524 shares issued and outstanding at December 31, 2023 and 2022, respectively</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,844,988<span></span>
</td>
<td class="nump">1,493,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,597,769)<span></span>
</td>
<td class="num">(1,413,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">185<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">247,949<span></span>
</td>
<td class="nump">79,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 394,076<span></span>
</td>
<td class="nump">$ 190,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609834240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">544,912,215<span></span>
</td>
<td class="nump">390,262,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">544,912,215<span></span>
</td>
<td class="nump">390,262,524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609026352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License fees and royalties</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">$ 1,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">125,046<span></span>
</td>
<td class="nump">95,518<span></span>
</td>
<td class="nump">85,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">69,135<span></span>
</td>
<td class="nump">43,628<span></span>
</td>
<td class="nump">29,665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">194,181<span></span>
</td>
<td class="nump">139,146<span></span>
</td>
<td class="nump">115,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(193,944)<span></span>
</td>
<td class="num">(138,550)<span></span>
</td>
<td class="num">(113,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">18,152<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,312)<span></span>
</td>
<td class="num">(6,882)<span></span>
</td>
<td class="num">(3,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income , net</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
<td class="num">$ (116,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share</a></td>
<td class="nump">570,645,405<span></span>
</td>
<td class="nump">380,784,846<span></span>
</td>
<td class="nump">327,631,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net loss per share</a></td>
<td class="nump">570,645,405<span></span>
</td>
<td class="nump">380,784,846<span></span>
</td>
<td class="nump">327,631,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609168864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
<td class="num">$ (116,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities</a></td>
<td class="nump">431<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (183,723)<span></span>
</td>
<td class="num">$ (141,947)<span></span>
</td>
<td class="num">$ (116,363)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219604387584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 210,947<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 1,366,188<span></span>
</td>
<td class="num">$ (1,155,629)<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,566,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(116,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs</a></td>
<td class="nump">20,385<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">20,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,571,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection exercise of warrants</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares', window );">Issuance of common stock in connection exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,906,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">8,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">126,416<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">1,398,006<span></span>
</td>
<td class="num">(1,271,741)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,731,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(141,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</a></td>
<td class="nump">69,916<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">69,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection exercise of warrants</a></td>
<td class="nump">15,163<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">15,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares', window );">Issuance of common stock in connection exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,663,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 79,998<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">1,493,469<span></span>
</td>
<td class="num">(1,413,642)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="nump">390,262,524<span></span>
</td>
<td class="nump">390,262,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</a></td>
<td class="nump">213,337<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">213,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection exercise of warrants</a></td>
<td class="nump">105,912<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">105,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares', window );">Issuance of common stock in connection exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,349,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">13,070<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">13,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,255,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">18,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 247,949<span></span>
</td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">$ 1,844,988<span></span>
</td>
<td class="num">$ (1,597,769)<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="nump">544,912,215<span></span>
</td>
<td class="nump">544,912,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares issued during the period in connection with exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued in connection with exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering stock issued during period value new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613607728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember', window );">Public Offering of Common Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 14,507<span></span>
</td>
<td class="nump">$ 5,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613693120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
<td class="num">$ (116,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and amortization on investments, net</a></td>
<td class="num">(11,150)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs/debt discount</a></td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Net gain on exchange and sales of equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation for services by non-employees</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation for employees and directors</a></td>
<td class="nump">18,526<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables', window );">Interest and other receivables</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="num">(1,381)<span></span>
</td>
<td class="num">(1,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid and other current assets</a></td>
<td class="num">(886)<span></span>
</td>
<td class="num">(2,630)<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposit and other assets</a></td>
<td class="nump">692<span></span>
</td>
<td class="num">(594)<span></span>
</td>
<td class="num">(3,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4,029)<span></span>
</td>
<td class="nump">3,503<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">7,208<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">14,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(640)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
<td class="num">(509)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(167,743)<span></span>
</td>
<td class="num">(127,379)<span></span>
</td>
<td class="num">(95,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(830)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(475,594)<span></span>
</td>
<td class="num">(258,007)<span></span>
</td>
<td class="num">(177,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">296,102<span></span>
</td>
<td class="nump">320,505<span></span>
</td>
<td class="nump">247,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities', window );">Proceeds from sales of equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(180,322)<span></span>
</td>
<td class="nump">62,067<span></span>
</td>
<td class="nump">71,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuances of common stock from equity plans</a></td>
<td class="nump">13,072<span></span>
</td>
<td class="nump">2,185<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs</a></td>
<td class="nump">213,337<span></span>
</td>
<td class="nump">69,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock from at market offerings, net of paid issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">105,912<span></span>
</td>
<td class="nump">15,163<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt financing, net of paid debt issuance costs and debt discounts</a></td>
<td class="nump">29,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,895<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">362,021<span></span>
</td>
<td class="nump">87,264<span></span>
</td>
<td class="nump">48,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">13,929<span></span>
</td>
<td class="nump">21,974<span></span>
</td>
<td class="nump">24,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">57,209<span></span>
</td>
<td class="nump">35,235<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">$ 71,138<span></span>
</td>
<td class="nump">$ 57,209<span></span>
</td>
<td class="nump">$ 35,235<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of unrealized losses and exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due for interest payments related to marketable securities and in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from public offering issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of other assets recognized in investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219612133040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
<td class="num">$ (116,112)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609017264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Arrangements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our last fiscal quarter, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:26%;"></td>
      <td style="width:12%;"></td>
      <td style="width:11%;"></td>
      <td style="width:14%;"></td>
      <td style="width:13%;"></td>
      <td style="width:9.72%;"></td>
      <td style="width:14.28%;"></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="border-top:0.5pt solid;padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Character of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Title</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Action</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rule 10b5-1*</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-Rule 10b5-1</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">**</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Shares to be Sold</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Date</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Faye Feller, M.D.</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:10.8pt;margin-top:0;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President and</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p><p style="text-indent:10.8pt;margin-top:0;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Medical Officer</span></p></div></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Termination</span></span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">1</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 25, 2023</span></span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,000</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 12, 2024</span></span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="7" style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td colspan="7" style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">** "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect when adopted on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Faye Feller, M.D.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">ExecutiveVice President and Chief Medical Officer<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">January 13, 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">October 25, 2023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">365 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">January 12, 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect when adopted on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading arrangement expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610636896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="note_1_" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms &#8220;Geron&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; and &#8220;us&#8221; as used in this report refer to Geron Corporation, which was incorporated in the State of Delaware on November 28, 1990, and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. Geron UK was incorporated in September 2021, and its operations commenced in January 2022. Geron Netherlands was incorporated in February 2023, and its operations commenced in June 2023.  We are a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, an innovative therapeutic for hematologic malignancies. We have global rights to imetelstat, an investigational first-in-class telomerase inhibitor, which was discovered and developed at Geron. Principal activities to date have included obtaining financing, securing operating facilities and conducting research and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. The resultant translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#8217; equity, on our consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,095,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,335,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. In January 2023, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68,007,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2023 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 9 on Stockholders' Equity for further discussion of our public offerings.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2023, 2022, and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the diluted net loss per share calculation excludes potential dilutive securities of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,458,854</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145,726,765</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,725,875</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations. We recognize a charge when the declines in the fair values below the amortized cost bases of our available for sale securities are judged to be other than temporary. We consider various factors in determining whether to recognize an other than temporary charge, including whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. Declines in market value judged as other than temporary result in a charge to interest income. We have not recorded any other&#8209;than&#8209;temporary impairment charges on our available&#8209;for&#8209;sale securities for the years ended December 31, 2023, 2022 and 2021. See Note 2 on Fair Value Measurements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure our investment in equity securities at fair value at each reporting date. Changes in fair value resulting from observable price changes are included in change in fair value of equity investment and changes in fair value resulting from foreign currency translation are included in other expense on our consolidated statements of operations.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current imetelstat clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and Amortization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record property and equipment at cost and calculate depreciation using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 9 on Stockholders&#8217; Equity.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#8217; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive management team represents our chief decision maker. We view our operations as a single segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued and Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2018-19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2018-19, for the purpose of clarifying certain aspects of ASU 2016-13. In May 2019, the FASB issued ASU 2019-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Targeted Transition Relief</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2019-05, to provide entities with more flexibility in applying the fair value option on adoption of the credit impairment standard. In November 2019, the FASB issued ASU 2019-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosure. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. ASU 2018-19, ASU 2019-05 and ASU 2019-11 have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 became effective for fiscal years beginning after December 15, 2022, using a modified retrospective approach, for smaller reporting companies. Early adoption is permitted. We adopted ASU 2016-13 and related updates as of January 1, 2023. The adoption of this standard did not have a material impact on our financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610636896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.869%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,201</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,598</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,268</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,409</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">402</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,974</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at December 31, 2022 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.869%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,142</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">247</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.44%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored <br/>&#160;&#160;&#160;enterprise securities <br/>&#160;&#160;&#160;(due in less than <br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury <br/>&#160;&#160;&#160;securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities <br/>&#160;&#160;&#160;(due in less than a year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored <br/>&#160;&#160;&#160;enterprise securities <br/>&#160;&#160;&#160;(due in less than <br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,962</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,721</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gross unrealized losses related to U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of December 31, 2023 and 2022 were due to changes in interest rates and not credit risk. We determined that the gross unrealized losses on our cash equivalents and marketable securities as of December 31, 2023 and 2022 were temporary in nature. Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflict between Ukraine and Russia, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We review our investments quarterly to identify and evaluate whether any investments have indications of possible other-than-temporary impairment. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. We currently do not intend to sell these securities before recovery of their amortized cost bases.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value on a Recurring Basis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We categorize financial instruments recorded at fair value on our consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:1.84%;"></td>
      <td style="width:7%;"></td>
      <td style="width:1%;"></td>
      <td style="width:90.16%;"></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 3</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 and indicates the fair value category assigned.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.040000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.86%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Active Markets for</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,742</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,742</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,268</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,268</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,930</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,974</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.074%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in restricted cash on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in current portion of marketable securities on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in noncurrent portion of marketable securities on our consolidated balance sheets.</span></div></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Investment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2007, we received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,842,625</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares in Sienna Cancer Diagnostics Limited, or Sienna, in connection with a license we granted to them for our hTERT technology for use in human diagnostics. The shares, which represented less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership, were recorded at a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cost basis under the cost method of accounting, upon receipt. Since the adoption of ASU 2016-01 on January 1, 2018, we reassessed the fair value of our equity investment in Sienna at each reporting date and any resulting change in fair value was recognized on our consolidated statements of operations. In April 2020, Sienna announced its merger with BARD1 Life Sciences Limited, or BARD1, subject to approval by Sienna&#8217;s shareholders. Effective August 3, 2020, the merger was complete, and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we received 13 BARD1 shares for every five shares of Sienna ordinary shares, resulting in our ownership of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,990,825</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of BARD1.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the first quarter of 2021, we sold all of our holdings in BARD1 and recognized a net gain of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,233,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the sales, including gains from foreign currency translation adjustments, which has been included in other income and expense on our consolidated statements of operations. As of March 31, 2021, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> value remained for our equity investment in BARD1.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple institutions in the United States. Generally, these deposits may be redeemed upon demand and therefore, bear minimal risk. Deposits with banks may exceed the amount of insurance provided on such deposits. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, government-sponsored enterprise securities, U.S. Treasury securities, municipal securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. However, we are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents to the extent recorded in our consolidated balance sheets. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk of our financial position at the depository institutions in which those deposits are held.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610750368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. PROPERTY AND EQUIPMENT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, stated at cost, is comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.6%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.48%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,273</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,554</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219615036688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LicenseAgreementDisclosureAbstract', window );"><strong>License Agreement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">LICENSE AGREEMENT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. LICENSE AGREEMENT</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Janssen Pharmaceuticals, Inc. License Agreement</span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 15, 2016, we entered into the License Agreement with Janssen Pharmaceuticals whereby we granted to Janssen Pharmaceuticals an exclusive worldwide license, or the Exclusive License, under our proprietary patents for the research, development and commercialization of products based on specialized oligonucleotide backbone chemistry and novel amidates for ribonucleic acid interference. In addition to the Exclusive License, we granted to Janssen Pharmaceuticals a non&#8209;exclusive worldwide license, or the Non&#8209;Exclusive License, under our patents covering the synthesis of monomers. This agreement was terminated effective April 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LicenseAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LicenseAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610513488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. ACCRUED LIABILITIES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.272%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.363%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.363%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CRO and clinical trial costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing activities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,629</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional legal and accounting fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,668</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610477744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purported Securities Lawsuits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed. The other two lawsuits, filed in the U.S. District Court for the Northern District of California, were consolidated by the court. In September 2022, the parties agreed to a settlement and entered into a Stipulation and Agreement of Settlement, which was subject to court approval. The court granted final approval of the settlement on September 28, 2023 and final judgment was entered on October 3, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the consolidated class action complaint, we agreed to pay and/or to cause our insurance carriers to pay a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash, which was paid into an escrow account under our available D&amp;O insurance coverage and, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash which was paid after final approval of the settlement by the court. The settlement does not constitute an admission of fault or wrongdoing by Geron or any of our officers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As of December 31, 2022, our portion of the settlement amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> had been included in accrued liabilities on our consolidated balance sheets and recognized as general and administrative expense on our consolidated statements of operations for the year ended December 31, 2022. Our portion of the settlement amount was paid in the fourth quarter of 2023. There is no liability outstanding as of December 31, 2023 as the matter was fully settled during the year ended December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  On December 21, 2022, the parties to the shareholder derivative action filed in the Delaware Court of Chancery entered into a stipulation of settlement, or the Derivative Stipulation, and on May 17, 2023, the Delaware Court of Chancery approved the Derivative Stipulation, and the case was dismissed with prejudice.  Subsequently, each of the remaining derivative cases were dismissed with prejudice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Derivative Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the consolidated shareholder derivative actions filed in the Northern District, we agreed to pay and/or to cause our insurance carriers to pay a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, comprised of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">525,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash, which was payable under our available D&amp;O insurance coverage and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">825,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash payable by us. The settlement does not constitute an admission of fault or wrongdoing by any of our officers or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">members of our board. As of December 31, 2022, we had recorded the total settlement amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as accrued liabilities and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">525,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as interest and other receivables on our consolidated balance sheets. For the year ended December 31, 2022, we had recognized our portion of the settlement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">825,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as general and administrative expense on our consolidated statements of operations. In the second quarter of 2023, our insurance carriers paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">525,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cash,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">825,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in cash, for an aggregate total payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Accordingly, there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding amount to settle against this as of December 31, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of any additional lawsuits, and we may not prevail. In addition, we have and may continue to incur substantial legal fees and costs in connection with such lawsuits. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive, and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Expenses associated with any potential future lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. We have not established any reserve for any potential liability relating to any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnifications to Officers and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Severance Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> severance plans that apply to all of our employees who are not subject to performance improvement plans, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> plan covering employees above the Vice President level, i.e., executives, and all other employees hired before January 1, 2022, and the other plan covering all non-executive employees hired on or after January 1, 2022.  The severance plans provide for, among other benefits: (i) a severance payment upon a Change of Control Triggering Event and Separation from Service and (ii) a severance payment for each non&#8209;executive employee upon a Non&#8209;Change of Control Triggering Event and Separation from Service. As defined in the severance plans, a Change of Control Triggering Event and Separation from Service requires a &#8220;double trigger&#8221; where: (i) an employee is terminated by us without cause in connection with a change of control or within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months following a change of control provided, however, that if an employee is terminated by us in connection with a change of control but immediately accepts employment with our successor or acquirer, the employee will not be eligible for the benefits outlined in the plans, (ii) an employee resigns because in connection with a change of control, the offered terms of employment (new or continuing) by us or our successor or acquirer within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> days after the change of control results in a material change in the terms of employment, or (iii) after accepting (or continuing) employment with us after a change of control, an employee resigns within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months following a change of control due to a material change in the terms of employment. Under the severance plans, a Non&#8209;Change of Control Triggering Event and Separation from Service is defined as an event where an employee is terminated by us without cause. Severance payments range from</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_b8827fb4-805f-47b4-9575-17566fb60e0f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months of base salary in connection with a Change of Control Triggering Event or from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0194cff7-90da-4ed5-a176-f5577cc6d08c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six weeks</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of base salary in connection with a Non-Change of Control Triggering Event, as well as a pro-rata portion of the employee&#8217;s annual target bonus, depending on the employee&#8217;s position with us, payable in a lump sum payment, and monthly COBRA payments for the severance period. The severance plans also provide that they shall not supersede the provisions of any individual employment agreements entered into between us and our employees, and that the employees with such agreements will be entitled to whichever benefits are greater under the severance plan or their employment agreement. A copy of the severance plan covering our executive officers is filed as an exhibit to our annual report on Form 10-K. As of December 31,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">all our executive officers have employment agreements with severance provisions and will receive the greater severance benefits of their agreements or those in the severance plan applicable to them.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610475744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. OPERATING LEASES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New Jersey Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one-time option to terminate the New Jersey Lease without cause as of the 103</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">rd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> month anniversary of the commencement date of the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date. Based on the initial term of the New Jersey Lease of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, the right-of-use asset and corresponding operating lease liability was approxima</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,356,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hich represented the present value of lease pay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ments over the initial lease term, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rent abatement period, using an incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% based o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n information available as of October 1, 2019. Under the New Jersey Lease, we are also obligated to pay certain variable expenses separately from the base rent, including electricity and common area maintenance. Such costs are being expensed in the period they are incurred. As of December 31, 2023, the remaining lease term for the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.8 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ye</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ars.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foster City Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foster City Lease commenced on March 10, 2020, upon the substantial completion of all tenant improvements. As of the l</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ease commencement date, the right-of-use asset and corresponding operating lease liability was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,868,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, wh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ich represented the present value of remaining lease payments using an incremental borro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">wing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% over the initial lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> rent abatement period. Under the Foster City Lease, we are also obligated to pay certain variable expenses separately from the base rent, including taxes and common area maintenance. Such costs are considered non-lease components and have been excluded from the calculation of the right-of-use asset and corresponding operating lease liability and are being expensed in the period they are incurred. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, the remaining lease term for the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.5 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, the Foster City Lease and a lease from a former location in Menlo Park, California, were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:19.516%;"></td>
        <td style="width:22.555%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.296999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.639%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.077%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.259%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.657%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">962</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">944</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,306</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,198</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:10%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:60%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div><div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.588888888888889%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable lease costs represent non-lease components, such as common area maintenance charges.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.686%;"></td>
        <td style="width:2.857%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.457%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">716</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">376</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">675</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,808</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">853</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,955</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610513488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. DEBT</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 30, 2020, or the Closing Date, we, Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, or SVB, entered into a term loan facility, or the Term Loan, up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was amended in August 2021, or the Original Loan Agreement. On June 30, 2022, we entered into a second amendment to the Original Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with such principal being available in a series of tranches, subject to certain terms and conditions. On December 14, 2023, we entered into a third amendment to the Original Loan Agreement, or as amended, the Loan Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million has been drawn under the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On the effective date of the second amendment, we paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a facility charge that we recognized as a debt discount and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method. Additional facility charges applied to future draw downs will be treated similarly. We also incurred legal fees in connection with the second amendment, which we recognized as debt issuance costs and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the third amendment, the aggregate principal amount drawn down and remaining available to us under the Term Loan remains at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with such principal being available in a series of tranches, subject to certain terms and conditions. The third amendment also provides that (i) the fourth tranche of the Term Loan was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, (ii) the commitment period for the fifth tranche of the Term Loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is available subject to achievement of a regulatory milestone and satisfaction of certain capitalization requirements, was extended through December 15, 2024, (iii) the variable annual interest rate on the outstanding loans has been decreased to the greater of: (x) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, or (y) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, plus (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%; and (iv) the interest only period of the Term Loan has been extended through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. In connection with the third amendment, on the third amendment effective date, we borrowed and received the entire fourth tranche of the Term Loan in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Afte</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r giving effect to such borrowing, the outstanding principal amount under the Loan Agreement is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On the effective date of the third amendment, we paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as a facility charge that we recognized as a debt discount and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method. Additional facility charges applied to future draw downs will be treated similarly. We also incurred legal fees in connection with the third amendment, which we recognize as debt issuance costs and amortize such cost to interest expense over the life of the loan using the effective interest rate method.  The third amendment of the Loan Agreement is not substantially different as compared to the Original Loan Agreement, and accordingly, we treated the amendment as a modification of the debt in accordance with ASC 470. On September 15, 2023, the third tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Term Loan expired and is no longer available for us, but was added to the fourth tranche as part of the third amendment to the Loan Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Term Loan as amended, the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term Loan matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or the Loan Maturity Date, and may be extended up to an additional six months upon the achievement of certain regulatory and financial milestones.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loan bears interest at a floating rate per annum equal to the greater of either (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or (ii) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, plus (B) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%  (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% as of December 31, 2023).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The interest only period of the Term Loan is through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. Following the expiration of the interest-only period, we are required to repay the Term Loan in equal monthly amortization payments of principal and interest until the Loan Maturity Date.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Upon </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">full repayment of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Term </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loan, we are also obligated to pay an end of term charge in an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.55</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the amount of the Term Loans actually borrowed. Such end of term charge is being accrued to interest expense over the term of the Term Loan using the effective interest rate method. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At our option, upon at least five business days&#8217; prior written notice to Hercules, we may prepay all or any portion greater than or equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the outstanding loan by paying the entire principal balance (or portion thereof) and all accrued and unpaid interest. There is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> prepayment charge for prepayments of drawdowns under Tranche 1 or Tranche 2.  Prepayments of drawdowns under Tranche 3, Tranche 4, Tranche 5 or Tranche 6 are subject to a prepayment charge of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the prepayment amount, if the prepayment is made prior to June 30, 2025. Thereafter, any prepayment of Tranche 3, Tranche 4, Tranche 5 or Tranche 6 is not subject to a prepayment charge.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Term Loan is secured by substantially all of Geron&#8217;s assets, except our intellectual property, which is the subject of a negative pledge. The Term Loan contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. We are in compliance with the covenants under the Term Loan as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event of default (subject, in certain instances, to specified grace periods), the principal, interest and any other monetary obligations on all then outstanding amounts under the Term Loan may become due and payable immediately. Upon the occurrence of an event of default, a default interest rate of an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% may be applied to the outstanding principal balance, and Hercules, as the administrative agent, may declare all outstanding obligations immediately due and payable (subject, in certain instances, to specified grace periods) and take such other actions as set forth in the Term Loan. Upon the occurrence of certain bankruptcy and insolvency events, the obligations under the Term Loan would automatically become due and payable.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Embedded Derivatives and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the net carrying value of the Term Loan was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hich includes the principal amount</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> less the net unamortized discounts and debt issuance costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">605,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> plus an accrued end of term charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,691,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value of the debt approximates the fair value as of December 31, 2023. The debt discounts and debt issuance costs are being amortized to interest expense over the life of loan amounts under Term Loan using the effective interest rate method.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future Minimum Payments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.552%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.698%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,066</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,262</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  amount representing interest</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,088</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  unamortized debt discount and issuance costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  unamortized end of term charge</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  current portion of debt</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent portion of debt</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610448880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Authorized Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023 our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">675,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public Offering</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 1, 2022, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">53,333,334</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,095,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2022 pre-funded warrant, together with accompanying warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,714,286</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, also known as the 2022 stock purchase warrants. The shares of common stock and the 2022 pre-funded warrant were immediately separable from the 2022 stock purchase warrants. All of the securities were issued separately. The combined public offering price of the common stock and accompanying 2022 stock purchase warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The 2022 stock purchase warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and are exercisable immediately. The term of the 2022 stock purchase warrants expired in the third quarter of 2023, pursuant to the terms of the warrant agreement.. The combined public offering price of the 2022 pre-funded warrant and accompanying 2022 stock purchase warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.049</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The 2022 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and may be exercised at any time until the 2022 pre-funded warrant is exercised in full. As of December 31, 2023, none of the 2022 pre-funded warrant and all of the 2022 stock purchase warrants have been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">69,916,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2022 pre-funded warrant and 2022 stock purchase warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the issuance of the 2022 pre-funded warrant and 2022 stock purchase warrants, we evaluated the terms of each warrant to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and FASB Accounting Standards Codification Topic 815,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2022 pre-funded warrant and the 2022 stock purchase warrants include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2022 pre-funded warrant and the 2022 stock purchase warrants should be classified as equity with no subsequent remeasurement as long as such warrants continue to be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2023 we completed an underwritten public offering consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68,007,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and the 2023 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The public offering price of the 2023 pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.449</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The 2023 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and may be exercised at any time until the 2023 pre-funded warrant is exercised in full. As of December 31, 2023, none of the 2023 pre-funded warrant has been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">213,337,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2023 pre-funded warrant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the issuance of the 2023 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and FASB Accounting Standards Codification Topic 815, Derivatives and Hedging. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2023 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2023 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrant Exercises</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">77,349,859</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,912,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The warrants were issued in connection with underwritten public offerings of common stock and pre-funded warrants, together with accompanying stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">purchase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warrants in May 2020, April 2022, and January 2023. As of December 31, 2023, the following warrants remained outstanding:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pre-funded warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">51,430,477</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, which have no expiration date; and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock purchase warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,474,503</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock related to the public offering of our common stock in May 2020, which expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,663,387</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,163,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The warrants were issued in connection with an underwritten public offering of common stock and a pre-funded warrant, together with accompanying stock purchase warrants in May 2020. As of December 31, 2022, the pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,335,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock was outstanding and stock purchase warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44,110,079</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock associated with the May 2020 public offering remained outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 4, 2020, we entered into an At Market Issuance Sales Agreement, or the 2020 Sales Agreement, with B. Riley Securities, Inc., or B. Riley, pursuant to which we were able to elect to issue and sell shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in such quantities and on such minimum price terms as we set from time to time through B. Riley as our sales agent. We agreed to pay B. Riley an aggregate commission rate equal to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2020 Sales Agreement. In connection with the 2020 Sales Agreement, we terminated the 2018 Sales </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreement. The 2020 Sales Agreement expired on September 4, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement with B. Riley, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from time to time through B. Riley as the sales agent. We have agreed to pay B. Riley an aggregate commission rate equal to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2023 Sales Agreement.  The 2023 Sales Agreement will automatically terminate upon the earlier of (i) the sale of all common stock subject to the 2023 Sales Agreement, or (ii) termination of the 2023 Sales Agreement in accordance with its terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2021, we sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,571,556</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock pursuant to the 2020 Sales Agreement, resulting in n</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">et cash proceeds to us of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting sales commissions and other offering expenses paid by us. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock were sold pursuant to the 2020 Sales Agreement or the 2023 Sales Agreement during the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2011 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2011, our stockholders approved the adoption of the 2011 Incentive Award Plan, or 2011 Plan. The 2011 Plan provided for grants of either incentive stock options or nonstatutory stock options and stock purchase rights to employees (including officers and employee directors) and consultants (including non&#8209;employee directors). Upon the adoption of the 2018 Equity Incentive Plan in May 2018 (see below), no further grants of stock options or stock purchase rights were made under the 2011 Plan. Stock options granted under the 2011 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Stock option exercise prices were equal to the fair market value of the underlying common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Service&#8209;based stock options under the 2011 Plan generally vested over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Other stock awards (restricted stock awards and restricted stock units) had variable vesting schedules which were determined by our board of directors on the date of grant. All outstanding awards granted under the 2011 Plan remain subject to the terms of the 2011 Plan and the individual award agreements thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 15, 2018, our stockholders approved the adoption of the 2018 Equity Incentive Plan, or 2018 Plan, as the successor to the 2011 Plan. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">awards that may be settled in cash, stock, or other property. Eligible participants under the 2018 Plan include our employees, consultants and non-employee directors. The number of shares reserved for issuance under the 2018 Plan (subject to adjustment for certain changes in capitalization) is equal to the sum of (i) the unallocated shares of common stock remaining available for grant under the 2011 Plan as of May 15, 2018, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> newly reserved shares of common stock and (iii) the number of shares subject to awards granted under the 2002 Equity Incentive Plan, and the 2011 Plan as such shares become available from time to time, referred to as the Prior Plans&#8217; Returning Shares. Such Prior Plans&#8217; Returning Shares become available for issuance under the 2018 Plan if outstanding stock awards granted under the 2002 Equity Incentive Plan and the 2011 Plan, after May 15, 2018, expire or terminate for any reason prior to exercise or settlement or are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or, subject to certain exceptions, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award. In May 2023, May 2022 and May 2021, our stockholders approved amendments to our 2018 Eq</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uity Incentive Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,360,000</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock options granted under the 2018 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. Stock option exercise prices shall be equal to the fair market value of the underlying common stock on the date of grant. If, at the time we grant a stock option, the optionee directly or by attribution owns stock possessing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total combined voting power of all classes of our stock, the stock option exercise price shall be at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the underlying common stock and shall not be exercisable more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We grant service-based and performance-based stock options to employees under the 2018 Plan. Service-based stock options generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of the stock option grant. Performance-based stock options vest upon the achievement of specified milestones. Other stock awards (restricted stock awards and restricted stock units) have variable vesting schedules as determined by our board of directors on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under certain circumstances, stock options may be exercised prior to vesting, subject to our right to repurchase the shares underlying such stock option at the exercise price paid per share. Our repurchase rights would generally terminate on a vesting schedule identical to the vesting schedule of the exercised stock option. During 2023 and 2022, we did not repurchase any shares under the 2018 Plan. As of December 31, 2023, we have no shares outstanding subject to repurchase under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our Non&#8209;Employee Director Compensation Policy adopted by our board of directors in March 2014, as amended and restated in February and March 2022, provides for the automatic grant to non&#8209;employee directors of the following types of equity awards under the 2018 Plan:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">First Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Each person who becomes a non&#8209;employee director, whether by election by our stockholders or by appointment by our board of directors to fill a vacancy, will automatically be granted a stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, or First Director Option, on the date such person first becomes a non&#8209;employee director. The First Director Option vests annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon each anniversary date of appointment to our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsequent Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  Each non&#8209;employee director (other than any director receiving a First Director Option on the date of the annual meeting) will automatically be granted a subsequent stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">125,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, a Subsequent Director Option, on the date of the annual meeting of stockholders in each year during such director&#8217;s service on our board of directors. The Subsequent Director Option vests in full on the earlier of: (i) the date of the next annual meeting of our stockholders or (ii) the first anniversary of the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2006 Directors&#8217; Stock Option Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2006 Directors&#8217; Stock Option Plan, or 2006 Directors Plan, was terminated by our board of directors and replaced by the 2011 Plan in March 2014. No further grants of stock options were made from the 2006 Directors Plan upon the 2006 Directors Plan&#8217;s termination. All outstanding awards granted under the 2006 Directors Plan remain subject to the terms of the 2006 Directors Plan and the individual award agreements thereunder.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock options granted to non-employee directors under the 2006 Directors Plan were nonstatutory stock options, and they expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant. The option exercise price was equal to the fair market value of the underlying common stock on the date of grant. The first director option granted to non-employee directors under the 2006 Directors Plan vested annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> upon each anniversary date of appointment to the board of directors. The subsequent director option granted to non-employee directors on the date of the annual meeting of stockholders in each year during such director&#8217;s service on our board of directors under the 2006 Directors Plan vested </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, our board of directors approved the adoption of the 2018 Inducement Award Plan, or the Inducement Plan, pursuant to which we reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock to be used exclusively for grants of inducement awards to individuals who were not previously Geron employees or non-employee directors, other than following a bona fide period of non-employment.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the compensation committee of our board of directors approved amendments to our 2018 Inducement Award Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13,900,000</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock. As of December 31, 2023, an aggregate total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32,306,638</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock have been reserved under the Inducement Plan, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,616,841</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> available for grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards, and all awards under the Inducement Plan are intended to meet the standards under Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved 2018 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Directors&#8217; Market Value Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2018, our board of directors adopted a Directors&#8217; Market Value Stock Purchase Plan, or the Directors Market Plan. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock have been reserved for the Directors Market Plan. Under the Directors Market Plan, non-employee directors may purchase shares of our common stock at the prevailing market price on the purchase date with cash compensation payable to them for their services as a board member. As stated in Geron&#8217;s Non-Employee Director Compensation Policy, each non-employee director receives annual cash compensation, payable quarterly in arrears, for their services on the board and various committees of the board. As provided in the Non-Employee Director Compensation Policy, a non-employee director may elect to receive fully vested shares of common stock in lieu of cash and such shares shall be issuable from the Directors Market Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the years ended December 31, 2023, 2022 and 2021, we issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,864</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,962</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,783</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, respectively, under the Directors Market Plan. The weighted average grant date fair value of stock granted during the years ended December 31, 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. The total fair value of vested stock grants during 2023, 2022 and 2021 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, 2006 Directors Plan, Inducement Plan and Directors Market Plan is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.994%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.117%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.977%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.918%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Available</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual Life</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,370,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,902,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">56,368,058</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,855,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,855,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Awards granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,869,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options cancelled/forfeited/expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,903,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,903,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">58,750,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">72,984,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.70</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,391,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercisable at <br/>&#160;&#160;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,995,642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.28</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,557,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options fully vested and expected<br/>&#160;&#160;&#160;&#160;to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,983,176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.67</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,169,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,936,030</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> perfo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rmance-based stock options granted that have not achieved the specified performance milestones.</span></div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on Geron&#8217;s closing stock price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, which would have been received by the option holders had all the option holders exercised their stock options as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not granted any stock options with an exercise price below or greater than the fair market value of our common stock on the date of grant in 2023, 2022, and 2021. As of December 31, 2023, 2022 and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,995,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,085,389</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30,459,136</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> exercisable stock options outstanding at weighted average exercise prices per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total pretax intrinsic value of stock options exercised during 2023, 2022, and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,986,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">787,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">93,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Cash received from the exercise of stock options in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 totaled approximatel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">y $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,356,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,799,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">556,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2014, our board of directors adopted the 2014 Employee Stock Purchase Plan, or 2014 Purchase Plan. The 2014 Purchase Plan was approved by our stockholders in May 2014. The 2014 Purchase Plan replaced the 1996 Employee Stock Purchase Plan, or 1996 Purchase Plan, which was terminated effective as of the date the 2014 Purchase Plan was approved by our stockholders. In May 2022, our stockholders approved an amendment to our 2014 Purchase Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, for an aggregate total reserve of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,254,162</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock have been issued under the 2014 Purchase Plan since its adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2014 Purchase Plan is comprised of a series of offering periods, each with a maximum duration (not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months) with new offering periods commencing on January 1st and July 1st of each year. The date an employee enters the offering period will be designated as the entry date for purposes of that offering period. An employee may participate only in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> offering period at a time. Each offering period consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive purchase periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8217; duration, with the last day of such period designated a purchase date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the 2014 Purchase Plan, employees can choose to have up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of their annual salary withheld to purchase our common stock, up to a limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per year. An employee may not make additional payments into such account or increase the withholding percentage during the offering period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purchase price per share at which common stock is purchased by the employee on each purchase date within the offering period is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the lower of (i) the fair market value per share of our common stock on the employee&#8217;s entry date into that offering period or (ii) the fair market value per share of our common stock on the purchase date. If the fair market value per share of our common stock on the purchase date is less than the fair</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">value at the beginning of the offering period, a new </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> month offering period will automatically begin on the first business day following the purchase date with a new fair market value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation for Employees and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure and recognize compensation expense for all share&#8209;based payment awards made to employees and directors, including employee stock options, restricted stock awards and employee stock purchases, based on grant&#8209;date fair values for these instruments. We use the Black-Scholes option&#8209;pricing model to estimate the grant&#8209;date fair value of our service-based and performance-based stock options and employee stock purchases. The fair value for service&#8209;based restricted stock awards is determined using the fair value of our common stock on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As stock&#8209;based compensation expense recognized on the consolidated statements of operations for the years ended December 31, 2023, 2022 and 2021 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures, but at a minimum, reflects the grant&#8209;date fair value of those awards that actually vested in the period. Forfeitures have been estimated at the time of grant based on historical data and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, 2022 and 2021, our board of directors awarded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">832,790</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,741,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">550,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> perform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ance-based stock options, respectively, to certain employees. These performance-based stock options are included in the outstanding stock options table above. Performance-based stock options vest only upon achievement of discrete milestones. Stock-based compensation expense for performance-based stock options is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being achieved, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize stock&#8209;based compensation expense for service-based stock options on a straight&#8209;line basis over the requisite service period, which is generally the vesting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,167,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2023. We did not recognize any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended Dec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ember 31, 2022 and 2021, as the achievement of the specified milestones was not considered probable during that time. </span><span style="font-size:11pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the stock&#8209;based compensation expense related to service-based stock options and employee stock purchases for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021, which was allocated as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.512%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.728%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.728%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.278%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,099</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,483</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense<br/>&#160;&#160;&#160;included in operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 has been estimated at the date of grant using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.5%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.25%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.25%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.25%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.815</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.827</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.772</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.817</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.775</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.783</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.42</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.69</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.51</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.30</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of employee stock purchases in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 has been estimated using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:22.5%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.8%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.95%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.791</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.832</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.614</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.865</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.507</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.707</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.73</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.40</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.79</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.09</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.16</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend yield is based on historical cash dividend payments and we have paid no cash dividends to date. The expected volatility range is based on historical volatilities of our stock, since traded options on our common stock do not correspond to option terms and the trading volume of options is limited. The risk&#8209;free interest rate range is based on the U.S. Zero Coupon Treasury Strip Yields for the expected term in effect on the date of grant for an award. The expected term of stock options is derived from actual historical exercise and post&#8209;vesting cancellation data and represents the period of time that stock options granted are expected to be outstanding. The expected term of employees&#8217; purchase rights is equal to the purchase period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the Black-Scholes option&#8209;pricing model, the weighted-average estimated fair value of stock options granted during the years ended December 31, 2023, 2022 and 2021 w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share, respectively. The weighted average estimated fair value of employees&#8217; purchase rights for the years ended December 31, 2023, 2022 and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.56</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, total compensation cost related to unvested share&#8209;based payment awards not yet recognized, net of estimated forfeitures and as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suming no probability of achievement for outstanding performance-based stock options, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">37,628,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, whi</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ch is expected to be recognized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months on a weighted&#8209;average basis.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation to Service Providers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We grant stock options to consultants from time to time in exchange for services performed for us. In general, the stock options vest over the contractual period of the consulting arrangement. The fair value of stock options held by consultants is recorded as operating expenses over the vesting term of the respective equity awards. With the adoption of Accounting Standards Update 2018-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2018-07, in the first quarter of 2019, the measurement date of stock options granted to consultants was fixed at the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recorded stock&#8209;based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">742,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">235,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the vest</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ed portion of the fair value of stock options held by consultants in 2023, 2022, and 2021, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.133%;"></td>
        <td style="width:1.667%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.201%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,984,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and awards available for grant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,750,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">745,838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,904,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">186,385,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610533904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. INCOME TAXES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.28%;"></td>
        <td style="width:5.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.1%;"></td>
        <td style="width:4.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.28%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss not benefitted</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of our deferred tax assets are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">395,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:15pt;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial performance. Forming a conclusion that a valuation allowance is not required is difficult when there is negative evidence such as cumulative losses in recent years. Because of our history of losses, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had domestic federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion. Of this, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">635.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will expire at various dates beginning in 2024 through 2037 and the remaining will carryforward indefinitely under the new tax laws, but is subject to an 80% taxable income limitation for tax years beginning after 2020. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">841.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expiring at various dates beginning in 2028 through 2043, if not utilized. We also had federal tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">72.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million expiring at various dates beginning in 2024 through 2043, if not utilized. Our state tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million carry forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized. The impact of any limitations that may be imposed due to such ownership changes has not yet been determined. Due to the Company's stock issuance in January 2023, the utilization of the Company's net operating loss and tax credit carryforwards are subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation may result in the expiration of the net operating loss and tax credit carryforwards before some or call of such amounts have been utilized. The final amount of the limitations imposed due to such ownership changes has not yet been determined.</span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March and December 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic, including among other items, several U.S. income tax provisions related to, among other things, net operating loss carrybacks, alternative minimum tax credits, modifications to interest expense limitations, and an option to defer payroll tax payments for a limited period. In 2021, we assessed our eligibility to claim a refund of employer taxes available under the Employee Retention Credit provisions of the CARES Act. For the years ended December 31, 2022 and 2021, we calculated eligible credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">483,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, provided by the CARES Act, which have been recognized as offsets to salaries costs in operating expenses in 2022 and 2021, respectively. As of December 31, 2022, the aggregate eligible credit amount has been accrued as a receivable on our consolidated balance sheets. We received the Employee Retention Credit from the IRS, and there are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding receivables as of December 31, 2023.</span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We adopted the provision of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, we recognized no material adjustment in the liability for unrecognized tax benefits. At December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized tax benefits, none of which would currently affect our effective tax rate if recognized due to our net deferred tax assets being fully offset by a valuation allowance.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If applicable, we would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2023, there has been no interest expense or penalties related to unrecognized tax benefits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently expect any significant changes to unrecognized tax benefits during the fiscal year ended December 31, 2023. In certain cases, our uncertain tax positions are related to tax years that remain subject to examination by the relevant tax authorities. Tax years for which we have carryforward net operating loss and credit attributes remain subject to examination by federal and most state tax authorities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610407248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.291%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.437000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental operating and investing activities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net unrealized loss on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Reclassification between prepaid and other<br/>&#160;&#160;&#160;current assets and deposits and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609059680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. The resultant translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#8217; equity, on our consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,095,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,335,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. In January 2023, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68,007,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of our common stock, or the 2023 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 9 on Stockholders' Equity for further discussion of our public offerings.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2023, 2022, and 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the diluted net loss per share calculation excludes potential dilutive securities of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75,458,854</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145,726,765</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105,725,875</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations. We recognize a charge when the declines in the fair values below the amortized cost bases of our available for sale securities are judged to be other than temporary. We consider various factors in determining whether to recognize an other than temporary charge, including whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. Declines in market value judged as other than temporary result in a charge to interest income. We have not recorded any other&#8209;than&#8209;temporary impairment charges on our available&#8209;for&#8209;sale securities for the years ended December 31, 2023, 2022 and 2021. See Note 2 on Fair Value Measurements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure our investment in equity securities at fair value at each reporting date. Changes in fair value resulting from observable price changes are included in change in fair value of equity investment and changes in fair value resulting from foreign currency translation are included in other expense on our consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Debt Discounts</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Licenses of Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current imetelstat clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock', window );">Depreciation and Amortization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation and Amortization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We record property and equipment at cost and calculate depreciation using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 9 on Stockholders&#8217; Equity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Accumulated Other Comprehensive Gain (Loss)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated Other Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#8217; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive management team represents our chief decision maker. We view our operations as a single segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued and Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2018-19, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2018-19, for the purpose of clarifying certain aspects of ASU 2016-13. In May 2019, the FASB issued ASU 2019-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Targeted Transition Relief</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASU 2019-05, to provide entities with more flexibility in applying the fair value option on adoption of the credit impairment standard. In November 2019, the FASB issued ASU 2019-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosure. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. ASU 2018-19, ASU 2019-05 and ASU 2019-11 have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 became effective for fiscal years beginning after December 15, 2022, using a modified retrospective approach, for smaller reporting companies. Early adoption is permitted. We adopted ASU 2016-13 and related updates as of January 1, 2023. The adoption of this standard did not have a material impact on our financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219614336064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of cash equivalents, restricted cash and marketable securities by security type</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.869%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,115</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,752</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,847</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,894</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86,201</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,598</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,268</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,409</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,628</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">402</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,974</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at December 31, 2022 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.869%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.882%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cost</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gains</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,771</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market fund</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,983</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,860</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,285</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116,142</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">247</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of cash equivalents and marketable securities with unrealized losses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.44%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.5%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored <br/>&#160;&#160;&#160;enterprise securities <br/>&#160;&#160;&#160;(due in less than <br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,952</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166,518</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury <br/>&#160;&#160;&#160;securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,497</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities <br/>&#160;&#160;&#160;(due in less than a year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored <br/>&#160;&#160;&#160;enterprise securities <br/>&#160;&#160;&#160;(due in less than <br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,454</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,962</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,721</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,435</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial instruments measured at fair value on recurring basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 and indicates the fair value category assigned.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.96%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.040000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.86%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Active Markets for</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant Other</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identical Assets</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Observable Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Inputs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,742</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,742</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,268</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,268</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,092</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,930</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">306,974</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324,904</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Municipal securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,846</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,199</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,901</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">156,036</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in cash and cash equivalents on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in restricted cash on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in current portion of marketable securities on our consolidated balance sheets.</span></div></div><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Included in noncurrent portion of marketable securities on our consolidated balance sheets.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610505200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, stated at cost</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, stated at cost, is comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.6%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.48%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.48%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,273</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,554</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">135</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">896</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,177</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219611838816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.272%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.363%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.363%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CRO and clinical trial costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing activities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,629</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional legal and accounting fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">556</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,668</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">561</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">814</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610466384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease costs</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, the Foster City Lease and a lease from a former location in Menlo Park, California, were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:19.516%;"></td>
        <td style="width:22.555%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.296999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.639%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.077%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.259%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.657%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">962</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">944</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">946</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">344</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,306</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,198</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.588888888888889%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable lease costs represent non-lease components, such as common area maintenance charges.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Undiscounted future non-cancellable lease payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.686%;"></td>
        <td style="width:2.857%;"></td>
        <td style="width:1%;"></td>
        <td style="width:26.457%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">987</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,014</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,040</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">716</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">376</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">675</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,808</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">853</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,955</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610494112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Minimum Payments Under Term Loan Facility</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.552%;"></td>
        <td style="width:12.75%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.698%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,066</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,262</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  amount representing interest</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,088</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  unamortized debt discount and issuance costs</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">605</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  unamortized end of term charge</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,691</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less:  current portion of debt</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,893</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Noncurrent portion of debt</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219612025632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of aggregate stock option and award activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, 2006 Directors Plan, Inducement Plan and Directors Market Plan is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.994%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.117%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.977%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.918%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding Stock Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Available</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual Life</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For Grant</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Per Share</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">18,370,729</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">65,902,400</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">56,368,058</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,855,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">20,855,230</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Awards granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">36,864</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,869,302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.39</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options cancelled/forfeited/expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,903,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,903,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">58,750,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">72,984,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.70</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,391,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options exercisable at <br/>&#160;&#160;December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">39,995,642</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.28</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">15,557,976</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options fully vested and expected<br/>&#160;&#160;&#160;&#160;to vest at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">71,983,176</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.67</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,169,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Include</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,936,030</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> perfo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rmance-based stock options granted that have not achieved the specified performance milestones.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of allocation of stock-based compensation expense related to share-based payment awards</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the stock&#8209;based compensation expense related to service-based stock options and employee stock purchases for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023, 2022 and 2021, which was allocated as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.512%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.728%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.728%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.278%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,426</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,720</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,099</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,281</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,483</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense<br/>&#160;&#160;&#160;included in operating expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,525</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,001</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,080</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate the fair value of stock options granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 has been estimated at the date of grant using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.5%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.25%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.25%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.25%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.815</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.827</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.772</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.817</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.775</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.783</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.42</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.69</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.51</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.30</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;yrs</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of employee stock purchases in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023, 2022, and 2021 has been estimated using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:22.5%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.8%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:16.95%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.791</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.832</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.614</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.865</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.507</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.707</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.73</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.40</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.79</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.09</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.16</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term range</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;mos</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of common stock reserved for future issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.133%;"></td>
        <td style="width:1.667%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.201%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,984,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options and awards available for grant</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,750,670</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">745,838</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53,904,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">186,385,839</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock reserved for future issuance, which may include but is not limited to outstanding options and outstanding warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219614323904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule reconciles the federal statutory tax rate to the effective income tax rate from continuing operations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.28%;"></td>
        <td style="width:5.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.1%;"></td>
        <td style="width:4.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.28%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss not benefitted</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the entity's deferred tax assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant components of our deferred tax assets are as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">272,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,800</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">396,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">395,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">349,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:15pt;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,600</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,300</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608844672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental schedule of non-cash operating and investing activities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.291%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.437000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.437000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2021</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental operating and investing activities:</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net unrealized loss on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">431</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Reclassification between prepaid and other<br/>&#160;&#160;&#160;current assets and deposits and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest paid</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,017</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,704</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608907776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>May 27, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering</a></td>
<td class="nump">68,007,741<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Public Offering of Common Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,095,238<span></span>
</td>
<td class="nump">8,335,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,095,238<span></span>
</td>
<td class="nump">8,335,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember', window );">2023 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember', window );">2023 Pre-funded Warrant | 2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219611801584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options and warrants excluded from diluted net loss per share calculation due to net loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)</a></td>
<td class="nump">75,458,854<span></span>
</td>
<td class="nump">145,726,765<span></span>
</td>
<td class="nump">105,725,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219610652848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603681968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 16,815<span></span>
</td>
<td class="nump">$ 39,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">16,815<span></span>
</td>
<td class="nump">39,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">306,784<span></span>
</td>
<td class="nump">116,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">306,974<span></span>
</td>
<td class="nump">115,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">16,815<span></span>
</td>
<td class="nump">39,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">16,815<span></span>
</td>
<td class="nump">39,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">843<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">843<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember', window );">U.S. Treasury securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">26,752<span></span>
</td>
<td class="nump">12,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">26,847<span></span>
</td>
<td class="nump">12,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInOneToTwoYearsMember', window );">U.S. Treasury securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember', window );">Municipal securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember', window );">Government-sponsored enterprise securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">86,250<span></span>
</td>
<td class="nump">9,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">86,201<span></span>
</td>
<td class="nump">9,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember', window );">Government-sponsored enterprise securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">13,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember', window );">Commercial paper (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">102,270<span></span>
</td>
<td class="nump">64,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">102,268<span></span>
</td>
<td class="nump">64,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember', window );">Corporate notes (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">48,409<span></span>
</td>
<td class="nump">26,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">48,360<span></span>
</td>
<td class="nump">$ 25,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember', window );">Corporate notes (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">26,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 26,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613063920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">$ 166,518<span></span>
</td>
<td class="nump">$ 75,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">166,518<span></span>
</td>
<td class="nump">104,156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember', window );">U.S. Treasury securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,921<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember', window );">Municipal securities (due in less than a year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember', window );">Government-sponsored enterprise securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">69,377<span></span>
</td>
<td class="nump">9,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">69,377<span></span>
</td>
<td class="nump">9,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember', window );">Commercial paper (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">58,622<span></span>
</td>
<td class="nump">52,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">58,622<span></span>
</td>
<td class="nump">52,454<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember', window );">Corporate notes (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">34,567<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">34,567<span></span>
</td>
<td class="nump">25,960<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">$ (55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember', window );">Corporate notes (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">3,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">3,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">$ (23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_MunicipalSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603638464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 324,904<span></span>
</td>
<td class="nump">$ 156,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">17,658<span></span>
</td>
<td class="nump">39,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">29,742<span></span>
</td>
<td class="nump">12,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">99,872<span></span>
</td>
<td class="nump">9,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">102,268<span></span>
</td>
<td class="nump">64,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">75,092<span></span>
</td>
<td class="nump">25,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">17,930<span></span>
</td>
<td class="nump">40,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">17,658<span></span>
</td>
<td class="nump">39,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">306,974<span></span>
</td>
<td class="nump">115,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">29,742<span></span>
</td>
<td class="nump">12,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">99,872<span></span>
</td>
<td class="nump">9,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">102,268<span></span>
</td>
<td class="nump">64,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 75,092<span></span>
</td>
<td class="nump">$ 25,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603938096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 03, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned</a></td>
<td class="nump">35,990,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,842,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod', window );">Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method</a></td>
<td class="text">we received 13 BARD1 shares for every five shares of Sienna ordinary shares, resulting in our ownership of 35,990,825 shares of BARD1.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized investment gains (losses)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CostMethodInvestmentOwnershipPercentage', window );">Cost method investments ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CostMethodInvestmentsCostBasis', window );">Cost method investments cost basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CostMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost method investment ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CostMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CostMethodInvestmentsCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost method investments cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CostMethodInvestmentsCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The method of determining the fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483580/946-220-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608851248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,408<span></span>
</td>
<td class="nump">$ 1,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(1,231)<span></span>
</td>
<td class="num">(896)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613234080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent', window );">CRO and clinical trial costs</a></td>
<td class="nump">$ 23,541<span></span>
</td>
<td class="nump">$ 17,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedManufacturingActivitiesCurrent', window );">Manufacturing activities</a></td>
<td class="nump">14,629<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional legal and accounting fees</a></td>
<td class="nump">556<span></span>
</td>
<td class="nump">9,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 40,308<span></span>
</td>
<td class="nump">$ 33,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedManufacturingActivitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedManufacturingActivitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608972928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Litigation Settlement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 21, 2022</div></th>
<th class="th"><div>Sep. 02, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountOutstanding', window );">Litigation Settlement Amount Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceClaimsMember', window );">Insurance Claims | Class Action Stipulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement to be paid by insurers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountPaidInCashOrKind', window );">Settlement to be paid in cash or shares as elected by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountAccruedLiabilitiesRecognized', window );">Litigation settlement amount, Accrued liabilities recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized', window );">Settlement amount, Interest and other receivable recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceClaimsMember', window );">Insurance Claims | Derivative Stipulation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount</a></td>
<td class="nump">$ 1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement to be paid by insurers</a></td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountPaidInCashOrKind', window );">Settlement to be paid in cash or shares as elected by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountAccruedLiabilitiesRecognized', window );">Litigation settlement amount, Accrued liabilities recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized', window );">Settlement amount, Interest and other receivable recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized', window );">Settlement amount, General and administrative expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LitigationSettlementAmountToBePaid', window );">Settlement amount to be paid</a></td>
<td class="nump">$ 825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LitigationSettlementAmountAccruedLiabilitiesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount, Accrued liabilities recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LitigationSettlementAmountAccruedLiabilitiesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount, General and administrative expense recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement Amount, Interest and other receivable Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LitigationSettlementAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LitigationSettlementAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LitigationSettlementAmountPaidInCashOrKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the settlement to be paid by the company in either cash or shares, at the company's election.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LitigationSettlementAmountPaidInCashOrKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LitigationSettlementAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation settlement amount to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LitigationSettlementAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceClaimsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_InsuranceClaimsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gern_ClassActionStipulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gern_ClassActionStipulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=gern_DerivativeStipulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=gern_DerivativeStipulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613264736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>Plan</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NumberOfSeverancePlan', window );">severance plans</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod', window );">Period within which employee is terminated by entity without cause following a change of control</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity', window );">Period within which no comparable employment is offered by the entity following a change of control</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment', window );">Period within which employee resigns following a change of control due to material change in terms of employment</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=gern_EmployeesAboveTheVicePresidentLevelMember', window );">Employees Above The Vice President Level</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NumberOfSeverancePlan', window );">severance plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan', window );">Period of base salary to be considered for severance payments</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent', window );">Period of base salary in connection with a non-change of control to be considered for severance payments</a></td>
<td class="text">42 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan', window );">Period of base salary to be considered for severance payments</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent', window );">Period of base salary in connection with a non-change of control to be considered for severance payments</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency period of current base salary to be paid under severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency period of current base salary to be paid under severance plan non change of control triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of months following a change in control when an employee is terminated without cause to be classified as a triggering event for severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period following change of control within which an employee is not offered comparable employment (new or continuing) by the entity or its successor or acquired and to be considered as triggering event for severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period within which employee resigns following a change of control due to material change in terms of employment and to be considered as triggering event for severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_NumberOfSeverancePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_NumberOfSeverancePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_SeverancePlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_SeverancePlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=gern_EmployeesAboveTheVicePresidentLevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=gern_EmployeesAboveTheVicePresidentLevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219604404368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 10, 2020</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,556,000<span></span>
</td>
<td class="nump">$ 4,147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=gern_NewJerseyOfficeSpaceLeaseMember', window );">New Jersey Office Space Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating Lease, Percentage of Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term, option to extend additional period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Operating lease term, option to terminate lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-time option to terminate the New Jersey Lease without cause as of the 103rd month anniversary of the commencement date of the lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_OperatingLeaseRentAbatementPeriod', window );">Operating lease, rent abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease,remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=gern_FosterCityOfficeSpaceLeaseMember', window );">Foster City Office Space Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating Lease, Percentage of Discount Rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 1,868,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, initial term</a></td>
<td class="text">87 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">87 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term, option to extend additional period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_OperatingLeaseRentAbatementPeriod', window );">Operating lease, rent abatement period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease,remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_OperatingLeaseRentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease rent abatement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_OperatingLeaseRentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gern_NewJerseyOfficeSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gern_NewJerseyOfficeSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gern_FosterCityOfficeSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gern_FosterCityOfficeSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613619232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 944<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 1,254<span></span>
</td>
<td class="nump">$ 1,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603556784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details) - New Jersey Lease And Foster City Lease<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 3,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gern_NewJerseyLeaseAndFosterCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gern_NewJerseyLeaseAndFosterCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219604058528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Additional Information (Details) - Hercules and Silicon Valley Bank [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding under term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Description of maturity date terms for term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Term Loan matures on April 1, 2025, or the Loan Maturity Date, and may be extended up to an additional six months upon the achievement of certain regulatory and financial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Term loan interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Term Loan bears interest at a floating rate per annum equal to the greater of either (i) 9.0% or (ii) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus 4.5%, plus (B) 9.0%  (8.5% as of December 31, 2023).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Term loan maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage added to prime rate for debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_InterestOnlyPeriodPaymentTermDescription', window );">Interest only period payment term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The interest only period of the Term Loan is through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. Following the expiration of the interest-only period, we are required to repay the Term Loan in equal monthly amortization payments of principal and interest until the Loan Maturity Date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentEndOfTermChargePercentage', window );">End of term charge for loan, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentMinimumPrepaymentAmount', window );">Minimum amount of prepayment allowed under debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Description of term loan payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">At our option, upon at least five business days&#8217; prior written notice to Hercules, we may prepay all or any portion greater than or equal to $5.0 million of the outstanding loan by paying the entire principal balance (or portion thereof) and all accrued and unpaid interest. There is no prepayment charge for prepayments of drawdowns under Tranche 1 or Tranche 2.  Prepayments of drawdowns under Tranche 3, Tranche 4, Tranche 5 or Tranche 6 are subject to a prepayment charge of 1.5% of the prepayment amount, if the prepayment is made prior to June 30, 2025. Thereafter, any prepayment of Tranche 3, Tranche 4, Tranche 5 or Tranche 6 is not subject to a prepayment charge.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfInterestOnPastDueOutstanding', window );">Additional percentage of interest on past due amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value of term loan, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedEndOfTermCharges', window );">Accrued end of term charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount amount</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding under term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage added to prime rate for debt instrument interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Minimum [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Maximum [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche One [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfPrepaymentCharge', window );">Prepayment charge (as a percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Two [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfPrepaymentCharge', window );">Prepayment charge (as a percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Three [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfPrepaymentCharge', window );">Prepayment charge (as a percentage)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentFaceAmountExpired', window );">Debt instrument face amount expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Four [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfPrepaymentCharge', window );">Prepayment charge (as a percentage)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Four [Member] | Minimum [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Four [Member] | Maximum [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Five [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfPrepaymentCharge', window );">Prepayment charge (as a percentage)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Tranche Six [Member] | Third Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfPrepaymentCharge', window );">Prepayment charge (as a percentage)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedEndOfTermCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued end of term charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedEndOfTermCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentEndOfTermChargePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding loan amount payable upon maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentEndOfTermChargePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentFaceAmountExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument face amount expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentFaceAmountExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentMinimumPrepaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount allowed to be prepaid under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentMinimumPrepaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_InterestOnlyPeriodPaymentTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest only period payment term description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_InterestOnlyPeriodPaymentTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PercentageOfInterestOnPastDueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Added percentage to current interest rate under debt instrument to past due amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PercentageOfInterestOnPastDueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PercentageOfPrepaymentCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayment amount to be paid upon prepayment under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PercentageOfPrepaymentCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=gern_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=gern_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=gern_ThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=gern_ThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613232848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 56,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">39,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LongTermDebtGross', window );">Total</a></td>
<td class="nump">95,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less: amount representing interest</a></td>
<td class="num">(10,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentUnamortizedEndOfTermCharge', window );">Less: unamortized end of term charge</a></td>
<td class="num">(2,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of debt</a></td>
<td class="num">(46,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion of debt</a></td>
<td class="nump">$ 35,051<span></span>
</td>
<td class="nump">$ 30,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentUnamortizedEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument unamortized end of term charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentUnamortizedEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LongTermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of term loan, including accrued interest payable and end of term charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LongTermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219614782496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 12, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">675,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603801104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - PUBLIC OFFERING (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember', window );">2023 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="nump">$ 213,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Public Offering | 2023 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">2.449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock per share</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember', window );">2022 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember', window );">2022 Underwritten Public Offering | 2022 Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,095,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember', window );">2022 Underwritten Public Offering | 2022 Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PublicOfferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PublicOfferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoPreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoPreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603585744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 105,912,000<span></span>
</td>
<td class="nump">$ 15,163,000<span></span>
</td>
<td class="nump">$ 2,479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock outstanding warrants to purchase</a></td>
<td class="nump">53,904,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock outstanding warrants to purchase</a></td>
<td class="nump">51,430,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember', window );">2020 Public Offering of Common Stock and Warrants | 2020 Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,335,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember', window );">2020 Public Offering of Common Stock and Warrants | Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock outstanding warrants to purchase</a></td>
<td class="nump">2,474,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiration date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | 2020 Stock Purchase Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised', window );">Warrants to purchase common stock exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,663,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,110,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised', window );">Warrants to purchase common stock exercised, shares</a></td>
<td class="nump">77,349,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 105,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_StockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_StockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608976224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2023</div></th>
<th class="th"><div>Sep. 04, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AtMarketIssuanceSalesAgreementsLineItems', window );"><strong>At Market Issuance Sales Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,385,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AtMarketIssuanceSalesAgreementsLineItems', window );"><strong>At Market Issuance Sales Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CommonStockAggregateOfferingPrice', window );">Aggregate offering price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_MaximumCommissionRate', window );">Maximum commission rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,571,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember', window );">2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AtMarketIssuanceSalesAgreementsLineItems', window );"><strong>At Market Issuance Sales Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CommonStockAggregateOfferingPrice', window );">Aggregate offering price of common stock</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_MaximumCommissionRate', window );">Maximum commission rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AtMarketIssuanceSalesAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AtMarketIssuanceSalesAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CommonStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate offering price for which the entity may elect to issue and sell shares of its common stock under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CommonStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_MaximumCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum commission rate, based on gross proceeds of sale price per share of common stock sold through sales agent under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_MaximumCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219607558032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EQUITY PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>May 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,385,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,750,670<span></span>
</td>
<td class="nump">18,370,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total pretax intrinsic value of stock options exercised (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,986,000<span></span>
</td>
<td class="nump">$ 787,000<span></span>
</td>
<td class="nump">$ 93,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercise of stock options (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,356,000<span></span>
</td>
<td class="nump">$ 1,799,000<span></span>
</td>
<td class="nump">$ 556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,995,642<span></span>
</td>
<td class="nump">36,085,389<span></span>
</td>
<td class="nump">30,459,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member', window );">2011 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of stock options from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue', window );">Minimum percentage of ownership required for granting stock options at least 110% of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock', window );">Minimum exercise price as a percentage of fair market value for employees having more than 10 % outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock', window );">Maximum expiration term of stock options granted to employees having more than 10 % outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Common stock, increase in shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,360,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan | First Director Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment', window );">Stock options to be granted to purchase shares upon appointment (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan | Subsequent Director Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares', window );">Stock options to be granted to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of stock options from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsPlan2006Member', window );">2006 Directors Plan | First Director Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsPlan2006Member', window );">2006 Directors Plan | Subsequent Director Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsPlan2006Member', window );">2006 Directors Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of stock options from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember', window );">2018 Inducement Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,306,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Common stock, increase in shares reserved for future issuance (in shares)</a></td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,616,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember', window );">Directors Market Value Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember', window );">Directors Market Value Stock Purchase Plan | Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,864<span></span>
</td>
<td class="nump">15,962<span></span>
</td>
<td class="nump">20,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock that vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,400<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award minimum exercise price of options granted to employees with more than 10 percentage of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum percentage of ownership required for granting of options at a price not less than 110 percent of the fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of options to be granted to purchase shares in each year during the optionee's service on the Board of Directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of options to be granted to purchase shares upon appointment to Board of Directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum expiration term of options granted to employees having more than 10 % outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_FirstDirectorOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_FirstDirectorOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_SubsequentDirectorOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_SubsequentDirectorOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_DirectorsPlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_DirectorsPlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608733392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">18,370,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">56,368,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="num">(20,855,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="num">(36,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet', window );">Stock options cancelled/forfeited/expired (in shares)</a></td>
<td class="nump">4,903,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">58,750,670<span></span>
</td>
<td class="nump">18,370,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">65,902,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">20,855,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="num">(8,869,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock options cancelled/forfeited/expired (in shares)</a></td>
<td class="num">(4,903,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">72,984,351<span></span>
</td>
<td class="nump">65,902,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable at the end of the period (in shares)</a></td>
<td class="nump">39,995,642<span></span>
</td>
<td class="nump">36,085,389<span></span>
</td>
<td class="nump">30,459,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options fully vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">71,983,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted (in dollars per share)</a></td>
<td class="nump">2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options exercised (in dollars per share)</a></td>
<td class="nump">1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options cancelled/forfeited/expired (in dollars per share)</a></td>
<td class="nump">2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">2.16<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">2.16<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Stock options fully vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weight Average Remaining Contractual Life (in years) - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable at the end of the period</a></td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options fully vested and expected to vest at the end of the period</a></td>
<td class="text">6 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at the end of the period (in dollars)</a></td>
<td class="nump">$ 25,391,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options exercisable at the end of the period (in dollars)</a></td>
<td class="nump">15,557,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options fully vested and expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">$ 25,169,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life (In years)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Available For Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled or that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613245936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">72,984,351<span></span>
</td>
<td class="nump">65,902,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">7,936,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609149008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Item </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,385,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan', window );">Aggregate shares issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Common stock, increase in shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod', window );">Maximum duration of offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime', window );">Number of offering periods in which an employee can participate at a time | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod', window );">Number of consecutive purchase periods in an offering period | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod', window );">Duration of the purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld', window );">Maximum percentage of annual salary that can be withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage applied to common stock market value in calculating purchase price under purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod', window );">Duration of the new offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear', window );">Maximum amount of annual salary that can be withheld to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate number of share instruments issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of new offering period in a case where the fair market value of common stock on the purchase date is less than the fair market value at the beginning of the offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of the purchase period under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum amount of annual salary that can be withheld per year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum duration of the offering period under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of offering periods in which an employee can participate at a time in the purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of annual salary that an employee can choose to have withheld to purchase common stock under the purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive purchase periods in an offering period in the purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608501744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">20,855,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 18,525,000<span></span>
</td>
<td class="nump">$ 8,001,000<span></span>
</td>
<td class="nump">$ 8,080,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">832,790<span></span>
</td>
<td class="nump">2,741,750<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 3,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613677920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 18,525<span></span>
</td>
<td class="nump">$ 8,001<span></span>
</td>
<td class="nump">$ 8,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">7,426<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
<td class="nump">3,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 11,099<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
<td class="nump">$ 4,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603761088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Compensation cost related to unvested stock awards not yet recognized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized, net of estimated forfeitures (in dollars)</a></td>
<td class="nump">$ 37,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of compensation cost on weighted average basis</a></td>
<td class="text">26 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility range, minimum (as a percent)</a></td>
<td class="nump">81.50%<span></span>
</td>
<td class="nump">77.20%<span></span>
</td>
<td class="nump">77.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility range, maximum (as a percent)</a></td>
<td class="nump">82.70%<span></span>
</td>
<td class="nump">81.70%<span></span>
</td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate range, minimum (as a percent)</a></td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate range, maximum (as a percent)</a></td>
<td class="nump">4.94%<span></span>
</td>
<td class="nump">4.57%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term range</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of employee stock options granted (in dollars per share)</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility range, minimum (as a percent)</a></td>
<td class="nump">79.10%<span></span>
</td>
<td class="nump">61.40%<span></span>
</td>
<td class="nump">50.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility range, maximum (as a percent)</a></td>
<td class="nump">83.20%<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
<td class="nump">70.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate range, minimum (as a percent)</a></td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate range, maximum (as a percent)</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">2.79%<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of other than employee stock options granted (in dollars per share)</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term range</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term range</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219604039168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Stock-Based Compensation to Service Providers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation for services by non-employees</a></td>
<td class="nump">$ 828,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=gern_ConsultantsMember', window );">Consultants | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems', window );"><strong>Stock-Based Compensation to Service Providers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation for services by non-employees</a></td>
<td class="nump">$ 742,000<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=gern_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=gern_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219611509712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">72,984,351<span></span>
</td>
<td class="nump">65,902,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options and awards available for grant (in shares)</a></td>
<td class="nump">58,750,670<span></span>
</td>
<td class="nump">18,370,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">53,904,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">186,385,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">745,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219603578144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal and state tax credits</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted', window );">Net operating loss not benefitted</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(5.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.80%)<span></span>
</td>
<td class="num">(27.50%)<span></span>
</td>
<td class="num">(28.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax Rate reconciliation net operating loss not benefitted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613086736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - DEFERRED TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Significant components of deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 272,300<span></span>
</td>
<td class="nump">$ 254,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsFederalAndStateCredits', window );">Federal and state tax credits</a></td>
<td class="nump">64,700<span></span>
</td>
<td class="nump">56,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">43,300<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">396,200<span></span>
</td>
<td class="nump">350,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(395,200)<span></span>
</td>
<td class="num">(349,600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets', window );">Operating leases, right-of-use assets</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">$ 45,600<span></span>
</td>
<td class="nump">$ 38,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to the treatment of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsFederalAndStateCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets federal and state credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsFederalAndStateCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219613689856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, expire beginning 2024 through 2037</a></td>
<td class="nump">635.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 841.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608501456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 72.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 21.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219609095024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - CARES ACT IMPACT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CARESActImpactAbstract', window );"><strong>C A R E S Act Impact [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_EmployerTaxReceivable', window );">Employee retention credit, CARES Act</a></td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_EmployeeRetentionCreditAmountOutstandingReceivables', window );">Employee Retention Credit, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CARESActImpactAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>CARES act impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CARESActImpactAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_EmployeeRetentionCreditAmountOutstandingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee retention credit amount outstanding receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_EmployeeRetentionCreditAmountOutstandingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_EmployerTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of employer taxes paid to tax authorities representing refunds based on calculated eligible credits. Also called employer tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_EmployerTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219604386224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits, if recognized would impact effective tax rate</a></td>
<td class="nump">$ 26,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the period</a></td>
<td class="nump">23,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the period</a></td>
<td class="nump">$ 26,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219614396928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental operating and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">$ (431)<span></span>
</td>
<td class="num">$ (68)<span></span>
</td>
<td class="num">$ (251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets', window );">Reclassification between prepaid and other current assets and deposits and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">$ (7,017)<span></span>
</td>
<td class="nump">$ 5,154<span></span>
</td>
<td class="nump">$ 2,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification between prepaid and other current assets and deposits and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140219608697328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,912,000<span></span>
</td>
<td class="nump">$ 15,163,000<span></span>
</td>
<td class="nump">$ 2,479,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="nump">68,007,741<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="nump">$ 213,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MX!;QP=4[_T>2A=$UP;KX<$+$:[M7[;:EIF4T/9A2*],Z6@%T5GH883%F[U;
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M;W)K<VAE971S+W-H965T,BYX;6RM6=MNVS@0_17"6^P%<&)>=+'2Q$!J9]$
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MRKP%JZS8_DV^[P;BH (B1RK@704\M +952!2!>P=J4!W%:A<X5@?G%T%1ZI
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M/NKJQO:-=G6L"84\7]8!0(U&H&@Q%)HX(7I%!YDEG8=5O5;8WA1S_K#".AW
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M'D-0LQ$H6@R%)K+;:SKT60\)4<V^%M_!\N9#<R-'OX-GD-$(U&@,A2;RV"M
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MC1\ "SU7(VB"D(,=F&'0,0RF&0XX;67=WPB+<7Z(BX1:2<D%7]3W4L:3\E"
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M@JU!QXR7JL*XO[!N]T8!I+6QJFR%B4$IJ^97?&T=\2T"PU9@N",0)R\()*U
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M\O0^#S>4FM?]M= +:@RAP)SH18,3.@>Z>3 W ZM6[LTY5Y9>L.YSB8+Z+MY
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MQ9;C\!1K<IEPG*'J&,H5CDA[E.Z([:/1W0%\=13'2;NCD+ _-CN01%H#MQ&
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M>8$ELT-=H:*93)N2.>J:/+:5098&4"GC9#0ZBDLF5+28A;$;LYCIVDFA\,:
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M4DUSX<TRO%1/C<<K>C@NI$ I6 #/9\;XYH(=;/[+<O$74$L#!!0    ( +*
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M.A9ZZPG,KF2N4IPA>5C"3I-S)/IB-XY!74NVSS*A[TX>L6*3:##)*S1U"!Z
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MSVYA2 BR!F(;P;]"%!D]^4&J(BP0GLR+>!MOX(W(M@!QD^6'+ ])1.'A.-V
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MP'*STN/VEX3Q\Y'X$"?R").:",3#4L"(!IMOZRE%%AI B=B,,IKP*57WJ&Z
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M6I%/<P68L04MR2&;R19S(L6<,N#!'S!2#N;3X'QS<3Z[,(+]-E11^(OX61]
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M&J#Q7"]$%KO#]1)/&$PPQD! D7IM$% &?#X!PPT87-H\8K\'52$;LS =H2I
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M!0U>)F08$A&- %VHI1&^@YW8^9CDD+H:$]J$,^+V6"N%G(4;WC([+M)(SVU
M9D^(8CL M\'V@41OQT!1'X]??(^@_9]A 0V1K;94'&/XSHMD$ 5Y!W8K?^V+
MA<^6=R#S#BPD+@X;5I1P^X85YSDAS4G*!B>X8N+?WI&%9@68^0K"9>*28+<;
M?H80C=X*Z20AT:@9+*2(%2,]5O +JNX3@Y*GF?Y4$L!HP2RP5T3ZP1634M[:
M-V32D>@#PR["?L#&CN(N:Z.T@66*G99>YV%O?18FW]VXEY&9B(#.0@1T-AFL
M_$R!YU"0,_G><%N.@67GG&=@2KWU24Z!&[=(.]P(A>6A2!)-"RIE? K5WQ M
M6O9&$@ESD&O8<$(\\&NGR&BQO^J%E;XZ )''7JQ]R(>[!./L$??C\3NU<SX-
M0 /)9OSH=5H/C08](475FG)9>CYH+R. U!O!IP_7+&J]8N'SV2*_LBUVO@.F
M79#>L,(!T0YR0RX:@!'#"H3A.L,@U:R*QJ['/H]G4#NP)@4[G#T<T733*Z@J
M)5(XDB'DU7>$A0&6.-[YB0^*EZ8&O^M#D*'6I U!H69'P K>'E)G!*$]-- '
M_%&H-*:Y!9O@BBC.!6^"@P1DB/D%U#-+:H3EMMT6$T-PNNRHBDIC_5-4%LTJ
M9&P0E77E.J?\P!=X"6,LA=VR>3(!6.S>B6<HV8] 6+X >>+=(Z:Y-'&D!NCS
MOXJW@<$-/8X"!8X7" =?6XEBR:6SY!29TQOPDM;KC10;T,[#F@ G:E9@$#ES
M_Q[(;V,V$,>JYEI;T[!/"-4.3T3(+H!9]".[*_2!A2]Z<^EB0$50MTMET=*E
MS>F<2(S+:*PX4-'08DZ&(0N8MP)R0$/DP]CZFG2_5!B!4]?&E\!SJ6U2=D71
MAL_7#>@3A6.&*4,C"LF&1#8'E(Z#68[20H*_"YL(,9JNZ]B]P+5I1XS +".?
M$9O[+HW.B:4XY$+T0A>4<G34%KRE]!8_AW:BVVL[+N%#:&E1V#-_P1A[(@D
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M.'HLC,YJ3"4PD\50 E*PG><+[%>UF.9$?"EC_QD8C]-6> H%ZP.VV"H(>TN
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M(245'D%O@P/1P46VX?!4')\X0([ MWB(TN_!=Y>T[46S![C/^KJ1B!:[F\A
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M2,IN<[6&ZI!?A<F=H4+B^/9]VGCWEMJB"M;I,X4YI4P;.H4%%IXYJS#)^PO
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M+TUS3=.,"CT!Y4N.,=1T] ;[_WE<_1M02P,$%     @ LH!<6#;>]>O2 @
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M?B\ 70^9VK&J](V]4);&A#=SFLNH70#M+Y6R6\<1-)-^\@=02P,$%     @
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M 92TU)9BR0'VM.(@L%S/IL/=SCMR9Y$[.=5AWIWOA58<^IC[M2UX?W39,/.
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M!#Q?"+Q3]QV]P?"9Z>0O4$L#!!0    ( +* 7%CE&;^)MP0  %\,   9
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M "IK0..9E&;W8B=H_E/,_P902P,$%     @ LH!<6-)_8!;9 @  "P8  !D
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ME< 6<WK@>BGJ[]CXN;5\F>#*/:%N>GT"V4%I431@HZ!@Y?%-GYOO< 9H=:X
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M!ID6&*>50D4[V>A!B:A.)(YPD^&9A,*6XVNJR 9U4P5!#5<;<KY9$U<,<HS
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MD;8&O_\&P\Z?IB!X$JN$!&]#@FWJ@RLJA)KA. <0@6N6R[E0\S\4,E&;BL[
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MH2?.=.CAL,;82S?$67KI5)D2:C<E;4W^LJMNQ^J]).=HH'C*]GC@XQT/U/=
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M"#T ^]><JV-%3U#\(S+Z%U!+ P04    " "R@%Q8/23Z8QX#  #0"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU5FM/VS 4_2M6AB:0@+R:IF5M
M)&A!0P+6%=@T3?M@DMO6(HF#[;2P7S\[24/3A@)3^)+8SCW'YUP_<GL+RN[Y
M#$"@QRB,>5^;"9$<Z3KW9Q!A?D@3B.67"641%K++ICI/&. @ T6A;AE&6X\P
MB36OEXV-F->CJ0A)#".&>!I%F#V=0$@7?<W4E@-C,IT)-:![O01/X1K$;3)B
MLJ>7+ &)(.:$QHC!I*\=FT<#,P-D$3\(+/A*&RDK=Y3>J\YYT-<,I0A"\(6B
MP/(UAP&$H6*2.AX*4JV<4P%7VTOVL\R\-'.'.0QH^),$8M;7.AH*8(+34(SI
MXBL4AAS%Y].09T^TR&,=&>RG7-"H $L%$8GS-WXL$K$",%LO *P"8+T58!<
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M,<.I$[3;@-^72MG]PAEHYMCAOU!+ P04    " "R@%Q8#/=DS+@%  ![,
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M=J#?%VE:-%^4@,W;[J[_#U!+ P04    " "R@%Q8R*"K=C0#  #5"@  &0
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M=ET75PW-*/-)5>:3(R9(YK]_4XVME+8UAH112!@#@AE28+>V'2YH&RIQ0*J
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M[: _GPNA-AM9@NK1J<F_4$L#!!0    ( +* 7%@XM3\#/04  )\B   9
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M.&D@SR\I%;N=)$'Q3<KH?U!+ P04    " "R@%Q8.09(ICP$  "%&0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6S-F6USHS80Q[^*AG;:W,S5/!D[
M26W/.$;M99K<I2%II]/I"P7+-A- 5)+M]-M7$AB;!*NFU;7-BP0!^]O5_J-E
M!:,MH<]LA3$'+UF:L[&UXKRXM&T6KW"&6(\4.!=7%H1FB(LA7=JLH!C-E5&6
MVI[C#.P,);DU&:ES=W0R(FN>)CF^HX"MLPS1/ZYP2K9CR[5V)^Z3Y8K+$_9D
M5* ECC!_+.ZH&-DU99YD.&<)R0'%B[$U=2^A&T@#=<=/"=ZR@V,@I_)$R+,<
M7,_'EB,CPBF.N40@\6>#9SA-)4G$\7L%M6J?TO#P>$?_3DU>3.8),3PCZ<_)
MG*_&UKD%YGB!UBF_)]L/N)J0"C F*5._P;:ZU[% O&:<9)6QB"!+\O(O>JD2
M<6#@]H\8>)6!=ZJ!7QGXKPT&1PSZE4'_5 ]!9:"F;I=S5XD+$4>3$25;0.7=
M@B8/5/:5M<A7DLM_E(A3<341=GP2/7R:_?#ATTT([Z.O ?SQ\?KA%_ -B*8W
M, +3[^\AO(4?'R)P%F*.DI2]$Q<?HQ"<??EN9',1@,38<>4L+)UY1YRY'K@E
M.5\Q /,YGC<!MHB\#M_;A7_E:8D?R:8''/<]\!S/;PEHIC>/<"',^\K<:9N/
MWCS$<0_XQ[W#T\U=33+\6DM?\?PCO"D'MX@^B^IRS=@:Y3$&$4HQ ],EQ5BL
M;L[ KS?""%QSG+'?6B*^*CWTVSW(JG7)"A3CL27*$L-T@ZW)5U^X ^?;MN2;
MA(4F8= 0K"%3OY:IKZ-/:G'( L0DRT2Y%,L\?@9)+L9Y7I70;<)7 '&QV)6D
M9+' -,F7[T&N1B#986+".&O34AM&5RU-PD*3,%C" @63S\7-Q'/\\\!QQ(K>
MM.@4U#H%6IUD37B]@-K2K*5T3;-)6&@2!@W!&E(,:BD&G[VR#4S*9!(6FH1!
M0["&3,-:IJ%VQ4R70HXEXKBN5J"@R=M*UR:/EMQ5GN&;DN ZU4]=$\K<FW0+
M#<$:N3^O<W^NS?TM>DFR=:;R+!X-JH^72IPA!A H,(W%*FGKV:ZTW*Z9+V$7
M!YEW>H[_*NDF/4)#L$;2+^JD7_S[CW)P)JS9"HEP6_72AM15+Y.PL(0-#L5O
M*@_?WN$ZP= -@D'[L]IU]OL8Y__15>GCZ)I_H[30* U6M&9GU6]6T:9:![M.
M]Z]Z*_^4WDJ/Z9QLD[30* V:HC4%\?:">)^]PZI<F!++)"TT2H.F:$VQ]OM\
M5[L__4=]5H4^H3>:Z:/HK(#1#;PI6E.!_1;>U>_A_WZW58'U'=),[[YSZHWN
MMTW1FJG?[\I=_;;\/^FY]#%U+FU&=_D53==VF7)82F8?O&[.,%VJ]_Q,)'*=
M\_+5;7VV_I8P56_07YT/Y3<&]1I[CRD_4(AGT3+)&4CQ0B"=WE!,@);O_,L!
M)X5ZJ?U$.">9.EQA-,=4WB"N+PCANX%T4']YF?P)4$L#!!0    ( +* 7%A/
M.*+\/0X   :Y   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;,6=:V_;
M.!:&_PKAO76 V5@7RY=N$B"-*)'<Z33;=#I8+/:#8C.Q4-GR2'+2 O/CEY(5
MR[05VBK>V<R'J>/P/)24\YJ'>D7Z_"G-ON1S*0OR=9$L\XO>O"A6;_O]?#J7
MBR@_2U=RJ7YSGV:+J% _9@_]?)7):%8%+9*^8UG#_B**E[W+\^J]F^SR/%T7
M2;R4-QG)UXM%E'U[)Y/TZ:)G]Y[?^!@_S(ORC?[E^2IZD+>R^&5UDZF?^EO*
M+%[(91ZG2Y+)^XO>E?U6>),RH&KQ.99/^<YK4I[*79I^*7_@LXN>51Z13.2T
M*!&1^N=17LLD*4GJ.'ZKH;UMGV7@[NMG>E"=O#J9NRB7UVGR:SPKYA>]<8_,
MY'VT3HJ/Z1.3]0EY)6^:)GGU?_)4M[5Z9+K.BW11!ZLC6,3+S;_1U_I"[ 0H
M3GN 4P<X^P'N"P%N'>">&C"H P;[ <,7 KPZP-L/&+P0,*P#AJ<&C.J T:D!
MXSI@?&K I Z8G'J5;.OY+V=5&;3YDU?YXD=%='F>I4\D*]LK7OFB2KHJ7J5)
MO"SU<5MDZK>QBBLN;S]]N/XG^_"33S_>_HW0?_W"/_V;_/WYQ<U/5S_?DC>^
M+*(XR7]0O_CEUB=O_OS#>;]0G9>(_K3NZ-VF(^>%CFSR/ET6\YS0Y4S.6N+I
MD7C' .BKL]Z>NO-\ZN\<(_%]](VX]H_$L1RWY7BN3XYV6J+]DZ/MMFMACO;E
M],QTZ,'IX6W''IX>WG;P[.1P>]P2SLWA'Z:%,5P<O_"VUQ:MY9"[E8];X=R7
MY#./,DG>J0_H&;E.%VK4RJ/J<_\JRZ+E@U0C24'>?2.[[6ZB;]7;5T]1-B/_
M^4DA"2_D(O]OFZHV_0_:^R]'S[?Y*IK*BYX:'G.9/<K>Y5__9 ^M?[2E-!+F
M(V$4"0N0L! )8T@81\($"*:I:+!5T<!$OU3*62C-J.%N^N5'DI=:R4G=S8RH
M(I#<KXNU$E"<Y^MH.97D3;RLV[4.1<;NNHH&"?.1,+J!#2M860@_7MKCH3OV
MQN[DO/^XJPADMR$2QI PCH0)$$Q3A+=5A&=4Q.U& ]&CJKNBNT16(GA00TK1
MENY&5M=T1\)\)(QZ!^GNC4>>-1Q9>]E^V- >NR-KY.S)(D0>'D/".!(F0# M
MDX?;3!X:*Z2KAX=,/D2%JG&611:KB?64?(Z2M523B0^KLE;*R8=UD1?1<A8O
M']K2>XA,;R3,1\(H$A8@82$2QI PCH0)$$R3R6@KDY&Y!$K27*7_I@8BJRRN
MBYQ9FB11EI.5S#8%3VN]8V1W50@2YB-A= ,;[WRN.V>VO??AC^PQ1,(8$L:1
M, &":9D_WF;^V)CYG](B2E3&RR+Z2N+M&/%8C1'I?:V(M!XJY%>93>-R&KVC
MCE9-&'OMJ@DDS$?"Z ;F[=8Z]F0\M*S]HNBPX6@\.F@6'C:;N >M&/(4.!(F
M0# ME2?;5)Z8/\2C?*[FK5,95_/6+%UL\_4PDX_EK[&KKOF+A/E(&)T<YJ_C
M>BWYV])P-)D<)O!A.Z\%QY GP9$P 8)I&6Q;C1]@&>OUG]>+.U5KJ'2MYZ G
ME^DU&)2Q4)H/I5$H+8#20BB-06D<2A,HFBZ4'>/,-M^B::M+JGLU44&*N21R
M.2ME5+Y4U7N<SH[=M31WV%E 2)H/I=&:MGN'QIU,)MYPX.Q]ZK>U'%ICSQWO
MW\MI:VD-O(GM#O<^^J'GPJ$T@:+I2>TT2>T8/_U_K9XG4,7+U:/,H@=)Z'/]
M<E--26_4T+#QLDX?%AQH5B-I/I1&H;0 2@NA- :E<2A-H&BZ@AI#V#8Z9=\[
M+)QVG\?<=V<M0>U@*(W6M+U[/</]T:&UU6A_9&AKY7K[HP+4FX72!(JFYW1C
MS]IF?]:Q;)O<)-&R-2>A9BN4YD-I%$H+H+002F-0&H?2!(JF:Z$Q9FWOE9_X
ML:%V+I3F0VD42@N@M!!*8U :A]($BJ8+JO&';:.O=OE9YD7I?-7%T/Y]TE:%
M0!UA*,V'TNB1:S<@WZ2J&EO5 '6 H30&I7$H3:!HNAH:&]@V^\#;4HO\3MY'
M7^/%>M&J *CC"Z7Y4!J%T@(H+832&)3&H32!HNFJ:"QB>_S:11?4+H;2?"B-
M0FD!E!9":0Q*XU":0-%T035&M6UVJNG759QM)%3(;''H3E?F]:Q\;$_]ZL4'
M3\V]=%8-U*6&TNB1ZVE;ADH,>2 AE,:@- ZE"11-7QS6&.&.T3\L*['QBS>]
MS+%=$Q]*\Z$T"J4%4%H(I3$HC4-I D73M=!XW8[]RO67 _6^H30?2J-06@"E
MA5 :@](XE"90-%U0C<_N&%W([[GI929V5@C41X?2Z)%K9[CI!3V.$$IC4!J'
MT@2*IJNA\<P=LV<.7_]I[J^S5J ^.91&H;0 2@NA- :E<2A-U#1MQ:&U^6_[
ME(&NC<9[=\S>^_MX6=X$+D>*J2JGRF>RU&B1/BUEEL_CE9+);^LXJV523=2;
M943/D_FH((F,\H+8MO67,OP^BC.RB+(OLF@66DQW5-@J*JC1#Z7Y4!JM:9.=
M/Z=UMK_."-IE"*4Q*(U#:0)%T_74^/>.>67ULYZV"S,V:^TBI9(]C1V*I)28
M7*R2])M4 ]0\>BREMDC5P%3,HR6Q+:+4U3P->5Q14*<?2O.A-%K3=A5E'RH*
M:N!#:0Q*XU":0-%T134&OF,VH6N;4BGJR#WE:G12(U618E4$?1H 2O.A-'KD
M#^$9)D;0IP&@- :E<2A-H&BZM)JG 9PCJ\*UB5&\G&:JC%/3H"5DDC0Z*%H'
MKCNT#M;*7;>TM.V]\K;.]Y:6CM?2DIK/O//$!>KK0VD,2N-0FD#1]/QN?'W'
MO/9[Z[&0WTD09VJ&XJNYS+10R;Q97=*:MU"K'DKSH30*I0506@BE,2B-0VD"
M1=,UTECUSN2UO1>HBP^E^5 :A=("*"V$TAB4QJ$T@:+I.W8VQKYK-O:_PWLQ
M$[LJ!$KSH31ZY-JY+T\QH,<10FD,2N-0FD#1=#4TUK[;91F[FIK?R=V)^FJ=
M3>?EG*.><*Q7Y:;FJU4:+XMJB'ECF&&8N^XL&ZBI#Z51]W#QN=,RZPF@O890
M&H/2.)0F4#1=)(U=[YHMY]UYRNWZ+I>_K<O</V&R8@9WE@#4M8?2*)060&DA
ME,:@- ZE"11-%\K.=NBOOA\Z=D-T[([HV"W1L7NB8S=%Q^Z*CMT6';LO^A^Q
M]-YM['_7;/]W+,^.W/(U=]99/% +'TJC->WP1O1^009U\:$T!J5Q*$V@:+HL
M&A??-;OXNP6989FDF=(YWZ$&.Y1&H;0 2@NA- :E<2A-H&BZ*AHGWC7OM?Y_
MJ+Z@7CN4YD-I%$H+H+002F-0&H?2!(JF"ZKQWUVS_PY:)FGNI;-JH*OUH31Z
MY'J:EDE"#R2$TAB4QJ$T@:+I$FDL?/>8A6\-MS?"\LYFOIG>61I0,Q]*HU!:
M *6%4!J#TCB4)E T72V-F>^^MIGO0LU\*,V'TBB4%D!I(93&H#0.I0D43?_B
MP,;,'\#-?#.QJT*@-!]*HT>NG<',AQY'"*4Q*(U#:0)%T]70F/D#LYG?7HQU
M<RS-7726!]2TA](HE!9 :2&4QJ T#J4)%$V73&/M#\P[WO_Q%=D ^@@ E.9#
M:11*"Z"T$$IC4!J'T@2*I@NJ>01@8%[,_ST5&=33A])\*(T>N79V59&UB@%J
MWT-I#$KC4)I T70Q['RQN=F^;R_(#(ZEF==9"E"''DJC4%H I850&H/2.)0F
M4#1='XV//WCMW?0'T$< H#0?2J-06@"EA5 :@](XE"90-%U0S2,  _,:<)!C
M:>ZELVJ@/C^41H]<3Y-C"3V0$$IC4!J'T@2*IDND,?4'1[?8'Q.^G*VG<F<<
M>6FG5S.LLQ*@WCV41J&T $H+H30&I7$H3:!HNC@:.W_PVCOM#Z"./Y3F0VD4
M2@N@M!!*8U :A]($BJ8+JG'\!T>^$QZ]MZ6YO\[Z@1K\4!JM:=HW^CJN-1RZ
MX[VG^*']AE ::SN+MKUS.+1;@:)I:>\UOKQG]I;_T)V+ZKZUQ1WNI.6:7IN/
MLFMZ0VD42@N@M!!*8U :A]($BJ;KI''LO2/+[S=JB!ZC.*F^)7B[C6MKXD.]
M>2C-A]*H=[B@WK:']G \V-\U$MIO"*4Q*(U#:0)%TQ._\=T]\Y+ZQA1YO]EB
M]7.UQ>IFO>/-\[+&EV;E9GAG(4 ]=2B-0FD!E!9":0Q*XU":0-%TL32>NO?:
MR^H]J 4/I?E0&H72 B@MA-(8E,:A-(&BZ8)J?'G/[,O#9^7F_CKK!^K;0VD4
M2@N@M!!*8U :KVDMWQ&A%[0"U:TNC<:2]\Q+ZT\OS,COY*/,BRR>EKM1;&S&
MJ!QM6A_R,G?;62%0(QY*HU!: *6%4!J#TCB4)E T74:-$>^]]EI\#^K10VD^
ME$:AM !*"Z$T!J5Q*$V@:+J@&MO>,]OV]9VRLB!34CE6CD%=>RC-A]*H=[CC
MOCL<#P?[=\E:-N;W)D-';Q:V-'.LT=C5FS'H*7 H3:!H>IHV!KIG7@__JXP?
MYF4]%#W*K/PFH>IF[N:)J^H;A39?)53F[RQ-DDC562N9;7*Y/96A?CF4YD-I
MM*:-=Y/OS!WM9_)A*_ML<I#(;:WV?4,&/7X.I0D43<_CQK?VS+[UI[2(DMV,
M3>_+";)>[1?SJ""/ZETY:TU=J%4-I?E0&JUIWDZZC;W!P6YS+<V<R<$,,#RM
M&8.> H?2!(JVR=Y^/I>R\*,BNCQ?R.Q!7LLDR<DT72^+L@3?>5<EZ;W*;OOM
ME=/K'[S_SG[KVRWO4_MM6+W?;_"7YROU^:TFP0_Q,B>)O%==66<C]5?)RH_X
MYQ^*='71LWOD+BV*=%&]G,MH)K.R@?K]?9H6SS^4'3REV9?J="[_!U!+ P04
M    " "R@%Q8N*SA;*D&  ! *P  &0   'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6R]FFM3XS84AO^*)NVTNS.%6)*O6\A,B+,L4Q8H@=WI1Q$KB6<=.Y45
M+OWUE1QCQQ>$346_@.U(KXZ>R-)[(AT]).Q'NJ*4@\=U%*?'@Q7GFT_#83I?
MT35)#Y,-C<4GBX2M"1>W;#E,-XR2(*NTCH;(,.SAFH3Q8'24/;MBHZ-DRZ,P
MIE<,I-OUFK"G$QHE#\<#.'A^<!TN5UP^&(Z.-F1)9Y3?;JZ8N!L6*D&XIG$:
M)C%@='$\&,-//L:R0E;B6T@?TKUK(+MRER0_Y,U9<#PP9$0THG,N)8CX=T\G
M-(JDDHCC[UQT4+0I*^Y?/ZM_SCHO.G-'4CI)HN]AP%?' W<  KH@VXA?)P]?
M:-XA2^K-DRC-_H*'O*PQ /-MRI-U7EE$L [CW7_RF(/8JX"L%RJ@O *J58#F
M"Q5P7@%WK6#F%<R,S*XK&0>?<#(Z8LD#8+*T4),7&<RLMNA^&,OO?<:9^#04
M]?AH=G,Y^>/+Y;D_O9[]"J9_WI[=_ 4.GB^NSL<7,W$[FWR9^K?G4W#Y&8Q/
M3Z^GI^.;*<CJ@LNKF[/+"S"^\,'X^_A:_)W<G'V3M3_XE),P2C\*A=N9#S[\
M_/%HR$70LNGA/ _P9!<@>B% B,#7).:K%$SC@ 95@:'H;=%E]-SE$Z14].G\
M$&#X&T &PBT!3;I71RW5_>[5H:(WN/@"<::'7_H"5X31%(SO!6ER%U$@7@=P
MRDC,VUCOM,QV+3G'?$HW9$Z/!V(222F[IX/1+S]!V_B]C9-.,5^36(6A63 T
M5>JC$Q*1>$X!X8"O*+BCRS".PW@)DD7V8$-9F 3@0QB#-,/=.HYW;=A9&W*Z
MO1]!%SN&@[RCX?T^-V4P?;EI$JMPLPINEI+;. A".7N3*.<"R):O$A;^0U^E
M935H63:V7<-R:[24(?2EI4FL0LLN:-E*6C.>S'^ 9".)I6 I7]'7,=D-3 ?(
M<"T+8:/&2=EX7TZ:Q"J<G(*3HQY5#X0%G0$Y34!B&-EFC8ZRR;YT-(E5Z+@%
M';?'*)K+>2N*:# 4%G!!0P%L2!\W(7L=G-L 9WH&]ARG1DX93E]RFL0JY+R"
MG-=GEJ=QT&]^]YHSENM8ANW4W\1FP?:%P%?&^T8:T"B=GZ%T#A?;]1UEDD'N
M(0[ 93ZL+K<\Y20.Q!K8ZM@,G39"JYJO2ZT*=<].P__!2N2-[ \AV_(,9!KU
ML:8.IS<\36I5>*B$A_2OD+GF/JL75DAUZ[U9:5*KLBIM/U0ZXAHK^DC9/$P[
MT,+-]=)U;0\;J$Y+J[W7I5:E51I\J';XVE9-V'3Y!^WKICJBWOS>P^?#TNA#
MM=/_KVLG;-I]L1RZ)K9@'5NS9/O4YZM#?BN2TLW#/G8^?P&S#/S-D)IF'WN>
M9]EFX]UL*6F+20^[=8O15M(P+0]BNRA9!5#:=*CVZ54 BVT4/8%[FLHI6U@'
M061#Y_*&)]GCMV-I6GP'>BZ&CEW'HM7EZU*KXBU]/G25]NQ[]I.EX#>^IXPL
M*9CF<SRX8J%X%:^$=\N,6P_?IM/+3[2J^;K4JK3+W #V2@Y4OBU(HHBP5#[:
M#=OV4;MKS]W/ @[=QB*A*07(&;Y'0H'*A (IO;7"OG5#ELM#O&_E#IWZY*>.
MHB\S76I59F6^@-3Y@LK&=:0&F]3@(:[_Z*B.HS>U]T@44)DHH#Z)PFMVKB-'
MU#;ZH%7GJ#6)T*56Y5@F$4B=1'2R=1WQX59\]24Z+Z:>%GUUV&_%4F8+J$^V
MT-G:=01E=@-E-D")4@U0;:6PU6[M4&GWD=KN:[5V';%8;?UMO'U:=P-TJ54I
MEQD$LCLXO,+?75.Y3R\]QR2).2-SOB41. \7-,/X1 7$C]W-'M*Y(3#1JN;K
M4JN"+S,7I,Y<7IOV6G&J)>W=]P-<L-[M5D,$ O*4MK+4FJ;H4JNR+-,4U&<_
MHLM<V4I7W8B5T\4%7>-ENEK3$EUJ5;IE6H+4:8FNB;B5N;KIYHB6R%N):TUB
M=*E53U.420Q6[XJ,ETM&EX13<"8FX3!.PSGX1J)MCS0;:]T>T:KFZU*KTBW3
M'=QK>T1I&%IM0JYO[=L$"WO0-G'-*J@CZ<WM/1(>7"8\N$_"T]>1MI-L[IM
MR[(<K_&SFCJVWB3?(^7!>\>E^NR;Z+&V[7QQRTB%MF<X];,)ZHA[\]6:.PWW
MCA:N*5MF1S1%RIUL8[X[<E<\+8Z!CK/#C[7G)_#39'>8LY39G2W]2MA2S+,@
MH@LA:1PZ AG;'=?<W?!DDQU@O$LX3];9Y8J2@#)90'R^2!+^?",;* [-COX%
M4$L#!!0    ( +* 7%BDQC+NV0(  )0(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;,56:V^;,!3]*Q:3ME9:"X&$/I8@49*VT;*&)6FK:=H'%VZ"
M5<#,=I+VW\\V!"5K&K52IGT!/^XYON=P;=->4O;($P"!GK(TYQTC$:(X-TT>
M)9!A?DP+R.7,E+(,"]EE,Y,7#'"L05EJVI;EFADFN>&U]5C(O#:=BY3D$#+$
MYUF&V?,%I'39,1K&:F!$9HE0 Z;7+O ,QB!NBY#)GEFSQ"2#G!.:(P;3CN$W
MS@-7Q>N .P)+OM9&2LD#I8^JTX\[AJ42@A0BH1BP?"T@@#151#*-WQ6G42^I
M@.OM%?NEUBZU/& . 4WO22R2CG%JH!BF>)Z*$5U>0Z6GI?@BFG+]1,LJUC)0
M-.>"9A589I"1O'SCI\J'-4"C^0K K@#V6P%.!7"TT#(S+:N+!?;:C"X14]&2
M336T-QHMU9!<?<6Q8'*62)SPQI-A\/5Z..CV1N-/J/?]MC_Y@8Y6C7#@WXQE
M=QQ<][JW@QX:7B+_ZFK4N_(G/:2Q:!A.^L,;Y-]TD7_OC^0SF/3O%/H@Q QR
MD8 @$4X/T4$7!"8I/Y2,/)%SO&T*J4%E8D95OA=EOO8K^78A.D9.XS.R+=O9
M @_>#K<WX:9TKK;/KNVS-9_SFGU*!KJ0=12C@&9R;W&LR]-G#.<SD/4NT,4S
M6H\+\;,>]I>8Q>CG0%*BOH",_]IF1[E^<_OZ:H^?\P)'T#'D)N; %F!X'S\T
M7.O+-G/V1+9AE5-;Y>QB]\:"1H^(%LH>CN2!P@7.8Y+/T ')JWHXW.9 2>MJ
M6G4H+;P3^^RTZ;0:;7.QKNYEH-LZL^RF9=6!&YDWZ\R;.S,/@>GC,H_@J/R$
MI99AJ65;SCL)W_O5]D2VH;U5:V_]YP)O[=.J/9%M6.765KG_IL#=EP5^YKB6
M8_U5WSN7?Z\X<^W.4/?U-\QF1.:=PE326\<GTDI6WH%E1]!"7R,/5,A+23<3
M^=L 3 7(^2FE8M51-U/](^+] 5!+ P04    " "R@%Q8=4.95-P$  !]%0
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M')H3-;<:GA],7A&QC)B$F"[0M'%T@G.+_*POOU$\-<=E=UPIGIC+D!+LHWH
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MBPZDQ/);1MX1=*W.W0]4P"E>-2.XF1$F ^#YDE*Q[\@)RKO>\#=02P,$%
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MO]>@C>V8:>+N\0;]UXR\(O. !1FRZ#L-Y>R\T6V D$SP(I)W;/69K FU4[R
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MU9:X-\(W1918]+8L>N;Z>IHK8ZH6QI*I^RZ-J'P&'"=3\C$U831>Q <PRX>
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MS?K1^MI$\VVAE7_K+JR[>Z!U-U?O'A2(#.7[AES_=;FY%LV=G1DQX=-LAXL
M 5LD,M_<L'UWNXOF(ML[4GG_$I[Y^5Z8 B;?FG.#^92JE1F1B8)43Q?J5L?S
MW2[YB63S;/_' Y.2Q=GAC."0\#1 ?3YA3&Y.T@&V>XX&_P%02P,$%     @
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M-#71FYKH4L_8HR9M4"L5LUU%;+\36L((#16^OR@B"Z1XGS_U;.U'&^*!Q#:
MC0;8Z%+W0H:C1X!+L;$HX'N=,EC$:3$'1VE1S^K7M@JL9&TI*\Z+A=?77<<T
MK-Y 7:S3[0;:EJOIIJ8U@1O.S<:YN8=S;AK )20Q;R[XHH0/&0+\I -S @OV
M%HRYX]%R^I9F][4MF-W GF/T-8[>#F,U,%8GS#TDPN=>,V#MFC9<S72=;=.=
MG_[@^K(;,+L3S,=YSH]L*B>KEH_EQ,PJ5A$$4DHK6$3H+5J[I?*VX5B.X6[A
M=AKZ(&Z_P>UWX@9YF>%GA&K@LB)1PO]IVH ZA?8]0@XDML'L-,S.0<Y,YY#
M!Q+; '8;8/?_K&EW]PPU^8)VMA9TIYM]6=6U"X.XK%U!,D_Y 9JA&9?7COO\
MM""K"]"JPW I[Q /F/$;B6PF_,Z(B C@XS.,V4M'7$N:6ZCW#U!+ P04
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MUJC(P:_/09>76['%$<PL53\$\#U8P6^_N$/GCSI_?R99^)/(+KSW*^_]-O9
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M94=5C]=ECUY+CZZ'[AB5B4 +&D-\+& K_#H&[S6&:Z]3<0[1!?+=3\AS/-\
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M2OTXZ"70'/;.-F+%,J"E(=& >8[N4;@0230>JJO.W'&9[1-?)V$<!4'/7Q\
M[C3 G9/  \((3Q&(!EV@P5U2SBE?@LB=H4))178(I]:-]W&B[C&<N,&)3^),
M>&HFFD+3*F;:8'HHS..3$KF&5R32-:@2BMI)<O#VXS^QXF-4W8:J^S]-0I[]
MO3W=?[HM?V]@E"B7;BPJ2,6*ZWIV--9F\M[4 ^>7>SVV[X@T=Z> 86Y"@ZNN
MR2WK45AOM*C<^%D(;8:96Q;FZX'2.ICS7 B]V]@$S?<H^0E02P,$%     @
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M>[!F/_W@!LZO74:9A(4F89%)V,(0[,S@06OPH(\^6W(6 R0"I9P5")Z!QT0
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ LH!<6"N/;UM]!0  CBP   \
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M9/.<2WWFO$FS7,W0=,@].K)[3J8^;XRJ@W3(03JZ@X!!,QFJD]F0@PST(0Z
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M.^KM!'H[ZNT$>COJ[01Z.^KM!'K[9+.;0&]'O9U ;T>]G4!O1[V=0&]'O9U
M;T>]G4#O0+V#0.] O8- [T"]@T#O0+V#0.] O8- [YA\K"30.U#O(- [4.\@
MT#M0[R#0.U#O(- [H]Z90.^,>F<"O3/JG0GTSJAW)M [H]Z90.^,>F<"O?/D
M9Q,"O3/JG;]3[SI^'DJ]]GRM\?G?2?5XOK=<'W]9?IV<L'/!.=U6U.>_4$L#
M!!0    ( +* 7%CB(3)"\0$  !DG   3    6T-O;G1E;G1?5'EP97-=+GAM
M;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0D;B;
M1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_# O*W6
M]H&8F,T,JUR?J$_3--0H%N>7M+2;-DVNMOGGV+A^7@1J8S&YV&T<LN:%];YM
M*IOR.GOLZT\IT]>$,I\<]\15X^-1WE"P+Q.&E>\#7L_=/%((34V36QO2M>WR
M+K9M64S/+<5R?XDO>G3+95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T^^0'
MYX]E]@7FG;?!^9@G%NCW<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S\_4^
MN; >YQ'9^#C\CC_.^+W^+_L0('U(D#X42!\:I \#TL<Q2!\G('V<@O3!9RB-
MH(C*44CE**9R%%0YBJH<A56.XBI'@96CR"I09!4HL@H4606*K )%5H$BJT"1
M5:#(*E!D%2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP*15:%(JM"
MD56AR*I09%4HLBH4616*K I%5H4BJT:15:/(JE%DU2BR:A19-8JL&D56C2*K
M1I%5H\AJ4&0U*+(:%%D-BJP&15:#(JM!D=7\IZSWSJW_.'Y\EIUM^K=\-OXC
M;O$"4$L! A0#%     @ LH!<6 =!36*!    L0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "R@%Q896L94N\    K
M @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " "R@%Q8F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +* 7%BQ$]WRIP@  ) U   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " "R@%Q8#O,ITST&  "&&@  &               @('K$   >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ LH!<6)G_3I+] @  $PH
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M965T-RYX;6Q02P$"% ,4    " "R@%Q8C+BII5X(  "=*   &
M    @('F+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
MLH!<6/_84*!E @  BP8  !@              ("!>C@  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( +* 7%C8[.(WZ@0  ,(0   9
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M970Q-"YX;6Q02P$"% ,4    " "R@%Q8>,Q*DL8"  #6!0  &0
M    @('T=@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M +* 7%CL,<,6O0T  %TH   9              " @?%Y  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ LH!<6 A*[#IG!@  <1$  !D
M             ("!Y8<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " "R@%Q8^Y:ZM?L+  #O)   &0              @(&#C@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +* 7%CVQWZ1Z!X
M #AV   9              " @;6:  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ LH!<6 62Y44,"P  (AX  !D              ("!
MU+D  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "R@%Q8
M/*7O#LD"   7!@  &0              @($7Q0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +* 7%BUC"\1!2   +MH   9
M      " @1?(  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ LH!<6))+A#%^!P  _Q@  !D              ("!4^@  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "R@%Q8-M[UZ]("  #U!0
M&0              @($(\   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( +* 7%B(/@UFO0(  *0%   9              " @1'S  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ LH!<6.79F;BI
M P  <P@  !D              ("!!?8  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " "R@%Q8? '^,/D"  !H!@  &0
M@('E^0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( +*
M7%AIM@*YZP8  '(2   9              " @17]  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ LH!<6.49OXFW!   7PP  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( +* 7%@EX[TX\ <  *,Y   9
M  " @:L6 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
MLH!<6%\Y%/=@!@  E2P  !D              ("!TAX! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " "R@%Q8:H)T#@P&  !J+@  &0
M            @(%I)0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( +* 7%@.Z7#Z&@0  !T1   9              " @:PK 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ LH!<6#TD^F,> P
MT L  !D              ("!_2\! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " "R@%Q84WHS+^@"   P"   &0              @(%2
M,P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +* 7%@;
M-Y7X.04  +(F   9              " @7$V 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ LH!<6"4SR>"Z P  TPX  !D
M     ("!X3L! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +* 7%C(H*MV- ,  -4*   9              "
M@<58 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ LH!<
M6.E##*!W @  ] 8  !D              ("!,%P! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " "R@%Q80=4Z0U<&  !&-0  &0
M        @('>7@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( +* 7%@XM3\#/04  )\B   9              " @6QE 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ LH!<6#D&2*8\!   A1D
M !D              ("!X&H! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " "R@%Q83SBB_#T.   &N0  &0              @(%3;P$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +* 7%BXK.%L
MJ08  $ K   9              " @<=] 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ LH!<6*3&,N[9 @  E @  !D
M ("!IX0! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "R
M@%Q8=4.95-P$  !]%0  &0              @(&WAP$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( +* 7%CYE?G@:P,   4-   9
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M970U.2YX;6Q02P$"% ,4    " "R@%Q8VV.93;<#  !&#0  &0
M    @('LH $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M +* 7%C2SS,R^0,  "X.   9              " @=JD 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ LH!<6'^@5Q.< @  9@<  !D
M             ("!"JD! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " "R@%Q8+.7(%6 "  ":!@  &0              @('=JP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( +* 7%BRZ%DMI@(
M .8'   9              " @72N 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ LH!<6,*DYLBX @  FP8  !D              ("!
M4;$! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " "R@%Q8
MVXS;YRT#   *"0  &0              @(% M $ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( +* 7%AK+T8\L@,  (@0   9
M      " @:2W 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%
M  @ LH!<6'C" M54 P  K!4   T              ( !C;L! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "R@%Q8EXJ[',     3 @  "P
M@ $,OP$ 7W)E;',O+G)E;'-02P$"% ,4    " "R@%Q8*X]O6WT%  ".+
M#P              @ 'UOP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MLH!<6,A<P5(@ @  T"<  !H              ( !G\4! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ LH!<6.(A,D+Q 0  &2<  !,
M             ( !]\<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $L
,2P"$%   &<H!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>228</ContextCount>
  <ElementCount>372</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - LICENSE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureLicenseAgreement</Role>
      <ShortName>LICENSE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES</Role>
      <ShortName>ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables</Role>
      <ShortName>ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995615 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995625 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995635 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995645 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995655 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995665 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995675 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995685 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995695 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995705 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995715 - Disclosure - FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995725 - Disclosure - FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995765 - Disclosure - ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails</Role>
      <ShortName>ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995775 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation Settlement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Litigation Settlement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995785 - Disclosure - COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995795 - Disclosure - OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails</Role>
      <ShortName>OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995805 - Disclosure - OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails</Role>
      <ShortName>OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995825 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails</Role>
      <ShortName>OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995835 - Disclosure - DEBT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails</Role>
      <ShortName>DEBT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995845 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails</Role>
      <ShortName>DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995855 - Disclosure - STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995865 - Disclosure - STOCKHOLDERS' EQUITY - PUBLIC OFFERING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - PUBLIC OFFERING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995875 - Disclosure - STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995885 - Disclosure - STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995895 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995905 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995915 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995925 - Disclosure - STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995935 - Disclosure - STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995945 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995955 - Disclosure - STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995965 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995975 - Disclosure - STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995985 - Disclosure - INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails</Role>
      <ShortName>INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995995 - Disclosure - INCOME TAXES - DEFERRED TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails</Role>
      <ShortName>INCOME TAXES - DEFERRED TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996005 - Disclosure - INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails</Role>
      <ShortName>INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996015 - Disclosure - INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails</Role>
      <ShortName>INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996025 - Disclosure - INCOME TAXES - CARES ACT IMPACT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails</Role>
      <ShortName>INCOME TAXES - CARES ACT IMPACT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails</Role>
      <ShortName>INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996045 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gern-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996055 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="gern-20231231.htm">gern-20231231.htm</File>
    <File>gern-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img43612817_0.jpg</File>
    <File>img43612817_1.jpg</File>
    <File>img43612817_2.jpg</File>
    <File>img43612817_3.jpg</File>
    <File>img43612817_4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="777">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gern-20231231.htm": {
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "gern-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "gern-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 308,
   "keyCustom": 64,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 49,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://www.geron.com/20231231": 2,
    "http://fasb.org/us-gaap/2023": 4,
    "http://xbrl.sec.gov/ecd/2023": 1
   },
   "contextCount": 228,
   "entityCount": 1,
   "segmentCount": 80,
   "elementCount": 735,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 777,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 11
   },
   "report": {
    "R1": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION",
     "longName": "100000 - Document - DOCUMENT AND ENTITY INFORMATION",
     "shortName": "DOCUMENT AND ENTITY INFORMATION",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "100040 - Statement - STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_66810d71-5d1a-4728-8f3a-817e2201e76e",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_66810d71-5d1a-4728-8f3a-817e2201e76e",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_42c6935a-1d5e-40dd-ab10-35f9472606c2",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_42c6935a-1d5e-40dd-ab10-35f9472606c2",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_3bb2a462-3594-4a43-8344-076ee590e035",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3bb2a462-3594-4a43-8344-076ee590e035",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "995455 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS",
     "longName": "995465 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT",
     "longName": "995475 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureLicenseAgreement",
     "longName": "995485 - Disclosure - LICENSE AGREEMENT",
     "shortName": "LICENSE AGREEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES",
     "longName": "995495 - Disclosure - ACCRUED LIABILITIES",
     "shortName": "ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES",
     "longName": "995505 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES",
     "longName": "995515 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT",
     "longName": "995525 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY",
     "longName": "995535 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES",
     "longName": "995545 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1",
     "longName": "995555 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "995575 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables",
     "longName": "995585 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables",
     "longName": "995595 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables",
     "longName": "995605 - Disclosure - ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables",
     "longName": "995615 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTTables",
     "longName": "995625 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables",
     "longName": "995635 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables",
     "longName": "995645 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables",
     "longName": "995655 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
     "longName": "995665 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_2eebd16c-0eef-470a-90b4-04639a5fa0b4",
      "name": "gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d88ef09-b3cf-469e-a8fe-49f54977425e",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1",
     "longName": "995675 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_38d32bf7-1b80-4b24-b2eb-46f7768d7421",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_38d32bf7-1b80-4b24-b2eb-46f7768d7421",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails",
     "longName": "995685 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails",
     "longName": "995695 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
     "longName": "995705 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
     "longName": "995715 - Disclosure - FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_5c78574d-4d3a-47d2-9453-d6f12deab799",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c78574d-4d3a-47d2-9453-d6f12deab799",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
     "longName": "995725 - Disclosure - FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_3bed0edb-6d63-45bc-b6ac-2fc53a07d1f3",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "us-gaap:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3bed0edb-6d63-45bc-b6ac-2fc53a07d1f3",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "us-gaap:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails",
     "longName": "995745 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails",
     "longName": "995765 - Disclosure - ACCRUED LIABILITIES (Details)",
     "shortName": "ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails",
     "longName": "995775 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation Settlement (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Litigation Settlement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "gern:LitigationSettlementAmountOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "gern:LitigationSettlementAmountOutstanding",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
     "longName": "995785 - Disclosure - COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "gern:NumberOfSeverancePlan",
      "unitRef": "U_Plan",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "gern:NumberOfSeverancePlan",
      "unitRef": "U_Plan",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
     "longName": "995795 - Disclosure - OPERATING LEASES (Details)",
     "shortName": "OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cea26a02-14ec-4995-aac7-14c8a668c2f9",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails",
     "longName": "995805 - Disclosure - OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)",
     "shortName": "OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails",
     "longName": "995825 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)",
     "shortName": "OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_eafcda82-47c3-4b44-8c80-5f3b1597ea98",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eafcda82-47c3-4b44-8c80-5f3b1597ea98",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
     "longName": "995835 - Disclosure - DEBT - Additional Information (Details)",
     "shortName": "DEBT - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_9909923d-f176-4cf6-ba61-369530284669",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9909923d-f176-4cf6-ba61-369530284669",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails",
     "longName": "995845 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)",
     "shortName": "DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails",
     "longName": "995855 - Disclosure - STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a814b358-835d-4bd9-9991-025af00007a2",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails",
     "longName": "995865 - Disclosure - STOCKHOLDERS' EQUITY - PUBLIC OFFERING (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - PUBLIC OFFERING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_95d2171c-44c4-4ef3-bcef-9a3bf9ca3146",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
     "longName": "995875 - Disclosure - STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_95534f32-aee8-4d09-9da3-068375f3be3c",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails",
     "longName": "995885 - Disclosure - STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_3e6e6755-b0cd-454c-bd57-da4270096040",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba",
      "name": "gern:CommonStockAggregateOfferingPrice",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
     "longName": "995895 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails",
     "longName": "995905 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_9a5c4c10-4219-41cc-b445-c46a46a9c509",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
     "longName": "995915 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d87baa2f-bd55-465b-8452-44ea0c0bd760",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
     "longName": "995925 - Disclosure - STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_34991f42-499f-4b50-9059-0999669562cd",
      "name": "gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
     "longName": "995935 - Disclosure - STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a771635-513d-4f44-938f-c72a1da4876b",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails",
     "longName": "995945 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88e8fe22-6578-4995-bace-a30be752ddd8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
     "longName": "995955 - Disclosure - STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
     "longName": "995965 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3ad6c2d6-0303-48fa-82c0-130aee8c97e6",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
     "longName": "995975 - Disclosure - STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5ed2423-f046-4a7d-980c-b9f3fb922f38",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails",
     "longName": "995985 - Disclosure - INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)",
     "shortName": "INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails",
     "longName": "995995 - Disclosure - INCOME TAXES - DEFERRED TAXES (Details)",
     "shortName": "INCOME TAXES - DEFERRED TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
     "longName": "996005 - Disclosure - INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)",
     "shortName": "INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_30549aaa-2d2b-429a-b2b7-bad54c937228",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_30549aaa-2d2b-429a-b2b7-bad54c937228",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails",
     "longName": "996015 - Disclosure - INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)",
     "shortName": "INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_30549aaa-2d2b-429a-b2b7-bad54c937228",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_30549aaa-2d2b-429a-b2b7-bad54c937228",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails",
     "longName": "996025 - Disclosure - INCOME TAXES - CARES ACT IMPACT (Details)",
     "shortName": "INCOME TAXES - CARES ACT IMPACT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_1e899757-4f56-49cf-873b-25770295bb58",
      "name": "gern:EmployerTaxReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1e899757-4f56-49cf-873b-25770295bb58",
      "name": "gern:EmployerTaxReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails",
     "longName": "996035 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)",
     "shortName": "INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f5f4fb9c-c772-432f-9a04-27782bb3ca05",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails",
     "longName": "996045 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996055 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)",
     "shortName": "SUBSEQUENT EVENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r688"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion and amortization on investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Research Organizations And Clinical Trial Costs Current",
        "terseLabel": "CRO and clinical trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AccruedEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AccruedEndOfTermCharge",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued end of term charge.",
        "label": "Accrued End Of Term Charge",
        "terseLabel": "Accrued end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AccruedEndOfTermCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AccruedEndOfTermCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued end of term charges.",
        "label": "Accrued End Of Term Charges",
        "verboseLabel": "Accrued end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "gern_AccruedManufacturingActivitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AccruedManufacturingActivitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Manufacturing Activities Current",
        "terseLabel": "Manufacturing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional legal and accounting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r153",
      "r525"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r86",
      "r158",
      "r522",
      "r538",
      "r539"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r13",
      "r35",
      "r436",
      "r439",
      "r475",
      "r534",
      "r535",
      "r801",
      "r802",
      "r803",
      "r810",
      "r811",
      "r812"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r547",
      "r810",
      "r811",
      "r812",
      "r865",
      "r891"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation for equity-based awards to employees and directors",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r360"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r109"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r726",
      "r736",
      "r762"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r717",
      "r729",
      "r739",
      "r765"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r730",
      "r740",
      "r757",
      "r766",
      "r770",
      "r778"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense included in operating expenses",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r400"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs/debt discount",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r461",
      "r673",
      "r674",
      "r807"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r154",
      "r184",
      "r213",
      "r226",
      "r230",
      "r269",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r429",
      "r433",
      "r452",
      "r518",
      "r586",
      "r688",
      "r703",
      "r828",
      "r829",
      "r874"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r159",
      "r184",
      "r269",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r429",
      "r433",
      "r452",
      "r688",
      "r828",
      "r829",
      "r874"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Change in fair value of equity investment, including foreign currency translation",
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "gern_AtMarketIssuanceSalesAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AtMarketIssuanceSalesAgreementsLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Issuance Sales Agreements.",
        "label": "At Market Issuance Sales Agreements [Line Items]",
        "terseLabel": "At Market Issuance Sales Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceSalesAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AtMarketIssuanceSalesAgreementsTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Issuance Sales Agreements.",
        "label": "At Market Issuance Sales Agreements [Table]",
        "terseLabel": "At Market Issuance Sales Agreements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At market issuance, 2018 sales agreement.",
        "label": "At Market Issuance Two Thousand And Eighteen Sales Agreement [Member]",
        "terseLabel": "2018 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At market issuance two thousand and twenty sales agreement.",
        "label": "At Market Issuance Two Thousand And Twenty Sales Agreement [Member]",
        "terseLabel": "2020 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Sales Agreement",
        "label": "At Market Issuance Two Thousand And Twenty Three Sales Agreement [Member]",
        "documentation": "At market issuance two thousand and twenty three sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Member.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r722"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r722"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r722"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r277",
      "r517"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r277",
      "r512",
      "r816"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r277"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Noncurrent marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r236",
      "r277"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "gern_BorrowingAvailableStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "BorrowingAvailableStartDate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First date to available to drawdown any amount under a tranche.",
        "label": "Borrowing Available Start Date",
        "terseLabel": "Start date to borrow under a tranche for a debt instrument"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method",
        "terseLabel": "Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method",
        "documentation": "The method of determining the fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "gern_CARESActImpactAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CARESActImpactAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES act impact.",
        "label": "C A R E S Act Impact [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Included in cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r150",
      "r658"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r117"
     ]
    },
    "gern_CashAndCashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CashAndCashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the gross unrealized gains for cash and cash equivalents.",
        "label": "Cash And Cash Equivalents Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CashAndCashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CashAndCashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_CashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the gross unrealized losses for cash and cash equivalents.",
        "label": "Cash And Cash Equivalents Unrealized Losses",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r94",
      "r182"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r94"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Amortized Cost",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r886"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ClassActionStipulationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ClassActionStipulationMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class action stipulation.",
        "label": "Class Action Stipulation [Member]",
        "terseLabel": "Class Action Stipulation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Warrants to purchase common stock, exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock, shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock, shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the period",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised",
        "terseLabel": "Warrants to purchase common stock exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding warrants to purchase",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "gern_ClinicalSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ClinicalSupplyAgreementMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that the company must pay after the termination of the Collaboration Agreement.",
        "label": "Collaborative Arrangement After Termination Cost Sharing Percentage Of Entity",
        "terseLabel": "Percentage of costs to be paid by Geron after termination of Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CollaborativeArrangementCostSharingPercentageOfCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CollaborativeArrangementCostSharingPercentageOfCounterparty",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that Janssen must pay during certain phases of the agreement.",
        "label": "Collaborative Arrangement Cost Sharing Percentage Of Counterparty",
        "terseLabel": "Percentage of costs to be paid by Janssen"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CollaborativeArrangementCostSharingPercentageOfEntity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CollaborativeArrangementCostSharingPercentageOfEntity",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that Geron must pay during certain phases of the agreement.",
        "label": "Collaborative Arrangement Cost Sharing Percentage Of Entity",
        "terseLabel": "Percentage of costs to be paid by Geron"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "LICENSE AGREEMENT",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136",
      "r145"
     ]
    },
    "gern_CollaborativeArrangementNumberOfStudies": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CollaborativeArrangementNumberOfStudies",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of agreed upon studies.",
        "label": "Collaborative Arrangement Number Of Studies",
        "terseLabel": "Number of agreed upon studies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "gern_CommercialPaperDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CommercialPaperDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to unsecured promissory note (generally negotiable) that provides institutions with short-term funds ), due in less than one year.",
        "label": "Commercial Paper Due In Less Than One Year [Member]",
        "terseLabel": "Commercial paper (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r73",
      "r519",
      "r573"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r286",
      "r287",
      "r654",
      "r825"
     ]
    },
    "gern_CommonStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CommonStockAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate offering price for which the entity may elect to issue and sell shares of its common stock under the sales agreement.",
        "label": "Common Stock Aggregate Offering Price",
        "terseLabel": "Aggregate offering price of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for future issuance (in shares)",
        "verboseLabel": "Common stock reserved for future issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r691",
      "r692",
      "r694",
      "r695",
      "r696",
      "r697",
      "r810",
      "r811",
      "r865",
      "r887",
      "r891"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r574"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r80",
      "r574",
      "r592",
      "r891",
      "r892"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 1,350,000,000 shares authorized; 544,912,215 and 390,262,524 shares issued and outstanding at December 31, 2023 and 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r521",
      "r688"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Significant components of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r164",
      "r166",
      "r172",
      "r513",
      "r530"
     ]
    },
    "us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRisksTypesNoConcentrationPercentageAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risks, Types, No Concentration Percentage [Abstract]",
        "terseLabel": "Credit Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r662"
     ]
    },
    "gern_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to consultants.",
        "label": "Consultants [Member]",
        "terseLabel": "Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CorporateNoteSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CorporateNoteSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in less than one year.",
        "label": "Corporate Note Securities Due In Less Than One Year [Member]",
        "terseLabel": "Corporate notes (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CorporateNoteSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in one to two years.",
        "label": "Corporate Note Securities Due In One To Two Years [Member]",
        "terseLabel": "Corporate notes (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate notes",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CostMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CostMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost method investment ownership percentage.",
        "label": "Cost Method Investment Ownership Percentage",
        "terseLabel": "Cost method investments ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CostMethodInvestmentsCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "CostMethodInvestmentsCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost method investments cost basis.",
        "label": "Cost Method Investments Cost Basis",
        "terseLabel": "Cost method investments cost basis"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r307",
      "r334",
      "r476",
      "r659",
      "r661"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinCashUponLicensingTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtCovenantMinCashUponLicensingTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash covenant required upon certain licensing transactions being executed.",
        "label": "Debt Covenant Min Cash Upon Licensing Transaction",
        "terseLabel": "Debt covenant minimum cash balance upon licensing transaction"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinCashUponRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtCovenantMinCashUponRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash covenant required upon achievement of certain regulatory milestones.",
        "label": "Debt Covenant Min Cash Upon Regulatory Milestone",
        "terseLabel": "Debt covenant minimum cash balance upon regulatory milestone achievement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinimumCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtCovenantMinimumCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Minimum Cash Balance",
        "label": "Debt Covenant Minimum Cash Balance",
        "terseLabel": "Debt covenant minimum cash balance"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtCovenantMinimumCashBalancePercentageOfLoanAmount",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of loan amount outstanding to be held as minimum cash balance under debt covenant.",
        "label": "Debt covenant minimum cash balance percentage of loan amount",
        "terseLabel": "Minimum cash balance as a percentage of loan amount outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantPercentageOfProductRevenueAgainstForecast": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtCovenantPercentageOfProductRevenueAgainstForecast",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of six-month product revenue forecast to satisfy minimum cash balance debt covenant.",
        "label": "Debt covenant percentage of product revenue against forecast",
        "verboseLabel": "Minimum cash balance requirement to be met as a percentage of six-month product revenue against forecast"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt, Current, Total",
        "label": "Debt, Current",
        "terseLabel": "Debt",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r183",
      "r303",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r319",
      "r326",
      "r327",
      "r329"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r77",
      "r78",
      "r119",
      "r120",
      "r188",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r462",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r808"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Variable interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Percentage added to prime rate for debt instrument interest rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal amount outstanding under term loan",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r120",
      "r330"
     ]
    },
    "gern_DebtInstrumentEndOfTermChargePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtInstrumentEndOfTermChargePercentage",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding loan amount payable upon maturity.",
        "label": "Debt Instrument End Of Term Charge Percentage",
        "terseLabel": "End of term charge for loan, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principle amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71",
      "r304",
      "r462",
      "r671",
      "r672"
     ]
    },
    "gern_DebtInstrumentFaceAmountExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtInstrumentFaceAmountExpired",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument face amount expired",
        "label": "Debt Instrument Face Amount Expired",
        "documentation": "Debt instrument face amount expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Term loan interest rate description",
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r69"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Minimum interest rate (as a percentage)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r305"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r462",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r808"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Term loan maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r670",
      "r866"
     ]
    },
    "gern_DebtInstrumentMinimumPrepaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtInstrumentMinimumPrepaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount allowed to be prepaid under debt instrument.",
        "label": "Debt Instrument Minimum Prepayment Amount",
        "terseLabel": "Minimum amount of prepayment allowed under debt instrument"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r188",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r462",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r808"
     ]
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Description of term loan payment terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r75"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r51",
      "r52",
      "r68",
      "r69",
      "r71",
      "r74",
      "r107",
      "r108",
      "r188",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r462",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r808"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt discount amount",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: unamortized debt discount and issuance costs",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r831"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r315",
      "r331",
      "r671",
      "r672"
     ]
    },
    "gern_DebtInstrumentUnamortizedEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DebtInstrumentUnamortizedEndOfTermCharge",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized end of term charge.",
        "label": "Debt Instrument Unamortized End Of Term Charge",
        "negatedLabel": "Less: unamortized end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "verboseLabel": "Available remaining loan principal under second amendment",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs and Debt Discounts",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater - Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r281",
      "r669"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Greater - Gross Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r281"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months - Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r281",
      "r669"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months - Gross Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r281"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total - Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r279",
      "r669"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total - Gross Unrealized Losses",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r280"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and marketable securities with unrealized losses",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r669",
      "r823"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Gross",
        "verboseLabel": "Debt issuance costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to the treatment of research and development costs.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DeferredTaxAssetsFederalAndStateCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DeferredTaxAssetsFederalAndStateCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets federal and state credits.",
        "label": "Deferred Tax Assets Federal And State Credits",
        "terseLabel": "Federal and state tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "gern_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r863"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r862"
     ]
    },
    "gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating leases right of use assets.",
        "label": "Deferred Tax Liabilities Operating Leases Right Of Use Assets",
        "negatedLabel": "Operating leases, right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Amortization related to 401(k) contributions",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "gern_DepositsAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.",
        "label": "Deposits And Other Assets Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Abstract]",
        "terseLabel": "Depreciation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion, and Amortization [Policy Text Block]",
        "terseLabel": "Depreciation and Amortization",
        "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized."
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "gern_DerivativeStipulationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DerivativeStipulationMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative stipulation.",
        "label": "Derivative Stipulation [Member]",
        "terseLabel": "Derivative Stipulation"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DirectorsMarketValueStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DirectorsMarketValueStockPurchasePlanMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors\u2019 market value stock purchase plan.",
        "label": "Directors Market Value Stock Purchase Plan [Member]",
        "terseLabel": "Directors Market Value Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DirectorsPlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DirectorsPlan2006Member",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2006 Directors Plan.",
        "label": "Directors Plan2006 [Member]",
        "terseLabel": "2006 Directors Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r722"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r722",
      "r758"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DollarPrepaymentCharge36MonthsAfterEffectiveDate",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment charge assessed upon debt prepayment occurring 36 months after June 30, 2022 under second amendment.",
        "label": "Dollar prepayment charge 36 months after effective date",
        "verboseLabel": "Charge for prepayment occurring 36 months after effective date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "gern_DueToCounterParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "DueToCounterParty",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due to counterparty. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Counter Party",
        "terseLabel": "Amount due to Janssen Biotech, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r211",
      "r443",
      "r444",
      "r514",
      "r531",
      "r664"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r205",
      "r207",
      "r208",
      "r209",
      "r211",
      "r443",
      "r444",
      "r514",
      "r531",
      "r664"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of unrealized losses and exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r406",
      "r423"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r864"
     ]
    },
    "gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax Rate reconciliation net operating loss not benefitted.",
        "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted",
        "terseLabel": "Net operating loss not benefitted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r864"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Federal and state tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r864"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "gern_EmployeeRetentionCreditAmountOutstandingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "EmployeeRetentionCreditAmountOutstandingReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Retention Credit, Outstanding",
        "label": "Employee Retention Credit Amount Outstanding Receivables",
        "documentation": "Employee retention credit amount outstanding receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized, net of estimated forfeitures (in dollars)",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]",
        "terseLabel": "Compensation cost related to unvested stock awards not yet recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of compensation cost on weighted average basis",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "verboseLabel": "Employee stock purchase",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "gern_EmployeesAboveTheVicePresidentLevelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "EmployeesAboveTheVicePresidentLevelMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees Above The Vice President Level",
        "label": "Employees Above The Vice President Level [Member]",
        "documentation": "Employees above the vice president level."
       }
      }
     },
     "auth_ref": []
    },
    "gern_EmployerTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "EmployerTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of employer taxes paid to tax authorities representing refunds based on calculated eligible credits. Also called employer tax refund receivable.",
        "label": "Employer Tax Receivable",
        "terseLabel": "Employee retention credit, CARES Act"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r146",
      "r168",
      "r169",
      "r170",
      "r189",
      "r190",
      "r191",
      "r193",
      "r199",
      "r201",
      "r212",
      "r270",
      "r271",
      "r337",
      "r393",
      "r394",
      "r395",
      "r420",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r475",
      "r534",
      "r535",
      "r536",
      "r547",
      "r615"
     ]
    },
    "gern_EquityInvestmentReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "EquityInvestmentReverseStockSplit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split ratio for equity investment.",
        "label": "Equity Investment Reverse Stock Split",
        "terseLabel": "Equity investment reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investment",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r698",
      "r699",
      "r700",
      "r893"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r726",
      "r736",
      "r762"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r723",
      "r733",
      "r759"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "gern_ExpiryDateOfTranche": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ExpiryDateOfTranche",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date to borrow under a tranche for a debt instrument",
        "label": "Expiry Date Of Tranche",
        "documentation": "Last date to drawdown any amounts under a tranche."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FacilityCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FacilityCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility charge",
        "label": "Facility Costs",
        "documentation": "Facility expenses incurred related to gas and oil produced and sold during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r132"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value on a Recurring Basis",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r450"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r450"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents, restricted cash and marketable securities by security type",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r447",
      "r483",
      "r484",
      "r485",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448",
      "r449",
      "r451"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r349",
      "r354",
      "r447",
      "r483",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r349",
      "r354",
      "r447",
      "r484",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r447",
      "r485",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r483",
      "r484",
      "r485",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r451"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r282",
      "r283",
      "r328",
      "r335",
      "r441",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r529",
      "r669",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "gern_FirstDirectorOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "FirstDirectorOptionMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the stock options to be granted by the entity to a person who first becomes a non-employee director.",
        "label": "First Director Option [Member]",
        "terseLabel": "First Director Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Gain (loss) related to foreign currency translation",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r594",
      "r701",
      "r868",
      "r869",
      "r890"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r766"
     ]
    },
    "gern_FormerCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "FormerCollaborativeArrangementMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former collaborative arrangement.",
        "label": "Former Collaborative Arrangement [Member]",
        "terseLabel": "Former Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_FosterCityOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "FosterCityOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foster City office space lease.",
        "label": "Foster City Office Space Lease [Member]",
        "terseLabel": "Foster City Office Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and computer equipment",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedLabel": "Net gain on exchange and sales of equity investment",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainOnSaleOfInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on Sale of Investments",
        "negatedLabel": "Gain on sales of available for sale securities",
        "documentation": "The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r805",
      "r807",
      "r882"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r598"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government sponsored enterprise securities due in less than one year.",
        "label": "Government Sponsored Enterprise Securities Due In Less Than One Year [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae) due in 1 to 2 years.",
        "label": "Government Sponsored Enterprise Securities Due In One To Two Years [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_HerculesAndSiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "HerculesAndSiliconValleyBankMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules and Silicon Valley Bank. member.",
        "label": "Hercules And Silicon Valley Bank [Member]",
        "terseLabel": "Hercules and Silicon Valley Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_HerculesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "HerculesMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules.",
        "label": "Hercules [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r709",
      "r722"
     ]
    },
    "gern_IncentiveAwardPlan2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "IncentiveAwardPlan2011Member",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2011 Incentive Award Plan.",
        "label": "Incentive Award Plan2011 [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r285",
      "r599"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r599"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r402",
      "r407",
      "r412",
      "r418",
      "r422",
      "r424",
      "r425",
      "r426",
      "r544"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r404",
      "r405",
      "r412",
      "r413",
      "r417",
      "r419",
      "r541"
     ]
    },
    "gern_IncreaseDecreaseDueToCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "IncreaseDecreaseDueToCounterparty",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period for amount due to counterparty.",
        "label": "Increase Decrease Due To Counterparty",
        "terseLabel": "Amount due to Janssen Biotech, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due for interest payments related to marketable securities and in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.",
        "label": "Increase Decrease In Accrued Interest Receivable Net And Other Receivables",
        "negatedLabel": "Interest and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposit and other assets",
        "totalLabel": "Increase (Decrease) in Deposit Assets, Total",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Increase (decrease) in fair value of equity investment",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r177"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "gern_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid and other current assets",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r730",
      "r740",
      "r757",
      "r766",
      "r770",
      "r778"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r782"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r782"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r782"
     ]
    },
    "us-gaap_InsuranceClaimsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceClaimsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Claims [Member]",
        "terseLabel": "Insurance Claims",
        "documentation": "A demand for payment of a policy benefit because of the occurrence of an insured event, such as the death or disability of the insured; the maturity of an endowment; the incurrence of hospital or medical bills; the destruction or damage of property and related deaths or injuries; defects in, liens on, or challenges to the title to real estate; or the occurrence of a surety loss; and the costs to process claims."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r123",
      "r171",
      "r217",
      "r460",
      "r600",
      "r701",
      "r889"
     ]
    },
    "gern_InterestOnlyPeriodPaymentTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "InterestOnlyPeriodPaymentTermDescription",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest only period payment term description.",
        "label": "Interest Only Period Payment Term Description",
        "terseLabel": "Interest only period payment term description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r180",
      "r181"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable",
        "negatedLabel": "Less: amount representing interest",
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r884"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r216"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Investment Owned, Fair Value, Ending Balance",
        "periodStartLabel": "Investment Owned, Fair Value, Beginning Balance",
        "label": "Investment Owned, Fair Value",
        "terseLabel": "Fair value of equity investment",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r549",
      "r550",
      "r551",
      "r553",
      "r555",
      "r556",
      "r557",
      "r560",
      "r565",
      "r566",
      "r577",
      "r578",
      "r619",
      "r622",
      "r623",
      "r625",
      "r630",
      "r631",
      "r634",
      "r635",
      "r636",
      "r639",
      "r640",
      "r643",
      "r645",
      "r646",
      "r692",
      "r703",
      "r888"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r560",
      "r621",
      "r632",
      "r642",
      "r692"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552",
      "r553",
      "r556",
      "r560",
      "r619",
      "r622",
      "r627",
      "r631",
      "r634",
      "r637",
      "r638",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650",
      "r692"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552",
      "r553",
      "r556",
      "r560",
      "r619",
      "r622",
      "r627",
      "r631",
      "r634",
      "r637",
      "r638",
      "r645",
      "r647",
      "r648",
      "r649",
      "r650",
      "r692"
     ]
    },
    "gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithWarrantExerciseShares",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares issued during the period in connection with exercise of warrants.",
        "label": "Issuance Of Common Stock In Connection With Warrant Exercise Shares",
        "terseLabel": "Issuance of common stock in connection exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "IssuanceOfCommonStockInConnectionWithWarrantExerciseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock issued in connection with exercise of warrants during the period.",
        "label": "Issuance Of Common Stock In Connection With Warrant Exercise Value",
        "terseLabel": "Issuance of common stock in connection exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Stock-based compensation for services by non-employees",
        "verboseLabel": "Stock-based compensation for services by non-employees",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "gern_JanssenBiotechIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "JanssenBiotechIncMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Janssen Biotech Inc.",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r687"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating Lease, Percentage of Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Undiscounted future non-cancellable lease payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Operating lease term, option to terminate lease",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease term, option to extend additional period",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, initial term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r184",
      "r269",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r430",
      "r433",
      "r434",
      "r452",
      "r572",
      "r665",
      "r703",
      "r828",
      "r874",
      "r875"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r121",
      "r524",
      "r688",
      "r809",
      "r822",
      "r867"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r149",
      "r184",
      "r269",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r430",
      "r433",
      "r434",
      "r452",
      "r688",
      "r828",
      "r874",
      "r875"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LicenseAgreementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LicenseAgreementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License Agreement Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityBorrowingCapacityDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityBorrowingCapacityDescription",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Borrowing Capacity, Description",
        "terseLabel": "Expiration date to borrow under a tranche for a debt instrument, description",
        "documentation": "Description of the credit facility's borrowing capacity including discussion of how the borrowing capacity is determined (for example, borrowing capacity based on the amount of current assets)."
       }
      }
     },
     "auth_ref": [
      "r797",
      "r798"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity under term loan",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LitigationSettlementAmountAccruedLiabilitiesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LitigationSettlementAmountAccruedLiabilitiesRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount, Accrued liabilities recognized",
        "label": "Litigation settlement amount, Accrued liabilities recognized",
        "terseLabel": "Settlement amount, Accrued liabilities recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "gern_LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount, General and administrative expense recognized.",
        "label": "Litigation settlement amount, General and administrative expense recognized",
        "terseLabel": "Settlement amount, General and administrative expense recognized"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LitigationSettlementAmountInterestAndOtherReceivableRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LitigationSettlementAmountInterestAndOtherReceivableRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement Amount, Interest and other receivable Recognized",
        "label": "Litigation Settlement Amount, Interest and other receivable Recognized",
        "terseLabel": "Settlement amount, Interest and other receivable recognized"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LitigationSettlementAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LitigationSettlementAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement Amount Outstanding",
        "label": "Litigation Settlement Amount Outstanding",
        "documentation": "Litigation settlement amount outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LitigationSettlementAmountPaidInCashOrKind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LitigationSettlementAmountPaidInCashOrKind",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the settlement to be paid by the company in either cash or shares, at the company's election.",
        "label": "Litigation Settlement Amount Paid in Cash or Kind",
        "terseLabel": "Settlement to be paid in cash or shares as elected by company"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LitigationSettlementAmountToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LitigationSettlementAmountToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement amount to be paid.",
        "label": "Litigation Settlement Amount to be Paid",
        "terseLabel": "Settlement amount to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "terseLabel": "Carrying value of term loan, net",
        "totalLabel": "Long-Term Debt, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r120",
      "r316",
      "r332",
      "r671",
      "r672",
      "r885"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: current portion of debt",
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "negatedLabel": "Less: current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_LongTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtDescription",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Description",
        "terseLabel": "Description of maturity date terms for term loan",
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r51"
     ]
    },
    "gern_LongTermDebtGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LongTermDebtGross",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of term loan, including accrued interest payable and end of term charge.",
        "label": "Long Term Debt Gross",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "gern_LongTermDebtGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r188",
      "r321"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": "gern_LongTermDebtGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r188",
      "r321"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Noncurrent debt",
        "totalLabel": "Noncurrent portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r293",
      "r826",
      "r827"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r293",
      "r826",
      "r827"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r293",
      "r826",
      "r827"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r293",
      "r826",
      "r827"
     ]
    },
    "gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency period of current base salary to be paid under severance plan.",
        "label": "Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan",
        "terseLabel": "Period of base salary to be considered for severance payments"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of base salary in connection with a non-change of control to be considered for severance payments",
        "label": "Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan Non Change of Control Triggering Event",
        "documentation": "Loss contingency period of current base salary to be paid under severance plan non change of control triggering event."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencySettlementAgreementDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencySettlementAgreementDate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Settlement Agreement, Date",
        "terseLabel": "Settlement agreement date",
        "documentation": "The effective date of a duly executed litigation settlement agreement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r103"
     ]
    },
    "gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of months following a change in control when an employee is terminated without cause to be classified as a triggering event for severance payments.",
        "label": "Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period",
        "terseLabel": "Period within which employee is terminated by entity without cause following a change of control"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period following change of control within which an employee is not offered comparable employment (new or continuing) by the entity or its successor or acquired and to be considered as triggering event for severance payments.",
        "label": "Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity",
        "terseLabel": "Period within which no comparable employment is offered by the entity following a change of control"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period within which employee resigns following a change of control due to material change in terms of employment and to be considered as triggering event for severance payments.",
        "label": "Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment",
        "terseLabel": "Period within which employee resigns following a change of control due to material change in terms of employment"
       }
      }
     },
     "auth_ref": []
    },
    "gern_MarketCapMinimumToUseOptionTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "MarketCapMinimumToUseOptionTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market capitalization required for this option to be available to meet the minimum cash balance debt covenant.",
        "label": "Market cap minimum to use option two",
        "verboseLabel": "Minimum market capitalization requirement for option"
       }
      }
     },
     "auth_ref": []
    },
    "gern_MaximumCommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "MaximumCommissionRate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of maximum commission rate, based on gross proceeds of sale price per share of common stock sold through sales agent under the sales agreement.",
        "label": "Maximum Commission Rate",
        "terseLabel": "Maximum commission rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r356",
      "r510",
      "r533",
      "r561",
      "r562",
      "r620",
      "r626",
      "r628",
      "r629",
      "r641",
      "r655",
      "r656",
      "r668",
      "r675",
      "r679",
      "r689",
      "r830",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "gern_MenloParkOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "MenloParkOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo park office space lease.",
        "label": "Menlo Park Office Space Lease [Member]",
        "terseLabel": "Menlo Park Office Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r356",
      "r510",
      "r533",
      "r561",
      "r562",
      "r620",
      "r626",
      "r628",
      "r629",
      "r641",
      "r655",
      "r656",
      "r668",
      "r675",
      "r679",
      "r689",
      "r830",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "MinimumPercentageOfNetProductRevenuesMaintenancePeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of net product revenues maintenance period.",
        "label": "Minimum percentage of net product revenues maintenance period",
        "verboseLabel": "Minimum percentage of net product revenues maintenance period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal securities",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "gern_MunicipalSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "MunicipalSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities due in less than one year.",
        "label": "Municipal Securities Due In Less Than One Year [Member]",
        "terseLabel": "Municipal securities (due in less than a year)",
        "verboseLabel": "Municipal securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_MunicipalSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "MunicipalSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities due in one to two years member.",
        "label": "Municipal Securities Due In One To Two Years [Member]",
        "terseLabel": "Municipal securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r96",
      "r122",
      "r147",
      "r163",
      "r165",
      "r170",
      "r184",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r206",
      "r213",
      "r225",
      "r229",
      "r231",
      "r269",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r444",
      "r452",
      "r528",
      "r595",
      "r613",
      "r614",
      "r666",
      "r701",
      "r828"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "gern_NewJerseyLeaseAndFosterCityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "NewJerseyLeaseAndFosterCityLeaseMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Jersey lease and Foster city lease member.",
        "label": "New Jersey Lease And Foster City Lease [Member]",
        "terseLabel": "New Jersey Lease And Foster City Lease"
       }
      }
     },
     "auth_ref": []
    },
    "gern_NewJerseyOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "NewJerseyOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New jersey office space lease.",
        "label": "New Jersey Office Space Lease [Member]",
        "terseLabel": "New Jersey Office Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r730",
      "r740",
      "r757",
      "r766"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Interest and other receivables",
        "totalLabel": "Nontrade Receivables, Current, Total",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "gern_NumberOfFinancialInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "NumberOfFinancialInstitutions",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institutions.",
        "label": "Number Of Financial Institutions",
        "terseLabel": "Number of financial institutions"
       }
      }
     },
     "auth_ref": []
    },
    "gern_NumberOfSeverancePlan": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "NumberOfSeverancePlan",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "severance plans",
        "label": "Number Of Severance Plan",
        "documentation": "Number of severance plan."
       }
      }
     },
     "auth_ref": []
    },
    "gern_NumberOfSharesSoldFromEquityInvestment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "NumberOfSharesSoldFromEquityInvestment",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares from equity investment that have been sold during the period.",
        "label": "Number Of Shares Sold From Equity Investment",
        "terseLabel": "Number Of Shares Sold From Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r225",
      "r229",
      "r231",
      "r666"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r687"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "gern_OperatingLeaseRentAbatementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "OperatingLeaseRentAbatementPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease rent abatement period.",
        "label": "Operating Lease Rent Abatement Period",
        "terseLabel": "Operating lease, rent abatement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating leases, right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "gern_OperatingLeaseTermAdditionalPeriodExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "OperatingLeaseTermAdditionalPeriodExtension",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term additional period extension.",
        "label": "Operating Lease Term Additional Period Extension",
        "terseLabel": "Operating lease term, additional period extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease,remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r687"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expire beginning 2028 through 2041",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "gern_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expire beginning 2024 through 2037",
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "gern_OptionOneMinCashDebtCovenantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "OptionOneMinCashDebtCovenantMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option one min cash debt covenant.",
        "label": "Option one min cash debt covenant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_OptionThreeMinCashDebtCovenantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "OptionThreeMinCashDebtCovenantMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option three min cash debt covenant.",
        "label": "Option three min cash debt covenant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_OptionTwoMinCashDebtCovenantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "OptionTwoMinCashDebtCovenantMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option two min cash debt covenant.",
        "label": "Option Two Min Cash Debt Covenant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r97",
      "r98",
      "r116"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax, Total",
        "terseLabel": "Net unrealized loss on marketable securities",
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized loss on marketable securities",
        "verboseLabel": "Other comprehensive loss",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r162",
      "r268"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income , net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r716",
      "r728",
      "r738",
      "r764"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r731",
      "r741",
      "r767"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r719",
      "r731",
      "r741",
      "r767"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesLitigationSettlementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Legal Settlements",
        "terseLabel": "Settlement to be paid by insurers",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "gern_PercentageOfInterestOnPastDueOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PercentageOfInterestOnPastDueOutstanding",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Added percentage to current interest rate under debt instrument to past due amounts.",
        "label": "Percentage Of Interest On Past Due Outstanding",
        "terseLabel": "Additional percentage of interest on past due amounts"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfPrepaymentCharge": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PercentageOfPrepaymentCharge",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment amount to be paid upon prepayment under debt instrument.",
        "label": "Percentage Of Prepayment Charge",
        "terseLabel": "Prepayment charge (as a percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining term commitments held under loan agreement.",
        "label": "Percentage of Remaining Term Commitments Held Under Loan Agreement",
        "terseLabel": "Percentage of remaining term commitments held under loan agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PerformanceBasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PerformanceBasedStockOptionsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based stock options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance-Based Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "gern_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants Purchase [Member]",
        "terseLabel": "Pre-Funded Warrants",
        "documentation": "Pre-funded warrants purchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r333"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r574"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r333"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r574",
      "r592",
      "r891",
      "r892"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r520",
      "r688"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock from at market offerings, net of paid issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from debt financing, net of paid debt issuance costs and debt discounts",
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r542"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuances of common stock from equity plans",
        "totalLabel": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds from public offering after deducting underwriting discount and other offering expenses",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r542"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r817"
     ]
    },
    "gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from public offering issuance of common stock and warrants.",
        "label": "Proceeds From Public Offering Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales of securities available for sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r174",
      "r235",
      "r267"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherAssetsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfOtherAssetsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Other Assets, Investing Activities",
        "terseLabel": "Proceeds from sales of equity investment",
        "documentation": "Amount of cash inflow from the sale of other assets recognized in investing activities."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from exercise of stock options (in dollars)",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r163",
      "r165",
      "r178",
      "r184",
      "r192",
      "r200",
      "r201",
      "r213",
      "r225",
      "r229",
      "r231",
      "r269",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r428",
      "r431",
      "r432",
      "r444",
      "r452",
      "r515",
      "r527",
      "r546",
      "r595",
      "r613",
      "r614",
      "r666",
      "r684",
      "r685",
      "r702",
      "r803",
      "r828"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r138",
      "r141",
      "r142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r152",
      "r526"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r516",
      "r526",
      "r688"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, stated at cost",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PublicOfferingLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Line Items]",
        "terseLabel": "Public Offering [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingOfCommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PublicOfferingOfCommonStockAndWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering of Common Stock and Warrants [Member]",
        "label": "Public Offering Of Common Stock And Warrants [Member]",
        "terseLabel": "Public Offering of Common Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PublicOfferingStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering stock issued during period shares new issues.",
        "label": "Public Offering Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PublicOfferingStockIssuedDuringPeriodValueNewIssue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs",
        "label": "Public Offering Stock Issued During Period Value New Issue",
        "documentation": "Public offering stock issued during period value new issues."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PublicOfferingTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Table]",
        "terseLabel": "Public Offering [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "PurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase warrants.",
        "label": "Purchase Warrants [Member]",
        "terseLabel": "Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r348",
      "r356",
      "r387",
      "r388",
      "r389",
      "r486",
      "r510",
      "r533",
      "r561",
      "r562",
      "r620",
      "r626",
      "r628",
      "r629",
      "r641",
      "r655",
      "r656",
      "r668",
      "r675",
      "r679",
      "r689",
      "r692",
      "r824",
      "r830",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r292",
      "r348",
      "r356",
      "r387",
      "r388",
      "r389",
      "r486",
      "r510",
      "r533",
      "r561",
      "r562",
      "r620",
      "r626",
      "r628",
      "r629",
      "r641",
      "r655",
      "r656",
      "r668",
      "r675",
      "r679",
      "r689",
      "r692",
      "r824",
      "r830",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized investment gains (losses)",
        "totalLabel": "Realized Investment Gains (Losses), Total",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification between prepaid and other current assets and deposits and other assets.",
        "label": "Reclassification Between Prepaid And Other Current Assets And Deposits And Other Assets",
        "terseLabel": "Reclassification between prepaid and other current assets and deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r723",
      "r733",
      "r759"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r307",
      "r334",
      "r476",
      "r660",
      "r661"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r724",
      "r734",
      "r760"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r713",
      "r725",
      "r735",
      "r761"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r732",
      "r742",
      "r768"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "totalLabel": "Amortized Cost",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r150",
      "r182"
     ]
    },
    "gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "RestrictedCashAndCashEquivalentsGrossUnrealizedLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents gross unrealized losses.",
        "label": "Restricted Cash And Cash Equivalents Gross Unrealized Losses",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "gern_RestrictedCashAndCashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "RestrictedCashAndCashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents unrealized gains.",
        "label": "Restricted Cash And Cash Equivalents Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Investments [Abstract]",
        "terseLabel": "Restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedInvestmentsAtFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Estimated Fair Value",
        "documentation": "The aggregate value of all restricted investments."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r633",
      "r644",
      "r652",
      "r653"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r109",
      "r523",
      "r537",
      "r539",
      "r543",
      "r575",
      "r688"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r189",
      "r190",
      "r191",
      "r193",
      "r199",
      "r201",
      "r270",
      "r271",
      "r393",
      "r394",
      "r395",
      "r420",
      "r421",
      "r435",
      "r437",
      "r438",
      "r440",
      "r442",
      "r534",
      "r536",
      "r547",
      "r891"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License fees and royalties",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r224",
      "r227",
      "r228",
      "r232",
      "r233",
      "r234",
      "r346",
      "r347",
      "r511"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r657"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease assets obtained in exchange for operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r687"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offering price per share",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Combined public offering price per share of pre-funded warrants and accompanying stock purchase warrants",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r357",
      "r813"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r357",
      "r785",
      "r813"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental schedule of non-cash operating and investing activities",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common stock reserved for future issuance, which may include but is not limited to outstanding options and outstanding warrants.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of common stock reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the entity's deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule reconciles the federal statutory tax rate to the effective income tax rate from continuing operations",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of allocation of stock-based compensation expense related to share-based payment awards",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial instruments measured at fair value on recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under Term Loan Facility",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of aggregate stock option and award activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Goods and Nonemployee Services Transaction [Table]",
        "terseLabel": "Schedule Of Share Based Goods And Nonemployee Services Transaction [Table]",
        "documentation": "Details pertaining to each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate the fair value of stock options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r861"
     ]
    },
    "gern_SecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "SecondAmendmentMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment.",
        "label": "Second Amendment [Member]",
        "verboseLabel": "Second Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r233",
      "r667"
     ]
    },
    "gern_SeverancePlanLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "SeverancePlanLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance plan.",
        "label": "Severance Plan [Line Items]",
        "terseLabel": "Severance Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_SeverancePlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "SeverancePlanTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance plan.",
        "label": "Severance Plan [Table]",
        "terseLabel": "Severance Plan [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation for employees and directors",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate number of share instruments issued under a share-based compensation plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Shares Issued Under Plan",
        "terseLabel": "Aggregate shares issued under plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period of stock options",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of new offering period in a case where the fair market value of common stock on the purchase date is less than the fair market value at the beginning of the offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Of New Offering Period",
        "terseLabel": "Duration of the new offering period"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of the purchase period under the employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Of Purchase Period",
        "terseLabel": "Duration of the purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "negatedLabel": "Awards granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of other than employee stock options granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of restricted stock that vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to estimate fair value of awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility range, maximum (as a percent)",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility range, minimum (as a percent)",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate range, maximum (as a percent)",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate range, minimum (as a percent)",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of annual salary that can be withheld to purchase shares",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Of Annual Salary That Can Be Withheld Per Year",
        "documentation": "Share based compensation arrangement by share based payment award maximum amount of annual salary that can be withheld per year."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum duration of the offering period under the employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Duration Of Offering Period",
        "terseLabel": "Maximum duration of offering period"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of offering periods in which an employee can participate at a time in the purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Offering Periods In Which Employee May Participate At One Time",
        "terseLabel": "Number of offering periods in which an employee can participate at a time"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum percentage of annual salary that an employee can choose to have withheld to purchase common stock under the purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Annual Salary That Can Be Withheld",
        "terseLabel": "Maximum percentage of annual salary that can be withheld"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award minimum exercise price of options granted to employees with more than 10 percentage of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Exercise Price Of Options Granted To Employees With More Than10 Percentage Of Common Stock",
        "terseLabel": "Minimum exercise price as a percentage of fair market value for employees having more than 10 % outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum percentage of ownership required for granting of options at a price not less than 110 percent of the fair market value of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Ownership Required For Granting Options At Minimum110 Percent Of Fair Market Value",
        "terseLabel": "Minimum percentage of ownership required for granting stock options at least 110% of fair market value of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of consecutive purchase periods in an offering period in the purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Consecutive Purchase Periods In Each Offering Period",
        "terseLabel": "Number of consecutive purchase periods in an offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Stock options and awards available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable at the end of the period (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercisable at the end of the period (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total pretax intrinsic value of stock options exercised (in dollars)",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Stock options cancelled/forfeited/expired (in shares)",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)",
        "negatedLabel": "Stock options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of employee stock options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value - Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "terseLabel": "Common stock, increase in option reserves (in shares)",
        "verboseLabel": "Common stock, increase in shares reserved for future issuance (in shares)",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance at the end of the period (in dollars)",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Stock options outstanding (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares - Options Outstanding",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share - Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of options to be granted to purchase shares in each year during the optionee's service on the Board of Directors.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares",
        "terseLabel": "Stock options to be granted to purchase shares (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of options to be granted to purchase shares upon appointment to Board of Directors.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares Upon Appointment",
        "terseLabel": "Stock options to be granted to purchase shares upon appointment (shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period (in dollars)",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Life (In years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]",
        "terseLabel": "Weight Average Remaining Contractual Life (in years) - Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Grant",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Roll Forward",
        "terseLabel": "Shares Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options cancelled/forfeited/expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum expiration term of options granted to employees having more than 10 % outstanding common stock.",
        "label": "Share Based Compensation By Share Based Payment Award Options Maximum Expiration Term For Options Granted To Optionees With Ownership Of More Than10 Percentage Of Common Stock",
        "terseLabel": "Maximum expiration term of stock options granted to employees having more than 10 % outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareBasedCompensationForfeituresAndExpirationsInPeriodNet",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled or that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Forfeitures And Expirations In Period Net",
        "terseLabel": "Stock options cancelled/forfeited/expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r365",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r396",
      "r397",
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "terseLabel": "Supplier",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Goods and Nonemployee Services Transaction [Line Items]",
        "verboseLabel": "Stock-Based Compensation to Service Providers",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "terseLabel": "Supplier",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with public offering",
        "terseLabel": "Issuance of common stock in connection with public offering (in shares)",
        "documentation": "Number of new shares of common stock issued during the period in connection with public offering.",
        "label": "Share Of Common Stock Issued During Period Shares New Issues Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Closing stock price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration term of stock options from date of grant",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term range",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Stock options exercisable at the end of the period (in dollars)",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options exercisable at the end of the period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance at the end of the period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "verboseLabel": "Percentage applied to common stock market value in calculating purchase price under purchase plan",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r110"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offering price of common stock per share",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Combined public offering price per share of common stock and accompanying stock purchase warrants",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "gern_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank.",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r146",
      "r168",
      "r169",
      "r170",
      "r189",
      "r190",
      "r191",
      "r193",
      "r199",
      "r201",
      "r212",
      "r270",
      "r271",
      "r337",
      "r393",
      "r394",
      "r395",
      "r420",
      "r421",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r475",
      "r534",
      "r535",
      "r536",
      "r547",
      "r615"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r212",
      "r511",
      "r540",
      "r548",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r693"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r357",
      "r785",
      "r786",
      "r813"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r212",
      "r511",
      "r540",
      "r548",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r593",
      "r597",
      "r598",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r693"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r715",
      "r727",
      "r737",
      "r763"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock options and warrants excluded from diluted net loss per share calculation due to net loss position",
        "verboseLabel": "Employee Stock Purchase Plan",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in connection with at market offering, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r80",
      "r109",
      "r542",
      "r615",
      "r651"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under equity plans (in shares)",
        "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r80",
      "r109",
      "r371"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock-based compensation related to issuance of common stock and options in exchange for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with at market offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r80",
      "r109",
      "r547",
      "r615",
      "r651",
      "r702"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under equity plans",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r79",
      "r80",
      "r109"
     ]
    },
    "gern_StockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "StockPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase warrants.",
        "label": "Stock Purchase Warrants [Member]",
        "terseLabel": "Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r99",
      "r576",
      "r592",
      "r616",
      "r617",
      "r688",
      "r703",
      "r809",
      "r822",
      "r867",
      "r891"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r618"
     ]
    },
    "gern_SubsequentDirectorOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "SubsequentDirectorOptionMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the stock options to be granted by the entity subsequent to the grant upon first appointment to the Board of Directors.",
        "label": "Subsequent Director Option [Member]",
        "terseLabel": "Subsequent Director Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r478"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r479"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails",
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Investment Holdings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r564",
      "r596",
      "r692"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfInvestmentHoldingsTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Investment Holdings [Table]",
        "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded 1 percent of net asset value of the registrant as of the close of the period."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r563",
      "r564",
      "r596",
      "r692"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental operating and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "gern_ThirdAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "ThirdAmendmentMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Amendment [Member]",
        "label": "Third Amendment [Member]",
        "documentation": "Third amendment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r873"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheAMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche A [Member]",
        "label": "Tranche A [Member]",
        "terseLabel": "Tranche A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche B [Member]",
        "label": "Tranche B [Member]",
        "terseLabel": "Tranche B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche C [Member]",
        "label": "Tranche C [Member]",
        "terseLabel": "Tranche C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheFiveMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Five [Member]",
        "documentation": "Tranche five."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheFourMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche four.",
        "label": "Tranche Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one.",
        "label": "Tranche One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheSixMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Six [Member]",
        "documentation": "Tranche six."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three.",
        "label": "Tranche Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r328",
      "r335",
      "r441",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r529",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "gern_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading arrangement expiration date.",
        "terseLabel": "Expiration Date",
        "label": "Trd Arr Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "gern_TwoThousandAndEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 equity incentive plan.",
        "label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandAndEighteenInducementAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandAndEighteenInducementAwardPlanMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen inducement award plan.",
        "label": "Two Thousand And Eighteen Inducement Award Plan [Member]",
        "terseLabel": "2018 Inducement Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyPreFundedWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Pre-funded warrants.",
        "label": "Two Thousand Twenty Pre Funded Warrants [Member]",
        "terseLabel": "2020 Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Public Offering of Common Stock and Warrants.",
        "label": "Two Thousand Twenty Public Offering Of Common Stock And Warrants [Member]",
        "terseLabel": "2020 Public Offering of Common Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty purchase warrants.",
        "label": "Two Thousand Twenty Purchase Warrants [Member]",
        "terseLabel": "2020 Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyStockPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Stock Purchase Warrants [Member]",
        "label": "Two Thousand Twenty Stock Purchase Warrants [Member]",
        "terseLabel": "2020 Stock Purchase Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyThreePreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyThreePreFundedWarrantMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Pre-funded Warrant",
        "label": "Two Thousand Twenty Three Pre Funded Warrant Member",
        "documentation": "Two thousand twenty three pre funded warrant."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyThreeUnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2023 Public Offering",
        "documentation": "2023 Underwritten Public Offering.",
        "label": "Two Thousand Twenty Three Underwritten Public Offering [Member]",
        "terseLabel": "2023 Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoPreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyTwoPreFundedWarrantMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 pre-funded warrant.",
        "label": "Two Thousand Twenty Two Pre Funded Warrant [Member]",
        "terseLabel": "2022 Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyTwoPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two purchase warrants.",
        "label": "Two Thousand Twenty Two Purchase Warrants [Member]",
        "terseLabel": "2022 Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyTwoStockPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Stock Purchase Warrants.",
        "label": "Two Thousand Twenty Two Stock Purchase Warrants [Member]",
        "terseLabel": "2022 Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "TwoThousandTwentyTwoUnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock. = 2022 Underwritten Public Offering [Member].",
        "label": "Two Thousand Twenty Two Underwritten Public Offering [Member]",
        "terseLabel": "2022 Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae, due in less than one year.",
        "label": "U S Government Sponsored Enterprises Debt Securities Due In Less Than One Year [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae), due in one to two years.",
        "label": "U S Government Sponsored Enterprises Debt Securities Due In One To Two Years [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprise securities",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r883"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "gern_USTreasurySecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "USTreasurySecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Treasury Securities Due In less than one Year Member.",
        "label": "U S Treasury Securities Due In Less Than One Year [Member]",
        "terseLabel": "U.S. Treasury securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_USTreasurySecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "USTreasurySecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Treasury securities due in one to two years member.",
        "label": "U S Treasury Securities Due In One To Two Years [Member]",
        "terseLabel": "U.S. Treasury securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt discount and issuance costs",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "gern_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20231231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPUBLICOFFERINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r408"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease related to prior year tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits, if recognized would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r135",
      "r137",
      "r139",
      "r140"
     ]
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceAbstract",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r687"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expiration date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r209"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.geron.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r209"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//230/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479583/944-40-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-4"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-9"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0000950170-24-022056-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-022056-xbrl.zip
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M&(/7:X$)I0%RB,Z8Y+E7>7"AZENC]C(]#Z3!K^^]XFOA>44%YRR R>L[ <Z
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MN/7PC*^#<ZQ+YKH6W%"*Q9AJ!E8W\T0"/9. 9Y6,"<NI%%+E^VY_O\M3/YH
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MHM$ZGIVT8;"Z?^TY+=Y,\OOZ_:<:+]/=FPHTB3K)/<46L?:3<  6! O$45[
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M1X/>M0RB/?- ?.26%)\Y+8P[[P;+AW=[JW:+1.[B%,-3[DP,1 @&LL5B12Z
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MC293*F JL6P)D(H#$@&I[P(K) <G:+8\V.$ZK892TWS0)_9KO6;"8_),D"1
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MT7!N\5C3$9.$(!+P ;&%:^ M%WQ6D9OAPH4!)<&\FROWU#FK)&B : #FR5B
MP@M@$,Z-YA1V50TWN4T?@O+>?]Z=30_JYL1CO:+# >]A;,KX7\%T;-,HWDXN
MVENRZZG,JF304)@92L(?W!R#=YILCHF:,MSTLI==&.QC/:A>E_YYR"F(I8@Z
M)"=)Z2JOVD*)#8:1'#-C(D1.XV!CR.[SF=I-K?6U93G-"81# O":N08",(&2
MH H0H^;1AD)34(.U\RX#CL_JYJAN@"W0][=-@K .2O&,9PG0CY><B60:@)HM
MFEB3E5>!"SZ\(LW#N;8\@$LK)@LF:4;XAZ&E)DEBM8]$A50T(#4OV6!E_7V\
M9W8GU;>CMBDP,)\2WB6D,1";$FQY23D ZJ/2#A;S/="JJ6M1=_<U"Y.V5EH-
MH,-IK :GO2<NX&$.RTHFSS.C@[WM=&6XTZ=Z75O_P*#N "*Z!%72>2!'GG@@
MDF.:=!X,"3XI&9TP?+BY?:[R;#R';X&>XK-Z-IDVQ_<%@!;M2[2 /9E7!CV%
M"75;)*5$F50.H@PY8]O@[SO=#2@5QBMGO2(B6E  #@^**9@6&C[/4=@2W6 O
MQO\&VCYCE'7CXW3FQ^]S<[@D,U_G3_^:FS8?OREE%//>D8^Y^\E]83@'/!5%
MB$045C ZR! ;!"=)6RJ2$[S(P08&#35Q"+-KO(&45'2RN]SK.9&990(J"QA(
M.U=\]$GHP:8NO[#NR@FZR@WV 7(RMV_*\WQ4MZ-;L-EN!];*HD*6/I$(RT:D
MD)H$0PU(-06VMA56EL'"VH%%)JTQV[>B3H ,YJ0$8_!F42+..&!(6WSV@D=Z
M^X'J6^-X\\;Q_18E*6;/72:T&+Q:0B.Q5DEB0D@25'!*8K!'K%<%8MU5PHT!
MX%[JJ/$>+S@6;F%;529>9D,H#V#+<+ PV6"3LEU^[G)XF!M4[&\]K,<VU/K[
M./RA.B@L6D)RQ!0$/E(2(E4DLRADD$Z*,-ACPJ'E+[N== 0F\62%<419]/QC
M16&O(IC4@2K8))9-O@^>_RV>N/5Z5Y8F:0(!>P1-D^R)%0%,DR!,M$ZQ% ?L
MV+S#W+6#%O5K!)Q914<3]X0%D0&9%! D @ G3YY1FE1,<;" \ZHCF9?U;&V0
MY(&=R=Q.MD.666*<4N)UQ&R'&$#JP=@Q&N\0%>FR'.R-Z.&X?Y?M&885T*]W
M7G;VT1O=%U(Y<0F*JE"I 2"B;\52S*)?1 EX+UH,5JU<8J8N'GEQ>#2NCW/>
M1)KZ]66 U%))"2PEI 8;,PJ,V+*%9*.3=MZ[R <+VK^Q+O=ON6W?'WBLSXVE
MN>_+3@EC5,X"=*YS"B"[I\2!305\) T+FGIO!AM;=XMU"*\]ACL+X;ZEVT/"
M>TN] HR.-8,5"\0[!6HWY5(X-?!G< =OMY\$<EBW;>[ 9ZB4"8IBV*:1>.@7
M'+&<1<*E3#:;8#:0:.>;I413PU2GQ[@Y4Q0*( R.L(U?C[_<TI>S9C+")&;P
MX,O19WQU;V[^4>9E";Q@ E<0Y=%JXD/0!/ LF%74R4@'>R@[F!P_M[,U6EM&
MDV%$)>:!?[@EMH#2M<QD#G 8<-&MB]4[._QT.H=H(B,FVDAD#IBB3'NB8@P^
M19>U')Q_\,[J"=[19:Q"60DFDYQ"Q&)20)K!1&(8*[&XJ+,=+ K\^HSMG^IA
MY&$X;V1G:Q+<LN\.K'"Z'CO")QUYTH0**O Z'U 0CR!%!/4YV^C,<%-D]H6L
M\2;.W^HZH5?K->S5PN[.S<=1S"WZ\5K?7</]]7AO=@2-YF9I,Y_5DW8VGJZS
MC,0%L'/%(_ =WQ M&FQ3J@,1!>/R:;0D1 E"*12IE4A6I\$Y=NXD(?W7WD^^
MG^2 I8Y9P91  JQ2Z6,FCF4P38VR*C//M1TLO+W"8?NR;J>Y>08COJ\!NR($
M[J6&YI23Z#P2Q H)R@6 ;<9L]53<>NKLKR=C1C=/QMFRDH)1A&4PH"5WE'A
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M':7.T/BHFH-6T+?7+@=;33P:"BF/GCZOXVQQ[VD8"PI&\M]/R&EE67[9<N;
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MRSE75CO*[Q+S['7L\&8V[5R$P&8K$K!GEF4A^.KURRO$8"< E7LLJ!N4$+R
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M_^EQU=V;]Z-.7!XO_Q:6:':4?,\@L(Q7NV(0R!<$*<#!>+Q:+>7*>+Q 90B
M1TV<';:=HFS/'E\\#!?GP/R9:_9J+Q'Y%S$G#VF7OW=']J^@,S]U"!\4;[?-
MO9[H'9HG<K"3R8?^3X04Z*L%'=@IVKGP[<L[P,CK^&>%N@*A5V=[]B+_>*=Z
M=8CBSR->>=S+Q45_J>Z$WA2U?=,IGU-M?)&_::%V87QYI_J/>E;UOKVJ"^9
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M<]*ZE'-VJE>+DX/5'E+=G3ZLACWY!D\(9QV\&S6=)=7,(S/3K \]:_J8FI-
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M@,O!3!6,,:#]H3)_E;>[_I"'#*B8VD8G['K=B%T]5PGO9DN^<3^1MQ703UI
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MBNMF/-_PVVCZEE9&/G49V11A1G@YKM.E1&V.FC Y,GCI+6\4URNH@#"2/&C
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M9M,7H>2WP7=8.U)A4>O][Z;0,>T#,]<R^^B/92,QE?*XH)X*Z=[ */8ZFE;
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M!4SB,ORL#):3!B.][087VKN0T!VWS1%)CN?H.P!8 4$V)R2@1PM)%[#QD8[
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M1&J'5*FUE2#@W3(>-?,-G1>&0E2&B048(9WA6>B2BY>XG367-:DO%3=\[#/
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M[:'8D-58>2A:S\0CTPM>?OC7Z:OM_M'*"KCMH;MWQ:!/,O#@%ND"[7+<RW*
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M..J]/2$S*B7A'TGRJ.ZT1%7AHYDS$0O=FF&,ZG^(JDR$<]:[3,(12&;Q!R[
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M<V;D?5E[ZL0]Q9;LKV%*!G,:_!QC^TP[9(Q$76Y!_Z6#3>R=*3KIH.'0=9Z
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MNNFW;B%EJ\8:Y,Z2/LO-]<M/8P%LZ0)OE:#TIU!P[&W->\LZ!GG,JURZS%C
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MN:&U4N-5%$XK]OSB JCK+#H-6:29K]")X+8EI$2W! @3>;B3/+NBO2ZT#5Z
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ML$YE[03#"G[(0JXF^P.-G2L)&NHD=W ;W^?;AZO,+0_/8[AZ])BP=9?'+\Y
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M9-_3S+DP$*ZZ6PMY$'>!Y?747+Z>4X-=YVCKQGG[W&]5>LA16Q( C6PR<;V
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M@!9 PHY<?J@TR6];;7EZ8MD/KI]6IP&)MWP0V&.RA% F>4W U$:.AAIR"MG
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MZVWA>_U:',H3 ]$*'T4EV)GVPSB2PK/(=0QL)18C']*NEO$?J%"'-W& M,?
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MY8LWG;00+A98,3XP"AOX$]D33[%Z#-'K$"_H!XOK$ E('?>9Y#P+[L^#!NN
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MPAAYCXL%W0\-8_A?LQYZ1N?O/W3VW06"[H_(T,O(]6@:Q"_(*KMH7UO@<N,
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MQU8;CAQ7M6@"%"4R'I6&\)'USGL>(^[W(.(21VD<4.Q.H:@T>$!MZ4S,=]R
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MR;^?_/;\Q;,GO[^://]Y\O39DU=/?CM_=?9J1)[<#/:#&[,0ST/'"RU<5HP
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MX5]:Y8?2 U][I>5662B(8^Y_^X=7<ID/"FG90C*=+T5=C4;C7YKXJRL1LO7
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M#O#(8%JCS606&_(S7-N"FAS6D_9%,U*=-J#II[L^6"RVJT+W-=Q1NLT%>F*
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M-EH8^9<C6<3EMA#V>/KQY"P!+':;N33%$ ^758!YOKPV'''[RQRN/(FHHO!
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M5B6K([T+_601=,YFX'39+K-=@BC"L08A#Y00K I 6 *2G2D=/!6)I:YJD5>
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M4)DD12@$33;R"K[6?[8<V,%W4Z! ]/7PBE*N]3E2M413C'A(P#Z_V&^/O<_
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M_'+9M>5I9?>/=0'F_/D-FEZHL5 4'Z=*-D.]H?P,Y&NAA$EK87$:\2AK%#$
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MD;B, ,6Q#SM5L]='IH\=4;L!DQG^_P#[L3Z2R[94//!KVD&O^1K)0SBW &&
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MJY\(6XQSJ+$Z4&@?4'L@]!"FL8;0R91OD#ZE P,G=PR*_AHAZ/*7TU'E?3R
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M#YHI:&.:ND)R=)?4.X\S__$OY_,G>9SY/L:9L]-[6$YO0RQQA3:J%[63Z3W
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MQ N]8PG;(57N(X@9KAOZ&$-\_OYBDQG:.W#FQ**@O^H/?B>0'"0]4C;L;-@
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M:1[D^P2>=QWECJ$$G8TY&S,7)U95S]R6-]8@H 7 50=-OT8Y6NB@K/G?00[
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M:X2KVI50@I$Z3Z#V'8]RO,%\15XQ><480I\V#4M(D,YOX)C/K!#F]*O.\0<
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M_)=VH]]MVVO!- @R*SF(PAN.>H@^R1<CGPRNB,I4[_LI$QIV]AFGY"H)JXK
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MFMI8G*&,R\A("1,X@-$ )KX38B-[9=24E*(J '/4_EA3+E1Q^Z0["-3S/'V
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M*H=FL@7K4[NX\Q$+#<^WLBY<: QI1Y[\;=6;Y%+JOKHNSQ<_A(>1A&4J(Y9
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M-0=W;]FD2=3UA-Z.]X98=@B%.$CHD&I#&)H^V9(TZ_FWMN). ^C8N'RBVX'
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M./%;F_A1Y#])<97X4)[XVS.@DH+):X[&0]\PNY72 *E2W/*.<-WLC$TP4K]
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M4'+9BHW)++V%4R8YSJ^K/\2DNPB7*OIC/ 3C(;!#L,Z7VN]6/98<C "0E5L
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M5,ZNBG@(M%3PC'?(;:ZJQH3Y@\$]"ZU-2-R<:V+R"JE/EX22 L%Z:.1-Q!O
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M\.WM+#PU?BRE^F>WW[@^0W1LLEW?97$S/69KZ<$0?KW%M<7Q.IW'UI*SGM.
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M%0F\!EA37L]N>(:SAUL3OOSEYL!<8@]!7^0"4C)(5(>./V)=J1KYU!5M*,O
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M[]T)B_:6P??,]#7I;&5<7V>\O5Q$3>/*E-N I\)]M\[QNA@@J3 R!G?3F]8
M8<:9A(P&2-[!3))0I.YIU11YS&:&YJ.DC*^D.=%3W*5HM<X3NRAZ[V]&.#6K
MI>Y$@8<*JZT\?2+& X>D_M#:>0YJ-J)8FM /RRH39CO@]H;%!H;"+OJB5?I
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MXWCQJL:&G$H$_R [Z;*7*VTDV)*/TH$Q9_)1 \$7@E.EVL :N>(1PW=8#NS
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MW CBH2H_>LW6YRN39K_.-E.8VMS$97.7Y- 1N6[__O[XY/3XZ.W)BS?_'O?
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MXG> XUI7L"R?SQW#5!FQR]\C6N'8$^L$%0=3>?T@3^H'( I%%GS7(K.V4NK
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M+MKSPEZ#%08K#%9H"Y8$H\")#508J#!08:#B_FS[8!2YVW+U/&NH:&]TXK]
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MM)6AV57!;[MO4IWT2#Q"W$.KDBOVB$G1Y"K8H/F ,^E@:8/:-=Q2E1=TA,N
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M=N^P*FRI,"V5B@.[#6[R@)!WJ-L0.4?2WY"AOT$\EY>7$[#PX'5],E#G:P
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MEFJCAZ<06RQ68]:U*,'$!"IS#&?51J,W9NSW=&=F?6^!@J6,O+/R1H16-79
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M/D[&]$[<55[AM>&U?)5CVR?V']HO8 W]3<-?-5PLO=CW=@VP-89\]D_P?C&
M+GYZ6S2%9'=_U7Y??4A\BG6K@Z]+O!,W_(,*K2[X>W@2^=V?_^=/DWKV92K8
M"BB]<+V_B8G(8.XK&=*%7RS8N=G78^.OC([5I^2>+XG<)NL?(D=\]<&X^,*)
M/2(B.V$K3J^+4;>I!#<3"R5^R<3C+4]\'=6R;%T^T4N^:%7N.50HH8\X5?.G
M2%<Y^+29=1>K-EC:0:@<OS"(E/>0L1WTHM95S?,___1?$E._%CV&?ZT[#/\J
MB:*^TBQ[_'[A6\7U6.F65S**(>[*2S=N3972[37=P1BET+W\].;T_!?K[.VK
M@</M+_]3?']55N7'J;A.B(&"/?C^:Y;9:>)$(<E\ZA$_2FP2Y]PE 4V"//%]
M&L;V3Q@$%J/Y#+ORYJOKITE G9CD>9H3G]*,I-3-212SD$9^EO.(_B3N2M=B
MGHP7KTXAEE#5L!QG;!=[Y;O=L@_F_)<U#<?'C^#G]9!O@3!LTUQ8&^Z6)C5Y
M!MM6Q#856?W:7'$^62/=Y_%G<E"[\XNJ_;K U^LH=60G-C0G=L43J_D*>A*%
MG1_<8:G9>3>0(S["D3G"CS_"0 M:\ROHTWC+OX*'^(F/\AM]0-8',: C/M*Q
M.=*//]):+]SFJ^0E?.(S?:&-J*T0?(<#.^*SG9BSO09<T^;J:P[-!YX:IKLN
M",=[A!/;'.$5CS $-KXZ7W=Q:%<G:3CBD^O<=W+%?R$@<?AA&E/;M]W:/G=P
MRDQMWS-DJVS/#_K)MQ>(V$9.PH^&*O8S3OT@%AP"V<,/)E[(+#7]UM6E1/S2
M5FZ\;2LW%F99[/DA,(29CY_[^4U1:MQ:]QJ$9M>?J>BWY%!8M]46&&;@Y*0E
M%N<-LJ9:YC\9?%J<;O42'O%&/N#G98R870_OT2"=:YBB-;@_]Z$#3&W57)[@
M@X6>&#UX_5'OKH'9W[EL/UC5%J?959LSK+?)5'5+4(-5L>5-,Q<GH+V$3*&V
MPQQTMN)U+3/M)6F3!4XLUWX]F-^B!#?\G//Z9^1&E/5=*(2CEGCK_J_+.A+H
M7$*+&AK:0JW4>-RG\*I.>,UHIDH2BT557KJV?XO3\?N]ZU=#%G!#60;\I]NK
M/OENH[L@2:^!_@]K8R"37>9'=UQD4"UW \M$>V-%%4.,G[87[W$2!AT::/:T
M= HYI:R)PU8SA$@\E$C,!C2;PH9JVO.NK.A6Q#1K^AR+HX0.5U;7RT%Q^,^6
MS-#Y>:2+Z!\;F5]?(O%A.:FKL:0LUIL780\EJ!%=1OJ:(KFID/^L+A J+-Z
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MZ8<,UU4VZ2UOA-UPHUM)<U>/A0F^NUBY[8/QZDID#Z\G]]TY6O=O#2G@3 ;
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MMFE_BJ+#%5@:*"6'A4;2($U\4(!+E(:9*@BDY@H$ 3$72%EN-MSY//X6.H$
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M6GC[\6&M$4-RA!D<NF@I8#942@X+S!C4FHJ(2<%; RCQ!J02E AKT(J@L<_
MM#,PRTKP/;#L$6ED!<D*D@V3DL-",B2P\RS-0^@3C030T*2P'=9I5%4TV#=:
M'VP[U+=3),,C) =O\A<T&RHE2U1A4.0NC'LLE"R,.RAR%\8]%DH.RWY0TN*
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M*'(7QCT62NZ5CW7G/E!%,33((*!8H(!2Y--,;PNPYT(AXZBW&Y%=RTSPUEO
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M_S!0,< Y4T&0^*':J(9^2$^X=\TT+N?7R,Y;+[Z3=(2P>.JA5<_/23LNJ2O
M6(!QP, 8#"'44 A(2.5R01L0L8VGP09((R8@<? Z,"(OE1)IG$$'IC8 *8@!
MF D!L6+&L(UF.3L$1HI&"J("C 48#YJ<!1CW"AB=Y%R9B(F88@8HCR"G".&
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MG[(,JJW*N^<)ZC$QPG"'/H]C\=\7H"U 6X#V6T"KO!/.(P(\)"@BI^3 *&T
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M XH_9&DP"*C#J-3\9SU&E0Y=K9WRO+56RA\V4.S'TCC>VW['_AD[-E@A>M\
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M6/&Y[P#)O)]>3_MV$L-OHWH\_FN0]9-^@;;?;&_P<\QH%=_;SUN"-[-+KSQ
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M3O;0@8E/ZSR!B<_WT(&/3^Y(CYZ/UYN.FAF1#3Z&.+82<1$LTMY9Y&QP2LK
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MY2$%Q&E6PCG&"FDA$Z+."Q.\BC38?>O22EQ@L^,(,T C0"- XPE"(^A1 !8
M%@ 6CVH9;93 "B/E</$O8HJ,%@EYFY03#CN.R5T]*H;D9, 612I)OL9AY$1B
M"$OJM4LX.+'W"@'0HR";[Y#=EN_KB>V#F-HB_]%+6A@PU%/7CT\IJ)YF0,]]
M-N-$998*3$A#! K&QM('BB K)48^J<!-PDKPU7X,+#$6L"XM2O,U3 ID,5?(
M4\>)E 9KZ9]@B(]A>)\RZPZ9')_4 J0$I 2DO#=2NB@-,U0B$XNF3I1%NM3A
M2.QB())+K5>T>TPLXS0:I+EWB%OMD.&.(^PE8Q%'@_G>ZW 8EA=&<8!*@$J
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M<9JT7VG-KTJA XL8):PD*D/ZLE+K:$D994:5']/^0[<71DG03P&QX#Q/!K%
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MO]OO_?/I^2^C\7CT#38*-@6^N49A5HL*\_V'7V]*SY)'FQ-WGYY8"[AZ $,
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M)U($]Z9TU)*D0)J(%"C8T4X3RL"PKJP/@O*5<T+*I"U5(HF"\!&AE$ %2I+
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M,KU( XOP!^'J85(P(>)*:TB*SI9446^%W9/I5=8Q&WQ%E*E H5OMB?-<$RM
M>$CAY9JC-Z^9<5BX+D ,P_2LQFH&; P,HLJ5X)K0L"?3DU*"T0'4&!-E"&*F
MB:9@>R@;!87!)I-6I&JIJ)->E AM;M%>H40SFTCE8FFX5AKTS9-/CZT]2+K'
M!SOWLA:$6N-P]8K^RC=@@)S;$%OC&H3AXOF#;,V4'.#K-9;T4GCX3E)WGC9^
MC>"]*2C_TO)A3Z^>$X$1,,43$S!0EQ/PL[N3BK_&\6C8NDS@4-=U1)2$^-W'
MB\;M0A-T,(C9TT9TH(LX1E3V&8A#DP;3[%$^/1HB)!9Z91>#&&"'BN4QX5@S
MNM4\>0\6H$8^S=A$V?S]9L=C'&G&D$^ICPR(C_3@H0]M!G*8O6;VV160HZ;<
M!'6WG]:P178,"SD_0D+CHBW6Z$ZXAE_JIFIC')L"C?.+07]>(=  G70O6P?<
MM>$4]\<&J?LQ&>%]6Y_VM14](28['4R*GUM:[>4=;DD0R'&"^PQDA<61%R#<
M$U;\? 'Q'-M#R/K/O588MDY=;R&5$#TXD':C?.AZ/AK&B1U?=@'/3(P8LQCD
MH\7ADO?8B-KUY-1DR0(9QB),FS-7D'X- MCY>0Q]"ZQY>=0< V:WU.=*(Z18
M9,7ARO1[N=JJ68DK.";I2OKMOIFSS@;C4YF(BRY#QI=$2Y' ;!!E)2H/+M>#
MTAM7+(9YKL!'6T_>3N/)?-ONXI/]9;]BJFWJ]4)1V^;BWS9LT:05+'3U:*2^
M#?"6?CT9-W(8%@UM!GP^+,"@"?L/EIZ\R! +%+Q"W0]@TOR<B?VCK8%K.+)9
M=E1OH \G*/I!G+=E^3-VV\A'W0"<'?XQGEY,_&6;-%"/!L!?\&MFL[HMHUZ8
MXSJF_C::#D!:3%$CY;Y1@TU,OKZHYQI!_3S:\+P#W9G+H]["EG[-M-6H=@P_
M%EV];/UPQ?9#MNDYS4;(<":FXW=@RWZ=V<9G?KMHLVX&W5';6CW8QZK+8=T/
ML<VG09D "J-;_#!;_+FIMYA^ Y>[?IJ.?7Y+5Y>9^X5FTRK77]9@K6?M,D\A
MZL_BQQFK(VO4AG6+U@SLRK:^VL%T5IVZ;ERM@W".(?I^F\F3@ZKP?I!9PU%W
M<#1#-YD7'L/+URK(EA7!RQGE .[(-<E39XTUW8B%"; L*(8^OKD9['#C('UF
M]Y;!9T,%:=*6$G>3SU9O>^U*@?2UZXAG(=G4A0'%@ZFY@_.I]59_0\5@"@)?
M-L@0RR2]C)ZZNWW;N[.L&,$Z4U$1+J5L(<-,B1@SU+D0E)&K0*WW:3"Q6%FY
M+;@.=F3VR-I;P%S<W2 :[3',Z3;UL@O5"N@=+M ^UO#K4MEDDB2T,B41)@ M
M2ZM($E*YRL-7= 5_=#<-5GY4^)H=CF" :0J=8IC.<6!F^">-*; .X6,?:54Q
MZBMF) F.(U:HBL0D(#[#*86OF&%BY13F/K2ZB)B#9-NNS+LF<><AX#D5E?L&
MGI/KP>QPEA"P)IUI'VDAZ53Y$#PQ4@N@!1:(Q9-RZK"5#96<E2L5''>AA1RA
M.6[6Y$HN7/T0"BA[E6%[1@/K4\B>T,5<:[)FJ60OP"WZGIV?1I(EVQ^WUVT*
M@.<S@"68I\UB#@-';:K>3#C>"L4H)^(LQU/OD;OW,H,NOS;>:)O35;0Y?TM!
MEJTVN3:E")J6FC : V8-2>*P8!@H1_,D&0W52K[:?9I<?_9G,4P'\22UM3S]
M6)^D1<O_%!W\6W2_?AFAI30OS\J!CS8F4W?ABO.60+K<FEYKV>,=2\<A31K<
M5;W5N^;8;(]:/Q8_Y^#P:%K#5.H_O]JSYD=/V=L^E_$TM-"^O1TL#NP5AK%?
MMW4X.!XLRX'AX^5D8"]'TPF\XGL,KYO75>R(_JF['O9V8"_J^*J+;G7+,,Z2
M+3_ZIVX(,(99*='7?MUW&:+O5?>,A0OARC!;J.:M\DC*\D]8:K3Y(E8>*7G3
M-3=];XXJH^_TD'_[U\EXW1R[BB?<2F?]'U_&H-8":?G!IT23?XV9?4U-U:NF
ML@H_V+04ZV@&-&@^@FAI#0CUL2NI[BG=-E$L%K$NU?=,PH\V^SO-=[47VVUF
M/!SMT7R7=_O&H.0V=G5M#=MCSCM+L"V2^09_2U2<@>%#5*GP=#MPHL'+(IYS
MPXT&<\JOI @FF41RQA.O%&9-@OED+!6D5$J7SG%OZ4IWHT5K:6Y%?9KEUV)R
M71O0>S_\ .\Z_18'7^/O(\3NVAA(XDN!I)O2[&35HU6UT4'[(3GA?DQ^/XV1
M\I^#QOC+$E[>06/<F4]F1===<?S%I*A'@WXHNNWX83CI/MM]\_2?J;+AE:V"
M-((X52*P#Z9A5T&14)FHM#&*F=4RG\=6-O\3[?CTVVA+.H:;7EF5CZACKB&>
M1CY3_N-PS^-[+G +OOK??RI_6N=SP^JM)^P;I/2B_XK/6'PF?2H7_@'\>3J:
MV,$+-'P.EO\\0R+YY+S7))8:(Z'2$"V3(MPD&:37R8<'">-\TK(HB?\Z'M7;
M,N6-[/%2'TSYIS#EUXC0/39L'\ GO\6Z?E5T"7^SDI+%L/0+)+ 7*3+7XFAN
M/TE'<\],"J2L*D5$\"!.)0>CN/3*!:%T3"OX]/>QA[LJA(]-3OB;)@'U>!@^
MC(9M-NJ6Y#*C/:J?F5R^7;#QSWMEXSYK ;V4\;32]FDY$^"'IKR#P-XW@<V=
ML<P+(AQF'"A-B2VU(DH"LY9>ZTJMU(_=1V#?V.GMXSB>]Z?G(,(7,]G>(,5_
MB-L2YA7=7'7V0_+33B3YP=2^G21?3?3XH6GM(+OW3'9'14W)3$EXE8'O8D5<
MI0WAD5D;N*]\6 &^NW.\8Z/@OI)KNB4)G;-.#S+Z8&T_HHQN'<09Y%RN<W1;
MC(0<3@.?^VG@TPAX6Z8@8Z@(XR4:YTX038T@,3IA*BP'#%N)IBS&M-]L-7HB
MJIXV_.4='A[L\GV1^?. X%/)^_*H1"H,HRFF!^]0XN\@I_ V*_'#"_\-B*C6
M*YIH14K)$"F2,F*Q9X\6%5>5$V6YVJGGH<)ZZ]%N+GM4/J;]?2V!_-CI'O S
MGD6L =V;M5=8^11N?6FE$_^65V-=]1.GEBO$554>L4M9I8F)UI%HN%#!&N?+
M%82#>U4_@<,:ST8#(,3ZW3^G_<GE\3#D#W^Q=>QZ7]6WJ'YZ]@5PYJCX?'KR
MYK_^X^2WM^\^?>Y Y-_]G[^]/_V?.]8$[JCZ:\LK<CR=G(W&.;[W9G1^#N+_
M\P1HY(7B+KW';F"73748PF+6N!8M:S4EL5\S#E+3>C[C\DQ&^<I/L<YM#(LW
MJ"12W[=P>^^'?C0&2ZUI3I8K7#U8L75L.E!@EE<!:LLUC8?M?#=J9.!<,N>;
M?<EC*=)XM+[?RRYKPEEE9.FC(D9*100M'>A]"S)/^!B8!:M K-0HT%(%7D5)
MC @(7(TG-5Q%DG0EI.;66,>N2KJ&0C.!9OE6SZEWR6!HUNYNO2(KE1$"]JQ"
M?!^;X@3#J$].D=(AY#@5C&CI0&5I4%51A!"UN[K;5C/AN,1NCQ)<?P=;;HQA
MA);2)AR8LN53[C;K<4GW<;^;R2S5IQ^:W#W9\C-:'9K<'9K</>TJ?'C*)G?/
MPX[_" XV^%DG*8&_-?SR0JW5DV%Q?#'N#XH&T*#,O:XRGGELX#H;'(:N.=9%
MLVBC=M'VL9N)$,9K!S:D9E00P16XS+QD1$FK& M"2+IB6L0*K(^D-:F\YD14
MGF+U$G;K"Z:"NQ5+9ND(.!L3)VG!O,#TG!C>3G%9FH;1C<$!,\U?U0V]=>3V
M8.M#\A[G^%?LG^F!9($.S9+7D9%?$2:$)"2I&71_[O$X'?LS=&CVC9A*KZT'
MXB"&YOB+$D17MB) 4"Y6E%9R%7T&XYQ@VD82 ^*/!VN)=LH3H+[DD_%5U'S%
M3AW8NCY)?V^6Y&3\"47=A^S3G:3/V)DA5[>]L8-!#+]<MM?5[87UPVU9W:-&
M]DJ^.:UWKZBIAQU T/M%F;6&J!#Y^TO,D-ZY(P-"#I_#!#)257M-O=>4)RRW
MC,4 +I'7()*,(]8$09RG2B8>1+(K>'G4:U6J2A!NJ,>F3" $#;4$R!'\*F:3
MLV;?*(_+GF*B5^K--?M[1GFY1>T?P]&W88=OGXFPD7(S>NJ(K$$TVQ")Z?"/
M-E QZ.+Q4@>'%M\93P9R$.?FEQ\WS5MR[Y799K;/S1IK!AF-_2$:S/!SUQ_"
M%U=U/9@)?@;PMBK:%SGLNC%E$..]@R1DU% )SR*)>4F$LQ2;I6)R 4],<A#T
M)5WI@>:JZ&P$GL3F4L(%1FP)5H-6*0HF3912KPVTUXVQ\!$7%&R%_-GR:17\
M&,-GC 8";Q[G$P'[%B&,QG5[=7N611>YK;RQ!=4UR;X[X+(+$,^9,QK*NY9J
MSNS7!G>^@;&/<W+<.UHJC9,!02T5 ZDMG.?$,.H(R&RN#0O45BM%EUL3W>_:
M]<G$-?MR)J_9T]"9V$\Z:R05_'>Q&<)2AYS3*SV=KZ7)^/TB=SEH&X1,SOKC
M4/QS:L>3)A3?@+O#?9BY/^DZ+.#CZ^[YG:2W7\8QYF8'=Y'"F_3&703R?LIC
M%64I+#,D: ?FCPJ>.&R=[H(5-E6,2;7BQ=W'\/YL$?(Q>W!;%\<W=P2D8J]
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M!0G(17!KG0K&1L>%HZD!270O +:GYP5Q7RC2%^*%M.5I=%G8;K;#W?-A01\
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MX!*RCGHDD@*[FP7%8X.GVF5$_+/L_X*G/F<*V<% GWY^F/&N19^W*K+;0FN
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M0K'MN]G9EH?SRJ,(F.B #$A#Q*6@R#+I4#[F[%/@/LI6E"[>+5???ODRB5_
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M?%2>\BG;0,74^\=520A3#((8J_XS&+75I?G);P8@F0=^)TU\N 1KKC+>"B6
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M+7R@6EBV-<G0/"JZKJ^)F@ZZE5 BB:IF4YFH,C4<:\/I#0=96/1]:F$>T-G
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MO67I6<K<XG7OYPZ"]9NX^S0,$F8J-V0##;6A@(CMK"A.%W8_&0#I)(ASV!B
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MZKM@F14/=J@>%1T\(R^I*E5E77%4=:8.R"H[U%.2WI^'\6,_!_5",>F/A&?
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M-EIF.&1\CZO*->'KF@O4E*OXGB;:%K;650U#)!+L>!U75C1*/<5S9BJ5K1)
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M?2++^D0X&'ESE?/50^5'13*.1IJY+NOI1XY&5D(C&J 18^=MV2:1%?%WFF9
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MPHE#;Q.$Z-UT?PBRT1;.+Z]_O%+E:Y?CJCOT^S]__.A<_VL9EM7:^LO<^?J
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M,X[\\?+]#Y<XMNC)S>6EOWL,^U$?GYO?/[G/[^0?:<):A]3&L8:P++'9O/Q
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M-M]?&<[OZ1]D6M.>2E!)YJ<R/6M>:+BQ%FN0M QGN7B!C=S'K6 QFS"<=8E
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M/_S93Q[(X>DR0%:G9M*G;@UGMT+<5"\6^)*L$I7HV)V/'N7*Z>K!%Y&)T\<
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MX[W'@C5G2SD0<U?,X2_P'S$6V])@S'*8P4R8'GM9PUF@/BO8?+:A)!3VC(<
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MAZ^J<!0]C$RCVHK<TPA;^C:-!Y,9^S*X>1BQV]%@_C ;W8[N%O,6'"$B?>,
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MA.VF->YN5DC_;J+!+_,.T+>I)^B[1M=G$(@ &V530B>''U:4]&\4\$;5&-%
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M'^JWJ2>K6>P@6=)85C2>.&9[]QA^C0<5E1LMJ%PGO_+#2)A^.Z>[)C;TPWK
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M&$O7=I_V=9@9F[ (T&VAS;/-H.?^K7;L?=$6:><+707#I#=8#W>%B_E,BXF
M6XTBNF288G/LK[?&*YHJ(H@H#"<=NY[\\R=,NL5"S.+?G/N_6L%Z^N+ *JRM
M[71UZWJ<<@W>RTJ^QE.\*E%](1D8>+$1TQ4 :.)X!Q);0OD)G\24:2\V6]O=
MPZ39VGC&ZV*#$+DBN>,]^W_T<A&QJD]=0)B=VS[E.3<*.30D5QIVF@BA!L;"
M-I(U$%)8R!Q#[EC('H9>(X-,<,@B%@\+5;UM;+G C_3/+>Z<K^&C:UDPD0'O
M$PQKXV3 XM8S)EG=\0!>"H(*CWY952I%O$<K! Y>AL#!60".(+?B[XT-Y4UC
MH!W&N%IRPDP&(ONZH6QC>+_S ">L!^F)!!X9:BO(^41/1K-%(U-4[?Z"O:PM
M<\WPZ\4H6NKX8I%,+0R0<FJ!\>HZ[F;?M@S=\-YE2=8J3T*-S:)Q$.N1;":B
M=( V@:]D>1+S <.%B**YO>8Y/XX)<7U_:'C>'KX1$K6J8,AKZA.F-<;HMH5C
M7C-G*2$\G;&'5HD(._K!,835@H<VD'N/;ZS=!JTBV%3:+\A\<0IXJ68@$0:1
M<.P+IHT>6D78MW("WPECR;$1Y0*_]Q93KEM<+;O^A?I:5B@U)_H7MM-6)V95
M% ]PS.S8EKU\\0*KL8=? /MCS%);2G3'6APDE/L&^MGEBDBS%T&[-4=(S=PE
M^4#$$ Q_!X,P,4H(D=FV^Z-FAN.>#]A+('L99['I[S8TU%SM;T%ZV7EDUAE[
M_+]VW#'W%6! -7(LI-<2)&@#7,74LB36>FN+DYJL%C]W$/2G8LGO/<OD,]>V
MI3#2G2%TJF*A8G4GC\(OU<09S?P<[**M[<5QX&7ZND4U@EJ-MM1%AZAT=$4K
M/,D_$;46ST1< H*=M_PYO,W&<NI\,3P+I7J,?/M0+:=&D8KL$%Z#2<Y-\Y8F
MZ-((3 S!X.8(N9Z=,;,QK.G(0FHLE\)XM/6L#:?M)$.3<):'\VAGPR,045F%
M=*9L4W,0.G>GR@(21U329"%1)JB>"S<)T*AMLZ1AARH#LRC1/-@%:]>K$-RH
MF^G#NL\1U3-B*);BIEFXPS+E1FM<8>"\]>2(4V+NJ7X8(CBY#A:/1/-/A-EU
M:I9]!/H5*T@IAV9J;*8-'I:K;*'H9Y-+$,N:)^:I-*QNDE_)93#5,B".L6\W
M6MM*?TGN7=L"KBN6P4%*%TS08G^7_VVQ DX-G.A[E1H3I:2W5D+@IMZ3X<A(
MK2'B+-C64A5;NQ=>[WBDF&'CY2Y*<6D2J[/4@)8')DT>7@):+ZMZ"21]F@2B
M&$V4%DV?*GH&H^* T6QUD1C[Z,C0T8R9FG*KU97ZO@TQT_WLT^!N\A^#Q61Z
MQP9WUVS^<'L[F/W&IF,VGWRZFXPGP\'=@@V&P^G#'15VNI_>3(:3YDL[1=5K
M4[13 1RX)_]"U3.9J+M'ZB\B=HK1I#^CS;NJG85(+->+@49/3QX9I^.5^2B$
MG6(O)(!CX_:B6N#R6\?$KP_\?C"?CQ:-?W6)F.8UQ/6DH9FW$T[3&'<Q'3C&
MHO+/4'D"/2Y%_-D(9'!%"%OO7S"'_LFVAM6J?^<S*._PM5,18 L>%]?Y8M@V
MWR.86"U^'36 ?*II"";&(,2R[]F&AFG6T5,_F_)LA^P-DMEKQZU3/WOZX<[;
MPA;1;Y^YL^.B9KW(L\<(MN$./JX-]^I13^0@XE-5P[ 7#!)4 W6AM33+>[R"
MI%@ F8?9AG)YL@_BCNH>2^DH!FY.P8[5[-/2;F0HJF3*?&K#D]F7]:C/"W87
M%JA6UKC8JG[Z(ZVJB,D<.2KDX\JPZ;4'N0 C(15L,OPHHS=;+'S<KS4"W=@+
MDE?ID3\A*"DH^G_XM4JOIAUJ:HFW6!MK1>+)E>MY[@OL5<@J;6P-(-QCR_,#
MPD9&^VC$(V($>\;+TGU!=76O I\%MK9!=E/0<YN5.6OD6M[#(47M]B2:[+II
M=.@:F8D?5YR]VK]'&N1PE^C &H<^Q!9].!1]4Y_CYO]^__W[]Q] TY,I7?^;
M?;CXX<?W%^_?T_\_=NS\;_;CG_YT\?.'CQ<?/_Q(W_0//[^_^/C3QXL?/_Y)
M-9<0SQ0YK65%P&UYS4T2S]D/'PAB_@=JA#%:%PQZ;@7 N-VX$:?JBB;Z]HC2
M!1D5FO> A4#P$P>T>KXP7M%YCG*R8X):)*R^:[S])\Y1$<1CU(Q3'= A)KR8
M!A5\Q(FP^$PNF)@+9E@D%8=, !&Y4.E.7_E*QC[.<)&>VT,@B8D0:]>&"\\7
MZ$*HPA\*#97=+OHP_R1K!PIM_EAB;]=ATO0"Q!Z;Q73XU\_3F^O1; ZK\.\/
MD\5O_00T3!$,,89N?%H,W8'<=*2$C9M6POJV(/J740E0,WTI&4Z/R?G]4=8U
M]L%U<\HT06.@/%A3:6FG*-%Z\\@C+UE8A79+L:@HMXKL1Z'64Y#5QM@S;L/C
MAP(O"6UT$?L<CHH4Y4"AM8!VS'$@9&*DXQMDBH4Q>?.%@6I?R@0ACH64F2(M
M@GG/B[.8OR[M2!SX@QJ/5]IYCA6(@(*Q]4H5<ZJ!P"J"=&@5R=8< /7QH^]6
MG"DL+KZCVDL@CFS;4#5ECJT&:",C,2L6DM,(7JC@SK/A):F@7(O8//7QH<-I
MM<<'A@O+&8\MWS1L+.<S<I85K$\J/%C0$W6,L%9AD[:G.MF(*7T=\))M-FXJ
M>.D.-&HLC8$0PXY_)LP=6;0O'XE#4Y?0J4I;"!""5_?2\D"P<KV.D+NJ7 UE
M]['A9''\[@:[I06+>6=L3JYH*B@P)-'3F<:>F1:F>P3)( Q@%<J51P@,TAPH
M@N;/@ ']_!-Z!(5<2'S%%F"9E6%1A.**_'TJ/EXI]>L KX (G@TG\0"(ZV.,
MT^;#7'QXB\TU82L\<]LE"5Q>>A6+=@O*,C@_I*UNU!:CF&IG,1Z^H_&YC 9H
MFBW,?%' [0OC]8H[?&4%OH(2\F%>.QLO# QA @W;]>[)8P]M[UV?PHQ._?#T
MH<G#H0:_B/"6PN'%+4,38&(&U"6<PU>U3HD0(^&::*E%6UH/+%2#2%QLV_1J
M"!L,"#3P%>!_T/;_;-AH5(M2J/!1J R7=F"M>\)KD>VB1#.;!B%ID@0LL@'@
M#SR:4L-&MD:606EMR H&I](/&GVF)=N)$<Z)R<2#34]>>WRI+QHA>S@G4&*_
MGAA40?%"("[[782;ULB3_C@)@HT>M#"XBB-"! @NB+A?9<Z^(D25&<Y@\O(0
MR9#+Z8J%U!JM/E ? P<W>!0[&M^*QFYES0A(R9N@D*/["JZO8[-@E+17]:-7
MHS$Y'+U$";;<&"1(BU="2ZL1T\B'P]G#Z)K=3 97DYO)HH740XPI,?%-2;;Q
M2#&]*6M=2U:Z9I@L9+7C4MNR'-/>+07^:U120?[UO*#W4\K"";SCOB'P9];D
M$U/^XRY^T9I\$LJZG9I\]*[>N,X3HGFC2>8DR\[!FQIYJ,.R H3&;;M8 4Y\
MG!0_*M\?'2HZ?)Q4I@)V-&''GAJ.J*Z\"$J\!CH"')XL7(V:Z.J9N&XJ;;["
MSB"XI?Q49<N<8\C)0$6<G 8:?'C^ B;&B RF- J+AFGV+#7!HQ+D\GEK&AJY
M,19CTEGW?#8 8CC!PI".;YE5@M0;PXT,9R=>]C_,NIZ4,[=T;;OQPO%ZJ0P%
M8#]U[@T_N-YQC?^J%R9!ZVTCK+W E3A0!W!Z,E3P$'(/;;Q8]1IK-<BZ#<U>
ML$VMB_S"XG59PLH!4X?A$ S&: /WLU%.8W?M<DD&></6SP!&BBK.X7(YW.#V
MT&E&,@YCSKUG"UZ:Y&M#:)T$?Q05^17>#7)95GETBZK6(D5J:&RM0!B)+]A
M) >V]53U8=$2$7_@.U)38G).+#T^/IP7]HMFIGQJ @BMDPH08\/D8D^K0;J
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M]"6($]AKKK(<_J*EV0\% @W-\ACJ4ZEE]C S6O;]<9'E'^&Q4Y>_&R.:!Y_
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M-#ZW2@%E1](=Y3Z[9W14O.:A7;X'@'<W7<#CHG8/X^Y]. 2OVZGGU[+<X_F
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MU"R!(_6@A8N!#YNH<1,^! C(B*$3/G:"@R=R]$0,G[#Q X*]E$"^?YUB0*>
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MQ=9GO1"D,XOV6T$757(3+VB;3 >\YH5XXE#EA8G\+O5;7"[/F?7)YB3G)8.
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MVBM>B 59$5=)]HHA*C13@N30LM=#W_5"T,=JM0KR#=0'R&_HERR!Y;7'.77
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MULFU^W$?Q$$;$L^>HH#/K"U5NO4I+Y;K>UGBO::&UZ.1%*T ;9,7I=#1+'V
MKP8L??; 708.4?Z?6 -ZLPO,=] .O%!9S9\+.!C1M%0BMF^X74][(4P;;+R"
MZM-=: #\">F45_%+JYQ'->2)"H("4^;V%])U/.J'& #)H5OP9YL[H)ZGG &
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MC:^,YD*\J.@\PY1,FJ^#O"6M;>\;XPMU('>JQ[2I7YFIE@<)?#_1BAU>\.W
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MD$OYF3U;"%<N^#/9Y2'(-Q)L'4T9@X.(W=<;Y'@-BKWM)!#[?7JQ7AK!7S.
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MOX<1.UMV8$KS M:3SI=TU0).4")C&+'PBR!:2B95RG=.M]X*=31BB62M$+L
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M4Q@IE^G-C5C.&KP!/V$;SNIMC)CXM?YE)1]CI'^\V!$N_F9L:W5''S4"6I1
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M%IY7@+*_[QM38Y=YWBF-C3P?-^W6]35:V<1/N/\0683O/ZFN\/N4O'CN;G6
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M<SJ9MYB[#TXB7)&>YBT+38WIXRS24Q\+E80^9 E" "<V=W^@/[%=EAD=]*5
M+XKQW /XZ.Q2XRS\LP<PK^'O)Z<@C+.(+>J&4):L;'AM #T@_?(1"K6+TSD,
MWM+(?N8VLWJ8=P>70/JM1EW,8%&%V1!R]5[>0V\%FR_.%I1!Y+V[=D/7?*^%
ML"N_AW8#V.0,*I8KQLMK!6ZRLHK0Z2L?6BM0;$?YU'%,EI0D;WG)F8R7'0XY
M7=SRAX9WR;A!5,S>8':Y$Z\F8J52S?K*A\5TMMS,)E_6L]0H-4AEY20,D:<?
M)B!I&B6G^)>2VPM;K),=1;'A:1Z$)Q!. P]."V5&<=] :4;$F8OWZS5&=QHD
M.)>0 ^_7TCG1(OJ)S?K--P#.2;@[PF=H\AH"C%=]4D3ME5Q?Q>?DP=T!O_35
MXC)35/.BO0Q0S--.<78?=Y2?RY=33(6O[$/:0$.\U>I0FAM#>4QNJ[%,Q]7@
M\RP:2C^A/+B4_/&+UU:<[-U&=+%45\4S_@=$!;[_=VX0@]UQX>_HKQ&MJ6H,
M81-WYWB;Y'SV/BY4C3XO=H>>=A@Y1B&?/-=_+:SDJT/J.RJSW^R!]*ZF_ HJ
M6%-EN)Y6-CG +VY!>"JY^BK9-[F!%:_V/@';((/SB;8[S49F2'DM6?R+OX\8
M=SUJK1B/-;]$B(ESQ:/&2Y+;)EN@U'&TH\9:B*NM*&EEZ8$5\'7!69?<N@7Y
M5BN@[DYHS>DPF5:/&MQ62IG+ :6**:/&3!6'Q!&IK+ E:*&?'.G""N"[I:8<
M[L(*A$TZVE45@1TI!'HYX&HWV8J-T7(O)!5,5F0YZ'0C"+JO_O(=:+;Q3Z;3
M]?/L_F$QN5L\++:+V3"-_$_.!R)[Z#A,=KLP<3Q>/".KAV+=*AX?[',>>@V1
MA"?_N I?'3_S$T/3R'_?AJ[CH4L?I<DYB";;J\?L9HV/CI\<((0)+EH%+]X;
MSL?"7PBGH\X("32]IS X@"C"]WX.: L2[*0Q9W>:>R0[^^Q%4!IKF_PJ/H(P
M0[94+(V]"$XGW<=*>!U22]#A9\>GOY?G]GIR:(7*I@6D/.IKA2PKB)LH@;="
MSI'$C/:.6"&*2&+%>[:LR*S6[DXRX%*;$\T(Y^M")D,%(]TX%V^G 13TH3SK
M[R .#Q"-5_RM#8BA8(:MSL8(;!R/VF+R4R<"U/!O9E/EKF(HTS56$&QB]XP"
M>]QZ9<JJIQBCO4:?2>J!X3H MQM#7T!V@/(LEB;'<NFE-#9G\G<?2P?%+R+%
M;_[/'PQ?78D!#%ED-C]FG@=6CUY=_JM4AQ*90&AD"-;X?6"[/C,Z&+*(C^)A
M*_RJG%CLBE,[:U2Y0+J)\L[#E\,]L6.,R&U5.WJ"T'W#>G*A!X_57-^)(7!!
MDQ-2X$_>'<@@[K<!9KM)CJSMQE >ID/[^"J)H]CQ41)-<J2.2$=]>4:<#\Q!
MS(/P ;PZ7C%):NHB1H_>0']RW/T"D?/C*ORGZ]?KU\GV[FW>33D)%5EY]0EE
M":\9J;?UY'H%R(#BNP?G %Q<0:;MNH1&[&U]7X /0L=#4O#^Y/IN%*<6R]F/
M,_(C;KM(\6%[6^DVN /H7L@MY-)+OZ,A3U8M><:Q)$@K--6MQ,]*L@>*4#?V
MRD;R\B =M9J@91UT5+<G&9#'BAI;N,U]RNDT;ZRXB,O1C(M'%5BM(/X"ZIZJ
MZ8@H#X\:*BE^@BF?6V' Y9-V&CGK IX!DRDY+<GM;+'9A@=["K.)G3,93985
M7A1RUY.I*[/"DT+),6OJ[JSPJ%""'5M_V(6KQ>BHG)C*THIJ=$KPE%"16E&@
M3@FHA3:VO[ITFN-:IJO'Q\469ZV<+.^GJ^5VL?PR6TX7L\T&E>M#(BA*[SD8
MYZDMFADJM;=WW]Q]XGA?W?BX!JE\B&KG;8,T(HSJ4R4[@F)CP>QT]H(/@*I(
M!6]@>P2_N7 +(-#N'D+] #?%HYNAQ3O?G+#:;E#E7I#<JFBM#/$<N?E3=>A/
M)7)F&D\3]=P\=)4^\9)NIOPUTG3(#?M-,(NB5(DDK_YKK]-ZA%S7*3E1)U;]
MO7_$*&YYQ6\6^GJIX2@HR)+;J78EJ-*L;>B^PG^'?YN]P=<P?_Y+4?&(>0F2
M>.I WG4>>%[P#AM/C^@4I,0;<H5/<(2 [(/0X>?ZO:W.#_9MK?S>ZZ:E<-#
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M/T.VYA'5AT1$1'07*AVZH?$3+H6?F 4B/HV;<PB<_<K/,S&@$TG+/"[<O1N
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M<M_HL1EE<,C$RJ8K12/0Q'@2*W**"<KII ,V:GQXK'$UKJ<+*$RB+]*,H2W
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MS(I*DA]=%,IT!2"2'U(<KB(T0Q!G9-I_?0BB:!G$=\ '!S>.&\6<% UJ]-'
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MM1L7S]'>0R[":L0,"RCJV);. 8+N/%N%YU#FC09U00D#R41NS%%:7-':1%!
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M!P0DK&VC%J:STG @ )2U)1HH<^#*"AT6F S(W HR"Z*8][15QPPJW%S.G9K
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M2O>!GPU5!I_]7AH"O>@N= ?_:OHABLU=[ POR"#KMG:Q2 0R_#UTNFJ.G*%
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M#,[+H1 L;V@=M%YJE" (WW!TZ'T.P(;7@SZFZ25LCH/&\+XUJA*>2HZ$X:@
M>,TU)VH8WE!HM .:/$-BD)/Z^0I/:I@LCR&P_Y\W[/-R189 ]W^9BN[1,DN&
MP/J?/BS6I0DH@UAE37"<B_'=,E]E$"Q"\J2,2[7Z$V$&.2!()DM@!R1.@QGD
M-#ZHY45B)QP$U<9JOT.'6PV";6-5V2D#OJ^QI\5N]LMB_G2_V"RMSY^WB\_6
M?D'';Q[WJ\W:6L^MK]9V;LWVJR]D"L:HC]ER[#JV=VN'P5_XU@YCY'88;2I
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M.8?J.M#1XL)D/I(ZI11X^ ^C+XVJ)$5A7MIN2!-0+QZ. @T_?P!R*%DT:P8
M\L"B\-5U4+0)9Y[MOEP(Y#\_ &;8IMP"!?_U 5! $L]\1(L>A.ZW)#=E$V5C
MBYS@V2>2<H&1/WT C BS#LNZ62,Z_I.Q0KP$-52!:BI?6;)<'OYVR8K%7\ES
MU$JILA=$&6),Z\EV&_BJ9DI>T/''CXF.+)V1)9U\,ENF[XR26@VI"S[^XP,P
MWB8Z^+5L+IBY9@F.R7?G"=H',T(F*#S;8:DV^*>/(+,UJ21E((W$[0M:KEF.
MXSS-[&HN%:RTE^5&"Y)LB8=F!*7J E-6M2EBNYA E 9,6@9T?(L]HY[HB)N
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M5C+I/;H:BVQ7HA&T2C7*S-KGI21J#?@T$-$SV.PEWQP*9^.B(H:<P1 V+^^
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M299F($Y ODQD @N#PL&+;D0(4YG@3U!^P,;"@4C09F6*=AC^A48#VHA^V7S
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MX\4QVSA%I$,(JO4%YHYGZ#KW1>[P/MCO8#0@O=NKGEN^2:**@*.;O$)3+RJ
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MF6^O<)E__V$8^?,?_N/[#^-T$OSP_P%02P,$%     @ LX!<6'I]U>_,=P(
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MV9?FS>$0/V7%$+['&WR@5Q$AJ'\Z5<C1=AQ+GS74R'\6Y2?)?*T>#<>XD+=
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MI!=_^/]6_^=[7IV/90JW_!!-87G>I_%$99F"GPQ565>V,<-=5L8]M'>?"(F
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M@?0UP1 ?0:($L&Q)Y6@=&#9C.-+"8*02I"H!]4!W' 2\0'7 'XW$,:^CSS
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M/##Q_D./CPAP]ZAA29\0580Z%??TCD1Z7I0V+TI%TB\1(EA=#CO@A9JKO,%
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M#B ;!B/]H,I_^S/F#I2G!%]8J4]L5K2;DCFGI5.CHT_$4F6I&GE=Z[.NU8J
MZ<CM_E&,T_[H&AJ:JSK 6>+>EVBZ) I>_R?X]\<(!X)_")<U_(LMZDJ!;(N]
MANR9.>D#W">J/A'-)OQ;]ZJGL=#T0Q6KG+[8>31%TY;:U@_1.M,DO7RI_;/
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ML,%.2OOO@+\^/GFK:XTT?H8^%F(WQ'*61>9X0/S]LF<4$C+BYY.3X$V:8S,
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M>U[MLVZV?SEQJO^HD9@)T7<@<$L$K^3TMI%T;]2P;) 6Y/  @72'^]Y&ZJ\
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M[ ==BI,8'!QK"\IIZ/:.&C)X>=R</*:?MU8:85=L9J:<,Q#?L8:AVD#8#CO
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MR5N_B_?O:W2WL$97GV^^0M=7Z#[N]KE5"3'<Z/31+"KC+;U-BL]628^)5%.
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MMZ !#04:+G:SZ-I)K;I0 J9KXN0_6ER)#EJ8Z)J^ER;BA;$0HZ"B>A$&)98
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MW2),6.(!GC3L)]FCB2N*$+T)^M5JV8QG>C-SOQX068ZJ*BG%&TGYK.$$ U/
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M= 4CDC_N[>__$% S2.$F /N$!J*0)M)Y<,CK"K[]!1V<RQJTIP[^7C0E5MG
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MOG3.EZ:2EL=RN=P5V[73=CD*1?[8.O/66V?^TC5>QM:98^O,S;3.#$_RK9O
M]]R6S!9H]$["DTV8K'3FELA(*&DV>N8BCR]4-=NK9I+M<RR&$;2.=CP>LG=B
M;9#,;;C1)9E-IDM=RN9-KZGR[P<':RRHVEL@].DBN(!,O3=0.'21ZWHO*@0_
MZ ^7KJ/5++3Q-QM&4)#TVK,:G]"=Z$T76$'WF=SM-:G;4TR1_N,T.@RNI.)>
MKX994^6W"5T\9ZN^B?YHJZR>9?Q ,9B?OZQQDWKR@A3Y),KF8GS6M2';BQU_
MLH4=%3F&E"LMRAG&%70_GQH:@*EYII>_/AB<W"?&#8HH"^R]&6Q=M@-"M9T4
M-5T( V%>E0MYM?1 LD]SUY!=]B/;^?_3^F?PZ]Z:NND6M-?U&YD#F3%D=GYC
MXS0UL6S@X%?G#JVLCFB;_(FFV[(QYEE5-]&,3@JFG-%V<[>.IF?\$W!ET*WM
M]X=D^M "O86*-37V9Z-&.IW-[4L;'Z,C?R5'_ND/Y,B_+QL(C!J2%"*5MC%Y
MAG 6K<M;T!&ISM:[\0-R4&( (D7Y<(=>*%WFG;\B:=J>A T<OZ)NJI9#"NHU
M=GQ%W'F!NXK8A;U=:J]Z-??[=UPD,W$<R[:![,5PU!!'S($FPU;\0JFBPW)
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M#)Q<=0DON508(B2 *:*MG<?]Q:'Y#0HFFF61U4RQY5%T\)E.RDP<%1[*#<C
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M%K=&'+M1N?O:S!/0C=X+P^)MZ**S5:%G4V/8H=-0:Z.663<"$CH:230G)P!
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M![SQ[T& HI< 4VN9SGJ2AP?5J7YZNS!UX="3K*C, &I)$V0^$/&7H"++RA,
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MH7('Z_#(1$^RQ?TH7H))RNX5>*W*4R"AD$;NQ$1M]+QB/XM.35LKU=[P])R
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M;Y=XMG5$/-Z3P]GBJ?@/SQT%7_*7/7?;/K7%=O2Y)+<(P V7)=563@.->3M
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M@_HH3J85*$G"@=1< 7-!VA^#8"4,T'<!JJBP"HIM3DT.\;[S9"*6"P(I9-2
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MF=&?EEJY>"I=K UZAB1M2:90!HNL^U,NWG-T 2N+TEN.6(KJ_#!J9Q%<=&G
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M*6R8XE[V_3W\)FB;5W<(4-'(Y^NL3O.RAE'XSC2-J<)F)C_NBEYL (PPG$W
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MUKAO\U'HNEU;1_Z;LVYHF?^._0Y6CI[])^P38K:E]E@*-PW&"A9].#9.$42
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MHC/"3@7@A$N; 8=6Q#+2'44EJ#95A=N2:J2J<^S6T IL:@+G2R.*5H?9F\(
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MC:*F(*JH>,*_M1PE/E;UER9UD27E*2MQ"UC TR OIDXDJ,U0N\1]6X[@:FP
M7&!X#I/QP-2#)BR+:FNF2'?IW'FD9< W1I!;@6Q0.+NR0)+*W5 W"X30GD/
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M%L8.^AR!ZP7UNX236T?"FZO]E\'@BV'+U*O520Y-\KP"5:H6.<OK+*IAG>(
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M$[TXP2Z:SL!@I.":JI0V,6'/P,K'M32+YK3"SD_!OXIK%:S!3^3=RQ;1%R"
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M!.EU79DYZ 972EE>$(^4G,17&6I2+H-5P4J"24)IC$&3@X1FSIQ&04KFG3D
MR-BG0[[*]4D/$P$G38'H#?BJ@<: 3HKQC\&H+F'7E^4/(+C.UA%IHV[\QO>)
M]/K1L7I$V$-!A+EXKKW/?P;1&/%+L%S@FZ#%9!&@H"<PG_DY?A]!56)WN=;T
MPI(@Q8?:"5O6LZX"#9<7%=PJR6WS:O5=36=TOI*:C*X&/*,V\LGB]1UO<=4[
M-E[):+-,;[(W[_2[V9[<BRKSVF_]P!!T'C7G47,/%S7W& /YO<X+>7R<S]@^
MT0Q;SW>FS]@^L/7D\7$>'^?Q<7T1GL?'/6@CUEM;/1"RM[:\M=77]>3Q<3^
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M[/S%\34]>)?/SE!1C_ 5)$H 8HM+9]>!87,"1UH83%2,%%NP/= =AP6>XW;
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MXJ;ZLOM+K\9#5N,Y!OQBIR/3 !39FJ1NHR@.9X)2V/SUO7,1PO1>PP64(K_
MB. 8%4'78J\QB]$.D/:QGMEG>5$?L*@WN.0P1PKA"^_4</+1?SL["N%QNM'
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M>)7P?L0B!U]_:.,YB=K*PB69.@F9M\C-1[=FO IUI405S=6&*E^;I4#$1$+
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M-:(^DKET)VF[6APZ=%]T$:44E]>47Y3V+W.L!@^#N<Y/,WD1ARDD7(_C4*2
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M-S0P?=P=-60+2&Q=,%C'NC.I92T5+IM,Q>Y+Z/=^_01;SO;[G]Z4=TC[2')
MVU-+7#BBP5#J6@/NV-R,9RIID  3G!T0'.$6T\MW#1Z$N7X1K71IB>7NTI%"
M<AX8A.S<=![5#;5:Q P>>1I9*L:Z%$,Z$45+_/6[_ME;^AF"N"EE5'%?R)#
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MFNAL$-=1>]49W3Y*.2NQC+*&HJ^Z17B:H1,I_C57-=D:5*\9N]2,O;*)L->
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M::];NVO[LPS*@-,1K=T9(>$@YT5$;Y?3(C6O7:W420S1<+HJK9SNXU0F2XW
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M)DM"C^,C.51ER<V'61S32C99WLKQ"A '9;P#_9:5%\6]$,5A@=TZDH@.HA/
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M-'"*?$+T83,LYZ6G!!W;#LN(2QXQ=<5J$YGT,8N,0KQQ14<RGI 888<-![>
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M*IHR5L%O::SRRNO-P^I-AP!U37'@OU@H[#EXGX*#URU\\1R\GH/WT3AX/5?
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MD=!\J<1V;Y96S7FAVQ:;._.@83W.[1Q=U=C%N4PJ[#9*,TO=2']^?A(&]PP
MW$'=^%*\\ZNTAOTLOH&G)*HLL<+3;P#!@6@Q2\SM,PCB@]]6*3PFPN[(%1(V
MPTUX54;! 8J&[H6<8K$8C%?D8J0U$#99E%9\<(8S0,/0]XQ*L(*F),^CX+IH
ML@17N53_;M*2^RO#GS68J?@$5*T@CA8XSW*OVDK?-?Z3Y=D^I^?^I!1CA6+D
MW!?T?*%*;AG-/^>[HKBVVE8'Z1R;1,,/27W3PFPU_#T**"G\A,=RZS0?KF\1
MND4J;PHXX](LM4_70^FM2BU\L<$J;1=;_914N]./]<^+BPV[1V6U#SZ=.S^
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MSDL-(N#7PX/*.T,EU(QW(#]-9=>"0P^6#*PD?5*2,6NQ5<RM&M.Y&6+<H<3
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MP7H.PO;LLX)7+--J#AO^M:1WZ=R3\7!E3[5(2PJI%G(HZJ$Z0V&95DO0&YZ
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M-;IK@N+P9YZB>B)"'5;MG>"Q+V#/:!9U\!%Q!*1#QFMY^;+EM6PN>O @@<<
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M9>%,]4\1Z>"U1LQI/:Z+7G)SFM+V[9SKML0JS?S7[((=,3G R8FI:K=$6KE
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M^E8(]PB!P.=Q=%J<5P6"!GD$%(TC7$:D"&@:F;-?B'"[O@,\,JP@T4[.BHG
M+9@)-IES3AN!M9B!I]EBZEX<GH$=,3&B.U$YS()^+E\:<=Q8?B8<),F38]F1
M<PK"T>["%;#Z.X91;$8'JNZ+O;259Z45A\+>8((@ 9X&R_IL78F?-K>(BME^
MG^A9"/9CYBFL808!Y+V?X:4CD].5&[8P$D?[TLMI; '5=4>&.7(T+C)! 8V,
M4+5T9IH+3_@-F8K69%,;UQ>! $A2-79M1/PP%?*W$#<.3)=4LA"R Y9CBHPS
MX"M.&]Z)< 7N9!^;I&3O3Q),EI -26Y.X53#W[%(MB==EK1(S\:4\I#\0:IO
M_CDQ]43C(K(R>B %AS S)#GG=\4+S[\8@EYX* E?A:<*A]^:+<TJQRHX3B:A
MX&N1Q5/WIH_2JJ'SGZDA7:M9,)_"V9?DH1H/OQ[!N+>;U 10A ATO([?P.<)
M4M[9%-[^F>3*W['BT)#@OJMX^V$@%A2N<TV2V7RL"I.CKZA/U$ ),N2VJH@I
MD!Q67S]L6RN%E(F\650^@8HT\7BP-5[]$<>&ROLR.%"VU6/H ]:=1@I#RT_)
MC&/\@!O5*:7O*]=#\@NX:PV<>)$4(>+H()]L4N98V0#JH.#BNV/_=&D#<0"6
M.GY8]<X,,5BR;R%FG2%EXH*TTP ZH:'.;G?TZJ>WXC%RTBR_F;N'LL'XC?YG
M6N:YH@D42]E:(-YAQD-\PAT3L[*8*\M/5MM5-N21EB\\RY?9,T9X2O!VI1,U
M'##Y630+*H&C9Z/SW:O? PX;$U67#]4>B3/?]L+..A9$$7.Y\W0$E[ZHF*D?
MOQ86(-QFQ' "/Y )Z%@[T\$?\%9YD3]115QQL."@]W1U>(^-+;F[CQ'Z1^'8
M9:MFQDQN->I\[>*K%RXZ=[ZC2SDI4>0:[%/[C ^FR[K*8BF$^"9I':_VPO[5
M6<(AZL761*WBITV[MLV^!^O(U$@KLY Z'$4]?HRHW#"1G!H%#I3_L1(P<^&X
M(YF%UG>\U]A7P[_&2-A1Q&M9<EKWI?D"P3H=&VT+64NFN,T;$=Q@<%3NRE%Y
M&#B9 QN:KX>7XO,?-GW-EAV!;Y8R&T^/#W+>B2^1EB[K$?NL2.Q0+&A(1/P(
MDX(%IA426*!E;BZ(U8S"/W!!L+70;<K2X&WQ-AMH/M!:K'4CZH'-^#NQHW5H
M0X5YG%.6@[P"3G))+D81J1-DGI@XJII(8!;"YL%G,K\3>]I3=[2OJGA\_DTN
MX%C2M=,#*Z^L=<6&&WZZGQGI#ZEPE;(JDG# RS?UDV+V9($R4+5?<NXLGAD9
M&9B*<>/<$X],I<=AIP-Q(JK+9FIF[6[M^A0QE? SYO;D8!-9)I-D/U13]0?_
MIM9@$<>^0VML' J6DQ;8:ES6JI;(6A#\"L;2/=+=FI'EM6'M8W3]6+3U-"']
M,VK38T57I(ROFFI!_Z1V,40/Y>03].; 7(3538)5D71^)%/T5&%Y.[$HWD8T
M""L9W>[UPL<MN2J)G$&2F%RN">=<)#LDYS$I/3&K:LE.)L,=)VW=#?HN"U[V
M#T(D0NWN:% 3]=^!$);.ZIFO=L^(*.V$>&S4JNMP1.%K(HM09)BP$VMVT?-J
MO1=[4F($DIL3\'6,9 LQ9I@U)-HA36G8ZA.&O#OB$Y*OO%C [=I.GM!E^_@
MA\*_E%9%.=(H"$([: VDV$.8@WJRZ6;2/0Z&%<CM3!^'D1U@@! 9RG]):K[W
MH7%CH)7$!B*1SCLU14F^O;>>KJ4*GB/E!#T?US$KH_Y/@T!U[O1:-."78*N_
MM>"M3E).VF/D4\"VA0?20FDH*#=)%[0**]I1J%J\9)K!K3Y+)?<+$^>#JE0I
M?WMJS:EBT^U> $Z>U/<=RAN2#<NK,6[MUP$HMCJ@V+V)0=PO4&SOX^_[A[N'
MGX^CC^^CMQ^/CC[^L7\TP#Q6"O/X:8!Y##"/@7OKUB>CG3Q *FAP]8KSZO7
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MJE]^O<'OQM35[]=\$ +&[1B0"*N8K"I1I%ZSM*QJKK=64G -<I%!S^HD(X
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M =:X6ECCLP'6., :!V:_M?:@'@8'^J^V:+<[A5BF,M$^M6"OU)_:C29I"7Z
M**-H5#_'6A!"95--?S(VQ-,VD;HAG>))M.39? Q'5XMMS$6$:$)RQFX#N$(V
MC?9J<R>^+&%"RM)!\5&H8;CF:K)93$7*.JV)Q7S9X%Z3XY;([\ [(!^2_,D,
M'1QIU<V+W*E:=12N8G(O:+ ^H$I0.>R,&=GU5^%*3UH"62<%BF-A;$GE4_"&
M*L63L90F0]UL:N;XK*4H05+C/KZ]*ID9)J0PV..<3"ZL+TRB7<0%,5\D.<'L
MTN0D+V#")O \DY%<)Z?GH\D@G6PW!KJ0[08I9MPN+<0=,^5F"G%04:+.#NO]
MFLV33?"/_+0@_]W(PGL4@E9_EUE\X&$Z;IP\36P!LA=1=5&1;-G2QX.[)4[<
MSHJ BM/KGR[B&3U))R1-)'*BOF%Z@E)@X\(KB0J?4)2492(@ *T 0CUGR1RF
MM3!2JV+^!7IL#TUPWBW&Y1S&T$>Z,0NMF@TSZEMX&C/]:YJ9JL9TY$&\[ \'
M$8NZ]_[MX(Z?XV9.\'!TWNSHO#<!@3N&TRU0B#6OUT!$?3='ZE(]'ES Y[3Q
M"9HS-;J/P!XC0<PM)QD=GF,#$? ,C@$N&*159IA01[[8I@#A-"'=AE1M,6>(
M*80I_6[837>YFQZ&^,(!:MF#1S59$V3?QNZ(TD26%?$+5<22"AF( NDMQ>7%
MA"A%R<<'2Q8ZKN'<0E0PU4]$/68,_\OGUP6+,%"A(6:RE=8W&%U#9Y;-U)E.
MXL^QL,G54IG4V@[(C8CDNY/HK,@:,!@E=J37W*T .QS+!,B>,KF0[YV%7\O]
MQS&O5-GFJ*FS),:0YS5C[AGP?NE+I2G*$W!__BU>H_)+F$!29,]1SCR9XKKG
M/V7I_S3I5+X$:QD>JK$VSM*1E>!LF9E*G8DQ)-JUAN3>45*\0<*O+#EO<4@B
M@I&T(PE:3IU8*@21]^EF 1_/$I?)=ZS@DJF8 %,\QR+-68Q.?-"ZA(="-4EF
MDI-YL\_'Y1P-$!)E-4N]QFJ1-0$28?_#F]DTX+KN[#S9^J^=_[2U7=_\Q2JU
MN'0<%]Q,X3OIH=R2F!@,6UR%R<%%'7(3V;OTS\SC -Y91B$8PS"MQCGN#D2#
MY1@#J($C<!6?B*_MZ(WL8'0R58B+/*$5/E_R%[O=,.:2B*HQ;2L=WKQ)G6-/
M_3?,B:=2YDZS+[(0O9Z&'A8IK4_+HCDYI4GB ;X=1<*.R']OI9_5"0KQ*(4\
M/B--:%)837X]P/W\!I1!)R=(AJ;:D>Q>6MO-XXD3:>/(<XP-#AKN!\Y#)8ID
MM))M=5((G^!3TH0A=R?7W38DZM4HYM8Q/ZJ=PC>#(5Z8J;>]"?W&;CT:G*,J
MU'?O\ . \47NOZ1*I\92M-GG@C_0Z%+[=U_DA:]A3TE&LK FR?Q8]*IN&5(V
MGU3JY0M33,XE#PAW[$0XAPN^;$[\!DV\X<9+3KOK1SPV>GSUU-ZR\]IL2@:1
M4WVD_6$"6RX,\Y'P S#P$VL6$RS]HJVBN3U!C]..6M95A;NHOGPD9S?=3LJZ
M^A4H5+=V[3J3+'4.U<J[Q!Y_ESGV)))TGIAPD8:[1)T-O'K/$L*]#U7O.W25
M[TV,Y4Y=Y=VZ3B:GY/*]B?[13$]6C\'9U3'AHBAMSJJ+^A"?!'D!Z3'X:*@,
MC("]AB3*S!FI088&S9D.OH)\]B]Y?/S)_ANO_E]HL<A&F:E7R170"G;(%#DX
MW1ML:5VW.RXN-'/DU"D-\!3)1BD)E51>.3A+;7+),EJ1$U2:OUSC/@W8?WL"
MAW9J2NR(!%MZEDX;<H@(4Q]*Z[*%PN;>!)[]GW__^]__)=3D>$7WU*69$W=J
MDW,_9(J3V.1B2_#"\!<Z%FD2$BT4?&XP-;"QW5,[S^OR@@]$R:3ZTP1\MORO
M@H#QA3M<SA-R&3#2X.?F\X1/!$+&BV=H?3&_5L1N:L=R,(%W: (?AOH0*XRK
MA.U*K5\_VM:B.39X8YTP<;A0'$NA +REB5?OAHBR*>V/(^6.)QJR6'B(D'8O
M*)8XLQOL(,?T@IF2JXQUJ:\3<9K%EK )0\/%129I=(E*[G_AV@?'5PXAHB^*
M5S#T%LQ7[)$3'Y_J8)3UGYC,N (0[/>FE#1\SZ7$H4+,SH7O"J]\JS49LO,T
MMZ3>-K2D2<"9KWKK,+Z5_"W8G^@7@N-\#AGB_6?^X'2I_H ;V@"(62D@YOD
MB!D ,3\ZS]>5;L2:DXE,+&F$/<M*[#^7/FV?5@.[/3<M-$3<,<]\_K1S?;Y3
M,N6ZKN73X+20$8?<4D?@U^PGY+@EQM3@,SY=SMVC]@BZA<,!T9YR?EIW6<7[
MA%(9&W^*67R])C_QA.>D[X'I)<D,T2#YU&L?>9BG)/H6E'N>+4>37(F4D;&3
MBZY!H'%X%L=+3]_-U3E>0[/L"KL*[ZU_J?.\=UO3W_]U_]W!_O$0?MY)^+GU
M0/K>?F8UUY4&G;\MI#=-19YX'B@ZQPZ"K-4#NL\(1M^Q%DM7Q#RYB"TA,N'N
M;#SCF;;D2+.-$T*M97/<MGD"<8MS$JZ9<D1FRT"M[E,F"U5!(ST)?55G[53R
M72?<^X!H=7'"X2GS3$2?2F,OM'<*N\W>8I(EU$UBYL),D\[G9HHN2';A^M[@
MFU2+W_#=?P1$;7K> 5?V.KV ,M3Z8F'"@J-'F#Z/]=ST/=3&-=3*^A\4_[+/
M<%3BC><_V=)OTH#9@6M,I)2KWH1E,IJ:]FRT\*YV//AR9DU)<^^7 7A,(TM@
ME&'.(W&.&R89O$.72P67VR05+QTST?W^%H?P7PR(I8)-HCIUS%=+=T?";$7&
MHC@P%VF=V03*5*KN#)IT2[OB?"9JZ<G/FM84+[/'UPP;2&T)50GO\2(A!6CY
MANR]/01HUF@YD,4<^SNG4K)=NI"NW+ $XZ)-2)0F%1PU"!]&#1,8 *>Y$6_[
MM9;RG57MZ6\0%3#+LG99U9E$L^<34V-3GV/V.VB.(I>21W>52'!O@_[SS9?/
M'F1_OF\8(YVD*(5W?E9,R$67TF EMEA0%UER/FN0);0N2GBG,$-/D/T0UN;K
MB##CDH8C.^5!ZCT'1/=4Z%@K%EQ$J%//&LD1:BO[%)..LL/'*=NNC(&",['3
MKN$9MEJ9S!#Q9 LZ\A=,!!)F2F0/^;Q ,#/QJ56-X;,(V_*PHHPPE<KNR? B
MTAZ8IT3R#-]SX128,<)$(")AT=0BO0;&/X6(,!G;VK%<KO)\1WQ\A$.-91[G
MR,668G0+_ZA0'Y#!6XX"SJ(Z8KY3++%P@#^0NX?V06O?8D2,'^-KX)?/BEK_
M1HHP'K7E&A!:;&F]6QY?)T6R[NAG'FDVU_!&,&2U,QGKJ230$,\@VX7NQ7WI
MRVKZO6'0P0(]#,$X< '0Q;T?4H,31@<4$DQ-FOF8KH&#F' :V>I9*D/NYJ)P
M.FE^/ET>UU7.,*J;2M#>%MEL XGP<@[+).!\/EHM]/P- Q@HI)-D@WJ91(^%
MO^.MHSKVDZ#,*%CVW_;VK.BO</ A2$L0"C%B8KBU!)>RZ%W".9GA<0)S4G%D
M[U%>C*J"!5E@8N#R_3PY-9,O*-#JF%F5MJR;:HQ:Z11RKEGI7HT;L= &IC,&
M?+6VD(4U\DS8W:8!F&(9;VH-KV.UG'BNTDV6G@#BH"U=P[%KW?;N;VM/=9:D
M+>6J]X\EW7*:20'&UDWZO,2@UPFF*R7 3Z\OZ'':KO2+MX9IR9S'UR*S\%]Q
MRWF*Q?OPB11 3H%48& ]Q7R9?[IQ,JG%//!!T+HL%99$TI.H(7'_-XO,."HX
MM:M)KM*=B>;:4X%/3TCX)&7'53"SXL;><$Z^/0ZR-3$6!/=/7B(F'D^G/M%R
MM6*607Q#.Y6<P;:W(&'EM;$)H>XS7FF!W+KNY2*0%E7\*!E(9VM,93\TMO@D
M\BN+B3+J9"Y16_G?AIS7E@55IFE)S*8>UKX9-Q#< 0N8^09>.MP@YM.RJNRQ
M.T=);-.Z#+ZT++MDU;FY=YALF%3",)ZQAX (#A=!#,J0MY;S>2A<(YG(:[R)
MWH.)G&0%*A#_*#D@%5%VO?WOM'9*-HL0PR00BS^@84O)O00+=*%,AS(G:&;(
M;5-Q;I5DV'.:,2*]W[#$/?DD[?#!)=%3J$\%EY[:FHX/CIC_Q'+\TL'A.($7
M>(CX5DJQ0)1Y@2LK,''7<Q8\''T&GT2X1CF)(O!QF#)A-J:+IV<$D\</BRH9
M9TG@N0*I^ZPRY^@8:4>)8G!+BNKPM?T7QY$P%Q5G'&!N-K:>CB!@R QR'A,2
MS'$V#Z"'E8(>?AI #P/H80 ]K%C;K$RQHU5XYB75K.)K'2O82G_0:8YPY?FX
MXZXZ/CWJ)-&.O 2Z-:)UZ1! ]H23W$J?\Y_)VJ>5+NU/4"TE3Z4A3:Z23_5(
M/W-W@@BM2U],@FD=/E?=&6FY$M#!%S8R/"^N]N4]?2C&''K$$A;[TU=Z<5#Z
M/<6>+G#-7U\S1RPK#G=0CV;1@\D2OT<EJCA\FYJM+%"#JAJDU+"OGYI,)1O0
M"HE:5W&GO7)^)D5E0_6RF*'?@XR3_J.<!#Q+JT)]?V8DJXH $Y2X0M>HM]2U
MM;6YM=VV1H_MY<)D%)CHEN"_]YT&LM+DR38YIS8")>C+2X5>0#K6&199!3;S
M=$2@*_GSJ./DTE)(N?4R\'@GIT7!R6;T6I%*1\EIT$IYY._Y?9IC;!&K_@J7
MHYOAW[0,%LE-V:3))2]7T3+"NSTM*#'M/S"*;7W$MJ133H>+!G\U.1YIF&:W
M]+:M1'E+1P%?K":7.&.&2P*_2:/'C*HA!A\9KE^FU33EK8Y+A .#=D+EEEVK
MM7KGO#W<62A4&(Z9BM!WZN26HW$"0RZF%S%WWY9GB5.D"4[GF>YFUE4&[**A
M]Y"Y#"/E!C0]#]$(R8KBHD.0-!RR7K>6]7H8_'"'1?1'@CB+U;87AON)EVQ>
MZ%88PM:6^)$EVZ.'KT,;.8]I8 F7./"=T:?!VAH6A!,R@#ZQ3_*&\/68<^@<
M 8B7'@XJ2%8/$,,[VG@/@UUJS]<FCJ1PL?(>-[O>N7X7%E5<5=M3.;C]FGJH
M$_DE:NOT78KYE[%[ECDGB&ZBR0RC2\XY^BAU^4;&YZINR_4N+KNOHX7$1T#_
M5S,[$'ECV6 A$?T>L@(4O5):UN?)EU;X% 7A-:9Q4,Q9';;]WNI5]XMM__7@
M>&__PX?=P_V/OQW__>_#^7,GY\_V X&X'Z.VB? ;K/3@^>,4'#:TM1 !52GA
MC@ET3-:Z<M7) *FJ3AXP4S @:6^FC ;<+^>Z'0.^N2/;@@!(IM7B7%NXB7%3
MBZ]WO;O#AT[3<2J)6X(7Z\O3:.C"EA)'+JF&[P=7Y*P+0P0-7VN;#YPVI4-R
MVLO03263*[>$M^@AX_*[1/'T(-!:MWJKYRO51SB=)'^JNL\^:#G?E55Y&""*
M0ZJ?K-2>['^=F 7AV3RJH.7Y,;2 :SVQ0R1C:$>I4R<V;/FF8^DCD2X,S-U(
M0X(%+GF4:C&?-\@RS=33(1++$4;#-S%MF)/T\#%XP=Q9,%)E'T9B"(9VOL"X
MDOES%JYE]3(061_^S,HESY.Z%@ FF@/EQ8O$M##1+$EO$9B.# P8+):>C-FG
M=Y38^!MV>PG3.O7]#UZVY;50[*%V"\?SZ%0BFQS1RPG6HBQ@,AG^BDE.[NFQ
MLUCZ?R.2%&P9_#LGE)G$\_Y=E>J/=#G/WLT?\;QRG(Q'V*Z&34A^=VHH4V=S
M>K_E9/[I';)W/S<EO'ZZ1R5MT4P8%LVPW(,X9A@77*1.3@2&DDY;O38!TI>9
MC3"5Q^<9@6Y3#E2XVG9576V)6>XFY6_)+ML+K]8P/]M\^=V&>2,9W6NP\)T<
MNS-72_R62NOVT]LJT/P4YNJ_&WORS3/RR_[1WF\?]H^CO=U/!Y]W/\31P>'>
MYO\U+O_[@SD!V_L.06 $@,;?[2(&@ [%B&ET\)>K.\QZ01T#*NN.45DO!E36
M@,JZ#U368['!SYX^C7[!K]3@U^V"FXB->\<-W"S:@44')O93DL&Q!7^/P4Y'
MT:MG.T^W\/<8DF:OO2G^#"[AXK3(C;//UZIF#G[.U7[.^,?S<Q2J9K7>3AN:
M\$.[._>W6^_XK=SN.?OM>=:##P=['P^CWW<_?-C_,WJ[>_B_'^4\/'_Z//JE
M.$]*#)9+@P1B[[,"0NZ=1SD=QTD>O<>N9]0!HXWTZMG6T^>R+6%'_NW[XXZG
MWSBV8+/>_]3@'.RS+8G69!+N9VFNC<<V^%EWYF=-?CP_RV*D5NMDK8G=_MF4
MX!?M%>5"ZB>/\O1ZM?4JVM^,?DFSK)IBW^';[&RZ:?W$[>=/5W=Z1(_RA;PO
M*BQ.[%$9F)R)9T^?/<J9T$'-_E?D[,'B^N]8 _I4&E3TD<+ZWBE*U_@RW$=L
MKY%6"/X;QTSV]RK$N<PMF<VN7WJE0T-$J&[CV3^^!8]Z_G^3C=J<%',NXR%U
M43Y+33;U?UG=_NP+#]<Q.KS7G."J'_9^7OT?S-0X*198RGR]9G/PD%[XVD02
M>Q\_8M;CPX=/CW0"MIYN17LPB%E1YFGB4A_/O]$ GZ'NV"3)Y+FJ9F%*-<P7
MFSLOOG&@]>D*?3;*!#W2%=*;"=K:>J2SP<FO57@$ZY/%M\FO2R?A4GSE@VFT
MY&95;E1F7AU&1B'VB5'"!(RB+E3+HJ!5B<<7499^,8+U&[H?;PVN^C"Z'_<A
M4J1F/H$WOT'X7CY=O=[B@.<;\'S_QW]_#OL.+*4#6\(6YI?ZUU)JIQ.)1US9
M2?!EVCLH:<M"+S,'+<7.-(0#(\UD[F##\H%^V+ ,AA4DF0M\@<HTHJA<&N:V
M89AL6LJ D%V"NBM2$2TOJ@1ALLC-&56GAH0_\R)_@AP33, G=*TSRMRD">EQ
M>C)V))'#8>'7S$E!>N#"]2[\[QH5K;]G:5HM]0\I'"=95\EH^1QPZP3]4R&]
MVPR5YHS$\^S3RH"C*1'^')M%;>9C^'DKCK:?;C]U;_D09N&=GP6W#$8W,0\#
M1/ N(((O!XC@ !&\9^*VX:!_P("V0V$-#9OM8M53'ISV>$0RHP4KWG6/(V$D
M3=";Q68<.)P7+)#"8JOS8LH])(:[I;"#?P(^]I1X9!VU3$\KH.+XVH%)EL[\
M#G-L0*[ANE>XT3 S9ZBZ$CP2D],69>QO;@]F:<=:1E++JC@A@=K-[]S#:;M!
MK/HU2>^BH*$,)W$1@I[6RL_JQ+*6LT-%8RJ6.VY.O+PI':7V=&KI:]4;H(NT
M!5N67A:]IM,D/R'%QEQ$N:DQUM,DV"FU+ZTH[6\"EG[N,[.KR_U$O5+$DQ C
MSQ0%Z;P>186$&2$J*WO062,R?'IUL?T4]3_Q\HU9\0;\,!09L.V]7K(@UDPP
MTC$G#]_IV;UBJK2>,_S8X>TG(4;QLK%-$'9)]2;R:E&G,%EGJ#M$#7RYI"R$
M1(*YQT7<WJX>O7C::T=:[S9V1[@Z2!>%=Z/PO#EZ.*O[PZQC1#9634[-M$'6
M_2F1ALT";6;2WX"GC_47NU\A;8QY 8&!L$,J"C,5'>#'2&V*+PGOMIF(9D9-
MWFVIKN?T$S:0H]D8)[KE%M6H]4#]X[)#<<%'KTK5$@-"'Q0Y)2<!X[1':]:D
M>!-MO(6MC\);5A%$/9J(L_@=I!2:E*Q2RTY>-3"EI 2WWQO9.](3FQ+=76P7
MY,T@4A#<4@JOW1&'=6VCO858H*3"))G;$5;/1.3 /5^2XR C;CC/L:^YQGHU
MI"Z+46.K0&!Y1B&JPFBT9G+N7IYOGGSYEA\@F6L<6]^ VOVP-ULB. R9/FX)
M?3?B71OS'J6^4]K97:( 38#Y$C^W.P4'9MK,HYVK;NLLH6875P;$,7_?Q((0
M+3NS3#*Y@%[_08_O6-1?J5'73G.L3H?V,8O?FS4UAJ:L(N]/$YC\:B *N*O,
MZ\.@OSHLL!::PCFR5WA-OI4S8+628=3O3K_#<Q>/B+]0,,=3.JJ<$[-UH 2:
M2ZX%S!FD"$BIN3/>0["3Q^E)0R=S&1'W@)B1E$;%[![";R*W0$5N\GC["4D"
M$JMTQL-1HQ8[WWI*\4^P8;Z9+RRQR+B!F#L7D@/'$T CB&;)65&*6#0L-O>C
M)8ZF.YVE9=TX8JZD ?-75J?IPAWD \_("LS'\X=B/M: MI(L!I.\88;:L*H7
MGJ#]?-ZT_4)W"<50BLSPZ0P[HD;76CE=/N)R"?SE@8R-4BZ1*O.'/O+>I7,*
M.2GZ:9 KUH]= B8[=/0=G.:5$R&A9X>)@-=16.8.9N5(+CPS?.M26DT&+YM#
MC".>+BM$D<LW-U/DVV=^$=:_LMS%EH-3M+^T](U5X<4P%)U?,+6)A'C*W$B2
M! ;H15;4H#P??ZSX[A4EH)N ]G@Q37":PA]Z'QS>O&&EVBEG</CB3":"USQ/
M;#"B]+*TG&#[C<C4A8Q.%<<QE'T=[.A=V=&?'H0=/6[*L_1LQ4KG*.NF*W.:
MBYSR1V"SSI.RQ$C1D*D5R6@R;]<OD9(_%0A$>KXB+P8M3I%-=R'\Q-J 'HKA
M?D/OK6Q%$RPU68:C6U=1D4&U7<5C*UG]T^9.3-&D_.<9_^<Y70'_]:+G/E;H
ML)>]+G:US" HMOD!SXCGR%EG2H)\B.ONS*"\>" &98*$:(5L@EW*-ZV>V?BR
M6.-RHR%G=(Z)#MDD:OOC5U7VI&CIHY/0F^-KX^0;2G>0"S'2(F_>)^-/+4UN
MM;/:RNOI';]-.[50"98?+90_\LQW0<:I1@8Z_P1AS'E6B!0KC *B2":T=)SN
M;<N(&7V^2NS2C^376?WB;_5][7/R W5UG +I6N^\7?6"KZFM4X7+7MZTKQ!P
M70""\JS ,+G"F;I<')B63V7E'8F4+Y<J(<^L+0%*-J]O8J^<UZ)<3B((<S'
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M(,!J@0!2B$<%6*3HA^/!(+^WU3DCM9/S%"RT%:/B6B?GQJRT=>6R?R'-J6?
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MVV2&@X5S([-/L>-; W^?A;,VP,O/T%@@;;3O;Y$YK +U7_O RD99 [P4#[Y
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M6K!KXYO(1JRBK6<OMF GEJ35#3\\LR[+7C$U<<".59L>.E)[!!(9.$N9@TU
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MX*1$LQ 64G5@B'/0*6_I$W\4>W\,(OJ4N? /CHXCTL#ZX\DKR2)<\)9,.GX
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M<T.1NGS8[?WT"Z >+%*4G[)%V<@Y'=L262RB4  *^ 'HM4Q48/Z^O*N$IV(
MQ9_;I:>]IZR)-Q8W5V@0%&0F,ITJ]R"E;<Q2I%3QZ8/"&/J4-(/Q#27^9BFL
M_"XP )SXI[3!XX@"P-2S1AU[5&Q?_VXNMT?PRIB81%)2LS6*U&K:5NT0$^_:
M3']Q]-\I9_\1$57<7[T7-92IO"2'+IXW=,&Q"XY=W"E<67A ::/?B)^BDO>P
ME6#":-=;V32+Q?,<UR90^R;/)JQ:[N+<<-'/%7B*O+5$RC2?Z@95B&<JXXN\
ME,3<4-X\>?1^*[#;'2%<^'$%EE74@*GDJB-6[@.R&8NYYQ1SEZLDY8*Q4[B
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M!37Y6K6()_Q?Q0)0:M7<-,Z3*$@OE! O !NH#>)DXGB"JC5ZYQS?YB/82AL
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MY$>?=5\3]?L1B!-C,?W'L_NU62G<ZU1\ A<<?NJ*[G2:Q)>@"KX$43#))^+
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M+P,G*[8L.TLDMLYJ^PNS[/U8]NTJL>S':X$]:VQKF!G.*\DYBZL=QCDZ .D
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M;S2;5,TIL?'=  ],^Z+9]&H*:W5]'TZ4,[!0)E5-E4WF)R;28B24#.7T(HY
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M1+@V\$D\(F-E+F4U2_E5KKU/S9*Y!/8/4$L#!!0    ( +. 7%@)0,;REP@
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MUBQ')*7"_:(C$44L &D,?@.)[OI"HC2@UO6^L2Z<!5Y?)!E-9\7'T#L@,4C
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MMI_O_@K<[6W'F:$4/](TL7T[DW72-K.=3:;.SNY7D(0DU!3! J!EW5]_SP,
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MHKA ,[LB1\H&06W1$]K_VK0.(SAAAMLH"L4DS.J!YC,@P1DJ<NBKH>@(A8!
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M#<P:B;^2ZP"^-<AU2UV2]:O0%=%W6J"!F^ /L\"E3>#2;@:"@,U8_-1*8)Y
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MVTKS'$S[6$-4-0:>&GG9Y*+6O&IT[L%)OP1-I+-6RK#)*.9E.^!L L*>)^P
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M(-K\6IG G*H@'+OD=Y+Q_K<5NI=C-<O89).F+0=; <JU:(LDCY(/D;N8";
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MF^</ICI;O/C;\P?SNLA?_#]02P,$%     @ LX!<6#$I[VC1J0( ]!X# !$
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M%F;3PH>[$@%,Z1B2;.CM/-N%J]]/F\Y/G+IOHL^\0M_ )VD[TW[_C!BVL#U
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MBFWK>[.5;I(N#SI9]8RN$)):">YTWA?87V%]/\@#P4;8?#+)-JLP,M+C$#/
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MK#Q,[4K.@47&.\A=I?B.NNJX&<BFW'S17I=<H21IKZPF7EN%$[#VXT2C> N
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MCB%/@*RMDL+?B15J%'T]+Q7Y\PPLPZ<Q!Z"+&14__&?3 +P[1^NXF6.!)'<
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M1:ESA#\ ,A:_9&*09)D50%B6X/.PQ,K0L2O#=TI"SEV2Q:P8I3L*G:0^6RT
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M&13([WAN"P+#8]?[1GN7!Q)BFR1$XYUO)R:X?8SP'>?IX+KNK2!!8 7B>>U
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MP1I,MJ&<2_%!)>3K=HY*E&"EO(. B@^/BH\FO9^6369(Z;0,#KZ2#+,DG5^
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M[71C6-V "WZD$1;TSY _,(58+S"%S%-:'!GM6<*"F#"E(OM^FS&L'P"Y6 -
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MO=AORZIGD:8%-?QRYDJ3U#M^BY6GN?UR4!G@6%VM"DU-2A%?<(KS7N\=E+V
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MN.P:D!G=3@V-FX<9^_++LJLY,^+Y6V0'$T3[VQ@L"'F!@:0D#U*&"*51A]G
M6(3"(V#9UW[KR6DXW3STWI>;2=DCVTSXY>#Y+WI'HTF;W0"RW')%#?JM)^H
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MKKN@@,>/\3J3M#;SC\7E%1,=$TRR:5^TG4&JB\<DJ=_4V^>>I4*L>IAKYM>
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ME#C7\CSJ&0(#<UC%^JO'Q/J+X*M>,7Q[9+-5N_#5&7N-"N-)3N7'&ZO]98"
ME>AAQ'GCJK>OY7 +! GXNS-,@(O,GRB6N@V;)T<A]1(T4'K5X1OKYUUYE5'
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M7;QST!6[%4LXW>W>9T3KFL^I,XWD[SV?:!NL_D063 !<">Y;,=6FZL].Z_^
MSF?O7'Q<7TX^.G,"*$ [!)EQK:S8M]M[%4>J&-EX2>(/-5X;AE!H9^^-ZN9J
MU3TW6B\Z\)(]1GB? &84P=BQ$T#O1Q5IBEGH(XJE>UK]Y<!W.SG)L.&1RL*4
MDAG \<B\D,!LWY)(.L(E&<T'3NIJ&UOXX)(O(VA6_G+MVZ/-(O.RSD"RJN'>
MO>K$]DN<AO.ZF]:!<=:)>4%UC)F7+\I,1"0 W-2U1,[#"M"(QXCHN>\&,@05
M@%I2 H#+F@@JB:8OWPE*KVLP^F);GA<3\.9U>CDG#59>HN@$H-^,;=.59$O1
M<JDX)M'=-?5)*&.("!+=/S(86YA#3AY/#W;6'0X6W-*O^D+7Z/Y:V5A'%^@;
M7$2.K#J&I]T-I8/9O-K+K_CZ#N'GU"LG[)" >^CT2=57TWTN[5V'ZP7H<*?Y
M:VFO,@AUDBJ);BL,2F^5XAYG;U*;-3)6;ZFZY>OQQPPM#L^U&UU!:WH2#=$D
M.]#UY8YP% 8^F6;<SH]I@FPQFM?LM9T I..*IF9X,!)O%.,&PQ@@J3G/VV8V
MX[P;6Y!H0MGHVUP?&,Q,9\[,3H,2U=Z^C0LQ>:I\360KF2U$0Y@=4UE\%,PL
M]5DD"?'<[/S#<.+QM6#E!6(W4O_<%0%2TB4%4VLRA8SV,I/[I(!KR,&066TH
M29Z*+;>3,+C5BI+ .%D,VNT%KYKL4+N/LK7-S4TIT^'6@,5W"I,N!ROO9SU^
M.U-T)&VF,;^;Y'JG3]2Z)'_M!,#HV^/!Z9[_7=] 5X[RJ762'MDE6H+:Q;%\
M2WJBN"Z9")6WV+%5AA. ;B&$U-A['.CC:$@&CU#NKI2VG/&[&?ZPJU<"KE6O
MCQ'JPWZ!+#!$FM='W8%;8,]'V>WVR<F3[1NSY.@Y<?.1RFY ]Z+>N40LE407
M?FM4T9_U(Z03RES'@!PFUZ_H/!!-\V/ZT-.2>,,&&);OJ[ Q&U7S?F47N)(E
M8%61X+7N17'/[8@(/ET3O?U@)-F.^Z;SK/D>J]J<E<$9XR4%BA54P?7V$OE^
M X&:\;+K0?R(?@^MIZ:TF_6,PSR:$4),9':-]LYC5)5EF[1Q;)568J8(T>?F
M@.<2E9L' \J;Y_7BB2&/4$\UZ54]0H(OG>\$L8TG# WEC?M/W>0HN10,"4!@
MOX&(RI"!2_+'P F'[L:^^DF+3$L890RZX-BSF3##560*NW2@.'-53Z<L6"$B
M$>:K[\EJVOV\QVF5?27.!U;?Q7N#22V41.82Z:.^]8MCEAO:HR*+BIF+17)^
MJ00<VL&R=,>-YI:'E-!TJVI@Y1>?O+BYQ7O#A4>5WDB$/G6'6L#;<*.^SJRI
MI>:K;!JWG9Z;A+M\Z3]6P^ V3E=Q2[#"J6%WFEC.I-G)RY=OOGMX=B9A&[]]
MUFU^=S[&6.";97_,^?/#3$\FWW3R!"9YYJ0/I/4Q;&+(%N^^VH8E&9!*Q@J?
MW5M%H]SV(DRS7>WW=>(5(A1J0CAJT6,C7J^Z=,MZ ^:0:D0WOH6J:_0&*#R,
M7MW5@\V%B!?#X_;6V/4<N?GSX.HN GUM&]C99V$,*&NSZJ![\&QH_#8(I0$D
MT)>RGFK3A )$OC#2MX.!D^@!:R>Q<I</S$D#==QB\YQ[+3,$KHQ)=K5[N0N]
M[Y([N.:5G@8UJ.5GJ2(5=@:,!(MW4)/\W)?TEU5&E+:;+:QMG%LY4I/I9,2S
MZ]$/&_,&=8CE.\W7'CB%"IXG?.Q5=<[2U46USR-/TK$G:5^^O-28B3'Z7/GT
M4?TG,2_UI-L]Q:M K9[\54;!-K':M#<A([5J4)O2]*SZ,+E;"M>-EKDBHO(3
MPXOZ!P:RK=;N;([[<DZ> )2+K43-D]^=1ZC 1]:6 (?8J*^OY0!.8EJO-N_4
M+2G*7)I!.)<HO"Q@H2)RH:].E';0S7CO1,?0.30W:SSX4C)3IO5LX&M+NRM>
M/8,OK*.T%(C/J;K8VFX!\]&&1_4;PVV.&Z7QC/LFB6G.PA1Z4C'ROBKCN5(<
M_;5*9!*PBN=AS;HU4XK<!I_?=L#=W\?Q$C5<ANW1.N)6RCZF%H<&:SGLS<8V
MR'+B]NNTI$U%X7 %:8]8I+P7DM@MZEK5\6R&X;S>)E%=TS?BNX.ZC7^5>JS<
M3PODXE-;%+SHL/%M,16N8R/W$F;<=CR)K-)#>Z<;CG[75CA7(1O=LLISX^#\
M]8(9BVI@5;PR^KF=BTVMF5]B9%B2"]&2G7QQ?G'A9%,N+*9WUB5&9'ENU9Z4
M8)&;(BG7=H4H,6#V8--=T"YLIT!<\FY:8#"ON!7* UA@M.RL6S"<IK45YFQ]
MO[3EQ<ZA5@Q#](7LB\R ,V.?<U-;28SXD%_E4QL&]BJ.*JP+Q\VK;_:N.[$K
MWAF_C]"SN"_#12!HU[K8DJTP&:_C=;,Z^E. @(3%?3<N/@1(+01F@[:M=W!U
M48I0C\8]2NX]DOX+ A O6EZR M9OC6NC=X&Z4L0=4XBQ9LW%PT"BP<8AMI1E
M-"U1FGJ.PB5.<MVQU>IE9!G<ZD[$%+&62C=)C.WEQXP78-)GJE7/B O-#-Q.
MM]PS! 8O773\F \_^S$CGO7;:Y(+S3:).;G=CNY5?$VZ\.,1,]'[P9IF1[E4
MWG8[@/[S;R9+-@6+[#([8?S3+]<<:B,XE'H.MLS#X^$Q59D+G>\HI(4-XU3<
MJXYL![(Y7,N_=<[7#SDC;,VCBSHE*\WOTMR$+@Z,%<!SZ2F0''FKQ3XH)YIW
MVW?, DMZFMSI>5]*1(&;IC7+HDRPG>'$;&UG;DP0M% UVWS5>I [ONR@9Z%E
M2*_"6?F5BBC3>!@P_VDY+H?+0M0J0[FAM=.K*9)&B?/;8IMTWYT!F^8$*T38
MN.471<JD$L8SNA0W#BK"Q:T$*[C]&,:/O$C9;:$SI**VJ&D)-#:J:8!.>ZLC
M=?PK2N-N=YRFX@MR%6DS)Q]I5933W]_OQ_S]_7Z*:H^TI_!!*&[/]YHE)?HU
M6;0_S_VW/TZF_TU/85^,?QO3@G\;@\!-NLNCZ%"#VX%[4U,4ET-ECW2-]JWR
M-N[X3@71-+!RME_[OEAH<\_,>?BJOGO"-628H0-M"+G_9@5C5HNIT,UCR]E^
M>/98W:T*U#KS!\C9HB+N&44'39AJBEUYT=;W!9AJ B>[: %?V49D2=&R!&]<
MJ^10553]0\#7(;E&U0U;C!\]%VX%98J%-X#Y/Z]MP5SWB?,*/[3L""U+*G*8
M+X27IP;RYERA61+MC:;>'W#W.@>^:F4!/P%<*_D'4;2O%2MR=YNB# 7J0='=
MNWEQ:P1J>-[-;> 2>>_7QN2HZ6=WY7G40NK*UR^-:'=-!BG(85$A\JB,6"8%
M/SF-\+N@OF@ZX=;,!E7GR(KA#=/'F04W]FJF]/MG^ADV=LIMH).L.T'"W^7L
MAPT&-Y$<[FK6J:^PET=R67KY=9/VB?C@SL'*GW*2Z,M#ZK1XE^*@_K>JAFG8
MM(?TB[%VC$'-GRAJN5)=K@]ICDU9N>8[S#62^VB\6;F_))R500AR>A'G,F!4
MF1WQN&]744]18KJ'PXG3<']R+?$$<&&:<72Q<:H"L:4*9E/2>/W$]1 B/^]4
MI=Q$MB M8#X3H!1WGV19>VJD/JSGP:I^!WRT([+.2L_O2:2C:T(6\$/&Z-*]
M<F_?JLK2LJ?='>S"P-B\I^]5$E?RW%>S(@MI>^"CJ]8[@F)7\:31KB5-U_5K
MK[W:OM:C(CR_^15CI::.]O.TR]4?>6":SN]E<;>RY W4',3*M)WPK/1[>O1?
MCU0K3=_WJOC/N-D]RHFZT.F!')!DU'WLR^$H3M/8G9^:XVK5\/(;ITQ:F)^9
MT<%SAM![7@0G@ =Y598*P\ID(^.ZKE1K!2DOI"#1IA$$OFR5SW<+!#?F8.>2
MJM+;LHK#%S<>T:4P?2DPE-R9V#:XO1?#V5\@,&(H])GRRS=3,H'I7/^+78>%
M(VY:M M; A?%R3R/5I,'B2H76SGU#"IL,Y.(^YB1'NZBRSZK^;;&KJ/SBA4&
M96>]AQGI$_IBUZH9=)?2.S@'9S4/Z$5O^']>J2V9!@8]0R_KP_N=V/F+XA0^
MKJQ&$SC=K%>JSP%N+VM[Z_5%#ZRDJE=1HILCN8 V$K&-EIG"0ZG^%7H"QYY-
M2E]\)EU,]A^M8$@=G-QS7>.F=@,,Y#+:36_?/ZC8$**(W:C'@E=!QX.@'0+]
M! >%B\;D^3[O:8ROABW8/51M/?M6-LUUQ-'DV06,M!6'.*H70H9(C^8-<A<2
MK+X.:5C%4K>$8>X_62$O?Y03@3K48LY:=#FTK@\8%L[;6CD3=N&L=Z>X6Q]_
MV'2H;/"WB1G>A"N>#IK< J+'#[.JJ\K*6/<]%G7VCGDM^X1E<N+<^&LNA2\Q
M*X>M0><T4OS9C:_\[_#:X/_^.+_U_N]?DF3QI%"SI'P\?6F0< -I87YF\CCK
M85(?'7GN]=O72*5PBXE]Q0?XP_O:1_>QB[#KC$<9V]DH_!%FCH#DX_H#I,\$
M=A*S!./D4J=M1^S5XHNJ1T"E$!&8-&VF<*RK40%F&Y3(O??V!-#%=]!'Q&I_
M<][L RH&^PK:&7.D")F/Q2P+1@?+^HKROT]/Q>K<FU<XSJ[!$S>WI\04?7!H
M05%_@73=P2S6:YW2-9OT]JQ,T??*(/;J(%V4F$5(B1K6%3&O0ZYR6MS2WPUI
MH\0LR3H5<T'LQQWW]P1\5&M_$?@XIC[-_E*6*]!P DC"W78]57&W7O )0(P&
M>TCA)\UM>F7ORST08OIG+='+S;.0[=J:]>S:E!#C,^X6\=,->&;H"LBX)&Z&
M7R2';.-V!_O=^5[^XH&$J^F.H(VPYE_,S"I3VB> ^<$3P'JR_BIY5: H80G4
M(15/P<Q]L <Y6E"KF60.P'I"<9X[>L"??9_L;:\YUFQ$2N,,=/TP\+'FIWX'
M)WT=G?=P5QDRA )?7_"3H7GJ!(#/&EKM8[^C>E@E4;OKG]B9@25KJ9G')V!/
M5L!A? ':7CC%J.DO4:#\V?-9AD,.#D0Y\ =+<VKC!JY!:=#][_E*T3%]BWND
MN:@UI]2F*R$'CA&G9,4?\83/]I#Q9V74^BJ[EI[>RP*BB2\W(T';\\RG/,2Q
MOP1*#UD]=:%/#CL,YXUQGM-^2H"#G@"W\)_8@U)"<E170'D::\Z0C?A:/#_S
M*=OQM0^@^6_*1RM:UQ7 ?1;.I'E]:\ZIS5<@79$X7%D,FPWG-O=818#3]%'U
MZK_9DY(H8YYHER-&5IJ#/^'"0 5:+\2W=P:X/8WWY9L2DJVZ M3+&5F#3(I[
M8SU,<7%J9-G<K<&@3PFE)RW,#V%<M;O?1CL77+'C6(_;> %1+.4YG(0"7F)B
MH9$;;T,_;V0=W$ #.=B(.8W(Y[P3P *0^QA#4:L"1BWLD>;WK[F,;WQ>_5E,
MGCIUN^:88/8$4/.VE(C54RGDR>&NS?PG/.=R"9YSN69_ ^+#C>&PLCTDQ&&!
M$**UDGI[=D7$?7>7CKLD<4O6$.L3P/T#R/K$"8!(99-A&/NF]P0P7HNEF(]4
M/8RBK\7)G0 (>@@;XG$F%$]-X,:3J1ZD6\3V" VJJUSREX"!/WMZU4"^[ABA
M=9S'=XCCL5C2C0Q(73L>PXMQ/(97C>2>,B%/L-T%XQO@-$A=!_QW%0[>LM'A
M^8X?\.)5%);X1;UN'2=_6$<S]OHV'.'J?OC%G\'IQNN9_#"9AS/I:]L *K:C
M.P&<=3/"<-+\0[;W#]E$<D_)/V1=,)RB_Y!%_2'KP\F=^7@5'7*D<!4'-@-7
MVX>OU1_?WX'X2(#\G0L8"O;TQWD(CI_@@K8U%$Z*1@<<;V(6Q<Z1C ><BWUF
MN^EU86=Z4[>;!SCHL &9SSP]L*>[!]VY!,5B0S8*N"#5XVIRX#U/G#SIJICR
MMM>%76ZT'B5TA^A4 !>[03Q]M3IN/N%\OC(@ASR?//+B !5O@CK0C'V026M=
M2#<;Y.@05!>#I1S-./X+![,F%</^S;P1.(CVPIM]=&H6@M:+_F46?[BJ L]W
MG86;LPMX[/ZLD.=/<88A0Q\+YC!7E_!<Q=:@!0K0\3%P$HSA'%8^/(=GX0:C
MM2)5>XX3?5?1A1#+9S7Q&^ <2-W('QB!&PC.7XJ&:M+ P>\_0&CA0=C^ 0)/
M+OPGWM0C4=+AS:?'6?Y8VUK\4<%+]DCL&S7<(.S!XJ; OUK5_Y^L6IAC.^OW
M,-HU<#NCGP$;^A4P/%7P+[4"MI20E160;:/O7C[[0<U9MP(,9\7O-JO@P-C\
M!D,QJZYR&H'/V+Y&R+V)$ U<.!%_AA/TAY?*[.C_.\OP_[#\N\,K\_U!19^/
M:RB!0Z6GG=:U^:R/R13;]G%B^M@<)VR+X<SYN]]BNGY0=5B**'#C0R(V0 $)
MV !G0^J&_M%])7F_ ZWU,]#7?T+/^-,@?K;\Q^ \ ?P##^0/6P_0A>9?O6&/
M'JS.D6X4<#:2UQ1MG(I^QXN.Z[LBZ[64#&TOL_,L2;%@)3\F"??D5EN#ZN\R
M>:?*?IW>Z7@9J9Y;1)1X0&SH_E%HZTC+V$5_T[F@@"R&[\!Y'JLMM94Q/8(5
M\)&F&+X@0]2C"8Y135M2B+-988&E9+[&_Y))'+&IX5]@C=$P9NROOB9R O""
MMFV!5T> )P &2]#>/C:RSI]7W+QEMX#C\$D.G^7U&,'-X0X'CM#F_:L?0ZM*
M*?08^P-#=+D4_*T%2VXCRI)ZG>+&M/PU%A9>2BO3YV5*.]WN-50J:KF[12@:
MOV29!,Z[ \X3N%/RS'&:4Y=SV%*KQ+Z5LPK5(\<];F)_R64.:IIK*6(1.CBF
M0/K1_DAY#!2DVK*;UK*;+)?W,9%%?K'1:D8?JEY3_KI6?&:K0>\5V%[&TZ)>
M"W4^P?$$ &_;DSH!<,@=N,UESKCUA"V#^=;HFR@1;.L(511UT"R\,GI#OXV6
M][D;^Q4:1EHL>9M5ULK<-;U'F_)GSG1/H*CHBTW<>IRUF)R0GFW3.JB8SL:=
MZ:XYHP0,QAAJR,8"O]3":=C/'JMZD:]:X!E%T1);/C@/I^0@,7/$ F$["J*Q
M=E O@@N6#&PWGNEJR6L&M6UD<CE=:FL(LK$QC3(^>C.26".?$[8L \ZC[>PO
M9>-'E45J'!-_@-,$&;I;<1JI1[V(*G,Y*+$;2%>&O7"-,/A,39?OG?9H6Z_1
MFZF=IX+VS<&V_GN\3[AECES^'%DM,DJV*\U)0<&H)LNY60OE^+7NVY8Y@=.%
M$6 ]3'!:O;J\0B%K;2[<\69:X$@6?5*4\FEW!3^WTA\?E(J/CS*J"FC61@5-
MC1Z70XI9AIC&'$*482+[>GT"+.]<8I"*-X2'FD-:-+U^M+,JG]M8:7$KI^#6
MU] '9]^*7-6%;D18>8$CCK,<9J=OC [C4]$DA.CB1HRJE9GZHB2$5FU7^HCS
MN2K2^Y+H8/)E>TD$X88 \>SN6/*]Q%=V3%O&- ES.28_^@J>3Q1)7H;2.!I6
MDU=TUXAK&%2 \ U3#!D;AX(S\J1<LHW&'Y#?T[)O(P<M]75*[F6_PO=7]]S8
MBDJJ$M<2JT= 3#D,FU+(.3M2E"MU@:ZH)-8"XO)D92^&['[[W4<O9*0U6W93
M&?N#G[N/6":0OR+37+%0*+!$/MR4RQRIM"'Z$GOQ+'U*3GKJ*[H('1@J9;"\
MX<8JR$?CI]*(?!!_;DKU5%]^\JMG7SCSVC_[2:!E&%T&MK.7Y.^RO7S0P@B_
M=QI>+5;I.T-Z<="-L&70SK5RW%TW/5M_W,"PLTA_1(XC&T"R(@=P[WN!CY-%
MV;V*._P6C6,\"C,6(Z[>6N5P0>32M=:+-UCT,O=W,_.<@F2^726&KVS*D#BG
MAO*IV^,G8T87^]B4.BOL6TK>@KF^E6[B"/&YQN.&PGMCX-!0BQ?P#C7%#XW/
M/?EY(L*S7;NF=0;Q@>J=CUI_N4=^\.J51H5VM,5L66QZG$RXC+"9<;BER*-3
M,/H][.RWS'&M#0UE2[ZHN-5H$*:9)W+7(>LV>7G5E6MO'L&80?+R1_JIYS@X
MKW=MRF+4 HJR7R7QL)%LO/WB.3QZ:+U_CES%,&OKC30G^0665/)BP+/?7X&R
MFE_YE<F+D%6:7$MNQ>>4[O+7GUJ_SI6G)J;TK[L)6++$#FKFBZ'[/:E=\5AW
M?)82:MT021$V90G;@U7FXQWS[3G<WJ 7,BZ3E)Q,1\$,O8?!IU/A?[4-Z;(
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M ,M,R-,?%NP]S5O38*GAXM[#ZMCG^^\5N13_L&^/JTS!X;G^0_E.8!S+;]&
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M^EEF):]-?LW7'-5+7#8H"Q*S9["("1US#E&13[37]WP7+!6.]PU0FDZT'WM
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MK_YVQ)\(XB7D_Q?*8_&)GA\:YSQFEQ?,.2))-Y$KY$ %](6[SNI -;Q1X:J
MUL,I0#,79',H_!;/U.9O_H"[CLU.^JAQOB@5,^L(5L5;HZMWX!#KHX/#   &
MRBO\6Z+..AX>G2PN0Z0"=KHK'9[Z(^DUZL ]>,^&PD_;X*4<\ /Z*+[)[(J
M>[R4T@@#=DX,#]J-P(-V2_H4T2X,#(1U;B<>N($3N[4;;7GR\H']!YH?V 8(
MD\5+NLYN"FH /GG&\5G#=N*WC .]_DZVO\U.O/RWV5D'C86%@5_8/I[^X[;(
M5\7&?_0_":3G']Z'^APXO"B_A73G[?6R'X01 3#M <3#W, 7A3D>'*3KV6'U
MJQZ$Q,KMKVTM7"VWD4JO4<^?78].O?D1Z8X;]SV09 ,H[P@SR =&?TW8<F_"
MPDWD^CPI=H]R>A^4;0>9_K77-H!+U@!.IR^97!('Y\LW[-67"]@  9@OO:F>
M.#%P!ZB&DPT17_IA+1F0[05E7/DC@)IW6=J-!HKSR"Z)X1D_#J1>3Z\E9+H;
MO+?%MG<A!;-;O0_RJ 7/=Y'NK.$V>#?Y*S%8J*V(7M/<4:C_*SUXSABVLULQ
M]>)H, !"HM?2FPF9[C^@ITS![$G_DU[OD'[@.%W^;^1[O\GK_R+/_N_D@&NS
MQA?4*]<7 5]2N,-[<.Z?]D&5AHC-.5_,#LSE\F[4H7.DIC8%\<DX7_073\,"
MP(.F^'!@78!F4M!A+ZQ"]CX(HC'8S(S/C8-!:A%7:P&<; 4F]!RYWDS8H6K[
M(/W/L):H[8_[()5Y8/[KVA9XB]?^((W*K'.T@=_R\7':XH3N;/GBL'!(3QIX
M?1([ ^DLW0>M;[HWCKW$IS<^*1<K_D4$.RQ;#9\8K3#\H_?3<WOO:PY2,Q)(
M)8>1/[HO.!R8O_)O*L'QG88.;W?!'L.AW6Y$4O7'PDX>^XETD^,P*3*00%]9
M GI/5L=OOG]:_C$A[<B$7"55&8=*HR-E/.5Z%P^4'_V=GG< 9=*/E(DO@^;T
M'_KEV[^K?4R9]'\4/_/_1K<,T+%[U%L"YJ_\;?[EW;##--&C['</&L"YHX!J
MYC38J! PP0EOUNZF-,ZMLISP-QVWM<47:<J,9R(A)+BTCPX9M+LQZ7Q!1CZ:
M;^L:1I2DIVP?5&AY7$%-<A98NM^!LV7?77_]^WY\[O\&27>\(??J8 \O__"V
M+8#4\!_0&Y?JVV0H.UT] 1:$']VNY1=^7;W0KSM0RT]L>.>'YRMQWTQ[^3'8
M!5VG-"62%M0/ O>/ WYW[]UF&A>IL]$=^1M/HRR6A/3<B%.>:F1=/6UM8J.Q
ML]^D'U/NZWMUKJ/VV:0T;&D=+Q_V<9<R-E,*RQ)Q<^MCE;C1_A^UT:ZUUXFO
M]5E+<(K5QRPT,"&2-38S(1<1"PCO:)+H%#+]'U9)C FA OL@=]Y)S0JNLLZ"
M9=H&ALW*$/NIS-Q;)*->(B!&K"W2I0N=^M*KABKZJ=RV Y4?(Z&A,T['(I=#
MJ>^.XK+C&G1%45XDVT)DIA *01L5Z@0R5X^0V&5J3\L6EAI9$WU9ZQ2@4FY@
M>:QJC&IA1$OMXGXI*-"EO_BN]8A=X_&%SA>WS^1?_R#KA;(*WMW\6D0%,7E%
MX2\ZE&_T"=R<CBZ=@Y"X22FCTMG"E$KI])^R3FB 70?CWK,&<39Y6>DO[L04
M5?A^8@EWGW_Y>=%2Z6*V"MHR>7;+@[83<SMMH)9+I\;TVJU>XH 0I$HOAO.7
MQ3#/5]'+&,YTAI.6B@Q\L9<2G6W6Z9<,7LNY;*P3^=VY8378LC+GC*869A7,
M-D;'L-9:TG(+U]S0TZX*T1FZ<U:SDV-)GY1@@'( S2O=(03Q+<P9U!K(#ZN]
M2G/>HBRT6G0^Y!%&NCU,!0T[W2A\:>A7RJ*1H.:5;W303R*;&(X+K"J6="C]
ML%1>3)DN\XV6Q_P1!CODNF2I'.\T97G5%G%RSPUHG?P:,FE+ZIS(JRT=Q\,L
MG:EOS-9.%&O0,Z28$DI->#S.7O5H;F^?O[=W+?]&>CV[E,KIH9_C2?:[& =]
MAKRNS7>ZY^PC?=B^+=W[CN7O^H4QI2YM>[5(4=EDH?UX4H?RW$8>U*?27R!5
M5O#+NB\4+4;F=O]+7L&*E3]W><:E>PL?HD6JPO8J)C3">[+=E)F<F.\T$$PI
M82_K2P>[7-)[[VH55-[7$*2>GO+4 JU=-:*ZJOC!V,[F5,>K<9$?\XAZ:HS%
M("V=0J"2<IM5/J>3G8*%L74!)5'2VU.>]4^4F),YFZ0N.UGU:'=?__IUL*UW
MP5Y&Y%?H"T71<<HAJ/X 1FX%.X5,&FDP=CX56$HHL@YBN= [;38^X]+#**;;
ME=EFM0=-[7F-X.;<=.79FG'2]:32N)3S]+Q#6&=05P*J1MY-/CD1GA%H2\U1
MS118559),]MO[2U!:I#P04>C*PO$KWM6K1@T^:6W1??$HJZP#VS"M'T?-#\'
MP9[5^$0TW!V>6-@S/?7B9U1N.G7YACC8/_*B]KS8R[Y^.;(/#EQ7 ]A8'=W4
MFX(^F.R#B!05HO*\%J_VJTZ]\\'L!([09"(8G*:@1.94D:NSK4/GXOFI0GZ&
M-/.U=BQO^O147!HVMSYYJV/@W@/3EY=)-+)1^O=3'[<E1K?/ZRR7S.Z)F6?*
MQA6Z:-:B;:Q34CQY"XC+SO)H#TV&30?*7U&C?PHO0BTJ50V+6P1*8B0IRQ)=
MUW/D:.K/%S.M/T";=\^NS"M;Y)L47N"+T$B__CT8<KX[TJ?_6M0;:Z%*PEGS
M]O#G]<P7)[(?LX0ZT8]74@J-+'-8N_:)S_C*N ;W=W?9F_C-B\&VU(O<4Y8&
MN:>=JEU>.67KHO629WL\SIOQ+"PF&=G-5MSKC(.#&A@WQS4T^(?UFFP%K")-
MS.AW0U]:=+O1< Y@KG0N,8N$GKOVGC2!31W\.5N:,6GA:G9F6_5KFZVF 04!
M1/Y*WCZHZI?>N?'K@J5<M^FI?9N0GW0][/LP6AT+W%^%3;ACD_)ELKYHLU6%
MWBRBH6P=:C*P-($$A5F_VWVB1KVD*#<>>MH6?.D$U&<8_(O*>HBL/O4Z<YAN
M2+9806I1AQ)2-4W-Z'[@W=+YM1F+:W4(U+*O]K-,VX2!(?+S'-4_]6J^S(=R
MQ-9YH4; 3H:6TM)Y.@KH7-#CLXZ>L0&$IQA%@4SHU&??!X5R)^^#2JS5I<C[
M?R6A31YU6DM+6W+NP*&>.6J3%4B4<@;[_7R=*94]C#\ZC4-%?][/=R6ANI#6
M?\1<HY6[NC\W45GDQZF ,(1^]6JZ"Z+F JVRHT&&DUI6:Y6@,6BZT.FT1WSQ
M\@5TF$9K 7&3] //I"*(4(TQ,9.*$Y><8KE%IUV@SFWT^Y062^?DA1+O$^[?
MR-[/*-=#?A;5?*]*3U<69KCI2FTPD?10-7F1VU$GCJ*&BN7\21<7E<=#VC5F
MI;6+\!+[HMBQ\ZZO[C6I9NL)=K5-R@LN5 %S$LL#8$5^]$Q24B+3/S D0SZ;
M&Q^!H,S+!UX"YK>:@YN(%8D>@E1KF2[*Q6V@2%R[@T(2ABTT^&\;TX3>&S/3
M))4!=XYZ"#U06^?LS=*P"-D!+WJ$QX]@L]N3*%9E>K4N^D.W*N\KF^%&9E7A
M3DF-]3_A^R##?9#U1A(59*-C(_U.#(?SNQUEC04"G(M'>()B"R8?RS&:0J3;
M**K\P"P!_V-E'W*C9Q_$D%X5PV[[PRV$#69,L _BAJWV.V[=VP?%C: 7H12K
M"G'2$WXQ@I[[(,G*U7[E!#P)\*6# J70KU",C7&E0?8FX%QAX_D)=PEQ.ON@
M\4JL2Q<%2G7QVJ!'LV1 ]L(5H.D^:'4$5\[6*H?!P/ $/10HN0*DS1Z; ]\^
MZ OAT:^18-)7TUAFM-***]BEFY(+ZHI_Z;U"NM0DQZ,% UB5&&1Z BA>P%@7
M*%H.:(3$8TAFZ[R.87<UVR8U(JFC7@%J.V084 G!-F?E?.0P6/ A27P<G@2<
MXVMTRND)>,<%LET/%%_A3KJPEC:@X('L;E:P5T45I0YZ5"&-D/N@-VJPEKZ#
M$QN5*W#2G;W#!J57%"G*RQ7'MRCVZ&=6@@%9>8>R8"@R\#H:MCR")[JM2"DU
MG&*#U4<:?6"\2(B# A4ZT G:$82('0QD>QE02.]&"A%4,W40II'2.P5!D8#7
M=P\;ASL)@G?<CXANI1!)Y:@6XS(5<GX!79P*,KT!F%\).'+E$60-<R3NDR(E
M1"M]$*:>U#M)^)H0LP\"[VWO@WI28%47*]>/J;XK4E3D:12[JT<9A0+V4<-:
M5H'E A3KHCR*AY=<!Y8%E;N;/40ODC:CR^LWM26#Y' 7;P,K@FD<]L!  O Z
M#K8,)(Q^V0F 5X%&"50MH7>\$G4"NGL6O+>)ET@*XL6>(L7N M;V&+*/176G
M;8.[@#*7O8[4%ZC+;Q,<2-E(0,WM@UKO K9DX\H=@/"Y6Q798!41:S&/T"Z5
M&Y<@VP!QMHK,RN;C/&R\RR5<^L"\WKM4\FR4RJI]6>"3&1COU(MQ5/L?)KP8
MSHA]T,<0P"0(UF7IM(3R9NE((R3U$0[:B)*KMO]S[@7Z>>4&&60;O_K4:TTA
MB@K(Q%3O!I).8IK)<91 U=SZ &")!'R,-JW<(#\B'$V!0W6S,2/!N 1?@.6H
M;[40P/+](4LH6ET!, Z_LH+M;H[@70C4^DT[I'/4,( MR.T&=)<(O >XN ?_
M1BS]R@V*0[;ZKX"DZP&6),(3&ITW]D&_=N+<@2FP!#;# 5MNV0<9*X*)-7"O
M4W! 3+<>SUR-8W<'2GD/:5Q+-> !YVD,1RV@1>J!%A&\& Z ^\<<X B,C7!A
M2B')KRB'[E0"W<\$51FU:A)+ZLT)J&D$J G9XWB!?E2Y0079!KI';K8LT)OG
M>Q%3&%]LK \.6AMG Z@1"YOA@2T#:6\,6$?T'C;#=7BD'P1$MF<5#!BX)WP!
M4^DOT>MV#;I+C-P#,JH/_[JFQ-]'&DE$+V85YM$'K#]XXUF; <P"?[.6PW
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MVGF-5R(QZ*>(,EHCY-VJX(IU**9],67\TX WJI\2NZ3#B]P)IT,-QZ28K5(
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M8I)%8HN$/E#V_]8>8+ P$57B.I]5SMOS@\WP^F!)&#ISYFG7(N1^<6>DZHD
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M!CVLR3G9=E4B:Q22F<A-%AI": 7X.-/D_\M#_LFS*<JISD*U.Z+R P(%G5C
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M6L,MWCVOT_PH-#6:@@J0]GG4'=1+J0_FN= \)7S;?TRVB6Q"(&C1D"#_>6<
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MUJ7'I.LJ31*UTD<YI[5BJN>DV;2EG1=.("8_L2[A(/H0<O2C( ETVBU5J9T
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M9,V_T,59F^8%?^B[<H9Y833=9,\H37?)E2-0ZE8 $R7M@R<4AME%I/A1.)^
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MA^%SJ.?+=76VT53;\(B"D9_:&S.AT;;"5?PJY=+04*A=W]M=]1U<&)&2QQZ
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M;"EF/AC.+2P]I89X6E'FWMYH:_/CPE?7L^EBQ//)(9]$7!1M'5V]B/*5+L&
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MK/*  VLP.+"7$?928Y8SU\EBH,O!6,%(_*=I.&*N7OWORG!N0!,/;,!J.52
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M )@Q?M?XS_<&%L$7I724D=_![%H]+X?>*_Q'II(_'2>#^02X1?YV0_M>MX/
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MX^4\,:QL\"!%MF)?'@:*909]!48&-U9(2P@4#K?;YF>/I16P?=ZT]D8Q$/\
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M6 9Y2$T,#PC%KGD\-U,"BA0XW2?!\?2;-?[))#<7RR<$V$L;>QX=ES*CV6W
MKU,VEH\K\&ZOB61KG47:QM"'WD)KH8%H+J509PP$M*M/HA[A>"FT'!CG/?%Y
M-<*YKZN-O9Z3Z?$)/7U35MIG7CD!K@P]O_Z2S?5"-\MA[B.3@0\YHDX!LT%%
MH\S(P($O;I9%*U&S3WR, SY@IY#UD?:<QAYS\/LY)#6O!J7HRA-J/'LCK?I8
M"7X%Z=6YN']7"7P,+QEV?@X.WM*?PA(>6EC"8\YP68*XS^AO525Q=C%8VA,C
MP\N7S %NX)$VF6$6GE%YU^<TYGG++F&HYC4IXWQZ>:[VIDW 5'FAO\) RCT=
MB1O).:X?G%M7+5HZTF6<8]W))M3>!;#*:^FLIR??(;B!1K'[,'-RV3G:DD8V
M(_P6K\ZVU^LJXQAGR:J?(95L+\SX<V+ND#=1?9[]C@Q]6':8J0M4#]6HY<@;
M)0K,3_M\!B#R8]@#J3@N)1\(F@^JR03)&J["LIP46(J3^N25/4,EGK)?3I/.
M-O]G';\R.7<._')GXL,$VZ-[T>LSV2)X(!M.64_T=;;  J1A&R.=O7N#R,&)
M?HSW%1/]HON&+$:32U_)2BT@CTZ\Y)?C@K9."6G-05<D:40V8L'\6[' ]!>B
M@W_U.3+:8(X\8N?%Y",-<^@N%X3BS>/M\IGPH,LK9.P0-IGPMS%^AO5\=\D0
MC?XSP$]*&^AA3EO9F@A4#/\,L.&W:E'?6?N>_,GBML*T[/ NO))!Z,C5L@V$
M^8&4I^%F(WE[X*V%%V;((R\YGN<D'SK(5_M,@8 %LH(D[&53"=:H:5J0Y$,O
MS"<R$=L>:6_:/OC\$@4 ;D--/Y&<L@R-5H)&5X(8$ZM[+!,DK"1E*T*,@S=\
M2>V&\YHL8X0>N<H96 QIB]55K54M"'_:^XPE-BI=59D?O4W0\ 3?A63G:VN3
M<DZD?![(D5E"@W5!RL@,Z0&Q,0!+82@*-+TB[2A5S.C?\IZ/';-\"H?WX#.6
M<^R[/JGT-TR- "'IG-2%!BT=]2U]\'.I"";V)A^-A51>:+B*1D]B?VI^R) ;
M$88/@(V2P;6.W!M@LDRD.Q'YD'K 0#8@ Y5BD'_):5R(8G!UIF; +(3^[GJ$
M:,A+=\-4,N*^!/F0(R$)TU=( FW/2#S% ?9AZEUQ9HFMST,F)]M"RBG;8"G-
M*:9"QG/\$:^TY\'V]5VS(E64U."68HI'Z 6S]A_CHPBR(HGDYB!O@07-*.RS
MH&[!W4XG89;2_.>&;CE/'5KNHQEA-.SN9U?+U!MOC@?,;[NIM7E[OQLI1TUY
MQ#?"F'$&>.L@5R#KNB>PA#/OA:=HB_W3/&.SU[^1#=0O,Z&:V1&2_O/E[9/#
MSW?0&2&^#?SZH\EY(5#URCH350(D#[.@:L:HJA(+@1^0V)^-<PXK0;LO7_LM
M0C@Q>!W+-O8LTKRIFQM%NX4$R"%/LA:1%3Q SSZU@VR_,AX0G@%6%&^1X@W)
M3<>QM&W3Y6S,W;#'IU;[]?Y@]E5?>N=T0?Q?<MQ\"A$K57PDWAN'_<BW_%9F
M-H>"'3@W13WMYD?/ )!OY&EX":F+^ <%NET'XHZ'!*]8^&P%CNT>$^"E"45D
MW/*_4Q")SS0:[K)Y>U$J:W@$,PE^I:(+NQRZYY[=MQ:]^DC%_ @1="U=KM5M
M2KQ&)HG!+G=%5 %Q)R 94;\E"H>>.0X5.P" L8,O(MJ7:>Y%S%W1!(FK\@Y9
M6"_<TW'JGNZD>$274R?(EBSMNH_A*3(RJ]CUB"VX?<PEQTCQ-8;%DD%)6#L.
M":K!:P7PT$O&JRUGN !5'OVM)9YCWU^J@WC#\*(BTU U1RC7LAGPT'[7C%Y6
M'&^O96%:_.HTKQ2\ NKCF\+D>UMG@"J1./:$RZ3!-X^YN732!D+-Z+E_U*=(
M<WT3V;]VQ%VL8E[/12YJ_B//D]?"3S2G7:QFAGRWL87-W^_^0U'$\[/02)?K
MG__S?CC$Y='_]7ZXLHN\Y>)*:OK+-5>VQS=9+@\V7^V70^S(LT/(4OF=C_!&
MTR568G^&Y17)-X!Y)S)G@!#/%/"P!GA7&Q@\G.0ZW!0M7#Q-C"G<//VSW$?J
MQT!C&P!-]&> $U?+^[<IZC&RILX&:01]Z3'C>#4XX&_#K*<>/#M:=5NY)T$5
MM:<OR'\R'#2LV3<\'OY9.6#R?/H1^XUT[1!)@]WLX/OZHAFN,4K5Q8:;<FR.
MALG&=M]["617[,.+\N3MCI*-/*W=R>MJ#_>&P)/^O[CD$A>%R3<C\EE*W69D
M-<=Y5@/1 U/*!&]1Q>(P(D_7^G$F8-5ET*0(-)H];[,*C.'%C'\S!L2P7Z$>
MZ$IPBGO'NRKW;',G0R\5(CZ:>D1\:HJ[J-++QWA2+,13S]]F<0; LW%"Z\E6
MUN9OQM;]_)GP8);K20L9VP#EP![IK5[#TCQ"[T&5><OM%N&?T4V'8(C&HC 5
M3_1;" FYF>,8S"(@"?:7[ U<?>UE+YK:ZF+[33F6GS"3C'H&6[!J"K,]!\+?
M15"?:DM[=%;&)\Q8_'AQ;TJ.'Y. B5UJV4?W<VPX4V>WLE0Z5RIL5$F8YE^.
M;//91MG!?RS@,^(5A9=@-M.-?1A3W_M\@B9:5OH+1HFCL@O>U"->7MYEM$P]
MIBWG$$$^<I\JH>HU7(96CAOL2%VWW/@$0_U^IDF\Z UFG%>N]-)+4UUY$J$\
MKY/#+=O=LVSH^?<)3[_(-/:]J)>B-..5OKJGKEWKY0>9DSA<_I6LZ!H_VCE!
M;JY?6 P5L20F8\@2N!DL3/NS7Z FB6;IZSR7;[ G!CWJLFOE14WGF\\KGKP%
M&O'US7GQ)&4E$CB/:V9:_FST]1[A5XH!9<7]C&YK,TCIKU5=H(CQ ,^<EKY-
MQ,+?3BI?3ICZG7BG@K0_402(Z=@&3+* 'UKX]!1WXUI,L,A6WL<MG4$FQM>1
MH-RS:0QNP?-0WU+_Z+39-2SN,]VY"[IKS/:(4/GV D'VAJ\752$L0>*KI69>
M-T(S <2])0EX-9J[I,NY6-:7P2+;MN'5PB73I@9JB.\M&"U?CB?S5_7SR/(T
MTRZJ_91.,T(%:!0ZGCKVFX62:*>D!9Z(6K]$\7>G(WT9>@,"FJ#=!/KN9;6N
M6:^;A>Q&49?1=61TB6%QC,6? ;3J-Q/\'.,8FXGFO[@(I!2/\GF_M90U?1H$
M^#93/BN31BTKOAPIZX7Z=V;_0IH;,_$*N'&9$_N^_N2+OP<<(^DB[M[&YPT'
MH*N][/)4X(RHH:X5P=464V!@YG_4/O<0*;30:_5HOIP5^S!2MA]*L<Q?W+A:
MXA#UU)K24'X>Q?86J&2"JF_F,(6EK#\OS]20:GM4L*4TE6.HR%7?76_AQ]KP
M2<<0XWAP[?[Q[AG@84+C.V5R8CU+@(VJPZNQ]$Y[I][#6?7"H1,%KK4 'RG"
MN[<8@!_XIH;Y].))N63H-XS=-"+B0+QKSK QR=(0%U'L[/SGEHMJTLSG0Q;-
M]>M)$&/6GQ4>]T(1%1X?,IR/I45(5.R_S% _:BE*Y1YH$+4F?7"=254J5XH+
M*AF";J/\P!S;2CM0ED#>OI4&="-_$=35DL76RM5R.X64RNX,<(-SVHYWB3/A
MH#=;%ZMYY;X5X;@X\&$N_P,@,E2[_0S@&>TRRN(K&U6[4:A9Q>@IA\_,XILN
M#C3,I7QP\ :J!^M=M3YAY@]J=PY$3D^X8NIX!GZ8WM,WWG?-7%6;KAT!SD+U
MK44V5L"!=(-.2'U'"U!HZ>&0 FOHL80_I]\Q;4W32(X$$@$EQ3[73MG@WE]G
M #:,W..3R5EYHJYT?G,>\,&OVN9"-YV$$6[-Q@<_3A2,!ZM(0LMC%)S>!]/0
M'->^6M/ <34#!N;OBTTL?PU>T',Z+<X\ _3(;$#/ *7PB[ZLS!-V<2IA,#NA
M7.0_V*&&M273)\$;0C3DZ,MW>,8^00Q)"MMF7RGJNY9*;#9E1QS1:Z^)^@R5
M06^>>)RB+NA9":T-#I^\T.ED/76TG^SZ#$F?L_6O&N]R_]4Q#Y'3[HA>7O88
MS;"V-@&9AI<*Y+?2?$E)K%9+?;<58S4./S:'[W@&^(6F?0:H8<S/$5 X WSP
MKCV>J23:++29D>PY$@P]5-X[A<4_EVK_LEK5C0H1-+TZ*T_.^[P*0H_5:9$I
M2U=TYG"1QI:TW#:G:ZIKHMD(I[GC-8P3ND=B/O]5O5E]9*T*2OEPHP6 <]..
M:?7K+5/>I=#H'_G#E$4]UH[SK^)2F7V[D2FPEYYB1KYS!=>'CHQ+^<Q,Y:FJ
MQ%>!&60%G >K")B9->]\.\DB,<),F--QX&!K9Z,=F_=V?KIF6+[+^QFK03*@
M;MI*BQ -*_CAQ_AI<;;OX/I:T8]Q#<&'I/9"[KV/24US1#?EX]DYPF:%F[,M
M&DD%GOP$9P?7'C\LJZ!#+MZBCMQ/>,=Y_&SY2Y)A9_Q+DNC"G"6@2T3>#XU6
M%/6/=&V1=52.:SJ8,"M!^$V"0C;"$1&3YN"]@O96??WVOL];;S,-^F/YOR'1
MVL=CRUL$WZF3\:$@^TQ6%(8TXIK:)B<S-*E4[#J!EFAJ2%R*^C!I8.Z>JX*,
MW6NE64M/I!Q)#^\1PI(C,S\K@ M_:O2+)T*!>V&]112 7X*Y?">G&3OF=W4/
MN]KHXC2?22,_$C3.F-W-P=,-NYO]E:R,-[4'U<RR 8J/6?>MN:$+_$-KP0GJ
MM#(&[GZB.:",7!B!?2AUP@,BC7V_,/J!C)MWD>T,,)R^]V.Z*+^?T_NC<31M
M< =E"6^.N.:'.8V,?=YD6EK:T*=8_8W)Y'>7-"@WL,X :WX1OX)/:(8$3&Y_
MVE30V9O=RB$J<I03YX1(6QO[=RBF2)%*>/@!5JW7]M Z?_3OCKK.)?R5NE.@
MX3Y+0M3>8\<2"DZ4JB<NT$9?()PE[U Q&G:49?2M+'Z]M6 YK0M52F@NC\F*
MK*R*F#MT(\EO,0>LR(#KA:9E_2W2%(K&\$=>+J0CGP%RE<R3P?6W#=DYMNT.
MB7Y&105I^I,K.T@_)@T.("#6Y4 A4P";9)$]!!_&+C91WXM;6%@)$K<=M)&M
MUA51]EE*PF$RHP;?443U<,'\Z5(XIK%4,C\]_+S,S8WR= RL-[A0:JM@Y40%
M9%!_YO7,4X$+]N9F_1SD;C/KLSMVO]+ DF7V<%@@0U\X)5W6<1FW?%KR&2\N
MDO+O8PRP/\2"5NTZ^9R*&J;ZE+BY(GF\/&!_0ZOG39Q4D\NC)M5 ?O:P2I)3
M7"5]]1=WE63%'R%R,,/+F@TJTV< ??+CAE_]#%+@X1;H)M11Z)4U5\TQ8I6K
M="CDI0$B'XRX2@'O7FQY.4\!_UV/\KP$Y6/LF-,7"1M$)L(V%Q4MOQZ@:]&E
M4OPO;QN +T31I9RO\OVQ?>#WF=]_E<"4.)=Y]Z(^#^"RRN7C"]:GB-/$EW4Y
M9YZG)%9TPU+5)CK"*46*)MRU0'A%]_S:"C #"[[1\S1+&WC!=,0_;0N)Q07:
MP?!B]$9@1ZBJ#A>,-D+46$=PO=*P8F9IABZ=I'^?'!<)9_2.&A?=PL$(I"'&
M=! M'8BX>X//,^U5P#86=E^&A9=@@G*?_,>TI4U0A=MTXKN?>2L!4]A]Y4)7
M^A<TM.C'65?ZC5)FLGBW2T_=U[G]G*_D.Y(T@$"CQ/!Z]N<@;GX:H1\EOZ+1
M&R[@7\!E:NZ5_WX&@%?AAW_K,U-S7W\)#[SZ.T(HG@_LX\G+3Q.G36':6GYK
MHR@DEKWV<2H^L:R?[C5?,;+1I2 ^1G@@ X'E'!OX')K6->X;'3+7/T7OL/J'
MW\U-S@#!FB*3^BM/$4(%K>\66(JPH6YW'\*7C0SC$(S<</!/8]CH_A4EA%C$
M/_V]8:JO>8TB[Q_ PI17KWST#R0W_I,'?_O@L[H1".1\Y< RS??7-;_\AZ;W
MV7%&U=YCTVIU5/LY"<?*[5 OG')FN+)S!&5;O+R&5"FT%J3?GWH^Y=0Q#"T?
M H-^@+OKE0-E.H-NUA/]1$1+X7';CQ$%%,?]')O53/V.,P!R[K%YZ79NXS*X
M:+5V89H.VE]P!DAXFZ-RA248SMET6JS]"SCC!!YQUM_9##N7#:2_<J7DOAKK
M//@EV$H=JG88I[\?%WER0DV.X YON^;BTW#97Y^NN!+.N<!PKM7_S 7\G[B&
MSKG"S[G4X5SM_]186[("9CB13SN6Z8:Y+GB-4>37H<S<M18,;4LYZ1#Y-]?Z
MA:SS*()-E*&FY*-.M>%>M"JG*69G *&^/]C@*F6/&2)W'D%'(2=96_P)B$]A
M#M,\ W0[YF@CQ%3"0YMV 7\8#E\2#O] 1J0H^PRP4 %DO7+LI;1<N+3@/Z7I
M_RM*I?KP*)&/<"?LC--!>XO. /%+.C6(;N7\.TP&YVRPW K!1R_QQ;SEAA-7
M.\*UL:\^%A;%HRVM7;"6P^/N6/NGQ.9SB:57$LL1$B?_9.L:^MUWR'\XUD;Y
M[L^!Y_3?]X.?CX"[G9*.)?JA'A ' ;@W4O[%!4L_K[&E.&A?]0>P21\\#.%G
M %@<9$^30.=Q(%: Q:'S>@.)A(>^E/$,P' "[E@"%S&++%3TGGZ!\P^50ZXZ
MJTC!$I@#>ZWM#-!6>S\%V@.'OR)]R5A]U=&"5ROT.QJ.[6NW<UM..EOW7.\I
MA$<1EQIH%'93-Z9*8TF?TE?^QJDV^ 1#QB=_;*K)*&O&,7[\P[6!S")YIA#G
M^I",9' Q"%X,L(V)UP:JQ]G-?7U7ABGBX_Q>-8I!<-G?DL8KB4<3HF>#G*\A
M\6;AR/>W[L)Q].-=CJ#G-KS2#+PN6[P>-J)>#449_\.P=C[\IE[@,%221?Q;
M]YP\G_2B+S#_,>4@F5+C5EY%^@$&6UG*;X-3PR] R,&)5^;4UU4:F/)?9 :_
MD 4#ZA1H.<=A'THCCUTA>5Q\/G#WPK[P'.-\4+] H1F8\B^_5F,2:Q^GPH9W
MA*5P1KD;L&C C9"%?8ADRAT1:>%.Q%UZ( ?#B8@+)URBJ %<\A.)YEU.=#C>
MTB]P__; O  ?VCFM8"S(2G0I(Q,^<%#B3><FIT8BF! #_I<DF%PXS_<)7X0G
M.'74C>QD98MAN!$4T[GITC!#0+!(J)3PG.N SY$409_]9)Y=53:Y*G/PX6*-
M,.GW[W<WKC80(GXP5)Y!;#9,13I?/]2Z*/%]G@61R#'C C4WO(4)4TK#37PD
M@\3Y@!)UY&+T88JW?/?W\\\ HMH;)VC@K:1C#XTSP&?( 11%Y'#($T_PPRJP
M*-+AR?5_P_JMC07Y+E[-&>"K[QF J#LQLO"\C@'XC_^+E#H%'Z%/@J>>G $"
M%9MP[27SJI./H\E'*UI.;]K4;OY5VQR\-FX$?5TZ>7CW##"KN0LOEK!&.]8#
M'1\2663T/ .\PH9R@JU7+H3Z()0%2>UC@X3G???7K\-VN<(WB$YW45?AZJO_
MPF/6*TGE@3&B4/[EM#(;W*-^#'O9)S]Y?J49$\J5($[R<96LS[,3^S?,R5G9
MZ_P6PGY\E-^%SJVJ/;?J#/ /LPY3DD*$WL!4@8]=@+]1]IY69L%>Q2\$F7OC
MVC_)\Y ^8(7E_<MG@"O4^FOC^C!9M7#=FKO*/X,-8%R<,%O 1^@39X"I)^#
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MM4Q9-T7LFU&(B'6NA5.^B'HD,[PRI4-^6]^P-JVO58Z@@1EF 5[?>J]UV(*
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MX6(Q:\=9VDK)]IF,YC@W,0$:&^Q;*[X$Q0&%=,\2'<<D./KY,BN\?.W</%U
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MXC4A)&QM1:W%C?^++H,K[5OZ5!I]F?AXKM[P6EK';%/V?&].H]DWX+W(58*
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MI]I_R#^S5HQ,ED0V/S&$EI57^OG%9BU$M6#0\9=C)80&RO>E. 1<I-UZ=\+
MT@@%AQUM)H\N954-XLSSSJ5"=GUL8I#+@NUS0R(HWD([.]4M+5RL*#C@SIU8
M /U11+65VTR,D!)EV!/ &_L\XJ .,Y+98H>!(@8V_> 9VG<Q)R*80<'R6S<A
M:8$+L$D@L"I4CD(<V8N<=R,(6NPBB6^U>:RL/1SU%\_6R1:=89H-*FIZCG V
M]5Z?AK1AX:/BCXV!Y 1,_$11/0K3VR?H:>_-3T8V#@H-CX'Y;R1+^ASKF'JH
MS@"@>,T!UNC#KP#CZ<>0]R^D$UMGWCD=A"J&93$RIS;=8+ICZ_!:")#ST(^,
M#'OK1-0P-4$^@='2\9Y%2>_2T6EYD.Z(/_V[*0/;XQIK3R$.19K<&X?"<N3&
M\1ZZ[QNFK$8>$*S$#G$QA&03.*$^S/HAN54[)EF:,#4\X>P<'1N1@&T<HFI2
M-K'O'$)V.W"S.S@5[<0B4"SK8:3N-S1JAX#@IX.0)VJU@RF:K#G)<1\,7,AP
M/9"^9CHJI[4Z'QAHY0I(6X8'I1AONI4'_9)/LU9[$\.I9O#!X>7/W:,=+7?N
M%+)\AYEJL34RWK3BL79\'H:?2 %[O#?*9/*MP$YF>(WJ.YP@VWB=ST;S^C)=
MKAX0LAJO4DX?AKY!1C>70HF.Z*#(M.= =Z]/P_>[W=L7%)@,;B3&>B/3UJHH
MZRR[2Y3;&!_%1JH/._=D8QD$\$8]^$(20-Y7GJE5:UA:4]T!S6?.AHQ^&1*=
M^8X:8.5D5O*1"6)TMPG]6<%G9525@!W-:)K<6S%NZ7+L4NT.%DQT=^^\'K^]
MD&*D))GW6GV[= S[OE+1I#-TQT;6DPRWM"SD#*!85!58,$_0<(MP%H1RKP6B
M']HXY%(1G\>R-B<GHC(B%7QSUN0X-^CMT3"C.%: \3HL-TX,>J@DPZ:_Z9C?
MTYGY7>,Y#Y%>1+_\L#5$<+OY_IR>6'KKQMB@G+ZJKV)!G\%[*O7"XKOESQ[)
M2W_;S\ZD;PY3J562J4J&]-L,+%D7"S%JEQ:%*D8O]^U/4'N/T#7Z,^0^&7@V
M0"0!,3)P2!]YRD+5SYJT'94G. B8TR9E%V*\%1&9'UCNCKV",Z]<4IN0T2>9
ML43D[)L)&@IVL:->IL"I,O?C+K$+"%WI7M(9QU430^?9X<A0ZAI>A,T=FI\N
M9K#S&A6[-C[NJO>J1IH&/F80^MTT!9P!BB;[=W+Y4K(M^IR>3<7E.!ID,7"I
M2>0:+9X!2K3. -T=^@??<[D.HU)$*1NRM=J)[[]+4WNF<,Q\*L*P4Q7-&.*#
MU!L='3GE GLA>I>\U$8>?(+$^+G?R4I8E_B87"/(YB\J]CH[P,T9HX%G>[?R
MZ'*6ZN0TXW7Y@V(J^!DA0-F\7FO.3@(=J>&_/1.7G= U)?]2Q7J=:5Z1S3,B
M\1%$))5KAB'YU[-'TI9;G<9*RAGB GN3NRP:[UNY^H9^Z9T!HKXO'N2;>S'V
MK5-Z!SBK2U%C\9%ID12\BHV?B4[$QI7:?Y]M7B#U;OMS9>!3H^?=5&PMPW@=
MFGIC2P?23B .<7;/(:V>BBUNB(L-%;9M!DGM"@I;M@<TY7&G$0/.?)7(="UR
M(L$G7JTTCUJAJF$;]O9E(CU(VO>F#%D[&P<S\A J/S:*D$>NLY0H7FJ\6T*U
M)U0C)HNO_\[K[Q''?7)S_Z6;X"Q5]#Q=D\4JY7#WUJ.C@<'H286X$AXFKBP/
M;4][GB Q)[3]II?"^I_BW0[6U"![!(F;:^NQ2AVE]YL>YC7W/.#K7M L4O/@
MA>J_(IMP=Z.I.3T#<%0,%J-Q[A7VF]8,K,8+2/5)60X^=:/D(Z0(<>BN_C_L
MO6=44^W6-1P%1:4)TKL441!0I/=>17IO*B ETD&Z 5'I(" @77I-(B7THO2.
MM-!;Z)W0A0!OP,9]SGG.^XSOWS?&^V/_8.QUS3777'/MO2]-=M24\9;VM \3
M8=M*]U6'?R -.%KG"#DQPM2_-KZ01E0_O_L\V)#53;&$-X+17'RUX47A0E5Y
M>81V'$*7XL7X[1?,;JO*8,>ZX%[8VK$[M>9#KO0-X.&A=27J0XDZ&VRW:OVZ
MSJPVG?-7?HCO":&B\H$\S%"Y+;ZU\HU<CQWOY39 M\A AVK@A-,,K\NB@SI4
MP*IGP]%88>!902\W4)Y0QJ,EZF8V&2:/VSS40H2AM'>GE:[LO3QSH"1W//N#
M4)6<+@\'_&FTBS-D.)5$,B1OJ>%R]RGW#_7 ]#UTH"^A<.WB:A5&BY-#SH0\
MG-WYSU5*[ _)8!6598);1S/7+A\YN!VS"D3G#4-L3)5A-C?8C)I537(M#A]4
M1+?-'YK%D03K*9%A1Y/]\.?CVR-68ST66:E7L2R-Z,0L*1(*+Y2MXGOV?>N!
MHXZ&A@?9AI?B80<8R/IJ]Q3PGI>ITO!YNWBO=:J)/0:7K-LEG<K@IPL9ME8N
M)171I3PQQUEY4H5*L_Z$W _O+7GS8I1N0LAUP^O3B,WX,:EN JVK],$/F->>
MRFE;?I1Z(R$ZT03D[W$QJ $%U;X *MZB%+6$3SIHE2Q6V=S/YQJ=Q)LP5,:N
M=]7I?!D?K7+U@8RT=K_SZ#UM*?V[YMA9-)ZK9B=/QVNBN@EU(N09M^0WI/72
M*,=C%8E9'3+,#IF=G%ST&D-* VX9])G%R5,X/JJ_[_'*M]^<65@NA\U9&%^Q
M?U*KD%1->9N+I%?F<E-G$CA)K)L,\CPZ[!FEWHDQW6%_7X6BQZ'(?(-  W!Z
M7*%.,QS"OB OZ<T33)6PK;.CJB?#PENJ3M[_<>UU'+7T2=;TFH:>\-  H0Y;
MQ&5ZG;W$ZA_\&RIZ5G$67RI[F8_4AN0?Q$T\O13!@T'[8-$!_5B76J1!'P7I
M-&*Q,8!KHSHE'2TSETE<])SV;U417B?/$//^( [ B43?\*H$,GVL$9CP5-[&
MX!I+V%;_2Y/!^6Z&)-:/&5DL+/JUMR5OW:TFG#@)CEO7+*M.,L.\'_'(VWTJ
MPHKB+EBML*!K?'SHGV\86D/_M><EV!B'HV>6;YOS%?(A]<O"&\!>GNCF)U?0
MR9L/KVNGC6BEW:#W,\?7NVWXUTPCYHS#?B32AFRL.7,0"C<FM'/=8;PTF"GC
M:+!@=0]8DT!$GUI!(VT% <NJKN]R>TKFU.<M)UOY4-]JDZKW2<C^MJ2\.9]A
MG6G<-:C?H#XJ?\G4L%'1),%E26?G>4Q1&#.S^)';D3$0OB] QBTL8HPGFS&F
M[&SS+#9]'.?9VZ^'P:&RU8J."&S2 2=!_]ME.EP[4F:>)(+Z0HY+.Q"KP.1G
ME).#2*[#<45&<-_FT&CO;KP'[:WVG%:J]Z26.BP^E?-=@D?]#ZWLFJ<]0AZD
M_>@=R__VGL?[ZL-=]&WIZ.[$2;)/7(,2J_N)8-SD2#M-6-:H!+4-&[N15P-N
MU0P9*G<^Q2UU.<8V6YY[KJH7U3O:3/:LL@;.G+(/>14=9@IUSD(1Y#\&OX 4
MH[ADQD/3GK$'L$=FQZ:)\R9C]F0_!P??E''#5(?A/JE3QM>WY ':-5&^_]!Z
M%^.U[%-\6H6ZSZ94H?<\[DZ< AX<=I2[O2R!'0X-(YD20Z+F"H?2"VQ+9:/)
M]=DH$S9!.%0>?28#SXQOM&<0179Y1'WBN3IV*<Q@OC!Q1)9]M6/503=4GNOC
M@*CS/<$A-?!&FXI6S7M(4:YD=GUFNMRRM;441R75!V6&D8S^W<8R))% 1FJ%
MFP1;RB:>!L#=BY4DD/@NM!EY_?F=C07;>A/'!H&!DK3[!$M(^2OYTK/7#KH_
MK44+O2;+@4)W0EZ85E?$K<,74_.7B)X-M)"U)03?"MWMZI%7#91G]W7-:2UE
M3%S+RFR*^M3[27$O**B%"?]3AA0.SU&P;[(=T$B9<#3LYE),8*0B[D>).Q&/
MW2*";^J<>&IS2!-FD M+XSR> A-%=Z\/4%]-S%ZJX*F)^=)N;W^U&??H<_[U
M%FIE;I&@!WV>W,+]10:CU]<U&>(&KW0-\&,QVG>#'8E?U^O6]#V/8+7T#I2,
M"?DN$+GRYF%<0$]%GY<HA@)?!CDP%0Y?G.QN+R_UMPZ)"7@WT#D+=&((9_^(
MQ8@S2_5!6@#75KYPP);C[>"^@X$L?<@BZ8OIR220PL+&KOZXTH?Q+@.ZNKN7
M-&6_4-W(DE>IV#\%I/.;\)L=960>[F_4_HB/\SH.6KQEJ=VK=(T76T">RN,'
M!B9!N")-2M:$Q>92Z1J7#%S&@CF$UTP_MW#^RR*8FLD#U:%U1Y[)#%:M6NT"
M'N6*,ZS.=\"F%O:YXCUY>SSZN0!^A@H<:M(/RZL<BHKF3[^?<NBSH6&116$?
M5'$GD][YEK*UZ!6S TH!O PS$Y*4*UM=SRO]VCHN.?!W.SZ.GI$O<K5Q*JD]
MTE#+"RO&'/7IWMQ>TN5Z'IE9'K_.[1_QYEUTO,NZ[>388EQ(?^D:]RJA@F)U
MA0PECA>E\*,UU1'CH>Z44X#9,BZ7!'_P=R6*]]\8KLAU*V<\[U$<9M6;<8WE
MY]<%UB:BGPZC>6!*3]J\2-J?%.DBK1D*W,0H2TT2,)I["RQ2(3=5M60TK2HB
MYD$#;P+O6077_?-_RW[^8-SOUYY)H/]X<..AXOD+F7U^;^C__(+7P__Q)U9Q
M5']]$?/WM>X,B0Z-=/:+K;]>N'[Q;0!_7CMRX1NA]RXU],('4?0T#*> STS[
MQS^X0'6W$:*'EXU!DY&&-"/)VQQ5AZ(FZC^,QY[WZ!MO^KN&G7C'3.[/]IP"
MKOGYGP(6KWN= EXK_8P4#E&> ]D'25O_ IE$@RB>!]8N8O];7(#B;\#2/X#_
MC#-JRMJJ+6M,+:F=OHDD/;YD6[O1FG9"@$\ ^DYR=(**$X:)SAN[>E DMYW,
MD 2.G +>2C88[URI.074WHGYKW&R?^+"#J2$I$\!8OH;1UN6'E:@CAKDK\!H
M=%J""VEI?\.]_M=B&1 </XN51=&+T*.59#M3LOJ_9_7\G=5BKQ_]2.LUO6H%
M8CT*UM/[;Y'%_X@</H\4_9\Q$7O<H*CC)F[B(K2Z87_4I=WT/PCZ)?N:Y2F
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M^,PQPFQG<5!T$VA^EOL7^1_E-OXCS/A FOL4\!O[YX#\UB7L'^=0]'&G@)^
M_VS(CE;SA7/H,I1 )][[%_WW,PR&3GHML_:7+.B)(QY$7\WQ+SA+^%?!0/2,
ML%ZDZ/R7!NQ?*3I?I%CQA\;%FI> QB<$AK]8]?X!WSXYIOCEU1MHK\ZCK4^[
M&;AR"MC!.OM8O,P?<-!DVJ\1>78V(J:J>J> _Q[XDR#G73#HXJG?_$0W>B[R
M0X>=(6P<8AK]C$)?CX\O<_Q+U MIXC,!(6@;B05U'^V@!209K%TD<$/K%W)!
M/T?.A^<"LD%!W^G/2A3]MSBC,_N5QQ)IU:)S[?]*=4)@[7'B0YJ\O]C[^Z)_
M/D:QX;_Z\0L.W0[8;ZH71.D(9#7^"W%VW2CYS=3B7_ 4S^0+ D[N7/NMWO\W
M0,2Y\3M:4F&G@ LUTE[$_CMNZ'K/'5CS1T#1:=(+PM#^GJ2.UK1SI4LJ?Z=#
M3["Q(7KFI!>.#R_.7$=K*JP6#0+ZFWFE]C]EYM(J1=$?;OQ4.N/?X9 _#6BJ
M!K\0A^Z(E\NOZB].TJ,[@?#?$$IG$* Z#@C:SW?^U<^F/7J3YXRNGS.*^8G'
M^[?#B,/J<\/< ^K_/7>F=,U9Z?'G2G\Y,^# \GGG(L^=\#>9Z#09NO9;?P3T
MO<C/Y *_A__"KP9ZWN$X5G3>D MYF_Y;WH?_0]XS1XM ]?\".J(!0>@BS]>
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M[:#9@;%E/><2<.;8TGYX -LZP\.*\*%3@-%NA(K*$T4'F/60TR#\BXXP*H8
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MQ"> 3S,YV"O0BL>]T&V_5O)[-L1$O <E33P6EUD$B<U,(A0MZJ6C*WTN3K;
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MOWF&HXEMNDMGCLR=$.YG^K+IO#P*:AZ?'Q6T$XAE$KPJW"2/8F5NYM46N7$
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MX,4"\4$^JJ_@]=EI]RBW(3P9:2(BL;9!R,N)$4');E?X)KVOI"5;VM>#^L*
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M?_#:(Q9UQS_9_!')W2+[<A.V+H&%S3WFWMD0)HD(^@J:W'JZWE26NQHJN7P
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MOWGTF<M&\V-BW/PR;K+Z:(UQV"UEVGJ:MZ%A0<W,898._1\KJF%K KL;4)_
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M(?L;PFG/RGGZ<\S-8HI>/OS%K5 ^/PE;LVG%JYT^;Z!IC5&<?M^4:.*X5AQ
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MXR%V4Y7M"+A;;RX*RH%KQ:\EY&P=VWLZXH(7)Z_;#F3>],D18+BW]<**P5\
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M>ZTOUG#1, [VQOCPF[F[]U]V= 2*O"PK6#0-D$KK5J])L35\1K* Z#((PY?
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M3:XZ(;2N0;Q7<FD,8D?5*<G^B?O"HB[A3<*P-$<VE%>"VT94J+7Q@5K24>S
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M$:NLJ2/XO8=ONU/=OU6C"*K"[LEV:0MF1UBGP'")D"U#?* #D5OPVZP9_I
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MK^X,"=X?6OG'C$7YK_@0\G>ACWEC(JN54T16:L&X!6[1N%!LFMLOLC!WJ M
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MUM2#C0B(L<K_PS[ZGP6 9=%@,@9\Z7V.NI&/T$"4_NK%&AHXY-93/2G66"!
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M&81/ZF;,%A.6O.\\45;<2+>A<4.L5BHQNX]&;^F%$6Y>\^=\6N/$V?DG<K=
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M<@\)^2J1PW5Z_G/I?I1PTQ87"2927/)HX+,_B@_RB\;%,1@%W8T'(VV:HGQ
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M2[@0506ZUSOY.J>C9[MO=V*U[\L M(:A1WC[D6]>528>E]@;9[8R]'TDY/Y
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MJCXX-R!R,UHX&\7Y9AC.X!!Y/XKN6FH*;ZJUZH)/]#["9WKS(XU>DDD&06V
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M^;_FB/\\  95$F6!\%IU]T;X!6LK./_ >^Q,Z0IN*]<IJ>*%5P\27EBL.)^
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M$UJ5I*3H,/7MG8(J)!%;ASX#&@CPZ>:OPCN)69*BS/ ;"7>@:%L-61BXT5[
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M.&K7E\"GNC;1)25+2&>V ],AD-'/Z:Q+)S.-.TV%65F73KUZS*9XW9+5]EW
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M)U.T!QU3-[_ZOX<&$*DHO_W';"QZ "L]61<?-V!_)#$TU6)!C, L]'K<,W\
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MV;[EE-ZL]*S_Y8@L?S1XP:Z5P#^<)%& ,C<48#C /<?3\.!6#C\=($$V+Z$
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MW+$U^TKPC;XTHC+R \4)R^44#VD-?UW%A(YLNZR(/ 13F/V]YS60PN-@U?Z
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MJ/23:=9+_ 7#V4,NO6XA8RKDEU0D"B V(D89<-%Q0'ZT4@Y5HRV-J2VR"7W
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MK@GFH<P>=S)=W&7[K_7:/"D,T_>5?P)LT-L'R^1>P (^\7"^0_()R-1U+-
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MCU78+A\IEDULN;IT3;O/>3G.YF-ZHLY2QF1#O87'0DA9IE>\%0S,Z/-*:+&
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M+MYK,<P;."384"4"Y]C/,OEB6!!.*:FW9ZY%$,HIUHQGT1*N*32Z# P8]"7
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MI^W>'L$?XVQ\&"09?04Q%'RXU']QEM[0J&.D^UF?C2PQ2&#QO>NN\/0EMJG
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M3;3W#&;%6V]VJT..K4UZ9$O9T73_FBR9->=UY9&C]NP.97->(1")0-/GC<3
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MJ;(M2;[W67QBNK=PG>5.S"%_;*@S46&8LLW5KX16?*2AJ\OK!I20\QB!1,X
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M?OZ_[7XF6#;B]\1!QQ+FW=[J>'>Q'YH>4$HT917D\^83""7F+HXD#XN=*W_
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MO9[6S?5B]+ -D"\HMY@664WK+GRD0O_UOM)A4,W1A?OHF^&S[Q!KH2[G#;'
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MW"8%$M_AG)5T_B)4<"W"W/FBS'N^!^Y\!WO9!5\>@DW7\RZ4Z_$8;?8$%J=
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M &!"C[J-XQN45.IF(KH92!8R%I(+W)/)%R&30O"#$WLL $*,&KA(]\ "0"[
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M7VC>RJ*8'9R,N$1#_2+_P;WZ'[T"CK-#3!$+8+R&!5PX"VPZ+Z6P7%H(7RP
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MAZ7+2I]><PV8AD!_$=7P,<AT(.9,H-=&YUN^30UF"70RD.X\=W(/"Z@/!^C
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M@TL&GM=0CE6@^[CZ73S?YR*CE@11A]<0FKM.(U4'18]M,'WAJ_+#8\W=L:Q
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MSET;>FP5"MIYW^R1T#]:S[A&(U@%R3 2[YS397IQ/X*'-_O1E:>M^7'&/GV
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ME[D*H&-.T7";'Z\<Y(0!1(INY?%[)PU:9]]T2BN.\[:+;+COXE-XO U@(G;
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MES=\/XYQ$\S>H\&9KHL**5C ,[Y$5].'0LD,395L-E_$7ON[$@?ML*#*%K"
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MF(?+J"FN258V9AH;H'::D>ECK.7$ Q "?FL76>0"D'QC3#0"9A_,3"JQ[#=
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MN]'<6G_S[W<A.]O=1'A'2]."JCZ(H(0:$/JI06_'RJ'M9+2:PS@^3!54]?B
MC5#6!$IM XT_-!XYU0&R\OX(Q.P@Y+*G7P(?QPBHMKG*!8O?Z@94,)^G<8I!
M^.)PW+/OO.EP:CH5\^TAS0509U(3T#?9&#IQ""AKXC,QJ1?/8C!?7%YYA0=E
M:(I?O)ZZ:05MGKP_V HZ1>JO-"?$]9Z'RA"D/;AZM6P\ J)?7<'#XAKD'Y+,
MQ?STUU\*&5\-? 2\DK1]*'#/<9=K_%&S!<((B1\5H2;%H$I:C*GX5$+2<S%
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MD7K%K6P)D@+5GG5;(SL> 2Q<FSRWQV6/@'UYW\2!0Q[RU:8H^%345P\I1JN
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MYS_%F_G;=I];H@3]/_Y$"%?E<^=L4L5*&#FM]'E*#;I3,ZL;\:VWJ-];U5C
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MK]M<A"^E-#==^F3B/7L:-,(O/W0L^IM5F735K_=/OZLM^1B2Y=>*F?-?(!>
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M!IVL>F',EOC__OH"&S:K-48PUQ^BA6#2_P]W(_"(8!%-Y2"_S=*J"KM%+F
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MIS=0.KE.QP[D^)[;2FIG/EBUQ6M7-W'K7^K4E_"&5]_8?<)&]YO3HQ<G>JJ
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MPTW+%ZZTSYFMMM\R?F<TSK'%3^XT(8:HE<A/>/#18:TLVD5\95JL/#U'F50
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MMV^9I+&7C5M9MF(C<CZ5.XT&^9/'MXBGR4]-'ZTG<!S/'<G*=DMFE*UV/E\
M5W=?>359Q]*))A[^'6"E>E'9<A3^P!8!'T,IQ@.K_=W1@=FE^'X<CE_L\PGN
M:X5E,?N6<0I(SKJ$K4_#&H9_0,DF)K$]>N/PSZO191Y'U$'6?WL\(MF*@+R_
MJMYX40SN-7O(I,SN^C9F(I=>\7I"5;G\[&:T%DT'*7T&=@>H?U6+W.17\@@=
MA5Y]DPB ME?*V@<WRE$IC*(%OTH#<!5*J('P,] _FNR^.DS\C%\C9&2NXE&6
M];KY6;DHAY23J?4_]*\$*0JHF?'> =[193BK>TCR/0-7O,-P*B.>5=@';-R<
M1;TU"OA]AH>NHEV=$@27H-Y^82%R_36T,ZQ?\E5*'0EU-V^/6U "4?:1=%/L
MSNY.R[M8$=0R^K@I[0RH8G;@-J5@/RUL>@G6=QD%LMSZ"/%*I;H(2%H2[+ Z
M% P^&IO-4^FP*_JKDZ&?+),T=18KJ=,*;YHZ AW:U@?Q(IE<^MFV-AP]I!BD
MR\_<&8D\VFE5T5\R&2,81VLS^&41Q'PN?P3,QB[B@SY8-7B<C;$DUXE$@QS(
MM!64N__/AXCRJ+%P9ZG/J])*[Z=8FZ(.D?FO+PA_ASI&#;#<]^4X,%/XQN/\
M&?0TP5QLYC&] (!<FMQT=#&_KOW? \JHU\_O (0-CSK8LK66C/[%D;LUU&'G
MRU.?3J!=]V'_4O/2B2?T#A!E3C:->Y?!EH>\CK9K"*#9-ULH&I?YV"X C5.2
M&YLKT5Z<,/8S,I/I]1.;K]I*Q)9T+8MCBAI_7BUM1EIS.^>UJM$ZORD L;L+
M?2-M>_ UUPJB[H131G?4EF.3NWV/(D8R%[>G?IO3EM@8J-P/D0,<B^2,MEUQ
M7!O9;UQ%U"ME^RNB4]O\4-G$?3+/(4.> <(,!"$7+G%VF5+6WAN=,@5T6Z9@
M]C[$5A1<$,7X?-?8.;MXB9JF?\ZWA_"]>TV"VJ"&@ 8^ ?GNM%;Y$!=><6;+
M+_!8UQ4,PM&(L0UUY@%Y#N9="_=2?HZA=-EZ95C],G3EKT>?/=@0NQSP803E
M.7[ 32%0 ;+95&'N4*1J^P007[6%FHW[&Y4 :63R*A2-5S[40^QBI]>YW;C]
MA<K=+P0>#0W(FXA0IB+"LD2]! =<@0(1<88+;JV0;PRH2%458V4RO<.?#L\;
M1L+^/'KK8VG]X'3H@<'#U:-'V.@>BR?<.-G/97\1>XU_]INXJ#-(T]//D5_%
M7JYFN29'G:IRDB'T::.<MI*!'528L=C) 36,X3BWQW=>'13*A#))Y0O'^,O/
MQZ')0^N!$;-V^5G%&[F*(M/'(,EN&5'T: O*S*!GSIC^MP/B6YKLY[87]VJR
M*IP!SW$)!BD#OO-HXE!/$SZ271E.3,!2P]QW9ZOGW%ZYWT&?J21)I2"A.4Z7
M;.WWHTKTU1_K*A];$&$-!LR)TW0FX=(BH2*QGMZLTZ(&$-ML_-O<?'3O)RM(
M@))<Q2KQ Z Y50/&4KVBB^<0ZG'QQOS[A4 ;Q^6RU,/1M>S<Q"/S:(5GL&Q<
M;UFACV);@;_:W"E7SK-=362BO0?DP]6/0*?S^!82JWN#.&E^XX[76/"%L6CX
M0(3S;0\4[$HB=%UFX%;W[8F.W.(;[9R!..!X*0M 10P/RC!K;")W+3R-A(E@
MHUW+$+$@*5&;DM[Y9I%B(^LLJ_SP7]J'/I5W $JLI$43IA7<^>M"A*MT"-#8
M7M^QR-0B%T-7_2J<8%U\E]BG8+>19B3*?$<TP=Q8_-67L)ZREZO'G =\=J@C
M( $3T/VW11?DS2S<'IGS AQU!U#6+59_)2*2U_T^IOEW[8.VY)@MP"?+=N,H
M1S>6Z%91 PL]<;(B42Z+W#5RTF$0G!5U]'#7-PWWTFV'TI<5=^!^3O^^E=;(
MI*K?O&(_@&#ZT%\*#=J,+'5H/?I^9-F)82L?/H_\K,,421D6)W42/, ^[FM]
M0:;K:3WSK:QPE/T?</#!^3U1D7P;C8F>ZL; ;?]P2WU1*?Q!*N=BI78&&G31
M>1J&JP_RJCEUOK+!NLF0A#HF>B-7M_DY8-TU!-B8GURZX-Q\^:(ID>B@DG+6
M'6'67[<P1JO  II("7\DJP7\#:M^@KW^M<.6O;IWP/AQ7+3>I*O\,IJGAEU2
MGET[^0XP2[[GH4W=O#/.2G8F=@=XB@TR#1#4UZ3;K=EU<XC>&+)W9ECP _].
M>9U.&R>WGH-A3YF4$L=0=DNXVYG3P,>K3[]Q<Q]Z$O/;-KY3070ITE*OX<2J
MC?,SRL\HF<3B"7 R]1/^]*5VK3]&2L<JJ*VGJPQ!@D,O>TAVXI9Q%U7>\N,R
M+%A-#9IGD=[(&R75: Y[[X!-[G$V,&%%CU63Q7#PGG!P$;:J1P?SI1:YX-%,
MB=#I/ZDO)4G8I?;*6D?[!:M_3&Y;*<UB@HYO^7NN'@![6XG#0)"KWR#Y#].@
M(Z>M1&/6GTPUEN5Y-2K28HRJD]AZ9.88%?BI]H30$ C5UL)/YA=N(]>H8)5T
M3YKL'"K[#%NMB"$_K[ M-+O)7U/+'&PUBVFC9?%D3DSYG+AC\J-E@Z)ZW+_6
M_C*+LE>6P(&!95**'V@E7.EF[QO;OM[_Y1,ULPX5+]GZ2;_K&73LNSG=?ZY?
MZVHMCMBZR:Y:N\?:_ZZNQF:L\:,MHI7FG\9*&40-Y"=^K-.8'D\-^E=8" X=
M2HEB*,W0L0,1GL!V/,W&ZU>-@HA(EJ2MIV$$+MW_?"L TGP?BBU!WE94^%-.
MX9A!KI:M*7"1"5B=Y'>5>-J:=\D+<5Q3V^7GDZU-93(CGF^DW M,@;=/9D[]
M1"-YG0Z,'R%TWN$SMP"R LEE0V%#,(O'=JUF4XH7%/I:"X,321_K7NK(O:2S
M]GWRM_PB;3:5,];/\V%KVP-YH6 \_FU\WQR'N"]S'%X&+</@S.Z+UNI>/H*]
MQN,%GN+X\VII^I_*RXZ?#3X!0@>W6 *%7:4HB]CCK3$N1D$-+ T4A=8^X+6M
M?L$V *][C!=4DV2W(F];%%&PH.F1FB@T0@B@M*'+L@Z>RNFNW&F:O4K- 078
M< X#W6F&2:L5]?_QN[#I9%-J]T;L'8#T!]H[K-K#@@8\;-":.G_0D)Z;M&3U
MA3>//'CY$2  &4-JVO0-Q[$V1M#EF;MM0/,@@VM1JL;"[#'A> 7$G>K7%_J6
M?K]SAA8%AIF]H-WN<[N3E0B&1]/^/ 78C-^WYT^'/+GFJRRSW9YRE0*:$0#'
M$&5JAI0R=$Z/ >0YFB(SWT%G8=C;T8;W?/]/A$?EVH.OOF\.S#S)BG1TVJ]B
MY7CBV)&VWX[@[+;5"J7#("Z+W2F+]Y^^?&)VR<4?9!3][6OM-TL9XL^S1HP/
M%,T(S/  =A*:.1#Y;(X>\_2^7G?2 G2)T7F-%;M(:T0%SOP3> M%ZK9/]M8W
MN!JRDVS7=^SKUI1-PXS%:/N4\/W?^>;'BL/C6<?$>_T28X^J(_]XZV ;U;E5
MF/D2G4LJ4B+?BB\>#),../&;/20KTAXRBI5CS_OE__)?4U\]$/TX*2QOR_J]
MS;ZR./AO6T62!EKIP6=?WXSQ_\X4XO_.E&:[*.D>@=P%IMHA "3*S\!"X5G!
MUM8N771:6M[#_\NW#( INRE;B;_[VP0$\=0O[!F$H!Z&_:TK&>FQ)F3\Z<'6
M%L7!(91Q*$JV?\V@L'KT!/O/SDBX@YV56\>?Q22UF>P*<L=*V?U1^6/UY(^
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M N).O^?ZAX?(?XZ%##RN^/RR$(*\2+-=IU[V7(%;5?A2R4G<6]#N_WI&K;3
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M#?*.,?>4<^\-\M\2&21=U5M8XNFI\)4/T? 4T/[>HWY"L&GAN-(\1E%MV!U
M/^TH;9V8IP(2K"X1RO9XTNT<+J1KE6SS98Y1E-;?CN2Z(\:OG?RS C*Z9^ C
MDB6WVC9MH6BTR*V0@'MV^["]I97M"RD!SI^G<\1&\; A6H+>B[\9.U'G!P3T
MD7I&G&ECF!-_*!":0E<?-V@ @2\/I4C1Y<<\+^9W\1!5KI(@Y5I+FYU&7EG&
M_K?ES(X8CKRY@0.YCTY@'KT(F[(=6Y/T U?]8.Y,-VM8',QMWSF;$]O).WYF
ML.UJ>_< @,N(NQ9WUJ!96_(/Y8S[:GE3]P,@VU)/.YLF.UC !S+3U=M)2WQV
MJ>&V.)B1 Z/DDJ1*&L$#I*M@QY73,5B+<6.9<&X@7J7&DG+62<)KW/F3Y(S3
M^#@Q':C3.C6M-4S,8>NH[R+3K6#I+I7%C:KIBK)6!% G*LFKIZD$Q9J>++!E
M]WR#%J_>3T+/KAL;'*\KJQ$O*)?KR_$GU1XV>1#^DI3VU&XZBII"?CT_KK%%
M 7NYO)QG)Y?40.;%.HLTSO+OW"E[-A/_'+,',-MD1$2XJV'MFY#7-G>T(U$W
M## 0L>(13H^%10-NCK:* Y@?-K4;^&QM,H;(O[EAWD2O,?O>/6KTKX+QO'T
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MT+3O]\XB5^H.)MQ#HMRST2G3;I5@1G# MLM'K(3CQE.1@\2A+%9U9GW>06]
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MG@#G2,K.\YB$VL*C2?.N7DTBM=%[@$CBY(Y*XV!A'  !$U ]ZW1.'HH^7&Q
M0D=%.#D(G-OU @V-MKA\/HSRJXTIY56?W&@6F<$2=,>/MUW.'RNQ''WYOLC=
MF<K4Y$"VJF5+A8O1P8QFI36UC%"3B[W,?-(LAUQ^0\PYN14 ;#B."WA>18PA
MCM"+/<]EU/L!NGOV<>$ 2HLIK,S#_OCV[F4_@.\[(><BG(K7O"#QA-HT"6<3
M9-IE2TO5175@BAI-#"K.G&>\O1D\6C"+I=LW.E+\>B8S,''&@XWLU6.S=)5=
M:89 BD<@%[##DQ4NZ]V%C6),PFS9 @1:6"D,W"H]EC#]O)N+RB''-1?AWK%
M]6=]@K2&M"-BWJ2-IDY7'HH$-VO2XZ\N2CKWH8JJT0EL_6L0LGW*/9/9"_2)
M<7M8E+&N5%\D3G,HZ_KZB6G-[-SD'#FPJ/_'-.-'06\[[_M/6,W2[P'$E&AV
M+MA((F)*%E9P(3U7YW436A4>:71L+O';\C=#0VIBZBJ+DZUDVS[U]:G^410]
MX?/O-?%(<X@MTCESFXX-P,?QINN*$57R3]<$I5]-;R)3C^>'K(_F:U@F:V,I
M[^UV(WQGT KTN,%BS0T(C5!Q$)S[\YA;DP/(8>?M?-?K]\T1EL3;-_R3Y_\V
M>U>!;;J@>E8X==:A5GJDE0GRA<G)BY@'>B\@H^G+SLB/F?W7/*S6K/WJJEZT
M[12!<L+AFUC"D5^SLN]>@[N7NR::V^YU%8DM$,>2]4_^V&6C#I2L 'D _SD?
MT-_C(=)RV/2CWMT>1^YD_L)8M17V&"IAPO,IT# ?%_!;KWX60CMSTC+&54#
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M82--IY.N68B<GYM8& !/[["%,-\Q5 X;8XE2"G:%*VQ756A3J\O;74:W'-W
M'/_#K#)]X!5M3]6^V=?3>0U5Y(&O,7>-/Q:!XYG7EF7?=&I6S >?9-U+_OEO
M7R5[]W/IW-SN!&X33ZJ(/D"*6[Q[ZMTUFR@3/TL=LS_??U%4,M)LIEM@T#H&
MS"L#0L== \ 5Y]_M(=Z4(PR.?%H_!P;DP\+&Y[)N_N'CQZ+A;NFK^C TS92
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M8UOL$BR*<4=4*7P %H$L3,J"N+_1HK<J=J+5^[8$ZR+T/R04^JU08Q62T16
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M!7U5[DE.+!LF//,^ MI.EE+U._DQI(7<WKY?6"OZ__Y/YW]S';;/.A&UQ4B
M2_\($N IRS]<COY$]/MZI9N0Y7@]JYO,??3DSZ@":2/81QM$$BZ_P593ETB
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M-FK>?_B]B9_\VL3.J$R&JA7RS4:0L[<JN8TEW2P=6,\;K^(A+FV?;?*#ED]
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M*=@004SDB51_%[88J!M^'6219[ ,.I< ,K3O9.03XUB$]JYD1"";!" B[Y
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M^ D^F0$:;YIFA:49"Z!^-T95%*[:PJ\VL4,4DO.1H((Y0 ]Z0@7P_CF7/W[
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M7HVTT[&9:P2%'E"!FT)*,^>GN_CFZN IE/XZJ-,KJ/XDKJ2X:TPK?0ESWVR
M:ZN/#5?LW&U%:.HO"_7_S*([DC>;)*-&#]_-E-MV ;U4LPJ/:B45HK>D..PO
MLBG13R"5NR%,WG:E%B1E5MOR.C^>'JA]P9[T(\ 12'-"U1)%VYN**K7']6Y+
M6Y^""S55840RNSE;H3]MFXV7U>@FETZ-MT\9*1;WI5AG3PT=G-<R5*R,6+.Y
M:Y1S#NE.L&=T,QKX0-#*F $Q]IZS%*?K&V-KTI_24!<DQ;*;)'/X[$#)#;JR
MWTP+Y3""IA1:#1\7Q[.T+))]H(K0YV[:R6F1?'-L<QF3X13A+N\CGQIU;;[1
MIJB=U,6_F_XUU$(<R+*UJ<:Y/-BF4KK&INY[<H;CCER-%2( ZLY<BZ_[&7+[
M*Q8F\]]D)I'W.EY8?CS&96):"L#Q2#=XK"7L[6$0#[+NRQ;'I.]3()B-U:+G
M[4@7I0K<8CO#F.R8/V7"Q+A FY\,9-$E?;[MC:[K!)2]F$4">[DF0ZN4>6*Z
MTD[4)Z*K$O3 PRBMGSK.N<ER"/&L#X?T4MW;Q[LPX&+OE-)*=&YBT"L3@YY5
MZOUL7M!11@_C)_19M_CBRF]?"-/:VM>7_ )C_JZKT8T8'T\%K _D#F"A;$O[
M7#EN#*$'_G2< _KH$9C&%KT92+QGW!C13B%3"0+O:S@3&>]VV]N@-CZ_^Z:!
MK_$H.Y1^1/=3E@A/(UGA/]3XV27G;\$VU?6@2 ]+#$7&39B%XSN?\W1=3"N\
MQM/TV/)SFD<_+E.1!PW1/>,@7V*MRD#@H0>.0=;.KCM Y9.G3J\_J&3_HB<:
MGVY1(RMGO5^G9"QN+X,(!E(<5]DKN"P@]^]Q9Z*P+?3ING;HCZ@?'TZR!<RR
M?$\&K,41<G4FE0Y?XE8_>0\ 8(0/)#$ZHJ+B?/TF0W_3<SO@L*F#[=;V;'$_
M0UUXXN"B'IDG\SGY5O;K-FQ!@8V!V>NF)O11JC5U4X9J-*6# KSZY-GO3_R@
M#3"'=$SZ:%'5-<6[T?#S'[N-*1^ @X?DZ:;Q=7C?79XRAZ@9%W@U3"3N&4D2
M&<.R.3- )8T)EN%ZA."25S]C0XB*.3.PR>LS:,4PMMF5/RN1A7+'<MEFWL("
MF8Q;1D%XKS ??2FR$3>S23SILR]N$KB9/),59OJ/EQA3I]HL;J>DCY6=[P#[
M<,9+JOP79C/R>U4D29MNBF5E2[F7L9-SKS"X??%(1X9>0T3,LH56%M<!M^HG
M"<ARO!7]'8#PUX@[#:QY(_X1<-'>C*-EXDSRQ0B=]P3B_81DKA<>/55.VD-%
M,XT]5L&EY/[M! 2HKLL8-Z:H-NC%?$#U0LK;LE\3"@?6KPQQ+A1-3B'[-J]A
MC='/;2;97VM&T;#KZ>$  .\ G%F84%"MLB/W]>MT$]<AJC$__S\KZGS?:J K
M;&R9&V#[-/1J%%RM\%HVM-N,/Z7[ G4.<;?RLZ6.9W%OIM:H3?KG.4:@H V^
M\L!ESAXHGE3:IW,X?JNKJ4HZ_F %WJ.-88LZNP-$^@Z$^W-[%^]J[1++G6AX
M/TM77IA^.]^,8S/XZ'X60N^/G9&BL^/VY(E@J,,;LDJ@4(A6=8D; N>-;;[Q
M8X5X-[D?67HAON;9EAOV^968]'G:LK.*Y7\:ZA%=BW>QO6C4/Q=.7#;3H*.8
M>./#DAQ2_F I:1*>>AX0T<?4=4F62FFLC$:&:/"0Q?4-BB]2.[?.28?YAK?E
M[R)N,V=I^@J]O1SV4&2_NCAD&$OS731SN$^?_AX2$8.PK>>$-#CJ2PKWF#7Z
M-=-^X51DMD--X?W)4[YDL&^ <MSDOYQ*0B89W:1+-RJ[/J(QT6(G9%T1??_.
M/R^"?!94T1MS7U&K\LJVU\]>*UF$^=AGA+PE#G!;+583>33ILL?"FJ']UT9M
M/8""D50&N2OT5*&.GYIDVK+&A&(,!R>,+0DH='(8@5P<(5V_ P3SG/U^M/)R
M1OOV1#-IX@\SE\7-3RI @&M?P&-Y0W;CT8T2-LXE=BA/*\8\ZEIO?=E 'LT[
MSW7@$7'L+"3>R^^4D3E 0RC:A2N5U31ZT]Y0B;7HNJPJV9BM3J@4X1_^W/1L
M"L=)KWV?0MQU,JEP#OI)Y^-!*92E9EKJC=WE:U#TH(W^A!HC@OO4Y[67=VQL
MJ:U 3\(I7>Q&D=,""&MO_JR!D7Q7ZZD3JG(G ;+U[[M.?V&RTR]JP/D@4Y&(
M<JX>J3B"<Y!+:"S*C!T=5]5:P!I3+.>HKQ?N8<O<^JGY*Q62/%)<T<13J,(:
MPUV,Y;H5MF>Q+T6^0OW,:K=)&KY$C1)5L7M8ME\]TU4LTC)S1R9A"-=LC;-F
M2Y"+RU(GPXGK"%%3B=*TAQ_='GJ_( HDT+A?,;)] 1",Z!E(6%P#I>-\WMHZ
M7&W,J507?!P/WSQEV)@+.U@^2/LW4^5]:I!M(_420Q&WH2J-CQU2I1U#L5NF
M:G34Q_:U%5"#EI\QO71/N $5>*]WD&(K^EJJ8M;,JXWF=XDV5^R\(RV71<3
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MS=7WOK2?9>%BPX,9^6T'S*=CG^ OVS'C-*78-'X:)\S:!T]B,E$5'5AA^E8
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M$ONK#*O1 ],G):N/!E7Q*.LVXM(NH]UNWN,!-L_ZV,(E5-<AO.L2@:28S/2
MOVWU]A7BK:)__,O$]''G179_C^'6>/UWVI1.TX0MO0L(&]F:<FALC"I.:".7
M8;[] )_<Z0U\@^&-%UK&[9YK^9KDG!_96VO:_34%N60=-O@ ]^.-I LW=L'?
M[ [P3"C8_Y++MQQH\AP6JS2A[,#D_Y->-B%$H+-@P:AP!3E64,M]+8G);EZ_
M /^#\YT3$9DPM;4=I)9/2A$^^8+#)'$Q0(^M.H:;(R%'4:<:H0)[<Z2[;H;&
M-I,FMA,#I/^B!RM[1GYWT7E!Y=$,=9Y56%+E65ZY+X=[TVHOXUQ:(P\$)K,,
MC6"PMI#,JD2_+'KRK78R;$R0*]IXI]^X 2Y@]KY.)/GA3P6.+5U/47K^P :1
ML.W[><?"?=XRD-MA_\5PBKU@V-10%%K]]P.Q3T2!HH6[0GZGXW;Y7C73=F;<
ML&I,52JRL:8C<?V6XA>/1<S;7-JFKV/F/\\WF&9;5)!G4#+S!7]#]%'$JQ=!
MUJL(-8F^'ZE+P9%=8SC!B%)03E_Z><&&]3VYD8SP<G\V.B/X@*8 SPOCE9?N
M];X(8BS#K7.:1;FZ(RXD&:)/U(CZ E^-7]M;(8/H8JA'"V,OO8J^A@LE_+0J
M\)2DW=U[MQ-Y+;O!2\K6NQ^/!_+M[]_*45=-*VIFT7YH3L#\G:XV^!L9_B;8
MYER[K=WB/'I.4BKZ> 2GMYUKHIW9$ OLU]Z=F[!+.5:S]K2FCJUXR34D<ZYS
MZ8YHX]2AC"LQ)>#+5=V@?4KC\O$SYC@%)].:NN]C[OJD16QS0K<1Z Z@/PLW
M#RJ^+]I!3I.GBS76?J7*OM7?_9%#>8]@*QJXF5Z#4#DH+O894700S%]IU6XR
MJ,X V$03XN.\+=&TV>O[>/3=R6P++2\IMF/ %US$%F(U)3CRI-\+ICH\F&[0
MFN";K-6IGGFVL_>DX0V/O<*L@DM9T:K.S-\JTO_[&PU<WGQL3_\MSS1<MA ;
M*,D_<=JF#F+4:HZ+YN)8M)#75-\EI$H:Q_>=]J,V_4>)HHBHF= RYAJVQUM^
M]]N%6 Y<\""#[H<X_MRS\AX,IV8[W)%_Y_TDUWI"R@*S8E.B)VZXU]]<3"<U
M.7'<95RKA^3#<EO?K)0*ISD:QVD13<YZJW673OY,XH0E@^=K.>3[*_QH^H-9
MOMUS*;;:%GOJ6:01I#=RN&F-?IX#M -Q7:W+Q]8Z$P%-9+T+XQY K6W703FH
MQU$[]M;.)OK9_4-J;5I2DRB6Z?,1_:,K:54X_,WV<Y"9XZ]^5+FZP&*1%8BH
MUZ*OG62JH0\FG(\Q^LYR@>JI/>L<6SZM".2\ R0 C>X T#<=ISAF0>@*8 -Z
MM9->P'#ZV9505GWM6S/(U5QWO)L2SKYV'LC4V;796'_78H8=RAZOB<WPSKT#
M=*L^&U^+RK_2]>7L/D!1B#SFWXG@Q%I/%7GR@>)U,+C?*CT[<(T0(W[^D;_)
M#XJTN3*EUI\ ;<=PJ <8?KYS]'PL.-H2?<QMWVLFBA:Z3?!;SVACTIG@K9H<
M73-^/R%9)^4RI+R)S]">=I2^A(U;AYAK8!@CX +(*2OG4OLGLN?#X\:BR4]<
MRI\N#51?^J)ODEH:-<\CC[;COD9M_" !%P$?@8F:JE0[ VG0$1%50NQP%F>[
M5*VF<$SBUQ0YISSJM$1)5X4(7##WV@SWF=\(R:',$P>>C:B-/X4,+!]OQETO
MU'V@O/_K*_?R6$:NMG4K;OV(CCEB/PRPBT(D"6$*"ED1CV2V*92EB[!_TT7'
M6UJUTNZ/=5R',,J,GY5Y9N'HM]H*V5=$'>9-(FSR'G_[EQF+[[B+2.:P4X:)
MC?05^CDEK4LRZ8_? 6 .O,@DU1Y2MX$O@,)P9MC;)T3&._5'T2O/ICUUIR 2
M,DYSVL*]^.!(U-2#A0\YHPW<^>C5.#@3S>* 8U#N\K<N8I6R'NM'^"]D"15W
M3'(&L((5SF$B*8F(;N:OT?125.,/67F$(SMW.R7%OT8J\)A477TO8FY.V#W5
MHW_(F2;(_8[SG-N'OMY>@#2S29/JUJ=B)D80CSW_V_\U)*XV3ODUT!&]RB0I
MG^G4WY\:)41= UCKKZ4AN^F-P:]IG/+LW?:+.?GE.>K8#C$G[&)TF#'??98X
MEJB-9/(-%[WD<%F<:>)=PTN1,$$"$M6(24%'J=^'E);%3\F]H1?JN!I.R?GI
MFUL!@Z[^<XJ,5V)!O^G'VQL9+Z54M@6'4>+]#.P8\VNVEJL%Q*[!F+US(>V&
M[8LP7Q4LATF.">;T=5N!6G7=Y,%&_90C]P&*:730<<-PPLW-)1? KRP=]]4N
MD!A]6%96E5=FD^XY<[Q!.N)4.4#/K[1#7V> ,A L6LI6'$JU&+X#6".+B:C\
M96\[WZ<;Y-@Y?L-_\%$U1,0]=(ZMRMWX#E"7<QU-,W837M5QKG(Z["@U-'NX
MO8>87*'-R&KWG^@M/T91F?YY L0)SOZ9[I1A4?P!8PO3GW45_V7$O6XXDWGV
M!4#-1F^K7IY\C<(^LCU>'-I)\^=*%P]BN-;)]GY&YHUIK?E;3O%![0LH?ZHK
M:!X1$0LG6B\]E?RH,"=6UX*72@)04GXI.8^))51WL4= !!=I.3,J8L0Y[7T.
MTR1[$^1*I][^-0E.D<A6LQA9"WJN5GK3;DZXR^O3&I3NJ,/2ID&7XUNDY^YN
M/ZZ>L56SM4HN)+YLOQ8?+L2M34R FEG.K,VEHA9O'G X&VAS#IQ4V4??(OXR
M">K[)L./DZD1WQ)R1B)VS)++;&'OBEJZRHR 9N\KZ2V:HBPU>_( (?R2=O:M
M-KS<18VMX6*H+6TH63FU"4-N:!=9LFZZUT+<E*.DMT3H1DZ<A'3I->]T93U$
M?56SI3V.AAU"IS(4O??G$'=)$U<'#*K*,6Q"9V8_1]\F;!@YS,YIP:(^JQ:S
M5P[39$;</A288ZH2GY,I 8GW^'I"1AK 8<6RSA["8S2+K L&$^%B# /1XQV3
M@BA9#0K*<XI&X?>/*8Y[(50XP6%,.&3-ZXDJEWS'0ZBZ0<%G8]_;V6T"Z=&-
MD5]G3[D5WJ2O]QOU#<P_Y-%+'EC6!G6=2BH_:9"BX3F*R2$S8/X*Y$NXW4S^
M^XXHW$.:Z%^$W*1#)8TZ?6Z85IHOB=CK*L0N3#@UU< +IC]N:DHN0JI(4O%'
M4>W@"9!:=$1,3_W6_JRI0*V"01[-:S0%Y\[;8R#!$&S!,BIL#1(/5<L>?3"<
MWU0JBGS$Z#0ON3?6LSO5>P>@OM98S^+EMZE>8/U%/LC(TOM+X4M)$ZV&U'??
MN?S]=HIQSXNXLS:&[DNE?N*=8-.?O@\57%'&^L)>LQ0UB/G%'D='JFYYO$?R
M#-\('Y.49VVF5)+1U/HQ_9&VAOY[C.WXKWTS3]Y)4=T!?IMA\^X II5W@--G
MG%."*.$!-:-4]5I8O5&A@,K+* NB5WNHX&$Z0@T)+?OB>829J2EB 2CCZ:&[
MI$:G N6C%ZFF=K#<$"S2$V%;O05,<Z4F)& H;Y4OHNX !Y2>=X#\=/CYF&++
MW!W@JWB N(;VA?9N]$3^F1N8T>9"W!4[!UWJ(I^!PR[X% 5)RI29$F0YRZA>
MAG8]\BI>, 8:(N3M+9P)&NIE'5P_!!/CYFIUDO.5#56V+KF%K0Z>W $>^<NC
MN[!^)2MF=K->SM8V"2:+PR^-+!+(.'EZ3A@4J>CFN-%[_5M2A-@-@Y9@U)2Q
MR 5:;N.1W,2+$@:L=#B!;]A1J(1 0-D=P&;%AL;DHO=00-DA]D_ ?;ZX ]UE
M\,\G@6-D;C*OJ59$-/5^QI*_1"N(]@'+R-&0WYO.[C%8ICL <T&/^=G^?86@
MF<'&59K9,#R9;5#CYV/9@M0I4W$VX=RLBP?/H2'#M.+VSY4@#HY(&"S2$4RE
M^?KE*9XHN4!Y"W]+N#[5R]@03A'FG1&GHE*$L)3O#$J"T1W=OF$PYR_+VK'.
MN2R&()4\41IVFTBD$"5#?F@LQX!=@3H]S'> VE*EGW4$;\P!7@;X&IL$OEZ_
MUHX(=MW'A+-R=U,F1XN8;5 _*'1F?#TD!U1F&VH;ZFM5Q8$V+^ODYZL5J0QG
M AZ" >>0+*NBUJ41[0 _PQTIFGU?LY*U&SQN:<V&IE^"6.\^NG+3M]$E;CM,
MN*'99\.W4W@:W6IRWY1(.S4:CQY[&[.%>=#C'=IGT2I6US2E.?IPK^E^$<BT
M)/P%V"@A+RB=1^SIZQCM48PO&W]LM0RWQ*^4[*J<GK9[ XEV=:*K/.:-IZ@Q
MG<?*]II9]2)8<[PSFBNM7DU2/XP7,O+9<-;:>^-TS8O>T9Q"JG90+"\;F_$K
M)/RN@H?H,SO2JM)E;C0RAOG.I&196Q0/E"",>\AC;;<J\0H^F7_TU5?/68/B
MV[9\:Z]&WZ8Z>Q%NI8A;ZNOLP5VQ>N6ST<9_V=0/;T:?#UQ6+%U_G/1G*]W7
M^6O&$""Q+%$]MBFYE!$="5_IP<F5.-GC3*]N0#?D#-SS8]?:.=APDK:H)5TL
MVV72A[<K(6KI/9.HQ->V5C/T>?SZ4XL8X!0W[T;LH8SKBX"(1<DWLRV$"38.
M<56I%L\-PX':*7^+ 3WX+X*/-ST'S$X5:K4:DSO6HJ8<E]:N33^O,5+LIZIZ
M5LJ6@)(^2NF8+IK>I&^3QIZ)XC_Q7=M(2-"5HM^G:8ST?[Q!2SL\5:EH>2$L
M;/S#A+;W>)2($70L=I0P!_&E:$9*$^U/<2%&8TI6_A0\5%[3]_=UZK\O$"G"
M7BT!A5XP"O0B4.YMPGU**>;B!.N@*+FC-_WG)%;/ V=/?]]2_Z4@-D=D8">5
M$(LCYH+$3$G'.Y)BEP;>ZXY^ZNC9&/?R?<J'ST4IN082!VI+#S7><SSG?88-
M'#!TU!^3GUJ;3DMTL@C6.P:QO7115]?P3Q^?$1PF,)M&[,&$&V?[0GT,^+C*
M$L:1P=1EF05O3CPLHNV$)0RZ&5Y-^&NM@ZZM-R2#%.HH_IDR*J=<<B'NBU-*
M+<'J/E&'1J=%+2;^.RMFM"1O'\$6'59(P6%9_W91T9-43'I?07W2]9NH:+^\
M\[V;Q44279)[$%U3RMX!>F?/DHL:P@KU8<+_B5IX )^=^(7O8[H'!ASE%\%\
MQ2A;AL?KSH2@?,:8;(+Z)DSEU!YICY?C$3@++^,3$\LWF1XG.O?)MML%9O *
M<[JYL-Y[R"O3UD&Z3,)?I5^G[GF]L3U[%*&Z^*F;-B+J8\(3JD^5"@9,H> &
MN_PB=8_4+WF$^F.46*,*0ZQX7S8?>BRRZG-U:X9.DF9#RE:OO2M9%E[-V@_
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MVFUA0&ZF>Z]FUS37-"V=21?QRU2''.61UERB\Z&;$35&/DJ7BG,@5,)\MY5
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M#5]V6_HF1U*)K#(Z:?NT;ZVN?)B^*UT?ZTF-7[<CY=K%RW9YHP76NH,FMUO
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MK/[XP')W%WE#6I,K[0\ALID5#_?WJ^=5-!L=YN-G[M5N$B;LF\7$./*[6SP
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M-%\?64W /JZ99[FJG;Q&<*ZV?.3?9 XM1>-AQ;K;O>VB#MTYD#JNI6J3L3G
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M\=!M<@M(B,.<7W_EO 4,KU6H3CD^*LUQH'<5ZVQ Q<^C"DYYLR8K4\T/L_.
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MKJFM:VUK[^CLZN[I'1T;GYB$3GV?7H0M+:^LKJUO;,(/#H^.3TX19\B??.$
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MG=QV'CH\/ R^D=(5;S-_N>%A-L)-??QVXP2-C9Z\A;2'*;O.LR^#-QRC]#%
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M#-7DMQ$&26J3F0"9R[*')9U=BPQ!EVEV-W<W E5K&%-;KJ,K"Q=+SVA1.AC
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M#VMS>V2CGC1.N@PHRS4(EF^@[>,+F6?T^@URQ3RUI9=FMAJ%6J8K)V+*E:,
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M I_Y'%ZX*@0V7N$39>"3%S>:-)G@%W[_F *;E^B!H'AE."EZ72#HG</;SP1
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MN'LT9M]FU<'VK)GIPV<H*%:@8E7J199]*/\6T.O'PRA@CXR"$59;+(+>911
M_/>%"5# NS*<6!A55BV]3&7+5O122'QP5Y:BUBON]P$+MFECV@X5J\_3-./D
MB%JN3$<+\YG:[<Z6P\XVN>1J'LZ3[92&3U@"(,XC\ (Z 2Z@OG.V!O=]BZ&^
MA #8L8 C?6/35!A8LQ\_O,MSZ3F%E;GZG$5P!$5"CBWEM:@ME2<U<0=<J[+U
M JH;B-#@&W+==3BZ#BGA-,R*T_>#CW<!\F>9Y:G+9NHNH5]XSARJD=\-:/F0
M=&IHF@#P'O0+-,>/6/LY98\I>=L(J9]]P;T,%6T+;=1X73)>.:!88X\4Y_AK
MLH[FV>(T=-S[I^FF56RQ7T!\]\$A M':Z+D]*3ZE!^7]I9C"0G;*\:_5R5&[
MS!G[IVM(C8?*!!C1"3+9"8F*NQM.#3,TV%W-?6#FSID6\EG9>X:C@E*>U=CW
M/_33 >^!HA_EVP*VCQK2&P_!D-HH_$V#B]]8<:HP[[4U3(#?BH(EUXD*5O.Q
MZV!LDV8,^,+$^#8B&(D53,_,,/296DQQ##@D $Z-$P"%)F^US!]G+'%P.7NW
M<'-_X_E'=F/NW"]9C2%_KPJ4P7*+Y:G\] NBA+*%0II YRI""@F 4MXK$6)>
MTP+8(M@F3A8L4 C9WFJ!C9=;J=?'XF_>$FCO(@#XWG@3 %!O+,ZAI.Y3^6#^
MDY+J4#6(T(:';"OZ9.09],6]01G*61%;:\\+DTZ9WT!06.BRTK[H:G^2JP?N
M+9Z]1.8X&NISHHP5<!^N^X-QJ8=.F*58AUUFD+"@,1A]Y>*CBV?%, :*QN9!
MTZ::09?9/IOE>%)O\S6QX(8G)9E;*Q;&/L.NK?:C2UHH#F];AW\N+]7"WI4X
M&Z#"L9,9W%C>GX@VJ9^6.NA7;\VUR.GS9^^5&\CN06HDA(T?N<1.WI$$/P6C
M#_S(GRS3RQA?#G% *+R81W0WHB=V6W<DD=QSO_AFJYA$N/PD.'\$H2\V_,O#
M/O[)8JU)6,7M\EKOW!4\^W;32WLOK?<)U$^;A919O4FWQ.37$N?Y:@1VI(X>
MR''%]7E":=J#^"]9CIY_Z%4@5J@SPJ3N";J*]<E#>VM]ZBN5"!GGMZ)*D*D7
MC#3,S2VXI2%_L&$:=7C4 L+,91, T^4"^!M5J3WMY9@D3T;)22(=%J,=6NNH
M>IU+\\QX-2^7T9J\< XV",GF5DVZ]*)M_N%!H?6VQFN!D!J&+#MOVJN-=$(
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M_W[D[OI7#%DBBID/H)HQ1O4RU0MN[%V8R*^G)"+(N24\4?-)O;#80@!4ZQ(
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MCIDG87NK_0Y")J5OQIY'/W1YS'I\YCAL%<]M6SZ2>'K51- '<N.&!)[]2<O
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M@7I;7:?95?6: ;Z,L".]#UI> 1ULV=39K1KD=GT*D!])8VPQ^O(_ZA+IZQ(
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M[YB;D 3&YUE,</[U%/?)6B4CJ7XEZJI;)7&]<*'))3=,.BX>Y(&39QP6W G
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M7I=V;;[MR7Q)9_?F)W&=0]!J:VA,[L/V,SPLTQ;$TJK ;<DDP,@ZC@$*(Z;
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M#A!;H_R'$'X2"XPMZJ+5U,?#X\0#BM-H/7_A= I)^?K*4TN0S6.68YC,R.1
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MB-H*[##&Z]R5Q%]S9EBV1PZ_. ?/O!Y[%%N3G8][RO$Q]Q@>[,SGSE=@$S(
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M3BR^_1DVZ/'>NKARQ1$LP8$'.52X-N^1Z%0MNIEV=K=@].DW6>B6L<7?>:-
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M4K!%X_&9YZ2P3+[R3Z(=3><^N'UJ"U=6 C 3 *H5/RKZ<N_A/X/QSVT'P/-
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M[92Y'[91@7_.HUWE@KXD%*?PK33 \T10$!F6/T?3>6"1)VS0>&SL46K1_)X
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MOSCT,0:5$AJ(9G1BO*!S3N;CJPA01>"=C,](*[=*+X53O]ZM 14;2"4\9Y%
M/SPY*; (;YU?S[77CM$\]UCN<]$6X)T_@U]*QW+[!8(KZK6Q\]!OX'Q]0U7R
M]_*@Y(",U-HNEOO1!&0?1O/6>]GKJ!TSNJENS)[LIHZ;=;?0('R^G=0#MP3J
MW9BK=VZ@7A6$;[C  K+SX#!T'2S\/67?^P_C3Y7YN0Q\**UI[W+V33$K%N,6
M/O[CAG1MDP)HT!):-Z&)C?/Y[>&$+L7'&O=-QTA7B(7\!^";-70D^CLF+)!*
M2N2#C<L\B1MLK7>#0D8'OD>01RWT=7SN*-TAS;"D7[NR<L.W'4[@&1M?Y#J.
M/@[?+/>ET3N6T"N$R8KA;XDS,O:K2<1/6&W>;.T&[+\;JVH9_RXS:CGE4KI^
M_N:@ 1@TYY^UWO!G8'@:)&]\K2# 1IN0F!3$B<_X+-XU<Q/ZCHZ[$]])]%<\
M)TQ"+)R8_#D0ZYX;KG9S2*VAM;,';="%28R=OKM!%;_E^VW8@$M)48NX.# 4
M63=*^DUXA+5>=P)1K/V[RMBRF? F2SZM-6[O>>;%HBXKOIS#[T8Z04%55%G[
M'<(GH?$0%S=HO;,Y_E;)5_8E(D^J<^C<(^C&LV%44FQ_QJD$R\X\=..H*YCP
M7*?CQ/G:"7GI$AF8U90U^+4;/KZR7'V@8JG& H\@N7O.8?8.9QP0_3(N *..
M^]5C 5#5'EX4IV*[75W6I\W,Q=GHC',@#>(^F!7A7GYU(3RG6=16W!3QL*,"
M"Z<H-9HZ2N=QN[#X@PR>-^8IPS)*0[.#S)?M<MI73>0W8^1?*Y9G>6_-UM _
MP;^3 J*\I?U&87JCRIN7966'=]6GYM+3<#.I*+50$8&F2XC>4YLA2^TCQ>HX
M)6*C*S[+<)$MG%R0.2/I+S-@9>N?D +>]T3SW@)Q3+'?99_I?&_<.Q-V9*CT
MRYU+I%W]K44UCW_(_!):&'@<H;*VAB>6#FFC&$14LN[GP64D;X"68-:5G=X2
MR'*P\1J 2A&XSW-CE]_7S;^9#M^Z&']D)S!>_0P5U8<B4*XH%RTE3HN.Q/)^
MNCHM@/_>Z\D8=1QEFLVZ,T]ZP;?;N)=7JI0CAT_3R>F &Y^\0VABJ^GONPTK
M/F[=PCU'\J/TAS1D7P,L9B3,F3]$/!5O--= E;X"]FW0-!&H'9A']NSF1'-V
MU#\#-C0O,<8;*]^E)R<?#5_K:SV 8W0@3#G35R/70Y=Y'ULGQ3X?KDM:T('#
MT@D4F-C$<=&R[-?-2I%>SP( *)9>0E&<;D18MYDX6."14_$5^2H;TKTOJF[C
M*>IZM_W_D$6QSF89-GJ(;*6YW2WL.+Q ^75;L#[*\1#TZ"F:/+Y\!(3^VPS.
M^P1T^Q>+#JSW7/F964F?'$JA7]2U3IRI=5V>1G2%GLT>A1:N4JAM=')<S6C0
M4#9N"^;QRXZ0#&RCLW#+D#&T)3L"1OW)5+69HDGQB\VS%C^M5=W+3[ 05*XZ
M*)I1U'!"/!RT8A/J7RK:8I@X/[RRE"*G56CKZ'#/:2M,S=!-4'6SD^_;IY>S
M&9!NS$Z%#GG]BCJ] :6_A:,NYUU:0(3;QBD;D]J&_F[<]/]4>ASQL4G.F)'F
MZU1])O_*>)+V2BB'5N^]4U:%@<U;I)\N:[TGS,Z,U 2ND#*CICZF;\9)W%XP
M]\0W$>6CF3Y(V@Q"[:VDK.X=C9U_PTT?)#0IX>-7=$QVZ6. !=EE"F4I9?:\
M[S+2(<^.\AFTV:)J(/0N!.<&NOEX,D;>S+Z)\,VJ-"]A@&413X8Q\#S^KIS<
M-M>A8)S4A>L LS#\%N8UX+%G_]+5U.D*9;!.@?+<<=3\71K1Q)DF9SL=7<Y!
M/H$85 .:\62L))M)]U&0MIV:J8/.P(W9'_YWD[H4M2>;S:T.NB844:6RJO/-
M>C;Q58PB^S!FCZ:,UI^2<76J%ZM0/$7T%V!Y\O%H.D_+&SGJV_347$8OR5IK
M<"M)N=HAM''?PJ7F)$Y',1VSS?EJK 6ONINL@M3X75IW%^V$M$U''U4EH(E%
MML0F)?$8]\'TUHYCR.N25G(61G#O\PSC/DOU^OZQ$7X,]LOZ]8V)>=+CXE$)
M4_P)T[R-":NYP.8+ZRE%F;&"]9-+M83J;=<;%7II2#XUZ:8;9V_.=%!=E=?,
MT/[5L!W@@%J+8HHLZ#X?#5W/>H87E5-NS0WI)Y)+S[7DUVO7.M(7PU-+OXT'
M>IJOX5('EI88X+0D=6=';5L*M$<.<1UW'WXFT#-:GL,>PUA;(+$[@7AQ]RGB
MQNA<'2W(K;F0V>T-/@1S 3&9K65E;O:HEV+OVVGW04.QAR2C]V+X(\RGBAG*
MVU*'\WU^5 'Z"8K_QM.4]SL>66Z^!F NUW. _4\1\OLFOZI#_'[2<#X,A! ^
MK#_?AD1]UT&^!WJQ7(V7$/JSI[^2A>%K-?="B^Z\K*X\L _R)#]7DQ^#]V[A
ME&T6'0@4 HE?&_)>;GA"EV%^JL;.CVJ)X7P]&.W4M9^JV2"9[U]47@.B-5J$
M24(5!YF/& 0J8["$%D+R0 PP<H:.I)+$O"Y?Q1S[5G'7H^&$;7\W6$4.VI..
M6M++<Y!BVL:>!> Y%TWEX>8U0'X7)A-H9C5K9BJR5ZY@"1T^Y"UM/4AE.CZ;
M:U4YOT%R+IP,H$Z3];Z3G".=^H)K@.OZ,QB3D2OCFE#H^67(>O$AY.@\YLJ#
M>Q__4^III-.$Y?'7U1**:\ .)%AW, LZ<Z'FJLUD:==4/@OL\V./IE99%UV#
M79:NVW7B*$7$TU:_.>*T8J&&>V=^:A!/HXV=<Y25\S#94\1_]VJ>H57)0[Z6
M)#-'J,@A&]I 94OV/$<H:[I*%N>YCB#*@=?H2V$4BK<STS7GP[DFCH+!Y(]A
M,Y"-U+,$E;5&-!QS98W:L*T'+V2YGC E<PYBRQM1O+VT-( "IU.>X5'E#*I)
M'C"J1&GP2JW_GKV21SA@P;!VS* ?;GM 3!1$TE4>J%46.Z]:!G_D//VE<O8"
MQ.Q6EH?C6,W=?VPRE')1:0$_..##8.2W?RKBYZCZ(?3CXUF2B.K(JLJNX82;
M:95)79!ULQ?G]9[/7@/.T=->WFS=JDE7-O(WAII36AZJSW;_ZT*9*)?&.W5*
M-N+VB1^JK')1"**#C5T*<&F8#!I\ ,0];J"DHU@]C9F,.F>^JZ"KD"GK4U(5
M13$W-*KOB7.Z%PC1$^&C]OKP[-*?85[,/Y-.%,TI]]&^O_63N<R[ ;(UA;N(
M[ F$]N4UX-G6'U-7UNE;T#=Z0#QV9H(8%K:I\K#N\9B!K-">9+@>,^4K2Z5>
MM0OC+_Z;H"=&#ZI>?($Q D,2*?(M[*MB:@M35QVDX=S8JCC?]Y!-WH:T!&,7
M6G5MV@Q)-1H>(3@=7FS5Y\&22F^NJ'QM#EF6C =$26Z>JUB4NE$I^J@9>/G6
MUO<=@%ZYWC8>+O@W$SWKK2^O?>8.@OYT'2SP(H-"+6;RNP\A#9!ME77!6=*]
M5!,G,2D:X1G%B9<>)TNOGT>?TS6Y7LB586Q7Y3&K!7EJ\V3?&0M+K=LOY?@:
M\/2*Q,7)\,IB@;=7OJ.@7[O4YLB\N[WG9'BU6NM0_(BQ05%*?.3@H.+&(!BQ
M]_V1E&:Z?J[MEI$2-&>L:PAYOG8(PP#RE2ZH83\ O<R64XCXX"R1M'923O(H
M]>NP%]KKHL2%R\.";7J_=;Q$P8(0=E+\T'ERTJV^N(^$5P_1J"!$A^<CK/Y'
M;_6%QU:L#\UQE"_11M<V=+$ITHO7KP$@V*Y@TM'IU4J>&B:A_(3R:?3JJ@-/
MWU?'#\J(*'IK-ZN2 K',%#\FP78R5J,3X3GU[@)RH?'UZ4D3YXJP;4$\T\*1
MG#5-V99"&R,G_3NOVQ\O1JX*RCXV7-I<\&O(ZS[:NO($?"Y:=LSCES@@-M1W
MADV7$- ^^&1L-;,R4.U.2L1Q88N%Z<67N.DA*P4&XZ=C8MW!)TS&9W;CP:KB
M,>YF-CF!+%U9V!D4V>5OED)7\>40+F+!'<3*SA\:2?WLWX* ?& TV433:"UP
MSXH]^28[A&^S(+=B/%;SQ.F*N%?JJ_1!?1M'P!RBHU2>D]O5@FN;N <H7F+0
MQ]%F+&58UIB&JKS,C>*PHZG*8S8<A&=!EV4*Z<<N>1LUY^%^,QXZJ**_\FTW
MD%6&Q;JCFO.=N*N_X6,9+)R-LK#G/Q27EG?8.B&=FWNL(NM@-OZ;AR&Z.)_3
M^,-7\#%_$SC%N49=T7LC=AC&H.HK24]HQ]B@$)5^8P.^-L%__L-IX?DS]>ES
M,^36]W2>M$OU\]3AG^X6%3C^;^U\(;P7=8]N>"C2T$7ST)C3.;[0S6\%J-$M
MIQF=CWQBG'JA),SMCDJD74@,:Z>1,GQ,#4Q9SV>_"T)T?;X&))%:7QS6SVE7
MQ#I::(CFF1W52T#ZIH/6&C5TSQ&,3=$G3B=:=;U\,N6D95RVL;&I?N/3$\[A
M*(I6&T6W5FXL=1?[_8N+,V*9:,3V5S$\U8C_;$9P@<DUX$5)G)8?BC)&)RG_
M:\&OAYR#OT7.,3DRJ+Q3&3[2^S3HE\,@55%M=H-/"58:N-$CK6W)WO:W#%Y9
M<FXZZG &OE\))-=EMSV#'I( 0PJD_*T.)P(1];">]R:J:I%2:7[E>T)IJ,A5
M+^NW"H4_PMRM";6$;C?=%_=0V:8<*&/AF #6G!WW5PHW!U%VV6L0"MTOC7PT
M;4XMY+],N7 ^HJ?VO;,:<WIJK@$WZO.3YP0::"$4N'\-\$:(P\KR#)V][PX9
M)<W1H^USZOUR5\17[I:E8+_4?Z1W3'IS)&..I\" T.!EOO2%4V1_JZXP8RY1
MC=C+EP]UDX"CNG$0'3$E7X;^#SER%^3,-X!B;OF?9Z[^;R'0DWE!:S-+3)/%
M/6#(S&;HAO:W?!6VH2FIFUZ/4TAA'%P,D&_BFQF?'-?BWL:[[!(.NC%E[-3<
MWB#8AD/B+#9C7Z.0=OKN(!HNXB&)J_U3&[&IJVX:$T"LR4DG'Z&;U7AV[A8=
MG*YIIFFD1J"X!7W2+JA1773"V1JC;_KX"O)@3]C72><:T+FSZ6 (;)98+_7$
MWQ-"Z*V<$#!M;FTRS9?" PQ\Z##>UP)R5E-KU7;R>)S^F1.')M%E*\4U UR4
MW$EFBM^[3C*2)#CU+GS22CV#:<40"\L#F&:,E:%^"T=!3.)8"W(V1WBU"XQY
M( U7[42-&'28[KGJKR4>?%L3:3V*0+J;F&6>34A0XNK[I'J)AO@<6OY2,BV4
MGT:U5R<-[WPZ-C:T;OBR/M-82.NB^O;W$F9D_>BS+H'%:"A6SWV$HCY,DWEW
M1-?5&60QODR>O;#5XE#CM#G,K>[6'L#/DI]S>JQAGF>PV6EOSS(7)/MH5BA>
M=9PA+TN.8Z$3W^AEYO(.52J4L?WGPXDK=*AZ4>V*[LB( >PT>_VZW M>JQ0[
MFODK'AZ=@X2*N_8"C4T8]1ZB.:WIQJF[B7VXF[-.*,YF+..G*O1VO,Z9]$.+
M:MJF'BO7-6!7N.WH\^D9H_4X<$+?@1SW-<V#GN0IMO--BB3-B53H"8."+X9%
M F>JP#C<6$W.;O*/MPK_"'>U50U8%]!^"-88>(Q^-1,3AK0U$F>9-CU>2F71
MT]<BL7V9?PO-"EXB9N<A'<HM5'X-P*OOFMG@Y'5U*$^],8UN,&C^E_]TL;'(
M/9;@I>CZ<KT/2=/9FY!:'6,:!F/&+_@T*!1'G4$-S_&E!F/:CTU.W?;3A,SB
MN?Q3N3(1K[/ Q61DCH:KP'(HPVR 0< MZJ#;Y'G<H@IEH]+) )9T /844*UR
MOX:9CT,E%>Y>H@UV'<H>'/O^FB&\Y1]&4O[?;R%_FT;\*U\5#F21/R.AO@84
M*E\#4D!<P!LU'.!I,N0<D_:;Y_5GV;H\C9O3VCK-;_A35!;I84&:*;M)%?YR
MZ_Y[:MB3"$C;G8+E:$E9%Q:::EGR\WP$RCY<R9D30:9-C*K61@MZ2ME,"9!A
MY9HVWO1L4'L'1E0DWZV_>YISE+=QQ:HP2#MPY$X>S)G74>P3PEX04L,V&VJH
M0V?S!'&PL+B%-AG8"(U!<9BT8D^^6!#V=1X"*(J!S%>P1> F@%UG;+-;S?B@
M+4+*@]69DV_95CM6*:6Q+TK!'>^"RBR,Z8@JA=Y"E\VID]YSINCCEGO7#VC;
M2>SBZ,%<EY::ATYLS6,M7,>#VQM"^D.VI[U4$YXM[T6E^TU;=E8F63 ^!'=Y
MV/:!%.=8<3J3M:1L[5^;#K.X5L39+%SY'B(?71;-SZ[6-!2.[&&>6,Z%0D[)
M+S;=>*"!F#AY_9X74S=&\]N)LN5"OQI^\%PMF]:S-^V3.Q7Q5VMZHVNKPN='
M):J>_;;7 *'@:X '5.A7\\28GM[)-8 V/U!%5:]4&]*;!IDQ"/W1".O\>_]Z
M,2O^ VX N)CJA5CKY3GWU3'#S\:MX5]]EO:CD8SY%^O_$&LUW5!$O=*-'LE$
M/(-YI"X@/$@1%_AQ&;+LW=G@<I/NS@<'V-AH^-V@TR$$)!PN/->[=!;WX>^P
MJGHI\[^I7_YB_?_&NJ=NT/<2X5!V@C'Q;(X. &'L2<\BFL;8&6G^*E;O.O9@
M56^=Y1JPL2Z_HAG5'7P+=P"SZ!H ]C]5:U+JQI,B&>>]DR*N;0IMO)/;@(%/
M8^DZ<\A1,/?87G0:(=;!6#C.(KS27[]3)/&CH6-R._?O_"U"D)U;;U9Q YK$
MKP%US92_F@#-U-RK/R<SWH]9C8=D <T[#@P].[2^V%3\T5#X3[/^&:R7\UN/
MM%3#1[:CU6,ADY+R[44N%)\*7FMG;,8;$DS(FEL/IUF@VV>.JW'_JHJ13ZH.
M;S,.[$[J\F7#0%$,7XL=^C$NC*NR'4*'VN#IF32C86A0J?GY/Q3FM<G__8/F
M_6Y)J!;^&/$27?/Z.9J NIZ)NB[QJ<;,;7AWP*^@M;\[2H_H_L$=?E1*'*[_
MR=TDUG >4XUKD^C9J4YC[+\OFVCW=^0'207\@\?ZW8D!__&_FE4H1^?Q5=GF
M6$U8TD<;E_F_L6.X&?Y!CSI\C/Z73*K_=JSEI)9-D6"?1 42&J& HO\&]>3_
M0Z2A2[5[Y!_@,&?L28=$JY$238PAA15XHD/DH-]MT2]"E$BQ"P_U:QZ<Z'1T
M=';ZNFW-^HB]FP45C^ 0V0L 4)OZQ>K6;0PV *6TYG]M 1,,T+@1:#N8MN2A
MHO=2W7BV +=9Y81@7WM[4ZW\DA8>2&#W SV+N1@7F.2(&D:80H9[ATKR0]$=
MP.T0J?.A#XI:Z1'%[%;;?[CV_^7&\F]$5>VC]1[+5IL#)\PYNSV_)$6'N&E%
M+:X;LY3K:[R;(ZP*F%A D@!RG=FQW#?Y#.,!2NR+60+-8:G&L6O;1/%^^D'N
MJK$,L)3;=_;3>/^MZ+<*U?]Q<3KX[U FMG OY_)&I9A!L"$TO]YS_47_.^FO
M2?,7_35I_J*_)LU?]-^0?ILT(&NKNE8KXWVCF#"N%G9+5%G5&36?3?.3.)K@
ML%#6"%D;0^"@/Y/1414$F*#NIARU&!T-"1]45&5BK9L,F3&-)<\BBK*1U2IH
MDWL*_>#$NT1(:(*G**;QR./DN#"Q7O^".ZH\B9NW1_X:H%D"@W%.R/-W7E#N
M&)MKT1X)6J:D5C+JXZWT+ '/XUKO+5#HJI[<#81\2#01Z$YSXC.MY8,"<X T
MJ#<,V?[5MN7_)[181ZVQ7G(JA]AX.6KED%D"CW6^X'ML7I8YRTT!RE*E.M"L
M.O8:7QD[WN KBUO<O@:$O9D7?LIS,:8<;QB:4^#>,MX3.1>*K+LZ[@=[.J5M
M7HZK!>\QBG;Z)D$'(FY'A@/ +A3+[C-(JX0@92G.IO$W.+3%3TR<&-!I$S/+
M-P).=0K7W+)\'.(P@?#H]8:&:?[LLL]/RKI>+;KEK*WIP %XC1PB848B$N"&
M)$52,^) HK (.SD&I#>G]2NYD)EGH4*L9^M))WV95Q$S")>L)8DQYFO "M13
M!;#SYY&TWD"$6];5X>-ZH_)K0.+C,\5C&<C9?%(4@/_/(PP'\S<';N:C!X;U
MC\L]_HV="/:O8P)_WC+NS^LI_^2G@%SSES!_"?.7,'\)\Y<P?PGSES!_"?.7
M,'\)\T^%>?RB_SX@'%WP+8;ICZOSP+<^&P<@D=_!0V+^EP>^_9^0BI+V5[RB
M9MK^](B53G$;S"LT-T#TS[?^/OO[,_+%B?O;1G[C*.PR-/&W%=BETHOJX$/Y
M^K7%B;Q;62)[G<0=Q8GS7DP_OWNBNE,(<Y@@+K0V#<$TNU<3T6:3FU:96T50
MP#GUB%GL]3;8X&/D?>ULD%%OQVF/B+X/TM=E+X[L'W%0^;7639H@_U=0':6-
M]@=";>&&YA3B&[XO;H?.\J0]WZ,(G]<2KQI@3:L*)C7<NJU!VA_E92S4A $8
M^HE5\RQ(?#.C] 6OKIJ<CC\_=#4.FV7 CYR;(5Y-9(A=OLLU+U^JY67DXZ+[
M^%9B,-R+EE(3,//SXDJ]^RX'<KO;><:9I4I3VMT<,C8/+\K")>=0BI/F2#\"
M^&+7LW_!XNP)2S[P<HYSIM9T(]W11V7;6^7=1/KAX:#?SBE*WF/.6 G([-N<
MCUV6,3O1F11'B[)J)34T3*H3ET.5;.4L^7,L5,GU- 8/R04+X?P9Y>5*A+8H
MT89]C%XR#U:1.)#<H"U]-1HII^$KH=+U&IEOKUZSDHI1NW^P(<)YH];]9^"6
MQGE/>=8I1-;]2FY6U"J=@8>IJ]4K-RW:\!NV&?(S:.ON#I0C"6]<QC:CIW>Q
MS2"6E\9L,:"66/T6T.!/@)EO?=\E8K"1SZ:B0HJ^(JJF6HN'T*&<G>)]X.3%
M,1Y2B9BI&4D-WS7 __!*]_88^5+5RWOQ'R;959(47"Z!XG\RR>5VZXG3SQXS
M/P%];G1U4]=ZMN7WH9">\F,RYM#/(#/U\=$ ,(?[!"D.HV7MLW.1S^,WHP),
MBGT> 1 CBY DST8V^3D/@9^&A*A.M:2'C(IJAR,>I]J2P1;;^EM:3S5%,O N
M[C,@9Z;&AD2T%(NOKWYA+X[WP7EVE^]/60IT1^<)_:P=C_J3AS"UV[;PY)=X
MH""]FIQ'7$44+5Y\T!^XFK'VZ*@@SI!S:W/O*_@6880&-KZ*,V?@'"NAZ/PW
MUB6_GOF^\4E779V.+>=GT+5'TU^CO %]:&(_77@/'ZJ4W ,0TQ[G:LH595E6
MN>FM.8?KC%<RT@44LV/?^>W1U3SA,'47B'2<XI#)/FQAP3O:21!?0JEI%Y!3
MNI'#6CIAF0-^5!)AU@BO.9TAIDE[%1X+@/^\C^+P48*PZ.#XA7*5EKOC0^=[
M4B:"M[)1BH2\'JARL!*8>=*Z+@P4CI@G7P.T,%OZ)1.7R%"19[X/W0\.1I8(
MNH'+IY9XYQ\V_4S'L!3%!Z2 AK2,#+2S=AZ,8!R=P3<2&6(YYB!J=PUTI,\J
M>=BYHHNXJV;(XO_V":R_UU$<2 ;0E3=T\ZL"6K<O/X]-:I)JA0([*W4*5A5U
M:">^L7^F(EG]L2C^KE9)1E_-/>8>J8H*XBY3;A4L7:7@->154YY4_2U&,A],
MTU06NYT! 6<U<Y2-O*2Q[$.+V#^HO+?"! H*>]+S5(OCST\O@>KKX8-,)K5U
M%2'3(_BLM,5DM_&^2WBH1^KBW$38;9AE\7![V/GLP7-:=OPC3.H<_>VG.K?_
MG)FJ\+O/!J4_)R(0\_SNZO=JBMML\#  )6*O7)Q;W.BACRK?RE9$;A',$E,E
M$D)%LM+ K]#11LI7_WRZWA%X'@[.FK(%7]"T:LT;&_:>UM3L=?5$ !Y2BIC!
M*:@)..^!SOG0G#D^\?7G3DON\S8=LA2U0P%3BB/X3T4@KS'H8%P.ECXF5:W\
M].I=QS><AZMI^[\OG_]AI$P;RQ!D((6+%5R$S$8:AS+K%H]\IB:;".<9,BD9
MH2H;G-;*"I15=B@X"<_UT68UW!J"L&'&N+5\RIH2!;OG:$QH:Y,]QQO,%?"_
M"I.3G],5S--X7G!:J+.[G6%H\4;,V6U -'LZ"%-6@/',&IWV_D+8K87E=JNH
M+$M]P^S30?4!H8=K9:RY%M# +&TFTXYH%&VP;SL=&5F1]MO(&>BW@1I<CBTN
M[_ENH5'M 28O,*M2!57/O;TEX3<%:%T\-)1>:%)SP0:CBB'K+2TR@=5@YHC!
MBV<@;!9MABD_!#4.ROER^3HF$*C#U0'D![K ME)TBIKO^ZI2?%$Y_.,[8,_5
M^S>/MEATN!7$(T:4,E^ @#5 U'';;PLHSL0%)"MR5:?ZSK:Y:[A2]G.\ZNT>
MF2WL(_0U?:';SD9;0[:# T!NK;[-FN=95V\5[@OFA.LL2&$$<,5OO794GG1.
MOO.&=QX(>:#>#C&VMHO6-9=Q79;U61*AK!%QG8CW#GL*_9:92JN8;YN:RH"1
MFP9 ZD.2^T.K8E$2N9BP$KAXRG*NN+NJO4B<-B;&[?!GE#[43[S1'0(DRX2-
MB<"]N^_.0]\[7NS@S#S#F)A8*Y<N6X-#1MI'74PZ7X7[?MF(/=1L&;U\DG7Z
MB2I0R3VS['W$2+^V@&UWO"UU#FDK.4[.43)&W:V1G3=BLQY U2'%^]LNO9\^
MZZOGX4\*?@3,!#LX?%L((8I@"%?B4,B%LN%A>V$W)/RQ#LBLH0Y7!H--YWI0
MCD#<G#@95S +DW,N;W!'V6FG;04^,7DK?H>%6E59>%[K'JJ6T\".U1&F)??
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MGW!1C7Q.^_QJ:JV..*<E:GGM[+?BI&DJ.6@K#7W\WF#L:GWQZ_JREI+%I/)
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MYKU$;:A;1]&P60](XR@!@F[HR'B8=:!EOU?QHR01#V\T'>#U1% 8S]?"E_E
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M[7=K-61!1\W6??_R-+#_-.&'%KB$#(IR]<O<'1Z>&L2U-C<G_,14<=&$Y05
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MA21G(0?9N+T,AE%&Y!+Y0BO8?*7+C[;3J,:I$=A)Y^.?8A=EG(P]C;#+1@&
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MUCO __LVXC2#O9#\R" H;V,1,<IE:?P&/R5-,N/)'>"OG9<D0F*C_G<KC@5
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M"U@:Q0A&D?T]Z? (\P>EX%%(6?KO*A][/=%QV+C+#::[N>[LDV;FZJRLAO;
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MC6ZXH=R4+UPE]2U<*+P&4L'>O7J/WK[->,KOM?1E\Z)1K@B&$KXWJR/XVQT
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ME3#<:$.M^'^Q]]9A475MW_ @*"(M):T"TJ)TCTBK.'2'BDB,,-(EC*"$I("
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M1D.#LG;L5>OHH\H%I!;&.8_TKV9W,X<LZVF#."=K#VFQQH+PVA$9Z6"S!V)
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M8B/=Y!8!I_322O6%3@XL K>]CIX2%PKGK9*;X#K* WQ.TZNW@\E'A![%^G8
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MHT4Z+HO5Q)IU\4OQ4%QVT%9FR4N#&4*R<FT]Y(IJO[_$U.R0SNBAO/8S2K%
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MADW/UU_W!+I;3WND(V5G+F@;QXI#D2:KSAM1-5,:R%/2\BC"45&/')%YC:]
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MR R%[WF];YJ8'[[5:*DUUOH=ZF!KASP\=V.?[E9PRI_80O%.07Q9%KFL/?T
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M/7/NAYGY4%_[]W35KEUK5ZVU]E##UN&38X4"8=):ZW<:#H,II2WSUY_G7X&
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MXAB]9UI')E^H3)ZY&6,NOPOG>L?S(F@B[7T/;V='!QTWL(%D'M+?O81$!*?
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MMG@%>;952PK>!F'*\F;AC;_E@=YNN:J,)S/TZ39WXN%K_ ^ .*H>NFN<Q@?
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M&OE#HRO ,VXIJMOLBH2D=D0O^<>J].UF*JGB,H;EOQGD"G(!2,:01])-"*E
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M;M5[=>I]6!][K>[^S3FFK#G'V-RF]Q+'H,N]M9=83P=FG'K2%=_IP@+SW+/
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M*1*=,VX2)T&I>C*N<Y;(V)0BZ!)H L_)&[YUVG?U.Y?#QY2<P\S&-0PD:GO
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M#DYVV;!#Z3)IZK:Y*6XN-]KS)R3XFFT*[Y.K9++&_I5S$1SXM\:K)C&-'[]
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MX84F71GY^FG'H3+!/1=A!VPQ\BL*7,O0(.KE(44IC7,TTC$HAM^13Z75Q9"
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MLJH-+LTE1]ECZ _*\-PYPYU;V:^KT\+MK= 8L4"KUC4EQMK%=QD:1?^TD5R
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M5R;)"^3CG0_AW9&I%V.B4F*5C3U.O OT,;."%.9-3(4+6CU>1?J9PPFWCJ1
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M)IH45ICQ%.1KY^-3M3MX/M@UC&1="X[OT43N067O9))*R^[ZU]Z]%.7Y"^3
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MXZF-$D(:22@Y7ZAB*LI(8DMNH5S4=.HV,.ZO6]92G]F7/BD\!3"/>SF7J@>
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M2PV(,R:012GM_E22JAK#0.:9KF5D'H! =6&4:*I:\[ELI20S>@0$.B M3A,
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M76Y<"D5Y)K::X#+9^[Q9)$D?B&<J./:1,Y:N41KO4=Y_29*[(LR>!+J(X&I
MCLZ!KTY4&]^P'GVQ,#3O?X&UZI'F5Z0%"ARXZOQX<&I;51%#(\:GI1HRFX(O
M0'EQS!((NR_WE%M] .!:Q&-I*.,K8[2)N8B2M;[2%(L0AWF+?\T".;X/7#8K
M3X/1QBPO.9R^^HP!<640QOW(&,YN<A.ISNI2(]V ,(#NV7+,[P]^UC6'D _=
MI9Q%UH_NZ4,(NIUMJ;KPW_P8R!P?V^2,_B%>)IC>*V8^D3U)LW82$I#RXQ>6
MI/)+";QPI+U0"%R-. >XBLFBKSJ_O@RB?J]U3&MBEQQ"R<>_$V5)3QC700!<
M<,R$43=;K44\V=%JEDM;7C&]"!!WK/<+1WZWW]GLZ)[>;8NS5\O90]O:Y$=R
MNMU87;N"JKAK2"L6:.']GRJ_Q?1QU3X8$97BY!U.JO+,JR:=,=[9*3O3/S]9
M)S\5<.1N?)(#8WE7(:M8-G^A31]B=EJ]*SS]7MAOT;=5PO%(YYX<)IJXWLQ^
M*ZD0E\31347ETF0MQ($H2H8+6-FB=^KSFF>^CU_+L4C51.N+@^![K +$GHW
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M4R1/.==[= ^NY3>9K5DX>[ 4@ 7RWL[V/Z7 B_L9\0#@6"5&_4Q]45L"+U.
M7N;D:>^K<HO9:"<R\./UO/HX7!<;_0/4)L#3YRG] (CY!KV];_WZ>"IFYK?\
M3<9$"%';:OV5DK1=F[!K\2]I@7W]CEC=_?C+V)K9LMQJ)I1;/R5[N*99_KZ&
MNT8J;Z:7W8_YCL8TZ5WTBU*Q=00>7\?=QY^J7\QU1$7WSE1 B*<T$2:@^X$K
M5;A0K@*R<,>RD%7RKYFB+MKKUE?B"";&'HT:?X>?-FDY"ZWA[JRI3:ZJYBTO
M;BGSGB]1\&CE/ "<$WNLBJ$[P;2PUZGTFSK>F28%3&&#+=^E=P"4WV)[AV=F
M9_ V?$A!9KIP#]; 1$>THZD;.HUX#M^)HDUC1@$]CXT\HI5=C1EB YI)H,V"
MUQ!OA0R+>]V[IXCV'+J?+N52M2P&FPVY!5^S+"8MR2,Z%N8ED&*D4;_%?FO;
M/)6R-_L;9J[WJZGJ9H+W=2W3S[Q"A6TT%&]'0$@>*3/HZ_H>76DOH*;%XR!%
M('="9?30?$"?]C-4UKKW62_"34PNNI^'>F2.*%J/='91<TQZ"A@9^3A5#9MY
M,4M17JYID]@-5.%W;M$RT(JPN,OADZ9IDS*_BC<5 5 INGFG9XF%M !TYXR'
MZHC#H>XG$?T?11M=[KF'U;I/#3PQ_4Y?LWKYX.^UH9QQ9Q_Z= 48PT,]4TD\
M,.>=O4I=YFG"N8<=.Y77T0BT]_KTR-B1\S#;;9YN"- $?&;_]U(+0PBI1SSW
MW:,]#0_:(<4]769/KM=M4^\VL%J9?ZS]ZX>(O:[CWWIGB]M^T5LZ<FQLFBJQ
M/F>),+-/&J$P;5C"(6U@CK]V:^^C=-0#]W:+/&$JSJCU_]A<UQ#(U)2L)5G-
M\@+-LT,+8-<IG&):T23P&.N@-)_ 4ZREK#M^'3!BH> YRM>]M($[E+ CG16,
MZ@5=FJ D3^A[8JOFB='7HF9"P62BO@ T-JWLA6--[NP)_0ALUW6<L$Q+Q5S.
M98-]QL:TZ9[%@7T,5+.,72]+6RS0BBQ,KY;XTM#<[W0EL83M+_^F2?Y^*B]<
MF@@5",*,J#:8S2D*=]?A@+P#C<] 3BLK:DR.Z>1HV$%#=7]GHR65K<38RMC9
M/K=EMR3G#.7%BE\OE?='_L/? :AC*?,>J5?!"+,<D"6(U49J>/BBEV-NKGM[
M: /"OG:@-POOS*'8>R,3U"1KLTX6@UO!_LM_R773F295K:&A!CK:<Q"AH!]M
M5 6Q1G7A4X516C>BL!W[9^[<91ZH=GM8K1N&3Y/<$(;96^7.R5%=+ KW;/FC
M*2Y1H/KW^,A;OJTIRDC97(XJ6  %=35H!IR?U.S7OB+MGP]]LA/=3"2CIN6N
MW#5,H 99G<RMA3@-AL6&V>?KNDD8W_?WTZ2Q1,)$*\<1EB&EW!YW.JQL?3S-
M)2G45BPU3W^492S-0%@9(A$R/NNCV."(6C]/1>Q#A^SIR?XO;=+[G0RTT:?'
MA,Q6"A?H*DL+F8=Q':"Q!X UO+-3E%1X08[%<)G=5#9013F?-7VB48&)/KYG
M60Y2/(I?54#Z,GC3N):G*_-,5)C_AT_A(QHYOO49-+I__9NBQD(D1DA1XI**
M3[&AI8X_</YUW.@M,Z=/'"CJN\Z))$PLR%/%_9"D&U]/RC&VHTKNUP. JQ8Z
M[&)(YFSQ!D&9I%_NVC#%H$5$JU<A?L:+[AWZ]G[*P8 +1I]6L*K@Q=S9F48+
M3E8\S0:G>3P/H8E_&R-)B5V/L-=1"ZLMB--FLY6<0I@] %[Q!8L=4C@^ 'XG
M-1VTM6()LY;"&3Y RHJWK>HW3%UU@PPD.79QA)X=VEXXS=SC69(7&M\Q2*?.
MXJ[9,M7BMFUZ$[7!'0[6B1.@ PLJ$[K2"1_\T&/X0V5G*"0I81'9D<H&?L&O
MLTR.\K?7-Y,UQQZ#[Q)<:#T*\4K%DH0O2>HHL<%/*&AY^I#/#C>O;^77S0Q/
MZ7)_)L(.X@R=K:VNKPK<-+O75@!HV':BP%XUK 3J2.PGPGHR"U.5/[6$#8X,
MAUFC8_FZPV8B1>L%7'48821=-,'N*H#F[H"Z*)$4Z0#<NW,T5:O$E9KLZD7U
MQEUWFC P&+H3P,/Z*;H%0SD>UU6,.>IV-_0LW8]7=6\^/935[(V9N/G710?)
MN!_E8A*R^9,:/A1[WAC0\T1VNEQ]1=EV3-O3'RLG>-?K-=Z4#X#^=W#_!X!A
MA<^NVJ>%>&P?W4C$I/+-[!P\JT@N%T1^3.%Y5_;Q:\4W&=4).Q_8TE0(=!YE
MS9;0ZAXK>I#.0/^H@.&$A3FH=Z/:^TG5_0NK\?20!NSD.4-#G=V-H]KG<Y+;
MK;^\=\BH.(+$CC1<P!M"KO"PM16\SFPK<B=SQ;C-A,L656X;4#OJ9L20#Y+2
M6\^:8_R8G5;CL18ZR\D]48QF*PFII7%=60X[5UD7V$E$+[0D@DLJ3!XZW!)A
M12M1ON"&^<:3@[_=_B0EO<1AA4#IVI,6$ZN;(9BU]MZL==VJN3@M6KI(FZMG
M4CSV'7QKK6]KJNR"(6W9[4-MI>W7N\4LE#%[@WZ#_UTS@D&"4E9S^H^"(GVV
M34T\[LO*CLHFQ5=$^ S+$M*<(MUNR.:<YC2430*4#>#[[+.%4:;X2\7#UL:?
MG]UQ6.98AGD>\UUV;X('0!E3Z_G3_-PK@P_JQ*/#U%'";Q<7^E'[J)D^917L
M#DACE+*OI9SJ[B6E!YFYN'$K[+%&_SK]PL#H\^8>H&FOAQO0Z@HS['TK+>8D
ME5Q[NZSY -";B*PP+["@&[FIN[-:5PK*LBS+R=:<CT/X'+R8S#C3$2M[8;8
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M_4EGAZ%3B'V#Y>YB[Y=G1HA542R8:2?V,1F*NPXU\.1_6B-1D[*=U3C'F;]
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M+E?]L\_"1\\CHBPY'<TJ4JS!TDRKSO)=D&%[<Z"0D[E5=<0S!MKN/6_V5#D
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MH>)4MGO\6MCAF,J,+ZR.XV AG!\]NS;A@6X:#5B'*9T=HV*06515;V:7  #
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MF=:E[(]]F.4(3/)2!M[0&TR5\]BPX]]/4+&;M6<0"Q]JJIM\QU_L5-OS[N,
M!D\L7X66F#1)-$,\[I61*IW-FP0U>,6% ME&LV<7O';BZ (<;\+6H&R%#?V7
MF8GN-:(9-^\\,.MA&H?WJ#TF-&19.G!@)!74F<RSK]\F!DG.K$%;>>D4PD(-
M-_)6:S1U)XY&3*S,-;7KVXR'> 1>F]Q&5TK@1>=? ^[8A7=LF$Y< PX(!7%<
M#1O%7KQ<BG8VCL6SA="4>G'D9E;B,SIEL\S,6YUKR=B?[KF;0%W<N+1!5-MH
MT#@$\6/L8F;$\L;P)9I>:-?\Y,>-E9B 4#UPB317BL$FY@-%^HI%[#-9_FN
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M;W->OMM(+43MQU2:M'SK0S]/A;/>/CQ%EA+ >WS#ZI<O.,' P,# P,# P,#
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M1L3HN"<?*HQZ4K*!NS?4Q.*9AO^/PBWGQ:.D0Y$'3UL=-^ 5,7'Y@;32/]!
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MI!.\A@M&QGU#>Z]UN0W&W5!.SZI4O?@8KGE!8XZ39RR& _GB'/VN4K7AUBK
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MRK+.,3C39&+$)1'$M!W=NNZ(*!EOWI1%4*H;>7[ZV8X<?SO)ZUY()0) SC5
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MH[?T_))"ZO/W[U)[_C\^04_.1V2C"@)!#P9G=%Q.^E3%IOWV@F8TD9MV.L:
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M)P^S@L^18_I;/*D_O511%JB$4<2!4:FN<BBY6QFJ8!239\*]15,;$;8F6F'
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MID>!Z4@ZJ&ZU6%EM<U05PI+"7_?05<851HS K"&P=I,[.$X%@"(/]#F-W6?
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M6NUG1R[^+:1!=H7,BP;">JKI@,G#%B61<M%W'+XR=I:)/KGR34\V(\[6B!K
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MS=(MCPK:U2$=]3K)^TWDFJ0J&;7A=PIZT?:W3R?R6Z'.4%\%MFK(A4Y>>;(
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MS<&#J=YE_]/%E9JK,+=7N5E'EM5CT=7Z6WU*O2-7.;,=[DQ:9ND&MAGMCR1
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MC$^ &9:&9>*5\DUYBE'-2BDK"7[VIQ;Z?R#4=CDDJ/GZ4&_JUU2D'O=>':V
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M=LK@"O8F(1<M5NV_'K6>#385X5Z7W*IO?M$?CP4Z5#0+%28 J^RF/QHW;W;
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M/Y63:A[X9_R3\:]B2L8K)&/FNQ>4R/)+JC;_0K3\;8O4P2K->WVF-GAM+80
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M74+\D17U1%$#W3-RF3FUG0<7GKJM3 \U(1I?\=WF:1F!;[.NS96&I^66//T
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MMO,::PG*("&]N'>ET-\\2VZ_='<]$ %9N59K:CC*&@Q1W3:OZR365#-!#K<
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M>(\NK?/$T<./'B=Q.-SN87YGO#>3I)H)5!4.&F;T!)F_%&69T=0Q>00@(RX
MP9B>B9BM8[X6ZS^\9(B=F.36U85]^<^V 2@I_W4,^-2<8'W&LKW:ERV."[XD
M^XGZI8^P20Z(U>'!.DJ[UNB51/5L3!3551+E,@OZV]REZJ8,:6RFO#T@; GV
M():&MP-K'DK.KI4T"'&DQ*W;@2[,6ZSDE.0KLD.Q._G,@3WV<4]5P]-IEIF
M9>5=+.MGE@D*=<90+XRV9Q-UH ]H&.N5^H')W:D!J?QCOA0*TC'^A7Q[RB,Q
MDA&9N_/2;&[YH(?*2F"Q%2?(^NCKH">@_C1OUW?THZ;A266+>BO=J*<ZRI>D
MWR_N/#2#C"^0W3+LZ^]:'".C2LQA5:>T?TC06,#"&>VC^63],&K/XF!K./,
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M1* CDEM$FT<*P>7G*%5V.)=4J&[',T.RIGW%^084585JN]Q*JV]9"/=QFWP
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MBOL1SUESMZ.V6P/I@P1+9IV  W4+JDM+_(IUX+MI+'J)2PFN[%&0299"N)?
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MWB:ED@\14D3%V._7@7T5]S;)&50]%6W$;^#9@]_UP/,>S''35#)_ME6%(I=
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MV$3,![#!B:AOXL_T_#6','AC(KTRTRFAQHEI2\@-K11[UJ"@,HQX^H^TW?W
MOP@_;# _;# _;##?'6>YF"4*'=LVB23-!#6"S-Y>C(F9KHK.N8N*3ON\'&:@
M(!%]-BZNL/#BB^:%>I$H;":D:VO/C!J]/L@LLN;8=#R0A)C9]XPV(PJL'5X7
M]:%4_"/WY9T<"[?I!8]CK^.6$>?N\A4(.(T!F,S'+YD^%/=&S$(;6>S(BF%
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M*/:T.*R4:_(;['.Y7#TK\0$->'4,?/WM/C1C*I:N0!;W$G:C'MGTAQPE-K_
M;L]41NG508R,#UG]I3?<+H\8&:Y(>)K> ?Q4*.]#9#RXI>'T]L'X[C*;>%ZC
M8J/*;O;+C8]1YV?7. 9T4IZGT1PS3TY7T1HJRA[?0>9<LQW;'3,!]CZ_DK0V
M<@ &OS_6-67AO>Z2R_2YI,/E<">.#>5B?J&08FFO00?8C,6WJ24>CJP6"9=]
MLY!_0;CZ@:466ZB JO6+1DZ[V$A/S/266[W0X")X6BDFV)AQ\]K%I^4!B6C
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MGF79[+($OH_HMS Y6LXD[P@()"/,3%4Z\Z<"2G)/?@_J]BO)L?BS600#$B
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M^KOGPG[@!_Y5L&1@)0#>Q!V<+4=,""H2 ->AN$L.NZ/[Q6T,7EH'%L'(3P2
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MGGE_#HJ"BK$+V,17PK;E70=V6*NWA7'&^D'1O9$O@B?#>K,C38WKGHJ4WT;
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M^W2R6KO)TVRU(_LA]J)\B8EA[S_?*DLR'Z;'_#(;5#;]4DN]K>_+@:4K$:I
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MORK$Z:2PG16]:6K7\2G2X-T)2MXM8)>B]GJ=:OCZ_8 +E@/ A ]%;B\_-!(
MSJAW8E1S*&'W.+%G7PW#'P#HCV:"Y-]S,/T]$+W]30YJ;<QODE3/]1$ MK[U
M\H?C,0:_:KA7SGVB/IJ =,6^@M=-LQZVDI-9B1,AU@*L:XLCN9?R&PL102DN
MUS4BJWQ-T5H%5N)1'6ND.B5FSS($9/1#JF@@$*TX;B4TD.^TQ[(.$B5(:9LB
MU_TQ@.G9U-C+,U;$*7)43["E<LDFX+KUM/,B S%(SP-3ZV3I7$D"H(1EAFFF
M,D(<RV'K9^N@:]D@Z]RG17,<G89^_2QL^]2.2,YCN0L0H;FY]DBJM$O,N9MA
MP!:<:</5LOHR1__<YAYC0:S2N2?G^,Y62-4HV 4OU)B8S&FR)L;_=ZRI/RRH
M_YL65.B018ISPN1%*8X#*<2WKFDF6-_L&]/9(-3@XW#^D,?-;F"R2S;C,2GZ
M$4#:ANEO'N%%W8NW6DM#/\]N9>"YYNL+)5]<<?8%;0);#GC[O0(F2.Y&G?@H
M9XH5OC%_">U@OC*AT^WX)*@E1SX\TU!!6D53XORJ'UP+/#!>\N:,GF=SO3V(
M(KP&2<SM)3G<O/0Q<G<54N_YZ40D'\6&!RK7/FL$+C']6="_RM,WFUEZ8T;<
M,ONY%3=4HHK?,!]89W2"]D95\FI#_&"JAX5=(W.CYJYP]]FR,LD(@7?8WM@S
M1:;0\QHUNT-)E4:^TLV1X[3E$E)'>ROUT/<VEOR[0:TRUPM_BGBQ5-YD@Y/"
MF>^C4X 0D#*#?K$O@UJ4^,YI!,U@@&.WO=^]#''(U;3/6#OE@=8N:?\+._4P
M3,(1'2(:,+T2HL(8*-[ECPW&>7PJ+GOL/T].);%&LSVG?QTFD228^<58&9OP
M&0U\4IN>@ZFM@E1U)ZN$*$\%UI2*GU'WZ%6"/9IO,.D6OQL=OQ*46  ":I@J
ML 44%8N6[&2OBE"?)EW6O:N^P'.5/"M8LI;>;:(26@LB51-3YQQ0N'QB"\-(
M^NJMT)Q)D'3@71FI%80+$-Z^=W'N4=&W4A)$+MQ:K2NF^3]HJZK_*9<K-M%=
M)RX[^DOV %WG3'0DMA:06'$"H!/=]8D .)N64.^+9R)Q2$2!VP4>?F]#^[\,
MX/=K&)^TU9&0"+6YG-;]EZ.>*M=FF8'E-ZT4_$+Y3< -R''SA;B-9<IY/ 6R
MYFL?=':0L^< C-D7KM:/6WQ;'MLFYM!QP%&IC'=)/(36!.&T$&D'^V+'8<D#
M6_M$6#9[H4C4>@#+A%T2$O&FLN()UXEZ1/)C.)-UWUN:FL+SW7;OL_ESTS&D
MFXIB3TV^]Y+Y6P#.0"F0DUW0Q7C\TTK^BL:)H ,$RZ$-J!6F1H)KFJU'GH_2
MO40 3)TE +[!C+5U?R&;*D^1?C?FD)>.R(DZS1]+;WCM22T$CE@#^9MM^KPG
M4^6Z?#^RY*&R'>JFLB+,<"8A4\NXDSN??\QNN,T1BJJZUF'58:''R&YCM@-L
M-:UBK>C/D2FG@+]3KM<CDVKF@RR-?[CK72FD,8VM+S6F]Y8!MUVWY[OY7LQL
M+I:NHI]%D>)18S09N$Q) 69T0TZNJ;6X,'SA07 2F1PO=;;I*(E\FL9NOELL
M&'O -18E>P,2UK![;NI..S@:%XY"J:J<: 3 B"VKNC-?V_&/4(;$<1?S5#$D
MID9*TJL<C;;%,4D[&[<C9J<Z_12)ZA#W7NT\+I;]>QWA.#$-_4V=-_!O"L']
M*54C >!@I/$?5,0K.IIBCJ?$V*?5GZ#6JRF=H7<M2G,?9,R/5+Z(G,MC@RG4
M#JEMFK:'5CS.[ H0,W0NYB83863R:1%I9 32.R']*BZ>32/7_GK[IF)->H-I
M8R$'^^SCF*02_YS+X.$$7T^#U-E@S=<9E7:,N=5Q\M&RIX[K&.G7,$ #9PVR
M%T.OCTN-75@;=+82?$Q-E4'_*4V7Y$)+JPI:.JI,.#E0)<R>$4RB'^GBT/C:
MV9$CBCF[A^362^I 6<2T5Y)%^D=FMQUB:SC067"NG N;H@FYZEG&FEC:YOX/
MBI:SS?@C!7L8,J&Y<Q#PA@"H,/WZC !0(0!6(M<XG/#B3<@1R*@;+BZAT1^G
MN/@+,32:BUL_[SVO":R'^L8HXA04?U2@_-NP@O.L9N)"^F"OYJK9A-#9B=%:
M<G-*J)!\P9X:*+'YYH=0^.OWWNG?X+X<6<J:AS%OJ=;\55+"$!]  2Q1H(--
MW?;HU*F59G]&X#.'('\\=?N+Z?)"OLO6A6*.DP[*:EIQX"5ETL/EPBTW!RWT
M];U@V?KB9-T4<[I'(?EW8FGNV4OX.X#&HVM6P(M%'T5C_/FQA:(71*@"(1>2
MXBG<QN'^'G-B@E?$14X[J2E'197?3Y,5T;@H1J%"\]T'[M\1L/*\XDJ?1D&]
MWFW(4Y3QUR<FLQ$.2>-C+W>NOM.V+I30W* =YI]I>)C_:#%P"M8S=:K7L/30
MNB:<IE5VIG%CBXI^L:MV<DAH8.EE_Z<,TU.SFJI/L\[QWBCK('5@WY$R>BNQ
M'SRO'<6F['Y.>&NQ)MD0<]4Q[W7\4GM4+?Y.1?=-A?7R&JA[)?+!FGEL+N!S
MED7/Z773V<A\ Z20_R+W;5%..=,H4@]/'37_D<";*IM.( 7P66JB&^$52;50
MTBBKVG0H_5EPCYGM.<XQLIHQCV]P#A/RG^QYB^*)G85B%&HW?['0G-&1P8M$
MZ&XU5X<Y!+TZDL@N\GMSHWM )[O_Q&M-!UHU0="IQTT\V$']Y*?YWM;\?YG7
M  KK?M*W_)KR'+5(^Z7GBK+W8SHC936BXPZN11Y'UZKC;ZRZ>,9&W0JN>>7)
M@MJ4GCW0.AI"Q^HA2)=TI00D(T!:01'!H#KF0C.JTGN0$:SAN @/)0#.W7Q/
M  BO8<E7._"BT!@GH(V^23O$['W@U6@#N66ZMF(/FWV-U[XG3UXV35$=3)!X
M<%=&[*6T541=>\DGB2>)*';I?\[?&K]YM+MLQ-$ZE*MVO;@A(Z@7) AC)@ N
M<M;!1X-S6AQH0H/NY;8):E^_K>84 QPWFC#RD5!*6F %D0L^1%QQ=<?L\V."
M03JI3BG \;C5O .QY5V:A0KZR4M:ZJ7G[7OL^%7D3RF1SMBQ4Y5(#3"$'BNF
MO3]8Y%\CVC;^9'QIA7OWO0W)=**,K&R+NGY-06)#9!3=DQT,:(TSX/:6L29W
MZ Y+=]D'G%2?JX20V2-C#%?FFGP=Y*2,Z0-1FZ'4BIKUO8D]9:9U2OVA/KNG
M=2%2W&$KB@D7I+L$(PM3%(<]A5F?O:]I2/%=8E^)2AI>",U2FY/A>8S:"KKH
M<)(6HH'1/QR;<C$QG="3,BU529=.ZIP6Y!RC#1!]MC%-<30A+FQ5<HH5=(^I
M>#$K$3'9H]?J@J^I*  V*?96%R>,5!=S%[H3:$P?8#AQ45WH/\7B9E&NO<G5
MK37<^955-OQE\*T/'GS[CT4P?X)UU;75PE3,*=?E1^_V&\K8V1-XB!Q"63/
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M(4UUY)VQ87%BZH5YD>L*P>*M\O%MB S6I/;RT&NJMSZ>"#%%KXYZ')'1L.F
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MJH95L/N9GP?HOZMW+A^_9#/'7S-THE9/UH5>;^+PJBEOK.S#TT^3KD5F/8R
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M)NSD9MEWI*+*DO%Q^PJOW:DF!#O-5<]_9%$Z0_LD<ZE4(Z@_MBUU<C74KO?
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M:Q;(#$$LFJJC^X0TN2YDG$E&RVMH0:RH'/CF=];(W9H'(<]UAMB>/5R5A.=
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MSJ04R1$@; N\E(*<UYD?/P+X:7V>:$)2D:; F4X484EH2^N17X!S>RT-554
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M%^SVIB/J3JL-M"F:$6]U!&!)[*I!53H= 9IN?3P"7""JT4DQGU\ICH7BSE^
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M%VN=/5Q5O<;CT@&\TYO-%A+S9+YT(S6@@W1&:K)RW2FF5*U%ZH;*EQJUF)]
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MDF?Z5:>,ZNY4NKMPBK'HO!1[92_?Y9QB/@1UDP<XP%//)E<_?>'R?05N<6C
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MYB_"BPUB0L'3Y\#[40.#[%/=NR?5"3/VLOB7;64?NHPGC \\B2V+F!ECLB/
MU,018 2MD^=4UVSIICYQ[3@/=^'7".WD')O?AL5-KE)>6^BT. +44Q [VL7!
MYC-S=#B YI\>!1*U)H[YA9"^*F^J?Z=."V+"DR55SWBQ2,[IK O50[(M1QID
M*]U2Y\&Y(P!+%G(I#R'$K?0YPFXB[VQVH1)3P!'@+)CX9Z[)5E&",>FK,AN*
MR$16'PM-7,E&"HI[Q8N3!]-PUE^K#P%D:,A9ZO[C:_S4<^SG$W*6MF);_M%I
M^1;#IYU@W8WM;MC <R3,B.%W9%%2ERW$/OLO;XKR/7QAJ:3AG5YQ:-P<YQUY
MCJ=H:C\O#K>BWQP7G17&:D^ZGP'LKNYM57*GG<,.)JGP+MUVTFYQ\9&DT,7'
ML'=-6-7R# (]T+;TS\'6\>52F+=R"*%YK8SUE!#7#,DAZH@(.5%6&UINWPC#
M,['CWZ!:UQHN:O>W.?E4QU(&1K]BF#\5?T++*WP\?XU]>V^R1E\>;W;V!#HJ
MZC 'KO_9;K.32L?O1*-5."A$%^_\N$4K_8[2]PT5V2:[S84U?3MEW;T3D+3U
MK0-E_>7OS,F#)NO]0$R0@(_H(FA(JOO<T@7D3FMFHYF%LF<I7PA0.T"X._9B
MC*?8L.H1P)/>I*"*T7Z::.[!%\J*2UT_^H#WQW6XA,YSG3@C/'<8II?;7:WB
M=K%CMWRX2ZS^"! ETO8:2>*MLRF40-%G?@JXM*+]=6+U]9>NM;82O2BIS(#G
MB?)NE*=<DVN:"#3S(5]X.78/X%+&?J4GOK:/0C'6Q60\ ;[9H4S)-<J._K3(
M;RG ;&I/P5KR_7(E8'*SAI>BFVU@TEPD% YN,'S$_$U_-DMUG!Q!$E!V,L^4
M"USRTL66+^"FG$/W!"-LC,G\3B?DK73=<Q$)7:!M*E-'S#D^?T.@I0K=I$$1
M@XY7QF>"CDVZZHN<\QYB .#Z:1G?>9M;7IPVMRK>Q_4?/#P=_XR[WBT1(N-7
M^1#$A(I1N_E^=[KRW4FW0:,@$T==L@K24$RD@9)+!SPB.>ES.J&-2R=N\>F3
M,4JT&6EGV-" 7UWC]X"=I.'J7E3 B]0]FD+@%:V!AWBT7<B%UZWUZ :<L5I4
MX;85,PR'$%"0U:L^?>4S)BB[,F&%HM%>"OIU)FQ+&,%,O_"]]<KCH)T;M5ZC
M4RG,79$JUQ98":YOV[,V><TRL'NBGBH/.TC?,8-7=":R=9EW/0((^\ -CD21
M@ZT(PI[03%6Y5IA$XLZ7W%'=2D5,J)?&YGA=B22?Z;']?L=0/R&"8\[X=DN^
M44N0\@BRQ';1K4Q#&N"=L/6VG;TGNK ]6^HEM3Q"++$Y_JSD1?@',]QV'OVX
M_<'B,O*R:V8DI^X1H'M"K[H2?7= +%%K)!-]U7<R(=F,R3&:ON0:_GV3>EP;
MN>6Z<(RL7&#J7D*6G'MG7>-764+E ^[#NL:\RT> O/(FRW4,] NO*5=MAJ/<
MXT)/F<\W]F-.]6=66Z2T?=7TC N03Q[E28-06#K_V4&>;MTE#%Q_B/;N[J[M
MVG-A?7T0Y9R4 &9DDI =%2+'OA68$";WL'URY09SW6WN^+I+)6?5F*91$]JV
MDLFNE07ZQ=G)Y7H$]H43H5%2<E;J.#' $:#R-3"/ABIG7K91RU!=);D:A42)
M2"=R)FWF+DAQP_58(!+(1-N>AR !)H%PR=P?+6%R+$EN*YA^_974M<7O5N+N
M.]F:;G6:$:(.M5O9[;:N1"OXXLN]4XLT9GD=LH13W'2N;\]&)F+N.1&&T._8
M!VZR:Z9#Z3;-=,@[YG)[D6.6)7I6[I=PAV&;0J,\?1.&HZ;,*3KG#I 9]:E3
M=S:%QYMMU/6,B?/JKR!I6"?6;U&PV#$JYD6Y(L)\>7/)$YE29=5;G"_% ZO;
M*V>#?3=56E1*S:,YB9JWQ$49:_4Z>',(!5V0P4)<6QKU=\!5L0/E")#.B]3*
M2S@@LU;ZVQ;$4JWFUK/-[-#);Y:RT55FNI$05+!PT3VQ""]5CD$,W3G>1TK"
M>FOY;/N]U#J9'S=S-%!?J*:'4L,?VW ]\B*_JKL-CA*XEYQ_(];UQNT,6&G"
M5:QY\U EMJ+)H4TCX@O=9:@*\W/7"MW3973"CV_Z#^^:U [9']@R70\?5<3(
MI\P[8:%)#>M=!W5K)BSPNQ1^XP4;&L]R1P50B[ &;2\*GC2RSL_41NWVZ\7W
MV7:;I<4A+\ 7-JV]%YRW<A-,Y.AY@/)NME\[QI[<!LNHTT!5>T>)YO4)M%?9
MNE2,P]D':EYR1@$-3RYY#7W<R\Q-L+CX$O,\!N*Y*M0^NV##?P1X1E]%$> X
M ]BENK"7YP4$^I6 ,"9!H2[ FU\F&%E"";O MQUCBG$\)Q>[$R?6(4G<_L,-
M4CFP6P>WL>PM:]+=F>A'WU,86=7WI[5\..=3ON<FF&DLPS[*9DT5'K!C+PZ(
M\$_UEB3C=1<;/%_*(8*!;UL@7JHT5.'S[IO&Y/;]D95))'F/1T779_+#'/).
MF2AY.FVA;?_T=LATFAJE?N7[736T\F]M&+H"Q_4P-<*K+&%04H9^7H4/>W[^
M;@)F^\DU(O]U8KQ\7Z-L-%@=J]/-J/E.OI+Z AO'J;W$6^T9W^H5/=Q)^VVK
M0%P-)Z4PFWF$YQ:9)]F"Y;TN0WDS#P3[.-I;ZEQ=M#H>$MC-Z,8M:ZD;,_./
M !IXF\QFW>&[>@IYCW=JKV+MSE$W!4'-07T)';-1="TNYB2^8= 5S-NE6Q*O
M4)-9 @*%IQA0]M:]'K'I RUFZ0?2_;SK?'R,'_+KU/!IUA_-XJ[P]MVH]GZF
M. ]/<!/3^G:U@5I37'#^&[@)<@5_N'@#6=V?'_/DN]>GL-I@XYNYW[-V+9PV
MS?0A3+Q8E\-:_=66G6 G[79DV+L'+4@!J: N:S1CGS>GT33OP(?:_L&%,4H7
M#[]S//C([7RQ-V(%\RX-U&J&:EVH)*M<O;$+#3=LMQ7RG(4&@KX);=.@.%-O
M_;W.ZU\U'%1G=8VEZ$6[H(F<$#KYS+):1V:%*6!+N,TMIAD2)W%:Q[=BW%X2
M%(4S;KRKHF^S2D=Q:G\PUM"P\ZF@"JB0]ZOP@DG!1:,M69]:_IM/SI163,*_
MF4(H0+2AZW'UR8F7U86>7[((5=Z:HOVHQV27.KW:['HGKX:ZX6E<4YO\R[:\
M@WM.AC?]:ID[/9<DERU,%L^B]?N$WMKSC<B1460Q#%[D8*3U*.A_YW(K!-%N
M1MI02U;<.P6-8[>1WF\8J/QP,NAB9 DT6"S\;77LXEU*GR*R?^1&QC\I8[_X
M$?E#2&^QQW&FD*_Z?G(5]Y3W<9*0$%$R@XHR&Y' &%G\L:_^ _;72D?]GOCG
M5Z1'_?DMZC7T=:N%=X@V3K5@[C\7X)P].J0_5M^C]CQR"VB+LL%DG\EW6POT
M)&'/J>G,9-*;YD9M9)F$7P%=![(6 K?8PM@R-;"7Y$6!<Z.\ZY>?)JW:7XKU
M(E7>>E2^5OQ@HY!6'4/2;#N;F&6P4'92EXW;N8L3*[2PN="AQ==[D?L=HE+)
MG>E)H14&K]+R8.RZ_D@IFX2#&6J--8S]0>O'YZODGF67N\^?D;\6*HO:##WG
M=CC.!4>,<WS3^OFV=:2E5?Y?>$6^\*Z9U!8)WOUR-V,7&KST8X92[B/NWG#+
M\C*WWU/I_V&:J89.736F@$7SA+(P\,$SS?PXAFM-\+XYMY/R52GM7II?QZ2H
M)\#>#&9]8B1759C,VYH.ZDEII'@(OX8_ D#8$DM4=@<Y,[L>91-A?ERDGB%3
M=!]RK-BP+1XJV^5Z8^_=S0..X;*#@_;=GB/ N>V\(P!8@.#:Z>6_1O"R.@+4
M6886?"/"N-PCP,YRW_1+Y^Z*7J(MYY6#[.ZH>^=U8AS^Q97BW+!!1].[%K;!
M=F.3JB- HMX18.T+.L.;(45A_"W0E?N#"RLIQGGR>J2+V*.BB(B*_AXY8//3
M?]J=8^X6JNLKW[/*9QXF>]U!1W))YYN99L>'$R-QNQN35J@9W,4*^^2%CL8K
M_)]&GAZ7V+3,04Y*PE15A^]A7A^D8#Q"/WA+W'0FJDYD5KY"L]0EWX:Q"SR:
MBA\JJ"9>$O7]H.$Z*T$N$+VW=*@*0#3]R_UC_SX$=/WE7*>5X9@#7[ZZI0@D
M-X[Y!%%V[R5N]=1M<F\^0G[,FG<R1;XB&?W[LCQ3N6D?!J%@G"0".S)]:P]>
M\9KQ(%^B)C&A_AH&#N'G?)X.GT;( 3%B6UP'/&TN)I(]&\TYXRL*ZF$O'BE=
M#YT\66!9%O>MM)U.=AZ^2&>B]#HG"#4GK$ZR0.\C>-6S#<$$^IP6ZQ)W)_LA
MXF.BE(91:*ZG0%70E9*A;-$F)Y$]WME$%J7KSB$3J@BAI;ZL]>(0%ROR'F6N
MZ1>S(MQ>.8[W<0XI&:WG#8A=370^+"HZG&%=Y.*>.?O)]F50&F.H08\W!T^3
M:?FS:ZN-@\X6DXQBN,MI6(_0A_#9[#*;S)&A6CRS33Y]A2=[KHO8PI05(WO6
MYJ)8Y:I6F!J:O%?J^B(DGV;Q<4](@_#H O.ES:4#EI&KZ;J3U8OE8B5[!BL9
MJ RI#+@<U&=[=/+6 K?SUT<Y@+FTQQBS]!VB2'G]PR3]?+0/U?_)5X2AF&3E
M'B,11?HA<>O'3=F#49Z@(T H4?L]KH%@FH\ =+$3X!<^*,Y\V=1?2\G6XZP.
MGB=4CWU(_$X?0Z@<3'4K)DAW&SF.J^^2JQ W)[RGX0AP4@'H.'5O&_:/WW>5
M7O(RT1WKI6IN:\1>T'>II ADMI]+KFTZO?PZ/KS_K;#1Y-XPUIM@H9[GGEZ(
MDQ*LL%-)\1@\G^56K(/]M#$W0OZDMWU11<_ZL7;S7?#%C +;4?&"/NSN38;&
M)V>JCP!0?*@SHH,E.)FT7/AC,8UI2U8J6C[Z3*0(=C(K, M\?:4KS^N)^CMG
M5M^AN%0U52#/DPWE#VQJSO.I@S E.V?#(FX VSA4*Q5_5;/_9!'@_1' S;3J
M&^M$6BJ+ZJ;RW%=@-_2*<L+R: )]ZK9")&R^TF_"^,:  FEY?KL<WEYR E(>
MEKQ]O<:R0;ZH[Q)OB8=T'ME&]JQ@]&N(N,UX,B8Z Y3J=KU!S4"%P9E9$Y3J
MTSLZ9$H;)14E#/SX RS[0BLOQO9+H;AJH<U^6N-6"3]5-# 2_^EZK*DC ,K$
MET"K(0=L=/V3S<^?K+#?1BZ% CQ?SDO=7\_:PZJF#94WZ,LK].9KJ,?N ,,2
MAIFB&\@M* ^XJT?I>LT-SM-"U_-0W%%*?,F/ N>=J=U :F%D+\VTEE I' WM
M(IHG9!)M5ZQS=%&!61>#F&6[F2=<R.,-GB<Z$C!6X/K3T\&RZRU' %B-)JK'
M#,27*L'+\1GW18I&.4BZPI2TC-B2J;H^NRC"G;LLZ60T)6==3)89X)ON>000
M>;Y%^_7\A2"IJ$01/U>W$;_"V(!\T (92"Y66S^9Z0Q%UH8X'JD3-)%K0;J@
M(16:J;"S8DZW!=PL&7C4]?7=8]O<8?9(_,;U+N(+M84LX^*"LW,%E4$6228:
M0@(<HYJ@^4^>7*D=M]8ML]O')<^8!&"Z9V \;8P:%"1\0;N+J)VL6@;KT\BG
M-KYXB.<8N=#W@/;GLMY .']JJQOW2QP,-,B.?YAVM?T>:9ER%]+O:9JW%JUP
M=G./EZ(;+"=I-A**&"-S38J8;0K=6--.Q;OFR"OR!##UPZGE5JXSD@4FM?08
M,B2<QZ:P4?8-9X$#T&$%9H[[TP.H7*:. #45%_,>2%K?:K)I^CDUR4M8^6&G
M@7.D!X!^0VI+?G/S_5PYQ;*G9Q\7%0CUG4K)50./WX@S<^JG];YLW:"IQ)?Q
MQOL[Q#&/VVBDN5PI5@%S5X91YO(SZL\:YE?,5SP>$V&QI3"UN.CN*Z&S(YOR
M8+\[,EP+U(GX<RGWZ,-Z- /U?7O/J1/[>B/TMJ(90D?:3WY1Z:1JI'5>JP0H
M4^TBEI4I!SJ^?C%'S"=-WDM.-D_5H5T[?5N!2^ZIQ@'/@(7!J^O,QD3!8-VP
MGK]Y?==?P&/ \8J<5_( ?<Z\>QIPR<GSYH,4! O8SZ9A?5#EJF?[(R\$1)U9
MCIZ'4=[M]:GX$YIYJ:N/"OF%U_@/Q->_/SR,2&PXX)[V)N])?@@9.P5Q%,CH
MH2D07.P&&/+MUJX4Q\4*D4-D_0HC$].\SC$';.)?@FCXH2;%_F=& GWU)+J+
MA'0O+N].4I#9?H\7CLS!0_S*G@N?>Q,0<J\%X[$%C.C(E@R#DYS&XL21_F4"
MAPMT2++>,KRBQ2D,SI@HVO*,,'*6N*V$CIZ'"WP!;V76DSDCSU23AQ(7N+7,
M^F0O6X.82"VH(KG(K;+[":RA3Y_UC>]'F(OT&?_;+1CKEHD\EBMGFJF\G&!8
MB$/NZ'*/EL_\ WJ^N/*F>%FF?LX^N\&T2HKZ/ VM3KZ9Q_F-\%/*CS-/*\D!
M6?\JY/RC"G=&[_XX(#V'](?J9B\ZT?Y$<X@$N9-3DG_S#\'GW/S@IC 7L#]1
M.>222P<%Z>B5?!4] @Q\33F4@R7'V=O=B!#-D_T8YSKY^G4+G>2'? 5-/.26
M!6J)<)+T>/^JH49ILPN^Q*I3J'FDS-7(?H1%Q4H94"F2/@)1V0MLCQW:5V4,
MU"987+B%@.C,!0A]/3A,9OR2W^8>L:\XDW#:*]IS0(;T#&I[17VB].VM&[V
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MR3AH5GB^I=/3PFQ@5O[,8AR$E;FUSDEH]-Q)6*+UJ.JKZ]%78L4?IM1[8H"
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M&T5/>[//K),K,29<K2>..ZO,GDI,-NL8 V)*O6=R06<F+E9;1J7V3,'$Y$C
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MQ2&US[CP[C16KNI/*2?:4@DJ[OO70?%YLC=2A88>B3.YJBM$<!GZA6OHC,7
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M=$L(&9K)6782&T)K/O_1<<"_(AB\![8+7XI?&?6.T8_8G7[O %WLV(0]$:>
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M?<#^9&.]N8ZAN80B;_KI>?L>#)!3<[;@2D5H@BX)0+F/=;7/L*X6!C^X&,[
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M&[YE%^P#&JR5MK>]G_82!"&<+:+OJ&." \C#UOIS]1N?N)6<&=]3(K:*^-;
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MADR^<M$KXBL,H#(O@W%^&KG +C=Z">(,=3^U<D7GJBY96(ZC1N]?3 #DTQ@
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M)FXR@8^<, #5O#@VR'_'-(*N(9YC3T5^%:8Q_<F_)Q&K8GTR;B0R*"?T6J-
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M=:U5GJU<2IOF[CD+WNS77A9Z+%J1+RI1%&=C5*5)AN]X8/-K_(-8EA_'5\S
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MXD:[FLLN*T%8S\8[WC\>;?M5'V8$"\6+'Y2+W'<](KB/237,TDO-5%2 3(B
M:'X\+68G2K"E@:.9]!_ O>X&-A@> =W^P26<B)(80 FCA2E6"?2[A!8!Y++?
MYC(1@-PT55AX%2#O>9J.8+([&+C;+G)P#,Z%"@9U8:R"XJ+:=+TRT8B$N>J2
MRMJ/VBOW)(F X_7L@;U<<5,A5FK7ISHT=Q_8G#W]L[-Y7O4MPN'6FM%[)X*K
MO'P+GD@;)&BT[NI*\B(^R5/L*<>C>$HMT@FC_;VIKA&KRY)6?:9B.7W=K(.^
M-?72#$.(K*KBS0:.V<0G\A=P7C34D0$@3FPV$1#,BMX^PE7@^W#]YR/IHXR4
M3@<??MP)\0!8SV(0728?5TN4/[9$J'4R:Z%-W&,;BR[]6N6-\>[BNL#,6SYO
M%A;'KQ@WSY]_ VX'.-IIFG,L1I]Z+ D:R7Y^M7N/ZE$4V):4QU4KWTLZ$4^?
MS[E/T!];-Z,;W&]IQO)SZBLD+UCB.-%'/**LD0%:+U-@,H"=V1M>O2=MQX%C
MJP.:[RLF7$,9-V T^-ND#+&-.^"BZ;V1')*Q!-AR<"Q->Z8L"Z6C]  Z 0".
MP(#K?S+AIZ.<LYHIM<[L$4KD I[_S<>]AZ!H C$M#^DX[.<*F3V\IZI['^GC
ME?GAU6,P1Y28B7\I!J4TNBCZE,;RC^L&L+SE+V4S\-#0^&FW"L :#VQW5T]5
MF0-%W.P68Z) J]]J8-QP@5[&X)]YU]NDQG[M!:5Z^' &EVQ>NOUQ@ M6TB[V
MD&W'%ES'@1$W^$C[P^;]Z<"FV<MTZ+.1/>K*6RBNRL3'H3BJ>8D]':67@>FQ
MBL!D5 U]UOK1[KQA!U/G388SG?315??*K[+:ND7-U^\@!;"H* 3>STN@L&CK
M?)ZSX@=>-E2^5,,V?<E7PH!+8Z^H"WX]MQ]Z,6N%CH.J^1T-=(468(D7Q.1A
M1@-UAB\DT9ONW]3.O 3@"-#M_],/CC47M*O?,6 EU 7[J9LPMOU*99EOIC2T
MM=K%]XFQ_SSJIW2G/PXC J8Y.W_L]UTV7M%F=CQSDP9KU/F/TY61<_0T1EX1
M%(S=,?G*\L\>LEVHQQJK5@\ZWGH"=VOMO'^ 9,:YSS&)@UB*]IOM+7:9Z\62
M#RDPH*;EHIZ^)5CK>R@U9BTE?)ER&':\0J'9-(=(@/G1%KI(>QO;+%5O9=0L
M:^)D,VRKWMV(,YFZ$5S.QSU_A,JD._^?4F)UJ6> +2C6'\,>F;ECZ F@4LY#
MV*_:)+,!![Q"ED:.R4\!W7W@:#'TSF]VJ<:=GCM1\2(?7FR3#&[_!4*!O_@D
M;TIK7X"73H*9E@7VVTPO86E6NZ1"VO5RXLTS1^#B*H$(_>'+OE>2YTK[@H^%
M*F_%OQHH)OQN ;CX\^*Z(&XYI76I3J#/-X&)Y_;Q0"ZT^3NA?4$K]TT%.HHT
MMA>_4U#IMG J<4%1_3CN>,4<D'3?/F)K8I#UR3OGUMQTBT5MOK-Z2M%G^1K8
M[P[_.?6Z8NIT_<>1-7W)[Q-4T#I!$DL?@M?_@I0WUJ93O-7BNVFU5G4^!DFA
MY'+)#6]\P8:BSYX@92MH7^=0V/G;K9H+E.V2)H5#$&Z%;K \OG&I>XS7ENM"
M]7I?8!UG35*W;<ZC%+07H30S R_0OZ?^5EPIZ^7I?@_ %42%IWX00!BJT5F^
M,7.122X%5?+L=OBM*&Z[?$ ;!<,QX*A@WC*[!KP0XV\UCT4Z8.Y4-:*[3&@<
MPS6TL9Q-M%S-56T'B5,_PKW0/C"9=?%->4'17ED;5;X(AM<!@G^V#J[GULC>
M+<A0\,$Q(RLC0-X.NQPJP7G)*WU=DG_F<7R@_@U>Y@/$I")N)$<B6<G=Z5[B
M0TIGKF-PWAJ+55DVJ:M8[G&QY4HT3N.9^H6V:%IMWZ=UM>V3A*RM_EIL^"T6
MC\1S:]RLG(N\$J/06Y@W$T+ODZ,*RL!1"*K&55(^A8A4PIEFV)13DWKKA=MN
M%!%@M!EW56(B(K\NX(4V90ANJ,6,"W,8/O=!?-"([T[@+?G$G]^@3H,+Y7H5
M):E6.KO7SUGO(36&Q0LTU*:_IC&U.RZ>D6@RP[/T"UM9V[Y6G$Z*77_(IA5%
M$&[+-Y*(27223JR88HA3Q>0TE(O9T1;."+')8RM>[)H>Q&)B%0>6KK;V<=$?
MK8B=0JK+RR(F[L1PZVN+[$1IGROYLU?AM9B29Y8*MQEYF=/I/T#=Q?JP*IT+
MN97FR^;:-L7>,B;4L;_-%TV"EW\Y7#TT)8S&/X>>HK&37%C$@72S#C=DX"$%
M)IT2' -].EJCFCG[>6/A_40X97N$%C/2(O_0P. P[D,RM[.RO-6% +E8)=RT
M95D7XWY1PP? Q1<J>SGK]:QO1K['RT)LNW_<O:1W+>C(@%" "54<L1)]LJ.L
M=7@!5 0NP0FB3U09FX?N/TN1 HT&R(4VL7!DS\.N4Y]4S-HN"V5Y'B)S]DY@
M/VPQQD1 GSBUMJV/1%J"_??)Y@"ZDX<27_^<L7 &,<AQS]P9B$P_7]3_GM9S
M^-V%<_?.<;22AB1&.&89<\M42J>\PN;:=\7S/D%0\X'1,\+Q^*C-/HE*I!?E
M$]1TVILK":<M9RN+,2H/KUV4'W%KL_^'6+Y]PRMF=^Y",6UVUK6PZSI17QN8
MD1X8CH 9-LR.49VH\Y3>,7V0>"U@:4;"+<IJ^)HIW85[T@QGVM?K+[_9O.3"
ML-*MVG:A!C(W&[U1HYZE=+[0D=EJNF\8C%@G FA*D)>G+B*L/QNRX;-(/NY5
M^3]Y/%V2\9:&OYN]+" GBSXJ0F2X+N[BU\>@(O.RP@RJ_$:9=V,1D$3SMW4<
M.L$5%9R*L-8JIXLX>DW,NY\//ORH)(DOZ-0'L);[)SUY*U8Y\K3^JT8.]J3/
MZ*A/K:8>9SOG6]3?[3"CZ7&KD7%?\!7$_\;0_EB927/0U$V26$G"F/9\O^@(
MQ]WVE:(\ E/.$P'A@G-/6)\."2Y3\TTX9P69-L^>*[GX!61;86[%#3.:'/!G
MM9G@[A!X'I>4\ZDRG<[M-Q'P[O6 @-+>/*0[)? >Y"MV.Q+>E&Q1H_UTD&XE
M"V49%E:MH_AVC$;?5.5IV?!F,G78R(=CA U%]QLB((;EV41N\JA[HDI/Q96$
M(S#M/)QCVFM0;ZBDG=>P.PBGRL13R[_[N^ZMM]NR^-"M7N<:^F7C*OJF4ZZ'
M[^6HER1%DK1M*(31L>\H0]^8]&;VO@]M/URJ/1NGQW?F(<#G3]J(Y\E+^>*I
M,JKX<E>&WWP]MD-WPGFBXX9)"AC53QFSRLDJ^,+;89_5.%:L^Z;873;K53VH
M*=:?7;FQ<*_+NZDS6_62AL<$ZE<TO=&'#J"<)>DJ$HE=5\W"\_3O??[X9'R!
MWU7J#P4$S/E?P8DN(E FP]>67*+N-2+=]"]]55'0:71BK'EY6TF?_<.K['2:
M3>\#&ZDVZ69!?,&25LC)MCQ?W@NM[MEC1C^E7,.V7"-5)^#EF&Q-X'L,$?!K
MD[6IJG]$T#+NV[D4*4VMT0!9&[ ]?UT@_#]I&I4,&3)DR) A0X8,&3)DR) A
M0X8,&3)DR) A0X8,&3)DR) A0X8,&3)DR) A0X8,&3)DR) A0X8,&3)DR) A
M0X8,F?\8;A-)D26GDON;KY,EW-<N?DOPO5A2+L,"_!C;9F02P^AXF_L$I>H@
M,]60<.N\H>651Y'&@?&^5P>4&$+^\@<CDR%#ALS_);C* [%0,_975H(!LF N
M(H ZIFU4K13KJ_5Z(+NFC2(*]19LRJ_SP;&7923GXG-.,,Z\V1D7V")TFY=&
M%J5@IH3Q7Y%3O;"E+^//N.ZXSO+1(@"8EN5M9>FNFR3^S)I^+C9,TN?<+U[!
M:FEIA#\H2E+X-L)RX:V9]?RTPA9>PYOY_N.$B*57THGTF9?6HZEVUERTKLA#
MN#;4J1-KBD/0FH\C6+(J/CQRXL[)N"O1@9<?EI_,2)^&"SY$!!FEWAP4BBP3
MNV:Q@Y!B56N#6GE-[6X^FFM)3!Q2?+Z3%</OP#KGARC*57)BAE9;)&,T%)\)
MXC<T85ZSO=5:(9+FMB/-GX@ @]\HD]Q&Y64:2*]N\5Z2'1\['X*K_^\^*O H
M=B[ARGS7C-813UT*\A/A+JS]R(_@F[S2!%41$OZM(I;]TZ].7FO97-_+G*#4
M!3H$+FH($T#SR'R\,!%P>Q%^DOB-U]+ZW?074L^[I#;^Z?>&DB%#A@R9/Z"\
MA;T]/..E[!70JP'M<.%,=,82 6_FZLJPYXNK![/":);JGHW.[Y06E! VWH%?
M,Z\,-$8:??,1;H04XD(,51NNP!Z9M<WY(HM7Q'KI)&-*?YM3"[7DA#.'MRY2
M'*&*H*K#4#B5%A-(+)UK)Z^ =43Y@Y7=TZ-MHY1IN\.K^P+C^><8Y:)8?EJ&
MK.L&T]^9NC2 58:?IN9_<HG]P+)>6R)M5%6YSGE!0O! 2N3)N.QW,5-X#$*I
M+FPAQ5$7V$9@7*-VRN<^_]W2/W$%?L-Q=$CA77'K4HM++ZA6-J_OD+=/BE)*
M% X&]=:Z_4Y-2KVS%U/O><X:@[QE4=FQ+[$G]<M7J7PHRYU)*!T^6([8I(#3
M(;7W?)I1> WK],F2!-'X"Q[+"4;@0ULK6VZ$\]EX$/]10NO,';C)"%R4O;A8
M^PQ"3>]H?-((^=/,6AV)-ZBJ_-P26?.HU(T:2]W\=L>=F:I/K6WPC6_1JY5'
M]E^^2$M,=F"^&!H[S'&X)&^42MOTLHZDY0YBMEN\+=*DD>H="8$:OI()!<9K
MH[8NU'G38RQ'0.WO<(TJK]>LIIK 07D&7)J-Q#5K6<*"T V>'P5*QLD\PY"N
M+Q]5Z@S,?B*,5D9;;:>]F %II3[J[R*FGBY3!T"6A</J^+\8C'"7/J=/HO[]
M8I0A;[>:G3'_1'IJ!LO9$F[]>; )^JB8L8TSS(Q+]*H$LTA:8E#.ZB%+:G_@
M^:FEZC'"-;MMFQ_>;'%QIBDEZ$QI[_SAD>OBG!$H@QWE),3.0H"&KW(P<A+R
M$2(GD Y']TGLM"(SIU90L4[.U<\U@0B<[9SJAD2%0RH1X.RS,.K.UU+0/)KH
M?=>U_5BQS@*7301P+1X>;4%6P^Y<:XB/B1(S%\/K$@%Q.R?X0XDTUCF)%CS5
MDG@]C@B(J2O -%*CJQ4U 6I'S]2)@%C<^NPV_IE3NA?/F-RG^"??ZXV&+G_Y
MH6QHRS?](Z<9QE:61#T^UE/F@E>#=! !Z!=>B?#%8<OE]$+39\_@^K6^X6,?
M>4>KM"B\U!P\=6*4HSXQUKF!F92O#/?J\^KZKZZ8TUMB)0OX*FOJW"XRGPGV
M*1QJ@S@M/47KJW G!ZD/O1S<L"A]^U"/S<5$N$7C->3!58C7)#/S_*I)[&'"
M#UGP%MK#TNOG7*'STX/1ET&W)BNUC'8G8\/J;L:;M/G=1F:[ZCX9K/3@3E@W
M)0+>$=BUD*MY/L]$I'\O51W=TK!S<1O.W;O:-!>21W&W(DV%HL@'_(YPQWA=
MLVSI.ITT-RIMG?.2N[IALK&7:^2ZJ7D3$M!E<:NJ3C$K"O$ (I/6T;HR"B_5
M_?G GBU7/N/C>]I\P(:(NHFU\U]?R2!#A@R9_YZ,,XC;4_4Q[N1$;=#FA#G.
MRLEEH49"M^#9T'6L0?O$6MB"A>\U4VEK6\/%%F#K$F6@HW\/@LOB_DW_TA4X
MX[X(>Y9D_>[@>5 ZDFL0832I'3P\?QB)7_^.2X4Z;F]0V<]-*^"#G?AF,JP%
M[M@YL)%"PP9A!#G!T<7'4S4;<>R45,2::"+4()T/IRZ4'R\0LY WIC"M;UF_
M*N[F%O-;]T.]3YQ+\*JDMTJ0D!&J15+7.@ ?L0>//,Z9+)&UF@S@O(_D&5@Z
MD2\XEQ/]K9J>9;9T*=S1,["Z@O%9;-WGRXEY)<[\V9\ HI"U6(JQ2'.Z"?E[
M9C<UH$/I$ZS3!M(JS\SU5W2\6=A3K'$6+5;A/MP.[XS*W#@92GF'H*)WGBY^
M<>(,AJ+$/K_V?&"88*Z MV7&1'D1 6GU:'.Y$712A?+=DX,'('1==K;--C?*
M]?'S4-9J\#>I9L&;7\U+6J(LBJ #[#6[L/P0%2+ 735/OM&;")!/( )F?Q(8
MEI5%/>T_@3_HQ\O .<W&9^VH!;\J7N3>+'2B-?VB\>HL*VN6SO$H;$P8M#P(
M.SF _4*N'.MO5&67'XMWGLM7%8$;5=]A99ZN-#D6:Y7:?/E;I<J\ANL9R5B@
MNCV3+JQMJ7XI2$$-S%YAB V)1]R_<I,(:(,LY7?1U([V8+5FGFP3V&9LJUZG
M"R$YY#\UH1#T84;2VAES-RGM43U7&@7:KC1OP<9U[;2^F\'ZLHB PPTB(%AO
M)4^V3$EF)_"'BAN64^_[\.+5B1+[EA]JJ!O9)E^,<0N4YSA*;_SMB+^5#6Z_
M3M4SZKV_S5QT52<Z:I'WKLEQ?=..=]7YA(34 0ISF;^YHSV54"Z;&MD74?>Z
M+I]C.9J=2\+')LTN5R*>@EI[N[4P QW&6@?>HR;6[/D'V453=MIM#%&37"?I
M:8E)FH8+SFI<]]B=Q2(V?DS]KAZKSAQO\_-_W\47K<J6? S[E<R(2,A^M)"?
MND+W6P;5^;VSOQN1<^XR9 49,B.H ='8X88EWV2X(-$7IHE2,6!L/;!.1WW!
MZP]\JQGX5A&L_IUI0CYQE9&QI\13^U.V:;M/Q,*[2M/>U;9D27FI>,D(Q9A[
M78T7JITNXA]78H9%)L.BBI%,?8Q37C_1CTQ5[XRF%+?A-5+<S,#Y.&.=P9]+
MS5N4A]HHGQ1^H%B/<RKO&]^T:"Q08R31HEKD,6NNA6EM:DM1,_\HHHB9C1$9
MTXJ#2_,W#8/S\%+8HNX;ZE;N(B(I_)=:LZF!S3,?>;8&'ZQ%/'9H+UH34S<)
MM?FK!84,&3)D_KL"CH9"BNE&7?E61&%&!T:__7G'!7O?#R9V/.Z%J D-*>LG
M_A[8#90<9ZREDO#4&V8A/!F/\> S^JKD8R!7L/< _KL,_@.29^C<%6=:WOSE
M# SM&<E.9Y?4Q [:F)!SL^!X!38O,J+ND7G2=ZAZ"NQ+J?=V&\JAGS8\8K&2
M/-3,S"_C'QE-1UT7:6B3U> IO1+ZO%I1))PJGW&V<JE67 896O9MMV6T/X8(
MF .NGAC6?#&<)ZRT>%'^4A><N16X[/0HBB"Q)^CRRKS6HOY2$74*,K;$HLB&
M%G!NH\O%_-[,0X>MQ; HAU? #=O+JJQ<-($B9E)8"G23VK;?*Y&W\6$RR5X^
MX;Z%ALF:9CO2VV=QB%FE*J GC2"KLWHZJ+<V'M5"N%+Y3OH$5+_UL<ZI<A#I
MP%98MB/T0$DQ2>R79&8B1V+-JK+CLARP\]*H?%P=-N>=X&U>R4GL3NQ=B'G3
M<4Q<D1'W07^#X6[SJSJ3RV8S<6$+[P\:D,8X?4C^V/3UBAC]=XBSWW\;2/#E
MMAY*Y9CI)B8_D&WQ,3\H#\WYH9-Z&@S]6?A<(B3O0273V!CR.V5W)E<N$HA[
MB]FP4T *-*A>>!X88_0M6.G&:P.>A/@JN?K&-.[81\/ZRR&\L4RRPYS+9I,O
MYT$7IR<+X#\=V[KELM?-Y<QLR@]T1=4=;L\/Z^LE0Z#YQ>8ZIM>RF==<AXKX
M?0R/#=9;Y>G+PGZR.KNT;7TLPKD]'W!?\9QL<NQ)H5$NW;VI/MD  "<,G:WE
M1$=_++(N4.)J$9T\U)4NS%%2EJJL 7;JEL9"+S$ T@$R9\Q%H7\S/,.6)79/
M&F_76?USW<C.>?:*5_U;MG<BS-E4F=RH*B\M]/X/+T?5<75UEQN J-^H\%48
ME@A@]P.C84<W!(B J2*7J[9 )O2+K.F^3S4:&:I?UP:-JN)BO//P=Y"J&7:8
M=K9"WQ]36#,DUKCI[-S /E6"J#4;'>27Z5-71KG++N"+_''#G5FF]U?\O#/L
MP@M6XTR_GI/N8TR=0S(HH#?E5=7?\N]=J.E#>T9)WAO*L>='W."M-<5]0==J
M/?NRZ3%8$V=/!!AD(AF[-@93/T]N&N?TL/>&/L)]S9K=4I]\IRS'!W SOG&,
M"D789PF]NIFWD+Z'_)SUO?['AZW QU8/GF0[/--I^SA4]P!H'0JNLI9I[@"J
MWI#3'-7(?V(/=W5\D)?&%.A=NOZ(2OJY@K2$&KO,P281X'DN1BL=:8Z#_+9U
MR#ZQFHB+>U\H8_ S_MW3KY3WTYHHKV.M3X*.]#Y$2.9R!#&4+J7E_M6J0H8,
M&3+_7=$7U%(O&W$PFUET8XUBJ59BI0!+"^/TS)B(@#1Z%3R_, VLCQ)Q$%%O
M*[_DW\D>D>R8>B')BKWH>[-+E*"1%4VVEJ*(NI)"=@S_+MHSU EAYOWUU9:K
M7?V_63/&5Q'CF(B>HXVR>G)_J8J%+\^A]KDM=V'@^P"? /^2$EWFH#RO1VHC
MS,ES A_7WQH*8A*:!":C!).W^?*?Q8^_7VW9BC%K:C 22E$(O-96],;9N,6)
MZ<DPX$&^T=W[4I5J=^T9+M/K)/-EB;$^P[2FYA=#/KWE19QW^P'EP0PCGG^U
M3]Y:^><-:;:A9X)SWK]\AUTWO5.:(AGW+AQ ,5&HH]I1VYKQL1T8-RK/9F.T
ME'WG=.'IZX0\1I2.8H(QG8[N0(H Z")>XES&X^#R2QL;FUS%I3$S5\+Z7^CM
M/7-UG8ZX%^6A!%EG<J=V.[?^0:)-'?.EZ9G:H+A@98R&IYYV-M_&+^VH<A5&
M:TQUTZA887\S>GC!S31",:Z5Z]*EMS%V:GRN3LY1%NQQ?6L<=(/NO,)RSWG[
M#<2@=S&374M,QNZ>XMHY=WY>R[E1=7]3MC%9\U-#XPVNT?)!B6C%7, E=X8O
M3JX?=,?X,B(>_=7OW21#A@P9,F3(D"'S?SE%GKE&AC<A>8-W'E#K)^_"(NMW
M+I42 ?ZE7S7T<M.//X_ N=GBQHF 7^J9L'Y%SNX!(N"B4#01H$ %$S.7L#P>
M2%@WRSFP!'W:)=0+M0W68^)79O<NA^Z*P_YI#53/<_D2TH*GG^F7Z)%=Q7M(
M/'>5U.FY6_@>SG]:6F+70*N(6;X$]OK14=#ZSH8?\'_9C<H_+P\=25A7UBKB
M'']/>'&,K^94^_\\+I4_#DO^/WI4/W"Q*J\!=I?C_=85[V:F2C6CDX;!W=<?
MGY9Q'@;[T:)!1Q1W7%]]CPC4D$V5AJKG;PQ4*S& +X[^U;\6>"0X?)D(*$P$
MK^L0 ;;/B8"^7V")N=A:SM'*SJ,-,S<91E,)A@V?8=&5D6_?%GQ4#A+A>/P=
MS@D#V"XF<6D/##IN?'9T!7F@!_J<%G>:;4T$@"[^SX6\:QE@A8R@.,K_BB_5
MJH(S[YU]PXWZHA\IC#N-/%W+M=Z_PUUY.3NQD>?H\^K-0%$Z6SM6I_W;WY#?
M(JLJYR6L7V1$W W[,^_])$.&#)F_$F /08@(:.='G1[O1?PM_E9]A[6%AP!Q
M3[$3?!EU89A?$7SI9_\5%S?JYP_^%IV@NU9$ .=W(J &N.)TD;1-9F!W=QV#
MYV]_'L<!)<9YCO2_N&AYIMTK<UME'^%:!6+P6R&4]H)_+<&W=>7AY_'G2*',
M>UG[7Z^D=V"./;EQ,G)>ZX^F%<-JC71QJ#PQW/.5LMDU)0WM25@>HX1_*'TP
MYQW!,1TE1LO@/_-N;3)DR)#Y*_&N;YD].F]$!-2;Q9DY83T)"@;UVR@#>ASV
M7@OL8IHL*><8X&#Z>^+Z( GOWT3 (+_6\!(!-RV1:?;_(CIX?T[Z%8.G;^XA
MQ9,:B^%_2/Z MT^:C^53WS@@MBTB7N)YD!-FD[,J2\:=W.8ZFMU@X^M\_^Z4
M1.%)CY/F]P\J;JYQE<R-7X%!'N)\WQZ)NS7_:&Z,"U%@7]W[%P<:'+A_T\_V
M^F.+8'?>,10G]M*2KP-WB6B)0\G.MYHNM"8RU\RKJ[.BYJ/A 3PQ1@G" HZ,
MB\K?Z5%NJR>%L+CO_[RMIQ_U0D1W)$<HN$> IFZ:M?#V\DJ5A).,U. W?]QQ
M^2\?2J&OWJ,VI-4V\<UP=TC<R,XC:1:[*=JQE_,:6!3Y1D?I5O#_YFRPA4;(
M[\&,EH&96)69V'631:B0+6&?:Q5CWJ! .A%I[O]FI7^*4]K_%+FRA:-]$D#!
M:9$.A"R]$=KRX[AGX!5GG,Z.[C1IKP9/=)1TATLA@CQ7!/?6+UT+,(HT82WV
MB%BN1TMCMD_/S>%7B(!W\TWU>]<B=_,7DUYYST^MV!0^P9M^[3ZCH2C98VML
M/FD:U<CGLJGZK9PEWO>Z348R$; VN6)+HR4I-]_]]/AU&M4#.LB2<8^;GCF;
M%E7=)V4A*NKJ*'!_'5O<XL!+SU?=OLFCV?*//T?+U&P6L)3H*%G:_WLYIT26
MDK2UME\/WXMI*I :1BO2J.ZK]=QBQ,2688+U]+.W$[6<Z)'A0R-MVT5;5IO%
M: B_041<E-VN1FL;1(G!0+GQ_X"?)I(A0^;_4?X66;/ 7_"F1,![?>3)_D@0
M0>ZIB/DOZQA2K-E3^;L/-M+Z-SG6\A=AW&GH*=K\D9<6X6&'V6LK3&8]!5;,
M(X(/R;3_1YY&_\6?G[3HJ? P3.: /A2V<YYS*P)+!$34[X#4]SE[:X/0L_BW
M*B<956M$P$6V-[!(KA\9$<ON<-85']J5DF&AFLJPWAE0:Z6NDT512:FUDM*S
M'\.;[M0O79QX5MK;Y4=2\[SJ508_%4WW_I+ISY@)6(BOK%9R_3A[!2KE,19R
MR)NC0) 8G#15\KS41>VHS'PA]'KYU7A?43O^TL73VBAE]=")S%JW>+P*9OB:
MMY9O:*_(6X(X7_GW^W>J93J!8IJHO5.]UX,.^SF/#*9L<[[_0W@U</R*&+.%
M8?>%.EN(@.!8-/)>SJ3_RPU0:YY2;9R0B_'/PHP?>[.75R>*SPXZ'!6I:1B[
M?$MKLI0.#]N3V*UO$51>E%,.4'W[$P^<V(^]OLKR,%ZV.CKF#!,RK<:WT&A=
M9BQM4 ,;H S)I+_1XY;$>*?+LB\#>G.3-_C-@47\JZ6R]9X:"2Q7DP$'^X_2
MBMI) 1=T""7E+@*NC*T+1L[X)6A5[?*TNK3A1G7?(::CT=(EB;T1$7?C.[]_
M]90&6(Z^#EI!N.ZVR= &77%Q+XE]29!@+X_%/WB#OEW3\4":<UZ_0ZAYMZUR
M:$#'>$K%G>HC3R='2'8>WYP\-^E,,A$!59#.NLNP]FTBX(S$6OU5V (-;%IB
MT9P*M.!)! 0DK^7@>5Q&".):F7P9@<YB)CDO= RKX!$EJ7<B9DSL;_^@;"8"
MJ,4#1?QVKT6]@$7KODMK3Y(N&A\;>.[C&?9F4_LM1!(_LOXEMTAPPON+/61X
M\"?[T' S]MV.0H:FA;3\<R0K[KF?'$'F(M>B-\%]VJNOS8BMZDW9P/1KW2R+
MLS4_T5NE%AFX"K-9]<7&OAX<2E^Z_O6>]%J/[Y,UOP=*+G!,"?XN$0 B M*)
M );5O1Y-%+@XYJ#GL($(<"_XW*K^QCVOU5ATD>%=,+-$I/=<S^W&SBD3!ZXB
M[B]C#MF5Y4JNO'/@D'-US^N.:N^!6LO$B8"KME5?SX[Z'7V;OU-U-<6L>S0C
MXFON^G4?/67C2DF^-3O=2HVQG?KH)-3U>$,!X9)[R_L%I,&>$P_1LV7E==I#
MR,[UA9?,7IXRHKY8TP<,.5@'$]B\FI3[B^*$MZ _;E!F>[C66T'8^"&34G[T
M'AF50/-P>>::"L-;M=-<;Y@XYTV?BMUI!@I8\TT%F<0(.GK<O6O?0;*O2G^1
MKP,G09V(@#B[24(5$:!CEFEFBJTG*!4X':^?*MFJS"OK$P$A?3R8OB G.<T&
M8[7PA-CDJEF<+@L*?_KH&!9MC ,12D&SA-(M_5JCP:C"&!_Q6]+3<%E3O"2J
MQ%FQM_ &_(/U\:@#,@*J@)X<4<V.LWC6SJ\,6?T8S;E]&YZ+%,-EHC\YBE>Z
M4\U1+PIC$'<5R\5*WJ]I+X"#9)PHO;X)7S;DH;.B_MB!^$P$C)3WH_IFJ?;!
M/T<6%6>!-  -/X#FBNJ^"2$QT="ULWTBZ@CM 2WV(P*X]HB ?0QD59@&UD['
M<E1V0E!9)0+6?Z,&_[CS[#V;!(++TB($][E8B9'M)_>5)+=@"IY*S5]JP+1*
M;%FHS9/D=5M.+6R^"U05TSUHKSY5YM(/BP9S5U_KXU@V5M+Y/E*X?V<:PH,=
M1>I-M/ Z9T3P 3)^NM-Z-/WQ>_P\#P,@5 4S*-_DVT=:33?2][;)7+GU<R7+
M50+WD(0R:?@MC'Z_SY ,(4E-HQ*CVHE^R="'TNXO#[,D-TPS*E7KN+P<+YYS
M-4.'-Y!&C%&59[AXC\ZO":V:Y!QFH7=Y+1L]=GSK2JHJO;.DQBRXF1]2[B&U
M<-:D=,J%\!MY#]=&Z@"2O:X 9?LX-5D;[FEL.)^E0>EKH;DBX-@LSP\&M+-1
MXI ;5FG+MNP^^K*PL#2V*H=B,\ME=DH<"L1=S0[%;KGKZ4/45X0SKSX\^1"U
M5#C\@4'G:;Q2.'5E X4XX!B84HOM#7[1;&+JP(6DP-NQ.H7YLU7[?9^Q/*7$
MC;BJ%\N1MB"N[ZO>[O3J:L/DASV)5UGI_]!+9,B0(?-? %(*5TW2Q +SP_7!
M_V7Z8JV1".#@84*BQ=IL,B*.N9K^7L6(]P=)R,=@,XQ[4N](&DN3N-OSK^I6
M8J(XG=FWN,]_3*]'^;PEV77*GGI&V()_TAHHU9>RJ?[H;.RADA<1T&)^Q)E]
M'+MLUHC9)CS,/!TP=8>]BY$!M<2-@WMGF>GD+'-.8S'(#,BR4U0-K@,V101<
MZJ/')D40F._D1#EME8R)3\M<I+ ?,Y4U2(4W"5J8EN\BW>\SAG70@8Y'ZC'U
M31^!-HY1L)H&>U3>;[K ?'=OTPS^-Y4C2]"A.6$*.PXFY8_WIP>\!<[;X+C:
M4#(FX(N>7&IG\1&MM4FM!CHS.-<E7I,%<(_V<Q62T]$SL/3?Z&:(&+QZ$ =M
ME;B]JN&:.GPHLQV-C#3^O+GY92A;/1=ZLS9D:%/Q-#N!>3(&ENA[/31S8I4%
MZFS,,](@D1?1,FI[4LU.39=<4R[__.>(A#GMNKKCKMI7D[.T?NSH6D.[8UU-
M60#]HAD75K=#</^ST(>7I.!>Y,/9>!)2B<G\R1;' THUM<P^SR5#VYKY=L6]
MQ6NY50?GWY-X;\AO.GT'6%0+WQC5[3EMZ8%.SYT<[1,!UW\ '95=VN:?#X2*
M#8_6:CY9K2CK0'K5X>,$",]$EK\CTJ',U9*S-H1!V?;>*=A^P6 ->_JC3%N1
MX(<T$4PH#7W^3=G'82^'P!^7NU$'$]M!2(5K6HMW3Z8+)N0NSC5CZ5)#&^)O
MGNE82(;%EMBX"Y[5M^P")T#EZAW$FAU>%07;>LSE360)CUQ%JF57B?7+O<0L
M.5TVU? H)^C"OS@=,:+K;@[$A/L[1*59FT'6U>&X@Z33)GS!DG 8:(<3%"TG
M-^EA.9?7 LS,&R#0RA=D3<[2/N9-J2Z;SUDU30HD,-4'2\#+OPQ(=457D&P,
M6/_W]A%#R?;QHG'IA[6>:9,9AIM%W&&."-W!Z6_O PJ&DS';K+B#;>TZ!Y"F
M4+4QZ_M]Q/J<6<6$?[1$E23+X[F:271:@'OMRRTAL+/)O8)LALS>]B+)A:]7
M)H2;:LV;;;AKJCZRS\XRRA=AJG4'7H@9F]449DKK$ &C2.^0.R%WE   0(Z,
M0)A^B$+>P4ZEN4%T31\<2C*WCQ1'@K]E#-Y#>]Q?30/.%CE>79NXKQW(K#!7
M<V,N))HQI 2%10Q:LA$D5NMI]WF&2ZYVCX\'Y^<G1"3S1*58_FXG_,?REC=$
MP+N. KP-7!E\!LO98OUX*+!AMN85.*@=0:@!SN&O"J2]IALDV4*F'$&-@HY6
MVLQ/ V^*K%O!L ?=WR0M=M,"J[9QNM<*S9R'"<YB4;#]_.W&::->=JD-W7O/
M/^]<E-Y'FH.53PIS5B!&B5;,SYD&,R\J;S];'I<3GGMP84?$P<5YO>:L'MUG
MI(6IT!(1T&1N^='CN:7"QP<JC'4#!>XZFA049W\D@KF\='4J?YL)XBR$DJ[-
MR']=LDZQ( UU$^M@.4FH!B):7&/Q&EY_&WZE?N$2J8$+\(OU"[Y:7PGN Y?B
MWTS>YW\6D1LOHX73T87U:_N;G]KM"]/8A#9-G&.Q3>H6H:]=-Q8'B^>KJ75O
M!/,IS/#&X9^.2%1(G+']%DZP[+7  S\.X:\@U]6XJZI2J5T]+QWF[4U"(A,K
MXL1N1U$8*&;9 0!G] I<"[BM^=D&JZU#3: LU1%34[2/?QY;P!=-['^N<UP=
M[E<5Z,SWHJSU4WS]SCV.<B38F[.E"V@<;!SL-1X'"@ZVU2Q(*(E:&X@"BVO.
M-YK=8IF)HQ8Y79J"&WE&0H6%PP7,9F21-\M]=F<##Y=\*S=W#Z_69OS(K>3]
M6BJU>7<-VC2// <*6BBG=U_^7'VL#Z?"RSDQ*/Z@[@-R@98CUNIDB #$4!U\
MW@A&!9KO!1V"LM_XJOH*.>;PYW Z=/6'JN'N'7M\9>\8#K+?C"64^I0FEH\+
M<@7='Q-)+E9R[73]N&Q_MY632D>)\?S?JY__'Y)C]?K^)@*.AXD V#&J$AP,
MO?51>E%CAQ]_VBN+*C]%3!+\;Q,!=2WZL*@H4(.&25*S<=@\)GC#OD&,]VSI
M/OWE,=OV'NYVE]-1QKGZRWAWCG+A\4)J;Z^)IM%$/BEN?;L(D=<J34^F]S-+
M51O9@:LBI!#8=-JW:@;"A#;%&[<?_OQV7>G(%3B6\HJ'8T1_T3LA)%)[^,CL
MW^1-NPZ'^-@A(@#5B,RJ(6WEIK0=EI5+3JJYQU;L^WR1EW"D.^=5L_4?X^.G
MV:_HRX%#C-N)JN+5AELL[@JU,:J%MCU*,VU*3^X7F&!.A$,F6G._(H2M%'VV
M.$_M//(P,8=JY6*-/H,5S+](I]*W@Z_V"4-;,LW+[%B.#?[3FBWK?1O#(_AC
M[/4\=(_MBXIX$\=+>@?(S#=^2A*R5,M/_0;@G36L<PZIM745A\X_XGOI]()F
M:L70#U9K,=7W[S?-'XV,JK8\Z0UR^1(D.X&&^LT;UH L!YH?::4X4,:9AF0Z
M.[PY6J8\?T-B%Q2Q_0V%-VAS>;%!N?Y'5*F60.K\DC2.*7'P;$E^>]:V6[,M
M[5?5BCSMC,FCI;H,_8!>JC^4^2N.\Q?&)EG/X?N%N$=@<[#,_XPKGW>;"=>Q
MUX.@>23IZ*2?T09.R<DR=OOH\2PI>U^BV2I2O:UZ@R9],+Y8)>W7CU05B;PB
M&37Z1W"L>?AO#"%E4,3 X]R9M)":N_N";JTL;4GG?@H(/&E?'47BGXX::V.O
MK3:&*]QLP$,&_5EP=H)B3ZYV<&ZKTM#:Q^?0.7Z[ZEAX9- ^_Q)WW]N3*LWT
M22B%--<?*C2#S(:DT=5,)8DQ?8A->2.Q5^3F+SJ0,;+W_/8;2D#I4TC9Z69D
M&L==,]G/G/0U+ZI.0SKJGC^C[EA >9I+XJX?[6VSW(DON]RMP!GM=[N0V55&
MSR!4H(3_W51FWFY]JYF<)?T))_IY\NOZ@JG)[(]I/_FX;.\:P9CO8^.)@$H"
MXS1>I%_ H&WS+&CF!1M*2S1:?+RG<U$_R_78LTG#PHAU:Y_9@MNM@B3.(>68
M+MW^E]Y%"+-7]X](-L6H+AA %_A90%64P>4]Y+P96(:#Y;J\ P89Y2Y(;V#L
M6\EM]?J2?GU(7=C@/M4^D+LB*C#+ PG ?<Y ).3[Y=^9L(0&F<5BX+J^<#HE
MMNB//:8V>4H:S/T)45/,LV:F=U(+^FZ=T;9,,*.?-^>869.)'%OM7:-X(<I1
M.@O5&IW5&LPJ56Y+3ER"TY1<*8)H<:]7W*014_N@&RO+;ENIJLB=+!4@$7N%
MS[<Z_-7T*18L(1QL%!-W,7EB?^&%6#!IK!^&O31\I:<-T#XOE_LRD-^_&/CA
M^T#QKD'<7)%U$TMRB\^0Z-D+K9OF#VU8NF5&TQ*:&_"9I)@DCJM$5PSVK[GP
M;C-CX_3\KZS'-Q !+ZS1L]DF@RGW!Q@65OOBTF9)NG5W[*^^X9/,_VL85H6&
M%XI/9CK)M2-DK[>(?QG3R*XL57(SQR2OPG:Q-T[WC4<]768FLK"7=:JN/-)P
MO)A3_(!!Y\G+_]]3(URB&8MA%,,H0837NL; %\B3> ZT<?8_[G!$QTQ#JDU0
M\FXW[)5;S%RYN'#$=9;%0>.6,V#'@.1R-76#,/T7>T^W;;ZU$BSMYBMR#%Z_
M_8_M>)S=0G'CH4X'3P"[DC,'%R[GV\H-P8NQO?P^7W.\/.="4I%3 D#.>,/Y
M)0G_7H/:L(.X6H1GB2X0F&MU,VA*=_CZ7W^*R#"2W/H-V (CA'#JH_2WNUA,
M#4'SS4V,>!ZO308=\\=>?V],GOO#[]&?_*H+P<#Q;^/KO/]UC6#IM?DE60SH
MFI1-1@0V5ON/VR:/RN>0^-C!4Y5=Y L<*76YJ4-807+B"OXH4=?KX-?'Y-E)
M"0\#K J(0&+BVE1P/V3YCV;G>?$QZH1E''B D11(M8[8DD[[,(48(H#9"QFP
M-QL"VZ'BW+JTM?[N'XJ^;PF_$5L_\[!B1N9G1:&JI$]4UY<J8 O04$+=>;^[
M<UI'9[7,)9I(NUP [6. 4/GNY>:MV#PTR8QRGF0>/5M]3P3DQIX.X//V.STX
M:+&>!'FMDWT4GI%D6I6UCM<)$NU04U)3$PBG[D3 >=B"3L(?3C;:70O'RP:*
MZ1UJ'F2JD8#=7"N^9BYDM.YJM!9RV 6VWY/8%PZ_+>;E<2PRDG&[[O60@T-A
MC<*"N3*[Z 7ZT32.T5<MYI_94T"L[GPOG[1\\-(&Y! !O[ D#[S<*K,7R7D6
M]VJIDUD9SCP5D%Q,!%PZ:3+?HU5+\S'OU,TQ/HKEJ<7UY)I-B@M;,5VHA%TT
M?= 78[\$NAMO_QZXPHD#S[ 0 >EV>J-U5)C3Q$X3A1?A_&P%=,,C-MR#BF_X
M57-X'$V(@+:2^BW.17,1J +)W![A(:N3_SHS%Y!JEC/_Y4?]MX0[^&]_OBNW
M?NK/X)74VH4*(4P Y,&:D/>8^F8@G(9G3% 'UZKA 6>Q9_&M$*)\K):':5/M
M+TWOGS'*;"^(5T545.0;94;8:?[\6<R)%V;7(D M,@DW8DA=("^"RH7]JL>@
M3BGB8_^I(0;0O?H/J/%1@D6C''B^ ,[0?-7W3>P226;4?T=>QXSTJH)J"=^J
MX/^\?&MBIJ'-=W')RU29%O'G[XY$A@IHKPXDP\4_=^%)0^0]R;N_025";Y+.
M\2SA+&3$_^\DWGJD++O]'[/L^W.S- IS@J!.EQ"3]P_73=D9N[]HKJS;2KR&
M#N3C'IE@]E?C!^\_?L3K+%TPH=(\_4PE\47:@S'I5VT2>XP]*3?"=-_0Y!0C
MI)HYZ<1KE7DDRU89LORV?5;U,P5Y8L"*.J,TYG1XI:%]USSQ]GA.-.-D)N7#
M-5>J=N1']^GKN[]DQI7<=NX=!<P7^<*;HCTTW)2LXR*9,#7#^EGQ2S$M.OD+
M1U854&52N^[^T:YX* ^I79ORH4>H(OS?^71DB'!-[(^&J0PH*;GQ)D+$X=.*
M,+5%V:?33LV21MPTAV+\]Y@;D0*C\@+3/2*!OQCB5!MN5W(R09+,;J.,QKGO
MB((Y'T7L@RYX46B6#]VJJ"Y794=Q351Y<VE*Q77TR<27B*O 2Y<C]P.?7O^!
MKJ\:>8NP\3E-$13*L 9$H<>2C^U0FJ4_F0)OPM5V9R,Y=^B=#N_^*EVT#-8-
MSO3H??;;$Q^"!$TA/9%4.)(^W"KH.P1.K\NIM-J&$%CDGLTCCS=E5PD2.9@@
M@MP\$>!V;&#=9KX_X3F$AVBA*?'>;83EO2).C$XR$>!E74A*?3L]_G=W\OT?
MDO_V,0^43+_&O<T.5^W#L!D0 ?C;,_<)B[.G!Y!O?YMC'##X&55DD9QX7GIF
MN:>,< GK/A1<J9Z:@S!$6:'[WF$+"UQ\MM@U/<I]#BX![X(3)&,X@'YJ9=<O
MKQYTG.,#Z,2<-X3M.^R)KT&(@ *GKX5T08N^VT><I(L.&62NZF5!>.B,ZBF?
MW0%I$0'F%^KB,6WX #2B4+E]O@GZ= QAWFPF/K0GW6Z;U,/YRP_RJ/DX?+"$
M>:NQ4>UHF!5YW2N);C%3E([66BWY(]+":,1$W#CU]5?L(X/A)1O[S<2W*WJC
M;DWS#TQ58V;<#;8*(:-[PF=791PRG,J4DP!;B&1JFZ($>_42?9GBV%]A>E;"
MX?"[D FSG!PX[A.SNC6N%S)11PUKS^3]0X59YNN$2/K5\0\% PN,,4&)&;2.
MQ(TF6O6H+;W)[#)JLYH+%<%9:[L,/]: +J+9[#BX:6^R*YQ"5NFOM"U[^1R#
MMI65H"/9JJ>1<]I%;=V4Z\\>H:U>^4O_7 .*E'5>EKU)T'^@/V3UO&3=4Y?.
M@C(VVPAAX%X4F+<6SU0RGN).#>;_EGT%KI4LL?8K>8JCK2OM;K7%7(?CDRY@
M2%L_ZJ4M-E.[I/R);JL ?S"^X /V 7*\YC6F6S1#:7JOQS<D%,U)O99L_XP'
MSGQ+3^2PQ6/86<>D<QFN*>8*1;11$ '4;<^( #C3:CS>83@[?!["]+U3R0>.
M!V[3POHE^(B 8#\T\OA"ME6?^I'&::K3DKPOIJ?+!-?+&BA9$G^]83/Y.%23
M>UQ9M:/%TMB+L^D@H;!_['9[+:U3AH -HS(@MT!'Z]7*X)MMM^78*-C.?>1)
MT#$X!R]&T@II(L 9_ EJ01JR/; ISL%:$)H4[MM. DOR\-Q66KA!V7R^C$K-
MIK:Z^QE%V6\!9XWQMO+TQ3L6)BD^!IZM&JJ.,S/3FD\=HL"/,"'-B$CV#J9E
MQM&]S+S64N374&P=.K/N9]0;JZ4R^2O&&<;A#UD_W\^',6_0-K_7O*!XAY.R
ME,$3XMK@H&4$6NP-*$'F;>CI*+FRA]Z=QUV'T?^H:&>6F(/1(XPXV17.G@[=
M(KAOF%_='NQKJA00-8QZ79.$+HVKQ-I+O; 4"(6W5JW":*?FB_#Z%BO'I(.F
M:_BKYV3(_+>%HH_ AZO7QJ0&EXRR>CX9DRWH@J'=<4F#_!MU<B3SP--V>HQ1
MV\BDJC#-C"A5O3LN-@X5QOH:#$MX"2*C7G+;NY@MGEMUN1POEO@ .#=I.S&!
MYE%\=+?]=ET"[N5<\,@;+_N%%Z^5.KAW!S-JQ1,'WO"7;7+UK_?6W?7JT\5\
MD'3(V>S.69K&H3)0D7A?DA]UD")9TT3NE,'7(U^T'=B0>*'ZJ\=*9CF8^I:)
MT$CQD\_(@ZWH[Y*H;O=M^!F20:?W)9R^,7BG)Q37HYR5LC&^OO?'NY2^_GN)
MG[D8U#Q9#SO2\)R-MI:"Y?AUG07N#S,]W7926L<Y=Q\+.O/++\/I:)/W= ^R
M-ALJ8-S(XOU*=7(8U3&R']H4>W1ECP@XA)BH_(KZ/GM-IHHOHZ*W_^_WL>)#
M9G% B;Y'79E!XV>%O+A1)9K0FX?IE'_O/OI&O I6M7_/^QS-_V#OO>.:W+:U
MT2@J-D24(-4H'0(B(")=1'J3#J&)="+2>R!([U&JHH!T$$($Z25(5Q!!6I3>
MJT H@1!"N&'MO?;9YYQ][]GW^SR_O=8Y_O'D!V_F'+.-.<9X9N:<[XDQ\'S=
MZCV_D4+.> 6.$1EO3"[,&NV$5V*O&/6<N8/B+2$(JHA*$C:?Z#,#7ST[4W((
MF-)XR=\1[6CMW"R(V0(N9IR79,GO>M-48"K+/.YP,,0"_LI?SB_=.65341''
M*E,+%D]*+E5(7)1B[SYQ-X+6G7:9NT3NW?_G<;$@?.3TR"& RKY;)'GLPV[)
M3KWF#-\$^_-U(EA%6<SHY:"CPN+\7_5G5^:4PR[C0AB_TUKI?*?0-]2SE>4C
MDL-J?PA8(YMZ1S.:&'<%>I].[<$T#VOOEVDPT8"O!QLT;0X#;LU5%R4UCNG3
M7\,(C2[[@1@=M$>5/><GT_86.(OQ <K]!B$?C#V]FU#0#<WFTQY,F/JJZLU=
M4'5VKDQSX^FI/I1E7>K,9VZWBG#(ZD[OW!W_D#W$/6R_$N'D>]7=SBW(P,<L
M0TN:-\<4[_+@6G<EDB/^7X\:!*WIAWV?-7NCBTLK07=?G7H?(P"!ND@A@!L"
M;4BX*L:V/+AKLW<CM7%2()(P$0'3<\H?]PE02W/! >>D>>#"K5>H7L_B2H*G
MN(B('?.%ZI+O.@B.'\[M.36K;LN\9*71P/X!C,#_:/P1-@SXY+=F7'#8)=V.
MGQYJ-WK$#NN\LV*6.VDL$2UUC:-5G>FA,_1MMEDWLWO"3O'RR@(\)F-33& _
M8\K\OD$H3!^[4U3HC;1Y7Q9ON&/IBLA58,F54A?DJ;;S,C]/KM5%F5'@&(8!
MN],^WZ%ZQNVRPLC=II(O1TL'*O]HZ4  U;JU=)G=P0AQ%_R!%5M9*6D+;.J?
MVPR93.Z@1R[>2J@)X[@]B,C^MY6$Y\>OW_4-I27,B?><.NI+$-<!885TEMR1
M?PU;F_"9F0Z^L4VWD^-51.%4'C)G;HTT"#=OROE0R%U/D##>*"D4^?'8I4GF
MR?<QDWM5=.N7W2V"S26("MC!]N<E4MM*\NBI<I+(MJ,-5)RCI-2AMX?Q]4(\
MF%%/C*'! ;91.C\.P$="=V1M"U0C%8"*%;Y)E9E.7A?C>8[I]$ VI)RF3 =C
M^]4MA2N5V>R6#"\MC@M7/%,\4\_SVAEJKQ."B[X9:]0$42*<(L?_I?V)Y9N!
ME)EY=FBV?MRZZ _M)YMQC/4*F"82QX A_UA;7S#&PS<\"$9/8@K]7I(JQ\7.
M^,4Y1I^0VIPSN]/[(\^TMY90"-PR;]U7*-^X5,BBFS%GKHHY-S-QHF/ZG%>U
MVIF@R8=N\@P%70]0E'<6!5HF:(8G[#QWHJ]-G'T8;!IM]J%LS[I]'0F;$ B5
MU,Q1+VNZ<2\A2+L6==HNG=U4W;8Q>1;E/%_BGKW!*2_>U\=_-7@&"8!"V-M%
MQFY/)->SW1M8JP>AA)0W+0+AN?XREVR^T[0':+W&4$T? L+U:Y?+2X%A&C5:
MGPISM3BZ^,,A"4ZI$J\@H)CR!IL3-]63/U!*5]3O.G=<W?'H,*O8ZNX(DI3-
MI:,3<+XKZ5C OXU@-!%4-L/INGQZZ_X(IY9DIJIX>51 TBG;\$NI^FWZ=UH(
M'=,3VGQ?V2-<BX\!I\5%6TQ52--B*!2G=HYH]ZI93_YP15J.<XI Q=U/.\5O
M%02_O]))S-U@B\<GD+70DK2$XL2K"\G.W.UC/L^XB[IHK_IV*>&>;^(U@QX,
M^@RFW%_3(T2XJGNW?\58R[ZI[86!NKHRVY*F(*QADEC1[)!!\\.]V_K'? *3
M,0O8MNGK>$EB$0P4\/49+G)Z(OPBM*SALVM$#I<716H[+Z_^\_K14:?+!?WU
MROG+*GEG9-F]1 *F">?L8N*5ZN[V0+#G,BB]$S1>Y.9@.!3O56CP,[5["=UR
M$YF4[>!"0G^0F]\U\LENVAR?AAQ>]LT>&;G8X;RZ;GH(:.:_;2HC^T)%L*'J
M[(*D,!9MOY:\_B"IREG)Q:S%UA:85"MWZ>19P$P#[WL5R0B>>QJP3;%U%J.*
MH4@>"HF+J5C$,8=2._2-*\(L;\^ D/XB7H]3//ON35I@F#$1WE53R,_BP3T/
M6<)-KN4KJ'SA S<;Z$2NTJ4F-72GCO(%VYO@\L9,%#WRQOC4XQ\]#M#;:JN,
MGN&?O^AT2?##0HS!.SR3.KK\G2[:GB%J<IV@JY$:5W4#:#)6[,V:_)6HL3EV
MGEH0(0,A2+0PXI)("4]8GSTYT^V"EL2[BBC'KA8.?[!\%%>Q((.-PU<V:P'?
MFI[X(E117N.06QCB4_!IR=W_7*%W4(>:@OT<!44IBAH?.A,R9'T3<GLQ<+@#
MZ*:"O=%8+!Y[;V=><&"])+P51!W?T?*>H_SX]"3JQ 4WG9.G5?V21+5SW/45
M*#^L[U&9P6O,ULV$L7[W!K8;($OKCNRA1C?/>:%LBE?J/F,NI.87SL(9^:@&
M/.,#-9.%B2N@*9D()/(&W9!7^Q7@2CKKUT=#Y=\?.HL*38)4L+&:4SNE.:8U
M[XPR6!C *JXQF1\_OVW7*OR"R)QM"+H3$C-CS["BW<;:1>\NIM.']NIWUZ0W
MJ;YRR8PU..:RV=:;)GYTM"-MZTN@L_**D6Y>]L!XFJ)T\JV"K*B/ _\H&)J5
MU-K-)F#$3$%_76N9<M/<+01I!I&.DUU'_5;!?\S Z_>7JT6"\G_S*HWC2!X8
M=. ED6_;^.ABD0+'QH&HU$:Y\&9$?/(/<H:R>_5U,W!BM/X$#D.(PC%N9403
M3-<*I_:]BY'CMI>L0@E1?2GM,450]=<99&>&*R21/U"N*!:\4>8RQ#WJR2I[
M]$)/-P[UZ&W)NI#S<N]1,UI'>5 D)#HL34E!%P$![!EK'V#BUECP(#N1;:^0
M>>7RTPST%Z%=,'\L:7'\5==)'Y9/CVCUPYN+^'U[M*T&+-/X6V&42^G0DMS\
M<_FE;2K8@G[CM/Q60_9JK.D/K?,US $*]:"FU!C?&]5T*T$F%Z!+7:_<:Y]F
M/9?C6:;RSH]&,VBD])D9)C]:K>:-2[IE4SS=A3ICJL%5:NA06?4.W':-[6K%
MRV)\BWK?=3>^ZH<2!B$CB^E"44X<TM\BEZD\AKE:TE2UDFP&4'D?EA'C";GT
MR]]X^Y,CF05B)36&29EL/)\ERO*!*_"3C;\O:+N926-O51+<!9>2%0RH/LEV
MDSW67_S3.M4LU?DPM56G]I*<K"4[>>Y/^KMQR]/ ZBKO5]GG&??ZIT7#Y_M@
MLARC=O>/A?7C,7U !,H[ &-2;F<M_ZGGL[RE2CZ;.%AG(7*AD1I];43D17EC
MRJ487H0#CAZU.A?\Q>C49UNDMTTI%KVO7F//9_-\4YG)3U]@1R:6#<Y#M9#2
MCX3R.K^JM:$IN@-6OMJ/]-Y5Z7L6]FJ!$EB5O4(WW)W5_60D3 C:5IX11LA#
M"J7=F[:B3$ W1+<,7UKT?'0R 4[?;:M],ZK,-[4_<79M*#R>J(\M?V8FC;K$
M_/$ SNC5 F=IR[]_:W_I]ES1]PH6\0GM2KLG; ;:%T0O),U*L^'UV WXW2R%
M;>./GZW6$$+PQ2QH/,B0I#8I&^1WFIDX'QACFZ"&'GJ\C>.7##RV"%WXM VB
M-Q3*?6\&E(3E(8>]==K$HT/KTI=D5ZK[=@3'9W8V1Q)W#IA:"9YU\_Y1]T:8
M[ E#W<X!9["2Z5?OK7I^,5R[AO$Q[&8_Z/<6$UD'2<"L9MKE#GJP)0E3F-CR
M?; +U.VZ_K63Q8> */3500\!.KZA9&U5NL]/M+:1['B'70C?938FOQ $^[%/
M(H/>M?;"L3QOD:VX:$>5X36IC8^GVWV'KD00;2VRAI7:M>;CDF92T,P;CL&T
ME:FKF/Q3V558@X@*FW.P)P I+UU>04BEW4KW8G8APLO#91IU:4[6*EX#O(@X
M;=<AUSM3 0X2*P:=(DI5]#[0%#2RLGA]<S^OKO>FH XD*Z6V\D8H%\C7^'5/
M;+G(T"V)P**705/0#^7\]Q::2->L4KAECY&2<)>Y+<(83E4+7(&)5V#DU"_S
M:7MTQJG3OF6OL7ZGGS,R'S>_$SS=(&%4J1!D\AK@MF+@P>_9I1;2)?GFO&VP
MV3FOR0F:I?-=#W?9*=H[PZBI\.^UG&[\& M9VM+SHU_W/[VSI3):FRQ]#5_O
M';8]#!&S.T?5F.8U<4Z2S_W@SJA)'CN7ZP%O1J@TG2*4UW1<N:&Q>KI!>WQ<
MPD[_S@"W5AR/;D&B#ZNX[NQ<CQ"$.ZOFRYM_=:#^"W]:4'20_K98I(%;AU^%
MSUZV)!UX\Q[@"!A_ZL"M%:)5_W!#;;:, @.P'W^N%?%F164_PNBTAM3R3O8;
MY$XP</1N!J=D)3@T]K,K&*4G!O15-HQ]N.:?;>F:XNFB$L/D>MS9;;@>/C-!
M]+-O--] 4H>D\QF/R?PP$ H@5@*5>X!R,WW)E?VEW\@FW_6>9,5CCX$4$7#Z
M%;,]+(AT=[=Q'?,4@X91'@*>2:WOX[Z:3XH=_?*ZG%K<XY1KJL[0DJ/6Z;]A
M?FN4J+/QR%0MNL!"[]L%:M00.GZ(3+$H_0X!)L9[!AVB&1O[+H< 4Z:]H3O>
M^7ZO'ED-%OL*A 5PX-,/ :V>MZNNC&3%JQ??] &E^5\WOX87)2D<B)+JJ.?,
MS;5;V5/?8?L<)5YC$"(22+9F4:]*U\?I@IM5^9"]?1)=531\D8T VD!YXC,.
M :PLAX!^ N.>=DF(3EQ!S/W4Y)B=C#!I"0QN'<B?GNDUWVP@X0QO;^A$V^&%
M#P%LM? :<]4AO3[M7LR%D;#\GG1Q?.2T.EM;5;*G5]VU&&)1<,>*&M:V%4'C
M<)4M:)Q O$6U^W2&@!'>$"4IDCG=;F-[#13ZDM_V4KN2Q2CCTH/HL Z^M\J:
M;DOF-##5_G)C/6W5SIF@\#LB<\.HMC$'?1F+6KMVOV 3T[Q7;U>VG@-\7DF=
MNVRP7D\Y375[HJ?F/0\(=2M;@V:T4.]UA:)Z+LQLR.*E^D&_4MJ'4PT)S:3;
MI9@?546K5B:5\VVPK$ZMJ*H'SE!5M:&U[;:DAYZMT>7$ 8T8J_+3!HEF^6A\
MU71L<KS9^/%V"Z***_@S"LV/#U(-=$0Q6/9<"R:)?/[F[07!C/B7:PI:CD7F
M#,+8BA??,A(&VD]WT^2?7KQ4J U)(T5N!&UPR0]P^AR[YI*ZTTT-J1KZH3\]
MNO$T'3H3%QZUHQF<2BS]G&HI:,&VD$ >S0/?J(&DDNALH_'/N[Y[B!EJ(L(+
MM(;I3]H"M8/VKJ[)C!W]=D^3QS5YY^P.$C3MGQP^N2(A8B2Y;7()W ;55/\J
MPF)!K+L3$]XO@KE3R*^AI*(5L/3=0>:*R)(5YY?5YWY6C.]S8>:#F<Y.:Q#Y
M]4#HJUJ\U[3J';7WADFR$UQ$\(MDKC#]V'8&C=.%#X(AM M:4IIOZ]EFHD&7
M[CYE>AQBM2:"\4 AB,(E)G;#.=KW5X,Z<VQC;-#(7APWCE^(P=)Q@G5A)6JN
M2//YHH=6T9>*6Y\ 5J_/SD@:SQS(M$0LMM8'[X??6@=YY\*D<E_?I.9])FPN
MM%Q;\:7(<TOMA[*4J$T:K\EPJ3ZR*VMT#6<>/?RY3["TU@[S[MH@DV:T-*>R
MFPO,2 H@,V/2GC"%U#%F-QS9"V'6C\LD=TLKQ.JJQ^#S^[@%(C@_.;5W?KX
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M>D4S%<*2:-'%HOF2)'0(^+@AL%^QD+0(9X#/>J<<#&]U_LC'LD7EM_<423/
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M1.9K4YH.7*@)P-(G?O-H1%9%K/W]3ET+MGE5IQ!I+N&"U)XSH[,8:":,J<I
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MJ>'WK&2*T@B1NWVT#*".6#OK(7B25NON3X46>ID71_[@/MZ FD!:])4Y!AQ
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MGWQX49"IK) G,YXJ;9BEF(8AC0[FR5S:?.+*=D\2Q%C]-$JZ\DX62]VPRP6
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MF".ZH://@0KU5>3[8JA\>VTUUW;)X%EYS;?.43G^'G^>\H,O-V3[+E-'KG-
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MK>U]+9&T-YY=">$RIKY/V*O5OZH6LEF#$]"''<<';S>@[*])?AREIVW(4%\
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M=7!NX #M^)O[]$+!E*LWO>"\BV%/Y1IAAQ&Z, IB/+ F>D)32[RCI%A'BIN
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MBTXY[ VPO<>"@]]-CKGE"P)7,7R'FP&3NQEUE'L680(2^P:G94O;+VO@KO#
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MU2C_)@49_;=E$J\&7EXF(MO+/5J_;6Y,,^]= !(#3L[KZ$;+AV[CWE13T 7
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M'D[1L6$M=7CXB+W]AUJ3P!RZS6-0%G:[]<#+>13<QLBF/!"@98=-2?&FS[T
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MM=KR#?Z%34U AH*I_1SUT;\RQ@)BP>:2_<@<_=+1]TZ&!KKJZ8Y=_$=D%1>
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M6.O9P3[BZ4A.VDR_1"&34#'EZP6:C2V(MG[J6M?:GWC#?WW'MIC"HR<$^B0
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MS(\HM#:)8E:VUV]I("91B+>[)2W[7JE%^.*6B11&.Z.=1R CY,9M<6[^):Q
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M7C34F'\0=M7@?9U?!M]BR]I,?$=T;+Z^=]6)_L$F.]ZB8W2[F]Y<NZXZA]-
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M#3B95M0?'W.[.PV5@_6A5-.)_YZ:=(H:MJAT/W2K-MCZM^!9OA/55H?)EI"
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M4XL%>N E+:@M0/3/<^ _5!0$?C[^'U/:#[%'@'FM8N$-35.@Q;J&[([XF2/
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M*70'AK"K/7D$F-I0Q<)\^%;E\ODM6YE&<&=SYN:?,2N\8F,C6#:R9L#?X[#
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M1_G2SM=))@!RDQVLE&^IU[$&A5;PAB*<5YN6:)#3>YKWSI[S3A^LZ/*.L3?
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M'>U2ABQ;E)_.OY+LJR]#CY<F>D0R3G@,^*(@LI&(5=TK.3@"[>'R> ))K6-
M8DN-0F=XS":UF\+X9S<'ORS3K#KFHC=R_DEDMF7PB\[F\*O0,%T5A@KZ6H9R
MQ%RX_+P]J!B-\U!A?ZLV]$]=&ZL'#JZ$624-%=F(%.5>:DY"]5>F--9<<5"Y
M9DXDYJ2:3=YRL2@]!>[<D1,>6N[RU,FT 3EV*#V9$A 7KE+EYOERBH[ ;(>X
MGG:+H_;>$SS7B0'<FTETW+GU79VHEE O+A;WI NQ&5RW;=4UC?+9%\?7$[!6
M1]ZJO3L)=[_DH\Z3[V(J@[M +A0';(>Z1W"&0Z!AO22^ Q<%!+&CFSE$DDD6
MX0N$,CY30V\'+BO4]O+$O90[D!F_K^3-2WK)/_N5>ARYC&JO-S!N0<(>6W@K
M0C^(4YET '4@@MZHY#:][;D!!DYU^@XG!O 3V]#VFJ>(46T9$B[8F@T3HGUR
M;TSI70<FI_:DAYMRL<EKV)KU)2. <8M_=@GSKCMHBMKB8I-\JL-UMA;UL6HG
M#$4@2DPVY[F+#CWWX/H%-\F0@QL>4_YT)O'&2J7T V=KSJ-]A2G"/*/Z0'4<
M*XLV YI,R]'^LA-!G9>=X<I2_%LR-KWO9RMN37<2>AT#;K$M??XZ$?U^CLN%
M6-)7\(C4,^\8(!GF&:G -[,Z0QREG<.6@$H065\.R2Q_]>S-!,%HR.P-HTW5
M6N6R_&MH+'MVK0-I^BH#\<N;44L[Y4_[A^705P5?7(03?+;QQNJ@A94.%)H3
MW*6Q/M%AZ*@(?\<+>B\_#R0XJU$#5Q[IPRC<2%Z6?9\M7P%/S.9EFCM12*_2
M?Y"8(-22O, ?0?EJK+'(<:J<D<,F.$(X@^I#U+#X[=8F"?(/Q7)/:GRE,VF<
M<NA^J<1 Y#&@+K2O9FZ#NSOT+Q:CY1Y9\V9@6.M(?8AO[3I4)#=95+0HJM,(
MTC<[AH=U<9L,VBHMC:>5-3*(T&X'23K$]MC"QK3^LH?[7TL*A^!#A4.8=.&V
MX39P^QT!.1RSCJZLL=<B3#QPY[+B'B4%%/T]ED?B%0%B)&R1S6P$&(]C<V1Z
M6(CUQU(MW:CJ!]RM)O>#"7;8T)>&QAA(79%S!Z;KS8\P-S-+'NG)("[>@2&/
M ;YT.?#.&<,T>QG2Y5A3OCFM%;8X0]]\^B(,7CR?%^-H[R%L7E22UMF!<TJK
MU_@\V\7*^K^N)/PO+Z8H:WFNXFYZ=@_DP<X2EW*/Z@LE*%N47 MCE8M5 ]VU
M)1'EHL+[YP[CP>%$9"/.DO416+>'B&$7LJ&+/$!US2Y.!V>(:.F#%WL#8GK&
MM^<7(Y\).9J>F1Q'1 \0,X';7D\\CM#72)!<7TP"9C8IBX!I<PYNA<S*"'CJ
MW=MJMYN;\,NI85CE]"3+YV+-6W[6#A&!3+L[8?#1C_O)G<U&C&V19>L5=23B
M]0:C39IR(ZF[>8=XDR#TJX#=3S2E2XBM($4ASG?:]$H%F1])E5,U7!Y?2V-7
M3'CZ62#SYDO2(E6]YD=_KQ)[8?S 3;+[?<1:?G^)Y3%@>N@HZN?DEB]21[D:
M430G!=V_6QN[U$:L>/<CF:_3-!?!Y\EWI37!3 ;9,/,I7LZK+[,H\^DPK'7B
MBMK]Z56(17[9>4*H\EVK,4?>+/:TU9Q8"4F,IW\F5F)CN/\[4U0S@>@ZK-63
MSEP+Z9C^M#Q2IHP&.7\,F)1='-_\3K$@^YL72[\=9]QJ%ZZ0FYKVV37;>:W>
MA^,8 )5-N&#U5;_>Y5HXWE6?I\0&5(GG'9Z%Z:Z$64NM&#1.'MY68E4)&9.Y
M\OG=4["X7"VW0SS?-]4:%^U^G%]B?)P?*\%R#/@$BCG<QL65G 61C5 *=^Y>
M_F, :74680.4^HZHBL%5F/EUU:@A/X:KJA]$X;]K7]5!LL3M/?-QW+ACHGF.
MH6B)W1)&]A2GV S>_Z)KK<_,CI-6\K-D/=U]G>2B:@W8 ^-/6-UHGZS(**K2
MS]E5GNZN]HIF2N"E><GABIC$/9+?L&7ZP^AU!H61:/Y*CML&.C3;[(JQ"=2Q
M M4"7U9O$>W,;VI+L&.#TH=UY*+![)P^CB@%PY?EY:U'P2[791<@(O Z\A 0
M;"#$$.)>%%W"_#E'JZ#!&2Y7@;$*#-YL&ARAX]]Z%G=VK%_H8Q,I47?AE@J1
M]OQKWV(?1N/SB(','/7X>:A"(L. ]8^W_0>5R3/YNT3=[RWA UJ;OWI8>\^D
MI1\#<OA=,Q=.&EC_N!R6;<[32A:91V#IX7]N/<?>Y^PE<4* ,Z>G>-\6%[1_
MX^+EJH K;B95)'+8J)0Q::K512%=6HZ=FHE@7HB,4XFZH G_W, QX,*JB:U%
M>B#>I+Y@AOB6L(46D9+RN 8V.%E7EU?70!8X[67 F@\3K.;KUV1\]9K2%["-
M^M SD9!",YE>%AC1@]CB)L3B*7<YMJRSOW6YPIZEGI'KP-R4I\^<3 3 VNU3
MR/K.Z!>2U9_3#Z8'7"& S$;8.IEJ/$G.Q:E+ZM\STQ_+[NMV5%:-ABFM:%K]
M.LB?>4[Y'S0[7[$BT=.72AZ)U6[]5/@*'&HV?IV?]N9!+1S_O+530M3:U2 &
M4J,H<5@P!J]^E%=KE,EQOE!0BS]/& 24I^SS^5JIPQ*/H;A?5D)DXT9CM:#A
M< P(A&CFQ1XB9H7C\@%@6I=UK1TPR^6 UZXVBAD'9%5^%@/J#4L)<5IQ125E
M,>(6N38\ DG3AM?PM5B8 R9<3:K]UXL12($HTL=&;R].KFD>B$ZLB$J#S"94
MA8YNZ7,K(-#"1;I4JFFMN26X8%,@^"\]TC\K>9T_V% 9.:8K1]-468"WI"'&
MB]&YR>2-97)>;!C(7*1ZADK#1\S>692Y ^O8SO<I'K#EU4ZU.=?#7\E\,8\Q
MP28SK9W<07(]T=FI%6]?1FPZS64M1(*9:1V=GJ %<L_B,'^5>)Y?QE9ME5Z2
M8+Q+@I@Y+F!@3 _GLE.S9'5'_)94%+6_25!CU>94^Z)W9@6N)3A1[6*?7*L+
M"T'<X:B.3X<L.+9>R#5BI/75R\W6F',22%.2TOZQG_Q'9<"L3'@F'>23_Z%U
MGL5OM[D"K$!'N>H+82?'_/][Q<1\Q#%@@WL$7G$(C,)2' /HD/X]!\"N2M/)
MK /9=$6+\XA7TP!D,]9I0K3SDHKM+B^3MZI7<3GIP =85CN;XE=VW?M?<.G2
MG(CT:8?KOP%.9YC\:1<7G\XP^7-P.L/D=(;)ORR\_T]P.L/D_T+\LWM/_QO\
M[WJG_S?1_)_H(?Z?XI\K;?]O\$]>W/T_Q>?>FGY/,C+_O<ZFM+]^^4+@SWPD
MH*3F,4"M!O+E9ZW,[*SOK](8V4M3'+>^K-NZ"P)P_<F$Z)]JT_L?0?/DRD%^
MDQ\A[]T5LQ^3:ZVDCC*UKL!/QE6\.P9HL)U5^!/# ]5OIUNM)$<D%6K+C@'Z
M]Z@@)R=<LT-BCW+[%O]4%:G[+<IEE_PZ9=I[)N//)4/_9.O3_P1_RC5P_TU<
M_9';%>]K,>_N?08D/MP_!OB::QF\W3T&$/3^^<.6_D6X4K$P$Z)&%D"FOF)W
M#'#OS]T)XB7G)]HQ=WUT@0C=>;@I.SQW]#WG&#"4M2![*CV5GDK_5=*+=B,*
M2^@W8:K>4BU+D)K?Q,[E;Z[2=!^BX&O(FD-D0B3<) /G2/?UC@'C?!ZGTO]$
M*3]UVX;';#OT&("3T>%6^MX-\V5_#ALU#Y35&O++4;N*@F2A>O<+MA^_+3$@
MN=MN>"K\_UW(BYS5HKPME[EAA^S[J["Q[?,=FJF8'_&S[QBPW+N5LL\OSG;6
M_\2^4T[%_\;B='1;[AV],(CD;\Y6Q?6-_L.+YTYM\-]5R)LP!=;/;4"\NGY5
M%O)[*^S]^%@X[:=WA9^L\,FW $D[N 2JVNQ4_)\D;G,QN!_]O)OQ TU6HSG\
MMPAY#( E[L^>^MG_0'&Z/%_X%='K0,7?UOBS%IMMQD6<O8Z/\R?]&S*T4^G?
MEIKRM^6F4C!1!=#0])?@(J;JR7?.)-Q./W>FG?O?,*DZE?Y>J@0+U#.*^SW?
M><1$$X)F*W]S!>_4#/^#I*:Q6:$89.";@D]B_?F_F2$RXA-E70'I,>!DK<''
M !PQ"L4YXG<$=">1,_14^F\KO5+L:!<MS)?%V[RK2Y;Q;Z5JI]+_AK09*2^Q
M20(Q_,VOJA6HO[8V-T2W'VY"Z/[] L&I]._78*>OG&:7_S>(.W^56D6%6VGZ
M,WX+DC=_[M!E[^SDG&G)^?/:E$YQBE.<XA2G.,4I3G&*4YSB%*<XQ2E.<8I3
MG.(4ISC%*4YQBE.<XA2G.,4I3G&*4YSB%*<XQ2E.<8I3G.(4ISC%*4YQBE.<
MXA2G.,4I3G&*4YSB_PJHCJC0HBLC/MM0$;9Y7+!9P:C7F7U33FH1$B/"I">/
MU=DJVA4EE^9C(6/$QX!W_O.235X8W;H'T_OWM^BF-3_=;MB7VQ6% -^@,<<
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M']QX5T$]*3A#^7F%%D&"; +.*9?4=[#0]-WWG6\,;4OE+$,+\_%$?<I'NIA
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M4G:]G\ DUVBG])@&)=!]B??@/6'6W5L%K[[L&'TQYH=)C&>/25@#JPX?4SR
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M?;$+B*9!;L#SZ0?3M3+'VSI8Q25.<XN&^B#)EV9#-C5L=XX$N10'#8(Z1IJ
M-G3)I&Q7@"1ZD(;Z]@()GW.?17Q'MBO!<\(F/ZT[&2]_/Q0,5"\2O&>)%RZJ
MA9U=_4;4:.W<I11K6WO:GEE@W$RV-UN.<5>>KKS$1QH@;==H _WRI%^B[=FX
MJ4KVZN(E>!;&-$EWT-;Y),TY"26T-6"HF<WD+,N^PBOG:;+5X1[8'GKAJ>(*
M51:.DD\EJ1)'UFC1'H=R_\!MF=R]K QCZ]VW5^=5ZAI*5&T;<-,Z.X =WQM4
M!".D6G)TE+-BA%8>01I8H73^:I\Y/<B)^G][J^@C> -L_#S3V+;K+(J7H'MA
MH^T/-PX^-+8M188V5U6<!"Q=NG]6BYTLN^2?TE/.4(;%R(WZ1I"!6W%/QB4'
M"I\^EVKPG+H\3.G/_%L7+S^<V!AYXA_:$O/L"0,D )NP]'ZLR,Z%X*E? $<:
M+/&<I#82A,_%&6Z77G0;N<^HS>S5291VSVQZ?QM"^?^L7J)/+!H-?4@?OX-M
MB0(WQ#AP$55PS"P$^9_C"<[:^9S372]('&+<GJL28&EA_"4$Y>;E ZYNIZ4Z
M>CW"10 MCL1*(UVT4[M%VQN%QQ^%*(I#-B#Y/&\3;!R&EQI<T#</=.N]Q*D?
MD]%'+1=L2MVOM'60V!D1S'2D2:WD:".[QUY:S#;12^07&^53>6Q;V>#ZBU6
M=USM,[?UT-3?4OY<E?'3+'?9C9:MXD>"^HK<"C<6(8^M\Z%&]R;5[,(**V+(
MD[YR;Y<)"AA)HWW;1I1MSD/2^ZV1J.RWA;$5@>HQ(>O!FY) I.GD<9#%78G6
MVO?BVI5[J]K: \+]P)<2B6C5KW7C:5:UU3\.TTWDLUVDJ"K'+)<VOE)HO\$
MD_/_XG*B\_>=F.Q7$$SS-N>^TS.BK^6X1!@L\K!>OSV;@P#Q:^:'.F:B+VQ
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M76:<SE<+"\FWCBK?&A#ZM7D#?'""=$4*!'S5_ 2O<]*(HGG_3Q?XY$'IZA6
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M$]?=?I7:K2EJ?.5NQ*8@K@#F[IYJ]!_>G""H4'(A,)EEMIIO=I']?;[S.6'
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M+](%9KQC=\]:O+^9,7)F= MTZ"C14E?GB(3 N!1!687R;,2U>,XPV+:59T[
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M9)5JPTQS1F%9B*P_FF\'-B)7"]W!AV,$\?:\40 &W'85&&L _\65_/8&'^J
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M%/-W9V1^HKX)*^F/V_24ZZA4'&]MMP'PUHOO2 PR+< (#Z/QE"W1"9)3;H>
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M<W<&;_@[QV;^1-_!5NA,NK8110N@/<@#=7:>#H$N15E.NZ-X=HDDKO(IW Z
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MC93.1HY2E:I-VO^@&?/Y\QI:$[Q#5 PRLIUB,1U40<G7V>J.>&QD5_Y&Q(-
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MJE"5@KT]X;(!SKB/PF6;XXV2'_EE,94C8D]#7$TYX(ZAT06?F9_O].MA?\H
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MA<9#[5&@R(P]5)=LX0LKT>6/Y?HH]+H^:4H#2,Y"F<$Q1JHY4D:>PF+)K#?
M/&='O<+;7^<:@\*-5C?"$#5I'E"/)-.%2(IZ@^\/[$A)R8VO>D"<O!R1[;9F
MC04O_L[O/MVQN*7@C[(OA=;NI&XV3<$S>7E/H(D?_)W;C]Z'&=/)KABI7ZC
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MU7/4UI6LKQJ'.#,86*3R$3DN%]@O/?[).\V$<,0UED0,J-DX,Q=>.*2O=TJ
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M^6E7 .P'H5> C=MH,DANC%H_EE/K?P]OL9<X4];L^ZZ"SH*9FHV\SS_".'>
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MX1S0+##SD6U;D^.+2Q-B$/OI1!$GV7PC*:Y?^*=JFQF7L>+P$5_Q.C<%PQG
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MJAUNB'F MVSB"GE0W =TBP,L+IL]0RF'()^2MX@Y(3@,E,*-7SW-<0LIWW6
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M]%9_5]'BY3=NIA8-6-YY0XJ&3JP[4:V,BG^9>^QOU$U!J?=*7\^$6D>1EB1
M=R"Q[CYPE$HI8O']XF4T-OH$YA'><+>)^>MA=9AD2*8R2I7Z M3^"*\FL )Y
MFA%&4;V,X"Q+\1-V% 1/6V;/'+BQIN5U]#@[5=P\.$T&,7X#0(6XG*6<L]S7
M,]?B>5,]WI&\2\N#Z!UAQ-T1.3/8N1:<PRR+$T3A[+8-9PIWO'LUDR2LLO0B
M4E9$X'(QSXG^41=J8J-,92E_X1^1IL0W69C/W74?OS'67^SZF !MDFC_WKTF
M*B68$\HLP&7UTM)4T>Q(7MKYV3><Y)+1,=A<V9CF\:/GWB&'+ JY"*LYS\\S
MA>.H?:U &2D?:Z<+!YE,5-U)]<&]\W^=9.>>PT-2UCO:$^,M]E".;28>?HWG
M3BK;'-#R82)XJ6E GWW$J0_K'Q<C2D-K>,RD&V,J;-XVF4G=19T#@L?;Z)&+
M R&3PHP0+Z9M=%2104]FRE#12!A[=4!X(80=_W)(*^@@X-ZC'IU=\.PO@G.3
M!'"S>4-\/CACQ5=\P!DIS1^1]>;>3I-NBCUG0ELTM"D+1'/1DZ?.^6_#5GT)
MLD/3F7W9&79_9RUAJYHL9A)>Y48IT?J+CYU<UXA&13LQ;FBX+M7UP:(8YRM*
M2'-9K$Z,9163U'A)M"GR#!TY!V\.U.3W.XVQ?[(.'-B'=MLTV6LNYM;Y9MF7
M#?]P)V5JQSM"5R8(IT5Q/Z%T&C: (H+;@LS$ODR:*I7!^.=[7B%PA.R[LX=F
M:>TF#EH?Q&ZN1EDL.C\>?Q+YL_4EZ4ZN'2EI5A$/=TZR289,7L:8QER7!XVK
M'SSN&AK294G+/U]*"&+G#<M.I;H"-'&;Z5[CB9J#R$11W7\R$]CWF%P_SK!_
M6BQFF^.H&('.PYL8]*WG"9>.U[/F)9E!'A_YA2"U[L7%$]T-SR#=?M%]K.5+
MLR,P>(+_+\DK-!A>"'O9Z42<XZ'2IC+V1/SX\--)S4*E[&6D1D78.N_FW"7C
MDA#7GVFXC8?8H3Y#Z:.0P-$%R;*[K\*T=\%@6,*EONRN+&-3)@T8 W ?59;$
MA)0K_?/\U8^H@T5VECU<_VK%.> 3?_M[#]%TZ"L=5XBM4&[R6GCZM=K40D>&
M#U>/G'/>3)J.^V5]!Y[V6PJ$7R6@*'>3DL)\\3DF6F%P#,7*Y1MC9-?)XW>S
MW62CO^34%H5G/,P%WD2$4=Y>SG&AGMNB'"K-N9:[UOUA _W1R9EO;7:'WU8E
M*MUH6M?48LSBI[=]GP&S&A,V >GH$5Y_YZNMWL(>*4MT"U("GU?S;L:TIZAS
MTO<$K>D#553;6E!RRLMH[_% ;4R.V]I'D!XK93/[J>KY9YKZGYTBSP&9B)Q&
M"[Y*1)YGD"PW/6VXS_04E7P@SI&PVL!0+ >W=:H\?GCTGEFI>SJ<<T&TYT##
M&/.U2/;>B@E%<C!'D)4((P>VSX(.:XTM>N4T6&"FKY\Z;:^9_;U4D;:+4-ED
M6,.0+P#"02RC5HU3QPJ$'1^X.W5Y.CN?5=AH'80:2)Q%4E#\O$;TJG'%M<!5
MAOE^-A&=L&OC [<1DHVHM]3-EJ1)55"X?,>DG62C^7$F<2+RW;.G1']VMHQ)
M. /[M2[5[O6<\%QWKM*9$=&87B.-GQNB_%3U!*F<F3>W>% G/]B7T0&*,,0(
M.P[LR_K+;E.6'U$N6V18&&_97;2XD3L%#:R2U3)*<".O\]S \*TWVWZ_[5<$
MI6RRX"G:6H^J*K!Z\AA4!ZYE7I5AJWEU_W6CZ8U2X1G5#AW][)\_=^VQNU_>
MP&^^\9O*FAG(S6!5A#$N]N8L/""R J>61-%9S*3PW-")W(SDMR%Y)6D89(U.
MR6Y]= *HNY=<)GL)L2![YW>^.JLH6?D+\_D7#\LJA1!MJN;DD4]#1"*5R#ZU
M<14;_C.FE+>4A_J)PRE_V&.[0=HF%9Z)23JC0P1* QN%M+R%#GUUFDVE=DSD
MDX1-V>#B-K&P94_.,%H^]H KY=E:Z&6=>")%]QFMDFR4O0,W=]H=6;9S>Z:"
M]IJM9WE8_7E<YB*_IO^O7+_:OV)/Z,OW+E/(82)F!N%^Y.8?.WZ]E&W4\#YH
MJ+V'^;B[72!C\Q'@6Y2MXP)1N B3)72T1J 7G__P '<B<LSZ9?.YY+QO^&UL
M+!1+R5WM7X[D "*SKFQCXN ]UQ'OIWHJRR;F2;DV@2;<<NKN$H4N(_3[U,U2
MGE>;?H>O V+6+74R/@J'\_GAK)W_^#$CWY$4]4^F%=AUV8[*% ^%!TURL@*3
MSH[ O8:H:'2W@\$#QA&S(]<QG<*J<T"X][?Y<X#;0A[D*U)@:R$KI86U9J+#
MQB;* F,&"_E4(/F"ZX$[C8ZBJJ)ZJ&;['QQNY6'/L4:(J:-2]Y9?RGB+P'$&
M>%Z6OBA+3X,N7^A]'^R]CR*L]GIQU-T,YL^1^7:^B]*K+R].%W^.WORK([*+
M[J:!?ZM_(^I95[0<TE&3L>QKZDOTU5<@@G@NR#%ED-,+P]'N>)@%W]9"\ZP)
MMGN90\:8_" 42@;Y%"688&'\,&5Y2PX0%ACQ[2%'_*7)E/ #PU;*K4Q@&J+T
ML\Q#A[NEA</#B9_U\7K7Q279%L$D[MY,J+0/EKX7];IRI[6I4>'K-XD'NM92
M3 FI@7LP'O=K<L[ -.D:(:Q-HS%@2_RXN63_9H[@_F:R3.K[[=$YWP6;BT*K
MQ!H+(O,*!_M<.V3UJ'>Z5.H%Z95A',)AW8HJ@PLHKQ5DJ?[N2S 0LOI145U2
M\.1 *%4-0=+-X[5=&Z8KY<M0;$.$GWVQ#9X7+/9&Y1TQ?(D)CA[.'BS'GI$&
M>WJHU]C]F*E5-#OQM".F&J;N*J<@+F\LX/06.*IL%H?*0JV;1GN"G5-#[G)R
MON87,LGF*_F<X);\?3=R=52O9+#V;=*3/=OY]= 4J8WDRX^-$@4M10AV]:C2
M_7J?U+9?MWWQ&'M\01&0 JU/1?_BBOA^5K0P2C6,EBG*D6'?0^*6ZSD@>7QL
MTTG&,.^''#TS:&Z*I$<(^L6?-VB1V0@[2-1A^'6Z8_]#'<,D=F:>^%4K-:*Z
M3.6Z IZKD21$>"2O"!F- !,0<_I*%)JMY5V*YHDIG&DO[R([OF%9\@RZ:U/]
M_RT'62=PHHX3L6;QM=[@N7%"C3-J,),Y$Y<5S*M^O](I7;D4GC$]P,>OM<'/
M?K'DA98\RQ8"0U5@1/X&.RFI.W1)ZQH!)7MG.=G@C?F3B;W,+-46W>5!O3_+
M.8O T*EM<64BXZVMKPG#Q/N*^K7. D^)+T:6*]O,J_S;_1QPC8(773L![*L6
M<51K'\=!O_6?+F#BJ_AF,03EW1%<B?.42MD59J*Y@? .GL-_TW-J4:Z.$619
MB@]R9#Z:>ZC! OZNM"LW[ILM-VU+/B9:0)CR]BOQLF^U'40]T4\ X5[.I^%,
MIE0_#@?0)) +T+FF6)JJ&AVQA>19>].>%G3=:?_"TP5+(/UZ C\'1%B-G1%]
MI(Z9:#WEX;WUVLFSXO'_Y.]8RNGXJ#/!71\: SXM/7_U(OO%UP^OE5,4#$2V
M4,5$U+\;'^3""I=ULYR1R*Q;T,U2AM!A2[6@&3)6;7JK9ITRS'B6BF2WOZ4T
M2_K"50EAGI"A7HA,_">C_O1S ,3[I@\#.@?T5O\]I8LEKZH=3I8LXSOGFD Y
M>,GW$B'NP5S;R\S6*U'%)-PZ]N8.8EB-41.6#D6V7_!6<5K:P0%W]PMJ7@V]
MXK+=Q<3^6")SCS-+IC)-:<R".)V U8839SSG_JRV-XB.Q* $"Z(+1"JCPXM_
M(D6/E2K8%=3;AA>C?1QI8<NMQ0DBUA\Q+_PN*GO@MU)O$YGH&WL6SJT^>LTU
M"J\HBXBM_F:)[D+7(0CKZU!87[K^:_2W&9.-+I9R1=8E(76CN(_=F6G?WI+"
M]&5+W0J.9::N3;N$#DJ?R$.YORQNB CN8K[N[5;V5LF!Z&WH(SX>AN=!-9/$
MHTW"F"ES9R,>/%FJ^[K+EF"&?8<9.JC?MRFQM /W#3D:#_=*YD1O"#C^+5RL
MG13+?#'D-A8T1K[&/QDR. =D -O1B93L;]\I>SZ-C4- #)/4L6P[#_R^#WI:
MKYHJA0L[O> Y*9B7*2%E9PL)[#KI> @4GV!(ZDN-:'QE7G$IRHB9!!JJV]R[
M;V:NR.@E9)5:4O4W#L*1+1$MCHF7X7;H&R>T&[V(_O#T\XOJU2&9N\/%B1^;
M/C$39 6[H#S(_ 7!4 O[[82Y@*O/;%@YQ7O2K!1@,TL;HDVPUP]Z;!?0JQ]"
MR0AA->I^/(<*&F7?5KNEE@47@#B9HN7^12WM'+V(/$J,06\*12[9G2]0F0.C
M_CQ<](.J ."+Z=)BY;1 /W)3DOG/\E4*S35W\.1GE3 IR:IXFQ?AU<]84]>&
M%T5IW<(@+0>"YM  '!R^^(6HF.G0]F\(REIAIDMWAF3T2]EJS*M*4$,PIKE-
M4E+."E/@%4+@?K?D)Y\SO<^83FCV&TUN$5>]OT'@]^1V&N51-J*_6HE+B[BM
MI*RV)7 9(6K>CWQ2..&TC9\(]>YDS7U(J0V*=-'Q$BJ('X\>S9^793X'S%D6
M$75MTE#9.<!_:ON1W-Y9\3"2*)\B?/O/*OQ,=HB/"9EJP/9./!L>A2:3[>:&
M>84-HGLR;2O>$QF?P;\8WQ/*]*.M4/4FB_OXEQTMUIVL,UYAH(0!Y'V<Y',G
MNTE2BWL#/* <8?C4B/+ HZE1L]FVLM"=TWY#Z+P?!6)*Y\\>C;&-C"Z3B"HF
MM4HZ)[TPM<XM+W(5%?(U_F:&P;.A_^SBB?_7QY5&&?"RTD/6,KG(S2X( 9P9
MX<$<LXF$_$2J]&%U>N]]G9C/<L +!(Z^ZZ^R2HU_R.%+1$6O*&6.T]&L)!U(
MS]1=,+ (6OMB(J$ TT' 5K0AJ)\=&R+&*FKL\9(RA?@[DS+Z[4%$.9V[). U
MCP-66LG2+&DX0YE;-;+9]8X@A4C^@;.1Y)9K:X<ZL[11>*"BT0GU_D?LI1?/
M3MVQTEOJ!H)FDPJ"K6)DLCSE,EX>;*#(M,K$9<&QJT&]JJ>@^2DFLP3KQD :
MQR8S#.VN\\>]2QGV5!KQ+U5.00NA=SD'3KQR/@=].P=(Z--BV/(I]H-W@0WK
MX-=(/OMFH#/8KADUNH2ZA95\^V*T>+?#,G]8F?1 T5.YV73?U)Y/%)EJ1_L5
M(MS%<<CJ&9!0W!-RHGU%J,I5O>ULW8=YIN>Z_1%+$I/,,U>5:K,P#41I/:0H
MT#L8;4[SLW7\MQ>D]!Q0;YKNUX,X!VSFFPPYG62VOS=<L*TT-GV\_N@GRS<,
M%R%G>M63MV^E[T%H+.\8B1?ER8,*NY.#\+-CVE"<\VW[V K:4<_\F.UN&1=C
M!=3C\CQ-8Z66^!,@_E9P#F<L.Y#7@[-ZK>+#N%;'JB4/@<S=O\G[SVS4R>JR
M^G%,4(.&S)NGGEWV%C)XF@<;B7QXR\;M"0?*=+G[C$""E@548<;N'5ME,%Q]
M\)9![6#9JH5CWK@/IND,&A\8[>K'<$374#'Y/6U91V'QZ>-LK6YIGD5$'8>=
M9G^<JT29VZK*;0[WI1_NE[,<CLC#4NS85!WI)35OL R2_O,5:(*:4"^N>O;N
MG VCH2HK55KQQ5!CXG$.!]\ BK^DW?7[ !98EZ4P&:>.A;?1SLC2H?.<]G(\
MBE^"2A,RP,M)9$X6Y@P/VV;T0I:R,5='NE2WNYJH3ZR(T'+7^2"G^8SAG]=F
MC\@(^K5^$CT>Q)T#*!94P*T<KI=SYA82!&;R#<YX9!(&G&?Z\S@2[<AH5>DW
M7"S!B,4FB"_/T#.1F9);Z4U23"[F DU YN).3/I(JU+S7)@<;<!615_]@670
MN@.#DG6;S*Y>$(?G\$I/HMG'W?! BVN?U M-5[]2<N2470.Z83/=,J=#Q%X8
MX>XI,EFEHNU5VR82'H6$%) ]3$[]\8]CUBXC8J[EG&YR'18H]AI"OA73WK?9
M^)"?EFE6T@B23]AI",4L<SQD3-95@BX:Q4&V G_9?%!ES#JNTQ0T=ZM><LWK
MEJA9U[3+WT.Z&[:^,Z0!>!MX5U-K59EI0*E]%#TM@WP%36E4!&*4HGY*8=/M
M+3CZ]XP&<2APC]4LN.>AFF3"G?B7^<X:_7R[K<\,\=G<XO4A15LM7%-/?(NV
MY.A)V4(^H8P.>W GKU G,_J7$J=,5FM(&IA0)"-NMY#=>VU_U_V]'V8/73NM
M?/)6X.\'U^5^5V>#\.&&=W]=B: Z,V %W+JDKNC*'"0]&WY(72QP-&_)-3RN
M=77F>41$ZB%%/Q:\%Q0F.Z<Y4+L:C:R>B4-L@#_>56RE(#ZI2K:^6TJY,=R&
MX+QU=F_:]'B78F2BN,5LQR*]PCP$<'?H$>DS,O<DJJ:,L>Q;E'Q^T<9HSZZV
M\>4/- 81] %2*?>T:3Y;E8,)?AE^KQ@S5,9CQN5HA_5%Z=Z8WK=_^?3*<2>)
MFN-KO1#O+W*IPV,/C?*LM:5)9,QE^FQ #RH>27]$*QL3$E)?;;1.MRH#[W>Y
MTDW16R7)6I66 ;?^%W/O&=5DUW4+!QN"(H* ]"B@* $$:4J+B'3ID$B- DH)
M17HQ$%$!"4U00%&*TDN(2*]!NE2I04!ZCT!"#3$D)WC?3SOO\X[S\_M^P!AL
M,I(K>^^UYIQKK[77.2JGRX<?[_./>0$Y98_UR]U8B)1G>AL?NE/\>WHW9]"Y
MWU(V#%7LF>ZRB>4/*%AJP;CC3HF])'N8@%/]@<?!\T)(?/JV7+_L05JN,N]N
MC>!\1[%4Y\D]C"2I^;3GRF/76XK;&%.,%*F=!KB0!^9=RB8*YV :^Q1(BE&B
ML1S7G\FGL00+[]X#+R50S;<BOF+V!:$'@S#=X5E5&66%1CECHP=F#&O66JW8
M_;/7D'WV-CV/I[CHJ'RKG@90B7$TG-4L5ST1X-'<M\\M00/@,S %$3^!NOO0
MF25*-/UU.]^AP^KK<=GPEZ3HQU.G;F)YQYN4KP4TR?4JSC8\+ &0*H;LXU3@
M*QM\R(["0.H:HMF>!A#VQ1SX6]8 3XFR$87Q>O![JEVLZ\GKUSQ<R@HX[I]F
MCAVGJCR@ 3R1B7K6$18+, 'DO/EA<W?L$)2)$$'5!"'WL&A_Y'\=]FTF:0D8
MS@DO[]Y'6<0"5N%+&U$AEY/<;&VN,[$F*9Z%_RQW5DX56S1<_RBWF1RY'D8#
M1%+Z-F[P'[A($6NK<X0@$*7T<,&3O!_2/>JL7[BN/6B&UEBMT&V&"^0TQ*IF
MH<HR>"+]H]4KQ@UAEE8?\U2=:NV!-QQV)M4#KNZ95^7*W%GS\F1[F/OT GDG
M.?27P%?0NF*275^8LPM62E8KV"WU8C X.3^4^DT;4&.*;2I(28WC!1FCNVS_
MN2SR\2NAN =&4RZ[08B[6X;<C2MUCZK<3.=.Q-]?XP[7>O SD)KH;*#IUL0(
M*W:"!,6^D]7\>>ISXXT5F!3<+T*#^,3J(VBA0S$8/N"A>JU+:7& [Q5X CQC
M"RUV,7&9O)BP:?1U_L&KYA,U3DW&$XOH&UWV*QO'II!.3MH+>],,9/.IL^/-
M!\^#)BV7NI1GJ_O"P)N@]+V(G>+,%O#FM4D: "=C/3#@>-<W=--W&4AXI2G=
MGH+M;2CI1]]7E(B7OD9.7%N#B<*0'<W  U_8$LS*:6KS^!?Z H$HA0C-CF:6
M6@D1MHN=&4#=!!3H#5X9-#=%"7&>,B3FAS#1 .U;2!QXV>5:')*XGQL,;LLF
MB=( P!ZZ-*0!/A9C][T\:8"NK7'1=_=?=BP!H-WI9Q%:WD7P+S\R*T;GQS($
MR[>!4<4-[3/CD=A:F)1:% W V[HB/H<V$'#O;-%S2L,0L(V/^6[L*+6<:8^3
M: V:\.,JN6 6RG&FT8Q7[NE@V?(T=R. :,D9O3B_[G'R2B%/4-+S!WGC.AP5
M_0F=MT1\,!^4G\P$(J31Y]Q[%@[6FLN#M6QAQ"@]*&%B;Y3'5FRY)_]>;]VY
MF XJ6\"[<J6KZ'6'FR^/6Z?5@X9!B\BPH*=EPRW65&(C)N<*FD_;YU) NLH?
MT9B"HU8CU2Q@9R@7)B_5_U0N$GX1#MB6*R3BJ)IP&'GAX+A/^O&&7S3 ^LA$
MCXD^MU<^Q#DM-7?93Q%QBA]"C#Z3868Y$@-'YO0P5=[NECH#LD7-U];W=H'N
M[9]O@:CK$+W'0RN[7B$5R0HS:W.V 8$V[_VD0(U481K@F]J?[N:*NQOTI18'
M'BYUP=A7F8381%ZEFBN?JL\TYB@[7VC.\T"KH@#[-,"<B+-@\0P'0V4YG,*(
MNBF^P[+,QXB=L8#QT!V&U.$3MC<:DK:&0K S-AXD45ZJ]"^]8]I>)7FJPY>O
M2VMP=OCQA[4_]?F=JH,1,;/KJ7H&RJCH+_MM=HJS2"].#9)3%?[SE)[0!>"D
M*_02&J$UX//H/@U0+_P[)@4;9,FVWFY:\.24Q7EX8S2K':BQ03+ 3T+R0>#I
M!UQ:TPPVG'MM3YPWQ=?6&79-D-F!-$!,W4/_6;T;GU(OG8R)K]>F^I9?,;A>
M*X4V88^)'Z?P#HUWZ6F^^5#AMUAOVC*6X%S#.;% 6'UG; LD>%/5"31 VLX4
MPG+H>,[;$N_?+4*)VI/9$0:0;._FXO5UBFGQQJ6WM:>CMQ<;GA.@S\1]@J5/
M?\_Z<H,EB1]%['L1]'BHSHCX2M6,I6\.=O=.FK5V^D^ *0;T).]>P-2D@UWG
MJ&0_L_T@Y_LG,ZG7=RKEBJRV/JRA4T!I:P(2ES4\/ [;(+APFMFCO%OYTX/5
MR(/+63)?&V3OQ*_"A$(W_<C,)02N*_-NAD'A;8I4SO-MV'TFY#AX60SY%/;$
MC +.IF^KKM<Q2.[=]"]?:0#EY,U<[14/-N^GG[**D!S6!Z]O5;W__:D:4H0/
M J6#*=K$2VWYQ7IVL>-L!*D@G VAMO%QCVM*ZNJ)F^U)LW4UT//4Z]&["?=O
M8O*W!92=QZR-HKTRB-O%!9B$J\();P(7Y[L\G7=?9=R;UCCZF=.2!E#_C*T,
M6*B(J3QR74MWX%.U>V^M\"+PI>VYU\V*;?A''N+/QB/<=Y:1)Y4-R"^NCUEW
M('VJK-/*\XG>>N<"[!9_'[TB38:^04@-'4_[<G9I+_:X+RPM+?=2?:H-:VYA
M(U49V?&HZZ!SKWR!81=SC$2D 2Z^O[8'$@/RE".?SE!D<FP#$M9!$NO]FHUS
MGSFW(R(0%W.=1IB \?QQ3_W9>@)SO^K=4,7)OE>U2X6/KQ;V3':DG+6NZ\8(
M)):)2C>B@L,0"T2757]B3$^MX[?3TBLC#8D801)Z^MN&_RH$G_1HZ>CEG.B$
MI&QHU./OU83G=S^_UD@PY?>X$)+E!1J,2:WFEBI63=Q<"J^S*B 9S'V[?&^M
M&=%5%HW[[ 3D*NNY(V("*MR^%"M6,)BX_C+;1+Y4"81A<?;7KT<+_4RKA9MP
MFYQ,D@6(10/$3JGHCI"EOO?P.7Z^KV]5Q!=L\"+YUC\Z#Q_^.$RMBM  /C2
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MALOIQ%<;B4^A*ZA.HC\%%91\X GNAO)._$IN0KQ^<+ITLLB8_934L3AOF%8
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M#'#K<A#>1H-?5$+D>>]7I]VQ..I_GP7.^<U@N=,P+3NMO6A%5>#SP*^Y<*6
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MC<[M0SNIH!11XJ^$1C5#V;-J?4%DA:_)+)X?V[J];AW=1A<69@N?5BKU% _
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M"*71]=(%O@WR[%1GP]U!Y)_FCD,T@"*YSX8.G"Q[!YX>"[#+SMA#[;N*3(4
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MU2?D&,<W(9U762^+6.UD# NP8_)()WD:P,GPAN_=+0O>#^DO57E7%">7$)G
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MKDRRSV(Z]5D5U[4+K5"? &LN7Y*VF+F?%,@DP,2)ZB-4F**Z(MA=Y:GH/3W
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MS-8:\LG/AIL3K^&$N2?W*S6]SSSZ2+B58]RSX%<Z^6UH(NYZ<>F74=]'PWO
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M=#[PJEB8/VK(TZ'97:8]T-[ UO(2,L)!OI#WA&(JYXT/Y,U^I=83/N><R=J
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M!LU>2T5 Q@$A#6=W6Y.1W[,4ABK!MS^%"NJ_E\.U<@@,UEIXL0%EVVLN;&>
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M&AQ_K3IO<_2^%#JEE,($K.QL+);.ES=*%K1Z+SUN,K.0[71-,%!!2RMQ))=
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M-6A8OW".3_X,17UQ/483E%B@<WD$-MK#GWP&G*)*7:,QUJ5T7?)-.ET4^\1
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MMW!\]V]\&9@G09+:--3(!#&G>6$QMH*/)3./V]&M448MNQVMZ?J#M6%G\&F
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M ";O)[U#:8Q4)N5+97A)TTS35N00) \6BPE>N3I6D.?]D9\ "VO:3HD-O];
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M2OO7$8*6MHIZEHHO>Y#?/,,/A;:,7^F5O"RXXB*NX5;^#8$%-ED/.AX0,,*
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MQ^T4;/GF![<277N8ON?THRB"T1(/QRTI$:Q]!79)!,N%&WK1EJ<:T\(WWIJ
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M[NG)SP&_(RXS&V%GJ9Y/W;SX8OIP<-4>DTL0_4^8+:Y>V5B8=M)$;%[)A)$
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MN*8<#V'#B8*^JW5O7+I%KC> YN0_.MO"Y[<5E^Y=B2' !BFR%5T+@G,X+!>
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MD^.9WJ<C6E"LM?WP:Y:U Z>L=G7TBW4L?KZ\!K@]NEVH(H<3,+2LV5:NWUM
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M3L+X,06Y!EJ_4R???S;?.,JN>VA97CXJ7&C*X>*2[?WB&H R/)4^R*XC171
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M3\-*1C1=PGFCPOT6Z\_P^?O'^F*!EZ$NT.-^V( 80QF\0*"MU@U%.2A"YT:
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M'RU[V1CVJ8@,?LPI)*;G>HZ<W;<MUQB+. F)X"0WH[[=QMGVW+*RD&IWC=C
MY+GXV[\R[+H<(='/<IW_E1(SHG1>4E /Z]47\2<L*VVZ)WLR.))]M#W+Q@A!
MMDIAPIKC2:JB;0''/W%W*9A+OI[E\:ZX4QM-='_H'ZI3C N:FY>37F;MA8,3
MBGZG6\L8\XO5'2IO\NH=G.B4_^=$9\MVB-AS_-30+G/3GT1/2^P8HJX9XQ-*
MBW;J49] FOY,=>8PC-)+W<]F/::/W;;= UBU+,7-& 9 * 'PY ;XUK9>S_F!
MS\8L5T]\U(F;K'BP=+E$,?&/QQ/$NQ,8!9[!H,%9@ME?B=>:<C-28T!J<HAM
MG$+#O+G:E,:/#0NR-7/+M$-R\_>E7O?59%7):S<9O_/3;.@OZP_EI:J.(8HJ
M;H5ZN!<'BNIT?^CIB';CEOH<B$$\6R$]9/>(C[FX1.<_&[:-<0YTBA0(> %\
M4];-LF$TAGX8![U'QKIV2"L]0-6F0%W1!2;O[M27?(Z!.S;P5!8LU2H^<67/
ME[EM&=PD"KO-/MPFDZQU?GCHX<6HJ>MCL#$8#/\LUY>R4NHM')H]%;\9+T[5
MV8M48@1&%Y<2OT\X(!I=_-_UE@J^7]WXE+ NN5[&14PKP_[+L<SY$GHB^VV_
M?$N-E,YS4)*'KMWL1^#;!-=?-^B7TPCK%7ELR-KAEB:K^QOA :,9QP;<RJ<3
M.06-FQ)"EU'6(S"A/4#FR!Y 9)X EL&D]Z1%),.PNP.U>X",R#U (&, *IJU
M=L#[_(*U8O#-C;3=8,?M$DRKO,\S]HK&SU\<]&4A57<3T:DB9<UQCBV=YIUU
M6S';)3,+O[C>$_L47P@%]3!,/<^M51U4X4\THY?^G'%YP\>;76K,EE^A4CA7
MZ+0#.&OZ#TWKK(4U*>?X,'MN.\Y?A-2AJ,52L7&V9)*=U:73$0%JSC)XWNF7
M7K%TWJDRH=+HULJ)B:JB+]R@<4A-/5Y;D?4JF8AJ=85!T6&O>7YNBWX,XJ7X
MYNG)R>V2SB;#E4WO;S3-]6<!2G?-RGS/$5=W:(1OOIM<T"_] _N$<*Y@Z8[2
M?FKWQ+^F=ET"]"E26VWCL7B',5SI5LG4#NC,?#:.,6I<\Q'I'K5<_?)/IO=Z
MC!>?Q)/$K6L9LC^2KYF*CP^B^816AG95R;N-F;/6VFY,(7R/*IA6+H6YKWZ]
MIGWVEE_8=\6%"7K*-JVO2F_.4=N"[^PW1%M?25<PZ^8JJ/M!D$QL#\G>DS3-
MNU%Q8Z#ZD;>N:8360-6"E=(4?X19O&5S5])S*W\Z(E*(4S-979\UNB''?U'^
M:U[O,?#0$<=E4_@>(/;"A5FMR#=VL<R^?7,PP<BFIQ@8/:_H/8V-X)(/EIK2
MQ#%QX\PT$$:V;'BG-".2C\C;[U^>,2715N:+>,5\E'QMB'7ME+*^+WAI4^^^
M.:KTEJ=JJ($K"OR\S'WN&]2'A\VB-:"TH2V%S^_3)?ZQM"-UC3?L9:?3S?+4
MRE!O0^]7[/RT4BK;EFRI>5Q0E=Z>FV5I>JSWJO;Q6Z>K/F%,RUF2"2F$#OG+
M&/PLKO36[A9MMT,9-[..F*KXM[L"TI-K,,:A&G9KR;5KCE>GFN^UH2YOFA0+
M]BV?N5&5?B,YNH\M*:,HJOU*F4=^5UVU0Q-]FUEDOF_4K1?1;X,?!\K=<Z^[
M\EW]!6\G[ELP1X!<@TRF4[7; X7GJ&(CTRI(]?7WFB4C"X-_H 5$*R;XB2C3
M=:@7W^H9W*_/;6V[$&T\;.3*QWR,9IC81;?+^;HIQUMX4E->:CI8GIMIE-=1
M53Z2BLHGT%\I%1#DX<,G$$B^8^VUF_"G\  Y;E_%A3=WQ] M8)<"="0^QT(2
MN%IB=7ZEO(+@8LR>JJ$W0@O6Z&Y-[7JX\[:OL,?LI@!'&2=)3@>!Q&2$.A<Z
MK14GA!DA'3^#ZW9*W/8 BFR[F^ ?RVN(R.#9M>".^'G8.=)V$&5_[)X8J <V
M;>2'J]WC(0N_V&&VVZC3V1WHXV)RE"M'O[B2FL[^+>I-GE?[/;/<R@@. 4BE
M*W[.I7F&\ .6@CD?'F BDQ8?$B);X=N[K>?L9\O]P/+KFTXS"3+_ [()LU@]
M,CY]VBR]<S+XU+#6C=CO-EF?;M0&U("7;!H(S]!J=1OWR;*L)ZM4Q^O'7G9Y
MM3!5<[K/8AI.YX4W\*U.\$]^+BP:SZO[DVE2_\YPA5U/M>Q=C"T7Y'YHNE%2
MDD#' XZ&SI14MFO)/L_&0XI%24V!Y*[OG7:.%X?D2-(?-]J/E\1(.GV=P#\D
M@S_5\3$,E%\,F!=,2.O'(7-Y1TQNKFGJ?6IACMIZU=+/*<@</8U;PXA&B8IZ
MXZ[ CX_=J0#6]4AOF;?"O21#YT2L*7O^X.[%/0#>DOQV72KLERFIQWHT>83T
MJ&6]AU!0;^@L6.P5W@W^\5;>+!+^2OU#=TS;5;-:7_=C[1FL,U&)C^1*"^GX
M"GK2_E2+Z0^"D I="$QI*^BCSW@O$=?DHU420KI+3,_C FCYRE)L3#1I[UMY
M>7TJPUP3A/N=H=VJ+S8,2SAA'*782KY>71?]3#Y>:;2":P-/EJU1<+YP1C ]
M(WU0N:=)V]-'>G$#EM/(2SL9.%XGZN%WZ=%)@^'B:#MFM- [XUY(=^MC5BW'
MT_I-LJL5]H;A-$7.**2\?3&<BTY$'M=3ZGC1T<M7$V\NG(/#MO['W^M(A0J5
M_RCQ1;982:A3%@,\O]ZM%32Q@$L"' 6\R/^GQ*5 (L?,UASW@C9OM43@ZX$@
M['Y?^%>;^)DITTU<*@X0+F83MZ2>.P==9I5M$Q;XD D'J"?W$-<%3#89DW'"
M0(8C-KCPTJ_I,]FJ@43$0:?F.L1P%3186>N5''ZR'[EJ0'=[<0OQ:QW1$??[
M6MH+;R7:VCJ=@#<&F<A#VL5Q@+5"0V6F1$&\S^OL!]G9D%B),&58TJ8PS>D:
M+**%-;,H^\".DE6P]&$!5&,^X6F.N_0+B)P0T;3CJIXVB(Z,Y!72NH#A*ECL
M<$C84<J_7;:KJ*.<D\$N6!$$9$2I<'90YB)B(RZ;@P-H&+0=N8G4=7:/:;!5
M#O0P/BSU>*HYORFF8=(H4(O *AUM"P+.0?L-@(/9&%V_D]T40PA%68Q3[0/Z
MZ@Q*C"F&!K9(X%=]BL]NQI.$7SWDP+R?RV(@U^$N_?0HWJ'3AH. /-]+):2>
M H 9KF^N>DUQ++L/=C"$93AVZ*Q5& Z(Z4WD)=!HS)# 1&?^$Y/8E?%.407Z
M"[2LF,&D4525" ZAKK<RJ^HFHZO0C]7W*U_+C0!CQ1\" ':A1L@W$^/UI(-H
MGQA1*1HM3K]@D";JL$##WUI*F888OC+]X:D@L&1Q46L(W:%+@&QC:N<_QJ"_
M0%G[)DZ8@NB'D?T&M!;@"$:LHLCE&JQ44J3*VKZ'D49H%6CGJ]) HBX<( '1
M:F=1C7,)!!G0"D;(:0@J?T3=\EGY2P, * .3N 9<# 2DM4#+=:J&;>$\T6K\
MXS%F<R(H86 %UX%N<G7-!>2TDOAM]]TL,:5]E%?MI'\@",B*5CD]'GDP-.N(
M/9-X&R2'/?G+6)C(R7(1%V$  !C:EYO(D+\'L."J&\RC"#:6(8<C!AR$%_I=
M'].PB45[O1>]8&2H#'[^TCE]Y[&2"/X,3JD>UZ*3>/B6$=?V1"9YK.(7_B>C
MLS!5QWE3X:RC@MK\XP8M.I0Y 34I/\U@-7CLA)60W9+P@9WX(&Q!3@C'-\TS
M;5FVRWJQ'SABC:2MLPA.632/?C=2A'?V<"SB"8'OLD>$@68V1<,L^4T2Z7DN
MA</(I-_E0\\"HEE24<(T;,[N:(]PJ04<'BG\@@-4?6#^$4\54,L""WI!_0[\
MU"N*9D1TA $%3<Z0R7[QU<M?A&E -=@K'>I9FZ'&^\?&N5^",@/!SVN$0$#T
M(GM*=WPF7B>>R#^N_/=<H9S@=@X:Q7FG+,:/-M64K=S=[:+=[L,/Q5T@RPNF
M?]T1WCBZ<7:HAFPQ9N NL@, '*!!N$<$(,[?&P2T7KR2-_OZVHX(,E*  P[
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M!7/[A_G*Q30ZT7X8F;M\RZ[,Z^"WON>D;MA?EE"&^Q&#KYG&OL]YJTUZ^PK
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M3/E%=5]LILQ#H-+8"$K>]+K 6-YW%MHM\\0\Q#QU G_;-PQ:-V[<5C\!+&L
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MX!X\,"7]+>GUNZ*CL]:.-?@S;.J@V7X>XO&;C:L,YN"!<X>!*XSPUT<+5GB
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M$/(J[+?PH.X*#C:*!Q0-MPVWB@(AFY?&(8A1R"*?:9B94#A.MDXSHP%"=I:
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M^]B8I0A],<R+87T?XT3;/#G6"9=.AMRNK;9]/1<J&KW$R!E XK:AW\@[?'O
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M2M\EWE7WPF*)I8#O,XISHBM<&>F^8L1HVTWB":8X_GIR 0.D#'[OX_F78\J
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M"]Z'6EWJ=K]0,=''4\ >K$'E9$IV97;_J**N0"A0^ FPI9'@47#<90P_?-5
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MM5_LM<D3@'1?_ O$N7C]4$LNV#6)FQ!W4AU;B9P"F<KQJK_GE2#!2PNN>ZG
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M8!6M*/Z9L/3$(@U",Y;!BD[!=U''2>6!-6-A/5[GK4?QK@=F0-_+C7/SVB?
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M/YVM&XHZ=P,5!V'E@PGN S"O2IJ\[YHR[[**\,^>A3'PK=8#-?[3N>3H<O^
MC@T0J#P\=VCV]E(X7#=*QDD(>R/#N!^LGCMW[>>\2SU2".7SA:M6!T?#@J-(
M6=5J)])6)<-IMD*L0B;Y>I&&WL:1'0@"\D-QX90JJ;12>PGMW5UB/,[9@BVL
M2TR<\QOR"4C]_.5I_*U\<WGE/^=#,F?#.SF#E68[,6 =*C,EI%66?KJD;I9X
MB&>ADS8$%=?9;Q@I&P*D C_VC#-2![2.M-$$1ZTW'R74+PKA!G$>9LNMUO^*
M4E<NCL)\N0W^WS"ZD;$'VND.!^JO_+=0H#0CV);0J(IE5=KZ/?"8:)K@["B?
MN?_1&(=OOTF?-+/LJ-TKP1OD6C-286[3/>8J2>45'U#TH7RW[_3 5",&@<*)
M;*J$& 4$T.F&?.SYE,*0R*;HH7LT5^ZNPMO18.W6T)6DN."IJD:FVCKO7,('
MZ^THL2S])9 8EG_U"3<5OBZ&$$N4QR\G'V5DZ)R#<PWMMIWE ]W6_R(=MR&Q
M]DA2(2N1'S.;I)())?EY('_9R+L!*<H<_07(P165TK&^3<3FQ_-0\/$S<=2(
MX%_@RA69<+,$)<>$1VN (MSQ/= MF"R/';X3L&+"X2E'S.JK^7>G@5=C\7^_
M5<< >P9(H>6A(@O:.I\_6;1",9KW#I)RZ")HQXZC)A,W##O3U&=X3O]O]);S
M8-9-*7!BSPSWC+F7V5*3UFM+%-UM2_*OL8S 87)-U7! 0.CPT=T$+S<.R;HY
M4TT:;3E6E[O:<]PZ\+?)MUU36@UDSN8>E2=CG@"F!(_A]JVEK\H#/^:XB;=S
MQ*.Z&RM7#OW(HBYS4FQ=J_\<0B,PR5, 7$VT(M2+V/4V<"#9D!]M&ET\A+1I
MX;\*&GC"=L*,S$EGY>BM=H)$[?".]7P%F,A\T9-+8ZARRXQ#QTR("QDQ]/!7
MCV=J[2/.-W7W@F GDS('RLRH %NK0G.0HN&O!8;DE7%6"V$*:ZK8U"X9VJXG
M@,YR!P[?^HPYR#$0GO3&!SH(8\[_U:Q/ZC;X'YS^?+BF')=<TDV&*3<ED7TC
M@N>J5F D.S-"R$SK2C1UQID+S/P!C+U9J@Y<N;PIG&M8%4M\C+THG8=H4!S!
M2H2S+^Q@4CEB$/UO/#FN[ ^(MG;6ZR/CH+<+5\^A$ L\A\RQ"M7/,<"NPPH=
M3K7E;PAZ5/ZEN".]M@2IS4?N/R2ZGU-]GOT*8*Y90X>IYNAFBR*:\K<>^PN5
MK $2<B) 9:R'%Q52[]:[H@:03CYC!-?6Y(S-YT1/@"^545$,'6>!D8G<X./P
M-Q\)06*2;6^JXM_8,[4Y]76IAS9Z(MWF!K*YAFN#=P.S-YR> %QN&P+/R>FT
M.2(7(!/!O=8B00RSGG&>VR;K!0S'2?(K>1O:[!9D:^OH\2T1&.=EW'SVN=*%
M?2-_A)&"ND12)OTM]0*[7_4Q"Q>=NP)!3+;-(.ICMD+[ZWAB <,WV!K:[K/-
M0G6$P5\<2&$V^052I96KC"K-TPUE2_.;'0)OB&U##D&DSG2F^S?"_PPOGKF]
M,%%KK$2CH%M1VIR/SOE,A?F*G04QD>8"2R+L]XT*Z=GJGSYK0J:(6%+)UV'Y
M?G,[!DL\NQ[&V!W.\%<XK9%LEJD4QJ_B?"-I*<BJFJ4))C.5%G6,,NY7^OMA
MBYLK)=LH 9X-=B#&7_?5,%/2@BK3P!SS]EEE(G24GO"MB77HL^>^(W?TV%^?
M  U D/KXD!<,.W7&'L:\^D@[FW/<Z/"*X4HGRJ7 MY<I=6 ]K7R)N",'-MGB
M68Q.4HC5BSXP#H-42^&C3PCX+G*MOC&2'YD]=^TA(G$*HK$PZ]WLI-5;)>01
M93^4H8L,%C]RM"433I[$QJJO1AP*:$/;?\PM#C89%* S=5%OT6E6/_=AX?KU
M9O83C$TS.&^3D9E::[]X,42KLK\_OCLCK2]9,SNZ<+B5?YB%F3+_<:!\[Q1?
MXK69Z^]_MB!QA6\]>T0W""LK+MY'>I<>\#MDOEL(FJ)R%&5)F[X$6PRU0Z,=
M[P-+[-J9]@N<FM)B=(D30L22XS^G:[I(Y.K2\@1Z]P7C.SLQHO 6=IX ,&N;
M]@RAYWJQH3_=^.8?!1$:>KLL7%,?8V!*6NL"5 VAH^HJ!2J!KNM"*-)BJ_=I
M17:10@L0W_]<)QA.#+4^<*)/%(+SK$$Q\"0,P[)_YPX7ZW;A.W?1[>(A,X4"
MO9.LU %6(O!N5G>EN2/A]TBIEBE+4J=JI;W7.G7[],8?$6A%*.,W%GV+=&7&
M;\HT'.[_(*"^7-75M08T>Z@]67U7Q\JDF>_^"W\U!*WMTN0TD&-"=A7H,"(+
M2=S3_#Y"G,;$+ILQ7M]+K1_A&SS,(7$#F04S+'R.73C=_&8<_3V$9?)C1_NV
M"]]<[#Y/G7, SN:#JLZ"I[UGEG5?^#CAR 4U>]WX"@O3@_VY?V5Y-9DP>,]*
MWG=5'"?1R<-S82IV)TG?YWZG_@W+,I21@5_ZOR> %&36AV,P;"B(K'D>]HYX
M^\=>O(<1\29BI0>AHMG0[DV9/H%G8EP_P]"<^JA#N;K*W&2HO9S2V.1Z*;D8
MX>L\U,$EJYKWS/#*]U-SCDXH*W)0Y:-VP-)WVI+X2TG]GAC\MBV-*,JA<="%
M^<;P;Y29).O_1=A7!K7AM7N&0I%BQ5T*M#@4=VWQ4MRM%"<$=Y="<2O2XNZ$
MXFY%@A27M,&#.T&#+__WO??NW9W9O7P*,YGDG)SGIV<RB2/GB&E Z3V^GO/C
MGZZ?B\G4]7+7H\HSVK_B=(*#@(;>(!@1]Z6E1@*;\ BBM:T>95BRP[T*Q!#@
M-'B94-T=M3'%L>E)*IC6RTN@A%+$.<P4GRTE:CKQVQ]2/&7\]4OCF)[AI(>*
M4DF3Z'RV>)/UNO7GI)YK)I@8=6S(#C 3(1Y(?S*?*EC)G1"VE\B2?J#)I#'
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M=,PN6/!=-(;ZTH;)Z<PF7ZH*KO'_-8\^SW\YS)LFYZ3YW"<]V@KJ3U>:;?9
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M:<(O;JTMU])7-2HE"C@:I#S]D49I;'DV^PH-T[W#Y0/(4N,3DX&[-N;HP_Y
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M1>Y%]+RIGS#%7_I-ZX@:#?F7?@>*5C?W2Q';B@:&FF[U?6PW6ECH";=0[?9
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MDY>HUPW&HPSAY$UO&Y;^=+T4 ;W3_#HHA=]8SA\)IK%NRB$7'U*FB.\+S;O
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MF[SB\*^C*[0 ]MBTLU[<5>SV ,*)VW<&&;T9>J1C3#L+O,>,/Z^E120"?]0
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M1>ZK-$YS-'YG;.N8=K2T]!NU5>$ 6#J:7]4FQ>?.2$@0+Q8L+3V<*!6.=+C
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M!V9 (EZ2X'+;WM0L?D@7P6[3]V20&KIOT>0> 07A[K/:(DOZ_FTYP%45 Z?
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MZG+;_9[O0\C$(,(DZAH='*Q"=C3ONWA/EHIO=J&42RE>G\)Y&@HWG61]40^
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MS!P4(<-6"RX]#QRYK(G28NGXGW]P7,_RFV-S437[_?'CX'$4F+_[I;=<:=@
MJFH=;\W=!\X2@"4U:"EI]O8"G#),DIKH%Q/,$(Y^7?))&/689]<8?V#!R$\J
M0D@=UDM,@ 5_Q2!=(>GR1P-!))K6ND:']_LW_[WL;LZN#.0[XPO97(MO-]IE
M9Z\7-)JMQRM5G]#B$=-G4[HOZ$5&4ZB$;K2[C]1-G;LO3DE#+!D/8"\J;<J"
M>RCH;@MGH20(QKXV8U.,MLZ&AM#Q8U6=G'D_[WX0A2[U,S&_ '8Z"&^VG\P)
M3KKYU\OPP_+OK]B"O,.<T=SW;-5CJR9%!%J7^M;Q\8SM"S]\-:SSFUY >XKY
MS7D26)?5;6?XT3#:]&)O+,>&>TG8O!][9 ;6JTAVYK'XPHSS31'U +GW!549
ME(Z7UI[5<%PZ63F0EF93P]+5^SK V#F-JE(QT-"ZU=[1O7V':PW#SC933"V?
M)F&^-=M+<Y+S3F>C+T^P'L[]ZAW3VTKRPCWL=O\RD7UHT@))R.J,&PCA9=3\
M35GUM:/[1DORN(BN' Z%M$,9*K.;^X6 <H9+2VNC6)S"H"3U-'?@0% 5S&@1
M\7WYH][^+G(^MBW["Z7+K%5GLPI]^\.D):WIBLD2^^_5B*!G9D %XY-]^S:=
MBYG%IE(T(%^%T,G0URS\T6_SC7>JA7+P;E0[T)I<0\XTS/LHK^$VR9C!DGSB
M@\>.7UB&(T';X:+(CYE=2?9)@;\P7#[=QM8?\A]L'P&"$M+B25KV#Z^F^<FG
M+DSDER>E%@F[L ,PM(P'0^ 2>/^46 8K.QAR"!R7GQ%BD<2DQOZ_1 #7$1C-
MOEON($V57"KO3.W6D[FC>A?<?8,>!(=#$V)0\04J0:AO%OZ6[:7OSRT)K8]S
M' )^ NTSX+6V9HL0IH_D-C-_;G6MH''^?%9EF=C9KB/LJ:"J.)9KM7P)E!NH
MT!J[T05BL,:#-,RKT$ZO*7J,.A]P*]O$FZ^$RJ9TQTZDHGU"FBH8!Y_ #:A4
MM3-NJL%A<$_AV6>Y'=V]%TO2TB/CJ]T3@H%S2_2I]O?_<!YZWY_'/\LZ[SW.
MJ"[R3I>#7L6Q:S6U6VZF"5VG^"9!:2]&D1"Y7,.ZD\OJ/"/#/=TVAQQ??5)L
MFGXK^:4B1"(&Q<4=;C>.]U>9N<;A LIW=I+T\31UO6Z.C"F0G-^2I]MT:UI#
MK8Z2( ='$^]<V;KFEIQMW89H=I]8PK04_SJ\\H1C/_4<YLFBJ04]$\/)W3W/
MS 1^$.[NQ>6^L5!(@XF8.B(AUHD;Q-":0:/Y/F;<9"_X6S+**E'(A"D;W0MO
M-R6G:%KV9C^6'-@P/&UY*>)SW(9Q/=IN[KMX,1UA.;,AX]_G)LS&TQ<+UBW3
MQWGM41_G_SVO<G*5R'2YR1>X>EI-#78B<DD/UK1Y'I!.EV7:QC 5Y 0<6XPE
M&=NN 5EJ6TBE%ZAM@QJ_?280OL9IJ)*M8CP/]N<,JC)5"V"2A0O$I9%#42RH
M,AE1:]84ZO6ZI;=MJ@WL27U3,TP-3.1<'-;9.3Y2J,'9!;>?YKK^9^A-@/TP
M)YAO8W@K;.O3ZB&$&8W &!H*<JKND(&SRD=Y%.T*?1;);_[.@LV%&?!TK.)T
M(_5=^$@_I983?CVHX$MCX_%31O$=IE\1]"SCSJ)9>$73SM'M@>^V',Y?5>^"
MBH* N+(+MV*.QPW78:.#+E=M'NO[QLVA#_1_@8@QDH?"S^G5?DR"DXP@.T8T
M!WJB8?$S;4ER0Z/[F %*E5_)^@O[? K4O"Q6+S![>@][2OP99AR83@[G9OX:
M"?3[IO2^YF'U0'5\ZY*DO49>;FP\UN"KHS6WE;PBUYWS9H'#\U14*/^%HH!K
M_<7Q-5FCU,UY^B- 6B!ZL<F9EN@GPBM*G-.JZA'PR\G-B7.DWL=ZD%GG5?2M
M3;&3-V._:$F^3]5.QM\(506E'QI'KTPJ>=^^-J))H"L#8[^;O7/+OV-MG..?
M.(CB'V*TUN$9@K[(L7"T&)\)^W8.?@3TP 1R?A0L KF?TI/M1"6*EX<?PQ==
M<B:<($P*\0!?=QH2DF^=';'P2WZN.Z<U/^P^.S?P'XBPF %.WJ'DEWB,=5V!
M>]^)]Y/,LR4=S9$^'T P!12K@.)4!;#+I!Y>,Z5\:;[)7V^S'OB9BJ6[D"OF
M(=PQKZ[>*A.C2TS;E *KW!\E91E"O;4\<CS"6P8*]^\ILLE'#;8/R#"\3OB1
MK1=Z9V4%5Z7M5RDSZ*IFDK2\G&Q9+!6_:V7R+/<GL<'-^>'^TSLBP,5P=SC'
M0.C[!,6'C?-]Y#F)VAHXVX(LY-RHY>!P>O,P8C?M-=YB3G4LE&?U4#: ?<TF
MVNFP)0>[O3GV1G"N]TYTVD7MAT(+<^/XZ2-@T)1J^KAKP*_:0,85CU(PQ4KM
MUC0WS@'"X=I?-[B'^(D#+J5/4 ]@CSXA"S\/0DH?4/I1^95[8+M(S-;+TQ3;
M4(@PY_!%0TYTLJXHI>+$&9W<=Y\7_YYO<JUEZ@>3HR )<ONGG>.;=@289P\L
M$-WAF[.2OS(.8XP=863CY,R3M%\>!+I--8K-=A_(IZO\I=:EL!7LB%];J$K+
MUALIKYYLUJ9:0'/]X9WZ+T=>),IL$"RGP M_PH]TFV:K:AP=0=7@@C0_76QQ
MVY[OP^.H>$NX6.4&2N5*I:]G5?T(L6@!?;[E.XKG&WH$JVK7=.(^CP"SQ$<
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M@D)1X/]$(!YT<3IS_@9YMFZ8'A*FTS"+B;13W$> 9F&2<5H,R5TN(>,<I[^
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MVRF6"=O\QA &M?>7CP^N3T)U^ZWQX=Y*V6R=.\@,N;;/4G4T_6V$8CHHF^Q
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M*_:\5M<DT\+1<,YA@>TWN&Z+,@YXHZ2&W?=2,@:?)B05XJI.Q^1>"D8/B%'
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M2\_Q&84=,:>DK$$D_X5RI]^(>MKWDU\%0LV.E'K>>*+M=R=+Y;ZGF\6ALE.
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M;@4YOOVU9Q@]M+<G<QH@="-E$J4;!R!E:%7&9 ^_Z;12@SM$^XCVKYV!?W%
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M[\2/*E8M-A4H<;GO#KO@Q:5$!!A&Z1 M*LFFFGN\7VHC))?B\!(=*1RD).^
MW$SA&*W(OI(L,2+=Q^=\G19'#-B%;Q#.JZI/7E]2O90:\I=2,] $_>KATDO:
M\$*IR2^4&D5.;4+YHJM.9K8W, U.B/G(FA)!J=Z0K(&5<9H]"OTP:>0LJF,_
MN[*"_]DX_9C5E+HND*L:>%Q> %V6DOVE3TKG!3KD#BP4N9\=_+_T0(X_%&9?
MXZ@GP6O#;EB_[<@L\-A4SZG.EMI\BSL0,P@*'*%S$<)=+#:W72>">T;NS3J
MY3O95D[YX0:8PGY['N7CG"[H[$M82(L9UW(?*V+?OYC$B ^V7EPU7F3KS0,Y
M*K?11K5.>GE4X(Y+DB#%BVS32Z] .*K#'4-35_3M]"GT2 =N&W2YA?I.[I0G
M@GWV7RJ9N@T[]9YTCO&AORB</OR6K<ZS2,_F(K2MK6'=(AOI$(G$X.X? (=9
M?8@2-TT7YEX36D0.(H+J*'RS?/^9D60$Y8 04E@5W4K"<8/&<RQ:V-8LL??)
MH#E.A-=G&U-4S)YMFP1,P7?&=O8(4W 8?V2-[W_,.+8NCW;V_&)[/)P%"NE[
MYH;[IV/II4"2K7:5@>5VJ)<UGW;;$V1Z)@$4?WF[MXVQU^W$:&&00D<Z3)PT
MI\L_]9Q8/:%#J\C)O2=1QQ\J;F,,RO8>W;?:I]X=\6FEJGT")AA+N@Q94A,:
M[&(A3_'BQO@R^U6N'[5!(CT):\ E#209)@HNA>Y2PP(G?W/+3BIII>$4J<U^
M%7IZ1>,,F<ZW7C%1 -:IM5Y!H(\JJ2RK$++,COL&)F)Q$*)U5&%H0V1G[PP<
MM7/LJ$SPLG1!)R'M0>YFZ&2(^BBG>,A3Y2Q&!]MO$S&SVH[' 2>O#MO:,S:W
MLU0<)7U"\1Q]>JU8C7#567008?827AIT+EFKGM@N[)J;HQ%/8RSUU3:5%+>^
MOOP/B"A?O'10C,)0;$B&]I?!,-O14FA?<D[@E72T+ZMKE<&2+51R6_=$S_6=
M(TOT3W<'4B".4T#Y34U!E)R]7K^SPEYC$WS@/@9-4Y$(,L:ET+<T2CL^_"GK
M->D!I"WC0]%:+S,0NSG<5WWK@M!V4>_][#G/FM:N@4SS]V-8G3@?7YQW[AR\
MN1IAK-T,_P3G#SUG5;NW_L&?VNS341E*TCMV20) V[J9TO;S<2Q9,C V'-U;
M61F:E4$PV@8E.3%1T&K7+[J5\8H*.?+-.LF)S;;V4L.\CM]4'J1N[^D#N]*V
M8AU5X9+=$8^:HKG9EC&I6EH^,<Y$FZVLHX[/S<64_U<#>LRK_4\;PBQL\5%X
M6_AD#7F C[V4K;6DL IRKC^2(-#_6F#D8G%QY1?;(^MVM:O!--A/[THQ_D'L
M5.[[6?_WK^=?$N0%>W8".8V"%#UUYAM^:U+( S%L"W$T7/2FPL&Z8M2'Z[1S
ML97]* R08\%?E6_&\76=! 48XTT-_0@T!/E-BTW^]YV@_[]1&^#RO?&D,J_]
MS]N.(-DACV#G>VUTTYU:?$2X9+@*[!\@%**QG&ZTO_.M(:Z29+-)O+-GBG#Y
M?U\4FHO0_>_J5<E_@!K'?X!"LL;8GUX9].NW+-8Y7/'Z,)YGFJCY83H\N=D5
M;K]E6I2422$@CO-ZHR][-7]$![=9I<@KU+9XKQB^S8[$15@-;D_9K"\G7,$:
MW;*U2Q.Y]7+0X5%POJJZB\@F[;\/BCH[V!@2?P%^64[:EJ+4.NP.*4+WIK!!
M78H!O7=Z)\M5K$B_WGS-#%KB7J0XP9\;SJ%?=/MPHXC6UZ>C)3HG.CC4<RI4
M]:72;'$QJARV&H:0+.<X5%RF2JP)V;)Z3%8D?F[M?HZQ=5&-76L+ME]1%QL?
MADY%NI75/+)NS3E]MMPZW\<;BE_G$1_R0R#3+L8&X"*R170W3ZHE]'D;#^F#
MMU$%+W=51Z:F0Q 0Z=[:OXPS 8OS&_>$F@C7?P":B^CA)\F:?X#KUP6J46WR
MENB=(G]JP[VG(M-ZR/Q>9K#;*A_ [S>QNDV7&!/C,224\V9WTXJFO1L=T4:%
M;Y.FKNP (4[E:N1OFFWR3:7PNCZ9JJL*^$'\-C?,VR6RD('HEQPR;O)=C=?U
M9LAU%15N+U^+&+VQC9>/WQ?WSL):64,S)YG[<R._HXF/@C8-3Y)$LU+7E!QP
MME:"C/!P$>'70TDQXP3-VF+J:_8"],1 '($):]F="'-$@/-VM+R6V2N*V_HF
MB+06=$1)F&SO$;EHX_@9YW=2_Y VY 3?2TUO&$MZQ+372%OL\7ZAT[-_&N&Z
MQ1^Q&?8L?]$HO-HQ28!_.D9^#E\(R,;AV-^[0MFSR]3#C;RIQ3/66X5:1Q(%
M40O7,F;B"V)X?3UI]@3D=-KE0]Q]%#%E6N<OLHK!;8XNJ+*G@#M&@)]M=V@@
M)=Z,! F5:4C0/X !I+4V^K9A]5&TS5JEK9?%5:ZP#?7@<D0\U#+IY^PRL4>A
M"_*.,C%;^E/;.E[\ ZUCAMF#]KU,=,U3R["2\^+?A5R2DR3;;LQS,"O.FB.K
M(RO5'\^?4M\B"AV^>U+'V-<D*;K*49+:FZ]^=9MJ^-M^R9<RK%S[W1MNY+G5
M+A^MO'S[#W"&,;Z_O"9/EC/B:79U@E@8FM+75S.\;9WUY6Y=V(<5_]"&FFM!
MG*%?62UE^]/#A%*&QY>>>?-WQ(D"^F@M2M?(^=OD,^>;W&(>-SF^R<5OB[,C
MQ\SGH/P#)&)^^@>H)>F^QC.X&&S%9Q7NKY<YCLA8Q?HS# !0T67(?M1H^ )%
MOA$G0Y1*-I,U%6]]C9;"$IE(^W1.\]F)]*<SPN.FIE =4AKR-5QEEF?9W:IE
MR22*^,T;TX3!>,FCJ4Z+1^GYJM-G*MLID?+H3(\PO-RN<XZ6FY/<O"KA6&TM
MV'#PX_L"Z*_J&U&)+]96+8;CCI<Q\+4P"<"]2D%1LHQV W@\%Y8."I&&N)TX
MOCOT@#1YQ_2M,V?JQW./)UQKD5R</!,FPAE5(#MPJ["\YMF"))(+B+PT/[5?
M@02J1HQOX+N8!=P(;\'9_&F]BP'OL,( MDKTRQH&E4S_[VT#>4@A03G.69XU
MX=O,;QZ5-[V H9\J3.H.T5>B6HHR;#S?=6:P(4(&^.^-^Q\F] VG617@0LPZ
MC7TZR_(5P?HD%SG9E<I&< 5*JAE6MMB&58.UGU&SDU2=+#$"JH>B)[3;=X_)
MK-I/AP'7MEI4 Q^*Y3=0C,&GJ7R),C.R'E&X">>1X+A-:;/1(_4WY7I/&[M\
MT-;6?P!TQP@>GW8^N%BXO5WINL)OS&C]7.X1CX>"3W$Y.T%:C\H[4K"+")X)
M5K?16KUG00P6-#9#_^.@.90<61$<V[#R3?T)O1Z]8R/N[IQ9Z<]X!3]033X9
MO$7SU3#Z?__4\D?>QCIQ$GW\4,9S]K8HOS*<(>AU2E,I8[(C#[&8PZ@PL_<-
M<K/132P<3771#'X09MH\^SZ1MLVSWLP%#:K_[1S%;+=7X*#:UE?Q'R A/"3@
M5!CMB@ $^P$_"-QU(7R].]YR/?H&4(II*.SV+>5T88)"?? ^)S)O:3R@H Q2
M>QY:#8[Q1/I9)X*/Z*':02Q,$*O!%3(2P)!K81T3Z_'JM6+(C1KG97T"CM<Q
M4P"!=9MXQ/?-.7?='VHBF6>&].A,(X6",?=!-S6VXRJ+'1]W%)G[V^+*>#.Q
M%<TOZ1-?K4JH6.T/KU,>;)1PF-+M%"S>+Y6ZW0AMX-LF'^8 NQ=8JT/_I-:1
M^I;8Y_]T6=V\)A4/M;*E9(M;[$D$)6$&B):&,89M>&!VA$HH/.E?UT1MOSFO
M+FY.]Y1D(G"_03%9C$5\DW5$"_<E%W9(EH.P&>V(KS;_318;+ +X??BA;I2;
M(-LX]2EDB&,"!D-4YV,0+918\P>,2XY\S H F0E4D-5&Q0A9_:BI=;/S8EBH
MV51FDYI:C@[\\DIZG?2VAE%] TB6&ZB1X-#QY:TD5;\]^P7H]K7R@:'V0+%&
M)TR/&J.R1C\0S311>Y1@,7=7F;LN^_\C!FHCTH2*%_M8U12-E>.&3OY$>''^
MH2?WG>]=91H>T,)#Y/9<"F*$:/2:3;]K)K3Z7XZK2@RS>3*@@GXP!,T-0/W#
M,CJ;0X-F3"+E10=[9-<Y4 T88?$U2H(U=XK=X9JS9^Z8WQ3X.5E&<UI,$W/]
M[7 '-BX5;HP?4$9?/"Y6O(?JDMK:^.: ZK(L)<LA32UEKHXXZM$ 2KB0FE:J
MPU=8M9%\ZZ/IE_?A^'0M'$'YJX9J2"@^@HV7"D/?#LJCY<#[BU+PK!3_Z^-F
M^3EYXLW!;%.MA3QN'$3=Z+=.S74A=F5KSQ5RD@:54??=]$WA=N@?*F@7+O@J
M^0Q--TR9V7.BV8ETN$31 %^1^1USXV3RP/-'(2#$VR\VV9:L\P'/WKJ&P,3=
MPW%+]=EG 9.*T([(^RPG>=N> 9.O>Y65S=[RBM8*F9Z<EGJGM-IUG:,IVY_-
M^HJOFB\%>ST',FU84#X0].OGWR!DZO@_6KLY;UI;YJ];;\0)U]?]XHX<3,)T
M"E0F.VX!UQ-L.F65-Q0KWL#!V\IM1X2!?O4UN1?;]AR90#44!H#]+8K$- L.
M:#?L:MYN;61E5WQG,R'67&8?1R%$BO2GY778<Z:V"-AT[&L Y=;ZY[\9[]%S
MM\5,C_Y2C97[?@JV?GX/TH/??'1;L<'7=^^45-\=D29=?4->CW9PI#2FR-"&
MJ9'>C!9U,\&M];L1+A7O:(.:_R%X_1BR\T?SY].\DS3*K?BN#IPJAG$.G.F'
M+#FG5/K_\/5686U\4=MW6BC2%B^N15NT2'!(*<5*@>(2I!0GQ2UX@>(.18H6
M=Y?@[NZ!X.YNP<+'_WT/ON?D?0[G8%]S[=EKK?O^K3TSNWB4-NG'^7.9U]Y+
MSH<7CP""),T6C,96"'!:U,#;X8WF>U$[N3=?R*<VOO_"*U&9V(Q40"Z7=GMT
M" $I!77ZT\/W"C/B/,_R(J\LF$@+#T2:PQ\$-$[5H@QZ\Y'.6$<K06*-DLZO
M-5\[G&V<Y45<=MV+3GM\N2UM,!P[W/#UM)1NBEK\9=7/8(M&*SZ^W.S65_=[
M@=*.W0NJMR76::N[+K@?Z;;B18H/T^?Z'<6H8&T_N/ <BI(YRR&I-_F'F+:T
MA@CW!L>JQO1*GNPI1N>;-C76$71UA:U^[!=_>-]"<*I[>X&(2,V?]?33F#3&
MM@-X[DEZSJCNV-TW0^C9'@QZ:-AGJAL]]158%":RM;2MU+W&1?#MYQ.IL_S"
M7@Z?,'X WZN>&O/#SPT^1[6UFB?9 !=]P^>LD4(TL[V6'D5QRXYLC7\\: OW
MG1%YH>P7'*2'5;55=@RCHIGOC"C+,=RJJ&@P9QJ57B(;UK6FCO_[^@8U,O/S
ME^M;O&9&R?&I6WL0-]+(@SN)ZQ!$UK[%D@0L6.BMLYYO? IDBP:/X,)[^]:&
MRN]75Q3?:^NB<36'.*+J+Q\!:PI"V?,:;ZQCF)$NCP &VO!'P 'G\G!AVVE
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M6,WN^RHI3B->!2FTPPA[M_V7C!8$7HSP1M1=EXDC%1X!C&?KJ)925O4DZ\7
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ML3Z[>)W8:G;I6.7RJIX>Z4:M*3NY-:W0D27QFOU-N=?OV#&'_D/=J1;>4Y+
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MH6FQIQW90X%J! ZU$(\='E7/N[[^L7>T/DCZ6OCF.V[:=HC3(R H\Y2KXQ&
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MB%B;#'^@D\YO-F3;P[-(W]P+:^J20UR9>.IE@  K);D3IE_O)XB9?)I\*OV
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M_)>+S' ;%I=I1GMHQ0 *=ZP907IWC9;L-Z!29HJP)O*TU#NWAT:.["*$OZ7
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M[C@ _*HM+P#?I.O33TGM]^1K TK/$+6O:-A10^G,QL5E)9FLG)2T9OJL@39
M7"1.=<;.?<R.!T:F;#BK#>"SJ$U1\9KUF-<-D83D;7&L2+*E[O1M#ZHA_V)9
MM[NBIX.0MG/6>I)/ GND+,'!A'VB/H6FIEY*J.H=X09M\ 754I)ZVY>\$#<V
M31F"NYA_1]&> E6/SI4O/._(1?],SL6X#2>FQCV.EBT9*+)<N6^#F>N/\N[%
M:2Y=6L]V:ZL)YIS<2/& IEB;&Z?\@2!>K%YK)2C7'X$X7C^.B;N?11 E# M
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MB-KXVJQH1=R)4<P,9()+ZYMQ U[7W@+=V3TC$;RCE@5APIN&+5]0G0K8VM7
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MN]>AQIB"P_@MHL;:^TG:%MHMDF(Z&MM./^M=8-*@)L*2YZS4L#W1@ L6*4.
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M9CAM#NN*?X=_63G)=?%I[;BK\Y8]!J,?2O_YT9/3K:U2P(ML@XF 'V!$+B7
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M=1('6E](OB=*NA]J'FW%GCI3#+H2YPB%K"W??";OM_1@:I(J64^M_K )8GQ
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M)BY(RX*AH\6C="0&Y,.JL?7!V;SI8B<[DRTMZE3.;#0\^F7%T'^GWO__\?\
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M?=E&/TJ/STVSP363(.(LP'!%"&DJBVYN)F*O<')1"_S@TG:ZB >_ZLYE,^E
M1KR1D,&!F,A/8#=E6WM7L)ORO>H-VYN](!5,4/WGSKJ@^L!9DKFV3M%]^OZ1
M[Z-[IWTN*!KL5L3ZU/ZU9/G"'<!R6>[)PJ"U']7 PGT:?&SHMNMLNR/NI&>6
MKK'G:H19(8[5)6J]Z[N^M0+!ASTQAD"*0OR?J15/-&872SJI@!Q3#T0-N?'
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MJ6+U-0VS#NLM7WE<J0;)G*CQ\:BF&KG?U[6/O#NB9\_#K>3#/&'_WWNH5Z\
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M\?IV=TXH;4XWORB\S%[V.##M]R_6M]>5&[\9QXFQ3%A1)K/>*D&O,$)X?X)
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M5EF6+^11<SEG0V3;P[,*+R><@2_YC7F A?$\8%;JQ?B2["O1%>E/V"P$Q4^
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M!+BQ,"'="<\NP$C\S^+EVS!?]P%J-S$JFJO[#"-_F&U#RS.$_;#83$%E)_A
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M?C)S6KX9O:RSA4OKYU^T_!#;D[!QE&O!-<,E(WT84WU6F^[-^5GBAQ!2WPF
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M+Z\*>=?@RN!V?&<Q6V-" !#LH[ED<-PF?1.C?^/<GFK.0!G/"Z'NVPY9^O/
M?.LGWX?3ZDP"[>RC*!0'G]*[3"H2N=>BHQA;2NR)P->4MS >DB65'Q'!5_;3
M.Z93['90[^'Q)2S<AG.%]VB3O*C+VBEH.0\^L&=:8$+JQ&P08)=\.^9R)%9O
M;B=>%KC?DZAZOW6U?5OI$".&_IRMHZ3OAQC7432,5F F92#0=QL=$6867(P=
M8^\^N+CZK(<X]Y^E,7];M$WE8&O45Y<]8J50LQ*$MA3>LRV([O6$LVD:E3E5
MR6+=EGY,#I:[9DTEAR5H9-?;XZ3],EY:/#'TT3#)UM9).$WJ0KN[TT#K$];
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M+9L+S%HK['3,][E^".*,)$2T</:.<'@M)!D^ 8#*M&@6GB/98B]<_VVU6_O
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MO\^.B!FZ8FN>BZ2L0^AE]CNNRYVM_=W[,[L[9Q7C?XAG*?IK7,X[ GK;B<V
M;SWV#S4%(BD\0$-/\_JL?[=ZA^,48%)3!U\UF/-#BH)!1J55ZXH,'E^T>;&[
MMNC;_/LGGP". 41_%@3]=<7ZVX"O4M6'C^XG8Q6NS?D'3TW3-JIQ]U=IZ_F
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MV]Y[ [8V\G=.O ,$_HWUJLQ?C7GJ1,N?'EP712^T4W_Y@II<5^//P]]=#Z4
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MX1C']4(AMB?H@:$KH-#).TETC*&F<@.9GADN$R ;'(WX51:6,V^9^_N0OW^
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M3L]2$[Y)3DE"UIP1Q!,>-R':_QBJP/[,1U.%D%+0$2C.&LCVZG6\=TEH7[T
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MD^>'(2XU5N+[)Z#I5L>XE[(O>JG;!ABQEV4;X>6.?QN#^TOMPG3(8=LYNK<
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M4ZRV^H6=T2E_YB<W/S5_.ULZFD%(>-LZU];.)6]&T0Y$';Z$0]835!48:(F
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M>[&LCCSZLW T?%2%,M;V_^$;X'_U7_U7_]5_]?^?\.YF_P=02P$"% ,4
M" "S@%Q8(ZN\Z:HT! !3?2X $0              @ $     9V5R;BTR,#(S
M,3(S,2YH=&U02P$"% ,4    " "S@%Q8\T$)L?.I 0!+\A< $0
M    @ '9- 0 9V5R;BTR,#(S,3(S,2YX<V102P$"% ,4    " "S@%Q8+Z4,
M,9D2  ! J0  $               @ '[W@4 9V5R;BUE>#$P7S(S+FAT;5!+
M 0(4 Q0    ( +. 7%@]>Q0')S4  /G? 0 0              "  <+Q!0!G
M97)N+65X,3!?,S N:'1M4$L! A0#%     @ LX!<6'I]U>_,=P( J2<7 !
M             ( !%R<& &=E<FXM97@Q,%\S.2YH=&U02P$"% ,4    " "S
M@%Q84*Y#[= !  "6"@  #P              @ $1GP@ 9V5R;BUE>#(Q7S$N
M:'1M4$L! A0#%     @ LX!<6,_+D1RG!   "R8   \              ( !
M#J$( &=E<FXM97@R,U\Q+FAT;5!+ 0(4 Q0    ( +. 7%@)0,;REP@  %$S
M   /              "  >*E" !G97)N+65X,S%?,2YH=&U02P$"% ,4
M" "S@%Q8$L<.19@(  "<-   #P              @ &FK@@ 9V5R;BUE>#,Q
M7S(N:'1M4$L! A0#%     @ LX!<6!O?GUG_!0  [1L   \
M ( !:[<( &=E<FXM97@S,E\Q+FAT;5!+ 0(4 Q0    ( +. 7%C352GC$ 8
M .,<   /              "  9>]" !G97)N+65X,S)?,BYH=&U02P$"% ,4
M    " "S@%Q85FKX;J44  "*=@  #@              @ '4PP@ 9V5R;BUE
M>#1?,2YH=&U02P$"% ,4    " "S@%Q81.)39NL7   %N0  #P
M    @ &EV @ 9V5R;BUE>#DW7S$N:'1M4$L! A0#%     @ LX!<6#$I[VC1
MJ0( ]!X# !$              ( !O? ( &EM9S0S-C$R.#$W7S N:G!G4$L!
M A0#%     @ LX!<6#]F7O/4V ( 27H# !$              ( !O9H+ &EM
M9S0S-C$R.#$W7S$N:G!G4$L! A0#%     @ LX!<6+AW$E>,=0( $TL# !$
M             ( !P',. &EM9S0S-C$R.#$W7S(N:G!G4$L! A0#%     @
MLX!<6%)*U=>UD 4 I:@* !$              ( !>^D0 &EM9S0S-C$R.#$W
M7S,N:G!G4$L! A0#%     @ LX!<6,Y!&.>O< ( 2/\" !$
M ( !7WH6 &EM9S0S-C$R.#$W7S0N:G!G4$L%!@     2 !( 6@0  #WK&
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>gern-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:gern="http://www.geron.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gern-20231231.xsd" xlink:type="simple"/>
    <context id="C_ad45d3b5-1c71-49f5-8e18-c743e63e20bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_804bcb69-7593-4583-b546-4f5094a6b055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9e0d68e1-858b-451d-bee9-b7d9aeb45b2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2e8f230f-35de-44f7-93b7-6df504f45fde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d275d231-4e07-4121-baa6-cdf238ed26ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3f33d08-a5ce-4365-a047-c2b41669086c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ec95cdaa-3268-4317-a48c-594ad28bd481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_03cae945-a223-49bc-8a34-e80048f4e61f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-10</instant>
        </period>
    </context>
    <context id="C_794b0098-1158-41ef-a669-a1b32cd93046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d9939d7d-974b-4606-83bd-5a5ddf499439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_5b6ebae4-b1af-4bd1-a220-87fe4159e558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9627054b-a059-4769-a822-511b43eb7d07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49393210-70a6-4185-bfbb-56a280b6cb40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="C_f6fcdb67-4d24-4d5f-be19-775334a4320f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_827f4149-4d34-435f-8a68-7494c346ac68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_56aeac30-b895-473c-8b3a-f12592932ce7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5a771635-513d-4f44-938f-c72a1da4876b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_510848a8-05e3-469a-b372-8265983b572a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4d1ea305-4988-4375-9ee4-69c9f837ffb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3bd9d30b-b6ce-417e-b7b2-8eb4d19cca93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_56700b86-6b39-4ff6-939d-369ca954edba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6102220c-7833-4b4f-aa22-7bbaf7d6a11e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4d124dfd-42e3-4007-856f-2bc59dc7e2da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_42c6935a-1d5e-40dd-ab10-35f9472606c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5c78574d-4d3a-47d2-9453-d6f12deab799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_29eb0b35-f0bd-4b06-8287-c9e8fdd6d5b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:ClassActionStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4453fc4-f1fc-4c46-81b8-a6f6809e0b65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_95534f32-aee8-4d09-9da3-068375f3be3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3bed0edb-6d63-45bc-b6ac-2fc53a07d1f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="C_e0d1eeee-15a6-49e0-b2a9-feba2070ca4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_2d9d0c34-60e7-4259-a55f-9fe02c166dc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3f7e8c6c-6681-4a1d-9f84-ed77636d8cd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e3194e6b-9d7d-47dd-b6df-8d8c89d54d48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_70402503-27b5-4f37-815e-29f46b76e9fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_75ecfc92-1a60-40ee-a4cb-7d76a1d3e92a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_320fa289-b36d-4239-a6c5-883f073fb751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a94a3320-6443-4a71-a8ed-f5a63144da7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_38d32bf7-1b80-4b24-b2eb-46f7768d7421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4a5892be-7d37-498c-be3e-05e931beae2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:SubsequentDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cefcefdd-0850-4f7b-b6b5-cd1f2132fb46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_11088b90-d0a5-4112-af3e-c26b5cbb2191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:ClassActionStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-02</startDate>
            <endDate>2022-09-02</endDate>
        </period>
    </context>
    <context id="C_ec2e5c75-1f30-4a48-82c7-38c0000d374c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_31e1df9f-50c4-415c-947c-3b83ba778c1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9edf5ddf-277c-4136-a6a5-53a0c72bd66c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ebd1ac89-5dde-4a45-937c-75b1eb1b2f48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="C_95d2171c-44c4-4ef3-bcef-9a3bf9ca3146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e685bf88-6c83-46c0-b720-48d9693271f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="C_16cb4e12-d0a4-4036-b565-a780727a5c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-27</instant>
        </period>
    </context>
    <context id="C_1fc0a461-b7df-4953-9697-a90dae088624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_4111e6aa-d02c-4fab-8c2a-dc8d69eddc4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2022-12-21</endDate>
        </period>
    </context>
    <context id="C_503221bc-7adf-491b-8898-576757f733b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8069d28b-213c-446c-bde1-39089012764b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_7906f3d1-d5d9-439c-a646-5ec2a8601afe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_f483b420-dc65-4430-8e6f-a781504fe525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e1c57478-5d84-4116-a7da-630b0b684aa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_df5a5ad0-ae6b-4ec7-b61c-d48e757c3148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_027d36e5-94d9-4e80-a37e-f864583a9ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="C_ff875ec1-8c1a-4ae6-b136-1138204345ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_dbd86ffc-7423-4bbf-b014-4111ef73acb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9e13ec08-4d34-4c19-b5b5-3b79b45e37fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76c77a60-0095-4c7c-b9a6-6d9d39af8387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_76b2a7dd-0da9-4a9f-bf20-e3fdac920246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_6cd1fdca-3697-4478-905e-43127481507e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_472cbb86-89e4-4a2f-aaed-c8771e492ab5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d042016-74bf-4e4b-9d87-54569fff49ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0f69f345-ac6c-4afc-bd0d-534fc2cdd78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f801a8f-cd52-49ca-bf06-5622142e1b2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_5aba5b57-05d2-4c06-90d4-6885ef672ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ff3a58b5-efcc-4001-a2ea-2794d695b861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_b74ea932-55f5-4ec3-97d7-4567ead94da1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0880c107-5216-4914-bd93-f39768e97006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_93ba27f0-5156-41ac-9f7e-063e7a0e3462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-15</instant>
        </period>
    </context>
    <context id="C_88e8fe22-6578-4995-bace-a30be752ddd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_be269b1c-429d-477f-bb7d-ad125a3758a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91f09572-5c03-4d4f-9e6e-6b7a9683db52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c84962fe-b876-484c-8ac0-436ed90912a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:SubsequentDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsPlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b6410ed5-b65f-42da-b01e-341e5ebcf276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3891a9a9-b40f-43be-a57b-26dd8899f2e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_6310966f-16be-4280-aead-d0c892e948b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d0942a03-12fc-439e-b31b-902f477607aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25ad2b3f-4a16-403c-a2dc-3b7d1fe99046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e976b4cb-7c40-4469-90e7-51a6622581cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1520a1d5-d2fd-4004-a5ce-578541558369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8fb6bb85-bc11-42d4-90c8-60d500a4ce63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ff30090-bcbe-4192-9979-96ad9f967d1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_cdaff13f-48a1-4aed-808e-efa7e46b169b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_a550d37d-7683-427c-9abd-810070f5905c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_44d11214-5ff1-4fe2-9231-445ae761557a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_270b5c42-ba2a-4860-81af-6be293878e33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_94686802-cc00-4b2a-8c6f-27ed9da5c87a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_12a38d5d-ad5a-4d9a-a905-53cbdd8ad7e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c5bfecec-6498-49b3-b2ca-dff2fad0c618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a74175ba-db98-47c3-a243-217ab36ff82c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_44f56c70-bcea-4e2b-ac28-fae20f129a98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8a0297cb-3318-4836-a868-af5440cc2bbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c52ecd16-7cd9-4157-8e8e-31af27e39a63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_b6536834-7d1a-4219-88e2-57d47d5dd378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9909923d-f176-4cf6-ba61-369530284669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_89681771-d544-4757-ace7-4696d541ae50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_950b9119-6687-42b5-9831-7ca4ebac5451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7e22f4a9-1f60-4ad4-9a3b-88792070760f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-10</startDate>
            <endDate>2020-03-10</endDate>
        </period>
    </context>
    <context id="C_2d88ef09-b3cf-469e-a8fe-49f54977425e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_3a0593af-b72d-4eff-a7fa-e7458afe7976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74722c61-6ec4-4448-b0c8-a626d2b72e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_01a342e9-84cb-4a8b-94b4-0c633e0e9043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1e899757-4f56-49cf-873b-25770295bb58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7346f9b8-492d-46b8-8c82-4d22ec08ac7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5e5d5abf-c356-4752-8616-9b666f658b7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0c872764-390c-4717-890a-1fb8ba1afba9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_042608dc-1dba-4a63-acb9-58cb22cee7c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8226d454-2be9-44b7-b692-bf6354a4b418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:MunicipalSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b446414-84fd-4c21-bce4-7d4596128fd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_aa683e66-a550-45b2-b8b1-c738b0dfae20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyLeaseAndFosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_46da631c-8b1d-4cf0-a98f-1721c6e53088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b86372fa-858a-445d-b041-163879e9a211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b3710957-e7c5-401f-a659-86f0bc21e8ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e1a70717-d878-4158-aada-2b23be1cd942">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b59a05ad-a041-4c67-b50f-9f5d30c4be93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gern:EmployeesAboveTheVicePresidentLevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cf14b58a-81bb-4655-8483-d56e1f8dafe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_730d222b-ee44-44a3-8ae6-6f60f92122a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3acb4904-a13f-4209-a193-1dd7ea1e9043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_82f9062a-632d-417d-b946-eaa6dd00480f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9a5c4c10-4219-41cc-b445-c46a46a9c509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f7589db9-9bed-4ce5-b958-b8edb41a3509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c819bdf8-44a4-49a8-b407-9353eb20da0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_6812ec1e-cd7d-4990-a1fa-445d65e04803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f2693cf9-67f1-4ebd-9653-66d0ae99298c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_d9733c1c-7fd3-461a-9714-dca4f2863d20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a814b358-835d-4bd9-9991-025af00007a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="C_09926111-0e38-4a7f-b821-d79344c2f8f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7c46d828-b7f0-4eb1-b271-019ea82aead2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_40e9b0a7-aa9d-4ad8-8b64-211cce52e280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_34991f42-499f-4b50-9059-0999669562cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-04</startDate>
            <endDate>2020-09-04</endDate>
        </period>
    </context>
    <context id="C_ca648008-6ad8-4d06-8ece-4407c06a3407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:SecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_3e6e6755-b0cd-454c-bd57-da4270096040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fb78444b-50bb-4a99-b63f-30026eed0bd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f95129c1-8a90-4b89-bb9a-b7b27d613844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_eca18dbf-5f65-4638-9ffe-5784859f233f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a4961fb6-61f4-47d9-9582-c48ee1cf31fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5bf7166f-5b00-4240-90ed-a7f7c7a104bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1754f765-5745-4731-b5dc-3a11a9d12c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_c15f606e-8272-43fe-9517-3931c73040da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3599ea48-8821-4d91-8b3f-c643d3f1153a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_7fc0d7c6-e2ff-4bd5-b6f5-508937b233e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_23c9ef8f-d893-45f7-9dae-127a81af3541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df1f41e8-3c99-453f-9b1f-eb930e82b8d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3a2cda13-d3d5-412b-8639-f1337e897a80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d87baa2f-bd55-465b-8452-44ea0c0bd760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0a1035cc-6adb-4cec-b9e1-c39d76644c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_7e59e3e0-f076-4d12-8cb2-4da3978cb2ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a432a676-25a6-4e7b-8197-e0e0d30df151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_38ded4c9-172f-4a2a-a52d-e82dc8942a05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="C_58825751-7a3a-48d2-a155-deb56a5efc70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9015a27f-f086-4d25-b575-d3055945fe84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_7f268f91-b8d0-43cd-a929-2ac72e87b0eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2eebd16c-0eef-470a-90b4-04639a5fa0b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="C_e71ee43c-b505-4d11-b82b-9dd17fd5ffe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_933b24f2-1289-480e-b2b0-cd7ef795363d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dcf8dab7-019f-4b57-8582-d13f9fbce0ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8c590e1f-224c-4339-bfb7-fb2401f33f87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_aaf64096-d2f0-4874-95f7-f1e081c29515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">gern:DerivativeStipulationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:InsuranceClaimsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-21</instant>
        </period>
    </context>
    <context id="C_5e69d88b-4f35-4715-a7e6-4dd1f9e014e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_dd0bdfe4-5cbf-42ce-ab92-4660dc42c7cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_18fdb42c-1e4c-4ab6-babf-f250735da19f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_423727df-44e5-4ea3-a181-865b8e657957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7044d4ee-a54a-4427-9cc2-9922f4676346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_49ff1dd8-46db-4d4f-baa8-c884bec8fd8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1d320b3d-6dfc-4827-907c-1c7a097695e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9c110582-d865-4864-a523-b15ea80bf6ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_f48fce0b-30ab-418f-a2f6-a6573c219376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5b06c91e-d34a-427e-a1ea-6394120ede9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_c14e1cc2-f8b1-4804-970a-08b5df83f4b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_71f2bda0-5d65-46ba-85a1-918c8c1ac142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="C_228019f9-7d33-40bf-8f26-f89bae5c27ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_0998544a-c764-4cf1-9f09-2276209f95bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_404e5fe1-4fb6-4444-9f07-c398ecd07fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsPlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_43c6bd94-f041-48f0-8b71-ece113bc20c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_edfb6d0a-e261-47b0-b5f3-062c8bf0db56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea12e420-2fee-416f-88f6-87e5a5b23293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7e3140e2-0589-47d4-86ac-5bdf695ba419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cc68db16-fd2f-40cb-8dd2-0fdeb8ec048d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_688486b0-96f1-46aa-9bfc-41e54da2e10b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_30549aaa-2d2b-429a-b2b7-bad54c937228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f6afc8ee-1a57-40bd-8ddc-ffc4d5eb3fd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_37a598a5-3c81-4923-b06f-67a5ec38fc90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9eb3c3bc-3f1f-46d7-8b32-d6803d932f4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_8d5c94ef-47a2-4e1e-9aa3-b699facad362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4f5be4ad-c744-4346-b707-675df68384fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5093ace2-fb77-487d-9798-18faea32c09f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4dcea29e-0f7f-420c-8854-7bbd432fdd3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0907aaf0-4f28-425e-a4e7-02bd5e2c9311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_06b531c7-ec9f-4ac0-bc05-e1c34b4943b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d2d8379-582f-499f-a5c1-4b051c31e7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1780d47b-7074-43ea-83b7-6b37c8951dc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e5c90d2a-1b3e-42ff-a354-2da100d5cdcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">gern:ThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_1e1d1200-a6c0-43f1-9a9e-761058f49e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_f5ed2423-f046-4a7d-980c-b9f3fb922f38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_264544f1-3468-4c3f-888f-e76d69aa9c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3775ee3a-1995-4ba0-9943-4a471b60aa73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_73aa80a5-7000-451b-a950-0deff207777e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_557b50d4-874f-47b9-821c-244d8e7b719f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_01a4fb2f-1285-4c86-abb6-10590d094c02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_66810d71-5d1a-4728-8f3a-817e2201e76e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_96ebc7c1-7c8c-4ebe-ab6a-5ccbadc9e64d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoPreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_3ad6c2d6-0303-48fa-82c0-130aee8c97e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f677506b-3ffc-40c8-bc4c-7bf4653d86d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsPlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7a801fab-431b-4ace-91e0-07585e1a2682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3bb2a462-3594-4a43-8344-076ee590e035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e81fdb75-1e1c-4290-ae83-e0a59c23e05d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_351a0c01-2dc4-4490-a644-a98d7ccf7278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a862b4ec-a5b7-430d-9f24-f6c95dc41dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_95b50b47-d6b5-4c38-bcae-9f23b73905ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4e79587f-734c-4e35-ae7f-098dee077ab7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cea26a02-14ec-4995-aac7-14c8a668c2f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-01</instant>
        </period>
    </context>
    <context id="C_21726de3-6057-4051-a03b-5bca72d4eae2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_Item">
        <measure>gern:Item</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Plan">
        <measure>gern:Plan</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <ecd:TrdArrDuration
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_6ec6a41d-9455-4ff8-83c5-b2d8d51cbf16">P365D</ecd:TrdArrDuration>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e009aa17-7b37-43f5-8f1e-7fd2d9e48a0b">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_47cf54a7-69b5-41ae-879b-70186fb43482">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_0fad2783-060e-47c0-a45e-43c7dd5b4410">0000886744</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      id="F_3c679760-c5e2-4438-adcc-f87bf3505474"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      id="F_30281e46-cdbe-4120-b004-3005ac2cc30f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      id="F_27f9fc38-8870-42a0-a389-b678747cd923"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      id="F_1802a09d-4883-4f3c-b335-1ded5d8337fd"
      unitRef="U_USD"
      xsi:nil="true"/>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan
      contextRef="C_96ebc7c1-7c8c-4ebe-ab6a-5ccbadc9e64d"
      id="F_b8827fb4-805f-47b4-9575-17566fb60e0f">P3M</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent
      contextRef="C_96ebc7c1-7c8c-4ebe-ab6a-5ccbadc9e64d"
      id="F_0194cff7-90da-4ed5-a176-f5577cc6d08c">P42D</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent>
    <dei:DocumentType
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_a5fc1cd0-88cc-4741-9fe0-9991e900970c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_532737b9-f6d8-4b5d-a449-0a68859e6ca4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_c9cd4196-94ea-4013-b956-f2a4e81541d7">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_94d5be6f-9740-4ebe-bba1-f504085a79fd">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_82e25e09-e2cd-40e8-acf3-898271f45a06">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b49a62ec-c83b-47b4-a16c-dfe079f90c95">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e2aff6fa-687c-49f3-9709-e64ab465d4ac">000-20859</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e05ce1b2-5253-4536-a1db-e068b0112309">GERON CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_8feacefd-a18b-4853-88b8-9b9dd3a7bf51">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b733ccc4-e7a8-4cea-b559-075d31018a91">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_65b9cea3-cb65-4135-8b1c-faab34f1c870">919 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e625c121-c629-4466-848a-e98f145f38ef">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_825fe9de-be78-447e-b95d-04c7aa4b010a">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_42567756-fa97-45a8-9ae9-282511bfd81d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_c5f3813a-20ab-422e-a68e-2ee0380d6e06">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b8778445-1f8e-4acf-a115-5d780bcc071a">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_3c29291d-66e0-457a-acc6-c64412bde901">473-7700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_fb68594f-5ed0-46b6-bab2-bdc31ac3f654">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_38d47595-c97b-43e2-9c9f-75fe0b38d8e8">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b3357df8-958a-420a-b40c-27a4820f0560">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b245f16b-73f4-4c26-89e2-262a75e7c5ac">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_c97f3e77-cc60-47fe-9196-aaf907c6b3cd">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_5f2bd12a-2956-4e60-bde2-294a173564f0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_533440eb-b7c0-4023-9d67-371c6d83bb35">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_aaef2127-ae2e-4708-85ee-ab262a3608e1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_d0f0756b-3aaa-48e1-8f46-4337b698866e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_25f7c16a-8b95-4762-ba9d-fdd9a514a1d4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b97f3786-bb2f-4930-9717-a68a5a5e1c01">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_855d7962-0932-41b2-9931-840039d87b90">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_9b79e0e0-46b3-4c4b-9ca4-c5027648c5c7">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_c52ecd16-7cd9-4157-8e8e-31af27e39a63"
      decimals="0"
      id="F_174fb681-0350-4a87-90ff-0f651cb06796"
      unitRef="U_USD">1394546000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_dd0bdfe4-5cbf-42ce-ab92-4660dc42c7cf"
      decimals="INF"
      id="F_b0cb9095-bc97-4a08-ae8d-7db2ba6da53e"
      unitRef="U_shares">546059309</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_07a2c449-a49e-4316-be25-638415335b53">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:90%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:9%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:7pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Document&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Form 10&#x2011;K&lt;br/&gt;Parts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s definitive proxy statement for the 2024 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;III&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_cc0b9176-c4a3-4790-8fe2-5a95f944a680">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_09fd0e72-40de-47d4-85d4-935343e8d38b">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_ce34b79c-2cd0-4e99-b868-1b7373d5a57f">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_96e78744-7542-4d5c-b9b8-f5add86a8c7e"
      unitRef="U_USD">70023000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_9a26895f-4bfa-43f6-a3e3-0e2587852794"
      unitRef="U_USD">56845000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_8e37ab9f-a4d2-4fbe-b4a9-77808837a3c3"
      unitRef="U_USD">1115000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_e26ccb83-66af-429c-b215-87766702959b"
      unitRef="U_USD">364000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_de3fd88a-079b-4b28-813d-ec3713921528"
      unitRef="U_USD">263676000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_b4e8ddaa-f08b-4928-b289-f7b7a1af4b14"
      unitRef="U_USD">115901000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_a1ed8a62-dd8d-4908-bcd2-d613eb337c71"
      unitRef="U_USD">1655000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_1a6b8f6a-ef97-4bb8-bf95-9d7450d46c76"
      unitRef="U_USD">3144000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_b91e583f-86c9-4461-92d9-b23ebfea40bf"
      unitRef="U_USD">4879000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_8a4ce8a1-374c-492b-ae90-b1d733d703d7"
      unitRef="U_USD">3992000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_4f734e9f-463c-4533-a4d8-0cbf6a9bdc3d"
      unitRef="U_USD">341348000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_e9091835-6399-4874-acb9-b613c90cce0c"
      unitRef="U_USD">180246000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_324a8568-fc2d-40e4-86a1-d58c9630a40d"
      unitRef="U_USD">43298000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_8c72ffa9-e600-4b50-afbf-b61906a885c3"
      unitRef="U_USD">1177000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_572663b7-d6af-44d1-b138-48aa28ed0106"
      unitRef="U_USD">793000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_f638481a-5bc9-4b02-8fa3-cd935af86415"
      unitRef="U_USD">3556000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_a4a69e75-d1d2-4908-ae85-40c91f6e8919"
      unitRef="U_USD">4147000</us-gaap:OperatingLeaseRightOfUseAsset>
    <gern:DepositsAndOtherAssetsNoncurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_7553ea67-ce99-498b-9729-50baa286d179"
      unitRef="U_USD">4697000</gern:DepositsAndOtherAssetsNoncurrent>
    <gern:DepositsAndOtherAssetsNoncurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_a89dae08-b78e-4704-8253-af08fb64af55"
      unitRef="U_USD">5389000</gern:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_c76656fe-2524-4565-b4c5-e8d1e2cf5d9d"
      unitRef="U_USD">394076000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_27c681b5-d03a-41f8-92e6-24b0edda3f01"
      unitRef="U_USD">190575000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_2ce165fa-414d-4b44-a3d4-8da789680fce"
      unitRef="U_USD">6161000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_6b4ac2dd-f0df-408a-8f25-9d7ce7826066"
      unitRef="U_USD">10190000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_1a5f1547-e7f3-4967-8697-caa1a12a94b2"
      unitRef="U_USD">13759000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_e7e20a03-ed21-42cf-808f-c0a43e3cd15e"
      unitRef="U_USD">11534000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_f945105e-dda5-41c6-baf4-93e0018813fd"
      unitRef="U_USD">949000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_5b4da910-c247-4909-9cd3-377f88af04eb"
      unitRef="U_USD">925000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_d7941ce1-34a2-4d83-ae74-6502090d5c4a"
      unitRef="U_USD">46893000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_cdcdc5ec-26bb-4ec1-ad0f-64fcf01edea6"
      unitRef="U_USD">20945000</us-gaap:DebtCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_9a2142b7-1836-477b-a18a-ff6fb8c893d0"
      unitRef="U_USD">40308000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_21b30ef9-bc87-486a-9b7b-7220c1962c1f"
      unitRef="U_USD">33100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_b2f462b7-29aa-41ad-af20-04dc850b6cf6"
      unitRef="U_USD">108070000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_a72d03f4-e95b-47e2-8b38-936688809858"
      unitRef="U_USD">76694000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_69a60f85-0196-44a0-903c-dd8b0be532dd"
      unitRef="U_USD">3006000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_842740a1-62c6-4481-8e16-cfd36930fcef"
      unitRef="U_USD">3671000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_533629ce-23b6-416e-8cf1-1ca5fa51ebfa"
      unitRef="U_USD">35051000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_a0645178-41e2-42fd-b461-468a2d784b5f"
      unitRef="U_USD">30212000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_d1d1a6e9-efb6-4a78-9439-cd667dd4b566"
      unitRef="U_USD">146127000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_7dea445f-a9fe-4038-900f-b6c8265ab41b"
      unitRef="U_USD">110577000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_2c31a1f5-ba52-492c-81cc-61f4a1f43924"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_73e5faf0-370a-4384-a343-b370f0b61b0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_aae23ae3-0fb9-4da0-9ff0-d4ff36be72ae"
      unitRef="U_shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_51f892e0-81d5-48e2-aa4b-6685e2331c21"
      unitRef="U_shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_9d43c7c7-a9ce-406e-a1b8-176e3ecd85fe"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_7e8c7036-9173-454d-b262-248f62abb592"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_8f00ce9b-bd1a-4a74-b879-8c1abab81c6f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_e93498a0-2755-42eb-9327-e7f49857745e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_a3274547-0d74-4e6a-8931-405a514db895"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_97743461-5cda-475c-9d2f-2ebaab5d0923"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_76d79208-ce66-4400-b87e-f2d22fe0559a"
      unitRef="U_shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_275d4538-8014-4380-9d4d-cb9f1a54aeea"
      unitRef="U_shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_f913a196-798a-413d-923d-d7ca08354b5c"
      unitRef="U_shares">544912215</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_75d3f43a-c17c-4d75-96b8-5ffc3566ab1c"
      unitRef="U_shares">544912215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_4f2539ca-ae83-4dde-a9e0-741e1483a463"
      unitRef="U_shares">390262524</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_355c2c25-1c1c-4146-949e-c56bcadd2497"
      unitRef="U_shares">390262524</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_bc07f928-c764-45fa-b5e1-6fd34dde0a0f"
      unitRef="U_USD">545000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_6174f495-6b98-4798-a150-564e7b265e18"
      unitRef="U_USD">390000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_ca42bf12-fa04-4384-b99d-8e55b7417f50"
      unitRef="U_USD">1844988000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_4cc60e00-444a-47ba-adcb-2e6a959e65c7"
      unitRef="U_USD">1493469000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_95a3516b-73fc-44ce-bb23-db0bfc31a554"
      unitRef="U_USD">-1597769000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_0cc2de7f-b62b-4a9d-b514-20227c8cb636"
      unitRef="U_USD">-1413642000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_e1a566f8-a391-4cb2-b83c-d77abc74ce04"
      unitRef="U_USD">185000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_ce6a5110-3589-48e0-86fd-bf0e4dcc730e"
      unitRef="U_USD">-219000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_6514281c-4eca-41f2-9753-5fc2241db17b"
      unitRef="U_USD">247949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_b7cc4ede-04fa-4708-8c0a-a9bf3708662f"
      unitRef="U_USD">79998000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_4c688ffc-c8d4-485e-bc13-85d0c123c803"
      unitRef="U_USD">394076000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_d9877a77-e56f-4ede-b590-36f680c4bb38"
      unitRef="U_USD">190575000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_7d7bfed2-deb6-48f1-be83-cda699b2a52d"
      unitRef="U_USD">237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_f2508cc5-77a3-45f8-b669-ff3e559746d9"
      unitRef="U_USD">596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_5e008cca-9f23-4d85-97e3-e6d120ced327"
      unitRef="U_USD">1393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_fd6a70d3-243e-4f63-a6ba-63be03b08688"
      unitRef="U_USD">125046000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_50e6b317-aa38-4c45-8fc1-439ad6645db6"
      unitRef="U_USD">95518000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_61d6cf41-b97b-49c3-88a6-6c3605c36184"
      unitRef="U_USD">85727000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_a727a3e9-e4eb-4695-b009-80ba005fd114"
      unitRef="U_USD">69135000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_ba14dfbd-6e92-4aa1-9370-021a00b22218"
      unitRef="U_USD">43628000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_8850eb62-563d-462c-b531-cc04ccf700b5"
      unitRef="U_USD">29665000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_728d1984-53ea-4825-9796-375d08591736"
      unitRef="U_USD">194181000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_703f4064-6463-4e83-8aed-3267571b8ea0"
      unitRef="U_USD">139146000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_58b03b09-8e55-4c18-8830-73b3d99df273"
      unitRef="U_USD">115392000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_0855f919-ecbb-46d3-97e6-91adedef7195"
      unitRef="U_USD">-193944000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_53cc5d2c-3623-4269-8ab6-436c139a9ec8"
      unitRef="U_USD">-138550000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_54df5fff-c268-419d-96c1-fe30ce19a727"
      unitRef="U_USD">-113999000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_a52e6509-ad2d-415b-96d2-36ec61ed6872"
      unitRef="U_USD">18152000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_82fcb17b-915e-4363-a3c5-ad3fe365f51a"
      unitRef="U_USD">2529000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_30b23999-c02e-4d84-bc78-621dcd8483e5"
      unitRef="U_USD">527000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_bce75a29-a098-4497-a469-25fd96c246e8"
      unitRef="U_USD">8312000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_73ce4e55-4935-4d1d-be84-6f66573559f1"
      unitRef="U_USD">6882000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_03b29610-5ba3-47b6-8154-752c0485258b"
      unitRef="U_USD">3740000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_2641c639-dc53-4cd8-9bf1-e86a5d1b9835"
      unitRef="U_USD">-23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_5e8b4e69-3b35-43af-bb45-9b79edaded73"
      unitRef="U_USD">1002000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_c9e6972e-50a5-486c-bdad-1f5b9f11f770"
      unitRef="U_USD">1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_3362c50d-de2e-4fd2-80d4-aa048e4dc1d9"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_bfafc08c-f1e8-4f14-930a-a84ba62d3a03"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_421f2891-f73b-4644-9c86-2233fcc6e53f"
      unitRef="U_USD">-116112000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="2"
      id="F_d55e74eb-8447-4f64-bdc5-d59823e42dac"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="2"
      id="F_e785b969-4044-4cf3-b767-02691ab72ba5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="2"
      id="F_880d150e-53c7-476b-979f-4cedee346e9a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="2"
      id="F_1784ef86-643a-4773-ac8d-89ff389a756c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="2"
      id="F_c3ba698c-b84b-4f59-b703-60cad99bfec3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="2"
      id="F_9c62addb-5188-44ff-86e3-926471f3c8af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="0"
      id="F_0739a0a3-f077-4894-9e08-408aef773437"
      unitRef="U_shares">570645405</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="0"
      id="F_a434ab23-68e1-47d8-8f85-7e6ca6933b57"
      unitRef="U_shares">570645405</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="0"
      id="F_a74e87dc-c1b6-4664-bb1c-d3d6efe27043"
      unitRef="U_shares">380784846</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="0"
      id="F_2baaa623-cc5c-4786-822a-865ea82a69ad"
      unitRef="U_shares">380784846</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="0"
      id="F_0f76e89e-8467-4125-be9e-be354189dbbe"
      unitRef="U_shares">327631814</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="0"
      id="F_9df9957c-431b-44ed-b265-65b3450593f1"
      unitRef="U_shares">327631814</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_74dee74a-9bb5-43e7-b1a1-ee9770e86915"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_b7b88a84-c50e-45d8-805d-28008dd1cd3e"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_7d3781ad-5b65-47e6-a381-3fda478edf9f"
      unitRef="U_USD">-116112000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_b4d43b35-5294-4d40-b2c2-17e10ccccbaf"
      unitRef="U_USD">431000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_ece6c32c-b173-4e88-8166-e9d13818b9be"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_b9fab7e0-70ef-47b3-abb5-63379237a174"
      unitRef="U_USD">-251000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_fae564c9-3531-4e6d-bd76-edf50eac961a"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_028f6d5f-c94d-4d49-94dc-f3f829b43867"
      unitRef="U_USD">22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_8611a863-8d8a-40ed-8dd3-091654360d33"
      unitRef="U_USD">-183723000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_500327a5-2ec0-4021-a219-70f6bee3b14f"
      unitRef="U_USD">-141947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_5bc230d1-eed8-47c4-baf0-440067615ff4"
      unitRef="U_USD">-116363000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4f5be4ad-c744-4346-b707-675df68384fb"
      decimals="INF"
      id="F_873153e3-cb1e-48e6-8942-5c0d6ec9e742"
      unitRef="U_shares">310566853</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4f5be4ad-c744-4346-b707-675df68384fb"
      decimals="-3"
      id="F_258a4d10-3ad7-4733-87ed-3bf78f9827a6"
      unitRef="U_USD">310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c15f606e-8272-43fe-9517-3931c73040da"
      decimals="-3"
      id="F_07bb334c-c5f7-4f13-9cf4-b87750e2084c"
      unitRef="U_USD">1366188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ff875ec1-8c1a-4ae6-b136-1138204345ef"
      decimals="-3"
      id="F_a41be74c-15b8-419b-acee-592f3708ae9f"
      unitRef="U_USD">-1155629000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ec95cdaa-3268-4317-a48c-594ad28bd481"
      decimals="-3"
      id="F_3ad1fcda-d98f-4987-89b5-6dcd0fb78af8"
      unitRef="U_USD">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_66810d71-5d1a-4728-8f3a-817e2201e76e"
      decimals="-3"
      id="F_8b1a3ef9-681d-4590-8a69-f7026719c6b2"
      unitRef="U_USD">210947000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_423727df-44e5-4ea3-a181-865b8e657957"
      decimals="-3"
      id="F_205c381a-4e05-4367-a806-7ef75fc536f1"
      unitRef="U_USD">-116112000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_f8283365-aa3b-42ee-a447-ce7d8e09b4e0"
      unitRef="U_USD">-116112000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_3acb4904-a13f-4209-a193-1dd7ea1e9043"
      decimals="-3"
      id="F_b8dc3b44-7794-4454-bb2a-0517b1a64fb7"
      unitRef="U_USD">-251000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_071b0acd-1403-4c0d-8a80-cad57a5f1e2d"
      unitRef="U_USD">-251000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_42c6935a-1d5e-40dd-ab10-35f9472606c2"
      decimals="-3"
      id="F_1b2146d6-07c4-4a03-9e3b-e8453a35558c"
      unitRef="U_USD">470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="INF"
      id="F_7c12e88d-7520-4cf6-b02b-876a9c101095"
      unitRef="U_shares">10571556</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="-3"
      id="F_12ec2a8a-ab42-4104-bbc0-c032d9d82e47"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6cd1fdca-3697-4478-905e-43127481507e"
      decimals="-3"
      id="F_2bf151a3-b4a3-477f-b803-bb416e14b13b"
      unitRef="U_USD">20374000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_774d46b7-6a56-4229-94ac-7f016b0f2b13"
      unitRef="U_USD">20385000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="INF"
      id="F_fa4d1767-f6a4-469f-977a-877b03b53417"
      unitRef="U_shares">1906341</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="-3"
      id="F_7114e0a3-1187-401a-a3ad-09cf37813896"
      unitRef="U_USD">2000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_6cd1fdca-3697-4478-905e-43127481507e"
      decimals="-3"
      id="F_9526ca7d-bf3c-4945-89bb-a44cdb769487"
      unitRef="U_USD">2477000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_cb964c39-87ec-4547-85b6-bdaf6ec9e2c6"
      unitRef="U_USD">2479000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="INF"
      id="F_35355664-2f33-4b0f-be7a-e6c1481a5469"
      unitRef="U_shares">20783</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_6cd1fdca-3697-4478-905e-43127481507e"
      decimals="-3"
      id="F_dc8ac768-9b98-48df-9864-3e6572951a08"
      unitRef="U_USD">91000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_aceb7648-3836-47af-96bb-24c09b132951"
      unitRef="U_USD">91000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="INF"
      id="F_c051fa51-fb7d-4fde-a099-c64a7a9cf769"
      unitRef="U_shares">666058</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_b3710957-e7c5-401f-a659-86f0bc21e8ec"
      decimals="-3"
      id="F_f1002965-87a5-4e4d-b2ca-1f4adb82668b"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_6cd1fdca-3697-4478-905e-43127481507e"
      decimals="-3"
      id="F_d51e2c61-8754-4717-ab5e-597528995fe1"
      unitRef="U_USD">796000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_7aa533bc-ef43-4f23-8b2c-c22ab49ce672"
      unitRef="U_USD">797000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6cd1fdca-3697-4478-905e-43127481507e"
      decimals="-3"
      id="F_fc9b65a7-ae39-41d3-8c8c-dd413b95bfbc"
      unitRef="U_USD">8080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_b9753806-358a-422e-b139-5c65e7ae0509"
      unitRef="U_USD">8080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_dcf8dab7-019f-4b57-8582-d13f9fbce0ca"
      decimals="INF"
      id="F_34511551-e003-485e-8d00-a8ac1f01afa0"
      unitRef="U_shares">323731591</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dcf8dab7-019f-4b57-8582-d13f9fbce0ca"
      decimals="-3"
      id="F_386493bf-072c-47c8-8415-fc56f1126d5f"
      unitRef="U_USD">324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_06b531c7-ec9f-4ac0-bc05-e1c34b4943b6"
      decimals="-3"
      id="F_852d4a74-9657-4911-b804-182bd928ce7e"
      unitRef="U_USD">1398006000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a4961fb6-61f4-47d9-9582-c48ee1cf31fd"
      decimals="-3"
      id="F_13119ccd-df4b-4bff-84d3-31f758e01e64"
      unitRef="U_USD">-1271741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cefcefdd-0850-4f7b-b6b5-cd1f2132fb46"
      decimals="-3"
      id="F_b8a4dde7-05eb-4564-839b-0bdab72f8ac4"
      unitRef="U_USD">-173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba"
      decimals="-3"
      id="F_e0f7a5ec-33f7-414f-be32-3bedfc7ac8df"
      unitRef="U_USD">126416000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_8226d454-2be9-44b7-b692-bf6354a4b418"
      decimals="-3"
      id="F_fed609eb-671f-421b-ac45-1a7e8f788791"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_11cbe750-5148-4da0-ace1-331ab20fb521"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_a550d37d-7683-427c-9abd-810070f5905c"
      decimals="-3"
      id="F_a34e2b0f-07e2-41f6-8c11-cb4b64d26438"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_481b25d6-cc6e-459d-b8b6-1f06e3e0538e"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_a550d37d-7683-427c-9abd-810070f5905c"
      decimals="-3"
      id="F_fd68bc0c-9ab6-445d-841e-c165d1c1ebb2"
      unitRef="U_USD">22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_c0c3a519-c621-4ef7-a1af-d474e2db00a7"
      unitRef="U_USD">22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_4dcea29e-0f7f-420c-8854-7bbd432fdd3c"
      decimals="-3"
      id="F_1ae3dd23-8882-47bc-a778-db1f070cf799"
      unitRef="U_USD">5066000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="INF"
      id="F_a7209852-46c1-4058-848d-dfbdcfbe6e52"
      unitRef="U_shares">53333334</gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="-3"
      id="F_61744273-46b3-45a2-854e-142dc2f335f4"
      unitRef="U_USD">53000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70"
      decimals="-3"
      id="F_13a13635-e6e9-426a-96ab-5d3420286430"
      unitRef="U_USD">69863000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_1c9ad256-1688-409d-acfc-569ebd49259b"
      unitRef="U_USD">69916000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="INF"
      id="F_ad98a163-ee38-4e67-96c1-37a4343ff336"
      unitRef="U_shares">11663387</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="-3"
      id="F_bfa4e491-07dd-4f73-87b0-9f06693aaba7"
      unitRef="U_USD">12000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70"
      decimals="-3"
      id="F_73ff568f-8bdd-41fa-abb0-0457f7e0bd89"
      unitRef="U_USD">15151000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_2addaff9-411e-4cfc-a5a9-695f0d752ef7"
      unitRef="U_USD">15163000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="INF"
      id="F_8b573458-09da-4180-a889-59b64b51dfd0"
      unitRef="U_shares">15962</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70"
      decimals="-3"
      id="F_c4cb02bf-1dfe-4c39-b792-40ad3ac90b09"
      unitRef="U_USD">264000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_49a872c6-a68d-4be7-8dd5-8ca16131e99e"
      unitRef="U_USD">264000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="INF"
      id="F_3cd2aa6c-b531-4083-b7a5-b5b1a922f46a"
      unitRef="U_shares">1518250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_804bcb69-7593-4583-b546-4f5094a6b055"
      decimals="-3"
      id="F_50aa4793-fecb-43eb-bd89-400c7fa2e055"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70"
      decimals="-3"
      id="F_172de5bc-a9da-4187-a0b5-de2ad68bf566"
      unitRef="U_USD">2184000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_98c2f102-731b-4eb9-b9ba-005e572ce6b8"
      unitRef="U_USD">2185000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_58825751-7a3a-48d2-a155-deb56a5efc70"
      decimals="-3"
      id="F_e1fbe03c-508f-4627-b5fc-7ca44ab21a53"
      unitRef="U_USD">8001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_e0f2bd9d-afba-42cd-bee5-eec577ad3050"
      unitRef="U_USD">8001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1d320b3d-6dfc-4827-907c-1c7a097695e8"
      decimals="INF"
      id="F_1c9b2b72-5007-4baa-a71c-7934db53f7d6"
      unitRef="U_shares">390262524</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1d320b3d-6dfc-4827-907c-1c7a097695e8"
      decimals="-3"
      id="F_7ba171ed-e549-4383-a2e7-93c8f800874e"
      unitRef="U_USD">390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6102220c-7833-4b4f-aa22-7bbaf7d6a11e"
      decimals="-3"
      id="F_504e7f1e-0f56-4195-b54e-13305197cff1"
      unitRef="U_USD">1493469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_91f09572-5c03-4d4f-9e6e-6b7a9683db52"
      decimals="-3"
      id="F_c804a4fa-266b-4177-a9da-0cf40d0771e8"
      unitRef="U_USD">-1413642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4111e6aa-d02c-4fab-8c2a-dc8d69eddc4f"
      decimals="-3"
      id="F_bf70377b-a4b1-421b-b11e-ee5fc413ac3b"
      unitRef="U_USD">-219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_cb32f55c-6cc4-4a7f-8590-ab1fe9c0ddc5"
      unitRef="U_USD">79998000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_e1a70717-d878-4158-aada-2b23be1cd942"
      decimals="-3"
      id="F_3791e9fe-b4f8-44a8-a950-610e096ef654"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_61737cbe-3b3e-45d1-9360-b40957a32e78"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_c5bfecec-6498-49b3-b2ca-dff2fad0c618"
      decimals="-3"
      id="F_9420b1b1-95f4-441e-bd8c-2e6791bd4ec4"
      unitRef="U_USD">431000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_84046cbc-48f8-443d-adfe-b57f0556aedb"
      unitRef="U_USD">431000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_c5bfecec-6498-49b3-b2ca-dff2fad0c618"
      decimals="-3"
      id="F_b829d0a8-ec61-499d-8afc-36a69545ff9a"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_3ca0e2ba-3022-410f-b2ab-780bb0c42124"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0880c107-5216-4914-bd93-f39768e97006"
      decimals="-3"
      id="F_e51e1396-1796-4e9e-b0c2-d527d8c17291"
      unitRef="U_USD">14507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="INF"
      id="F_3f61e952-256f-4442-bb41-c95e723d0630"
      unitRef="U_shares">68007741</gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="-3"
      id="F_748b7476-358e-4fa1-8f83-bc6794fc011b"
      unitRef="U_USD">68000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2"
      decimals="-3"
      id="F_969bb75c-46f7-49d7-8810-2483f201c09e"
      unitRef="U_USD">213269000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_f0fd9589-ffab-42c9-a7b3-9e8c668e895e"
      unitRef="U_USD">213337000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="INF"
      id="F_4294f9a7-1d04-43c0-9c02-25a21d685ec5"
      unitRef="U_shares">77349858</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="-3"
      id="F_e767fd73-4995-454a-86ef-e88f46d6fbd5"
      unitRef="U_USD">78000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2"
      decimals="-3"
      id="F_deb46f6f-8999-423b-b35f-4c5daec62fac"
      unitRef="U_USD">105834000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_d3e4443b-5b1b-443e-99fb-f706959c896c"
      unitRef="U_USD">105912000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="INF"
      id="F_2ca483d6-d5eb-4b06-8b16-8905258496aa"
      unitRef="U_shares">36864</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="-3"
      id="F_6a5baa7a-65fb-4b8a-9d58-5e8927563148"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2"
      decimals="-3"
      id="F_eb13a7a8-11a1-473a-ba1c-21d8c10e9025"
      unitRef="U_USD">828000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_33c9b18e-bc4d-4f1b-9855-270c77ae50a3"
      unitRef="U_USD">829000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="INF"
      id="F_b8b40c7d-e6ab-4317-b493-4a80c0b874a6"
      unitRef="U_shares">9255228</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_82179eaf-4f6a-450a-9d12-0e71a94bbc1c"
      decimals="-3"
      id="F_850e4448-6e84-4727-8d7b-ae8115c6e0a6"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2"
      decimals="-3"
      id="F_d88c061f-e597-41b6-a7c1-34430e88c2c8"
      unitRef="U_USD">13062000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_ec8ce1af-5df2-453e-b942-3742ace19a12"
      unitRef="U_USD">13070000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_21726de3-6057-4051-a03b-5bca72d4eae2"
      decimals="-3"
      id="F_7a9de9b1-5bc5-400f-a53c-904f6a8f4471"
      unitRef="U_USD">18526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_15c2e8ab-3d71-416d-87fa-67b709b22e81"
      unitRef="U_USD">18526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_351a0c01-2dc4-4490-a644-a98d7ccf7278"
      decimals="INF"
      id="F_f729517d-d770-4af6-9557-27c70dfe9715"
      unitRef="U_shares">544912215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_351a0c01-2dc4-4490-a644-a98d7ccf7278"
      decimals="-3"
      id="F_4419e880-c2a0-4589-8b19-374368af1d21"
      unitRef="U_USD">545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3bd9d30b-b6ce-417e-b7b2-8eb4d19cca93"
      decimals="-3"
      id="F_40f67997-5eb2-440d-9a19-cb4dd066ec35"
      unitRef="U_USD">1844988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01a4fb2f-1285-4c86-abb6-10590d094c02"
      decimals="-3"
      id="F_1d2af714-0681-452f-a415-d00f8a5f93a4"
      unitRef="U_USD">-1597769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5aba5b57-05d2-4c06-90d4-6885ef672ae4"
      decimals="-3"
      id="F_24fe18dd-47be-476f-9002-8553364ff6a9"
      unitRef="U_USD">185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_7847ddd8-a5f7-4879-9b8d-df4aff05bac2"
      unitRef="U_USD">247949000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_597756fc-7f56-4956-b095-6659f73f5695"
      unitRef="U_USD">-184127000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_fb334b40-3fd2-4fab-a746-a531a15703d0"
      unitRef="U_USD">-141901000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_d8669bd2-2425-46cf-9336-6a1672be007c"
      unitRef="U_USD">-116112000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_3eb02f97-200a-4eb7-8643-87adbcf965ac"
      unitRef="U_USD">442000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_fb0d1c99-0542-44c4-8ea1-a75e3ea938eb"
      unitRef="U_USD">288000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_bda21805-6d3f-4e6d-a678-537cdd077a36"
      unitRef="U_USD">215000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_972ea37d-46ff-4c76-b948-05ede80b6e18"
      unitRef="U_USD">11150000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_de3a7c9a-3ad6-4f0f-8c5b-82d3f9e31b17"
      unitRef="U_USD">965000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_b1e10370-362d-4f12-9eb1-29a48508a015"
      unitRef="U_USD">-1424000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_3e6c271f-cb19-4b19-a07c-9785de79d726"
      unitRef="U_USD">1088000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_0469eec6-df42-4115-8626-dd51d006b50f"
      unitRef="U_USD">1327000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_72da0a58-aca3-47c0-993d-a17d95e20241"
      unitRef="U_USD">893000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_990a87ea-e679-4489-b033-c7afd1c110ea"
      unitRef="U_USD">1233000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_22adb65e-9b09-40ce-aec5-5941ab57a9b6"
      unitRef="U_USD">828000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_f2b506be-3eb3-4890-b16d-396f50051974"
      unitRef="U_USD">264000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_037714fd-ba91-447a-b45c-a78ad4b1b141"
      unitRef="U_USD">91000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_74dd5f8d-e77e-40c0-86f5-50b33e16ec87"
      unitRef="U_USD">18526000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_19b0fc41-970f-4db5-b909-4f6c0756b5a0"
      unitRef="U_USD">8001000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_a6e924c0-6028-4629-8ff6-8901f0029b5c"
      unitRef="U_USD">8080000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_d47ab903-1ca7-4891-bdab-d8bd68c2ba58"
      unitRef="U_USD">591000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_3569dfb8-cd3c-4b1f-81f7-330d3759997a"
      unitRef="U_USD">580000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_34dbbcb0-db64-4a5b-8e77-2c8eee5592b1"
      unitRef="U_USD">568000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_02dcd237-67cb-413f-8b10-39307ba921ad"
      unitRef="U_USD">-1490000</gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables>
    <gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_faae59d4-4b3f-407a-9f20-669a1e694b3f"
      unitRef="U_USD">1381000</gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables>
    <gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_b25019a8-bb92-4c0d-989f-d9b23cf27540"
      unitRef="U_USD">1041000</gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_339630e2-c6c6-43ef-a822-ad379516777a"
      unitRef="U_USD">886000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_ce045212-6690-4eae-a366-6e4c8ebfe0fb"
      unitRef="U_USD">2630000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_8ffa8769-ac38-4838-b2b8-cc46579e374e"
      unitRef="U_USD">-1317000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_789ea9d8-7768-4d2e-a9cd-82ee05a4f1bb"
      unitRef="U_USD">-692000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_7a7f0f2d-1657-4fbd-ae87-b0bfe04aebe8"
      unitRef="U_USD">594000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_5ec8db5f-b70d-495a-a00e-70c5edc0c5c0"
      unitRef="U_USD">3807000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_47938ac9-f462-47cb-aa8d-7d493b7a5683"
      unitRef="U_USD">-4029000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_9fef0634-fcca-4a4f-9c69-027133bc4fce"
      unitRef="U_USD">3503000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_46252dd5-f607-4a66-89d9-352d3bbe505c"
      unitRef="U_USD">-232000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_bf8f1d55-5dc8-4cbd-b9d8-615b0fea1875"
      unitRef="U_USD">2224000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_847a55ed-8f03-489f-976b-5d7cf92b7bc2"
      unitRef="U_USD">3435000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_9065cc4f-2d1f-4acc-8b25-b9a888cbea37"
      unitRef="U_USD">-119000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_7203a634-d6cf-4f32-98a8-c23a09c5eca4"
      unitRef="U_USD">7208000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_3a88b438-5a95-4bcc-8585-29ef568ad4b4"
      unitRef="U_USD">3266000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_6da15e19-a495-431e-8cc4-1e22e975937f"
      unitRef="U_USD">14909000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_e63827b3-a2df-4a10-a9b4-3fddb3a41edb"
      unitRef="U_USD">-640000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_db6c43e6-7180-4ea6-a291-3a936da61b71"
      unitRef="U_USD">-572000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_7d74b814-cd55-492a-a975-1f77ae9ba519"
      unitRef="U_USD">-509000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_ffebb767-1efa-43de-98a6-c8a90e283b26"
      unitRef="U_USD">-167743000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_bf13bf97-6b21-4392-a32d-19067c421949"
      unitRef="U_USD">-127379000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_4fb10952-5c70-41ba-9ca1-9014c43ab79e"
      unitRef="U_USD">-95556000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_77754d66-2d2d-4f66-b9f2-0ddc056f69d8"
      unitRef="U_USD">830000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_3d4141db-7f1c-4062-8372-4050b8cbc6d9"
      unitRef="U_USD">431000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_1e6b2d20-4dd4-443a-ab15-1f89716f3d6c"
      unitRef="U_USD">207000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_9b1b48be-4510-4283-b367-6ad6c7dedc6f"
      unitRef="U_USD">475594000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_b81ee287-500b-46c4-a59f-9ca8886cd737"
      unitRef="U_USD">258007000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_88606d97-5763-46e9-b295-50d8d007cb4e"
      unitRef="U_USD">177434000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_41ebc8d5-180a-4cbc-88ce-3e34465c14d3"
      unitRef="U_USD">296102000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_42d32376-7bab-4f31-8c6f-6a2fc3df9e55"
      unitRef="U_USD">320505000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_89464e94-7400-4403-a31f-78b1400689fb"
      unitRef="U_USD">247994000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_7dfcf174-3dbc-48f2-95d7-92405c5eb733"
      unitRef="U_USD">1594000</us-gaap:ProceedsFromSaleOfOtherAssetsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_b4e7eb27-5f6c-4b20-aeaa-8af8ff0f6bd2"
      unitRef="U_USD">-180322000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_0a989827-f60e-4683-a7c2-b59ea9370e93"
      unitRef="U_USD">62067000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_4bfe93f0-4bb2-4d82-a781-6dc7d427a6f5"
      unitRef="U_USD">71947000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_1bb83e91-c594-4607-b49e-ab0b1ea970f5"
      unitRef="U_USD">13072000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_b14a0d32-dbe5-463b-880b-9efa02026c90"
      unitRef="U_USD">2185000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_ba9f5065-780e-408e-a9a3-5afc436b9c21"
      unitRef="U_USD">797000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_e950d705-42bc-477c-bb7a-1101ed4954fc"
      unitRef="U_USD">213337000</gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants>
    <gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_474932e9-2e19-49a3-88a5-b21b3fd22110"
      unitRef="U_USD">69916000</gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_8d1492ec-f181-4dc3-9bbd-5a191fe4bc5b"
      unitRef="U_USD">20385000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_2c1a23a2-d135-4242-a41f-fadc44cbad9e"
      unitRef="U_USD">105912000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_e1718c85-c2fc-4c6f-b7d5-d1cd753e4438"
      unitRef="U_USD">15163000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_f8901fc8-0548-4482-ab2f-629eb44d321c"
      unitRef="U_USD">2479000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_adca3948-6052-4438-b131-314f8ef7950c"
      unitRef="U_USD">29700000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_16c8ceff-b92d-4c78-806b-2bbea2b98ce7"
      unitRef="U_USD">24895000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_d0e88fe5-8a5e-49f9-b482-12a5f4e04ab3"
      unitRef="U_USD">362021000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_ac1e458a-69ba-4805-b8e3-cdf37ebec46f"
      unitRef="U_USD">87264000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_1d32b09c-2ae3-4860-889c-bbb9c6227735"
      unitRef="U_USD">48556000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_014bb4d4-0d67-4b9e-b686-cb2a15eac420"
      unitRef="U_USD">-27000</gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_791d6cd1-0d04-432b-9dce-f9a5b7044abb"
      unitRef="U_USD">22000</gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_f553a7d7-cabc-408e-975a-657c972965b1"
      unitRef="U_USD">13929000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_eede17b2-ee4b-4426-8b50-7972379e64fa"
      unitRef="U_USD">21974000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_33ae5d07-d187-49a3-a99a-830b30fe4f64"
      unitRef="U_USD">24947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_1fd40d79-cc00-413c-890d-a30c7acfc082"
      unitRef="U_USD">57209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba"
      decimals="-3"
      id="F_9ed7de13-e031-4286-b9ab-2abc25d4b306"
      unitRef="U_USD">35235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_66810d71-5d1a-4728-8f3a-817e2201e76e"
      decimals="-3"
      id="F_cb10d437-3bf7-4ef2-bb54-5c210956d996"
      unitRef="U_USD">10288000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_ba5906cb-d9ce-45f1-a7be-a3b7e8e862b0"
      unitRef="U_USD">71138000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_8a6fbbbf-3250-4f57-a324-20ac59ca22fb"
      unitRef="U_USD">57209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba"
      decimals="-3"
      id="F_6fa51378-98c2-4c8a-9192-8cbd7c33768b"
      unitRef="U_USD">35235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_3b3f3a6a-3248-4273-8a7d-b40707492541">&lt;p id="note_1_" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The terms &#x201c;Geron&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; and &#x201c;us&#x201d; as used in this report refer to Geron Corporation, which was incorporated in the State of Delaware on November 28, 1990, and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. Geron UK was incorporated in September 2021, and its operations commenced in January 2022. Geron Netherlands was incorporated in February 2023, and its operations commenced in June 2023.  We are a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, an innovative therapeutic for hematologic malignancies. We have global rights to imetelstat, an investigational first-in-class telomerase inhibitor, which was discovered and developed at Geron. Principal activities to date have included obtaining financing, securing operating facilities and conducting research and development.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. The resultant translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#x2019; equity, on our consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,095,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,335,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. In January 2023, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,007,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, or the 2023 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 9 on Stockholders' Equity for further discussion of our public offerings.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2023, 2022, and 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the diluted net loss per share calculation excludes potential dilutive securities of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,458,854&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,726,765&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,725,875&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations. We recognize a charge when the declines in the fair values below the amortized cost bases of our available for sale securities are judged to be other than temporary. We consider various factors in determining whether to recognize an other than temporary charge, including whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. Declines in market value judged as other than temporary result in a charge to interest income. We have not recorded any other&#x2011;than&#x2011;temporary impairment charges on our available&#x2011;for&#x2011;sale securities for the years ended December 31, 2023, 2022 and 2021. See Note 2 on Fair Value Measurements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We measure our investment in equity securities at fair value at each reporting date. Changes in fair value resulting from observable price changes are included in change in fair value of equity investment and changes in fair value resulting from foreign currency translation are included in other expense on our consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt Issuance Costs and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our current imetelstat clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We record property and equipment at cost and calculate depreciation using the straight&#x2011;line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 9 on Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Other Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#x2019; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our executive management team represents our chief decision maker. We view our operations as a single segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued and Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2018-19, for the purpose of clarifying certain aspects of ASU 2016-13. In May 2019, the FASB issued ASU 2019-05, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Targeted Transition Relief&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2019-05, to provide entities with more flexibility in applying the fair value option on adoption of the credit impairment standard. In November 2019, the FASB issued ASU 2019-11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosure. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. ASU 2018-19, ASU 2019-05 and ASU 2019-11 have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 became effective for fiscal years beginning after December 15, 2022, using a modified retrospective approach, for smaller reporting companies. Early adoption is permitted. We adopted ASU 2016-13 and related updates as of January 1, 2023. The adoption of this standard did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e4ca573c-d58b-4ee1-a693-9955d60a3960">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. The resultant translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#x2019; equity, on our consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_2cac5860-b3fb-49fc-bdf8-6f246e0bd897">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,095,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,335,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. In January 2023, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,007,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, or the 2023 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 9 on Stockholders' Equity for further discussion of our public offerings.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2023, 2022, and 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the diluted net loss per share calculation excludes potential dilutive securities of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,458,854&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145,726,765&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,725,875&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_2d88ef09-b3cf-469e-a8fe-49f54977425e"
      decimals="INF"
      id="F_ebdc0cd8-5b12-4c4f-9b0a-497beeeff33e"
      unitRef="U_shares">18095238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_16cb4e12-d0a4-4036-b565-a780727a5c13"
      decimals="INF"
      id="F_0c1063df-4fb8-4564-ac82-5db5fc4ae562"
      unitRef="U_shares">8335239</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2d88ef09-b3cf-469e-a8fe-49f54977425e"
      decimals="INF"
      id="F_744d80a1-bbae-4782-95c8-84395200bf97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_16cb4e12-d0a4-4036-b565-a780727a5c13"
      decimals="INF"
      id="F_106d4e1d-fe05-4ea2-a0cd-a3ef3696ae27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_c4453fc4-f1fc-4c46-81b8-a6f6809e0b65"
      decimals="INF"
      id="F_bb99fc41-2e9f-4c27-b5d4-7a972186c062"
      unitRef="U_shares">68007741</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_95d2171c-44c4-4ef3-bcef-9a3bf9ca3146"
      decimals="INF"
      id="F_f26c2f3e-7710-41df-838d-8faed3da147d"
      unitRef="U_shares">25000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_38d32bf7-1b80-4b24-b2eb-46f7768d7421"
      decimals="INF"
      id="F_02b14e9d-7941-4b23-9588-dc936facc0c4"
      unitRef="U_shares">75458854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ec2e5c75-1f30-4a48-82c7-38c0000d374c"
      decimals="INF"
      id="F_e7a37b0e-402f-4f22-9db2-0f0005c274fd"
      unitRef="U_shares">145726765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7fc0d7c6-e2ff-4bd5-b6f5-508937b233e0"
      decimals="INF"
      id="F_d4a13a6b-a9ad-4bea-9040-1f65b70f8d27"
      unitRef="U_shares">105725875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_ad19d589-afae-4847-96b0-ee4d8f46679d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_c27b14ac-179a-49f9-9102-330edb20aec4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations. We recognize a charge when the declines in the fair values below the amortized cost bases of our available for sale securities are judged to be other than temporary. We consider various factors in determining whether to recognize an other than temporary charge, including whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. Declines in market value judged as other than temporary result in a charge to interest income. We have not recorded any other&#x2011;than&#x2011;temporary impairment charges on our available&#x2011;for&#x2011;sale securities for the years ended December 31, 2023, 2022 and 2021. See Note 2 on Fair Value Measurements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We measure our investment in equity securities at fair value at each reporting date. Changes in fair value resulting from observable price changes are included in change in fair value of equity investment and changes in fair value resulting from foreign currency translation are included in other expense on our consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_364698c1-7758-485f-ab9f-418b462cebc2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_43cf0323-ae2f-4ffd-9bbd-33a9c854caed">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt Issuance Costs and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_a0059992-d67a-4150-9114-6ccab40ff503">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e2589ce4-8877-403a-a5e2-d01b2534f5fe">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_f584c6b5-f009-4a38-af35-292385a6f280">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our current imetelstat clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_35853b32-8948-4b6a-aa59-04cf1fd627fc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We record property and equipment at cost and calculate depreciation using the straight&#x2011;line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      id="F_cd40f709-d3b2-4e98-bca8-170a7a5049c5">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e61000b3-a972-416d-9661-92e312eeda16">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 9 on Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_c5d7c0ea-8564-4a16-8355-d976fa9b532d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated Other Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#x2019; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_5b346028-465d-4e6a-9e23-ad6bf8b702d3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_4379adb0-f416-46a4-b6e2-a6824936d5f7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our executive management team represents our chief decision maker. We view our operations as a single segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_1a646171-4322-48de-9393-67a5601b3eed">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued and Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2016-13. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. Subsequent to issuing ASU 2016-13, the FASB issued ASU 2018-19, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2018-19, for the purpose of clarifying certain aspects of ASU 2016-13. In May 2019, the FASB issued ASU 2019-05, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Targeted Transition Relief&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2019-05, to provide entities with more flexibility in applying the fair value option on adoption of the credit impairment standard. In November 2019, the FASB issued ASU 2019-11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which expands the scope of the practical expedient that allows entities to exclude the accrued interest component of amortized cost from various disclosure. Entities that elect to apply the practical expedient must disclose the total amount of accrued interest that they exclude from their disclosures of amortized cost. ASU 2018-19, ASU 2019-05 and ASU 2019-11 have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13 became effective for fiscal years beginning after December 15, 2022, using a modified retrospective approach, for smaller reporting companies. Early adoption is permitted. We adopted ASU 2016-13 and related updates as of January 1, 2023. The adoption of this standard did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_97725b5a-55e8-4ba9-9955-71832cc3bf7d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.869%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.869%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored &lt;br/&gt;&#160;&#160;&#160;enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than &lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;br/&gt;&#160;&#160;&#160;(due in less than&lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury &lt;br/&gt;&#160;&#160;&#160;securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal securities &lt;br/&gt;&#160;&#160;&#160;(due in less than a year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored &lt;br/&gt;&#160;&#160;&#160;enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than &lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;br/&gt;&#160;&#160;&#160;(due in less than&lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The gross unrealized losses related to U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of December 31, 2023 and 2022 were due to changes in interest rates and not credit risk. We determined that the gross unrealized losses on our cash equivalents and marketable securities as of December 31, 2023 and 2022 were temporary in nature. Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflict between Ukraine and Russia, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We review our investments quarterly to identify and evaluate whether any investments have indications of possible other-than-temporary impairment. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether we intend to sell the security or whether it is more likely than not that we would be required to sell the security before recovery of the amortized cost basis. We currently do not intend to sell these securities before recovery of their amortized cost bases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value on a Recurring Basis&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We categorize financial instruments recorded at fair value on our consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:1.84%;"&gt;&lt;/td&gt;
      &lt;td style="width:7%;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;"&gt;&lt;/td&gt;
      &lt;td style="width:90.16%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 and indicates the fair value category assigned.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Active Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Identical Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.074%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in cash and cash equivalents on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in restricted cash on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in current portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(4)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in noncurrent portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity Investment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2007, we received &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,842,625&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ordinary shares in Sienna Cancer Diagnostics Limited, or Sienna, in connection with a license we granted to them for our hTERT technology for use in human diagnostics. The shares, which represented less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership, were recorded at a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cost basis under the cost method of accounting, upon receipt. Since the adoption of ASU 2016-01 on January 1, 2018, we reassessed the fair value of our equity investment in Sienna at each reporting date and any resulting change in fair value was recognized on our consolidated statements of operations. In April 2020, Sienna announced its merger with BARD1 Life Sciences Limited, or BARD1, subject to approval by Sienna&#x2019;s shareholders. Effective August 3, 2020, the merger was complete, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;we received 13 BARD1 shares for every five shares of Sienna ordinary shares, resulting in our ownership of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,990,825&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of BARD1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the first quarter of 2021, we sold all of our holdings in BARD1 and recognized a net gain of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,233,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the sales, including gains from foreign currency translation adjustments, which has been included in other income and expense on our consolidated statements of operations. As of March 31, 2021, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; value remained for our equity investment in BARD1.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple institutions in the United States. Generally, these deposits may be redeemed upon demand and therefore, bear minimal risk. Deposits with banks may exceed the amount of insurance provided on such deposits. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, government-sponsored enterprise securities, U.S. Treasury securities, municipal securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. However, we are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents to the extent recorded in our consolidated balance sheets. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk of our financial position at the depository institutions in which those deposits are held.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_804ae974-4309-400a-92ce-9f8ba9c253ff">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.869%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;48,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.869%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74"
      decimals="-3"
      id="F_168e1ed0-e6f5-4ba8-b3e3-add2682a3252"
      unitRef="U_USD">16815000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74"
      decimals="-3"
      id="F_bc67e1e7-e0f2-472b-8671-bf40605d2163"
      unitRef="U_USD">16815000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_fc45ec68-e843-4728-8010-6244824bd7e1"
      unitRef="U_USD">16815000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_08d40d39-39ef-417b-bd85-fd51fc3c5c50"
      unitRef="U_USD">16815000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74"
      decimals="-3"
      id="F_d02974c3-ce31-49e1-a6c8-1bc1502e9389"
      unitRef="U_USD">843000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_74722c61-6ec4-4448-b0c8-a626d2b72e74"
      decimals="-3"
      id="F_e03119b4-98a4-4bb7-98fe-8f4dfc803634"
      unitRef="U_USD">843000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_3a0593af-b72d-4eff-a7fa-e7458afe7976"
      decimals="-3"
      id="F_35a3f31e-936e-4fd1-bf5d-170d45e96c81"
      unitRef="U_USD">272000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_3a0593af-b72d-4eff-a7fa-e7458afe7976"
      decimals="-3"
      id="F_712dd065-d93f-4fdd-8cd5-d1ecdc85c263"
      unitRef="U_USD">272000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_bed47220-3c55-4a62-b6ff-ea42c75d2fef"
      unitRef="U_USD">1115000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_4303875f-8fcd-408d-aa0d-52ddaf8d8b69"
      unitRef="U_USD">1115000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_264544f1-3468-4c3f-888f-e76d69aa9c26"
      decimals="-3"
      id="F_c5828eb6-4e61-42e2-aad5-4c0fb93fb91a"
      unitRef="U_USD">26752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_264544f1-3468-4c3f-888f-e76d69aa9c26"
      decimals="-3"
      id="F_6351ab1c-8065-4673-8126-cd2a8e5a6859"
      unitRef="U_USD">95000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_264544f1-3468-4c3f-888f-e76d69aa9c26"
      decimals="-3"
      id="F_46888630-93dc-47c2-a67e-75ac1974b05a"
      unitRef="U_USD">26847000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fb78444b-50bb-4a99-b63f-30026eed0bd9"
      decimals="-3"
      id="F_34b4fe22-3a6d-4262-9b45-26b66dd3c5f1"
      unitRef="U_USD">2877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fb78444b-50bb-4a99-b63f-30026eed0bd9"
      decimals="-3"
      id="F_4d432630-22e7-4056-976c-6bd2661478d6"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fb78444b-50bb-4a99-b63f-30026eed0bd9"
      decimals="-3"
      id="F_1a8af07c-19e3-460a-a431-a19c2ca549a0"
      unitRef="U_USD">2894000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509"
      decimals="-3"
      id="F_cbb75585-a6ba-4975-9e4b-72a3a1538c2a"
      unitRef="U_USD">86250000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509"
      decimals="-3"
      id="F_5b6bbc50-0a37-416b-afcb-086cda22db58"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509"
      decimals="-3"
      id="F_a6048dd0-bbac-410b-9e94-759b8b15f78c"
      unitRef="U_USD">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f7589db9-9bed-4ce5-b958-b8edb41a3509"
      decimals="-3"
      id="F_5a5ce75e-bd12-4c88-8876-b3349d6a7def"
      unitRef="U_USD">86201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6310966f-16be-4280-aead-d0c892e948b2"
      decimals="-3"
      id="F_8d79f045-9dea-48a0-9e36-8fa9908c7f39"
      unitRef="U_USD">13598000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6310966f-16be-4280-aead-d0c892e948b2"
      decimals="-3"
      id="F_b1065203-6204-41e1-9c1f-e429b95fe9a0"
      unitRef="U_USD">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6310966f-16be-4280-aead-d0c892e948b2"
      decimals="-3"
      id="F_33769c3d-7ebd-4a2e-9f0c-a47598329043"
      unitRef="U_USD">13670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_0df574f8-1c03-46d2-bca1-dd5ad46aba61"
      unitRef="U_USD">102270000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_4b680e92-4782-48b3-8ff0-6955380ed441"
      unitRef="U_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_ec7286df-ef1e-4848-a4bb-5483feacf81e"
      unitRef="U_USD">33000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_0e0fb2b6-5400-4583-b3b2-522a9ddc31c0"
      unitRef="U_USD">102268000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_80fdebb2-afb5-42f1-8838-fcfc74487c1a"
      unitRef="U_USD">48409000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_3fd80df9-6f2e-45ac-8f7f-eff7f5be1e1c"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_e183486d-e0d3-4dba-8bea-f371ec9602e1"
      unitRef="U_USD">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_d6904fbd-6186-4483-b5c1-7ae5a6b6ee9c"
      unitRef="U_USD">48360000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_ce0edead-617d-4629-999c-3b19abc179fd"
      unitRef="U_USD">26628000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_15ea9d0e-887c-4ad2-99af-b0bc01dbe1fd"
      unitRef="U_USD">130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_2eda6da9-d00c-414b-b2c1-fc960aee3acb"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_dd741336-bbdf-4bc3-8693-90ff4306e40f"
      unitRef="U_USD">26734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_cc37614a-dc8c-493b-8bbc-8a9341fe11d9"
      unitRef="U_USD">306784000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_4a71c176-ae54-4d29-9521-a42a7df86290"
      unitRef="U_USD">402000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_7a48b35a-92f5-4b7c-a497-9b1951c7f887"
      unitRef="U_USD">212000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_0db96cf8-ca5a-4d5e-960a-102f30297868"
      unitRef="U_USD">306974000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7"
      decimals="-3"
      id="F_16812dcb-0e0f-48e6-b75a-11eee7bfced7"
      unitRef="U_USD">39771000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7"
      decimals="-3"
      id="F_54a428fb-c98a-4cec-98b0-93c8437bbe9e"
      unitRef="U_USD">39771000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_372c62b9-8f81-4b39-ba2b-c96171a84540"
      unitRef="U_USD">39771000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_d39c7b69-977e-4b90-b0ef-254bde2d2165"
      unitRef="U_USD">39771000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7"
      decimals="-3"
      id="F_d26cb5a6-539d-4769-9e6d-98668e6c91ef"
      unitRef="U_USD">93000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_56aeac30-b895-473c-8b3a-f12592932ce7"
      decimals="-3"
      id="F_a0259a10-ebfe-4dd6-9194-b11a2ee39eaf"
      unitRef="U_USD">93000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_8d5c94ef-47a2-4e1e-9aa3-b699facad362"
      decimals="-3"
      id="F_24632914-b537-4423-9c2e-847d87724634"
      unitRef="U_USD">271000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_8d5c94ef-47a2-4e1e-9aa3-b699facad362"
      decimals="-3"
      id="F_c89ea9f9-7fff-4f58-9fd2-0adbabb0d033"
      unitRef="U_USD">271000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_e2942cce-2012-4d16-907a-0c8b1fac17e2"
      unitRef="U_USD">364000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_290b2bba-1bd2-499f-929a-ed3c119a5c9b"
      unitRef="U_USD">364000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_bddae142-88c5-46c3-aeb8-6ecbed7c9ee3"
      unitRef="U_USD">12983000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_8bfa084e-b551-496c-a52a-057a2339a669"
      unitRef="U_USD">62000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_2573afc7-3840-4a3a-9d18-16b28cb2daf5"
      unitRef="U_USD">12921000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b6536834-7d1a-4219-88e2-57d47d5dd378"
      decimals="-3"
      id="F_1c36ea5f-2ebb-4c08-adc3-8420d18764e0"
      unitRef="U_USD">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b6536834-7d1a-4219-88e2-57d47d5dd378"
      decimals="-3"
      id="F_97a8af28-4cd2-42b8-9b5a-bc6345518a9a"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b6536834-7d1a-4219-88e2-57d47d5dd378"
      decimals="-3"
      id="F_3447fbc0-6b32-4ef3-afdd-ea9157e8a7d3"
      unitRef="U_USD">2976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0"
      decimals="-3"
      id="F_2f0b8114-d60e-4d8f-ad3c-247508842698"
      unitRef="U_USD">9860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0"
      decimals="-3"
      id="F_4149ca6a-1187-47e0-b965-9cbcb722b2f8"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b7a28230-234c-44dd-9d95-7f2a08c8c7d0"
      decimals="-3"
      id="F_05f0374d-7838-426f-8db9-d8777acd959b"
      unitRef="U_USD">9846000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_b11f9498-a12a-48a1-a1c9-f7755aba0dcf"
      unitRef="U_USD">64285000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_1be0fe6a-beef-4f4f-b2aa-e66e92d47804"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_5f0e3e1e-d404-46ba-86ea-400b041470c5"
      unitRef="U_USD">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_a5fa21ee-c4ab-4ece-a20c-9fde2924844f"
      unitRef="U_USD">64199000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_8ac1b1c5-a2d3-4ed6-9d77-0f36a0bcf66d"
      unitRef="U_USD">26014000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_98c8e6a4-2668-46ea-a9c1-e1c5c60e0f32"
      unitRef="U_USD">55000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_aa84f6d1-fa9a-496a-9baf-95f595ceb411"
      unitRef="U_USD">25959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_9c1b3433-f89e-4bcd-ad37-af131366b4c1"
      unitRef="U_USD">116142000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_04c62937-f1d2-48cc-a780-832861cd7e47"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_6efd393e-320e-4ab2-8128-54fd2b8fd3aa"
      unitRef="U_USD">247000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_61acfbd5-b736-4aec-afa4-804a49aacbd6"
      unitRef="U_USD">115901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_32c9e1fb-d747-438e-9c39-75f3745dc2a0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored &lt;br/&gt;&#160;&#160;&#160;enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than &lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;br/&gt;&#160;&#160;&#160;(due in less than&lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury &lt;br/&gt;&#160;&#160;&#160;securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal securities &lt;br/&gt;&#160;&#160;&#160;(due in less than a year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored &lt;br/&gt;&#160;&#160;&#160;enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than &lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;br/&gt;&#160;&#160;&#160;(due in less than&lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,721&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20"
      decimals="-3"
      id="F_62fad5d1-395d-4308-abef-9e7b44c83313"
      unitRef="U_USD">69377000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20"
      decimals="-3"
      id="F_8b4ad9ac-4bb5-4f2b-910f-d3ff1e6b27e6"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20"
      decimals="-3"
      id="F_ca1d3e8b-521c-4e69-a8b8-175339464562"
      unitRef="U_USD">69377000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_d9733c1c-7fd3-461a-9714-dca4f2863d20"
      decimals="-3"
      id="F_c494367d-1d3a-4448-a8d4-5652ab7b2d00"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_f3d1633c-5821-4d62-8eea-a137f68ac0bd"
      unitRef="U_USD">58622000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_4f5847f7-a2bc-4501-aab5-a771b2d5996c"
      unitRef="U_USD">33000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_d5a1664e-27de-4c76-ba0b-cb79285893bc"
      unitRef="U_USD">58622000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_54b0b4f7-fffe-40c8-a901-31c5169f8ff7"
      decimals="-3"
      id="F_1a26beb0-f9fc-4f77-b801-af9578d44714"
      unitRef="U_USD">33000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_4dfb4388-f637-4497-9b2d-a36397247dc7"
      unitRef="U_USD">34567000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_116f73a6-2ccb-4007-81f1-7e5e820fb179"
      unitRef="U_USD">63000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_c0adc5bf-8f34-46be-b64c-07f0a839198c"
      unitRef="U_USD">34567000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_a74175ba-db98-47c3-a243-217ab36ff82c"
      decimals="-3"
      id="F_da1deba4-bdd6-4dba-8628-fdee4a216c89"
      unitRef="U_USD">63000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_1641015a-c275-4123-b2d3-916225d8e109"
      unitRef="U_USD">3952000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_6a51a618-5a62-4fd6-838a-449dccd20070"
      unitRef="U_USD">23000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_12f4e3a7-36e9-4eb7-8464-955ec2c084f9"
      unitRef="U_USD">3952000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_827f4149-4d34-435f-8a68-7494c346ac68"
      decimals="-3"
      id="F_7c02de60-fa44-4544-9dd0-cc1d688d0a59"
      unitRef="U_USD">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_b6578b20-8596-40e2-8115-16c572262217"
      unitRef="U_USD">166518000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_1995ce93-a075-437e-b613-814626518afa"
      unitRef="U_USD">211000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_4477fe09-8132-4cce-9098-28efa8a2a5e3"
      unitRef="U_USD">166518000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_6ee0b6ab-cab3-48b2-8bf3-91b596b80976"
      unitRef="U_USD">211000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_abfb3d33-abfb-469f-a9ac-c8a1a9715064"
      unitRef="U_USD">11424000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_22f90508-a2d7-4565-8ad9-371a7ec0c456"
      unitRef="U_USD">57000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_4337f37c-b948-4768-9db3-71f729852ad2"
      unitRef="U_USD">1497000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_a5cdd829-4928-47d1-bdda-b0f42cdef1a1"
      unitRef="U_USD">5000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_474fd431-e0b6-4cce-98d5-19d2071ded0b"
      unitRef="U_USD">12921000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_950b9119-6687-42b5-9831-7ca4ebac5451"
      decimals="-3"
      id="F_9eb5f622-0b14-4204-9a27-5f44a6c3af5a"
      unitRef="U_USD">62000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60"
      decimals="-3"
      id="F_8395a4e3-40a6-45da-8cba-badb766d3d50"
      unitRef="U_USD">2976000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60"
      decimals="-3"
      id="F_51da83ad-e779-408a-87f5-0d0021015cd0"
      unitRef="U_USD">24000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60"
      decimals="-3"
      id="F_e527e889-40cc-40d4-beff-e4a11923a1d5"
      unitRef="U_USD">2976000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_0cdf3cf4-78a2-4fe2-a6e8-a889f1177c60"
      decimals="-3"
      id="F_5090a276-981a-4b8b-b585-87bc523c975f"
      unitRef="U_USD">24000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_503221bc-7adf-491b-8898-576757f733b9"
      decimals="-3"
      id="F_1ff3fce6-48bc-4fd1-b24a-6301c106b085"
      unitRef="U_USD">9845000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_503221bc-7adf-491b-8898-576757f733b9"
      decimals="-3"
      id="F_ddf33baa-d079-4a5c-9d78-dafa3d83648b"
      unitRef="U_USD">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_503221bc-7adf-491b-8898-576757f733b9"
      decimals="-3"
      id="F_eeb63b5b-17d2-4874-adb4-90fc194eef14"
      unitRef="U_USD">9845000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_503221bc-7adf-491b-8898-576757f733b9"
      decimals="-3"
      id="F_7071479c-1880-4dc9-b5df-4579021c22a0"
      unitRef="U_USD">14000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_90f0d736-db46-43d4-849a-70b5031f9950"
      unitRef="U_USD">52454000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_22971dfe-85ab-4ada-9eaa-61cfc85b0768"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_9eafe069-9419-4a5a-a140-4e1b568c7c36"
      unitRef="U_USD">52454000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_d0942a03-12fc-439e-b31b-902f477607aa"
      decimals="-3"
      id="F_bb31f120-44b4-4b72-a026-415445a24916"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_cb5f31bc-6ea0-41f8-a2f7-bc5ec15b72e0"
      unitRef="U_USD">1998000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_c1bf8414-c332-46ad-a5db-de2e9240b470"
      unitRef="U_USD">2000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_8498dac1-3b2f-44a9-83d6-e44195445d60"
      unitRef="U_USD">23962000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_27913af5-23b8-40a3-a122-1f612a5917a1"
      unitRef="U_USD">53000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_4c378df3-1c99-4b7c-936e-f22e0efe9628"
      unitRef="U_USD">25960000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_75e9b7cb-0353-47d0-97b8-f14e804eefeb"
      decimals="-3"
      id="F_a374cbe6-825b-495c-a3d5-0877fe14e853"
      unitRef="U_USD">55000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_dba6317a-f4ce-4aa9-a56d-67d3863ed613"
      unitRef="U_USD">75721000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_662b7589-1c9b-48e1-898c-4fa371140f8e"
      unitRef="U_USD">165000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_3f33f4b6-47a4-4328-a86e-ce95d8bf10b1"
      unitRef="U_USD">28435000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_5299059d-fe7e-43b2-a710-978cef9647fb"
      unitRef="U_USD">82000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_427b6e3c-4e2f-4022-a0b7-a4414bb44c0d"
      unitRef="U_USD">104156000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_b6fb3bb3-ff1d-46d6-89b5-8a072564a189"
      unitRef="U_USD">247000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b01ef453-3f39-4490-b16a-7fac3fccaf07">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 and indicates the fair value category assigned.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.040000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Active Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Identical Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Observable Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;324,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Municipal securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;156,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in cash and cash equivalents on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in restricted cash on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in current portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(4)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in noncurrent portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2e8f230f-35de-44f7-93b7-6df504f45fde"
      decimals="-3"
      id="F_70cfece5-5e04-411a-8e56-15e6828989fb"
      unitRef="U_USD">17658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c14e1cc2-f8b1-4804-970a-08b5df83f4b4"
      decimals="-3"
      id="F_a598f6b0-9ece-44fd-9500-e3dc89498398"
      unitRef="U_USD">17658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3f7e8c6c-6681-4a1d-9f84-ed77636d8cd2"
      decimals="-3"
      id="F_4639dbe4-6cba-4d7f-b33e-5fe949aafa0f"
      unitRef="U_USD">272000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7d2d8379-582f-499f-a5c1-4b051c31e7ed"
      decimals="-3"
      id="F_a700ccfb-3aff-40a0-8f8d-d0b996941be7"
      unitRef="U_USD">272000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_49ff1dd8-46db-4d4f-baa8-c884bec8fd8e"
      decimals="-3"
      id="F_92a70d80-b47b-481c-9563-a5e48f8b228d"
      unitRef="U_USD">29742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_df1f41e8-3c99-453f-9b1f-eb930e82b8d9"
      decimals="-3"
      id="F_95008b90-e9ea-42a6-8da3-e4691a35750a"
      unitRef="U_USD">29742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7044d4ee-a54a-4427-9cc2-9922f4676346"
      decimals="-3"
      id="F_898e6471-0822-40ae-b04c-64c82c354ddd"
      unitRef="U_USD">99872000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6812ec1e-cd7d-4990-a1fa-445d65e04803"
      decimals="-3"
      id="F_91ac7770-bf2a-4b7f-ac8e-f885e851fb0c"
      unitRef="U_USD">99872000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0907aaf0-4f28-425e-a4e7-02bd5e2c9311"
      decimals="-3"
      id="F_6933a5ec-f58d-43c3-877d-8a624440141b"
      unitRef="U_USD">102268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5e5d5abf-c356-4752-8616-9b666f658b7f"
      decimals="-3"
      id="F_300be5e3-c86e-49e9-a8bb-242d6af4d18c"
      unitRef="U_USD">102268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4d124dfd-42e3-4007-856f-2bc59dc7e2da"
      decimals="-3"
      id="F_3c3f8193-8e98-43db-b2f2-b01c3f20ba8c"
      unitRef="U_USD">75092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_edfb6d0a-e261-47b0-b5f3-062c8bf0db56"
      decimals="-3"
      id="F_46975070-7b06-4702-985f-caf7b5b0b401"
      unitRef="U_USD">75092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d3f33d08-a5ce-4365-a047-c2b41669086c"
      decimals="-3"
      id="F_7d356915-d9ae-4811-a660-cf7d49f0754a"
      unitRef="U_USD">17930000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_01a342e9-84cb-4a8b-94b4-0c633e0e9043"
      decimals="-3"
      id="F_be693926-9e61-417a-8c8e-60bed1646881"
      unitRef="U_USD">306974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5c78574d-4d3a-47d2-9453-d6f12deab799"
      decimals="-3"
      id="F_480f736b-f806-4907-9462-4a28b58c304e"
      unitRef="U_USD">324904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cc68db16-fd2f-40cb-8dd2-0fdeb8ec048d"
      decimals="-3"
      id="F_6ccc70fe-27c0-4088-810c-e67f55615797"
      unitRef="U_USD">39864000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_23c9ef8f-d893-45f7-9dae-127a81af3541"
      decimals="-3"
      id="F_1d50e916-17de-4533-ad83-1240780e59e6"
      unitRef="U_USD">39864000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5093ace2-fb77-487d-9798-18faea32c09f"
      decimals="-3"
      id="F_77824295-0957-4da6-ab20-b0562344cf43"
      unitRef="U_USD">271000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8a0297cb-3318-4836-a868-af5440cc2bbf"
      decimals="-3"
      id="F_aecfb94c-47d2-45cf-8164-30e8cfa2c54c"
      unitRef="U_USD">271000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8fb6bb85-bc11-42d4-90c8-60d500a4ce63"
      decimals="-3"
      id="F_149391b9-e365-40a7-9137-bcf91168c2e7"
      unitRef="U_USD">12921000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1520a1d5-d2fd-4004-a5ce-578541558369"
      decimals="-3"
      id="F_3b8bf624-a20a-40ea-8c80-1e2c0576869f"
      unitRef="U_USD">12921000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7e59e3e0-f076-4d12-8cb2-4da3978cb2ff"
      decimals="-3"
      id="F_c106b46d-bba1-40e3-b191-e9f3d742f8ca"
      unitRef="U_USD">2976000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1780d47b-7074-43ea-83b7-6b37c8951dc8"
      decimals="-3"
      id="F_7b29f9f3-a974-497a-be2f-11d8de1115e6"
      unitRef="U_USD">2976000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_56700b86-6b39-4ff6-939d-369ca954edba"
      decimals="-3"
      id="F_55e26582-5768-40c3-9934-14d4511605d2"
      unitRef="U_USD">9846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_eca18dbf-5f65-4638-9ffe-5784859f233f"
      decimals="-3"
      id="F_c64b589c-04bb-44e9-b5f5-a645495a8d37"
      unitRef="U_USD">9846000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_44f56c70-bcea-4e2b-ac28-fae20f129a98"
      decimals="-3"
      id="F_8205d90f-6b83-4619-b8ad-f6568f435957"
      unitRef="U_USD">64199000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0f69f345-ac6c-4afc-bd0d-534fc2cdd78f"
      decimals="-3"
      id="F_3de3ab2b-01a8-4a69-a5d0-08bec3a515e5"
      unitRef="U_USD">64199000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_794b0098-1158-41ef-a669-a1b32cd93046"
      decimals="-3"
      id="F_9a4d967d-373a-41f8-9415-51fcfa1546c6"
      unitRef="U_USD">25959000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_46da631c-8b1d-4cf0-a98f-1721c6e53088"
      decimals="-3"
      id="F_231cd8ee-27b5-4698-9844-988fb3dc3913"
      unitRef="U_USD">25959000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_82f9062a-632d-417d-b946-eaa6dd00480f"
      decimals="-3"
      id="F_196107cc-9729-4b55-a579-2d1b83188964"
      unitRef="U_USD">40135000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_94686802-cc00-4b2a-8c6f-27ed9da5c87a"
      decimals="-3"
      id="F_135e002c-c79c-4208-b4d0-480ee89cd83a"
      unitRef="U_USD">115901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_09926111-0e38-4a7f-b821-d79344c2f8f9"
      decimals="-3"
      id="F_56e2e29c-31f6-46b3-a42d-507cc98650c3"
      unitRef="U_USD">156036000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="C_5b06c91e-d34a-427e-a1ea-6394120ede9b"
      decimals="INF"
      id="F_2f9261de-d5cc-44a4-8394-58dc252c29be"
      unitRef="U_shares">13842625</us-gaap:InvestmentOwnedBalanceShares>
    <gern:CostMethodInvestmentOwnershipPercentage
      contextRef="C_e3194e6b-9d7d-47dd-b6df-8d8c89d54d48"
      decimals="INF"
      id="F_f4c6f8fb-304a-419b-b513-1cff2afd10c0"
      unitRef="U_pure">0.20</gern:CostMethodInvestmentOwnershipPercentage>
    <gern:CostMethodInvestmentsCostBasis
      contextRef="C_8069d28b-213c-446c-bde1-39089012764b"
      decimals="0"
      id="F_10d27198-80cc-4273-a453-33dc283642a7"
      unitRef="U_USD">0</gern:CostMethodInvestmentsCostBasis>
    <us-gaap:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod
      contextRef="C_71f2bda0-5d65-46ba-85a1-918c8c1ac142"
      id="F_4a88c15c-5ea6-4e60-9150-3f050c18628a">we received 13 BARD1 shares for every five shares of Sienna ordinary shares, resulting in our ownership of 35,990,825 shares of BARD1.</us-gaap:BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="C_3bed0edb-6d63-45bc-b6ac-2fc53a07d1f3"
      decimals="0"
      id="F_e4ed767e-22af-41bd-90a0-635c79c4be21"
      unitRef="U_shares">35990825</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="C_18fdb42c-1e4c-4ab6-babf-f250735da19f"
      decimals="0"
      id="F_809d96d3-a736-43ac-a2eb-9517cb94b99b"
      unitRef="U_USD">1233000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="C_a94a3320-6443-4a71-a8ed-f5a63144da7f"
      decimals="INF"
      id="F_713af094-0de8-409a-b8fb-1decc3837474"
      unitRef="U_shares">0</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_329f0a08-5830-4ccb-b072-7432675311a8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, stated at cost, is comprised of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_9fc3b9bc-2b53-414a-b24f-3eea2d7d3f92">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, stated at cost, is comprised of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;896&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_557b50d4-874f-47b9-821c-244d8e7b719f"
      decimals="-3"
      id="F_cd641f00-15e2-4c47-bbf9-e593edeceac0"
      unitRef="U_USD">2273000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a862b4ec-a5b7-430d-9f24-f6c95dc41dca"
      decimals="-3"
      id="F_c13f97c8-c89e-4aa1-8ccb-b62d6d8c6398"
      unitRef="U_USD">1554000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_730d222b-ee44-44a3-8ae6-6f60f92122a6"
      decimals="-3"
      id="F_dc1b89de-0f3c-4959-ac8d-ac0c034aeba9"
      unitRef="U_USD">135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d1ea305-4988-4375-9ee4-69c9f837ffb5"
      decimals="-3"
      id="F_ef3de22f-c674-40d5-9bf6-3df589ee13b6"
      unitRef="U_USD">135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_bb8590cb-3c2d-4fa6-ae29-b7d99b4fcae8"
      unitRef="U_USD">2408000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_07e82a78-9b96-4fe6-b2a6-8b3b6a76c40a"
      unitRef="U_USD">1689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_ef70d7b2-a574-470e-951f-f19d3f57755b"
      unitRef="U_USD">1231000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_3e91058e-6857-455f-90da-09d5ce3acded"
      unitRef="U_USD">896000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_94923e1f-9df3-4b58-ab2f-e9cd9d4632fd"
      unitRef="U_USD">1177000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_d1c70c8a-ff0b-4e01-91a3-3dafd63630e0"
      unitRef="U_USD">793000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_d1528ea9-2476-48cf-8906-819b9c8c4bda">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. LICENSE AGREEMENT&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Janssen Pharmaceuticals, Inc. License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 15, 2016, we entered into the License Agreement with Janssen Pharmaceuticals whereby we granted to Janssen Pharmaceuticals an exclusive worldwide license, or the Exclusive License, under our proprietary patents for the research, development and commercialization of products based on specialized oligonucleotide backbone chemistry and novel amidates for ribonucleic acid interference. In addition to the Exclusive License, we granted to Janssen Pharmaceuticals a non&#x2011;exclusive worldwide license, or the Non&#x2011;Exclusive License, under our patents covering the synthesis of monomers. This agreement was terminated effective April 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_ce597597-0187-4bd5-b782-6ad06c1c0511">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. ACCRUED LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.272%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.363%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.363%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CRO and clinical trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Manufacturing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_3206d9da-757a-4ab1-a460-1ff1eb9b554c">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.272%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.363%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.363%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;CRO and clinical trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Manufacturing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_0f3bc72e-a0f5-407e-993a-334ccb790720"
      unitRef="U_USD">23541000</gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent>
    <gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_dc4a0d34-6a4c-4a5a-8153-fda15eb582a3"
      unitRef="U_USD">17040000</gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent>
    <gern:AccruedManufacturingActivitiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_755c6ab2-b1b8-481a-b5cb-dd15aeaf1eff"
      unitRef="U_USD">14629000</gern:AccruedManufacturingActivitiesCurrent>
    <gern:AccruedManufacturingActivitiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_9efac7de-05e1-494e-8ef2-fb0e2d07aaca"
      unitRef="U_USD">5321000</gern:AccruedManufacturingActivitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_f32e26be-df4d-46fb-a694-102867031fee"
      unitRef="U_USD">556000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_0860775a-1778-4514-8595-b6b7c0931093"
      unitRef="U_USD">9668000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_3217666e-6093-4731-8469-0d357f939cda"
      unitRef="U_USD">768000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_c5fc9169-fe66-420d-8ffe-d4a44fbf0e9e"
      unitRef="U_USD">561000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_db160ac6-0a06-4f6f-a832-1777086c485b"
      unitRef="U_USD">814000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_82b8f9c3-d54f-49ff-a8a9-28ff188f455e"
      unitRef="U_USD">510000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_68d81d41-3e33-4d84-a0e4-1c6fd83e67da"
      unitRef="U_USD">40308000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_dfa1e9f8-279f-4e7a-8b26-5ed08eb5d836"
      unitRef="U_USD">33100000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_5b2d1ce9-ed13-4389-b0f2-49376cf43005">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Purported Securities Lawsuits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed. The other two lawsuits, filed in the U.S. District Court for the Northern District of California, were consolidated by the court. In September 2022, the parties agreed to a settlement and entered into a Stipulation and Agreement of Settlement, which was subject to court approval. The court granted final approval of the settlement on September 28, 2023 and final judgment was entered on October 3, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the consolidated class action complaint, we agreed to pay and/or to cause our insurance carriers to pay a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in cash, which was paid into an escrow account under our available D&amp;amp;O insurance coverage and, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in cash which was paid after final approval of the settlement by the court. The settlement does not constitute an admission of fault or wrongdoing by Geron or any of our officers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As of December 31, 2022, our portion of the settlement amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; had been included in accrued liabilities on our consolidated balance sheets and recognized as general and administrative expense on our consolidated statements of operations for the year ended December 31, 2022. Our portion of the settlement amount was paid in the fourth quarter of 2023. There is no liability outstanding as of December 31, 2023 as the matter was fully settled during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  On December 21, 2022, the parties to the shareholder derivative action filed in the Delaware Court of Chancery entered into a stipulation of settlement, or the Derivative Stipulation, and on May 17, 2023, the Delaware Court of Chancery approved the Derivative Stipulation, and the case was dismissed with prejudice.  Subsequently, each of the remaining derivative cases were dismissed with prejudice.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Derivative Stipulation, in exchange for the release and dismissal with prejudice of all claims against the defendants in the consolidated shareholder derivative actions filed in the Northern District, we agreed to pay and/or to cause our insurance carriers to pay a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, comprised of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;525,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in cash, which was payable under our available D&amp;amp;O insurance coverage and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;825,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in cash payable by us. The settlement does not constitute an admission of fault or wrongdoing by any of our officers or &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;members of our board. As of December 31, 2022, we had recorded the total settlement amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as accrued liabilities and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;525,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as interest and other receivables on our consolidated balance sheets. For the year ended December 31, 2022, we had recognized our portion of the settlement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;825,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as general and administrative expense on our consolidated statements of operations. In the second quarter of 2023, our insurance carriers paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;525,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;cash,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;we paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;825,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; in cash, for an aggregate total payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Accordingly, there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; outstanding amount to settle against this as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant resources in the defense of any additional lawsuits, and we may not prevail. In addition, we have and may continue to incur substantial legal fees and costs in connection with such lawsuits. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive, and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Expenses associated with any potential future lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. We have not established any reserve for any potential liability relating to any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Indemnifications to Officers and Directors&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Severance Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have adopted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; severance plans that apply to all of our employees who are not subject to performance improvement plans, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; plan covering employees above the Vice President level, i.e., executives, and all other employees hired before January 1, 2022, and the other plan covering all non-executive employees hired on or after January 1, 2022.  The severance plans provide for, among other benefits: (i) a severance payment upon a Change of Control Triggering Event and Separation from Service and (ii) a severance payment for each non&#x2011;executive employee upon a Non&#x2011;Change of Control Triggering Event and Separation from Service. As defined in the severance plans, a Change of Control Triggering Event and Separation from Service requires a &#x201c;double trigger&#x201d; where: (i) an employee is terminated by us without cause in connection with a change of control or within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months following a change of control provided, however, that if an employee is terminated by us in connection with a change of control but immediately accepts employment with our successor or acquirer, the employee will not be eligible for the benefits outlined in the plans, (ii) an employee resigns because in connection with a change of control, the offered terms of employment (new or continuing) by us or our successor or acquirer within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; days after the change of control results in a material change in the terms of employment, or (iii) after accepting (or continuing) employment with us after a change of control, an employee resigns within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months following a change of control due to a material change in the terms of employment. Under the severance plans, a Non&#x2011;Change of Control Triggering Event and Separation from Service is defined as an event where an employee is terminated by us without cause. Severance payments range from&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_b8827fb4-805f-47b4-9575-17566fb60e0f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months of base salary in connection with a Change of Control Triggering Event or from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0194cff7-90da-4ed5-a176-f5577cc6d08c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six weeks&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of base salary in connection with a Non-Change of Control Triggering Event, as well as a pro-rata portion of the employee&#x2019;s annual target bonus, depending on the employee&#x2019;s position with us, payable in a lump sum payment, and monthly COBRA payments for the severance period. The severance plans also provide that they shall not supersede the provisions of any individual employment agreements entered into between us and our employees, and that the employees with such agreements will be entitled to whichever benefits are greater under the severance plan or their employment agreement. A copy of the severance plan covering our executive officers is filed as an exhibit to our annual report on Form 10-K. As of December 31,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;all our executive officers have employment agreements with severance provisions and will receive the greater severance benefits of their agreements or those in the severance plan applicable to them.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="C_11088b90-d0a5-4112-af3e-c26b5cbb2191"
      decimals="0"
      id="F_6f68dfcf-83e8-4a1b-9685-2b5817f168db"
      unitRef="U_USD">24000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="C_11088b90-d0a5-4112-af3e-c26b5cbb2191"
      decimals="0"
      id="F_5a3781d6-aa08-4caa-b17f-08ab0f3f5f82"
      unitRef="U_USD">17000000</us-gaap:PaymentsForLegalSettlements>
    <gern:LitigationSettlementAmountPaidInCashOrKind
      contextRef="C_11088b90-d0a5-4112-af3e-c26b5cbb2191"
      decimals="0"
      id="F_5321a977-8658-425d-9eb0-c72bc7fcb752"
      unitRef="U_USD">7000000</gern:LitigationSettlementAmountPaidInCashOrKind>
    <gern:LitigationSettlementAmountAccruedLiabilitiesRecognized
      contextRef="C_29eb0b35-f0bd-4b06-8287-c9e8fdd6d5b7"
      decimals="0"
      id="F_49f64e11-c491-4672-bea6-cbbee1dfdb11"
      unitRef="U_USD">7000000</gern:LitigationSettlementAmountAccruedLiabilitiesRecognized>
    <gern:LitigationSettlementAmountInterestAndOtherReceivableRecognized
      contextRef="C_29eb0b35-f0bd-4b06-8287-c9e8fdd6d5b7"
      decimals="0"
      id="F_8dea7891-354d-4ffe-b29f-ef74dc45d7b2"
      unitRef="U_USD">7000000</gern:LitigationSettlementAmountInterestAndOtherReceivableRecognized>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5"
      decimals="0"
      id="F_c3e6ac04-b114-4379-bbef-ad9f26d28c3f"
      unitRef="U_USD">1350000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5"
      decimals="0"
      id="F_18ed6b5d-f455-4871-b41b-3297257ca8a3"
      unitRef="U_USD">525000</us-gaap:PaymentsForLegalSettlements>
    <gern:LitigationSettlementAmountToBePaid
      contextRef="C_aaf64096-d2f0-4874-95f7-f1e081c29515"
      decimals="0"
      id="F_3052b7ae-62a7-4819-9528-2198ed2aba36"
      unitRef="U_USD">825000</gern:LitigationSettlementAmountToBePaid>
    <gern:LitigationSettlementAmountAccruedLiabilitiesRecognized
      contextRef="C_9edf5ddf-277c-4136-a6a5-53a0c72bd66c"
      decimals="0"
      id="F_b6f8619e-c296-4c42-b2b9-2d20d76ec6c5"
      unitRef="U_USD">1350000</gern:LitigationSettlementAmountAccruedLiabilitiesRecognized>
    <gern:LitigationSettlementAmountInterestAndOtherReceivableRecognized
      contextRef="C_9edf5ddf-277c-4136-a6a5-53a0c72bd66c"
      decimals="0"
      id="F_699c44d6-b02d-487e-9398-75f3c099641c"
      unitRef="U_USD">525000</gern:LitigationSettlementAmountInterestAndOtherReceivableRecognized>
    <gern:LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized
      contextRef="C_9e13ec08-4d34-4c19-b5b5-3b79b45e37fd"
      decimals="0"
      id="F_0c1dce66-076a-41cd-9125-b4b6089aa845"
      unitRef="U_USD">825000</gern:LitigationSettlementAmountGeneralAndAdministrativeExpenseRecognized>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="C_cdaff13f-48a1-4aed-808e-efa7e46b169b"
      decimals="0"
      id="F_1be668aa-5c82-4858-8bea-4428d609e95b"
      unitRef="U_USD">525000</us-gaap:PaymentsForLegalSettlements>
    <gern:LitigationSettlementAmountPaidInCashOrKind
      contextRef="C_cdaff13f-48a1-4aed-808e-efa7e46b169b"
      decimals="0"
      id="F_70351dbb-a3fb-405a-b0f4-53518aefb43f"
      unitRef="U_USD">825000</gern:LitigationSettlementAmountPaidInCashOrKind>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="C_b86b7637-5f77-4ff1-b473-0c977da2a5e5"
      decimals="0"
      id="F_6a51d12f-9d67-49e0-8d08-52d7b567148d"
      unitRef="U_USD">1350000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <gern:LitigationSettlementAmountOutstanding
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_672b5cda-c9ae-4136-a223-2e7d6a073085"
      unitRef="U_USD">0</gern:LitigationSettlementAmountOutstanding>
    <gern:NumberOfSeverancePlan
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="0"
      id="F_cd438123-39e2-413a-81b3-79210b14f42e"
      unitRef="U_Plan">2</gern:NumberOfSeverancePlan>
    <gern:NumberOfSeverancePlan
      contextRef="C_b59a05ad-a041-4c67-b50f-9f5d30c4be93"
      decimals="0"
      id="F_107363a6-8267-40f6-a807-6acf63f1ecb3"
      unitRef="U_Plan">1</gern:NumberOfSeverancePlan>
    <gern:LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_5a41a71d-276c-4c8a-aa7b-2c99fd443efb">P12M</gern:LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod>
    <gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_d6bbd2c2-61e0-44b3-907a-a23b77554ca4">P30D</gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity>
    <gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_a85eebe9-cbd7-4e90-9459-77c45a84e0a6">P12M</gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan
      contextRef="C_31e1df9f-50c4-415c-947c-3b83ba778c1f"
      id="F_8bc14150-8106-4a55-aac6-19c720db0e59">P18M</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent
      contextRef="C_31e1df9f-50c4-415c-947c-3b83ba778c1f"
      id="F_332247f8-d4f1-4611-a9cc-cbfe443e0452">P12M</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_41e9743a-0a9c-458e-8405-4f1284f66175">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. OPERATING LEASES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;New Jersey Office Space Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years with an option to extend for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one-time option to terminate the New Jersey Lease without cause as of the 103&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;rd&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; month anniversary of the commencement date of the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date. Based on the initial term of the New Jersey Lease of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, the right-of-use asset and corresponding operating lease liability was approxima&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;tely $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,356,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;hich represented the present value of lease pay&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ments over the initial lease term, net of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; rent abatement period, using an incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% based o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;n information available as of October 1, 2019. Under the New Jersey Lease, we are also obligated to pay certain variable expenses separately from the base rent, including electricity and common area maintenance. Such costs are being expensed in the period they are incurred. As of December 31, 2023, the remaining lease term for the New Jersey Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.8 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ye&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foster City Office Space Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months with an option to extend for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Foster City Lease commenced on March 10, 2020, upon the substantial completion of all tenant improvements. As of the l&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ease commencement date, the right-of-use asset and corresponding operating lease liability was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,868,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, wh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ich represented the present value of remaining lease payments using an incremental borro&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;wing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% over the initial lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months, net of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; rent abatement period. Under the Foster City Lease, we are also obligated to pay certain variable expenses separately from the base rent, including taxes and common area maintenance. Such costs are considered non-lease components and have been excluded from the calculation of the right-of-use asset and corresponding operating lease liability and are being expensed in the period they are incurred. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, the remaining lease term for the Foster City Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, the Foster City Lease and a lease from a former location in Menlo Park, California, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.516%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.555%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.296999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.639%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.077%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.259%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.657%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:10%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:60%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.588888888888889%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Variable lease costs represent non-lease components, such as common area maintenance charges.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.686%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.857%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.457%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9"
      id="F_291871e8-42f6-4e42-b14e-69c49f78c102">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_7906f3d1-d5d9-439c-a646-5ec2a8601afe"
      id="F_c4e01abc-ef11-4c40-b674-2f0cdc89f702">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_7906f3d1-d5d9-439c-a646-5ec2a8601afe"
      id="F_a5c24fea-b2bb-4986-8a2e-8ac39276179e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_1e1d1200-a6c0-43f1-9a9e-761058f49e47"
      id="F_fdb9d8bf-ea4e-4c02-98c5-cd92b42b8738">one-time option to terminate the New Jersey Lease without cause as of the 103rd month anniversary of the commencement date of the lease</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9"
      id="F_ae44e612-9efc-4af0-a9c6-767205bcb40d">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9"
      decimals="0"
      id="F_acf0bdb9-06a6-4fad-bbcf-40b9cd5988db"
      unitRef="U_USD">2356000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9"
      decimals="0"
      id="F_1f366c8d-c3a9-4287-bd30-dc4b67ed502e"
      unitRef="U_USD">2356000</us-gaap:OperatingLeaseLiability>
    <gern:OperatingLeaseRentAbatementPeriod
      contextRef="C_ebd1ac89-5dde-4a45-937c-75b1eb1b2f48"
      id="F_e1457d1e-7afc-4166-bcb7-db2733451703">P7M</gern:OperatingLeaseRentAbatementPeriod>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_cea26a02-14ec-4995-aac7-14c8a668c2f9"
      decimals="INF"
      id="F_aa682da2-c57a-4770-a01b-81da0df1f5b1"
      unitRef="U_pure">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_37a598a5-3c81-4923-b06f-67a5ec38fc90"
      id="F_bb6bc4ef-b0ff-4595-8064-4ed275a5b822">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_70402503-27b5-4f37-815e-29f46b76e9fd"
      id="F_1452dc22-027e-40e7-97c0-76a691746880">P87M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_70402503-27b5-4f37-815e-29f46b76e9fd"
      id="F_c2062ab6-43ca-46de-a534-97add136d436">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_03cae945-a223-49bc-8a34-e80048f4e61f"
      decimals="0"
      id="F_5a17cc91-e174-4f97-844b-f348cbba7d40"
      unitRef="U_USD">1868000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_03cae945-a223-49bc-8a34-e80048f4e61f"
      decimals="INF"
      id="F_dfc46e3d-d6b4-4ced-95f2-ccb9bb2e5f2b"
      unitRef="U_pure">0.07</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_03cae945-a223-49bc-8a34-e80048f4e61f"
      id="F_9ecb7549-78cd-45bd-8ca1-4bb39a307224">P87M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <gern:OperatingLeaseRentAbatementPeriod
      contextRef="C_7e22f4a9-1f60-4ad4-9a3b-88792070760f"
      id="F_0035037a-06b8-42dd-a4d1-02b9d0240f0e">P3M</gern:OperatingLeaseRentAbatementPeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7a801fab-431b-4ace-91e0-07585e1a2682"
      id="F_e643dea4-a236-428c-9b8f-264818689a66">P3Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_42c98f87-63a3-44dd-ae7d-c0bb298db9c3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, the Foster City Lease and a lease from a former location in Menlo Park, California, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.516%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.555%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.296999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.639%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.077%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.259%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.657%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.588888888888889%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Variable lease costs represent non-lease components, such as common area maintenance charges.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_bfcdba67-74e2-4f33-a98d-360eeac8c391"
      unitRef="U_USD">962000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_f84a133c-4181-490e-bf8c-aadd44a411f3"
      unitRef="U_USD">944000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_a9d8c8f3-5fda-4e0f-bd7f-85e152c5bfef"
      unitRef="U_USD">946000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_632eddb0-d2c0-45d6-8d9c-93c2f75aa360"
      unitRef="U_USD">344000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_1fcc61cb-6bdd-43d5-b3e0-d606a74f1a08"
      unitRef="U_USD">310000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_85a0ce35-5297-4643-bb96-e81925b283fa"
      unitRef="U_USD">252000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_7bf9473e-7a50-4514-8d4d-babd090eb2ce"
      unitRef="U_USD">1306000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_3b6587f5-732b-4e9d-b490-c80d9a6d0f9a"
      unitRef="U_USD">1254000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_3e7f3623-aa6e-4da2-bb90-56947fb7ff24"
      unitRef="U_USD">1198000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_f017d692-ade9-4c9f-adfa-38d39d666a2b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:35.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.686%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.857%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:26.457%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;853&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_411d1890-0fed-4819-977e-43d6800cfed7"
      unitRef="U_USD">987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_68839025-e750-482d-a078-af0e19a3a0b7"
      unitRef="U_USD">1014000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_3a565abf-4e30-452f-9519-455e493dd08d"
      unitRef="U_USD">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_986f6be8-8c95-4c55-b684-ef6c60fae9bd"
      unitRef="U_USD">716000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_94e516d7-93ca-40f1-ae19-3fa04e2c7f88"
      unitRef="U_USD">376000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_de196555-aca9-45f2-8e0c-44d22c818051"
      unitRef="U_USD">675000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_a65a95ec-e3c8-4b2a-b461-eaf7880c4578"
      unitRef="U_USD">4808000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_185085e0-02d6-46d2-bfc1-effe73753516"
      unitRef="U_USD">853000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_eafcda82-47c3-4b44-8c80-5f3b1597ea98"
      decimals="-3"
      id="F_52ad9738-6c61-4798-a7aa-15aa0088d9bd"
      unitRef="U_USD">3955000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_f15aca69-0431-4fae-a30c-7e7c55de2e72">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. DEBT&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 30, 2020, or the Closing Date, we, Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, or SVB, entered into a term loan facility, or the Term Loan, up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was amended in August 2021, or the Original Loan Agreement. On June 30, 2022, we entered into a second amendment to the Original Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with such principal being available in a series of tranches, subject to certain terms and conditions. On December 14, 2023, we entered into a third amendment to the Original Loan Agreement, or as amended, the Loan Agreement. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million has been drawn under the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On the effective date of the second amendment, we paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as a facility charge that we recognized as a debt discount and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method. Additional facility charges applied to future draw downs will be treated similarly. We also incurred legal fees in connection with the second amendment, which we recognized as debt issuance costs and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the third amendment, the aggregate principal amount drawn down and remaining available to us under the Term Loan remains at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, with such principal being available in a series of tranches, subject to certain terms and conditions. The third amendment also provides that (i) the fourth tranche of the Term Loan was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, (ii) the commitment period for the fifth tranche of the Term Loan of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is available subject to achievement of a regulatory milestone and satisfaction of certain capitalization requirements, was extended through December 15, 2024, (iii) the variable annual interest rate on the outstanding loans has been decreased to the greater of: (x) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, or (y) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, plus (B) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%; and (iv) the interest only period of the Term Loan has been extended through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. In connection with the third amendment, on the third amendment effective date, we borrowed and received the entire fourth tranche of the Term Loan in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Afte&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;r giving effect to such borrowing, the outstanding principal amount under the Loan Agreement is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On the effective date of the third amendment, we paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as a facility charge that we recognized as a debt discount and are amortizing such cost to interest expense over the life of the loan using the effective interest rate method. Additional facility charges applied to future draw downs will be treated similarly. We also incurred legal fees in connection with the third amendment, which we recognize as debt issuance costs and amortize such cost to interest expense over the life of the loan using the effective interest rate method.  The third amendment of the Loan Agreement is not substantially different as compared to the Original Loan Agreement, and accordingly, we treated the amendment as a modification of the debt in accordance with ASC 470. On September 15, 2023, the third tranche of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Term Loan expired and is no longer available for us, but was added to the fourth tranche as part of the third amendment to the Loan Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Term Loan as amended, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Term Loan matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or the Loan Maturity Date, and may be extended up to an additional six months upon the achievement of certain regulatory and financial milestones.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Term Loan bears interest at a floating rate per annum equal to the greater of either (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or (ii) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, plus (B) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%  (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% as of December 31, 2023).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The interest only period of the Term Loan is through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. Following the expiration of the interest-only period, we are required to repay the Term Loan in equal monthly amortization payments of principal and interest until the Loan Maturity Date.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Upon &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;full repayment of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Term &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Loan, we are also obligated to pay an end of term charge in an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the amount of the Term Loans actually borrowed. Such end of term charge is being accrued to interest expense over the term of the Term Loan using the effective interest rate method. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At our option, upon at least five business days&#x2019; prior written notice to Hercules, we may prepay all or any portion greater than or equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the outstanding loan by paying the entire principal balance (or portion thereof) and all accrued and unpaid interest. There is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; prepayment charge for prepayments of drawdowns under Tranche 1 or Tranche 2.  Prepayments of drawdowns under Tranche 3, Tranche 4, Tranche 5 or Tranche 6 are subject to a prepayment charge of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the prepayment amount, if the prepayment is made prior to June 30, 2025. Thereafter, any prepayment of Tranche 3, Tranche 4, Tranche 5 or Tranche 6 is not subject to a prepayment charge.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Term Loan is secured by substantially all of Geron&#x2019;s assets, except our intellectual property, which is the subject of a negative pledge. The Term Loan contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. We are in compliance with the covenants under the Term Loan as of December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the event of default (subject, in certain instances, to specified grace periods), the principal, interest and any other monetary obligations on all then outstanding amounts under the Term Loan may become due and payable immediately. Upon the occurrence of an event of default, a default interest rate of an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% may be applied to the outstanding principal balance, and Hercules, as the administrative agent, may declare all outstanding obligations immediately due and payable (subject, in certain instances, to specified grace periods) and take such other actions as set forth in the Term Loan. Upon the occurrence of certain bankruptcy and insolvency events, the obligations under the Term Loan would automatically become due and payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Embedded Derivatives and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the net carrying value of the Term Loan was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;hich includes the principal amount&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; less the net unamortized discounts and debt issuance costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; plus an accrued end of term charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,691,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying value of the debt approximates the fair value as of December 31, 2023. The debt discounts and debt issuance costs are being amortized to interest expense over the life of loan amounts under Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future Minimum Payments&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.552%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.698%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  unamortized end of term charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  current portion of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent portion of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_ff3a58b5-efcc-4001-a2ea-2794d695b861"
      decimals="INF"
      id="F_5a7078d4-84f5-46bd-a82a-4c7c00073579"
      unitRef="U_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_ff3a58b5-efcc-4001-a2ea-2794d695b861"
      decimals="INF"
      id="F_3417e435-8240-41c3-88b3-048c84535171"
      unitRef="U_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_9909923d-f176-4cf6-ba61-369530284669"
      decimals="INF"
      id="F_960a6646-48f9-44ee-a02c-343b122c7194"
      unitRef="U_USD">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844"
      decimals="INF"
      id="F_02d28245-17ce-4a18-b9b4-590dd5553381"
      unitRef="U_USD">80000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_ca648008-6ad8-4d06-8ece-4407c06a3407"
      decimals="INF"
      id="F_57f08a9d-fae9-4dc4-8944-d1bc672eb23a"
      unitRef="U_USD">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_3891a9a9-b40f-43be-a57b-26dd8899f2e1"
      decimals="-5"
      id="F_0324f9a0-713b-438c-a0ea-602aa1bbe64b"
      unitRef="U_USD">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_7ff30090-bcbe-4192-9979-96ad9f967d1a"
      decimals="-5"
      id="F_4673669c-dfce-4d69-905a-8e109639bb97"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_cf14b58a-81bb-4655-8483-d56e1f8dafe5"
      decimals="-5"
      id="F_0e31bb5e-ba50-4d12-9fa4-05e6f917b176"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_89681771-d544-4757-ace7-4696d541ae50"
      decimals="-5"
      id="F_92cf9df8-efbd-448d-93de-ca97297327c2"
      unitRef="U_USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_8c590e1f-224c-4339-bfb7-fb2401f33f87"
      decimals="3"
      id="F_cc801f29-c4d8-4e09-b786-c9780562efba"
      unitRef="U_pure">0.09</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_1754f765-5745-4731-b5dc-3a11a9d12c42"
      decimals="INF"
      id="F_d2dd6b71-511d-45f2-82be-87e1a8512421"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_9015a27f-f086-4d25-b575-d3055945fe84"
      decimals="INF"
      id="F_43c92b0a-f709-4fd0-99b8-01bcb6acd403"
      unitRef="U_pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e5c90d2a-1b3e-42ff-a354-2da100d5cdcc"
      decimals="-5"
      id="F_f3d7014a-866a-4666-b8e2-a64f0c65d145"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_3891a9a9-b40f-43be-a57b-26dd8899f2e1"
      decimals="-5"
      id="F_9212eb2e-116f-4b48-a803-32b850d73c24"
      unitRef="U_USD">80000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_43c6bd94-f041-48f0-8b71-ece113bc20c9"
      decimals="0"
      id="F_24b26fb1-c3bb-4395-bf7e-2fcc52989747"
      unitRef="U_USD">300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <gern:DebtInstrumentFaceAmountExpired
      contextRef="C_93ba27f0-5156-41ac-9f7e-063e7a0e3462"
      decimals="-5"
      id="F_a3bd8284-36a1-4b91-bed1-7118194ca917"
      unitRef="U_USD">20000000</gern:DebtInstrumentFaceAmountExpired>
    <us-gaap:LongTermDebtDescription
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      id="F_847e7abe-6d3c-47d6-8595-b1fd3122ea59">Term Loan matures on April 1, 2025, or the Loan Maturity Date, and may be extended up to an additional six months upon the achievement of certain regulatory and financial milestones.</us-gaap:LongTermDebtDescription>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      id="F_76c8ed04-711e-480f-8eda-4fa9b22b399e">2025-04-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate
      contextRef="C_44d11214-5ff1-4fe2-9231-445ae761557a"
      id="F_1c8707c5-eb7b-45cf-ac8c-9e9f9755f956">The Term Loan bears interest at a floating rate per annum equal to the greater of either (i) 9.0% or (ii) the sum of (A) the Prime Rate (as reported in The Wall Street Journal) minus 4.5%, plus (B) 9.0%  (8.5% as of December 31, 2023).</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      decimals="3"
      id="F_f637dec9-f3ee-4f69-b7ba-7325e870d319"
      unitRef="U_pure">0.09</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_d9939d7d-974b-4606-83bd-5a5ddf499439"
      decimals="INF"
      id="F_930f01d2-2e49-450c-b738-b876c59b5706"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_e81fdb75-1e1c-4290-ae83-e0a59c23e05d"
      decimals="INF"
      id="F_f03738ee-43ec-48f4-becc-1273fa11b9fa"
      unitRef="U_pure">0.09</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_9627054b-a059-4769-a822-511b43eb7d07"
      decimals="INF"
      id="F_3d51d0d7-021d-4320-a964-1c109de077b0"
      unitRef="U_pure">0.085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <gern:InterestOnlyPeriodPaymentTermDescription
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      id="F_c5372fa3-6165-4448-83b9-363e2853893d">The interest only period of the Term Loan is through June 30, 2024, and is further extendable to December 31, 2024 upon achievement of a regulatory and financial milestone and satisfaction of certain capitalization requirements. Following the expiration of the interest-only period, we are required to repay the Term Loan in equal monthly amortization payments of principal and interest until the Loan Maturity Date.</gern:InterestOnlyPeriodPaymentTermDescription>
    <gern:DebtInstrumentEndOfTermChargePercentage
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      decimals="4"
      id="F_e5224456-0390-484c-a709-0da41d65e11a"
      unitRef="U_pure">0.0655</gern:DebtInstrumentEndOfTermChargePercentage>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      id="F_ab9e32be-730b-4d60-9ee9-9412b2b7745f">At our option, upon at least five business days&#x2019; prior written notice to Hercules, we may prepay all or any portion greater than or equal to $5.0 million of the outstanding loan by paying the entire principal balance (or portion thereof) and all accrued and unpaid interest. There is no prepayment charge for prepayments of drawdowns under Tranche 1 or Tranche 2.  Prepayments of drawdowns under Tranche 3, Tranche 4, Tranche 5 or Tranche 6 are subject to a prepayment charge of 1.5% of the prepayment amount, if the prepayment is made prior to June 30, 2025. Thereafter, any prepayment of Tranche 3, Tranche 4, Tranche 5 or Tranche 6 is not subject to a prepayment charge.</us-gaap:DebtInstrumentPaymentTerms>
    <gern:DebtInstrumentMinimumPrepaymentAmount
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      decimals="-5"
      id="F_322817b7-50b3-4756-ab04-e5f1cad1d638"
      unitRef="U_USD">5000000</gern:DebtInstrumentMinimumPrepaymentAmount>
    <gern:PercentageOfPrepaymentCharge
      contextRef="C_f2693cf9-67f1-4ebd-9653-66d0ae99298c"
      decimals="INF"
      id="F_bb2b8907-2d80-4a43-bfe2-f46e333a944c"
      unitRef="U_pure">0</gern:PercentageOfPrepaymentCharge>
    <gern:PercentageOfPrepaymentCharge
      contextRef="C_688486b0-96f1-46aa-9bfc-41e54da2e10b"
      decimals="INF"
      id="F_d5bf4e4b-7c1a-4b69-9dce-ae53e181d67c"
      unitRef="U_pure">0</gern:PercentageOfPrepaymentCharge>
    <gern:PercentageOfPrepaymentCharge
      contextRef="C_5e69d88b-4f35-4715-a7e6-4dd1f9e014e6"
      decimals="3"
      id="F_21434346-ff79-4efe-8ca2-a005934e51e4"
      unitRef="U_pure">0.015</gern:PercentageOfPrepaymentCharge>
    <gern:PercentageOfPrepaymentCharge
      contextRef="C_e0d1eeee-15a6-49e0-b2a9-feba2070ca4a"
      decimals="3"
      id="F_34702154-f502-435f-ae20-ab4591b28cb4"
      unitRef="U_pure">0.015</gern:PercentageOfPrepaymentCharge>
    <gern:PercentageOfPrepaymentCharge
      contextRef="C_c819bdf8-44a4-49a8-b407-9353eb20da0d"
      decimals="3"
      id="F_6ab1adc6-7963-4a8c-bc38-a4e1054c59fa"
      unitRef="U_pure">0.015</gern:PercentageOfPrepaymentCharge>
    <gern:PercentageOfPrepaymentCharge
      contextRef="C_270b5c42-ba2a-4860-81af-6be293878e33"
      decimals="3"
      id="F_555865a2-ef01-4d08-8023-7ae403ebf9fc"
      unitRef="U_pure">0.015</gern:PercentageOfPrepaymentCharge>
    <gern:PercentageOfInterestOnPastDueOutstanding
      contextRef="C_9c110582-d865-4864-a523-b15ea80bf6ff"
      decimals="INF"
      id="F_bad9cf2f-bebc-4002-854f-8042646c8849"
      unitRef="U_pure">0.05</gern:PercentageOfInterestOnPastDueOutstanding>
    <us-gaap:LongTermDebt
      contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844"
      decimals="-5"
      id="F_ee5ea7e7-3555-45f2-892e-420bbdd79597"
      unitRef="U_USD">81900000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844"
      decimals="-5"
      id="F_827af9f5-0692-49d9-b5a7-f457b6cf9f02"
      unitRef="U_USD">80000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844"
      decimals="0"
      id="F_710c6195-db38-4e7e-9f89-930010c19144"
      unitRef="U_USD">605000</us-gaap:UnamortizedDebtIssuanceExpense>
    <gern:AccruedEndOfTermCharges
      contextRef="C_f95129c1-8a90-4b89-bb9a-b7b27d613844"
      decimals="0"
      id="F_f8f6cddc-9584-4e1d-adce-0b672e05312d"
      unitRef="U_USD">2691000</gern:AccruedEndOfTermCharges>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_924d8028-10ed-4a45-b606-ece83f510d68">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.552%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.75%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.698%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  unamortized end of term charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less:  current portion of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Noncurrent portion of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_f4631a74-7275-48d3-8053-c339398606ca"
      unitRef="U_USD">56066000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_36a6d594-b729-4742-b6d7-d69e7899719c"
      unitRef="U_USD">39262000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <gern:LongTermDebtGross
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_efcfbcc8-e28f-4a59-85f7-39f5d5c8fcdc"
      unitRef="U_USD">95328000</gern:LongTermDebtGross>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_883c19fd-2667-4dcf-9532-b2c7bd478efe"
      unitRef="U_USD">10088000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_83b9a1c4-4bed-4780-a287-750fc2c88679"
      unitRef="U_USD">605000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <gern:DebtInstrumentUnamortizedEndOfTermCharge
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_e7092192-360b-4de6-b689-3e1aad3c6cdf"
      unitRef="U_USD">2691000</gern:DebtInstrumentUnamortizedEndOfTermCharge>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_a2fd5ed6-132d-47b4-8094-eeb4965ea7de"
      unitRef="U_USD">46893000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_dac70f06-251b-4f01-a165-846376b4223d"
      unitRef="U_USD">35051000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_30a377e6-7c02-4168-9eab-e9347da9bc27">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Authorized Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023 our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;675,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 1, 2022, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,333,334&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,095,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, or the 2022 pre-funded warrant, together with accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,714,286&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, also known as the 2022 stock purchase warrants. The shares of common stock and the 2022 pre-funded warrant were immediately separable from the 2022 stock purchase warrants. All of the securities were issued separately. The combined public offering price of the common stock and accompanying 2022 stock purchase warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The 2022 stock purchase warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and are exercisable immediately. The term of the 2022 stock purchase warrants expired in the third quarter of 2023, pursuant to the terms of the warrant agreement.. The combined public offering price of the 2022 pre-funded warrant and accompanying 2022 stock purchase warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.049&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The 2022 pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and may be exercised at any time until the 2022 pre-funded warrant is exercised in full. As of December 31, 2023, none of the 2022 pre-funded warrant and all of the 2022 stock purchase warrants have been exercised. The net cash proceeds from this offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69,916,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2022 pre-funded warrant and 2022 stock purchase warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon the issuance of the 2022 pre-funded warrant and 2022 stock purchase warrants, we evaluated the terms of each warrant to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and FASB Accounting Standards Codification Topic 815,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2022 pre-funded warrant and the 2022 stock purchase warrants include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2022 pre-funded warrant and the 2022 stock purchase warrants should be classified as equity with no subsequent remeasurement as long as such warrants continue to be classified as equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 10, 2023 we completed an underwritten public offering consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,007,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock and the 2023 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The public offering price of the 2023 pre-funded warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.449&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The 2023 pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and may be exercised at any time until the 2023 pre-funded warrant is exercised in full. As of December 31, 2023, none of the 2023 pre-funded warrant has been exercised. The net cash proceeds from this offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;213,337,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2023 pre-funded warrant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon the issuance of the 2023 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and FASB Accounting Standards Codification Topic 815, Derivatives and Hedging. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2023 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2023 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrant Exercises&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2023, warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77,349,859&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock were exercised for net cash proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,912,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The warrants were issued in connection with underwritten public offerings of common stock and pre-funded warrants, together with accompanying stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;purchase &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;warrants in May 2020, April 2022, and January 2023. As of December 31, 2023, the following warrants remained outstanding:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;pre-funded warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,430,477&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, which have no expiration date; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;stock purchase warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,474,503&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock related to the public offering of our common stock in May 2020, which expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2022, warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,663,387&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock were exercised for net cash proceeds of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,163,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The warrants were issued in connection with an underwritten public offering of common stock and a pre-funded warrant, together with accompanying stock purchase warrants in May 2020. As of December 31, 2022, the pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,335,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock was outstanding and stock purchase warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,110,079&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock associated with the May 2020 public offering remained outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Sales Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On September 4, 2020, we entered into an At Market Issuance Sales Agreement, or the 2020 Sales Agreement, with B. Riley Securities, Inc., or B. Riley, pursuant to which we were able to elect to issue and sell shares of our common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in such quantities and on such minimum price terms as we set from time to time through B. Riley as our sales agent. We agreed to pay B. Riley an aggregate commission rate equal to up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2020 Sales Agreement. In connection with the 2020 Sales Agreement, we terminated the 2018 Sales &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Agreement. The 2020 Sales Agreement expired on September 4, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement with B. Riley, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from time to time through B. Riley as the sales agent. We have agreed to pay B. Riley an aggregate commission rate equal to up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2023 Sales Agreement.  The 2023 Sales Agreement will automatically terminate upon the earlier of (i) the sale of all common stock subject to the 2023 Sales Agreement, or (ii) termination of the 2023 Sales Agreement in accordance with its terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2021, we sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,571,556&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock pursuant to the 2020 Sales Agreement, resulting in n&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;et cash proceeds to us of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting sales commissions and other offering expenses paid by us. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock were sold pursuant to the 2020 Sales Agreement or the 2023 Sales Agreement during the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2011 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2011, our stockholders approved the adoption of the 2011 Incentive Award Plan, or 2011 Plan. The 2011 Plan provided for grants of either incentive stock options or nonstatutory stock options and stock purchase rights to employees (including officers and employee directors) and consultants (including non&#x2011;employee directors). Upon the adoption of the 2018 Equity Incentive Plan in May 2018 (see below), no further grants of stock options or stock purchase rights were made under the 2011 Plan. Stock options granted under the 2011 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant. Stock option exercise prices were equal to the fair market value of the underlying common stock on the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Service&#x2011;based stock options under the 2011 Plan generally vested over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant. Other stock awards (restricted stock awards and restricted stock units) had variable vesting schedules which were determined by our board of directors on the date of grant. All outstanding awards granted under the 2011 Plan remain subject to the terms of the 2011 Plan and the individual award agreements thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 15, 2018, our stockholders approved the adoption of the 2018 Equity Incentive Plan, or 2018 Plan, as the successor to the 2011 Plan. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;performance &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;awards that may be settled in cash, stock, or other property. Eligible participants under the 2018 Plan include our employees, consultants and non-employee directors. The number of shares reserved for issuance under the 2018 Plan (subject to adjustment for certain changes in capitalization) is equal to the sum of (i) the unallocated shares of common stock remaining available for grant under the 2011 Plan as of May 15, 2018, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; newly reserved shares of common stock and (iii) the number of shares subject to awards granted under the 2002 Equity Incentive Plan, and the 2011 Plan as such shares become available from time to time, referred to as the Prior Plans&#x2019; Returning Shares. Such Prior Plans&#x2019; Returning Shares become available for issuance under the 2018 Plan if outstanding stock awards granted under the 2002 Equity Incentive Plan and the 2011 Plan, after May 15, 2018, expire or terminate for any reason prior to exercise or settlement or are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or, subject to certain exceptions, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award. In May 2023, May 2022 and May 2021, our stockholders approved amendments to our 2018 Eq&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;uity Incentive Plan to increase the total number of shares issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-variant:small-caps;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,360,000&lt;/span&gt;&lt;span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock options granted under the 2018 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant. Stock option exercise prices shall be equal to the fair market value of the underlying common stock on the date of grant. If, at the time we grant a stock option, the optionee directly or by attribution owns stock possessing more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total combined voting power of all classes of our stock, the stock option exercise price shall be at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value of the underlying common stock and shall not be exercisable more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; after the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We grant service-based and performance-based stock options to employees under the 2018 Plan. Service-based stock options generally vest over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of the stock option grant. Performance-based stock options vest upon the achievement of specified milestones. Other stock awards (restricted stock awards and restricted stock units) have variable vesting schedules as determined by our board of directors on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under certain circumstances, stock options may be exercised prior to vesting, subject to our right to repurchase the shares underlying such stock option at the exercise price paid per share. Our repurchase rights would generally terminate on a vesting schedule identical to the vesting schedule of the exercised stock option. During 2023 and 2022, we did not repurchase any shares under the 2018 Plan. As of December 31, 2023, we have no shares outstanding subject to repurchase under the 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, our Non&#x2011;Employee Director Compensation Policy adopted by our board of directors in March 2014, as amended and restated in February and March 2022, provides for the automatic grant to non&#x2011;employee directors of the following types of equity awards under the 2018 Plan:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;First Director Option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  Each person who becomes a non&#x2011;employee director, whether by election by our stockholders or by appointment by our board of directors to fill a vacancy, will automatically be granted a stock option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, or First Director Option, on the date such person first becomes a non&#x2011;employee director. The First Director Option vests annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon each anniversary date of appointment to our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Subsequent Director Option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  Each non&#x2011;employee director (other than any director receiving a First Director Option on the date of the annual meeting) will automatically be granted a subsequent stock option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, a Subsequent Director Option, on the date of the annual meeting of stockholders in each year during such director&#x2019;s service on our board of directors. The Subsequent Director Option vests in full on the earlier of: (i) the date of the next annual meeting of our stockholders or (ii) the first anniversary of the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2006 Directors&#x2019; Stock Option Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2006 Directors&#x2019; Stock Option Plan, or 2006 Directors Plan, was terminated by our board of directors and replaced by the 2011 Plan in March 2014. No further grants of stock options were made from the 2006 Directors Plan upon the 2006 Directors Plan&#x2019;s termination. All outstanding awards granted under the 2006 Directors Plan remain subject to the terms of the 2006 Directors Plan and the individual award agreements thereunder.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The stock options granted to non-employee directors under the 2006 Directors Plan were nonstatutory stock options, and they expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant. The option exercise price was equal to the fair market value of the underlying common stock on the date of grant. The first director option granted to non-employee directors under the 2006 Directors Plan vested annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; upon each anniversary date of appointment to the board of directors. The subsequent director option granted to non-employee directors on the date of the annual meeting of stockholders in each year during such director&#x2019;s service on our board of directors under the 2006 Directors Plan vested &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2018 Inducement Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2018, our board of directors approved the adoption of the 2018 Inducement Award Plan, or the Inducement Plan, pursuant to which we reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock to be used exclusively for grants of inducement awards to individuals who were not previously Geron employees or non-employee directors, other than following a bona fide period of non-employment.  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the compensation committee of our board of directors approved amendments to our 2018 Inducement Award Plan to increase the total number of shares issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,900,000&lt;/span&gt;&lt;span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock. As of December 31, 2023, an aggregate total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,306,638&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock have been reserved under the Inducement Plan, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,616,841&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; available for grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards, and all awards under the Inducement Plan are intended to meet the standards under Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved 2018 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Directors&#x2019; Market Value Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2018, our board of directors adopted a Directors&#x2019; Market Value Stock Purchase Plan, or the Directors Market Plan. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock have been reserved for the Directors Market Plan. Under the Directors Market Plan, non-employee directors may purchase shares of our common stock at the prevailing market price on the purchase date with cash compensation payable to them for their services as a board member. As stated in Geron&#x2019;s Non-Employee Director Compensation Policy, each non-employee director receives annual cash compensation, payable quarterly in arrears, for their services on the board and various committees of the board. As provided in the Non-Employee Director Compensation Policy, a non-employee director may elect to receive fully vested shares of common stock in lieu of cash and such shares shall be issuable from the Directors Market Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the years ended December 31, 2023, 2022 and 2021, we issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,864&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,962&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,783&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, respectively, under the Directors Market Plan. The weighted average grant date fair value of stock granted during the years ended December 31, 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. The total fair value of vested stock grants during 2023, 2022 and 2021 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, 2006 Directors Plan, Inducement Plan and Directors Market Plan is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.994%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.117%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.977%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.918%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Available&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;For Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,370,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,902,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,368,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,855,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,855,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Awards granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,869,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options cancelled/forfeited/expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,903,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,903,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,750,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,984,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,391,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options exercisable at &lt;br/&gt;&#160;&#160;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,995,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.28&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,557,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options fully vested and expected&lt;br/&gt;&#160;&#160;&#160;&#160;to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,983,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.67&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,169,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Include&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,936,030&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; perfo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;rmance-based stock options granted that have not achieved the specified performance milestones.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on Geron&#x2019;s closing stock price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, which would have been received by the option holders had all the option holders exercised their stock options as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We have not granted any stock options with an exercise price below or greater than the fair market value of our common stock on the date of grant in 2023, 2022, and 2021. As of December 31, 2023, 2022 and 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,995,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,085,389&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,459,136&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; exercisable stock options outstanding at weighted average exercise prices per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.17&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total pretax intrinsic value of stock options exercised during 2023, 2022, and 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,986,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;787,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively. Cash received from the exercise of stock options in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023, 2022, and 2021 totaled approximatel&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;y $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,356,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,799,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;556,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2014, our board of directors adopted the 2014 Employee Stock Purchase Plan, or 2014 Purchase Plan. The 2014 Purchase Plan was approved by our stockholders in May 2014. The 2014 Purchase Plan replaced the 1996 Employee Stock Purchase Plan, or 1996 Purchase Plan, which was terminated effective as of the date the 2014 Purchase Plan was approved by our stockholders. In May 2022, our stockholders approved an amendment to our 2014 Purchase Plan to increase the total number of shares issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock, for an aggregate total reserve of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,254,162&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of our common stock have been issued under the 2014 Purchase Plan since its adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2014 Purchase Plan is comprised of a series of offering periods, each with a maximum duration (not to exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months) with new offering periods commencing on January 1st and July 1st of each year. The date an employee enters the offering period will be designated as the entry date for purposes of that offering period. An employee may participate only in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; offering period at a time. Each offering period consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive purchase periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2019; duration, with the last day of such period designated a purchase date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the 2014 Purchase Plan, employees can choose to have up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of their annual salary withheld to purchase our common stock, up to a limit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per year. An employee may not make additional payments into such account or increase the withholding percentage during the offering period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The purchase price per share at which common stock is purchased by the employee on each purchase date within the offering period is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the lower of (i) the fair market value per share of our common stock on the employee&#x2019;s entry date into that offering period or (ii) the fair market value per share of our common stock on the purchase date. If the fair market value per share of our common stock on the purchase date is less than the fair&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;market &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;value at the beginning of the offering period, a new &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; month offering period will automatically begin on the first business day following the purchase date with a new fair market value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation for Employees and Directors&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We measure and recognize compensation expense for all share&#x2011;based payment awards made to employees and directors, including employee stock options, restricted stock awards and employee stock purchases, based on grant&#x2011;date fair values for these instruments. We use the Black-Scholes option&#x2011;pricing model to estimate the grant&#x2011;date fair value of our service-based and performance-based stock options and employee stock purchases. The fair value for service&#x2011;based restricted stock awards is determined using the fair value of our common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As stock&#x2011;based compensation expense recognized on the consolidated statements of operations for the years ended December 31, 2023, 2022 and 2021 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures, but at a minimum, reflects the grant&#x2011;date fair value of those awards that actually vested in the period. Forfeitures have been estimated at the time of grant based on historical data and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In 2023, 2022 and 2021, our board of directors awarded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;832,790&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,741,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;550,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; perform&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ance-based stock options, respectively, to certain employees. These performance-based stock options are included in the outstanding stock options table above. Performance-based stock options vest only upon achievement of discrete milestones. Stock-based compensation expense for performance-based stock options is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being achieved, if ever.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recognize stock&#x2011;based compensation expense for service-based stock options on a straight&#x2011;line basis over the requisite service period, which is generally the vesting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;period. We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,167,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2023. We did not recognize any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended Dec&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ember 31, 2022 and 2021, as the achievement of the specified milestones was not considered probable during that time. &lt;/span&gt;&lt;span style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the stock&#x2011;based compensation expense related to service-based stock options and employee stock purchases for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021, which was allocated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.512%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.728%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.728%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;br/&gt;&#160;&#160;&#160;included in operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023, 2022, and 2021 has been estimated at the date of grant using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.25%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.772&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.775&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of employee stock purchases in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023, 2022, and 2021 has been estimated using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.95%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.791&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.614&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.507&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Dividend yield is based on historical cash dividend payments and we have paid no cash dividends to date. The expected volatility range is based on historical volatilities of our stock, since traded options on our common stock do not correspond to option terms and the trading volume of options is limited. The risk&#x2011;free interest rate range is based on the U.S. Zero Coupon Treasury Strip Yields for the expected term in effect on the date of grant for an award. The expected term of stock options is derived from actual historical exercise and post&#x2011;vesting cancellation data and represents the period of time that stock options granted are expected to be outstanding. The expected term of employees&#x2019; purchase rights is equal to the purchase period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on the Black-Scholes option&#x2011;pricing model, the weighted-average estimated fair value of stock options granted during the years ended December 31, 2023, 2022 and 2021 w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.17&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;share, respectively. The weighted average estimated fair value of employees&#x2019; purchase rights for the years ended December 31, 2023, 2022 and 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, total compensation cost related to unvested share&#x2011;based payment awards not yet recognized, net of estimated forfeitures and as&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;suming no probability of achievement for outstanding performance-based stock options, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;37,628,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, whi&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ch is expected to be recognized over the next &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months on a weighted&#x2011;average basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation to Service Providers&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We grant stock options to consultants from time to time in exchange for services performed for us. In general, the stock options vest over the contractual period of the consulting arrangement. The fair value of stock options held by consultants is recorded as operating expenses over the vesting term of the respective equity awards. With the adoption of Accounting Standards Update 2018-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASU 2018-07, in the first quarter of 2019, the measurement date of stock options granted to consultants was fixed at the grant date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We recorded stock&#x2011;based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;742,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;235,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the vest&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ed portion of the fair value of stock options held by consultants in 2023, 2022, and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.133%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.667%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.201%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,984,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and awards available for grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,750,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;745,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,904,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;186,385,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_027d36e5-94d9-4e80-a37e-f864583a9ab1"
      decimals="INF"
      id="F_16952ce7-9557-402b-9aa2-44ced1a5f44a"
      unitRef="U_shares">675000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a814b358-835d-4bd9-9991-025af00007a2"
      decimals="INF"
      id="F_d910cfb7-2b79-4041-85b8-f8ba2e4dde8b"
      unitRef="U_shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_e685bf88-6c83-46c0-b720-48d9693271f9"
      decimals="INF"
      id="F_449c8b57-8104-4378-9321-75a711d4450b"
      unitRef="U_shares">53333334</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83"
      decimals="INF"
      id="F_2c8ac685-9002-4174-86a6-321be6006568"
      unitRef="U_shares">18095238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0c872764-390c-4717-890a-1fb8ba1afba9"
      decimals="INF"
      id="F_4a3a11ed-f8c8-469b-a9d4-bc075f3d4fa4"
      unitRef="U_shares">35714286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5b6ebae4-b1af-4bd1-a220-87fe4159e558"
      decimals="2"
      id="F_10905000-f1c5-4ba0-9414-803f15306520"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0c872764-390c-4717-890a-1fb8ba1afba9"
      decimals="2"
      id="F_29b5de1d-719b-4bc3-910b-d4f3891d0a6c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83"
      decimals="3"
      id="F_7e524a19-d8b8-47dc-b84c-bda4af61157b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.049</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_4f01fb7e-edbc-4daa-8b7c-711fcf9c6e83"
      decimals="3"
      id="F_90063f64-8a7c-495d-abb7-7681dd058254"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_e685bf88-6c83-46c0-b720-48d9693271f9"
      decimals="0"
      id="F_211e0910-e5fe-4d7f-a096-2287a5285968"
      unitRef="U_USD">69916000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_2eebd16c-0eef-470a-90b4-04639a5fa0b4"
      decimals="INF"
      id="F_1e402330-e092-4fc7-9515-8cd63eb2fb9b"
      unitRef="U_shares">68007741</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0a1035cc-6adb-4cec-b9e1-c39d76644c1a"
      decimals="2"
      id="F_ffd0acde-d6d6-4de9-90a2-33b29b8fee8c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.45</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc"
      decimals="3"
      id="F_e17544a3-67c4-4058-b063-4033a591475a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.449</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cb81f6e8-3561-4fc3-8790-dfee5de05bcc"
      decimals="3"
      id="F_f25d1ff4-dad9-4175-b89d-d6df93ac963b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_2eebd16c-0eef-470a-90b4-04639a5fa0b4"
      decimals="0"
      id="F_3bba52c5-f0a8-4a24-acef-5036830082d8"
      unitRef="U_USD">213337000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised
      contextRef="C_f48fce0b-30ab-418f-a2f6-a6573c219376"
      decimals="INF"
      id="F_4c8e023a-199a-4ddc-ad2d-49664431b05e"
      unitRef="U_shares">77349859</gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_be269b1c-429d-477f-bb7d-ad125a3758a2"
      decimals="0"
      id="F_2c89cd9e-877b-4fb4-8e5f-498527eaff97"
      unitRef="U_USD">105912000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_95534f32-aee8-4d09-9da3-068375f3be3c"
      decimals="3"
      id="F_af32b43d-4614-4e8c-ad10-6d81309f33a6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_95534f32-aee8-4d09-9da3-068375f3be3c"
      decimals="INF"
      id="F_d7ae604a-c35e-40ec-b0a8-0dcdda0ebbb0"
      unitRef="U_shares">51430477</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_510848a8-05e3-469a-b372-8265983b572a"
      decimals="2"
      id="F_bc501508-9d01-4a3a-8045-92fbe0b1a911"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_510848a8-05e3-469a-b372-8265983b572a"
      decimals="INF"
      id="F_1de18eae-18c9-4324-a1b3-16bdd165dba8"
      unitRef="U_shares">2474503</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_510848a8-05e3-469a-b372-8265983b572a"
      id="F_1eb7cdc1-b2c6-4803-ab5b-63305b4da528">2025-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised
      contextRef="C_75ecfc92-1a60-40ee-a4cb-7d76a1d3e92a"
      decimals="INF"
      id="F_d0f70b2b-b58e-48a4-ad1f-99720b0d80d3"
      unitRef="U_shares">11663387</gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_472cbb86-89e4-4a2f-aaed-c8771e492ab5"
      decimals="0"
      id="F_d59c1d85-d60f-440c-a600-108931e00324"
      unitRef="U_USD">15163000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7f268f91-b8d0-43cd-a929-2ac72e87b0eb"
      decimals="INF"
      id="F_69a41c90-1a1d-42d5-a559-b932255fa5c2"
      unitRef="U_shares">8335239</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_75ecfc92-1a60-40ee-a4cb-7d76a1d3e92a"
      decimals="INF"
      id="F_e9fb57ec-a179-481c-8b5e-0d4b32214599"
      unitRef="U_shares">44110079</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <gern:CommonStockAggregateOfferingPrice
      contextRef="C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba"
      decimals="INF"
      id="F_50259692-9eec-4fe9-9781-a824aaadf46a"
      unitRef="U_USD">100000000</gern:CommonStockAggregateOfferingPrice>
    <gern:MaximumCommissionRate
      contextRef="C_4f80a569-e790-4ec9-8ee0-56f5ad0146ba"
      decimals="INF"
      id="F_8f0e6864-bba8-4de7-a504-41951c919378"
      unitRef="U_pure">0.030</gern:MaximumCommissionRate>
    <gern:CommonStockAggregateOfferingPrice
      contextRef="C_38ded4c9-172f-4a2a-a52d-e82dc8942a05"
      decimals="INF"
      id="F_1eba0409-59c1-4fba-90e2-8c290f500cdf"
      unitRef="U_USD">100000000</gern:CommonStockAggregateOfferingPrice>
    <gern:MaximumCommissionRate
      contextRef="C_38ded4c9-172f-4a2a-a52d-e82dc8942a05"
      decimals="INF"
      id="F_7e335d8a-e1dd-4eb3-8411-743457a9b24c"
      unitRef="U_pure">0.030</gern:MaximumCommissionRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9e0d68e1-858b-451d-bee9-b7d9aeb45b2f"
      decimals="INF"
      id="F_d3511f12-200c-484f-95aa-c47447574686"
      unitRef="U_shares">10571556</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9e0d68e1-858b-451d-bee9-b7d9aeb45b2f"
      decimals="-5"
      id="F_92ce0a27-8a34-4093-a103-d64bda72acad"
      unitRef="U_USD">20400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_95b50b47-d6b5-4c38-bcae-9f23b73905ee"
      decimals="INF"
      id="F_45639911-4ed5-4d3d-86c6-361a566f61d7"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7e3140e2-0589-47d4-86ac-5bdf695ba419"
      decimals="INF"
      id="F_ca3ca787-39eb-4562-a4a4-99dfcb549f6e"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_933b24f2-1289-480e-b2b0-cd7ef795363d"
      id="F_95c4a761-f42f-4831-abda-0ddd76fd1e0c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_aa683e66-a550-45b2-b8b1-c738b0dfae20"
      id="F_6f95737e-ad71-44d1-9717-4dc495aea7de">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_49393210-70a6-4185-bfbb-56a280b6cb40"
      decimals="INF"
      id="F_4dd6fb19-2e97-4849-bc81-e8660f5dfd4d"
      unitRef="U_shares">10000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_df5a5ad0-ae6b-4ec7-b61c-d48e757c3148"
      decimals="INF"
      id="F_0f17c12c-d3f3-4faa-91e0-fd87377f6440"
      unitRef="U_shares">43360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_3599ea48-8821-4d91-8b3f-c643d3f1153a"
      decimals="INF"
      id="F_784f0e99-0068-428a-8d13-24650425b0b3"
      unitRef="U_shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_3b446414-84fd-4c21-bce4-7d4596128fd2"
      decimals="INF"
      id="F_9d32a3e6-2b64-43bc-b836-8e9c6a613ec8"
      unitRef="U_shares">12500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_dbd86ffc-7423-4bbf-b014-4111ef73acb3"
      id="F_ab532651-a3f9-45ab-a19b-353a236ca254">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue
      contextRef="C_5bf7166f-5b00-4240-90ed-a7f7c7a104bc"
      decimals="INF"
      id="F_4e21d48f-93dd-48ef-b1cc-f57037c042fd"
      unitRef="U_pure">0.10</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock
      contextRef="C_5bf7166f-5b00-4240-90ed-a7f7c7a104bc"
      decimals="INF"
      id="F_17d9c8ac-900e-474b-ad72-edef8413d89a"
      unitRef="U_pure">1.10</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock>
    <gern:ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock
      contextRef="C_7c46d828-b7f0-4eb1-b271-019ea82aead2"
      id="F_2cf50216-55e1-4687-a7d2-e6c031073690">P5Y</gern:ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_7c46d828-b7f0-4eb1-b271-019ea82aead2"
      id="F_b81d23bc-2151-4ed9-8a5b-63a749f5dcc1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment
      contextRef="C_3775ee3a-1995-4ba0-9943-4a471b60aa73"
      decimals="INF"
      id="F_c7d10bb2-93ad-4ded-b090-7337975bb518"
      unitRef="U_shares">200000</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_40e9b0a7-aa9d-4ad8-8b64-211cce52e280"
      id="F_6c14a7cc-2c7e-4fe2-9848-185dbab3596e">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares
      contextRef="C_4a5892be-7d37-498c-be3e-05e931beae2a"
      decimals="INF"
      id="F_def348a6-8d98-414f-98c8-ad2c121b3241"
      unitRef="U_shares">125000</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_f677506b-3ffc-40c8-bc4c-7bf4653d86d8"
      id="F_1e294b98-3d0b-4529-957f-822f80678b76">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_404e5fe1-4fb6-4444-9f07-c398ecd07fcd"
      id="F_f83965ed-8436-4950-a563-d3c601c986d3">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_c84962fe-b876-484c-8ac0-436ed90912a4"
      id="F_6f5a036f-777e-43b8-9578-1e2348f26815">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9eb3c3bc-3f1f-46d7-8b32-d6803d932f4e"
      decimals="INF"
      id="F_31c038a4-d1e4-479f-807a-6348cbfb5026"
      unitRef="U_shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_1fc0a461-b7df-4953-9697-a90dae088624"
      decimals="INF"
      id="F_1e373c7e-e340-4f35-93e9-69a0c36952b5"
      unitRef="U_shares">13900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a432a676-25a6-4e7b-8197-e0e0d30df151"
      decimals="INF"
      id="F_1164f62e-9bb2-4624-b3aa-ff1864b4daff"
      unitRef="U_shares">32306638</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_a432a676-25a6-4e7b-8197-e0e0d30df151"
      decimals="INF"
      id="F_c54a6eab-f424-40da-bece-2975b183572a"
      unitRef="U_shares">11616841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_76b2a7dd-0da9-4a9f-bf20-e3fdac920246"
      decimals="INF"
      id="F_fb17b212-d5bc-4f39-86da-bbb58e77f1cb"
      unitRef="U_shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_042608dc-1dba-4a63-acb9-58cb22cee7c4"
      decimals="INF"
      id="F_2ee1d149-2851-4cef-9126-05db733faabd"
      unitRef="U_shares">36864</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_b6410ed5-b65f-42da-b01e-341e5ebcf276"
      decimals="INF"
      id="F_ee3d4f3e-bbc8-4935-9657-0667be438bff"
      unitRef="U_shares">15962</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28"
      decimals="INF"
      id="F_a8a036b1-f93f-4c5a-bf13-a4eb1048cd0f"
      unitRef="U_shares">20783</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_042608dc-1dba-4a63-acb9-58cb22cee7c4"
      decimals="2"
      id="F_ec82237a-a3ac-46d9-9e34-d4765f175b89"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b6410ed5-b65f-42da-b01e-341e5ebcf276"
      decimals="2"
      id="F_de4c7bc2-dfea-4822-b989-a79b54d41115"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28"
      decimals="2"
      id="F_2a67f90a-188d-4514-a687-a385b247c1a0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_042608dc-1dba-4a63-acb9-58cb22cee7c4"
      decimals="INF"
      id="F_c69d6e2d-8ff4-41bf-ab2c-5f7b103d74e0"
      unitRef="U_USD">85400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_b6410ed5-b65f-42da-b01e-341e5ebcf276"
      decimals="INF"
      id="F_3bd5d1e3-04ed-41fa-a969-6cc0fea51e16"
      unitRef="U_USD">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_ede5805a-ba18-4e30-b6dc-3d55d8c51f28"
      decimals="INF"
      id="F_8657594e-fb3f-4a4b-9f0f-ed19e9d17194"
      unitRef="U_USD">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_f1450160-3765-4081-aa00-e8819f122cb7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, 2006 Directors Plan, Inducement Plan and Directors Market Plan is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.994%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.117%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.977%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.918%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Available&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;For Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,370,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,902,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,368,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,855,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,855,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Awards granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,869,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options cancelled/forfeited/expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,903,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,903,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,750,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,984,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.70&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,391,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options exercisable at &lt;br/&gt;&#160;&#160;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,995,642&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.28&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,557,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options fully vested and expected&lt;br/&gt;&#160;&#160;&#160;&#160;to vest at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,983,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.67&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,169,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.13%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Include&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,936,030&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; perfo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;rmance-based stock options granted that have not achieved the specified performance milestones.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_e39a1952-2f72-485d-bb08-d4fdcf52e196"
      unitRef="U_shares">18370729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_edc19717-cb3b-4687-8fdd-ef4924f0f264"
      unitRef="U_shares">65902400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="2"
      id="F_c1d2930e-4769-40c5-bad7-8ac5c02abfe0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_9b6e606d-1a4d-4c97-bb1d-7446d48e3fc8"
      unitRef="U_shares">56368058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_574dfc62-2dc8-47e4-a41f-827cccbe9bbe"
      unitRef="U_shares">20855230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_68760ca3-2392-4b26-aa7d-c83776961c6a"
      unitRef="U_shares">20855230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="2"
      id="F_a3226ebb-c950-4bfd-b9a3-be20e983e33a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_aa70ef11-ba24-4d0d-bb89-b58f05aa1694"
      unitRef="U_shares">36864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_168350dd-98b5-40a7-8fb4-48f996d8f9b3"
      unitRef="U_shares">8869302</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="2"
      id="F_9c3b7031-64cf-4a0d-9860-67b4da0de951"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gern:ShareBasedCompensationForfeituresAndExpirationsInPeriodNet
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_4daaaae6-ffc8-4699-97a5-88066f5c399b"
      unitRef="U_shares">4903977</gern:ShareBasedCompensationForfeituresAndExpirationsInPeriodNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="INF"
      id="F_e8ba4143-41e6-45f2-9850-c9997b8a8d5f"
      unitRef="U_shares">4903977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="2"
      id="F_11c501f1-037b-4eab-8aea-9be657f773ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_0bc7cd4d-4d21-435f-be5b-e3b394f28ab5"
      unitRef="U_shares">58750670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_283003cf-edbd-4792-9357-5c0ac76d189f"
      unitRef="U_shares">72984351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="2"
      id="F_e1c382a9-2507-4b75-9534-a47c73b36b9f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_eaf3d11b-810b-4745-b919-09f0e2fadcfd">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="0"
      id="F_e0be7f18-f0f7-4d46-a980-f30c7f995bfa"
      unitRef="U_USD">25391643</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_1016c619-5f8a-4aed-a717-8b4c95110e73"
      unitRef="U_shares">39995642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="2"
      id="F_0f914b65-62fc-4569-98e6-d2d02febd5c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_1fdddbb4-3fbc-4146-814a-37ee6626689e">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="0"
      id="F_5c9c8f46-1729-47da-8be9-e3ca2b69d1ed"
      unitRef="U_USD">15557976</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_e6decdf3-f873-43d7-a788-229d00293b31"
      unitRef="U_shares">71983176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="2"
      id="F_8a0295f9-2fad-4923-b590-6d61ebff9d8c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_fbfeb147-65e6-489d-82d3-f25b680a8765">P6Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="0"
      id="F_ee5d018d-9fe7-4652-a36b-c382cfd4ce63"
      unitRef="U_USD">25169074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d87baa2f-bd55-465b-8452-44ea0c0bd760"
      decimals="INF"
      id="F_242647d4-6222-4da6-aef1-99712c736013"
      unitRef="U_shares">7936030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="2"
      id="F_9d42a355-0b3c-4c2c-a33c-ffb6942bc654"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.11</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_8cc5c97c-925e-401c-9ac1-bd2067c75bde"
      unitRef="U_shares">39995642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="INF"
      id="F_6729774b-11db-4710-afd7-24d24f05c6fa"
      unitRef="U_shares">36085389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba"
      decimals="INF"
      id="F_29840fa2-0ac5-43c3-bc38-31828fdc30b1"
      unitRef="U_shares">30459136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="2"
      id="F_ea67676d-309d-49b7-8ac1-715b8b330276"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="2"
      id="F_c5501358-ebab-4ccb-b75d-b2db19e0e08e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0d042016-74bf-4e4b-9d87-54569fff49ba"
      decimals="2"
      id="F_463c5734-8d78-4a78-a1d1-3f3dba8f82e4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="0"
      id="F_3455db7a-7984-4f7d-9c57-7a82b0386dad"
      unitRef="U_USD">11986000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="0"
      id="F_1fe9e446-596d-4f8b-8a2d-127f021de3ed"
      unitRef="U_USD">787000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="0"
      id="F_95724eab-b727-47e4-9243-3f29d8025560"
      unitRef="U_USD">93000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="0"
      id="F_e26e225f-91c5-40b0-9ea2-465ad18a29ea"
      unitRef="U_USD">12356000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="0"
      id="F_ce2838e7-fcec-45dc-86d3-a1c540d1e410"
      unitRef="U_USD">1799000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="0"
      id="F_3637cf62-207a-47af-820c-84f4976c3b9f"
      unitRef="U_USD">556000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_228019f9-7d33-40bf-8f26-f89bae5c27ff"
      decimals="INF"
      id="F_90e55705-4718-4db4-b7fe-d231e136090b"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9f801a8f-cd52-49ca-bf06-5622142e1b2a"
      decimals="INF"
      id="F_e4878368-c6a6-44eb-8b52-d5843abdb0fd"
      unitRef="U_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="INF"
      id="F_03a883e3-5d8e-4d77-9612-fd1738c42dad"
      unitRef="U_shares">1254162</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      id="F_583a06de-61ae-4ee2-82df-1a48eed4eea2">P12M</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="INF"
      id="F_a5beea9d-ea6a-48d7-b738-bc1daef19a41"
      unitRef="U_Item">1</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="INF"
      id="F_583945e1-ba6e-4ff9-8cf0-9a5cb753c88c"
      unitRef="U_Item">2</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      id="F_b99bd1f8-441b-483e-b798-0d2c64772086">P6M</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="INF"
      id="F_535389d2-83dd-4ec6-a20c-ef327a18aa95"
      unitRef="U_pure">0.10</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear
      contextRef="C_f6fcdb67-4d24-4d5f-be19-775334a4320f"
      decimals="INF"
      id="F_b9595ff3-6a2b-4051-808a-b809d5bab54b"
      unitRef="U_USD">25000</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="INF"
      id="F_0b2e4137-39b9-4ad1-a926-8abfe70ad069"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      id="F_89d712c6-7f8b-4c16-9195-351be7028ead">P12M</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_5a771635-513d-4f44-938f-c72a1da4876b"
      decimals="INF"
      id="F_faaa8869-df64-4907-87cf-09359aa618c9"
      unitRef="U_shares">832790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ea12e420-2fee-416f-88f6-87e5a5b23293"
      decimals="INF"
      id="F_033962a5-485a-4558-9139-c6e6111478a6"
      unitRef="U_shares">2741750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_25ad2b3f-4a16-403c-a2dc-3b7d1fe99046"
      decimals="INF"
      id="F_053c3e8e-ff32-4073-889c-ed83329475c2"
      unitRef="U_shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5a771635-513d-4f44-938f-c72a1da4876b"
      decimals="0"
      id="F_4223f4c6-dc0e-4151-b697-81d1b42f525b"
      unitRef="U_USD">3167000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_901dbeb0-29d8-4a8c-b637-46407a169bef">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the stock&#x2011;based compensation expense related to service-based stock options and employee stock purchases for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023, 2022 and 2021, which was allocated as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.512%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.728%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.728%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.278%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;br/&gt;&#160;&#160;&#160;included in operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_88e8fe22-6578-4995-bace-a30be752ddd8"
      decimals="-3"
      id="F_da42649c-286d-4829-843c-68ae2c8bb714"
      unitRef="U_USD">7426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7346f9b8-492d-46b8-8c82-4d22ec08ac7d"
      decimals="-3"
      id="F_5b13955a-b152-4560-a0d9-6c40be798362"
      unitRef="U_USD">3720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_76c77a60-0095-4c7c-b9a6-6d9d39af8387"
      decimals="-3"
      id="F_a72d8b0c-685e-411c-a39f-f28d5ed7cb16"
      unitRef="U_USD">3597000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e71ee43c-b505-4d11-b82b-9dd17fd5ffe9"
      decimals="-3"
      id="F_1b6540c5-c431-4974-9dfb-e12e9eb42b2d"
      unitRef="U_USD">11099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f6afc8ee-1a57-40bd-8ddc-ffc4d5eb3fd9"
      decimals="-3"
      id="F_a78a9138-b590-4b2d-99c4-62ece9486e5e"
      unitRef="U_USD">4281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b86372fa-858a-445d-b041-163879e9a211"
      decimals="-3"
      id="F_bc49b197-34cd-4321-bbe7-42868501ecde"
      unitRef="U_USD">4483000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_bb316d28-c9ee-4a41-acb5-73b3cb773f06"
      unitRef="U_USD">18525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_74a6f27f-e1dd-45f3-86bb-de7f48b4b35e"
      unitRef="U_USD">8001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_ce80c1b6-237c-4a4c-970f-b65be3998627"
      unitRef="U_USD">8080000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_899cadcd-21a6-4048-b430-784eebb67d26">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023, 2022, and 2021 has been estimated at the date of grant using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.25%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.815&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.772&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.775&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      decimals="2"
      id="F_29cbb3a8-1a6d-4733-8301-44623f728279"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      decimals="2"
      id="F_f7512326-b601-47a5-8552-1a993fc26f3b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      decimals="2"
      id="F_7f15468c-7e71-4bfd-a2a2-b8d8a9ee97e8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      decimals="3"
      id="F_d9000d78-e9d3-4ab4-9d22-bcf0f6138822"
      unitRef="U_pure">0.815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      decimals="3"
      id="F_fa6c5a21-311a-4101-b9d6-de1c5194bbd5"
      unitRef="U_pure">0.827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      decimals="3"
      id="F_0b103ff9-6ffc-440e-bf0e-44fd31ef595d"
      unitRef="U_pure">0.772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      decimals="3"
      id="F_739c1da5-d5f3-49d7-a8d7-634a2b48ad32"
      unitRef="U_pure">0.817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      decimals="3"
      id="F_05f7cb8e-eb89-403e-81fe-c02f1389bb64"
      unitRef="U_pure">0.775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      decimals="3"
      id="F_f84f42da-b996-492a-a996-e1d5aaad23ad"
      unitRef="U_pure">0.783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      decimals="4"
      id="F_9a60ba76-df76-4169-9b39-efc338774225"
      unitRef="U_pure">0.0342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      decimals="4"
      id="F_1f8b979f-8cf3-4b8b-8f33-3d8d421a1829"
      unitRef="U_pure">0.0494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      decimals="4"
      id="F_214b55b9-4875-4c06-a548-b113818510ee"
      unitRef="U_pure">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      decimals="4"
      id="F_2b9c7830-f405-4ca9-955a-d999b58bcf1d"
      unitRef="U_pure">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      decimals="4"
      id="F_f4c47cd7-6cbb-4630-af88-bc23b96a8fef"
      unitRef="U_pure">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      decimals="4"
      id="F_eb1ab1af-c8f0-45ad-a9a6-f79212fbe2f6"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      id="F_3e0f681e-d232-4de6-a3ef-a161f08b5037">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      id="F_fddab3cc-5090-4cc6-b010-da0a6144d173">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      id="F_06fd0b79-87e2-454a-be22-927098e019b8">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b9121cf3-b742-492d-84b4-ff95adca227b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of employee stock purchases in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2023, 2022, and 2021 has been estimated using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:22.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.25%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.95%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.791&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.614&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.507&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="2"
      id="F_0cf2115e-b48d-4ed6-a71e-cbd9d0629e8d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7"
      decimals="2"
      id="F_29dfa152-0a70-47dc-9400-67e3aa62f9ad"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae"
      decimals="2"
      id="F_31dce189-bdd7-4a0e-a5a6-11b933e679fc"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="3"
      id="F_4b8884ff-47ef-4a93-88ed-e8fa6066b448"
      unitRef="U_pure">0.791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="3"
      id="F_6805872c-ce33-4eae-bff7-1af4c9761066"
      unitRef="U_pure">0.832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7"
      decimals="3"
      id="F_4086a0fa-f3ac-4ac3-bd8a-42e362048d84"
      unitRef="U_pure">0.614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7"
      decimals="3"
      id="F_7e3ce0b1-d452-4942-9358-2b383c890d3c"
      unitRef="U_pure">0.865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae"
      decimals="3"
      id="F_2e466ad9-9ff1-45fd-bc20-543cdcd435df"
      unitRef="U_pure">0.507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae"
      decimals="3"
      id="F_c3d1b35a-02c0-43dc-94a9-516ab245ff3e"
      unitRef="U_pure">0.707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="4"
      id="F_717ba260-ac2c-4a3f-824d-66e174e1510d"
      unitRef="U_pure">0.0473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="3"
      id="F_0d03a596-e6a6-426a-8a01-547b61672cde"
      unitRef="U_pure">0.054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7"
      decimals="4"
      id="F_e68b15da-d203-428b-a665-72b4af71bd49"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7"
      decimals="4"
      id="F_39ed6c2c-3d1a-4f92-aaf7-905525ff5dcc"
      unitRef="U_pure">0.0279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae"
      decimals="4"
      id="F_13eb59f3-cb96-4990-80b1-722a1e10ff74"
      unitRef="U_pure">0.0009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae"
      decimals="4"
      id="F_4d74d8c4-c7e8-49b7-8f97-575f0e7dd6d3"
      unitRef="U_pure">0.0016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ad45d3b5-1c71-49f5-8e18-c743e63e20bf"
      id="F_4aca52f2-0ad6-4f87-b4d4-d48b59796394">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f6fcdb67-4d24-4d5f-be19-775334a4320f"
      id="F_296b7038-75e6-4e52-92b4-ed27c22c3163">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e976b4cb-7c40-4469-90e7-51a6622581cb"
      id="F_1fe5c3e5-76cd-4d6c-9702-6a5da736a79d">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_73aa80a5-7000-451b-a950-0deff207777e"
      id="F_b1d7a707-c794-4dbd-8367-482ea618b024">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3a2cda13-d3d5-412b-8639-f1337e897a80"
      id="F_5b6cbae1-c19d-43fb-837a-b4a253f69522">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f483b420-dc65-4430-8e6f-a781504fe525"
      id="F_35ac0297-dbc5-4059-8c94-b6cd20836cf3">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e1c57478-5d84-4116-a7da-630b0b684aa3"
      decimals="2"
      id="F_cf74c997-73f5-4c3d-854a-f560c0e65d2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_320fa289-b36d-4239-a6c5-883f073fb751"
      decimals="2"
      id="F_362179eb-6207-4c9a-b52b-7315599ebb57"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b74ea932-55f5-4ec3-97d7-4567ead94da1"
      decimals="2"
      id="F_7219dfb4-68bd-4651-8515-3aa7d22dbd32"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_34991f42-499f-4b50-9059-0999669562cd"
      decimals="2"
      id="F_2803f2ed-cd5d-48c1-9fdb-f17515eda2a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4e79587f-734c-4e35-ae7f-098dee077ab7"
      decimals="2"
      id="F_4692d2f8-1293-426a-9467-b852390b7e67"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d275d231-4e07-4121-baa6-cdf238ed26ae"
      decimals="2"
      id="F_cc693409-6021-4a75-9b89-a7572d427255"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="0"
      id="F_d8e74e4d-c50a-48e7-ad16-bb1c6c5493ee"
      unitRef="U_USD">37628000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_64ba28db-f1ae-4371-b189-3f6e2cd7859d">P26M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_3ad6c2d6-0303-48fa-82c0-130aee8c97e6"
      decimals="0"
      id="F_3e3fbb64-e218-4f0e-a648-a0fc99b895d3"
      unitRef="U_USD">742000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_2d9d0c34-60e7-4259-a55f-9fe02c166dc0"
      decimals="0"
      id="F_65eafb12-e63e-4fb6-b105-9a3d1f1187f1"
      unitRef="U_USD">235000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_12a38d5d-ad5a-4d9a-a905-53cbdd8ad7e8"
      decimals="0"
      id="F_d4d3cf96-0cce-44b9-9f9b-2e4321c40ae6"
      unitRef="U_USD">62000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_292566fa-eca5-4b1c-a06e-519739c7eeab">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Common stock reserved for future issuance as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.133%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.667%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.201%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,984,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options and awards available for grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,750,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;745,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;53,904,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;186,385,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_a6ea0819-7652-4f0b-ac87-f5cb0f2e1fc1"
      unitRef="U_shares">72984351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_bff0aed6-5486-4372-9b64-7869056873f9"
      unitRef="U_shares">58750670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f5ed2423-f046-4a7d-980c-b9f3fb922f38"
      decimals="INF"
      id="F_c17f173f-0e73-43e4-b3fa-e19a976b4e28"
      unitRef="U_shares">745838</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_8efe1832-0f76-4699-95b3-7bd713e5a707"
      unitRef="U_shares">53904980</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_1bd872c5-ae50-46b7-948a-cf66dcb3ebf4"
      unitRef="U_shares">186385839</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_d9e4ddb8-50ab-40fe-b804-fa7de86205f0">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.28%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss not benefitted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of our deferred tax assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;395,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases, right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial performance. Forming a conclusion that a valuation allowance is not required is difficult when there is negative evidence such as cumulative losses in recent years. Because of our history of losses, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we had domestic federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; billion. Of this, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;635.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will expire at various dates beginning in 2024 through 2037 and the remaining will carryforward indefinitely under the new tax laws, but is subject to an 80% taxable income limitation for tax years beginning after 2020. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;841.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expiring at various dates beginning in 2028 through 2043, if not utilized. We also had federal tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million expiring at various dates beginning in 2024 through 2043, if not utilized. Our state tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million carry forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized. The impact of any limitations that may be imposed due to such ownership changes has not yet been determined. Due to the Company's stock issuance in January 2023, the utilization of the Company's net operating loss and tax credit carryforwards are subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation may result in the expiration of the net operating loss and tax credit carryforwards before some or call of such amounts have been utilized. The final amount of the limitations imposed due to such ownership changes has not yet been determined.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March and December 2020, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic, including among other items, several U.S. income tax provisions related to, among other things, net operating loss carrybacks, alternative minimum tax credits, modifications to interest expense limitations, and an option to defer payroll tax payments for a limited period. In 2021, we assessed our eligibility to claim a refund of employer taxes available under the Employee Retention Credit provisions of the CARES Act. For the years ended December 31, 2022 and 2021, we calculated eligible credits of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;483,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, provided by the CARES Act, which have been recognized as offsets to salaries costs in operating expenses in 2022 and 2021, respectively. As of December 31, 2022, the aggregate eligible credit amount has been accrued as a receivable on our consolidated balance sheets. We received the Employee Retention Credit from the IRS, and there are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; outstanding receivables as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We adopted the provision of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, we recognized no material adjustment in the liability for unrecognized tax benefits. At December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, we had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized tax benefits, none of which would currently affect our effective tax rate if recognized due to our net deferred tax assets being fully offset by a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If applicable, we would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2023, there has been no interest expense or penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;We do not currently expect any significant changes to unrecognized tax benefits during the fiscal year ended December 31, 2023. In certain cases, our uncertain tax positions are related to tax years that remain subject to examination by the relevant tax authorities. Tax years for which we have carryforward net operating loss and credit attributes remain subject to examination by federal and most state tax authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_eb9860c1-573e-4703-b160-39419a4cd6c4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.28%;"&gt;&lt;/td&gt;
        &lt;td style="width:5.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:4.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.28%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss not benefitted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_969cf705-0930-48ff-bd1b-6893b932da00"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_92aa6f5d-34a9-46f3-a7e2-f6cb03b56b1a"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_361550f3-4cd3-4938-9f39-e62f0dd42aff"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_9a85d897-e701-40b3-bf72-bd0d8e3852d8"
      unitRef="U_pure">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_730ae8a2-5cb8-4c84-934a-d69028330cd1"
      unitRef="U_pure">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_65b4da2c-5eba-4175-a055-78e9277775e4"
      unitRef="U_pure">0.09</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_9c743879-0c3e-4f69-8b84-78de8a04ca51"
      unitRef="U_pure">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_cbe2d79b-72eb-4134-ac67-575f5640416b"
      unitRef="U_pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_26cafdc7-eadb-47c1-9b60-897630c0161d"
      unitRef="U_pure">0.057</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_6036096c-7c8e-4314-bbf8-74c1100da70d"
      unitRef="U_pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_8e1cf9c8-e088-4654-b089-e70dc0af5b2c"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_ac00d061-919c-4ea2-bd20-784938788e83"
      unitRef="U_pure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_cff43695-c831-455c-b243-b8983a55cf8a"
      unitRef="U_pure">-0.057</gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted>
    <gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_7ae758ff-d73d-4336-846b-d7b6cc4f4b33"
      unitRef="U_pure">-0.043</gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted>
    <gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_8b67d981-fe6e-49a7-828d-00fc2cc5b6c2"
      unitRef="U_pure">-0.054</gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_9ccf0906-62d6-4758-b30f-749d5aeb3780"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_a8364aa4-c96d-466e-bd2b-aa23ee4f3d32"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_1b39108f-983a-4338-8d50-08eca6dadfa1"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_a2e22b2a-b103-49da-8d62-2817cd226eda"
      unitRef="U_pure">-0.248</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_31879fca-199f-448c-bddd-bd45c895fbb3"
      unitRef="U_pure">-0.275</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_3762dcc2-8aec-4e44-a32e-01fa7e7bafcb"
      unitRef="U_pure">-0.289</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="3"
      id="F_23ab15ba-79eb-441d-b40b-f0341682b005"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="3"
      id="F_3ce77d5b-e5b2-4f8c-8a10-5fdcd5a919e9"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="3"
      id="F_13752874-08e0-4639-bbb0-59e3c1671037"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_f1e9feb3-7b30-4bcc-982c-938e4a932f11">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Significant components of our deferred tax assets are as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;56,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;396,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;350,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;395,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;349,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating leases, right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_4ee896ac-4160-4240-bec0-e73ff4ab05de"
      unitRef="U_USD">272300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_79f268b9-18e7-4f29-85e3-65d4076b578f"
      unitRef="U_USD">254500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <gern:DeferredTaxAssetsFederalAndStateCredits
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_527507d7-97cd-42b4-926a-cc063c29304c"
      unitRef="U_USD">64700000</gern:DeferredTaxAssetsFederalAndStateCredits>
    <gern:DeferredTaxAssetsFederalAndStateCredits
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_cf698b17-7c37-48bf-aa53-3f9801d3e3e3"
      unitRef="U_USD">56700000</gern:DeferredTaxAssetsFederalAndStateCredits>
    <gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_5541fed8-495d-4a3a-ba35-930dbf92403c"
      unitRef="U_USD">43300000</gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_9808dfab-6fa0-4a1e-a18b-d4c5f997714c"
      unitRef="U_USD">21800000</gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_98599bcb-8df6-4b09-a1d0-10251782760f"
      unitRef="U_USD">11200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_90bb985c-0152-4ae4-a583-3f98ff52cb17"
      unitRef="U_USD">10800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <gern:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_51f4567c-304b-476f-96d2-6ef4249a9c42"
      unitRef="U_USD">1100000</gern:DeferredTaxAssetsOperatingLeaseLiabilities>
    <gern:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_8ebad8ee-54e4-487e-b5dc-d1f26692c03e"
      unitRef="U_USD">1300000</gern:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_5c48c2e4-efd6-41e9-af37-46eabb607232"
      unitRef="U_USD">3600000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_a7b59155-c8ed-4c80-8218-33023736e946"
      unitRef="U_USD">5600000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_5b1f1234-121b-439f-9fac-0cd753bd1db3"
      unitRef="U_USD">396200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_e1864984-f1c5-4ca1-89bd-5469201cc699"
      unitRef="U_USD">350700000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_82af20e5-f11f-4e71-bab8-ab14886e2357"
      unitRef="U_USD">395200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_270ee073-469e-4234-9f83-a5ecd4f6788f"
      unitRef="U_USD">349600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_3a96c5ff-90d4-4bad-8be9-a8e702efff83"
      unitRef="U_USD">1000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_989e2445-e82a-4c77-ad18-9ad014d2912c"
      unitRef="U_USD">1100000</us-gaap:DeferredTaxAssetsNet>
    <gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_7e184533-eb6a-4dfa-a84f-197480f829fc"
      unitRef="U_USD">1000000</gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets>
    <gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_b8acede7-adbf-4092-a9ba-929b6fc4f914"
      unitRef="U_USD">1100000</gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_9cdf0cc4-5ef0-4033-86c9-4a1f3e5e76ee"
      unitRef="U_USD">1000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_194064de-ccf4-459c-aea0-349e1a31e6b8"
      unitRef="U_USD">1100000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-5"
      id="F_816c0717-ed98-426e-9f5f-6c98cb9c6dcd"
      unitRef="U_USD">45600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-5"
      id="F_d9d60867-dbc7-489b-9f4e-517d0a07978d"
      unitRef="U_USD">38900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_30549aaa-2d2b-429a-b2b7-bad54c937228"
      decimals="-8"
      id="F_1f11833d-b76e-4007-8854-f7632e00b769"
      unitRef="U_USD">1000000000</us-gaap:OperatingLossCarryforwards>
    <gern:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_30549aaa-2d2b-429a-b2b7-bad54c937228"
      decimals="-5"
      id="F_bcd2be68-abfb-4745-88dd-1c12f5ecaae4"
      unitRef="U_USD">635600000</gern:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0998544a-c764-4cf1-9f09-2276209f95bc"
      decimals="-5"
      id="F_bb27c04d-a7a6-453e-8133-94ddc07eefb6"
      unitRef="U_USD">841200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_30549aaa-2d2b-429a-b2b7-bad54c937228"
      decimals="-5"
      id="F_84543349-62e2-47f3-b731-4a06036cdf8d"
      unitRef="U_USD">72700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0998544a-c764-4cf1-9f09-2276209f95bc"
      decimals="-5"
      id="F_9bb7941c-1214-4c3f-af88-b7aeadff4f9c"
      unitRef="U_USD">21400000</us-gaap:TaxCreditCarryforwardAmount>
    <gern:EmployerTaxReceivable
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="0"
      id="F_005b3019-93d0-4a0c-9580-c43eee54392f"
      unitRef="U_USD">483000</gern:EmployerTaxReceivable>
    <gern:EmployerTaxReceivable
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-5"
      id="F_3f7c1e8a-0bf4-4713-95da-84cc59a68883"
      unitRef="U_USD">1100000</gern:EmployerTaxReceivable>
    <gern:EmployeeRetentionCreditAmountOutstandingReceivables
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="INF"
      id="F_92f69fb3-4a42-41c8-89e7-330b560c992d"
      unitRef="U_USD">0</gern:EmployeeRetentionCreditAmountOutstandingReceivables>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-5"
      id="F_34420faf-fede-4317-8c0d-5bdaaf28f609"
      unitRef="U_USD">26300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_b8d07f78-5ac6-4b1f-8a00-17e508a997bc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:15pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9a5c4c10-4219-41cc-b445-c46a46a9c509"
      decimals="-3"
      id="F_97671845-553f-4083-b892-da18090e29a7"
      unitRef="U_USD">23700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_637ef20c-0d73-4ef6-baf8-12f875343e74"
      unitRef="U_USD">2600000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="-3"
      id="F_67834848-8632-4777-acb2-a14e809fe533"
      unitRef="U_USD">26300000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_fd84b3fc-9a2d-4ede-b214-033e3152b336">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. CONSOLIDATED STATEMENTS OF CASH FLOWS DATA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.291%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental operating and investing activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net unrealized loss on &lt;br/&gt;&#160;&#160;&#160;marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Reclassification between prepaid and other&lt;br/&gt;&#160;&#160;&#160;current assets and deposits and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      id="F_e6d5c536-6737-41e5-b4d2-bec85fcc7f8f">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.291%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Supplemental operating and investing activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net unrealized loss on &lt;br/&gt;&#160;&#160;&#160;marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Reclassification between prepaid and other&lt;br/&gt;&#160;&#160;&#160;current assets and deposits and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_44bf290a-5c51-4056-91f7-9d5d2c53a547"
      unitRef="U_USD">-431000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_e00cbf67-d151-45bb-aa6c-60277a1305ad"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_8ec3ce2c-6173-4ee7-a292-783929c619e3"
      unitRef="U_USD">-251000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <gern:ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_87242a63-5734-496c-b95f-39b0c0764988"
      unitRef="U_USD">-5000</gern:ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets>
    <us-gaap:InterestPaidNet
      contextRef="C_24b95a18-ffbf-4aac-ba2f-78d6a74cfe7a"
      decimals="-3"
      id="F_161b5c87-8ba3-42e8-b91d-c6053a9e5fc8"
      unitRef="U_USD">-7017000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_1e899757-4f56-49cf-873b-25770295bb58"
      decimals="-3"
      id="F_b91c2fd4-9842-4366-a03b-bc124eed2db6"
      unitRef="U_USD">5154000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_3e6e6755-b0cd-454c-bd57-da4270096040"
      decimals="-3"
      id="F_bb9eae10-5375-4b47-87f8-f7c2eb3820a0"
      unitRef="U_USD">2704000</us-gaap:InterestPaidNet>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_707b78ca-5291-4e64-9726-0583e688992f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Trading Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During our last fiscal quarter, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:26%;"&gt;&lt;/td&gt;
      &lt;td style="width:12%;"&gt;&lt;/td&gt;
      &lt;td style="width:11%;"&gt;&lt;/td&gt;
      &lt;td style="width:14%;"&gt;&lt;/td&gt;
      &lt;td style="width:13%;"&gt;&lt;/td&gt;
      &lt;td style="width:9.72%;"&gt;&lt;/td&gt;
      &lt;td style="width:14.28%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="border-top:0.5pt solid;padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Character of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid;padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid;padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
      &lt;td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Name and Title&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Action&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rule 10b5-1*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non-Rule 10b5-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total Shares to be Sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Faye Feller, M.D.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Executive&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:10.8pt;margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vice President and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:10.8pt;margin-top:0;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Chief Medical Officer&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Termination&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;October 25, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 12, 2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0.01in;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0.01in;border-right:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td colspan="7" style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td colspan="7" style="padding-top:0.01in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;** "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect when adopted on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 13, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_13b342b6-71e2-42af-9baa-da680acd4e93">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_b969e258-fa57-4fdc-b3a3-d58290cd463e">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_a7b9b832-6591-4f5a-b250-1b7f19801c34">Faye Feller, M.D.</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_265f1640-30ab-4771-8e4b-ba41b605aae9">ExecutiveVice President and Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_2955f0c9-dba8-4ebb-8a84-1c93ac0a64e6">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrTerminationDate
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_77ad96f4-d53b-467e-a388-ebab05d54427">October 25, 2023</ecd:TrdArrTerminationDate>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_c16ae972-0664-4fe1-a6c0-2d8316960998">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_f5f4fb9c-c772-432f-9a04-27782bb3ca05"
      decimals="0"
      id="F_a46bd2e9-9f8d-4bed-b110-fc25f1f802b5"
      unitRef="U_shares">30000</ecd:TrdArrSecuritiesAggAvailAmt>
    <gern:TrdArrExpirationDate
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_18dd4e09-ffbf-40f0-a2f3-62dc6d7d2911">January 12, 2024</gern:TrdArrExpirationDate>
    <ecd:TrdArrAdoptionDate
      contextRef="C_3bb2a462-3594-4a43-8344-076ee590e035"
      id="F_63cbcee6-1fd4-4451-823f-7b86954faf0e">January 13, 2023</ecd:TrdArrAdoptionDate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_77ad96f4-d53b-467e-a388-ebab05d54427"
          xlink:label="F_77ad96f4-d53b-467e-a388-ebab05d54427"
          xlink:type="locator"/>
        <link:footnote id="FNT_d30983c0-aaf8-4127-9c9f-03919a470b03" xlink:label="FNT_d30983c0-aaf8-4127-9c9f-03919a470b03" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Represents the termination of a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), as then in effect when adopted on </xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2023</xhtml:span></xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_77ad96f4-d53b-467e-a388-ebab05d54427"
          xlink:to="FNT_d30983c0-aaf8-4127-9c9f-03919a470b03"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
